PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Schmidt, SLG; Gomes, XV; Burgers, PMJ				Schmidt, SLG; Gomes, XV; Burgers, PMJ			ATP utilization by yeast replication factor C III. The ATP-binding domains of Rfc2, Rfc3, and Rfc4 are essential for DNA recognition and clamp loading	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; POLYMERASE-DELTA; SITE MUTANTS; PROTEIN; SUBUNIT; COMPLEX; MUTATIONS; OVERPRODUCTION; F1-ATPASE; HOMOLOGY	The conserved lysine in the Walker A motif of the ATP-binding domain encoded by the yeast RFC1, RFC2, RFC3, and RFC4 genes was mutated to glutamic acid. Complexes of replication factor C with a N-terminal truncation (Delta2-273) of the Rfc1 subunit (RFC) containing a single mutant subunit were overproduced in Escherichia coli for biochemical analysis. All of the mutant RFC complexes were capable of interacting with PCNA. Complexes containing a rfc1-K359E mutation were similar to wild type in replication activity and ATPase activity,however, the mutant complex showed increased susceptibility to proteolysis. In contrast, complexes containing either a rfc2-K71E mutation or a rfc3-K59E mutation were severely impaired in ATPase and clamp loading activity. In addition to their defects in ATP hydrolysis, these complexes were defective for DNA binding. A mutant complex containing the rfc4-K55E mutation performed as well as a wild type complex in clamp loading, but only at very high ATP concentrations. Mutant RFC complexes containing rfc2-K71R or rfc3-K59R, carrying a conservative lysine --> arginine mutation, had much milder clamp loading defects that could be partially (rfc2-K71R) or completely (rfc3-K59R) suppressed at high ATP concentrations.	Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA	Washington University (WUSTL)	Burgers, PMJ (corresponding author), Washington Univ, Sch Med, Dept Biochem & Mol Biophys, 660 S Euclid Ave, St Louis, MO 63110 USA.	burgers@biochem.wustl.edu	Burgers, Peter M/AAW-6621-2021		NIGMS NIH HHS [R01 GM032431, GM32431] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032431] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAUER GA, 1988, P NATL ACAD SCI USA, V85, P7506, DOI 10.1073/pnas.85.20.7506; BURGERS PMJ, 1993, J BIOL CHEM, V268, P19923; Cai JS, 1998, P NATL ACAD SCI USA, V95, P11607, DOI 10.1073/pnas.95.20.11607; CULLMANN G, 1995, MOL CELL BIOL, V15, P4661; FRY DC, 1986, P NATL ACAD SCI USA, V83, P907, DOI 10.1073/pnas.83.4.907; Gerik KJ, 1997, J BIOL CHEM, V272, P1256, DOI 10.1074/jbc.272.2.1256; Gomes XV, 2001, J BIOL CHEM, V276, P34776, DOI 10.1074/jbc.M011743200; Gomes XV, 2001, J BIOL CHEM, V276, P34768, DOI 10.1074/jbc.M011631200; Gomes XV, 2000, J BIOL CHEM, V275, P14541, DOI 10.1074/jbc.275.19.14541; Green CM, 2000, CURR BIOL, V10, P39, DOI 10.1016/S0960-9822(99)00263-8; Guenther B, 1997, CELL, V91, P335, DOI 10.1016/S0092-8674(00)80417-1; Hishida T, 1999, J BIOL CHEM, V274, P25335, DOI 10.1074/jbc.274.36.25335; LI XY, 1994, P NATL ACAD SCI USA, V91, P868, DOI 10.1073/pnas.91.3.868; LI XY, 1994, J BIOL CHEM, V269, P21880; LI XY, 1995, J BIOL CHEM, V270, P22109, DOI 10.1074/jbc.270.38.22109; Mizushima T, 2000, GENE DEV, V14, P1631; Mizushima T, 1998, J BIOL CHEM, V273, P20847, DOI 10.1074/jbc.273.33.20847; Neuwald AF, 1999, GENOME RES, V9, P27; OBrien MC, 1996, J BIOL CHEM, V271, P15874, DOI 10.1074/jbc.271.27.15874; PARSONAGE D, 1988, J BIOL CHEM, V263, P4740; PODUST LM, 1994, NUCLEIC ACIDS RES, V22, P2970, DOI 10.1093/nar/22.15.2970; Podust VN, 1998, J BIOL CHEM, V273, P12935, DOI 10.1074/jbc.273.21.12935; Podust VN, 1998, J BIOL CHEM, V273, P31992, DOI 10.1074/jbc.273.48.31992; Schmidt SLG, 2001, J BIOL CHEM, V276, P34792, DOI 10.1074/jbc.M011671200; Smith CV, 1998, BIOCHEMISTRY-US, V37, P9658, DOI 10.1021/bi9801309; TAN CK, 1986, J BIOL CHEM, V261, P2310; Uhlmann F, 1997, J BIOL CHEM, V272, P10058; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; XIAO H, 1995, J BIOL CHEM, V270, P13378, DOI 10.1074/jbc.270.22.13378; Yang G, 1997, BIOCHEMISTRY-US, V36, P4751, DOI 10.1021/bi9631677; You ZY, 1999, MOL CELL BIOL, V19, P8003	31	50	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					34784	34791		10.1074/jbc.M011633200	http://dx.doi.org/10.1074/jbc.M011633200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11432854	hybrid			2022-12-25	WOS:000171024600060
J	Chatah, NEH; Abrams, CS				Chatah, NEH; Abrams, CS			G-protein-coupled receptor activation induces the membrane translocation and activation of phosphatidylinositol-4-phosphate 5-kinase I alpha by a Rac- and Rho-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; PLECKSTRIN HOMOLOGY DOMAINS; GTP-BINDING PROTEINS; 4-PHOSPHATE 5-KINASE; PHOSPHOLIPASE-D; ADENOVIRUS INFECTION; 4,5-BISPHOSPHATE SYNTHESIS; DOWNSTREAM EFFECTOR; SIGNAL-TRANSDUCTION; ACID PHOSPHOLIPIDS	Phosphatidylinositol 4,5-bisphosphate (PI4,5P(2)) mediates cell motility and changes in cell shape in response to extracellular stimuli. In platelets, it is synthesized from P14P by PIP5K in response to stimulation of a G-protein-coupled receptor by an agonist, such as the thrombin. In the present study, we have addressed the pathway that induces PIP5K I alpha activation following the addition of thrombin. Under resting condition expressed PIP5K I alpha was predominantly localized in a perinuclear distribution. After stimulation of the thrombin receptor, PAR1, or overexpression of a constitutively active variant of G alpha (q), PIP5K I alpha translocated to the plasma membrane. Movement of PIP5K I alpha to the cell membrane was dependent on both GTP-bound Rac and Rho, but not Arf, because: 1) inactive GDP-bound variants of either Rac or Rho blocked the translocation induced by constitutively active G alpha (q), 2) constitutively GTP-bound active variants of Rac or Rho induced PIP5K I alpha translocation in the absence of other stimuli, and 3) constitutively active variants of Arf1 or Arf6 failed to induce membrane translocation of PIP5K I alpha. In addition, a dominant negative variant of Rho blocked the PIP5K I alpha membrane translocation induced by constitutively active Rac, whereas dominant negative variants of either Rac or Arf6 failed to block PIP5K I alpha membrane translocation induced by constitutively active Rho. This implies that the effect on PIP5K I alpha by Rac is indirect, and requires the activation of Rho. In contrast to the findings with PIP5K I alpha, the related lipid kinase PIP4K failed to undergo translocation after stimulation by small GTP-binding proteins Rac or Rho. We also tested whether membrane localization of PIP5K I alpha correlated with an increase in its lipid kinase activity and found that co-expressing of PIP5K I alpha with either constitutively active G alpha (q), Rac, or Rho led to a 5- to 7-fold increase in PIP5K I alpha activity. Thus, these findings suggest that stimulation of a G-protein-coupled receptor (PAR1) leads to the sequential activation of G alpha (q), Rac, Rho, and PIP5K I alpha. Once activated and translocated to the cell membrane, PIP5K I alpha becomes available to phosphorylate PI4P to generate P14,5P(2) on the plasma membrane.	Univ Penn, Div Hematol Oncol, Dept Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Abrams, CS (corresponding author), Univ Penn, Div Hematol Oncol, Dept Med, 421 Curie Blvd,Basic Res Bldg 2-3,Rm 912, Philadelphia, PA 19104 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL040387, P50HL054500] Funding Source: NIH RePORTER; NHLBI NIH HHS [P50 HL54500, P01 HL40387] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAMS CS, 1995, J BIOL CHEM, V270, P14485, DOI 10.1074/jbc.270.24.14485; ANDERSON RA, 1985, NATURE, V318, P295, DOI 10.1038/318295a0; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; Azim AC, 2000, BLOOD, V95, P959, DOI 10.1182/blood.V95.3.959.003k22_959_964; Azuma T, 1998, EMBO J, V17, P1362, DOI 10.1093/emboj/17.5.1362; BELLETT AJD, 1989, J VIROL, V63, P303, DOI 10.1128/JVI.63.1.303-310.1989; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BOKOCH GM, 1994, J BIOL CHEM, V269, P31674; Boronenkov IV, 1998, MOL BIOL CELL, V9, P3547, DOI 10.1091/mbc.9.12.3547; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; Dustin ML, 2000, CELL, V103, P283, DOI 10.1016/S0092-8674(00)00120-3; FUKAMI K, 1994, J BIOL CHEM, V269, P1518; Godi A, 1999, NAT CELL BIOL, V1, P280, DOI 10.1038/12993; GRONDIN P, 1991, J BIOL CHEM, V266, P15705; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; Hammond SM, 1997, J BIOL CHEM, V272, P3860, DOI 10.1074/jbc.272.6.3860; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; HASHIMOTO S, 1993, EXP CELL RES, V205, P270, DOI 10.1006/excr.1993.1086; HAY JC, 1995, NATURE, V374, P173, DOI 10.1038/374173a0; Hinchliffe KA, 1996, EMBO J, V15, P6516, DOI 10.1002/j.1460-2075.1996.tb01042.x; Honda A, 1999, CELL, V99, P521, DOI 10.1016/S0092-8674(00)81540-8; HOXIE JA, 1993, J BIOL CHEM, V268, P13758; Itoh T, 1998, J BIOL CHEM, V273, P20292, DOI 10.1074/jbc.273.32.20292; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; JANMEY PA, 1994, ANNU REV PHYSIOL, V56, P169, DOI 10.1146/annurev.ph.56.030194.001125; JENKINS GH, 1994, J BIOL CHEM, V269, P11547; Jones DH, 2000, J BIOL CHEM, V275, P13962, DOI 10.1074/jbc.C901019199; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; LENK R, 1980, VIROLOGY, V105, P19, DOI 10.1016/0042-6822(80)90152-X; LISCOVITCH M, 1995, CELL, V81, P659, DOI 10.1016/0092-8674(95)90525-1; Loijens JC, 1996, J BIOL CHEM, V271, P32937, DOI 10.1074/jbc.271.51.32937; MICHELL RH, 1965, BIOCHEM BIOPH RES CO, V21, P333, DOI 10.1016/0006-291X(65)90198-1; MORITZ A, 1992, J BIOL CHEM, V267, P7207; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Penninger JM, 1999, CELL, V96, P9, DOI 10.1016/S0092-8674(00)80954-X; PERTILE P, 1995, J BIOL CHEM, V270, P5130, DOI 10.1074/jbc.270.10.5130; Rameh LE, 1997, NATURE, V390, P192, DOI 10.1038/36621; RANDAZZO PA, 1994, J BIOL CHEM, V269, P10758; Randazzo PA, 1997, J BIOL CHEM, V272, P7688; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Ren XD, 1996, MOL BIOL CELL, V7, P435, DOI 10.1091/mbc.7.3.435; Shibasaki Y, 1997, J BIOL CHEM, V272, P7578, DOI 10.1074/jbc.272.12.7578; SMITH CD, 1989, J BIOL CHEM, V264, P3206; STAUFENBIEL M, 1986, J VIROL, V60, P1186, DOI 10.1128/JVI.60.3.1186-1191.1986; TERUI T, 1994, J BIOL CHEM, V269, P28130; Toker A, 1998, CURR OPIN CELL BIOL, V10, P254, DOI 10.1016/S0955-0674(98)80148-8; Tolias KF, 2000, CURR BIOL, V10, P153, DOI 10.1016/S0960-9822(00)00315-8; Tolias KF, 1998, MOL CELL BIOL, V18, P762, DOI 10.1128/MCB.18.2.762; URUMOW T, 1986, FEBS LETT, V207, P253, DOI 10.1016/0014-5793(86)81499-5; Varnai P, 1998, J CELL BIOL, V143, P501, DOI 10.1083/jcb.143.2.501; Weernink PAO, 2000, J BIOL CHEM, V275, P10168, DOI 10.1074/jbc.275.14.10168; Westergren T, 1999, PLANT PHYSIOL, V121, P507, DOI 10.1104/pp.121.2.507; Wong K, 1997, J BIOL CHEM, V272, P13236, DOI 10.1074/jbc.272.20.13236; Yamamoto M, 2001, J CELL BIOL, V152, P867, DOI 10.1083/jcb.152.5.867; ZHANG J, 1993, J BIOL CHEM, V268, P22251; Zhang XL, 1997, J BIOL CHEM, V272, P17756, DOI 10.1074/jbc.272.28.17756	60	67	67	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					34059	34065		10.1074/jbc.M104917200	http://dx.doi.org/10.1074/jbc.M104917200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11431481	hybrid			2022-12-25	WOS:000170910200103
J	Khanna, R; Myers, MP; Laine, M; Papazian, DM				Khanna, R; Myers, MP; Laine, M; Papazian, DM			Glycosylation increases potassium channel stability and surface expression in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-QT SYNDROME; TRANSMEMBRANE CONDUCTANCE REGULATOR; SHAKER K+ CHANNEL; ENDOPLASMIC-RETICULUM; QUALITY-CONTROL; LINKED OLIGOSACCHARIDES; SECRETORY PATHWAY; CYSTEINE RESIDUES; XENOPUS-OOCYTES; MOLECULAR-BASIS	N-linked glycosylation is not required for the cell surface expression of functional Shaker potassium channels in Xenopus oocytes (Santacruz-Toloza, L., Huang, Y., John, S. A., and Papazian, D. M. (1994) Biochemistry 33, 5607-5613). We have now investigated whether glycosylation increases the stability, cell surface expression, and proper folding of Shaker protein expressed in mammalian cells. The turnover rates of wild-type protein and an unglycosylated mutant (N259Q,N263Q) were compared in pulse-chase experiments. The wild-type protein was stable, showing little degradation after 48 h. In contrast, the unglycosylated mutant was rapidly degraded (t(1/2) = similar to 18 h). Lactacystin slowed the degradation of the mutant protein, implicating cytoplasmic proteasomes in its turnover. Rapid lactacystin-sensitive degradation could be conferred on wild-type Shaker by a glycosylation inhibitor. Expression of the unglycosylated mutant on the cell surface, assessed using immunofluorescence microscopy and biotinylation, was dramatically reduced compared with wild type. Folding and assembly were analyzed by oxidizing intersubunit disulfide bonds, which provides a fortuitous hallmark of the native structure. Surprisingly, formation of disulfide-bonded adducts was quantitatively similar in the wildtype and unglycosylated mutant proteins. Our results indicate that glycosylation increases the stability and cell surface expression of Shaker protein but has little effect on acquisition of the native structure.	Univ Calif Los Angeles, Sch Med, Dept Physiol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Papazian, DM (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Physiol, Box 951751, Los Angeles, CA 90095 USA.			Khanna, Rajesh/0000-0002-9066-2969	NIGMS NIH HHS [GM43459] Funding Source: Medline; NINDS NIH HHS [NS07101-20] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Basiry SS, 1999, J NEUROSCI, V19, P644; Bennett E, 1997, J GEN PHYSIOL, V109, P327, DOI 10.1085/jgp.109.3.327; Breuer P, 1998, J BIOL CHEM, V273, P33254, DOI 10.1074/jbc.273.50.33254; Chung DH, 2000, J BIOL CHEM, V275, P4981, DOI 10.1074/jbc.275.7.4981; de Virgilio M, 1999, MOL BIOL CELL, V10, P4059, DOI 10.1091/mbc.10.12.4059; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Fagioli C, 2001, J BIOL CHEM, V276, P12885, DOI 10.1074/jbc.M009603200; Fenteany G, 1998, J BIOL CHEM, V273, P8545, DOI 10.1074/jbc.273.15.8545; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; Hille B., 1992, IONIC CHANNELS EXCIT; Jakob CA, 1998, J CELL BIOL, V142, P1223, DOI 10.1083/jcb.142.5.1223; Jiang YX, 2001, NEURON, V29, P593, DOI 10.1016/S0896-6273(01)00236-7; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Khanna R, 2001, AM J PHYSIOL-CELL PH, V280, pC796, DOI 10.1152/ajpcell.2001.280.4.C796; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; Kreusch A, 1998, NATURE, V392, P945, DOI 10.1038/31978; Liu Y, 1999, J BIOL CHEM, V274, P5861, DOI 10.1074/jbc.274.9.5861; Liu Y, 1997, J BIOL CHEM, V272, P7946, DOI 10.1074/jbc.272.12.7946; Nagaya N, 1997, J BIOL CHEM, V272, P3022, DOI 10.1074/jbc.272.5.3022; Nagaya N, 1999, RECEPTOR CHANNEL, V6, P229; Nerbonne JM, 2000, J PHYSIOL-LONDON, V525, P285, DOI 10.1111/j.1469-7793.2000.t01-1-00285.x; Papazian DM, 1999, NEURON, V23, P7, DOI 10.1016/S0896-6273(00)80746-1; Parodi AJ, 2000, ANNU REV BIOCHEM, V69, P69, DOI 10.1146/annurev.biochem.69.1.69; Petrecca K, 1999, J PHYSIOL-LONDON, V515, P41, DOI 10.1111/j.1469-7793.1999.041ad.x; RAPOSO G, 1995, J CELL BIOL, V131, P1403, DOI 10.1083/jcb.131.6.1403; SANTACRUZTOLOZA L, 1994, BIOCHEMISTRY-US, V33, P5607, DOI 10.1021/bi00184a033; Satler CA, 1998, HUM GENET, V102, P265, DOI 10.1007/s004390050690; Schulteis CT, 1996, BIOCHEMISTRY-US, V35, P12133, DOI 10.1021/bi961083s; SCHULTEIS CT, 1995, BIOCHEMISTRY-US, V34, P1725, DOI 10.1021/bi00005a029; Schulteis CT, 1998, J BIOL CHEM, V273, P26210, DOI 10.1074/jbc.273.40.26210; Schumacher MA, 2001, NATURE, V410, P1120, DOI 10.1038/35074145; SCHWARZ TL, 1988, NATURE, V331, P137, DOI 10.1038/331137a0; SCHWARZ TL, 1990, NEURON, V4, P119, DOI 10.1016/0896-6273(90)90448-O; Spiro RG, 2000, J BIOL CHEM, V275, P35657, DOI 10.1074/jbc.R000022200; Splawski I, 2000, CIRCULATION, V102, P1178, DOI 10.1161/01.CIR.102.10.1178; TIMPE LC, 1988, NATURE, V331, P143, DOI 10.1038/331143a0; Tokunaga F, 2000, J BIOL CHEM, V275, P40757, DOI 10.1074/jbc.M001073200; Wang J, 2000, BIOCHEMISTRY-US, V39, P8993, DOI 10.1021/bi000027v; WARD CL, 1994, J BIOL CHEM, V269, P25710; White AL, 1999, J LIPID RES, V40, P275; WIELAND FT, 1987, CELL, V50, P289, DOI 10.1016/0092-8674(87)90224-8; Xiong XM, 1997, J CLIN INVEST, V100, P1079, DOI 10.1172/JCI119618; Yang M, 1998, J EXP MED, V187, P835, DOI 10.1084/jem.187.6.835; Zhou ZF, 1998, J BIOL CHEM, V273, P21061, DOI 10.1074/jbc.273.33.21061	45	68	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					34028	34034		10.1074/jbc.M105248200	http://dx.doi.org/10.1074/jbc.M105248200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11427541	hybrid			2022-12-25	WOS:000170910200099
J	Magez, S; Radwanska, M; Stijlemans, B; Van Xong, H; Pays, E; De Baetselier, P				Magez, S; Radwanska, M; Stijlemans, B; Van Xong, H; Pays, E; De Baetselier, P			A conserved flagellar pocket exposed high mannose moiety is used by African trypanosomes as a host cytokine binding molecule	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; VARIANT SURFACE GLYCOPROTEINS; FACTOR-ALPHA; TRANSFERRIN-RECEPTOR; LINKED OLIGOSACCHARIDES; BLOOD-STREAM; BRUCEI; RESISTANCE; LECTIN; INTERLEUKIN-2	Trypanosomes use antigenic variation of their variant- specific surface glycoprotein (VSG) coat as defense against the host immune system. However, in order to sustain their growth, they need to expose conserved epitopes, allowing host macromolecule binding and receptor-mediated endocytosis. Here we show that Trypanosoma bruce! uses the conserved chitobiose-oligomannose G1(L)CNAc2-Man(5-9)) moieties of its VSG as a binding ligand for tumor necrosis factor TNF), a host cytokine with lectin-like properties. As endocytosis, in trypanosomes is restricted to the flagellar pocket, we show that soluble flagellar pocket extracts, and in particular soluble VSG, inhibit the binding of I-125-TNF to trypanosomes. The interaction between TNF and VSG is confirmed by affinity chromatography, biosensor, and dot-blot affinity measurements, and soluble VSG inhibition of TNF-mediated trypanolysis. In all approaches, removal of N-linked carbohydrates abrogates the TNF-VSG interaction. In addition, synthetic high mannose oligosaccharides can block TNF-VSG interactions, and a VSG glycopeptide carrying the G1(L)CNAc2-Man(5-9) moiety is shown to inhibit TNF-mediated trypanosome killing in mixed parasite macrophage cell cultures. Together, these results support the observation that TNF plays a role in growth control of trypanosomes and, moreover, suggest that, by the use of conserved VSG carbohydrates as lectin-binding epitopes, trypanosomes can limit the necessity to express large numbers of invariant surface exposed receptors.	Free Univ Brussels VIB, Dept Immunol Parasitol & Ultrastruct, B-1640 Rhode St Genese, Belgium; Free Univ Brussels, Inst Mol & Med Biol, Mol Parasitol Lab, B-6041 Gosselies, Belgium	Flanders Institute for Biotechnology (VIB); Vrije Universiteit Brussel	Magez, S (corresponding author), Free Univ Brussels VIB, Dept Immunol Parasitol & Ultrastruct, Paardenstr 65, B-1640 Rhode St Genese, Belgium.	stemagez@vub.ac.be	De Baetselier, Patrick/D-3866-2014; Magez, Stefan/AAC-5682-2021; Radwanska, Magdalena/Q-4279-2018; Magez, Stefan/D-9497-2014; Stijlemans, Benoit/AAD-9122-2021	Magez, Stefan/0000-0003-3760-7968; Radwanska, Magdalena/0000-0002-0797-6001; Magez, Stefan/0000-0003-3760-7968; Stijlemans, Benoit/0000-0003-0082-9751				Bitter W, 1998, NATURE, V391, P499, DOI 10.1038/35166; Borst P, 1998, ANNU REV MICROBIOL, V52, P745, DOI 10.1146/annurev.micro.52.1.745; BRICKMAN MJ, 1990, J PROTOZOOL, V37, P219, DOI 10.1111/j.1550-7408.1990.tb01131.x; CROSS GAM, 1990, ANNU REV IMMUNOL, V8, P83, DOI 10.1146/annurev.iy.08.040190.000503; Daulouede S, 2001, J INFECT DIS, V183, P988, DOI 10.1086/319257; Dwek RA, 1996, CHEM REV, V96, P683, DOI 10.1021/cr940283b; EDWARDS PR, 1995, J ANAL BIOCH, V321, P210; HAGER KM, 1994, J CELL BIOL, V126, P155, DOI 10.1083/jcb.126.1.155; HERSHKOVIZ R, 1995, IMMUNOLOGY, V85, P125; Hertz CJ, 1999, CELL IMMUNOL, V192, P24, DOI 10.1006/cimm.1998.1429; Hertz CJ, 1998, J IMMUNOL, V161, P6775; Kaushik RS, 2000, CYTOKINE, V12, P1024, DOI 10.1006/cyto.2000.0685; LANGRETH SG, 1975, J PROTOZOOL, V22, P40, DOI 10.1111/j.1550-7408.1975.tb00943.x; LANHAM SM, 1968, NATURE, V218, P1273, DOI 10.1038/2181273a0; LUCAS R, 1994, SCIENCE, V263, P814, DOI 10.1126/science.8303299; Magez S, 1997, J CELL BIOL, V137, P715, DOI 10.1083/jcb.137.3.715; Magez S, 1999, INFECT IMMUN, V67, P3128, DOI 10.1128/IAI.67.6.3128-3132.1999; Mehlert A, 1998, MOL BIOCHEM PARASIT, V91, P145, DOI 10.1016/S0166-6851(97)00187-4; MUCHMORE AV, 1987, J IMMUNOL, V138, P2541; Nolan DP, 1999, CURR BIOL, V9, P1169, DOI 10.1016/S0960-9822(00)80018-4; Overath P, 1997, TRENDS CELL BIOL, V7, P27, DOI 10.1016/S0962-8924(97)10046-0; PAYS E, 1994, ANNU REV MICROBIOL, V48, P25, DOI 10.1146/annurev.mi.48.100194.000325; RIDER C, 1993, IMMUNOL TODAY, V14, P615, DOI 10.1016/0167-5699(93)90202-V; SALMON D, 1994, CELL, V78, P75, DOI 10.1016/0092-8674(94)90574-6; Salmon D, 1997, EMBO J, V16, P7272, DOI 10.1093/emboj/16.24.7272; SEYFANG A, 1990, J PROTOZOOL, V37, P546, DOI 10.1111/j.1550-7408.1990.tb01263.x; SMITH MR, 1990, J IMMUNOL, V144, P162; STEVERDING D, 1995, J CELL BIOL, V131, P1173, DOI 10.1083/jcb.131.5.1173; TRESELER CB, 1992, INFECT IMMUN, V60, P183, DOI 10.1128/IAI.60.1.183-188.1992; WEBSTER P, 1993, PARASITOL TODAY, V9, P201, DOI 10.1016/0169-4758(93)90008-4; WOODS A, 1989, J CELL SCI, V93, P491; ZAMZE SE, 1990, EUR J BIOCHEM, V187, P657, DOI 10.1111/j.1432-1033.1990.tb15350.x; Zanetta JP, 1996, BIOCHEM J, V318, P49, DOI 10.1042/bj3180049	33	22	22	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33458	33464		10.1074/jbc.M103412200	http://dx.doi.org/10.1074/jbc.M103412200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11404356	hybrid			2022-12-25	WOS:000170910200024
J	Montalvetti, A; Bailey, BN; Michael, MB; Severin, GW; Oldfield, E; Docampo, R				Montalvetti, A; Bailey, BN; Michael, MB; Severin, GW; Oldfield, E; Docampo, R			Bisphosphonates are potent inhibitors of Trypanosoma cruzi farnesyl pyrophosphate synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; NITROGEN-CONTAINING BISPHOSPHONATES; DIPHOSPHATE SYNTHASE; IN-VITRO; APOPTOSIS; BIOSYNTHESIS; EXPRESSION; CLONING; GROWTH; SITE	We report the cloning and sequencing of a gene encoding the farnesyl pyrophosphate synthase of Trypanosoma cruzi. The protein (T. cruzi farnesyl pyrophosphate synthase, TcFPPS) is an attractive target for drug development, since the growth of T. cruzi is inhibited by carbocation transition state/reactive intermediate analogs of its substrates, the nitrogen-containing bisphosphonates currently in use in bone resorption therapy. The protein predicted from the nucleotide sequence of the gene has 362 amino acids and a molecular mass of 41.2 kDa. Several sequence motifs found in other FPPSs are present in TeFPPS. Heterologous expression of TcFPPS in Escherichia coli produced a functional enzyme that was inhibited by the nitrogen-containing bisphosphonates alendronate, pamidronate, homorisedronate, and risedronate but was less sensitive to the non-nitrogen-containing bisphosphonate etidronate, which, unlike the nitrogen-containing bisphosphonates, does not affect parasite growth-The protein contains a unique 11-mer insertion located near the active site, together with other sequence differences that may facilitate the development of novel anti-Chagasic agents.	Univ Illinois, Coll Vet Med, Dept Pathobiol, Mol Parasitol Lab, Urbana, IL 61802 USA; Univ Illinois, Dept Chem, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Docampo, R (corresponding author), Univ Illinois, Coll Vet Med, Dept Pathobiol, Mol Parasitol Lab, 2001 S Lincoln Ave, Urbana, IL 61802 USA.	rodoc@uiuc.edu	Severin, Gregory/C-2230-2015; Severin, Gregory/AAN-1369-2021	Severin, Gregory/0000-0003-1189-7311; Severin, Gregory/0000-0003-1189-7311	NIGMS NIH HHS [GM-50694] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMEISEN JC, 1995, CELL DEATH DIFFER, V2, P285; Amin D, 1996, ARZNEIMITTEL-FORSCH, V46, P759; ASHBY MN, 1989, J BIOL CHEM, V264, P635; ATTUCCI S, 1995, ARCH BIOCHEM BIOPHYS, V321, P493, DOI 10.1006/abbi.1995.1422; AUSUBEL FM, 1987, CURRENT PROTOCOLS MO, pCH6; Bergstrom JD, 2000, ARCH BIOCHEM BIOPHYS, V373, P231, DOI 10.1006/abbi.1999.1502; BONE GJ, 1956, NATURE, V178, P308, DOI 10.1038/178308a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bringaud F, 1998, P NATL ACAD SCI USA, V95, P7963, DOI 10.1073/pnas.95.14.7963; Brown DL, 1999, J CLIN PHARMACOL, V39, P651, DOI 10.1177/00912709922008272; COPPENS I, 1995, MOL BIOCHEM PARASIT, V69, P29, DOI 10.1016/0166-6851(94)00192-P; CORNILLON S, 1994, J CELL SCI, V107, P2691; Cromartie TH, 1999, PESTIC BIOCHEM PHYS, V63, P114, DOI 10.1006/pest.1999.2397; Danesi R, 1996, MOL PHARMACOL, V49, P972; DING VDH, 1991, BIOCHEM J, V275, P61, DOI 10.1042/bj2750061; DIXON M, 1972, BIOCHEM J, V129, P197, DOI 10.1042/bj1290197; Docampo R, 1997, PARASITOL TODAY, V13, P129, DOI 10.1016/S0169-4758(97)01021-1; Docampo R, 1999, PARASITOL TODAY, V15, P443, DOI 10.1016/S0169-4758(99)01531-8; Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235; Furuya T, 2000, J BIOL CHEM, V275, P6428, DOI 10.1074/jbc.275.9.6428; Gaffe J, 2000, PLANT PHYSIOL, V123, P1351, DOI 10.1104/pp.123.4.1351; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Grove JE, 2000, J BONE MINER RES, V15, P971, DOI 10.1359/jbmr.2000.15.5.971; Hill JE, 2000, BIOCHEM J, V351, P281, DOI 10.1042/0264-6021:3510281; HUGHES DE, 1995, J BONE MINER RES, V10, P1478; Keller RK, 1999, BIOCHEM BIOPH RES CO, V266, P560, DOI 10.1006/bbrc.1999.1849; Koyama T, 1996, BIOCHEMISTRY-US, V35, P9533, DOI 10.1021/bi960137v; Koyama T, 1999, BIOSCI BIOTECH BIOCH, V63, P1671, DOI 10.1271/bbb.63.1671; LERNER EC, 1995, J BIOL CHEM, V270, P26802, DOI 10.1074/jbc.270.45.26802; Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581; Martin MB, 1999, BIOCHEM BIOPH RES CO, V263, P754, DOI 10.1006/bbrc.1999.1404; Martin MB, 2001, J MED CHEM, V44, P909, DOI 10.1021/jm0002578; Moreira MEC, 1996, J CELL PHYSIOL, V167, P305, DOI 10.1002/(SICI)1097-4652(199605)167:2&lt;305::AID-JCP15&gt;3.0.CO;2-6; OGURA K, 1985, METHOD ENZYMOL, V110, P167; Overhand M, 1998, BIOORG CHEM, V26, P269, DOI 10.1006/bioo.1998.1101; PENDERGAST GC, 1994, MOL CELL BIOL, V14, P4193; PEREZSALA D, 1994, BIOCHEM BIOPH RES CO, V199, P1209, DOI 10.1006/bbrc.1994.1359; QUESNEYHUNEEUS V, 1979, P NATL ACAD SCI USA, V76, P5056, DOI 10.1073/pnas.76.10.5056; RILLING HC, 1985, METHOD ENZYMOL, V110, P145; Rodan GA, 1998, ANNU REV PHARMACOL, V38, P375, DOI 10.1146/annurev.pharmtox.38.1.375; Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508; Rogers MJ, 1997, CANCER, V80, P1652, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1652::AID-CNCR15>3.0.CO;2-Z; SINENSKY M, 1985, P NATL ACAD SCI USA, V82, P3257, DOI 10.1073/pnas.82.10.3257; SKEIKY YAW, 1992, J EXP MED, V176, P201, DOI 10.1084/jem.176.1.201; SOMMER JM, 1994, ANNU REV MICROBIOL, V48, P105, DOI 10.1146/annurev.mi.48.100194.000541; SONG LS, 1994, P NATL ACAD SCI USA, V91, P3044, DOI 10.1073/pnas.91.8.3044; Supattapone S, 2000, J VIROL, V74, P11928, DOI 10.1128/JVI.74.24.11928-11934.2000; TARSHIS LC, 1994, BIOCHEMISTRY-US, V33, P10871, DOI 10.1021/bi00202a004; Tarshis LC, 1996, P NATL ACAD SCI USA, V93, P15018, DOI 10.1073/pnas.93.26.15018; Urbina JA, 1999, J BIOL CHEM, V274, P33609, DOI 10.1074/jbc.274.47.33609; van Beek E, 1999, BIOCHEM BIOPH RES CO, V264, P108, DOI 10.1006/bbrc.1999.1499; Welburn SC, 1997, PARASITOL TODAY, V13, P22, DOI 10.1016/S0169-4758(96)10076-4; Welburn SC, 1996, CELL DEATH DIFFER, V3, P229; Wu JW, 1999, ACTA BIOCHIM POL, V46, P591, DOI 10.18388/abp.1999_4131; Yokoyama K, 1998, MOL BIOCHEM PARASIT, V94, P87, DOI 10.1016/S0166-6851(98)00053-X; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	56	138	145	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33930	33937		10.1074/jbc.M103950200	http://dx.doi.org/10.1074/jbc.M103950200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11435429	hybrid			2022-12-25	WOS:000170910200087
J	Taggart, CC; Lowe, GJ; Greene, CM; Mulgrew, AT; O'Neill, SJ; Levine, RL; McElvaney, NG				Taggart, CC; Lowe, GJ; Greene, CM; Mulgrew, AT; O'Neill, SJ; Levine, RL; McElvaney, NG			Cathepsin B, L, and S cleave and inactivate secretory leucoprotease inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOCYTE PROTEASE INHIBITOR; RESPIRATORY EPITHELIAL SURFACE; STABLE PROTEINASE-INHIBITOR; ALPHA-1-PROTEINASE INHIBITOR; LEUKOPROTEASE INHIBITOR; PSEUDOMONAS-AERUGINOSA; CYSTEINE PROTEASES; HUMAN-NEUTROPHIL; ELASTASE; METALLOPROTEINASES	A number of serine proteases, matrix metalloproteases, and cysteine proteases were evaluated for their ability to cleave and inactivate the antiprotease, secretory leueoprotease inhibitor (SLPI). None of the serine proteases or the matrix metalloproteases examined cleaved the SLPI protein. However, incubation with cathepsins B, L, and S resulted in the cleavage and inactivation of SLPI. All three cathepsins initially cleaved SLPI between residues Thr(67) and Tyr(68). The proteolytic cleavage of SLPI by all three cathepsins resulted in the loss of the active site of SLPI and the inactivation of SLPI anti-neutrophil elastase capacity. Cleavage and inactivation were catalytic with respect to the cathepsins, so that the majority of a 400-fold excess of SLPI was inactivated within 15 min by cathepsins L and S. Analysis of epithelial lining fluid samples from individuals with emphysema indicated the presence of cleaved SLPI in these samples whereas only intact SLPI was observed in control epithelial lining fluid samples. Active cathepsin L was shown to be present in emphysema epithelial lining fluid and inhibition of this protease prevented the cleavage of recombinant SLPI added to emphysema epithelial lining fluid. Taken together with previous data that demonstrates that cathepsin L inactivates alpha (1)-antitrypsin, these findings indicate the involvement of cathepsins in the diminution of the lung antiprotease screen possibly leading to lung destruction in emphysema.	Beaumont Hosp, Royal Coll Surg Ireland, Educ & Res Ctr, Dept Med,Pulm Res Div, Dublin 9, Ireland; NHLBI, Biochem Lab, NIH, Bethesda, MD 20892 USA	Royal College of Surgeons - Ireland; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	McElvaney, NG (corresponding author), Beaumont Hosp, Royal Coll Surg Ireland, Educ & Res Ctr, Dept Med,Pulm Res Div, Dublin 9, Ireland.		Taggart, Clifford C/G-4492-2014; Levine, Rodney L/D-9885-2011; Greene, Catherine M/D-3513-2012; McElvaney, Noel/A-6809-2010	Greene, Catherine M/0000-0003-2549-2569; Taggart, Clifford/0000-0002-9930-2978; mcelvaney, Noel/0000-0002-0152-4370	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL000225, Z01HL000225] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABE T, 1991, J CLIN INVEST, V87, P2207, DOI 10.1172/JCI115255; Chapman HA, 1997, ANNU REV PHYSIOL, V59, P63, DOI 10.1146/annurev.physiol.59.1.63; CHAPMAN HA, 1984, J CLIN INVEST, V74, P1693, DOI 10.1172/JCI111586; DESROCHERS PE, 1988, J CLIN INVEST, V81, P1646, DOI 10.1172/JCI113500; DESROCHERS PE, 1991, J CLIN INVEST, V87, P2258, DOI 10.1172/JCI115262; Draper D, 1998, J INFECT DIS, V178, P815, DOI 10.1086/515366; GAUTHIER F, 1982, BIOCHIM BIOPHYS ACTA, V700, P178, DOI 10.1016/0167-4838(82)90095-4; GRUTTER MG, 1988, EMBO J, V7, P345, DOI 10.1002/j.1460-2075.1988.tb02819.x; Hiemstra PS, 1998, EUR RESPIR J, V12, P1200, DOI 10.1183/09031936.98.12051200; Jin FY, 1997, CELL, V88, P417, DOI 10.1016/S0092-8674(00)81880-2; JOHNSON DA, 1986, J BIOL CHEM, V261, P4748; KIRSCHKE H, 1994, METHOD ENZYMOL, V244, P500; KLECH H, 1989, EUR RESPIR J, V2, P561; KRAMPS JA, 1981, J HISTOCHEM CYTOCHEM, V29, P712, DOI 10.1177/29.6.6788837; KRAMPS JA, 1984, AM REV RESPIR DIS, V129, P959; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lentsch AB, 1999, AM J PATHOL, V154, P239, DOI 10.1016/S0002-9440(10)65270-4; MASON RW, 1986, BIOCHEM J, V233, P925, DOI 10.1042/bj2330925; MCELVANEY NG, 1992, J CLIN INVEST, V90, P1296, DOI 10.1172/JCI115994; MCELVANEY NG, 1997, LUNG, P2119; MCNEELY TB, 1995, J CLIN INVEST, V96, P456, DOI 10.1172/JCI118056; MORIHARA K, 1979, INFECT IMMUN, V24, P188, DOI 10.1128/IAI.24.1.188-193.1979; REILLY JJ, 1991, AM J PHYSIOL, V261, pL41, DOI 10.1152/ajplung.1991.261.2.L41; RUDOLPHUS A, 1991, CLIN SCI, V81, P777, DOI 10.1042/cs0810777; Sallenave JM, 1997, J LEUKOCYTE BIOL, V61, P695, DOI 10.1002/jlb.61.6.695; SEEMULLER U, 1986, FEBS LETT, V199, P43, DOI 10.1016/0014-5793(86)81220-0; Senior RM, 1998, FISHMANS PULMONARY D, P659; SHAPIRO SD, 1994, AM J RESP CRIT CARE, V150, pS160, DOI 10.1164/ajrccm/150.6_Pt_2.S160; SHI GP, 1992, J BIOL CHEM, V267, P7258; SNIDER GL, 1985, AM REV RESPIR DIS, V132, P182; SPONER M, 1991, BIOL CHEM H-S, V372, P963, DOI 10.1515/bchm3.1991.372.2.963; Taggart C, 2000, J BIOL CHEM, V275, P27258; TAKEHASHI H, 1993, AM REV RESPIR DIS, V147, P1562; Takeyabu K, 1998, EUR RESPIR J, V12, P1033, DOI 10.1183/09031936.98.12051033; VISSERS MCM, 1988, J CLIN INVEST, V82, P706, DOI 10.1172/JCI113651; VOGELMEIER C, 1991, J CLIN INVEST, V87, P482, DOI 10.1172/JCI115021; Zhang YH, 1997, J CLIN INVEST, V99, P894, DOI 10.1172/JCI119254; ZHANG Z, 1994, BBA-GEN SUBJECTS, V1199, P224, DOI 10.1016/0304-4165(94)90119-8	38	143	146	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33345	33352		10.1074/jbc.M103220200	http://dx.doi.org/10.1074/jbc.M103220200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11435427	hybrid, Green Submitted			2022-12-25	WOS:000170910200010
J	Baba, T; Mimura, J; Gradin, K; Kuroiwa, A; Watanabe, T; Matsuda, Y; Inazawa, J; Sogawa, K; Fujii-Kuriyama, Y				Baba, T; Mimura, J; Gradin, K; Kuroiwa, A; Watanabe, T; Matsuda, Y; Inazawa, J; Sogawa, K; Fujii-Kuriyama, Y			Structure and expression of the Ah receptor repressor gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ARYL-HYDROCARBON RECEPTOR; HEAT-SHOCK PROTEIN; COOPERATIVE INTERACTION; DIOXIN RECEPTOR; 2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN TCDD; TRANSCRIPTION FACTORS; INDUCIBLE EXPRESSION; SIGNAL-TRANSDUCTION; INTERFERON-GAMMA	The aryl hydrocarbon receptor (AhR) repressor (AhRR) gene has been isolated and characterized from a mouse genomic library. The gene is distributed as 11 exons in a total length of about 60 kilobase pairs. Fluorescence in situ hybridization analysis has shown that the AhRR gene is located at mouse chromosome 13C2, at rat chromosome 1p11.2, and at human chromosome 5p15.3. The AhRR gene has a TATA-less promoter and several transcription start sites. In addition, putative regulatory DNA sequences such as xenobiotic responsive element (XRE), GC box, and NF-kappaB-binding sites have been identified in the 5'-upstream region of the AhRR gene. Transient transfection analyses of HeLa cells with reporter genes that contain deletions and point mutations in the AhRR promoter revealed that all three XREs mediated the inducible expression of the AhRR gene by 3-methylcholanthrene treatment, and furthermore, GC box sequences were indispensable for a high level of inducible expression and for constitutive expression. Moreover, by using gel mobility shift assays we were able to show that the AhR/Arnt heterodimer binds to the XREs with very low affinity, which is due to three varied nucleotides outside the XRE core sequence. We have also shown that Sp1 and Sp3 can bind to the GC boxes. Finally, both transient transfection analysis and gel mobility shift assay revealed that the AhRR gene is up-regulated by a p65/p50 heterodimer that binds to the NF-kappaB site when the cells has been exposed to 12-O-tetradecanoylphorbol-13-acetate, and this inducible expression was further enhanced by cotreatment of 12-O-tetradecanoylphorbol-13-acetate and 3-methylcholanthrene.	Tohoku Univ, Grad Sch Life Sci, Dept Biomol Sci, Aoba Ku, Sendai, Miyagi 9808578, Japan; Japan Sci & Technol, Core Res Evolut Sci & Technol, Tokyo 1500002, Japan; Hokkaido Univ, Lab Cytogenet, Div Biosci, Grad Sch Environm Earth Sci, Sapporo, Hokkaido 0600810, Japan; Hokkaido Univ, Chromosome Res Unit, Fac Sci, Sapporo, Hokkaido 0600810, Japan; Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Cytogenet, Tokyo 1138519, Japan	Tohoku University; Japan Science & Technology Agency (JST); Hokkaido University; Hokkaido University; Tokyo Medical & Dental University (TMDU)	Fujii-Kuriyama, Y (corresponding author), Tohoku Univ, Grad Sch Life Sci, Dept Biomol Sci, Aoba Ku, Sendai, Miyagi 9808578, Japan.	ykfujii@mail.cc.tohoku.ac.jp	Mimura, Junsei/E-7893-2013	Kuroiwa, Asato/0000-0002-3942-3372				BARKER CW, 1992, J BIOL CHEM, V267, P8050; Calleja C, 1997, BIOCHEM BIOPH RES CO, V239, P273, DOI 10.1006/bbrc.1997.7468; DENHARDT DT, 1966, BIOCHEM BIOPH RES CO, V23, P641, DOI 10.1016/0006-291X(66)90447-5; DENIS M, 1988, BIOCHEM BIOPH RES CO, V155, P801, DOI 10.1016/S0006-291X(88)80566-7; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Fitzgerald CT, 1998, DNA CELL BIOL, V17, P811, DOI 10.1089/dna.1998.17.811; Gradin K, 1999, J BIOL CHEM, V274, P13511, DOI 10.1074/jbc.274.19.13511; GROSS-BELLARD MM, 1973, EUR J BIOCHEM, V36, P32, DOI 10.1111/j.1432-1033.1973.tb02881.x; Heid SE, 2000, MOL PHARMACOL, V57, P82; INAZAWA J, 1991, GENOMICS, V10, P1075, DOI 10.1016/0888-7543(91)90202-P; Kazlauskas A, 1999, J BIOL CHEM, V274, P13519, DOI 10.1074/jbc.274.19.13519; Kobayashi A, 1996, J BIOL CHEM, V271, P12310, DOI 10.1074/jbc.271.21.12310; KRISHNAN V, 1995, MOL CELL BIOL, V15, P6710; Lyon M. F., 1996, Mammalian Genome, V94, P29; Maehara K, 1999, FEBS LETT, V449, P115, DOI 10.1016/S0014-5793(99)00408-1; MATSUDA Y, 1995, ELECTROPHORESIS, V16, P261, DOI 10.1002/elps.1150160142; MATSUDA Y, 1992, CYTOGENET CELL GENET, V61, P282, DOI 10.1159/000133423; MCGUIRE J, 1994, MOL CELL BIOL, V14, P2438, DOI 10.1128/MCB.14.4.2438; Meyer BK, 1998, MOL CELL BIOL, V18, P978, DOI 10.1128/MCB.18.2.978; Meyer BK, 1999, BIOCHEMISTRY-US, V38, P8907, DOI 10.1021/bi982223w; Mimura J, 1999, GENE DEV, V13, P20, DOI 10.1101/gad.13.1.20; Mimura J, 1997, GENES CELLS, V2, P645, DOI 10.1046/j.1365-2443.1997.1490345.x; Nair SC, 1996, CELL STRESS CHAPERON, V1, P237, DOI 10.1379/1466-1268(1996)001<0237:APOMCI>2.3.CO;2; PERDEW GH, 1988, J BIOL CHEM, V263, P13802; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; SATOH H, 1989, CYTOGENET CELL GENET, V50, P151, DOI 10.1159/000132747; Scheidereit C, 1998, NATURE, V395, P225, DOI 10.1038/26121; Serikawa T, 1998, EXP ANIM TOKYO, V47, P1, DOI 10.1538/expanim.47.1; Shimizu Y, 2000, P NATL ACAD SCI USA, V97, P779, DOI 10.1073/pnas.97.2.779; SWANSON HI, 1995, J BIOL CHEM, V270, P26292, DOI 10.1074/jbc.270.44.26292; Tian Y, 1999, J BIOL CHEM, V274, P510, DOI 10.1074/jbc.274.1.510; Weiss C, 1996, EXP CELL RES, V226, P154, DOI 10.1006/excr.1996.0214; Xia CL, 1997, INT J BIOCHEM CELL B, V29, P1525, DOI 10.1016/S1357-2725(97)00083-6; Yang XY, 1999, J BIOL CHEM, V274, P27981, DOI 10.1074/jbc.274.39.27981	36	124	126	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					33101	33110		10.1074/jbc.M011497200	http://dx.doi.org/10.1074/jbc.M011497200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11423533	hybrid			2022-12-25	WOS:000170746000096
J	Jang, GF; Van Hooser, JP; Kuksa, V; McBee, JK; He, YG; Janssen, JJM; Driessen, CAGG; Palczewski, K				Jang, GF; Van Hooser, JP; Kuksa, V; McBee, JK; He, YG; Janssen, JJM; Driessen, CAGG; Palczewski, K			Characterization of a dehydrogenase activity responsible for oxidation of 11-cis-retinol in the retinal pigment epithelium of mice with a disrupted RDH5 gene - A model for the human hereditary disease fundus albipunctatus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHORT-CHAIN DEHYDROGENASES; BINDING PROTEIN GENE; ALL-TRANS-RETINOL; VISUAL CYCLE; TARGETED DISRUPTION; 9-CIS-RETINOIC ACID; BIOCHEMICAL ASPECTS; MEMBRANE TOPOLOGY; JAPANESE PATIENTS; PHASE PARTITION	In the vertebrate retina, the final step of visual chromophore production is the oxidation of 11-cis-retinol to 11-cis-retinal. This reaction is catalyzed by 11-cis-retinol dehydrogenases (11-cis-RDHs), prior to the chromophore rejoining with the visual pigment apo-proteins. The RDH5 gene encodes a dehydrogenase that is responsible for the majority of RDH activity. In humans, mutations in this gene are associated with fundus albipunctatus, a disease expressed by delayed dark adaptation of both cones and rods. In this report, an animal model for this disease, 11-cis-rdh-/- mice, was used to investigate the flow of retinoids after a bleach, and microsomal membranes from the retinal pigment epithelium of these mice were employed to characterize remaining enzymatic activities oxidizing 11-cis-retinol. Lack of 11-cis-RDH leads to an accumulation of cis-retinoids, particularly 13-cis-isomers. The analysis of 11-cis-rdh-/- mice showed that the RDH(s) responsible for the production of 11-cis-retinal displays NADP-dependent specificity toward 9-cis- and 11-cis-retinal but not 13-cis-retinal. The lack of 13-cis-RDH activity could be a reason why 13-cis-isomers accumulate in the retinal pigment epithelium of 11-cis-rdh-/- mice. Furthermore, our results provide detailed characterization of a mouse model for the human disease fundus albipunctatus and emphasize the importance of 11-cis-RDH in keeping the balance between different components of the retinoid cycle.	Univ Washington, Dept Ophthalmol, Seattle, WA 98195 USA; Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA; Univ Washington, Dept Chem, Seattle, WA 98195 USA; Univ Nijmegen, Dept Ophthalmol, NL-6525 EX Nijmegen, Netherlands	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Radboud University Nijmegen	Driessen, CAGG (corresponding author), Univ Washington, Dept Ophthalmol, Box 356485, Seattle, WA 98195 USA.	C.Driessen@ohk.azn.nl; palezews@u.washington.edu			NEI NIH HHS [F32 EY007031, EY08061, EY07031, R01 EY008061, T32 EY007031] Funding Source: Medline; NATIONAL EYE INSTITUTE [R29EY008061, R01EY008061] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Ahn J, 2000, J BIOL CHEM, V275, P20399, DOI 10.1074/jbc.M000555200; BERNSTEIN PS, 1986, BIOCHEMISTRY-US, V25, P6473, DOI 10.1021/bi00369a020; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burstedt MSI, 1999, INVEST OPHTH VIS SCI, V40, P995; Chen P, 2001, J BIOL CHEM, V276, P21098, DOI 10.1074/jbc.M010441200; Cideciyan AV, 2000, VISUAL NEUROSCI, V17, P667, DOI 10.1017/S0952523800175029; DEIGNER PS, 1989, SCIENCE, V244, P968, DOI 10.1126/science.2727688; DRIESSEN CA, 2001, IN PRESS OPHTHALMOLO; Driessen CAGG, 2000, MOL CELL BIOL, V20, P4275, DOI 10.1128/MCB.20.12.4275-4287.2000; Driessen CAGG, 1998, FEBS LETT, V428, P135, DOI 10.1016/S0014-5793(98)00473-6; DRIESSEN CAGG, 1995, INVEST OPHTH VIS SCI, V36, P1988; Dryja TP, 2000, AM J OPHTHALMOL, V130, P547, DOI 10.1016/S0002-9394(00)00737-6; Ghyselinck NB, 1999, EMBO J, V18, P4903, DOI 10.1093/emboj/18.18.4903; Gonzalez-Fernandez F, 1999, MOL VIS, V5, pU1; Gottesman ME, 2001, BIOESSAYS, V23, P409, DOI 10.1002/bies.1059; Hao WS, 2000, METHOD ENZYMOL, V316, P413; Hirose E, 2000, INVEST OPHTH VIS SCI, V41, P3933; Jang GF, 2000, J BIOL CHEM, V275, P28128; JORNVALL H, 1995, BIOCHEMISTRY-US, V34, P6003, DOI 10.1021/bi00018a001; KROOK M, 1992, EUR J BIOCHEM, V209, P233, DOI 10.1111/j.1432-1033.1992.tb17281.x; Kuroiwa S, 2000, AM J OPHTHALMOL, V130, P672, DOI 10.1016/S0002-9394(00)00765-0; Liou GI, 1998, J NEUROSCI, V18, P4511; MARGOLIS S, 1987, OPHTHALMOLOGY, V94, P1416; Mata NL, 1998, BBA-LIPID LIPID MET, V1394, P16, DOI 10.1016/S0005-2760(98)00078-2; Maw MA, 1997, NAT GENET, V17, P198, DOI 10.1038/ng1097-198; McBee JK, 2000, BIOCHEMISTRY-US, V39, P11370, DOI 10.1021/bi001061c; McBee JK, 2001, PROG RETIN EYE RES, V20, P469, DOI 10.1016/S1350-9462(01)00002-7; MERCER EI, 1997, CONCISE ENCY BIOCH M; Mertz JR, 1997, J BIOL CHEM, V272, P11744, DOI 10.1074/jbc.272.18.11744; Morimura H, 1999, INVEST OPHTH VIS SCI, V40, P1000; Nakamura M, 2000, INVEST OPHTH VIS SCI, V41, P3925; Okada T, 2001, TRENDS BIOCHEM SCI, V26, P318, DOI 10.1016/S0968-0004(01)01799-6; Paik J, 2000, BIOCHEMISTRY-US, V39, P8073, DOI 10.1021/bi992152g; PALCZEWSKI K, 1994, BIOCHEMISTRY-US, V33, P13741, DOI 10.1021/bi00250a027; Palczewski K, 1999, BIOCHEMISTRY-US, V38, P12012, DOI 10.1021/bi990504d; Rando RR, 1996, CHEM BIOL, V3, P255, DOI 10.1016/S1074-5521(96)90105-2; Rattner A, 2000, J BIOL CHEM, V275, P11034, DOI 10.1074/jbc.275.15.11034; Redmond TM, 1998, NAT GENET, V20, P344, DOI 10.1038/3813; Ripps H, 2000, VISUAL NEUROSCI, V17, P97, DOI 10.1017/S095252380017110X; Saari JC, 2001, NEURON, V29, P739, DOI 10.1016/S0896-6273(01)00248-3; Saari JC, 2000, METHOD ENZYMOL, V316, P359; Saari JC, 1998, VISION RES, V38, P1325, DOI 10.1016/S0042-6989(97)00198-3; SAARI JC, 1988, EXP EYE RES, V46, P569, DOI 10.1016/S0014-4835(88)80013-7; SAARI JC, 1993, ANAL BIOCHEM, V213, P128, DOI 10.1006/abio.1993.1395; Simon A, 2000, METHOD ENZYMOL, V316, P344; SIMON A, 1995, J BIOL CHEM, V270, P1107, DOI 10.1074/jbc.270.34.19979; Simon A, 1999, J CELL SCI, V112, P549; Stecher H, 1999, BIOCHEMISTRY-US, V38, P13542, DOI 10.1021/bi9913294; Stecher H, 2000, METHOD ENZYMOL, V316, P330; Stecher H, 1999, J BIOL CHEM, V274, P8577, DOI 10.1074/jbc.274.13.8577; Su J, 1999, ENDOCRINOLOGY, V140, P5275, DOI 10.1210/endo.140.11.7137; Sun H, 1999, J BIOL CHEM, V274, P8269, DOI 10.1074/jbc.274.12.8269; Tao L, 1998, Mol Vis, V4, P25; TREHAN A, 1990, BIOCHEMISTRY-US, V29, P309, DOI 10.1021/bi00454a001; Van Hooser JP, 2000, P NATL ACAD SCI USA, V97, P8623, DOI 10.1073/pnas.150236297; Wada Y, 2000, INVEST OPHTH VIS SCI, V41, P1894; Wang J, 1999, BIOCHEM J, V338, P23, DOI 10.1042/0264-6021:3380023; Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9; Winston A, 1998, BIOCHEMISTRY-US, V37, P2044, DOI 10.1021/bi971908d; Yamamoto H, 1999, NAT GENET, V22, P188, DOI 10.1038/9707; ZIMMERMAN WF, 1975, EXP EYE RES, V21, P325, DOI 10.1016/0014-4835(75)90043-3; ZIMMERMAN WF, 1976, J BIOL CHEM, V251, P4700; ZIMMERMAN WF, 1976, EXP EYE RES, V23, P159, DOI 10.1016/0014-4835(76)90199-8	64	53	59	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					32456	32465		10.1074/jbc.M104949200	http://dx.doi.org/10.1074/jbc.M104949200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11418621	Green Published, hybrid, Green Accepted			2022-12-25	WOS:000170746000013
J	Negishi, Y; Ui, N; Nakajima, M; Kawashima, K; Maruyama, K; Takizawa, T; Endo, H				Negishi, Y; Ui, N; Nakajima, M; Kawashima, K; Maruyama, K; Takizawa, T; Endo, H			p21(Cip-1/SDI-1/WAF-1) gene is involved in chondrogenic differentiation of ATDC5 cells in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEASOME PATHWAY; DEPENDENT KINASE INHIBITOR; CDK INHIBITOR; GROWTH-FACTOR; TRANSCRIPTIONAL ACTIVATION; DNA-SYNTHESIS; EXPRESSION; LINE; P21; P21(WAF1/CIP1)	Development of skeletal cartilage is characterized with coupling growth arrest and cell differentiation. Here, to understand the cyclin-dependent kinase inhibitors involved in the progression of chondrogenic differentiation, we examined changes in the expression levels of cyclin-dependent kinase inhibitor members using mouse ATDC5 prechondrocytes as a widely used in vitro model of cartilage differentiation. Up-regulation of p21 and p27 mRNA was observed following a decrease in growth rate of prechondrocytes, and both transcripts subsequently accumulated during chondrogenic differentiation; p15, p18, and p19 mRNA, in contrast, did not change during differentiation. Only the up-regulation of p21 mRNA during differentiation was prevented by the continuous treatment of early chondrogenic inhibitor, parathyroid hormone, indicating a close correlation between differentiation and p21 induction in ATDC5 cells. Therefore, to examine the role of p21 during chondrogenesis, we established stable cell lines overexpressing full-length p21 antisense RNA in ATDC5. The reduction of endogenous p21 in these cell lines caused inhibition of early chondrogenic differentiation in ATDC5, indicating that p21 gene plays an important role in this process of the cells in vitro. Furthermore, the level of p21 protein and p21-CDK2 complexes transiently increased during differentiation, but not in undifferentiated cells, leading to a decrease in CDK2-associated kinase. However, differentiation-dependent expressed p21 protein was degraded by a proteasome-dependent pathway. Thus, the progression of chondrogenic differentiation requires down-regulation of CDK2-associated kinase with an increase in p21 protein and subsequent degradation of this protein by a proteasomal pathway.	Teikyo Univ, Fac Pharmaceut Sci, Dept Physiol Chem, Sagamiko, Kanagawa 1990195, Japan; Teikyo Univ, Fac Pharmaceut Sci, Dept Pharmaceut, Sagamiko, Kanagawa 1990195, Japan	Teikyo University; Teikyo University	Negishi, Y (corresponding author), Teikyo Univ, Fac Pharmaceut Sci, Dept Physiol Chem, Sagamiko, Kanagawa 1990195, Japan.	yo-negi@pharm.teikyo-u.ac.jp						ABE N, 1994, BBA-PROTEIN STRUCT M, V1204, P61, DOI 10.1016/0167-4838(94)90033-7; Asahina I, 1996, EXP CELL RES, V222, P38, DOI 10.1006/excr.1996.0005; ATSUMI T, 1990, CELL DIFFER DEV, V30, P109, DOI 10.1016/0922-3371(90)90079-C; BARRETT AJ, 1982, BIOCHEM J, V201, P189, DOI 10.1042/bj2010189; Blagosklonny MV, 1996, BIOCHEM BIOPH RES CO, V227, P564, DOI 10.1006/bbrc.1996.1546; Chellappan SP, 1998, CURR TOP MICROBIOL, V227, P57; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Di Cunto F, 1998, SCIENCE, V280, P1069, DOI 10.1126/science.280.5366.1069; Erhardt JA, 1998, J BIOL CHEM, V273, P23517, DOI 10.1074/jbc.273.36.23517; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Franklin DS, 1996, MOL BIOL CELL, V7, P1587, DOI 10.1091/mbc.7.10.1587; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; HARPER JW, 1993, CELL, V75, P805; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; HIRAKI Y, 1987, MOL CELL BIOCHEM, V76, P185; HIRAKI Y, 1988, BIOCHIM BIOPHYS ACTA, V969, P91, DOI 10.1016/0167-4889(88)90092-4; HOWLETT CR, 1979, J ANAT, V128, P377; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; Kihara-Negishi F, 1998, INT J CANCER, V76, P523, DOI 10.1002/(SICI)1097-0215(19980518)76:4<523::AID-IJC14>3.0.CO;2-8; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; Matsumura I, 1997, MOL CELL BIOL, V17, P2933, DOI 10.1128/MCB.17.5.2933; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; Morrison RF, 1999, J BIOL CHEM, V274, P17088, DOI 10.1074/jbc.274.24.17088; Negishi Y, 2000, BIOCHEM BIOPH RES CO, V268, P450, DOI 10.1006/bbrc.2000.2076; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Ohnuma S, 1999, CELL, V99, P499, DOI 10.1016/S0092-8674(00)81538-X; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; QUELLE DE, 1995, CELL, V83, P993; QUELLE DE, 1995, ONCOGENE, V11, P635; SCHNEIDER WC, 1957, METHOD ENZYMOL, V3, P680, DOI 10.1016/S0076-6879(57)03442-4; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Shukunami C, 1998, EXP CELL RES, V241, P1, DOI 10.1006/excr.1998.4045; Shukunami C, 1996, J CELL BIOL, V133, P457, DOI 10.1083/jcb.133.2.457; STOCUM DL, 1979, J EMBRYOL EXP MORPH, V54, P155; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; Zabludoff SD, 1998, CELL GROWTH DIFFER, V9, P1	47	42	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					33249	33256		10.1074/jbc.M010127200	http://dx.doi.org/10.1074/jbc.M010127200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11406616	hybrid			2022-12-25	WOS:000170746000111
J	Zeng, HY; Sanyal, S; Mukhopadhyay, D				Zeng, HY; Sanyal, S; Mukhopadhyay, D			Tyrosine residues 951 and 1059 of vascular endothelial growth factor receptor-2 (KDR) are essential for vascular permeability factor/vascular endothelial growth factor-induced endothelium migration and proliferation, respectively	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; PHOSPHORYLATION SITES; EXTRACELLULAR-MATRIX; TUMOR-CELLS; FACTOR VEGF; IN-VIVO; ANGIOGENESIS; DOMAIN; KINASE; IDENTIFICATION	Vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) exerts its multiple functions by activating two receptor tyrosine kinases, Flt-1 (VEGFR-1) and KDR (VFGFR-2), both of which are selectively expressed on primary vascular endothelium. To dissect the respective signaling pathways and biological functions mediated by these receptors in primary endothelial cells with two receptors intact, we, recently developed chimeric receptors (EGDR and EGLT) in which the extracellular domain of the epidermal growth factor receptor was fused to the transmembrane domain and intracellular domain of KDR and Flt-1, respectively. With these fusion receptors, we have shown that KDR is solely responsible for VPF/VEGF-induced human umbilical vein endothelial cell (HUVEC) proliferation and migration, whereas Flt-1 showed an inhibitory effect on KDR-mediated proliferation but not migration. To further characterize the VPF/VEGF-stimulated HUVEC proliferation and migration here, we have created several EGDR mutants by site-directed mutagenesis. We show that tyrosine residues 1059 and 951 of KDR are essential for VPF/VEGF-induced HUVEC proliferation and migration, respectively. Furthermore, the mutation of tyrosine 1059 to phenylanaline results in the complete loss of KDR/EGDR-mediated intracellular Ca2+ mobilization and MAPK phosphorylation, but the mutation of tyrosine 951 to phenylanaline did not affect these events. Our results suggest that KDR mediates different signaling pathways for HUVEC proliferation and migration and, moreover, intracellular Ca2+ mobilization and MAPK phosphorylation are not essential for VPF/VEGF-induced HUVEC migration.	Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA; Harvard Univ, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University	Mukhopadhyay, D (corresponding author), Beth Israel Deaconess Med Ctr, Dept Pathol, 330 Brookline Ave, Boston, MA 02215 USA.				NCI NIH HHS [CA78383] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078383, R29CA078383] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENEZRA M, 1993, BLOOD, V81, P3324; Bernatchez PN, 1999, J BIOL CHEM, V274, P31047, DOI 10.1074/jbc.274.43.31047; BROCK TA, 1991, AM J PATHOL, V138, P213; Dayanir V, 2001, J BIOL CHEM, V276, P17686, DOI 10.1074/jbc.M009128200; Dougher M, 1999, ONCOGENE, V18, P1619, DOI 10.1038/sj.onc.1202478; DOUGHERVERMAZEN M, 1994, BIOCHEM BIOPH RES CO, V205, P728, DOI 10.1006/bbrc.1994.2726; Dvorak H.F., 1984, DEV ONCOL, V22, P96; DVORAK HF, 1990, PROG CLIN BIOL RES, V354, P317; Dvorak HF, 1999, CURR TOP MICROBIOL, V237, P97; DVORAK HF, 1979, J IMMUNOL, V122, P166; Ferrara N, 1999, CURR TOP MICROBIOL, V237, P1; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Folkman J, 1996, SCI AM, V275, P150, DOI 10.1038/scientificamerican0996-150; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Gagnon ML, 2000, P NATL ACAD SCI USA, V97, P2573, DOI 10.1073/pnas.040337597; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Gille H, 2001, J BIOL CHEM, V276, P3222, DOI 10.1074/jbc.M002016200; Ito N, 1998, J BIOL CHEM, V273, P23410, DOI 10.1074/jbc.273.36.23410; Joukov V, 1997, EMBO J, V16, P3898, DOI 10.1093/emboj/16.13.3898; Kanno S, 2000, ONCOGENE, V19, P2138, DOI 10.1038/sj.onc.1203533; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; Petrova TV, 1999, EXP CELL RES, V253, P117, DOI 10.1006/excr.1999.4707; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; SEETHARAM L, 1995, ONCOGENE, V10, P135; Seghezzi G, 1998, J CELL BIOL, V141, P1659, DOI 10.1083/jcb.141.7.1659; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; SENGER DR, 1986, CANCER RES, V46, P5629; Shalaby F, 1997, CELL, V89, P981, DOI 10.1016/S0092-8674(00)80283-4; Shibuya M, 1999, CURR TOP MICROBIOL, V237, P59; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; VLODAVSKY I, 1991, J CELL BIOCHEM, V45, P167, DOI 10.1002/jcb.240450208; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Zeng HY, 2001, J BIOL CHEM, V276, P26969, DOI 10.1074/jbc.M103213200	36	124	138	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					32714	32719		10.1074/jbc.M103130200	http://dx.doi.org/10.1074/jbc.M103130200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11435426	hybrid			2022-12-25	WOS:000170746000046
J	Rau, A; Hogg, T; Marquardt, R; Hilgenfeld, R				Rau, A; Hogg, T; Marquardt, R; Hilgenfeld, R			A new lysozyme fold - Crystal structure of the muramidase from Streptomyces coelicolor at 1.65 angstrom resolution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-DIMENSIONAL STRUCTURE; GENOME SEQUENCE; N,O-DIACETYLMURAMIDASE; PURIFICATION; MOLSCRIPT; BARREL; FORMS; GENE	Cellosyl is a bacterial muramidase from Streptomyces coelicolor. Similar to other lysozymes, the enzyme cleaves the beta -1,4-glycosidic bond between N-acetylmuramic acid and N-acetylglucosamine units, but it also exhibits a beta -1,4-N,6-O-diacetylmuramidase activity. The latter enables Cellosyl to degrade the cell walls of Staphylococcus aureus, which are not hydrolyzed by chicken-, goose-, or bacteriophage T4-type lysozymes. The enzymatic activity and amino acid sequence of Cellosyl group it with lysozymes of the Chalaropsis type, for which no detailed structural information has been available so far. The crystal structure of Cellosyl from S. coelicolor has been determined to a resolution of 1.65 Angstrom and refined to an R-factor of 15.2%. The enzyme is comprised of a single domain and possesses an unusual beta/alpha -barrel fold. The last strand, beta8, of the (beta/alpha)(5)beta (3)-barrel is found to be antiparallel to strands beta7 and beta1. Asp-9, Asp-98, and Glu-100 are located at the active site. The structure of Cellosyl exhibits a new lysozyme fold and represents a new class of polysaccharide-hydrolyzing beta/alpha -barrels.	Inst Mol Biotechnol, Dept Struct Biol & Crystallog, D-07745 Jena, Germany; Dechema EV, Dept Biotechnol, D-60486 Frankfurt, Germany		Hilgenfeld, R (corresponding author), Inst Mol Biotechnol, Dept Struct Biol & Crystallog, Beutenbergstr 11, D-07745 Jena, Germany.	hilgenfd@imb-jena.de	Hilgenfeld, Rolf/C-9675-2011					Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BRAU B, 1991, APPL MICROBIOL BIOT, V34, P481; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHANG JJ, 1979, J BIOL CHEM, V254, P7772; CROUX C, 1991, GENE, V104, P25, DOI 10.1016/0378-1119(91)90460-S; Cutfield SM, 1999, J MOL BIOL, V294, P771, DOI 10.1006/jmbi.1999.3287; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Dominguez R, 1996, J MOL BIOL, V257, P1042, DOI 10.1006/jmbi.1996.0222; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; FABER GK, 1990, TRENDS BIOCHEM SCI, V15, P228; Fastrez J, 1996, EXS, V75, P35; FELCH JW, 1975, J BIOL CHEM, V250, P3713; FOUCHE PB, 1978, J BIOL CHEM, V253, P6787; HARADA S, 1981, J BIOL CHEM, V256, P1600; HARADA S, 1989, J MOL BIOL, V207, P851, DOI 10.1016/0022-2836(89)90254-4; HASH JH, 1967, J BIOL CHEM, V242, P5586; HILGENFELD R, 1992, J CRYST GROWTH, V122, P330, DOI 10.1016/0022-0248(92)90265-K; Holm L, 1996, SCIENCE, V273, P595, DOI 10.1126/science.273.5275.595; Holtje J V, 1996, EXS, V75, P65; HUGHEY VL, 1987, APPL ENVIRON MICROB, V53, P2165, DOI 10.1128/AEM.53.9.2165-2170.1987; JOLLES P, 1984, MOL CELL BIOCHEM, V63, P165; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEBIODA L, 1989, J BIOL CHEM, V264, P3685; LYNE JE, 1990, J BIOL CHEM, V265, P6928; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MORITA T, 1978, J BIOCHEM, V83, P893, DOI 10.1093/oxfordjournals.jbchem.a131987; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; REARDON D, 1995, FASEB J, V9, P497, DOI 10.1096/fasebj.9.7.7737457; Riboldi-Tunnicliffe A, 1999, J APPL CRYSTALLOGR, V32, P1003, DOI 10.1107/S0021889899008584; SANZ JM, 1992, BIOCHEMISTRY-US, V31, P8495, DOI 10.1021/bi00151a016; Shiba T, 2000, ACTA CRYSTALLOGR D, V56, P1462, DOI 10.1107/S0907444900010374; Simpson AJG, 2000, NATURE, V406, P151, DOI 10.1038/35018003; WEAVER LH, 1985, J MOL EVOL, V21, P97, DOI 10.1007/BF02100084; Weiss MS, 1997, J APPL CRYSTALLOGR, V30, P203, DOI 10.1107/S0021889897003907	39	53	57	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					31994	31999		10.1074/jbc.M102591200	http://dx.doi.org/10.1074/jbc.M102591200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11427528	hybrid			2022-12-25	WOS:000170613500072
J	Small, D; Kovalenko, D; Kacer, D; Liaw, L; Landriscina, M; Di Serio, C; Prudovsky, I; Maciag, T				Small, D; Kovalenko, D; Kacer, D; Liaw, L; Landriscina, M; Di Serio, C; Prudovsky, I; Maciag, T			Soluble jagged 1 represses the function of its transmembrane form to induce the formation of the Src-dependent chord-like phenotype	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VEIN ENDOTHELIAL-CELLS; GROWTH-FACTOR-I; V-SRC; TYROSINE PHOSPHORYLATION; NUCLEAR TRANSLOCATION; INTRACELLULAR DOMAIN; INDUCED ANGIOGENESIS; PROGENITOR CELLS; MAMMALIAN NOTCH; EPH RECEPTORS	We have previously demonstrated that the expression of the soluble extracellular domain of the transmembrane ligand for Notch receptors, Jagged 1 (sJ1), in NIH 3T3 cells results in the formation of a matrix-dependent chord-like phenotype, the loss of contact inhibition of growth, and an inhibition of pro-al(I) collagen expression. In an effort to define the mechanism by which sJ1 induces this phenotype, we report that sJ1 transfectants display biochemical and cytoskeletal alterations consistent with the activation of Src. Indeed, cotransfection of sJ1 transfectants with a dominant-negative mutant of Src resulted in the loss of matrix-dependent chord formation and correlated with the restoration of type I collagen expression and contact inhibition of growth. We also report that the sJ1-mediated induction of Src activity and related phenotypes, including chord formation, may result from. the inhibition of endogenous Jagged 1-mediated Notch signaling since it was not possible to detect an sJ1-dependent induction of CSL-dependent transcription in these cells. Interestingly, NIH 3T3 cells transfected with dominant-negative (but not constitutively active) mutants of either Notch I or Notch 2 displayed a similar Src-related phenotype as the sJ1 transfectants. These data suggest that the ability, of sJ1 to mediate chord formation is Src-dependent and requires the repression of endogenous Jagged 1-mediated Notch signaling, which is tolerant to the destabilization of the actin cytoskeleton, a mediator of cell migration.	Maine Med Ctr, Inst Res, Ctr Mol Med, Scarborough, ME 04074 USA; Univ Maine, Ctr Biophys Sci, Orono, ME 04469 USA	Maine Medical Center; University of Maine System; University of Maine Orono	Maciag, T (corresponding author), Maine Med Ctr, Inst Res, Ctr Mol Med, 81 Res Dr, Scarborough, ME 04074 USA.	maciat@mmc.org	Prudovsky, Igor/GVU-1521-2022; Landriscina, Matteo/K-1092-2016	Landriscina, Matteo/0000-0003-0591-9799	NATIONAL CENTER FOR RESEARCH RESOURCES [P40RR001555] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL003567] Funding Source: NIH RePORTER; NCRR NIH HHS [RR1555] Funding Source: Medline; NHLBI NIH HHS [HL3567] Funding Source: Medline; NINR NIH HHS [NRSA-CA92255] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR))		Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; BYERS HR, 1991, AM J PATHOL, V139, P423; Carreira CM, 1998, J BIOL CHEM, V273, P22224, DOI 10.1074/jbc.273.35.22224; CHITNIS A, 1995, NATURE, V375, P761, DOI 10.1038/375761a0; DELAMO FF, 1993, GENOMICS, V15, P259, DOI 10.1006/geno.1993.1055; delaPompa J, 1997, DEVELOPMENT, V124, P1139; Dodelet VC, 2000, ONCOGENE, V19, P5614, DOI 10.1038/sj.onc.1203856; Eliceiri BP, 1999, MOL CELL, V4, P915, DOI 10.1016/S1097-2765(00)80221-X; Fitzgerald K, 2000, ONCOGENE, V19, P4191, DOI 10.1038/sj.onc.1203766; FRANKFORT BJ, 1995, BIOCHEM BIOPH RES CO, V206, P916, DOI 10.1006/bbrc.1995.1130; Franklin JL, 1999, CURR BIOL, V9, P1448, DOI 10.1016/S0960-9822(00)80114-1; Garfinkel S, 1996, J CELL BIOL, V134, P783, DOI 10.1083/jcb.134.3.783; Gray GE, 1999, AM J PATHOL, V154, P785, DOI 10.1016/S0002-9440(10)65325-4; Han W, 2000, BLOOD, V95, P1616, DOI 10.1182/blood.V95.5.1616.005k31_1616_1625; Hock B, 1998, P NATL ACAD SCI USA, V95, P9779, DOI 10.1073/pnas.95.17.9779; Hsieh JJD, 1996, MOL CELL BIOL, V16, P952; Huang CK, 1997, J BIOL CHEM, V272, P17, DOI 10.1074/jbc.272.1.17; Hubbard EJA, 1996, SCIENCE, V273, P112, DOI 10.1126/science.273.5271.112; Hukriede NA, 1997, DEVELOPMENT, V124, P3427; Ikeya T, 1999, DEVELOPMENT, V126, P4455; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Landriscina M, 2000, J BIOL CHEM, V275, P32753, DOI 10.1074/jbc.M002336200; Lardelli M, 1996, MECH DEVELOP, V59, P177, DOI 10.1016/0925-4773(96)00589-8; LARDELLI M, 1993, EXP CELL RES, V204, P364, DOI 10.1006/excr.1993.1044; LaVallee TM, 1998, J CELL BIOL, V141, P1647, DOI 10.1083/jcb.141.7.1647; Li LH, 1997, NAT GENET, V16, P243, DOI 10.1038/ng0797-243; Li LH, 1998, GENOMICS, V51, P45, DOI 10.1006/geno.1998.5330; LINDNER V, 2001, IN PRESS AM J PATHOL; LINDSELL CE, 1995, CELL, V80, P909, DOI 10.1016/0092-8674(95)90294-5; MACIAG T, 1982, J CELL BIOL, V94, P511, DOI 10.1083/jcb.94.3.511; Matsuno K, 1998, NAT GENET, V19, P74, DOI 10.1038/ng0598-74; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; Meijne AML, 1997, EXP CELL RES, V234, P477, DOI 10.1006/excr.1997.3637; Miele L, 1999, J CELL PHYSIOL, V181, P393, DOI 10.1002/(SICI)1097-4652(199912)181:3<393::AID-JCP3>3.0.CO;2-6; Morrissette JJD, 2001, HUM MOL GENET, V10, P405, DOI 10.1093/hmg/10.4.405; NANUS DM, 1991, ONCOGENE, V6, P2105; Nofziger D, 1999, DEVELOPMENT, V126, P1689; Oda T, 1997, NAT GENET, V16, P235, DOI 10.1038/ng0797-235; Qi HL, 1999, SCIENCE, V283, P91, DOI 10.1126/science.283.5398.91; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Shawber C, 1996, DEVELOPMENT, V122, P3765; Shimizu K, 2000, MOL CELL BIOL, V20, P6913, DOI 10.1128/MCB.20.18.6913-6922.2000; Shimizu K, 2000, BIOCHEM BIOPH RES CO, V276, P385, DOI 10.1006/bbrc.2000.3469; Shutter JR, 2000, GENE DEV, V14, P1313; Soriano JV, 2000, INT J CANCER, V86, P652; Stein E, 1998, GENE DEV, V12, P667, DOI 10.1101/gad.12.5.667; Sun X, 1997, DEVELOPMENT, V124, P3439; Uyttendaele H, 2000, MICROVASC RES, V60, P91, DOI 10.1006/mvre.2000.2254; Uyttendaele H, 1996, DEVELOPMENT, V122, P2251; Varnum-Finney B, 2000, J CELL SCI, V113, P4313; Vincenti MP, 1998, MOL CARCINOGEN, V21, P194, DOI 10.1002/(SICI)1098-2744(199803)21:3<194::AID-MC7>3.0.CO;2-M; Weinmaster G, 1998, CURR OPIN GENET DEV, V8, P436, DOI 10.1016/S0959-437X(98)80115-9; Wong MKK, 2000, BIOCHEM BIOPH RES CO, V268, P853, DOI 10.1006/bbrc.2000.2173; Xue YZ, 1999, HUM MOL GENET, V8, P723, DOI 10.1093/hmg/8.5.723; ZHAN X, 1993, J BIOL CHEM, V268, P24427; ZHAN X, 1993, J BIOL CHEM, V268, P9611; Zhu XT, 1999, STRUCTURE, V7, P651, DOI 10.1016/S0969-2126(99)80086-0; Zimrin AB, 1996, J BIOL CHEM, V271, P32499, DOI 10.1074/jbc.271.51.32499	60	101	104	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					32022	32030		10.1074/jbc.M100933200	http://dx.doi.org/10.1074/jbc.M100933200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11427524	hybrid			2022-12-25	WOS:000170613500076
J	Zhao, Y; Zhang, ZY				Zhao, Y; Zhang, ZY			The mechanism of dephosphorylation of extracellular signal-regulated kinase 2 by mitogen-activated protein kinase phosphatase 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DUAL-SPECIFICITY PHOSPHATASE; OF-FUNCTION MUTATION; P42 MAP KINASE; TYROSINE-PHOSPHATASE; TRANSITION-STATE; CATALYTIC ACTIVATION; CRYSTAL-STRUCTURE; IN-VIVO; ERK2; PHOSPHORYLATION	The mitogen-activated protein (MAP) kinase phosphatase-3 (MKP3) is a dual specificity phosphatase that specifically inactivates one subfamily of MAP kinases, the extracellular signal-regulated kinases (ERKs). Inactivation of MAP kinases occurs by dephosphorylation of Thr(P) and Tyr(P) in the TXY kinase activation motif. To gain insight into the mechanism of ERK2 inactivation by MKP3, we have carried out an analysis of the MKP3-catalyzed dephosphorylation of the phosphorylated ERK2. We find that ERK2/pTpY dephosphorylation by MKP3 involves an ordered, distributive mechanism in which MKP3 binds the bisphosphorylated ERK2/pTpY, dephosphorylates Tyr(P) first, dissociates and releases the monophosphorylated ERK2/pT, which is then subjected to dephosphorylation by a second MKP3, yielding the fully dephosphorylated ERK2. The bisphosphorylated ERK2 is a highly specific substrate for MKP3 with a k(cat)/K-m of 3.8 x 10(6) m(-1) s(-1), which is more than 6 orders of magnitude higher than that for small molecule aryl phosphates and an ERK2-derived phosphopeptide encompassing the pTEpY motif. This strikingly high substrate specificity displayed by MKP3 may result from a combination of high affinity binding interactions between the N-terminal domain of MKP3 and ERK2 and specific ERK2-induced allosteric activation of the MKP3 C-terminal phosphatase domain.	Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Zhang, ZY (corresponding author), Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	zyzhang@aecom.yu.edu			NCI NIH HHS [CA69202] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA069202] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHN NG, 1991, J BIOL CHEM, V266, P4220; ALESSI DR, 1995, CURR BIOL, V5, P283, DOI 10.1016/S0960-9822(95)00059-5; BOTT CM, 1994, FEBS LETT, V352, P201, DOI 10.1016/0014-5793(94)00958-9; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; Burack WR, 1997, BIOCHEMISTRY-US, V36, P5929, DOI 10.1021/bi970535d; Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; CHO HJ, 1992, J AM CHEM SOC, V114, P7296, DOI 10.1021/ja00044a052; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; Denu JM, 1996, P NATL ACAD SCI USA, V93, P2493, DOI 10.1073/pnas.93.6.2493; DUCLOS B, 1991, METHOD ENZYMOL, V201, P10; Dunn D, 1996, J BIOL CHEM, V271, P168, DOI 10.1074/jbc.271.1.168; Ferrell JE, 1997, J BIOL CHEM, V272, P19008, DOI 10.1074/jbc.272.30.19008; Ferrell JE, 1998, SCIENCE, V280, P895, DOI 10.1126/science.280.5365.895; Fjeld CC, 2000, J BIOL CHEM, V275, P6749, DOI 10.1074/jbc.275.10.6749; Fox T, 1999, FEBS LETT, V461, P323, DOI 10.1016/S0014-5793(99)01488-X; Groom LA, 1996, EMBO J, V15, P3621, DOI 10.1002/j.1460-2075.1996.tb00731.x; GUAN KL, 1991, J BIOL CHEM, V266, P17026; HAYSTEAD TAJ, 1992, FEBS LETT, V306, P17, DOI 10.1016/0014-5793(92)80828-5; HENGGE AC, 1995, BIOCHEMISTRY-US, V34, P13982, DOI 10.1021/bi00043a003; Hoff RH, 1999, J AM CHEM SOC, V121, P9514, DOI 10.1021/ja992361o; Hoff RH, 2000, BIOCHEMISTRY-US, V39, P46, DOI 10.1021/bi991570i; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; Keng YF, 1999, EUR J BIOCHEM, V259, P809, DOI 10.1046/j.1432-1327.1999.00090.x; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; KIRBY AJ, 1967, J AM CHEM SOC, V89, P415, DOI 10.1021/ja00978a044; KYTE J, 1995, STRUCTURE PROTEIN CH, P59; LUO KX, 1991, METHOD ENZYMOL, V201, P149; Mansour SJ, 1996, BIOCHEMISTRY-US, V35, P15529, DOI 10.1021/bi961854s; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Mourey RJ, 1996, J BIOL CHEM, V271, P3795; Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205; Muda M, 1996, J BIOL CHEM, V271, P4319; Muda M, 1998, J BIOL CHEM, V273, P9323, DOI 10.1074/jbc.273.15.9323; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; Pulido R, 1998, EMBO J, V17, P7337, DOI 10.1093/emboj/17.24.7337; Robinson MJ, 1996, BIOCHEMISTRY-US, V35, P5641, DOI 10.1021/bi952723e; Saxena M, 1999, J BIOL CHEM, V274, P11693, DOI 10.1074/jbc.274.17.11693; Stewart AE, 1999, NAT STRUCT BIOL, V6, P174; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Sun H, 1998, METH MOL B, V84, P307; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Todd JL, 1999, J BIOL CHEM, V274, P13271, DOI 10.1074/jbc.274.19.13271; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Wiland AM, 1996, J BIOL CHEM, V271, P33486, DOI 10.1074/jbc.271.52.33486; Wilsbacher JL, 1999, J BIOL CHEM, V274, P16988, DOI 10.1074/jbc.274.24.16988; Wu L, 1996, BIOCHEMISTRY-US, V35, P5426, DOI 10.1021/bi952885a; Yao Z, 2000, FEBS LETT, V468, P37, DOI 10.1016/S0014-5793(00)01191-1; Yuvaniyama J, 1996, SCIENCE, V272, P1328, DOI 10.1126/science.272.5266.1328; Zhang YL, 1999, BIOCHEMISTRY-US, V38, P12111, DOI 10.1021/bi990836i; ZHANG ZY, 1994, P NATL ACAD SCI USA, V91, P1624, DOI 10.1073/pnas.91.5.1624; Zhang ZY, 1998, CRIT REV BIOCHEM MOL, V33, P1, DOI 10.1080/10409239891204161; ZHANG ZY, 1994, BIOCHEMISTRY-US, V33, P15266, DOI 10.1021/bi00255a007; ZHENG CF, 1993, J BIOL CHEM, V268, P16116; Zhou B, 2001, J BIOL CHEM, V276, P6506, DOI 10.1074/jbc.M009753200; Zhou B, 1999, J BIOL CHEM, V274, P35526, DOI 10.1074/jbc.274.50.35526; ZHOU GC, 1994, J BIOL CHEM, V269, P28084	60	153	157	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					32382	32391		10.1074/jbc.M103369200	http://dx.doi.org/10.1074/jbc.M103369200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11432864	hybrid			2022-12-25	WOS:000170613500121
J	Jager, AC; Rasmussen, M; Bisgaard, HC; Singh, KK; Nielsen, FC; Rasmussen, LJ				Jager, AC; Rasmussen, M; Bisgaard, HC; Singh, KK; Nielsen, FC; Rasmussen, LJ			HNPCC mutations in the human DNA mismatch repair gene hMLH1 influence assembly of hMutL alpha and hMLH1-hEXO1 complexes	ONCOGENE			English	Article						hEXO1; hMLH1; hPMS2; DNA mismatch repair; HNPCC	NONPOLYPOSIS COLORECTAL-CANCER; SACCHAROMYCES-CEREVISIAE EXO1; MEIOTIC CROSSING-OVER; HUMAN MUTL HOMOLOGS; MITOTIC RECOMBINATION; MLH1 MUTATIONS; EXONUCLEASE-I; TUMOR-CELLS; IDENTIFICATION; HETERODIMER	Hereditary nonpolyposis colorectal cancer (HNPCC) is common inherited form of neoplasia caused by germline mutations in DNA mismatch repair (MMR) genes, MMR proteins have been reported to associate with several proteins, including the human exonuclease 1 (hEXO1). We report here novel HNPCC-hMLH1 mutant proteins (T117M, Q426X and 1813insA) in Danish HNPCC patients, We demonstrate that these mutant HNPCC-hMLH1 proteins are unable to form complexes with hEXO1 and hPMS2 in vivo. The results indicate that mutations found in HNPCC gene carriers disrupt hMLH1 - hEXO1 complex formation and hMutL alpha heterodimer assembly essential for MMR activity.	Roskilde Univ, Dept Chem & Life Sci, DK-4000 Roskilde, Denmark; Rigshosp, Dept Clin Biochem, DK-2100 Copenhagen, Denmark; Johns Hopkins Univ, Sch Med, Johns Hopkins Oncol Ctr, Baltimore, MD 21231 USA	Roskilde University; Rigshospitalet; University of Copenhagen; Johns Hopkins University; Johns Hopkins Medicine	Rasmussen, LJ (corresponding author), Roskilde Univ, Dept Chem & Life Sci, DK-4000 Roskilde, Denmark.		Nielsen, Finn Cilius/AAA-4926-2020	Nielsen, Finn Cilius/0000-0002-9829-1031; Rasmussen, Lene Juel/0000-0001-6864-963X	PHS HHS [R01 09714-02] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Baker SM, 1996, NAT GENET, V13, P336, DOI 10.1038/ng0796-336; BAKER SM, 1995, CELL, V82, P309, DOI 10.1016/0092-8674(95)90318-6; Ban C, 1999, CELL, V97, P85, DOI 10.1016/S0092-8674(00)80717-5; Drummond JT, 1997, P NATL ACAD SCI USA, V94, P10144, DOI 10.1073/pnas.94.19.10144; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; Edelmann W, 1996, CELL, V85, P1125, DOI 10.1016/S0092-8674(00)81312-4; Fiorentini P, 1997, MOL CELL BIOL, V17, P2764, DOI 10.1128/MCB.17.5.2764; Guerrette S, 1999, J BIOL CHEM, V274, P6336, DOI 10.1074/jbc.274.10.6336; Guerrette S, 1998, MOL CELL BIOL, V18, P6616, DOI 10.1128/MCB.18.11.6616; Jager AC, 1997, AM J HUM GENET, V61, P129, DOI 10.1086/513896; Jiricny J, 1998, MUTAT RES-DNA REPAIR, V409, P107, DOI 10.1016/S0921-8777(98)00056-1; Jiricny J, 1998, EMBO J, V17, P6427, DOI 10.1093/emboj/17.22.6427; LI GM, 1995, P NATL ACAD SCI USA, V92, P1950, DOI 10.1073/pnas.92.6.1950; Lipkin SM, 2000, NAT GENET, V24, P27, DOI 10.1038/71643; Nicholson A, 2000, GENETICS, V154, P133; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266; Peltomaki P, 1997, GASTROENTEROLOGY, V113, P1146, DOI 10.1053/gast.1997.v113.pm9322509; Raschle M, 1999, J BIOL CHEM, V274, P32368, DOI 10.1074/jbc.274.45.32368; Rasmussen LJ, 2000, MUTAT RES-DNA REPAIR, V460, P41, DOI 10.1016/S0921-8777(00)00012-4; Risinger JI, 1998, CANCER RES, V58, P2978; Saparbaev M, 1996, GENETICS, V142, P727; Schmutte C, 1998, CANCER RES, V58, P4537; Shcherbakova PV, 1999, MOL CELL BIOL, V19, P3177; Shimodaira H, 1998, NAT GENET, V19, P384, DOI 10.1038/1277; Sugawara N, 1997, P NATL ACAD SCI USA, V94, P9214, DOI 10.1073/pnas.94.17.9214; Tishkoff DX, 1998, CANCER RES, V58, P5027; Tishkoff DX, 1997, P NATL ACAD SCI USA, V94, P7487, DOI 10.1073/pnas.94.14.7487; Tsubouchi H, 2000, MOL BIOL CELL, V11, P2221, DOI 10.1091/mbc.11.7.2221; Wilson DM, 1998, NUCLEIC ACIDS RES, V26, P3762, DOI 10.1093/nar/26.16.3762	30	59	63	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 14	2001	20	27					3590	3595		10.1038/sj.onc.1204467	http://dx.doi.org/10.1038/sj.onc.1204467			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	445VB	11429708				2022-12-25	WOS:000169478300017
J	Bu, W; Su, LK				Bu, W; Su, LK			Regulation of microtubule assembly by human EB1 family proteins	ONCOGENE			English	Article						EB1; EBF3; microtubule-associated protein; microtubule; microtubule bundle	TUMOR-SUPPRESSOR PROTEIN; BINDING PROTEIN; CYTOPLASMIC DYNEIN; ALPHA-TUBULIN; DISTAL ENDS; CELL-CYCLE; APC; DYNAMICS; CANCER; YEAST	The EB1 family proteins are highly conserved microtubule-associated proteins, The EB1 protein in yeast has been shown to play an important role in regulating microtubule dynamics and chromosome segregation. Human EB1 family proteins include EB1, RP1 and EBF3. Although EB1 and RP1 have been shown to associate with microtubules, the subcellular localization of endogenous EBF3 had not been characterized. The function of human EB1 family proteins was also not clear. We therefore investigated the cellular localization of EBF3 and the regulation of microtubule organization by EB1 family proteins. As do EB1 and RP1, EBF3 was found to colocalize with microtubules, preferentially at their plus ends, throughout the cell cycle. Moreover, there was a very strong EBF3 signal at the centrosome in interphase cells and at the spindle poles in mitotic cells. When EB1 family proteins were overexpressed, they associated with the entire microtubule cytoskeleton, In addition, EB1 and EBF3 induced microtubule bundling in some cells overexpressing these proteins. These microtubule bundles were more resistant to nocodazole and were more acetylated than regular microtubules. Our results demonstrate for the first time that human EB1 family proteins could regulate microtubule assembly and stability.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Su, LK (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [R29CA070371, P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA 70371, CA 16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adames NR, 2000, J CELL BIOL, V149, P863, DOI 10.1083/jcb.149.4.863; Askham JM, 2000, ONCOGENE, V19, P1950, DOI 10.1038/sj.onc.1203498; Beinhauer JD, 1997, J CELL BIOL, V139, P717, DOI 10.1083/jcb.139.3.717; Berrueta L, 1999, CURR BIOL, V9, P425, DOI 10.1016/S0960-9822(99)80190-0; Berrueta L, 1998, P NATL ACAD SCI USA, V95, P10596, DOI 10.1073/pnas.95.18.10596; Cassimeris L, 1999, CURR OPIN CELL BIOL, V11, P134, DOI 10.1016/S0955-0674(99)80017-9; Desai A, 1997, ANNU REV CELL DEV BI, V13, P83, DOI 10.1146/annurev.cellbio.13.1.83; Desai A, 1999, CELL, V96, P69, DOI 10.1016/S0092-8674(00)80960-5; Doxsey S, 1998, NAT GENET, V20, P104, DOI 10.1038/2392; Dumontet C, 1999, J CLIN ONCOL, V17, P1061, DOI 10.1200/JCO.1999.17.3.1061; Jordan MA, 1998, CURR OPIN CELL BIOL, V10, P123, DOI 10.1016/S0955-0674(98)80095-1; Juwana JP, 1999, INT J CANCER, V81, P275, DOI 10.1002/(SICI)1097-0215(19990412)81:2<275::AID-IJC18>3.0.CO;2-Z; KANAI Y, 1989, J CELL BIOL, V109, P1173, DOI 10.1083/jcb.109.3.1173; Korinek WS, 2000, SCIENCE, V287, P2257, DOI 10.1126/science.287.5461.2257; Lee L, 2000, SCIENCE, V287, P2260, DOI 10.1126/science.287.5461.2260; LEWIS SA, 1989, NATURE, V342, P498, DOI 10.1038/342498a0; Miller RK, 2000, MOL BIOL CELL, V11, P2949, DOI 10.1091/mbc.11.9.2949; Mimori-Kiyosue Y, 2000, CURR BIOL, V10, P865, DOI 10.1016/S0960-9822(00)00600-X; Mimori-Kiyosue Y, 2000, J CELL BIOL, V148, P505, DOI 10.1083/jcb.148.3.505; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950; Morrison EE, 1997, NEUROSCIENCE, V81, P553, DOI 10.1016/S0306-4522(97)00099-7; Morrison EE, 1998, ONCOGENE, V17, P3471, DOI 10.1038/sj.onc.1202247; Muhua L, 1998, NATURE, V393, P487, DOI 10.1038/31014; MUNEMITSU S, 1994, CANCER RES, V54, P3676; Nakagawa H, 2000, ONCOGENE, V19, P210, DOI 10.1038/sj.onc.1203308; Pancer Z, 1996, CANCER LETT, V109, P155, DOI 10.1016/S0304-3835(96)04440-0; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; PIPERNO G, 1987, J CELL BIOL, V104, P289, DOI 10.1083/jcb.104.2.289; Salisbury JL, 1999, BIOL CELL, V91, P451, DOI 10.1016/S0248-4900(99)80086-0; SCHULZE E, 1987, J CELL BIOL, V105, P2167, DOI 10.1083/jcb.105.5.2167; Schwartz K, 1997, MOL BIOL CELL, V8, P2677, DOI 10.1091/mbc.8.12.2677; SMITH KJ, 1994, CANCER RES, V54, P3672; Su LK, 2001, GENOMICS, V71, P142, DOI 10.1006/geno.2000.6428; SU LK, 1995, CANCER RES, V55, P2972; TAKEMURA R, 1992, J CELL SCI, V103, P953; Tirnauer JS, 2000, J CELL BIOL, V149, P761, DOI 10.1083/jcb.149.4.761; Tirnauer JS, 1999, J CELL BIOL, V145, P993, DOI 10.1083/jcb.145.5.993; Vaughan KT, 1999, J CELL SCI, V112, P1437	39	43	44	1	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 31	2001	20	25					3185	3192		10.1038/sj.onc.1204429	http://dx.doi.org/10.1038/sj.onc.1204429			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	440ET	11423968				2022-12-25	WOS:000169163500002
J	Peluso, G; Petillo, O; Barbarisi, A; Melone, MAB; Reda, E; Nicolai, R; Calvani, M				Peluso, G; Petillo, O; Barbarisi, A; Melone, MAB; Reda, E; Nicolai, R; Calvani, M			Carnitine protects the molecular chaperone activity of lens alpha-crystallin and decreases the posttranslational protein modifications induced by oxidative stress	FASEB JOURNAL			English	Article						alpha-crystallin; carnitine; cataract; lens proteins; oxidative stress	NON-ENZYMIC GLYCOSYLATION; A-CRYSTALLIN; POSSIBLE MECHANISM; CATARACT FORMATION; ASPIRIN PREVENTS; CROSS-LINKING; IN-VITRO; E-DOMAIN; TRANSGLUTAMINASE; EYE	alpha-Crystallin prevents heat-induced lens protein aggregation by acting as a molecular chaperone. We investigated whether oxidative stress in an in vitro model of cataract increases the posttranslational modifications to lens proteins induced by transglutaminase (TGase). We also investigated whether carnitine safeguards the chaperone activity of alpha-crystallin and inhibits the TGase-mediated aggregation of lens proteins and lens opacification. One lens of each pair of rat lenses was cultured without H2O2 (controls), and the controlateral lens was exposed to 500 muM H2O2, an as oxidizing agent, in the presence and absence of 300 muM L-carnitine. Lenses treated with H2O2 alone became opaque, whereas the L-carnitine-treated lenses remained clear. Incubation with 500 muM H2O2 significantly increased the level of TGase-mediated cross-links of lens protein and decreased the ability of a-crystallin to prevent heat-induced aggregation of beta(L)-crystallin, L-carnitine prevented both these negative effects. After H2O2, glutathione and free carnitine levels dropped dramatically. L-carnitine did not prevent the loss of glutathione, but it did prevent carnitine from falling below control values. In conclusion, carnitine safeguards the chaperone activity of alpha-crystallin that prevents protein aggregation in the lens, and it decreases the protein posttranslational modifications induced by oxidative stress. This process is not mediated by glutathione.	CNR, Inst Prot Biochem & Enzymol, I-80072 Naples, Italy; Natl Canc Inst, Dept Expt Oncol, Naples, Italy; Univ Naples 2, Sch Med, Inst Clin Surg, Naples, Italy; Univ Naples 2, Sch Med, Div Neurol 2, Naples, Italy; Sigma Tau Pharmaceut Co, Dept Sci, Rome, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biochimica delle Proteine (IBP-CNR); IRCCS Fondazione Pascale; Universita della Campania Vanvitelli; Universita della Campania Vanvitelli; Italfarmaco; Leadiant Biosciences	Peluso, G (corresponding author), CNR, Inst Prot Biochem & Enzymol, Via Toiano 6, I-80072 Naples, Italy.	peluso@daffne.ibpe.na.cnr.it	Melone, Mariarosa Anna Beatrice/N-6788-2015; terracciano, chiara/C-2955-2018	Melone, Mariarosa Anna Beatrice/0000-0002-7213-9277; terracciano, chiara/0000-0002-1853-5578; Barbarisi, Alfonso/0000-0003-2357-1132				AJIBOYE R, 1989, EXP EYE RES, V49, P31, DOI 10.1016/0014-4835(89)90073-0; Andley UP, 1998, J BIOL CHEM, V273, P31252, DOI 10.1074/jbc.273.47.31252; ANDLEY UP, 1987, PHOTOCHEM PHOTOBIOL, V46, P1057, DOI 10.1111/j.1751-1097.1987.tb04893.x; ARDUINI A, 1992, AM HEART J, V123, P1726, DOI 10.1016/0002-8703(92)90850-U; ARDUINI A, 1992, J BIOL CHEM, V267, P12673; Augusteyn R., 1981, MECH CATARACT FORMAT, P72; Bettelheim F. A., 1985, OCULAR LENS STRUCTUR, P265; BLAKYTNY R, 1992, EXP EYE RES, V54, P509; BLOEMENDAL H, 1982, CRC CR REV BIOCH MOL, V12, P1, DOI 10.3109/10409238209105849; CARVER JA, 1994, BBA-PROTEIN STRUCT M, V1204, P195, DOI 10.1016/0167-4838(94)90009-4; CHERIAN M, 1993, LIFE SCI, V52, P1699, DOI 10.1016/0024-3205(93)90478-L; CHERIAN M, 1995, BIOCHEM BIOPH RES CO, V212, P184, DOI 10.1006/bbrc.1995.1954; CROMPTON M, 1985, EXP EYE RES, V40, P297, DOI 10.1016/0014-4835(85)90014-4; DAVIES KJA, 1987, J BIOL CHEM, V262, P9914; de Jong W W, 1974, Eur J Biochem, V48, P271; DILLON J, 1985, OCULAR LENS STRUCTUR, P349; Francis PJ, 1999, TRENDS GENET, V15, P191, DOI 10.1016/S0168-9525(99)01738-2; Gibala MJ, 1998, AM J PHYSIOL-ENDOC M, V275, pE235; GROENEN PJTA, 1993, BIOCHEM J, V295, P399, DOI 10.1042/bj2950399; GROENEN PJTA, 1994, EUR J BIOCHEM, V225, P1, DOI 10.1111/j.1432-1033.1994.00001.x; Harding J.J., 1981, MOL CELLULAR BIOL EY, P327; HASAN A, 1993, EXP EYE RES, V57, P29, DOI 10.1006/exer.1993.1095; HOHL D, 1991, J BIOL CHEM, V266, P6626; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; Horwitz J, 1998, METHOD ENZYMOL, V290, P365, DOI 10.1016/S0076-6879(98)90032-5; HUBY R, 1988, EXP EYE RES, V47, P53, DOI 10.1016/0014-4835(88)90023-1; JONES RHV, 1993, EXP EYE RES, V57, P783, DOI 10.1006/exer.1993.1186; JONES RHV, 1999, EXP EYE RES, V69, P291; KIM SY, 1995, J INVEST DERMATOL, V104, P211, DOI 10.1111/1523-1747.ep12612769; KONIGSBERG WH, 1983, P NATL ACAD SCI-BIOL, V80, P2467, DOI 10.1073/pnas.80.9.2467; KRAMPS JA, 1978, BIOCHIM BIOPHYS ACTA, V533, P487, DOI 10.1016/0005-2795(78)90394-X; Kreis R, 1999, NMR BIOMED, V12, P471, DOI 10.1002/(SICI)1099-1492(199911)12:7<471::AID-NBM591>3.0.CO;2-A; Lee JS, 1997, J PROTEIN CHEM, V16, P283, DOI 10.1023/A:1026305025816; Lorand L, 1998, P NATL ACAD SCI USA, V95, P537, DOI 10.1073/pnas.95.2.537; LORAND L, 1992, P NATL ACAD SCI USA, V89, P11161, DOI 10.1073/pnas.89.23.11161; LORAND L, 1981, P NATL ACAD SCI-BIOL, V78, P1356, DOI 10.1073/pnas.78.3.1356; MACLEANFLETCHER S, 1980, BIOCHEM BIOPH RES CO, V96, P18, DOI 10.1016/0006-291X(80)91175-4; MOCKROS LF, 1974, BIOPHYS CHEM, V2, P164, DOI 10.1016/0301-4622(74)80037-2; Murthy SNP, 1998, EXP EYE RES, V67, P273; NAKAOKA H, 1994, SCIENCE, V264, P1593, DOI 10.1126/science.7911253; NICHOLL ID, 1994, EMBO J, V13, P945, DOI 10.1002/j.1460-2075.1994.tb06339.x; Peluso C, 2000, J CELL BIOCHEM, V80, P1; Perng MD, 1999, J CELL SCI, V112, P2099; PERNG MD, 1999, J BIOL CHEM, V47, P33235; PESSOTTO P, 1994, J OCUL PHARMACOL, V10, P643, DOI 10.1089/jop.1994.10.643; Pessotto P, 1997, EXP EYE RES, V64, P195, DOI 10.1006/exer.1996.0188; RAO GN, 1988, BIOCHEM BIOPH RES CO, V151, P991, DOI 10.1016/S0006-291X(88)80463-7; RAO GN, 1985, BIOCHEM BIOPH RES CO, V128, P1125, DOI 10.1016/0006-291X(85)91057-5; Rasmussen BB, 1999, ANNU REV NUTR, V19, P463, DOI 10.1146/annurev.nutr.19.1.463; RICHARD RC, 1998, P SOC EXP BIOL MED, V217, P397; Robertson JD, 1997, TOXICOLOGY, V124, P11, DOI 10.1016/S0300-483X(97)00126-1; SAMOKHIN GP, 1995, J BIOL CHEM, V270, P21827, DOI 10.1074/jbc.270.37.21827; Sims NR, 2000, MOL BRAIN RES, V77, P176, DOI 10.1016/S0169-328X(00)00049-8; Smulders RHPH, 1996, J BIOL CHEM, V271, P29060, DOI 10.1074/jbc.271.46.29060; SPECTOR A, 1981, EXP EYE RES, V33, P673, DOI 10.1016/S0014-4835(81)80107-8; SPECTOR A, 1995, FASEB J, V9, P1173, DOI 10.1096/fasebj.9.12.7672510; Swamy-Mruthinti S, 1999, EXP EYE RES, V69, P109, DOI 10.1006/exer.1999.0680; TAKEMOTO L, 1992, CURR EYE RES, V11, P651, DOI 10.3109/02713689209000738; TARDIEU A, 1988, ANNU REV BIOPHYS BIO, V17, P47; TAYLOR A, 1987, FREE RADICAL BIO MED, V3, P371, DOI 10.1016/0891-5849(87)90015-3; vandenIjssel PRLA, 1996, OPHTHALMIC RES, V28, P39, DOI 10.1159/000267941; VANKLEEF FSM, 1976, EUR J BIOCHEM, V66, P477; VARMA SD, 1984, CURR EYE RES, V3, P35, DOI 10.3109/02713688408997186; WISTOW GJ, 1988, ANNU REV BIOCHEM, V57, P479, DOI 10.1146/annurev.bi.57.070188.002403; Wuensch SA, 1997, COMP BIOCHEM PHYS B, V118, P599, DOI 10.1016/S0305-0491(97)00242-3; ZIGLER JS, 1989, FREE RADICAL BIO MED, V7, P499; Zigman S., 1981, MECHANISMS CATARACT, P117; Zigman S., 1985, OCULAR LENS STRUCTUR, P301	68	24	28	1	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY 29	2001	15	7					1604	+		10.1096/fj.00-0727fje	http://dx.doi.org/10.1096/fj.00-0727fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519CQ	11427500				2022-12-25	WOS:000173707700025
J	Quan, N; Ho, E; Lai, WM; Tsai, YH; Bray, T				Quan, N; Ho, E; Lai, WM; Tsai, YH; Bray, T			Administration of NF-kappa B decoy inhibits pancreatic activation of NF-kappa B and prevents diabetogenesis by alloxan in mice	FASEB JOURNAL			English	Article						hyperglycemia; insulin; oxidative stress; pancreas	IN-VIVO TRANSFECTION; INSULIN	Many risk factors can trigger the development of insulin-dependent diabetes mellitus (IDDM). The induction of IDDM in vivo is strongly associated not only with the generation of reactive oxygen species but also with the activation of the transcription factor nuclear factor-kappaB (NF-kappaB). The purpose of this study was to determine the role of NF-kappaB activation in diabetogenesis. Alloxan, a diabetogenic compound that causes diabetic conditions by selectively killing the insulin-producing pancreatic beta-cells, was used as a model chemical compound to induce diabetes. We show here that the injection of alloxan in mice rapidly and specifically induced the activation of NF-kappaB in the pancreas. Intravenous administration of synthetic oligodeoxynucleotides, which are exact copies of the DNA binding site of NF-kappaB (NF-kappaB decoy), given before the alloxan injection, effectively blocked pancreatic NF-kappaB activation in mice and subsequently prevented pancreatic cell death, restored insulin secretion, and abolished hyperglycemia. Injection of scrambled NF-kappaB decoy oligodeoxynucleotides to mice had no effect on alloxan-induced diabetic conditions, These results demonstrate that NF-kappaB activation in the pancreas is required for the induction of chemically induced diabetes by alloxan.	Ohio State Univ, Dept Human Nutr, Columbus, OH 43210 USA; Ohio State Univ, Dept Oral Biol, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Bray, T (corresponding author), Ohio State Univ, Dept Human Nutr, 350 E Campbell Hall,1787 Neil Ave, Columbus, OH 43210 USA.	bray.21@osu.edu						Abdel-Mageed AB, 1998, J UROLOGY, V160, P2000, DOI 10.1016/S0022-5347(01)62224-9; Arnush M, 1998, J CLIN INVEST, V102, P516, DOI 10.1172/JCI844; Demarchi F, 1996, J VIROL, V70, P4427, DOI 10.1128/JVI.70.7.4427-4437.1996; DERYCKERE F, 1994, BIOTECHNIQUES, V16, P405; Gill JS, 2000, NEUROBIOL DIS, V7, P448, DOI 10.1006/nbdi.2000.0312; Ho E, 1999, P SOC EXP BIOL MED, V222, P205, DOI 10.1046/j.1525-1373.1999.d01-137.x; Ho E, 1999, FASEB J, V13, P1845, DOI 10.1096/fasebj.13.13.1845; Hofmann MA, 1998, DIABETES CARE, V21, P1310, DOI 10.2337/diacare.21.8.1310; Kawamura I, 1999, GENE THER, V6, P91, DOI 10.1038/sj.gt.3300819; Li JF, 1997, J BIOL CHEM, V272, P16498, DOI 10.1074/jbc.272.26.16498; Miagkov AV, 1998, P NATL ACAD SCI USA, V95, P13859, DOI 10.1073/pnas.95.23.13859; MIYAMOTO S, 1995, ADV CANCER RES, V66, P255, DOI 10.1016/S0065-230X(08)60257-2; Morishita R, 1997, NAT MED, V3, P894, DOI 10.1038/nm0897-894; Ono S, 1999, HUM GENE THER, V10, P335; Ono S, 1998, HUM GENE THER, V9, P1003, DOI 10.1089/hum.1998.9.7-1003; Rabinovitch A, 1998, BIOCHEM PHARMACOL, V55, P1139, DOI 10.1016/S0006-2952(97)00492-9; REDDY S, 1985, AUST J BIOL SCI, V38, P59, DOI 10.1071/BI9850059; Schmitt R, 2000, EDN, V45, P77; Sharma HW, 1996, ANTICANCER RES, V16, P61; Tomita T, 1999, ARTHRITIS RHEUM, V42, P2532, DOI 10.1002/1529-0131(199912)42:12<2532::AID-ANR5>3.0.CO;2-2; West IC, 2000, DIABETIC MED, V17, P171, DOI 10.1046/j.1464-5491.2000.00259.x	21	22	23	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY 29	2001	15	7					1616	+		10.1096/fj.00-0855fje	http://dx.doi.org/10.1096/fj.00-0855fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519CQ	11427504				2022-12-25	WOS:000173707700015
J	Brem, R; Certa, U; Neeb, M; Nair, APK; Moroni, C				Brem, R; Certa, U; Neeb, M; Nair, APK; Moroni, C			Global analysis of differential gene expression after transformation with the v-H-ras oncogene in a murine tumor model	ONCOGENE			English	Article						ras transformation; DNA microarray; transcript imaging	MAST-CELLS; CANCER; IDENTIFICATION; PROLIFERATION; FIBROBLASTS; PROGRESSION; INTEGRIN; DISPLAY; CLONING; BCL-2	Mouse PB-3c mast cells stably transfected with the v-H-ras oncogene induce tumor formation in vivo when implanted into mice. Such tumor cells are characterized by an autocrine IL-3 loop. DNA microarrays allow simultaneous transcript imaging of several thousand genes and the technique was applied in this tumor model to analyse gene expression following malignant transformation. Using three independent tumor lines derived from the same precursor the expression of about 400 out of 11000 genes was modulated in each tumor. A subset of only 75 genes (0.68%) is shared and up- or downregulated in all three lines. A significant portion of this gene pool possesses functions related to tumorigenesis such as cell adhesion, signaling or transcriptional regulation. Apart from a number of expressed sequence tags (EST's) we find downregulation of four interferon-inducible genes in the tumor lines. Finally, when we extrapolate our data to the complete mouse genome, we estimate that about 500 genes are differentially expressed in tumor cells compared to the precursor cell PB-3c.	F Hoffmann La Roche & Co Ltd, Dept Roche Genet, CH-4070 Basel, Switzerland; Inst Med Microbiol, CH-4051 Basel, Switzerland	Roche Holding	Certa, U (corresponding author), F Hoffmann La Roche & Co Ltd, Dept Roche Genet, CH-4070 Basel, Switzerland.			Brem, Reto/0000-0002-0171-1248				ASHLEY DJB, 1969, BRIT J CANCER, V23, P313, DOI 10.1038/bjc.1969.41; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BOS JL, 1989, CANCER RES, V49, P4682; Buess M, 1999, ONCOGENE, V18, P1487, DOI 10.1038/sj.onc.1202445; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; CERTA U, 2001, IN PRESS DNA ARRAYS; CUTLER ML, 1992, MOL CELL BIOL, V12, P3750, DOI 10.1128/MCB.12.9.3750; DEBLANDRE GA, 1995, J BIOL CHEM, V270, P23860, DOI 10.1074/jbc.270.40.23860; DENKO NC, 1994, P NATL ACAD SCI USA, V91, P5124, DOI 10.1073/pnas.91.11.5124; DIAMANTIS ID, 1989, P NATL ACAD SCI USA, V86, P9299, DOI 10.1073/pnas.86.23.9299; DOUGHERTY GJ, 1989, J BIOL CHEM, V264, P6509; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HIRSCH HH, 1993, J EXP MED, V178, P403, DOI 10.1084/jem.178.2.403; Inohara N, 1998, J BIOL CHEM, V273, P8705, DOI 10.1074/jbc.273.15.8705; JALANKO H, 1978, INT J CANCER, V21, P453, DOI 10.1002/ijc.2910210409; Kleeff J, 1998, CANCER RES, V58, P3769; KLEIN G, 1987, SCIENCE, V238, P1539, DOI 10.1126/science.3317834; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Malumbres M, 1998, FRONT BIOSCI-LANDMRK, V3, P887; NAIR APK, 1989, MOL CELL BIOL, V9, P1183, DOI 10.1128/MCB.9.3.1183; Pariat M, 1997, MOL CELL BIOL, V17, P2806, DOI 10.1128/MCB.17.5.2806; Puthier D, 1999, LEUKEMIA, V13, P289, DOI 10.1038/sj.leu.2401302; RA C, 1989, J BIOL CHEM, V264, P15323; SAGER R, 1993, FASEB J, V7, P964, DOI 10.1096/fasebj.7.10.8344495; SMITH TJ, 1994, IMMUNITY, V1, P393, DOI 10.1016/1074-7613(94)90070-1; Vasavada RC, 2000, J BIOL CHEM, V275, P15399, DOI 10.1074/jbc.275.20.15399; Yan SQ, 1998, BIOL CHEM, V379, P113; ZIEGLER I, 1993, J BIOL CHEM, V268, P12544; Zuber J, 2000, NAT GENET, V24, P144, DOI 10.1038/72799	30	23	24	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 17	2001	20	22					2854	2858		10.1038/sj.onc.1204403	http://dx.doi.org/10.1038/sj.onc.1204403			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	432TP	11420697				2022-12-25	WOS:000168712000013
J	Varley, JM; Attwooll, C; White, G; McGown, G; Thorncroft, M; Kelsey, AM; Greaves, M; Boyle, J; Birch, JM				Varley, JM; Attwooll, C; White, G; McGown, G; Thorncroft, M; Kelsey, AM; Greaves, M; Boyle, J; Birch, JM			Characterization of germline TP53 splicing mutations and their genetic and functional analysis	ONCOGENE			English	Article						TP53; Li-Fraumeni; splicing	LI-FRAUMENI FAMILIES; P53 MUTATIONS; HUMAN TUMORS; CANCER; EXPRESSION; SEQUENCE; PATIENT	Germline TP53 splicing mutations have been described infrequently (>2%) in the literature, however in a series of 40 patients and families identified by our group in which there are germline TP53 mutations, seven affect splicing (18%), The low figure reported in the literature might reflect the method of mutation detection, which in many studies does not include all splice junctions, These data indicate that a significant proportion of TP53 germline mutations are currently unrecognized. We have carried out detailed studies of the effects of the different mutations on splicing, and see distinct variations in the effects of the same mutation in different patients, Furthermore we have identified the usage of a nonconsensus splice donor site in four families with an intron 4 splice donor mutation.	Paterson Inst Canc Res, CRC, Canc Genet Grp, Manchester M20 4BX, Lancs, England; Royal Manchester Childrens Hosp, Dept Histopathol, Manchester M27 1HA, Lancs, England; Royal Manchester Childrens Hosp, CRC, PFCRG, Manchester M27 1HA, Lancs, England	Paterson Institute for Cancer Research; Royal Manchester Children's Hospital; Royal Manchester Children's Hospital	Varley, JM (corresponding author), Paterson Inst Canc Res, CRC, Canc Genet Grp, Wilmslow Rd, Manchester M20 4BX, Lancs, England.							BARTEK J, 1991, ONCOGENE, V6, P1699; Beroud C, 1998, NUCLEIC ACIDS RES, V26, P200, DOI 10.1093/nar/26.1.200; Birch JM, 1998, ONCOGENE, V17, P1061, DOI 10.1038/sj.onc.1202033; BIRCH JM, 1994, BRIT J CANCER, V70, P1176, DOI 10.1038/bjc.1994.468; BIRCH JM, 1994, CANCER RES, V54, P1298; Boyle JM, 1999, BRIT J CANCER, V79, P1657, DOI 10.1038/sj.bjc.6690265; Boyle JM, 1998, BRIT J CANCER, V77, P2181, DOI 10.1038/bjc.1998.364; BRUGIERES L, 1993, CANCER RES, V53, P452; Casey G, 1996, ONCOGENE, V13, P1971; Chen SY, 2000, P NATL ACAD SCI USA, V97, P593, DOI 10.1073/pnas.97.2.593; FELIX CA, 1993, ONCOGENE, V8, P1203; FREBOURG T, 1995, AM J HUM GENET, V56, P608; Hernandez-Boussard T, 1999, HUM MUTAT, V14, P1; JOLLY KW, 1994, ONCOGENE, V9, P97; LI FP, 1988, CANCER RES, V48, P5358; LI FP, 1969, ANN INTERN MED, V71, P747, DOI 10.7326/0003-4819-71-4-747; MIDGLEY CA, 1992, J CELL SCI, V101, P183; Mount SM, 2000, AM J HUM GENET, V67, P788, DOI 10.1086/303098; Sedlacek Z, 1998, NUCLEIC ACIDS RES, V26, P214, DOI 10.1093/nar/26.1.214; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; Varley JM, 1998, BRIT J CANCER, V78, P1081, DOI 10.1038/bjc.1998.631; Varley JM, 1999, AM J HUM GENET, V65, P995, DOI 10.1086/302575; Varley JM, 1998, ONCOGENE, V16, P3291, DOI 10.1038/sj.onc.1201878; Varley JM, 1997, ONCOGENE, V14, P865, DOI 10.1038/sj.onc.1201041; Varley JM, 1997, CANCER RES, V57, P3245; VARLEY JM, 1995, J MED GENET, V32, P942, DOI 10.1136/jmg.32.12.942; Varley JM, 1996, ONCOGENE, V12, P2437; Varley JM, 1997, BRIT J CANCER, V76, P1, DOI 10.1038/bjc.1997.328; Varley JM, 1996, CANCER GENET CYTOGEN, V90, P14, DOI 10.1016/0165-4608(96)00059-3; Verselis SJ, 2000, ONCOGENE, V19, P4230, DOI 10.1038/sj.onc.1203758; WARNEFORD SG, 1992, CELL GROWTH DIFFER, V3, P839	31	44	46	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 10	2001	20	21					2647	2654		10.1038/sj.onc.1204369	http://dx.doi.org/10.1038/sj.onc.1204369			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	431VN	11420676				2022-12-25	WOS:000168652600005
J	Ebina, M; Martinez, A; Birrer, MJ; Linnoila, RI				Ebina, M; Martinez, A; Birrer, MJ; Linnoila, RI			In situ detection of unexpected patterns of mutant p53 gene expression in non-small cell lung cancers	ONCOGENE			English	Article						p53; lung cancer; immunohistochemistry; in situ PCR; in situ RT-PCR	TRANSFORMED-CELLS; MUTATIONS; RAS; ABNORMALITIES; ANTIGEN	Many solid tumors, including non-small cell lung cancers (NSCLCs), are characterized by heterogenous expression of p53 protein in the neoplastic cells. To analyse the molecular implications of this finding, we examined topographic distribution of p53 mutations using in situ polymerase chain reaction (PCR) in primary NSCLCs, showing distinct patterns of variable p53 overexpression by immunohistochemistry, Unique sets of primers for each mutation were designed, and optimal PCR conditions were determined by standard PCR using DNA from cloned mutants or cell lines established from these tumors. Ail tumor cell nuclei, regardless of the status of p53 overexpression, demonstrated homogeneous distribution of mutant p53 with specific primers, indicating that only subgroups of the mutated cells overexpressed p53 protein. In situ reverse transcription (RT)-PCR was applied to detect mutant mRNA in the individual tumor cells using specific primers. We found that in each case the distribution of mutant p53 mRNA coincided with that of immunohistochemical overexpression of p53 protein. Our results suggest that the regulation of mutant p53 expression, but not the genotype, is heterogeneous in the neoplastic cells, The topographic genomapping of p53 in NSCLC using in situ PCR provides a novel approach to view molecular mechanisms of lung carcinogenesis.	Tohoku Univ, Inst Dev Aging & Canc, Div Canc Control, Sendai, Miyagi 9808575, Japan; NCI, Dept Cell & Canc Biol, Med Branch, NIH, Bethesda, MD 20892 USA	Tohoku University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Ebina, M (corresponding author), Tohoku Univ, Inst Dev Aging & Canc, Div Canc Control, Sendai, Miyagi 9808575, Japan.		Martinez, Alfredo/GQH-5998-2022	Martinez, Alfredo/0000-0003-4882-4044				BODNER SM, 1992, ONCOGENE, V7, P743; BRAMBILLA E, 1993, AM J PATHOL, V143, P199; Cha R S, 1992, PCR Methods Appl, V2, P14; EBINA M, 1994, CANCER RES, V54, P2496; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Hall KL, 1997, GYNECOL ONCOL, V65, P330, DOI 10.1006/gyno.1997.4653; HASSE AT, 1990, P NATL ACAD SCI USA, V87, P4971; HORIO Y, 1993, CANCER RES, V53, P1; Kanazawa H, 2000, AM J PATHOL, V156, P1289, DOI 10.1016/S0002-9440(10)64999-1; Kirch HC, 1999, ONCOGENE, V18, P2728, DOI 10.1038/sj.onc.1202626; MARTINEZ A, 1995, J HISTOCHEM CYTOCHEM, V43, P739, DOI 10.1177/43.8.7542678; MITSUDOMI T, 1992, ONCOGENE, V7, P171; Nuovo GJ, 1999, P NATL ACAD SCI USA, V96, P12754, DOI 10.1073/pnas.96.22.12754; NUOVO GJ, 1994, PCR IN SITU HYBRIDIZ, P169; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; Park IW, 1999, J NATL CANCER I, V91, P1863, DOI 10.1093/jnci/91.21.1863; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; REIHSAUS E, 1990, ONCOGENE, V5, P137; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; Shaw GL, 1996, J CELL BIOCHEM, P173; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494	21	11	13	1	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 3	2001	20	20					2579	2586		10.1038/sj.onc.1204351	http://dx.doi.org/10.1038/sj.onc.1204351			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	431VM	11420668				2022-12-25	WOS:000168652500009
J	Boulanger, CA; Smith, GH				Boulanger, CA; Smith, GH			Reducing mammary cancer risk through premature stem cell senescence	ONCOGENE			English	Article						mammary; stem cell; cancer risk; cellular senescence; MMTV	GROWTH-FACTOR-BETA; TRANSFORMING GROWTH-FACTOR-BETA-1 TRANSGENE; TUMOR VIRUS; EXPRESSION; MICE; GLAND; DIFFERENTIATION; TISSUES	The reproductive capacity of the mammary epithelial stem cell is reduced coincident with the number of symmetric divisions it must perform. In a study of FVB/ N mice with the transgene, WAP-TGF beta1, we discovered that mammary epithelial stem tells were prematurely aged due to ectopic expression of TGF-beta1. To test whether premature aging of mammary epithelial stem cells would have an impart on susceptibility or resistance to mammary cancer, female littermates from FVB/ N x WAP-TGF-beta1 mating were injected with mouse mammary tumor virus (MMTV) at 8-10 weeks of age. A total of 44 females were inoculated, maintained as breeders and observed for tumor development for up to 18 months. Only one mammary tumor appeared in 17 TGF-beta1 females while 15 were collected from 29 wild type sisters. Premalignant mammary epithelial cells in infected glands were identified by transplantation of single cell(1 x 10(5)) suspensions into nulliparous hosts and testing for hyperplastic outgrowth. Although the number of positive takes was significantly reduced with TGF-beta1 cells, both MMTV-infected TGF-beta1 and wild type cells produced hyperplastic outgrowths suggesting that premalignant transformation was achieved in each group. The results suggest a positive correlation between the procreative life-span of mammary epithelial stem cells and mammary cancer risk.	NCI, Tumor Immunol & Biol Lab, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Smith, GH (corresponding author), NIH, Bldg 10,Room 8H07,9000 Rockville Pike, Bethesda, MD 20892 USA.							ARTHUR LO, 1978, INT J CANCER, V22, P433, DOI 10.1002/ijc.2910220411; BUGGIANO V, 2001, IN PRESS INT J CANC; DANIEL CW, 1968, P NATL ACAD SCI USA, V61, P53, DOI 10.1073/pnas.61.1.53; DANIEL CW, 1971, EXP GERONTOL, V6, P95, DOI 10.1016/0531-5565(71)90053-2; DANIEL CW, 1971, EXP CELL RES, V65, P27, DOI 10.1016/S0014-4827(71)80046-0; DEOME KB, 1959, CANCER RES, V19, P515; DEOME KB, 1978, CANCER RES, V38, P2103; DEOME KB, 1978, CANCER RES, V38, P4050; FELLUGA B, 1969, J NATL CANCER I, V43, P319; HEINE UI, 1987, J CELL BIOL, V105, P2861, DOI 10.1083/jcb.105.6.2861; HELD W, 1994, IMMUNOL TODAY, V15, P184, DOI 10.1016/0167-5699(94)90317-4; Hook LM, 2000, J VIROL, V74, P8876, DOI 10.1128/JVI.74.19.8876-8883.2000; IMAI S, 1994, J VIROL, V68, P3437, DOI 10.1128/JVI.68.5.3437-3442.1994; JHAPPAN C, 1993, EMBO J, V12, P1835, DOI 10.1002/j.1460-2075.1993.tb05832.x; Kamiya K, 1999, J RADIAT RES, V40, P128, DOI 10.1269/jrr.40.S128; Katakura Y, 1999, BIOCHEM BIOPH RES CO, V255, P110, DOI 10.1006/bbrc.1999.0129; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KORDON EC, 1995, DEV BIOL, V168, P47, DOI 10.1006/dbio.1995.1060; Kordon EC, 1998, DEVELOPMENT, V125, P1921; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MEDINA D, 1973, METHOD CANCER RES, V7, P3; NICOLL CHARLES S., 1965, LIFE SCI, V4, P993, DOI 10.1016/0024-3205(65)90203-1; PIERCE DF, 1995, P NATL ACAD SCI USA, V92, P4254, DOI 10.1073/pnas.92.10.4254; Rasmussen S. B., 2000, METHODS MAMMARY GLAN, P75; Ross SR, 1998, IMMUNOL RES, V17, P209, DOI 10.1007/BF02786445; ROUBINIAN JR, 1980, J NATL CANCER I, V65, P795, DOI 10.1093/jnci/65.4.795; SELL S, 1994, LAB INVEST, V70, P6; Smith GH, 1996, BREAST CANCER RES TR, V39, P21, DOI 10.1007/BF01806075; SMITH GH, 1984, CANCER RES, V44, P3426; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPORN MB, 1992, J CELL BIOL, V119, P1017, DOI 10.1083/jcb.119.5.1017; SQUARTINI F, 1983, CANCER RES, V43, P5879; VANNIE R, 1977, INT J CANCER, V19, P383, DOI 10.1002/ijc.2910190316; YANG HAS, 2000, P AM ASSOC CANC RES, V41, P225; YOUNG LJT, 1971, EXP GERONTOL, V6, P49, DOI 10.1016/0531-5565(71)90048-9	35	73	73	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 26	2001	20	18					2264	2272		10.1038/sj.onc.1204312	http://dx.doi.org/10.1038/sj.onc.1204312			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	427KZ	11402321				2022-12-25	WOS:000168404500008
J	Wang, PL; Sait, F; Winter, G				Wang, PL; Sait, F; Winter, G			The 'wildtype' conformation of p53: epitope mapping using hybrid proteins	ONCOGENE			English	Article						p53 conformation; epitope mapping; recombination; p53-DNA interaction	HUMAN PAPILLOMAVIRUS TYPE-16; DNA-BINDING DOMAIN; TUMOR-SUPPRESSOR PROTEIN; MONOCLONAL-ANTIBODY; ESCHERICHIA-COLI; MURINE P53; SIMIAN VIRUS-40; E6 ONCOPROTEIN; MUTATIONS; PRODUCE	The function of p53 correlates with its 'wildtype' conformation, specifically recognized by antibodies PAb1620 and PAb246, and many cancer-associated mutations cause loss of this conformation. The epitopes of these antibodies were identified using hybrid p53 proteins created by a new method. Plasmids carrying homologous genes cut at appropriate sites recombined efficiently when transformed into RecE(+) E, coli, PAb1620 and PAb246 recognize mouse but not chicken p53; we created mouse-chicken hybrids of the p53 core domain and tested antibody reactivity, PAb246 binding mapped to residues 201-212, while PAb1620 required both residues 145-157 and 201-212 (human p53 numbering used throughout). An alanine-scan show-ed that the key residues for PAb246 and PAb1620 are completely distinct: PAb246 recognizes residues 202-204 (Tyr-Pro-Glu) while PAb1620 recognizes residues Arg156, Leu206, Arg209, and Gln/Asn210, the last two residues being essential, Both antibody epitopes are far from the p53 interface with DNA, but near the epitope of the 'mutant' conformation antibody PAb240, These epitope locations may help in dissecting the interactions of p53, including those with E6/E6-AP and in its DNA-bound state.	Ctr Prot Engn, Cambridge CB2 2QH, England; Mol Biol Lab, Cambridge CB2 2QH, England	University of Cambridge; MRC Laboratory Molecular Biology	Wang, PL (corresponding author), Ctr Prot Engn, Hills Rd, Cambridge CB2 2QH, England.							BALAGURUMOORTHY P, 1995, P NATL ACAD SCI USA, V92, P8591, DOI 10.1073/pnas.92.19.8591; BALL RK, 1984, EMBO J, V3, P1485, DOI 10.1002/j.1460-2075.1984.tb02000.x; Bullock AN, 1997, P NATL ACAD SCI USA, V94, P14338, DOI 10.1073/pnas.94.26.14338; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CHUNG CT, 1989, P NATL ACAD SCI USA, V86, P2172, DOI 10.1073/pnas.86.7.2172; Cohen PA, 1999, FEBS LETT, V463, P179, DOI 10.1016/S0014-5793(99)01603-8; COOK A, 1990, BRIT J CANCER, V61, P548, DOI 10.1038/bjc.1990.123; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GILLEN JR, 1981, J BACTERIOL, V145, P521, DOI 10.1128/JB.145.1.521-532.1981; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; Hainaut P, 1998, NUCLEIC ACIDS RES, V26, P205, DOI 10.1093/nar/26.1.205; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HALL AR, 1995, ONCOGENE, V10, P561; Hansen S, 1998, J MOL BIOL, V275, P575, DOI 10.1006/jmbi.1997.1507; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KOLODNER R, 1994, MOL MICROBIOL, V11, P23, DOI 10.1111/j.1365-2958.1994.tb00286.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lane DP, 1996, ONCOGENE, V12, P2461; LEGROS Y, 1994, ONCOGENE, V9, P2071; LEGROS Y, 1994, ONCOGENE, V9, P3689; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li XQ, 1996, J VIROL, V70, P4509, DOI 10.1128/JVI.70.7.4509-4516.1996; Li XQ, 1996, J BIOL CHEM, V271, P4447; McLure KG, 1996, ONCOGENE, V13, P1297; MEDCALF EA, 1993, ONCOGENE, V8, P2847; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MILNER J, 1987, ONCOGENE, V1, P453; MOLINARI M, 1995, ONCOGENE, V10, P1849; Muller-Tiemann BF, 1998, P NATL ACAD SCI USA, V95, P6079, DOI 10.1073/pnas.95.11.6079; Ravera MW, 1998, ONCOGENE, V16, P1993, DOI 10.1038/sj.onc.1201717; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Soussi T, 1996, J MOL BIOL, V260, P623, DOI 10.1006/jmbi.1996.0425; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; VOJTESEK B, 1995, ONCOGENE, V10, P389; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; WANG PL, 2001, DIS MARKERS, V16; WANG Y, 1995, MOL CELL BIOL, V15, P2157; WOLKOWICZ R, 1995, ONCOGENE, V10, P1167; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986	44	39	40	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 26	2001	20	18					2318	2324		10.1038/sj.onc.1204316	http://dx.doi.org/10.1038/sj.onc.1204316			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	427KZ	11402327				2022-12-25	WOS:000168404500014
J	Richnau, N; Aspenstrom, P				Richnau, N; Aspenstrom, P			RICH, a rho GTPase-activating protein domain-containing protein involved in signaling by Cdc42 and Rac1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALDRICH-SYNDROME PROTEIN; BINDING-PROTEINS; ACTIN; FAMILY; PEPTIDES; HOMOLOGY; DYNAMIN; SYSTEM; KINASE; PSTPIP	A previously unidentified Rho GTPase-activating protein (GAP) domain-containing protein was found in a yeast two-hybrid screen for cDNAs encoding proteins binding to the Src homology 3 domain of Cdc42-interacting protein 4 (CIP4). The protein was named RICH-1 (RhoGAP interacting with CIP4 homologues), and, in addition to the RhoGAP domain, it contained an N-terminal domain with endophilin homology and a C-terminal proline-rich domain. Transient transfections of RICH-1 indicated that it bound to CIP4 in vivo, as shown by co-immunoprecipitation experiments, as well as colocalization assays. In vitro assays demonstrated that the RhoGAP domain of RICH-1 catalyzed GTP hydrolysis on Cdc42 and Rac1, but not on RhoA. Ectopic expression of the RhoGAP domain as well as the full-length protein interfered with platelet-derived growth factor BB-induced membrane ruffling, but not with serum-induced stress fiber formation, further emphasizing the notion that, in vivo, RICH-1 is a GAP for Cdc42 and Rac1.	Ludwig Inst Canc Res, Ctr Biomed, S-75124 Uppsala, Sweden	Ludwig Institute for Cancer Research	Aspenstrom, P (corresponding author), Ludwig Inst Canc Res, Ctr Biomed, Box 595, S-75124 Uppsala, Sweden.	pontus.aspenstrom@LICR.uu.se						Aspenstrom P, 1997, CURR BIOL, V7, P479, DOI 10.1016/S0960-9822(06)00219-3; Aspenstrom P, 1999, EXP CELL RES, V246, P20, DOI 10.1006/excr.1998.4300; ASPENSTROM P, 1995, METHOD ENZYMOL, V256, P228; Aspenstrom P, 1999, CURR OPIN CELL BIOL, V11, P95, DOI 10.1016/S0955-0674(99)80011-8; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; Burbelo PD, 1999, P NATL ACAD SCI USA, V96, P9083, DOI 10.1073/pnas.96.16.9083; Chan DC, 1996, EMBO J, V15, P1045, DOI 10.1002/j.1460-2075.1996.tb00442.x; CHANG JH, 1995, J CELL BIOL, V130, P355, DOI 10.1083/jcb.130.2.355; CICCHETTI P, 1995, EMBO J, V14, P3127, DOI 10.1002/j.1460-2075.1995.tb07315.x; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; DERRY JMJ, 1994, CELL, V78, P635, DOI 10.1016/0092-8674(94)90528-2; ERIKSSON A, 1992, EMBO J, V11, P543, DOI 10.1002/j.1460-2075.1992.tb05085.x; FANKHAUSER C, 1995, CELL, V82, P435, DOI 10.1016/0092-8674(95)90432-8; Gomez J, 1998, IMMUNOL CELL BIOL, V76, P125, DOI 10.1046/j.1440-1711.1998.00723.x; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Joberty G, 1999, MOL CELL BIOL, V19, P6585; Kjoller L, 1999, EXP CELL RES, V253, P166, DOI 10.1006/excr.1999.4674; KOZAK M, 1991, J BIOL CHEM, V266, P19867; Kozma R, 1996, MOL CELL BIOL, V16, P5069; Kriegler M., 1990, GENE TRANSFER EXPRES; LAMARCHE N, 1994, TRENDS GENET, V10, P436, DOI 10.1016/0168-9525(94)90114-7; Lamarche-Vane N, 1998, J BIOL CHEM, V273, P29172, DOI 10.1074/jbc.273.44.29172; Lippincott J, 2000, MICROSC RES TECHNIQ, V49, P168, DOI 10.1002/(SICI)1097-0029(20000415)49:2<168::AID-JEMT9>3.0.CO;2-T; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; Merilainen J, 1997, J BIOL CHEM, V272, P23278, DOI 10.1074/jbc.272.37.23278; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; Ochs HD, 1998, SPRINGER SEMIN IMMUN, V19, P435, DOI 10.1007/BF00792601; Pirone DM, 2000, J BIOL CHEM, V275, P22650, DOI 10.1074/jbc.M002832200; Pollard TD, 2000, ANNU REV BIOPH BIOM, V29, P545, DOI 10.1146/annurev.biophys.29.1.545; Qualmann B, 2000, J CELL BIOL, V148, P1047, DOI 10.1083/jcb.148.5.1047; Qualmann B, 1999, MOL BIOL CELL, V10, P501, DOI 10.1091/mbc.10.2.501; Ren XD, 2000, METHOD ENZYMOL, V325, P264; RIDLEY AJ, 1993, EMBO J, V12, P5151, DOI 10.1002/j.1460-2075.1993.tb06210.x; Ringstad N, 1997, P NATL ACAD SCI USA, V94, P8569, DOI 10.1073/pnas.94.16.8569; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sasaki T, 1998, BIOCHEM BIOPH RES CO, V245, P641, DOI 10.1006/bbrc.1998.8253; Schmidt A, 1999, NATURE, V401, P133, DOI 10.1038/43613; Schmidt A, 1998, ANNU REV CELL DEV BI, V14, P305, DOI 10.1146/annurev.cellbio.14.1.305; Sekimata M, 1999, J BIOL CHEM, V274, P17757, DOI 10.1074/jbc.274.25.17757; SELF AJ, 1995, METHOD ENZYMOL, V256, P67; SELF AJ, 1995, METHOD ENZYMOL, V256, P3; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; Snapper SB, 1999, ANNU REV IMMUNOL, V17, P905, DOI 10.1146/annurev.immunol.17.1.905; Spencer S, 1997, J CELL BIOL, V138, P845, DOI 10.1083/jcb.138.4.845; Taylor JM, 1999, J CELL SCI, V112, P231; Tian L, 2000, J BIOL CHEM, V275, P7854, DOI 10.1074/jbc.275.11.7854; VAN AL, 1997, GENE DEV, V11, P2295; Vignal E, 2000, J BIOL CHEM, V275, P36457, DOI 10.1074/jbc.M003487200; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; Wu Y, 1998, J BIOL CHEM, V273, P5765, DOI 10.1074/jbc.273.10.5765; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; Zalcman G, 1999, Prog Mol Subcell Biol, V22, P85; Zigmond SH, 2000, J CELL BIOL, V150, pF117, DOI 10.1083/jcb.150.6.F117	54	86	94	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					35060	35070		10.1074/jbc.M103540200	http://dx.doi.org/10.1074/jbc.M103540200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11431473	hybrid			2022-12-25	WOS:000171024600095
J	Oyarce, AM; Steveson, TC; Jin, LX; Eipper, BA				Oyarce, AM; Steveson, TC; Jin, LX; Eipper, BA			Dopamine beta-monooxygenase signal/anchor sequence alters trafficking of peptidylglycine alpha-hydroxylating monooxygenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-BOUND FORMS; ADRENAL CHROMAFFIN GRANULES; PEPTIDE PROCESSING ENZYME; UNCLEAVED SIGNAL PEPTIDE; AMIDATING MONOOXYGENASE; SECRETORY GRANULES; MESSENGER-RNA; ENDOPLASMIC-RETICULUM; NEUROENDOCRINE CELLS; MOLECULAR-CLONING	Dopamine beta -monooxygenase (DBM) and peptidylglycine a-hydroxylating monooxygenase (PHM) are essential for the biosynthesis of catecholamines and amidated peptides, respectively. The enzymes share a conserved catalytic core. We studied the role of the DBM signal sequence by appending it to soluble PHM (PHMs) and expressing the DBMsignal/PHMs chimera in AtT-20 and Chinese hamster ovary cells. PHMs produced as part of DBMsignal/PHMs was active. In vitro translated and cellular DBMsignal/PHMs had similar masses, indicating that the DBM signal was not removed. DBMsignaI/PHMs was membrane-associated and had the properties of an intrinsic membrane protein. After in vitro translation in the presence of microsomal membranes, trypsin treatment removed 2 kDa from DBMsignal/PHMs while PHMs was entirely protected. In addition, a Cys residue in DBMsignal/PHMs was accessible to Cys-directed biotinylation. Thus the chimera adopts the topology of a type Il membrane protein. Pulse-chase experiments indicate that DBMsignal/PHMs turns over rapidly after exiting the trans-Golgi network. Although PHMs is efficiently localized to secretory granules, DBMsignal/PHMs is largely localized to the endoplasmic reticulum in AtT-20 cells. On the basis of stimulated secretion, the small amount of PHMs generated is stored in secretory granules. In contrast, the expression of DBMsignal/PHMs in PC12 cells yields protein that is localized to secretory granules.	Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA	Johns Hopkins University	Oyarce, AM (corresponding author), Med Coll Ohio, Dept Pharmacol & Therapeut, BHSB 209, Toledo, OH 43614 USA.				NIDA NIH HHS [DA-11269, DA-00266] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [P50DA000266, R03DA011269] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Arvan P, 1998, BIOCHEM J, V332, P593, DOI 10.1042/bj3320593; BLOBEL G, 1976, BIOCHEM BIOPH RES CO, V68, P1, DOI 10.1016/0006-291X(76)90001-2; BON S, 1991, J NEUROCHEM, V57, P1100, DOI 10.1111/j.1471-4159.1991.tb08267.x; CHANAT E, 1991, J CELL BIOL, V115, P1505, DOI 10.1083/jcb.115.6.1505; Chen JG, 1998, J BIOL CHEM, V273, P12675, DOI 10.1074/jbc.273.20.12675; Cubells JF, 1998, HUM GENET, V102, P533, DOI 10.1007/s004390050736; Dannies PS, 1999, ENDOCR REV, V20, P3, DOI 10.1210/er.20.1.3; EIPPER BA, 1992, J BIOL CHEM, V267, P4008; EIPPER BA, 1983, P NATL ACAD SCI-BIOL, V80, P5144, DOI 10.1073/pnas.80.16.5144; EIPPER BA, 1993, PROTEIN SCI, V2, P489; Emoto N, 1999, J BIOL CHEM, V274, P1509, DOI 10.1074/jbc.274.3.1509; FENG ZH, 1992, J BIOL CHEM, V267, P21808; GIBSON KR, 1993, J BIOL CHEM, V268, P9490; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; HOUHOU L, 1995, J BIOL CHEM, V270, P12601, DOI 10.1074/jbc.270.21.12601; HURTLEY SM, 1993, J CELL SCI, V106, P649; HUSTEN EJ, 1991, J BIOL CHEM, V266, P17004; KENDALL DA, 1986, NATURE, V321, P706, DOI 10.1038/321706a0; KOBAYASHI K, 1989, NUCLEIC ACIDS RES, V17, P1089, DOI 10.1093/nar/17.3.1089; KOZAK M, 1989, MOL CELL BIOL, V9, P5073, DOI 10.1128/MCB.9.11.5073; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; KULATHILA R, 1994, ARCH BIOCHEM BIOPHYS, V311, P191, DOI 10.1006/abbi.1994.1225; LADURON PM, 1975, FEBS LETT, V52, P132, DOI 10.1016/0014-5793(75)80654-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMOUROUX A, 1987, EMBO J, V6, P3931, DOI 10.1002/j.1460-2075.1987.tb02734.x; LEWIS EJ, 1990, J BIOL CHEM, V265, P1021; LEWIS EJ, 1992, J BIOL CHEM, V267, P494; MAINS RE, 1995, MOL ENDOCRINOL, V9, P3, DOI 10.1210/me.9.1.3; MBIKAY M, 1995, EXP CELL RES, V220, P79, DOI 10.1006/excr.1995.1294; MCHUGH EM, 1985, J BIOL CHEM, V260, P4409; MCMAHON A, 1990, J NEUROSCI RES, V25, P395, DOI 10.1002/jnr.490250317; MELLMAN I, 1992, CELL, V68, P829, DOI 10.1016/0092-8674(92)90027-A; MERKLER DJ, 1995, FEBS LETT, V366, P165, DOI 10.1016/0014-5793(95)00516-C; MILGRAM SL, 1994, J CELL BIOL, V124, P33, DOI 10.1083/jcb.124.1.33; MILGRAM SL, 1992, J CELL BIOL, V117, P717, DOI 10.1083/jcb.117.4.717; MILGRAM SL, 1993, J CELL BIOL, V121, P23, DOI 10.1083/jcb.121.1.23; MOORE HPH, 1983, CELL, V35, P531, DOI 10.1016/0092-8674(83)90187-3; Murakami Y, 2000, BIOCHEM BIOPH RES CO, V267, P1, DOI 10.1006/bbrc.1999.1706; NAKANO T, 1992, BIOCHEM BIOPH RES CO, V189, P590, DOI 10.1016/0006-291X(92)91598-K; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; OUAFIK L, 1993, GENOMICS, V18, P319, DOI 10.1006/geno.1993.1471; Oyarce AM, 2000, J BIOL CHEM, V275, P3270, DOI 10.1074/jbc.275.5.3270; Oyarce AM, 1996, J NEUROCHEM, V67, P229; OYARCE AM, 1995, J CELL SCI, V108, P287; PAPINI E, 1995, J BIOL CHEM, V270, P1332, DOI 10.1074/jbc.270.3.1332; Parks GD, 1996, J BIOL CHEM, V271, P7187, DOI 10.1074/jbc.271.12.7187; Partoens P, 1998, J CELL SCI, V111, P681; SABBAN EL, 1983, J BIOL CHEM, V258, P7812; SAXENA A, 1983, J BIOL CHEM, V258, P4147; SCHEELE G, 1980, J CELL BIOL, V87, P611, DOI 10.1083/jcb.87.3.611; Schubert U, 2000, NATURE, V404, P770, DOI 10.1038/35008096; SOUTHAN C, 1989, FEBS LETT, V255, P116, DOI 10.1016/0014-5793(89)81072-5; STAFFORD FJ, 1991, J CELL BIOL, V115, P1225, DOI 10.1083/jcb.115.5.1225; STEWART LC, 1988, ANNU REV BIOCHEM, V57, P551; TALJANIDISZ J, 1989, BIOCHEMISTRY-US, V28, P10054, DOI 10.1021/bi00452a026; Tanner VA, 1996, J HISTOCHEM CYTOCHEM, V44, P1481, DOI 10.1177/44.12.8985140; TAUSK FA, 1992, MOL ENDOCRINOL, V6, P2185, DOI 10.1210/me.6.12.2185; TAYLOR CS, 1989, J BIOL CHEM, V264, P14; Toyo-oka K, 1999, INT IMMUNOL, V11, P2043, DOI 10.1093/intimm/11.12.2043; WIKSTROM L, 1992, J BIOL CHEM, V267, P5; WINKLER H, 1986, NEUROSCIENCE, V18, P261, DOI 10.1016/0306-4522(86)90154-5; WU HJ, 1990, J NEUROCHEM, V55, P97, DOI 10.1111/j.1471-4159.1990.tb08826.x; YUN HY, 1993, ARCH BIOCHEM BIOPHYS, V301, P77, DOI 10.1006/abbi.1993.1117; ZHOU A, 1994, J BIOL CHEM, V269, P17440	64	6	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					33265	33272		10.1074/jbc.M101088200	http://dx.doi.org/10.1074/jbc.M101088200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11418593	hybrid			2022-12-25	WOS:000170746000113
J	Gil-Henn, H; Volohonsky, G; Elson, A				Gil-Henn, H; Volohonsky, G; Elson, A			Regulation of protein-tyrosine phosphatases alpha and epsilon by calpain-mediated proteolytic cleavage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SRC-FAMILY KINASES; RPTP-ALPHA; PTP-ALPHA; INSULIN-RECEPTOR; DOWN-REGULATION; MAMMARY-TUMORS; EXPRESSION; INTEGRIN; ISOFORM; SIGNAL	The precise subcellular localization of non-receptor tyrosine phosphatases is a major factor in regulating their physiological functions. We have previously shown that cellular processing of protein-tyrosine phosphatase epsilon (PTP epsilon) generates a physiologically distinct, cytoplasmic form of this protein, p65 PTP epsilon. Here we describe a novel protein form of the related receptor-type tyrosine phosphatase alpha (RPTP alpha), p66 PTP alpha, which is detected in nearly all cell types where RPTPa is expressed. Both p66 PTP alpha and p65 PTP epsilon are produced by calpain-mediated proteolytic cleavage in vivo. Cleavage is inhibited in living cells by a variety of calpain inhibitors, can be induced in primary cortical neurons treated with calcium chloride, and is observed in lysates of brain or of cultured cells following addition of purified calpain. Cleavage occurs within the intracellular juxtamembrane domain of RPTPa, releasing the phosphatase catalytic domains from their membranal anchors and translocating them to the cytoplasm. Translocation reduces the ability of PTPa to act on membrane-associated substrates, as it loses its ability to dephosphorylate Src at its C-terminal regulatory site, and its ability to dephosphorylate the Kv2.1 voltage-gated potassium channel is severely impaired. In all, the data indicate that control of phosphatase function via post-translational processing occurs also among receptor-type phosphatases, and demonstrate the molecular complexity of regulating these parameters within the PTP alpha /PTP epsilon phosphatase subfamily.	Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Elson, A (corresponding author), Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel.	ari.elson@weizmann.ac.il		Elson, Ari/0000-0001-9808-9135				Andersen JN, 2001, BIOCHEM J, V354, P581, DOI 10.1042/0264-6021:3540581; Ardini E, 2000, ONCOGENE, V19, P4979, DOI 10.1038/sj.onc.1203869; Bhandari V, 1998, J BIOL CHEM, V273, P8691, DOI 10.1074/jbc.273.15.8691; Bilwes AM, 1996, NATURE, V382, P555, DOI 10.1038/382555a0; Blanchetot C, 2000, J BIOL CHEM, V275, P12446, DOI 10.1074/jbc.275.17.12446; CHAMAK B, 1989, DEVELOPMENT, V106, P483; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DAUM G, 1994, J BIOL CHEM, V269, P10524; den Hertog J, 1999, MECH DEVELOP, V85, P3, DOI 10.1016/S0925-4773(99)00089-1; DENHERTOG J, 1994, EMBO J, V13, P3020, DOI 10.1002/j.1460-2075.1994.tb06601.x; DENHERTOG J, 1993, EMBO J, V12, P3789, DOI 10.1002/j.1460-2075.1993.tb06057.x; Dick LR, 1996, J BIOL CHEM, V271, P7273, DOI 10.1074/jbc.271.13.7273; Elson A, 1996, GENOMICS, V31, P373, DOI 10.1006/geno.1996.0061; Elson A, 1999, ONCOGENE, V18, P7535, DOI 10.1038/sj.onc.1203098; ELSON A, 1995, J BIOL CHEM, V270, P26116, DOI 10.1074/jbc.270.44.26116; Elson A, 1995, P NATL ACAD SCI USA, V92, P12235, DOI 10.1073/pnas.92.26.12235; Fischer EH, 1999, ADV ENZYME REGUL, V39, P359, DOI 10.1016/S0065-2571(98)00014-4; FRANGIONI JV, 1993, EMBO J, V12, P4843, DOI 10.1002/j.1460-2075.1993.tb06174.x; Gil-Henn H, 2000, ONCOGENE, V19, P4375, DOI 10.1038/sj.onc.1203790; Gu MX, 1996, J BIOL CHEM, V271, P27751, DOI 10.1074/jbc.271.44.27751; Gurd JW, 1999, J NEUROCHEM, V73, P1990; Harder KW, 1998, J BIOL CHEM, V273, P31890, DOI 10.1074/jbc.273.48.31890; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Jacob KK, 1998, J BIOL CHEM, V273, P4800, DOI 10.1074/jbc.273.8.4800; Jiang GL, 1999, NATURE, V401, P606, DOI 10.1038/44170; Jiang GQ, 2000, MOL CELL BIOL, V20, P5917, DOI 10.1128/MCB.20.16.5917-5929.2000; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; Lammers R, 1998, BIOCHEM BIOPH RES CO, V242, P32, DOI 10.1006/bbrc.1997.7906; Lammers R, 2000, J BIOL CHEM, V275, P3391, DOI 10.1074/jbc.275.5.3391; Lammers R, 1997, FEBS LETT, V404, P37, DOI 10.1016/S0014-5793(97)00080-X; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; Lim KL, 1997, EUR J BIOCHEM, V245, P693, DOI 10.1111/j.1432-1033.1997.00693.x; Majeti R, 1998, SCIENCE, V279, P88, DOI 10.1126/science.279.5347.88; MAURO LJ, 1994, TRENDS BIOCHEM SCI, V19, P151, DOI 10.1016/0968-0004(94)90274-7; MOLLER NPH, 1995, J BIOL CHEM, V270, P23126, DOI 10.1074/jbc.270.39.23126; Nakamura K, 1996, BIOCHEM BIOPH RES CO, V218, P726, DOI 10.1006/bbrc.1996.0129; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Nguyen TH, 1999, J NEUROCHEM, V73, P1995; Pariat M, 1997, MOL CELL BIOL, V17, P2806, DOI 10.1128/MCB.17.5.2806; Peretz A, 2000, EMBO J, V19, P4036, DOI 10.1093/emboj/19.15.4036; Petrone A, 2000, J CELL SCI, V113, P2345; Ponniah S, 1999, CURR BIOL, V9, P535, DOI 10.1016/S0960-9822(99)80238-3; Rock MT, 1997, J BIOL CHEM, V272, P33377, DOI 10.1074/jbc.272.52.33377; Schaapveld R, 1997, MOL BIOL REP, V24, P247, DOI 10.1023/A:1006870016238; Stein-Gerlach M, 1998, INT J BIOCHEM CELL B, V30, P559, DOI 10.1016/S1357-2725(98)00002-8; Su J, 1999, CURR BIOL, V9, P505, DOI 10.1016/S0960-9822(99)80234-6; TABITI K, 1995, CANCER LETT, V93, P239, DOI 10.1016/0304-3835(95)03816-F; Tanuma N, 1999, EUR J BIOCHEM, V259, P46, DOI 10.1046/j.1432-1327.1999.00004.x; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; Tsai W, 1999, EMBO J, V18, P109, DOI 10.1093/emboj/18.1.109; Zeng L, 1999, J CELL BIOL, V147, P707, DOI 10.1083/jcb.147.4.707; Zheng XM, 2000, EMBO J, V19, P964, DOI 10.1093/emboj/19.5.964; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0; Zondag GCM, 1997, BIOCHIMIE, V79, P477, DOI 10.1016/S0300-9084(97)82739-3	55	49	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					31772	31779		10.1074/jbc.M103395200	http://dx.doi.org/10.1074/jbc.M103395200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11429406	hybrid			2022-12-25	WOS:000170613500041
J	Hauser, F; Strassner, J; Schaller, A				Hauser, F; Strassner, J; Schaller, A			Cloning, expression, and characterization of tomato (Lycopersicon esculentum) aminopeptidase P	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLINE SPECIFIC PEPTIDASES; ESCHERICHIA-COLI; BOVINE LUNG; METHIONINE AMINOPEPTIDASE; PURIFICATION; ENZYME; RAT; BRADYKININ; PROTEINS; POLYPEPTIDE	A cDNA (LeAPP2) was cloned from tomato coding for a 654 amino acid protein of 72.7 kDa. The deduced amino acid sequence was > 40% identical with that of mammalian aminopeptidase P, a metalloexopeptidase. All amino acids reported to be important for binding of the active site metals and catalytic activity, respectively, were conserved between LeAPP2 and its mammalian homologues. LeAPP2 was expressed in Escherichia coli in N-terminal fusion with glutathione S-transferase and was purified from bacterial extracts. LeAPP2 was verified as an aminopeptidase P, hydrolyzing the amino-terminal Xaa-Pro bonds of bradykinin and substance P. LeAPP2 also exhibited endoproteolytic activity cleaving, albeit at a reduced rate, the internal -Phe-Gly bond of substance P. Apparent K-m (15.2 +/- 2.4 muM) and K-m/k(cat) (0.94 +/- 0.11 mM(-1) x s(-1)) values were obtained for H-Lys(Abz)-Pro-Pro-pNA as the substrate. LeAPP2 activity was maximally stimulated by addition of 4 rom MnCl2 and to some extent also by Mg2+, Ca2+, and Co2+, whereas other divalent metal ions (Cu2+, Zn2+) were inhibitory. Chelating agents and thiolmodifying reagents inhibited the enzyme. The data are consistent with LeAPP2 being a Mn(II)-dependent metalloprotease. This is the first characterization of a plant aminopeptidase, P.	ETH Zurich, Inst Plant Sci, CH-8092 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Schaller, A (corresponding author), ETH Zurich, Inst Plant Sci, Univ Str 2, CH-8092 Zurich, Switzerland.		, None/H-5163-2019; Schaller, Andreas/AAC-1940-2020; Hauser, Felix/M-9670-2013; Hauser, Felix/K-1030-2015	, None/0000-0001-6725-9760; Schaller, Andreas/0000-0001-6872-9576; Hauser, Felix/0000-0001-6725-9760; Hauser, Felix/0000-0001-6725-9760				Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BARRETT AJ, 1998, HDB PROTEOLYTIC ENZY, P1394; BAZAN JF, 1994, P NATL ACAD SCI USA, V91, P2473, DOI 10.1073/pnas.91.7.2473; Blais C, 2000, PEPTIDES, V21, P1903, DOI 10.1016/S0196-9781(00)00348-X; Cottrell GS, 2000, BIOCHEMISTRY-US, V39, P15129, DOI 10.1021/bi0015865; Cottrell GS, 2000, BIOCHEMISTRY-US, V39, P15121, DOI 10.1021/bi001585c; Cunningham DF, 1997, BBA-PROTEIN STRUCT M, V1343, P160, DOI 10.1016/S0167-4838(97)00134-9; Czirjak G, 1999, BBA-GENE STRUCT EXPR, V1444, P326, DOI 10.1016/S0167-4781(99)00005-6; D'souza VM, 2000, BIOCHEMISTRY-US, V39, P3817, DOI 10.1021/bi9925827; D'souza VM, 1999, BIOCHEMISTRY-US, V38, P11079, DOI 10.1021/bi990872h; Gorlach J, 1996, GENE, V170, P145, DOI 10.1016/0378-1119(95)00825-X; HARBECK HT, 1991, EUR J BIOCHEM, V198, P451, DOI 10.1111/j.1432-1033.1991.tb16035.x; HOOPER NM, 1990, BIOCHEM J, V267, P509, DOI 10.1042/bj2670509; Hyde RJ, 1996, BIOCHEM J, V319, P197, DOI 10.1042/bj3190197; Kim KS, 2000, J PHARMACOL EXP THER, V292, P295; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lloyd GS, 1996, BIOCHEM PHARMACOL, V52, P229, DOI 10.1016/0006-2952(96)00180-3; LLOYD GS, 1995, BIOCHEM SOC T, V33, pS60; MEDEIROS MS, 1994, BIOCHIMIE, V76, P283, DOI 10.1016/0300-9084(94)90159-7; MENTLEIN R, 1988, FEBS LETT, V234, P251, DOI 10.1016/0014-5793(88)80092-9; ORAWSKI AT, 1995, BIOCHEMISTRY-US, V34, P11227, DOI 10.1021/bi00035a032; ORAWSKI AT, 1987, MOL CELL BIOCHEM, V75, P123; PEARCE G, 1991, SCIENCE, V253, P895, DOI 10.1126/science.253.5022.895; RAWLINGS ND, 1995, METHOD ENZYMOL, V248, P183; RODERICK SL, 1993, BIOCHEMISTRY-US, V32, P3907, DOI 10.1021/bi00066a009; RUSU I, 1992, EUR J BIOCHEM, V210, P93, DOI 10.1111/j.1432-1033.1992.tb17395.x; Ryan CA, 2001, PLANT PHYSIOL, V125, P65, DOI 10.1104/pp.125.1.65; RYAN JW, 1992, BIOCHIM BIOPHYS ACTA, V1119, P140, DOI 10.1016/0167-4838(92)90384-P; RYAN JW, 1994, J PHARMACOL EXP THER, V269, P941; Sambrook J., 2002, MOL CLONING LAB MANU; Schaller A, 1999, PLANT CELL, V11, P263, DOI 10.1105/tpc.11.2.263; Schaller A, 1999, PLANT MOL BIOL, V40, P763, DOI 10.1023/A:1006279409687; SCHALLER A, 2001, IN PRESS BIOACTIVE N; SCHMID J, 1992, PLANT J, V2, P375; SIMMONS WH, 1992, J BIOL CHEM, V267, P4897; SMITH TA, 1991, P NATL ACAD SCI USA, V88, P5159, DOI 10.1073/pnas.88.12.5159; Sprinkle TJ, 2000, ARCH BIOCHEM BIOPHYS, V378, P51, DOI 10.1006/abbi.2000.1792; Stockel-Maschek A, 2000, BBA-PROTEIN STRUCT M, V1479, P15, DOI 10.1016/S0167-4838(00)00054-6; VANHOOF G, 1995, FASEB J, V9, P736, DOI 10.1096/fasebj.9.9.7601338; Veneman RC, 1997, BBA-GENE STRUCT EXPR, V1354, P45, DOI 10.1016/S0167-4781(97)00126-7; Wilce MCJ, 1998, P NATL ACAD SCI USA, V95, P3472, DOI 10.1073/pnas.95.7.3472; YARON A, 1993, CRIT REV BIOCHEM MOL, V28, P31, DOI 10.3109/10409239309082572; YARON A, 1968, BIOCHEM BIOPH RES CO, V32, P658, DOI 10.1016/0006-291X(68)90289-1; YOSHIMOTO T, 1994, ARCH BIOCHEM BIOPHYS, V311, P28, DOI 10.1006/abbi.1994.1204; YOSHIMOTO T, 1988, J BIOCHEM, V104, P93, DOI 10.1093/oxfordjournals.jbchem.a122430	45	16	18	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					31732	31737		10.1074/jbc.M103179200	http://dx.doi.org/10.1074/jbc.M103179200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11423553	hybrid			2022-12-25	WOS:000170613500036
J	Kimura, T; Sato, K; Kuwabara, A; Tomura, H; Ishiwara, M; Kobayashi, I; Ui, M; Okajima, F				Kimura, T; Sato, K; Kuwabara, A; Tomura, H; Ishiwara, M; Kobayashi, I; Ui, M; Okajima, F			Sphingosine 1-phosphate may be a major component of plasma lipoproteins responsible for the cytoprotective actions in human umbilical vein endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; CULTURED HUMAN; RECEPTORS; ACTIVATION; KINASE; ATHEROSCLEROSIS; LYSOPHOSPHATIDYLCHOLINE; PROLIFERATION; PHOSPHOLIPIDS; MECHANISMS	Sphingosine 1-phosphate (S1P), a novel lipid mediator, is concentrated in the fraction of lipoproteins that include high density lipoprotein (EDL) and low density lipoprotein (LDL) in human plasma. Here, we show that oxidation of IDL resulted in a marked reduction in the S1P level in association with a marked accumulation of lysophosphatidylcholine (LPC). We therefore investigated the role of the lipoprotein-associated lipids especially S1P in the lipoprotein-induced cytoprotective or cytotoxic actions in human umbilical vein endothelial cells. The viability of the cells gradually decreased in the absence of serum or growth factors in the culture medium. The addition of oxidized LDL (ox-LDL) accelerated the decrease in the cell viability. LPC and 7-ketocholesterol mimicked ox-LDL actions. On the other hand, HDL and LDL almost completely reversed the serum deprivation- or ox-LDL-induced cytotoxicity. Exogenous S1P mimicked cytoprotective actions. Moreover, the S1P-rich fraction and chromatographically purified S1P from HDL exerted cytoprotective actions, but the rest of the fractions did not. The cytoprotective actions of HDL and S1P were associated with extracellular signal-regulated kinase (EM activation and were almost completely inhibited by pertussis toxin and PD98059, an ERK kinase inhibitor. The HDL-induced action was specifically desensitized in the S1P-pretreated cells. Taken together, these results indicate that the lipoprotein-associated S1P and the lipid receptor-mediated signal pathways may be responsible for the lipoprotein-induced cytoprotective actions. Furthermore, the decrease in the S1P content, in addition to the accumulation of cytotoxic substances such as LPC, may be important for the acquisition of the cytotoxic property to ox-LDL.	Gunma Univ, Inst Mol & Cellular Regulat, Lab Signal Transduct, Maebashi, Gumma 3718512, Japan; Gunma Univ, Sch Med, Dept Lab Med, Maebashi, Gumma 3718511, Japan; Tokyo Metropolitan Inst Med Sci, Tokyo 113, Japan	Gunma University; Gunma University; Tokyo Metropolitan Institute of Medical Science	Okajima, F (corresponding author), Gunma Univ, Inst Mol & Cellular Regulat, Lab Signal Transduct, 3-39-15 Showa Machi, Maebashi, Gumma 3718512, Japan.	fokajima@showa.gunma-u.ac.jp		Sato, Koichi/0000-0001-7694-4014				An SZ, 2000, J BIOL CHEM, V275, P288, DOI 10.1074/jbc.275.1.288; Diaz MN, 1997, NEW ENGL J MED, V337, P408, DOI 10.1056/NEJM199708073370607; Harada-Shiba M, 1998, J BIOL CHEM, V273, P9681, DOI 10.1074/jbc.273.16.9681; HEERY JM, 1995, J CLIN INVEST, V96, P2322, DOI 10.1172/JCI118288; HESS HH, 1975, ANAL BIOCHEM, V63, P607, DOI 10.1016/0003-2697(75)90388-7; Hla T, 1999, BIOCHEM PHARMACOL, V58, P201; Igarashi J, 2001, J BIOL CHEM, V276, P12420, DOI 10.1074/jbc.M008375200; KAWAKAMI K, 1989, CLIN CHIM ACTA, V185, P147, DOI 10.1016/0009-8981(89)90037-5; Kimura T, 2000, BIOCHEM J, V348, P71, DOI 10.1042/0264-6021:3480071; Kon J, 1999, J BIOL CHEM, V274, P23940, DOI 10.1074/jbc.274.34.23940; KUME N, 1992, J CLIN INVEST, V90, P1138, DOI 10.1172/JCI115932; Kwon YG, 2001, J BIOL CHEM, V276, P10627, DOI 10.1074/jbc.M011449200; Lee MJ, 1999, CELL, V99, P301, DOI 10.1016/S0092-8674(00)81661-X; Moolenaar WH, 1999, EXP CELL RES, V253, P230, DOI 10.1006/excr.1999.4702; Murata N, 2000, ANAL BIOCHEM, V282, P115, DOI 10.1006/abio.2000.4580; Murata N, 2000, BIOCHEM J, V352, P809, DOI 10.1042/0264-6021:3520809; PARTHASARATHY S, 1990, P NATL ACAD SCI USA, V87, P9741, DOI 10.1073/pnas.87.24.9741; Pyne S, 2000, BIOCHEM J, V349, P385, DOI 10.1042/0264-6021:3490385; QUINN MT, 1988, P NATL ACAD SCI USA, V85, P2805, DOI 10.1073/pnas.85.8.2805; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Sachinidis A, 1999, ARTERIOSCL THROM VAS, V19, P2412, DOI 10.1161/01.ATV.19.10.2412; Sata M, 1998, J CLIN INVEST, V102, P1682, DOI 10.1172/JCI3531; Sato K, 1999, MOL PHARMACOL, V55, P126, DOI 10.1124/mol.55.1.126; Siess W, 1999, P NATL ACAD SCI USA, V96, P6931, DOI 10.1073/pnas.96.12.6931; Spiegel S, 1996, FASEB J, V10, P1388, DOI 10.1096/fasebj.10.12.8903509; Steinberg D, 1997, J BIOL CHEM, V272, P20963, DOI 10.1074/jbc.272.34.20963; Suc I, 1997, ARTERIOSCL THROM VAS, V17, P2158, DOI 10.1161/01.ATV.17.10.2158; Sugano M, 2000, BIOCHEM BIOPH RES CO, V272, P872, DOI 10.1006/bbrc.2000.2877; Tamama K, 2001, BIOCHEM J, V353, P139, DOI 10.1042/bj3530139; Watson AD, 1997, J BIOL CHEM, V272, P13597, DOI 10.1074/jbc.272.21.13597; Xia P, 1999, J BIOL CHEM, V274, P33143, DOI 10.1074/jbc.274.46.33143; Xia P, 1999, J BIOL CHEM, V274, P34499, DOI 10.1074/jbc.274.48.34499; Yamazaki Y, 2000, BIOCHEM BIOPH RES CO, V268, P583, DOI 10.1006/bbrc.2000.2162	34	222	228	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					31780	31785		10.1074/jbc.M104353200	http://dx.doi.org/10.1074/jbc.M104353200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11427538	hybrid			2022-12-25	WOS:000170613500042
J	Lemoine, FJ; Marriott, SJ				Lemoine, FJ; Marriott, SJ			Accelerated G(1) phase progression induced by the human T cell leukemia virus type I (HTLV-I) tax oncoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CYCLIN-E; S-PHASE; HUMAN-LYMPHOCYTES; E2F COMPLEXES; PROTEIN; GENE; KINASE; EXPRESSION; TRANSITION; TRANSFORMATION	Tax, the human T cell leukemia virus type I oncoprotein, plays a crucial role in viral transformation and the development of the virally associated disease adult T cell leukemia. Because oncogenesis involves alterations in cell growth, it is important to examine the effects of Tax on cell cycle progression. Using a synchronized cell system, we have found that Tax expression accelerates G(1) phase progression and S phase entry with concomitant DNA replication. This accelerated progression is accompanied by an earlier onset of cdk2 kinase activity. In contrast to the shortening of G(1) phase, the length of S phase is unaffected by Tax expression. As a result of a more rapid cell cycle progression, cells expressing Tax exhibit faster growth kinetics and display an altered cell cycle distribution. Additionally, the decreased time allowed for growth in the presence of Tax results in a decreased cell size. Tax-associated acceleration of cell cycle progression may play a role in the ability of this viral oncoprotein to mediate cellular transformation and promote the development of human T cell leukemia virus type I-associated diseases.	Baylor Coll Med, Interdepartmental Program Cell & Mol Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Marriott, SJ (corresponding author), 1 Baylor Plaza, Houston, TX 77030 USA.				NCI NIH HHS [CA-77371, CA09197] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077371] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akagi T, 1996, ONCOGENE, V12, P1645; Cereseto A, 1999, ONCOGENE, V18, P2441, DOI 10.1038/sj.onc.1202567; Cereseto A, 1996, BLOOD, V88, P1551, DOI 10.1182/blood.V88.5.1551.bloodjournal8851551; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Ekholm SV, 2000, CURR OPIN CELL BIOL, V12, P676, DOI 10.1016/S0955-0674(00)00151-4; GRASSMANN R, 1992, J VIROL, V66, P4570, DOI 10.1128/JVI.66.7.4570-4575.1992; GROSSMAN WJ, 1995, P NATL ACAD SCI USA, V92, P1057, DOI 10.1073/pnas.92.4.1057; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; IKEDA MA, 1993, MOL CELL BIOL, V13, P7029, DOI 10.1128/MCB.13.11.7029; Kao SY, 2000, ONCOGENE, V19, P2240, DOI 10.1038/sj.onc.1203559; Kao SY, 1999, J VIROL, V73, P4299, DOI 10.1128/JVI.73.5.4299-4304.1999; Low KG, 1997, J VIROL, V71, P1956, DOI 10.1128/JVI.71.3.1956-1962.1997; Mesnard JM, 1999, VIROLOGY, V257, P277, DOI 10.1006/viro.1999.9685; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; Moberg K, 1996, MOL CELL BIOL, V16, P1436; Mulloy JC, 1998, J VIROL, V72, P8852, DOI 10.1128/JVI.72.11.8852-8860.1998; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; Neuveut C, 1998, MOL CELL BIOL, V18, P3620, DOI 10.1128/MCB.18.6.3620; NEVINS JR, 1992, SCIENCE, V258, P424; OAKAGI T, 1997, FEBS LETT, V406, P263; Ohtani K, 2000, J BIOL CHEM, V275, P11154, DOI 10.1074/jbc.275.15.11154; Philpott SM, 1999, J NATL CANCER I, V91, P933, DOI 10.1093/jnci/91.11.933; Pise-Masison CA, 1998, J VIROL, V72, P1165, DOI 10.1128/JVI.72.2.1165-1170.1998; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; POZZATTI R, 1990, MOL CELL BIOL, V10, P413, DOI 10.1128/MCB.10.1.413; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; Santiago F, 1999, J VIROL, V73, P9917, DOI 10.1128/JVI.73.12.9917-9927.1999; Schmitt I, 1998, J VIROL, V72, P633, DOI 10.1128/JVI.72.1.633-640.1998; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; Smith EJ, 1996, MOL CELL BIOL, V16, P6965; Suzuki T, 1999, VIROLOGY, V259, P384, DOI 10.1006/viro.1999.9760; Suzuki T, 1996, EMBO J, V15, P1607, DOI 10.1002/j.1460-2075.1996.tb00505.x; TSAI LH, 1993, ONCOGENE, V8, P1593; van der Sman J, 1999, J BIOL CHEM, V274, P12009, DOI 10.1074/jbc.274.17.12009; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WIMMEL A, 1994, ONCOGENE, V9, P995	40	48	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					31851	31857		10.1074/jbc.M105195200	http://dx.doi.org/10.1074/jbc.M105195200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11435441	hybrid			2022-12-25	WOS:000170613500053
J	Toyotome, T; Suzuki, T; Kuwae, A; Nonaka, T; Fukuda, H; Imajoh-Ohmi, S; Toyofuku, T; Hori, M; Sasakawa, C				Toyotome, T; Suzuki, T; Kuwae, A; Nonaka, T; Fukuda, H; Imajoh-Ohmi, S; Toyofuku, T; Hori, M; Sasakawa, C			Shigella protein IpaH(9.8) is secreted from bacteria within mammalian cells and transported to the nucleus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENTEROPATHOGENIC ESCHERICHIA-COLI; EPITHELIAL-CELLS; III SECRETION; HOST-CELLS; MOLECULAR-BASIS; IPA INVASINS; FLEXNERI; VIRULENCE; PLASMID; GENES	Various pathogenic bacteria such as Shigella deliver effector proteins into mammalian cells via the type III secretion system. The delivered Shigella effectors have been shown to variously affect host functions required for efficient bacterial internalization into the cells. In the present study, we investigated the IpaH proteins for their ability to be secreted via the type III secretion system and their fate in mammalian cells. Upon incubation in a medium containing Congo red, the bacteria secrete IpaH into the medium, but secretion of IpaH occurs later than that of IpaBCD. Immunofluorescence microscopy indicated that IpaH(9.8) is secreted from intracellular bacteria and transported into the nucleus. On microinjection of the protein, intracellular IpaH(9.8) is accumulated at one place around the nucleus and transported into the nucleus. This movement seems to be dependent on the microtubule network, since nuclear accumulation of IpaH(9.8) is inhibited in cells treated with microtubule-destabilizing agents. In nuclear import assay, IpaH9.8 was efficiently transported into the nucleus, which was completely blocked by treatment with wheat germ agglutinin. The nuclear transport of IpaH(9.8) does not depend on host cytosolic factors but is partially dependent on ATP/GTP, suggesting that, like beta -catenin, IpaH(9.8) secreted from intracellular Shigella can be transported into the nucleus.	Univ Tokyo, Inst Med Sci, Dept Microbiol & Immunol,Div Bacterial Infect, Minato Ku, Tokyo 1088639, Japan; Univ Tokyo, Inst Med Sci, Div Cell Biol & Biochem,Dept Basic Med Sci, Minato Ku, Tokyo 1088639, Japan; Osaka Univ, Grad Sch Med, Dept Internal Med & Therapeut, Suita, Osaka 5650871, Japan	University of Tokyo; University of Tokyo; Osaka University	Sasakawa, C (corresponding author), Univ Tokyo, Inst Med Sci, Dept Microbiol & Immunol,Div Bacterial Infect, Minato Ku, Tokyo 1088639, Japan.	sasakawa@ims.u-tokyo.ac.jp	Nonaka, Takashi/L-8572-2017	Nonaka, Takashi/0000-0002-0830-9403; Toyotome, Takahito/0000-0003-2822-2767				ADAM SA, 1992, METHOD ENZYMOL, V219, P97; ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; Alconada A, 1999, J VIROL, V73, P377, DOI 10.1128/JVI.73.1.377-387.1999; Bleves S, 2000, MICROBES INFECT, V2, P1451, DOI 10.1016/S1286-4579(00)01300-9; Bliska JB, 2000, TRENDS MICROBIOL, V8, P205, DOI 10.1016/S0966-842X(00)01738-8; Bourdet-Sicard R, 1999, EMBO J, V18, P5853, DOI 10.1093/emboj/18.21.5853; Buchanan SGS, 1996, PROG BIOPHYS MOL BIO, V65, P1, DOI 10.1016/S0079-6107(96)00003-X; Buchrieser C, 2000, MOL MICROBIOL, V38, P760, DOI 10.1046/j.1365-2958.2000.02179.x; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; Celli J, 2000, CELL MICROBIOL, V2, P1, DOI 10.1046/j.1462-5822.2000.00033.x; Cornelis GR, 2000, ANNU REV MICROBIOL, V54, P735, DOI 10.1146/annurev.micro.54.1.735; Cornelis GR, 2000, P NATL ACAD SCI USA, V97, P8778, DOI 10.1073/pnas.97.16.8778; Demers B, 1998, EMBO J, V17, P2894, DOI 10.1093/emboj/17.10.2894; DeVinney R, 1999, CURR OPIN MICROBIOL, V2, P83, DOI 10.1016/S1369-5274(99)80014-9; DeVinney R, 1999, CELL MOL LIFE SCI, V55, P961, DOI 10.1007/s000180050347; Fagotto F, 1998, CURR BIOL, V8, P181, DOI 10.1016/S0960-9822(98)70082-X; Fernandez-Prada CM, 2000, INFECT IMMUN, V68, P3608, DOI 10.1128/IAI.68.6.3608-3619.2000; Finlay BB, 2000, PHILOS T ROY SOC B, V355, P623, DOI 10.1098/rstb.2000.0603; Freiberg C, 1997, NATURE, V387, P394, DOI 10.1038/387394a0; Goodson HV, 1997, CURR OPIN CELL BIOL, V9, P18, DOI 10.1016/S0955-0674(97)80147-0; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; HARTMAN AB, 1990, J BACTERIOL, V172, P1905, DOI 10.1128/jb.172.4.1905-1915.1990; HIGH N, 1992, EMBO J, V11, P1991, DOI 10.1002/j.1460-2075.1992.tb05253.x; Hoque M, 1999, J VIROL, V73, P7912, DOI 10.1128/JVI.73.9.7912-7915.1999; Hueck CJ, 1998, MICROBIOL MOL BIOL R, V62, P379, DOI 10.1128/MMBR.62.2.379-433.1998; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; LANFORD RE, 1984, CELL, V37, P801, DOI 10.1016/0092-8674(84)90415-X; MAURELLI AT, 1984, INFECT IMMUN, V43, P397, DOI 10.1128/IAI.43.1.397-401.1984; MENARD R, 1994, EMBO J, V13, P5293, DOI 10.1002/j.1460-2075.1994.tb06863.x; NHIEU GTV, 1999, EMBO J, V18, P3249; Niebuhr K, 2000, MOL MICROBIOL, V38, P8, DOI 10.1046/j.1365-2958.2000.02041.x; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; PAINE PL, 1975, NATURE, V254, P109, DOI 10.1038/254109a0; SASAKAWA C, 1993, J BACTERIOL, V175, P2334, DOI 10.1128/JB.175.8.2334-2346.1993; SASAKAWA C, 1986, INFECT IMMUN, V51, P470, DOI 10.1128/IAI.51.2.470-475.1986; SASAKAWA C, 1988, J BACTERIOL, V170, P2480, DOI 10.1128/jb.170.6.2480-2484.1988; Skrzypek E, 1998, MOL MICROBIOL, V30, P1051, DOI 10.1046/j.1365-2958.1998.01135.x; Sodeik B, 1997, J CELL BIOL, V136, P1007, DOI 10.1083/jcb.136.5.1007; SORENY B, 1957, ACTA MICROBIOL HUNG, V4, P367; Suomalainen M, 1999, J CELL BIOL, V144, P657, DOI 10.1083/jcb.144.4.657; Tamano K, 2000, EMBO J, V19, P3876, DOI 10.1093/emboj/19.15.3876; TOBE T, 1991, MOL MICROBIOL, V5, P887, DOI 10.1111/j.1365-2958.1991.tb00762.x; Tsolis RM, 1999, INFECT IMMUN, V67, P6385; UCHIYA KI, 1995, MOL MICROBIOL, V17, P241, DOI 10.1111/j.1365-2958.1995.mmi_17020241.x; Vallance BA, 2000, P NATL ACAD SCI USA, V97, P8799, DOI 10.1073/pnas.97.16.8799; Van Nhieu GT, 1999, CURR OPIN MICROBIOL, V2, P51; VanNhieu GT, 1997, EMBO J, V16, P2717, DOI 10.1093/emboj/16.10.2717; VENKATESAN MM, 1991, MOL MICROBIOL, V5, P2435, DOI 10.1111/j.1365-2958.1991.tb02089.x; Wallis TS, 2000, MOL MICROBIOL, V36, P997, DOI 10.1046/j.1365-2958.2000.01892.x; WATARAI M, 1995, EMBO J, V14, P2461, DOI 10.1002/j.1460-2075.1995.tb07243.x; Yokoya F, 1999, MOL BIOL CELL, V10, P1119, DOI 10.1091/mbc.10.4.1119; Yoneda Y, 2000, GENES CELLS, V5, P777, DOI 10.1046/j.1365-2443.2000.00366.x; YONEDA Y, 1987, EXP CELL RES, V173, P586, DOI 10.1016/0014-4827(87)90297-7	53	64	70	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					32071	32079		10.1074/jbc.M101882200	http://dx.doi.org/10.1074/jbc.M101882200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11418613	hybrid			2022-12-25	WOS:000170613500083
J	van Eenennaam, H; Lugtenberg, D; Vogelzangs, JHP; van Venrooij, WJ; Pruijn, GJM				van Eenennaam, H; Lugtenberg, D; Vogelzangs, JHP; van Venrooij, WJ; Pruijn, GJM			hPop5, a protein subunit of the human RNase AMP and RNase P endoribonucleases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN RIBONUCLEASE-P; PRECURSOR RIBOSOMAL-RNA; SACCHAROMYCES-CEREVISIAE; PROCESSING ENZYME; CDNA CLONING; MRP; RIBONUCLEOPROTEIN; NUCLEOLUS; ANTIBODIES; COMPONENT	The RNase MRP and RNase P particles both function as endoribonucleases. RNase AMP has been implicated in the processing of precursor-rRNA, whereas RNase P has been shown to function in the processing of pre-tRNA. Both ribonucleoprotein particles have an RNA component that can be folded into a similar secondary structure and share several protein components. We have identified human, rat, mouse, cow, and Drosophila homologues of the Pop5p protein subunit of the yeast RNase MRP and RNase P complexes. The human Pop5 cDNA encodes a protein of 163 amino acids with a predicted molecular mass of 18.8 kDa. Polyclonal antibodies raised against recombinant hPop5 identified a 19-kDa polypeptide in HeLa cells and showed that hPop5 is associated with both RNase MRP and RNase P. Using affinity-purified anti-hPop5 antibodies, we demonstrated that the endogenous hPop5 protein is localized in the nucleus and accumulates in the nucleolus, which is consistent with its association with RNase MRP and RNase P. Catalytically active RNase P was partially purified from HeLa cells, and hPop5 was shown to be associated with it. Finally, the evolutionarily conserved acidic C-terminal tail of hPop5 appeared to be required neither for complex formation nor for RNase P activity.	Univ Nijmegen, Dept Biochem, NL-6500 HB Nijmegen, Netherlands	Radboud University Nijmegen	Pruijn, GJM (corresponding author), Univ Nijmegen, Dept Biochem 161, POB 9101, NL-6500 HB Nijmegen, Netherlands.		Pruijn, Ger/D-6664-2012; Lugtenberg, Dorien/B-6338-2018					Altman S, 2000, RNA, V6, P1689, DOI 10.1017/S1355838200001783; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BARTKIEWICZ M, 1989, GENE DEV, V3, P488, DOI 10.1101/gad.3.4.488; Chamberlain JR, 1998, GENE DEV, V12, P1678, DOI 10.1101/gad.12.11.1678; CHANG DD, 1987, EMBO J, V6, P409, DOI 10.1002/j.1460-2075.1987.tb04770.x; CHANG DD, 1987, SCIENCE, V235, P1178, DOI 10.1126/science.2434997; Chu S, 1997, RNA, V3, P382; CHU S, 1994, P NATL ACAD SCI USA, V91, P659, DOI 10.1073/pnas.91.2.659; Collins LJ, 2000, J MOL EVOL, V51, P194, DOI 10.1007/s002390010081; Dichtl B, 1997, EMBO J, V16, P417, DOI 10.1093/emboj/16.2.417; Eder PS, 1997, P NATL ACAD SCI USA, V94, P1101, DOI 10.1073/pnas.94.4.1101; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; GIRARD JP, 1994, J BIOL CHEM, V269, P18499; GOLD HA, 1989, SCIENCE, V245, P1377, DOI 10.1126/science.2476849; GOLD HA, 1988, P NATL ACAD SCI USA, V85, P5483, DOI 10.1073/pnas.85.15.5483; HARDIN JA, 1982, J CLIN INVEST, V70, P141, DOI 10.1172/JCI110587; Harlow E., 1988, ANTIBODIES LAB MANUA; HASHIMOTO C, 1983, J BIOL CHEM, V258, P1379; Jarrous N, 1998, RNA, V4, P407; Jarrous N, 1999, J CELL BIOL, V146, P559, DOI 10.1083/jcb.146.3.559; Jarrous N, 1999, RNA, V5, P153, DOI 10.1017/S135583829800185X; Koonin EV, 2001, GENOME RES, V11, P240, DOI 10.1101/gr.162001; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; Lee B, 1996, P NATL ACAD SCI USA, V93, P11471, DOI 10.1073/pnas.93.21.11471; Lygerou Z, 1996, EMBO J, V15, P5936, DOI 10.1002/j.1460-2075.1996.tb00980.x; LYGEROU Z, 1994, GENE DEV, V8, P1423, DOI 10.1101/gad.8.12.1423; Lygerou Z, 1996, SCIENCE, V272, P268, DOI 10.1126/science.272.5259.268; Pluk H, 1998, MOL CELL BIOL, V18, P488, DOI 10.1128/MCB.18.1.488; REDDY R, 1983, J BIOL CHEM, V258, P1383; REIMER G, 1988, EXP CELL RES, V176, P117, DOI 10.1016/0014-4827(88)90126-7; Ridanpaa M, 2001, CELL, V104, P195, DOI 10.1016/S0092-8674(01)00205-7; SCHMIDTZACHMANN MS, 1993, J CELL SCI, V105, P799; SCHMITT ME, 1994, GENE DEV, V8, P2617, DOI 10.1101/gad.8.21.2617; SCHMITT ME, 1993, MOL CELL BIOL, V13, P7935, DOI 10.1128/MCB.13.12.7935; SILLEKENS PTG, 1987, EMBO J, V6, P3841, DOI 10.1002/j.1460-2075.1987.tb02721.x; Stolc V, 1998, P NATL ACAD SCI USA, V95, P6716, DOI 10.1073/pnas.95.12.6716; Stolc V, 1997, GENE DEV, V11, P2926, DOI 10.1101/gad.11.21.2926; Tollervey D, 1997, CURR OPIN CELL BIOL, V9, P337, DOI 10.1016/S0955-0674(97)80005-1; van Eenennaam H, 1999, NUCLEIC ACIDS RES, V27, P2465, DOI 10.1093/nar/27.12.2465; van Eenennaam H, 2000, IUBMB LIFE, V49, P265; VERHEIJEN R, 1994, J IMMUNOL METHODS, V169, P173, DOI 10.1016/0022-1759(94)90261-5; YAN C, 1993, J CELL BIOL, V123, P1081, DOI 10.1083/jcb.123.5.1081	42	39	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					31635	31641		10.1074/jbc.M103399200	http://dx.doi.org/10.1074/jbc.M103399200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11413139	Green Published, hybrid			2022-12-25	WOS:000170613500024
J	Zhang, BH; Tang, ED; Zhu, TQ; Greenberg, ME; Vojtek, AB; Guan, KL				Zhang, BH; Tang, ED; Zhu, TQ; Greenberg, ME; Vojtek, AB; Guan, KL			Serum- and glucocorticoid-inducible kinase SGK phosphorylates and negatively regulates B-Raf	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; MAP KINASE; SIGNALING PATHWAY; REQUIRES PHOSPHORYLATION; SERINE/THREONINE KINASE; ACTIVATION; IDENTIFICATION; INHIBITION; C-RAF-1; SITES	Phosphorylation can both positively and negatively regulate activity of the Raf kinases. Akt has been shown to phosphorylate and inhibit C-Raf activity. We have recently reported that Akt negatively regulates B-Raf kinase activation by phosphorylating multiple residues within its amino-terminal regulatory domain. Here we investigated the regulation of B-Raf by serum and glucocorticoid-inducible kinase, SGK, which shares close sequence identity with the catalytic domain of Akt but lacks the pleckstrin homology domain. We observed that SGK inhibits B-Raf activity. A comparison of substrate specificity between SGK and Akt indicates that SGK is a potent negative regulator of B-Raf. In contrast to Akt, SGK negatively regulates B-Raf kinase activity by phosphorylating only a single Akt consensus site, Ser(364). Under similar experimental conditions, SGK displays a measurably stronger inhibitory effect on B-Raf kinase activity than Akt, whereas Akt; exhibits a more inhibitory effect on the forkhead transcription factor, FKHR. The selective substrate specificity is correlated with an enhanced association between Akt or SGK and their preferred substrates, FKHR and B-Raf, respectively. These results indicate that B-Raf kinase activity is negatively regulated by Akt and SGK, suggesting that the cross-talk between the B-Raf and other signaling pathways can be mediated by both Akt and SGK.	Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Inst Gerontol, Ann Arbor, MI 48109 USA; Harvard Univ, Sch Med, Childrens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard Medical School	Guan, KL (corresponding author), Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA.	kunliang@umich.edu	Guan, Kun-Liang/ADK-7088-2022					Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Barnard D, 1998, ONCOGENE, V17, P1539, DOI 10.1038/sj.onc.1202061; Bell LM, 2000, J BIOL CHEM, V275, P25262, DOI 10.1074/jbc.M002076200; Brunet A, 2001, MOL CELL BIOL, V21, P952, DOI 10.1128/MCB.21.3.952-965.2001; Buse P, 1999, J BIOL CHEM, V274, P7253, DOI 10.1074/jbc.274.11.7253; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chong H, 2001, EMBO J, V20, P3716, DOI 10.1093/emboj/20.14.3716; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; Cutler RE, 1998, P NATL ACAD SCI USA, V95, P9214, DOI 10.1073/pnas.95.16.9214; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DENT P, 1995, SCIENCE, V268, P1902, DOI 10.1126/science.7604263; English J, 1999, EXP CELL RES, V253, P255, DOI 10.1006/excr.1999.4687; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Gonzalez-Robayna IJ, 2000, MOL ENDOCRINOL, V14, P1283, DOI 10.1210/me.14.8.1283; Gorman C, 1996, J BIOL CHEM, V271, P6713, DOI 10.1074/jbc.271.12.6713; Guan KL, 2000, J BIOL CHEM, V275, P27354; Hagemann C, 1999, EXP CELL RES, V253, P34, DOI 10.1006/excr.1999.4689; JANSEN HW, 1984, NATURE, V307, P281, DOI 10.1038/307281a0; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; Kobayashi T, 1999, BIOCHEM J, V344, P189, DOI 10.1042/0264-6021:3440189; MAGNUSON NS, 1994, SEMIN CANCER BIOL, V5, P247; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Mott HR, 1996, P NATL ACAD SCI USA, V93, P8312, DOI 10.1073/pnas.93.16.8312; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; Park J, 1999, EMBO J, V18, P3024, DOI 10.1093/emboj/18.11.3024; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; Perrotti N, 2001, J BIOL CHEM, V276, P9406, DOI 10.1074/jbc.M007052200; Prasad N, 2000, BIOCHEMISTRY-US, V39, P6929, DOI 10.1021/bi000387i; RESING KA, 1995, BIOCHEMISTRY-US, V34, P2610, DOI 10.1021/bi00008a027; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; SCHRAMM K, 1994, BIOCHEM BIOPH RES CO, V201, P740, DOI 10.1006/bbrc.1994.1763; Sidovar MF, 2000, J BIOL CHEM, V275, P28688, DOI 10.1074/jbc.M909351199; Stokoe D, 1997, EMBO J, V16, P2384, DOI 10.1093/emboj/16.9.2384; Tamada M, 1997, ONCOGENE, V15, P2959, DOI 10.1038/sj.onc.1201582; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; VOJTEK AB, 1993, J CELL SCI, V105, P777; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; WEBSTER MK, 1993, MOL CELL BIOL, V13, P2031, DOI 10.1128/MCB.13.4.2031; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; Zhang BH, 2000, EMBO J, V19, P5429, DOI 10.1093/emboj/19.20.5429; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	51	86	91	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					31620	31626		10.1074/jbc.M102808200	http://dx.doi.org/10.1074/jbc.M102808200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11410590	hybrid			2022-12-25	WOS:000170613500022
J	Chen, M; He, HP; Zhan, SX; Krajewski, S; Reed, JC; Gottlieb, RA				Chen, M; He, HP; Zhan, SX; Krajewski, S; Reed, JC; Gottlieb, RA			Bid is cleaved by calpain to an active fragment in vitro and during myocardial ischemia/reperfusion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN-BINDING PROTEIN; VACUOLAR PROTON ATPASE; CYTOCHROME-C RELEASE; OXIDATIVE-PHOSPHORYLATION; CASPASE ACTIVATION; CELL-DEATH; APOPTOSIS; MITOCHONDRIA; ISCHEMIA; CARDIOMYOCYTES	Reperfusion after myocardial ischemia is associated with a rapid influx of calcium, leading to activation of various enzymes including calpain. Isolated perfused adult rabbit hearts subjected to global ischemia and reperfusion were studied. Calpain or a calpain-like activity was activated within 15 min after reperfusion, and preconditioning suppressed calpain activation. In contrast, caspase activation was not detected although cytochrome c was released after ischemia and reperfusion. The pro-apoptotic BH3-only Bcl-2 family member, Bid, was cleaved during ischemia/reperfusion in the adult rabbit heart. Recombinant Bid was cleaved by calpain to a fragment that was able to mediate cytochrome c release. The calpain cleavage site was mapped to a region within Bid that is extremely susceptible to proteolysis. These findings suggest that there is cross-talk between apoptotic and necrotic pathways in myocardial ischemia/reperfusion injury.	Scripps Res Inst, MEM220, La Jolla, CA 92037 USA; Burnham Inst, La Jolla, CA 92037 USA	Scripps Research Institute; Sanford Burnham Prebys Medical Discovery Institute	Gottlieb, RA (corresponding author), Scripps Res Inst, MEM220, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	robbieg@scripps.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036821] Funding Source: NIH RePORTER; NINDS NIH HHS [NS36821] Funding Source: Medline; PHS HHS [60590] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Bialik S, 1999, CIRC RES, V85, P403, DOI 10.1161/01.RES.85.5.403; Bialik S, 1997, J CLIN INVEST, V100, P1363, DOI 10.1172/JCI119656; Black SC, 1998, J MOL CELL CARDIOL, V30, P733, DOI 10.1006/jmcc.1998.0660; Borutaite V, 1995, BBA-MOL BASIS DIS, V1272, P154, DOI 10.1016/0925-4439(95)00080-1; Chen ZM, 2000, J BIOL CHEM, V275, P22619, DOI 10.1074/jbc.C000207200; de Moissac D, 2000, J MOL CELL CARDIOL, V32, P53, DOI 10.1006/jmcc.1999.1057; Di Lisa F, 1998, MOL CELL BIOCHEM, V184, P379, DOI 10.1023/A:1006810523586; Di Lisa F, 2001, J BIOL CHEM, V276, P2571, DOI 10.1074/jbc.M006825200; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; DUAN JM, 1989, MOL CELL BIOCHEM, V90, P47; Ferrari C, 1996, ANNU REV FLUID MECH, V28, P1; FINEGAN BA, 1995, AM J PHYSIOL-HEART C, V269, pH1767, DOI 10.1152/ajpheart.1995.269.5.H1767; Gao G, 2000, J CELL BIOCHEM, V80, P53; Gao WD, 1997, CIRC RES, V80, P393, DOI 10.1161/01.res.0000435855.49359.47; Gao WD, 1996, CIRC RES, V78, P455; GOTTLIEB RA, 1994, J CLIN INVEST, V94, P1621, DOI 10.1172/JCI117504; Gottlieb RA, 2000, METHOD ENZYMOL, V322, P213; Gottlieb RA, 1996, J CLIN INVEST, V97, P2391, DOI 10.1172/JCI118683; KAHLES H, 1977, BASIC RES CARDIOL, V72, P563, DOI 10.1007/BF01907037; Kakkar R, 2001, CELL CALCIUM, V29, P59, DOI 10.1054/ceca.2000.0157; Kakkar R, 2000, J PATHOL, V191, P208, DOI 10.1002/(SICI)1096-9896(200006)191:2<208::AID-PATH618>3.0.CO;2-6; Karwatowska-Prokopczuk E, 1998, CIRC RES, V82, P1139, DOI 10.1161/01.RES.82.11.1139; Kobara M, 1996, J MOL CELL CARDIOL, V28, P417, DOI 10.1006/jmcc.1996.0038; MURRY CE, 1990, CIRC RES, V66, P913, DOI 10.1161/01.RES.66.4.913; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; Olivetti G, 1996, J MOL CELL CARDIOL, V28, P2005, DOI 10.1006/jmcc.1996.0193; Piot CA, 1997, CIRCULATION, V96, P1598, DOI 10.1161/01.CIR.96.5.1598; Saraste A, 1997, CIRCULATION, V95, P320; STEENBERGEN C, 1993, CIRC RES, V72, P112, DOI 10.1161/01.RES.72.1.112; Stoka V, 2001, J BIOL CHEM, V276, P3149, DOI 10.1074/jbc.M008944200; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Toleikis A, 1983, Adv Myocardiol, V4, P409; TSUCHIDA A, 1994, CIRC RES, V75, P576, DOI 10.1161/01.RES.75.3.576; Tsujimoto Yoshihide, 1997, Leukemia (Basingstoke), V11, P380; Veinot JP, 1997, HUM PATHOL, V28, P485, DOI 10.1016/S0046-8177(97)90039-3; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Wang KKW, 2000, TRENDS NEUROSCI, V23, P59, DOI 10.1016/S0166-2236(99)01536-2; Wood DE, 2000, EXP CELL RES, V256, P375, DOI 10.1006/excr.2000.4859	39	312	321	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					30724	30728		10.1074/jbc.M103701200	http://dx.doi.org/10.1074/jbc.M103701200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11404357	hybrid			2022-12-25	WOS:000170472900020
J	Espey, MG; Miranda, KM; Thomas, DD; Wink, DA				Espey, MG; Miranda, KM; Thomas, DD; Wink, DA			Distinction between nitrosating mechanisms within human cells and aqueous solution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE; S-NITROSATION; KINETICS; OXIDATION; OXYGEN; NO; GLUTATHIONE; CHEMISTRY; INSIGHTS; THIOLS	The quintessential nitrosating species produced during NO autoxidation is N2O3. Nitrosation of amine, thiol, and hydroxyl residues can modulate critical cell functions. The biological mechanisms that control reactivity of nitrogen oxide species formed during autoxidation of nano- to micromolar levels of NO were examined using the synthetic donor NaEt2NN(O)NO (DEA/NO), hum an tumor cells, and 4,5-diaminofluorescein (DAF). Both the disappearance of NO and formation of nitrosated product from DAF in aerobic aqueous buffer followed second order processes; however, consumption of NO and nitrosation within intact cells were exponential. An optimal ratio of DEA/NO and 2-phenyl-4,4,5,5-tetramethylimidazole-1-oxyl 3-oxide (PTIO) was used to form N2O3 through the intermediacy of NO2. This route was found to be most reflective of the nitrosative mechanism within intact cells and was distinct from the process that occurred during autoxidation of NO in aqueous media. Manipulation of the endogenous scavengers ascorbate and glutathione indicated that the location, affinity, and concentration of these substances were key determinants in dictating nitrosative susceptibility of molecular targets. Taken together, these findings suggest that the functional effects of nitrosation may be organized to occur within discrete domains or compartments. Nitrosative stress may develop when scavengers are depleted and this architecture becomes compromised. Although NO2 was not a component of aqueous NO autoxidation, the results suggest that the intermediacy of this species may be a significant factor in the advent of either nitrosation or oxidation chemistry in biological systems.	NCI, Radiat Biol Branch, NIH, Div Clin Sci, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Espey, MG (corresponding author), NCI, Radiat Biol Branch, NIH, Div Clin Sci, Bldg 10,Rm B3-B69, Bethesda, MD 20892 USA.	sp@nih.gov	Miranda, Katrina M/B-7823-2009	Thomas, Douglas/0000-0003-1252-0786; Wink, David/0000-0002-5652-7480; Azad, Mahan/0000-0002-8633-3513				Abu-Soud HM, 2000, J BIOL CHEM, V275, P17349, DOI 10.1074/jbc.M000050200; ABUSOUD HM, 1995, J BIOL CHEM, V270, P22997, DOI 10.1074/jbc.270.39.22997; Akaike T, 1996, METHOD ENZYMOL, V268, P211; AKAIKE T, 1993, BIOCHEMISTRY-US, V32, P827, DOI 10.1021/bi00054a013; Al-Mehdi AB, 2000, J BIOL CHEM, V275, P39807, DOI 10.1074/jbc.C000702200; BONNER FT, 1996, METHODS NITRIC OXIDE, P1; Brown LA, 1999, J NEUROSCI METH, V92, P101, DOI 10.1016/S0165-0270(99)00098-9; Burney S, 1999, MUTAT RES-FUND MOL M, V424, P37, DOI 10.1016/S0027-5107(99)00006-8; CHALLIS BC, 1978, J CHEM SOC PERK T 2, P1296, DOI 10.1039/p29780001296; Christodoulou D, 1996, METHOD ENZYMOL, V268, P69; CZAPSKI G, 1995, FREE RADICAL BIO MED, V19, P785, DOI 10.1016/0891-5849(95)00081-8; Espey MG, 2000, J BIOL CHEM, V275, P11341, DOI 10.1074/jbc.275.15.11341; ESPEY MG, 2000, ANN NY ACAD SCI, V288, P209; ESPEY MG, 2000, OXIDAT STRESS DIS, V5, P523; FORD PC, 1993, FEBS LETT, V326, P1, DOI 10.1016/0014-5793(93)81748-O; Fukuto J M, 1995, Adv Pharmacol, V34, P1; Gbadegesin M, 1999, AM J PHYSIOL-CELL PH, V277, pC673, DOI 10.1152/ajpcell.1999.277.4.C673; GOLDSTEIN S, 1995, J AM CHEM SOC, V117, P12078, DOI 10.1021/ja00154a007; Griffith OW, 1999, FREE RADICAL BIO MED, V27, P922, DOI 10.1016/S0891-5849(99)00176-8; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; HIBBS JB, 1987, SCIENCE, V235, P473, DOI 10.1126/science.2432665; HRABIE JA, 1993, J ORG CHEM, V58, P1472, DOI 10.1021/jo00058a030; Jourd'heuil D, 2000, FREE RADICAL BIO MED, V28, P409, DOI 10.1016/S0891-5849(99)00257-9; JUBERT AH, 1984, THEOR CHIM ACTA, V64, P313, DOI 10.1007/BF00551015; Keefer LK, 1996, METHOD ENZYMOL, V268, P281; Keshive M, 1996, CHEM RES TOXICOL, V9, P988, DOI 10.1021/tx960036y; KHARITONOV VG, 1995, J BIOL CHEM, V270, P28158; Kojima H, 1998, ANAL CHEM, V70, P2446, DOI 10.1021/ac9801723; LAVAL F, 1994, CARCINOGENESIS, V15, P443, DOI 10.1093/carcin/15.3.443; LEWIS RS, 1994, CHEM RES TOXICOL, V7, P568, DOI 10.1021/tx00040a013; LIEBMANN JE, 1993, CANCER RES, V53, P2066; Liu XP, 1998, P NATL ACAD SCI USA, V95, P2175, DOI 10.1073/pnas.95.5.2175; Lopez-Figueroa MO, 2000, BIOCHEM BIOPH RES CO, V272, P129, DOI 10.1006/bbrc.2000.2748; MIRANDA KM, 2000, NITRIC OXIDE BIOL PA, P41; Ogawa R, 2001, FREE RADICAL BIO MED, V30, P268, DOI 10.1016/S0891-5849(00)00470-6; OLBREGTS J, 1985, INT J CHEM KINET, V17, P835, DOI 10.1002/kin.550170805; PIRES M, 1994, INT J CHEM KINET, V26, P1207, DOI 10.1002/kin.550261208; Rossig L, 1999, J BIOL CHEM, V274, P6823, DOI 10.1074/jbc.274.11.6823; Thomas DD, 2001, P NATL ACAD SCI USA, V98, P355, DOI 10.1073/pnas.98.1.355; VEDIA LM, 1992, J BIOL CHEM, V267, P24929; Vidwans AS, 1999, J NEUROCHEM, V72, P1843, DOI 10.1046/j.1471-4159.1999.0721843.x; Wang X, 1999, J PHOTOCH PHOTOBIO A, V122, P1, DOI 10.1016/S1010-6030(99)00012-X; Williams D. L. H., 1988, NITROSATION; Wink DA, 1998, FREE RADICAL BIO MED, V25, P434, DOI 10.1016/S0891-5849(98)00092-6; WINK DA, 1994, CARCINOGENESIS, V15, P2125, DOI 10.1093/carcin/15.10.2125; WINK DA, 1993, CHEM RES TOXICOL, V6, P23, DOI 10.1021/tx00031a003; Wink DA, 1997, J BIOL CHEM, V272, P11147; WINK DA, 1994, CHEM RES TOXICOL, V7, P519, DOI 10.1021/tx00040a007; Wolin Michael S., 1996, Microcirculation (Philadelphia), V3, P1, DOI 10.3109/10739689609146778; Xu L, 1998, SCIENCE, V279, P234, DOI 10.1126/science.279.5348.234; Zharikov SI, 2001, AM J PHYSIOL-LUNG C, V280, pL465, DOI 10.1152/ajplung.2001.280.3.L465; Zhou XL, 2000, J BIOL CHEM, V275, P21241, DOI 10.1074/jbc.M904498199	52	125	127	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30085	30091		10.1074/jbc.M101723200	http://dx.doi.org/10.1074/jbc.M101723200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11404354	hybrid			2022-12-25	WOS:000170558000065
J	Nishizuka, M; Honda, K; Tsuchiya, T; Nishihara, T; Imagawa, M				Nishizuka, M; Honda, K; Tsuchiya, T; Nishihara, T; Imagawa, M			RGS2 promotes adipocyte differentiation in the presence of ligand for peroxisome proliferator-activated receptor gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; 3T3-L1 CELLS; TRANSCRIPTIONAL REGULATION; ADIPOGENESIS; PROTEINS; OBESITY; CASCADE; FAMILY	The events at the earliest stage of adipocyte differentiation are yet to be fully elucidated. Previously, we cloned the genes that are induced at the beginning of the differentiation of mouse 3T3-L1 preadipocyte cells. We found that the gene expression of regulators of G protein signaling-2 (RGS2) rapidly increased after the addition of inducers and decreased at 3-12 h. The expression pattern of RGS2 mRNAs differed among growth-arrested and proliferating 3T3-L1 cells and NIH-3T3 cells, indicating a specificity for adipogenesis. Here we report that the ectopic expression of RGS2 using a retroviral system in mouse NIH-3T3 cells promotes adipogenesis only in the presence of BRL49653, which is a ligand for the peroxisome proliferator-activated receptor gamma (PPAR gamma). These results strongly suggest that RGS2 play a crucial role in the program of adipocyte differentiation and may contribute to the function of PPAR gamma.	Nagoya City Univ, Grad Sch Pharmaceut Sci, Dept Mol Biol, Mizuho Ku, Nagoya, Aichi 4678603, Japan; Osaka Univ, Grad Sch Pharmaceut Sci, Lab Environm Biochem, Suita, Osaka 5650871, Japan	Nagoya City University; Osaka University	Imagawa, M (corresponding author), Nagoya City Univ, Grad Sch Pharmaceut Sci, Dept Mol Biol, Mizuho Ku, 3-1 Tanabe Dori, Nagoya, Aichi 4678603, Japan.	imagawa@phar.nagoya-cu.ac.jp						Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; Brun RP, 1996, CURR OPIN CELL BIOL, V8, P826, DOI 10.1016/S0955-0674(96)80084-6; CHAPMAN AB, 1984, J BIOL CHEM, V259, P5548; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CORNELIUS P, 1994, ANNU REV NUTR, V14, P99, DOI 10.1146/annurev.nu.14.070194.000531; DOGLIO A, 1986, BIOCHEM J, V238, P123, DOI 10.1042/bj2380123; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; Friedman JM, 2000, NATURE, V404, P632, DOI 10.1038/35007504; Heximer SP, 2001, J BIOL CHEM, V276, P14195, DOI 10.1074/jbc.M009942200; Imagawa M, 1999, BIOCHEM BIOPH RES CO, V254, P299, DOI 10.1006/bbrc.1998.9937; Kim KM, 2001, J BIOL CHEM, V276, P37409, DOI 10.1074/jbc.M106728200; Kopelman PG, 2000, NATURE, V404, P635, DOI 10.1038/35007508; MACDOUGALD OA, 1995, ANNU REV BIOCHEM, V64, P345, DOI 10.1146/annurev.bi.64.070195.002021; Mandrup S, 1997, J BIOL CHEM, V272, P5367, DOI 10.1074/jbc.272.9.5367; Oliveira-dos-Santos AJ, 2000, P NATL ACAD SCI USA, V97, P12272, DOI 10.1073/pnas.220414397; PAULAUSKIS JD, 1988, J BIOL CHEM, V263, P7049; Reusch JEB, 2000, MOL CELL BIOL, V20, P1008, DOI 10.1128/MCB.20.3.1008-1020.2000; Rosen ED, 2000, GENE DEV, V14, P1293; SADOWSKI HB, 1992, J BIOL CHEM, V267, P4722; Schwarz EJ, 1997, MOL CELL BIOL, V17, P1552, DOI 10.1128/MCB.17.3.1552; Siderovski DP, 1996, CURR BIOL, V6, P211, DOI 10.1016/S0960-9822(02)00454-2; Song L, 2001, BIOCHEM BIOPH RES CO, V283, P102, DOI 10.1006/bbrc.2001.4742; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; Steppan CM, 2001, NATURE, V409, P307, DOI 10.1038/35053000; Tanaka T, 1997, EMBO J, V16, P7432, DOI 10.1093/emboj/16.24.7432; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168	26	42	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					29625	29627		10.1074/jbc.C100272200	http://dx.doi.org/10.1074/jbc.C100272200			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11418611	hybrid			2022-12-25	WOS:000170558000005
J	Chen, F; Zhang, Z; Leonard, SS; Shi, XL				Chen, F; Zhang, Z; Leonard, SS; Shi, XL			Contrasting roles of NF-kappa B and JNK in arsenite-induced p53-independent expression of GADD45 alpha	ONCOGENE			English	Article						arsenite; GADD45 alpha; NF-kappa B; JNK; cell cycle; p53	CELL-CYCLE CHECKPOINT; GENE-EXPRESSION; EPITHELIAL-CELLS; IKK-BETA; ACTIVATION; INDUCTION; KINASE; STRESS; TRANSCRIPTION; BRCA1	Growth arrest and DNA damage-inducible protein 45 alpha (GADD45 alpha) is an important cell cycle checkpoint protein that arrests cells at G2/M phase by inhibiting the activity of G2-specific kinase, cyclin B/p34cdc2. We report here that arsenite induces GADD45 alpha expression in a p53-independent fashion and that this GADD45a induction by arsenite is regulated by NF-KB and c-Jun-N-terminal kinase (JNK) oppositely. In human bronchial epithelial cells overexpressing a kinase-mutated form of I kappaB kinase beta (IKK beta -KM), the activation of NF-kappaB was inhibited. However, the G2/M cell cycle arrest and expression of GADB45 alpha was substantially enhanced in response to arsenite in these cells. Expression of a dominant-negative mutant of SEK1 that blocks JNK activation decreased arsenite-induced GADD45a expression. Analysis of GADD45 alpha expression in both wild-type and p53-/- fibroblasts indicated that the induction of GADD45a by arsenite was independent of the status of p53 protein.	NIOSH, Hlth Effects Lab Div, Morgantown, WV 26505 USA	Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH)	Chen, F (corresponding author), NIOSH, Hlth Effects Lab Div, 1095 Willowdale Rd, Morgantown, WV 26505 USA.		Zhang, Zhuo/B-8601-2012; Shi, Xianglin/B-8588-2012					Barchowsky A, 1996, FREE RADICAL BIO MED, V21, P783, DOI 10.1016/0891-5849(96)00174-8; Cavigelli M, 1996, EMBO J, V15, P6269, DOI 10.1002/j.1460-2075.1996.tb01017.x; Chen F, 1999, CLIN CHEM, V45, P7; Chu WM, 1999, IMMUNITY, V11, P721, DOI 10.1016/S1074-7613(00)80146-6; Du J, 2000, J BIOL CHEM, V275, P19661, DOI 10.1074/jbc.M907258199; Gebel T, 2000, TOXICOLOGY, V144, P155, DOI 10.1016/S0300-483X(99)00202-4; Geleziunas R, 1998, MOL CELL BIOL, V18, P5157, DOI 10.1128/MCB.18.9.5157; GERWIN BI, 1992, P NATL ACAD SCI USA, V89, P2759, DOI 10.1073/pnas.89.7.2759; Guttridge DC, 2000, SCIENCE, V289, P2363, DOI 10.1126/science.289.5488.2363; Hamilton JW, 1998, ENVIRON HEALTH PERSP, V106, P1005, DOI 10.2307/3434145; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; HOLLANDER MC, 1993, J BIOL CHEM, V268, P24385; Huang SC, 1998, CARCINOGENESIS, V19, P889, DOI 10.1093/carcin/19.5.889; Jaspers I, 1999, J BIOL CHEM, V274, P31025, DOI 10.1074/jbc.274.43.31025; Jin SQ, 2000, ONCOGENE, V19, P4050, DOI 10.1038/sj.onc.1203759; Jin SQ, 2000, J BIOL CHEM, V275, P16602, DOI 10.1074/jbc.M000284200; Kapahi P, 2000, J BIOL CHEM, V275, P36062, DOI 10.1074/jbc.M007204200; Karin M, 1998, P NATL ACAD SCI USA, V95, P9067, DOI 10.1073/pnas.95.16.9067; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kayajanian GM, 2000, ECOTOX ENVIRON SAFE, V45, P195, DOI 10.1006/eesa.1999.1865; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Mazumder DNG, 1998, INT J EPIDEMIOL, V27, P871, DOI 10.1093/ije/27.5.871; O'Reilly MA, 2000, AM J PHYSIOL-LUNG C, V278, pL552, DOI 10.1152/ajplung.2000.278.3.L552; Roussel RR, 2000, ARCH BIOCHEM BIOPHYS, V377, P204, DOI 10.1006/abbi.2000.1770; Russell P, 1998, TRENDS BIOCHEM SCI, V23, P399, DOI 10.1016/S0968-0004(98)01291-2; Shaulian E, 1999, J BIOL CHEM, V274, P29595, DOI 10.1074/jbc.274.42.29595; Simeonova Petia P., 2000, Journal of Environmental Pathology Toxicology and Oncology, V19, P281; Simeonova PP, 2000, CANCER RES, V60, P3445; Styblo M, 1999, CHEM RES TOXICOL, V12, P560, DOI 10.1021/tx990050l; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Wang XT, 1999, J BIOL CHEM, V274, P29599, DOI 10.1074/jbc.274.42.29599; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Yang Q, 2000, J BIOL CHEM, V275, P36892, DOI 10.1074/jbc.M005319200; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Zheng L, 2000, MOL CELL, V6, P757, DOI 10.1016/S1097-2765(00)00075-7	36	26	27	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 14	2001	20	27					3585	3589		10.1038/sj.onc.1204442	http://dx.doi.org/10.1038/sj.onc.1204442			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	445VB	11429707				2022-12-25	WOS:000169478300016
J	de Bruijn, DRH; dos Santos, NR; Thijssen, J; Balemans, M; Debernardi, S; Linder, B; Young, BD; van Kessel, AG				de Bruijn, DRH; dos Santos, NR; Thijssen, J; Balemans, M; Debernardi, S; Linder, B; Young, BD; van Kessel, AG			The synovial sarcoma associated protein SYT interacts with the acute leukemia associated protein AF10	ONCOGENE			English	Article						synovial sarcoma; SYT; yeast two hybrid; protein-protein interactions; AF10; acute leukemia	KRUPPEL-ASSOCIATED BOX; RING FINGER; TRANSCRIPTIONAL REPRESSION; T(10-11) TRANSLOCATION; DROSOPHILA-TRITHORAX; SET DOMAIN; GENE; SSX; MOTIF; FUSION	As a result of the synovial sarcoma associated t(X;18) translocation, the human SYT gene on chromosome 18 is fused to either the SSX1 or the SSX2 gene on the X chromosome. Although preliminary evidence indicates that the (fusion) proteins encoded by these genes may play a role in transcriptional regulation, little is known about their exact function. We set out to isolate interacting proteins through yeast two hybrid screening of a human cDNA library using SYT as a bait. Of the positive clones isolated, two were found to correspond to the acute leukemia t(10;11) associated AF10 gene, a fusion partner of MLL, Confirmation of these results was obtained via co-immunoprecipitation of endogenous and exogenous, epitope-tagged, SYT and AF10 proteins from cell line extracts and colocalization of epitope-tagged SYT and AF10 proteins in transfected cells. Subsequent sequential mutation analysis revealed a highly specific interaction of N-terminal SYT fragments with C-terminal AF10 fragments, The N-terminal interaction domain of the SYT protein was also found to be present in several SYT orthologs and homologs, The C-terminal interaction domain of AF10 is located outside known functional domains. Based on these results, a model is proposed in which the SYT and AF10 proteins act in concert as bipartite transcription factors. This model has implications for the molecular mechanisms underlying the development of both human synovial sarcomas and acute leukemias.	Univ Nijmegen Hosp, Dept Human Genet, NL-6500 HB Nijmegen, Netherlands; St Bartholomews Hosp, Imperial Canc Res Fund, Med Oncol Unit, London EC1A 7BE, England	Radboud University Nijmegen; Cancer Research UK; University of London; Queen Mary University London	de Bruijn, DRH (corresponding author), Univ Nijmegen Hosp, Dept Human Genet, POB 9101, NL-6500 HB Nijmegen, Netherlands.		van Kessel, Ad Geurts/A-2810-2010; dos Santos, Nuno Rodrigues/F-4411-2012; de Bruijn, D.R.H./L-4233-2015	dos Santos, Nuno Rodrigues/0000-0001-7347-2592; 				AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; Bairoch A, 1997, NUCLEIC ACIDS RES, V25, P217, DOI 10.1093/nar/25.1.217; BELLEFROID EJ, 1991, P NATL ACAD SCI USA, V88, P3608, DOI 10.1073/pnas.88.9.3608; Brett D, 1997, HUM MOL GENET, V6, P1559, DOI 10.1093/hmg/6.9.1559; CHAPLIN T, 1995, BLOOD, V86, P2073, DOI 10.1182/blood.V86.6.2073.bloodjournal8662073; CHAPLIN T, 1995, BLOOD, V85, P1435, DOI 10.1182/blood.V85.6.1435.bloodjournal8561435; CLARK J, 1994, NAT GENET, V7, P502, DOI 10.1038/ng0894-502; CREW AJ, 1995, EMBO J, V14, P2333, DOI 10.1002/j.1460-2075.1995.tb07228.x; deBruijn DRH, 1996, ONCOGENE, V13, P643; DEBRUIJN DRH, 1994, DIFFERENTIATION, V58, P141; DEBRUIJN DRH, 2001, IN PRESS CYTOGENET C; DELEEUW B, 1995, HUM MOL GENET, V4, P1097, DOI 10.1093/hmg/4.6.1097; deLeeuw B, 1996, CYTOGENET CELL GENET, V73, P179, DOI 10.1159/000134334; DELEEUW B, 1994, CANCER GENET CYTOGEN, V73, P89, DOI 10.1016/0165-4608(94)90191-0; DJABALI M, 1992, NAT GENET, V2, P113, DOI 10.1038/ng1092-113; dos Santos NR, 2000, EXP CELL RES, V256, P192, DOI 10.1006/excr.2000.4813; dos Santos NR, 2000, CANCER RES, V60, P1654; dosSantos NR, 1997, HUM MOL GENET, V6, P1549, DOI 10.1093/hmg/6.9.1549; Eid JE, 2000, CELL, V102, P839, DOI 10.1016/S0092-8674(00)00072-6; EPSTEIN H, 1992, BIOESSAYS, V14, P411, DOI 10.1002/bies.950140612; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; Friedman JR, 1996, GENE DEV, V10, P2067, DOI 10.1101/gad.10.16.2067; Gure AO, 1997, INT J CANCER, V72, P965, DOI 10.1002/(SICI)1097-0215(19970917)72:6<965::AID-IJC8>3.0.CO;2-N; Huth JR, 1997, NAT STRUCT BIOL, V4, P657, DOI 10.1038/nsb0897-657; Jenuwein T, 1998, CELL MOL LIFE SCI, V54, P80, DOI 10.1007/s000180050127; KANAZAWA S, 1988, MOL CELL BIOL, V8, P664, DOI 10.1128/MCB.8.2.664; Kawai A, 1998, NEW ENGL J MED, V338, P153, DOI 10.1056/NEJM199801153380303; Kim SS, 1996, P NATL ACAD SCI USA, V93, P15299, DOI 10.1073/pnas.93.26.15299; Lim FL, 1998, ONCOGENE, V17, P2013, DOI 10.1038/sj.onc.1202122; Linder B, 2000, J MOL BIOL, V299, P369, DOI 10.1006/jmbi.2000.3766; Linder B, 1998, BBA-GENE STRUCT EXPR, V1443, P285, DOI 10.1016/S0167-4781(98)00226-7; MA Q, 1993, P NATL ACAD SCI USA, V90, P6350, DOI 10.1073/pnas.90.13.6350; MARGOLIN JF, 1994, P NATL ACAD SCI USA, V91, P4509, DOI 10.1073/pnas.91.10.4509; Moosmann P, 1996, NUCLEIC ACIDS RES, V24, P4859, DOI 10.1093/nar/24.24.4859; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Rozenblatt-Rosen O, 1998, P NATL ACAD SCI USA, V95, P4152, DOI 10.1073/pnas.95.8.4152; SAHA V, 1995, P NATL ACAD SCI USA, V92, P9737, DOI 10.1073/pnas.92.21.9737; Satijn DPE, 1997, MOL CELL BIOL, V17, P4105, DOI 10.1128/MCB.17.7.4105; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SINGH PB, 1994, J CELL SCI, V107, P2653; Skytting B, 1999, J NATL CANCER I, V91, P974, DOI 10.1093/jnci/91.11.974; Slany RK, 1998, MOL CELL BIOL, V18, P122, DOI 10.1128/MCB.18.1.122; STASSEN MJ, 1995, MECH DEVELOP, V52, P209, DOI 10.1016/0925-4773(95)00402-M; Thaete C, 1999, HUM MOL GENET, V8, P585, DOI 10.1093/hmg/8.4.585; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; Tripoulas N, 1996, GENETICS, V143, P913; TSCHIERSCH B, 1994, EMBO J, V13, P3822, DOI 10.1002/j.1460-2075.1994.tb06693.x; TURCCAREL C, 1987, P NATL ACAD SCI USA, V84, P1981, DOI 10.1073/pnas.84.7.1981; vanKessel AG, 1997, CANCER GENET CYTOGEN, V95, P67, DOI 10.1016/S0165-4608(96)00241-5; Verrijzer CP, 1996, TRENDS BIOCHEM SCI, V21, P338, DOI 10.1016/0968-0004(96)10044-X; WITZGALL R, 1994, P NATL ACAD SCI USA, V91, P4514, DOI 10.1073/pnas.91.10.4514	51	38	41	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 31	2001	20	25					3281	3289		10.1038/sj.onc.1204419	http://dx.doi.org/10.1038/sj.onc.1204419			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	440ET	11423977				2022-12-25	WOS:000169163500011
J	Legler, DF; Doucey, MA; Cerottini, JC; Bron, C; Luescher, IF				Legler, DF; Doucey, MA; Cerottini, JC; Bron, C; Luescher, IF			Selective inhibition of CTL activation by a dipalmitoyl-phospholipid that prevents the recruitment of signaling molecules to lipid rafts	FASEB JOURNAL			English	Article						signal transduction; dipalmitoyl-phosphatidylethanolamine; TCR	T-CELL ACTIVATION; GPI-ANCHORED PROTEINS; POLYUNSATURATED FATTY-ACIDS; INSOLUBLE MEMBRANE DOMAINS; ANTIGEN RECEPTOR; LIGAND INTERACTIONS; PALMITOYLATION; MICRODOMAINS; LYMPHOCYTES; LOCALIZATION	Antigen-specific T-cell activation implicates a redistribution of plasma membrane-bound molecules in lipid rafts, such as the coreceptors CD8 and CD4, the Src kinases Lek and Fyn, and the linker for activation of T cells (LAT), that results in the formation of signaling complexes. These molecules partition in lipid rafts because of palmitoylation of cytoplasmic, membrane proximal cysteines, which is essential for their functional integrity in T-cell activation. Here, we show that exogenous dipalmitoyl-phosphatidylethanolamine (DPPE), but not the related unsaturated dioleoyl-phosphatidylethanolamine (DOPE), partitions in lipid rafts. DPPE inhibits activation of CD8(+) T lymphocytes by sensitized syngeneic antigen-presenting cells or specific major histocompatibility complex (MHC) peptide tetramers, as indicated by esterase release and intracellular calcium mobilization. Cytotoxic, T lymphocyte (CTL)-target cell conjugate formation is not affected by DPPE, indicating that engagement of the T-cell receptor by its cognate ligand is intact in lipid-treated cells. In contrast to other agents known to block raft-dependent signaling, DPPE efficiently inhibits the MHC peptide-induced recruitment of palmitoylated signaling molecules to lipid rafts and CTL activation without affecting cell viability or lipid raft integrity.	Univ Lausanne, Inst Biochem, BIL Biomed Res Ctr, CH-1066 Epalinges, Switzerland; Univ Lausanne, BIL Biomed Res Ctr, Ludwig Inst Canc Res, Lausanne Branch, CH-1066 Epalinges, Switzerland	University of Lausanne; Ludwig Institute for Cancer Research; University of Lausanne	Legler, DF (corresponding author), Univ Lausanne, Inst Biochem, BIL Biomed Res Ctr, Chemin Boveresses 155, CH-1066 Epalinges, Switzerland.	daniel.legler@ib.unil.ch		Legler, Daniel F./0000-0001-8610-4764				Anderson HA, 2000, NAT IMMUNOL, V1, P156, DOI 10.1038/77842; Arcaro A, 2000, J IMMUNOL, V165, P2068, DOI 10.4049/jimmunol.165.4.2068; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Cantrell D, 1996, ANNU REV IMMUNOL, V14, P259, DOI 10.1146/annurev.immunol.14.1.259; CRISE B, 1992, J BIOL CHEM, V267, P13593; Deckert M, 1996, J CELL BIOL, V133, P791, DOI 10.1083/jcb.133.4.791; DOUCEY MA, 2001, IN PRESS EUR J IMMUN; Friedrichson T, 1998, NATURE, V394, P802, DOI 10.1038/29570; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; Janes PW, 1999, J CELL BIOL, V147, P447, DOI 10.1083/jcb.147.2.447; Kabouridis PS, 1997, EMBO J, V16, P4983, DOI 10.1093/emboj/16.16.4983; KOEGL M, 1994, BIOCHEM J, V303, P749, DOI 10.1042/bj3030749; KWONG J, 1995, BIOCHEM BIOPH RES CO, V207, P868, DOI 10.1006/bbrc.1995.1266; Lanzavecchia A, 1999, CELL, V96, P1, DOI 10.1016/S0092-8674(00)80952-6; Lin J, 1999, J BIOL CHEM, V274, P28861, DOI 10.1074/jbc.274.41.28861; London E, 2000, BBA-BIOMEMBRANES, V1508, P182, DOI 10.1016/S0304-4157(00)00007-1; LUESCHER IF, 1995, NATURE, V373, P353, DOI 10.1038/373353a0; LUESCHER IF, 1995, IMMUNITY, V3, P51, DOI 10.1016/1074-7613(95)90158-2; Matsuzaki K, 1996, BIOCHEMISTRY-US, V35, P11361, DOI 10.1021/bi960016v; Millan J, 1999, TISSUE ANTIGENS, V53, P33, DOI 10.1034/j.1399-0039.1999.530104.x; Monks CRF, 1998, NATURE, V395, P82, DOI 10.1038/25764; Montixi C, 1998, EMBO J, V17, P5334, DOI 10.1093/emboj/17.18.5334; OFFNER H, 1987, J IMMUNOL, V139, P3295; PASTERNACK MS, 1986, NATURE, V322, P740, DOI 10.1038/322740a0; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; Rietveld A, 1998, BBA-REV BIOMEMBRANES, V1376, P467, DOI 10.1016/S0304-4157(98)00019-7; Schutz GJ, 2000, EMBO J, V19, P892, DOI 10.1093/emboj/19.5.892; SHENOYSCARIA AM, 1994, J CELL BIOL, V126, P353, DOI 10.1083/jcb.126.2.353; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Stulnig TM, 1998, J CELL BIOL, V143, P637, DOI 10.1083/jcb.143.3.637; Stulnig TM, 2000, FASEB J, V14, P939, DOI 10.1096/fasebj.14.7.939; van't Hof W, 1999, J CELL BIOL, V145, P377, DOI 10.1083/jcb.145.2.377; vantHof W, 1997, J CELL BIOL, V136, P1023, DOI 10.1083/jcb.136.5.1023; Varma R, 1998, NATURE, V394, P798, DOI 10.1038/29563; Viola A, 1999, SCIENCE, V283, P680, DOI 10.1126/science.283.5402.680; Webb Y, 2000, J BIOL CHEM, V275, P261, DOI 10.1074/jbc.275.1.261; Wolven A, 1997, MOL BIOL CELL, V8, P1159, DOI 10.1091/mbc.8.6.1159; Xavier R, 1998, IMMUNITY, V8, P723, DOI 10.1016/S1074-7613(00)80577-4; YURCHAK LK, 1995, MOL CELL BIOL, V15, P6914, DOI 10.1128/mcb.15.12.6914; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8	40	19	20	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY 29	2001	15	7					1601	+		10.1096/fj.00-0841fje	http://dx.doi.org/10.1096/fj.00-0841fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519CQ	11427499				2022-12-25	WOS:000173707700019
J	Bai, LQ; Xu, H; Collins, JF; Ghishan, FK				Bai, LQ; Xu, H; Collins, JF; Ghishan, FK			Molecular and functional analysis of a novel neuronal vesicular glutamate transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INORGANIC-PHOSPHATE COTRANSPORTER; GAMMA-AMINOBUTYRIC-ACID; BRAIN SYNAPTIC VESICLES; ENERGY-DEPENDENCE; ACTIVE-TRANSPORT; H+-ATPASE; LOCALIZATION; EXPRESSION; CLONING; NEUROTRANSMISSION	Glutamate is the major excitatory neurotransmitter in the mammalian central nervous system. Packaging and storage of glutamate into glutamatergic neuronal vesicles requires ATP-dependent vesicular glutamate uptake systems, which utilize the electrochemical proton gradient as a driving force. VGLUT1, the first identified vesicular glutamate transporter, is only expressed in a subset of glutamatergic neurons. We report here the molecular cloning and functional characterization of a novel glutamate transporter, VGLUT2, from mouse brain. VGLUT2 has all major functional characteristics of a synaptic vesicle glutamate transporter, including ATP dependence, chloride stimulation, substrate specificity, and substrate affinity. It has 75 and 79% amino acid identity with human and rat VGLUT1, respectively. However, expression patterns of VGLUT2 in brain are different from that of VGLUT1. In addition, VGLUT2 activity is dependent on both membrane potential and pH gradient of the electrochemical proton gradient, whereas VGLUT1 is primarily dependent on only membrane potential. The presence of VGLUT2 in brain regions lacking VGLUT1 suggests that the two isoforms together play an important role in vesicular glutamate transport in glutamatergic neurons.	Univ Arizona, Hlth Sci Ctr, Steele Mem Childrens Res Ctr, Dept Pediat, Tucson, AZ 85724 USA; Univ Arizona, Hlth Sci Ctr, Steele Mem Childrens Res Ctr, Dept Physiol, Tucson, AZ 85724 USA	University of Arizona; University of Arizona Health Sciences; University of Arizona; University of Arizona Health Sciences	Ghishan, FK (corresponding author), Univ Arizona, Hlth Sci Ctr, Steele Mem Childrens Res Ctr, Dept Pediat, 1501 N Campbell Ave, Tucson, AZ 85724 USA.	lqbai@yahoo.com; fghishan@peds.arizona.edu			NIDDK NIH HHS [2R01-R37DK-33209] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033209] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aihara Y, 2000, J NEUROCHEM, V74, P2622, DOI 10.1046/j.1471-4159.2000.0742622.x; ANDERSON DC, 1982, BIOCHEMISTRY-US, V21, P3037, DOI 10.1021/bi00256a001; BAI L, 2000, AM J PHYSIOL, V278, pC1131; Bai LQ, 1996, J BIOL CHEM, V271, P5171; Bai LQ, 1999, AM J PHYSIOL-REG I, V277, pR1112, DOI 10.1152/ajpregu.1999.277.4.R1112; Bellocchio EE, 1998, J NEUROSCI, V18, P8648; Bellocchio EE, 2000, SCIENCE, V289, P957, DOI 10.1126/science.289.5481.957; BURGER PM, 1989, NEURON, V3, P715, DOI 10.1016/0896-6273(89)90240-7; CARLSON MD, 1989, J BIOL CHEM, V264, P7369; CIDON S, 1989, J BIOL CHEM, V264, P8281; FISCHERBOVENKERK C, 1988, J NEUROCHEM, V51, P1054, DOI 10.1111/j.1471-4159.1988.tb03068.x; Forgac M, 2000, J EXP BIOL, V203, P71; Fykse EM, 1996, NEUROCHEM RES, V21, P1053, DOI 10.1007/BF02532415; HARTINGER J, 1993, J BIOL CHEM, V268, P23122; HELL JW, 1990, J BIOL CHEM, V265, P2111; KANNER BI, 1978, BIOCHEMISTRY-US, V17, P3949, DOI 10.1021/bi00612a011; KISH PE, 1989, P NATL ACAD SCI USA, V86, P3877, DOI 10.1073/pnas.86.10.3877; KISH PE, 1989, METHOD ENZYMOL, V174, P9; KNOTH J, 1981, BIOCHEMISTRY-US, V20, P6625, DOI 10.1021/bi00526a016; Lee RYN, 1999, J NEUROSCI, V19, P159, DOI 10.1523/JNEUROSCI.19-01-00159.1999; LOGAN WJ, 1972, BRAIN RES, V42, P413, DOI 10.1016/0006-8993(72)90540-9; Masson J, 1999, PHARMACOL REV, V51, P439; MAYCOX PR, 1988, J BIOL CHEM, V263, P15423; MORIYAMA Y, 1990, J BIOCHEM, V108, P689, DOI 10.1093/oxfordjournals.jbchem.a123264; NAITO S, 1983, J BIOL CHEM, V258, P696; NAITO S, 1985, J NEUROCHEM, V44, P99, DOI 10.1111/j.1471-4159.1985.tb07118.x; Ni BH, 1996, J NEUROCHEM, V66, P2227; NI BH, 1995, J NEUROSCI, V15, P5789; NI BH, 1994, P NATL ACAD SCI USA, V91, P5607, DOI 10.1073/pnas.91.12.5607; Ozkan ED, 1998, JPN J PHARMACOL, V77, P1, DOI 10.1254/jjp.77.1; RAIZEN DM, 1994, NEURON, V12, P483, DOI 10.1016/0896-6273(94)90207-0; Reimer RJ, 1998, CURR OPIN NEUROBIOL, V8, P405, DOI 10.1016/S0959-4388(98)80068-8; TABB JS, 1992, J BIOL CHEM, V267, P15412; TABB JS, 1991, J NEUROSCI, V11, P1822; Takamori S, 2000, NATURE, V407, P189, DOI 10.1038/35025070	35	164	174	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36764	36769		10.1074/jbc.M104578200	http://dx.doi.org/10.1074/jbc.M104578200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11432869	hybrid			2022-12-25	WOS:000171194500094
J	Gnoth, MJ; Rudloff, S; Kunz, C; Kinne, RKH				Gnoth, MJ; Rudloff, S; Kunz, C; Kinne, RKH			Investigations of the in vitro transport of human milk oligosaccharides by a Caco-2 monolayer using a novel high performance liquid chromatography-mass spectrometry technique	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL-CELL LINE; TRANSEPITHELIAL TRANSPORT; MODEL; LACTOSE	Complex lactose-derived oligosaccharides belong to the main components of human milk and are believed to exert multiple functions in the breast-fed infant. Therefore, we investigated the transepithelial transport of human milk oligosaccharides over Caco-2 monolayers. Main human milk oligosaccharides (HMOs) in the apical, basolateral, or intracellular compartment were separated by high performance liquid chromatography using a Hypercarb(TM) column and analyzed on line by mass spectrometry. This method allowed the identification and quantification of these components in intra- and extracellular fractions without prior purification. Using this technique we were able to show that acidic and neutral HMOs cross the epithelial barrier. The transepithelial flux of neutral, but not acidic, oligosaccharides was temperature-sensitive and partly inhibited by brefeldin A and bafilomycin A. Furthermore, net flux from the apical to the basolateral compartment was only observed for the neutral components. Similarly, apical cellular uptake was only found for neutral components but not for acidic oligosaccharides. Intracellular concentrations of neutral HMOs were significantly increased by inhibitors of transcytosis such as brefeldin A, N-ethylmaleimide, or bafilomycin A. The cellular uptake was saturable, and an apparent K-m for lacto-N-facopentaose I of 1.7 +/- 0.1 mmol/liter and for lacto-N-tetraose of 1.8 +/- 0.4 mmol/liter was determined. Furthermore, the uptake of lacto-N-facopentaose I could be inhibited by the addition of the stereoisomer lacto-N-fucopentaose II but not by lacto-N-tetraose. These findings suggest that neutral HMOs are transported across the intestinal epithelium by receptor-mediated transcytosis as well as via paracellular pathways, whereas translocation of acidic HMOs solely represents paracellular flux.	Max Planck Inst Mol Physiol, D-44227 Dortmund, Germany; Inst Ernahrungswissensch, D-35392 Giessen, Germany	Max Planck Society	Kinne, RKH (corresponding author), Max Planck Inst Mol Physiol, Otto Hahn Str 11, D-44227 Dortmund, Germany.	rolf.kinne@mpi-dortmund.mpg.de						ARTURSSON P, 1990, J PHARM SCI-US, V79, P476, DOI 10.1002/jps.2600790604; BACHER A, 1992, EXP CELL RES, V200, P97, DOI 10.1016/S0014-4827(05)80076-X; Bayer N, 1998, J VIROL, V72, P9645, DOI 10.1128/JVI.72.12.9645-9655.1998; DAVIES M, 1992, J CHROMATOGR, V609, P125, DOI 10.1016/0021-9673(92)80155-N; Delie F, 1997, CRIT REV THER DRUG, V14, P221; Finke B, 2000, ANAL BIOCHEM, V284, P256, DOI 10.1006/abio.2000.4680; Finke B, 1999, ANAL CHEM, V71, P3755, DOI 10.1021/ac990094z; Gnoth MJ, 2000, J NUTR, V130, P3014, DOI 10.1093/jn/130.12.3014; GNOTH MJ, 2001, IN PRESS FOOD RES IN; HIDALGO IJ, 1989, GASTROENTEROLOGY, V96, P736; JUMARIE C, 1991, J CELL PHYSIOL, V149, P24, DOI 10.1002/jcp.1041490105; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; Kunz C, 1999, BRIT J NUTR, V82, P391, DOI 10.1017/S0007114599001798; Kunz C, 2000, ANNU REV NUTR, V20, P699, DOI 10.1146/annurev.nutr.20.1.699; KUNZ C, 1993, ACTA PAEDIATR, V82, P903, DOI 10.1111/j.1651-2227.1993.tb12597.x; Maksymowych AB, 1998, J BIOL CHEM, V273, P21950, DOI 10.1074/jbc.273.34.21950; Mizuuchi H, 2000, PHARMACEUT RES, V17, P539, DOI 10.1023/A:1007560731098; MU JZ, 1994, BBA-MOL CELL RES, V1222, P483, DOI 10.1016/0167-4889(94)90058-2; Newburg DS, 1999, CURR MED CHEM, V6, P117; Obermeier S, 1999, ISOT ENVIRON HEALT S, V35, P119, DOI 10.1080/10256019908234084; Rudloff S, 1996, ACTA PAEDIATR, V85, P598, DOI 10.1111/j.1651-2227.1996.tb14095.x; Takata K, 1996, J ELECTRON MICROSC, V45, P275, DOI 10.1093/oxfordjournals.jmicro.a023443	22	83	87	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					34363	34370		10.1074/jbc.M104805200	http://dx.doi.org/10.1074/jbc.M104805200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11423546	hybrid			2022-12-25	WOS:000171024600003
J	Liou, JY; Deng, WG; Gilroy, DW; Shyue, SK; Wu, KK				Liou, JY; Deng, WG; Gilroy, DW; Shyue, SK; Wu, KK			Colocalization and interaction of cyclooxygenase-2 with caveolin-1 in human fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; SECRETORY PHOSPHOLIPASE A(2); INDUCIBLE CYCLOOXYGENASE; SCAFFOLDING DOMAIN; PROSTAGLANDIN; PROTEIN; MEMBRANE; INHIBITION; EXPRESSION; TRANSPORT	Results from our previous study suggest that cyclooxygenase-2 (COX-2) induced by phorbol 12-myristate 13-acetate (PMA) may be localized to caveolae-like structures (Liou, J.-Y., Shyue, S.-K., Tsai, M.-J., Chung, C.-L., Chu, K.-Y., and Wu, K. K. (2000) J. Biol. Chem. 275, 15314-15320). In this study, we determined subcellular localization of COX-2 and caveolin-1 by confocal microscopy. COX-2 in human foreskin fibroblasts stimulated by PMA (100 mM) or interleukin-1 beta (1 ng/ml) for 6 h was localized to plasma membrane in addition to endoplasmic reticulum and nuclear envelope. Caveolin-1 was localized to plasma membrane, and image overlay showed colocalization of COX-2 with caveolin-1. This was confirmed by the presence of COX-2 and caveolin-1 in the detergent-insoluble membrane fraction of cells stimulated by PMA. Immunoprecipitation showed complex formation of COX-2 with caveolin-1 in a time-dependent manner. A larger quantity of COX-2 was complexed with caveolin-1 in PMA-treated than in interleukin-Ig-treated cells. Purified COX-2 complexed with glutathione S-transferase-fused caveolin-1, which was not inhibited by the scaffolding domain peptide. Caveolin-1-bound COX-2 was catalytically active, and its activity was not inhibited by the scaffolding domain peptide. These results suggest that COX-2 induced by PMA and interleukin-10 is colocalized with caveolin-1 in the segregated caveolae compartment. Because caveolae, are rich in signaling molecules, this COX-2 compartment may play an important role in diverse pathophysiological processes.	Univ Texas, Sch Med, Vasc Biol Res Ctr, Houston, TX 77030 USA; Univ Texas, Sch Med, Div Hematol, Houston, TX 77030 USA; Acad Sinica, Inst Biomed Sci, Vasc Res Program, Taipei 115, Taiwan	University of Texas System; University of Texas System; Academia Sinica - Taiwan	Wu, KK (corresponding author), Univ Texas, Sch Med, Vasc Biol Res Ctr, 6431 Fannin,MSB 5-016, Houston, TX 77030 USA.	Kenneth.K.Wu@uth.tmc.edu	Wu, Kenneth Kun-Yu/B-1070-2010; Liou, Jun-Yang/B-1065-2010; Gilroy, Derek/AAP-7227-2020; Gilroy, Derek W/C-2588-2009; Shyue, Song-Kun/Q-2583-2018	Gilroy, Derek/0000-0003-3476-0844; Shyue, Song-Kun/0000-0002-1057-8696	NHLBI NIH HHS [R01 HL50675] Funding Source: Medline; NINDS NIH HHS [P50 NS23327] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050675] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS023327] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Balsinde J, 1998, P NATL ACAD SCI USA, V95, P7951, DOI 10.1073/pnas.95.14.7951; Bazan NG, 2001, NAT MED, V7, P414, DOI 10.1038/86477; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; Engelman JA, 1998, AM J HUM GENET, V63, P1578, DOI 10.1086/302172; GarciaCardena G, 1996, P NATL ACAD SCI USA, V93, P6448, DOI 10.1073/pnas.93.13.6448; Gilroy DW, 1999, NAT MED, V5, P698, DOI 10.1038/9550; Guzzi F, 2001, BIOCHEM J, V355, P323, DOI 10.1042/0264-6021:3550323; KARGMAN SL, 1995, CANCER RES, V55, P2556; KULMACZ RJ, 1989, J BIOL CHEM, V264, P14136; Kurumbail RG, 1996, NATURE, V384, P644, DOI 10.1038/384644a0; Kuwata H, 1999, ADV EXP MED BIOL, V469, P183; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liou JY, 2000, J BIOL CHEM, V275, P15314, DOI 10.1074/jbc.275.20.15314; Luetterforst R, 1999, J CELL BIOL, V145, P1443, DOI 10.1083/jcb.145.7.1443; Murakami M, 1999, J BIOL CHEM, V274, P3103, DOI 10.1074/jbc.274.5.3103; Oh P, 1998, J CELL BIOL, V141, P101, DOI 10.1083/jcb.141.1.101; Oka N, 1997, J BIOL CHEM, V272, P33416, DOI 10.1074/jbc.272.52.33416; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; Santhamma KR, 2000, J BIOL CHEM, V275, P23253, DOI 10.1074/jbc.M000593200; Schievella AR, 1995, J BIOL CHEM, V270, P30749, DOI 10.1074/jbc.270.51.30749; Schreiber S, 2000, J BIOL CHEM, V275, P24115, DOI 10.1074/jbc.M001876200; SEIBERT K, 1994, P NATL ACAD SCI USA, V91, P12013, DOI 10.1073/pnas.91.25.12013; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; SMITH WL, 1991, PHARMACOL THERAPEUT, V49, P153, DOI 10.1016/0163-7258(91)90054-P; Spencer AG, 1998, J BIOL CHEM, V273, P9886, DOI 10.1074/jbc.273.16.9886; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; VANE JR, 1994, P NATL ACAD SCI USA, V91, P2046, DOI 10.1073/pnas.91.6.2046; Wu K K, 1995, Adv Pharmacol, V33, P179, DOI 10.1016/S1054-3589(08)60669-9; Xu XM, 1996, AM J PHYSIOL-CELL PH, V270, pC259, DOI 10.1152/ajpcell.1996.270.1.C259	32	86	89	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					34975	34982		10.1074/jbc.M105946200	http://dx.doi.org/10.1074/jbc.M105946200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11432874	hybrid			2022-12-25	WOS:000171024600084
J	James, CM; Ferguson, TK; Leykam, JF; Krzycki, JA				James, CM; Ferguson, TK; Leykam, JF; Krzycki, JA			The amber codon in the gene encoding the monomethylamine methyltransferase isolated from Methanosarcina barkeri is translated as a sense codon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE LEUKEMIA-VIRUS; RELEASE FACTOR-II; M METHYL TRANSFER; CORRINOID PROTEIN; READ-THROUGH; RECONSTITUTION; METHANOGENESIS; SELENOCYSTEINE; SUPPRESSION; METABOLISM	Each of the genes encoding the methyltransferases initiating methanogenesis from trimethylamine, dimethylamine, or monomethylamine by various Methanosarcina species possesses one naturally occurring in-frame amber codon that does not appear to act as a translation stop during synthesis of the biochemically characterized methyltransferase. To investigate the means by which suppression of the amber codon within these genes occurs, MtmB, a methyltransferase initiating metabolism of monomethylamine, was examined. The C-terminal sequence of MtmB indicated that synthesis of this mtmB1 gene product did not cease at the internal amber codon, but at the following ochre codon. Antibody raised against MtmB revealed that Escherichia coli transformed with mtmB1 produced the amber termination product. The same antibody detected primarily a 50-kDa protein in Methanosarcina barkeri, which is the mass predicted for the amber readthrough product of the mtmB1 gene. Sequencing of peptide fragments from MtmB by Edman degradation and mass spectrometry revealed no change in the reading frame during mtmB1 expression. The amber codon position corresponded to a lysyl residue using either sequencing technique. The amber codon is thus read through during translation at apparently high efficiency and corresponds to lysine in tryptic fragments of MtmB even though canonical lysine codon usage is encountered in other Methanosarcina genes.	Ohio State Univ, Dept Microbiol, Columbus, OH 43210 USA; Michigan State Univ, Dept Biochem, Macromol Struct Sequencing & Synth Facil, E Lansing, MI 48823 USA	University System of Ohio; Ohio State University; Michigan State University	Krzycki, JA (corresponding author), Ohio State Univ, Dept Microbiol, 484 W 12th Ave, Columbus, OH 43210 USA.	Krzycki.1@osu.edu						Alam SL, 1999, P NATL ACAD SCI USA, V96, P14177, DOI 10.1073/pnas.96.25.14177; Boone David R., 1993, P35; Burke SA, 1997, J BIOL CHEM, V272, P16570, DOI 10.1074/jbc.272.26.16570; Burke SA, 1998, J BACTERIOL, V180, P3432, DOI 10.1128/JB.180.13.3432-3440.1998; CAO XJ, 1991, J BACTERIOL, V173, P5439, DOI 10.1128/jb.173.17.5439-5448.1991; Commans S, 1999, FEMS MICROBIOL REV, V23, P335, DOI 10.1111/j.1574-6976.1999.tb00403.x; CRAIGEN WJ, 1986, NATURE, V322, P273, DOI 10.1038/322273a0; CRAIGEN WJ, 1985, P NATL ACAD SCI USA, V82, P3616, DOI 10.1073/pnas.82.11.3616; Farabaugh PJ, 1996, MICROBIOL REV, V60, P103, DOI 10.1128/MMBR.60.1.103-134.1996; FENG YX, 1990, P NATL ACAD SCI USA, V87, P8860, DOI 10.1073/pnas.87.22.8860; Ferguson DJ, 1997, J BACTERIOL, V179, P846, DOI 10.1128/jb.179.3.846-852.1997; Ferguson DJ, 1996, J BIOL CHEM, V271, P5189; Ferguson DJ, 2000, J BIOL CHEM, V275, P29053, DOI 10.1074/jbc.M910218199; Ferry JG, 1999, FEMS MICROBIOL REV, V23, P13, DOI 10.1016/S0168-6445(98)00029-1; GELLER AI, 1980, NATURE, V283, P41, DOI 10.1038/283041a0; Gesteland RF, 1996, ANNU REV BIOCHEM, V65, P741, DOI 10.1146/annurev.bi.65.070196.003521; Herr AJ, 2000, ANNU REV BIOCHEM, V69, P343, DOI 10.1146/annurev.biochem.69.1.343; Ivanov IP, 2000, NUCLEIC ACIDS RES, V28, P3185, DOI 10.1093/nar/28.17.3185; JACKS T, 1988, CELL, V55, P447, DOI 10.1016/0092-8674(88)90031-1; KING GM, 1984, GEOMICROBIOL J, V3, P276; KRZYCKI JA, 1989, J BIOL CHEM, V264, P7217; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; OSAWA S, 1992, MICROBIOL REV, V56, P229, DOI 10.1128/MMBR.56.1.229-264.1992; Paul L, 2000, J BACTERIOL, V182, P2520, DOI 10.1128/JB.182.9.2520-2529.2000; Persson BC, 1998, J BACTERIOL, V180, P3462, DOI 10.1128/JB.180.13.3462-3466.1998; Rother M, 2000, J MOL BIOL, V299, P351, DOI 10.1006/jmbi.2000.3756; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Stadtman TC, 1996, ANNU REV BIOCHEM, V65, P83, DOI 10.1146/annurev.bi.65.070196.000503; TAYLOR JM, 1974, J BIOL CHEM, V249, P2188; Thauer RK, 1998, MICROBIOL-UK, V144, P2377, DOI 10.1099/00221287-144-9-2377; WILLS NM, 1991, P NATL ACAD SCI USA, V88, P6991, DOI 10.1073/pnas.88.16.6991; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576	32	58	63	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					34252	34258		10.1074/jbc.M102929200	http://dx.doi.org/10.1074/jbc.M102929200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11435424	hybrid			2022-12-25	WOS:000170910200128
J	Basak, A; Koch, P; Dupelle, M; Fricker, LD; Devi, LA; Chretien, M; Seidah, NG				Basak, A; Koch, P; Dupelle, M; Fricker, LD; Devi, LA; Chretien, M; Seidah, NG			Inhibitory specificity and potency of proSAAS-derived peptides toward proprotein convertase 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROHORMONE CONVERTASE-1; SUBSTRATE-SPECIFICITY; SERINE PROTEINASES; ACTIVATION; PRECURSOR; FURIN; 7B2; IDENTIFICATION; EMBRYOGENESIS; POLYPEPTIDES	Prohormone convertase I (PCI), mediating the proteolytic processing of neural and endocrine precursors, is thought to be regulated by the neuroendocrine protein proSAAS. The PCI inhibitory sequence is mostly confined within a 10-12-amino acid segment near the C terminus of the conserved human proSAAS and contains the critical KR244 dibasic motif. Our results show that the decapeptide proSAAS-(235-244) (235)VLGALLRVKR(244) is the most potent reversible competitive PC1-inhibitor (K-i similar to9 nM). The C-terminally extended proSAAS-(235-246) exhibits a 5-6-fold higher K-i (similar to 51 nM). The additional LE sequence at P1'-P2', resulted in a competitive substrate cleaved by PCI at KR244 down arrow LE246. Systematic alanine scanning and in some cases lysine scanning tested the contribution of each residue within proSAAS(235-246) toward the PCI-inhibition's specificity and potency. The amino acids P1 Arg, P2 Lys, and P4 Arg are all critical for inhibition. Moreover, the aliphatic P3 Val and P5, P6, and P1' Leu significantly affect the degree of enzyme inactivation and PC1 specificity. Interestingly, a much longer N- and C-terminally extended endogenous rat proSAAS-(221-254) called little PenLen, was found to be a 3-fold less potent PCI inhibitor with reduced selectivity but a much better substrate than proSAAS-(235-246). Molecular modeling studies and circular dichroism analysis indicate an extended and poly-L-proline II type structural conformation for proSAAS-(235-244), the most potent PC1 inhibitor, a feature not present in poor PC1 inhibitors.	Ottawa Hosp, Loeb Hlth Res Inst, Ageing Ctr, Lab Mol Med & Dis, Ottawa, ON K1Y 4K9, Canada; Yeshiva Univ Albert Einstein Coll Med, Mol Pharmacol Lab, Bronx, NY 10461 USA; NYU, Sch Med, Pharmacol Lab, New York, NY 10016 USA; Clin Res Inst Montreal, Biochem Neuroendocrinol Lab, Montreal, PQ H2W 1R7, Canada	University of Ottawa; Ottawa Hospital Research Institute; Yeshiva University; Albert Einstein College of Medicine; New York University; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal	Basak, A (corresponding author), Ottawa Hosp, Loeb Hlth Res Inst, Ageing Ctr, Lab Mol Med & Dis, 725 Parkdale Ave, Ottawa, ON K1Y 4K9, Canada.		Seidah, Nabil/I-3596-2013; Devi P, Lakshmi/GXM-5982-2022	Seidah, Nabil/0000-0001-6503-9342; Devi P, Lakshmi/0000-0001-9274-4776; CHRETIEN, Michel/0000-0002-8588-4460				Apletalina E, 1998, J BIOL CHEM, V273, P26589, DOI 10.1074/jbc.273.41.26589; Apletalina EV, 2000, BIOCHEM BIOPH RES CO, V267, P940, DOI 10.1006/bbrc.1999.2060; BASAK A, 1990, INT J PEPT PROT RES, V36, P7; Basak A, 2001, BIOCHEM J, V353, P537, DOI 10.1042/0264-6021:3530537; BENJANNET S, 1992, J BIOL CHEM, V267, P11417; Beynon R.J, 1989, PROTEOLYTIC ENZYMES, P83; Boudreault A, 1998, PROTEIN EXPRES PURIF, V14, P353, DOI 10.1006/prep.1998.0964; Boudreault A, 1998, J BIOL CHEM, V273, P31574, DOI 10.1074/jbc.273.47.31574; Cameron A, 2000, FEBS LETT, V473, P135, DOI 10.1016/S0014-5793(00)01511-8; CHRETIEN M, 1995, P ASSOC AM PHYSICIAN, V107, P47; CHRETIEN M, 1997, B CAN SOC BIOCH CELL, P86; COPELAND RA, 1996, ENZYMES PRACTICAL IN; Fricker LD, 2000, J NEUROSCI, V20, P639, DOI 10.1523/JNEUROSCI.20-02-00639.2000; Greenfield NJ, 1996, ANAL BIOCHEM, V235, P1, DOI 10.1006/abio.1996.0084; Jackson RS, 1997, NAT GENET, V16, P303, DOI 10.1038/ng0797-303; LEDUC R, 1992, J BIOL CHEM, V267, P14304; LINDBERG I, 1995, BIOCHEMISTRY-US, V34, P5486, DOI 10.1021/bi00016a020; LIPKIND G, 1995, J BIOL CHEM, V270, P13277, DOI 10.1074/jbc.270.22.13277; MILHIET PE, 1992, ANAL BIOCHEM, V205, P57, DOI 10.1016/0003-2697(92)90578-U; Molloy SS, 1999, TRENDS CELL BIOL, V9, P28, DOI 10.1016/S0962-8924(98)01382-8; Muller L, 2000, PROG NUCLEIC ACID RE, V63, P69, DOI 10.1016/S0079-6603(08)60720-5; Muller L, 2000, J BIOL CHEM, V275, P39213, DOI 10.1074/jbc.M003547200; Mzhavia N, 2001, J BIOL CHEM, V276, P6207, DOI 10.1074/jbc.M009067200; Qian YM, 2000, J BIOL CHEM, V275, P23596, DOI 10.1074/jbc.M001583200; ROTHE G, 1992, BIOL CHEM H-S, V373, P547, DOI 10.1515/bchm3.1992.373.2.547; Seebach D, 2000, HELV CHIM ACTA, V83, P2849, DOI 10.1002/1522-2675(20001108)83:11<2849::AID-HLCA2849>3.0.CO;2-R; Seidah NG, 1999, BRAIN RES, V848, P45, DOI 10.1016/S0006-8993(99)01909-5; SEIDAH NG, 1983, ARCH BIOCHEM BIOPHYS, V225, P525, DOI 10.1016/0003-9861(83)90063-2; Seidah NG, 1998, ANN NY ACAD SCI, V839, P9, DOI 10.1111/j.1749-6632.1998.tb10727.x; SIEZEN RJ, 1991, PROTEIN ENG, V4, P719, DOI 10.1093/protein/4.7.719; Tsuji A, 1999, J BIOCHEM, V126, P591, DOI 10.1093/oxfordjournals.jbchem.a022491; Williams J W, 1979, Methods Enzymol, V63, P437; Zhong M, 1999, J BIOL CHEM, V274, P33913, DOI 10.1074/jbc.274.48.33913; Zhou A, 1999, J BIOL CHEM, V274, P20745, DOI 10.1074/jbc.274.30.20745	34	49	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					32720	32728		10.1074/jbc.M104064200	http://dx.doi.org/10.1074/jbc.M104064200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11435430	hybrid			2022-12-25	WOS:000170746000047
J	Kishida, M; Hino, S; Michiue, T; Yamamoto, H; Kishida, S; Fukui, A; Asashima, M; Kikuchi, A				Kishida, M; Hino, S; Michiue, T; Yamamoto, H; Kishida, S; Fukui, A; Asashima, M; Kikuchi, A			Synergistic activation of the Wnt signaling pathway by Dvl and casein kinase I epsilon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOMATOUS POLYPOSIS-COLI; GLYCOGEN-SYNTHASE KINASE-3-BETA; TRANSCRIPTION FACTOR LEF-1; F-BOX PROTEIN; BETA-CATENIN; AXIS FORMATION; NEGATIVE REGULATOR; BINDING PROTEIN; POLARITY GENE; GSK-3-BETA-DEPENDENT PHOSPHORYLATION	Although casein kinase I epsilon (CKI epsilon) has been shown to regulate the Wnt signaling pathway positively, its mode of action is not clear. In this study we show that CKI epsilon activates the Wnt signaling pathway in co-operation with Dv1. CKI epsilon and Axin associated with different sites of Dv1, and CKI epsilon and Dv1 interacted with distinct regions on Axin. Therefore, these three proteins formed a ternary complex. Either low expression of Dv1 or CKI epsilon alone did not accumulate beta -catenin, but their co-expression accumulated greatly. Dv1 and CKI epsilon activated the transcriptional activity of T cell factor (Tcf) synergistically. Although the Dv1 mutant that binds to Axin but not to CKI epsilon activated Tcf, it did not synergize with CKI epsilon Another Dv1 mutant that does not bind to Axin did not activate Tcf irrespective of the presence of CKI epsilon Furthermore, Dv1 and CKI epsilon co-operatively induced axis duplication of Xenopus embryos. These results indicate that Dv1 and CKI epsilon synergistically activated the Writ signaling pathway and that the binding of the complex of Dv1 and CKI epsilon to Axin is necessary for their synergistic action.	Hiroshima Univ, Fac Med, Dept Biochem, Minami Ku, Hiroshima 7348551, Japan; Japan Sci & Technol Corp, PRESTO, Hiroshima, Japan; Univ Tokyo, Dept Life Sci Biol, Meguro Ku, Tokyo 1538902, Japan; Univ Tokyo, Crest Project, Meguro Ku, Tokyo 1538902, Japan	Hiroshima University; Japan Science & Technology Agency (JST); University of Tokyo; Japan Science & Technology Agency (JST); University of Tokyo	Kikuchi, A (corresponding author), Hiroshima Univ, Fac Med, Dept Biochem, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.			kishida, shosei/0000-0003-0405-851X				Axelrod JD, 1998, GENE DEV, V12, P2610, DOI 10.1101/gad.12.16.2610; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Boutros M, 1998, CELL, V94, P109, DOI 10.1016/S0092-8674(00)81226-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Cegielska A, 1998, J BIOL CHEM, V273, P1357, DOI 10.1074/jbc.273.3.1357; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; Dale TC, 1998, BIOCHEM J, V329, P209; Fagotto F, 1999, J CELL BIOL, V145, P741, DOI 10.1083/jcb.145.4.741; FISH KJ, 1995, J BIOL CHEM, V270, P14875, DOI 10.1074/jbc.270.25.14875; FUNAYAMA N, 1995, J CELL BIOL, V128, P959, DOI 10.1083/jcb.128.5.959; Gross SD, 1998, CELL SIGNAL, V10, P699, DOI 10.1016/S0898-6568(98)00042-4; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Hino SI, 2001, MOL CELL BIOL, V21, P330, DOI 10.1128/MCB.21.1.330-342.2001; Hinoi T, 2000, J BIOL CHEM, V275, P34399, DOI 10.1074/jbc.M003997200; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; Huelsken J, 2000, J CELL BIOL, V148, P567, DOI 10.1083/jcb.148.3.567; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Ikeda S, 2000, ONCOGENE, V19, P537, DOI 10.1038/sj.onc.1203359; Itoh K, 1998, CURR BIOL, V8, P591, DOI 10.1016/S0960-9822(98)70229-5; Itoh K, 2000, MOL CELL BIOL, V20, P2228, DOI 10.1128/MCB.20.6.2228-2238.2000; Julius MA, 2000, BIOCHEM BIOPH RES CO, V276, P1162, DOI 10.1006/bbrc.2000.3607; Kadoya T, 2000, J BIOL CHEM, V275, P37030, DOI 10.1074/jbc.M005984200; Kikuchi A, 1999, CELL SIGNAL, V11, P777, DOI 10.1016/S0898-6568(99)00054-6; Kishida M, 1999, ONCOGENE, V18, P979, DOI 10.1038/sj.onc.1202388; Kishida S, 1999, MOL CELL BIOL, V19, P4414; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Klingensmith J, 1996, MECH DEVELOP, V58, P15, DOI 10.1016/S0925-4773(96)00549-7; KLINGENSMITH J, 1994, GENE DEV, V8, P118, DOI 10.1101/gad.8.1.118; Kloss B, 1998, CELL, V94, P97, DOI 10.1016/S0092-8674(00)81225-8; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; KREIG PA, 1984, NUCLEIC ACIDS RES, V12, P7057; Lee JS, 1999, J BIOL CHEM, V274, P21464, DOI 10.1074/jbc.274.30.21464; Li L, 1999, J BIOL CHEM, V274, P129, DOI 10.1074/jbc.274.1.129; Li L, 1999, EMBO J, V18, P4233, DOI 10.1093/emboj/18.15.4233; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Moon RT, 1998, BIOESSAYS, V20, P536, DOI 10.1002/(SICI)1521-1878(199807)20:7<536::AID-BIES4>3.3.CO;2-U; Moriguchi T, 1999, J BIOL CHEM, V274, P30957, DOI 10.1074/jbc.274.43.30957; Peters JM, 1999, NATURE, V401, P345, DOI 10.1038/43830; Pizzuti A, 1996, HUM MOL GENET, V5, P953, DOI 10.1093/hmg/5.7.953; Rothbacher U, 2000, EMBO J, V19, P1010, DOI 10.1093/emboj/19.5.1010; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Sakamoto I, 2000, J BIOL CHEM, V275, P32871, DOI 10.1074/jbc.M004089200; Sakanaka C, 1998, P NATL ACAD SCI USA, V95, P3020, DOI 10.1073/pnas.95.6.3020; Sakanaka C, 1999, P NATL ACAD SCI USA, V96, P12548, DOI 10.1073/pnas.96.22.12548; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Smalley MJ, 1999, EMBO J, V18, P2823, DOI 10.1093/emboj/18.10.2823; Sokol SY, 1996, CURR BIOL, V6, P1456, DOI 10.1016/S0960-9822(96)00750-6; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Strovel ET, 2000, J BIOL CHEM, V275, P2399, DOI 10.1074/jbc.275.4.2399; Strutt DI, 1997, NATURE, V387, P292, DOI 10.1038/387292a0; SUSSMAN DJ, 1994, DEV BIOL, V166, P73, DOI 10.1006/dbio.1994.1297; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; THEISEN H, 1994, DEVELOPMENT, V120, P347; Tian Q, 1999, DEVELOPMENT, V126, P3371; Willert K, 1997, EMBO J, V16, P3089, DOI 10.1093/emboj/16.11.3089; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Yamamoto H, 1998, MOL CELL BIOL, V18, P2867, DOI 10.1128/MCB.18.5.2867; Yamamoto H, 1999, J BIOL CHEM, V274, P10681, DOI 10.1074/jbc.274.16.10681; YANAGAWA SI, 1995, GENE DEV, V9, P1087, DOI 10.1101/gad.9.9.1087; Yost C, 1998, CELL, V93, P1031, DOI 10.1016/S0092-8674(00)81208-8; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4	69	95	96	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					33147	33155		10.1074/jbc.M103555200	http://dx.doi.org/10.1074/jbc.M103555200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11425858	hybrid			2022-12-25	WOS:000170746000101
J	Smith, WL; Garavito, RM; Ferguson-Miller, S				Smith, WL; Garavito, RM; Ferguson-Miller, S			Membrane protein structural biology minireview series	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							DOMAIN		Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA	Michigan State University	Smith, WL (corresponding author), Michigan State Univ, Dept Biochem & Mol Biol, Biochem Bldg,Rm 513, E Lansing, MI 48824 USA.							Bogdanov M, 1999, J BIOL CHEM, V274, P36827, DOI 10.1074/jbc.274.52.36827; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Davletov B, 1998, J BIOL CHEM, V273, P19093, DOI 10.1074/jbc.273.30.19093; Prabhakar P, 2000, J BIOL CHEM, V275, P19416, DOI 10.1074/jbc.M001952200; Rees DC, 2000, J BIOL CHEM, V275, P713, DOI 10.1074/jbc.275.2.713; Spencer AG, 1999, J BIOL CHEM, V274, P32936, DOI 10.1074/jbc.274.46.32936; Wurmser AE, 1999, J BIOL CHEM, V274, P9129, DOI 10.1074/jbc.274.14.9129	7	9	9	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					32393	32394		10.1074/jbc.R100044200	http://dx.doi.org/10.1074/jbc.R100044200			2	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11432879	hybrid			2022-12-25	WOS:000170746000001
J	Brosnan, JT; Brosnan, ME; Yudkoff, M; Nissim, H; Daikhin, Y; Lazarow, A; Horyn, O; Nissim, I				Brosnan, JT; Brosnan, ME; Yudkoff, M; Nissim, H; Daikhin, Y; Lazarow, A; Horyn, O; Nissim, I			Alanine metabolism in the perfused rat liver - Studies with N-15	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-METABOLISM; GLUTAMINE-METABOLISM; CHROMATOGRAPHY; ENRICHMENT; UREA	We have utilized [N-15]alanine or (NH3)-N-15 as metabolic tracers in order to identify sources of nitrogen for hepatic ureagenesis in a liver perfusion system. Studies were done in the presence and absence of physiologic concentrations of portal venous ammonia in order to test the hypothesis that, when the NH4+:aspartate ratio is >1, increased hepatic proteolysis provides cytoplasmic aspartate in order to support ureagenesis. When 1 mM [N-15]alanine was the sole nitrogen source, the amino group was incorporated into both nitrogens of urea and both nitrogens of glutamine. However, when studies were done with 1 mM alanine and 0.3 mM NH4Cl, anine failed to provide aspartate at a rate that would have detoxified all administered ammonia. Under these circumstances, the presence of ammonia at a physiologic concentration stimulated hepatic proteolysis. In perfusions with alanine alone, similar to 400 nmol of nitrogen/min/g liver was needed to satisfy the balance between nitrogen intake and nitrogen output. When the model included alanine and NH4Cl, 1000 nmol of nitrogen/min/g liver were formed from an intra-hepatic source, presumably proteolysis. In this manner, the internal pool provided the cytoplasmic aspartate that allowed the liver to dispose of mitochondrial carbamyl phosphate that was rapidly produced from external ammonia. This information may be relevant to those clinical situations (renal failure, cirrhosis, starvation, low protein diet, and malignancy) when portal venous NH4+ greatly exceeds the concentration of aspartate. Under these circumstances, the liver must summon internal pools of protein in order to accommodate the ammonia burden.	Univ Penn, Sch Med, Dept Pediat, Abramson Res Ctr,Div Child Dev, Philadelphia, PA 19104 USA; Mem Univ Newfoundland, Dept Biochem, St John, NF A1B 3X9, Canada	University of Pennsylvania; Pennsylvania Medicine; Memorial University Newfoundland	Nissim, I (corresponding author), Univ Penn, Sch Med, Dept Pediat, Abramson Res Ctr,Div Child Dev, Rm 510, Philadelphia, PA 19104 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053761, R56DK053761] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-53761] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BROSNAN JT, 1970, BIOCHEM J, V117, P91, DOI 10.1042/bj1170091; Brosnan JT, 1996, J BIOL CHEM, V271, P16199, DOI 10.1074/jbc.271.27.16199; Butterworth RE, 2000, J HEPATOL, V32, P171, DOI 10.1016/S0168-8278(00)80424-9; Cordoba J, 1997, AM J GASTROENTEROL, V92, P1429; FELIG P, 1975, ANNU REV BIOCHEM, V44, P933, DOI 10.1146/annurev.bi.44.070175.004441; FORISSIER M, 1981, BIOCHEM J, V200, P27, DOI 10.1042/bj2000027; GEBHARDT R, 1983, EMBO J, V2, P567, DOI 10.1002/j.1460-2075.1983.tb01464.x; GEYER JW, 1971, ANAL BIOCHEM, V39, P412, DOI 10.1016/0003-2697(71)90431-3; JONES BN, 1983, J CHROMATOGR, V266, P471, DOI 10.1016/S0021-9673(01)90918-5; KIRSTEN E, 1963, BIOCHEM Z, V337, P312; Lopez HW, 1998, J NUTR, V128, P1487, DOI 10.1093/jn/128.9.1487; MASTSUZAWA T, 1997, BIOCHIM BIOPHYS ACTA, V1340, P115; Nieto R, 1996, J MASS SPECTROM, V31, P289, DOI 10.1002/(SICI)1096-9888(199603)31:3<289::AID-JMS299>3.0.CO;2-Z; Nissim I, 1999, J BIOL CHEM, V274, P28958, DOI 10.1074/jbc.274.41.28958; Nissim I, 1996, J BIOL CHEM, V271, P31234, DOI 10.1074/jbc.271.49.31234; NISSIM I, 1992, ARCH BIOCHEM BIOPHYS, V292, P393, DOI 10.1016/0003-9861(92)90008-K; PATTERSON BW, 1993, BIOL MASS SPECTROM, V22, P518, DOI 10.1002/bms.1200220905; PISTERS PWT, 1990, ANNU REV NUTR, V10, P107, DOI 10.1146/annurev.nu.10.070190.000543; Reeds PJ, 2000, J NUTR, V130, p978S, DOI 10.1093/jn/130.4.978S; Sies H, 1978, Methods Enzymol, V52, P48; SOUBA WW, 1993, J NUTR BIOCHEM, V4, P2, DOI 10.1016/0955-2863(93)90013-M; STOLL B, 1991, HEPATOLOGY, V13, P247, DOI 10.1002/hep.1840130208; Walser M, 2000, BLOOD PURIFICAT, V18, P304, DOI 10.1159/000014453; WATFORD M, 1994, BBA-GEN SUBJECTS, V1200, P73, DOI 10.1016/0304-4165(94)90029-9; Yang DW, 2000, AM J PHYSIOL-ENDOC M, V278, pE469, DOI 10.1152/ajpendo.2000.278.3.E469	25	30	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					31876	31882		10.1074/jbc.M103890200	http://dx.doi.org/10.1074/jbc.M103890200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11423541	hybrid			2022-12-25	WOS:000170613500057
J	Chao, SH; Price, DH				Chao, SH; Price, DH			Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CARCINOMA CELLS; ELONGATION-FACTOR-B; HIV-1 TAT; KINASE INHIBITORS; CYCLIN T1; IN-VITRO; TRANSACTIVATION; PROTEIN; REPLICATION; PITALRE	Flavopiridol (L86-8275, HMR1275) is a cyclin-dependent kinase (Cdk) inhibitor in clinical trials as a cancer therapy that has been recently shown to block human immunodeficiency virus Tat transactivation and viral replication through inhibition of positive transcription elongation factor b (P-TEFb). Flavopiridol is the most potent P-TEFb inhibitor reported and the first Cdk inhibitor that is not competitive with ATP. We examined the ability of flavopiridol to inhibit P-TEFb (Cdk9/cyclin T1) phosphorylation of both RNA polymerase II and the large subunit of the 5, 6-dichloro-1-beta -D-ribofuranosyl-benzimidazole (DRB) sensitivity-inducing factor and found that the IC50 determined was directly related to the concentration of the enzyme. We concluded that the flavonoid associates with P-TEFb with 1:1 stoichiometry even at concentrations of enzyme in the low nanomolar range. These results indicate that the apparent lack of competition with ATP could be caused by a very tight binding of the drug. We developed a novel immobilized P-TEFb assay and demonstrated that the drug remains bound for minutes even in the presence of high salt. Flavopiridol remained bound in the presence of a 1000-fold excess of the commonly used inhibitor DRB, suggesting that the immobilized P-TEFb could be used in a simple screening assay that would allow the discovery or characterization of compounds with binding properties similar to flavopiridol. Finally, we compared the ability of flavopiridol and DRB to inhibit transcription in vivo using nuclear run-on assays and concluded that P-TEFb is required for transcription of most RNA polymerase II molecules in vivo.	Univ Iowa, Program Mol Biol, Iowa City, IA 52242 USA; Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA	University of Iowa; University of Iowa	Price, DH (corresponding author), Univ Iowa, Program Mol Biol, Iowa City, IA 52242 USA.		Price, David H/F-6173-2010	Price, David/0000-0002-5597-385X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043691] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035500] Funding Source: NIH RePORTER; NIAID NIH HHS [AI43691] Funding Source: Medline; NIGMS NIH HHS [GM35500] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bieniasz PD, 1999, MOL CELL BIOL, V19, P4592, DOI 10.1128/mcb.19.7.4592; Carlson B, 1999, CANCER RES, V59, P4634; Carlson BA, 1996, CANCER RES, V56, P2973; Chang TC, 1997, BIOCHEM PHARMACOL, V53, P969, DOI 10.1016/S0006-2952(96)00868-4; Chao SH, 2000, J BIOL CHEM, V275, P28345, DOI 10.1074/jbc.C000446200; DE AWJ, 1996, P NATL ACAD SCI USA, V93, P2735; De Falco G, 1998, J CELL PHYSIOL, V177, P501, DOI 10.1002/(SICI)1097-4652(199812)177:4<501::AID-JCP1>3.0.CO;2-4; Egyhazi E, 1996, CHROMOSOMA, V104, P422, DOI 10.1007/s004120050134; Flores OL, 1999, P NATL ACAD SCI USA, V96, P7208, DOI 10.1073/pnas.96.13.7208; Fu TJ, 1999, J BIOL CHEM, V274, P34527, DOI 10.1074/jbc.274.49.34527; Fujinaga K, 1998, J VIROL, V72, P7154, DOI 10.1128/JVI.72.9.7154-7159.1998; Garber ME, 1998, GENE DEV, V12, P3512, DOI 10.1101/gad.12.22.3512; Gold MO, 1998, J VIROL, V72, P4448, DOI 10.1128/JVI.72.5.4448-4453.1998; Gray N, 1999, CURR MED CHEM, V6, P859; Gray NS, 1998, SCIENCE, V281, P533, DOI 10.1126/science.281.5376.533; Kelland LR, 2000, EXPERT OPIN INV DRUG, V9, P2903, DOI 10.1517/13543784.9.12.2903; Kim KS, 2000, J MED CHEM, V43, P4126, DOI 10.1021/jm000231g; KIRN JB, 2001, J BIOL CHEM, V276, P12317; LOSIEWICZ MD, 1994, BIOCHEM BIOPH RES CO, V201, P589, DOI 10.1006/bbrc.1994.1742; Mancebo HSY, 1997, GENE DEV, V11, P2633, DOI 10.1101/gad.11.20.2633; MARCINIAK RA, 1991, EMBO J, V10, P4189, DOI 10.1002/j.1460-2075.1991.tb04997.x; Murthi KK, 2000, BIOORG MED CHEM LETT, V10, P1037, DOI 10.1016/S0960-894X(00)00156-6; Peng JM, 1998, GENE DEV, V12, P755, DOI 10.1101/gad.12.5.755; Ping YH, 2001, J BIOL CHEM, V276, P12951, DOI 10.1074/jbc.M006130200; Price DH, 2000, MOL CELL BIOL, V20, P2629, DOI 10.1128/MCB.20.8.2629-2634.2000; REEDER RH, 1972, J MOL BIOL, V67, P433, DOI 10.1016/0022-2836(72)90461-5; Senderowicz AM, 2000, JNCI-J NATL CANCER I, V92, P376, DOI 10.1093/jnci/92.5.376; Senderowicz AM, 1998, J CLIN ONCOL, V16, P2986, DOI 10.1200/JCO.1998.16.9.2986; Taube R, 1999, VIROLOGY, V264, P245, DOI 10.1006/viro.1999.9944; Toledo LM, 1999, CURR MED CHEM, V6, P775; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	32	527	566	1	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					31793	31799		10.1074/jbc.M102306200	http://dx.doi.org/10.1074/jbc.M102306200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11431468	hybrid			2022-12-25	WOS:000170613500044
J	Fernandes, RJ; Hirohata, S; Engle, JM; Colige, A; Cohn, DH; Eyre, DR; Apte, SS				Fernandes, RJ; Hirohata, S; Engle, JM; Colige, A; Cohn, DH; Eyre, DR; Apte, SS			Procollagen II amino propeptide processing by ADAMTS-3 - Insights on dermatosparaxis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EHLERS-DANLOS-SYNDROME; BOVINE DERMATOSPARAXIS; EXTRACELLULAR-MATRIX; FIBRILLAR COLLAGENS; DEXTRAN SULFATE; N-PROTEINASE; VII-C; CLEAVAGE; FAMILY; FIBROBLASTS	The amino and carboxyl propeptides of procollagens I and Il are removed by specific enzymes as a prerequisite for fibril assembly. Null mutations in procollagen I N-propeptidase (ADAMTS-2) cause dermatosparaxis in cattle and the Ehlers-Danlos syndrome (dermatosparactic type) in humans by preventing proteolytic excision of the N-propeptide of procollagen I. We have found that procollagen II is processed normally in dermatosparactic nasal cartilage, suggesting the existence of another N-propeptidase(s). We investigated such a role for ADAMTS-3 in Swarm rat chondrosarcoma RCS-LTC cells, which fail to process the procollagen II N-propeptide. Stable transfection of RCS-LTC cells with bovine ADAMTS-2 or human ADAMTS-3 partially rescued the, processing defect, suggesting that ADAMTS-3 has procollagen II N-propeptidase activity. Human skin and skin fibroblasts showed 30-fold higher mRNA levels of ADAMTS-2 than ADAMTS-3, whereas ADAMTS-3 mRNA was 5-fold higher than ADAMTS-2 mRNA in human cartilage. We propose that both ADAMTS-2 and ADAMTS-3 process procollagen II, but ADAMTS-3 is physiologically more relevant, given its preferred expression in cartilage. The findings provide an explanation for the sparing of cartilage in dermatosparaxis and, perhaps, for the relative sparing of some procollagen I-containing tissues.	Cleveland Clin Fdn, Lerner Res Inst, Dept Biomed Engn, Cleveland, OH 44195 USA; Univ Washington, Dept Orthopaed & Sports Med, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Lab Biol Tissus Conjonctifs, B-4000 Sart Tilman Par Liege, Belgium; Univ Calif Los Angeles, Sch Med,Steven Spielberg Pediat Res Ctr, Ahmanson Dept Pediat, Burns & Allen Cedars Sinai Res Inst, Los Angeles, CA 90048 USA; Univ Calif Los Angeles, Sch Med, Dept Human Genet, Los Angeles, CA 90048 USA; Univ Calif Los Angeles, Sch Med, Dept Pediat, Los Angeles, CA 90048 USA	Cleveland Clinic Foundation; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Apte, SS (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Biomed Engn, ND-20,9500 Euclid Ave, Cleveland, OH 44195 USA.	aptes@bme.ri.ccf.org		Apte, Suneel/0000-0001-8441-1226	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD022657] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR036794, R01AR037318, R37AR037318] Funding Source: NIH RePORTER; NIAMS NIH HHS [R37 AR037318, AR37318, R01 AR036794] Funding Source: Medline; NICHD NIH HHS [HD22657] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BALDWIN CT, 1989, BIOCHEM J, V262, P521, DOI 10.1042/bj2620521; BATEMAN JF, 1990, BIOCHEM J, V267, P573, DOI 10.1042/bj2670573; Birk DE., 1991, MATRIX ASSEMBLY, P221; Colige A, 1997, P NATL ACAD SCI USA, V94, P2374, DOI 10.1073/pnas.94.6.2374; Colige A, 1999, AM J HUM GENET, V65, P308, DOI 10.1086/302504; DOMBROWSKI KE, 1988, J BIOL CHEM, V263, P16545; Fernandes RJ, 1997, EUR J BIOCHEM, V247, P620, DOI 10.1111/j.1432-1033.1997.00620.x; FERNANDES RJ, 1993, THESIS RUSH U CHICAG; Fertala A, 1996, J BIOL CHEM, V271, P14864, DOI 10.1074/jbc.271.25.14864; FERTALA A, 1994, J BIOL CHEM, V269, P11584; Fujimoto A, 1997, AM J MED GENET, V68, P25, DOI 10.1002/(SICI)1096-8628(19970110)68:1<25::AID-AJMG5>3.0.CO;2-X; FUKAI N, 1994, METHOD ENZYMOL, V245, P3; GAVEL Y, 1990, PROTEIN ENG, V3, P433, DOI 10.1093/protein/3.5.433; HANSET R, 1974, J HERED, V65, P356, DOI 10.1093/oxfordjournals.jhered.a108549; HOJIMA Y, 1994, ANAL BIOCHEM, V223, P173, DOI 10.1006/abio.1994.1569; Hurskainen TL, 1999, J BIOL CHEM, V274, P25555, DOI 10.1074/jbc.274.36.25555; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Kuno K, 1997, J BIOL CHEM, V272, P556, DOI 10.1074/jbc.272.1.556; Kuno K, 1998, J BIOL CHEM, V273, P13912, DOI 10.1074/jbc.273.22.13912; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPIERE CM, 1993, ARCH DERMATOL, V129, P1316, DOI 10.1001/archderm.129.10.1316; LAPIERE CM, 1971, P NATL ACAD SCI USA, V68, P3054, DOI 10.1073/pnas.68.12.3054; LENAERS A, 1971, EUR J BIOCHEM, V23, P533, DOI 10.1111/j.1432-1033.1971.tb01651.x; Li SW, 2001, BIOCHEM J, V355, P271, DOI 10.1042/0264-6021:3550271; Li SW, 1996, P NATL ACAD SCI USA, V93, P5127, DOI 10.1073/pnas.93.10.5127; METSARANTA M, 1992, J CELL BIOL, V118, P203, DOI 10.1083/jcb.118.1.203; Nagase T, 1997, DNA Res, V4, P141, DOI 10.1093/dnares/4.2.141; Nardi JB, 1999, INSECT BIOCHEM MOLEC, V29, P883, DOI 10.1016/S0965-1748(99)00064-8; NUSGENS BV, 1992, NAT GENET, V1, P214, DOI 10.1038/ng0692-214; OHARA PJ, 1970, LAB INVEST, V23, P307; Olsen BR, 1991, CELL BIOL EXTRACELLU, P177; PETTY EM, 1993, ARCH DERMATOL, V129, P1310, DOI 10.1001/archderm.129.10.1310; Reardon W, 1995, Clin Dysmorphol, V4, P1; SMITH LT, 1992, AM J HUM GENET, V51, P235; SPRANGER J, 1994, EUR J PEDIATR, V153, P56, DOI 10.1007/BF01959208; Tortorella M, 2000, J BIOL CHEM, V275, P25791, DOI 10.1074/jbc.M001065200; VANDERREST M, 1991, FASEB J, V5, P2814, DOI 10.1096/fasebj.5.13.1916105; WERTELECKI W, 1992, J PEDIATR-US, V121, P558, DOI 10.1016/S0022-3476(05)81144-8; WIESTNER M, 1982, EMBO J, V1, P513, DOI 10.1002/j.1460-2075.1982.tb01200.x	39	172	181	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					31502	31509		10.1074/jbc.M103466200	http://dx.doi.org/10.1074/jbc.M103466200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11408482	hybrid			2022-12-25	WOS:000170613500006
J	Loo, TW; Clarke, DM				Loo, TW; Clarke, DM			Cross-linking of human multidrug resistance P-glycoprotein by the substrate, Tris-(2-maleimidoethyl)amine, is altered by ATP hydrolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING SITES; PREDICTED TRANSMEMBRANE DOMAIN; CYSTEINE-SCANNING MUTAGENESIS; HIV-1 PROTEASE INHIBITORS; BLOOD-BRAIN-BARRIER; DRUG-BINDING; FUNCTIONAL CONSEQUENCES; CATALYTIC CYCLE; LABELING SITES; TRANSPORTER	We identified a thiol-reactive substrate, Tris-(-2-maleimidoethyl)amine (TMEA), to explore the contribution of the TM segments 6 and 12 of the human multidrug resistance P-glycoprotein (P-gp) during transport. TMEA is a trifunctional maleimide and stimulated the ATPase activity of Cys-less P-gp about 7-fold. Cysteine-scanning mutagenesis of TM12 showed that the activity of mutant V982C was inhibited by TMEA. P-gp mutants containing V982C (TM12) and another cysteine in TM6 were constructed and tested for cross-linking with TAMA. A cross-linked product was observed in SDS-polyacrylamide gel electrophoresis for mutant L339C(TM6)/V982C(TM12). Cross-linking by TMEA also inhibited the ATPase activity of the mutant protein. Substrates such as cyclosporin A, vinblastine, colchicine, or verapamil inhibited cross-linking by TMEA. In the presence of ATP at 37 degreesC, cross-linking of mutant L339C/V982C was decreased. In contrast, there was enhanced cross-linking of mutant F343C(TM6)/V982C(TM12) in the presence of ATP. These results show that cross-linking must be within the drug-binding domain, that residues L339C(TM6)/V982C(TM12) must be at least 10 Angstrom, apart, and that ATP hydrolysis promotes rotation of one or both TM helices.	Univ Toronto, Dept Med, Canadian Inst Hlth, Res Grp Membrane Biol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada	University of Toronto; University of Toronto	Clarke, DM (corresponding author), Univ Toronto, Dept Med, Canadian Inst Hlth, Res Grp Membrane Biol, Rm 7342,Med Res Bldg,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.		Clarke, David M./A-1112-2008	Clarke, David M./0000-0003-4335-7184; Loo, Tip W/0000-0003-2108-0188	NATIONAL CANCER INSTITUTE [R01CA080900] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA80900] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ambudkar SV, 1997, J BIOL CHEM, V272, P21160, DOI 10.1074/jbc.272.34.21160; Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361; AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; BRUGGEMANN EP, 1992, J BIOL CHEM, V267, P21020; CHAN HS, 1996, EUR J CANCER, V6, P1051; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; Chen G, 1997, J BIOL CHEM, V272, P5974, DOI 10.1074/jbc.272.9.5974; CHIFFLET S, 1988, ANAL BIOCHEM, V168, P1, DOI 10.1016/0003-2697(88)90002-4; CORDONCARDO C, 1989, P NATL ACAD SCI USA, V86, P695, DOI 10.1073/pnas.86.2.695; Demeule M, 1998, BIOCHEMISTRY-US, V37, P18110, DOI 10.1021/bi981992c; Demmer A, 1997, J BIOL CHEM, V272, P20913, DOI 10.1074/jbc.272.33.20913; DEVINE SE, 1992, P NATL ACAD SCI USA, V89, P4564, DOI 10.1073/pnas.89.10.4564; Dey S, 1997, P NATL ACAD SCI USA, V94, P10594, DOI 10.1073/pnas.94.20.10594; Druley TE, 2001, BIOCHEMISTRY-US, V40, P4312, DOI 10.1021/bi001371v; GOODNO CC, 1982, METHOD ENZYMOL, V85, P116; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GREENBERGER LM, 1993, J BIOL CHEM, V268, P11417; GROS P, 1991, P NATL ACAD SCI USA, V88, P7289, DOI 10.1073/pnas.88.16.7289; Hafkemeyer P, 1998, BIOCHEMISTRY-US, V37, P16400, DOI 10.1021/bi980871+; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Holland IB, 1999, J MOL BIOL, V293, P381, DOI 10.1006/jmbi.1999.2993; Hrycyna CA, 1998, J BIOL CHEM, V273, P16631, DOI 10.1074/jbc.273.27.16631; Julien M, 2000, BIOCHEMISTRY-US, V39, P4559, DOI 10.1021/bi992744z; KAJIJI S, 1993, BIOCHEMISTRY-US, V32, P4185, DOI 10.1021/bi00067a005; Kast C, 1996, J BIOL CHEM, V271, P9240, DOI 10.1074/jbc.271.16.9240; Kim RB, 1998, J CLIN INVEST, V101, P289, DOI 10.1172/JCI1269; Lee CGL, 1998, BIOCHEMISTRY-US, V37, P3594, DOI 10.1021/bi972709x; Liu RH, 1996, BIOCHEMISTRY-US, V35, P11865, DOI 10.1021/bi960823u; Loo TW, 1997, J BIOL CHEM, V272, P709, DOI 10.1074/jbc.272.2.709; Loo TW, 2000, J BIOL CHEM, V275, P19435, DOI 10.1074/jbc.C000222200; Loo TW, 1996, J BIOL CHEM, V271, P27488, DOI 10.1074/jbc.271.44.27488; Loo TW, 1999, BBA-BIOMEMBRANES, V1461, P315, DOI 10.1016/S0005-2736(99)00165-0; Loo TW, 1999, J BIOL CHEM, V274, P35388, DOI 10.1074/jbc.274.50.35388; Loo TW, 1999, J BIOL CHEM, V274, P24759, DOI 10.1074/jbc.274.35.24759; Loo TW, 1997, J BIOL CHEM, V272, P20986, DOI 10.1074/jbc.272.34.20986; LOO TW, 1993, J BIOL CHEM, V268, P3143; Loo TW, 1996, J BIOL CHEM, V271, P27482, DOI 10.1074/jbc.271.44.27482; Loo TW, 1997, J BIOL CHEM, V272, P31945, DOI 10.1074/jbc.272.51.31945; Loo TW, 2000, J BIOL CHEM, V275, P5253, DOI 10.1074/jbc.275.8.5253; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; LOO TW, 1994, BIOCHEMISTRY-US, V33, P14049, DOI 10.1021/bi00251a013; LOO TW, 1995, J BIOL CHEM, V270, P21449, DOI 10.1074/jbc.270.37.21449; LOO TW, 1994, J BIOL CHEM, V269, P7750; Loo TW, 2001, J BIOL CHEM, V276, P14972, DOI 10.1074/jbc.M100407200; Loo TW, 2000, J BIOL CHEM, V275, P39272, DOI 10.1074/jbc.M007741200; LOO TW, 1995, J BIOL CHEM, V270, P22957, DOI 10.1074/jbc.270.39.22957; LOO TW, 1993, J BIOL CHEM, V268, P19965; Loo TW, 2000, JNCI-J NATL CANCER I, V92, P898, DOI 10.1093/jnci/92.11.898; Martin C, 2000, MOL PHARMACOL, V58, P624, DOI 10.1124/mol.58.3.624; MORRIS DI, 1994, MOL PHARMACOL, V46, P329; Pascaud C, 1998, BIOCHEM J, V333, P351, DOI 10.1042/bj3330351; Qu Q, 2001, BIOCHEMISTRY-US, V40, P1413, DOI 10.1021/bi002035h; Robert J, 1999, EUR J CLIN INVEST, V29, P536, DOI 10.1046/j.1365-2362.1999.00495.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sauna ZE, 2000, P NATL ACAD SCI USA, V97, P2515, DOI 10.1073/pnas.97.6.2515; Sauna ZE, 2001, J BIOL CHEM, V276, P11653, DOI 10.1074/jbc.M011294200; SCHINKEL AH, 1994, CELL, V77, P491, DOI 10.1016/0092-8674(94)90212-7; Senior AE, 1995, FEBS LETT, V377, P285, DOI 10.1016/0014-5793(95)01345-8; Senior AE, 1997, SEMIN CANCER BIOL, V8, P143, DOI 10.1006/scbi.1997.0065; Shapiro AB, 1997, EUR J BIOCHEM, V250, P130, DOI 10.1111/j.1432-1033.1997.00130.x; Shapiro AB, 1999, EUR J BIOCHEM, V259, P841, DOI 10.1046/j.1432-1327.1999.00098.x; Sharom FJ, 1997, J MEMBRANE BIOL, V160, P161, DOI 10.1007/s002329900305; Sonveaux N, 1996, J BIOL CHEM, V271, P24617, DOI 10.1074/jbc.271.40.24617; THIEBAUT F, 1987, P NATL ACAD SCI USA, V84, P7735, DOI 10.1073/pnas.84.21.7735; URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/jbc.270.33.19383; URBATSCH IL, 1995, J BIOL CHEM, V270, P26956, DOI 10.1074/jbc.270.45.26956; Walmsley AR, 2001, J BIOL CHEM, V276, P6378, DOI 10.1074/jbc.M008105200; ZHANG XP, 1995, J BIOL CHEM, V270, P5441, DOI 10.1074/jbc.270.10.5441; Zheleznova EE, 1999, CELL, V96, P353, DOI 10.1016/S0092-8674(00)80548-6; Zhou Y, 1999, MOL PHARMACOL, V56, P997, DOI 10.1124/mol.56.5.997	70	70	71	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					31800	31805		10.1074/jbc.M103498200	http://dx.doi.org/10.1074/jbc.M103498200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11429407	hybrid			2022-12-25	WOS:000170613500045
J	Pan, Z; Bhat, MB; Nieminen, AL; Ma, J				Pan, Z; Bhat, MB; Nieminen, AL; Ma, J			Synergistic movements of Ca2+ and Bax in cells undergoing apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; INTRACELLULAR CALCIUM STORES; CHANNEL-FORMING ACTIVITY; ENDOPLASMIC-RETICULUM; RYANODINE RECEPTOR; SKELETAL-MUSCLE; AMYLOID-BETA; BCL-2; MITOCHONDRIA; SIGNALS	Apoptosis is a physiological counterbalance to mitosis and plays important roles in tissue development and homeostasis. Cytosolic Ca2+ has been implicated as a proapoptotic second messenger involved in both triggering apoptosis and regulating cell death-specific enzymes. A critical early event in apoptosis is associated with the redistribution of Bax from cytosol to mitochondria and endoplasmic reticulum (ER) membranes; however, the molecular mechanism of Bax translocation and its relationship to Ca2+ is largely unknown. Here we provide functional evidence for a synergistic interaction between the movements of intracellular Ca2+ and cytosolic Bax in the induction of apoptosis. Overexpression of Bax in cultured cells causes a loss of ER Ca2+ content. Depletion of ER Ca2+ through activation of the ryanodine receptor enhances the participation of Bax into the mitochondrial membrane. Neither Bax translocation nor Bax-induced apoptosis is affected by buffering of cytosolic Ca2+ with 1,2-bis(2-aminophenoxy)-ethane-N,N N ' ,N ' -tetraacetic acid, suggesting that depletion of ER Ca2+ rather than elevation of cytosolic Ca2+ is the signal for cell apoptosis. This dynamic interplay of Ca2+ and Bax movements may serve as an amplifying factor in the initial signaling steps of apoptosis.	Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Anat, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Ma, J (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, 675 Hoes Lane, Piscataway, NJ 08854 USA.	jxm63@po.cwru.edu		Pan, Zui/0000-0003-4105-901X	NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR014690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039469] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG015556] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA85834] Funding Source: Medline; NCRR NIH HHS [S10-RR14690] Funding Source: Medline; NIA NIH HHS [R01-AG15556] Funding Source: Medline; NINDS NIH HHS [R01-NS39469] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Andjelic S, 1997, J IMMUNOL, V158, P2527; Antonsson B, 2000, BIOCHEM J, V345, P271, DOI 10.1042/0264-6021:3450271; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; BAFFY G, 1993, J BIOL CHEM, V268, P6511; Basanez G, 1999, P NATL ACAD SCI USA, V96, P5492, DOI 10.1073/pnas.96.10.5492; Bian XP, 1997, AM J PHYSIOL-CELL PH, V272, pC1241, DOI 10.1152/ajpcell.1997.272.4.C1241; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Guo Q, 1997, J NEUROSCI, V17, P4212; Hayek SM, 2000, BIOCHEM J, V351, P57, DOI 10.1042/0264-6021:3510057; Heiskanen KM, 1999, J BIOL CHEM, V274, P5654, DOI 10.1074/jbc.274.9.5654; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Ichimiya M, 1998, AM J PHYSIOL-CELL PH, V275, pC832, DOI 10.1152/ajpcell.1998.275.3.C832; Jayaraman T, 1997, MOL CELL BIOL, V17, P3005, DOI 10.1128/MCB.17.6.3005; JIANG S, 1994, EXP CELL RES, V212, P84, DOI 10.1006/excr.1994.1121; KAISER N, 1977, P NATL ACAD SCI USA, V74, P638, DOI 10.1073/pnas.74.2.638; Kuo TH, 1998, ONCOGENE, V17, P1903, DOI 10.1038/sj.onc.1202110; MA J, 1988, SCIENCE, V242, P99, DOI 10.1126/science.2459777; Manjunatha B, 1997, J GEN PHYSIOL, V110, P749, DOI 10.1085/jgp.110.6.749; Margineantu D, 2000, BIOPHYS J, V79, P1833, DOI 10.1016/S0006-3495(00)76433-2; McGahon A. J., 1995, METHOD CELL BIOL, V46, P172; Miyakawa T, 1999, EMBO J, V18, P1303, DOI 10.1093/emboj/18.5.1303; Murphy AN, 1996, P NATL ACAD SCI USA, V93, P9893, DOI 10.1073/pnas.93.18.9893; Murphy KM, 1999, ONCOGENE, V18, P5991, DOI 10.1038/sj.onc.1203001; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nakamura K, 2000, J CELL BIOL, V150, P731, DOI 10.1083/jcb.150.4.731; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Pan Z, 2000, J BIOL CHEM, V275, P19978, DOI 10.1074/jbc.M908329199; Pawlowski J, 2000, P NATL ACAD SCI USA, V97, P529, DOI 10.1073/pnas.97.2.529; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Reynolds JE, 1996, EXP CELL RES, V225, P430, DOI 10.1006/excr.1996.0194; Reynolds JE, 1996, J BIOL CHEM, V271, P27739, DOI 10.1074/jbc.271.44.27739; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Szalai G, 1999, EMBO J, V18, P6349, DOI 10.1093/emboj/18.22.6349; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Wei HF, 1998, J NEUROCHEM, V70, P2305; Williams SS, 2000, CANCER RES, V60, P4358; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129	42	69	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					32257	32263		10.1074/jbc.M100178200	http://dx.doi.org/10.1074/jbc.M100178200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11413128	hybrid			2022-12-25	WOS:000170613500106
J	Bernoud-Hubac, N; Davies, SS; Boutaud, O; Montine, TJ; Roberts, LJ				Bernoud-Hubac, N; Davies, SS; Boutaud, O; Montine, TJ; Roberts, LJ			Formation of highly reactive gamma-ketoaldehudes (Neuroketals) as products of the neuroprostane pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID-PEROXIDATION PRODUCT; IMPAIRS GLUTAMATE TRANSPORT; DOCOSAHEXAENOIC ACID; ALZHEIMERS-DISEASE; OXIDATIVE STRESS; IN-VIVO; CEREBROSPINAL-FLUID; IMMUNOHISTOCHEMICAL DETECTION; HUNTINGTONS-DISEASE; ALDEHYDIC PRODUCT	Neuroprostanes are prostaglandin-like compounds produced by free radical-induced peroxidation of docosahexaenoic acid, which is highly enriched in the brain. We previously described the formation of highly reactive gamma -ketoaldehydes (isoketals) as products of the isoprostane pathway of free radical-induced peroxidation of arachidonic acid. We therefore explored whether isoketal-like compounds (neuroketals) are also formed via the neuroprostane pathway. Utilizing mass spectrometric analyses, neuroketals were found to be formed in abundance in vitro during oxidation of docosahexaenoic acid and were formed in greater abundance than isoketals during co-oxidation of docosahexaenoic and arachidonic acid. Neuroketals were shown to rapidly adduct to lysine, forming lactam and Schiff base adducts. Neuroketal lysyl-lactam protein adducts were detected in nonoxidized rat brain synaptosomes at a level of 0.09 ng(mg of protein, which increased 19-fold following oxidation in vitro. Neuroketal lysyl-lactam protein adducts were also detected in vivo in normal human brain at a level of 9.9 +/- 3.7 ng/g of brain tissue. These studies identify a new class of highly reactive molecules that may participate in the formation of protein adducts and protein-protein cross-links in neurodegenerative diseases and contribute to the injurious effects of other oxidative pathologies in the brain.	Vanderbilt Univ, Dept Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Med, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Roberts, LJ (corresponding author), Vanderbilt Univ, Dept Pharmacol, Nashville, TN 37232 USA.	jack.roberts@mcmail.vanderbilt.edu		Davies, Sean/0000-0001-9879-8062	NCI NIH HHS [CA68486] Funding Source: Medline; NIDDK NIH HHS [DK26657] Funding Source: Medline; NIGMS NIH HHS [GM42056, GM15431] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK026657] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM042056, P50GM015431, R01GM042056, P01GM015431] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON RE, 1970, EXP EYE RES, V10, P339, DOI 10.1016/S0014-4835(70)80046-X; BAZAN NG, 1990, UPSALA J MED SCI, P97; Bernoud N, 1998, J LIPID RES, V39, P1816; BLAKELY RD, 1986, J NEUROCHEM, V47, P1013; Blanc EM, 1997, J NEUROCHEM, V69, P570; Blanc EM, 1998, GLIA, V22, P149, DOI 10.1002/(SICI)1098-1136(199802)22:2<149::AID-GLIA6>3.0.CO;2-2; Boutaud O, 1999, BIOCHEMISTRY-US, V38, P9389, DOI 10.1021/bi990470+; Brame CJ, 1999, J BIOL CHEM, V274, P13139, DOI 10.1074/jbc.274.19.13139; Browne SE, 1997, ANN NEUROL, V41, P646, DOI 10.1002/ana.410410514; de la Monte SM, 2000, CELL MOL LIFE SCI, V57, P1471, DOI 10.1007/PL00000630; Dratz E. A., 1986, Health effects of polyunsaturated fatty acids in seafoods, P319; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; Floyd RA, 1999, P SOC EXP BIOL MED, V222, P236, DOI 10.1046/j.1525-1373.1999.d01-140.x; GRAHAM DG, 1995, CRIT REV TOXICOL, V25, P91, DOI 10.3109/10408449509021609; IYER RS, 1989, PROSTAGLANDINS, V37, P471, DOI 10.1016/0090-6980(89)90096-8; JANOWSKY A, 1998, CURRENT PROTOCOLS NE; Jensen MM, 1996, BBA-LIPID LIPID MET, V1300, P203, DOI 10.1016/0005-2760(96)00007-0; Keller JN, 1997, NEUROSCIENCE, V80, P685, DOI 10.1016/S0306-4522(97)00065-1; Knight JA, 1997, ANN CLIN LAB SCI, V27, P11; Lehning EJ, 2000, TOXICOL APPL PHARM, V165, P127, DOI 10.1006/taap.2000.8937; LONGMIRE AW, 1994, BIOCHEM PHARMACOL, V47, P1173, DOI 10.1016/0006-2952(94)90389-1; Lovell MA, 1997, NEUROBIOL AGING, V18, P457, DOI 10.1016/S0197-4580(97)00108-5; Makrides M, 1996, LIPIDS, V31, P115, DOI 10.1007/BF02522420; Mark RJ, 1997, J NEUROSCI, V17, P1046; Markesbery WR, 1997, FREE RADICAL BIO MED, V23, P134, DOI 10.1016/S0891-5849(96)00629-6; Montine KS, 1997, J NEUROPATH EXP NEUR, V56, P866, DOI 10.1097/00005072-199708000-00004; Montine KS, 1997, AM J PATHOL, V150, P437; Montine TJ, 1999, NEUROLOGY, V52, P1104, DOI 10.1212/WNL.52.5.1104; Montine TJ, 1998, ANN NEUROL, V44, P410, DOI 10.1002/ana.410440322; MOORE SA, 1991, J NEUROCHEM, V56, P518, DOI 10.1111/j.1471-4159.1991.tb08180.x; Morrow JD, 1996, J BIOL CHEM, V271, P23185, DOI 10.1074/jbc.271.38.23185; MORROW JD, 1990, P NATL ACAD SCI USA, V87, P9383, DOI 10.1073/pnas.87.23.9383; MORROW JD, 1994, J BIOL CHEM, V269, P4317; MORROW JD, 1990, ANAL BIOCHEM, V184, P1, DOI 10.1016/0003-2697(90)90002-Q; MURTHI KK, 1993, BIOCHEMISTRY-US, V32, P4090, DOI 10.1021/bi00066a034; Neely MD, 1999, J NEUROCHEM, V72, P2323, DOI 10.1046/j.1471-4159.1999.0722323.x; NEURINGER M, 1988, ANNU REV NUTR, V8, P517, DOI 10.1146/annurev.nu.08.070188.002505; Nourooz-Zadeh J, 1998, BIOCHEM BIOPH RES CO, V242, P338, DOI 10.1006/bbrc.1997.7883; OBRIEN JS, 1965, J LIPID RES, V6, P537; Perry G, 2000, INT J DEV NEUROSCI, V18, P417, DOI 10.1016/S0736-5748(00)00006-X; Reich EE, 2001, AM J PATHOL, V158, P293, DOI 10.1016/S0002-9440(10)63968-5; Reich EE, 2000, BIOCHEMISTRY-US, V39, P2376, DOI 10.1021/bi992000l; Roberts LJ, 1998, J BIOL CHEM, V273, P13605, DOI 10.1074/jbc.273.22.13605; SALOMON RG, 1984, J AM CHEM SOC, V106, P6049, DOI 10.1021/ja00332a049; Sayre LM, 1997, J NEUROCHEM, V68, P2092; Simonian NA, 1996, ANNU REV PHARMACOL, V36, P83, DOI 10.1146/annurev.pa.36.040196.000503; Smith RG, 1998, ANN NEUROL, V44, P696, DOI 10.1002/ana.410440419; STEINBERG D, 1995, ADV EXP MED BIOL, V369, P39; Taber DF, 1997, PROSTAGLANDINS, V53, P63, DOI 10.1016/S0090-6980(97)00005-1; VANKUIJK FJGM, 1990, BIOCHIM BIOPHYS ACTA, V1043, P116, DOI 10.1016/0005-2760(90)90118-H; Werkman SH, 1996, LIPIDS, V31, P91, DOI 10.1007/BF02522417; Yoritaka A, 1996, P NATL ACAD SCI USA, V93, P2696, DOI 10.1073/pnas.93.7.2696	52	75	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					30964	30970		10.1074/jbc.M103768200	http://dx.doi.org/10.1074/jbc.M103768200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11413140	hybrid			2022-12-25	WOS:000170472900051
J	Mistry, SJ; Atweh, GF				Mistry, SJ; Atweh, GF			Stathmin inhibition enhances okadaic acid-induced mitotic arrest - A potential role for stathmin in mitotic exit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLE-REGULATED PHOSPHORYLATION; DEPENDENT PROTEIN-KINASE; INTACT-CELLS; MICROTUBULE DYNAMICS; PHOSPHOPROTEIN P18; LEUKEMIC-CELLS; ONCOPROTEIN-18; PHOSPHATASES; IDENTIFICATION; INVOLVEMENT	Stathmin is a microtubule-destabilizing phosphoprotein that plays a critical role in the regulation of mitosis. The microtubule-depolymerizing activity of stathmin is lost upon phosphorylation in mitosis. Although the role of phosphorylation of stathmin by p34(cdc2) kinase in the assembly of the mitotic spindle is well established, the role of dephosphorylation of stathmin in mitosis is unknown. In this study, we tested the hypothesis that dephosphorylation of stathmin may be critically important for the depolymerization of the mitotic spindle and the exit from mitosis. We compared the effects of okadaic acid, a specific inhibitor of serine/threonine protein phosphatases, on different parameters of mitotic progression in the presence or absence of stathmin deficiency. Because okadaic acid prevents dephosphorylation of stathmin and results in accumulation of the inactive phosphorylated form, exposure to okadaic acid would be expected to have a more profound effect on mitosis in the presence of relative stathmin deficiency. We found that inhibition of stathmin expression results in increased sensitivity to the antimitotic effects of okadaic acid. This was reflected by increased growth inhibition associated with mitotic arrest. A vast majority of the stathmin-inhibited cells were found to be arrested in late metaphase/anaphase and had severe mitotic spindle abnormalities. Exposure to okadaic acid also resulted in a bigger ratio of polymerized/unpolymerized tubulin in stathmin-inhibited cells relative to control cells. Because the only difference between the control and the stathmin-inhibited cells is the deficiency of stathmin in the latter, the increased susceptibility of the stathmin-inhibited cells to okadaic acid-induced mitotic arrest implies a role for stathmin in the later stages of mitosis.	Mt Sinai Sch Med, Div Hematol, Dept Med, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Atweh, GF (corresponding author), Mt Sinai Sch Med, Div Hematol, Dept Med, 1 Gustave L Levy Pl,Box 1079, New York, NY 10029 USA.	george.atweh@mssm.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054184] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL54184] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Belmont LD, 1996, CELL, V84, P623, DOI 10.1016/S0092-8674(00)81037-5; BERETTA L, 1993, J BIOL CHEM, V268, P20076; CARON JM, 1989, J CELL PHYSIOL, V138, P603, DOI 10.1002/jcp.1041380322; DOONAN JH, 1989, CELL, V57, P987, DOI 10.1016/0092-8674(89)90337-1; EICHHORN JH, 1979, J CELL BIOL, V82, P572, DOI 10.1083/jcb.82.2.572; ENGELHARD HH, 1991, CYTOMETRY, V12, P68, DOI 10.1002/cyto.990120110; GHOSH S, 1992, EXP CELL RES, V200, P215, DOI 10.1016/S0014-4827(05)80091-6; Gradin HM, 1998, J CELL BIOL, V140, P131, DOI 10.1083/jcb.140.1.131; Gradin HM, 1997, MOL CELL BIOL, V17, P3459, DOI 10.1128/MCB.17.6.3459; HARDIE DG, 1991, METHOD ENZYMOL, V201, P469; Horwitz SB, 1997, J BIOL CHEM, V272, P8129, DOI 10.1074/jbc.272.13.8129; Howell B, 1999, J CELL SCI, V112, P3713; Jeha S, 1996, CANCER RES, V56, P1445; LARSSON N, 1995, J BIOL CHEM, V270, P14175, DOI 10.1074/jbc.270.23.14175; LUO XN, 1994, J BIOL CHEM, V269, P10312; MARKLUND U, 1993, J BIOL CHEM, V268, P15039; Marklund U, 1996, EMBO J, V15, P5290, DOI 10.1002/j.1460-2075.1996.tb00914.x; MINOTTI AM, 1991, J BIOL CHEM, V266, P3987; Mistry SJ, 1998, BIOCHEM J, V334, P23, DOI 10.1042/bj3340023; OHKURA H, 1989, CELL, V57, P997, DOI 10.1016/0092-8674(89)90338-3; PICARD A, 1989, J CELL BIOL, V109, P3347, DOI 10.1083/jcb.109.6.3347; SCHONTHAL A, 1992, NEW BIOL, V4, P16; SEGER M, 1984, J LEUKOCYTE BIOL, V35, P303; VANDOLAH FM, 1992, J CELL PHYSIOL, V152, P190, DOI 10.1002/jcp.1041520124; VANDRE DD, 1992, J CELL SCI, V101, P79; ZHENG B, 1991, J BIOL CHEM, V266, P10031	26	47	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					31209	31215		10.1074/jbc.M011654200	http://dx.doi.org/10.1074/jbc.M011654200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11418586	hybrid			2022-12-25	WOS:000170472900082
J	Rivolta, I; Abriel, H; Tateyama, M; Liu, HH; Memmi, M; Vardas, P; Napolitano, C; Priori, SG; Kass, RS				Rivolta, I; Abriel, H; Tateyama, M; Liu, HH; Memmi, M; Vardas, P; Napolitano, C; Priori, SG; Kass, RS			Inherited Brugada and long QT-3 syndrome mutations of a single residue of the cardiac sodium channel confer distinct channel and clinical phenotypes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ST-SEGMENT ELEVATION; NA+ CHANNEL; MOLECULAR MECHANISM; LQT-3 MUTATION; ALPHA-SUBUNIT; SCN5A; ARRHYTHMIA; DEATH; DIAGNOSIS; THERAPY	Defects of the SCN5A gene encoding the cardiac sodium channel a-subunit are associated with both the long,QT-3 (LQT-3) subtype of long-QT syndrome and Brugada syndrome (BrS). One previously described SCN5A mutation (1795insD) in the C terminus results in a clinical phenotype combining QT prolongation and ST segment elevation, indicating a close interrelationship between the two disorders. Here we provide additional evidence that these two disorders are closely related. We report the analysis of two novel mutations on the same codon, Y1795C (LQT-3) and Y1795H (BrS), expressed in HEK 293 cells and characterized using whole-cell patch clamp procedures. We find marked and opposing effects on channel gating consistent with activity associated with the cellular basis of each clinical disorder. Y1795H speeds and Y1795C slows the onset of inactivation. The Y1795H, but not the Y1795C, mutation causes a marked negative shift in the voltage dependence of inactivation, and neither mutation affects the kinetics of the recovery from inactivation. Interestingly, both mutations increase the expression of sustained Na+ channel activity compared with wild type (WT) channels, although this effect is most pronounced for the Y1795C mutation, and both mutations promote entrance into an intermediate or a slowly developing inactivated state. These data confirm the key role of the C-terminal tail of the cardiac Na+ channel in the control of channel gating, illustrate how subtle changes in channel biophysics can have significant and distinct effects in human disease, and, additionally, provide further evidence of the close interrelationship between BrS and LQT-3 at the molecular level.	Columbia Univ Coll Phys & Surg, Dept Pharmacol, New York, NY 10032 USA; IRCCS, Fdn Salvatore Maugeri, Mol Cardiol Lab, Pavia, Italy; Heraklion Univ Hosp, Dept Cardiol, Stavrakia, Crete, Greece	Columbia University; Istituti Clinici Scientifici Maugeri IRCCS; University of Pavia; University Hospital of Heraklion	Kass, RS (corresponding author), Columbia Univ Coll Phys & Surg, Dept Pharmacol, 630 W 168th St,PH 7W 318, New York, NY 10032 USA.		napolitano, carlo/ABI-4608-2020; Vardas, Panos/AAD-5219-2022; Priori, Silvia G G/A-6116-2014; Vardas, Panos/AAP-5694-2021; vardas, panos/ABF-7144-2020; memmi, mirella/AAB-9428-2020; Abriel, Hugues/B-9800-2009; Priori, Silvia G/ABH-6894-2020; Napolitano, Carlo/K-4760-2016	napolitano, carlo/0000-0002-7643-4628; Priori, Silvia G G/0000-0001-6877-0288; memmi, mirella/0000-0003-4006-5661; Abriel, Hugues/0000-0003-0465-5138; Priori, Silvia G/0000-0001-6877-0288; Napolitano, Carlo/0000-0002-7643-4628	NHLBI NIH HHS [HL-568105-04] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abriel H, 2001, CIRC RES, V88, P740, DOI 10.1161/hh0701.089668; An RH, 1996, CIRC RES, V79, P103, DOI 10.1161/01.RES.79.1.103; An RH, 1998, CIRC RES, V83, P141, DOI 10.1161/01.RES.83.2.141; Antzelevitch C, 1999, CURR OPIN CARDIOL, V14, P274, DOI 10.1097/00001573-199905000-00013; Baroudi G, 2000, FEBS LETT, V487, P224, DOI 10.1016/S0014-5793(00)02360-7; Benhorin J, 1998, Hum Mutat, V12, P72, DOI 10.1002/(SICI)1098-1004(1998)12:1<72::AID-HUMU17>3.0.CO;2-Z; BENNETT PB, 1993, FEBS LETT, V326, P21, DOI 10.1016/0014-5793(93)81752-L; BENNETT PB, 1995, NATURE, V376, P683, DOI 10.1038/376683a0; Bezzina C, 1999, CIRC RES, V85, P1206; Bezzina CR, 2001, CARDIOVASC RES, V49, P257, DOI 10.1016/S0008-6363(00)00272-8; Brugada P, 2000, HEART, V84, P1, DOI 10.1136/heart.84.1.1; Brugada P, 2000, Curr Cardiol Rep, V2, P507, DOI 10.1007/s11886-000-0035-0; Chen QY, 1998, NATURE, V392, P293, DOI 10.1038/32675; Clancy CE, 1999, NATURE, V400, P566, DOI 10.1038/23034; Clayton RH, 2001, J THEOR BIOL, V208, P215, DOI 10.1006/jtbi.2000.2212; Deschenes I, 2000, CARDIOVASC RES, V46, P55, DOI 10.1016/S0008-6363(00)00006-7; Dumaine R, 1999, CIRC RES, V85, P803, DOI 10.1161/01.RES.85.9.803; Grant AO, 2001, AM J MED, V110, P296, DOI 10.1016/S0002-9343(00)00714-2; Gussak I, 1999, J AM COLL CARDIOL, V33, P5, DOI 10.1016/S0735-1097(98)00528-2; Moss AJ, 2000, CIRCULATION, V101, P616, DOI 10.1161/01.CIR.101.6.616; Priori SG, 2000, J CARDIOVASC ELECTR, V11, P1174, DOI 10.1111/j.1540-8167.2000.tb01766.x; Priori SG, 2000, CIRCULATION, V102, P945, DOI 10.1161/01.CIR.102.9.945; Priori SG, 2000, CIRCULATION, V102, P2509, DOI 10.1161/01.CIR.102.20.2509; Priori SG, 2000, LANCET, V355, P808, DOI 10.1016/S0140-6736(99)05277-0; Rook MB, 1999, CARDIOVASC RES, V44, P507, DOI 10.1016/S0008-6363(99)00350-8; Schott JJ, 1999, NAT GENET, V23, P20, DOI 10.1038/12618; Schwartz PJ, 2000, NEW ENGL J MED, V343, P262, DOI 10.1056/NEJM200007273430405; SCHWARTZ PJ, 1995, CIRCULATION, V92, P3381, DOI 10.1161/01.CIR.92.12.3381; Swan H, 1998, J AM COLL CARDIOL, V32, P486, DOI 10.1016/S0735-1097(98)00248-4; Tan HL, 2001, NATURE, V409, P1043, DOI 10.1038/35059090; Veldkamp MW, 2000, CIRC RES, V86, pE91, DOI 10.1161/01.RES.86.9.e91; Wang DW, 2000, CIRC RES, V87, pE37, DOI 10.1161/01.RES.87.8.e37; WANG Q, 1995, CELL, V80, P805, DOI 10.1016/0092-8674(95)90359-3; Wehrens XHT, 2000, CIRCULATION, V102, P584; Wei J, 1999, CIRCULATION, V99, P3165, DOI 10.1161/01.CIR.99.24.3165; Wilde AAM, 2000, EUR HEART J, V21, P1483, DOI 10.1053/euhj.2000.2231; Yan GX, 1999, CIRCULATION, V100, P1660, DOI 10.1161/01.CIR.100.15.1660; Zhang L, 2000, CIRCULATION, V102, P2849	38	139	143	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					30623	30630		10.1074/jbc.M104471200	http://dx.doi.org/10.1074/jbc.M104471200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11410597	hybrid			2022-12-25	WOS:000170472900007
J	Zaccaro, MC; Ivanisevic, L; Perez, P; Meakin, SO; Saragovi, HU				Zaccaro, MC; Ivanisevic, L; Perez, P; Meakin, SO; Saragovi, HU			p75 co-receptors regulate ligand-dependent and ligand-independent Trk receptor activation, in part by altering Trk docking subdomains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; IMMUNOGLOBULIN-LIKE DOMAINS; HUMAN INSULIN-RECEPTOR; FACTOR BINDING-SITE; LEUCINE-RICH MOTIF; NEUROTROPHIN RECEPTORS; EXTRACELLULAR DOMAIN; SIGNAL-TRANSDUCTION; MONOCLONAL-ANTIBODIES; KINASE DOMAIN	Neurotrophins signal via Trk tyrosine kinase receptors and a common receptor called p75. Nerve growth factor is the cognate ligand for TrkA, brain-derived neurotrophic factor for TrkB, and neurotrophin-3 (NT-3) for TrkC. NT-3 also binds TrkA and TrkB as a heterologous ligand. All neurotrophins bind p75, which regulates ligand affinity and Trk signals. Trk extracellular domain has five subdomains: a leucine-rich motif, two cysteine-rich clusters, and immunoglobulin-like subdomains IgG-C1 and IgG-C2. The IgG-C1 subdomain is surface exposed in the tertiary structure and regulates ligand-independent activation. The IgG-C2 subdomain is less exposed but regulates cognate ligand binding and Trk activation. NT-3 as a heterologous ligand of TrkA and TrkB optimally requires the IgG-C2 but also binds other subdomains of these receptors. When p75 is co-expressed, major changes are observed; NGF-TrkA activation can occur also via the cysteine I subdomain, and brain-derived neurotrophic factor-TrkB activation requires the TrkB leucine-rich motif and cysteine 2 subdomains. We propose a two-site model of Trk binding and activation, regulated conformationally by the IgG-C1 subdomain. Moreover, p75 affects Trk subdomain utilization in ligand-dependent activation, possibly by conformational or allosteric control.	McGill Univ, Montreal, PQ H3G 1Y6, Canada; Univ Salamanca, Salamanca 37007, Spain; John P Robarts Res Inst, London, ON N6A 5K8, Canada	McGill University; University of Salamanca; Western University (University of Western Ontario)	Zaccaro, MC (corresponding author), McGill Univ, 3655 Drummond St 1320, Montreal, PQ H3G 1Y6, Canada.		Meakin, Susan/K-8823-2013; Perez, Pilar/B-4948-2010	Meakin, Susan/0000-0003-2469-6615; Perez, Pilar/0000-0003-3557-2247				Arevalo JC, 2000, MOL CELL BIOL, V20, P5908, DOI 10.1128/MCB.20.16.5908-5916.2000; Arevalo JC, 2001, ONCOGENE, V20, P1229, DOI 10.1038/sj.onc.1204215; Bamji SX, 1998, J CELL BIOL, V140, P911, DOI 10.1083/jcb.140.4.911; BARBACID M, 1994, J NEUROBIOL, V25, P1386, DOI 10.1002/neu.480251107; BARKER PA, 1994, NEURON, V13, P203, DOI 10.1016/0896-6273(94)90470-7; Bibel M, 1999, EMBO J, V18, P616, DOI 10.1093/emboj/18.3.616; Brennan C, 1999, NAT NEUROSCI, V2, P699, DOI 10.1038/11158; CLARY DO, 1994, MOL BIOL CELL, V5, P549, DOI 10.1091/mbc.5.5.549; COULIER F, 1990, MOL CELL BIOL, V10, P4202, DOI 10.1128/MCB.10.8.4202; Cunningham ME, 1997, J BIOL CHEM, V272, P10957; EIDE FF, 1993, EXP NEUROL, V121, P200, DOI 10.1006/exnr.1993.1087; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; Holden PH, 1997, NAT BIOTECHNOL, V15, P668, DOI 10.1038/nbt0797-668; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; Kadari A, 1997, J NEUROSCI RES, V50, P402; KAPLAN DR, 1994, J NEUROBIOL, V25, P1404, DOI 10.1002/neu.480251108; Kohn J, 1999, J NEUROSCI, V19, P5393; Livnah O, 1998, NAT STRUCT BIOL, V5, P993, DOI 10.1038/2965; MacDonald JIS, 1996, MOL CELL NEUROSCI, V7, P371, DOI 10.1006/mcne.1996.0027; MacPhee IJ, 1997, J BIOL CHEM, V272, P23547, DOI 10.1074/jbc.272.38.23547; MAHADEO D, 1994, J BIOL CHEM, V269, P6884; Maliartchouk S, 1997, J NEUROSCI, V17, P6031; MORGAN DO, 1986, BIOCHEMISTRY-US, V25, P1364, DOI 10.1021/bi00354a026; Mufson EJ, 1997, EXP NEUROL, V146, P91, DOI 10.1006/exnr.1997.6504; Ninkina N, 1997, J BIOL CHEM, V272, P13019, DOI 10.1074/jbc.272.20.13019; PEREZ P, 1995, MOL CELL NEUROSCI, V6, P97, DOI 10.1006/mcne.1995.1010; Remy I, 1999, SCIENCE, V283, P990, DOI 10.1126/science.283.5404.990; Saragovi HU, 1999, EXPERT OPIN THER PAT, V9, P737, DOI 10.1517/13543776.9.6.737; Saragovi HU, 1998, J BIOL CHEM, V273, P34933, DOI 10.1074/jbc.273.52.34933; SARAGOVI HU, 1992, BIO-TECHNOL, V10, P773, DOI 10.1038/nbt0792-773; SCHNEIDER R, 1991, ONCOGENE, V6, P1807; SOOS MA, 1986, BIOCHEM J, V235, P199, DOI 10.1042/bj2350199; Urfer R, 1998, J BIOL CHEM, V273, P5829, DOI 10.1074/jbc.273.10.5829; URFER R, 1995, EMBO J, V14, P2795, DOI 10.1002/j.1460-2075.1995.tb07279.x; Wells JA, 1996, SCIENCE, V273, P449, DOI 10.1126/science.273.5274.449; Wiesmann C, 1999, NATURE, V401, P184, DOI 10.1038/43705; WINDISCH JM, 1995, BIOCHEMISTRY-US, V34, P11256, DOI 10.1021/bi00035a035; WINDISCH JM, 1995, J BIOL CHEM, V270, P28133; Woo SB, 1998, PROTEIN SCI, V7, P1006	39	79	85	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					31023	31029		10.1074/jbc.M104630200	http://dx.doi.org/10.1074/jbc.M104630200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11425862	hybrid			2022-12-25	WOS:000170472900058
J	Sansom, OJ; Toft, NJ; Winton, DJ; Clarke, AR				Sansom, OJ; Toft, NJ; Winton, DJ; Clarke, AR			Msh-2 suppresses in vivo mutation in a gene dose and lesion dependent manner	ONCOGENE			English	Article						mismatch repair; apoptosis; mutation; heterozygosity; cisplatin; alkylation	DNA MISMATCH REPAIR; COLORECTAL-CANCER; MSH2-DEFICIENT MICE; DRUG-RESISTANCE; YEAST STRAINS; TUMOR-CELLS; MLH1; P53; HETEROZYGOSITY; PHENOTYPES	Mice deficient for the mismatch repair (MMR) gene Msh2 show accelerated tumourigenesis and a reduced apoptotic response to DNA damage of methylation type, Here we examine the effect of mutation for Msh2 on in vivo mutation frequencies in the intestine as determined by loss of function at the Dolichos biflorus (Dlb-1) locus. Spontaneous mutation frequencies were scored in cohorts of ageing mice either wild type or mutant for Msh2. In mice less than 1 year old, mutation frequencies were only elevated in Msh2 null mice. However, beyond this age heterozygous Msh2 mice showed significantly higher mutation frequencies than controls. These findings implicate a gene dose dependent requirement for Msh2 in mutation suppression and prompted an analysis of young Msh2 mutants following exposure to DNA damage. Following exposure to N-methyl-N ' -nitro-N-nitrosoguanidine (MNNG), Msh2 deficient mice show a reduced apoptotic response and an increase in mutation frequency. Heterozygotes did not differ from controls. Following exposure to cisplatin, no significant elevation was seen in mutation frequencies, even within homozygotes. This is particularly surprising given the association between cisplatin resistance and MMR deficiency, These findings therefore demonstrate a complex reliance upon functional Msh2 in mutation surveillance. We have identified three separate scenarios. First, where retention of both Msh2 alleles ol er an extended period of time appears critical to the suppression of spontaneous mutation; second, 3 weeks following exposure to MNNG, where only complete loss of Msh2 results in elevated mutation; and finally following cisplatin exposure, where induced levels of mutation are independent of Msh2 status.	Cardiff Univ, Sch Biosci, Cardiff C10 3US, S Glam, Wales; Univ Edinburgh, Sch Med, Dept Pathol, Edinburgh EH8 9AG, Midlothian, Scotland; Univ Cambridge, Addenbrookes Hosp, Canc Res Campaign, Human Genet Res Grp, Cambridge CB2 2QQ, England	Cardiff University; University of Edinburgh; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; CRUK Cambridge Institute; University of Cambridge	Clarke, AR (corresponding author), Cardiff Univ, Sch Biosci, POB 911, Cardiff C10 3US, S Glam, Wales.		clarke, alan r/P-2820-2014; Clarke, Alan R/A-6256-2008	Sansom, Owen J./0000-0001-9540-3010; Clarke, Alan/0000-0002-4281-426X				Andrew SE, 1998, P NATL ACAD SCI USA, V95, P1126, DOI 10.1073/pnas.95.3.1126; Branch P, 2000, ONCOGENE, V19, P3138, DOI 10.1038/sj.onc.1203668; Brown R, 1997, ONCOGENE, V15, P45, DOI 10.1038/sj.onc.1201167; Buermeyer AB, 1999, ANNU REV GENET, V33, P533, DOI 10.1146/annurev.genet.33.1.533; de Wind N, 1998, CANCER RES, V58, P248; DeWeese TL, 1998, P NATL ACAD SCI USA, V95, P11915, DOI 10.1073/pnas.95.20.11915; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; Drotschmann K, 1999, P NATL ACAD SCI USA, V96, P2970, DOI 10.1073/pnas.96.6.2970; Drotschmann K, 2000, TOXICOL LETT, V112, P239, DOI 10.1016/S0378-4274(99)00276-3; Fink D, 1998, CLIN CANCER RES, V4, P1; Hickman MJ, 1999, P NATL ACAD SCI USA, V96, P10764, DOI 10.1073/pnas.96.19.10764; Kawate H, 2000, CARCINOGENESIS, V21, P301, DOI 10.1093/carcin/21.2.301; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; Prolla TA, 1998, NAT GENET, V18, P276, DOI 10.1038/ng0398-276; Reitmair AH, 1996, CANCER RES, V56, P3842; Reitmair AH, 1997, CANCER RES, V57, P3765; Sansom OJ, 2000, MUTAT RES-FUND MOL M, V452, P149, DOI 10.1016/S0027-5107(00)00089-0; Shcherbakova PV, 1999, MOL CELL BIOL, V19, P3177; SHOEMAKER AR, 1995, CANCER RES, V55, P4479; STRATHDEE G, 2001, IN PRESS ONCOGENE; Toft NJ, 1999, P NATL ACAD SCI USA, V96, P3911, DOI 10.1073/pnas.96.7.3911; Wheeler JMD, 2000, GUT, V47, P148, DOI 10.1136/gut.47.1.148; WINTON DJ, 1988, NATURE, V333, P463, DOI 10.1038/333463a0	24	18	19	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 14	2001	20	27					3580	3584		10.1038/sj.onc.1204449	http://dx.doi.org/10.1038/sj.onc.1204449			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	445VB	11429706				2022-12-25	WOS:000169478300015
J	Chinni, SR; Li, YW; Upadhyay, S; Koppolu, PK; Sarkar, FH				Chinni, SR; Li, YW; Upadhyay, S; Koppolu, PK; Sarkar, FH			Indole3-carbinol (I3C) induced cell growth inhibition, G1 cell cycle arrest and apoptosis in prostate cancer cells	ONCOGENE			English	Article						G1 cell cycle arrest; apoptosis; indole-3-carbinol (I3C); prostate cancer (PCa)	DEPENDENT KINASE INHIBITOR; FACTOR-BETA; TRANSCRIPTIONAL ACTIVATION; ESTRADIOL METABOLISM; POTENTIAL MEDIATOR; EPITHELIAL-CELLS; LEUKEMIC-CELLS; CDK INHIBITOR; DNA-ADDUCTS; INDOLE-3-CARBINOL	Prostate cancer is one of the most common cancers in men and it is the second leading cause of cancer related death in men in the United States. Recent dietary and epidemiological studies have suggested the benefit of dietary intake of fruits and vegetables in lowering the incidence of prostate cancer. A diet rich in fruits and vegetables provides phytochemicals, particularly indole-3-carbinol (I3C), which may be responsible for the prevention of many types of cancer, including hormone-related cancers such as prostate. Studies to elucidate the role and the molecular mechanism(s) of action of I3C in prostate cancer, however, have not been conducted. In the current study, we investigated whether I3C had any effect against prostate cancer cells and, if so, attempts were made to identify the potential molecular mechanism(s) by which I3C elicits its biological effects on prostate cancer cells. Here we report for the first time that I3C inhibits the growth of PC-3 prostate cancer cells. Induction of G1 cell cycle arrest was also observed in PC-3 cells treated with I3C, which may be due to the observed effects of I3C in the up-regulation of p21(WAF1) and p27(Klp1) CDK inhibitors, followed by their association with cyclin D1 and E and down-regulation of CDK6 protein kinase levels and activity. The induction of p21(WAF1) appears to be transcriptionally upregulated and independent of the p53 responsive element. In addition, I3C inhibited the hyperpohosphorylation of the Retinoblastoma (Rb) protein in PC-3 cells. Induction of apoptosis was also observed in this cell line when treated with I3C, as measured by DNA laddering and poly (ADP-ribose) polymersae (PARP) cleavage. We also found an up-regulation of Bax, and down-regulation of Bcl-2 in I3C-treated cells. These effects may also be mediated by the down-regulation of NF-kappaB observed in I3C treated PC-3 cells. From these results, we conclude that I3C inhibits the growth of PC-3 prostate cancer cells by inducing G1 cell cycle arrest leading to apoptosis, and regulates the expression of apoptosis-related genes. These findings suggest that I3C may be an effective chemopreventive or therapeutic agent against prostate! cancer. Oncogene (2001) 20, 2927-2936.	Wayne State Univ, Sch Med, Dept Pathol, Karmanos Canc Inst, Detroit, MI 48201 USA	Barbara Ann Karmanos Cancer Institute; Wayne State University	Sarkar, FH (corresponding author), Wayne State Univ, Sch Med, Dept Pathol, Karmanos Canc Inst, 9374 Scott Hall,540 E Canfield Ave, Detroit, MI 48201 USA.							*ACS, 2000, CANC FACTS FIG; BAILEY G, 1987, ENVIRON HEALTH PERSP, V71, P147, DOI 10.2307/3430422; BEIER RC, 1990, REV ENVIRON CONTAM T, V113, P47; Biggs JR, 1999, J BIOL CHEM, V274, P36987, DOI 10.1074/jbc.274.52.36987; Biggs JR, 1996, J BIOL CHEM, V271, P901, DOI 10.1074/jbc.271.2.901; BRADFIELD CA, 1991, ADV EXP MED BIOL, V289, P153; Broadbent TA, 1998, CURR MED CHEM, V5, P469; Cohen JH, 2000, JNCI-J NATL CANCER I, V92, P61, DOI 10.1093/jnci/92.1.61; Costello JF, 1997, CANCER RES, V57, P1250; Cover CM, 1998, J BIOL CHEM, V273, P3838, DOI 10.1074/jbc.273.7.3838; CRAM EJ, 2000, AM ASS CANC RES, V91, P10; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; Dashwood RH, 1998, CHEM-BIOL INTERACT, V110, P1, DOI 10.1016/S0009-2797(97)00115-4; DASHWOOD RH, 1989, CARCINOGENESIS, V10, P175, DOI 10.1093/carcin/10.1.175; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Feldman D., 1996, SYNTHETIC POLYM, DOI [DOI 10.1002/(SICI)1097-4644(1996)25+<1::AID-JCB1>3.0.CO;2-4, 10.1002/(SICI)1097-0126(199701)42:13.0.CO;2-G, DOI 10.1002/(SICI)1097-0126(199701)42:13.0.CO;2-G]; Gartel AL, 1996, EXP CELL RES, V227, P171, DOI 10.1006/excr.1996.0264; Ge XK, 1996, BIOCHEM BIOPH RES CO, V228, P153, DOI 10.1006/bbrc.1996.1631; GRUBBS CJ, 1995, ANTICANCER RES, V15, P709; Herman DG, 1995, CARCINOGENESIS, V16, P2931, DOI 10.1093/carcin/16.12.2931; Huang P, 1997, CANCER RES, V57, P3407; Huber WW, 1997, MUTAT RES-FUND MOL M, V376, P115, DOI 10.1016/S0027-5107(97)00033-X; Katdare M, 1998, ONCOL REP, V5, P311; Kim DJ, 1997, CARCINOGENESIS, V18, P377, DOI 10.1093/carcin/18.2.377; KOJIMA T, 1994, CANCER RES, V54, P1446; Kolonel LN, 2000, CANCER EPIDEM BIOMAR, V9, P795; Krongrad A, 1998, Semin Urol Oncol, V16, P30; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Liu M, 1996, J BIOL CHEM, V271, P31723, DOI 10.1074/jbc.271.49.31723; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; Michnovicz JJ, 1997, JNCI-J NATL CANCER I, V89, P718, DOI 10.1093/jnci/89.10.718; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; NIWA T, 1994, STEROIDS, V59, P523, DOI 10.1016/0039-128X(94)90070-1; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; SAFE SH, 1995, ENVIRON HEALTH PERSP, V103, P346, DOI 10.2307/3432287; SAKR WA, 1995, PATHOL RES PRACT, V191, P838, DOI 10.1016/S0344-0338(11)80965-9; Salomons GS, 1997, INT J CANCER, V71, P959, DOI 10.1002/(SICI)1097-0215(19970611)71:6<959::AID-IJC9>3.0.CO;2-X; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; Steinmetz KA, 1996, J AM DIET ASSOC, V96, P1027, DOI 10.1016/S0002-8223(96)00273-8; Teixeira C, 1997, MOL ENDOCRINOL, V11, P1191, DOI 10.1210/me.11.9.1191; Telang NT, 1997, P SOC EXP BIOL MED, V216, P246, DOI 10.3181/00379727-216-44174; Timmermann S, 1997, CELL GROWTH DIFFER, V8, P361; TIWARI RK, 1994, J NATL CANCER I, V86, P126, DOI 10.1093/jnci/86.2.126; VAN AD, 1996, SCIENCE, V274, P787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wong GYC, 1997, J CELL BIOCHEM, P111; Xu M, 1996, CARCINOGENESIS, V17, P1429, DOI 10.1093/carcin/17.7.1429	57	254	270	4	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 24	2001	20	23					2927	2936		10.1038/sj.onc.1204365	http://dx.doi.org/10.1038/sj.onc.1204365			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	435VA	11420705				2022-12-25	WOS:000168901800008
J	Baba, M; Hirai, S; Kawakami, S; Kishida, T; Sakai, N; Kaneko, S; Yao, M; Shuin, T; Kubota, Y; Hosaka, M; Ohno, S				Baba, M; Hirai, S; Kawakami, S; Kishida, T; Sakai, N; Kaneko, S; Yao, M; Shuin, T; Kubota, Y; Hosaka, M; Ohno, S			Tumor suppressor protein VHL is induced at high cell density and mediates contact inhibition of cell growth	ONCOGENE			English	Article						VHL; tumor suppressor; contact inhibition; renal cell carcinoma; epithelial cells	HIPPEL-LINDAU GENE; BIOLOGICALLY-ACTIVE PRODUCT; F-BOX PROTEIN; BETA-CATENIN; DEPENDENT PROTEOLYSIS; SOMATIC MUTATIONS; UBIQUITIN LIGASE; RENAL-CARCINOMA; HUMAN TISSUES; CYCLE ARREST	In spite of the general recognition of von Hippel-Lindau (VHL) as a tumor suppressor gene, the physiological and pathological importance of VHL protein in cell growth regulation and tumorigenesis remains unclear, Here we show that in normal human renal proximal tubule epithelial cells (RPTEC), the steady-state amount of VHL protein is strictly regulated by cell density. The cellular VHL content is more than 100-fold higher in dense cultures than in sparse cultures, The increase in VHL protein at high cell density was also observed for NIH3T3 fibroblasts, suggesting the generality of the phenomenon. The growth rates of renal cell carcinoma cells lacking an intact VHL gene and their derivatives with wild-type or mutant VHL expression vector do not differ significantly when they are growing in log-phase. Importantly, however, there is a difference when they reach confluency: cells lacking wild-type VHL grew continuously, while cells expressing exogenous VHL protein showed relatively limited cell growth. Using an ecdysone-inducible VHL expressing cell line, we also show that the growth inhibition at high cell density can be released by attenuating the VHL expression, Taken together, we propose that VHL protein functions as a growth suppressor at high cell density, and this might be the basis of the tumor suppressor function of VHL.	Yokohama City Univ, Sch Med, Dept Biol Mol, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan; Yokohama City Univ, Sch Med, Dept Urol, Yokohama, Kanagawa 2360004, Japan; Kochi Med Sch, Dept Urol, Kochi 7838505, Japan	Yokohama City University; Yokohama City University; Kochi University	Hirai, S (corresponding author), Yokohama City Univ, Sch Med, Dept Biol Mol, Kanazawa Ku, 3-9 Fukuura, Yokohama, Kanagawa 2360004, Japan.		Baba, Masaya/ABE-4893-2020; Baba, Masaya/L-7490-2013; Ohno, Shigeo/B-1768-2010	Baba, Masaya/0000-0002-5308-6683; Ohno, Shigeo/0000-0002-1294-5269				Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Blankenship C, 1999, ONCOGENE, V18, P1529, DOI 10.1038/sj.onc.1202473; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Corless CL, 1997, HUM PATHOL, V28, P459, DOI 10.1016/S0046-8177(97)90035-6; Feng H, 1999, NAT CELL BIOL, V1, P486, DOI 10.1038/70272; FOSTER K, 1994, HUM MOL GENET, V3, P2169, DOI 10.1093/hmg/3.12.2169; GAO JZ, 1995, CANCER RES, V55, P743; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; HINCK L, 1994, J CELL BIOL, V124, P729, DOI 10.1083/jcb.124.5.729; Iliopoulos O, 1998, P NATL ACAD SCI USA, V95, P11661, DOI 10.1073/pnas.95.20.11661; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; Iwai K, 1999, P NATL ACAD SCI USA, V96, P12436, DOI 10.1073/pnas.96.22.12436; JUDAH F, 1995, NAT MED, V1, P27; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Kandikonda S, 1996, CELL ADHES COMMUN, V4, P13, DOI 10.3109/15419069609010760; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; Kim M, 1998, BIOCHEM BIOPH RES CO, V253, P672, DOI 10.1006/bbrc.1998.9839; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; LAMIELL JM, 1989, MEDICINE, V68, P1; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; Lee S, 1996, P NATL ACAD SCI USA, V93, P1770, DOI 10.1073/pnas.93.5.1770; LEHNER CF, 1989, CELL, V56, P957, DOI 10.1016/0092-8674(89)90629-6; Liakopoulos D, 1999, P NATL ACAD SCI USA, V96, P5510, DOI 10.1073/pnas.96.10.5510; Lieubeau-Teillet B, 1998, CANCER RES, V58, P4957; Lisztwan J, 1999, GENE DEV, V13, P1822, DOI 10.1101/gad.13.14.1822; Lonergan KM, 1998, MOL CELL BIOL, V18, P732, DOI 10.1128/MCB.18.2.732; Los M, 1996, LAB INVEST, V75, P231; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; MELMON KL, 1964, AM J MED, V36, P595, DOI 10.1016/0002-9343(64)90107-X; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Okuda H, 1999, BIOCHEM BIOPH RES CO, V263, P491, DOI 10.1006/bbrc.1999.1347; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Orford K, 1999, J CELL BIOL, V146, P855, DOI 10.1083/jcb.146.4.855; Pal S, 1997, J BIOL CHEM, V272, P27509, DOI 10.1074/jbc.272.44.27509; Pause A, 1998, P NATL ACAD SCI USA, V95, P993, DOI 10.1073/pnas.95.3.993; Pause A, 1997, P NATL ACAD SCI USA, V94, P2156, DOI 10.1073/pnas.94.6.2156; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197; Schoenfeld A, 1998, P NATL ACAD SCI USA, V95, P8817, DOI 10.1073/pnas.95.15.8817; SHUIN T, 1994, CANCER RES, V54, P2852; Soler C, 1999, FEBS LETT, V442, P178, DOI 10.1016/S0014-5793(98)01648-2; St Croix B, 1998, J CELL BIOL, V142, P557, DOI 10.1083/jcb.142.2.557; TALIAN JC, 1983, J CELL BIOL, V97, P1277, DOI 10.1083/jcb.97.4.1277; Wada H, 1999, J BIOL CHEM, V274, P36025, DOI 10.1074/jbc.274.50.36025; WATABE M, 1994, J CELL BIOL, V127, P247, DOI 10.1083/jcb.127.1.247; Ye Y, 1998, INT J CANCER, V78, P62, DOI 10.1002/(SICI)1097-0215(19980925)78:1<62::AID-IJC11>3.0.CO;2-7	50	39	39	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 17	2001	20	22					2727	2736		10.1038/sj.onc.1204397	http://dx.doi.org/10.1038/sj.onc.1204397			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	432TP	11420685				2022-12-25	WOS:000168712000001
J	Jin, SQ; Fan, FY; Fan, WH; Zhao, HC; Tong, T; Blanck, P; Alomo, I; Rajasekaran, B; Zhan, QM				Jin, SQ; Fan, FY; Fan, WH; Zhao, HC; Tong, T; Blanck, P; Alomo, I; Rajasekaran, B; Zhan, QM			Transcription factors Oct-1 and NF-YA regulate the p53-independent induction of the GADD45 following DNA damage	ONCOGENE			English	Article						GADD45; p53; DNA damage; transcription; factor Oct-1; NF-YA	TUMOR-SUPPRESSOR P53; HISTONE H2B GENE; HUMAN-CELLS; EXPRESSION; ACTIVATION; PROTEINS; GROWTH; INHIBITION; PROMOTER; ELEMENTS	The p53-regulated GADD45 gene is one of the important players in cellular response to DNA damage, and probably involved in the control of cell cycle checkpoint, apoptosis and DNA repair, There are both the p53-dependent and -independent pathways that regulate GADD45 induction. Following ionizing radiation, induction of the GADD45 gene is regulated by p53 through the p53-binding motif located in the third intron of the GADD45 gene. In contrast, GADD45 induction by methyl methanesulfonate (MMS), UV radiation (UV), and medium starvation is independent of p53 status although p53 may contribute to these responses. However, the regulatory elements that control the p53-independent induction of GADD45 remain uncertain. In this report, we have performed detailed analyses to characterize the responsive components that are required for the induction of the GADD45 promoter. We have found that the region between -107 and -62 of the GADD45 promoter is crucial for the induction. Sequence analysis indicates that there are two OCT-1 sites and one CAAT box located in this region. Site-directed mutations of both OCT-1 and CAAT motifs substantially abrogate the induction of the GADD45 promoter by DNA damage. In addition, both Oct-1 protein (binding to OCT-1 site) and NP-YA protein (binding to CAAT hox) are induced after cell exposure to DNA damaging agents. Moreover, the Electrophoretic Mobility Shift Assay (EMSA) has demonstrated the direct bindings of Oct-1 and NF-YA proteins to their consensus sequences in the GADD45 promoter. Therefore, these results have presented the novel observation that transcription factors Oct-1 and NF-YA participate in the cellular response to DNA damage and are involved in the regulation of stress-inducible genes.	Univ Pittsburgh, Sch Med, Inst Canc, Dept Radiat Oncol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Inst Canc, Dept Mol Genet & Biochem, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Zhan, QM (corresponding author), Univ Pittsburgh, Sch Med, Inst Canc, Dept Radiat Oncol, BST W-945,200 Lothrop St, Pittsburgh, PA 15213 USA.							BERGMAN Y, 1984, P NATL ACAD SCI-BIOL, V81, P7041, DOI 10.1073/pnas.81.22.7041; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Eraly SA, 1998, MOL ENDOCRINOL, V12, P469, DOI 10.1210/me.12.4.469; Fadel BM, 1999, J BIOL CHEM, V274, P20376, DOI 10.1074/jbc.274.29.20376; FLETCHER C, 1987, CELL, V51, P773, DOI 10.1016/0092-8674(87)90100-0; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; HINKLEY C, 1992, MOL CELL BIOL, V12, P4400, DOI 10.1128/MCB.12.10.4400; Hollander MC, 1999, NAT GENET, V23, P176, DOI 10.1038/13802; Inamoto S, 1997, J BIOL CHEM, V272, P29852, DOI 10.1074/jbc.272.47.29852; JENUWEIN T, 1991, GENE DEV, V5, P932, DOI 10.1101/gad.5.6.932; Jin SQ, 2000, ONCOGENE, V19, P4050, DOI 10.1038/sj.onc.1203759; Jin SQ, 2000, J BIOL CHEM, V275, P16602, DOI 10.1074/jbc.M000284200; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; LABELLA F, 1988, GENE DEV, V2, P32, DOI 10.1101/gad.2.1.32; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Mantovani R, 1999, GENE, V239, P15, DOI 10.1016/S0378-1119(99)00368-6; Matuoka K, 1999, EXP CELL RES, V253, P365, DOI 10.1006/excr.1999.4605; MIYASHITA T, 1995, CELL, V80, P293; MURPHY S, 1989, CELL, V59, P1071, DOI 10.1016/0092-8674(89)90763-0; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; Prives C, 1999, J PATHOL, V187, P112; ROBERTS SB, 1991, SCIENCE, V253, P1022, DOI 10.1126/science.1887216; Schwachtgen JL, 1998, BLOOD, V92, P1247, DOI 10.1182/blood.V92.4.1247.416k08_1247_1258; STURM RA, 1988, NUCLEIC ACIDS RES, V16, P8571, DOI 10.1093/nar/16.17.8571; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; Zhan QM, 1998, MOL CELL BIOL, V18, P2768, DOI 10.1128/MCB.18.5.2768; Zhan QM, 1996, DNA CELL BIOL, V15, P805, DOI 10.1089/dna.1996.15.805; ZHAN QM, 1994, CANCER RES, V54, P2755; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; ZHAN QM, 1994, ONCOGENE, V9, P3743; Zhao HC, 2000, CANCER RES, V60, P6276	35	92	95	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 10	2001	20	21					2683	2690		10.1038/sj.onc.1204390	http://dx.doi.org/10.1038/sj.onc.1204390			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	431VN	11420680				2022-12-25	WOS:000168652600009
J	Paggi, MG; Bonetto, F; Severino, A; Baldi, A; Battista, T; Bucci, F; Felsani, A; Lombardi, D; Giordano, A				Paggi, MG; Bonetto, F; Severino, A; Baldi, A; Battista, T; Bucci, F; Felsani, A; Lombardi, D; Giordano, A			The retinoblastoma-related Rb2/p130 gene is an effector downstream of AP-2 during neural differentiation	ONCOGENE			English	Article						AP-2; Rb2/p130; differentiation; NGF; PC12	TRANSCRIPTION FACTOR AP-2; NERVE GROWTH-FACTOR; PC12 CELLS; NEUROBLASTOMA-DIFFERENTIATION; EXPRESSION; PROTEINS; FAMILY; P107; P130; PROMOTER	Rb2/p130, a member of the Retinoblastoma family of growth and tumour suppressor genes, is extensively implicated in the control of cell cycle and differentiation. The minimal promoter region of Rb2/p130 in T98G human glioblastoma cells was identified and its analysis revealed the presence of a KER1 palindromic sequence able to bind the transcription factor AP-2, a regulatory protein that plays a crucial role in ectodermal differentiation, This KER1 site interacted in vitro with AP-2, and AP-2 overexpression increased Rb2/p130 transcription and translation, We also found that rat PC12 pheochromocytoma cells, when induced to differentiate by NGF, displayed an increase of AP-2 protein levels and of Rb2/p130 transcription and protein levels, AP-2-transfected PC12 cells displayed enhanced transcription and translation of Rb2/p130 and of the cdk inhibitor p21(WAF1/CIP1), a gene known to be under the control of AP-2, but unable by itself to elicit PC12 differentiation. Overexpression of either AP-2 or Rb2/p130 elicited per se cell differentiation in the absence of NGF, while coexpression of AP-IB, a negative regulator of AP-2 transcriptional activity, inhibited only AP-2-induced differentiation, Altogether, these results indicate that Rb2/p130 is a critical effector of AP-2 in sustaining ectodermal differentiation.	Regina Elena Canc Inst, Ctr Expt Res, Lab Cell Metab & Pharmacokinet, I-00158 Rome, Italy; CNR, Ist Tecnol Biomed, I-00137 Rome, Italy; Univ Aquila, Dept Expt Med, I-67100 Laquila, Italy; Thomas Jefferson Univ, Jefferson Med Coll, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA	Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); University of L'Aquila; Jefferson University	Paggi, MG (corresponding author), Regina Elena Canc Inst, Ctr Expt Res, Lab Cell Metab & Pharmacokinet, Via Messi Doro 156, I-00158 Rome, Italy.		Baldi, Alfonso/ABG-2397-2021; Felsani, Armando/D-1784-2010; Giordano, Antonio/F-1927-2010; Paggi, Marco G./K-3494-2018; Severino, Anna/S-3417-2019	Felsani, Armando/0000-0001-8851-6295; Giordano, Antonio/0000-0002-5959-016X; Severino, Anna/0000-0002-6276-7747; Baldi, Alfonso/0000-0002-8693-3842	NATIONAL CANCER INSTITUTE [R01CA060999] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS036466] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 60999-01A1] Funding Source: Medline; NINDS NIH HHS [P01 NS 36466] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BALDI A, 1995, J CELL BIOCHEM, V59, P402, DOI 10.1002/jcb.240590311; Baldi A, 1996, P NATL ACAD SCI USA, V93, P4629, DOI 10.1073/pnas.93.10.4629; Baldi A, 1997, CLIN CANCER RES, V3, P1691; Batsche E, 1998, MOL CELL BIOL, V18, P3647, DOI 10.1128/MCB.18.7.3647; BENNETT GS, 1985, DEV BIOL, V107, P94, DOI 10.1016/0012-1606(85)90379-3; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; BUETTNER R, 1993, MOL CELL BIOL, V13, P4174, DOI 10.1128/MCB.13.7.4174; CLAUDIO PP, 1994, CANCER RES, V54, P5556; Di Fiore B, 1999, NUCLEIC ACIDS RES, V27, P2852; ELDEIRY WS, 1994, CANCER RES, V54, P1169; Erhardt JA, 1998, ONCOGENE, V16, P443, DOI 10.1038/sj.onc.1201577; Fajas L, 2000, FEBS LETT, V471, P29, DOI 10.1016/S0014-5793(00)01363-6; FUCHS E, 1994, CURR OPIN GENET DEV, V4, P725, DOI 10.1016/0959-437X(94)90140-X; Garriga J, 1998, BIOCHEM J, V333, P645, DOI 10.1042/bj3330645; GAUBATZ S, 1995, EMBO J, V14, P1508, DOI 10.1002/j.1460-2075.1995.tb07137.x; Gervasi F, 1996, CELL GROWTH DIFFER, V7, P1689; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; KALMAN D, 1993, MOL BIOL CELL, V4, P353, DOI 10.1091/mbc.4.4.353; KIESS M, 1995, CELL GROWTH DIFFER, V6, P1287; LEASK A, 1991, P NATL ACAD SCI USA, V88, P7948, DOI 10.1073/pnas.88.18.7948; LEASK A, 1990, GENE DEV, V4, P1985, DOI 10.1101/gad.4.11.1985; LUSCHER B, 1989, GENE DEV, V3, P1507, DOI 10.1101/gad.3.10.1507; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MARTELLI F, 1994, ONCOGENE, V9, P3579; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; Mulligan G, 1998, TRENDS GENET, V14, P223, DOI 10.1016/S0168-9525(98)01470-X; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; OLOPADE OI, 1992, CANCER RES, V52, P2523; Paggi MG, 1996, J CELL BIOCHEM, V62, P418; Paramio JM, 1998, ONCOGENE, V17, P949, DOI 10.1038/sj.onc.1202031; Persengiev SP, 1999, MOL CELL BIOL, V19, P6048; PERTILE P, 1995, CELL GROWTH DIFFER, V6, P1659; PHILIPP J, 1994, DEV BIOL, V165, P602, DOI 10.1006/dbio.1994.1279; Puri PL, 1998, CANCER RES, V58, P1325; Raschella G, 1998, CELL DEATH DIFFER, V5, P401, DOI 10.1038/sj.cdd.4400359; Raschella G, 1997, J CELL BIOCHEM, V67, P297, DOI 10.1002/(SICI)1097-4644(19971201)67:3<297::AID-JCB2>3.0.CO;2-R; Richon VM, 1997, J BIOL CHEM, V272, P10117, DOI 10.1074/jbc.272.15.10117; RILEY DJ, 1994, ANNU REV CELL BIOL, V10, P1, DOI 10.1146/annurev.cb.10.110194.000245; Schorle H, 1996, NATURE, V381, P235, DOI 10.1038/381235a0; Sidle A, 1996, CRIT REV BIOCHEM MOL, V31, P237, DOI 10.3109/10409239609106585; Somasundaram K, 1996, P NATL ACAD SCI USA, V93, P3088, DOI 10.1073/pnas.93.7.3088; STEINMAN RA, 1994, ONCOGENE, V9, P3389; vanGrunsven LA, 1996, ONCOGENE, V12, P1347; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; WINNING RS, 1991, NUCLEIC ACIDS RES, V19, P3709, DOI 10.1093/nar/19.13.3709; Wu F, 1998, NUCLEIC ACIDS RES, V26, P4837, DOI 10.1093/nar/26.21.4837; Yan GZ, 1997, J NEUROSCI, V17, P6122; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78; Zhang JA, 1996, NATURE, V381, P238, DOI 10.1038/381238a0	53	13	14	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 3	2001	20	20					2570	2578		10.1038/sj.onc.1204356	http://dx.doi.org/10.1038/sj.onc.1204356			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	431VM	11420667				2022-12-25	WOS:000168652500008
J	Gyles, SL; Burns, CJ; Whitehouse, BJ; Sugden, D; Marsh, PJ; Persaud, SJ; Jones, PM				Gyles, SL; Burns, CJ; Whitehouse, BJ; Sugden, D; Marsh, PJ; Persaud, SJ; Jones, PM			ERKs regulate cyclic AMP-induced steroid synthesis through transcription of the steroidogenic acute regulatory (StAR) gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; FACTOR-I; GRANULOSA-CELLS; ANGIOTENSIN-II; MESSENGER-RNA; EXPRESSION; HORMONE; INHIBITOR; RECEPTORS; PHOSPHORYLATION	Cyclic AMP-dependent expression of the steroidogenic acute regulatory (StAR) protein is thought to be the controlling step for steroid production, but the mechanisms through which external signals are translated into increased transcription of the StAR gene are unknown. We demonstrate that cyclic AMP-induced steroid synthesis is dependent upon the phosphorylation and activation of ERKs and that ERK activation results in enhanced phosphorylation of SF-1 and increased steroid production through increased transcription of the StAR gene. Adenylate cyclase activation with forskolin (FSK) caused a time-dependent increase in ERK activity and translocation from cytoplasm to nucleus, which correlated with an increase in StAR mRNA levels, StAR protein accumulation, and steroidogenesis. Similarly, ERK inhibition led to a reduction in the levels of FSK-stimulated StAR mRNA, StAR protein, and steroid secretion. These effects were attributed to the finding that ERK activity is required for SF-1 phosphorylation, a transcription factor required for the regulation of StAR gene transcription. This conclusion was supported by our demonstration of an ERK-dependent increase in the binding of SF-1 from FSK-treated Y1 nuclei to three consensus double-stranded DNA sequences from the StAR promoter region. These observations suggest that the activation of ERK2/1 by increasing cAMP is an obligatory and regulated stage in the stimulation of steroid synthesis by cyclic AMP-generating stimuli.	Kings Coll London, GKT Sch Biomed Sci, Endocrinol & Reprod Res Grp, London SE1 1UL, England; Kings Coll London, GKT Sch Biomed Sci, Randall Ctr, London SE1 1UL, England	University of London; King's College London; University of London; King's College London	Jones, PM (corresponding author), Kings Coll London, GKT Sch Biomed Sci, Endocrinol & Reprod Res Grp, New Hunts House,3rd Fl N, London SE1 1UL, England.	peter.jones@kcl.ac.uk	Burns, Chris/D-9161-2013; Persaud, Shanta/AAH-3200-2021	Persaud, Shanta/0000-0002-4933-5958; Jones, Peter/0000-0003-1201-2335				AGUILERA G, 1980, ENDOCRINOLOGY, V107, P55, DOI 10.1210/endo-107-1-55; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ASCOLI M, 1981, J BIOL CHEM, V256, P179; Bose HS, 2000, J CLIN ENDOCR METAB, V85, P3636, DOI 10.1210/jc.85.10.3636; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burns CJ, 2000, BIOCHEM BIOPH RES CO, V273, P35, DOI 10.1006/bbrc.2000.2890; Cameron MR, 1996, BIOL REPROD, V55, P111, DOI 10.1095/biolreprod55.1.111; Carlone DL, 1997, J STEROID BIOCHEM, V61, P223, DOI 10.1016/S0960-0760(97)80016-7; Caron KM, 1997, MOL ENDOCRINOL, V11, P138, DOI 10.1210/me.11.2.138; Christenson LK, 1998, J BIOL CHEM, V273, P30729, DOI 10.1074/jbc.273.46.30729; Christenson LK, 2000, BBA-MOL CELL BIOL L, V1529, P175, DOI 10.1016/S1388-1981(00)00147-5; Clark BJ, 1997, ENDOCRINOLOGY, V138, P4893, DOI 10.1210/en.138.11.4893; CLARK BJ, 1995, MOL ENDOCRINOL, V9, P1346, DOI 10.1210/me.9.10.1346; CLARK BJ, 1994, J BIOL CHEM, V269, P28314; COOKE BA, 1990, MOL CELL ENDOCRINOL, V69, pC11, DOI 10.1016/0303-7207(90)90081-I; Das S, 1996, ENDOCRINOLOGY, V137, P967, DOI 10.1210/en.137.3.967; DEWI DA, 2000, J ENDOCRINOL, V167, p3C17; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Force T, 1998, HYPERTENSION, V31, P152, DOI 10.1161/01.HYP.31.1.152; Hammer GD, 1999, MOL CELL, V3, P521, DOI 10.1016/S1097-2765(00)80480-3; Jacob AL, 1998, J BIOL CHEM, V273, P13391, DOI 10.1074/jbc.273.22.13391; Jones PM, 2000, J MOL ENDOCRINOL, V24, P233, DOI 10.1677/jme.0.0240233; Kang SK, 2001, ENDOCRINOLOGY, V142, P671, DOI 10.1210/en.142.2.671; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Liu J, 1996, J ENDOCRINOL, V150, P43, DOI 10.1677/joe.0.1500043; Lopez-Ilasaca M, 1998, BIOCHEM PHARMACOL, V56, P269, DOI 10.1016/S0006-2952(98)00059-8; Lotfi CFP, 2000, ENDOCR RES, V26, P873, DOI 10.3109/07435800009048611; Lotfi CFP, 1997, J BIOL CHEM, V272, P29886, DOI 10.1074/jbc.272.47.29886; Lotfi CFP, 2000, BRAZ J MED BIOL RES, V33, P1133, DOI 10.1590/S0100-879X2000001000002; Nalbant D, 1998, ENDOCRINOLOGY, V139, P272, DOI 10.1210/en.139.1.272; PARISSENTI AM, 1993, MOL ENDOCRINOL, V7, P283, DOI 10.1210/me.7.2.283; POTTS GO, 1978, STEROIDS, V32, P257, DOI 10.1016/0039-128X(78)90010-7; Reinhart AJ, 1999, MOL ENDOCRINOL, V13, P729, DOI 10.1210/me.13.5.729; Reyland ME, 2000, J BIOL CHEM, V275, P36637, DOI 10.1074/jbc.M006456200; Sandhoff TW, 1998, ENDOCRINOLOGY, V139, P4820, DOI 10.1210/en.139.12.4820; Schimmer B P, 1979, Methods Enzymol, V58, P570; SCHIMMER BP, 1981, FUNCTIONALLY DIFFERE, P61; Seger R, 2001, J BIOL CHEM, V276, P13957, DOI 10.1074/jbc.M006852200; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SIROIS J, 1993, J BIOL CHEM, V268, P21931; Stocco DM, 2000, BBA-MOL CELL BIOL L, V1486, P184, DOI 10.1016/S1388-1981(00)00056-1; Stocco DM, 1996, ENDOCR REV, V17, P221, DOI 10.1210/er.17.3.221; Stocco DM, 2000, NAT STRUCT BIOL, V7, P445, DOI 10.1038/75834; Stocco DM, 1998, REV REPROD, V3, P82, DOI 10.1530/ror.0.0030082; Sugawara T, 2000, ENDOCRINOLOGY, V141, P2895, DOI 10.1210/en.141.8.2895; SUGAWARA T, 1995, P NATL ACAD SCI USA, V92, P4778, DOI 10.1073/pnas.92.11.4778; Tai CJ, 2001, J CLIN ENDOCR METAB, V86, P375, DOI 10.1210/jc.86.1.375; Wang XJ, 2000, J BIOL CHEM, V275, P20204, DOI 10.1074/jbc.M003113200; Watanabe G, 1996, J BIOL CHEM, V271, P22570, DOI 10.1074/jbc.271.37.22570; Watanabe G, 1997, J BIOL CHEM, V272, P20063, DOI 10.1074/jbc.272.32.20063; WONG M, 1989, J BIOL CHEM, V264, P12867; Wooton-Kee CR, 2000, ENDOCRINOLOGY, V141, P1345, DOI 10.1210/en.141.4.1345; Yarwood SJ, 1996, BIOCHEM BIOPH RES CO, V224, P734, DOI 10.1006/bbrc.1996.1092; Zenkert S, 2000, EUR J ENDOCRINOL, V142, P294, DOI 10.1530/eje.0.1420294; Zhang PL, 1996, MOL ENDOCRINOL, V10, P147, DOI 10.1210/me.10.2.147	55	149	153	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					34888	34895		10.1074/jbc.M102063200	http://dx.doi.org/10.1074/jbc.M102063200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11410589	hybrid			2022-12-25	WOS:000171024600073
J	Matsumoto, M; Hisatake, K; Nogi, Y; Tsujimoto, M				Matsumoto, M; Hisatake, K; Nogi, Y; Tsujimoto, M			Regulation of receptor activator of NF-kappa B ligand-induced tartrate-resistant acid phosphatase gene expression by PU.1-interacting protein/interferon regulatory factor-4 - Synergism with microphthalmia transcription factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; OSTEOCLAST DIFFERENTIATION; INTERFERON-GAMMA; BONE-RESORPTION; PROTEIN-KINASE; KEY REGULATOR; FACTOR FAMILY; CELL-GROWTH; STEM-CELLS; OSTEOPETROSIS	The receptor activator of NF-kappaB ligand induces the expression of tartrate-resistant acid phosphatase (TRAP) and transcription factor, PU.1-interacting protein (Pip), during osteoclastogenesis. In this paper, we have examined the role of transcription factors in the regulation of TRAP gene expression employing reporter constructs containing the promoter region of TRAP gene. Transient transfection of RAW264 cells with sequential 5'-deletions of mouse TRAP gene promoter-luciferase fusion constructs indicated that at least two sites are required for the full promoter activity. Deletion and site-directed mutation studies revealed that M-box and interferon regulatory factor element sites are critical for TRAP gene expression in the cell, suggesting that microphthalmia transcription factor (MITF) and Pip could induce the gene expression independently. Moreover, the overexpression of MITF and Pip functionally stimulated TRAP promoter activity in a synergistic manner. Analysis of the deletion mutants of Pip protein indicated that both N-terminal DNA-binding and C-terminal regulatory domains are indispensable to the promoter-enhancing activity. Subcellular localization of green fluorescence protein-fused Pip and its mutant proteins indicated that the C-terminal domain is required for the translocation of Pip into the nucleus. These results suggest that Pip regulates and acts synergistically with MITF to induce the promoter activity of TRAP gene.	RIKEN, Inst Phys & Chem Res, Lab Cellular Biochem, Wako, Saitama 3510198, Japan; Saitama Med Sch, Dept Biochem, Iruma, Saitama 3500495, Japan	RIKEN; Saitama Medical University	Tsujimoto, M (corresponding author), RIKEN, Inst Phys & Chem Res, Lab Cellular Biochem, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.			Hisatake, Koji/0000-0002-5795-3115				Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; Arai F, 1999, J EXP MED, V190, P1741, DOI 10.1084/jem.190.12.1741; ASH P, 1980, NATURE, V283, P669, DOI 10.1038/283669a0; Brass AL, 1999, EMBO J, V18, P977, DOI 10.1093/emboj/18.4.977; Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412; EISENBEIS CF, 1995, GENE DEV, V9, P1377, DOI 10.1101/gad.9.11.1377; Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; Harada H, 1998, BIOCHIMIE, V80, P641, DOI 10.1016/S0300-9084(99)80017-0; Hayashi SI, 1998, BIOCHEM CELL BIOL, V76, P911; Hayman AR, 1996, DEVELOPMENT, V122, P3151; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540; Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197-1285; Kawaguchi N, 2000, EXP CELL RES, V260, P284, DOI 10.1006/excr.2000.5020; Kimura T, 1996, GENES CELLS, V1, P115, DOI 10.1046/j.1365-2443.1996.08008.x; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; KURIHARA N, 1990, ENDOCRINOLOGY, V126, P2733, DOI 10.1210/endo-126-5-2733; KURIHARA N, 1989, BLOOD, V74, P1295; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Luchin A, 2000, J BONE MINER RES, V15, P451, DOI 10.1359/jbmr.2000.15.3.451; MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506; Matsumoto M, 2000, FEBS LETT, V486, P23, DOI 10.1016/S0014-5793(00)02231-6; Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200; Matsumoto M, 1999, BIOL CHEM, V380, P699, DOI 10.1515/BC.1999.087; MATSUYAMA T, 1995, NUCLEIC ACIDS RES, V23, P2127, DOI 10.1093/nar/23.12.2127; Mittrucker HW, 1997, SCIENCE, V275, P540, DOI 10.1126/science.275.5299.540; REDDY SV, 1993, J BONE MINER RES, V8, P1263; Roodman GD, 1996, ENDOCR REV, V17, P308, DOI 10.1210/er.17.4.308; Rosenbauer F, 1999, BLOOD, V94, P4274, DOI 10.1182/blood.V94.12.4274.424k05_4274_4281; Saftig P, 1998, P NATL ACAD SCI USA, V95, P13453, DOI 10.1073/pnas.95.23.13453; TAKAHASHI N, 1994, DEV BIOL, V163, P212, DOI 10.1006/dbio.1994.1137; Takaoka A, 2000, SCIENCE, V288, P2357, DOI 10.1126/science.288.5475.2357; Tanaka N, 2000, SEMIN CANCER BIOL, V10, P73, DOI 10.1006/scbi.2000.0310; Taniguchi T, 2001, ANNU REV IMMUNOL, V19, P623, DOI 10.1146/annurev.immunol.19.1.623; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; Tondravi MM, 1997, NATURE, V386, P81, DOI 10.1038/386081a0; UDAGAWA N, 1990, P NATL ACAD SCI USA, V87, P7260, DOI 10.1073/pnas.87.18.7260; Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190; Yamagata T, 1996, MOL CELL BIOL, V16, P1283; Yamano Y, 1998, BIOSCI BIOTECH BIOCH, V62, P237, DOI 10.1271/bbb.62.237; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597	42	19	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					33086	33092		10.1074/jbc.M104299200	http://dx.doi.org/10.1074/jbc.M104299200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11425859	hybrid			2022-12-25	WOS:000170746000094
J	Kojima, T; Zama, T; Wada, K; Onogi, H; Hagiwara, M				Kojima, T; Zama, T; Wada, K; Onogi, H; Hagiwara, M			Cloning of human PRP4 reveals interaction with Clk1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-SPECIFIC KINASE; SPLICING FACTOR SF2/ASF; FISSION YEAST; SCHIZOSACCHAROMYCES-POMBE; SR PROTEINS; CELL-CYCLE; INTRANUCLEAR DISTRIBUTION; SUBCELLULAR-LOCALIZATION; FUNCTIONAL-ANALYSIS; SERINE-RICH	Prp4 is a protein kinase of Schizosaccharomyces pombe identified through its role in pre-mRNA splicing, and belongs to a kinase family including mammalian serine/arginine-rich protein-specific kinases and Clks, whose substrates are serine/arginine-rich proteins. We cloned human PRP4 (hPRP4) full-length cDNA and the antiserum raised against a partial peptide of hPRP4 recognized 170-kDa polypeptide in HeLa S3 cell extracts. Northern blot analysis revealed that hPRP4 mRNA was ubiquitously expressed in multiple tissues. The extended NH2-terminal region of hPRP4 contains an arginine/serine-rich domain and putative nuclear localization signals. hPRP4 phosphorylated and interacted with SF2/ASF, one of the essential splicing factors. Indirect immunofluorescence analysis revealed that endogenous hPRP4 was distributed in a nuclear speckled pattern and colocalized with SF2/ASF in HeLa S3 cells. Furthermore, hPRP4 interacted directly with Clk1 on its COOH terminus, and the arginine/serine-rich domain of hPRP4 was phosphorylated by Clk1 in vitro. Overexpression of Clk1 caused redistribution of hPRP4, from the speckled to the diffuse pattern in nucleoplasm, whereas inactive mutant of Clk1 caused no change of hPRP4 localization. These findings suggest that the NH2-terminal region of hPRP4 may play regulatory roles under an unidentified signal transduction pathway through Clk1.	Tokyo Med & Dent Univ, Med Res Inst, Dept Funct Genom, Bunkyo Ku, Tokyo 1138510, Japan; Keio Univ, Sch Med, Dept Med, Shinjuku Ku, Tokyo 1600016, Japan; Tokai Univ, Sch Med, Inst Med Sci, Isehara, Kanagawa 2591193, Japan; Tokai Univ, Sch Med, Dept Med, Isehara, Kanagawa 2591193, Japan	Tokyo Medical & Dental University (TMDU); Keio University; Tokai University; Tokai University	Hagiwara, M (corresponding author), Tokyo Med & Dent Univ, Med Res Inst, Dept Funct Genom, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.		Wada, Kazuhiro/A-6548-2012					ALAHARI SK, 1993, NUCLEIC ACIDS RES, V21, P4079, DOI 10.1093/nar/21.17.4079; Becker W, 1998, J BIOL CHEM, V273, P25893, DOI 10.1074/jbc.273.40.25893; BENDAVID Y, 1991, EMBO J, V10, P317, DOI 10.1002/j.1460-2075.1991.tb07952.x; BENDER J, 1994, P NATL ACAD SCI USA, V91, P12105, DOI 10.1073/pnas.91.25.12105; CACERES JF, 1993, EMBO J, V12, P4715, DOI 10.1002/j.1460-2075.1993.tb06160.x; Colwill K, 1996, EMBO J, V15, P265, DOI 10.1002/j.1460-2075.1996.tb00357.x; Colwill K, 1996, J BIOL CHEM, V271, P24569, DOI 10.1074/jbc.271.40.24569; Duncan PI, 1997, MOL CELL BIOL, V17, P5996, DOI 10.1128/MCB.17.10.5996; Duncan PI, 1998, EXP CELL RES, V241, P300, DOI 10.1006/excr.1998.4083; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; Gilbert W, 2001, RNA, V7, P302, DOI 10.1017/S1355838201002369; Gross T, 1997, NUCLEIC ACIDS RES, V25, P1028, DOI 10.1093/nar/25.5.1028; GUI JF, 1994, NATURE, V369, P678, DOI 10.1038/369678a0; HANES J, 1994, J MOL BIOL, V244, P665, DOI 10.1006/jmbi.1994.1763; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HOWELL BW, 1991, MOL CELL BIOL, V11, P568, DOI 10.1128/MCB.11.1.568; Huang Y, 2000, BIOCHEM BIOPH RES CO, V271, P456, DOI 10.1006/bbrc.2000.2651; JOHNSON KW, 1991, J BIOL CHEM, V266, P3402; Kim YH, 1998, J BIOL CHEM, V273, P25875, DOI 10.1074/jbc.273.40.25875; Koizumi J, 1999, J BIOL CHEM, V274, P11125, DOI 10.1074/jbc.274.16.11125; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; KRAINER AR, 1990, CELL, V62, P35, DOI 10.1016/0092-8674(90)90237-9; Kuroyanagi H, 2000, MECH DEVELOP, V99, P51, DOI 10.1016/S0925-4773(00)00477-9; Kuroyanagi N, 1998, BIOCHEM BIOPH RES CO, V242, P357, DOI 10.1006/bbrc.1997.7913; Lee K, 1996, J BIOL CHEM, V271, P27299, DOI 10.1074/jbc.271.44.27299; Longman D, 2000, EMBO J, V19, P1625, DOI 10.1093/emboj/19.7.1625; Miyata Y, 1999, BIOCHEM BIOPH RES CO, V266, P291, DOI 10.1006/bbrc.1999.1705; Nayler O, 1997, BIOCHEM J, V326, P693, DOI 10.1042/bj3260693; OKAJIMA T, 1996, BIOIMAGES, V4, P117; Okamoto Y, 1998, BIOCHEM BIOPH RES CO, V249, P872, DOI 10.1006/bbrc.1998.9247; POTASHKIN J, 1989, EMBO J, V8, P551, DOI 10.1002/j.1460-2075.1989.tb03409.x; Prasad J, 1999, MOL CELL BIOL, V19, P6991; ROSENBERG GH, 1991, MOL GEN GENET, V226, P305, DOI 10.1007/BF00273617; Rossi F, 1996, NATURE, V381, P80, DOI 10.1038/381080a0; Schmidt H, 1999, GENETICS, V153, P1183; Schwelnus W, 2001, EMBO REP, V2, P35, DOI 10.1093/embo-reports/kve009; Siebel CW, 1999, P NATL ACAD SCI USA, V96, P5440, DOI 10.1073/pnas.96.10.5440; TAKEUCHI M, 1993, MOL BIOL CELL, V4, P247, DOI 10.1091/mbc.4.3.247; Tang ZH, 1998, J BIOL CHEM, V273, P5963, DOI 10.1074/jbc.273.10.5963; Tate P, 1998, J CELL SCI, V111, P2575; Urushiyama S, 1996, MOL GEN GENET, V253, P118, DOI 10.1007/s004380050304; Wang HY, 1998, J CELL BIOL, V140, P737, DOI 10.1083/jcb.140.4.737; WOPPMANN A, 1993, NUCLEIC ACIDS RES, V21, P2815, DOI 10.1093/nar/21.12.2815; Xiao SH, 1997, GENE DEV, V11, P334, DOI 10.1101/gad.11.3.334; Yoshida K, 1998, MOL BRAIN RES, V57, P241, DOI 10.1016/S0169-328X(98)00089-8; YUN B, 1994, GENE DEV, V8, P1160, DOI 10.1101/gad.8.10.1160; Yun CY, 2000, J CELL BIOL, V150, P707, DOI 10.1083/jcb.150.4.707; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837	48	53	56	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					32247	32256		10.1074/jbc.M103790200	http://dx.doi.org/10.1074/jbc.M103790200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11418604	hybrid			2022-12-25	WOS:000170613500105
J	Paik, J; During, A; Harrison, EH; Mendelsohn, CL; Lai, K; Blaner, WS				Paik, J; During, A; Harrison, EH; Mendelsohn, CL; Lai, K; Blaner, WS			Expression and characterization of a murine enzyme able to cleave beta-carotene - The formation of retinoids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VITAMIN-A; 15,15'-DIOXYGENASE ACTIVITY; DIOXYGENASE ACTIVITY; INTESTINAL-MUCOSA; ESCHERICHIA-COLI; ACID RECEPTORS; IN-VITRO; METABOLISM; PROTEIN; ABSORPTION	Because animals are not able to synthesize retinoids de novo, ultimately they must derive them from dietary provitamin A carotenoids through a process known as carotene cleavage. The enzyme responsible for catalyzing carotene cleavage (beta -carotene 15,15 ' -dioxygenase) has been characterized primarily in rat intestinal scrapings. Using a recently reported cDNA sequence for a carotene cleavage enzyme from Drosophila, we identified a cDNA encoding a mouse homolog of this enzyme. When the cDNA was expressed in either Escherichia coli or Chinese hamster ovary cells, expression conferred upon bacterial and Chinese hamster ovary cell homogenates the ability to cleave beta -carotene to retinal. Several lines of evidence obtained upon kinetic analyses of the recombinant enzyme suggested that carotene cleavage enzyme interacts with other proteins present within cell or tissue homogenates. This was confirmed by pull-down experiments upon incubation of recombinant enzyme with tissue 12,000 x g supernatants. Matrix-assisted laser desorption ionization-mass spectrometry analysis of pulled-down proteins indicates that an atypical testis-specific isoform of lactate de-hydrogenase associates with recombinant carotene cleavage enzyme. mRNA transcripts for the carotene cleavage enzyme were detected by reverse transcription-polymerase chain reaction in mouse testes, liver, kidney, and intestine. In situ hybridization studies demonstrated that carotene cleavage enzyme is expressed prominently in maternal tissue surrounding the embryo but not in embryonic tissues at 7.5 and 8.5 days postcoitus. This work offers new insights for understanding the biochemistry of carotene cleavage to retinoids.	Columbia Univ, Dept Med, New York, NY 10032 USA; Columbia Univ, Dept Urol, New York, NY 10032 USA; USDA ARS, Beltsville Human Nutr Res Ctr, Beltsville, MD 20705 USA	Columbia University; Columbia University; United States Department of Agriculture (USDA)	Blaner, WS (corresponding author), Columbia Univ, Dept Med, HHSB Rm 502,701 W 168th St, New York, NY 10032 USA.		During, Alexandrine/I-5405-2015; Harrison, Earl H/AAN-5378-2021; Mendelsohn, Cathy/H-4280-2016; During, Alexandrine/AAA-2931-2021	During, Alexandrine/0000-0002-6878-0870; Mendelsohn, Cathy/0000-0002-4026-4073; 	NATIONAL EYE INSTITUTE [R01EY012858] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049879] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK082963, R01DK044498, R01DK061459, R01DK065719, R01DK061310] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY12858] Funding Source: Medline; NHLBI NIH HHS [R01 HL49879, R01 HL049879] Funding Source: Medline; NIDDK NIH HHS [R01 DK061310, R01 DK061459-07S1, R01 DK061459-09, R01 DK061459, R56 DK082963-01, R01 DK061459-06, R56 DK082963, R01 DK061459-07, R01 DK061459-08, R01 DK44498, R01 DK065719] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BLANCO A, 1976, BIOCHEM J, V153, P165, DOI 10.1042/bj1530165; Blaner W.S., 1999, HANDB EXP PHARM, P117; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; During A, 1996, ANAL BIOCHEM, V241, P199, DOI 10.1006/abio.1996.0400; During A, 1998, J NUTR, V128, P1614, DOI 10.1093/jn/128.10.1614; During A, 1998, BIOCHEM BIOPH RES CO, V249, P467, DOI 10.1006/bbrc.1998.9160; Duszka C, 1996, J NUTR, V126, P2550, DOI 10.1093/jn/126.10.2550; FIDGE NH, 1969, BIOCHEM J, V114, P689, DOI 10.1042/bj1140689; GOODMAN DS, 1965, SCIENCE, V149, P879, DOI 10.1126/science.149.3686.879; GOODMAN DS, 1969, AM J CLIN NUTR, V22, P963; GOODMAN DS, 1967, J BIOL CHEM, V242, P3543; GOODMAN DS, 1966, J BIOL CHEM, V241, P1929; GOODMAN DWS, 1966, J CLIN INVEST, V45, P1615, DOI 10.1172/JCI105468; Grolier P, 1997, ARCH BIOCHEM BIOPHYS, V348, P233, DOI 10.1006/abbi.1997.0388; LAKSHMAN MR, 1993, J NUTR BIOCHEM, V4, P659, DOI 10.1016/0955-2863(93)90040-4; Lakshman MR, 1996, NUTR CANCER, V26, P49, DOI 10.1080/01635589609514462; LEVIN MS, 1990, METHOD ENZYMOL, V189, P506; LI E, 1987, J BIOL CHEM, V262, P13773; Mangelsdorf David J., 1994, P319; Mendelsohn C, 1999, DEVELOPMENT, V126, P1139; MILLER AD, 1993, METHOD ENZYMOL, V217, P581; NAPOLI JL, 1986, METHOD ENZYMOL, V123, P112, DOI 10.1016/S0076-6879(86)23015-3; OLSON JA, 1961, J BIOL CHEM, V236, P349; OLSON JA, 1965, P NATL ACAD SCI USA, V54, P1364, DOI 10.1073/pnas.54.5.1364; Olson JA., 1991, HDB VITAMINS, P1; Ong David E., 1994, P283; PEMRICK SM, 1994, LEUKEMIA, V8, P1; PETKOVICH M, 1992, ANNU REV NUTR, V12, P443, DOI 10.1146/annurev.nu.12.070192.002303; Rock CL, 1997, PHARMACOL THERAPEUT, V75, P185, DOI 10.1016/S0163-7258(97)00054-5; Saari John C., 1994, P351; Schwartz SH, 1997, SCIENCE, V276, P1872, DOI 10.1126/science.276.5320.1872; SINGH H, 1974, BIOCHIM BIOPHYS ACTA, V370, P49, DOI 10.1016/0005-2744(74)90030-8; SKLAN D, 1983, BRIT J NUTR, V50, P417, DOI 10.1079/BJN19830109; Sporn M.B., 1994, RETINOIDS BIOL CHEM; STAHL W, 1992, ARCH BIOCHEM BIOPHYS, V294, P173, DOI 10.1016/0003-9861(92)90153-N; Tajima S, 1999, LIFE SCI, V65, P841, DOI 10.1016/S0024-3205(99)00311-2; THOMAS K, 1990, DEVELOPMENT, V109, P483; THOMPSON SY, 1950, BRIT J NUTR, V4, P398, DOI 10.1079/BJN19500063; vanVliet T, 1996, INT J VITAM NUTR RES, V66, P77; vanVliet T, 1996, J NUTR, V126, P499, DOI 10.1093/jn/126.2.499; Vieira AV, 1998, SUB CELL BIOCHEM, V30, P29; Vogel S, 2001, J BIOL CHEM, V276, P1353, DOI 10.1074/jbc.M005118200; VOGEL S, 1999, HANDB EXP PHARM, V139, P31; von Lintig J, 2000, J BIOL CHEM, V275, P11915, DOI 10.1074/jbc.275.16.11915; Wyss A, 2000, BIOCHEM BIOPH RES CO, V271, P334, DOI 10.1006/bbrc.2000.2619	45	123	127	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					32160	32168		10.1074/jbc.M010086200	http://dx.doi.org/10.1074/jbc.M010086200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11418584	Green Submitted, hybrid			2022-12-25	WOS:000170613500094
J	Memon, RA; Moser, AH; Shigenaga, JK; Grunfeld, C; Feingold, KR				Memon, RA; Moser, AH; Shigenaga, JK; Grunfeld, C; Feingold, KR			In vivo and in vitro regulation of sterol 27-hydroxylase in the liver during the acute phase response - Potential role of hepatocyte nuclear factor-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHOLESTEROL 7-ALPHA-HYDROXYLASE GENE; BILE-ACID BIOSYNTHESIS; MESSENGER-RNA LEVELS; RETINOID-X-RECEPTOR; OXYSTEROL 7-ALPHA-HYDROXYLASE; DOWN-REGULATION; TRANSCRIPTIONAL REGULATION; CYP7A1 TRANSCRIPTION; DECREASED EXPRESSION; SERUM-LIPOPROTEINS	The host response to infection is associated with several alterations in lipid metabolism that promote lipoprotein production. These changes can be reproduced by lipopolysaccharide (LPS) administration. LPS stimulates hepatic cholesterol synthesis and suppresses the conversion of cholesterol to bile acids. LPS down-regulates hepatic cholesterol 7 alpha -hydroxylase, the rate-limiting enzyme in the classic pathway of bile acid synthesis. We now demonstrate that LPS markedly decreases the activity of sterol 27-hydroxylase, the rate-limiting enzyme in the alternate pathway of bile acid synthesis, in the liver of Syrian hamsters. Moreover, LPS progressively decreases hepatic sterol 27-hydroxylase mRNA levels by 75% compared with controls over a 24-h treatment period. LPS also decreases oxysterol 7 alpha -hydroxylase mRNA levels in mouse liver. In vitro studies in HepG2 cells demonstrate that tumor necrosis factor and interleukin (IL)-1 decrease sterol 27-hydroxylase MRNA levels by 48 and 80%, respectively, whereas IL-6 has no such effect. The IL-1-induced decrease in sterol 27-hydroxylase mRNA expression occurs early, is sustained for 48 h, and requires very low doses. In vivo IL-1 treatment also lowers hepatic sterol 27-hydroxylase mRNA levels in Syrian hamsters. Studies investigating the molecular mechanisms of LPS-induced decrease in sterol 27-hydroxylase show that LPS markedly decreases mRNA and protein levels of hepatocyte nuclear factor-1 a transcription factor that regulates sterol 27-hydroxylase, in the liver. Moreover, LPS decreases the binding activity of HNF-1 by 70% in nuclear extracts in hamster liver, suggesting that LPS may down-regulate sterol 27-hydroxylase by decreasing the binding of HNF-1 to its promoter. Coupled with our earlier studies on cholesterol 7 alpha -hydroxylase, these data indicate that LPS suppresses both the classic and alternate pathways of bile acid synthesis. A decrease in bile acid synthesis mi liver would reduce cholesterol catabolism and thereby contribute to the increase in hepatic lipoprotein production that is induced by LPS and cytokines.	Dept Vet Affairs Med Ctr, Metab Sect 111F, Dept Med, San Francisco, CA 94121 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94121 USA	University of California System; University of California San Francisco	Memon, RA (corresponding author), Dept Vet Affairs Med Ctr, Metab Sect 111F, Dept Med, 4150 Clement St, San Francisco, CA 94121 USA.							Akiyama TE, 2000, J BIOL CHEM, V275, P27117; Beigneux AP, 2000, J BIOL CHEM, V275, P16390, DOI 10.1074/jbc.M000953200; Bone RC, 1996, ANN INTERN MED, V125, P680, DOI 10.7326/0003-4819-125-8-199610150-00009; BURKE PA, 1994, SURGERY, V116, P285; Burke PA, 1996, SURGERY, V120, P374, DOI 10.1016/S0039-6060(96)80312-6; CABANA VG, 1989, J LIPID RES, V30, P39; CALI JJ, 1991, J BIOL CHEM, V266, P7774; Camp HS, 1999, ENDOCRINOLOGY, V140, P392, DOI 10.1210/en.140.1.392; Cereghini S, 1996, FASEB J, V10, P267, DOI 10.1096/fasebj.10.2.8641560; Chiang JYL, 2000, J BIOL CHEM, V275, P10918, DOI 10.1074/jbc.275.15.10918; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DeFabiani E, 1996, BIOCHEM BIOPH RES CO, V226, P663, DOI 10.1006/bbrc.1996.1412; Feingold KR, 1996, J LIPID RES, V37, P223; FEINGOLD KR, 1993, J LIPID RES, V34, P2147; FEINGOLD KR, 1995, J LIPID RES, V36, P1474; FEINGOLD KR, 1992, J LIPID RES, V33, P1765; Gabay C, 1999, NEW ENGL J MED, V340, P448, DOI 10.1056/NEJM199902113400607; Grunfeld C, 1996, J CLIN INVEST, V97, P2152, DOI 10.1172/JCI118653; Gupta S, 2001, J BIOL CHEM, V276, P15816, DOI 10.1074/jbc.M010878200; HAGAN DL, 1994, J BIOL CHEM, V269, P28737; Hardardottir Ingibjorg, 1994, Current Opinion in Lipidology, V5, P207, DOI 10.1097/00041433-199405030-00008; HARRIS HW, 1990, J CLIN INVEST, V86, P696, DOI 10.1172/JCI114765; HILL M, 1991, J CLIN INVEST, V88, P811, DOI 10.1172/JCI115381; Ishibashi S, 1996, J BIOL CHEM, V271, P18017, DOI 10.1074/jbc.271.30.18017; JAVITT NB, 1994, FASEB J, V8, P1308, DOI 10.1096/fasebj.8.15.8001744; JELINEK DF, 1990, J BIOL CHEM, V265, P8190; Koj A, 1996, BBA-MOL BASIS DIS, V1317, P84, DOI 10.1016/S0925-4439(96)00048-8; KUO CJ, 1990, P NATL ACAD SCI USA, V87, P9838, DOI 10.1073/pnas.87.24.9838; LANZAJACOBY S, 1990, AM J PHYSIOL, V258, pE678, DOI 10.1152/ajpendo.1990.258.4.E678; Lee HY, 2000, J BIOL CHEM, V275, P32193, DOI 10.1074/jbc.M005490200; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; Liao W, 1996, BIOCHEM J, V313, P873, DOI 10.1042/bj3130873; LOPESVIRELLA MF, 1993, EUR HEART J, V14, P118; Magee TR, 1998, J BIOL CHEM, V273, P30024, DOI 10.1074/jbc.273.45.30024; Marrapodi M, 2000, J LIPID RES, V41, P514; Memon RA, 1997, J LIPID RES, V38, P1620; Memon RA, 1999, BBA-MOL CELL BIOL L, V1440, P118, DOI 10.1016/S1388-1981(99)00120-1; Metz RP, 2000, MOL PHARMACOL, V58, P319, DOI 10.1124/mol.58.2.319; Muller M, 2000, SEMIN LIVER DIS, V20, P323, DOI 10.1055/s-2000-9387; Navasa M, 1998, J LIPID RES, V39, P1220; NEISH AS, 1995, J BIOL CHEM, V270, P28903, DOI 10.1074/jbc.270.48.28903; NOLTEN LA, 1995, MOL ENDOCRINOL, V9, P1488, DOI 10.1210/me.9.11.1488; Pandak WM, 1997, J LIPID RES, V38, P2483; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; QIAN XB, 1995, MOL CELL BIOL, V15, P1364; Rao YP, 1999, J STEROID BIOCHEM, V70, P1, DOI 10.1016/S0960-0760(99)00099-0; Repa JJ, 1999, CURR OPIN BIOTECH, V10, P557, DOI 10.1016/S0958-1669(99)00031-2; Rosen H, 1998, J BIOL CHEM, V273, P14805, DOI 10.1074/jbc.273.24.14805; Russell DW, 1999, CELL, V97, P539, DOI 10.1016/S0092-8674(00)80763-1; Schwarz M, 1996, J BIOL CHEM, V271, P18024, DOI 10.1074/jbc.271.30.18017; Schwarz M, 1997, J BIOL CHEM, V272, P23995, DOI 10.1074/jbc.272.38.23995; Souidi M, 1999, LIFE SCI, V64, P1585, DOI 10.1016/S0024-3205(99)00089-2; SPADY DK, 1995, J CLIN INVEST, V96, P700, DOI 10.1172/JCI118113; Spady DK, 1998, J BIOL CHEM, V273, P126, DOI 10.1074/jbc.273.1.126; SPITZER JJ, 1958, J PAREN ENTER NUTR, V12, P53; Stravitz RT, 1996, J STEROID BIOCHEM, V57, P337, DOI 10.1016/0960-0760(95)00282-0; Su GL, 1995, CRIT REV IMMUNOL, V15, P201, DOI 10.1615/CritRevImmunol.v15.i3-4.10; Trauner M, 1999, J GASTROEN HEPATOL, V14, P946, DOI 10.1046/j.1440-1746.1999.01982.x; TRONCHE F, 1989, MOL CELL BIOL, V9, P4759, DOI 10.1128/MCB.9.11.4759; Vlahcevic ZR, 1997, GASTROENTEROLOGY, V113, P1949, DOI 10.1016/S0016-5085(97)70015-5; Vlahcevic ZR, 1999, GASTROENTEROL CLIN N, V28, P1, DOI 10.1016/S0889-8553(05)70041-8; Vlahcevic ZR, 1996, AM J PHYSIOL-GASTR L, V270, pG646, DOI 10.1152/ajpgi.1996.270.4.G646; Watson AM, 1999, J BIOCHEM MOL TOXIC, V13, P63, DOI 10.1002/(SICI)1099-0461(1999)13:2<63::AID-JBT1>3.3.CO;2-9; Wu ZL, 1999, J LIPID RES, V40, P2195; YANUKAKASHLES O, 1994, MOL CELL BIOL, V14, P7124, DOI 10.1128/MCB.14.11.7124	65	69	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30118	30126		10.1074/jbc.M102516200	http://dx.doi.org/10.1074/jbc.M102516200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11406622	hybrid			2022-12-25	WOS:000170558000070
J	Niu, MY; Menard, M; Reed, JC; Krajewski, S; Pratt, MAC				Niu, MY; Menard, M; Reed, JC; Krajewski, S; Pratt, MAC			Ectopic expression of cyclin D1 amplifies a retinoic acid-induced mitochondrial death pathway in breast cancer cells	ONCOGENE			English	Article						apoptosis; cyclin D1; retinoic acid; breast cancer	INDUCED CONFORMATIONAL CHANGE; MAMMARY EPITHELIAL-CELLS; CYTOCHROME-C RELEASE; RECEPTOR-BETA; BCL-2 FAMILY; IN-VITRO; HISTONE ACETYLTRANSFERASE; CHEMOPREVENTIVE AGENTS; GROWTH-INHIBITION; GENE-EXPRESSION	All-trans retinoic acid inhibits growth associated with downregulation of cyclin D1 and can cause lon level apoptosis in estrogen receptor positive breast cancer cell lines, The cyclin D1 gene is amplified and/or the protein overexpressed in about one-third of breast cancers. Constitutive expression of cyclin D1 in estrogen receptor positive MCF-7 and ZR-75 breast cancer cells (MCF-7(cycD1) and ZR-75(cycD1)) Increased the fraction of cells in S phase and reduced the G1 accumulation following retinoic acid treatment compared with control cells, However, culture of MCF-7(cycD1) with 1 muM all-trans retinoic acid resulted in about threefold greater growth inhibition compared with vector-transfected cells. Hoechst staining of DNA and lit situ DNA end-labeling analysis indicated that MCF-7(cycD1) and ZR-75(cycD1) cultures contained 4-6-fold more retinoic acid-induced apoptotic nuclei as vector-transfected cells. Retinoic acid treatment of vector-transfected clones resulted in Bax protein activation as assessed by exposure of the NH2-terminus of Bax but the proportion of cells containing activated Bax was increased in cyclin D-expressing cells treated with retinoic acid. The latter cells also displayed both immunocytochemical and biochemical evidence of translocation of cytochrome c into the cytosol following RA-treatment, Retinoic acid markedly decreased the Bcl-2 levels in MCF-7 and ZR-75 cells. Accordingly, coexpression of Bcl-2 and cyclin D1 rendered the cells resistant to retinoic acid-induced apoptosis, We conclude that constitutive expression of cyclin D1 sensitizes ER-positive breast cancer cells to a retinoic acid-induced mitochondrial death pathway involving Bax activation, cytochrome c release and caspase-9 cleavage.	Univ Ottawa, Dept Cellular & Mol Med, Ottawa, ON K1H 8M5, Canada; Burnham Inst Canc Res, La Jolla, CA USA	University of Ottawa; Sanford Burnham Prebys Medical Discovery Institute	Pratt, MAC (corresponding author), Univ Ottawa, Dept Cellular & Mol Med, 451 Smyth Rd, Ottawa, ON K1H 8M5, Canada.				NIGMS NIH HHS [GM60554] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060554] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Bardon S, 1998, INT J ONCOL, V12, P355; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Eck KM, 1998, BRIT J CANCER, V77, P2129, DOI 10.1038/bjc.1998.357; Elstner E, 1998, P NATL ACAD SCI USA, V95, P8806, DOI 10.1073/pnas.95.15.8806; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Fliss H, 1996, CIRC RES, V79, P949, DOI 10.1161/01.RES.79.5.949; Gianni M, 2000, CELL DEATH DIFFER, V7, P447, DOI 10.1038/sj.cdd.4400673; Glass CK, 1997, BIOCHEM SOC T, V25, P602, DOI 10.1042/bst0250602; Green A, 1999, CARCINOGENESIS, V20, P1535, DOI 10.1093/carcin/20.8.1535; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; GUDAS LJ, 1992, CELL GROWTH DIFFER, V3, P655; Hakem A, 1999, J EXP MED, V189, P957, DOI 10.1084/jem.189.6.957; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Hsu YT, 1997, J BIOL CHEM, V272, P13829, DOI 10.1074/jbc.272.21.13829; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Krajewski S, 1999, P NATL ACAD SCI USA, V96, P5752, DOI 10.1073/pnas.96.10.5752; Kurokawa R, 1998, SCIENCE, V279, P700, DOI 10.1126/science.279.5351.700; LAMMIE GA, 1991, ONCOGENE, V6, P439; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lippman M.E., 1985, TXB ENDOCRINOLOGY, P1309; Lippman SC, 2000, J NUTR, V130, p479S, DOI 10.1093/jn/130.2.479S; Liu Y, 1996, MOL CELL BIOL, V16, P1138; Mangiarotti R, 1998, BRIT J CANCER, V77, P186, DOI 10.1038/bjc.1998.32; Manna SK, 2000, ONCOGENE, V19, P2110, DOI 10.1038/sj.onc.1203547; Meier CA, 1997, J RECEPT SIGNAL TR R, V17, P319, DOI 10.3109/10799899709036612; MOON RC, 1992, CANCER DETECT PREV, V16, P73; Murphy KM, 2000, J BIOL CHEM, V275, P17225, DOI 10.1074/jbc.C900590199; Nagy L, 1998, CELL DEATH DIFFER, V5, P11, DOI 10.1038/sj.cdd.4400337; Oh Youngman, 1995, Progress in Growth Factor Research, V6, P503, DOI 10.1016/0955-2235(95)00025-9; OSWALD F, 1994, ONCOGENE, V9, P2029; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Raffo P, 2000, ANTICANCER RES, V20, P1535; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; ROMAN SD, 1992, CANCER RES, V52, P2236; SALO S, 1994, P NATL ACAD SCI USA, V91, P923; Schmidt EV, 1996, BIOESSAYS, V18, P6, DOI 10.1002/bies.950180104; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; SEEWALDT VL, 1995, CELL GROWTH DIFFER, V6, P1077; Seewaldt VL, 1997, CELL GROWTH DIFFER, V8, P631; Seewaldt VL, 1999, EXP CELL RES, V249, P70, DOI 10.1006/excr.1999.4462; SGAMBATO A, 1995, CARCINOGENESIS, V16, P2193, DOI 10.1093/carcin/16.9.2193; Shang YF, 1999, J BIOL CHEM, V274, P18005, DOI 10.1074/jbc.274.25.18005; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; SoferLevi Y, 1996, ONCOGENE, V13, P2431; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Spinella MJ, 1999, J BIOL CHEM, V274, P22013, DOI 10.1074/jbc.274.31.22013; Sukumar S, 1995, MUTAT RES-FUND MOL M, V333, P37, DOI 10.1016/0027-5107(95)00129-8; Teixeira C, 1997, MOL ENDOCRINOL, V11, P1191, DOI 10.1210/me.11.9.1191; VANDERVELDEN J, 1992, INT J GYNECOL CANCER, V2, P157, DOI 10.1046/j.1525-1438.1992.02030157.x; Wang Q, 2000, CANCER RES, V60, P2040; Zhang DM, 2000, J CELL PHYSIOL, V185, P1, DOI 10.1002/1097-4652(200010)185:1<1::AID-JCP1>3.0.CO;2-O; Zhou Q, 1997, ONCOGENE, V15, P107, DOI 10.1038/sj.onc.1201142; Zwijsen RML, 1996, MOL CELL BIOL, V16, P2554	64	37	38	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 14	2001	20	27					3506	3518		10.1038/sj.onc.1204453	http://dx.doi.org/10.1038/sj.onc.1204453			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	445VB	11429697				2022-12-25	WOS:000169478300006
J	Leone, A; Mitsiades, N; Ward, Y; Spinelli, B; Poulaki, V; Tsokos, M; Kelly, K				Leone, A; Mitsiades, N; Ward, Y; Spinelli, B; Poulaki, V; Tsokos, M; Kelly, K			The Gem GTP-binding protein promotes morphological differentiation in neuroblastoma	ONCOGENE			English	Article						Gem; neuroblastoma; ganglia; morphology; RGK proteins; cytoskeleton	RAS-FAMILY; MEMBER; CELLS; PHOSPHORYLATION; ACTIVATION; KIR; REM	Gem is a small GTP-binding protein within the Ras superfamily whose function has not been determined. We report here that ectopic Gem expression is sufficient to stimulate cell flattening and neurite extension in N1E-115 and SH-SY5Y neuroblastoma cells, suggesting a role for Gem in cytoskeletal rearrangement and/or morphological differentiation of neurons. Consistent with this potential function, in clinical samples of neuroblastoma, Gem protein was most highly expressed within cells which had differentiated to express ganglionic morphology. Gem was also observed in developing trigeminal nerve ganglia in 12.5 day mouse embryos, demonstrating that Gem expression is a property of normal ganglionic development. Although Gem expression is rare in epithelial and hematopoietic cancer cell lines, constitutive Gem levels were detected in several neuroblastoma cell lines and could be further induced as much as 10-fold following treatment with PMA or the acetylcholine muscarinic agonist, carbachol.	NCI, Div Clin Sci, Med Branch, Cell & Canc Biol Dept, Bethesda, MD 20892 USA; NCI, Pathol Lab, Div Clin Sci, Pediat Tumor Biol Sect, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Kelly, K (corresponding author), NCI, Div Clin Sci, Med Branch, Cell & Canc Biol Dept, Bldg 10,Room 3B43,9000, Bethesda, MD 20892 USA.		Leone, Alvaro/K-6410-2016; leone, alvaro/AAQ-7051-2020	Leone, Alvaro/0000-0003-3815-9052; 				AMBROS IM, 1995, EUR J CANCER, V31A, P429, DOI 10.1016/0959-8049(95)00051-J; COHEN L, 1994, P NATL ACAD SCI USA, V91, P12448, DOI 10.1073/pnas.91.26.12448; Cool RH, 1999, MOL CELL BIOL, V19, P6297; Dorin D, 1995, ONCOGENE, V11, P2267; Finlin BS, 1999, ARCH BIOCHEM BIOPHYS, V368, P401, DOI 10.1006/abbi.1999.1316; Finlin BS, 1997, J BIOL CHEM, V272, P21982, DOI 10.1074/jbc.272.35.21982; Finlin BS, 2000, BIOCHEM J, V347, P223, DOI 10.1042/0264-6021:3470223; HACHITANDA Y, 1994, HUM PATHOL, V25, P67, DOI 10.1016/0046-8177(94)90173-2; Hirose M, 1998, J CELL BIOL, V141, P1625, DOI 10.1083/jcb.141.7.1625; Katoh H, 1998, J BIOL CHEM, V273, P2489, DOI 10.1074/jbc.273.5.2489; KIMHI Y, 1976, P NATL ACAD SCI USA, V73, P462, DOI 10.1073/pnas.73.2.462; MAGUIRE J, 1994, SCIENCE, V265, P241, DOI 10.1126/science.7912851; Moyers JS, 1998, BIOCHEM J, V333, P609, DOI 10.1042/bj3330609; Pan JY, 2000, J CELL BIOL, V149, P1107, DOI 10.1083/jcb.149.5.1107; REYNET C, 1993, SCIENCE, V262, P1441, DOI 10.1126/science.8248782; Shimada H, 1999, CANCER, V86, P349, DOI 10.1002/(SICI)1097-0142(19990715)86:2<349::AID-CNCR20>3.3.CO;2-P; Shimada H, 1999, CANCER, V86, P364, DOI 10.1002/(SICI)1097-0142(19990715)86:2<364::AID-CNCR21>3.3.CO;2-Z; SHIMADA H, 1985, HUM PATHOL, V16, P471, DOI 10.1016/S0046-8177(85)80085-X; Son JH, 1996, MOL BRAIN RES, V36, P300, DOI 10.1016/0169-328X(95)00255-Q; Vanhove B, 1997, ENDOTHELIUM-J ENDOTH, V5, P51, DOI 10.3109/10623329709044158; Wess J, 1997, LIFE SCI, V60, P1007, DOI 10.1016/S0024-3205(97)00041-6	21	37	38	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 31	2001	20	25					3217	3225		10.1038/sj.onc.1204420	http://dx.doi.org/10.1038/sj.onc.1204420			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	440ET	11423971				2022-12-25	WOS:000169163500005
J	Kagedal, K; Johansson, U; Ollinger, K				Kagedal, K; Johansson, U; Ollinger, K			The lysosomal protease cathepsin D mediates apoptosis induced by oxidative stress	FASEB JOURNAL			English	Article						caspases; cell death; naphthazarin p53; pepstatin A	PROGRAMMED CELL-DEATH; T-CELLS; ACTIVATION; RELEASE; DEGRADATION; SUPPRESSION; RELOCATION; CASPASE-3; TAU	It has been suggested that lysosomes and the lysosomal proteases cathepsin D and B act as proapoptotic mediators of apoptosis, in addition to mitochondrial release of cytochrome c and the activation of the caspase family of proteases. We found that cathepsin D was implicated in the onset of apoptosis in fibroblasts exposed to oxidative stress generated by redox cycling of naphthazarin (NZ)(5,8-dihydroxy-1,4-naphthoquinon). At the start of NZ treatment, the intracellular reduced glutathione concentration was diminished and cathepsins D, B, and L were all translocated from lysosomes to the cytosol before any biochemical or morphological signs of apoptosis were detected. Increase in cathepsin D activity and in the level of p53 protein, a transcription factor for cathepsin D, was observed before activation of caspase-3. Moreover, pretreatment with the cathepsin D inhibitor pepstatin A or the caspase-3 inhibitor Ac-DEVD-CHO prevented apoptosis, although the increase of cathepsin D activity was still detected when caspase-3 was inhibited. Cathepsin B activity decreased following oxidative stress, and inhibition of the protease did not affect the apoptotic process. We suggest that translocation of lysosomal proteases is an early event in NZ-induced apoptosis and that the release and increased activity of cathepsin D allow this protease to exert an apoptosis-mediating effect upstream of the caspase cascade.	Linkoping Univ, Fac Hlth Sci, Div Pathol 2, Linkoping, Sweden	Linkoping University	Kagedal, K (corresponding author), Linkoping Univ Hosp, Div Pathol 2, S-58185 Linkoping, Sweden.	katka@inr.liu.se						BANDA NK, 1992, J EXP MED, V176, P1099, DOI 10.1084/jem.176.4.1099; Barrett A, 1977, PROTEINASES MAMMALIA, P209; BARRETT AJ, 1994, METHOD ENZYMOL, V244, P536; Bednarski E, 1996, J NEUROCHEM, V67, P1846, DOI 10.1046/j.1471-4159.1996.67051846.x; Brunk UT, 1999, REDOX REP, V4, P3, DOI 10.1179/135100099101534675; Brunk UT, 1997, FREE RADICAL BIO MED, V23, P616, DOI 10.1016/S0891-5849(97)00007-5; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Deiss LP, 1996, EMBO J, V15, P3861, DOI 10.1002/j.1460-2075.1996.tb00760.x; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Guicciardi ME, 2000, J CLIN INVEST, V106, P1127, DOI 10.1172/JCI9914; Heinrich M, 1999, EMBO J, V18, P5252, DOI 10.1093/emboj/18.19.5252; HONEGGER CG, 1989, J CHROMATOGR-BIOMED, V487, P463, DOI 10.1016/S0378-4347(00)83056-X; Isahara K, 1999, NEUROSCIENCE, V91, P233, DOI 10.1016/S0306-4522(98)00566-1; Kagedal K, 1999, FREE RADICAL RES, V31, P419, DOI 10.1080/10715769900300981; Kenessey A, 1997, J NEUROCHEM, V69, P2026; LOO DT, 1993, P NATL ACAD SCI USA, V90, P7951, DOI 10.1073/pnas.90.17.7951; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATUS A, 1987, BIOCHEMISTRY-US, V26, P8083, DOI 10.1021/bi00399a010; McIlroy D, 2000, GENE DEV, V14, P549; Monney L, 1998, EUR J BIOCHEM, V251, P295, DOI 10.1046/j.1432-1327.1998.2510295.x; MORIYAMA A, 1980, J BIOCHEM, V88, P619, DOI 10.1093/oxfordjournals.jbchem.a133013; Neuzil J, 1999, FEBS LETT, V445, P295, DOI 10.1016/S0014-5793(99)00141-6; Ollinger K, 2000, ARCH BIOCHEM BIOPHYS, V373, P346, DOI 10.1006/abbi.1999.1567; OLLINGER K, 1995, FREE RADICAL BIO MED, V19, P565, DOI 10.1016/0891-5849(95)00062-3; Roberg K, 1998, J HISTOCHEM CYTOCHEM, V46, P411, DOI 10.1177/002215549804600316; Roberg K, 1998, AM J PATHOL, V152, P1151; Roberg K, 1999, FREE RADICAL BIO MED, V27, P1228, DOI 10.1016/S0891-5849(99)00146-X; Roberts Lewis R., 1999, Cell Biochemistry and Biophysics, V30, P71, DOI 10.1007/BF02737885; ROWAN AD, 1992, J BIOL CHEM, V267, P15993; Sarin A, 1996, J EXP MED, V184, P2445, DOI 10.1084/jem.184.6.2445; SENSIBAR JA, 1990, PROSTATE, V16, P263, DOI 10.1002/pros.2990160310; Shibata M, 1998, BIOCHEM BIOPH RES CO, V251, P199, DOI 10.1006/bbrc.1998.9422; Stoka V, 2001, J BIOL CHEM, V276, P3149, DOI 10.1074/jbc.M008944200; Vancompernolle K, 1998, FEBS LETT, V438, P150, DOI 10.1016/S0014-5793(98)01275-7; Wu GS, 1998, ONCOGENE, V16, P2177, DOI 10.1038/sj.onc.1201755; Wu YC, 2000, GENE DEV, V14, P536	37	220	228	1	21	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY 29	2001	15	7					1592	+		10.1096/fj.00-0708fje	http://dx.doi.org/10.1096/fj.00-0708fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519CQ	11427496				2022-12-25	WOS:000173707700021
J	Wagner, EF				Wagner, EF			AP-1 - Introductory remarks	ONCOGENE			English	Editorial Material						AP-1; Fos; Jun; oncogene; signal transduction; transcription factor		This issue attempts to give a 'state of the art' overview of the AP-1 transcription factor family, a fundamental class of transcriptional regulators. The AP-1 family consists of several bZIP (basic region leucine zipper) domain proteins, the Jun, the Fos, and the ATF subfamilies, which all have to dimerize before they can bind to their DNA target sites, AP-1 has been a paradigm for transcription factors that regulate many aspects of cell physiology in response to environmental changes such as stress, radiation, or to growth factor signals thereby acting like an environmental biosensor, Although we have come a long way from discovering its major components, the heterodimer between c-Fos and c-Jun, it is daunting to realize that we still lack a detailed molecular knowledge of how these factors interact with DNA to activate or repress genes in the nucleus, It is also not clear how the response of AP-1 to growth factor signaling from the cell surface to the nucleus a interpreted at the molecular level and whether AP-1 is relevant for human disease.	Res Inst Mol Pathol, IMP, A-1030 Vienna, Austria	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Wagner, EF (corresponding author), Res Inst Mol Pathol, IMP, Dr Bohr Gasse 7, A-1030 Vienna, Austria.			Wagner, Erwin F/0000-0001-7872-0196					0	113	115	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 30	2001	20	19					2334	2335		10.1038/sj.onc.1204416	http://dx.doi.org/10.1038/sj.onc.1204416			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	430HP	11402330				2022-12-25	WOS:000168568700001
J	Geddis, AE; Fox, NE; Kaushansky, K				Geddis, AE; Fox, NE; Kaushansky, K			Phosphatidylinositol 3-kinase is necessary but not sufficient for thrombopoietin-induced proliferation in engineered Mp1-bearing cell lines as well as in primary megakaryocytic progenitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; CYCLIN D1 EXPRESSION; TYROSINE PHOSPHORYLATION; PI 3-KINASE; AKT KINASE; G1 PHASE; C-MPL; RECEPTOR; INHIBITION; PATHWAY	Thrombopoietin and its receptor (Mpl) support survival and proliferation in megakaryocyte progenitors and in BaF3 cells engineered to stably express Mpl (BaF3/Mpl). The binding of thrombopoietin to Mpl activates multiple kinase pathways, including the Jak/STAT, Ras/Raf/MAPK, and phosphatidylinositol 3-kinase pathways, but it is not clear how these kinases promote cell cycling. Here, we show that thrombopoietin induces phosphatidylinositol 3-kinase and that phosphatidylinositol 3-kinase is required for thrombopoietin-induced cell cycling in BaF3/Mpl cells and in primary megakaryocyte progenitors. Treatment of BaF3/Mpl cells and megakaryocytes with the phosphatidylinositol 3-kinase inhibitor LY294002 inhibited mitotic and endomitotic cell cycl-ing. BaF3/Mpl cells treated with thrombopoietin and LY294002 were blocked in G(1), whereas megakaryocyte progenitors treated with thrombopoietin and LY294002 showed both a G(1) and a G(2) cell cycle block. Expression of constitutively active Akt in BaF3/Mpl cells restored the ability of thrombopoietin to promote cell cycling in the presence of LY294002. Constitutively active Akt was not sufficient to drive proliferation of BaF3/Mpl cells in the absence of thrombopoietin. We conclude that in BaF3/Mpl cells and megakaryocyte progenitors, thrombopoietin-induced phosphatidylinositol 3-kinase activity is necessary but not sufficient for thrombopoietin-induced cell cycle progression. Phosphatidylinositol 3-kinase activity is likely to be involved in regulating the G(1)/S transition.	Univ Washington, Dept Med, Div Hematol, Seattle, WA 98195 USA; Fred Hutchinson Canc Res Ctr, Div Pediat Hematol Oncol, Seattle, WA 98104 USA	University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center	Kaushansky, K (corresponding author), Univ Washington, Dept Med, Div Hematol, Box 357710, Seattle, WA 98195 USA.	kkaushan@u.washington.edu						Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Alexander WS, 1996, BLOOD, V87, P2162, DOI 10.1182/blood.V87.6.2162.bloodjournal8762162; Alexander WS, 1996, EMBO J, V15, P6531, DOI 10.1002/j.1460-2075.1996.tb01044.x; ANDO K, 1993, P NATL ACAD SCI USA, V90, P9571, DOI 10.1073/pnas.90.20.9571; Aoki M, 1998, P NATL ACAD SCI USA, V95, P14950, DOI 10.1073/pnas.95.25.14950; BACON CM, 1995, FEBS LETT, V370, P63, DOI 10.1016/0014-5793(95)00796-C; Bacqueville D, 1998, BIOCHEM BIOPH RES CO, V244, P630, DOI 10.1006/bbrc.1997.7885; Beslu N, 1996, J BIOL CHEM, V271, P20075, DOI 10.1074/jbc.271.33.20075; Blume-Jensen P, 1998, CURR BIOL, V8, P779, DOI 10.1016/S0960-9822(98)70302-1; Brennan P, 1997, IMMUNITY, V7, P679, DOI 10.1016/S1074-7613(00)80388-X; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; Carow CE, 2001, J CELL PHYSIOL, V188, P291, DOI 10.1002/jcp.1120; Casagrande F, 1998, FEBS LETT, V422, P385, DOI 10.1016/S0014-5793(98)00043-X; Cerezo A, 1998, MOL BIOL CELL, V9, P3107, DOI 10.1091/mbc.9.11.3107; COREY S, 1993, EMBO J, V12, P2681, DOI 10.1002/j.1460-2075.1993.tb05929.x; COUGHLIN SR, 1989, SCIENCE, V243, P1191; Craddock BL, 1999, J BIOL CHEM, V274, P10633, DOI 10.1074/jbc.274.15.10633; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; DAMEN JE, 1995, J BIOL CHEM, V270, P23402, DOI 10.1074/jbc.270.40.23402; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Dong F, 2000, BLOOD, V95, P1656, DOI 10.1182/blood.V95.5.1656.005k29_1656_1662; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; DRACHMAN JG, 1995, J BIOL CHEM, V270, P4979, DOI 10.1074/jbc.270.10.4979; Drachman JG, 1997, P NATL ACAD SCI USA, V94, P2350, DOI 10.1073/pnas.94.6.2350; Drachman JG, 1999, METHODS, V17, P238, DOI 10.1006/meth.1998.0734; Duckworth BC, 1997, J BIOL CHEM, V272, P27665, DOI 10.1074/jbc.272.44.27665; Ferby IM, 1996, J BIOL CHEM, V271, P11684, DOI 10.1074/jbc.271.20.11684; FERBY IM, 1994, J BIOL CHEM, V269, P30485; Grewe M, 1999, CANCER RES, V59, P3581; Haseyama Y, 1999, BLOOD, V94, P1568, DOI 10.1182/blood.V94.5.1568.417a07_1568_1577; Hodohara K, 2000, BLOOD, V95, P769, DOI 10.1182/blood.V95.3.769.003a49_769_775; Izzard RA, 1999, CANCER RES, V59, P2581; Jaster R, 1997, CELL SIGNAL, V9, P175, DOI 10.1016/S0898-6568(96)00138-6; JHUN BH, 1994, MOL CELL BIOL, V14, P7466, DOI 10.1128/MCB.14.11.7466; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KAUSHANSKY K, 1995, BLOOD, V86, P419, DOI 10.1182/blood.V86.2.419.bloodjournal862419; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Minshall C, 1996, J IMMUNOL, V156, P939; Miyakawa Y, 2001, J BIOL CHEM, V276, P2494, DOI 10.1074/jbc.M002633200; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; Nagata Y, 1997, J CELL BIOL, V139, P449, DOI 10.1083/jcb.139.2.449; Rojnuckarin P, 1999, BLOOD, V94, P1273, DOI 10.1182/blood.V94.4.1273.416k04_1273_1282; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Rosenzweig KE, 1997, CLIN CANCER RES, V3, P1149; Roy L, 2001, BLOOD, V97, P2238, DOI 10.1182/blood.V97.8.2238; Sattler M, 1997, J CELL PHYSIOL, V171, P28; Scheid MP, 1996, J BIOL CHEM, V271, P18134, DOI 10.1074/jbc.271.30.18134; Shigematsu H, 1997, J BIOL CHEM, V272, P14334, DOI 10.1074/jbc.272.22.14334; Sitnicka E, 1996, BLOOD, V87, P4998, DOI 10.1182/blood.V87.12.4998.bloodjournal87124998; Takuwa N, 1999, MOL CELL BIOL, V19, P1346; Timokhina I, 1998, EMBO J, V17, P6250, DOI 10.1093/emboj/17.21.6250; Vitrat N, 1998, BLOOD, V91, P3711; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WANG ZY, 1995, BLOOD, V86, P3783, DOI 10.1182/blood.V86.10.3783.bloodjournal86103783; WENDLING F, 1986, VIROLOGY, V149, P242, DOI 10.1016/0042-6822(86)90125-X; Yagi M, 1999, P NATL ACAD SCI USA, V96, P8126, DOI 10.1073/pnas.96.14.8126; YAMADA M, 1995, BIOCHEM BIOPH RES CO, V217, P230, DOI 10.1006/bbrc.1995.2768; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Zhang X, 1997, LEUKEMIA RES, V21, P849, DOI 10.1016/S0145-2126(97)00055-6; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345; Zimmet JM, 1997, MOL CELL BIOL, V17, P7248, DOI 10.1128/MCB.17.12.7248	62	66	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					34473	34479		10.1074/jbc.M105178200	http://dx.doi.org/10.1074/jbc.M105178200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11418622	hybrid			2022-12-25	WOS:000171024600018
J	Gomes, XV; Burgers, PMJ				Gomes, XV; Burgers, PMJ			ATP utilization by yeast replication factor C I. ATP-mediated interaction with DNA and with proliferating cell nuclear antigen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; LARGE SUBUNIT; COMPLEX-FORMATION; ESCHERICHIA-COLI; POLYMERASE-DELTA; SLIDING CLAMP; PROTEIN COMPLEX; BINDING; GENE; IDENTIFICATION	Eukaryotic replication factor C is the heteropentameric complex that loads the replication clamp proliferating cell nuclear antigen (PCNA) onto primed DNA. In this study we used a derivative, designated RFC, with a N-terminal truncation of the Rfc1 subunit removing a DNA-binding domain not required for clamp loading. Interactions of yeast RFC with PCNA and DNA were studied by surface plasmon resonance. Binding of RFC to PCNA was stimulated by either adenosine (3-thiotriphosphate) (ATP gammaS) or ATP. RFC bound only to primer-template DNA coated with the single-stranded DNA-binding protein RPA if ATP gammaS was also present. Binding occurred without dissociation of RPA. ATP did not stimulate binding of RFC to DNA, suggesting that hydrolysis of ATP dissociated DNA-bound RFC. However, when RFC and PCNA together were flowed across the DNA chip in the presence of ATP, a signal was observed suggesting loading of PCNA by RFC. With ATP gammaS present instead of ATP, long-lived response signals were observed indicative of loading complexes arrested on the DNA. A primer with a 3' single-stranded extension also allowed loading of PCNA, yet turnover of the reaction intermediates was dramatically slowed down. Filter binding experiments and analysis of proteins bound to DNA-magnetic beads confirmed the conclusions drawn from the surface plasmon resonance studies.	Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA	Washington University (WUSTL)	Burgers, PMJ (corresponding author), Washington Univ, Sch Med, Dept Biochem & Mol Biophys, 660 S Euclid Ave, St Louis, MO 63110 USA.	burgers@biochem.wustl.edu	Burgers, Peter M/AAW-6621-2021		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032431] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM032431, GM32431] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen BL, 1998, NUCLEIC ACIDS RES, V26, P3877, DOI 10.1093/nar/26.17.3877; Ason B, 2000, J BIOL CHEM, V275, P3006, DOI 10.1074/jbc.275.4.3006; AYYAGARI R, 1995, MOL CELL BIOL, V15, P4420; BUNZ F, 1993, P NATL ACAD SCI USA, V90, P11014, DOI 10.1073/pnas.90.23.11014; BURGERS PMJ, 1991, J BIOL CHEM, V266, P22698; BURGERS PMJ, 1993, J BIOL CHEM, V268, P19923; Cai JS, 1997, J BIOL CHEM, V272, P18974, DOI 10.1074/jbc.272.30.18974; CULLMANN G, 1995, MOL CELL BIOL, V15, P4661; FIEN K, 1992, MOL CELL BIOL, V12, P155, DOI 10.1128/MCB.12.1.155; Fotedar R, 1996, EMBO J, V15, P4423, DOI 10.1002/j.1460-2075.1996.tb00815.x; Gary SL, 1995, NUCLEIC ACIDS RES, V23, P4986, DOI 10.1093/nar/23.24.4986; Gerik KJ, 1997, J BIOL CHEM, V272, P1256, DOI 10.1074/jbc.272.2.1256; Gomes XV, 2001, J BIOL CHEM, V276, P34776, DOI 10.1074/jbc.M011743200; Gomes XV, 2000, J BIOL CHEM, V275, P14541, DOI 10.1074/jbc.275.19.14541; Gomes XV, 2000, EMBO J, V19, P3811, DOI 10.1093/emboj/19.14.3811; Green CM, 2000, CURR BIOL, V10, P39, DOI 10.1016/S0960-9822(99)00263-8; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; Hingorani MM, 1999, EMBO J, V18, P5131, DOI 10.1093/emboj/18.18.5131; HOWELL EA, 1994, MOL CELL BIOL, V14, P255, DOI 10.1128/MCB.14.1.255; KIM CS, 1992, MOL CELL BIOL, V12, P3050, DOI 10.1128/MCB.12.7.3050; KOUPRINA N, 1994, GENETICS, V138, P1067; Latham GJ, 1996, J MOL BIOL, V264, P426, DOI 10.1006/jmbi.1996.0651; LEE SH, 1991, J BIOL CHEM, V266, P594; LI XY, 1994, P NATL ACAD SCI USA, V91, P868, DOI 10.1073/pnas.91.3.868; LI XY, 1994, J BIOL CHEM, V269, P21880; Mossi R, 1997, J BIOL CHEM, V272, P1769, DOI 10.1074/jbc.272.3.1769; NOSKOV V, 1994, NUCLEIC ACIDS RES, V22, P1527, DOI 10.1093/nar/22.9.1527; PAN ZQ, 1993, P NATL ACAD SCI USA, V90, P6, DOI 10.1073/pnas.90.1.6; Podust VN, 1998, J BIOL CHEM, V273, P31992, DOI 10.1074/jbc.273.48.31992; Schmidt SLG, 2001, J BIOL CHEM, V276, P34792, DOI 10.1074/jbc.M011671200; Schmidt SLG, 2001, J BIOL CHEM, V276, P34784, DOI 10.1074/jbc.M011633200; Schuck P, 1997, CURR OPIN BIOTECH, V8, P498, DOI 10.1016/S0958-1669(97)80074-2; Sexton DJ, 1998, BIOCHEMISTRY-US, V37, P7749, DOI 10.1021/bi980088h; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X; TSURIMOTO T, 1989, MOL CELL BIOL, V9, P609, DOI 10.1128/MCB.9.2.609; TSURIMOTO T, 1990, P NATL ACAD SCI USA, V87, P1023, DOI 10.1073/pnas.87.3.1023; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; Turner J, 1999, EMBO J, V18, P771, DOI 10.1093/emboj/18.3.771; Uhlmann F, 1997, J BIOL CHEM, V272, P10065; Uhlmann F, 1997, J BIOL CHEM, V272, P10058; Waga S, 1998, MOL CELL BIOL, V18, P4177, DOI 10.1128/MCB.18.7.4177; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Yao N, 2000, J BIOL CHEM, V275, P11440, DOI 10.1074/jbc.275.15.11440; YODER BL, 1991, J BIOL CHEM, V266, P22689; Yuzhakov A, 1999, EMBO J, V18, P6189, DOI 10.1093/emboj/18.21.6189	45	112	113	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					34768	34775		10.1074/jbc.M011631200	http://dx.doi.org/10.1074/jbc.M011631200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11432853	hybrid			2022-12-25	WOS:000171024600058
J	Gupta-Rossi, N; Le Bail, O; Gonen, H; Brou, C; Logeat, F; Six, E; Ciechanover, A; Israel, A				Gupta-Rossi, N; Le Bail, O; Gonen, H; Brou, C; Logeat, F; Six, E; Ciechanover, A; Israel, A			Functional interaction between SEL-10, an F-box protein, and the nuclear form of activated Notch1 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RBP-J-KAPPA; INTRACELLULAR DOMAIN; UBIQUITIN LIGASE; SIGNAL-TRANSDUCTION; PROTEOLYTIC RELEASE; NEOPLASTIC LESIONS; BETA-TRCP; IN-VIVO; CLEAVAGE; TRANSCRIPTION	The Notch signaling pathway is essential in many cell fate decisions in invertebrates as well as in vertebrates. After ligand binding, a two-step proteolytic cleavage releases the intracellular part of the receptor which translocates to the nucleus and acts as a transcriptional activator. Although Notch-induced transcription of genes has been reported extensively, its endogenous nuclear form has been seldom visualized. We report that the nuclear intracellular domain of Notch1 is stabilized by proteasome inhibitors and is a substrate for polyubiquitination in vitro. SEL-10, an F-box protein of the Cdc4 family, was isolated in a genetic screen for Lin12/Notch-negative regulators in Caenorhabditis elegans. We isolated human and murine counterparts of SEL-10 and investigated the role of a dominant-negative form of this protein, deleted of the F-box, on Notch1 stability and activity. This molecule could stabilize intracellular Notch1 and enhance its transcriptional activity but had no effect on inactive membrane-anchored forms of the receptor. We then demonstrated that SEL-10 specifically interacts with nuclear forms of Notch1 and that this interaction requires a phosphorylation event. Taken together, these data suggest that SEL-10 is involved in shutting off Notch signaling by ubiquitin-proteasome-mediated degradation of the Active transcriptional factor after a nuclear phosphorylation event.	Inst Pasteur, CNRS, FRE 2364, Unite Biol Mol Express Gen, F-75724 Paris 15, France; Technion Israel Inst Technol, Fac Med, Dept Biochem, IL-31096 Haifa, Israel	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Israel, A (corresponding author), Inst Pasteur, CNRS, FRE 2364, Unite Biol Mol Express Gen, 25 Rue Dr Roux, F-75724 Paris 15, France.	aisrael@pasteur.fr	Six, Emmanuelle/H-7891-2017; Ciechanover, Aaron J/C-9166-2017; Gupta-Rossi, Neetu/AAE-3117-2022	Six, Emmanuelle/0000-0001-7806-0968; Gupta-Rossi, Neetu/0000-0003-0043-264X				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Aster JC, 1997, J BIOL CHEM, V272, P11336; BAILEY AM, 1995, GENE DEV, V9, P2609, DOI 10.1101/gad.9.21.2609; Blaumueller CM, 1997, CELL, V90, P281, DOI 10.1016/S0092-8674(00)80336-0; Bray S, 1998, CELL, V93, P499, DOI 10.1016/S0092-8674(00)81180-0; Brou C, 2000, MOL CELL, V5, P207, DOI 10.1016/S1097-2765(00)80417-7; Cenciarelli C, 1999, CURR BIOL, V9, P1177, DOI 10.1016/S0960-9822(00)80020-2; Cornell M, 1999, GENETICS, V152, P567; Daniel B, 1997, J GEN VIROL, V78, P1095, DOI 10.1099/0022-1317-78-5-1095; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Floyd ZE, 2001, J BIOL CHEM, V276, P22468, DOI 10.1074/jbc.M009388200; Gridley T, 1997, MOL CELL NEUROSCI, V9, P103, DOI 10.1006/mcne.1997.0610; HERSHKO A, 1987, P NATL ACAD SCI USA, V84, P1829, DOI 10.1073/pnas.84.7.1829; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hubbard EJA, 1997, GENE DEV, V11, P3182, DOI 10.1101/gad.11.23.3182; Jackson PK, 2000, TRENDS CELL BIOL, V10, P429, DOI 10.1016/S0962-8924(00)01834-1; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Jarriault S, 1998, MOL CELL BIOL, V18, P7423, DOI 10.1128/MCB.18.12.7423; JHAPPAN C, 1992, GENE DEV, V6, P345, DOI 10.1101/gad.6.3.345; Kidd S, 1998, GENE DEV, V12, P3728, DOI 10.1101/gad.12.23.3728; KOPAN R, 1994, DEVELOPMENT, V120, P2385; Kopan R, 1996, P NATL ACAD SCI USA, V93, P1683, DOI 10.1073/pnas.93.4.1683; Lecourtois M, 1998, CURR BIOL, V8, P771, DOI 10.1016/S0960-9822(98)70300-8; LIEBER T, 1993, GENE DEV, V7, P1949, DOI 10.1101/gad.7.10.1949; Logeat F, 1998, P NATL ACAD SCI USA, V95, P8108, DOI 10.1073/pnas.95.14.8108; Margottin F, 1998, MOL CELL, V1, P565, DOI 10.1016/S1097-2765(00)80056-8; Minoguchi S, 1997, MOL CELL BIOL, V17, P2679, DOI 10.1128/MCB.17.5.2679; Molinari E, 1999, EMBO J, V18, P6439, DOI 10.1093/emboj/18.22.6439; Mumm JS, 2000, MOL CELL, V5, P197, DOI 10.1016/S1097-2765(00)80416-5; NYE JS, 1994, DEVELOPMENT, V120, P2421; Orian A, 2000, EMBO J, V19, P2580, DOI 10.1093/emboj/19.11.2580; Qiu L, 2000, J BIOL CHEM, V275, P35734, DOI 10.1074/jbc.M007300200; Radtke F, 1999, IMMUNITY, V10, P547, DOI 10.1016/S1074-7613(00)80054-0; Rand MD, 2000, MOL CELL BIOL, V20, P1825, DOI 10.1128/MCB.20.5.1825-1835.2000; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Redmond L, 2000, NAT NEUROSCI, V3, P30, DOI 10.1038/71104; Robey E, 1996, CELL, V87, P483, DOI 10.1016/S0092-8674(00)81368-9; Ronchini C, 2000, ONCOGENE, V19, P3914, DOI 10.1038/sj.onc.1203719; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Schweisguth F, 1999, P NATL ACAD SCI USA, V96, P11382, DOI 10.1073/pnas.96.20.11382; Sestan N, 1999, SCIENCE, V286, P741, DOI 10.1126/science.286.5440.741; Shimizu K, 2000, MOL CELL BIOL, V20, P6913, DOI 10.1128/MCB.20.18.6913-6922.2000; Song WH, 1999, P NATL ACAD SCI USA, V96, P6959, DOI 10.1073/pnas.96.12.6959; Struhl G, 2000, MOL CELL, V6, P625, DOI 10.1016/S1097-2765(00)00061-7; Struhl G, 1998, CELL, V93, P649, DOI 10.1016/S0092-8674(00)81193-9; Tamura K, 1995, CURR BIOL, V5, P1416, DOI 10.1016/S0960-9822(95)00279-X; Weinmaster G, 1997, MOL CELL NEUROSCI, V9, P91, DOI 10.1006/mcne.1997.0612; Wu GY, 1998, P NATL ACAD SCI USA, V95, P15787, DOI 10.1073/pnas.95.26.15787; Ye YH, 1999, NATURE, V398, P525, DOI 10.1038/19096; ZAGOURAS P, 1995, P NATL ACAD SCI USA, V92, P6414, DOI 10.1073/pnas.92.14.6414	53	297	302	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					34371	34378		10.1074/jbc.M101343200	http://dx.doi.org/10.1074/jbc.M101343200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11425854	hybrid			2022-12-25	WOS:000171024600004
J	Han, YW; Iwasaki, H; Miyata, T; Mayanagi, K; Yamada, K; Morikawa, K; Shinagawa, H				Han, YW; Iwasaki, H; Miyata, T; Mayanagi, K; Yamada, K; Morikawa, K; Shinagawa, H			A unique beta-hairpin protruding from AAA(+) ATPase domain of RuvB motor protein is involved in the interaction with RuvA DNA recognition protein for branch migration of Holliday junctions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI RUVA; CRYSTAL-STRUCTURE; HEXAMERIC RINGS; RECOMBINATION; BINDING; COMPLEX; REPAIR	The Escherichia coh RuvB protein is a motor protein that forms a complex with RuvA and promotes branch migration of Holliday junctions during homologous recombination. This study describes the characteristics of two RuvB mutants, I148T and I150T, that do not promote branch migration in the presence of RuvA. These RuvB mutants hydrolyzed ATP and bound duplex DNA with the same efficiency as wild-type RuvB, but the mutants did not form a complex with RuvA and were defective in loading onto junction DNA in a RuvA-assisted manner. A recent crystallographic study revealed that Ile(148) and Ile(150) are in a unique beta -hairpin that protrudes from the AAA(+) ATPase domain of RuvB. We propose that this beta -hairpin interacts with hydrophobic residues in the mobile third domain of RuvA and that this interaction is vital for the RuvA-assisted loading of RuvB onto Holliday junction DNA.	Osaka Univ, Microbial Dis Res Inst, Osaka 5650871, Japan; Japan Sci & Technol Corp, Precursory Res Embyron Sci & Technol, Osaka 5650871, Japan; Biomol Engn Res Inst, Osaka 5650874, Japan	Osaka University; Japan Science & Technology Agency (JST)	Iwasaki, H (corresponding author), Yokohama City Univ, Grad Sch Integrated Sci, Tsurumi Ku, 1-7-29 Suehiro Cho, Yokohama, Kanagawa 2300045, Japan.		Han, Yong-Woon/L-2426-2017; Iwasaki, Hiroshi/Y-7946-2018	Iwasaki, Hiroshi/0000-0002-0153-6873				Ariyoshi M, 2000, P NATL ACAD SCI USA, V97, P8257, DOI 10.1073/pnas.140212997; BACHMANN BJ, 1972, BACTERIOL REV, V36, P525, DOI 10.1128/MMBR.36.4.525-557.1972; Eggleston AK, 1997, CELL, V89, P607, DOI 10.1016/S0092-8674(00)80242-1; Hishida T, 1999, J BIOL CHEM, V274, P25335, DOI 10.1074/jbc.274.36.25335; HOLLIDAY R, 1964, GENET RES, V5, P282, DOI 10.1017/S0016672300001233; Iwasaki H, 2000, MOL MICROBIOL, V36, P528, DOI 10.1046/j.1365-2958.2000.01842.x; IWASAKI H, 1992, GENE DEV, V6, P2214, DOI 10.1101/gad.6.11.2214; MITCHELL AH, 1994, J MOL BIOL, V243, P208, DOI 10.1006/jmbi.1994.1648; Miyata T, 2000, J STRUCT BIOL, V131, P83, DOI 10.1006/jsbi.2000.4290; Nishino T, 1998, STRUCTURE, V6, P11, DOI 10.1016/S0969-2126(98)00003-3; Nishino T, 2000, J MOL BIOL, V298, P407, DOI 10.1006/jmbi.2000.3675; Ohnishi T, 2000, GENES GENET SYST, V75, P233, DOI 10.1266/ggs.75.233; Rafferty JB, 1996, SCIENCE, V274, P415, DOI 10.1126/science.274.5286.415; Sambrook J., 2002, MOL CLONING LAB MANU; SHIBA T, 1993, MOL GEN GENET, V237, P395, DOI 10.1007/BF00279443; SHIBA T, 1991, P NATL ACAD SCI USA, V88, P8445, DOI 10.1073/pnas.88.19.8445; Shinagawa H, 1996, TRENDS BIOCHEM SCI, V21, P107, DOI 10.1016/0968-0004(96)10014-1; STASIAK A, 1994, P NATL ACAD SCI USA, V91, P7618, DOI 10.1073/pnas.91.16.7618; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TSANEVA IR, 1992, CELL, V69, P1171, DOI 10.1016/0092-8674(92)90638-S; West SC, 1997, ANNU REV GENET, V31, P213, DOI 10.1146/annurev.genet.31.1.213; Yamada K, 1999, MOL GEN GENET, V261, P1001, DOI 10.1007/s004380051049; Yamada K, 2001, P NATL ACAD SCI USA, V98, P1442, DOI 10.1073/pnas.031470598; Yu X, 1997, J MOL BIOL, V266, P217, DOI 10.1006/jmbi.1996.0799	24	33	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					35024	35028		10.1074/jbc.M103611200	http://dx.doi.org/10.1074/jbc.M103611200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11427534	hybrid			2022-12-25	WOS:000171024600090
J	Heuberger, EHML; Smits, E; Poolman, B				Heuberger, EHML; Smits, E; Poolman, B			Xyloside transport by XylP, a member of the galactoside-pentoside-hexuronide family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							QUINOPROTEIN GLUCOSE-DEHYDROGENASE; SUGAR SPECIFICITY MUTATIONS; ACINETOBACTER-CALCOACETICUS; LACTOBACILLUS-PENTOSUS; LACTOSE TRANSPORT; STREPTOCOCCUS-THERMOPHILUS; MEMBRANE-PROTEINS; LACTOCOCCUS-LACTIS; RECONSTITUTION; PERMEASE	This paper describes the functional characterization of the xyloside transporter, XylP, of Lactobacillus pentosus with the aid of a spectroscopy-based assay system. In order to monitor the transport reaction, the natural xyloside isoprimeverose, a building block of hemicellulose, and the analogue methyl-isoprimeverose were chemically synthesized by a new and efficient procedure. The XylP protein was purified by metal affinity chromatography, following high level expression in Lactococcus lactis from. the nisin-inducible promoter. The purified XylP protein was incorporated into liposomes, in which the glucose dehydrogenase from Acinetobacter calcoaceticus (sGDH) was entrapped. sGDH can oxidize aldose sugars in the presence of dichlorophenol-indophenol as electron acceptor. The coupled assay thus involves XyIP-mediated isoprimeverose uptake followed by internal oxidation of the sugar by sGDH, which can be monitored from the reduction of 2,6-dichlorophenol-indophenol at 600 run. The uptake of isoprimeverose was stimulated by the presence of the non-oxidizable methyl-isoprimeverose on the trans-side of the membrane, indicating that exchange transport is faster than unidirectional downhill uptake. Unlike other members of the galactoside-pentoside-hexuronide family, XylP does not transport monosaccharides (xylose) but requires a glycosidic linkage at the anomeric carbon position. Consistent with a proton motive force-driven mechanism, the uptake was stimulated by a membrane potential (inside negative relative to outside) and inhibited by a pH gradient (inside acidic relative to outside). The advantages of the here-described transport assay for studies of carbohydrate transport are discussed.	Univ Groningen, Dept Biochem, Groningen Biomol Sci & Biotechnol Inst, NL-9747 AG Groningen, Netherlands	University of Groningen	Poolman, B (corresponding author), Univ Groningen, Dept Biochem, Groningen Biomol Sci & Biotechnol Inst, Nijenborgh 4, NL-9747 AG Groningen, Netherlands.	b.poolman@chem.rug.nl	Poolman, Bert/D-1882-2012					BARON C, 1975, BIOCHIM BIOPHYS ACTA, V382, P276, DOI 10.1016/0005-2736(75)90270-9; BROOKER RJ, 1991, J BIOL CHEM, V266, P4131; Chaillou S, 1998, J BACTERIOL, V180, P4011, DOI 10.1128/JB.180.15.4011-4014.1998; Chaillou S, 1998, J BACTERIOL, V180, P2312, DOI 10.1128/JB.180.9.2312-2320.1998; deRuyter PGGA, 1996, J BACTERIOL, V178, P3434, DOI 10.1128/jb.178.12.3434-3439.1996; DUINE JA, 1979, FEBS LETT, V108, P443, DOI 10.1016/0014-5793(79)80584-0; EELKEMA JA, 1991, J BIOL CHEM, V266, P4139; Friesen RHE, 2000, J BIOL CHEM, V275, P40658; GEIGER O, 1989, BIOCHEM J, V261, P415, DOI 10.1042/bj2610415; HAUGE JG, 1964, J BIOL CHEM, V239, P3630; HELFERICH B, 1927, LIEBIGS ANN CHEM, V455, P168; Heuberger EHML, 2000, EUR J BIOCHEM, V267, P228, DOI 10.1046/j.1432-1327.2000.00993.x; JENNINGS HJ, 1968, CAN J CHEMISTRY, V46, P2799, DOI 10.1139/v68-464; Knol J, 1998, BIOCHEMISTRY-US, V37, P16410, DOI 10.1021/bi981596u; Knol J, 1996, J BIOL CHEM, V271, P15358, DOI 10.1074/jbc.271.26.15358; KUIPERS OP, 1995, J BIOL CHEM, V270, P27299, DOI 10.1074/jbc.270.45.27299; LOKMAN BC, 1991, MOL GEN GENET, V230, P161, DOI 10.1007/BF00290664; Lokman BC, 1997, J BACTERIOL, V179, P5391, DOI 10.1128/jb.179.17.5391-5397.1997; LOLKEMA JS, 1995, J BIOL CHEM, V270, P12670, DOI 10.1074/jbc.270.21.12670; MATSUSHITA K, 1995, BIOSCI BIOTECH BIOCH, V59, P1548, DOI 10.1271/bbb.59.1548; Olsthoorn AJJ, 1998, EUR J BIOCHEM, V255, P255, DOI 10.1046/j.1432-1327.1998.2550255.x; Olsthoorn AJJ, 1996, ARCH BIOCHEM BIOPHYS, V336, P42, DOI 10.1006/abbi.1996.0530; Picon A, 2000, J BACTERIOL, V182, P1600, DOI 10.1128/JB.182.6.1600-1608.2000; POOLMAN B, 1983, EUR J BIOCHEM, V135, P41, DOI 10.1111/j.1432-1033.1983.tb07615.x; Poolman B, 1996, MOL MICROBIOL, V19, P911, DOI 10.1046/j.1365-2958.1996.397949.x; POOLMAN B, 1995, J BIOL CHEM, V270, P12995, DOI 10.1074/jbc.270.22.12995; POSNO M, 1991, APPL ENVIRON MICROB, V57, P2764, DOI 10.1128/AEM.57.9.2764-2766.1991; RIGAUD JL, 1995, BBA-BIOENERGETICS, V1231, P223, DOI 10.1016/0005-2728(95)00091-V; RIGAUD JL, 1988, BIOCHEMISTRY-US, V27, P2677, DOI 10.1021/bi00408a007; RIGAUD JL, 1995, LIPOSOMES TOOLS BASI, P71; Veenhoff LM, 1999, J BIOL CHEM, V274, P33244, DOI 10.1074/jbc.274.47.33244; Zemplen G, 1939, BER DTSCH CHEM GES, V72, P1160, DOI 10.1002/cber.19390720607	32	14	15	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					34465	34472		10.1074/jbc.M105460200	http://dx.doi.org/10.1074/jbc.M105460200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11408491	Green Published, Green Submitted, hybrid			2022-12-25	WOS:000171024600017
J	Lindorff-Larsen, K; Lerche, MH; Poulsen, FM; Roepstorff, P; Winther, JR				Lindorff-Larsen, K; Lerche, MH; Poulsen, FM; Roepstorff, P; Winther, JR			Barley lipid transfer protein, LTP1, contains a new type of lipid-like post-translational modification	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACIDS; STRUCTURAL CHARACTERIZATION; SPOROTHRIX FLOCCULOSA; MASS-SPECTROMETRY; BINDING; GENE; SPECTROSCOPY; EXPRESSION; FAMILY; BEER	In plants a group of proteins termed nonspecific lipid transfer proteins are found. These proteins bind and catalyze transfer of lipids in vitro, but their in vivo function is unknown. They have been suggested to be involved in different aspects of plant physiology and cell biology, including the formation of cutin and involvement in stress and pathogen responses, but there is yet no direct demonstration of an in vivo function. We have found and characterized a novel post-translational modification of the barley nonspecific lipid transfer protein, LTP1. The protein-modification bond is of a new type in which an aspartic acid in LTP1 is bound to the modification through what most likely is an ester bond. The chemical structure of the modification has been characterized by means of two-dimensional homo- and heteronuclear nuclear magnetic resonance spectroscopy as well as mass spectrometry and is found to be lipid-like in nature. The modification does not resemble any standard lipid post-translational modification but is similar to a compound with known antimicrobial activity.	Carlsberg Lab, Dept Yeast Genet, DK-2500 Copenhagen, Denmark; Inst Mol Biol, Dept Prot Chem, DK-1353 Copenhagen K, Denmark; Univ So Denmark, Dept Biochem & Mol Biol, DK-5230 Odense M, Denmark	University of Southern Denmark	Winther, JR (corresponding author), Carlsberg Lab, Dept Yeast Genet, Gamle Carlsberg Vej 10, DK-2500 Copenhagen, Denmark.	jnv@crc.dk	Poulsen, Flemming M/E-6848-2010; Lindorff-Larsen, Kresten/K-6469-2014; Winther, Jakob R./K-4451-2014; Lerche, Mathilde Hauge/J-5487-2017	Lindorff-Larsen, Kresten/0000-0002-4750-6039; Winther, Jakob R./0000-0001-6995-9154; Lerche, Mathilde Hauge/0000-0002-5899-2781				Arondel V, 2000, PLANT SCI, V157, P1, DOI 10.1016/S0168-9452(00)00232-6; Avis TJ, 2001, APPL ENVIRON MICROB, V67, P956, DOI 10.1128/AEM.67.2.956-960.2001; BELL RP, 1941, ACID BASE CATALYSIS, P1; Benyagoub M, 1996, J CHEM ECOL, V22, P405, DOI 10.1007/BF02033644; BIZZOZERO OA, 1995, METHOD ENZYMOL, V250, P361; BODENHAUSEN G, 1980, CHEM PHYS LETT, V69, P185, DOI 10.1016/0009-2614(80)80041-8; BOTHNERBY AA, 1984, J AM CHEM SOC, V106, P811, DOI 10.1021/ja00315a069; BOX A, 1986, J AM CHEM SOC, V108, P2093; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; CHOUDHURY SR, 1994, J NAT PROD, V57, P700, DOI 10.1021/np50108a003; Douliez JP, 2000, BBA-BIOMEMBRANES, V1467, P65, DOI 10.1016/S0005-2736(00)00197-8; Douliez JP, 2000, J CEREAL SCI, V32, P1, DOI 10.1006/jcrs.2000.0315; Douliez JP, 2001, J AGR FOOD CHEM, V49, P1805, DOI 10.1021/jf001327m; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; DUNN MA, 1991, MOL GEN GENET, V229, P389, DOI 10.1007/BF00267460; Evans DE, 1999, J I BREWING, V105, P159; Han GW, 2001, J MOL BIOL, V308, P263, DOI 10.1006/jmbi.2001.4559; Heinemann B, 1996, PROTEIN SCI, V5, P13; Jegou S, 2000, J AGR FOOD CHEM, V48, P5023, DOI 10.1021/jf000075m; Kader JC, 1997, TRENDS PLANT SCI, V2, P66, DOI 10.1016/S1360-1385(97)82565-4; KADER JC, 1975, BIOCHIM BIOPHYS ACTA, V380, P31, DOI 10.1016/0005-2760(75)90042-9; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUMAR A, 1981, J AM CHEM SOC, V103, P3654, DOI 10.1021/ja00403a008; Kupce E, 2001, J MAGN RESON, V148, P115, DOI 10.1006/jmre.2000.2224; Lerche MH, 1997, STRUCTURE, V5, P291, DOI 10.1016/S0969-2126(97)00186-X; Lerche MH, 1998, PROTEIN SCI, V7, P2490, DOI 10.1002/pro.5560071202; LUSK LT, 1995, J AM SOC BREW CHEM, V53, P93; MOLINA A, 1993, FEBS LETT, V316, P119, DOI 10.1016/0014-5793(93)81198-9; MUNDY J, 1986, PLANTA, V169, P51, DOI 10.1007/BF01369775; Park SY, 2000, PLANT CELL, V12, P151, DOI 10.1105/tpc.12.1.151; PIANTINI U, 1982, J AM CHEM SOC, V104, P6800, DOI 10.1021/ja00388a062; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; Roepstorff P, 1997, CURR OPIN BIOTECH, V8, P6, DOI 10.1016/S0958-1669(97)80151-6; SATTLER W, 1991, ANAL BIOCHEM, V198, P184, DOI 10.1016/0003-2697(91)90526-Y; SHAPIRO S, 1996, ORAL MICROBIOL IMMUN, V5, P350; SORENSEN SB, 1993, MBAA TECH Q, V30, P136; STERK P, 1991, PLANT CELL, V3, P907, DOI 10.1105/tpc.3.9.907; SVENSSON B, 1986, CARLSBERG RES COMMUN, V51, P493, DOI 10.1007/BF02906891; TORRESSCHUMANN S, 1992, PLANT MOL BIOL, V18, P749, DOI 10.1007/BF00020016; Trevino MB, 1998, PLANT PHYSIOL, V116, P1461, DOI 10.1104/pp.116.4.1461; Van Loon LC, 1999, PHYSIOL MOL PLANT P, V55, P85, DOI 10.1006/pmpp.1999.0213; Wheelan P, 1996, J AM SOC MASS SPECTR, V7, P129, DOI 10.1016/1044-0305(95)00629-X; WHEELAN P, 1993, BIOL MASS SPECTROM, V22, P465, DOI 10.1002/bms.1200220808; Zachowski A, 1998, EUR J BIOCHEM, V257, P443, DOI 10.1046/j.1432-1327.1998.2570443.x; [No title captured]	45	36	39	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33547	33553		10.1074/jbc.M104841200	http://dx.doi.org/10.1074/jbc.M104841200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11435437	hybrid			2022-12-25	WOS:000170910200036
J	Liu, XF; Fernandez, M; Wouters, MA; Heyberger, S; Husain, A				Liu, XF; Fernandez, M; Wouters, MA; Heyberger, S; Husain, A			Arg(1098) is critical for the chloride dependence of human angiotensin I-converting enzyme C-domain catalytic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-AMYLASE; ACTIVATION; SPECIFICITIES; SUBSTRATE; CHYMASE; BINDING	Angiotensin (Ang) 1-converting enzyme (ACE) is a Zn2+ metalloprotease with two homologous catalytic domains. Both the N- and C-terminal domains are peptidyl dipeptidases. Hydrolysis by ACE of its decapeptide substrate Ang I is increased by Cl-, but the molecular mechanism of this regulation is unclear. A search for single substitutions to Gln among all conserved basic residues (Lys/Arg) in human ACE C-domain identified R1098Q as the sole: mutant that lacked Cl- dependence. Cl- dependence is also lost when the equivalent Arg in the N-domain, Arg(500), is substituted with Gln. The Arg(1098) to Lys substitution reduced Cl- binding affinity by similar to 100-fold. In the absence of Cl-, substrate binding affinity (1/K-m) of and catalytic, efficiency (k(cat)/K-m) for Ang I hydrolysis are increased 6.9- and 32-fold, respectively, by the Arg(1098) to Gln substitution, and are similar (<2-foId difference) to the respective wild-type C-domain catalytic constants in the presence of optimal [Cl-]. The Arg(1098) to Gln substitution also eliminates Cl- dependence for hydrolysis of tetrapeptide substrates, but activity toward these substrates is similar to that of the Wildtype C-domain in the absence of Cl-. These findings indicate that: 1) Arg(1098) is a critical residue of the C-domain Cl--binding site and 2) a basic side chain is necessary for Cl- dependence. For tetrapeptide substrates, the inability of R1098Q to recreate the high affinity state generated by the Cl-C-domain interaction suggests that substrate interactions with the enzyme-bound Cl- are much more important for the hydrolysis of short substrates than for Ang 1. Since Cl- concentrations are saturating under physiological conditions and Arg(1098) is not critical for Ang I hydrolysis, we speculate that the evolutionary pressure for the maintenance of the Cl--binding site is its ability to allow cleavage of short cognate peptide substrates at high catalytic efficiencies.	Victor Chang Cardiac Res Inst, Enzyme Res Unit, Sydney, NSW 2010, Australia; Univ New S Wales, Sch Biochem & Mol Genet, Sydney, NSW 2033, Australia	Victor Chang Cardiac Research Institute; University of New South Wales Sydney	Husain, A (corresponding author), Victor Chang Cardiac Res Inst, Enzyme Res Unit, 384 Victoria St, Sydney, NSW 2010, Australia.		Wouters, Merridee A/G-2481-2015; Wouters, Merridee/F-4310-2010; Wouters, Merridee/D-2046-2012; Husain, Ahsan/J-6861-2012	Wouters, Merridee A/0000-0002-2121-912X; Husain, Ahsan/0000-0003-3426-3469				BARRETT AJ, 1998, HDB PROTEOLYTIC ENZY, P992; BRAYER GD, 1995, PROTEIN SCI, V4, P1730, DOI 10.1002/pro.5560040908; BUNNING P, 1983, BIOCHEMISTRY-US, V22, P110, DOI 10.1021/bi00270a016; Chandrasekharan UM, 1996, SCIENCE, V271, P502, DOI 10.1126/science.271.5248.502; CORVOL P, 1998, HDB PROTEOLYTIC ENZY, P1066; CREIGHTON TE, 1984, PROTEINS STRUCTURAL, P2; Desiraju G.R., 1999, WEAK HYDROGEN BOND S, P246; Feller G, 1996, J BIOL CHEM, V271, P23836, DOI 10.1074/jbc.271.39.23836; Fernandez M, 2001, J BIOL CHEM, V276, P4998, DOI 10.1074/jbc.M009009200; HUBERT C, 1991, J BIOL CHEM, V266, P15377; JASPARD E, 1993, J BIOL CHEM, V268, P9496; KIM YA, 1992, J BIOL CHEM, V267, P12330; KREGE JH, 1995, NATURE, V375, P146, DOI 10.1038/375146a0; KUBY SA, 1991, STUDY ENZYMES ENZYME, V1, P299; Lamango NS, 1996, BIOCHEM J, V314, P639, DOI 10.1042/bj3140639; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sanker S, 1997, J BIOL CHEM, V272, P2963, DOI 10.1074/jbc.272.5.2963; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SHAPIRO R, 1983, BIOCHEMISTRY-US, V22, P5315, DOI 10.1021/bi00292a010; SHAPIRO R, 1983, BIOCHEMISTRY-US, V22, P3850, DOI 10.1021/bi00285a021; SOUBRIER F, 1988, P NATL ACAD SCI USA, V85, P9386, DOI 10.1073/pnas.85.24.9386; Sturrock ED, 1997, BIOCHEM BIOPH RES CO, V236, P16, DOI 10.1006/bbrc.1997.6841; WEI L, 1991, J BIOL CHEM, V266, P9002; WELLS JA, 1990, BIOCHEMISTRY-US, V29, P8509, DOI 10.1021/bi00489a001	24	49	56	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33518	33525		10.1074/jbc.M101495200	http://dx.doi.org/10.1074/jbc.M101495200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11432860	Green Published, hybrid			2022-12-25	WOS:000170910200032
J	Pessach, I; Leto, TL; Malech, HL; Levy, R				Pessach, I; Leto, TL; Malech, HL; Levy, R			Essential requirement of cytosolic phospholipase A(2) for stimulation of NADPH oxidase-associated diaphorase activity in granulocyte-like cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; SUPEROXIDE-GENERATING SYSTEM; GTP-GAMMA-S; HUMAN-NEUTROPHILS; CONFORMATIONAL-CHANGES; ACTIN POLYMERIZATION; SUBUNIT P47(PHOX); H+ CHANNEL; PERMEABILIZED NEUTROPHILS; INDEPENDENT ACTIVATION	We have previously established a model of cytosolic phospholipase A(2) (cPLA(2))-deficient differentiated PLB-985 cells (PLB-D cells) and demonstrated that cPLA(2)-generated arachidonic acid (AA) is essential for NADPH oxidase activation. In this study we used this model to investigate the physiological role of cPLA2 in regulation of NADPH oxidase-associated diaphorase activity. A novel diaphorase activity assay, using 4-iodonitrotetrazolium. violet as an electron acceptor, was used in permeabilized neutrophils and PLB-985 cells differentiated toward the granulocytic or monocytic phenotypes. Phorbol 12-myristate 13-acetate, guanosine 5'-3-O-(thio)triphosphate (GTP gammaS), or FMLP stimulated a similar diphenylene iodonium-sensitive diaphorase activity pattern in neutrophils and in differentiated parent PLB-985 cells. This diaphorase activity was not detected in undifferentiated cells, but developed during differentiation. Furthermore, diaphorase activity could not be stimulated in permeabilized neutrophils from X-linked CGD patients and in differentiated gp91(phox)-targeted PLB-985 cells that lacked normal expression of gp91(phox), but was restored to these cells following transduction with retrovirus encoding gp91(phox). The differentiated PLB-D cells showed no diaphorase activity when stimulated by either GTP gammaS or FMLP, and only partial activation when stimulated with phorbol 12-myristate 13-acetate. Diaphorase activity in response to either agonists was fully restored by the addition of 10 muM free AA. The permeabilized cell 4-iodonitrotetrazolium violet reduction assay offers a unique tool for the evaluation of NADPH oxidase-associated diaphorase activity in stimulated whole cells. These results establish an essential and specific physiological requirement of cPLA(2)-generated AA in activation of electron transfer through the FAD reduction center of NADPH oxidase.	Ben Gurion Univ Negev, Fac Hlth Sci, Dept Clin Biochem, Infect Dis Lab, IL-84105 Beer Sheva, Israel; Soroka Med Ctr, IL-84105 Beer Sheva, Israel; NIAID, Host Def Lab, NIH, Bethesda, MD 20892 USA	Ben Gurion University; Ben Gurion University; Soroka Medical Center; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Levy, R (corresponding author), Ben Gurion Univ Negev, Fac Hlth Sci, Dept Clin Biochem, Infect Dis Lab, IL-84105 Beer Sheva, Israel.			Malech, Harry/0000-0001-5874-5775	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000614, ZIAAI000614, ZIAAI000644, Z01AI000644] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; BRENNER S, 2001, MOL THER, V3, pS223; CROSS AR, 1985, BIOCHEM J, V226, P881, DOI 10.1042/bj2260881; CROSS AR, 1984, BIOCHEM J, V223, P337, DOI 10.1042/bj2230337; CROSS AR, 1982, BIOCHEM J, V204, P479, DOI 10.1042/bj2040479; CROSS AR, 1995, J BIOL CHEM, V270, P6543, DOI 10.1074/jbc.270.12.6543; CROSS AR, 1986, BIOCHEM J, V237, P111, DOI 10.1042/bj2370111; Cross AR, 1999, J BIOL CHEM, V274, P15519, DOI 10.1074/jbc.274.22.15519; CROSS AR, 1994, J BIOL CHEM, V269, P21448; Dana R, 1998, J BIOL CHEM, V273, P441, DOI 10.1074/jbc.273.1.441; Diebold BA, 2001, NAT IMMUNOL, V2, P211, DOI 10.1038/85259; DOUSSIERE J, 1991, BIOCHEM BIOPH RES CO, V175, P143, DOI 10.1016/S0006-291X(05)81212-4; DOUSSIERE J, 1992, EUR J BIOCHEM, V208, P61, DOI 10.1111/j.1432-1033.1992.tb17159.x; Doussiere J, 1999, BIOCHEMISTRY-US, V38, P3694, DOI 10.1021/bi9823481; ELLIS JA, 1988, BIOCHEM J, V251, P887, DOI 10.1042/bj2510887; ELLIS JA, 1989, BIOCHEM J, V262, P575, DOI 10.1042/bj2620575; ENGLISH D, 1974, J IMMUNOL METHODS, V5, P249, DOI 10.1016/0022-1759(74)90109-4; FUJII H, 1991, BIOCHIM BIOPHYS ACTA, V1095, P201, DOI 10.1016/0167-4889(91)90100-C; GREEN TR, 1990, J BIOL CHEM, V265, P19324; HANCOCK JT, 1987, BIOCHEM J, V242, P103, DOI 10.1042/bj2420103; Hata K, 1998, J BIOL CHEM, V273, P4232, DOI 10.1074/jbc.273.7.4232; HAZAV P, 1989, CANCER RES, V49, P72; HENDERSON LM, 1987, BIOCHEM J, V246, P325, DOI 10.1042/bj2460325; HENDERSON LM, 1988, BIOCHEM J, V251, P563, DOI 10.1042/bj2510563; Henderson LM, 1997, BIOCHEM J, V325, P701, DOI 10.1042/bj3250701; KAPUS A, 1992, BIOCHEM J, V281, P697, DOI 10.1042/bj2810697; Koga H, 1999, J BIOL CHEM, V274, P25051, DOI 10.1074/jbc.274.35.25051; Koshkin V, 1995, BBA-BIOENERGETICS, V1232, P225, DOI 10.1016/0005-2728(95)00123-9; KOSHKIN V, 1994, FEBS LETT, V338, P285, DOI 10.1016/0014-5793(94)80285-8; LAPORTE F, 1990, EUR J BIOCHEM, V194, P301, DOI 10.1111/j.1432-1033.1990.tb19457.x; Leto TL., 1999, INFLAMMATION BASIC P, P769; LEVY R, 1990, J IMMUNOL, V145, P2595; LI F, 1994, BLOOD, V84, P53, DOI 10.1182/blood.V84.1.53.bloodjournal84153; Li JR, 1997, BIOCHEMISTRY-US, V36, P5529, DOI 10.1021/bi963013r; Lowenthal A, 1999, J BIOL CHEM, V274, P21603, DOI 10.1074/jbc.274.31.21603; LU DJ, 1990, J BIOL CHEM, V265, P13721; MIKI T, 1992, J BIOL CHEM, V267, P18695; MUKHERJEE G, 1994, J LEUKOCYTE BIOL, V55, P685, DOI 10.1002/jlb.55.6.685; NANDA A, 1993, P NATL ACAD SCI USA, V90, P760, DOI 10.1073/pnas.90.2.760; NISIMOTO Y, 1990, BIOCHIM BIOPHYS ACTA, V1040, P260, DOI 10.1016/0167-4838(90)90085-T; ODONNELL VB, 1993, BIOCHEM J, V290, P41, DOI 10.1042/bj2900041; Park HS, 1998, BBA-PROTEIN STRUCT M, V1387, P406, DOI 10.1016/S0167-4838(98)00152-6; Park HS, 1999, BIOCHEM BIOPH RES CO, V259, P38, DOI 10.1006/bbrc.1999.0721; Park HS, 1998, ARCH BIOCHEM BIOPHYS, V360, P165, DOI 10.1006/abbi.1998.0938; REDMOND T, 1994, J BIOL CHEM, V269, P21657; RUBINEK T, 1993, BIOCHIM BIOPHYS ACTA, V1176, P51, DOI 10.1016/0167-4889(93)90176-P; SEGAL AW, 1993, TRENDS BIOCHEM SCI, V18, P43, DOI 10.1016/0968-0004(93)90051-N; TARDIF M, 1995, J BIOL CHEM, V270, P28075; Yu LX, 1999, BLOOD, V94, P2497, DOI 10.1182/blood.V94.7.2497.419k11_2497_2504; ZHEN L, 1993, P NATL ACAD SCI USA, V90, P9832, DOI 10.1073/pnas.90.21.9832; Zigmond SH, 1997, J CELL BIOL, V138, P363, DOI 10.1083/jcb.138.2.363	52	30	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33495	33503		10.1074/jbc.M011417200	http://dx.doi.org/10.1074/jbc.M011417200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11432850	hybrid			2022-12-25	WOS:000170910200029
J	Ryser, S; Tortola, S; van Haasteren, G; Muda, M; Li, SL; Schlegel, W				Ryser, S; Tortola, S; van Haasteren, G; Muda, M; Li, SL; Schlegel, W			MAP kinase phosphatase-1 gene transcription in rat neuroendocrine cells is modulated by a calcium-sensitive block to elongation in the first exon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; THYROTROPIN-RELEASING-HORMONE; FOS MESSENGER-RNA; C-FOS; PITUITARY-CELLS; CATALYTIC ACTIVATION; TYROSINE-PHOSPHATASE; EXPRESSION; INDUCTION; CA2+	Transcriptional elongation of many eukaryotic, prokaryotic, and viral genes is tightly controlled, which contributes to gene regulation. Here we describe this phenomenon for the MAP kinase phosphatase 1 (MKP-1) immediate early gene. In rat GH4C1 pituitary cells, MKP-1 mRNA is rapidly and transiently induced by the thyrotropin-releasing hormone (TRH) and the epidermal growth factor EGF via transcriptional activation of the gene. Ca2+ signals are necessary for the induction of MKP-1 in response to TRH but not to EGF. Reporter gene analysis with the newly cloned rat promoter sequence shows only limited induction in response to various stimuli, including TRH or EGF. By nuclear run-on assays we demonstrate that in basal conditions, a strong block to elongation in the first exon regulates the MKP-1 gene and that stimulation with either TRH or EGF overcomes the block. Ca2+ signals are important to release the MKP-1 elongation block in a manner similar to the c-fos oncogene. These results suggest that a common mechanism of intragenic regulation may be conserved between MKP-1 and c-fos in mammalian cells.	Univ Geneva, Fondat Rech Med, CH-1211 Geneva, Switzerland	University of Geneva	Schlegel, W (corresponding author), Univ Geneva, Fondat Rech Med, 64 Av Roseraie, CH-1211 Geneva, Switzerland.	werner.schlegel@medecine.unige.ch						BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BIRAGYN A, 1995, J IMMUNOL, V155, P674; BIUNNO I, 1988, BRIT J CANCER, V57, P464, DOI 10.1038/bjc.1988.108; Brondello JM, 1999, SCIENCE, V286, P2514, DOI 10.1126/science.286.5449.2514; Brown SA, 1996, GENE DEV, V10, P1479, DOI 10.1101/gad.10.12.1479; Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; CARR FE, 1993, ENDOCRINOLOGY, V133, P1700, DOI 10.1210/en.133.4.1700; Carrion AM, 1999, NATURE, V398, P80, DOI 10.1038/18044; CHARLES CH, 1992, ONCOGENE, V7, P187; COLLART MA, 1987, J IMMUNOL, V139, P949; COLLART MA, 1991, MOL CELL BIOL, V11, P2826, DOI 10.1128/MCB.11.5.2826; Coulon V, 1999, J BIOL CHEM, V274, P30439, DOI 10.1074/jbc.274.43.30439; Crabtree GR, 2001, J BIOL CHEM, V276, P2313, DOI 10.1074/jbc.R000024200; De Cesare D, 1999, TRENDS BIOCHEM SCI, V24, P281, DOI 10.1016/S0968-0004(99)01414-0; EICK D, 1994, ANAL BIOCHEM, V218, P347, DOI 10.1006/abio.1994.1190; FORT P, 1987, NUCLEIC ACIDS RES, V15, P5657, DOI 10.1093/nar/15.14.5657; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GOURDJI D, 1982, FRONT NEUROENDOCRIN, V7, P317; Guo YL, 1998, J BIOL CHEM, V273, P10362, DOI 10.1074/jbc.273.17.10362; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; Hutter D, 2000, BIOCHEM J, V352, P155, DOI 10.1042/0264-6021:3520155; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KWAK SP, 1994, J BIOL CHEM, V269, P3596; Laderoute KR, 1999, J BIOL CHEM, V274, P12890, DOI 10.1074/jbc.274.18.12890; Leav I, 1996, LAB INVEST, V75, P361; LEE G, 1994, MOL CELL BIOL, V14, P4579, DOI 10.1128/MCB.14.7.4579; Li SL, 1996, J MOL ENDOCRINOL, V16, P229, DOI 10.1677/jme.0.0160229; LI SL, 1994, J MOL ENDOCRINOL, V13, P303, DOI 10.1677/jme.0.0130303; Lim HW, 2001, J BIOL CHEM, V276, P15913, DOI 10.1074/jbc.M100452200; Loda M, 1996, AM J PATHOL, V149, P1553; Magi-Galluzzi C, 1998, VIRCHOWS ARCH, V432, P407, DOI 10.1007/s004280050184; MagiGalluzzi C, 1997, LAB INVEST, V76, P37; NOGUCHI T, 1993, MOL CELL BIOL, V13, P5195, DOI 10.1128/MCB.13.9.5195; PASSEGUE E, 1995, MOL CELL ENDOCRINOL, V107, P29, DOI 10.1016/0303-7207(94)03417-R; Pinaud S, 1998, J MOL BIOL, V280, P785, DOI 10.1006/jmbi.1998.1905; PLET A, 1995, ONCOGENE, V10, P319; SCHLEGEL W, 1987, NATURE, V329, P719, DOI 10.1038/329719a0; SCHLEGEL W, 1984, J CELL BIOL, V99, P83, DOI 10.1083/jcb.99.1.83; Scimeca JC, 1997, ONCOGENE, V15, P717, DOI 10.1038/sj.onc.1201231; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; Sommer A, 2000, FEBS LETT, V474, P146, DOI 10.1016/S0014-5793(00)01566-0; SPENCER CA, 1990, ONCOGENE, V5, P777; STROBL LJ, 1992, EMBO J, V11, P3307, DOI 10.1002/j.1460-2075.1992.tb05409.x; Susini S, 2000, FASEB J, V14, P128, DOI 10.1096/fasebj.14.1.128; Tashjian A H Jr, 1979, Methods Enzymol, V58, P527; Uptain SM, 1997, ANNU REV BIOCHEM, V66, P117, DOI 10.1146/annurev.biochem.66.1.117; URABE A, 1992, J PATHOL, V168, P281, DOI 10.1002/path.1711680307; van Haasteren G, 2000, NEUROENDOCRINOLOGY, V72, P368, DOI 10.1159/000054606; WALKER RA, 1991, J PATHOL, V163, P323, DOI 10.1002/path.1711630409; WERLEN G, 1993, J BIOL CHEM, V268, P16596	52	45	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33319	33327		10.1074/jbc.M102326200	http://dx.doi.org/10.1074/jbc.M102326200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11423551	hybrid			2022-12-25	WOS:000170910200007
J	van der Wel, H; Morris, HR; Panico, M; Paxton, T; North, SJ; Dell, A; Thomson, JM; West, CM				van der Wel, H; Morris, HR; Panico, M; Paxton, T; North, SJ; Dell, A; Thomson, JM; West, CM			A non-golgi alpha 1,2-fucosyltransferase that modifies Skp1 in the cytoplasm of Dictyostelium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFERASE; GENES; IDENTIFICATION; CLASSIFICATION; GLYCOSYLATION; BIOSYNTHESIS; PURIFICATION; EXPRESSION; PROTEINS; PATHWAY	Skp1 is a subunit of the SCF-E3 ubiquitin ligase that targets cell cycle and other regulatory factors for degradation. In Dictyostelium, Skp1 is modified by a pentasaccharide containing the type I blood group H trisaccharide at its core. To address how the third sugar, fucose alpha1,2-linked to galactose, is attached, a proteomics strategy was applied to determine the primary structure of FT85, previously shown to copurify with the GDPFuc:Skp1 alpha1,2-fucosyltransferase. Tryptic-generated peptides of FT85 were sequenced de novo using Q-TOF tandem mass spectrometry. Degenerate primers were used to amplify FT85 genomic. DNA, which was further extended by a novel linker polymerase chain reaction method to yield an intronless open reading frame of 768 amino acids. Disruption of the FT85 gene by homologous recombination resulted in viable cells, which had altered light scattering properties as revealed by flow cytometry. FT85 was necessary and sufficient for Skp1 fucosylation, based on biochemical analysis of FT85 mutant cells and Escherichia coli that express FT85 recombinantly. FT85 lacks sequence motifs that characterize all other known alpha1,2-fucosyltransferases and lacks the signal-anchor sequence that targets them to the secretory pathway. The C-terminal region of FT85 harbors motifs found in inverting Family 2 glycosyltransferase domains, and its expression in FT85 mutant cells restores fucosyltransferase activity toward a simple disaccharide substrate. Whereas most prokaryote and eukaryote Family 2 glycosyltransferases are membrane-bound and oriented toward the cytoplasm where they glycosylate lipid-linked or polysaccharide precursors prior to membrane translocation, the soluble, eukaryotic Skp1-fucosyltransferase modifies a protein that resides in the cytoplasm and nucleus.	Univ Florida, Coll Med, Dept Anat & Cell Biol, Gainesville, FL 32610 USA; Univ London Imperial Coll Sci Technol & Med, Dept Biochem, London SW7 2AY, England	State University System of Florida; University of Florida; Imperial College London	West, CM (corresponding author), Univ Florida, Coll Med, Dept Anat & Cell Biol, 1600 SW Archer Rd,Rm B1-3, Gainesville, FL 32610 USA.	westcm@college.med.ufl.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037539] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-37539] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALONSO MD, 1995, FASEB J, V9, P1126, DOI 10.1096/fasebj.9.12.7672505; Breton C, 1998, J BIOCHEM, V123, P1000; Burda P, 1999, BBA-GEN SUBJECTS, V1426, P239, DOI 10.1016/S0304-4165(98)00127-5; Campbell JA, 1997, BIOCHEM J, V326, P929, DOI 10.1042/bj3260929u; Charnock SJ, 1999, BIOCHEMISTRY-US, V38, P6380, DOI 10.1021/bi990270y; Chong SR, 1997, GENE, V192, P271, DOI 10.1016/S0378-1119(97)00105-4; Comer FI, 2000, J BIOL CHEM, V275, P29179, DOI 10.1074/jbc.R000010200; Delmer DP, 1999, ANNU REV PLANT PHYS, V50, P245, DOI 10.1146/annurev.arplant.50.1.245; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Freed E, 1999, GENE DEV, V13, P2242, DOI 10.1101/gad.13.17.2242; Garinot-Schneider C, 2000, J BIOL CHEM, V275, P31407, DOI 10.1074/jbc.M004524200; GONZALEZYANES B, 1992, J BIOL CHEM, V267, P9595; GONZALEZYANES B, 1989, DEV BIOL, V133, P576, DOI 10.1016/0012-1606(89)90060-2; Gstaiger M, 1999, EXP CELL RES, V247, P554, DOI 10.1006/excr.1999.4386; Jing W, 2000, GLYCOBIOLOGY, V10, P883, DOI 10.1093/glycob/10.9.883; Kapitonov D, 1999, GLYCOBIOLOGY, V9, P961, DOI 10.1093/glycob/9.10.961; KOZAROV E, 1995, J BIOL CHEM, V270, P3022, DOI 10.1074/jbc.270.7.3022; Kreil DP, 2000, TRENDS BIOCHEM SCI, V25, P270, DOI 10.1016/S0968-0004(00)01594-2; Linton D, 2000, MOL MICROBIOL, V37, P501, DOI 10.1046/j.1365-2958.2000.02020.x; Marks DL, 1999, J BIOL CHEM, V274, P451, DOI 10.1074/jbc.274.1.451; Morris HR, 1996, RAPID COMMUN MASS SP, V10, P889, DOI 10.1002/(SICI)1097-0231(19960610)10:8<889::AID-RCM615>3.0.CO;2-F; Morris HR, 1997, J PROTEIN CHEM, V16, P469, DOI 10.1023/A:1026309410737; MORRIS HR, 1998, MASS SPECTROMETRY BI, V2, P53; NELLEN W, 1987, METHOD CELL BIOL, V28, P67; Oriol R, 1999, GLYCOBIOLOGY, V9, P323, DOI 10.1093/glycob/9.4.323; Pang KM, 1999, PLASMID, V41, P187, DOI 10.1006/plas.1999.1391; Puta F, 1998, FOLIA BIOL-PRAGUE, V44, P185; Roux Kenneth H., 1995, P53; SALZMAN GC, 1975, ACTA CYTOL, V19, P374; Sassi S, 2001, GLYCOBIOLOGY, V11, P283, DOI 10.1093/glycob/11.4.283; SATIR BH, 1990, J CELL BIOL, V111, P901, DOI 10.1083/jcb.111.3.901; SAXENA IM, 1995, J BACTERIOL, V177, P1419, DOI 10.1128/jb.177.6.1419-1424.1995; Schulman BA, 2000, NATURE, V408, P381, DOI 10.1038/35042620; Seol JH, 2001, NAT CELL BIOL, V3, P384, DOI 10.1038/35070067; SIEBERT PD, 1995, NUCLEIC ACIDS RES, V23, P1087, DOI 10.1093/nar/23.6.1087; STEEL LF, 1991, DEV GENET, V12, P98, DOI 10.1002/dvg.1020120117; Teng-umnuay P, 1998, J BIOL CHEM, V273, P18242, DOI 10.1074/jbc.273.29.18242; Teng-umnuay P, 1999, J BIOL CHEM, V274, P36392, DOI 10.1074/jbc.274.51.36392; Tiede A, 1999, BIOL CHEM, V380, P503, DOI 10.1515/BC.1999.066; Trinchera M, 1996, FEBS LETT, V395, P68, DOI 10.1016/0014-5793(96)01003-4; Unligil UM, 2000, CURR OPIN STRUC BIOL, V10, P510, DOI 10.1016/S0959-440X(00)00124-X; WANG IN, 1993, P NATL ACAD SCI USA, V90, P3840, DOI 10.1073/pnas.90.9.3840; Weigel PH, 1997, J BIOL CHEM, V272, P13997, DOI 10.1074/jbc.272.22.13997; West CM, 1996, J BIOL CHEM, V271, P12024, DOI 10.1074/jbc.271.20.12024; Whitfield C, 1999, MOL MICROBIOL, V31, P1307, DOI 10.1046/j.1365-2958.1999.01276.x; Yamasaki S, 1999, GENE, V237, P321, DOI 10.1016/S0378-1119(99)00344-3; Zhang YY, 1999, J CELL SCI, V112, P4367	47	34	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33952	33963		10.1074/jbc.M102555200	http://dx.doi.org/10.1074/jbc.M102555200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11423539	hybrid			2022-12-25	WOS:000170910200090
J	Pan, L; Xie, YH; Black, TA; Jones, CA; Pruitt, SC; Gross, KW				Pan, L; Xie, YH; Black, TA; Jones, CA; Pruitt, SC; Gross, KW			An Abd-B class HOX center dot PBX recognition sequence is required for expression from the mouse Ren-1(c) gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RENIN-ANGIOTENSIN-SYSTEM; COOPERATIVE DNA-BINDING; SEGMENTAL EXPRESSION; NUCLEAR IMPORT; MURINE REN-1; PROTEINS; SPECIFICITY; EXTRADENTICLE; COMPLEXES; ENHANCER	Expression from the mouse Ren-1(c) gene in As4.1 cells is dependent on a proximal promoter element (PPE) located at approximately -60 and a 241-base pair enhancer region located at -2625 relative to the transcription start site. The PPE (TAATAAATCAA) is identical to a consensus HOX-PBX binding sequence. Further, PBX1b has been shown to be a component of a PPE-specific binding complex present in nuclear extracts from As4.1 cells. The binding affinities of different paralog HOX members to the PPE were examined in the absence or presence of PBX1b. HOXB6, -B7, and -C8 failed to bind the PPE alone but showed weak affinity in the presence of PBX1b. In contrast, HOXD10 and to a lesser degree HOXB9 bound the PPE with high affinities regardless of whether PBX1b was present. Abd-B HOX members, including HOXD10, -A10, -A9, -B9, and -C9, are expressed in As4.1 cells. The ability of HOX and PBX1b to form a ternary complex with PREP1 on the PPE is also demonstrated both in vivo and in vitro. Point mutations in either the HOX or PBX half-site of the PPE disrupted the formation of the HOX-PBX complex and dramatically decreased transcriptional activity of the Ren-1(c) gene demonstrating that both the HOX and PBX half-sites are critical for mouse renin gene expression. These results strongly implicate Abd-B class Hox genes and their cofactors as major determinants of the sites of renin expression.	Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Gross, KW (corresponding author), Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Elm & Carlton St, Buffalo, NY 14263 USA.	gross@acsu.buffalo.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD036416] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA016056] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048459] Funding Source: NIH RePORTER; NCI NIH HHS [CA16056] Funding Source: Medline; NHLBI NIH HHS [HL48459] Funding Source: Medline; NICHD NIH HHS [HD36416] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ABEL KJ, 1990, GENETICS, V124, P937; ABEL KJ, 1988, NUCLEIC ACIDS RES, V16, P2111, DOI 10.1093/nar/16.5.2111; Abu-Shaar M, 1999, GENE DEV, V13, P935, DOI 10.1101/gad.13.8.935; Berthelsen J, 1998, EMBO J, V17, P1434, DOI 10.1093/emboj/17.5.1434; Berthelsen J, 1999, GENE DEV, V13, P946, DOI 10.1101/gad.13.8.946; Botas J, 1993, CURR OPIN CELL BIOL, V5, P1015, DOI 10.1016/0955-0674(93)90086-6; CHANG CP, 1995, GENE DEV, V9, P663, DOI 10.1101/gad.9.6.663; Chang CP, 1996, MOL CELL BIOL, V16, P1734; Chen J, 1998, J BIOL CHEM, V273, P24670, DOI 10.1074/jbc.273.38.24670; de Gasparo M, 2000, PHARMACOL REV, V52, P415; FABIAN JR, 1989, J BIOL CHEM, V264, P17589; Ferretti E, 2000, DEVELOPMENT, V127, P155; Gomez RA, 1998, KIDNEY INT, V54, pS12, DOI 10.1046/j.1523-1755.1998.06703.x; Grieder NC, 1997, EMBO J, V16, P7402, DOI 10.1093/emboj/16.24.7402; GRIENDLING KK, 1993, CIRCULATION, V87, P1816, DOI 10.1161/01.CIR.87.6.1816; Jacobs Y, 1999, MOL CELL BIOL, V19, P5134, DOI 10.1128/mcb.19.7.5134; Jones CA, 1997, EUR J BIOCHEM, V243, P181, DOI 10.1111/j.1432-1033.1997.0181a.x; JONES CA, 1990, MOL ENDOCRINOL, V4, P375, DOI 10.1210/mend-4-3-375; Li XL, 1999, DEVELOPMENT, V126, P5581; Lu Q, 1996, MOL CELL BIOL, V16, P1632; LU QA, 1995, MOL CELL BIOL, V15, P3786; MARTIN KJ, 1990, NATURE, V346, P147, DOI 10.1038/346147a0; Neuteboom STC, 1997, MOL CELL BIOL, V17, P4696, DOI 10.1128/MCB.17.8.4696; Nishimura H, 1999, INTERNAL MED, V38, P315, DOI 10.2169/internalmedicine.38.315; Passner JM, 1999, NATURE, V397, P714, DOI 10.1038/17833; Penkov D, 2000, J BIOL CHEM, V275, P16681, DOI 10.1074/jbc.M909345199; Petrovic N, 1996, J BIOL CHEM, V271, P22499, DOI 10.1074/jbc.271.37.22499; Phelan ML, 1997, J BIOL CHEM, V272, P8635, DOI 10.1074/jbc.272.13.8635; Piper DE, 1999, CELL, V96, P587, DOI 10.1016/S0092-8674(00)80662-5; POPPERL H, 1995, CELL, V81, P1031, DOI 10.1016/S0092-8674(05)80008-X; Rieckhof GE, 1997, CELL, V91, P171, DOI 10.1016/S0092-8674(00)80400-6; Ryoo HD, 1999, GENE DEV, V13, P1704, DOI 10.1101/gad.13.13.1704; Ryoo HD, 1999, DEVELOPMENT, V126, P5137; Saleh M, 2000, MOL CELL BIOL, V20, P8623, DOI 10.1128/MCB.20.22.8623-8633.2000; Schutz S, 1996, AM J PATHOL, V149, P2067; SCOTT MP, 1993, NUCLEIC ACIDS RES, V21, P1687, DOI 10.1093/nar/21.8.1687; Shanmugam K, 1999, MOL CELL BIOL, V19, P7577; Shen WF, 1999, MOL CELL BIOL, V19, P3051; Shen WF, 1997, J BIOL CHEM, V272, P8198, DOI 10.1074/jbc.272.13.8198; Shen WF, 1997, MOL CELL BIOL, V17, P6448, DOI 10.1128/MCB.17.11.6448; SIGMUND CD, 1991, HYPERTENSION, V18, P446, DOI 10.1161/01.HYP.18.4.446; SIGMUND CD, 1990, J BIOL CHEM, V265, P19916; SUN JD, 1993, J BIOL CHEM, V268, P1505; White RAH, 2000, MECH DEVELOP, V91, P217, DOI 10.1016/S0925-4773(99)00306-8; WILSON JX, 1984, ENDOCR REV, V5, P45, DOI 10.1210/edrv-5-1-45; Wintour EM, 1997, TRENDS ENDOCRIN MET, V8, P199	46	48	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					32489	32494		10.1074/jbc.M011541200	http://dx.doi.org/10.1074/jbc.M011541200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11432851	hybrid			2022-12-25	WOS:000170746000017
J	Winkler, GS; Petrakis, TG; Ethelberg, S; Tokunaga, M; Erdjument-Bromage, H; Tempst, P; Svejstrup, JQ				Winkler, GS; Petrakis, TG; Ethelberg, S; Tokunaga, M; Erdjument-Bromage, H; Tempst, P; Svejstrup, JQ			RNA polymerase II elongator holoenzyme is composed of two discrete subcomplexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; TRANSCRIPTIONAL REGULATION; HISTONE ACETYLTRANSFERASE; PROTEIN; MEDIATOR; YEAST; SENSITIVITY; COMPLEXES; SUBUNIT; ROLES	Elongator is a histone acetyltransferase complex that associates with the elongating form of RNA polymerase IL We purified Elongator to virtual homogeneity via a rapid three-step procedure based largely on affinity chromatography. The purified factor, holo-Elongator, is a labile six-subunit factor composed of two discrete subcomplexes: one comprised of the previously identified Elp1, Elp2, and Elp3 proteins and another comprised of three novel polypeptides, termed Elp4, Elp5, and Elp6. Disruption of the yeast genes encoding the new Elongator proteins confers phenotypes indistinguishable from those previously described for the other elp mutants, and concomitant disruption of genes encoding proteins in either subcomplex does not confer new phenotypes. Taken together, our results indicate that holo-Elongator is a functional entity in vitro as well as in vivo. Metazoan homologues of Elp1 and Elp3 have previously been reported. We cloned the human homologue of yeast ELP4 and show that this gene is ubiquitously expressed in human tissues.	Imperial Canc Res Fund, Clare Hall Labs, Mechanisms Gene Transcript Lab, S Mimms EN6 3LD, Herts, England; Kagoshima Univ, Fac Agr, Kagoshima 8900065, Japan; Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA	Kagoshima University; Memorial Sloan Kettering Cancer Center	Svejstrup, JQ (corresponding author), Imperial Canc Res Fund, Clare Hall Labs, Mechanisms Gene Transcript Lab, Blanche Lane, S Mimms EN6 3LD, Herts, England.			Tempst, Paul/0000-0002-6680-3987; Svejstrup, Jesper/0000-0003-4964-6147; Erdjument-Bromage, Hediye/0000-0003-0224-3594; Winkler, Sebastiaan/0000-0002-0476-162X; Ethelberg, Steen/0000-0002-9709-356X	NCI NIH HHS [P30 CA08748] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Cairns BR, 1998, MOL CELL, V2, P639, DOI 10.1016/S1097-2765(00)80162-8; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; Erdjument-Bromage H, 1998, J CHROMATOGR A, V826, P167, DOI 10.1016/S0021-9673(98)00705-5; Fellows J, 2000, J BIOL CHEM, V275, P12896, DOI 10.1074/jbc.275.17.12896; Frohloff F, 2001, EMBO J, V20, P1993, DOI 10.1093/emboj/20.8.1993; Geromanos S, 2000, ANAL CHEM, V72, P777, DOI 10.1021/ac991071n; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; JONES EW, 1977, GENETICS, V85, P23; Lui M, 1996, ANAL BIOCHEM, V241, P156, DOI 10.1006/abio.1996.0393; Malik S, 2000, TRENDS BIOCHEM SCI, V25, P277, DOI 10.1016/S0968-0004(00)01596-6; MANN M, 1993, BIOL MASS SPECTROM, V22, P338, DOI 10.1002/bms.1200220605; Miles C, 1998, P NATL ACAD SCI USA, V95, P13068, DOI 10.1073/pnas.95.22.13068; Myers LC, 2000, ANNU REV BIOCHEM, V69, P729, DOI 10.1146/annurev.biochem.69.1.729; Otero G, 1999, MOL CELL, V3, P109, DOI 10.1016/S1097-2765(00)80179-3; SIKORSKI RS, 1989, GENETICS, V122, P19; Svejstrup JQ, 1997, P NATL ACAD SCI USA, V94, P6075, DOI 10.1073/pnas.94.12.6075; Svejstrup JQ, 1996, TRENDS BIOCHEM SCI, V21, P346, DOI 10.1016/0968-0004(96)10046-3; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TOKUNAGA M, 1989, NUCLEIC ACIDS RES, V17, P3435, DOI 10.1093/nar/17.9.3435; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; USHEVA A, 1992, CELL, V69, P871, DOI 10.1016/0092-8674(92)90297-P; Wittschieben BO, 2000, EMBO J, V19, P3060, DOI 10.1093/emboj/19.12.3060; Wittschieben BO, 1999, MOL CELL, V4, P123, DOI 10.1016/S1097-2765(00)80194-X; Yajima H, 1997, BIOSCI BIOTECH BIOCH, V61, P704, DOI 10.1271/bbb.61.704; Yudkovsky N, 2000, NATURE, V408, P225, DOI 10.1038/35041603	26	136	149	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					32743	32749		10.1074/jbc.M105303200	http://dx.doi.org/10.1074/jbc.M105303200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11435442	hybrid			2022-12-25	WOS:000170746000050
J	Beall, MJ; Pearce, EJ				Beall, MJ; Pearce, EJ			Human transforming growth factor-beta activates a receptor serine/threonine kinase from the intravascular parasite Schistosoma mansoni	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I RECEPTOR; SIGNAL-TRANSDUCTION; LARVAL DEVELOPMENT; SMAD PROTEINS; SCID MICE; ACTIVIN; PHOSPHORYLATION; IDENTIFICATION; SPECIFICITY; COMPLEXES	The biology of the helminth parasite Schistosoma mansoni is closely integrated with that of its mammalian host. SmRK1, a divergent type I transforming growth factor-beta (TGF-beta) receptor of unknown ligand specificity, was previously identified as a candidate for a receptor that allows schistosomes to respond to host-derived growth factors. The TGF-beta family includes activin, bone morphogenetic proteins (BMPs), and TGF-beta, all of which can play crucial roles in metazoan development. The downstream signaling protein of receptors that respond to TGF-beta and activin is Smad2, whereas the receptors that respond to BMPs signal via Smad1. When a constitutively active mutant of SmRK1 was overexpressed with either schistosome Smad1 (SmSmad1) or SmSmad2, a receptor-dependent modulation of SmSmad phosphorylation and luciferase reporter activity occurred only with SmSmad2. To evaluate potential ligand activators of SmRK1, a chimeric receptor containing the extracellular domain of SmRK1 joined to the intracellular. lar domain of the human type I TGF-beta receptor was used. The chimeric receptor bound radiolabeled TGF-beta and could activate a luciferase reporter gene in response to both TGF-beta1 and TGF-beta3 but not BMP7. Confirmatory results were obtained using full-length SmRK1. These experiments implicate TGF-beta as a ligand for SmRK1 and as a potential host-derived regulator of parasite growth and development.	Cornell Univ, Coll Vet Med, Dept Microbiol & Immunol, Ithaca, NY 14853 USA	Cornell University	Pearce, EJ (corresponding author), Cornell Univ, Coll Vet Med, Dept Microbiol & Immunol, Ithaca, NY 14853 USA.				NIAID NIH HHS [AI30985, F32-AI10513] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R03AI030985, F32AI010513] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMIRI P, 1992, NATURE, V356, P604, DOI 10.1038/356604a0; ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; Basch P, 1991, SCHISTOSOMES DEV REP; Beall MJ, 2000, MOL BIOCHEM PARASIT, V111, P131, DOI 10.1016/S0166-6851(00)00307-8; Brummel T, 1999, GENE DEV, V13, P98, DOI 10.1101/gad.13.1.98; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; Cheever AW, 1999, INFECT IMMUN, V67, P2201, DOI 10.1128/IAI.67.5.2201-2208.1999; Chen YG, 1998, GENE DEV, V12, P2144, DOI 10.1101/gad.12.14.2144; Chitsulo L, 2000, ACTA TROP, V77, P41, DOI 10.1016/S0001-706X(00)00122-4; Das P, 1999, GENES CELLS, V4, P123, DOI 10.1046/j.1365-2443.1999.00244.x; Davies SJ, 1998, J BIOL CHEM, V273, P11234, DOI 10.1074/jbc.273.18.11234; Derynck R, 1997, BIOCHIM BIOPHYS ACTA, V1333, P105; Feng XH, 1997, EMBO J, V16, P3912, DOI 10.1093/emboj/16.13.3912; GomezEscobar N, 1997, GENE, V199, P101, DOI 10.1016/S0378-1119(97)00353-3; Gunther CV, 2000, DEVELOPMENT, V127, P3337; Kawabata M, 1999, J BIOCHEM, V125, P9, DOI 10.1093/oxfordjournals.jbchem.a022273; Kusanagi K, 2000, MOL BIOL CELL, V11, P555, DOI 10.1091/mbc.11.2.555; Lo RS, 1998, EMBO J, V17, P996, DOI 10.1093/emboj/17.4.996; Lux A, 1999, J BIOL CHEM, V274, P9984, DOI 10.1074/jbc.274.15.9984; Macias-Silva M, 1998, J BIOL CHEM, V273, P25628, DOI 10.1074/jbc.273.40.25628; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; McGonigle S, 2001, MOL BIOCHEM PARASIT, V114, P119, DOI 10.1016/S0166-6851(01)00232-8; McGonigle S, 2001, FEBS LETT, V490, P65, DOI 10.1016/S0014-5793(01)02133-0; Mehra A, 2000, METH MOL B, V142, P67; Nakao A, 1997, J BIOL CHEM, V272, P2896, DOI 10.1074/jbc.272.5.2896; NOHNO T, 1995, J BIOL CHEM, V270, P22522, DOI 10.1074/jbc.270.38.22522; Osman A, 2001, J BIOL CHEM, V276, P10072, DOI 10.1074/jbc.M005933200; Pearce E. J., 1994, Parasitic infections and the immune system., P203; Persson U, 1997, J BIOL CHEM, V272, P21187, DOI 10.1074/jbc.272.34.21187; VIVIEN D, 1995, J BIOL CHEM, V270, P7134, DOI 10.1074/jbc.270.13.7134; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1	35	58	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					31613	31619		10.1074/jbc.M104685200	http://dx.doi.org/10.1074/jbc.M104685200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11406634	hybrid			2022-12-25	WOS:000170613500021
J	De la Cruz, EM; Ostap, EM; Sweeney, HL				De la Cruz, EM; Ostap, EM; Sweeney, HL			Kinetic mechanism and regulation of myosin VI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED ATP HYDROLYSIS; UNCONVENTIONAL MYOSIN; F-ACTIN; PHOSPHORYLATION; KINESIN; MOTOR; HEAD; BINDING; DOMAIN; KINASE	Myosin VI is the only pointed end-directed myosin identified and is likely regulated by heavy chain phosphorylation (HCP) at the actin-binding site in vivo. We undertook a detailed kinetic analysis of the actomyosin VI ATPase cycle to determine whether there are unique adaptations to support reverse directionality and to determine the molecular basis of regulation by HCP. ADP release is the rate-limiting step in the cycle. ATP binds slowly and with low affinity. At physiological nucleotide concentrations, myosin VI is strongly bound to actin and populates the nucleotide-free (rigor) and ADP-bound states. Therefore, myosin VI is a high duty ratio motor adapted for maintaining tension and has potential to be processive. A mutant mimicking HCP increases the rate of P-i release, which lowers the K-ATPase, but does not affect ADP release. These measurements are the first to directly measure the steps regulated by HCP for any myosin. Measurements with double-headed myosin VI demonstrate that the heads are not independent, and the native dimer hydrolyzes multiple ATPs per diffusional encounter with an actin filament. We propose an alternating site model for the stepping and processivity of two-headed high duty ratio myosins.	Univ Penn, Sch Med, Dept Physiol, Penn Muscle Inst, Philadelphia, PA 19104 USA	University of Pennsylvania	Sweeney, HL (corresponding author), Univ Penn, Sch Med, Dept Physiol, Penn Muscle Inst, A700 Richards Bldg,3700 Hamilton Walk, Philadelphia, PA 19104 USA.		Sweeney, H Lee/F-1862-2010		NIAMS NIH HHS [AR35661] Funding Source: Medline; NIGMS NIH HHS [GM57247, R01 GM057247] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035661] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM057247, R01GM057247] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBANESI JP, 1983, J BIOL CHEM, V258, P176; AVRAHAM KB, 1995, NAT GENET, V11, P369, DOI 10.1038/ng1295-369; BEMENT WM, 1995, CELL MOTIL CYTOSKEL, V31, P87, DOI 10.1002/cm.970310202; Brzeska H, 1996, J BIOL CHEM, V271, P27056, DOI 10.1074/jbc.271.43.27056; Buss F, 1998, J CELL BIOL, V143, P1535, DOI 10.1083/jcb.143.6.1535; Coluccio LR, 1999, J BIOL CHEM, V274, P21575, DOI 10.1074/jbc.274.31.21575; DANTZIG JA, 1992, J PHYSIOL-LONDON, V451, P247, DOI 10.1113/jphysiol.1992.sp019163; De la Cruz EM, 2000, BIOCHEMISTRY-US, V39, P14196, DOI 10.1021/bi001701b; De la Cruz EM, 2000, BIOPHYS J, V79, P1524, DOI 10.1016/S0006-3495(00)76403-4; De La Cruz EM, 1999, P NATL ACAD SCI USA, V96, P13726, DOI 10.1073/pnas.96.24.13726; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; Geeves MA, 2000, J BIOL CHEM, V275, P21624, DOI 10.1074/jbc.M000342200; HACKNEY DD, 1994, P NATL ACAD SCI USA, V91, P6865, DOI 10.1073/pnas.91.15.6865; HACKNEY DD, 1995, NATURE, V377, P448, DOI 10.1038/377448a0; HASSON T, 1994, J CELL BIOL, V127, P425, DOI 10.1083/jcb.127.2.425; HIRATSUKA T, 1983, BIOCHIM BIOPHYS ACTA, V742, P496, DOI 10.1016/0167-4838(83)90267-4; HOUK TW, 1974, ANAL BIOCHEM, V62, P66, DOI 10.1016/0003-2697(74)90367-4; Kelleher JF, 2000, CURR BIOL, V10, P1489, DOI 10.1016/S0960-9822(00)00828-9; Mehta A, 2001, J CELL SCI, V114, P1981; Mehta AD, 1999, NATURE, V400, P590, DOI 10.1038/23072; MERMALL V, 1994, NATURE, V369, P560, DOI 10.1038/369560a0; Ostap EM, 1996, J CELL BIOL, V132, P1053, DOI 10.1083/jcb.132.6.1053; Rief M, 2000, P NATL ACAD SCI USA, V97, P9482, DOI 10.1073/pnas.97.17.9482; ROTH K, 1991, MAGNET RESON MED, V22, P505, DOI 10.1002/mrm.1910220258; Sakamoto T, 2000, BIOCHEM BIOPH RES CO, V272, P586, DOI 10.1006/bbrc.2000.2819; TAYLOR EW, 1991, J BIOL CHEM, V266, P294; Trybus KM, 1997, P NATL ACAD SCI USA, V94, P48, DOI 10.1073/pnas.94.1.48; Vale RD, 2000, SCIENCE, V288, P88, DOI 10.1126/science.288.5463.88; Walker ML, 2000, NATURE, V405, P804, DOI 10.1038/35015592; Wang ZY, 1998, P NATL ACAD SCI USA, V95, P15200, DOI 10.1073/pnas.95.26.15200; Wells AL, 1999, NATURE, V401, P505, DOI 10.1038/46835; White HD, 1997, BIOCHEMISTRY-US, V36, P11828, DOI 10.1021/bi970540h; Wu CL, 1996, J BIOL CHEM, V271, P31787, DOI 10.1074/jbc.271.50.31787; Xing J, 2000, J BIOL CHEM, V275, P35413, DOI 10.1074/jbc.M004232200; Yengo CM, 2000, J BIOL CHEM, V275, P25481, DOI 10.1074/jbc.M002910200; YOUNT RG, 1995, BIOPHYS J, V68, pS44	36	190	191	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					32373	32381		10.1074/jbc.M104136200	http://dx.doi.org/10.1074/jbc.M104136200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11423557	hybrid			2022-12-25	WOS:000170613500120
J	Demarchi, F; Verardo, R; Varnum, B; Brancolini, C; Schneider, C				Demarchi, F; Verardo, R; Varnum, B; Brancolini, C; Schneider, C			Gas6 anti-apoptotic signaling requires NF-kappa B activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE RECEPTOR; SURVIVAL ACTIVITIES; CELL-SURVIVAL; GROWTH-FACTOR; PC12 CELLS; EXPRESSION; INDUCTION; PROTEIN; FIBROBLASTS; INSULIN	The growth arrest-specific 6 gene product Gas6 is a growth and survival factor related to protein S. Gas6 is the ligand of AxI receptor tyrosine kinase; upon binding to its receptor Gas6 activates the phosphatidylinositol 3-OH kinase (PI3K) and its downstream targets S6K and Akt. Gas6 anti-apoptotic signaling was previously shown to require functional PI3K and Akt and to involve Bad phosphorylation in serum-starved NIH 3T3 cells. Here we demonstrate that Gas6 induces a rapid and transient increase in nuclear NF-kappaB binding activity coupled to transcription activation from NF-kappaB-responsive promoters and increase in Bcl-x(L) protein level. Gas6 survival function is impaired in cells lacking p65/RelA and in NIH 3T3 cells transfected with a dominant negative I kappaB, indicating that NF-kappaB activation plays a central role in promoting survival in this system. Moreover, NF-kappaB activation can be blocked by a dominant negative Akt and by wortmannin, an inhibitor of PI3K, thus suggesting that NF-kappaB activation is a downstream event with respect to PI3K and Akt, as already described for other growth factors. In addition, we show that glycogen synthase kinase 3, which is phosphorylated in response to Gas6, can physically associate with NFKB1/p105 in living cells and can phosphorylate it in vitro. Furthermore, Gas6 treatment is coupled to a decrease in p105 protein level. Altogether these data suggest the involvement of NF-kappaB and glycogen synthase kinase 3 in Gas6 anti-apoptotic signaling and unveil a possible link between these survival pathways.	Lab Nazl Consorzio Interuniv Biotechnol, I-34012 Trieste, Italy; Univ Udine, Dipartimento Sci & Tecnol Biomed, I-33100 Udine, Italy; Amgen Inc, Thousand Oaks, CA 91320 USA	Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); University of Udine; Amgen	Schneider, C (corresponding author), Lab Nazl Consorzio Interuniv Biotechnol, AREA Sci Pk,Padriciano 99, I-34012 Trieste, Italy.			BRANCOLINI, Claudio/0000-0002-6597-5373; Demarchi, Francesca/0000-0003-1565-3162				Angelillo-Scherrer A, 2001, NAT MED, V7, P215, DOI 10.1038/84667; BALDWIN AS, 1991, MOL CELL BIOL, V11, P4943, DOI 10.1128/MCB.11.10.4943; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Bellosta P, 1997, ONCOGENE, V15, P2387, DOI 10.1038/sj.onc.1201419; Bertrand F, 1998, J BIOL CHEM, V273, P2931, DOI 10.1074/jbc.273.5.2931; Bittner M, 2000, NATURE, V406, P536, DOI 10.1038/35020115; Bournat JC, 2000, J NEUROSCI RES, V61, P21, DOI 10.1002/1097-4547(20000701)61:1<21::AID-JNR3>3.0.CO;2-7; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; Chen WS, 1999, INT J CANCER, V83, P579, DOI 10.1002/(SICI)1097-0215(19991126)83:5<579::AID-IJC1>3.0.CO;2-R; CRAVEN RJ, 1995, INT J CANCER, V60, P791, DOI 10.1002/ijc.2910600611; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Demarchi F, 1996, J VIROL, V70, P4427, DOI 10.1128/JVI.70.7.4427-4437.1996; Dormady SP, 2000, P NATL ACAD SCI USA, V97, P12260, DOI 10.1073/pnas.97.22.12260; Evans-Storms RB, 2000, ENDOCRINOLOGY, V141, P1854, DOI 10.1210/en.141.5.1854; Foo SY, 1999, TRENDS GENET, V15, P229; FUJIMOTO J, 1994, ONCOGENE, V9, P693; Georgescu MM, 1999, MOL CELL BIOL, V19, P1171; Glasgow JN, 2000, J NEUROCHEM, V75, P1377, DOI 10.1046/j.1471-4159.2000.0751377.x; Goruppi S, 1999, ONCOGENE, V18, P4224, DOI 10.1038/sj.onc.1202788; Goruppi S, 1997, MOL CELL BIOL, V17, P4442, DOI 10.1128/MCB.17.8.4442; Goruppi S, 1996, ONCOGENE, V12, P471; Goruppi S, 2001, MOL CELL BIOL, V21, P902, DOI 10.1128/MCB.21.3.902-915.2001; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; Harhaj E, 1996, VIROLOGY, V216, P284, DOI 10.1006/viro.1996.0062; Heck S, 1999, J BIOL CHEM, V274, P9828, DOI 10.1074/jbc.274.14.9828; Heissmeyer V, 1999, EMBO J, V18, P4766, DOI 10.1093/emboj/18.17.4766; Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574; Katagiri M, 2001, J BIOL CHEM, V276, P7376, DOI 10.1074/jbc.M007393200; Kim L, 2000, CURR OPIN GENET DEV, V10, P508, DOI 10.1016/S0959-437X(00)00120-9; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; Li RH, 1996, J NEUROSCI, V16, P2012; Lu QX, 1999, NATURE, V398, P723, DOI 10.1038/19554; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Maggirwar SB, 2000, J NEUROCHEM, V74, P527, DOI 10.1046/j.1471-4159.2000.740527.x; Mantovani F, 1998, NUCLEIC ACIDS RES, V26, P1433, DOI 10.1093/nar/26.6.1433; Mercurio F, 1999, CURR OPIN CELL BIOL, V11, P226, DOI 10.1016/S0955-0674(99)80030-1; NAKANO T, 1995, J BIOL CHEM, V270, P5702, DOI 10.1074/jbc.270.11.5702; O'Donnell K, 1999, AM J PATHOL, V154, P1171, DOI 10.1016/S0002-9440(10)65369-2; Oldereid NB, 2001, MOL HUM REPROD, V7, P403, DOI 10.1093/molehr/7.5.403; Ozes ON, 1999, NATURE, V401, P82; Parsadanian AS, 1998, J NEUROSCI, V18, P1009; Perkins ND, 2000, TRENDS BIOCHEM SCI, V25, P434, DOI 10.1016/S0968-0004(00)01617-0; Prieto AL, 2000, J COMP NEUROL, V425, P295; Rodriguez I, 1997, EMBO J, V16, P2262, DOI 10.1093/emboj/16.9.2262; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Yanagita M, 2001, AM J PATHOL, V158, P1423, DOI 10.1016/S0002-9440(10)64093-X; Yang CH, 2001, J BIOL CHEM, V276, P13756, DOI 10.1074/jbc.M011006200; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	51	89	93	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					31738	31744		10.1074/jbc.M104457200	http://dx.doi.org/10.1074/jbc.M104457200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11425860	hybrid			2022-12-25	WOS:000170613500037
J	Heiss, E; Herhaus, C; Klimo, K; Bartsch, H; Gerhauser, C				Heiss, E; Herhaus, C; Klimo, K; Bartsch, H; Gerhauser, C			Nuclear factor kappa B is a molecular target for sulforaphane-mediated anti-inflammatory mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; NECROSIS-FACTOR-ALPHA; DNA-BINDING ACTIVITY; COLON-CANCER CELLS; TRANSCRIPTION FACTOR; BACTERIAL LIPOPOLYSACCHARIDE; RAW-264.7 MACROPHAGES; CYCLOOXYGENASE-2 GENE; SIGNAL-TRANSDUCTION; INTERFERON-GAMMA	Sulforaphane (SFN), an aliphatic isothiocyanate, is a known cancer chemopreventive agent. Aiming to investigate anti-inflammatory mechanisms of SFN, we here report a potent decrease in lipopolysaccharide (LPS)induced secretion of pro-inflammatory and pro-careinogenic signaling factors in cultured Raw 264.7 macrophages after SFN treatment, i.e. NO, prostaglandin E-2, and tumor necrosis factor a. SFN did not directly interact with NO, nor did it inhibit inducible nitric-oxide synthase enzymatic activity. Western blot analyses revealed time- and dose-dependent reduction of LPS-induced inducible nitric-oxide synthase as well as Cox-2 protein expression, which was suppressed at the transcriptional level. To reveal the target of SFN beyond its anti-inflammatory action, we performed electrophoretic mobility shift assay analyses of transcription factor-DNA binding. Consequently, nuclear factor kappaB (NF-kappaB), a pivotal transcription factor in LPS-stimulated proinflammatory response, was identified as the key mediator. SFN selectively reduced DNA binding of NF-kappaB without interfering with LPS-induced degradation of the inhibitor of NF-kappaB nor with nuclear translocation of NF-kappaB. Because SFN can interact with thiol. groups by dithiocarbamate formation, it may impair the redox-sensitive DNA binding and transactivation of NF-kappaB. Sulforaphane could either directly inactivate NF-kappaB subunits by binding to essential Cys residues or interact with glutathione or other redox regulators like thioredoxin and Ref-1 relevant for NF-kappaB function. Our data provide novel evidence that anti-inflammatory mechanisms contribute to sulforaphane-mediated cancer chemoprevention.	Deutsch Krebsforschungszentrum, Div Toxicol & Canc Risk Factors, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Gerhauser, C (corresponding author), Deutsch Krebsforschungszentrum, Div Toxicol & Canc Risk Factors, C0202 Chemoprevent,Neuenheimer Feld 280, D-69120 Heidelberg, Germany.		Heiss, Elke/B-6086-2015	Heiss, Elke/0000-0001-7618-5505; Gerhauser, Clarissa/0000-0002-5792-3901				Akira S, 1997, INT J BIOCHEM CELL B, V29, P1401, DOI 10.1016/S1357-2725(97)00063-0; ANDERSON MT, 1994, P NATL ACAD SCI USA, V91, P11527, DOI 10.1073/pnas.91.24.11527; ARNER ESJ, 1995, J BIOL CHEM, V270, P3479, DOI 10.1074/jbc.270.8.3479; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; BENAV P, 1995, FEBS LETT, V372, P83, DOI 10.1016/0014-5793(95)00956-A; BUCHMULLERROUILLER Y, 1995, CELL IMMUNOL, V164, P73, DOI 10.1006/cimm.1995.1144; Chen CC, 1997, FEBS LETT, V412, P30, DOI 10.1016/S0014-5793(97)00697-2; Chen CC, 1998, J IMMUNOL, V161, P6206; Chung FL, 2000, CARCINOGENESIS, V21, P2287, DOI 10.1093/carcin/21.12.2287; DING AH, 1988, J IMMUNOL, V141, P2407; Evans AR, 2000, MUTAT RES-DNA REPAIR, V461, P83, DOI 10.1016/S0921-8777(00)00046-X; Fahey JW, 1999, FOOD CHEM TOXICOL, V37, P973, DOI 10.1016/S0278-6915(99)00082-4; Fujiki H, 2000, CANCER DETECT PREV, V24, P91; FUJIKI H, 1994, J BIOCHEM-TOKYO, V115, P1; Gamet-Payrastre L, 2000, CANCER RES, V60, P1426; Gerhaeuser C., 1999, Proceedings of the American Association for Cancer Research Annual Meeting, V40, P359; Gerhauser C, 1997, CANCER RES, V57, P272; GOODWIN JS, 1983, J CLIN IMMUNOL, V3, P295, DOI 10.1007/BF00915791; Graziewicz M, 1996, CARCINOGENESIS, V17, P2501, DOI 10.1093/carcin/17.11.2501; Hantraye P, 1996, NAT MED, V2, P1017, DOI 10.1038/nm0996-1017; Hiramoto M, 1998, J IMMUNOL, V160, P810; Hirota K, 2000, BIOCHEM BIOPH RES CO, V274, P177, DOI 10.1006/bbrc.2000.3106; Hirota K, 1999, J BIOL CHEM, V274, P27891, DOI 10.1074/jbc.274.39.27891; Holmes-McNary M, 2000, CANCER RES, V60, P3477; HOOPER DC, 1997, P NATL ACAD SCI USA, V94, P2328; KIM S, 1986, J ORG CHEM, V51, P2613, DOI 10.1021/jo00363a046; Lee SK, 1999, ANTICANCER RES, V19, P35; Lin YL, 1997, MOL PHARMACOL, V52, P465, DOI 10.1124/mol.52.3.465; Liu GY, 1998, MOL CARCINOGEN, V22, P235, DOI 10.1002/(SICI)1098-2744(199808)22:4<235::AID-MC5>3.0.CO;2-I; LOWENSTEIN CJ, 1993, P NATL ACAD SCI USA, V90, P9730, DOI 10.1073/pnas.90.20.9730; MATTHEWS JR, 1992, NUCLEIC ACIDS RES, V20, P3821, DOI 10.1093/nar/20.15.3821; MITOMO K, 1994, GENE, V145, P197; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; OHSHIMA H, 1994, MUTAT RES, V305, P253, DOI 10.1016/0027-5107(94)90245-3; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Sambrook J., 2002, MOL CLONING LAB MANU; SCHMID H, 1948, HELV CHIM ACTA, V31, P1497, DOI 10.1002/hlca.19480310608; Schmidt TJ, 1999, BIOORGAN MED CHEM, V7, P2849, DOI 10.1016/S0968-0896(99)00234-5; Sen CK, 2000, CURR TOP CELL REGUL, V36, P1; Sheng HM, 1998, CANCER RES, V58, P362; Shimizu N, 2000, NAT BIOTECHNOL, V18, P877, DOI 10.1038/78496; Simonian NA, 1996, ANNU REV PHARMACOL, V36, P83, DOI 10.1146/annurev.pa.36.040196.000503; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SPORN MB, 1979, FED PROC, V38, P2528; SPORN MB, 1986, J CLIN INVEST, V78, P329, DOI 10.1172/JCI112580; Steer JH, 2000, J BIOL CHEM, V275, P18432, DOI 10.1074/jbc.M906304199; Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603; Subbaramaiah K, 1997, P SOC EXP BIOL MED, V216, P201; Subbaramaiah K, 2000, CANCER RES, V60, P2399; Suh N, 1998, CANCER RES, V58, P717; Takahashi M, 1997, CANCER RES, V57, P1233; Tsai SH, 1999, BRIT J PHARMACOL, V126, P673, DOI 10.1038/sj.bjp.0702357; VODOVOTZ Y, 1993, J EXP MED, V178, P605, DOI 10.1084/jem.178.2.605; Wadleigh DJ, 2000, J BIOL CHEM, V275, P6259, DOI 10.1074/jbc.275.9.6259; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x; Xia CL, 1997, INT J BIOCHEM CELL B, V29, P1525, DOI 10.1016/S1357-2725(97)00083-6; Xie QW, 1997, J BIOL CHEM, V272, P14867, DOI 10.1074/jbc.272.23.14867; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779; Yu R, 1999, J BIOL CHEM, V274, P27545, DOI 10.1074/jbc.274.39.27545; Yuan CJ, 2000, CANCER RES, V60, P1084; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; ZHANG YS, 1992, P NATL ACAD SCI USA, V89, P2399, DOI 10.1073/pnas.89.6.2399; ZHANG YS, 1994, P NATL ACAD SCI USA, V91, P3147, DOI 10.1073/pnas.91.8.3147; Zhang YS, 2000, CARCINOGENESIS, V21, P1175, DOI 10.1093/carcin/21.6.1175; ZHENG S, 1991, BIOCHEM BIOPH RES CO, V175, P48, DOI 10.1016/S0006-291X(05)81198-2	68	505	526	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					32008	32015		10.1074/jbc.M104794200	http://dx.doi.org/10.1074/jbc.M104794200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11410599	hybrid			2022-12-25	WOS:000170613500074
J	Kansra, V; Groves, C; Gutierrez-Ramos, JC; Polakiewicz, RD				Kansra, V; Groves, C; Gutierrez-Ramos, JC; Polakiewicz, RD			Phosphatidylinositol 3-kinase-dependent extracellular calcium influx is essential for CX(3)CR1-mediated activation of the mitogen-activated protein kinase cascade	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRACTALKINE RECEPTOR CX(3)CR1; SIGNAL-REGULATED KINASE; CA2+ CHANNELS; PHOSPHOINOSITIDE 3-KINASE; CHEMOKINE RECEPTORS; COUPLED RECEPTORS; GAMMA; CELLS; INHIBITION; PATHWAY	Fractalkine, the first member of the CX3C chemokine family, induces leukocyte chemotaxis through activation of its high affinity receptor, CX(3)CR1. Like other chemokine receptors, CX(3)CR1 is coupled to a pertussis toxin-sensitive heterotrimeric G(i) protein, which is necessary for rapid rise in the concentration of intracellular calcium. Using a Chinese hamster ovary cell line stably transfected with the CX(3)CR1 receptor, we show that the source of calcium mobilized by fractalkine stimulation is the extracellular pool. Calcium influx is blocked by extracellular calcium chelators, as well as by divalent heavy metals such as Ni2+, Co2+, and Cd2+ without affecting the integrity of intracellular stores. Remarkably, selective phosphoinositide 3-kinase (PI3K) inhibitors, wortmannin and LY294002, abolish the wave extracellular calcium, suggesting that an active PI3K is necessary for this event. The influx of extracellular calcium is in turn required to trigger the activation of the p42/44 mitogen-activated protein/extracellular signal-regulated kinase pathway, but is not necessary for other signals downstream to PI3K, such as phosphorylation of Akt. The potential role of this signaling cascade in fractalkine-mediated chemotaxis is discussed.	Cell Signaling Technol, Beverly, MA 01915 USA; Millennium Pharmaceut Inc, Cambridge, MA 02139 USA	Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals	Polakiewicz, RD (corresponding author), Cell Signaling Technol, Beverly, MA 01915 USA.	rpolakiewicz@cellsignal.com						Barritt GJ, 1999, BIOCHEM J, V337, P153, DOI 10.1042/0264-6021:3370153; Bijlenga P, 2000, P NATL ACAD SCI USA, V97, P7627, DOI 10.1073/pnas.97.13.7627; Blaheta RA, 1998, IMMUNOLOGY, V94, P213, DOI 10.1046/j.1365-2567.1998.00504.x; Blair LAC, 1997, NEURON, V19, P421, DOI 10.1016/S0896-6273(00)80950-2; Boehme SA, 2000, J IMMUNOL, V165, P397, DOI 10.4049/jimmunol.165.1.397; Chapman GA, 2000, J NEUROSCI, V20, DOI 10.1523/JNEUROSCI.20-15-j0004.2000; CHEN CF, 1988, SCIENCE, V239, P1024, DOI 10.1126/science.2449730; Chen SH, 1998, J EXP MED, V188, P193, DOI 10.1084/jem.188.1.193; Combadiere C, 1998, J BIOL CHEM, V273, P23799, DOI 10.1074/jbc.273.37.23799; Faure S, 2000, SCIENCE, V287, P2274, DOI 10.1126/science.287.5461.2274; Feng LL, 1999, KIDNEY INT, V56, P612, DOI 10.1046/j.1523-1755.1999.00604.x; Fong AM, 1998, J EXP MED, V188, P1413, DOI 10.1084/jem.188.8.1413; Fong AM, 2000, J BIOL CHEM, V275, P3781, DOI 10.1074/jbc.275.6.3781; Harrison JK, 1998, P NATL ACAD SCI USA, V95, P10896, DOI 10.1073/pnas.95.18.10896; Haskell CA, 1999, J BIOL CHEM, V274, P10053, DOI 10.1074/jbc.274.15.10053; Herlitze S, 1996, NATURE, V380, P258, DOI 10.1038/380258a0; Hirsch E, 2000, SCIENCE, V287, P1049, DOI 10.1126/science.287.5455.1049; Hsu AL, 2000, J BIOL CHEM, V275, P16242, DOI 10.1074/jbc.M002077200; Ikeda SR, 1996, NATURE, V380, P255, DOI 10.1038/380255a0; Imai T, 1997, CELL, V91, P521, DOI 10.1016/S0092-8674(00)80438-9; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Knall C, 1997, P NATL ACAD SCI USA, V94, P3052, DOI 10.1073/pnas.94.7.3052; Li Z, 2000, SCIENCE, V287, P1046, DOI 10.1126/science.287.5455.1046; Lijnen P, 1998, AM J HYPERTENS, V11, P1461, DOI 10.1016/S0895-7061(98)00179-4; Locati M, 1999, ANNU REV MED, V50, P425, DOI 10.1146/annurev.med.50.1.425; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Mennicken F, 1999, TRENDS PHARMACOL SCI, V20, P73, DOI 10.1016/S0165-6147(99)01308-5; Meucci O, 2000, P NATL ACAD SCI USA, V97, P8075, DOI 10.1073/pnas.090017497; Meucci O, 1998, P NATL ACAD SCI USA, V95, P14500, DOI 10.1073/pnas.95.24.14500; Monteil A, 2000, J BIOL CHEM, V275, P6090, DOI 10.1074/jbc.275.9.6090; Mulvaney JM, 1999, J BIOL CHEM, V274, P29796, DOI 10.1074/jbc.274.42.29796; Murga C, 1998, J BIOL CHEM, V273, P19080, DOI 10.1074/jbc.273.30.19080; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; Pan Y, 1997, NATURE, V387, P611, DOI 10.1038/42491; Polakiewicz RD, 1998, J BIOL CHEM, V273, P12402, DOI 10.1074/jbc.273.20.12402; Polakiewicz RD, 1998, J BIOL CHEM, V273, P23534, DOI 10.1074/jbc.273.36.23534; Ricci A, 1996, EUR J PHARMACOL, V301, P189, DOI 10.1016/0014-2999(96)00016-7; Ruiz-Velasco V, 2000, J NEUROSCI, V20, P2183; Sasaki T, 2000, SCIENCE, V287, P1040, DOI 10.1126/science.287.5455.1040; Servant G, 2000, SCIENCE, V287, P1037, DOI 10.1126/science.287.5455.1037; Sorin B, 1998, J BIOL CHEM, V273, P28461, DOI 10.1074/jbc.273.43.28461; Sotsios Y, 1999, J IMMUNOL, V163, P5954; SOZZANI S, 1993, J IMMUNOL, V150, P1544; Strobeck MW, 1999, J BIOL CHEM, V274, P15694, DOI 10.1074/jbc.274.22.15694; TANG CM, 1988, SCIENCE, V240, P213, DOI 10.1126/science.2451291; Tytgat J, 1996, EUR J PHARMACOL, V296, P189, DOI 10.1016/0014-2999(95)00691-5; Viard P, 1999, FASEB J, V13, P685, DOI 10.1096/fasebj.13.6.685; VINCENTEMANNZAN.M, 1999, J IMMUNOL, V163, P4001	49	45	46	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					31831	31838		10.1074/jbc.M009374200	http://dx.doi.org/10.1074/jbc.M009374200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11432847	hybrid			2022-12-25	WOS:000170613500050
J	Klekotka, PA; Santoro, SA; Wang, HC; Zutter, MM				Klekotka, PA; Santoro, SA; Wang, HC; Zutter, MM			Specific residues within the alpha(2) integrin subunit cytoplasmic domain regulate migration and cell cycle progression via distinct MAPK pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE CASCADE; GROWTH-FACTOR ACTIVATION; FOCAL ADHESION KINASE; MEDIATED ACTIVATION; SIGNAL-TRANSDUCTION; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; ALPHA-2-BETA-1 INTEGRIN; EXTRACELLULAR-MATRIX; GENE-EXPRESSION; CANCER-CELLS	The alpha (2) integrin subunit cytoplasmic domain is necessary for epidermal growth factor (EGF)-stimulated chemotactic migration and insulin-dependent entry into S-phase of mammary epithelial cells adherent to type I collagen. Truncation mutants revealed that the seven amino acids, KYEKMTK, in addition to the GFFKR motif were sufficient for these functions. Mutation of tyrosine 1134 to alanine inhibited the ability of the cells to phosphorylate p38 MAPK and to migrate in response to EGF but had only a modest effect on the ability of the cells to induce sustained phosphorylation of the ERK MAPK, to up-regulate cyclin E and cdk2 expression, and to enter S-phase when adherent to type I collagen. Conversely, mutation of the lysine 1136 inhibited the ability of the cells to increase cyclin E and cdk2 expression, to maintain long term phosphorylation of the ERK MAPK, and to enter S-phase but had no effect on the ability of the cells to phosphorylate the p38 MAPK or to migrate on type I collagen in response to EGF. Methionine 1137 was essential for both migration and entry into S-phase. Thus, distinctly different structural elements of the a2 integrin cytoplasmic domain are-required to engage the signaling pathways leading to cell migration or cell cycle progression.	Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA	Washington University (WUSTL)	Zutter, MM (corresponding author), Washington Univ, Sch Med, Dept Pathol & Immunol, 660 S Euclid,Box 8118, St Louis, MO 63110 USA.				NCI NIH HHS [CA83690, CA70275] Funding Source: Medline; NHLBI NIH HHS [HL63446] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA083690, R01CA070275] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063446] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alahari SK, 2000, J CELL BIOL, V151, P1141, DOI 10.1083/jcb.151.6.1141; Aplin AE, 1999, J BIOL CHEM, V274, P31223, DOI 10.1074/jbc.274.44.31223; Barret C, 2000, J CELL BIOL, V151, P1067, DOI 10.1083/jcb.151.5.1067; Bottazzi ME, 1997, TRENDS CELL BIOL, V7, P348, DOI 10.1016/S0962-8924(97)01114-8; Chen QM, 1996, J BIOL CHEM, V271, P18122, DOI 10.1074/jbc.271.30.18122; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; COPPOLINO M, 1995, J BIOL CHEM, V270, P23132, DOI 10.1074/jbc.270.39.23132; de Fougerolles AR, 2000, J CLIN INVEST, V105, P721, DOI 10.1172/JCI7911; Deleage G, 1997, BIOCHIMIE, V79, P681, DOI 10.1016/S0300-9084(97)83524-9; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Fishman DA, 1998, INVAS METAST, V18, P15, DOI 10.1159/000024495; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Gotwals PJ, 1996, J CLIN INVEST, V97, P2469, DOI 10.1172/JCI118693; HALL DE, 1990, J CELL BIOL, V110, P2175, DOI 10.1083/jcb.110.6.2175; Henriet P, 2000, P NATL ACAD SCI USA, V97, P10026, DOI 10.1073/pnas.170290997; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; Howe AK, 1998, J BIOL CHEM, V273, P27268, DOI 10.1074/jbc.273.42.27268; Hughes PE, 1996, J BIOL CHEM, V271, P6571, DOI 10.1074/jbc.271.12.6571; IGNATIUS MJ, 1990, J CELL BIOL, V111, P709, DOI 10.1083/jcb.111.2.709; Ivaska J, 1999, J CELL BIOL, V147, P401, DOI 10.1083/jcb.147.2.401; KASSNER PD, 1994, J BIOL CHEM, V269, P19859; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Kieffer JD, 1995, BIOCHEM BIOPH RES CO, V217, P466, DOI 10.1006/bbrc.1995.2799; Klekotka PA, 2001, J BIOL CHEM, V276, P9503, DOI 10.1074/jbc.M006286200; KLEKOTKA PA, 2001, IN PRESS AM J PATHOL; Lang SH, 1997, CLIN EXP METASTAS, V15, P218, DOI 10.1023/A:1018465213641; Langholz O, 1995, J CELL BIOL, V131, P1903, DOI 10.1083/jcb.131.6.1903; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Lee D, 1998, J BIOL CHEM, V273, P13022, DOI 10.1074/jbc.273.21.13022; LEUNGHAGESTEIJN CY, 1994, J CELL SCI, V107, P589; Liu S, 1999, NATURE, V402, P676, DOI 10.1038/45264; Lundstrom A, 1998, BIOCHEM BIOPH RES CO, V250, P735, DOI 10.1006/bbrc.1998.9389; Mainiero F, 1997, EMBO J, V16, P2365, DOI 10.1093/emboj/16.9.2365; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; Oktay M, 1999, J CELL BIOL, V145, P1461, DOI 10.1083/jcb.145.7.1461; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; Renshaw MW, 1999, J CELL BIOL, V147, P611, DOI 10.1083/jcb.147.3.611; Renshaw MW, 1997, EMBO J, V16, P5592, DOI 10.1093/emboj/16.18.5592; RIIKONEN T, 1995, J BIOL CHEM, V270, P13548, DOI 10.1074/jbc.270.22.13548; ROJIANI MV, 1991, BIOCHEMISTRY-US, V30, P9859, DOI 10.1021/bi00105a008; SANTORO SA, 1994, METHOD ENZYMOL, V245, P147; SANTORO SA, 1986, CELL, V46, P913, DOI 10.1016/0092-8674(86)90073-5; Sato M, 1996, CANCER LETT, V102, P183, DOI 10.1016/0304-3835(96)04158-4; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; STAATZ WD, 1990, J BIOL CHEM, V265, P4778; TLSTY T, 1995, METHOD ENZYMOL, V254, P125; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; Werr J, 2000, BLOOD, V95, P1804, DOI 10.1182/blood.V95.5.1804.005k11_1804_1809; Wixler V, 1999, FEBS LETT, V445, P351, DOI 10.1016/S0014-5793(99)00151-9; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3; YU FX, 1992, J BIOL CHEM, V267, P14616; Zutter MM, 1999, AM J PATHOL, V155, P927, DOI 10.1016/S0002-9440(10)65192-9; ZUTTER MM, 1995, P NATL ACAD SCI USA, V92, P7411, DOI 10.1073/pnas.92.16.7411	54	54	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					32353	32361		10.1074/jbc.M101921200	http://dx.doi.org/10.1074/jbc.M101921200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11418614	hybrid			2022-12-25	WOS:000170613500118
J	Pathan, N; Marusawa, H; Krajewska, M; Matsuzawa, S; Kim, H; Okada, K; Tori, S; Kitada, S; Krajewski, S; Welsh, K; Pio, F; Godzik, A; Reed, JC				Pathan, N; Marusawa, H; Krajewska, M; Matsuzawa, S; Kim, H; Okada, K; Tori, S; Kitada, S; Krajewski, S; Welsh, K; Pio, F; Godzik, A; Reed, JC			TUCAN, an antiapoptotic caspase-associated recruitment domain family protein overexpressed in cancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DEATH PROTEASE; CYTOCHROME-C; APOPTOSIS; ACTIVATION; APAF-1; CARD	Caspase-associated recruitment domains (CARDs) are protein interaction domains that participate in activation or suppression of CARD-carrying members of the caspase family of apoptosis-inducing proteases. A novel CARD-containing protein was identified that is overexpressed in some types of cancer and that binds and suppresses activation of procaspase-9, which we term TUCAN (tumor-upregulated CARD-containing antagonist of caspase nine). The CARD domain of TUCAN selectively binds itself and procaspase-9. TUCAN interferes with binding of Apaf1 to procaspase-9 and suppresses caspase activation induced by the Apaf1 activator, cytochrome c. Overexpression of TUCAN in cells by stable or transient transfection inhibits apoptosis and caspase activation induced by Apaf1/ caspase-9-dependent stimuli, including Bax, VP16, and staurosporine, but not by Apafl/caspase-9-independent stimuli, Fas and granzyme B. High levels of endogenous TUCAN protein were detected in several tumor cell lines and in colon cancer specimens, correlating with shorter patient survival. Thus, TUCAN represents a new member of the CARD family that selectively suppresses apoptosis induced via the mitochondrial pathway for caspase activation.	Burnham Inst, La Jolla, CA 92037 USA; Yonsei Univ, Coll Med, Dept Pathol, Seoul 120749, South Korea	Sanford Burnham Prebys Medical Discovery Institute; Yonsei University; Yonsei University Health System	Reed, JC (corresponding author), Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Godzik, Adam/AAW-1467-2020; Godzik, Adam/A-7279-2009	Godzik, Adam/0000-0002-2425-852X; Godzik, Adam/0000-0002-2425-852X; Marusawa, Hiroyuki/0000-0002-4286-2712; pio, frederic/0000-0003-2050-847X	NCI NIH HHS [CA69381] Funding Source: Medline; NIA NIH HHS [AG15402] Funding Source: Medline; NINDS NIH HHS [NS36821] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA069381] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036821] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG015402] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chu ZL, 2001, J BIOL CHEM, V276, P9239, DOI 10.1074/jbc.M006309200; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Haraguchi M, 2000, J EXP MED, V191, P1709, DOI 10.1084/jem.191.10.1709; Hlaing T, 2001, J BIOL CHEM, V276, P9230, DOI 10.1074/jbc.M009853200; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; Krajewska M, 1997, CANCER RES, V57, P1605; Krajewski S, 1999, P NATL ACAD SCI USA, V96, P5752, DOI 10.1073/pnas.96.10.5752; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LI W, 2001, IN PRESS BIOINFORMAT; Nagase T, 1998, DNA Res, V5, P277, DOI 10.1093/dnares/5.5.277; Reed JC, 1999, J CLIN ONCOL, V17, P2941, DOI 10.1200/JCO.1999.17.9.2941; RENTROP M, 1986, HISTOCHEM J, V18, P271, DOI 10.1007/BF01676237; Rychlewski L, 2000, PROTEIN SCI, V9, P232, DOI 10.1110/ps.9.2.232; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; WEINSTEIN J, 1997, SCIENCE, V17, P343; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Zhou P, 1999, P NATL ACAD SCI USA, V96, P11265, DOI 10.1073/pnas.96.20.11265; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	32	86	92	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					32220	32229		10.1074/jbc.M100433200	http://dx.doi.org/10.1074/jbc.M100433200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11408476	hybrid			2022-12-25	WOS:000170613500102
J	Sim, SP; Liu, LF				Sim, SP; Liu, LF			Nucleolytic cleavage of the mixed lineage leukemia breakpoint cluster region during apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-TOPOISOMERASE-II; ACUTE MYELOID-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; DOUBLE-STRAND BREAKS; CHROMOSOME TRANSLOCATIONS; MAMMALIAN-CELLS; HOMOLOGOUS RECOMBINATION; 11Q23 TRANSLOCATIONS; BINDING-SITES; MLL GENE	VP-16 (etoposide) has recently been shown to induce topoisomerase II (TOP2)-mediated DNA cleavage within the mixed lineage leukemia (MLL) breakpoint cluster region (ber), suggesting a role of TOP2 in MLL gene rearrangement. In our current studies, we have compared the induction of DNA cleavage within the MLL bcr in different cell lines after treatment with various anticancer drugs. All anticancer drugs tested including VP-16 (a TOP2-directed drug), camptothecin (a topoisomerase I-directed drug), 5-fluorouracil and methotrexate (antimetabolites), and vinblastine (a microtubule inhibitor) induced the same site-specific cleavage within the MLL her. This cleavage was shown to nuclease-mediated but not TOP2-mediated by the following observations: 1) drug- induced cleavage within the MLL her was not protein-linked; 2) unlike TOP2-mediated cleavage, drug-induced DNA cleavage with the MLL her was kinetically slow and coincided with the formation of the apoptotic nucleosomal DNA ladder; 3) drug-induced cleavage within the I ML ber was unaffected in cells with reduced nuclear TOP2; and 4) drug-induced cleavage within the MLL ber was abolished by the caspase inhibitor, Z-Asp(OCH3)-Glu(OCH3)-Val-Asp(OCH3)-FMK. The possibility that an apoptotic, nuclease may be involved in cleavage of the MLL her and MLL gene translocation is discussed.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, Piscataway, NJ 08854 USA; Canc Inst New Jersey, New Brunswick, NJ 08901 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey	Liu, LF (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, 675 Hoes Ln, Piscataway, NJ 08854 USA.		Sim, Sai-Peng/N-6455-2018	Sim, Sai-Peng/0000-0002-0256-2803; Liu, Leroy/0000-0001-9396-763X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027731] Funding Source: NIH RePORTER; NCI NIH HHS [CA39962] Funding Source: Medline; NIGMS NIH HHS [GM27731] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aratani Y, 1996, MUTAT RES-DNA REPAIR, V362, P181, DOI 10.1016/0921-8777(95)00049-6; BAE YS, 1991, GENE, V101, P285; BODLEY AL, 1993, MOL CELL BIOL, V13, P6190, DOI 10.1128/MCB.13.10.6190; Broeker PLS, 1996, BLOOD, V87, P1912, DOI 10.1182/blood.V87.5.1912.bloodjournal8751912; CHEN GL, 1984, J BIOL CHEM, V259, P3560; CIMINO G, 1991, CANCER RES, V51, P6712; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Desai SD, 1997, J BIOL CHEM, V272, P24159, DOI 10.1074/jbc.272.39.24159; DJABALI M, 1992, NAT GENET, V2, P113, DOI 10.1038/ng1092-113; DOMER PH, 1995, LEUKEMIA, V9, P1305; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; FELIX CA, 1995, CANCER RES, V55, P4287; FELIX CA, 1995, BLOOD, V85, P3250, DOI 10.1182/blood.V85.11.3250.bloodjournal85113250; Fujimaki K, 1996, SOMAT CELL MOLEC GEN, V22, P279, DOI 10.1007/BF02369567; GU Y, 1994, CANCER RES, V54, P2327; GU Y, 1992, P NATL ACAD SCI USA, V89, P10464, DOI 10.1073/pnas.89.21.10464; HARKER WG, 1989, CANCER RES, V49, P4542; HARKER WG, 1995, CANCER RES, V55, P1707; HSIANG YH, 1989, J BIOL CHEM, V264, P9713; HUNGER SP, 1993, BLOOD, V81, P3197; Jeggo PA, 1998, RADIAT RES, V150, pS80, DOI 10.2307/3579810; KOBAYASHI Y, 1995, LEUKEMIA LYMPHOMA, V17, P391, DOI 10.3109/10428199509056849; KUBOTA M, 1994, ACTA HAEMATOL-BASEL, V92, P33; Labhart P, 1999, EUR J BIOCHEM, V265, P849, DOI 10.1046/j.1432-1327.1999.00805.x; Li TK, 1999, GENE DEV, V13, P1553, DOI 10.1101/gad.13.12.1553; LIM M, 1986, CELL BIOL TOXICOL, V2, P485, DOI 10.1007/BF00117850; Martins LM, 1997, BLOOD, V90, P4283, DOI 10.1182/blood.V90.11.4283.4283_4283_4296; Masuda Y, 1997, BIOCHEM BIOPH RES CO, V234, P641, DOI 10.1006/bbrc.1997.6690; NEGRINI M, 1993, CANCER RES, V53, P4489; PEDERSENBJERGAARD J, 1991, BLOOD, V78, P1147; Pfeiffer P, 2000, MUTAGENESIS, V15, P289, DOI 10.1093/mutage/15.4.289; PUI CH, 1989, NEW ENGL J MED, V321, P136, DOI 10.1056/NEJM198907203210302; PUI CH, 1990, LANCET, V336, P417, DOI 10.1016/0140-6736(90)91956-B; REED KC, 1985, NUCLEIC ACIDS RES, V13, P7207, DOI 10.1093/nar/13.20.7207; ROWLEY JD, 1993, SEMIN CANCER BIOL, V4, P377; Rowley JD, 1998, ANNU REV GENET, V32, P495, DOI 10.1146/annurev.genet.32.1.495; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Sathees CR, 1999, MUTAT RES-DNA REPAIR, V433, P1, DOI 10.1016/S0921-8777(98)00055-X; SMITH MA, 1994, MED PEDIATR ONCOL, V23, P86, DOI 10.1002/mpo.2950230205; Stanulla M, 1997, MOL CELL BIOL, V17, P4070, DOI 10.1128/MCB.17.7.4070; Strick R, 2000, P NATL ACAD SCI USA, V97, P4790, DOI 10.1073/pnas.070061297; SUPER HJG, 1993, BLOOD, V82, P3705; Takata M, 1998, EMBO J, V17, P5497, DOI 10.1093/emboj/17.18.5497; TEWEY KM, 1984, SCIENCE, V226, P466, DOI 10.1126/science.6093249; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; Tsukamoto Y, 1998, GENES CELLS, V3, P135, DOI 10.1046/j.1365-2443.1998.00180.x; Wang HM, 2001, BIOCHEMISTRY-US, V40, P3316, DOI 10.1021/bi002786j; YANG L, 1985, CANCER RES, V45, P5872; ZIEMINVANDERPOEL S, 1991, P NATL ACAD SCI USA, V88, P10735, DOI 10.1073/pnas.88.23.10735	50	45	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					31590	31595		10.1074/jbc.M103962200	http://dx.doi.org/10.1074/jbc.M103962200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11406628	hybrid, Green Submitted			2022-12-25	WOS:000170613500018
J	Castro-Rivera, E; Samudio, I; Safe, S				Castro-Rivera, E; Samudio, I; Safe, S			Estrogen-regulation of cyclin D1 gene expression in ZR-75 breast cancer cells involves multiple enhancer elements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATHEPSIN-D GENE; TRANSCRIPTION FACTOR SP1; CAMP-RESPONSIVE ELEMENT; FACTOR-KAPPA-B; GROWTH-FACTOR; MCF-7 CELLS; PROGESTERONE-RECEPTOR; INDEPENDENT ACTIVATION; PHASE PROGRESSION; DEPENDENT KINASES	Cyclin D1 gene expression is induced by 17 beta -estradiol (E2) in human breast cancer cells and is important for progression of cells through the G(1) phase of the cell cycle. The mechanism of activation of cyclin D1 is mitogen- and cell context-dependent, and this study describes the role of multiple promoter elements required for induction of cyclin D1 by E2 in estrogen receptor (ER)-positive ZR-75 breast cancer cells. Transcriptional activation of cyclin DI by E2 was dependent, in part, on a proximal cAMP-response element at -66, and this was linked to induction of protein kinase A-dependent pathways. These results contrasted to a recent report showing that induction of cyclin DI by E2 in ER-positive MCF-7 and HeLa cells was due to up-regulation of c-jun and subsequent interaction of c-Jun-ATF-2 with the CRE. Moreover, further examination of the proximal region of the cyclin D1 promoter showed that three GC-rich Spl-binding sites at -143 to -110 were also E2-responsive, and interaction of ER alpha and Sp1 proteins at these sites was confirmed by electromobility shift and chromatin immunoprecipitation assays. Thus, induction of cyclin D1 by E2 in ZR-75 cells is regulated through nuclear ER alpha /Sp1 and epigenetic protein kinase A activation pathways, and our results suggest that this mechanism may be cell context-dependent even among ER-positive breast cancer cell lines.	Texas A&M Univ, Dept Vet Physiol & Pharmacol, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station	Safe, S (corresponding author), Texas A&M Univ, Dept Vet Physiol & Pharmacol, 4466 TAMU, College Stn, TX 77843 USA.	ssafe@cvm.tamu.edu	Samudio, Ismael/D-3581-2013	Samudio, Ismael/0000-0001-8676-1035	NATIONAL CANCER INSTITUTE [R01CA076636] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES009106, R01ES009253] Funding Source: NIH RePORTER; NCI NIH HHS [CA76636] Funding Source: Medline; NIEHS NIH HHS [ES09253, ES09106] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Adnane J, 1999, ONCOGENE, V18, P239, DOI 10.1038/sj.onc.1202297; Albanese C, 1999, J BIOL CHEM, V274, P34186, DOI 10.1074/jbc.274.48.34186; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Altucci L, 1996, ONCOGENE, V12, P2315; ARONICA SM, 1991, ENDOCRINOLOGY, V128, P2045, DOI 10.1210/endo-128-4-2045; ARONICA SM, 1994, P NATL ACAD SCI USA, V91, P8517, DOI 10.1073/pnas.91.18.8517; ARONICA SM, 1993, MOL ENDOCRINOL, V7, P743, DOI 10.1210/me.7.6.743; AUGEREAU P, 1994, MOL ENDOCRINOL, V8, P693, DOI 10.1210/me.8.6.693; Barnes DM, 1998, BREAST CANCER RES TR, V52, P1, DOI 10.1023/A:1006103831990; BERRY M, 1989, P NATL ACAD SCI USA, V86, P1218, DOI 10.1073/pnas.86.4.1218; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; CAVAILLES V, 1989, MOL ENDOCRINOL, V3, P552, DOI 10.1210/mend-3-3-552; CAVAILLES V, 1993, P NATL ACAD SCI USA, V90, P203, DOI 10.1073/pnas.90.1.203; D'Amico M, 2000, J BIOL CHEM, V275, P32649, DOI 10.1074/jbc.M000643200; Dong LA, 1999, J BIOL CHEM, V274, P32099, DOI 10.1074/jbc.274.45.32099; Duan R, 1998, ENDOCRINOLOGY, V139, P1981, DOI 10.1210/en.139.4.1981; ElTanani MKK, 1997, MOL ENDOCRINOL, V11, P928, DOI 10.1210/me.11.7.928; Foster JS, 1996, MOL ENDOCRINOL, V10, P488, DOI 10.1210/me.10.5.488; Gillesby BE, 1997, BIOCHEMISTRY-US, V36, P6080, DOI 10.1021/bi962131b; Hulit J, 2000, J BIOL CHEM, V275, P21203, DOI 10.1074/jbc.M000321200; Joyce D, 1999, J BIOL CHEM, V274, P25245, DOI 10.1074/jbc.274.36.25245; Kitazawa S, 1999, J BIOL CHEM, V274, P28787, DOI 10.1074/jbc.274.40.28787; KRISHNAN V, 1995, MOL CELL BIOL, V15, P6710; KRISHNAN V, 1994, J BIOL CHEM, V269, P15912; Kyo S, 1999, CANCER RES, V59, P5917; Lech JJ, 1996, FUND APPL TOXICOL, V30, P229, DOI 10.1006/faat.1996.0060; Lee RJ, 2000, MOL CELL BIOL, V20, P672, DOI 10.1128/MCB.20.2.672-683.2000; Lee RJ, 1999, J BIOL CHEM, V274, P7341, DOI 10.1074/jbc.274.11.7341; LEVENSON AS, 1994, J STEROID BIOCHEM, V51, P229, DOI 10.1016/0960-0760(94)90035-3; Lu S, 2000, MOL ENDOCRINOL, V14, P753, DOI 10.1210/me.14.5.753; Matsumura I, 1999, EMBO J, V18, P1367, DOI 10.1093/emboj/18.5.1367; McMahon C, 1999, P NATL ACAD SCI USA, V96, P5382, DOI 10.1073/pnas.96.10.5382; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; MUSGROVE EA, 1993, MOL CELL BIOL, V13, P3577, DOI 10.1128/MCB.13.6.3577; Nagata D, 2001, J BIOL CHEM, V276, P662, DOI 10.1074/jbc.M005522200; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; Nurse P, 1998, NAT MED, V4, P1103, DOI 10.1038/2594; Owen GI, 1998, J BIOL CHEM, V273, P10696, DOI 10.1074/jbc.273.17.10696; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; Pavletich NP, 1999, J MOL BIOL, V287, P821, DOI 10.1006/jmbi.1999.2640; Petz LN, 2000, MOL ENDOCRINOL, V14, P972, DOI 10.1210/me.14.7.972; Pipaon C, 1999, MOL CELL BIOL, V19, P2734; Planas-Silva MD, 1999, CANCER RES, V59, P4788; PlanasSilva MD, 1997, MOL CELL BIOL, V17, P4059, DOI 10.1128/MCB.17.7.4059; Porter W, 1996, MOL ENDOCRINOL, V10, P1371, DOI 10.1210/me.10.11.1371; Porter W, 1997, MOL ENDOCRINOL, V11, P1569, DOI 10.1210/me.11.11.1569; Prall OWJ, 1997, J BIOL CHEM, V272, P10882; Qin CH, 1999, ENDOCRINOLOGY, V140, P2501, DOI 10.1210/en.140.6.2501; Rohr O, 1997, J BIOL CHEM, V272, P31149, DOI 10.1074/jbc.272.49.31149; Sabbah M, 1999, P NATL ACAD SCI USA, V96, P11217, DOI 10.1073/pnas.96.20.11217; Salvatori L, 2000, ENDOCRINOLOGY, V141, P2266, DOI 10.1210/en.141.6.2266; Samudio I, 2001, ENDOCRINOLOGY, V142, P1000, DOI 10.1210/en.142.3.1000; Sathya G, 1997, MOL ENDOCRINOL, V11, P1994, DOI 10.1210/me.11.13.1994; Saville B, 2000, J BIOL CHEM, V275, P5379, DOI 10.1074/jbc.275.8.5379; SAVOURET JF, 1991, EMBO J, V10, P1875, DOI 10.1002/j.1460-2075.1991.tb07713.x; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Sherr CJ, 2000, CANCER RES, V60, P3689; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Shie JL, 2000, NUCLEIC ACIDS RES, V28, P2969, DOI 10.1093/nar/28.15.2969; Stoner M, 2000, J BIOL CHEM, V275, P22769, DOI 10.1074/jbc.M002188200; Sun GL, 1998, MOL ENDOCRINOL, V12, P882, DOI 10.1210/me.12.6.882; Suzuki Y, 1999, BLOOD, V93, P4264, DOI 10.1182/blood.V93.12.4264.412k27_4264_4276; Tanaka N, 2000, J BIOL CHEM, V275, P25781, DOI 10.1074/jbc.M001235200; Wang F, 1998, NUCLEIC ACIDS RES, V26, P3044, DOI 10.1093/nar/26.12.3044; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Wang WL, 1999, MOL ENDOCRINOL, V13, P1373, DOI 10.1210/me.13.8.1373; Wang WL, 1998, ARCH BIOCHEM BIOPHYS, V356, P239, DOI 10.1006/abbi.1998.0782; Watanabe G, 1998, MOL CELL BIOL, V18, P3212, DOI 10.1128/MCB.18.6.3212; Watanabe G, 1996, P NATL ACAD SCI USA, V93, P12861, DOI 10.1073/pnas.93.23.12861; WEBB P, 1995, MOL ENDOCRINOL, V9, P443, DOI 10.1210/me.9.4.443; WEINSTATSASLOW D, 1995, NAT MED, V1, P1257, DOI 10.1038/nm1295-1257; WEISZ A, 1990, NUCLEIC ACIDS RES, V18, P5097, DOI 10.1093/nar/18.17.5097; Xie W, 2000, ENDOCRINOLOGY, V141, P2439, DOI 10.1210/en.141.7.2439; Xie W, 1999, ENDOCRINOLOGY, V140, P219, DOI 10.1210/en.140.1.219; ZACHAREWSKI TR, 1994, CANCER RES, V54, P2707; ZWIJSEN RM, 1988, GENE DEV, V12, P3488; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6	81	161	173	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					30853	30861		10.1074/jbc.M103339200	http://dx.doi.org/10.1074/jbc.M103339200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11410592	hybrid			2022-12-25	WOS:000170472900037
J	Corps, E; Carter, C; Karecla, P; Ahrens, T; Evans, P; Kilshaw, P				Corps, E; Carter, C; Karecla, P; Ahrens, T; Evans, P; Kilshaw, P			Recognition of E-cadherin by integrin alpha(E)beta(7) - Requirement for cadherin dimerization and implications for cadherin and integrin function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION; INTRAEPITHELIAL LYMPHOCYTES; (CD103)-DEFICIENT MICE; CRYSTAL-STRUCTURE; EPITHELIAL-CELLS; CALCIUM-BINDING; TERMINAL DOMAIN; UVOMORULIN; SITE; HOMOASSOCIATION	We have investigated the importance of dimerization of E-cadherin in the heterophilic adhesive interaction between E-cadherin and integrin alpha (E)beta (7). Dimerization of cadherin molecules in parallel alignment is known to be essential for homophilic adhesion and has been attributed to Ca2+-dependent interactions in the domain 1-2 junction or to cross-intercalation of Trp2 from one molecule to the other. We have disrupted either or both of these proposed mechanisms by point mutations in E-cadherin-Fc and have tested the modified proteins for alpha (E)beta (7)-mediated cell adhesion. Prevention of Trp2 intercalation had no adverse effect on integrin-mediated adhesion, whereas disruption of Ca2+ binding permitted adhesion but with reduced efficiency. Both modifications in combination abolished recognition by alpha (E)beta (7). In EGTA, alpha (E)beta (7) adhered to wild type E-cadherin but not to the Trp2 deletion mutant. Independent evidence that the mutations prevented either or both mechanisms for dimerization is presented. The data show that dimerization is required for recognition by alpha (E)beta (7) and that it can take place by either of two mechanisms. Implications for the roles of the alpha (E) and beta (7) integrin subunits in ligand binding and for Trp2 and Ca2+ in the assembly of cadherin complexes are discussed.	Babraham Inst, Mol Immunol Programme, Cambridge CB2 4AT, England; Univ Basel, Biozentrum, Dept Biophys Chem, CH-4056 Basel, Switzerland	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; University of Basel	Kilshaw, P (corresponding author), Babraham Inst, Mol Immunol Programme, Cambridge CB2 4AT, England.							Alattia JR, 1997, FEBS LETT, V417, P405, DOI 10.1016/S0014-5793(97)01333-1; ANDREW DP, 1994, J IMMUNOL, V153, P3847; Baumgartner W, 2000, P NATL ACAD SCI USA, V97, P4005, DOI 10.1073/pnas.070052697; Beagley KW, 1998, CRIT REV IMMUNOL, V18, P237, DOI 10.1615/CritRevImmunol.v18.i3.40; Berg RW, 1999, IMMUNOL CELL BIOL, V77, P337, DOI 10.1046/j.1440-1711.1999.00832.x; Brieher WM, 1996, J CELL BIOL, V135, P487, DOI 10.1083/jcb.135.2.487; Casasnovas JM, 1998, P NATL ACAD SCI USA, V95, P4134, DOI 10.1073/pnas.95.8.4134; CEPEK KL, 1994, NATURE, V372, P190, DOI 10.1038/372190a0; Chitaev NA, 1998, J CELL BIOL, V142, P837, DOI 10.1083/jcb.142.3.837; Dall'Acqua W, 1998, BIOCHEMISTRY-US, V37, P9266, DOI 10.1021/bi980270i; GONZALEZ AL, 1995, TRENDS GENET, V11, P216, DOI 10.1016/S0168-9525(00)89051-4; Higgins JMG, 1998, J CELL BIOL, V140, P197, DOI 10.1083/jcb.140.1.197; Higgins JMG, 2000, J BIOL CHEM, V275, P25652, DOI 10.1074/jbc.M001228200; Huber O, 1999, J CELL SCI, V112, P4415; Karecla PI, 1996, J BIOL CHEM, V271, P30909, DOI 10.1074/jbc.271.48.30909; KARECLA PI, 1995, EUR J IMMUNOL, V25, P852, DOI 10.1002/eji.1830250333; KILSHAW PJ, 1988, IMMUNOL LETT, V18, P149, DOI 10.1016/0165-2478(88)90056-9; Kitagawa M, 2000, BIOCHEM BIOPH RES CO, V271, P358, DOI 10.1006/bbrc.2000.2636; Klingelhofer J, 2000, J CELL SCI, V113, P2829; Koch AW, 1997, BIOCHEMISTRY-US, V36, P7697, DOI 10.1021/bi9705624; Lu CF, 2001, P NATL ACAD SCI USA, V98, P2387, DOI 10.1073/pnas.041606398; Lu CF, 2001, P NATL ACAD SCI USA, V98, P2393, DOI 10.1073/pnas.041618598; Nagar B, 1996, NATURE, V380, P360, DOI 10.1038/380360a0; Nakashima A, 1999, J NEURAL TRANSM, V106, P819, DOI 10.1007/s007020050202; OZAWA M, 1990, MECH DEVELOP, V33, P49, DOI 10.1016/0925-4773(90)90134-8; Ozawa M, 1998, J BIOL CHEM, V273, P6166, DOI 10.1074/jbc.273.11.6166; OZAWA M, 1990, CELL, V63, P1033, DOI 10.1016/0092-8674(90)90506-A; Ozawa M, 1998, J CELL BIOL, V142, P1605, DOI 10.1083/jcb.142.6.1605; OZAWA M, 1990, J CELL BIOL, V111, P1645, DOI 10.1083/jcb.111.4.1645; Pertz O, 1999, EMBO J, V18, P1738, DOI 10.1093/emboj/18.7.1738; PURZONMCLAUGHLI.W, 2000, J BIOL CHEM, V275, P7795; Schon MP, 2000, J IMMUNOL, V165, P6583, DOI 10.4049/jimmunol.165.11.6583; Schon MP, 1999, J IMMUNOL, V162, P6641; Shan WS, 2000, J CELL BIOL, V148, P579, DOI 10.1083/jcb.148.3.579; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; SIRAYOSHI Y, 1986, CELL STRUCT FUNCT, V11, P245; Strauch UG, 2001, J IMMUNOL, V166, P3506, DOI 10.4049/jimmunol.166.5.3506; Takeda H, 1999, NAT STRUCT BIOL, V6, P310, DOI 10.1038/7542; Tamura K, 1998, NEURON, V20, P1153, DOI 10.1016/S0896-6273(00)80496-1; Taraszka KS, 2000, J EXP MED, V191, P1555, DOI 10.1084/jem.191.9.1555; Thies MJW, 1999, J MOL BIOL, V293, P67, DOI 10.1006/jmbi.1999.3128; Tidswell M, 1997, J IMMUNOL, V159, P1497; Tolosa E, 1996, J IMMUNOL METHODS, V192, P165, DOI 10.1016/0022-1759(96)00042-7; Troyanovsky RB, 1999, J CELL SCI, V112, P4379; Vleminckx K, 1999, BIOESSAYS, V21, P211, DOI 10.1002/(SICI)1521-1878(199903)21:3<211::AID-BIES5>3.3.CO;2-G; WEARNE SJ, 1990, FEBS LETT, V263, P23, DOI 10.1016/0014-5793(90)80696-G; Zang Q, 2000, J BIOL CHEM, V275, P22202, DOI 10.1074/jbc.M002883200	47	24	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					30862	30870		10.1074/jbc.M101712200	http://dx.doi.org/10.1074/jbc.M101712200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11413131	hybrid			2022-12-25	WOS:000170472900038
J	Goossens, A; Dever, TE; Pascual-Ahuir, A; Serrano, R				Goossens, A; Dever, TE; Pascual-Ahuir, A; Serrano, R			The protein kinase Gcn2p mediates sodium toxicity in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; UNCHARGED TRANSFER-RNA; MEMBRANE H+-ATPASE; SACCHAROMYCES-CEREVISIAE; TRANSLATIONAL REGULATION; SALT TOLERANCE; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; ION HOMEOSTASIS; FACTOR EIF2B	Phosphorylation of the a-subunit of eukaryotic initiation factor 2 (eIF2 alpha) is a conserved mechanism regulating protein synthesis in response to various stresses. A screening for negative factors in yeast salt stress tolerance has led to the identification of Gcn2p, the single yeast eIF2a kinase that is activated by amino acid starvation in the general amino acid control response. Mutation of other components of this regulatory circuit such as GCN1 and GCN3 also resulted in improved NaCl tolerance. The gcn2 phenotype was not accompanied by changes in sodium or potassium homeostasis. NaCl induced a Gcn2p-dependent phosphorylation of eIF2a and translational activation of Gcn4p, the transcription factor that mediates the general amino acid control response. Mutations that activate Gcn4p function, such as gcd7-201, cpc2, and deletion of the translational regulatory region of the GCN4 gene, also cause salt sensitivity. It can be postulated that sodium activation of the Gcn2p pathway has toxic effects on growth under NaCl stress and that this novel mechanism of sodium toxicity may be of general significance in eukaryotes.	Univ Politecn Valencia, CSIC, Inst Biol Mol & Celular Plantas, Valencia 46022, Spain; NICHHD, Lab Eukaryotic Gene Regulat, Bethesda, MD 20892 USA	Consejo Superior de Investigaciones Cientificas (CSIC); Universitat Politecnica de Valencia; CSIC-UPV - Instituto de Biologia Molecular y Celular de Plantas (IBMCP); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Serrano, R (corresponding author), Univ Politecn Valencia, CSIC, Inst Biol Mol & Celular Plantas, Camino Vera S-N, Valencia 46022, Spain.	serrano@ibmcp.upv.es	Pascual-ahuir, Amparo/K-1338-2014	PASCUAL-AHUIR, AMPARO/0000-0001-6173-1526; Dever, Thomas/0000-0001-7120-9678; Goossens, Alain/0000-0002-1599-551X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001010] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001010] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Albrecht G, 1998, J BIOL CHEM, V273, P12696, DOI 10.1074/jbc.273.21.12696; BONNET J, 1975, FEBS LETT, V53, P154, DOI 10.1016/0014-5793(75)80008-1; BONNET J, 1975, EUR J BIOCHEM, V58, P193, DOI 10.1111/j.1432-1033.1975.tb02364.x; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; BURNS N, 1994, GENE DEV, V8, P1087, DOI 10.1101/gad.8.9.1087; BUSHMAN JL, 1993, MOL CELL BIOL, V13, P1920, DOI 10.1128/MCB.13.3.1920; DEALDANA CRV, 1994, MOL CELL BIOL, V14, P7920; DEALDANA CRV, 1995, EMBO J, V14, P3184, DOI 10.1002/j.1460-2075.1995.tb07321.x; deHaro C, 1996, FASEB J, V10, P1378, DOI 10.1096/fasebj.10.12.8903508; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; Dichtl B, 1997, EMBO J, V16, P7184, DOI 10.1093/emboj/16.23.7184; Dong JS, 2000, MOL CELL, V6, P269, DOI 10.1016/S1097-2765(00)00028-9; ENGELBERG D, 1994, CELL, V77, P381, DOI 10.1016/0092-8674(94)90153-8; FLORENTZ C, 1990, FEBS LETT, V261, P335, DOI 10.1016/0014-5793(90)80585-7; Garcia-Barrio M, 2000, EMBO J, V19, P1887, DOI 10.1093/emboj/19.8.1887; GAXIOLA R, 1992, EMBO J, V11, P3157, DOI 10.1002/j.1460-2075.1992.tb05392.x; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; GLASER HU, 1993, EMBO J, V12, P3105, DOI 10.1002/j.1460-2075.1993.tb05979.x; Goossens A, 2000, MOL CELL BIOL, V20, P7654, DOI 10.1128/MCB.20.20.7654-7661.2000; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; Guthrie C, 1991, GUIDE YEAST GENETICS; HARO R, 1991, FEBS LETT, V291, P189, DOI 10.1016/0014-5793(91)81280-L; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; Hinnebusch AG, 1997, J BIOL CHEM, V272, P21661, DOI 10.1074/jbc.272.35.21661; HINNEBUSCH AG, 1984, P NATL ACAD SCI-BIOL, V81, P6442, DOI 10.1073/pnas.81.20.6442; HINNEBUSCH AG, 1985, MOL CELL BIOL, V5, P2349, DOI 10.1128/MCB.5.9.2349; Hoffmann B, 1999, MOL MICROBIOL, V31, P807, DOI 10.1046/j.1365-2958.1999.01219.x; Hohmann S., 1997, YEAST STRESS RESPONS, P101; Jia MH, 2000, PHYSIOL GENOMICS, V3, P83, DOI 10.1152/physiolgenomics.2000.3.2.83; LANKER S, 1992, CELL, V70, P647, DOI 10.1016/0092-8674(92)90433-D; Marquez JA, 1996, FEBS LETT, V382, P89, DOI 10.1016/0014-5793(96)00157-3; MUELLER PP, 1986, CELL, V45, P201, DOI 10.1016/0092-8674(86)90384-3; Mulet JM, 1999, MOL CELL BIOL, V19, P3328; MURGUIA JR, 1995, SCIENCE, V267, P232; Murguia JR, 1996, J BIOL CHEM, V271, P29029, DOI 10.1074/jbc.271.46.29029; Nass R, 1997, J BIOL CHEM, V272, P26145, DOI 10.1074/jbc.272.42.26145; Norbeck J, 1998, FEMS MICROBIOL LETT, V158, P121, DOI 10.1016/S0378-1097(97)00511-9; Norbeck J, 2000, YEAST, V16, P121, DOI 10.1002/(SICI)1097-0061(20000130)16:2<121::AID-YEA511>3.0.CO;2-A; OCONNELL KF, 1995, MOL CELL BIOL, V15, P1879; Pascual-Ahuir M, 2001, MOL CELL BIOL, V21, P16, DOI 10.1128/MCB.21.1.16-25.2001; Pavitt GD, 1997, MOL CELL BIOL, V17, P1298, DOI 10.1128/MCB.17.3.1298; Pavitt GD, 1998, GENE DEV, V12, P514, DOI 10.1101/gad.12.4.514; Prior C, 1996, FEBS LETT, V387, P89, DOI 10.1016/0014-5793(96)00470-X; Qiu HF, 2000, MOL CELL BIOL, V20, P2505, DOI 10.1128/MCB.20.7.2505-2516.2000; Rep M, 2000, J BIOL CHEM, V275, P8290, DOI 10.1074/jbc.275.12.8290; ROLFES RJ, 1993, MOL CELL BIOL, V13, P5099, DOI 10.1128/MCB.13.8.5099; SEIN KT, 1971, ARCH BIOCHEM BIOPHYS, V145, P164, DOI 10.1016/0003-9861(71)90023-3; Serrano R, 1999, J EXP BOT, V50, P1023, DOI 10.1093/jexbot/50.suppl_1.1023; SMITH DWE, 1969, J BIOL CHEM, V244, P896; Tavernarakis N, 1996, GENE, V179, P271, DOI 10.1016/S0378-1119(96)00379-4; THEVELEIN JM, 1994, YEAST, V10, P1753, DOI 10.1002/yea.320101308; TZAMARIAS D, 1989, CELL, V57, P947, DOI 10.1016/0092-8674(89)90333-4; VALLEJO CG, 1989, YEAST, V5, P307, DOI 10.1002/yea.320050411; WEK RC, 1989, P NATL ACAD SCI USA, V86, P4579, DOI 10.1073/pnas.86.12.4579; WEK SA, 1995, MOL CELL BIOL, V15, P4497; Yang RJ, 2000, MOL CELL BIOL, V20, P2706, DOI 10.1128/MCB.20.8.2706-2717.2000; Yang WM, 1996, MOL CELL BIOL, V16, P6603	57	55	58	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					30753	30760		10.1074/jbc.M102960200	http://dx.doi.org/10.1074/jbc.M102960200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11408481	hybrid			2022-12-25	WOS:000170472900024
J	Kurokawa, K; Mochizuki, N; Ohba, Y; Mizuno, H; Miyawaki, A; Matsuda, M				Kurokawa, K; Mochizuki, N; Ohba, Y; Mizuno, H; Miyawaki, A; Matsuda, M			A pair of fluorescent resonance energy transfer-based probes for tyrosine phosphorylation of the CrkII adaptor protein in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SH3 DOMAINS; C-CRK; V-CRK; CELL-MIGRATION; LIVING CELLS; IN-VIVO; IDENTIFICATION; ASSOCIATION; KINASE; INDICATOR	An adaptor protein, CrkII, which is involved in a variety of signaling cascades such as cell growth, migration, and apoptosis, becomes phosphorylated on Tyr.. upon stimulation. Here, we report on a fluorescent resonance energy transfer-based sensor, which consists of CrkII sandwiched with cyan- and yellow-emitting variants of green fluorescent protein. This protein enabled us to monitor rapid and transient phosphorylation of CrkII upon epidermal growth factor stimulation in a living cell. However, rapid diffusion of the probes prevented us from specifying where the phosphorylation started within the cell. To overcome this problem, we fused the CAAX box of Ki-Ras to the carboxyl terminus of this probe and restricted its localization mostly to the plasma membrane. With this modified probe, we found that epidermal growth factor-induced phosphorylation of CrkII was initiated at the peripheral plasma membrane, moving toward the center of the cell. Moreover, this CAAX box-fused probe showed improvement in sensitivity and time resolution of the monitoring of CrkII phosphorylation. Thus, this pair of CrkII probes visualizes dynamic changes in the total and local levels of the tyrosine phosphorylation of CrkII in a living cell.	Osaka Univ, Res Inst Microbial Dis, Dept Tumor Virol, Suita, Osaka 5650871, Japan; Natl Cardiovasc Res Inst, Dept Struct Anal, Suita, Osaka 5658565, Japan; RIKEN, Brain Sci Inst, Lab Cell Funct & Dynam, Wako, Saitama 3510198, Japan	Osaka University; National Cerebral & Cardiovascular Center - Japan; RIKEN	Matsuda, M (corresponding author), Osaka Univ, Res Inst Microbial Dis, Dept Tumor Virol, 3-1 Yamadaoka, Suita, Osaka 5650871, Japan.		Miyawaki, Atsushi/K-3569-2014; Ohba, Yusuke/E-7944-2011; Kurokawa, Kazuo/E-9130-2013; Mizuno, Hideaki/AAH-5737-2021	Miyawaki, Atsushi/0000-0002-2329-3235; Kurokawa, Kazuo/0000-0003-3549-4795; Mizuno, Hideaki/0000-0002-6983-5255; Matsuda, Michiyuki/0000-0002-5876-9969				BEITNERJOHNSON D, 1995, J BIOL CHEM, V270, P5187, DOI 10.1074/jbc.270.10.5187; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; Blakesley VA, 1997, J BIOL CHEM, V272, P16211, DOI 10.1074/jbc.272.26.16211; Cotton GJ, 2000, CHEM BIOL, V7, P253, DOI 10.1016/S1074-5521(00)00100-9; Escalante M, 2000, J BIOL CHEM, V275, P24787, DOI 10.1074/jbc.M000711200; EVANS GA, 1995, J BIOL CHEM, V270, P28858, DOI 10.1074/jbc.270.48.28858; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; Galletta BJ, 1999, GENE, V228, P243, DOI 10.1016/S0378-1119(99)00010-4; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; Hashimoto Y, 1998, J BIOL CHEM, V273, P17186, DOI 10.1074/jbc.273.27.17186; Honda A, 2001, P NATL ACAD SCI USA, V98, P2437, DOI 10.1073/pnas.051631298; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; Kraynov VS, 2000, SCIENCE, V290, P333, DOI 10.1126/science.290.5490.333; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; Miyawaki A, 1999, P NATL ACAD SCI USA, V96, P2135, DOI 10.1073/pnas.96.5.2135; Miyawaki A, 2000, METHOD ENZYMOL, V327, P472, DOI 10.1016/S0076-6879(00)27297-2; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; Mochizuki N, 2001, NATURE, V411, P1065, DOI 10.1038/35082594; Nagai Y, 2000, NAT BIOTECHNOL, V18, P313, DOI 10.1038/73767; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; Reddien PW, 2000, NAT CELL BIOL, V2, P131, DOI 10.1038/35004000; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; Ribon V, 1996, J BIOL CHEM, V271, P7375, DOI 10.1074/jbc.271.13.7375; ROSEN MK, 1995, NATURE, V374, P477, DOI 10.1038/374477a0; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SCHALLER MD, 1995, J CELL BIOL, V130, P1181, DOI 10.1083/jcb.130.5.1181; Zaccolo M, 2000, NAT CELL BIOL, V2, P25, DOI 10.1038/71345	33	118	133	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					31305	31310		10.1074/jbc.M104341200	http://dx.doi.org/10.1074/jbc.M104341200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11406630	hybrid			2022-12-25	WOS:000170472900094
J	Ni, YG; Chen, JG; Androutsellis-Theotokis, A; Huang, CJ; Moczydlowski, E; Rudnick, G				Ni, YG; Chen, JG; Androutsellis-Theotokis, A; Huang, CJ; Moczydlowski, E; Rudnick, G			A lithium-induced conformational change in serotonin transporter alters cocaine binding, ion conductance, and reactivity of Cds-109	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN DOPAMINE TRANSPORTER; CLONING; NOREPINEPHRINE; ACCESSIBILITY; EXPRESSION; PERMEATION; SUBSTRATE; RESIDUES; CYSTEINE; CHANNEL	Inactivation of serotonin transporter (SERT) expressed in HeLa cells by [2-(trimethylammonium)ethyl]-methanethiosulfonate (MTSET) occurred much more readily when Na+ in the reaction medium was replaced with Li+. This did not result from a protective effect of Na+ but rather from a Li+-specific increase in the reactivity of Cys-109 in the first external loop of the transporter. Li+ alone of the alkali cations caused this increase in reactivity. Replacing Na+ with N-methyl-D-glucamine (NMDG(+)) did not reduce the affinity of cocaine for SERT, as measured by displacement of a high affinity cocaine analog, but replacement of Na+ with Li+ led to a 2-fold increase in the KD for cocaine. The addition of either cocaine or serotonin (5-HT) protected SERT against MTSET inactivation. When SERT was expressed in Xenopus oocytes, inward currents were elicited by superfusing the cell with 5-HT (in the presence of Na+) or by replacing Na+ with Li+ but not NMDG(+). MTSET treatment of oocytes in Li+ but not in Na+ decreased both 5-HT and Li+ induced currents, although 5-HT-induced currents were inhibited to a greater extent. Na+ antagonized the effects of Li+ on both inactivation and current. These results are consistent with Li+ inducing a conformational change that exposes Cys-109, decreases cocaine affinity, and increases the uncoupled inward current.	Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06510 USA	Yale University	Rudnick, G (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, 333 Cedar St, New Haven, CT 06510 USA.		Moczydlowski, Edward G/D-1734-2013	Androutsellis-Theotokis, Andreas/0000-0002-1985-4589				BLAKELY RD, 1994, J EXP BIOL, V196, P263; BLAKELY RD, 1991, ANAL BIOCHEM, V194, P302, DOI 10.1016/0003-2697(91)90233-J; BLAKELY RD, 1991, NATURE, V354, P66, DOI 10.1038/354066a0; Chen JG, 2000, P NATL ACAD SCI USA, V97, P1044, DOI 10.1073/pnas.97.3.1044; Chen JG, 1997, BIOCHEMISTRY-US, V36, P1479, DOI 10.1021/bi962256g; Chen JG, 1997, J BIOL CHEM, V272, P28321, DOI 10.1074/jbc.272.45.28321; Chen NH, 2000, J BIOL CHEM, V275, P1608, DOI 10.1074/jbc.275.3.1608; Ferrer JV, 1998, P NATL ACAD SCI USA, V95, P9238, DOI 10.1073/pnas.95.16.9238; Galli A, 1996, P NATL ACAD SCI USA, V93, P8671, DOI 10.1073/pnas.93.16.8671; GIROS B, 1991, FEBS LETT, V295, P149, DOI 10.1016/0014-5793(91)81406-X; GU H, 1994, J BIOL CHEM, V269, P7124; Gu HH, 1996, J BIOL CHEM, V271, P6911, DOI 10.1074/jbc.271.12.6911; HOFFMAN BJ, 1991, SCIENCE, V254, P579, DOI 10.1126/science.1948036; HUMPHREYS CJ, 1991, BIOCHEM SOC T, V19, P95, DOI 10.1042/bst0190095; HUMPHREYS CJ, 1994, BIOCHEMISTRY-US, V33, P9118, DOI 10.1021/bi00197a014; JENCKS WP, 1969, CATALYSIS CHEM ENZYM, P358; Kamdar G, 2001, J BIOL CHEM, V276, P4038, DOI 10.1074/jbc.M008483200; Karlin A, 1998, METHOD ENZYMOL, V293, P123; Lin F, 1996, BIOPHYS J, V71, P3126, DOI 10.1016/S0006-3495(96)79506-1; Loo DDF, 1998, P NATL ACAD SCI USA, V95, P7789, DOI 10.1073/pnas.95.13.7789; Mager S, 1996, J NEUROSCI, V16, P5405; MAGER S, 1994, NEURON, V12, P845, DOI 10.1016/0896-6273(94)90337-9; Nelson N, 1998, J NEUROCHEM, V71, P1785; PEERCE BE, 1984, J BIOL CHEM, V259, P4105; Petersen CI, 1999, NAT NEUROSCI, V2, P605, DOI 10.1038/10158; Smicun Y, 1999, J BIOL CHEM, V274, P36058, DOI 10.1074/jbc.274.51.36058; Sonders MS, 1997, J NEUROSCI, V17, P960; TALVENHEIMO J, 1983, J BIOL CHEM, V258, P6115; WALL SC, 1993, MOL PHARMACOL, V43, P264	29	33	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					30942	30947		10.1074/jbc.M104653200	http://dx.doi.org/10.1074/jbc.M104653200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11408487	hybrid			2022-12-25	WOS:000170472900048
J	Vila, R; Ponte, I; Collado, M; Arrondo, JLR; Suau, P				Vila, R; Ponte, I; Collado, M; Arrondo, JLR; Suau, P			Induction of secondary structure in a COOH-terminal peptide of histone H1 by interaction with the DNA - An infrared spectroscopy study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; TRANSCRIPTION IN-VIVO; GLOBULAR DOMAIN; GENE-EXPRESSION; AQUEOUS-SOLUTION; LINKER HISTONES; ALPHA-HELICES; PROTEINS; BINDING; CHROMATIN	We have studied the conformation of the peptide Ac-EPKRSVAFKKTKKEVKKVATPKK (CH-1), free in solution and bound to the DNA, by Fourier-transform infrared spectroscopy. The peptide belongs to the COOH-terminal domain of histone H1(0) (residues 99-121) and is adjacent to the central globular domain of the protein. In aqueous (D2O) solution the amide I ' is dominated by component bands at 1643 cm(-1) and 1662 cm(-1), which have been assigned to random coil conformations and turns, respectively. In accordance with previous NMR results, the latter component has been interpreted as arising in turn-like conformations in rapid equilibrium with unfolded states. The peptide becomes fully structured either in 90% trifluoroethanol (TFE) solution or upon interaction with the DNA. In these conditions, the contributions of turn (1662 cm(-1)) and random coil components virtually disappear. In TFE, the spectrum is dominated by the a-helical component (1654 cm(-1)). The band at 1662 cm(-1) shifts to 1670 cm(-1), and has been assigned to the COOH-terminal TPKK motif in a more stable turn conformation. A band at 1637 cm(-1), also present in TFE, has been assigned to 3(10) helical structure. The amide I ' band of the complexes with the DNA retains the components that were attributed to 3(10) helix and the TPKK turn. In the complexes with the DNA, the a-helical component observed in TFE splits into two components at 1657 cm(-1) and 1647 cm(-1). Both components are inside the spectral region of alpha -helical structures. Our results support the presence of inducible helical and turn elements, both sharing the character of DNA-binding motifs.	Univ Autonoma Barcelona, Fac Ciencias, Dept Bioquim & Biol Mol, Barcelona 08193, Spain; Univ Basque Country, Dept Bioquim, E-48080 Bilbao, Spain	Autonomous University of Barcelona; University of Barcelona; University of Basque Country	Suau, P (corresponding author), Univ Autonoma Barcelona, Fac Ciencias, Dept Bioquim & Biol Mol, Barcelona 08193, Spain.	Pere.Suau@uab.es	Vila, Roger/A-1817-2012; Ponte, Inma/AGN-5337-2022; Ponte, Inma/E-6848-2015; Suau, Pedro/D-2695-2009	Vila, Roger/0000-0002-2447-4388; Ponte, Inma/0000-0002-9448-6915; Suau, Pedro/0000-0001-6673-8209				ABBOTT TP, 1991, APPL SPECTROSC, V45, P1665, DOI 10.1366/0003702914335265; ALVAREZ J, 1987, BIOCHIM BIOPHYS ACTA, V916, P5, DOI 10.1016/0167-4838(87)90204-4; Arrondo JLR, 1999, PROG BIOPHYS MOL BIO, V72, P367, DOI 10.1016/S0079-6107(99)00007-3; BOUVET P, 1994, GENE DEV, V8, P1147, DOI 10.1101/gad.8.10.1147; BYLER DM, 1986, BIOPOLYMERS, V25, P469, DOI 10.1002/bip.360250307; CERF C, 1993, BIOCHEMISTRY-US, V32, P11345, DOI 10.1021/bi00093a011; CLARK DJ, 1988, EMBO J, V7, P69, DOI 10.1002/j.1460-2075.1988.tb02784.x; CLORE GM, 1987, EMBO J, V6, P1833, DOI 10.1002/j.1460-2075.1987.tb02438.x; Crane-Robinson C, 1999, BIOESSAYS, V21, P367, DOI 10.1002/(SICI)1521-1878(199905)21:5<367::AID-BIES2>3.0.CO;2-4; Dou YL, 1999, MOL CELL, V4, P641, DOI 10.1016/S1097-2765(00)80215-4; DWIVEDI AM, 1984, BIOPOLYMERS, V23, P2025, DOI 10.1002/bip.360231016; DYSON HJ, 1988, J MOL BIOL, V201, P201, DOI 10.1016/0022-2836(88)90447-0; Galan A, 2001, J BIOL CHEM, V276, P957, DOI 10.1074/jbc.M006861200; GOORMAGHTIGH E, 1989, BIOCHIM BIOPHYS ACTA, V1006, P147, DOI 10.1016/0005-2760(89)90338-X; HARIS PI, 1995, BIOPOLYMERS, V37, P251, DOI 10.1002/bip.360370404; HARTMAN PG, 1977, EUR J BIOCHEM, V77, P45, DOI 10.1111/j.1432-1033.1977.tb11639.x; HERZYK E, 1987, BIOCHIM BIOPHYS ACTA, V922, P145, DOI 10.1016/0005-2760(87)90148-2; HILL CS, 1989, EMBO J, V8, P2591, DOI 10.1002/j.1460-2075.1989.tb08398.x; HOLLOWAY PW, 1989, BIOCHEMISTRY-US, V28, P931, DOI 10.1021/bi00429a002; Howe L, 1998, BIOCHEMISTRY-US, V37, P7077, DOI 10.1021/bi980410o; JACKSON M, 1992, BIOCHEMISTRY-US, V31, P7289, DOI 10.1021/bi00147a012; JACKSON M, 1991, BIOCHEMISTRY-US, V30, P9681, DOI 10.1021/bi00104a016; KHOCHBIN S, 1994, EUR J BIOCHEM, V225, P501, DOI 10.1111/j.1432-1033.1994.00501.x; Lee HL, 1998, EMBO J, V17, P1454, DOI 10.1093/emboj/17.5.1454; MIICK SM, 1992, NATURE, V359, P653, DOI 10.1038/359653a0; MORAN F, 1985, BIOPHYS CHEM, V22, P125, DOI 10.1016/0301-4622(85)80033-8; PRESTRELSKI SJ, 1991, INT J PEPT PROT RES, V37, P508; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; Shen XT, 1996, CELL, V86, P475, DOI 10.1016/S0092-8674(00)80120-8; SUREWICZ WK, 1990, BIOCHEMISTRY-US, V29, P8106, DOI 10.1021/bi00487a017; SUREWICZ WK, 1993, BIOCHEMISTRY-US, V32, P389, DOI 10.1021/bi00053a001; Susi H., 1969, STRUCTURE STABILITY, P575; SUZUKI M, 1993, PROTEIN ENG, V6, P565, DOI 10.1093/protein/6.6.565; SUZUKI M, 1989, EMBO J, V8, P797, DOI 10.1002/j.1460-2075.1989.tb03440.x; Vermaak D, 1998, CURR BIOL, V8, P533, DOI 10.1016/S0960-9822(98)70206-4; Vila R, 2000, PROTEIN SCI, V9, P627; Wolffe AP, 1997, BIOESSAYS, V19, P249, DOI 10.1002/bies.950190311; WUTHRICH K, 1984, J MOL BIOL, V180, P715, DOI 10.1016/0022-2836(84)90034-2; ZLATANOVA J, 1992, J CELL SCI, V103, P889	39	61	62	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					30898	30903		10.1074/jbc.M104189200	http://dx.doi.org/10.1074/jbc.M104189200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11413144	hybrid			2022-12-25	WOS:000170472900043
J	Berezovska, O; Jack, C; Deng, A; Gastineau, N; Rebeck, GW; Hyman, BT				Berezovska, O; Jack, C; Deng, A; Gastineau, N; Rebeck, GW; Hyman, BT			Notch1 and amyloid precursor protein are competitive substrates for presenilin1-dependent gamma-secretase cleavage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; A-BETA; CELL FATE; PRESENILIN-1 MUTATIONS; NUCLEAR TRANSLOCATION; INTRACELLULAR DOMAIN; SIGNAL-TRANSDUCTION; PROTEOLYTIC RELEASE; IN-VIVO; NEURONS	Proteolytic processing of the amyloid precursor protein (APP) by beta- and gamma -secretases results in the production of a highly amyloidogenic A beta peptide, which deposits in the brains of Alzheimer's disease patients. Similar gamma -secretase processing occurs in another transmembrane protein, Notch1, releasing a potent signaling molecule, the Notch C-terminal domain. It has been shown that both events are dependent on a presenilin-dependent protease. We now test the hypothesis that activated Notch1 and APP are competitive substrates for the same proteolytic activity in neurons. Treatment of neurons with the native Notch ligand, Delta, induces endogenous Notch1 intramembraneous cleavage. and diminishes A beta production in a dose-dependent manner. Complementary experiments showed that the converse was also true. Overexpressing human APP (APP(695SW)) in neurons leads to a decrease in endogenous Notch1 signal transduction, as assessed by a CBF1 luciferase transcription assay, by Notch C-terminal domain nuclear translocation in vitro and by analysis of Notch C-terminal domain generation and Notch1 staining in vivo. In summary, two complementary approaches suggest that APP and Notch1 are physiologically relevant competitive substrates for gamma -secretase activity.	Harvard Univ, Sch Med, Massachusetts Gen Hosp, Alzheimers Dis Res Lab,Alzheimers Dis Unit, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital	Hyman, BT (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Alzheimers Dis Res Lab,Alzheimers Dis Unit, Rm 2009,114-16th St, Charlestown, MA 02129 USA.		Jack, Clifford R/F-2508-2010; Rebeck, George William/J-2192-2012	Jack, Clifford R/0000-0001-7916-622X; Rebeck, George William/0000-0001-6276-248X	NIA NIH HHS [P01 AG15379, AG14744] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG015379, R01AG014744] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; Aster JC, 1997, J BIOL CHEM, V272, P11336; Baumeister R, 1997, Genes Funct, V1, P149; Berezovska O, 1999, MOL BRAIN RES, V69, P273, DOI 10.1016/S0169-328X(99)00119-9; Berezovska O, 1997, J NEUROPATH EXP NEUR, V56, P40, DOI 10.1097/00005072-199701000-00004; Berezovska O, 1999, NEUROSCIENCE, V93, P433, DOI 10.1016/S0306-4522(99)00157-8; Berezovska O, 2000, J NEUROCHEM, V75, P583, DOI 10.1046/j.1471-4159.2000.0750583.x; Berezovska O, 1998, J NEUROPATH EXP NEUR, V57, P738, DOI 10.1097/00005072-199808000-00003; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; Capell A, 2000, NAT CELL BIOL, V2, P205, DOI 10.1038/35008626; Chitnis AB, 1999, CURR OPIN NEUROBIOL, V9, P18, DOI 10.1016/S0959-4388(99)80003-8; Citron M, 1996, P NATL ACAD SCI USA, V93, P13170, DOI 10.1073/pnas.93.23.13170; De Strooper B, 2000, J CELL SCI, V113, P1857; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; delaPompa J, 1997, DEVELOPMENT, V124, P1139; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; Gridley T, 1997, MOL CELL NEUROSCI, V9, P103, DOI 10.1006/mcne.1997.0610; Herreman A, 2000, NAT CELL BIOL, V2, P461, DOI 10.1038/35017105; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Hsieh JJD, 1996, MOL CELL BIOL, V16, P952; Jack C, 2001, MOL BRAIN RES, V87, P166, DOI 10.1016/S0169-328X(01)00010-9; KNOPS J, 1995, J BIOL CHEM, V270, P2419, DOI 10.1074/jbc.270.6.2419; Kopan R, 1996, CURR OPIN NEUROBIOL, V6, P594, DOI 10.1016/S0959-4388(96)80090-0; Kopan R, 1996, P NATL ACAD SCI USA, V93, P1683, DOI 10.1073/pnas.93.4.1683; Kulic L, 2000, P NATL ACAD SCI USA, V97, P5913, DOI 10.1073/pnas.100049897; LEEM J, 2000, SOC NEUR M NEW ORL A; Levitan D, 1996, P NATL ACAD SCI USA, V93, P14940, DOI 10.1073/pnas.93.25.14940; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; MUSKAVITCH MAT, 1994, DEV BIOL, V166, P415, DOI 10.1006/dbio.1994.1326; Nitsch RM, 2000, ANN NEUROL, V48, P913, DOI 10.1002/1531-8249(200012)48:6<913::AID-ANA12>3.3.CO;2-J; Petit A, 2001, NAT CELL BIOL, V3, P507, DOI 10.1038/35074581; Qian S, 1998, NEURON, V20, P611, DOI 10.1016/S0896-6273(00)80999-X; Qiu ZH, 1999, J NEUROCHEM, V73, P1393, DOI 10.1046/j.1471-4159.1999.0731393.x; Ray WJ, 1999, J BIOL CHEM, V274, P36801, DOI 10.1074/jbc.274.51.36801; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Selkoe DJ, 1998, TRENDS CELL BIOL, V8, P447, DOI 10.1016/S0962-8924(98)01363-4; SELKOE DJ, 1988, P NATL ACAD SCI USA, V85, P7341, DOI 10.1073/pnas.85.19.7341; Sestan N, 1999, SCIENCE, V286, P741, DOI 10.1126/science.286.5440.741; Song WH, 1999, P NATL ACAD SCI USA, V96, P6959, DOI 10.1073/pnas.96.12.6959; Steiner H, 1999, J BIOL CHEM, V274, P28669, DOI 10.1074/jbc.274.40.28669; Struhl G, 1998, CELL, V93, P649, DOI 10.1016/S0092-8674(00)81193-9; Sudoh S, 1998, J NEUROCHEM, V71, P1535; Wang SL, 1998, NEURON, V21, P63, DOI 10.1016/S0896-6273(00)80515-2; Weinmaster G, 1997, MOL CELL NEUROSCI, V9, P91, DOI 10.1006/mcne.1997.0612; Wilson CA, 1999, J NEUROPATH EXP NEUR, V58, P787, DOI 10.1097/00005072-199908000-00001; Wittenburg N, 2000, NATURE, V406, P306, DOI 10.1038/35018575; Wolfe MS, 1998, J MED CHEM, V41, P6, DOI 10.1021/jm970621b; Wolfe MS, 1999, BIOCHEMISTRY-US, V38, P11223, DOI 10.1021/bi991080q; Wolfe MS, 1999, BIOCHEMISTRY-US, V38, P4720, DOI 10.1021/bi982562p; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Zhang ZH, 2000, NAT CELL BIOL, V2, P463, DOI 10.1038/35017108	54	76	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30018	30023		10.1074/jbc.M008268200	http://dx.doi.org/10.1074/jbc.M008268200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11408475	hybrid			2022-12-25	WOS:000170558000055
J	Curcio, C; Baqui, MMA; Salvatore, D; Rihn, BH; Mohr, S; Harney, JW; Larsen, PR; Bianco, AC				Curcio, C; Baqui, MMA; Salvatore, D; Rihn, BH; Mohr, S; Harney, JW; Larsen, PR; Bianco, AC			The human type 2 iodothyronine deiodinase is a selenoprotein highly expressed in a mesothelioma cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTRATE-BINDING SUBUNIT; II 5-DEIODINASE; RAT-BRAIN; CLONING; DEGRADATION; ASTROCYTES; FAMILY; GENE	Types 1 and 3 iodothyronine deiodinases are known to be selenocysteine-containing enzymes. Although a putative human type 2 iodothyronine deiodinase (D2) gene (hDio2) encoding a similar selenoprotein has been identified, basal D2 activity is not selenium (Se)-dependent nor has D2 been labeled with Se-75. A human mesothelioma cell line (MSTO-211H) has recently been shown to have similar to 40-fold higher levels of hDio2 mRNA than mesothelial cells. Mesothelioma cell lysates activate thyroxine (T-4) to 3,5,3 ' -triiodothyronine with typical characteristics of D2 such as low K-m (T-4), 1.3 mi, resistance to propylthiouracil, and a short half-life (similar to 30 min). D2 activity is similar to 30-fold higher in Se-supplemented than in Se-depleted medium. An antiserum prepared against a peptide deduced from the Dio2 mRNA sequence precipitates a Se-75 protein of the predicted 31-kDa size from Se-75-labeled mesothelioma cells. Bromoadenosine 3 '5 ' cyclic monophosphate increases D2 activity and Se-75-p31 similar to2.5-fold whereas substrate (T-4) reduces both D2 activity and Se-75-p31 similar to2-3-fold. MG132 or lactacystin (10 muM), inhibitors of the proteasome pathway by which D2 is degraded, increase both D2 activity and Se-75-p31 3-4-fold and prevent the loss of D2 activity during cycloheximide or substrate (T-4) exposure. Immunocytochemical studies with affinity-purified anti-hD2 antibody show a Se-dependent increase in immunofluorescence. Thus, human D2 is encoded by hDio2 and is a member of the selenodeiodinase family accounting for its highly catalytic efficiency in T-4 activation.	Brigham & Womens Hosp, Dept Med, Div Thyroid, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Inst Natl Rech & Secur, F-54501 Vandoeuvre Les Nancy, France	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Bianco, AC (corresponding author), Brigham & Womens Hosp, Dept Med, Div Thyroid, 77 Ave Louis Pasteur,HIM Bldg 550, Boston, MA 02115 USA.	abianco@rics.bwh.harvard.edu	Salvatore, Domenico/D-4881-2013; Bianco, Antonio C/A-4965-2008; Baqui, Munira M. A/H-5243-2013; Bianco, Antonio/AAK-6336-2020	Bianco, Antonio C/0000-0001-7737-6813; Baqui, Munira M. A/0000-0002-7945-2899; Bianco, Antonio/0000-0001-7737-6813; SALVATORE, DOMENICO/0000-0002-4556-7620	NIDDK NIH HHS [DK36256, DK58538] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036256, R01DK058538] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baqui MMA, 2000, ENDOCRINOLOGY, V141, P4309, DOI 10.1210/en.141.11.4309; Bartha T, 2000, ENDOCRINOLOGY, V141, P229, DOI 10.1210/en.141.1.229; BEHNE D, 1988, BIOCHIM BIOPHYS ACTA, V966, P12, DOI 10.1016/0304-4165(88)90123-7; BERRY MJ, 1991, NATURE, V349, P438, DOI 10.1038/349438a0; BERRY MJ, 1991, NATURE, V353, P273, DOI 10.1038/353273a0; Buettner C, 1998, J BIOL CHEM, V273, P33374, DOI 10.1074/jbc.273.50.33374; CHANOINE JP, 1992, ENDOCRINOLOGY, V131, P1787, DOI 10.1210/en.131.4.1787; CHANOINE JP, 1992, ENDOCRINOLOGY, V131, P479, DOI 10.1210/en.131.1.479; Croteau W, 1996, J CLIN INVEST, V98, P405, DOI 10.1172/JCI118806; FARWELL AP, 1989, J BIOL CHEM, V264, P20561; Farwell AP, 1996, J BIOL CHEM, V271, P16369, DOI 10.1074/jbc.271.27.16369; Gereben B, 2000, MOL ENDOCRINOL, V14, P1697, DOI 10.1210/me.14.11.1697; Gereben B, 1999, J BIOL CHEM, V274, P13768, DOI 10.1074/jbc.274.20.13768; Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848; Huang SA, 2000, NEW ENGL J MED, V343, P185, DOI 10.1056/NEJM200007203430305; Kohrle J, 2000, ACTA MED AUST, V27, P1; Kohrle J, 2000, CELL MOL LIFE SCI, V57, P1853, DOI 10.1007/PL00000667; Leonard DM, 2000, J BIOL CHEM, V275, P25194, DOI 10.1074/jbc.M002036200; Leonard JL, 1999, ENDOCRINOLOGY, V140, P2206, DOI 10.1210/en.140.5.2206; LEONARD JL, 1981, SCIENCE, V214, P571, DOI 10.1126/science.7291997; LEONARD JL, 1988, BIOCHEM BIOPH RES CO, V151, P1164, DOI 10.1016/S0006-291X(88)80488-1; Low SC, 1996, TRENDS BIOCHEM SCI, V21, P203, DOI 10.1016/0968-0004(96)10025-6; Pallud S, 1997, J BIOL CHEM, V272, P18104, DOI 10.1074/jbc.272.29.18104; Rihn BH, 2000, FEBS LETT, V480, P95, DOI 10.1016/S0014-5793(00)01913-X; Safran M, 1996, J BIOL CHEM, V271, P16363, DOI 10.1074/jbc.271.27.16363; SAFRAN M, 1993, J BIOL CHEM, V268, P14224; SAFRAN M, 1991, J BIOL CHEM, V266, P13477; SAFRAN M, 1991, J BIOL CHEM, V266, P3233; Salvatore D, 1999, BIOCHIMIE, V81, P535, DOI 10.1016/S0300-9084(99)80106-0; Salvatore D, 1996, ENDOCRINOLOGY, V137, P3308, DOI 10.1210/en.137.8.3308; Salvatore D, 1996, J CLIN INVEST, V98, P962, DOI 10.1172/JCI118880; SANDSTROM BE, 1990, BIOCHEM J, V271, P17, DOI 10.1042/bj2710017; SCHNEIDER M, 2000, 12 INT THYROID C KYO; Stachelek SJ, 2000, J BIOL CHEM, V275, P31701, DOI 10.1074/jbc.M004221200; Steinsapir J, 2000, ENDOCRINOLOGY, V141, P1127, DOI 10.1210/en.141.3.1127; Steinsapir J, 1998, J CLIN INVEST, V102, P1895, DOI 10.1172/JCI4672; STGERMAIN DL, 1986, ENDOCRINOLOGY, V119, P840; STGERMAIN DL, 1994, P NATL ACAD SCI USA, V91, P7767, DOI 10.1073/pnas.91.16.7767	38	72	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30183	30187		10.1074/jbc.C100325200	http://dx.doi.org/10.1074/jbc.C100325200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11425850	hybrid			2022-12-25	WOS:000170558000078
J	Stewart, JJ; Stargell, LA				Stewart, JJ; Stargell, LA			The stability of the TFIIA-TBP-DNA complex is dependent on the sequence of the TATAAA element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-II TRANSCRIPTION; BINDING PROTEIN; CRYSTAL-STRUCTURE; MINOR-GROOVE; YEAST TRANSCRIPTION; REINITIATION RATE; IN-VIVO; ACTIVATION; PROMOTER; INITIATION	To determine the mechanistic differences between canonical and noncanonical TATA elements, we compared the functional activity of two sequences: TATAAA (canonical) and CATAAA (noncanonical). The TATAAA element can support high levels of transcription in vivo, whereas the CATAAA element is severely defective for this function.. This dramatic functional difference is not likely to be due to a difference in TBP (TATA-binding protein) binding efficiency because protein-DNA complex studies in vitro indicate little difference between the two DNA sequences in the formation and stability of the TBP-DNA complex. In addition, the binding and stability of the TFIIB-TBP-DNA complex is similar for the two elements. In striking contrast, the TFIIA-TBP-DNA complex is significantly less stable on the CATAAA element when compared with the TATAAA element. A role for TFIIA in distinguishing between TATAAA and CATAAA in vivo was tested by fusing. a subunit of TFIIA to TBP. We found that fusion of TFIIA to TBP dramatically increases transcription from CATAAA, in yeast cells. Taken together, these results indicate that the stability of the TFIIA-TBP complex depends strongly on the sequence of the core promoter element and that the TFIIA-TBP complex plays an important function in recognizing optimal promoters in vivo.	Colorado State Univ, Dept Biochem & Mol Biol, Ft Collins, CO 80523 USA; Univ Hawaii, Pacific Biomed Res Ctr, Honolulu, HI 96813 USA	Colorado State University; University of Hawaii System	Stargell, LA (corresponding author), Colorado State Univ, Dept Biochem & Mol Biol, Ft Collins, CO 80523 USA.	lstargel@lamar.colostate.edu	Stargell, Laurie/GWC-7423-2022		NIGMS NIH HHS [GM56884] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056884] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUBLE DT, 1993, GENE DEV, V7, P844, DOI 10.1101/gad.7.5.844; AUBLE DT, 1994, GENE DEV, V8, P1920, DOI 10.1101/gad.8.16.1920; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; Campbell KM, 2000, BIOCHEMISTRY-US, V39, P2633, DOI 10.1021/bi9922998; CHATTERJEE S, 1995, NATURE, V374, P820, DOI 10.1038/374820a0; CHEN W, 1988, P NATL ACAD SCI USA, V85, P2691, DOI 10.1073/pnas.85.8.2691; Chi TH, 1996, GENE DEV, V10, P2540, DOI 10.1101/gad.10.20.2540; Clemens KE, 1996, MOL CELL BIOL, V16, P4656; COLLART MA, 1994, GENE DEV, V8, P525, DOI 10.1101/gad.8.5.525; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; Damania B, 1998, MOL CELL BIOL, V18, P3926, DOI 10.1128/MCB.18.7.3926; Geiger JH, 1996, SCIENCE, V272, P830, DOI 10.1126/science.272.5263.830; HAHN S, 1989, P NATL ACAD SCI USA, V86, P5718, DOI 10.1073/pnas.86.15.5718; Hampsey M, 1998, MICROBIOL MOL BIOL R, V62, P465, DOI 10.1128/MMBR.62.2.465-503.1998; HAWLEY DK, 1987, J BIOL CHEM, V262, P3452; HOOPES BC, 1992, J BIOL CHEM, V267, P11539; Hoopes BC, 1998, J MOL BIOL, V277, P1015, DOI 10.1006/jmbi.1998.1651; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; IMBALZANO AN, 1994, J BIOL CHEM, V269, P8280; Iyer V, 1996, P NATL ACAD SCI USA, V93, P5208, DOI 10.1073/pnas.93.11.5208; IYER V, 1995, MOL CELL BIOL, V15, P7059; JIANG Y, 1993, MOL CELL BIOL, V13, P4572, DOI 10.1128/MCB.13.8.4572; KANG JJ, 1995, MOL CELL BIOL, V15, P1234; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KLAGES N, 1995, NATURE, V374, P822, DOI 10.1038/374822a0; KLEIN C, 1994, SCIENCE, V266, P280, DOI 10.1126/science.7939664; KOBAYASHI N, 1995, MOL CELL BIOL, V15, P6465; Kokubo T, 1998, MOL CELL BIOL, V18, P1003, DOI 10.1128/MCB.18.2.1003; Kuras L, 2000, SCIENCE, V288, P1244, DOI 10.1126/science.288.5469.1244; Kuras L, 1999, NATURE, V399, P609, DOI 10.1038/21239; LEE DK, 1992, MOL CELL BIOL, V12, P5189, DOI 10.1128/MCB.12.11.5189; LEE DK, 1991, CELL, V67, P1241, DOI 10.1016/0092-8674(91)90300-N; Lemaire M, 2000, MOL MICROBIOL, V36, P163, DOI 10.1046/j.1365-2958.2000.01839.x; LI WZ, 1991, MOL CELL BIOL, V11, P666, DOI 10.1128/MCB.11.2.666; Li XY, 1999, NATURE, V399, P605, DOI 10.1038/21232; LIEBERMAN PM, 1994, GENE DEV, V8, P995, DOI 10.1101/gad.8.9.995; Liu Q, 1999, MOL CELL BIOL, V19, P8673; MAHADEVAN S, 1990, MOL CELL BIOL, V10, P4447, DOI 10.1128/MCB.10.9.4447; MARTINEZ E, 1994, EMBO J, V13, P3115, DOI 10.1002/j.1460-2075.1994.tb06610.x; Moqtaderi Z, 1996, NATURE, V383, P188, DOI 10.1038/383188a0; Muldrow TA, 1999, MOL CELL BIOL, V19, P2835; MYERS RM, 1986, SCIENCE, V232, P613, DOI 10.1126/science.3457470; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; NOTHIAS JY, 1995, J BIOL CHEM, V270, P22077, DOI 10.1074/jbc.270.38.22077; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; OZER J, 1994, GENE DEV, V8, P2324, DOI 10.1101/gad.8.19.2324; Ozer J, 1998, MOL CELL BIOL, V18, P2559, DOI 10.1128/MCB.18.5.2559; Patikoglou G, 1997, ANNU REV BIOPH BIOM, V26, P289, DOI 10.1146/annurev.biophys.26.1.289; Patikoglou GA, 1999, GENE DEV, V13, P3217, DOI 10.1101/gad.13.24.3217; PONTICELLI AS, 1990, MOL CELL BIOL, V10, P2832, DOI 10.1128/MCB.10.6.2832; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RANISH JA, 1992, SCIENCE, V255, P1127, DOI 10.1126/science.1546313; ROY A, 1990, MOL CELL BIOL, V10, P5257, DOI 10.1128/MCB.10.10.5257; SINGER VL, 1990, GENE DEV, V4, P636, DOI 10.1101/gad.4.4.636; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; STARGELL LA, 1995, SCIENCE, V269, P75, DOI 10.1126/science.7604282; Stargell LA, 2000, J BIOL CHEM, V275, P12374, DOI 10.1074/jbc.275.17.12374; STARR DB, 1991, CELL, V67, P1231, DOI 10.1016/0092-8674(91)90299-E; STARR DB, 1995, J MOL BIOL, V250, P434; Struhl K, 1995, ANNU REV GENET, V29, P651, DOI 10.1146/annurev.ge.29.120195.003251; STRUHL K, 1986, MOL CELL BIOL, V6, P3847, DOI 10.1128/MCB.6.11.3847; Tan S, 1996, NATURE, V381, P127, DOI 10.1038/381127a0; Weideman CA, 1997, J MOL BIOL, V271, P61, DOI 10.1006/jmbi.1997.1152; WOBBE CR, 1990, MOL CELL BIOL, V10, P3859, DOI 10.1128/MCB.10.8.3859; WONG I, 1993, P NATL ACAD SCI USA, V90, P5428, DOI 10.1073/pnas.90.12.5428; XIAO H, 1995, MOL CELL BIOL, V15, P5757; Xie J, 2000, EMBO J, V19, P672, DOI 10.1093/emboj/19.4.672; Yean D, 1997, MOL CELL BIOL, V17, P3809, DOI 10.1128/MCB.17.7.3809; Yean D, 1999, NUCLEIC ACIDS RES, V27, P831, DOI 10.1093/nar/27.3.831; Yudkovsky N, 2000, NATURE, V408, P225, DOI 10.1038/35041603; ZAWEL L, 1995, GENE DEV, V9, P1479, DOI 10.1101/gad.9.12.1479	73	42	43	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30078	30084		10.1074/jbc.M105276200	http://dx.doi.org/10.1074/jbc.M105276200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11402056	hybrid			2022-12-25	WOS:000170558000064
J	Trent, JT; Watts, RA; Hargrove, MS				Trent, JT; Watts, RA; Hargrove, MS			Human neuroglobin, a hexacoordinate hemoglobin that reversibly binds oxygen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE; LIGAND-BINDING; HEME POCKET; MYOGLOBIN; LEGHEMOGLOBIN; KINETICS; GENE; CYANOBACTERIUM; COOPERATIVITY; GLOBIN	Neuroglobin is a newly discovered mammalian hemoglobin that is expressed predominately in the brain (Burmester, T., Welch, B., Reinhardt, S., and Hankeln, T. (2000) Nature 407, 520-523). Neuroglobin has less than 25% identity with other vertebrate globins and shares less than 30% identity with the annelid nerve myoglobin it most closely resembles among known hemoglobins. Spectroscopic and kinetic experiments with the recombinant protein indicate that human neuroglobin is the first example of a hexacoordinate hemoglobin in vertebrates and is similar to plant and bacterial hexacoordinate, hemoglobins in several respects. The ramifications of hexacoordination and potential physiological roles are explored in light of the determination of an O-2 affinity that precludes neuroglobin from functioning in traditional O-2 storage and transport.	Iowa State Univ Sci & Technol, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA; CSIRO, Div Plant Ind, Canberra, ACT 2601, Australia	Iowa State University; Commonwealth Scientific & Industrial Research Organisation (CSIRO)	Hargrove, MS (corresponding author), Iowa State Univ Sci & Technol, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA.		Watts, Richard A/D-2744-2009					APPLEBY CA, 1984, ANNU REV PLANT PHYS, V35, P443, DOI 10.1146/annurev.pp.35.060184.002303; Arredondo-Peter R, 1998, PLANT PHYSIOL, V118, P1121, DOI 10.1104/pp.118.4.1121; ArredondoPeter R, 1997, PLANT PHYSIOL, V115, P1259, DOI 10.1104/pp.115.3.1259; AUSTIN RH, 1975, BIOCHEMISTRY-US, V14, P5355, DOI 10.1021/bi00695a021; Barrick D, 1997, NAT STRUCT BIOL, V4, P78, DOI 10.1038/nsb0197-78; Bolognesi M, 1997, PROG BIOPHYS MOL BIO, V68, P29, DOI 10.1016/S0079-6107(97)00017-5; Burmester T, 2000, NATURE, V407, P520, DOI 10.1038/35035093; Couture M, 1999, P NATL ACAD SCI USA, V96, P11223, DOI 10.1073/pnas.96.20.11223; Couture M, 1999, J BIOL CHEM, V274, P6898, DOI 10.1074/jbc.274.11.6898; Couture M, 2000, EUR J BIOCHEM, V267, P4770, DOI 10.1046/j.1432-1327.2000.01531.x; Dewilde S, 1996, J BIOL CHEM, V271, P19865, DOI 10.1074/jbc.271.33.19865; Duff SMG, 1997, J BIOL CHEM, V272, P16746, DOI 10.1074/jbc.272.27.16746; Gardner PR, 1998, P NATL ACAD SCI USA, V95, P10378, DOI 10.1073/pnas.95.18.10378; Goodman MD, 2001, J BIOL CHEM, V276, P6834, DOI 10.1074/jbc.M009254200; HANKELN T, 1988, GENE, V64, P297, DOI 10.1016/0378-1119(88)90344-7; Hargrove MS, 2000, BIOPHYS J, V79, P2733, DOI 10.1016/S0006-3495(00)76512-X; Hargrove MS, 1997, J MOL BIOL, V266, P1032, DOI 10.1006/jmbi.1996.0833; Hargrove MS, 2000, STRUCTURE, V8, P1005, DOI 10.1016/S0969-2126(00)00194-5; Merx Marc W., 2001, FASEB Journal, V15, P1077; Minning DM, 1999, NATURE, V401, P497, DOI 10.1038/46822; MOORE EG, 1976, J BIOL CHEM, V251, P2788; MURRAY JD, 1971, J BIOL CHEM, V246, P5903; Olson J S, 1981, Methods Enzymol, V76, P631; Olson JS, 1997, J BIOL INORG CHEM, V2, P544, DOI 10.1007/s007750050169; Olson JS, 1996, J BIOL CHEM, V271, P17593, DOI 10.1074/jbc.271.30.17593; PERUTZ MF, 1970, NATURE, V228, P726, DOI 10.1038/228726a0; Perutz MF, 1998, ANNU REV BIOPH BIOM, V27, P1, DOI 10.1146/annurev.biophys.27.1.1; Pesce A, 2000, EMBO J, V19, P2424, DOI 10.1093/emboj/19.11.2424; POTTS M, 1992, SCIENCE, V256, P1690, DOI 10.1126/science.256.5064.1690; Royer WE, 2001, TRENDS BIOCHEM SCI, V26, P297, DOI 10.1016/S0968-0004(01)01811-4; Sowa AW, 1998, P NATL ACAD SCI USA, V95, P10317, DOI 10.1073/pnas.95.17.10317; SPRINGER BA, 1994, CHEM REV, V94, P699, DOI 10.1021/cr00027a007; TAYLOR ER, 1994, PLANT MOL BIOL, V24, P853, DOI 10.1007/BF00014440; Trent JT, 2001, BIOCHEMISTRY-US, V40, P6155, DOI 10.1021/bi0100790; Trevaskis B, 1997, P NATL ACAD SCI USA, V94, P12230, DOI 10.1073/pnas.94.22.12230; WATTS R, 1999, THESIS AUSTR NATL U; Weber RE, 2001, PHYSIOL REV, V81, P569, DOI 10.1152/physrev.2001.81.2.569; WEBSTER DA, 1988, ADV INORG BIOCHEM, V7, P245; WHITAKER TL, 1995, BIOCHEMISTRY-US, V34, P8221, DOI 10.1021/bi00026a002; WITTENBE.JB, 1966, J BIOL CHEM, V241, P104; WITTENBERG JB, 1972, J BIOL CHEM, V247, P527; WYMAN J, 1966, J BIOL CHEM, V241, P115	42	213	222	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30106	30110		10.1074/jbc.C100300200	http://dx.doi.org/10.1074/jbc.C100300200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11429401	hybrid			2022-12-25	WOS:000170558000068
J	Li, W; Belsham, GJ; Proud, CG				Li, W; Belsham, GJ; Proud, CG			Eukaryotic initiation factors 4A (eIF4A) and 4G (eIF4G) mutually interact in a 1 : 1 ratio in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOX RNA HELICASE; PROTEIN-SYNTHESIS; SACCHAROMYCES-CEREVISIAE; DROSOPHILA-MELANOGASTER; CRYSTAL-STRUCTURE; CORE DOMAIN; FACTOR 4F; TRANSLATION; YEAST; SEQUENCE	mRNA translation in eukaryotic cells involves a set of proteins termed translation initiation factors (eIFs), several of which are involved in the binding of ribosomes to mRNA. These include eIF4G, a modular scaffolding protein, and eIF4A, an RNA helicase, of which two closely related forms are known in mammals, eIF4A(I) and eIF4A(II). In mammals, eIF4G possesses two independent sites for binding eIF4A, whereas in other eukaryotes (e.g. yeast) only one site appears to be present, thus raising the issue of the stoichiometry of eIF4G.eIF4A complexes in different eukaryotes. We show that in human embryonic kidney cells eIF4G is associated with eIF4A(I) or eIF4A(II) but not with both simultaneously, suggesting a stoichiometry of 1:1 rather than 1:2. To confirm this, eIF4A(I) or eIF4A(II) was expressed in a tagged form in these cells, and complexes with eIF4G were again isolated. Complexes containing tagged eIF4A(I) or eIF4A(II) contained no endogenous eIF4A, supporting the notion that eIF4G binds only one molecule of eIF4A. Each binding site in eIF4G can bind either eIF4A(I) or eIF4A(II). The data imply that the second binding site in mammalian eIF4A does not bind an additional eIF4A molecule and that initiation factor complexes in different eukaryotes contain one eIF4A per eIF4G.	Univ Dundee, Sch Life Sci, Div Mol Physiol, Dundee DD1 5EH, Scotland; AFRC, Inst Anim Hlth, Pirbright Lab, Biotechnol & Biol Sci Res Council, Woking GU24 0NF, Surrey, England	University of Dundee; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; Pirbright Institute	Proud, CG (corresponding author), Univ Dundee, Sch Life Sci, Div Mol Physiol, Dow St, Dundee DD1 5EH, Scotland.	c.g.proud@clundee.ac.uk	Belsham, Graham/J-3132-2019; Belsham, Graham J./H-8589-2019	Belsham, Graham/0000-0003-1187-4873; Belsham, Graham J./0000-0003-1187-4873; Proud, Christopher/0000-0003-0704-6442				ALLEN ML, 1992, J BIOL CHEM, V267, P23232; Benz J, 1999, STRUCTURE, V7, P671, DOI 10.1016/S0969-2126(99)80088-4; Caruthers JM, 2000, P NATL ACAD SCI USA, V97, P13080, DOI 10.1073/pnas.97.24.13080; CONROY SC, 1990, ARCH BIOCHEM BIOPHYS, V282, P363, DOI 10.1016/0003-9861(90)90130-Q; De Gregorio E, 1999, EMBO J, V18, P4865, DOI 10.1093/emboj/18.17.4865; de la Cruz J, 1999, TRENDS BIOCHEM SCI, V24, P192, DOI 10.1016/S0968-0004(99)01376-6; Dominguez D, 1999, J BIOL CHEM, V274, P26720, DOI 10.1074/jbc.274.38.26720; Dominguez D, 2001, BIOCHEM J, V355, P223, DOI 10.1042/0264-6021:3550223; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; GOYER C, 1989, J BIOL CHEM, V264, P7603; GOYER C, 1993, MOL CELL BIOL, V13, P4860, DOI 10.1128/MCB.13.8.4860; Herbert TP, 2000, J BIOL CHEM, V275, P11249, DOI 10.1074/jbc.275.15.11249; Hernandez G, 1998, EUR J BIOCHEM, V253, P27, DOI 10.1046/j.1432-1327.1998.2530027.x; Holzmann K, 2000, BIOCHEM BIOPH RES CO, V267, P339, DOI 10.1006/bbrc.1999.1973; Imataka H, 1997, MOL CELL BIOL, V17, P6940, DOI 10.1128/MCB.17.12.6940; Johnson ER, 1999, RNA, V5, P1526, DOI 10.1017/S1355838299991410; Korneeva NL, 2001, J BIOL CHEM, V276, P2872, DOI 10.1074/jbc.M006345200; LAMPHEAR BJ, 1995, J BIOL CHEM, V270, P21975, DOI 10.1074/jbc.270.37.21975; Li QY, 1999, MOL CELL BIOL, V19, P7336; Morino S, 2000, MOL CELL BIOL, V20, P468, DOI 10.1128/MCB.20.2.468-477.2000; Neff CL, 1999, MOL CELL BIOL, V19, P5557; NIELSEN PJ, 1988, EMBO J, V7, P2097, DOI 10.1002/j.1460-2075.1988.tb03049.x; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; PAUSE A, 1994, EMBO J, V13, P1205, DOI 10.1002/j.1460-2075.1994.tb06370.x; PRAT A, 1990, BIOCHIM BIOPHYS ACTA, V1050, P140, DOI 10.1016/0167-4781(90)90155-U; PRICE NT, 1989, BIOCHIM BIOPHYS ACTA, V1008, P177, DOI 10.1016/0167-4781(80)90005-6; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; Scheper GC, 2001, MOL CELL BIOL, V21, P743, DOI 10.1128/MCB.21.3.743-754.2001; Svitkin YV, 2001, RNA, V7, P1743; ZAPATA JM, 1994, J BIOL CHEM, V269, P18047	30	33	36	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29111	29115		10.1074/jbc.C100284200	http://dx.doi.org/10.1074/jbc.C100284200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11408474	hybrid			2022-12-25	WOS:000170346000065
J	Von Eckardstein, A; Langer, C; Engel, T; Schaukal, I; Cignarella, A; Reinhardt, R; Lorkowski, S; Li, ZC; Zhou, XQ; Cullen, P; Assmann, G				Von Eckardstein, A; Langer, C; Engel, T; Schaukal, I; Cignarella, A; Reinhardt, R; Lorkowski, S; Li, ZC; Zhou, XQ; Cullen, P; Assmann, G			ATP binding cassette transporter ABCA1 modulates the secretion of apolipoprotein E from human monocyte-derived macrophages	FASEB JOURNAL			English	Article						ABCA1; Tangier disease; apoE	CHOLESTEROL EFFLUX; TANGIER-DISEASE; APOPTOTIC CELLS; PLASMA-MEMBRANE; MICE; GENE; ATHEROSCLEROSIS; LIPOPROTEINS; EXPRESSION; HYPERCHOLESTEROLEMIA	Apolipoprotein E (apoE) produced by macrophages in the arterial wall protects against atherosclerosis, but the regulation of its secretion by these cells is poorly understood. Here we investigated the contribution of the adenosine triphosphate binding cassette transporters ABCA1 and ABC8 to the secretion of apoE from either primary human monocyte-derived macrophages (HMDM) or human THP1 macrophages. During incubations of up to 6 h, apoE secretion from both THP1 macrophages and HMDM was stimulated by 8-Br-cAMP, which activates ABCA1 expression. The putative ABCA1 inhibitor glyburide and antisense oligonucleotides directed against ABCA1 mRNA significantly reduced apoE secretion from THP1 macrophages and HMDM. Antisense oligonucleotides directed against ABC8 mRNA also inhibited apoE secretion, although this inhibition was less pronounced and consistent than in the case of ABCA1. ApoE secretion from HMDM of ABCA1-deficient patients with Tangier disease was also decreased. ApoE mRNA expression was not affected by inhibition of ABCA1 or ABC8 in normal HMDM or the lack of functional ABCA1 in HMDM from Tangier disease patients. Inhibition of ABCA1 in HMDM prevented the occurrence of anti-apoE-immunoreactive granular structures in the plasma membrane. We conclude that ABCA1 and, to a lesser extent, ABC8 both promote secretion of apoE from human macrophages.	Univ Munster, Cent Lab, Inst Clin Chem & Lab Med, D-48129 Munster, Germany; Inst Arteriosclerosis Res, D-48149 Munster, Germany; Univ Milan, Inst Pharmacol Sci, I-20133 Milan, Italy; Univ Munster, Inst Physiol, D-48129 Munster, Germany	University of Munster; University of Milan; University of Munster	Von Eckardstein, A (corresponding author), Univ Munster, Cent Lab, Inst Clin Chem & Lab Med, Albert Schweitzer Str 33, D-48129 Munster, Germany.	vonecka@uni-muenster.de	Lorkowski, Stefan/B-9689-2008	Lorkowski, Stefan/0000-0002-9649-840X				Andrei C, 1999, MOL BIOL CELL, V10, P1463, DOI 10.1091/mbc.10.5.1463; Assmann G, 2001, METABOLIC MOL BASES, P2937; Becq F, 1997, J BIOL CHEM, V272, P2695, DOI 10.1074/jbc.272.5.2695; BELLOSTA S, 1995, J CLIN INVEST, V96, P2170, DOI 10.1172/JCI118271; Bielicki JK, 1999, J LIPID RES, V40, P85; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Bortnick AE, 2000, J BIOL CHEM, V275, P28634, DOI 10.1074/jbc.M003407200; BRAND K, 1993, J CLIN INVEST, V91, P2031, DOI 10.1172/JCI116425; BROWN MS, 1980, J BIOL CHEM, V255, P9344; Cullen P, 1998, J CLIN INVEST, V101, P1670, DOI 10.1172/JCI119887; Curtiss LK, 2000, CURR OPIN LIPIDOL, V11, P243, DOI 10.1097/00041433-200006000-00004; Daum U, 1999, J MOL MED, V77, P614, DOI 10.1007/s001099900034; DENG JT, 1995, J LIPID RES, V36, P2129; Fazio S, 1997, P NATL ACAD SCI USA, V94, P4647, DOI 10.1073/pnas.94.9.4647; Feussner G, 1996, AM J HUM GENET, V58, P281; Hamon Y, 2000, NAT CELL BIOL, V2, P399, DOI 10.1038/35017029; Hamon Y, 1997, BLOOD, V90, P2911, DOI 10.1182/blood.V90.8.2911; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; Heeren J, 1999, J CELL SCI, V112, P349; Huang YD, 1995, J CLIN INVEST, V96, P2693, DOI 10.1172/JCI118336; Ishigami M, 1998, J BIOL CHEM, V273, P20156, DOI 10.1074/jbc.273.32.20156; Klucken J, 2000, P NATL ACAD SCI USA, V97, P817, DOI 10.1073/pnas.97.2.817; Langmann T, 1999, BIOCHEM BIOPH RES CO, V257, P29, DOI 10.1006/bbrc.1999.0406; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; Lin CY, 1999, J LIPID RES, V40, P1618; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MAHLEY RW, 1984, J LIPID RES, V25, P1277; Mazzone T, 1996, CURR OPIN LIPIDOL, V7, P303, DOI 10.1097/00041433-199610000-00008; McNeish J, 2000, P NATL ACAD SCI USA, V97, P4245, DOI 10.1073/pnas.97.8.4245; MENDEZ AJ, 1995, J BIOL CHEM, V270, P5891, DOI 10.1074/jbc.270.11.5891; Oram JF, 2000, CURR OPIN LIPIDOL, V11, P253, DOI 10.1097/00041433-200006000-00005; Oram JF, 2000, J BIOL CHEM, V275, P34508, DOI 10.1074/jbc.M006738200; Oram JF, 1996, J LIPID RES, V37, P2473; Orso E, 2000, NAT GENET, V24, P192, DOI 10.1038/72869; Panousis CG, 2000, ARTERIOSCL THROM VAS, V20, P1565, DOI 10.1161/01.ATV.20.6.1565; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; Rees D, 1999, J BIOL CHEM, V274, P27925, DOI 10.1074/jbc.274.39.27925; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Schmitz G, 2000, CURR OPIN LIPIDOL, V11, P493, DOI 10.1097/00041433-200010000-00007; SCHMITZ G, 1985, P NATL ACAD SCI USA, V82, P6305, DOI 10.1073/pnas.82.18.6305; Schwede F, 2000, PHARMACOL THERAPEUT, V87, P199, DOI 10.1016/S0163-7258(00)00051-6; Smith JD, 1996, J BIOL CHEM, V271, P30647, DOI 10.1074/jbc.271.48.30647; Stannard AK, 1999, ATHEROSCLEROSIS, V144, P86, DOI 10.1016/S0021-9150(99)80328-1; Takahashi Y, 2000, BBA-GENE STRUCT EXPR, V1492, P385, DOI 10.1016/S0167-4781(00)00133-0; Takahashi Y, 1999, P NATL ACAD SCI USA, V96, P11358, DOI 10.1073/pnas.96.20.11358; Wang N, 2000, J BIOL CHEM, V275, P33053, DOI 10.1074/jbc.M005438200; Wenner C, 2001, BIOCHEM BIOPH RES CO, V282, P608, DOI 10.1006/bbrc.2001.4611; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543; Zhao YW, 2000, J BIOL CHEM, V275, P4759, DOI 10.1074/jbc.275.7.4759	49	88	89	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2001	15	9					1555	1561		10.1096/fj.00-0798com	http://dx.doi.org/10.1096/fj.00-0798com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	460PV	11427487				2022-12-25	WOS:000170318500007
J	Danialou, G; Comtois, AS; Dudley, R; Karpati, G; Vincent, GV; Des Rosiers, C; Petrof, BJ				Danialou, G; Comtois, AS; Dudley, R; Karpati, G; Vincent, GV; Des Rosiers, C; Petrof, BJ			Dystrophin-deficient cardiomyocytes are abnormally vulnerable to mechanical stress-induced contractile failure and injury	FASEB JOURNAL			English	Article						Duchenne/Becker muscular dystrophies cardiomyopathy; mdx mouse; cytoskeleton; amyocardial injury	FIBROBLAST-GROWTH-FACTOR; MUSCULAR-DYSTROPHY; MDX MOUSE; IN-VIVO; DILATED CARDIOMYOPATHY; MUSCLE; HEART; SKELETAL; MYOPATHY; SARCOGLYCANS	Although absence of the cytoskeletal protein dystrophin leads to dilated cardiomyopathy in humans, the functional role of dystrophin in cardiac muscle remains undefined. We have addressed the hypothesis that dystrophin could help protect the heart against injury and contractile dysfunction induced by mechanical stress. In normal and dystrophin-deficient (mdx) mice, cardiac mechanical stress was first manipulated ex vivo in a perfused working heart preparation. Despite an afterload level in the normal physiologic range, ex vivo perfused mdx hearts developed severe contractile dysfunction and nonischemic tissue damage, as is shown by excessive LDH release without a rise in coronary lactate. Injury to dystrophin-deficient hearts was significantly correlated with cardiac work, and reducing the afterload level improved contractility and prevented injury in mdx hearts studied ex vivo. The response to mechanical stress in vivo was also assessed by using the vital dye Evans blue, which penetrates into cardiomyocytes with a disrupted sarcolemma. In the mdx group only, cardiomyocyte injury was increased markedly by acute elevations of mechanical stress induced by isoproterenol or brief aortic occlusion. Strikingly accelerated mortality and cardiac necrosis were also observed in the mdx group subjected to chronically increased cardiac mechanical stress via subtotal aortic constriction. Taken together, our results provide the first direct evidence that dystrophin serves to protect cardiomyocytes from mechanical stress and workload-induced damage. Accordingly, reducing cardiac work in patients with dystrophin deficiency could be beneficial not only in treating established cardiomyopathy, but also in preventing the onset of cardiac disease.	McGill Univ, Dept Med, Ctr Hlth, Montreal, PQ H3A 1A1, Canada; McGill Univ, Meakins Christie Labs, Montreal, PQ H3A 1A1, Canada; Univ Montreal, CHUM, Ctr Rech, Physiol Resp Lab, Montreal, PQ H2L 4M1, Canada; McGill Univ, Montreal Neurol Inst, Neuromuscular Res Grp, Montreal, PQ H3A 2B4, Canada; Univ Montreal, Dept Biochim, Lab Metab Intermediaire, Montreal, PQ H2L 4M1, Canada; Univ Montreal, Dept Nutr, Montreal, PQ H2L 4M1, Canada	McGill University; McGill University; Universite de Montreal; McGill University; Universite de Montreal; Universite de Montreal	Petrof, BJ (corresponding author), Royal Victoria Hosp, Room L4-11,687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.	basil.petrof@muhc.mcgill.ca	Rosiers, Christine Des/O-6285-2014					ANDERSON JE, 1994, MUSCLE NERVE, V17, P64, DOI 10.1002/mus.880170109; Badorff C, 1999, NAT MED, V5, P320, DOI 10.1038/6543; BANERJEE A, 1991, AM J PHYSIOL, V261, pH590, DOI 10.1152/ajpheart.1991.261.2.H590; Bergmeyer HU, 1974, METHODS ENZYMATIC AN; BRIDGES LR, 1986, J NEUROL SCI, V72, P147, DOI 10.1016/0022-510X(86)90003-1; BRUNET J, 1995, FREE RADICAL BIO MED, V19, P627, DOI 10.1016/0891-5849(95)00077-B; CLARKE MSF, 1995, CIRC RES, V76, P927, DOI 10.1161/01.RES.76.6.927; CLARKE MSF, 1993, J CELL SCI, V106, P121; Coral-Vazquez R, 1999, CELL, V98, P465, DOI 10.1016/S0092-8674(00)81975-3; Cox GF, 1997, CURR OPIN CARDIOL, V12, P329; Dalakas MC, 2000, NEW ENGL J MED, V342, P770, DOI 10.1056/NEJM200003163421104; DILISA F, 1995, BIOCHEM J, V308, P57, DOI 10.1042/bj3080057; Durbeej M, 2000, MOL CELL, V5, P141, DOI 10.1016/S1097-2765(00)80410-4; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; FONG P, 1990, SCIENCE, V250, P673, DOI 10.1126/science.2173137; Grady RM, 1997, CELL, V90, P729, DOI 10.1016/S0092-8674(00)80533-4; GRUPP IL, 1993, AM J PHYSIOL, V265, pH1401, DOI 10.1152/ajpheart.1993.265.4.H1401; GRUPP IL, 1984, METHOD PHARMACOL, P111; Hack AA, 2000, J CELL SCI, V113, P2535; Hack AA, 1999, P NATL ACAD SCI USA, V96, P10723, DOI 10.1073/pnas.96.19.10723; Hayes A, 1997, J APPL PHYSIOL, V82, P435, DOI 10.1152/jappl.1997.82.2.435; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; Larsen TS, 1999, PFLUG ARCH EUR J PHY, V437, P979, DOI 10.1007/s004240050870; Lu S, 2000, J MOL CELL CARDIOL, V32, P143, DOI 10.1006/jmcc.1999.1063; Maeda M, 1997, CIRCULATION, V95, P17, DOI 10.1161/01.CIR.95.1.17; MCNEIL PL, 1992, AM J PATHOL, V140, P1097; McNeil PL, 1997, J CELL BIOL, V137, P1, DOI 10.1083/jcb.137.1.1; Megeney LA, 1999, P NATL ACAD SCI USA, V96, P220, DOI 10.1073/pnas.96.1.220; NG WA, 1991, CIRC RES, V68, P1742, DOI 10.1161/01.RES.68.6.1742; Olson TM, 1998, SCIENCE, V280, P750, DOI 10.1126/science.280.5364.750; PETROF BJ, 1993, P NATL ACAD SCI USA, V90, P3710, DOI 10.1073/pnas.90.8.3710; PETROF BJ, 1993, AM J PHYSIOL, V265, pC834; PONS F, 1994, CIRCULATION, V90, P369, DOI 10.1161/01.CIR.90.1.369; PORTER GA, 1992, J CELL BIOL, V117, P997, DOI 10.1083/jcb.117.5.997; ROCKMAN HA, 1993, CIRCULATION, V87, P14; SadouletPuccio HM, 1997, P NATL ACAD SCI USA, V94, P12413, DOI 10.1073/pnas.94.23.12413; SICINSKI P, 1989, SCIENCE, V244, P1578, DOI 10.1126/science.2662404; STEDMAN HH, 1991, NATURE, V352, P536, DOI 10.1038/352536a0; Stevenson S, 1997, CIRC RES, V80, P269, DOI 10.1161/01.RES.80.2.269; Straub V, 1997, J CELL BIOL, V139, P375, DOI 10.1083/jcb.139.2.375; TORRES LFB, 1987, BRAIN, V110, P269, DOI 10.1093/brain/110.2.269; Towbin JA, 1998, CURR OPIN CELL BIOL, V10, P131, DOI 10.1016/S0955-0674(98)80096-3; Vilquin JT, 1998, MUSCLE NERVE, V21, P567, DOI 10.1002/(SICI)1097-4598(199805)21:5<567::AID-MUS2>3.0.CO;2-6; WELLER B, 1990, J NEUROL SCI, V100, P9, DOI 10.1016/0022-510X(90)90005-8; Yoshida T, 1998, J BIOL CHEM, V273, P1583, DOI 10.1074/jbc.273.3.1583; YUNGE L, 1989, AM J PATHOL, V134, P171	46	139	141	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY 29	2001	15	7					1655	+		10.1096/fj.01-0030fje	http://dx.doi.org/10.1096/fj.01-0030fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519CQ	11427517				2022-12-25	WOS:000173707700005
J	Genever, PG; Skerry, TM				Genever, PG; Skerry, TM			Regulation of spontaneous glutamate release activity in osteoblastic cells and its role in differentiation and survival: evidence for intrinsic glutamatergic signaling in bone	FASEB JOURNAL			English	Article						intercellular communication; osteoblasts; osteoclasts	SODIUM-CHANNEL EXPRESSION; NITRIC-OXIDE; IN-VITRO; RECEPTORS; RESORPTION; RILUZOLE; DEATH; NEUROTOXICITY; INHIBITION; APOPTOSIS	Maintenance of bone mass depends on numerous osteoblast-derived autocrine and paracrine signaling factors that ensure the coupled resorptive and formative activity of osteoclasts and osteoblasts. Here, we provide the first evidence that osteoblasts actively secrete glutamate, an amino acid neurotransmitter found at excitatory synapses in the central nervous system, complementing previous reports of functional glutamate receptor expression by bone cells, Several osteoblastic cell-types spontaneously released between 2-7 nmoles glutamate per mg protein, equivalent to or greater than reported levels of glutamate release from depolarized neurons. Osteoblastic glutamate exocytosis appeared dependent on an AMPA-type glutamate autoreceptor, and addition of depolarizing concentrations of KCl caused significant calcium-dependent inhibition of glutamate release. Levels of exocytosed and intracellular free glutamate, and susceptibility to depolarization-induced inhibition of glutamate release, increased during osteoblastic differentiation of MC3T3-E1 cells. Pharmacological inhibition of glutamate release with riluzole (1-25 muM) significantly inhibited differentiation and induced morphological and biochemical characteristics of apoptosis in osteoblastic cells. Exogenous glutamate application increased survival rates of osteoblasts grown in serum-free medium, and proinflammatory cytokines (tumor necrosis factor-alpha and interferon-gamma) significantly inhibited osteoblastic glutamate release. These findings provide evidence for an intrinsic synaptic-like glutamatergic signaling network in bone that is essential for in vitro osteoblast differentiation and survival.	Univ York, Dept Biol, York YO10 5YW, N Yorkshire, England	University of York - UK	Genever, PG (corresponding author), Univ York, Dept Biol, POB 373, York YO10 5YW, N Yorkshire, England.	pg5@york.ac.uk		Genever, Paul/0000-0002-5730-8976; Skerry, Timothy/0000-0003-1319-5575				BELLOWS CG, 1986, CALCIFIED TISSUE INT, V38, P143, DOI 10.1007/BF02556874; BERTOLINI DR, 1986, NATURE, V319, P516, DOI 10.1038/319516a0; BETZ WJ, 1992, SCIENCE, V255, P200, DOI 10.1126/science.1553547; Bezzi P, 1998, NATURE, V391, P281, DOI 10.1038/34651; BHANGU PS, 2001, IN PRESS BONE; Black JA, 1996, DEV NEUROSCI-BASEL, V18, P139, DOI 10.1159/000111403; BLACK JA, 1995, MOL BRAIN RES, V34, P89, DOI 10.1016/0169-328X(95)00141-E; Breukel AIM, 1998, EUR J NEUROSCI, V10, P106, DOI 10.1046/j.1460-9568.1998.00008.x; Chenu C, 1998, BONE, V22, P295, DOI 10.1016/S8756-3282(97)00295-0; Damoulis PD, 1997, J BONE MINER RES, V12, P412, DOI 10.1359/jbmr.1997.12.3.412; Duncan RL, 1998, SEMIN NEPHROL, V18, P178; Espinosa L, 1999, J PHYSIOL-LONDON, V518, P47, DOI 10.1111/j.1469-7793.1999.0047r.x; ESTEVEZ AG, 1995, EUR J PHARMACOL, V280, P47, DOI 10.1016/0014-2999(95)00186-O; GOWEN M, 1986, J BONE MINER RES, V1, P469; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; Hilfiker S, 1999, PHILOS T ROY SOC B, V354, P269, DOI 10.1098/rstb.1999.0378; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; Itzstein C, 2000, BIOCHEM BIOPH RES CO, V268, P201, DOI 10.1006/bbrc.2000.2097; Jilka RL, 1998, J BONE MINER RES, V13, P793, DOI 10.1359/jbmr.1998.13.5.793; Kato Y, 1997, J BONE MINER RES, V12, P2014, DOI 10.1359/jbmr.1997.12.12.2014; Kizer N, 1997, P NATL ACAD SCI USA, V94, P1013, DOI 10.1073/pnas.94.3.1013; Laketic-Ljubojevic I, 1999, BONE, V25, P631, DOI 10.1016/S8756-3282(99)00224-0; Ludolph AC, 1999, J NEURAL TRANSM-SUPP, P79; Lynch MP, 1998, J CELL BIOCHEM, V68, P31; MacDermott AB, 1999, ANNU REV NEUROSCI, V22, P443, DOI 10.1146/annurev.neuro.22.1.443; MALAVAL L, 1994, J CELL PHYSIOL, V158, P555, DOI 10.1002/jcp.1041580322; MALGOURIS C, 1994, NEUROSCI LETT, V177, P95, DOI 10.1016/0304-3940(94)90053-1; Mason DJ, 1997, BONE, V20, P199, DOI 10.1016/S8756-3282(96)00386-9; Mogi M, 1999, BIOCHEM PHARMACOL, V58, P649, DOI 10.1016/S0006-2952(99)00131-8; Moreau R, 1997, J BONE MINER RES, V12, P1984, DOI 10.1359/jbmr.1997.12.12.1984; NICHOLLS DG, 1987, J NEUROCHEM, V49, P50, DOI 10.1111/j.1471-4159.1987.tb03393.x; NICHOLLS DG, 1986, NATURE, V321, P772, DOI 10.1038/321772a0; Patel DR, 1997, EUR J PHARMACOL, V332, P143, DOI 10.1016/S0014-2999(97)01077-7; Patton AJ, 1998, BONE, V22, P645, DOI 10.1016/S8756-3282(98)00061-1; Peet NM, 1999, FASEB J, V13, P2179, DOI 10.1096/fasebj.13.15.2179; Rossi DJ, 2000, NATURE, V403, P316, DOI 10.1038/35002090; SanchezPrieto J, 1996, TRENDS NEUROSCI, V19, P235, DOI 10.1016/0166-2236(96)10031-X; Spencer GJ, 1999, J BONE MINER RES, V14, P1033; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Zona C, 1998, NEUROSCIENCE, V85, P931, DOI 10.1016/S0306-4522(97)00604-0	40	64	67	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY 29	2001	15	7					1586	+		10.1096/fj.00-0594fje	http://dx.doi.org/10.1096/fj.00-0594fje			29	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519CQ	11427494				2022-12-25	WOS:000173707700028
J	Murdoch, B; Gallacher, L; Awaraji, C; Hess, DA; Keeney, M; Jay, K; Chadwick, K; Foley, SR; Howson-Jan, K; Chin, YI; Wu, DM; Srour, E; Fellows, F; Bhatia, M				Murdoch, B; Gallacher, L; Awaraji, C; Hess, DA; Keeney, M; Jay, K; Chadwick, K; Foley, SR; Howson-Jan, K; Chin, YI; Wu, DM; Srour, E; Fellows, F; Bhatia, M			Circulating hematopoietic stem cells serve as novel targets for in utero gene therapy	FASEB JOURNAL			English	Article						fetal; gene therapy; xenotransplantation	HUMAN-IMMUNODEFICIENCY-VIRUS; REPOPULATING CELLS; RETROVIRAL VECTORS; NOD/SCID MICE; ASSAY; BLOOD; TRANSPLANTATION; IDENTIFICATION; LEUKEMIA; MARROW	In utero gene therapy has been proposed as a method for permanent correction of somatic disorders that affect the hematopoietic system before disease initiation (1, 2). However, clinical trials using transplantation of allogenic fetal liver, bone marrow, or adult stem cells have been unsuccessful, largely due to the failure of sustained hematopoietic reconstitution in fetal recipients (3). Here, we reveal that retroviral transduction of unique repopulating stem cells found in the human fetal circulation is superior to full-gestation cord blood or adult sources. In contrast to postnatal human stem cells, the fetal circulation is highly enriched for actively cycling blood stem cells, thereby forming the basis for enhanced transduction. Our findings indicate that active, transducible hematopoietic reconstituting cells are present in the circulation of the human fetus and that they represent novel target cells for future in utero gene therapy trials using autologous transplantation.	John P Robarts Res Inst, London, ON N6A 5K8, Canada; Univ Western Ontario, London, ON, Canada; St Josephs Hosp, Fetal Med Div, London, ON N6A 4V2, Canada; London Hlth Sci Ctr, Dept Med & Hematol, London, ON, Canada; Hamilton Civ Hosp, Dept Hematol, Hamilton, ON, Canada; Indiana Univ, Sch Med, Dept Med & Pediat, Bloomington, IN 47405 USA	Western University (University of Western Ontario); Western University (University of Western Ontario); McGill University; Western University (University of Western Ontario); London Health Sciences Centre; McMaster University; Indiana University System; Indiana University Bloomington	Bhatia, M (corresponding author), John P Robarts Res Inst, 100 Perth Dr, London, ON N6A 5K8, Canada.	mbhatia@rri.on.ca	Chin-Yee, Ian/G-3286-2011; Hess, David A/M-2828-2013					ALONSO K, 1995, ARCH PATHOL LAB MED, V119, P179; Bernstein I M, 1996, J Matern Fetal Med, V5, P124; Bhatia M, 1999, J EXP MED, V189, P1139, DOI 10.1084/jem.189.7.1139; Bhatia M, 1997, J EXP MED, V186, P619, DOI 10.1084/jem.186.4.619; Bhatia M, 1997, P NATL ACAD SCI USA, V94, P5320, DOI 10.1073/pnas.94.10.5320; Dick JE, 1997, STEM CELLS, V15, P204; Dick JE, 2000, NAT MED, V6, P624, DOI 10.1038/76188; Dick JE, 1997, STEM CELLS, V15, P199, DOI 10.1002/stem.5530150826; Douar AM, 1996, MOL HUM REPROD, V2, P633, DOI 10.1093/molehr/2.9.633; Drager AM, 1998, BRAZ J MED BIOL RES, V31, P49; Flake AW, 1999, BLOOD, V94, P2179, DOI 10.1182/blood.V94.7.2179.419k43_2179_2191; Gallacher L, 2000, BLOOD, V96, P1740, DOI 10.1182/blood.V96.5.1740.h8001740_1740_1747; Gallacher L, 2000, BLOOD, V95, P2813, DOI 10.1182/blood.V95.9.2813.009k20_2813_2820; Giannina G, 1998, FETAL DIAGN THER, V13, P94, DOI 10.1159/000020813; Gordon DF, 1996, DNA CELL BIOL, V15, P531, DOI 10.1089/dna.1996.15.531; Gothot A, 1997, BLOOD, V90, P4384, DOI 10.1182/blood.V90.11.4384.4384_4384_4393; Herrero RL, 1999, J REPROD MED, V44, P674; Kiem HP, 1997, BLOOD, V90, P4638; LAPIDOT T, 1992, SCIENCE, V255, P1137, DOI 10.1126/science.1372131; Larochelle A, 1996, NAT MED, V2, P1329, DOI 10.1038/nm1296-1329; Leung BL, 1999, J IMMUNOL, V163, P1334; LEWIS P, 1992, EMBO J, V11, P3053, DOI 10.1002/j.1460-2075.1992.tb05376.x; LEWIS PF, 1994, J VIROL, V68, P510, DOI 10.1128/JVI.68.1.510-516.1994; Mielcarek M, 1997, Curr Opin Hematol, V4, P176; MILLER AD, 1993, METHOD ENZYMOL, V217, P581; Morrison SJ, 1995, ANNU REV CELL DEV BI, V11, P35, DOI 10.1146/annurev.cb.11.110195.000343; Rowley JD, 1998, NAT MED, V4, P150, DOI 10.1038/nm0298-150; Schneider H, 1999, NAT MED, V5, P256, DOI 10.1038/6458; Wagner JE, 1998, LEUKEMIA, V12, pS30; WILLIAMS DA, 1994, BLOOD CELLS, V20, P504; Zanjani ED, 1999, SCIENCE, V285, P2084, DOI 10.1126/science.285.5436.2084	31	19	21	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY 29	2001	15	7					1628	+		10.1096/fj.00-0654fje	http://dx.doi.org/10.1096/fj.00-0654fje			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519CQ	11427508				2022-12-25	WOS:000173707700014
J	Rokhlin, OW; Guseva, N; Tagiyev, A; Knudson, CM; Cohen, MB				Rokhlin, OW; Guseva, N; Tagiyev, A; Knudson, CM; Cohen, MB			Bcl-2 oncoprotein protects the human prostatic carcinoma cell line PC3 from TRAIL-mediated apoptosis	ONCOGENE			English	Article						Bcl-2; prostatic neoplasms; TRAIL; apoptosis	CYTOCHROME-C; CD95 APO-1/FAS; MITOCHONDRIAL; DEATH; FAS; CASPASE-8; FAMILY; RELEASE; LIGAND; LOCALIZATION	The role of Bcl-2 in TRAIL-induced apoptosis has been investigated in lymphoid cells, Here we show that the human prostatic carcinoma cell line PC3 was sensitive to TRAIL treatment whereas PC3 overexpressing of Bcl-2 was resistant. TRAIL receptors ligation in PC3 activated caspases -2, -3, -7, -8, and -9, induced Bid processing, dissipation of mitochondrial transmembrane potential (Delta Psi (m)), and cytochrome c release. We have detected caspases -8 and -3 only in the cytosolic fraction of cells, but caspases -2, -7, and -9 were found both in cytosolic and mitochondrial fractions. Bcl-2 overexpression did not affect caspase-8 activation although it did change the processing pattern of caspase-3, At the same time, Bcl-2 overexpression inhibited the activation of mitochondrial localized caspases -2, -7, and -9, Bcl-2 also abrogated TRAIL-induced cytochrome c release and dissipation of Delta Psi (m). These findings suggest that TRAIL-induced apoptosis in the epithelial cell line PC3 depends both on mitochondrial integrity and caspase activation.	Univ Iowa, Dept Pathol, Iowa City, IA 52242 USA; Univ Iowa, Dept Urol, Iowa City, IA 52242 USA; Univ Iowa, Dept Epidemiol, Iowa City, IA 52242 USA; Vet Affairs Med Ctr, Iowa City, IA 52242 USA	University of Iowa; University of Iowa; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System	Cohen, MB (corresponding author), Univ Iowa, Dept Pathol, 200 Hawkins Dr,1117 ML, Iowa City, IA 52242 USA.			Knudson, Charles Michael/0000-0003-3964-5466	NCI NIH HHS [CA 76673] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076673] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAFFY G, 1993, J BIOL CHEM, V268, P6511; Bonavida B, 1999, INT J ONCOL, V15, P793; Chandler JM, 1998, J BIOL CHEM, V273, P10815, DOI 10.1074/jbc.273.18.10815; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Gewies A, 2000, CANCER RES, V60, P2163; Gotow T, 2000, CELL DEATH DIFFER, V7, P666, DOI 10.1038/sj.cdd.4400694; Green D, 1998, TRENDS CELL BIOL, V8, P267, DOI 10.1016/S0962-8924(98)01273-2; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Keogh SA, 2000, FEBS LETT, V471, P93, DOI 10.1016/S0014-5793(00)01375-2; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Mancini M, 1998, J CELL BIOL, V140, P1485, DOI 10.1083/jcb.140.6.1485; Mancini M, 2000, J CELL BIOL, V149, P603, DOI 10.1083/jcb.149.3.603; Nicholson DW, 2000, NATURE, V407, P810, DOI 10.1038/35037747; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Peter ME, 1996, CELL DEATH DIFFER, V3, P161; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Rokhlin OW, 1998, CANCER RES, V58, P5870; Rokhlin OW, 2000, ONCOGENE, V19, P1959, DOI 10.1038/sj.onc.1203453; Rokhlin OW, 1997, CANCER RES, V57, P1758; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Screaton GR, 1997, CURR BIOL, V7, P693, DOI 10.1016/S0960-9822(06)00297-1; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Shimizu S, 1996, ONCOGENE, V13, P21; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Susin SA, 1999, J EXP MED, V189, P381, DOI 10.1084/jem.189.2.381; Utz PJ, 2000, CELL DEATH DIFFER, V7, P589, DOI 10.1038/sj.cdd.4400696; Walczak H, 2000, CANCER RES, V60, P3051; Walczak H, 2000, EXP CELL RES, V256, P58, DOI 10.1006/excr.2000.4840; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; WILLEY SR, 1995, IMMUNITY, V3, P673; Yamada H, 1999, BIOCHEM BIOPH RES CO, V265, P130, DOI 10.1006/bbrc.1999.1641; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; Zhivotovsky B, 1999, CELL DEATH DIFFER, V6, P644, DOI 10.1038/sj.cdd.4400536	39	67	71	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 17	2001	20	22					2836	2843		10.1038/sj.onc.1204410	http://dx.doi.org/10.1038/sj.onc.1204410			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	432TP	11420695				2022-12-25	WOS:000168712000011
J	Ao, Y; Rohde, LH; Naumovski, L				Ao, Y; Rohde, LH; Naumovski, L			p53-interacting protein 53BP2 inhibits clonogenic survival and sensitizes cells to doxorubicin but not paclitaxel-induced apoptosis	ONCOGENE			English	Article						53BP2; p53; apoptosis; doxorubicin; paclitaxel	P53; PROGRESSION; INTERACTS; DOMAINS; BINDS; DEATH	53BP2 was initially identified as a protein interacting with p53 in a yeast two-hybrid screen and subsequently shown to enhance p53 transcriptional transactivation and induce apoptosis when transiently overexpressed in cell lines. In order to further study the biologically relevant effects of 53BP2, we have constructed HEK293 stable cell lines where 53BP2 expression can be regulated using an ecdysone inducible expression system. Our results indicate that the response of cells is dependent on the amount of 53BP2 that is expressed, High levels of 53BP2 expression(greater than or equal to 140-fold above endogenous) impede cell cycle progression and induce apoptosis, Lower levels of 53BP2 expression (6-11-fold above endogenous) suppress colony formation hut do not lead to detectable perturbations in the cell cycle or apoptosis, Lower levels of 53BP2 expression sensitized cells to apoptosis induced by DNA damaging chemotherapy agents doxorubicin, ara-C and VP16, but not microtubule active agents paclitaxel and vinblastine, Our results demonstrate that high levels of 53BP2 expression have profound biological effects ultimately leading to apoptosis, whereas lower levels of 53BP2 expression have more subtle effects on growth and sensitize cells to some chemotherapy agents.	Stanford Univ, Sch Med, Dept Pediat, Div Hematol Oncol, Stanford, CA 94305 USA	Stanford University	Naumovski, L (corresponding author), Stanford Univ, Sch Med, Dept Pediat, Div Hematol Oncol, 269 Campus Dr,CCSR Rm 1215, Stanford, CA 94305 USA.				NATIONAL CANCER INSTITUTE [R01CA076316] Funding Source: NIH RePORTER; NCI NIH HHS [CA 76316] Funding Source: Medline; NHLBI NIH HHS [HL09552] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; Helps NR, 1995, FEBS LETT, V377, P295, DOI 10.1016/0014-5793(95)01347-4; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; Iwabuchi K, 1998, J BIOL CHEM, V273, P26061, DOI 10.1074/jbc.273.40.26061; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lopez CD, 2000, MOL CELL BIOL, V20, P8018, DOI 10.1128/MCB.20.21.8018-8025.2000; Naumovski L, 1996, MOL CELL BIOL, V16, P3884; NAUMOVSKI L, 1994, BLOOD, V83, P2261; Yang JP, 1999, ONCOGENE, V18, P5177, DOI 10.1038/sj.onc.1202904	13	27	32	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 10	2001	20	21					2720	2725		10.1038/sj.onc.1204352	http://dx.doi.org/10.1038/sj.onc.1204352			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	431VN	11420684				2022-12-25	WOS:000168652600013
J	Graveel, CR; Jatkoe, T; Madore, SJ; Holt, AL; Farnham, PJ				Graveel, CR; Jatkoe, T; Madore, SJ; Holt, AL; Farnham, PJ			Expression profiling and identification of novel genes in hepatocellular carcinomas	ONCOGENE			English	Article						hepatocellular carcinoma; representational difference analysis; expression profiling; oligonucleotide microarrays	REPRESENTATIONAL DIFFERENCE ANALYSIS; C3H/HEJ MICE; OSTEOPONTIN; CANCER; RNA; HEPATOCARCINOGENESIS; C57BL/6J; DOMAINS; GROWTH; TUMORS	Liver cancer is the fifth most common cancer worldwide and unlike certain other cancers, such as colon cancer, a mutational model has not Set been developed. We have performed gene expression profiling of normal and neoplastic livers in C3H/HeJ mice treated with diethylnitrosamine. Using oligonucleotide microarrays, we compared gene expression in liver tumors to three different states of the normal liver: quiescent adult, regenerating adult, and newborn. Although each comparison revealed hundreds of differentially expressed genes, only 22 genes were found to be deregulated in the tumors in all three comparisons. Three of these genes were examined in human hepatocellular carcinomas and were found to be upregulated. As a second method of analysis, we used Representational Difference Analysis (RDA) to clone mRNA fragments differentially expressed in Ih er tumors versus regenerating livers. We cloned several novel mRNAs that are differentially regulated in murine liver tumors. Here we report the sequence of a novel cDNA whose expression is upregulated in both murine and human hepatocellular carcinomas. Our results suggest that DEN-treated mice provide an excellent model for human hepatocellular carcinomas.	Univ Wisconsin, McArdle Lab Canc Res, Madison, WI 53706 USA; Pfizer Inc, Genom & Bioinformat, Ann Arbor, MI 48105 USA	University of Wisconsin System; University of Wisconsin Madison; Pfizer	Farnham, PJ (corresponding author), Univ Wisconsin, McArdle Lab Canc Res, 1400 Univ Ave, Madison, WI 53706 USA.			Farnham, Peggy/0000-0003-4469-7914	NCI NIH HHS [CA22484] Funding Source: Medline; NIGMS NIH HHS [GM08349] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA022484] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ariel I, 1998, J CLIN PATHOL-MOL PA, V51, P21, DOI 10.1136/mp.51.1.21; BENNETT LM, 1995, MOL CARCINOGEN, V14, P46, DOI 10.1002/mc.2940140109; Bosch FX, 1999, SEMIN LIVER DIS, V19, P271, DOI 10.1055/s-2007-1007117; Buendia MA, 2000, SEMIN CANCER BIOL, V10, P185; Chen SQ, 2001, J CELL BIOL, V152, P87, DOI 10.1083/jcb.152.1.87; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; FARBER E, 1976, LIVER CELL CANCER, P243; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; Hubank M, 1999, METHOD ENZYMOL, V303, P325; Kojiro M, 1999, SEMIN LIVER DIS, V19, P287, DOI 10.1055/s-2007-1007118; Lukas ER, 1999, MOL CARCINOGEN, V25, P295, DOI 10.1002/(SICI)1098-2744(199908)25:4<295::AID-MC8>3.0.CO;2-9; Parkin DM, 1999, INT J CANCER, V80, P827, DOI 10.1002/(SICI)1097-0215(19990315)80:6&lt;827::AID-IJC6&gt;3.0.CO;2-P; Schultz J, 2000, NUCLEIC ACIDS RES, V28, P231, DOI 10.1093/nar/28.1.231; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Shijubo N, 1999, AM J RESP CRIT CARE, V160, P1269, DOI 10.1164/ajrccm.160.4.9807094; Singhal H, 1997, CLIN CANCER RES, V3, P605; SLANSKY JE, 1993, MOL CELL BIOL, V13, P7201; Tuck AB, 1999, ONCOGENE, V18, P4237, DOI 10.1038/sj.onc.1202799; Tuck AB, 1998, INT J CANCER, V79, P502, DOI 10.1002/(SICI)1097-0215(19981023)79:5<502::AID-IJC10>3.0.CO;2-3; Ue T, 1998, INT J CANCER, V79, P127, DOI 10.1002/(SICI)1097-0215(19980417)79:2<127::AID-IJC5>3.0.CO;2-V; Welford SM, 1998, NUCLEIC ACIDS RES, V26, P3059, DOI 10.1093/nar/26.12.3059; Yamada Y, 1999, LAB INVEST, V79, P1059; Ye XQ, 1997, BIOCHEM BIOPH RES CO, V239, P660, DOI 10.1006/bbrc.1997.7529; Yoong KF, 1999, HEPATOLOGY, V30, P100, DOI 10.1002/hep.510300147	24	76	83	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 10	2001	20	21					2704	2712		10.1038/sj.onc.1204391	http://dx.doi.org/10.1038/sj.onc.1204391			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	431VN	11420682				2022-12-25	WOS:000168652600011
J	Liu, Y; Wang, Y; Yamakuchi, M; Masuda, S; Tokioka, T; Yamaoka, S; Maruyama, I; Kitajima, I				Liu, Y; Wang, Y; Yamakuchi, M; Masuda, S; Tokioka, T; Yamaoka, S; Maruyama, I; Kitajima, I			Phosphoinositide-3 kinase-PKB/Akt pathway activation is involved in fibroblast Rat-1 transformation by human T-cell leukemia virus type I tax	ONCOGENE			English	Article						PI3K; Akt; NF-kappa B; Tax; transformation; PI5K; HTLV-I; IKK gamma	NF-KAPPA-B; PHOSPHATIDYLINOSITOL 3-KINASE; CONSTITUTIVE ACTIVATION; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; PROTEIN; AKT; APOPTOSIS; ONCOGENE; SUBUNIT	Activated phosphoinositide 3-kinase (PI3K) and its downstream target Akt are essential for the fibroblast transformation induced by many viral products. Tax, encoded by human T-cell leukemia virus type I (HTLVI), has been demonstrated to induce the transformation of rat fibroblast Rat-1 cell through NF-kappaB activation, By stable transfection of Rat-1 cells with expressing constructs of Tax and its mutant M47, which is defective in HTLV-I LTR transactivation, we selected their transformed clones, which have characteristics of NF-kappaB activation and colony formation beyond the cell monolayer (a malignant phenotype), However, these two characteristics in the transformed clones of Tax and M47 disappear after these cells have been treated with wortmannin, a specific inhibitor of PI3K. Further, increased activity of the PI3K/Akt is observed in the transformed clones of Tax and M47 as compared to the clones of empty vector Neo and the M148, which is defective in NF-kappaB activation and cell transformation, Increased activity of PI5K is present in the transformed clones of both Tax and M47 and in the M148 clone as compared to that in the Neo cell, It is known that the efficiency of Tax-induced cell transformation is not high; a minority of Tax-expressing clones show transformation, although the majority of Tax-expressing clones show activated NF-kappaB, A Tax-expressing, nontransformed clone after transfection with an active form of the catalytic subunit of PI3K, p110 alpha, becomes transformed, Consistent with these results, a Tax highly-expressing human T-cell line MT2 exhibits both higher polyphosphoinositide turnover and higher activities of PI3K and PI5K than those of Jurkat or MT1 and HTLV-I-negative and a Tax-unexpressing cell line, respectively, These results demonstrate that the activation of the PI3K/Akt signaling pathway, excepting for the NF-kappaB, is also required for the cell transformation induced by Tax.	Toyama Med & Pharmaceut Univ, Dept Lab Med, Toyama 9300194, Japan; Kagoshima Univ, Fac Med, Dept Lab & Mol Med, Kagoshima 8908520, Japan; Tokyo Med & Dent Univ, Sch Med, Dept Microbiol, Bunkyo Ku, Tokyo 1138519, Japan	University of Toyama; Kagoshima University; Tokyo Medical & Dental University (TMDU)	Kitajima, I (corresponding author), Toyama Med & Pharmaceut Univ, Dept Lab Med, 2630 Sugitani, Toyama 9300194, Japan.							Akagi T, 2000, P NATL ACAD SCI USA, V97, P7290, DOI 10.1073/pnas.140210297; Akagi T, 1997, ONCOGENE, V14, P2071, DOI 10.1038/sj.onc.1201045; Aoki M, 1998, P NATL ACAD SCI USA, V95, P14950, DOI 10.1073/pnas.95.25.14950; Aoki M, 2000, J BIOL CHEM, V275, P6267, DOI 10.1074/jbc.275.9.6267; ARIMA N, 1991, J VIROL, V65, P6892, DOI 10.1128/JVI.65.12.6892-6899.1991; BEIMLING P, 1989, ONCOGENE, V4, P511; Beraud C, 1999, P NATL ACAD SCI USA, V96, P429, DOI 10.1073/pnas.96.2.429; Borlado LR, 2000, FASEB J, V14, P895; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; Chu ZL, 1999, J BIOL CHEM, V274, P15297, DOI 10.1074/jbc.274.22.15297; Coscoy L, 1998, VIROLOGY, V248, P332, DOI 10.1006/viro.1998.9298; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Duronio V, 1998, CELL SIGNAL, V10, P233, DOI 10.1016/S0898-6568(97)00129-0; FERRELL JE, 1984, J CELL BIOL, V98, P1992, DOI 10.1083/jcb.98.6.1992; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; FUJISAWA J, 1985, P NATL ACAD SCI USA, V82, P2277, DOI 10.1073/pnas.82.8.2277; FUKUI Y, 1989, ONCOGENE RES, V4, P283; Gehrmann T, 1998, EUR J BIOCHEM, V253, P357, DOI 10.1046/j.1432-1327.1998.2530357.x; Geleziunas R, 1998, MOL CELL BIOL, V18, P5157, DOI 10.1128/MCB.18.9.5157; GIAM CZ, 1986, P NATL ACAD SCI USA, V83, P7192, DOI 10.1073/pnas.83.19.7192; GROSSMAN WJ, 1995, P NATL ACAD SCI USA, V92, P1057, DOI 10.1073/pnas.92.4.1057; Harhaj EW, 1999, J BIOL CHEM, V274, P22911, DOI 10.1074/jbc.274.33.22911; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; Iwanaga Y, 1999, J VIROL, V73, P1271, DOI 10.1128/JVI.73.2.1271-1277.1999; Jimenez C, 1998, EMBO J, V17, P743, DOI 10.1093/emboj/17.3.743; Jin DY, 1999, J BIOL CHEM, V274, P17402, DOI 10.1074/jbc.274.25.17402; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Kao SY, 2000, ONCOGENE, V19, P2240, DOI 10.1038/sj.onc.1203559; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kitajima I, 1997, ARTHRITIS RHEUM, V40, P2118, DOI 10.1002/art.1780401205; KITAJIMA I, 1992, SCIENCE, V258, P1792, DOI 10.1126/science.1299224; KITAJIMA I, 1991, J CLIN INVEST, V88, P1315, DOI 10.1172/JCI115436; Klippel A, 1998, MOL CELL BIOL, V18, P5699, DOI 10.1128/MCB.18.10.5699; LACOSTE J, 1995, J VIROL, V69, P564, DOI 10.1128/JVI.69.1.564-569.1995; Li XH, 1999, J BIOL CHEM, V274, P34417, DOI 10.1074/jbc.274.48.34417; Liu QR, 1999, GENE DEV, V13, P786, DOI 10.1101/gad.13.7.786; Loijens JC, 1996, ADV ENZYME REGUL, V36, P115, DOI 10.1016/0065-2571(95)00005-4; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Mori N, 1999, BLOOD, V93, P2360; Nicot C, 1998, J VIROL, V72, P6777, DOI 10.1128/JVI.72.8.6777-6784.1998; Osada M, 1999, MOL CELL BIOL, V19, P6333; Ozes ON, 1999, NATURE, V401, P82; Penuel E, 1999, MOL BIOL CELL, V10, P1693, DOI 10.1091/mbc.10.6.1693; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; POZZATTI R, 1990, MOL CELL BIOL, V10, P413, DOI 10.1128/MCB.10.1.413; RIZZO MT, 1994, CANCER RES, V54, P2611; Robek MD, 1999, J VIROL, V73, P4856, DOI 10.1128/JVI.73.6.4856-4865.1999; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; RUBEN S, 1988, SCIENCE, V241, P89, DOI 10.1126/science.2838905; SERUNIAN LA, 1991, METHOD ENZYMOL, V198, P78; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; SINGHAL RL, 1994, CANCER RES, V54, P5574; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Sun SC, 1999, ONCOGENE, V18, P6948, DOI 10.1038/sj.onc.1203220; Webster MA, 1998, MOL CELL BIOL, V18, P2344, DOI 10.1128/MCB.18.4.2344; YAMADA T, 1994, J VIROL, V68, P3374, DOI 10.1128/JVI.68.5.3374-3379.1994; Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031	61	58	58	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 3	2001	20	20					2514	2526		10.1038/sj.onc.1204364	http://dx.doi.org/10.1038/sj.onc.1204364			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	431VM	11420661				2022-12-25	WOS:000168652500002
J	Kannan, K; Amariglio, N; Rechavi, G; Jakob-Hirsch, J; Kela, I; Kaminski, N; Getz, G; Domany, E; Givol, D				Kannan, K; Amariglio, N; Rechavi, G; Jakob-Hirsch, J; Kela, I; Kaminski, N; Getz, G; Domany, E; Givol, D			DNA microarrays identification of primary and secondary target genes regulated by p53	ONCOGENE			English	Article						DNA microarray; cycloheximide; ts-p53; target genes; expression profile, clustering	CELL-CYCLE; EXPRESSION; GROWTH; INDUCTION; STABILITY; PROMOTER; REVEALS; BINDING; ARREST; MUTANT	The transcriptional program regulated by the tumor suppressor p53 was analysed using oligonucleotide microarrays. A human lung cancer cell line that expresses the temperature sensitive murine p53 was utilized to quantitate mRNA levels of various genes at different time points after shifting the temperature to 32 degreesC. Inhibition of protein synthesis by cycloheximide (CHX) was used to distinguish between primary and secondary target genes regulated by p53. In the absence of CHX, 259 and 125 genes were up or down-regulated respectively; only 38 and 24 of these genes were up and down-regulated by p53 also in the presence of CHX and are considered primary targets in this cell line. Cluster analysis of these data using the super paramagnetic clustering (SPC) algorithm demonstrate that the primary genes can be distinguished as a single cluster among a large pool of p53 regulated genes. This procedure identified additional genes that co-cluster with the primary targets and can also be classified as such genes, In addition to cell cycle (e.g. p21, TGF-beta, Cyclin E) and apoptosis (e.g, Fas, Bak, IAP) related genes, the primary targets of p53 include genes involved in many aspects of cell function, including cell adhesion (e.g, Thymosin, Smoothelin), signaling (e.g. H-Ras, Diacylglycerol kinase), transcription (e.g. ATF3, LISCH7), neuronal growth (e.g. Ninjurin, NSCL2) and DNA repair (e.g. BTG2, DDB2), The results suggest that p53 activates concerted opposing signals and exerts its effect through a diverse network of transcriptional changes that collectively alter the cell phenotype in response to stress.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; Chaim Sheba Med Ctr, Dept Pediat Hematol Oncol, Tel Aviv, Israel; Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel; Chaim Sheba Med Ctr, Funct Genom Unit, Tel Aviv, Israel	Weizmann Institute of Science; Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Chaim Sheba Medical Center	Givol, D (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.		DOMANY, EYTAN/K-1560-2012	Kaminski, Naftali/0000-0001-5917-4601				Ausubel FA, 1990, CURRENT PROTOCOLS MO; Blatt M, 1996, PHYS REV LETT, V76, P3251, DOI 10.1103/PhysRevLett.76.3251; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Getz G, 2000, PHYSICA A, V279, P457, DOI 10.1016/S0378-4371(99)00524-5; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Jimenez GS, 2000, NAT GENET, V26, P37, DOI 10.1038/79152; Kaminski N, 2000, P NATL ACAD SCI USA, V97, P1778, DOI 10.1073/pnas.97.4.1778; Kannan K, 2000, FEBS LETT, V470, P77, DOI 10.1016/S0014-5793(00)01291-6; Komarova EA, 1998, ONCOGENE, V17, P1089, DOI 10.1038/sj.onc.1202303; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MICHIELI P, 1994, CANCER RES, V54, P3391; O'Hagan RC, 2000, NAT GENET, V24, P113, DOI 10.1038/72761; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Scherer SJ, 2000, J BIOL CHEM, V275, P37469, DOI 10.1074/jbc.M006990200; Sherlock G, 2000, CURR OPIN IMMUNOL, V12, P201, DOI 10.1016/S0952-7915(99)00074-6; SHIVAKUMAR CV, 1995, MOL CELL BIOL, V15, P6785; Tan MJ, 2000, P NATL ACAD SCI USA, V97, P109, DOI 10.1073/pnas.97.1.109; Tang BW, 1998, NAT MED, V4, P802, DOI 10.1038/nm0798-802; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Young RA, 2000, CELL, V102, P9, DOI 10.1016/S0092-8674(00)00005-2; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Zhan QM, 1998, MOL CELL BIOL, V18, P2768, DOI 10.1128/MCB.18.5.2768; Zhao RB, 2000, GENE DEV, V14, P981	30	274	291	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 26	2001	20	18					2225	2234		10.1038/sj.onc.1204319	http://dx.doi.org/10.1038/sj.onc.1204319			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	427KZ	11402317				2022-12-25	WOS:000168404500004
J	Wang, HC; Zeng, ZC; Bui, TA; Sonoda, E; Takata, M; Takeda, S; Iliakis, G				Wang, HC; Zeng, ZC; Bui, TA; Sonoda, E; Takata, M; Takeda, S; Iliakis, G			Efficient rejoining of radiation-induced DNA double-strand breaks in vertebrate cells deficient in genes of the RAD52 epistasis group	ONCOGENE			English	Review						double-strand breaks (DSB); homologous recombination; RAD51; RAD51B; RAD52; RAD54; KU70; repair	DEPENDENT PROTEIN-KINASE; RECOMBINATIONAL REPAIR GENE; FIELD GEL-ELECTROPHORESIS; HOMOLOGY-DIRECTED REPAIR; SENSITIVE IRS MUTANTS; SACCHAROMYCES-CEREVISIAE; V(D)J RECOMBINATION; IONIZING-RADIATION; LIGASE IV; PROKARYOTIC RECA	Rejoining of ionizing radiation (IR) induced DNA DSBs usually follows biphasic kinetics with a fast (t(50): 5-30 min) component attributed to DNA-PK-dependent non-homologous endjoining (NHEJ) and a slow (t(50): 1-20 h), as of yet uncharacterized, component. To examine whether homologous recombination (HR) contributes to DNA DSB rejoining, a systematic genetic study was undertaken using the hyper-recombinogenic DT40 chicken cell line and a series of mutants defective in HR, We show that DT40 cells rejoin IR-induced DNA DSBs with half times of 13 min and 4.5 h and contributions by the fast (78%) and the slow (22%) components similar to those of other vertebrate cells with 1000-fold lower levels of HR, We also show that deletion of RAD51B, RAD52 and RAD54 leaves unchanged the rejoining half times and the contribution of the slow component, as does also a conditional knock out mutant of RAD51, A significant reduction (to 37%) in the contribution of the fast component is observed in Ku70 / DT40 cells, but the slow component, operating with a half time of 18.4 h, is still able to rejoin the majority (63%) of DSBs, ri double mutant Ku70(-/-)/RAD54 / shows similar half times to Ku70(-/-) cells. Thus, variations in HR by several orders of magnitude leave unchanged the kinetics of rejoining of DNA DSBs, and fail to modify the contribution of the slow component in a way compatible with a dependence on HR, We propose that, in contrast to yeast, cells of vertebrates are 'hard-wired' in the utilization of NHEJ as the main pathway for rejoining of IR-induced DNA DSBs and speculate that the contribution of homologous recombination repair (HRR) is at a stage after the initial rejoining.	Thomas Jefferson Univ, Jefferson Med Coll, Kimmel Canc Ctr, Dept Radiat Oncol, Philadelphia, PA 19107 USA; Kyoto Univ, Fac Med, Bayer Chair Dept Mol Immunol & Allergol, Sakyo Ku, Kyoto 6068501, Japan; JST, CREST, Tsukuba, Ibaraki, Japan	Jefferson University; Kyoto University; Japan Science & Technology Agency (JST)	Iliakis, G (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Kimmel Canc Ctr, Dept Radiat Oncol, Thompson Bldg Room B-1, Philadelphia, PA 19107 USA.			Takata, Minoru/0000-0002-4926-3675; Takeda, Shunichi/0000-0002-7924-7991	NCI NIH HHS [P30-CA56036, CA42026] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042026, P30CA056036] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABOUSSEKHRA A, 1992, MOL CELL BIOL, V12, P3224, DOI 10.1128/MCB.12.7.3224; Asaad NA, 2000, ONCOGENE, V19, P5788, DOI 10.1038/sj.onc.1203953; BADIE C, 1995, RADIAT RES, V144, P26, DOI 10.2307/3579232; BASES R, 1986, RADIAT RES, V105, P259, DOI 10.2307/3576551; BASES R, 1990, INT J RADIAT BIOL, V58, P35, DOI 10.1080/09553009014551421; BASILE G, 1992, MOL CELL BIOL, V12, P3235, DOI 10.1128/MCB.12.7.3235; Baumann P, 1998, TRENDS BIOCHEM SCI, V23, P247, DOI 10.1016/S0968-0004(98)01232-8; Bennett CB, 1997, CANCER RES, V57, P1970; Bennett CB, 1996, MOL CELL BIOL, V16, P4414; Benson FE, 1998, NATURE, V391, P401, DOI 10.1038/34937; Bezzubova O, 1997, CELL, V89, P185, DOI 10.1016/S0092-8674(00)80198-1; BEZZUBOVA OY, 1994, EXPERIENTIA, V50, P270, DOI 10.1007/BF01924010; BEZZUBOVA OY, 1993, NUCLEIC ACIDS RES, V21, P5945, DOI 10.1093/nar/21.25.5945; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; Boulton SJ, 1996, NUCLEIC ACIDS RES, V24, P4639, DOI 10.1093/nar/24.23.4639; Boulton SJ, 1996, EMBO J, V15, P5093, DOI 10.1002/j.1460-2075.1996.tb00890.x; Boulton SJ, 1998, EMBO J, V17, P1819, DOI 10.1093/emboj/17.6.1819; BUERSTEDDE JM, 1991, CELL, V67, P179, DOI 10.1016/0092-8674(91)90581-I; CHEONG N, 1994, MUTAT RES, V314, P77, DOI 10.1016/0921-8777(94)90063-9; CHEONG N, 1992, MUTAT RES, V274, P111, DOI 10.1016/0921-8777(92)90058-B; CHOULIKA A, 1995, MOL CELL BIOL, V15, P1968; CONTOPOULOU CR, 1987, YEAST, V3, P71, DOI 10.1002/yea.320030203; D'Mello SR, 1998, J NEUROCHEM, V70, P1809; Dibiase SJ, 2000, CANCER RES, V60, P1245; DIKOMEY E, 1986, INT J RADIAT BIOL, V50, P893, DOI 10.1080/09553008614551311; Dronkert MLG, 2000, MOL CELL BIOL, V20, P3147, DOI 10.1128/MCB.20.9.3147-3156.2000; Dynan WS, 1998, NUCLEIC ACIDS RES, V26, P1551, DOI 10.1093/nar/26.7.1551; Essers J, 2000, EMBO J, V19, P1703, DOI 10.1093/emboj/19.7.1703; Essers J, 1997, CELL, V89, P195, DOI 10.1016/S0092-8674(00)80199-3; Evans JW, 1996, RADIAT RES, V145, P39, DOI 10.2307/3579193; FRANKENBERGSCHWAGER M, 1989, RADIOTHER ONCOL, V14, P307, DOI 10.1016/0167-8140(89)90143-6; FRANKENBERGSCHWAGER M, 1990, RADIAT ENVIRON BIOPH, V29, P273, DOI 10.1007/BF01210408; FRANKENBURGSCHWAGER M, 1994, INT J RADIAT BIOL, V66, P543, DOI 10.1080/09553009414551591; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; FULLER LF, 1988, MUTAT RES, V193, P109, DOI 10.1016/0167-8817(88)90041-7; GAME JC, 1993, SEMIN CANCER BIOL, V4, P73; Grawunder U, 1998, MOL CELL, V2, P477, DOI 10.1016/S1097-2765(00)80147-1; Grawunder U, 1998, J BIOL CHEM, V273, P24708, DOI 10.1074/jbc.273.38.24708; HABER J E, 1992, Current Opinion in Cell Biology, V4, P401, DOI 10.1016/0955-0674(92)90005-W; Haber JE, 1999, TRENDS BIOCHEM SCI, V24, P271, DOI 10.1016/S0968-0004(99)01413-9; HENDRICKSON EA, 1991, P NATL ACAD SCI USA, V88, P4061, DOI 10.1073/pnas.88.10.4061; HENNER WD, 1983, J BIOL CHEM, V258, P711; HO KSY, 1975, MUTAT RES, V30, P327, DOI 10.1016/0165-1218(75)90058-0; ILIAKIS G, 1992, INT J RADIAT BIOL, V61, P315, DOI 10.1080/09553009214550991; ILIAKIS G, 1991, BIOESSAYS, V13, P641; ILIAKIS GE, 1991, INT J RADIAT BIOL, V59, P343, DOI 10.1080/09553009114550321; ILIAKIS GE, 1991, INT J RADIAT BIOL, V59, P321, DOI 10.1080/09553009114550311; Ivanov EL, 1996, GENETICS, V142, P693; JACKSON SP, 1995, TRENDS BIOCHEM SCI, V20, P412, DOI 10.1016/S0968-0004(00)89090-8; Jeggo PA, 1998, ADV GENET, V38, P185, DOI 10.1016/S0065-2660(08)60144-3; Johnson RD, 1999, NATURE, V401, P397, DOI 10.1038/43935; JONES NJ, 1990, MUTAGENESIS, V5, P15, DOI 10.1093/mutage/5.1.15; Kanaar R, 1998, TRENDS CELL BIOL, V8, P483, DOI 10.1016/S0962-8924(98)01383-X; KEMP LM, 1984, MUTAT RES, V132, P189, DOI 10.1016/0167-8817(84)90037-3; Kogoma T, 1996, CELL, V85, P625, DOI 10.1016/S0092-8674(00)81229-5; Lewis LK, 1999, GENETICS, V152, P1513; Lewis LK, 1998, MOL CELL BIOL, V18, P1891, DOI 10.1128/MCB.18.4.1891; Liang F, 1998, P NATL ACAD SCI USA, V95, P5172, DOI 10.1073/pnas.95.9.5172; Lieber MR, 1997, CURR OPIN GENET DEV, V7, P99, DOI 10.1016/S0959-437X(97)80116-5; Lim DS, 1996, MOL CELL BIOL, V16, P7133; Liu N, 1998, MOL CELL, V1, P783, DOI 10.1016/S1097-2765(00)80078-7; Lobrich M, 1995, P NATL ACAD SCI USA, V92, P12050, DOI 10.1073/pnas.92.26.12050; LOVETT ST, 1994, GENE, V142, P103, DOI 10.1016/0378-1119(94)90362-X; METZGER L, 1991, INT J RADIAT BIOL, V59, P1325, DOI 10.1080/09553009114551201; Mortensen UH, 1996, P NATL ACAD SCI USA, V93, P10729, DOI 10.1073/pnas.93.20.10729; Nevaldine B, 1997, RADIAT RES, V147, P535, DOI 10.2307/3579619; New JH, 1998, NATURE, V391, P407, DOI 10.1038/34950; OKAYASU R, 1993, RADIAT RES, V138, P34; Ouyang H, 1997, J EXP MED, V186, P921, DOI 10.1084/jem.186.6.921; Peng L, 1998, GENOMICS, V54, P529, DOI 10.1006/geno.1998.5536; Petes T. D., 1991, MOL CELLULAR BIOL YE, P407; Petrini J H, 1997, Semin Immunol, V9, P181, DOI 10.1006/smim.1997.0067; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; RESNICK MA, 1976, J THEOR BIOL, V59, P97, DOI 10.1016/S0022-5193(76)80025-2; Riballo E, 1999, CURR BIOL, V9, P699, DOI 10.1016/S0960-9822(99)80311-X; Rice MC, 1997, P NATL ACAD SCI USA, V94, P7417, DOI 10.1073/pnas.94.14.7417; Rijkers T, 1998, MOL CELL BIOL, V18, P6423, DOI 10.1128/MCB.18.11.6423; Rothstein R, 2000, GENE DEV, V14, P1; ROUET P, 1994, MOL CELL BIOL, V14, P8096, DOI 10.1128/MCB.14.12.8096; Sargent RG, 1997, MOL CELL BIOL, V17, P267, DOI 10.1128/MCB.17.1.267; Schoenmakers EFPM, 1999, CANCER RES, V59, P19; SHINOHARA A, 1993, NAT GENET, V4, P239, DOI 10.1038/ng0793-239; SHINOHARA A, 1995, TRENDS BIOCHEM SCI, V20, P387, DOI 10.1016/S0968-0004(00)89085-4; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; Shinohara A, 1998, NATURE, V391, P404, DOI 10.1038/34943; Siede W, 1996, GENETICS, V142, P91; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; Sung P, 1997, J BIOL CHEM, V272, P28194, DOI 10.1074/jbc.272.45.28194; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; Taghian DG, 1997, MOL CELL BIOL, V17, P6386, DOI 10.1128/MCB.17.11.6386; Takata M, 2000, MOL CELL BIOL, V20, P6476, DOI 10.1128/MCB.20.17.6476-6482.2000; Takata M, 1998, EMBO J, V17, P5497, DOI 10.1093/emboj/17.18.5497; Teo SH, 1997, EMBO J, V16, P4788, DOI 10.1093/emboj/16.15.4788; Thacker J, 1999, TRENDS GENET, V15, P166, DOI 10.1016/S0168-9525(99)01733-3; THACKER J, 1990, MUTAT RES, V235, P49, DOI 10.1016/0921-8777(90)90057-C; Thompson LH, 1999, BIOCHIMIE, V81, P87, DOI 10.1016/S0300-9084(99)80042-X; Tsuzuki T, 1996, P NATL ACAD SCI USA, V93, P6236, DOI 10.1073/pnas.93.13.6236; VAINIO O, 1995, IMMUNOL TODAY, V16, P365, DOI 10.1016/0167-5699(95)80002-6; Wachsberger PR, 1999, RADIAT RES, V151, P398, DOI 10.2307/3579826; WARD JF, 1985, RADIAT RES, V104, pS103, DOI 10.2307/3576637; WEAVER DT, 1995, ADV IMMUNOL, V58, P29, DOI 10.1016/S0065-2776(08)60619-7; Weaver DT, 1996, CRIT REV EUKAR GENE, V6, P345, DOI 10.1615/CritRevEukarGeneExpr.v6.i4.20; WIEBEZAHN KF, 1981, NUCLEIC ACIDS RES, P3139; Yamaguchi-Iwai Y, 1998, MOL CELL BIOL, V18, P6430, DOI 10.1128/MCB.18.11.6430	105	126	132	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 26	2001	20	18					2212	2224		10.1038/sj.onc.1204350	http://dx.doi.org/10.1038/sj.onc.1204350			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	427KZ	11402316				2022-12-25	WOS:000168404500003
J	Gelkop, S; Babichev, Y; Isakov, N				Gelkop, S; Babichev, Y; Isakov, N			T cell activation induces direct binding of the Crk adapter protein to the regulatory subunit of phosphatidylinositol 3-kinase (p85) via a complex mechanism involving the Cbl protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT SIGNALING PATHWAYS; GROWTH-FACTOR RECEPTOR; PROTOONCOGENE C-CBL; SYK TYROSINE KINASE; ANTIGEN-RECEPTOR; SH3 DOMAIN; IMMUNOLOGICAL SYNAPSE; NEGATIVE REGULATOR; NUCLEAR FACTOR; V-CRK	The Crk adapter proteins are assumed to play a role in T lymphocyte activation because of their induced association with tyrosine-phosphorylated proteins, such as ZAP-70 and Cbl, and with the phosphatidylinositol 3-kinase regulatory subunit, p85, following engagement of the T cell antigen receptor. Although the exact mechanism of interaction between these molecules has not been fully defined, it has been generally accepted that Crk, ZAP-70, and p85 interact with tyrosine-phosphorylated Cbl, which serves as a major scaffold protein in activated T lymphocytes. Our present results demonstrate a cell activation-dependent reciprocal co-Immunoprecipitation of CrkII and p85 from lysates of Jurkat T cells and a direct binding of CrkII to p85 in an overlay assay. The use of bead-immobilized GST fusion proteins indicated a complex mechanism of interaction between CrkII and p85 involving two distinct and mutually independent regions in each molecule. A relatively high affinity binding of the CrkII-SH3(N) domain to p85 and the p85-proline-B cell receptor-proline (PBP) region to CrkII was observed in lysates of either resting or activated T cells. Direct physical interaction between the CrkII-SH3(N) and the p85-PBP domain was demonstrated using recombinant fusion proteins and was further substantiated by binding competition studies. In addition, immobilized fusion proteins possessing the CrkII-SH2 and p85-SH3 domains were found to pull down p85 and CrkII, respectively, but only from lysates of activated T cells. Nevertheless, the GST-CrkII-SH2 fusion protein was unable to mediate direct association with p85 from lysates of either resting or activated T cells. Our results support a model in which T cell activation dependent conformational changes in CrkII and/or p85 promote an initial direct or indirect low affinity interaction between the two molecules, which is then stabilized by a secondary high affinity interaction mediated by direct binding of the CrkII-SH3(N) to the p85-PBP domain.	Ben Gurion Univ Negev, Fac Hlth Sci, Dept Microbiol & Immunol, IL-84105 Beer Sheva, Israel; Ben Gurion Univ Negev, Canc Res Ctr, IL-84105 Beer Sheva, Israel	Ben Gurion University; Ben Gurion University	Isakov, N (corresponding author), Ben Gurion Univ Negev, Fac Hlth Sci, Dept Microbiol & Immunol, POB 653, IL-84105 Beer Sheva, Israel.	noah@bgumail.bgu.ac.il	ISAKOV, NOAH/F-1659-2012	Isakov, Noah/0000-0002-1412-0957				Anafi M, 1996, J BIOL CHEM, V271, P21365, DOI 10.1074/jbc.271.35.21365; Andoniou CE, 1996, ONCOGENE, V12, P1981; Barber DL, 1997, BLOOD, V89, P3166, DOI 10.1182/blood.V89.9.3166; BEITNERJOHNSON D, 1995, J BIOL CHEM, V270, P5187, DOI 10.1074/jbc.270.10.5187; BOOKER GW, 1993, CELL, V73, P813, DOI 10.1016/0092-8674(93)90259-S; Boussiotis VA, 1997, SCIENCE, V278, P124, DOI 10.1126/science.278.5335.124; Buday L, 1996, J BIOL CHEM, V271, P6159, DOI 10.1074/jbc.271.11.6159; Clements JL, 1999, ANNU REV IMMUNOL, V17, P89, DOI 10.1146/annurev.immunol.17.1.89; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; Dustin ML, 2000, NAT IMMUNOL, V1, P23, DOI 10.1038/76877; Evans EK, 1997, EMBO J, V16, P230, DOI 10.1093/emboj/16.2.230; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; Fields PE, 1996, SCIENCE, V271, P1276, DOI 10.1126/science.271.5253.1276; Fukazawa T, 1996, J BIOL CHEM, V271, P14554, DOI 10.1074/jbc.271.24.14554; Gelkop S, 1999, J BIOL CHEM, V274, P21519, DOI 10.1074/jbc.274.31.21519; Gesbert F, 1998, J BIOL CHEM, V273, P3986, DOI 10.1074/jbc.273.7.3986; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; HARTLEY D, 1995, J BIOL CHEM, V270, P18260, DOI 10.1074/jbc.270.31.18260; Hashimoto Y, 1998, J BIOL CHEM, V273, P17186, DOI 10.1074/jbc.273.27.17186; Healy JI, 1998, ANNU REV IMMUNOL, V16, P645, DOI 10.1146/annurev.immunol.16.1.645; Hunter S, 1999, J BIOL CHEM, V274, P2097, DOI 10.1074/jbc.274.4.2097; Husson H, 1997, ONCOGENE, V14, P2331, DOI 10.1038/sj.onc.1201074; Isakov N, 1998, ADV IMMUNOL, V69, P183, DOI 10.1016/S0065-2776(08)60608-2; Isakov N, 1996, J BIOL CHEM, V271, P15753, DOI 10.1074/jbc.271.26.15753; Janes PW, 1999, J CELL BIOL, V147, P447, DOI 10.1083/jcb.147.2.447; JANEWAY CA, 1994, CELL, V76, P275, DOI 10.1016/0092-8674(94)90335-2; JENKINS MK, 1991, ADV EXP MED BIOL, V292, P167; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KizakaKondoh S, 1996, P NATL ACAD SCI USA, V93, P12177, DOI 10.1073/pnas.93.22.12177; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Li W, 1996, SCIENCE, V271, P1272, DOI 10.1126/science.271.5253.1272; Liu YC, 1998, CELL SIGNAL, V10, P377, DOI 10.1016/S0898-6568(97)00179-4; Liu YC, 1997, J BIOL CHEM, V272, P168; Lupher ML, 1999, IMMUNOL TODAY, V20, P375, DOI 10.1016/S0167-5699(99)01484-X; Matsuda M, 1996, J BIOL CHEM, V271, P14468, DOI 10.1074/jbc.271.24.14468; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; Monks CRF, 1998, NATURE, V395, P82, DOI 10.1038/25764; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; Murphy MA, 1998, MOL CELL BIOL, V18, P4872, DOI 10.1128/MCB.18.8.4872; Ota S, 2000, J BIOL CHEM, V275, P414, DOI 10.1074/jbc.275.1.414; Ota Y, 1997, SCIENCE, V276, P418, DOI 10.1126/science.276.5311.418; Peterson EJ, 1998, CURR OPIN IMMUNOL, V10, P337, DOI 10.1016/S0952-7915(98)80173-8; Qian DP, 1997, CURR OPIN CELL BIOL, V9, P205, DOI 10.1016/S0955-0674(97)80064-6; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; Reif K, 1997, CURR BIOL, V7, P285, DOI 10.1016/S0960-9822(06)00151-5; Rellahan BL, 1997, J BIOL CHEM, V272, P30806, DOI 10.1074/jbc.272.49.30806; ROSEN MK, 1995, NATURE, V374, P477, DOI 10.1038/374477a0; Rudd CE, 1999, CELL, V96, P5, DOI 10.1016/S0092-8674(00)80953-8; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SAKODA T, 1992, ONCOGENE, V7, P1705; Sattler M, 1997, J BIOL CHEM, V272, P10248; Sawasdikosol S, 1996, J IMMUNOL, V157, P110; Schwartz RH, 1996, J EXP MED, V184, P1, DOI 10.1084/jem.184.1.1; Sorokin A, 1998, ONCOGENE, V16, P2425, DOI 10.1038/sj.onc.1201781; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; TANAKA S, 1993, MOL CELL BIOL, V13, P4409, DOI 10.1128/MCB.13.7.4409; TENG KK, 1995, J BIOL CHEM, V270, P20677, DOI 10.1074/jbc.270.35.20677; TSUCHIE H, 1989, ONCOGENE, V4, P1281; van Leeuwen JEM, 1999, J BIOL CHEM, V274, P5153, DOI 10.1074/jbc.274.8.5153; Vuori K, 1996, MOL CELL BIOL, V16, P2606; Zhang ZH, 1999, J BIOL CHEM, V274, P4883, DOI 10.1074/jbc.274.8.4883; Zwartkruis FJT, 1999, EXP CELL RES, V253, P157, DOI 10.1006/excr.1999.4695; [No title captured]	65	33	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36174	36182		10.1074/jbc.M100731200	http://dx.doi.org/10.1074/jbc.M100731200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11418612	hybrid			2022-12-25	WOS:000171194500019
J	Hosoda, T; Monzen, K; Hiroi, Y; Oka, T; Takimoto, E; Yazaki, Y; Nagai, R; Komuro, I				Hosoda, T; Monzen, K; Hiroi, Y; Oka, T; Takimoto, E; Yazaki, Y; Nagai, R; Komuro, I			A novel myocyte-specific gene Midori promotes the differentiation of P19CL6 cells into cardiomyocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOGLOBULIN-LIKE DOMAIN; GROWTH-FACTOR RECEPTOR; HEART TUBE FORMATION; FACTOR PDGF RECEPTOR; TRANSCRIPTION FACTOR; MESSENGER-RNA; BINDING-SITE; MUSCLE DIFFERENTIATION; VENTRAL MORPHOGENESIS; IN-VITRO	Although several cardiac-specific transcription factors have been shown to play vital roles in various steps during the heart formation, the precise mechanism of the early stage of cardiogenesis has yet to be elucidated. By differential display technique, we tried to identify molecules that are expressed earlier than cardiac transcription factors such as CSX-/NKX2-5 and GATA-4 and are involved in cardiomyocyte differentiation using the P19CL6 cell line, which efficiently differentiates into cardiomyocytes when treated with dimethyl sulfoxide. We isolated a novel gene designated Midori. Its deduced amino acid sequence contained an ATP/GTP-binding site, Ig-like domain, and Kringle-like domain. Northern blot analysis revealed that expression of Midori was restricted to the fetal and adult heart and adult skeletal muscle in mice. In whole mount in situ hybridization, Midori was expressed in cardiac crescent and developing heart but not in somites. The MIDORI protein was localized in the nucleus and overexpression of Midori induced expression of endogenous Midori itself, suggesting that MIDORI may act as a transcriptional regulator. Permanent P19CL6 cell lines overexpressing Midori more efficiently differentiated into cardiomyocytes than did parental cells, whereas those overexpressing the antisense Midori less efficiently differentiated. These results suggest that Midori may promote the differentiation of P19CL6 into cardiomyocytes.	Chiba Univ, Grad Sch Med, Dept Cardiovasc Sci & Med, Chuo Ku, Chiba 2608670, Japan; Univ Tokyo, Grad Sch Med, Dept Cardiovasc Med, Tokyo 1138655, Japan; Shinshu Univ, Sch Med, Dept Med 1, Matsumoto, Nagano 3908621, Japan; Int Med Ctr Japan, Tokyo 1628655, Japan	Chiba University; University of Tokyo; Shinshu University; National Center for Global Health & Medicine - Japan	Komuro, I (corresponding author), Chiba Univ, Grad Sch Med, Dept Cardiovasc Sci & Med, Chuo Ku, 1-8-1 Inohana, Chiba 2608670, Japan.		Hosoda, Toru/G-1873-2010	Hosoda, Toru/0000-0002-7273-0630				Benson DW, 1999, J CLIN INVEST, V104, P1567, DOI 10.1172/JCI8154; BODMER R, 1993, DEVELOPMENT, V118, P719; Bush EW, 1996, J BIOL CHEM, V271, P548, DOI 10.1074/jbc.271.1.548; CHAN AML, 1991, SCIENCE, V254, P1382, DOI 10.1126/science.1720571; Chirgadze DY, 1999, NAT STRUCT BIOL, V6, P72; Chirgadze DY, 1998, FEBS LETT, V430, P126, DOI 10.1016/S0014-5793(98)00558-4; Cioce V, 1996, J BIOL CHEM, V271, P13110, DOI 10.1074/jbc.271.22.13110; Davis-Smyth T, 1998, J BIOL CHEM, V273, P3216, DOI 10.1074/jbc.273.6.3216; DavisSmyth T, 1996, EMBO J, V15, P4919, DOI 10.1002/j.1460-2075.1996.tb00872.x; Dietz UH, 1996, J BIOL CHEM, V271, P3311, DOI 10.1074/jbc.271.6.3311; EDWARDS MKS, 1983, MOL CELL BIOL, V3, P2280, DOI 10.1128/MCB.3.12.2280; Grepin C, 1997, DEVELOPMENT, V124, P2387; GREPIN C, 1995, MOL CELL BIOL, V15, P4095; HabaraOhkubo A, 1996, CELL STRUCT FUNCT, V21, P101, DOI 10.1247/csf.21.101; Herley MT, 1999, BIOCHEM BIOPH RES CO, V262, P731, DOI 10.1006/bbrc.1999.1282; Hosoda T, 1999, JPN CIRC J, V63, P425, DOI 10.1253/jcj.63.425; Iyemere VP, 1998, NUCLEIC ACIDS RES, V26, P2098, DOI 10.1093/nar/26.9.2098; KOMURO I, 1993, P NATL ACAD SCI USA, V90, P8145, DOI 10.1073/pnas.90.17.8145; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; Kuo CT, 1997, GENE DEV, V11, P1048, DOI 10.1101/gad.11.8.1048; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Lin Q, 1997, SCIENCE, V276, P1404, DOI 10.1126/science.276.5317.1404; LINTS TJ, 1993, DEVELOPMENT, V119, P419; Lokker NA, 1997, J BIOL CHEM, V272, P33037, DOI 10.1074/jbc.272.52.33037; Lough J, 1996, DEV BIOL, V178, P198, DOI 10.1006/dbio.1996.0211; LYONS I, 1995, GENE DEV, V9, P1654, DOI 10.1101/gad.9.13.1654; MAHADEVAN D, 1995, J BIOL CHEM, V270, P27595, DOI 10.1074/jbc.270.46.27595; MCBURNEY MW, 1982, NATURE, V299, P165, DOI 10.1038/299165a0; MIMA T, 1995, P NATL ACAD SCI USA, V92, P467, DOI 10.1073/pnas.92.2.467; Miyazaki T, 1996, J BIOL CHEM, V271, P14567, DOI 10.1074/jbc.271.24.14567; Molkentin JD, 1997, GENE DEV, V11, P1061, DOI 10.1101/gad.11.8.1061; Monzen K, 1999, MOL CELL BIOL, V19, P7096; Nagase T, 2000, DNA RES, V7, P65, DOI 10.1093/dnares/7.1.65; Park M, 1999, BIOCHEM BIOPH RES CO, V264, P730, DOI 10.1006/bbrc.1999.1580; Schott JJ, 1998, SCIENCE, V281, P108, DOI 10.1126/science.281.5373.108; SUGI Y, 1993, DEV BIOL, V157, P28, DOI 10.1006/dbio.1993.1109; Venot C, 1998, EMBO J, V17, P4668, DOI 10.1093/emboj/17.16.4668; Wang XK, 1996, J BIOL CHEM, V271, P24286, DOI 10.1074/jbc.271.39.24286; WU XS, 1995, DEV BIOL, V169, P619, DOI 10.1006/dbio.1995.1174	39	42	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35978	35989		10.1074/jbc.M100485200	http://dx.doi.org/10.1074/jbc.M100485200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11418590	hybrid			2022-12-25	WOS:000171109300100
J	Brown, LS; Dioumaev, AK; Lanyi, JK; Spudich, EN; Spudich, JL				Brown, LS; Dioumaev, AK; Lanyi, JK; Spudich, EN; Spudich, JL			Photochemical reaction cycle and proton transfers in neurospora rhodopsin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIORHODOPSIN PHOTOCYCLE; N-INTERMEDIATE; SCHIFF-BASE; ASPARTIC ACID-96; INFRARED-SPECTRA; NATRONOBACTERIUM-PHARAONIS; CHROMOPHORE STRUCTURE; VIBRATIONAL ANALYSIS; RAMAN-SPECTROSCOPY; STRUCTURAL-CHANGES	It was recently found that NOP-1, a membrane protein of Neurospora crassa, shows homology to haloarchaeal rhodopsins and binds retinal after heterologous expression in Pichia pastoris. We report on spectroscopic properties of the Neurospora rhodopsin (NR). The photocycle was studied with flash photolysis and time-resolved Fourier-transform infrared spectroscopy in the pH range 5-8. Proton release and uptake during the photocycle were monitored with the pH-sensitive dye, pyranine. Kinetic and spectral analysis revealed six distinct states in the NR photocycle, and we describe their spectral properties and pH-dependent kinetics in the visible and infrared ranges. The phenotypes of the mutant NR proteins, D131E and E142Q, in which the homologues of the key carboxylic acids of the light-driven proton pump bacteriorhodopsin, Asp-85 and Asp-96, were replaced, show that Glu-142 is not involved in reprotonation of the Schiff base but Asp-131 may be. This implies that, if the NR photocycle is associated with proton transport, it has a low efficiency, similar to that of haloarchaeal sensory rhodopsin II. Fourier-transform Raman spectroscopy revealed unexpected differences between NR and bacteriorhodopsin in the configuration of the retinal chromophore, which may contribute to the less effective reprotonation switch of NR.	Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA; Univ Texas, Sch Med, Dept Microbiol & Mol Genet, Houston, TX 77030 USA	University of California System; University of California Irvine; University of Texas System	Brown, LS (corresponding author), Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA.	lsbrown@uci.edu	Brown, Leonid/X-7445-2019; Lanyi, Janos/C-3808-2011; Brown, Leonid/A-1050-2008	Brown, Leonid/0000-0002-5614-8317; Brown, Leonid/0000-0002-5614-8317	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM029498, R01GM029498, R37GM027750, R01GM027750] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM29498, GM27750] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Althaus T, 1995, ISRAEL J CHEM, V35, P227; Beja O, 2000, SCIENCE, V289, P1902, DOI 10.1126/science.289.5486.1902; Bergo V, 2000, BIOCHEMISTRY-US, V39, P2823, DOI 10.1021/bi991676d; Bergo V, 2000, BIOPHYS J, V78, p477A; Bieszke JA, 1999, P NATL ACAD SCI USA, V96, P8034, DOI 10.1073/pnas.96.14.8034; Bieszke JA, 1999, BIOCHEMISTRY-US, V38, P14138, DOI 10.1021/bi9916170; BIVIN DB, 1986, J GEN MICROBIOL, V132, P2167; BOGOMOLNI RA, 1994, P NATL ACAD SCI USA, V91, P10188, DOI 10.1073/pnas.91.21.10188; BRAIMAN MS, 1988, BIOCHEMISTRY-US, V27, P8516, DOI 10.1021/bi00423a002; BRAIMAN MS, 1991, P NATL ACAD SCI USA, V88, P2388, DOI 10.1073/pnas.88.6.2388; Brown LS, 1997, P NATL ACAD SCI USA, V94, P5040, DOI 10.1073/pnas.94.10.5040; Brown LS, 1998, BIOPHYS J, V75, P1455, DOI 10.1016/S0006-3495(98)74064-0; Brown LS, 1998, BIOCHEMISTRY-US, V37, P3982, DOI 10.1021/bi9728396; BROWN LS, 1995, J BIOL CHEM, V270, P27122, DOI 10.1074/jbc.270.45.27122; BUTT HJ, 1989, EMBO J, V8, P1657, DOI 10.1002/j.1460-2075.1989.tb03556.x; CASADIO R, 1980, BIOCHEMISTRY-US, V19, P3374, DOI 10.1021/bi00555a043; CHEN BW, 1994, BIOTECHNIQUES, V17, P657; Chizhov I, 1998, BIOPHYS J, V75, P999, DOI 10.1016/S0006-3495(98)77588-5; Dioumaev AK, 1997, BIOPHYS CHEM, V67, P1, DOI 10.1016/S0301-4622(96)02268-5; Dioumaev AK, 1998, BIOCHEMISTRY-US, V37, P2496, DOI 10.1021/bi971842m; Dioumaev AK, 1999, BIOCHEMISTRY-US, V38, P10070, DOI 10.1021/bi990873+; DUNN R, 1981, P NATL ACAD SCI-BIOL, V78, P6744, DOI 10.1073/pnas.78.11.6744; Engelhard M, 1996, FEBS LETT, V395, P195, DOI 10.1016/0014-5793(96)01041-1; ENGELHARD M, 1985, BIOCHEMISTRY-US, V24, P400, DOI 10.1021/bi00323a024; FODOR SPA, 1988, BIOCHEMISTRY-US, V27, P7097, DOI 10.1021/bi00418a064; GRZESIEK S, 1986, FEBS LETT, V208, P337, DOI 10.1016/0014-5793(86)81045-6; HESSLING B, 1993, BIOPHYS J, V65, P1929, DOI 10.1016/S0006-3495(93)81264-5; HOLZ M, 1989, P NATL ACAD SCI USA, V86, P2167, DOI 10.1073/pnas.86.7.2167; Hu JG, 1998, BIOCHEMISTRY-US, V37, P8088, DOI 10.1021/bi973168e; Ihara K, 1999, J MOL BIOL, V285, P163, DOI 10.1006/jmbi.1998.2286; IMAMOTO Y, 1992, PHOTOCHEM PHOTOBIOL, V56, P1129, DOI 10.1111/j.1751-1097.1992.tb09737.x; KAKITANI H, 1983, J PHYS CHEM-US, V87, P3620, DOI 10.1021/j100242a011; KALISKY O, 1977, BIOPHYS J, V19, P185, DOI 10.1016/S0006-3495(77)85579-3; KATAOKA M, 1994, J MOL BIOL, V243, P621, DOI 10.1016/0022-2836(94)90037-X; LANYI JK, 1992, BIOCHIM BIOPHYS ACTA, V1099, P102, DOI 10.1016/0167-4838(92)90458-P; LAZAREV YA, 1980, BIOCHIM BIOPHYS ACTA, V590, P324, DOI 10.1016/0005-2728(80)90203-0; LITVIN FF, 1975, BIOORG KHIM+, V1, P1767; LOZIER RH, 1975, BIOPHYS J, V15, P955, DOI 10.1016/S0006-3495(75)85875-9; Luecke H, 2000, J MOL BIOL, V300, P1237, DOI 10.1006/jmbi.2000.3884; Luecke H, 1999, SCIENCE, V286, P255, DOI 10.1126/science.286.5438.255; Luecke H, 1998, SCIENCE, V280, P1934, DOI 10.1126/science.280.5371.1934; MARINETTI T, 1989, P NATL ACAD SCI USA, V86, P529, DOI 10.1073/pnas.86.2.529; NAGLE JF, 1981, J CHEM PHYS, V74, P1367, DOI 10.1063/1.441199; OESTERHELT D, 1973, P NATL ACAD SCI USA, V70, P2853, DOI 10.1073/pnas.70.10.2853; Oesterhelt D, 1974, Methods Enzymol, V31, P667; OTTO H, 1989, P NATL ACAD SCI USA, V86, P9228, DOI 10.1073/pnas.86.23.9228; PFEFFERLE JM, 1991, BIOCHEMISTRY-US, V30, P6548, DOI 10.1021/bi00240a027; Richter HT, 1996, BIOCHEMISTRY-US, V35, P15461, DOI 10.1021/bi9612430; Sasaki J, 1999, BIOPHYS J, V77, P2145, DOI 10.1016/S0006-3495(99)77055-4; SASAKI J, 1994, BIOCHEMISTRY-US, V33, P3178, DOI 10.1021/bi00177a006; SAWATZKI J, 1990, P NATL ACAD SCI USA, V87, P5903, DOI 10.1073/pnas.87.15.5903; Schmies G, 2000, BIOPHYS J, V78, P967, DOI 10.1016/S0006-3495(00)76654-9; Schmies G, 2001, P NATL ACAD SCI USA, V98, P1555, DOI 10.1073/pnas.031562298; SEIDEL R, 1995, P NATL ACAD SCI USA, V92, P3036, DOI 10.1073/pnas.92.7.3036; Shimono K, 2000, PHOTOCHEM PHOTOBIOL, V72, P141; SMITH SO, 1987, J PHYS CHEM-US, V91, P804, DOI 10.1021/j100288a011; SMITH SO, 1987, J AM CHEM SOC, V109, P3108, DOI 10.1021/ja00244a038; SMITH SO, 1983, BIOCHEMISTRY-US, V22, P6141, DOI 10.1021/bi00295a016; Spudich JL, 1996, CURR OPIN CELL BIOL, V8, P452, DOI 10.1016/S0955-0674(96)80020-2; Spudich JL, 1998, MOL MICROBIOL, V28, P1051, DOI 10.1046/j.1365-2958.1998.00859.x; Spudich JL, 2000, ANNU REV CELL DEV BI, V16, P365, DOI 10.1146/annurev.cellbio.16.1.365; Subramaniam S, 2000, NATURE, V406, P653, DOI 10.1038/35020614; Sudo Y, 2001, BIOPHYS J, V80, P916, DOI 10.1016/S0006-3495(01)76070-5; VARO G, 1990, BIOCHEMISTRY-US, V29, P6858, DOI 10.1021/bi00481a015; VARO G, 1991, BIOCHEMISTRY-US, V30, P5008, DOI 10.1021/bi00234a024; Zhang WS, 1996, P NATL ACAD SCI USA, V93, P8230, DOI 10.1073/pnas.93.16.8230; Zimanyi L, 1997, J PHYS CHEM B, V101, P1930, DOI 10.1021/jp963346y; ZIMANYI L, 1989, BIOCHEMISTRY-US, V28, P1656, DOI 10.1021/bi00430a034; Zscherp C, 1997, J PHYS CHEM B, V101, P10542, DOI 10.1021/jp971047i	69	61	61	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					32495	32505		10.1074/jbc.M102652200	http://dx.doi.org/10.1074/jbc.M102652200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11435422	hybrid			2022-12-25	WOS:000170746000018
J	Sanbe, A; Gulick, J; Fewell, J; Robbins, J				Sanbe, A; Gulick, J; Fewell, J; Robbins, J			Examining the in vivo role of the amino terminus of the essential myosin light chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL HYPERTROPHIC CARDIOMYOPATHY; SKELETAL-MUSCLE; SHORTENING VELOCITY; TRANSGENIC MICE; N-TERMINUS; F-ACTIN; HEAVY; ISOFORMS; MOTOR; HEART	The functional significance of the actin binding region at the amino terminus of the cardiac essential myosin light chain (ELC) remains obscure. Previous experiments carried out in vitro indicated that modulation of residues 5-14 could induce an inotropic effect, increasing maximal ATPase activity at submaximal Ca2+ concentrations (Rarick, H. M., Opgenorth, T. J., von Geldern, T. W., Wu-Wong, J. R., and Solaro, R. J. (1996) J. Biol. Chem. 271, 27039-27043). Using transgenesis, we effected a cardiac-specific replacement of ELC with a protein containing a 10-amino acid deletion at positions 5-14. Both the ventricular (ELC1v Delta5-14) and atrial (ELC1a Delta5-14) isoforms lacking this peptide were stably incorporated into the sarcomere at high efficiencies. Surprisingly when the kinetics of skinned fibers isolated from the ELC1v Delta5-14 or ELC1a Delta5-14 mice were examined, no alterations in either unloaded shortening or maximum shortening velocities were apparent. Myofibrillar Mg2+-ATPase activity was also unchanged in these preparations. No significant changes in the fiber kinetics in the cognate compartments were observed when either deletion-containing protein replaced endogenous ELC1v or ELC1a. The data indicate that the previously postulated importance of this region in mediating critical protein interactions between the cardiac ELCs and the carboxyl-terminal residues of actin in vivo should be reassessed.	Childrens Hosp Res Fdn, Div Mol Cardiovasc Res, Dept Pediat, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation	Robbins, J (corresponding author), Childrens Hosp Res Fdn, Div Mol Cardiovasc Res, Dept Pediat, 3333 Burnet Ave, Cincinnati, OH 45229 USA.				NHLBI NIH HHS [HL56370, HL52318, HL56620, HL60546, HL41496] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL052318, P01HL041496, R01HL056620, R01HL056370, R01HL060546] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andreev OA, 1999, BIOCHEMISTRY-US, V38, P2480, DOI 10.1021/bi981706x; Andreev OA, 1997, CIRC RES, V81, P688; BOTTINELLI R, 1994, J MUSCLE RES CELL M, V15, P413, DOI 10.1007/BF00122115; Fewell JG, 1998, J CLIN INVEST, V101, P2630, DOI 10.1172/JCI2825; James J, 1999, TRANSGENIC RES, V8, P9, DOI 10.1023/A:1008894507995; JOHARA M, 1993, P NATL ACAD SCI USA, V90, P2127, DOI 10.1073/pnas.90.6.2127; LOWEY S, 1993, J BIOL CHEM, V268, P20414; MCAULIFFE JJ, 1990, CIRC RES, V66, P1204, DOI 10.1161/01.RES.66.5.1204; MORANO I, 1995, CIRC RES, V76, P720, DOI 10.1161/01.RES.76.5.720; Morano I, 1997, FEBS LETT, V408, P71, DOI 10.1016/S0014-5793(97)00390-6; Palermo J, 1996, CIRC RES, V78, P504, DOI 10.1161/01.RES.78.3.504; Rarick HM, 1996, J BIOL CHEM, V271, P27039, DOI 10.1074/jbc.271.43.27039; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; Robbins J, 2000, ANNU REV PHYSIOL, V62, P261, DOI 10.1146/annurev.physiol.62.1.261; Sanbe A, 2000, CIRC RES, V87, P296, DOI 10.1161/01.RES.87.4.296; Sanbe A, 2000, AM J PHYSIOL-HEART C, V279, pH1355, DOI 10.1152/ajpheart.2000.279.3.H1355; Sanbe A, 1999, J BIOL CHEM, V274, P21085, DOI 10.1074/jbc.274.30.21085; Schaub MC, 1998, CARDIOVASC RES, V37, P381, DOI 10.1016/S0008-6363(97)00258-7; SUBRAMANIAM A, 1991, J BIOL CHEM, V266, P24613; Sweeney H. L., 1995, BIOPHYS J, V68, p112S; SWEENEY HL, 1988, J BIOL CHEM, V263, P9034; Timson DJ, 1998, EUR J BIOCHEM, V255, P654, DOI 10.1046/j.1432-1327.1998.2550654.x; Timson DJ, 1997, FEBS LETT, V400, P31, DOI 10.1016/S0014-5793(96)01314-2; Yang QL, 1998, J CLIN INVEST, V102, P1292, DOI 10.1172/JCI3880	25	9	11	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					32682	32686		10.1074/jbc.M009975200	http://dx.doi.org/10.1074/jbc.M009975200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11432848	hybrid			2022-12-25	WOS:000170746000042
J	Schmutte, C; Sadoff, MM; Shim, KS; Acharya, S; Fishel, R				Schmutte, C; Sadoff, MM; Shim, KS; Acharya, S; Fishel, R			The interaction of DNA mismatch repair proteins with human exonuclease I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONPOLYPOSIS COLORECTAL-CANCER; SACCHAROMYCES-CEREVISIAE EXO1; ESCHERICHIA-COLI; MICROSATELLITE INSTABILITY; PROMOTER HYPERMETHYLATION; MUTATION AVOIDANCE; CRYSTAL-STRUCTURE; ATPASE ACTIVITY; SLIDING CLAMP; MUTL HOMOLOGS	Exonucleolytic degradation of DNA is an essential part of many DNA metabolic processes including DNA mismatch repair (MMR) and recombination. Human exonuclease I (hExoI) is a member of a family of conserved 5' --> 3' exonucleases, which are implicated in these processes by genetic studies. Here, we demonstrate that hExoI binds strongly to hMLH1, and we describe interaction regions between hExoI and the MMR proteins hMSH2, hMSH3, and hMLH1. In addition, hExoI forms an immunoprecipitable complex with hMLH1/hPMS2 in vivo. The study of interaction regions suggests a biochemical mechanism of the involvement of hExoI as a downstream effector in MMR and/or DNA recombination.	Thomas Jefferson Univ, Kimmel Canc Ctr, Genet & Mol Biol Program, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	Jefferson University	Schmutte, C (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, Genet & Mol Biol Program, Dept Microbiol & Immunol, BLSB933,233 S 10th St, Philadelphia, PA 19107 USA.	eschmutte@lac.jci.tju.edu; rfishel@hendrix.jci.tju.edu			NATIONAL CANCER INSTITUTE [R01CA067007, R01CA056542] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA067007, CA56542] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ban C, 1998, CELL, V95, P541, DOI 10.1016/S0092-8674(00)81621-9; Ban C, 1999, CELL, V97, P85, DOI 10.1016/S0092-8674(00)80717-5; Bjornson KP, 2000, BIOCHEMISTRY-US, V39, P3176, DOI 10.1021/bi992286u; Bowers J, 2001, J MOL BIOL, V306, P957, DOI 10.1006/jmbi.2001.4467; Burdett V, 2001, P NATL ACAD SCI USA, V98, P6765, DOI 10.1073/pnas.121183298; CHI NW, 1994, J BIOL CHEM, V269, P29984; COOPER DL, 1993, J BIOL CHEM, V268, P11823; Digilio FA, 1996, DEV BIOL, V178, P90, DOI 10.1006/dbio.1996.0200; Esteller M, 1998, ONCOGENE, V17, P2413, DOI 10.1038/sj.onc.1202178; Fiorentini P, 1997, MOL CELL BIOL, V17, P2764, DOI 10.1128/MCB.17.5.2764; Fishel R, 1999, NAT MED, V5, P1239, DOI 10.1038/15191; Fishel R, 1998, GENE DEV, V12, P2096, DOI 10.1101/gad.12.14.2096; Fishel R, 1997, CURR OPIN GENET DEV, V7, P105, DOI 10.1016/S0959-437X(97)80117-7; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Galio L, 1999, NUCLEIC ACIDS RES, V27, P2325, DOI 10.1093/nar/27.11.2325; Gradia S, 1997, CELL, V91, P995, DOI 10.1016/S0092-8674(00)80490-0; Gradia S, 1999, MOL CELL, V3, P255, DOI 10.1016/S1097-2765(00)80316-0; GRILLEY M, 1993, J BIOL CHEM, V268, P11830; Guerrette S, 1999, J BIOL CHEM, V274, P6336, DOI 10.1074/jbc.274.10.6336; Guerrette S, 1998, MOL CELL BIOL, V18, P6616, DOI 10.1128/MCB.18.11.6616; Habraken Y, 1998, J BIOL CHEM, V273, P9837, DOI 10.1074/jbc.273.16.9837; Hall MC, 1999, J BIOL CHEM, V274, P1306, DOI 10.1074/jbc.274.3.1306; Harris RS, 1998, J BACTERIOL, V180, P989, DOI 10.1128/JB.180.4.989-993.1998; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; HIRAOKA LR, 1995, GENOMICS, V25, P220, DOI 10.1016/0888-7543(95)80129-A; Iaccarino I, 2000, J BIOL CHEM, V275, P2080, DOI 10.1074/jbc.275.3.2080; Jiricny J, 1998, MUTAT RES-DNA REPAIR, V409, P107, DOI 10.1016/S0921-8777(98)00056-1; JOHNSON RE, 1995, SCIENCE, V269, P238, DOI 10.1126/science.7618086; Kane MF, 1997, CANCER RES, V57, P808; KOI M, 1994, CANCER RES, V54, P4308; Kolodner RD, 1999, CURR OPIN GENET DEV, V9, P89, DOI 10.1016/S0959-437X(99)80013-6; KUNKEL TA, 1981, SCIENCE, V213, P765, DOI 10.1126/science.6454965; LAHUE RS, 1989, SCIENCE, V245, P160, DOI 10.1126/science.2665076; LAHUE RS, 1987, P NATL ACAD SCI USA, V84, P1482, DOI 10.1073/pnas.84.6.1482; Lamers MH, 2000, NATURE, V407, P711, DOI 10.1038/35037523; Lee BI, 1999, NUCLEIC ACIDS RES, V27, P4114, DOI 10.1093/nar/27.20.4114; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; Mechanic LE, 2000, J BIOL CHEM, V275, P38337, DOI 10.1074/jbc.M006268200; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Nakagawa T, 1999, P NATL ACAD SCI USA, V96, P14186, DOI 10.1073/pnas.96.25.14186; Obmolova G, 2000, NATURE, V407, P703, DOI 10.1038/35037509; Peltomaki P, 1997, GASTROENTEROLOGY, V113, P1146, DOI 10.1053/gast.1997.v113.pm9322509; PROLLA TA, 1994, MOL CELL BIOL, V14, P407, DOI 10.1128/MCB.14.1.407; QIU J, 1998, NUCL ACIDS RES, V26; Qiu JZ, 1999, J BIOL CHEM, V274, P17893, DOI 10.1074/jbc.274.25.17893; ROBINS P, 1994, J BIOL CHEM, V269, P28535; Schmutte C, 1998, CANCER RES, V58, P4537; Spampinato C, 2000, J BIOL CHEM, V275, P9863, DOI 10.1074/jbc.275.13.9863; SZANKASI P, 1992, J BIOL CHEM, V267, P3014; Tishkoff DX, 1998, CANCER RES, V58, P5027; Tishkoff DX, 1997, P NATL ACAD SCI USA, V94, P7487, DOI 10.1073/pnas.94.14.7487; Tran HT, 1999, MOL CELL BIOL, V19, P2000; Tran PT, 2000, MOL CELL BIOL, V20, P6390, DOI 10.1128/MCB.20.17.6390-6398.2000; Viswanathan M, 1998, GENETICS, V149, P7; Wang TF, 1999, P NATL ACAD SCI USA, V96, P13914, DOI 10.1073/pnas.96.24.13914; Wheeler JMD, 1999, P NATL ACAD SCI USA, V96, P10296, DOI 10.1073/pnas.96.18.10296; Wilson DM, 1998, NUCLEIC ACIDS RES, V26, P3762, DOI 10.1093/nar/26.16.3762; Wilson T, 1999, J BIOL CHEM, V274, P21659, DOI 10.1074/jbc.274.31.21659; Wood RD, 2001, SCIENCE, V291, P1284, DOI 10.1126/science.1056154; Wu TH, 1999, J BIOL CHEM, V274, P5948, DOI 10.1074/jbc.274.9.5948; Yamaguchi M, 1998, J BIOL CHEM, V273, P9197, DOI 10.1074/jbc.273.15.9197	61	126	132	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					33011	33018		10.1074/jbc.M102670200	http://dx.doi.org/10.1074/jbc.M102670200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11427529	hybrid			2022-12-25	WOS:000170746000085
J	Shaked, GM; Shaked, Y; Kariv-Inbal, Z; Halimi, M; Avraham, I; Gabizon, R				Shaked, GM; Shaked, Y; Kariv-Inbal, Z; Halimi, M; Avraham, I; Gabizon, R			A protease-resistant prion protein isoform is present in urine of animals and humans affected with prion diseases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREUTZFELDT-JAKOB-DISEASE; SCRAPIE PRION; LIBYAN JEWS; INFECTIVITY; MUTATION; PATHOGENESIS; BRAINS; GENE; REPLICATION; FIBRILS	Prion protein (PrP)(Sc), the only known component of the prion, is present mostly in the brains of animals and humans affected with prion diseases. We now show that a protease-resistant PrP isoform can also be detected in the urine of hamsters, cattle, and humans suffering from transmissible spongiform encephalopathies. Most important, this PrP isoform (UPrPSc) was also found in the urine of hamsters inoculated with prions long before the appearance of clinical signs. Interestingly, intracerebrally inoculation of hamsters with UPrPSc did not cause clinical signs of prion disease even after 270 days, suggesting it differs in its pathogenic properties from brain PrPSc. We propose that the detection of UPrPSc can be used to diagnose humans and animals incubating prion diseases, as well as to increase our understanding on the metabolism of PrPSc in vivo.	Hadassah Univ Hosp, Agnes Ginges Ctr Human Neurogenet, Dept Neurol, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem	Gabizon, R (corresponding author), Hadassah Univ Hosp, Agnes Ginges Ctr Human Neurogenet, Dept Neurol, IL-91120 Jerusalem, Israel.							Berne R. M., 1998, PHYSIOLOGY, P677; Bradley R, 1992, Rev Sci Tech, V11, P605; Bruce ME, 1997, NATURE, V389, P498, DOI 10.1038/39057; CHATELAIN J, 1989, EUR J EPIDEMIOL, V5, P113, DOI 10.1007/BF00145057; CZUB M, 1986, J GEN VIROL, V67, P2005, DOI 10.1099/0022-1317-67-9-2005; CZUB M, 1988, J GEN VIROL, V69, P1753, DOI 10.1099/0022-1317-69-7-1753; De Armond S J, 1989, Prog Clin Biol Res, V317, P601; Fisher E, 1998, MAMM GENOME, V9, P497, DOI 10.1007/s003359900807; Gabizon R, 1996, NAT MED, V2, P59, DOI 10.1038/nm0196-59; GABIZON R, 1993, AM J HUM GENET, V53, P828; GABIZON R, 1987, P NATL ACAD SCI USA, V84, P4017, DOI 10.1073/pnas.84.12.4017; GOLDFARB LG, 1990, LANCET, V336, P637, DOI 10.1016/0140-6736(90)93443-S; Hill AF, 1999, J GEN VIROL, V80, P11, DOI 10.1099/0022-1317-80-1-11; Hill AF, 2000, P NATL ACAD SCI USA, V97, P10248, DOI 10.1073/pnas.97.18.10248; HOPE J, 1988, NATURE, V336, P390, DOI 10.1038/336390a0; HSIAO K, 1991, NEW ENGL J MED, V324, P1091, DOI 10.1056/NEJM199104183241604; Hsich G, 1996, NEW ENGL J MED, V335, P924, DOI 10.1056/NEJM199609263351303; Ironside JW, 2000, HISTOPATHOLOGY, V37, P1, DOI 10.1046/j.1365-2559.2000.00946.x; KIMBERLIN RH, 1986, J GEN VIROL, V67, P255, DOI 10.1099/0022-1317-67-2-255; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; MCKINLEY MP, 1983, CELL, V35, P57, DOI 10.1016/0092-8674(83)90207-6; Meri S, 1996, BIOCHEM J, V316, P923, DOI 10.1042/bj3160923; MEYER RK, 1986, P NATL ACAD SCI USA, V83, P2310, DOI 10.1073/pnas.83.8.2310; Miele G, 2001, NAT MED, V7, P361, DOI 10.1038/85515; NAKANO Y, 1994, ARCH BIOCHEM BIOPHYS, V311, P117, DOI 10.1006/abbi.1994.1216; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; RINDLER MJ, 1990, J BIOL CHEM, V265, P20784; Rosenmann H, 1997, NEUROLOGY, V49, P593, DOI 10.1212/WNL.49.2.593; Safar J, 1998, NAT MED, V4, P1157, DOI 10.1038/2654; SERBAN D, 1990, NEUROLOGY, V40, P110, DOI 10.1212/WNL.40.1.110; Shaked GM, 1999, J BIOL CHEM, V274, P17981, DOI 10.1074/jbc.274.25.17981; SHAKED GM, 2001, J BIOL CHEM, V4, P4; Simon ES, 2000, ANN NEUROL, V47, P257, DOI 10.1002/1531-8249(200002)47:2<257::AID-ANA20>3.0.CO;2-U; TARABOULOS A, 1992, P NATL ACAD SCI USA, V89, P7620, DOI 10.1073/pnas.89.16.7620; Tremblay P, 1998, P NATL ACAD SCI USA, V95, P12580, DOI 10.1073/pnas.95.21.12580; Zeidler M, 1997, LANCET, V350, P908, DOI 10.1016/S0140-6736(97)03148-6	37	134	146	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					31479	31482		10.1074/jbc.C100278200	http://dx.doi.org/10.1074/jbc.C100278200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11423531	hybrid			2022-12-25	WOS:000170613500002
J	Spizz, G; Blackshear, PJ				Spizz, G; Blackshear, PJ			Overexpression of the myristoylated alanine-rich C-kinase substrate inhibits cell adhesion to extracellular matrix components	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT TYROSINE PHOSPHORYLATION; CHONDROITIN SULFATE PROTEOGLYCANS; MEMBRANE ASSOCIATION; MARCKS PROTEIN; CYTOCHALASIN-B; MEDIATED PHOSPHORYLATION; CALMODULIN-BINDING; MOLECULAR-CLONING; ACTIN; FAMILY	Mice lacking the myristoylated alanine-rich C-kinase substrate, or MARCKS protein, exhibit abnormalities consistent with a defect in the ability of neurons to migrate appropriately during forebrain development. To investigate the possibility that this phenotype could be due to disruption of normal cellular adhesion to extracellular matrix, an assay was developed in which 293 cells co-expressing MARCKS and green fluorescent protein were tested for their adhesion competence on various substrates. Fluorescence-activated cell sorting of adherent and non-adherent green fluorescent protein-expressing cells demonstrated that wild-type MARCKS inhibited adhesion of cells to fibronectin, whereas a non-myristoylated mutant did not inhibit adhesion of cells to a variety of substrates. The fibronectin competitive inhibitor RGD peptide inhibited adhesion of cells expressing all MARCKS variants equally. Cytochalasin D inhibited the adhesion of cells expressing non-myristoylated MARCKS, but did not further decrease the adhesion of cells expressing adhesion-inhibitory proteins. Confocal microscopy demonstrated the presence of inhibitory, myristoylated MARCKS at the. plasma membrane, suggesting that localization at this region might be important for MARCKS to inhibit cellular adhesion. These data suggest a possible myristoylation-dependent function of MARCKS to inhibit cellular adhesion to extracellular matrix proteins, indicating a potential mechanism for the cell migration defects seen in the MARCKS-deficient. mice.	NIEHS, Off Clin Res, NIH, Res Triangle Pk, NC 27709 USA; NIEHS, Lab Signal Transduct, NIH, Res Triangle Pk, NC 27709 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Duke University; Duke University	Blackshear, PJ (corresponding author), NIEHS, Off Clin Res, NIH, 111 Alexander Dr, Res Triangle Pk, NC 27709 USA.	black009@niehs.nih.gov	Blackshear, Perry J./C-6206-2019	Blackshear, Perry J./0000-0002-9561-8529				ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; Berditchevski F, 1999, J CELL BIOL, V146, P477, DOI 10.1083/jcb.146.2.477; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; Blackshear PJ, 1997, EXP NEUROL, V145, P46, DOI 10.1006/exnr.1997.6475; Blackshear PJ, 1996, DEV BRAIN RES, V96, P62, DOI 10.1016/S0165-3806(96)00097-1; BLIOKH ZL, 1980, P NATL ACAD SCI-BIOL, V77, P5919, DOI 10.1073/pnas.77.10.5919; BODARY SC, 1990, J BIOL CHEM, V265, P5938; Bubb MR, 1999, J BIOL CHEM, V274, P36472, DOI 10.1074/jbc.274.51.36472; BYERS DM, 1993, J NEUROCHEM, V60, P1414, DOI 10.1111/j.1471-4159.1993.tb03303.x; Chen HC, 1998, J BIOL CHEM, V273, P25777, DOI 10.1074/jbc.273.40.25777; Christophe D, 2000, CELL SIGNAL, V12, P337, DOI 10.1016/S0898-6568(00)00077-2; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; DOHERTY DE, 1994, J IMMUNOL, V153, P241; GEORGE DJ, 1992, J BIOL CHEM, V267, P24879; GODFREY K, 1985, NEW ENGL J MED, V313, P1450, DOI 10.1056/NEJM198512053132305; GRAFF JM, 1989, MOL ENDOCRINOL, V3, P1903, DOI 10.1210/mend-3-11-1903; GRAFF JM, 1991, J BIOL CHEM, V266, P14390; GRAFF JM, 1989, J BIOL CHEM, V264, P21818; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAIMOVICH B, 1993, J BIOL CHEM, V268, P15868; Harlow E., 1988, ANTIBODIES LAB MANUA; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; HINRICHSEN RD, 1993, P NATL ACAD SCI USA, V90, P1585, DOI 10.1073/pnas.90.4.1585; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Jans DA, 2000, BIOESSAYS, V22, P532, DOI 10.1002/(SICI)1521-1878(200006)22:6<532::AID-BIES6>3.0.CO;2-O; KIM JY, 1994, J BIOL CHEM, V269, P28214; KIM JY, 1994, BIOPHYS J, V67, P227, DOI 10.1016/S0006-3495(94)80473-4; Li XL, 1998, J BIOL CHEM, V273, P19329, DOI 10.1074/jbc.273.30.19329; LIESI P, 1990, EXPERIENTIA, V46, P900, DOI 10.1007/BF01939382; Lin XH, 1996, MOL BIOL CELL, V7, P1977, DOI 10.1091/mbc.7.12.1977; LOBAUGH LA, 1990, J BIOL CHEM, V265, P18393; MANENTI S, 1993, J BIOL CHEM, V268, P6878; Manenti S, 1997, FEBS LETT, V419, P95, DOI 10.1016/S0014-5793(97)01438-5; MCILROY BK, 1991, J BIOL CHEM, V266, P4959; MCKEEHAN WL, 1976, J CELL BIOL, V71, P727, DOI 10.1083/jcb.71.3.727; MENKO AS, 1983, MOL CELL BIOL, V3, P113, DOI 10.1128/MCB.3.1.113; MOONEY DJ, 1995, J CELL SCI, V108, P2311; Myat MM, 1997, CURR BIOL, V7, P611, DOI 10.1016/S0960-9822(06)00262-4; Needham LK, 1998, J BIOL CHEM, V273, P14626, DOI 10.1074/jbc.273.23.14626; Oohira A, 2000, ARCH BIOCHEM BIOPHYS, V374, P24, DOI 10.1006/abbi.1999.1598; Palmantier R, 1996, CANCER RES, V56, P2206; PETER K, 1995, J EXP MED, V181, P315, DOI 10.1084/jem.181.1.315; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; Porumb T, 1997, EUR BIOPHYS J BIOPHY, V25, P239, DOI 10.1007/s002490050036; ROSEN A, 1990, J EXP MED, V172, P1211, DOI 10.1084/jem.172.4.1211; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Seykora JT, 1996, J BIOL CHEM, V271, P18797, DOI 10.1074/jbc.271.31.18797; Spizz G, 1997, J BIOL CHEM, V272, P23833, DOI 10.1074/jbc.272.38.23833; Spizz G, 1996, J BIOL CHEM, V271, P553, DOI 10.1074/jbc.271.1.553; STUMPO DJ, 1995, P NATL ACAD SCI USA, V92, P944, DOI 10.1073/pnas.92.4.944; STUMPO DJ, 1989, NUCLEIC ACIDS RES, V17, P3987, DOI 10.1093/nar/17.10.3987; STUMPO DJ, 1989, P NATL ACAD SCI USA, V86, P4012, DOI 10.1073/pnas.86.11.4012; Swierczynski SL, 1996, J BIOL CHEM, V271, P23424, DOI 10.1074/jbc.271.38.23424; SWIERCZYNSKI SL, 1995, J BIOL CHEM, V270, P13436, DOI 10.1074/jbc.270.22.13436; TANIGUCHI H, 1993, J BIOL CHEM, V268, P9960; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; URBANIK E, 1989, ARCH BIOCHEM BIOPHYS, V269, P181, DOI 10.1016/0003-9861(89)90098-2; VERGHESE GM, 1994, J BIOL CHEM, V269, P9361; WANG JKT, 1989, P NATL ACAD SCI USA, V86, P2253, DOI 10.1073/pnas.86.7.2253; Wojciak-Stothard B, 1999, J CELL BIOL, V145, P1293, DOI 10.1083/jcb.145.6.1293; WOODFORDTHOMAS TA, 1992, J CELL BIOL, V117, P401, DOI 10.1083/jcb.117.2.401; Zhang ZY, 1999, J BIOL CHEM, V274, P25093, DOI 10.1074/jbc.274.35.25093; Zhou XM, 2000, J BIOL CHEM, V275, P20217, DOI 10.1074/jbc.M909129199	64	38	38	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					32264	32273		10.1074/jbc.M103960200	http://dx.doi.org/10.1074/jbc.M103960200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11413143	hybrid			2022-12-25	WOS:000170613500107
J	Pitt, GS; Zuhlke, RD; Hudmon, A; Schulman, H; Reuter, H; Tsien, RW				Pitt, GS; Zuhlke, RD; Hudmon, A; Schulman, H; Reuter, H; Tsien, RW			Molecular basis of calmodulin tethering and Ca2+-dependent inactivation of L-type Ca2+ channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EF-HAND MOTIF; CA2+-SENSITIVE INACTIVATION; ALPHA(1C) SUBUNIT; CALCIUM-CHANNEL; EXONS 40-42; DETERMINANTS; FACILITATION; VOLTAGE; BINDING; RECOGNITION	Ca2+-dependent inactivation (CDI) of L-type Ca2+ channels plays a critical role in controlling Ca2+ entry and downstream signal transduction in excitable cells. Ca2+-insensitive forms of calmodulin (CaM) act as dominant negatives to prevent CDI, suggesting that CaM acts as a resident Ca2+ sensor. However, it is not known how the Ca2+ sensor is constitutively tethered. We have found that the tethering of Ca2+-insensitive CaM was localized to the C-terminal tail of arc, close to the CDI effector motif, and that it depended on nanomolar Ca2+ concentrations, likely attained in quiescent cells. Two stretches of amino acids were found to support the tethering and to contain putative CaM-binding sequences close to or overlapping residues previously shown to affect CDI and Ca2+-independent inactivation. Synthetic peptides containing these sequences displayed differences in CaM-binding properties, both in affinity and Ca2+ dependence, leading us to propose a novel mechanism for CDI. In contrast to a traditional disinhibitory scenario, we suggest that apoCaM is tethered at two sites and signals actively to slow inactivation. When the C-terminal lobe of CaM binds to the nearby CaM effector sequence (IQ motif), the braking effect is relieved, and CDI is accelerated.	Stanford Univ, Sch Med, Dept Cellular & Mol Physiol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Neurobiol, Stanford, CA 94305 USA; Univ Bern, Dept Pharmacol, CH-3010 Bern, Switzerland	Stanford University; Stanford University; University of Bern	Pitt, GS (corresponding author), Columbia Univ, Sch Med, Dept Pharmacol, 630 E 168th St,PH 7W-318, New York, NY 10032 USA.	gp2004@columbia.edu	Pitt, Geoffrey/L-4927-2019; Tuluc, Petronel/C-2527-2011		NHLBI NIH HHS [K08 HL003743-05, K08 HL003743-06, K08 HL003743-04, K08 HL03743, K08 HL003743-03] Funding Source: Medline; NIGMS NIH HHS [GM58234] Funding Source: Medline; NINDS NIH HHS [NS24067] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003743] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058234] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024067] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adams B, 1997, J GEN PHYSIOL, V110, P379, DOI 10.1085/jgp.110.4.379; BEELER GW, 1970, J PHYSIOL-LONDON, V207, P191, DOI 10.1113/jphysiol.1970.sp009056; Bernatchez G, 1998, BIOPHYS J, V75, P1727, DOI 10.1016/S0006-3495(98)77614-3; CRIVICI A, 1995, ANNU REV BIOPH BIOM, V24, P85, DOI 10.1146/annurev.bb.24.060195.000505; DASGUPTA M, 1989, J BIOL CHEM, V264, P17156; DELEON M, 1995, SCIENCE, V270, P1502, DOI 10.1126/science.270.5241.1502; DeMaria CD, 2001, NATURE, V411, P484, DOI 10.1038/35078091; Dzhura I, 2000, NAT CELL BIOL, V2, P173, DOI 10.1038/35004052; Ehlers MD, 1999, NATURE, V399, P105, DOI 10.1038/20079; HAACK JA, 1994, BIOPHYS J, V66, P1051, DOI 10.1016/S0006-3495(94)80886-0; Hofer GF, 1997, BIOPHYS J, V73, P1857, DOI 10.1016/S0006-3495(97)78216-X; Ivanina T, 2000, J BIOL CHEM, V275, P39846, DOI 10.1074/jbc.M005881200; Keen JE, 1999, J NEUROSCI, V19, P8830, DOI 10.1523/JNEUROSCI.19-20-08830.1999; KINCAID RL, 1982, J BIOL CHEM, V257, P638; KINK JA, 1990, CELL, V62, P165, DOI 10.1016/0092-8674(90)90250-I; LADANT D, 1988, J BIOL CHEM, V263, P2612; Lemaire S, 1998, BASIC RES CARDIOL, V93, P51; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; Meyers MB, 1998, J BIOL CHEM, V273, P18930, DOI 10.1074/jbc.273.30.18930; Mouton J, 2001, J BIOL CHEM, V276, P22359, DOI 10.1074/jbc.M100755200; NEWTON DL, 1984, J BIOL CHEM, V259, P4419; Pate P, 2000, J BIOL CHEM, V275, P39786, DOI 10.1074/jbc.M007158200; Peterson BZ, 2000, BIOPHYS J, V78, P1906, DOI 10.1016/S0006-3495(00)76739-7; Peterson BZ, 1999, NEURON, V22, P549, DOI 10.1016/S0896-6273(00)80709-6; Qin N, 1999, P NATL ACAD SCI USA, V96, P2435, DOI 10.1073/pnas.96.5.2435; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; Romanin C, 2000, FEBS LETT, V487, P301, DOI 10.1016/S0014-5793(00)02361-9; RUTH P, 1989, SCIENCE, V245, P1115, DOI 10.1126/science.2549640; Schumacher MA, 2001, NATURE, V410, P1120, DOI 10.1038/35074145; SINGER D, 1991, SCIENCE, V253, P1553, DOI 10.1126/science.1716787; Soldatov NM, 1998, J BIOL CHEM, V273, P957, DOI 10.1074/jbc.273.2.957; Soldatov NM, 1997, J BIOL CHEM, V272, P3560, DOI 10.1074/jbc.272.6.3560; Xia XM, 1998, NATURE, V395, P503, DOI 10.1038/26758; XIAO RP, 1994, P NATL ACAD SCI USA, V91, P9659, DOI 10.1073/pnas.91.20.9659; Zuhlke RD, 2000, J BIOL CHEM, V275, P21121, DOI 10.1074/jbc.M002986200; Zuhlke RD, 1998, P NATL ACAD SCI USA, V95, P3287, DOI 10.1073/pnas.95.6.3287; Zuhlke RD, 1999, NATURE, V399, P159, DOI 10.1038/20200	37	233	241	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					30794	30802		10.1074/jbc.M104959200	http://dx.doi.org/10.1074/jbc.M104959200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11408490	hybrid			2022-12-25	WOS:000170472900030
J	Scholz, GM; Cartledge, K; Hall, NE				Scholz, GM; Cartledge, K; Hall, NE			Identification and characterization of harc, a novel Hsp90-associating relative of Cdc37	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; HSP90 MOLECULAR CHAPERONE; CELL-FREE SYSTEM; IN-VIVO; GLUCOCORTICOID RECEPTOR; PROGESTERONE-RECEPTOR; TYROSINE KINASE; BINDING-SITE; P50(CDC37); COMPLEX	Although little is known about the precise mechanisms by which the molecular chaperone Hsp90 recognizes its client proteins, Cdc37 has been shown to play a critical role in the targeting of Hsp90 to client protein kinases. Described here is the identification and characterization of a novel 35-kDa human protein that is 31% identical to Cde37. We have named this novel protein Rare ((H) under bar sp90-(a) under bar ssociating (r) under bar elative of (C) under bar dc37). Northern blot analysis revealed the presence of Hare mRNA in several human tissues, including liver, skeletal muscle, and kidney. Biochemical fractionation and immunofluorescent localization of epitope-tagged Hare (ie. FLAG-Hare) indicated that it is present in the cytoplasm of cells. FLAG-Harc binds Hsp90 but unlike Cdc37 does not bind Src family kinases or Raf-l. Mapping experiments indicate that the central 120 amino acids of both Hare and Cdc37 constitute a Hsp90-binding domain not described previously. FLAG-Harc is basally serine-phosphorylated and hyperphosphorylated when co-expressed with an activated mutant of the Src family kinase Hck. Notably, FLAG-Harc forms complexes with Hsp90, Hsp70, p60Hop, immunophilins, and an unidentified p22 protein but not with the Hsp90 co-chaperone p23. Thus Hare likely represents a novel participant in Hsp90-mediated protein folding, potentially targeting Hsp90 to Hsp70-client protein heterocomplexes.	Royal Melbourne Hosp, Ludwig Inst Canc Res, Parkville, Vic 3050, Australia	Ludwig Institute for Cancer Research; Royal Melbourne Hospital	Scholz, GM (corresponding author), Royal Melbourne Hosp, Ludwig Inst Canc Res, POB 2008, Parkville, Vic 3050, Australia.	Glen.Scholz@ludwig.edu.au		Scholz, Glen/0000-0003-2722-6344; Hall, Nathan/0000-0001-8942-0498				Apweiler R, 2000, BIOINFORMATICS, V16, P1145, DOI 10.1093/bioinformatics/16.12.1145; Blagosklonny MV, 1996, P NATL ACAD SCI USA, V93, P8379, DOI 10.1073/pnas.93.16.8379; Bohen SP, 1998, MOL CELL BIOL, V18, P3330, DOI 10.1128/MCB.18.6.3330; BORKOVICH KA, 1989, MOL CELL BIOL, V9, P3919, DOI 10.1128/MCB.9.9.3919; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Chen SY, 1996, MOL ENDOCRINOL, V10, P682, DOI 10.1210/me.10.6.682; CUTFORTH T, 1994, CELL, V77, P1027, DOI 10.1016/0092-8674(94)90442-1; Dittmar KD, 1998, J BIOL CHEM, V273, P7358, DOI 10.1074/jbc.273.13.7358; Dittmar KD, 1997, J BIOL CHEM, V272, P21213, DOI 10.1074/jbc.272.34.21213; Fang YF, 1998, MOL CELL BIOL, V18, P3727, DOI 10.1128/MCB.18.7.3727; Freeman BC, 2000, GENE DEV, V14, P422; Garcia-Cardena G, 1998, NATURE, V392, P821, DOI 10.1038/33934; GERBER MR, 1995, P NATL ACAD SCI USA, V92, P4651, DOI 10.1073/pnas.92.10.4651; Grammatikakis N, 1999, MOL CELL BIOL, V19, P1661; Grenert JP, 1997, J BIOL CHEM, V272, P23843, DOI 10.1074/jbc.272.38.23843; Hartson SD, 2000, BIOCHEMISTRY-US, V39, P7631, DOI 10.1021/bi000315r; HARTSON SD, 1994, BIOCHEMISTRY-US, V33, P8912, DOI 10.1021/bi00196a008; Holt SE, 1999, GENE DEV, V13, P817, DOI 10.1101/gad.13.7.817; Johnson BD, 1998, J BIOL CHEM, V273, P3679, DOI 10.1074/jbc.273.6.3679; Jones DT, 1999, J MOL BIOL, V292, P195, DOI 10.1006/jmbi.1999.3091; Kimura Y, 1997, GENE DEV, V11, P1775, DOI 10.1101/gad.11.14.1775; Kosano H, 1998, J BIOL CHEM, V273, P32973, DOI 10.1074/jbc.273.49.32973; Nair SC, 1996, CELL STRESS CHAPERON, V1, P237, DOI 10.1379/1466-1268(1996)001<0237:APOMCI>2.3.CO;2; Nair SC, 1997, MOL CELL BIOL, V17, P594, DOI 10.1128/MCB.17.2.594; OWENSGRILLO JK, 1995, J BIOL CHEM, V270, P20479, DOI 10.1074/jbc.270.35.20479; OwensGrillo JK, 1996, J BIOL CHEM, V271, P13468, DOI 10.1074/jbc.271.23.13468; Panaretou B, 1998, EMBO J, V17, P4829, DOI 10.1093/emboj/17.16.4829; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; RAO J, 2000, J BIOL CHEM; Ratajczak T, 1996, J BIOL CHEM, V271, P2961, DOI 10.1074/jbc.271.6.2961; REED SI, 1980, GENETICS, V95, P561; Scheibel T, 1998, P NATL ACAD SCI USA, V95, P1495, DOI 10.1073/pnas.95.4.1495; Scholz G, 2000, MOL CELL BIOL, V20, P6984, DOI 10.1128/MCB.20.18.6984-6995.2000; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SCHULTE TW, 1995, J BIOL CHEM, V270, P24585, DOI 10.1074/jbc.270.41.24585; Schutz AR, 1997, J CELL BIOL, V136, P969, DOI 10.1083/jcb.136.5.969; Silverstein AM, 1998, J BIOL CHEM, V273, P20090, DOI 10.1074/jbc.273.32.20090; SMITH DF, 1993, MOL CELL BIOL, V13, P869, DOI 10.1128/MCB.13.2.869; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Stepanova L, 1996, GENE DEV, V10, P1491, DOI 10.1101/gad.10.12.1491; Stepanova L, 2000, MOL CELL BIOL, V20, P4462, DOI 10.1128/MCB.20.12.4462-4473.2000; Sullivan W, 1997, J BIOL CHEM, V272, P8007, DOI 10.1074/jbc.272.12.8007; WHITELAW ML, 1991, J BIOL CHEM, V266, P16436; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; XU Y, 1993, P NATL ACAD SCI USA, V90, P7074, DOI 10.1073/pnas.90.15.7074; Young JC, 2000, EMBO J, V19, P5930, DOI 10.1093/emboj/19.21.5930; Yue L, 1999, GENETICS, V151, P1065	50	31	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					30971	30979		10.1074/jbc.M103889200	http://dx.doi.org/10.1074/jbc.M103889200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11413142	hybrid			2022-12-25	WOS:000170472900052
J	Landesman-Bollag, E; Romieu-Mourez, R; Song, DH; Sonenshein, GE; Cardiff, RD; Seldin, DC				Landesman-Bollag, E; Romieu-Mourez, R; Song, DH; Sonenshein, GE; Cardiff, RD; Seldin, DC			Protein kinase CK2 in mammary gland tumorigenesis	ONCOGENE			English	Article						casein kinase II; CK2; transgenic mice; breast cancer; NF-kappa B; beta-catenin	NF-KAPPA-B; CASEIN KINASE-2; TRANSGENIC MICE; C-MYC; BREAST-CANCER; BETA-CATENIN; PEST DOMAIN; HA-RAS; EXPRESSION; ACTIVATION	Protein kinase CK2 is a ubiquitous and evolutionarily conserved serine/threonine kinase that is upregulated in many human cancers and can serve as an oncogene in lymphocytes. Recently, we have demonstrated that CK2 potentiates Wnt/beta -catenin signaling in mammary epithelial cells. To determine whether CK2 overexpression contributes to mammary tumorigenesis, we have performed comparative studies of human and rat breast cancer specimens and we have engineered transgenic mice with dysregulated expression of CK2 alpha in the mammary gland. We find that CK2 is highly expressed in human breast tumor specimens and in carcinogen-induced rat mammary tumors. Overexpression of CK2 alpha in the mammary gland of transgenic mice, under control of the MMTV-LTR, causes hyperplasia and dysplasia of the female mammary gland. Thirty per cent of the female MMTV-CK2 alpha transgenic mice develop mammary adenocarcinomas at a median of 23 months of age, often associated with Wnt pathway activation, as evidenced by upregulation of beta -catenin protein, NF-kappaB activation and upregulation of c-Myc also occur frequently. Thus, in mice, rats, and humans, dysregulated expression of CK2 is associated with and is capable of contributing to mammary tumorigenesis, Targeted inhibition of CK2 could be useful in the treatment of breast cancer.	Boston Med Ctr, Dept Med, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Pathol & Lab Med, Boston, MA 02118 USA; Boston Univ, Dept Chem, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Microbiol, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; Univ Calif Davis, Ctr Comparat Med, Davis, CA 95616 USA	Boston Medical Center; Boston University; Boston University; Boston University; Boston University; University of California System; University of California Davis	Seldin, DC (corresponding author), Boston Med Ctr, Dept Med, 650 Albany St,426A, Boston, MA 02118 USA.			Seldin, David C/0000-0003-0168-2333	NATIONAL CANCER INSTITUTE [R01CA082742] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 82742] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adam L, 1998, J BIOL CHEM, V273, P28238, DOI 10.1074/jbc.273.43.28238; AHMED K, 1994, CELL MOL BIOL RES, V40, P1; ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; Arsura M, 1997, CELL GROWTH DIFFER, V8, P1049; Barker N, 1999, AM J PATHOL, V154, P29, DOI 10.1016/S0002-9440(10)65247-9; Birchmeier C, 1996, ACTA ANAT, V156, P217; Bird TA, 1997, J BIOL CHEM, V272, P32606, DOI 10.1074/jbc.272.51.32606; Bren GD, 2000, J MOL BIOL, V297, P1245, DOI 10.1006/jmbi.2000.3630; Bui TD, 1997, ONCOGENE, V14, P1249, DOI 10.1038/sj.onc.1200936; Cardiff RD, 1999, J MAMMARY GLAND BIOL, V4, P105, DOI 10.1023/A:1018712905244; Cardiff RD, 1996, J MAMMARY GLAND BIOL, V1, P61, DOI 10.1007/BF02096303; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Dale TC, 1996, CANCER RES, V56, P4320; DAYAMAKIN M, 1994, CANCER RES, V54, P2262; DUYAO MP, 1990, P NATL ACAD SCI USA, V87, P4727, DOI 10.1073/pnas.87.12.4727; Faust RA, 1996, CANCER LETT, V101, P31, DOI 10.1016/0304-3835(96)04110-9; Foo SY, 1999, TRENDS GENET, V15, P229; Ford HL, 2000, J BIOL CHEM, V275, P22245, DOI 10.1074/jbc.M002446200; GAPANY M, 1995, MOL MED, V1, P659, DOI 10.1007/BF03401606; Glover CVC, 1998, PROG NUCLEIC ACID RE, V59, P95; Guerra B, 1999, ELECTROPHORESIS, V20, P391, DOI 10.1002/(SICI)1522-2683(19990201)20:2<391::AID-ELPS391>3.0.CO;2-N; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Heilker R, 1999, EUR J BIOCHEM, V259, P253, DOI 10.1046/j.1432-1327.1999.00028.x; HELLERHARRISON RA, 1989, BIOCHEMISTRY-US, V28, P9053, DOI 10.1021/bi00449a014; HOWARD DK, 1983, IN VITRO CELL DEV B, V19, P58, DOI 10.1007/BF02617995; HUGGINS C, 1961, NATURE, V189, P204, DOI 10.1038/189204a0; HUGUET EL, 1994, CANCER RES, V54, P2615; Israel A, 2000, TRENDS CELL BIOL, V10, P129, DOI 10.1016/S0962-8924(00)01729-3; ISSINGER OG, 1993, PHARMACOL THERAPEUT, V59, P1, DOI 10.1016/0163-7258(93)90039-G; Janosch P, 1996, J BIOL CHEM, V271, P13868, DOI 10.1074/jbc.271.23.13868; JOHNSON GG, 1988, J BIOL CHEM, V263, P9079; Kelliher MA, 1996, EMBO J, V15, P5160, DOI 10.1002/j.1460-2075.1996.tb00900.x; KESSLER DJ, 1992, J EXP MED, V176, P787, DOI 10.1084/jem.176.3.787; Kim DW, 2000, CARCINOGENESIS, V21, P871, DOI 10.1093/carcin/21.5.871; KUENZEL EA, 1987, J BIOL CHEM, V262, P9136; Kuhl M, 2000, TRENDS GENET, V16, P279, DOI 10.1016/s0168-9525(00)02028-x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Landesman-Bollag E, 1998, ONCOGENE, V16, P2965, DOI 10.1038/sj.onc.1201854; Lin RT, 1996, MOL CELL BIOL, V16, P1401; Liu ZP, 1997, GENE DEV, V11, P3413, DOI 10.1101/gad.11.24.3413; Mahler JF, 1996, TOXICOL PATHOL, V24, P710, DOI 10.1177/019262339602400606; McElhinny JA, 1996, MOL CELL BIOL, V16, P899; MESTRES P, 1994, ACTA ANAT, V149, P13; Mitev Vanio, 1994, Journal of Dermatological Science, V8, P45, DOI 10.1016/0923-1811(94)90320-4; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MORRIS JJ, 1992, MED HYPOTHESES, V38, P177, DOI 10.1016/0306-9877(92)90090-Y; MUNSTERMANN U, 1990, EUR J BIOCHEM, V189, P251, DOI 10.1111/j.1432-1033.1990.tb15484.x; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; NEBERT DW, 1987, BIOCHEM SOC T, V15, P586, DOI 10.1042/bst0150586; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; OHI Y, 1992, VIRCHOWS ARCH B, V62, P365, DOI 10.1007/BF02899705; OLEMOIYOI OK, 1993, EMBO J, V12, P1621, DOI 10.1002/j.1460-2075.1993.tb05807.x; Orlandini M, 1998, J BIOL CHEM, V273, P21291, DOI 10.1074/jbc.273.33.21291; Pancetti F, 1996, BIOCHEM BIOPH RES CO, V218, P35, DOI 10.1006/bbrc.1996.0007; Pando MP, 2000, J BIOL CHEM, V275, P21278, DOI 10.1074/jbc.M002532200; PENA JM, 1983, CANCER RES, V43, P1172; PEPPERKOK R, 1994, J BIOL CHEM, V269, P6986; PEREZ M, 1988, FEBS LETT, V238, P273, DOI 10.1016/0014-5793(88)80495-2; PERFETTI V, 1991, LEUKEMIA, V5, P1110; Pinna L A, 1997, Prog Cell Cycle Res, V3, P77; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; RANDERATH E, 1985, CARCINOGENESIS, V6, P1117, DOI 10.1093/carcin/6.8.1117; ROGERS AE, 1981, CANCER RES, V41, P3735; Roig J, 1999, MOL CELL BIOCHEM, V191, P229, DOI 10.1023/A:1006808816770; ROMIEUMOUREZ R, 2001, IN PRESS CANC RES; Roose J, 1999, BBA-REV CANCER, V1424, pM23, DOI 10.1016/S0304-419X(99)00026-8; SAFE S, 1984, CRC CR REV TOXICOL, V13, P319, DOI 10.3109/10408448409023762; Schlosshauer PW, 2000, CARCINOGENESIS, V21, P1453, DOI 10.1093/carcin/21.7.1453; Schwarz EM, 1996, MOL CELL BIOL, V16, P3554; SELDIN DC, 1995, SCIENCE, V267, P894, DOI 10.1126/science.7846532; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; Song DH, 2000, J BIOL CHEM, V275, P23790, DOI 10.1074/jbc.M909107199; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; Toczyski DP, 1997, CELL, V90, P1097, DOI 10.1016/S0092-8674(00)80375-X; Tran K, 1997, MOL CELL BIOL, V17, P5386, DOI 10.1128/MCB.17.9.5386; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; Webster MA, 1998, MOL CELL BIOL, V18, P2344, DOI 10.1128/MCB.18.4.2344; Willert K, 1997, EMBO J, V16, P3089, DOI 10.1093/emboj/16.11.3089; Xu X, 1999, NAT GENET, V23, P118, DOI 10.1038/12729	80	254	270	1	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 31	2001	20	25					3247	3257		10.1038/sj.onc.1204411	http://dx.doi.org/10.1038/sj.onc.1204411			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	440ET	11423974				2022-12-25	WOS:000169163500008
J	Hong, F; Nguyen, VA; Gao, B				Hong, F; Nguyen, VA; Gao, B			Tumor necrosis factor alpha attenuates interferon-alpha signaling in the liver: involvement of SOCS3 and SHP2 and implication in resistance to interferon therapy	FASEB JOURNAL			English	Article						interleukin 6; suppressor of cytokine signaling 3; SH2-containing protein-tyrosine phosphatase liver	CHRONIC HEPATITIS-C; MESSENGER-RNA EXPRESSION; DIFFERENTIAL REGULATION; TARGETED DISRUPTION; SUSTAINED RESPONSE; GENE-EXPRESSION; GROWTH-HORMONE; PROTEIN-KINASE; T-LYMPHOCYTES; MICE LACKING	Although interferon alpha (IFN-alpha) has been used for a decade to treat viral hepatitis, a disease that affects millions of people worldwide, more than 60% of viral hepatitis patients respond poorly. It has been reported that high levels of tumor necrosis factor alpha (TNF-alpha) correlated highly with resistance to IFN-alpha therapy. Here we demonstrate that injection of TNF-alpha suppresses IFN-alpha signaling and markedly induces expression of suppressor of cytokine signaling 3 (SOCS3) and SH2 containing protein-tyrosine phosphatase 2 (SHP2) in the liver. TNF-alpha induction of SOCS3 and SHP2 remains unchanged while induction of STAT1 protein expression is completely abolished in IL-6-deficient mice. Immunoprecipitation experiments show that injection of TNF-alpha increases SHP2 association with JAKs. Overexpression of SOCS3 and SHP2 inhibits IFN-alpha signaling in hepatic cells. Injection of carbon tetrachloride, which is known to induce TNF-alpha in the liver, attenuates IFN-alpha signaling in the liver. This attenuation is also observed in TNF-alpha receptor II- (TNF-R2-) deficient mice but is markedly diminished in TNF-R1-deficient mice. Taken together, these findings suggest that TNF-alpha may be involved in resistance to IFN-alpha therapy by induction of SOCS3 and SHP2, and they could be therapeutic targets for improving the efficacy of IFN-alpha therapy.	NIAAA, Sect Liver Biol, Lab Physiol Studies, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)	Gao, B (corresponding author), NIAAA, Sect Liver Biol, Lab Physiol Studies, NIH, Pk Bldg,Rm 120,12420 Parklawn Dr,MSC 8115, Bethesda, MD 20892 USA.	bgao@mail.nih.gov						Ahmad F, 1997, J CELL BIOCHEM, V64, P117, DOI 10.1002/(SICI)1097-4644(199701)64:1<117::AID-JCB14>3.0.CO;2-I; Aman NJ, 1997, CURR BIOL, V7, pR784, DOI 10.1016/S0960-9822(06)00405-2; Berenguer M, 1998, P ASSOC AM PHYSICIAN, V110, P98; Bradham CA, 1998, AM J PHYSIOL-GASTR L, V275, pG387, DOI 10.1152/ajpgi.1998.275.3.G387; Cassatella MA, 1999, BLOOD, V94, P2880, DOI 10.1182/blood.V94.8.2880.420k31_2880_2889; CHEMELLO L, 1995, J VIRAL HEPATITIS, V2, P91, DOI 10.1111/j.1365-2893.1995.tb00012.x; Chen XP, 2000, IMMUNITY, V13, P287, DOI 10.1016/S1074-7613(00)00028-5; Chisari FV, 1996, CURR TOP MICROBIOL, V206, P149; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; Colson A, 2000, ENDOCRINOLOGY, V141, P3687, DOI 10.1210/en.141.10.3687; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVID M, 1995, MOL CELL BIOL, V15, P7050; Davis GL, 2000, GASTROENTEROLOGY, V118, pS104, DOI 10.1016/S0016-5085(00)70009-6; DeCicco LA, 1998, TOXICOL LETT, V98, P115, DOI 10.1016/S0378-4274(98)00110-6; DeSalvo GL, 1997, J VIRAL HEPATITIS, V4, P79; Dumoulin FL, 1999, J INFECT DIS, V180, P1704, DOI 10.1086/315070; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; Edwards-Smith CJ, 1999, HEPATOLOGY, V30, P526, DOI 10.1002/hep.510300207; Gale M, 1998, PHARMACOL THERAPEUT, V78, P29, DOI 10.1016/S0163-7258(97)00165-4; GAO B, 1994, J BIOL CHEM, V269, P15762; GONZALEZAMARO R, 1994, J EXP MED, V179, P841, DOI 10.1084/jem.179.3.841; Hanck C, 2000, J HEPATOL, V32, P51, DOI 10.1016/S0168-8278(00)80189-0; Haque SJ, 1998, SEMIN ONCOL, V25, P14; Heim MH, 1999, J VIROL, V73, P8469, DOI 10.1128/JVI.73.10.8469-8475.1999; Hill DB, 2000, J LAB CLIN MED, V135, P387, DOI 10.1067/mlc.2000.106451; Hoofnagle JH, 1998, DIGESTION, V59, P563, DOI 10.1159/000007532; Horn TL, 2000, TOXICOL SCI, V54, P262, DOI 10.1093/toxsci/54.1.262; HUSSAIN MJ, 1994, J CLIN PATHOL, V47, P1112, DOI 10.1136/jcp.47.12.1112; Ito S, 1999, BLOOD, V93, P1456, DOI 10.1182/blood.V93.5.1456; KOZIEL MJ, 1995, J CLIN INVEST, V96, P2311, DOI 10.1172/JCI118287; Krebs DL, 2000, J CELL SCI, V113, P2813; LANDOLFO S, 1995, PHARMACOL THERAPEUT, V65, P415, DOI 10.1016/0163-7258(95)98599-L; Larrea E, 1996, HEPATOLOGY, V23, P210, DOI 10.1002/hep.510230203; Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626; LOHR HF, 1994, LIVER, V14, P161; McClain CJ, 1998, ALCOHOL CLIN EXP RES, V22, p248S, DOI 10.1111/j.1530-0277.1998.tb04011.x; McKay S, 2000, AM J RESP CELL MOL, V23, P103, DOI 10.1165/ajrcmb.23.1.3765; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; Mochida S, 1996, ALCOHOL CLIN EXP RES, V20, pA371, DOI 10.1111/j.1530-0277.1996.tb01811.x; Nelson DR, 1997, DIGEST DIS SCI, V42, P2487, DOI 10.1023/A:1018804426724; Neuman MG, 1999, CLIN BIOCHEM, V32, P537, DOI 10.1016/S0009-9120(99)00053-3; Nguyen VAT, 2000, BIOCHEM J, V349, P427, DOI 10.1042/0264-6021:3490427; Nicholson SE, 2000, P NATL ACAD SCI USA, V97, P6493, DOI 10.1073/pnas.100135197; Ohnishi K, 1996, AM J GASTROENTEROL, V91, P1374; Okamoto T, 1998, JPN J PHARMACOL, V77, P219, DOI 10.1254/jjp.77.219; OKAZAKI T, 1994, SCAND J GASTROENTERO, V29, P1039, DOI 10.3109/00365529409094883; OLD LJ, 1985, SCIENCE, V230, P630, DOI 10.1126/science.2413547; Paul C, 2000, EUR J BIOCHEM, V267, P5849, DOI 10.1046/j.1432-1327.2000.01395.x; Platanias LC, 1999, EXP HEMATOL, V27, P1583, DOI 10.1016/S0301-472X(99)00109-5; Schiff ER, 1997, HEPATOLOGY, V26, pS39, DOI 10.1002/hep.510260707; Schmitz J, 2000, J BIOL CHEM, V275, P12848, DOI 10.1074/jbc.275.17.12848; Schumann J, 2000, AM J PATHOL, V157, P1671, DOI 10.1016/S0002-9440(10)64804-3; Shen XN, 2000, FEBS LETT, V480, P132, DOI 10.1016/S0014-5793(00)01905-0; SHERON N, 1991, J HEPATOL, V12, P241, DOI 10.1016/0168-8278(91)90945-8; Song MM, 1998, J BIOL CHEM, V273, P35056, DOI 10.1074/jbc.273.52.35056; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Starr R, 1998, INT J BIOCHEM CELL B, V30, P1081, DOI 10.1016/S1357-2725(98)00067-3; Streetz K, 2000, GASTROENTEROLOGY, V119, P446, DOI 10.1053/gast.2000.9364; Taylor DR, 1999, SCIENCE, V285, P107, DOI 10.1126/science.285.5424.107; Tian ZG, 2000, J IMMUNOL, V165, P3959, DOI 10.4049/jimmunol.165.7.3959; TILG H, 1992, GASTROENTEROLOGY, V103, P264, DOI 10.1016/0016-5085(92)91122-K; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; van Huijsduijnen RH, 1998, GENE, V225, P1; VANDENBROEK MF, 1995, J VIROL, V69, P4792, DOI 10.1128/JVI.69.8.4792-4796.1995; Woo MH, 1997, ANN PHARMACOTHER, V31, P330, DOI 10.1177/106002809703100312; Yamada Y, 1997, P NATL ACAD SCI USA, V94, P1441, DOI 10.1073/pnas.94.4.1441; Yin TG, 1997, J BIOL CHEM, V272, P1032, DOI 10.1074/jbc.272.2.1032; You M, 1999, MOL CELL BIOL, V19, P2416, DOI 10.1128/mcb.19.3.2416	68	63	66	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY 29	2001	15	7					1595	+		10.1096/fj.00-0908fje	http://dx.doi.org/10.1096/fj.00-0908fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519CQ	11427497				2022-12-25	WOS:000173707700026
J	Schaefer, M; Albrecht, N; Hofmann, T; Gudermann, T; Schultz, G				Schaefer, M; Albrecht, N; Hofmann, T; Gudermann, T; Schultz, G			Diffusion-limited translocation mechanism of protein kinase C isotypes	FASEB JOURNAL			English	Article						protein kinase C; translocation; G-protein coupled receptors; calcium oscillation; green fluorescent protein; diffusion-driven redistribution; collisional coupling	GREEN FLUORESCENT PROTEIN; CELLULAR-DISTRIBUTION; CALCIUM; CELLS; ACTIVATION; ALPHA; VISUALIZATION; RECEPTOR; LOCALIZATION; MEMBRANE	The plasma membrane translocation. of protein kinase C (PKC) is driven by an as yet unidentified mechanism. We investigated the transport mechanisms of classical and novel PKCs coupled to fluorescent proteins. Classical PKCalpha and PKCbetaI half-maximally translocated 300-750 ms after receptor stimulation, whereas the novel isotypes PKCdelta and PKCepsilon were redistributed five to ten times more slowly. Although fluorescence recovery after photobleach experiments demonstrated that PKCs are freely diffusible in quiescent cells, the similar Stokes' radii of all fusion proteins indicated that diffusion velocities cannot account for the kinetic differences. Alternatively, active transport or different collisional coupling efficacies could explain the effects. A diffusion-driven translocation mechanism was demonstrated by confocal line-scan microscopy to follow subcellular PKC concentrations at high spatiotemporal resolution. The observation of a temporary subplasmalemmal depletion zone is direct evidence for a diffusion-limited binding process. Computer-assisted modeling revealed that Ca2+-bound PKCalpha molecules require only 2 or 3 collisions with the plasma membrane to achieve a binding event. Our data further demonstrate that the slower association kinetic of novel PKC isoenzymes relies on lower collisional. coupling efficacies. The superior collisional coupling of classical PKCs points to a role of Ca2+-binding C2-domains to electrostatically facilitate binding, an effect that is lacking in novel isoenzymes.	Free Univ Berlin, Inst Pharmakol, D-14195 Berlin, Germany	Free University of Berlin	Schaefer, M (corresponding author), Free Univ Berlin, Inst Pharmakol, Thielallee 67-73, D-14195 Berlin, Germany.	schae@zedat.fu-berlin.de						Almholt K, 1999, BIOCHEM J, V337, P211, DOI 10.1042/0264-6021:3370211; Berridge MJ, 1997, NATURE, V386, P759, DOI 10.1038/386759a0; BERRIDGE MJ, 1988, FASEB J, V2, P3074, DOI 10.1096/fasebj.2.15.2847949; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Deeney JT, 1996, J BIOL CHEM, V271, P18154, DOI 10.1074/jbc.271.30.18154; Einstein A, 1905, ANN PHYS-BERLIN, V17, P549, DOI 10.1002/andp.19053220806; FAQUIN WC, 1986, BIOCHIM BIOPHYS ACTA, V887, P142, DOI 10.1016/0167-4889(86)90048-0; Feng X, 1998, J BIOL CHEM, V273, P26870, DOI 10.1074/jbc.273.41.26870; Feng X, 1998, J BIOL CHEM, V273, P10755, DOI 10.1074/jbc.273.17.10755; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hirose K, 1999, SCIENCE, V284, P1527, DOI 10.1126/science.284.5419.1527; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; Jaken S, 2000, BIOESSAYS, V22, P245, DOI 10.1002/(SICI)1521-1878(200003)22:3<245::AID-BIES6>3.0.CO;2-X; KIKKAWA U, 1982, J BIOL CHEM, V257, P13341; MASTRO AM, 1984, P NATL ACAD SCI-BIOL, V81, P3414, DOI 10.1073/pnas.81.11.3414; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Mochly-Rosen D, 1998, FASEB J, V12, P35; Ng T, 1999, SCIENCE, V283, P2085, DOI 10.1126/science.283.5410.2085; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; Oancea E, 1998, CELL, V95, P307, DOI 10.1016/S0092-8674(00)81763-8; Ohmori S, 1998, MOL CELL BIOL, V18, P5263, DOI 10.1128/MCB.18.9.5263; Ormo M, 1996, SCIENCE, V273, P1392, DOI 10.1126/science.273.5280.1392; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; Ron D, 1999, FASEB J, V13, P1658, DOI 10.1096/fasebj.13.13.1658; Sakai N, 1997, J CELL BIOL, V139, P1465, DOI 10.1083/jcb.139.6.1465; Schaefer M, 2000, J BIOL CHEM, V275, P17517, DOI 10.1074/jbc.275.23.17517; Shirai Y, 1998, J CELL BIOL, V143, P511, DOI 10.1083/jcb.143.2.511; Stanley EF, 2000, J NEUROPHYSIOL, V83, P477, DOI 10.1152/jn.2000.83.1.477; Swaminathan R, 1997, BIOPHYS J, V72, P1900, DOI 10.1016/S0006-3495(97)78835-0; Thomas AP, 1996, FASEB J, V10, P1505, DOI 10.1096/fasebj.10.13.8940296; Vallentin A, 2000, J BIOL CHEM, V275, P6014, DOI 10.1074/jbc.275.8.6014; Wang QMJ, 1999, J BIOL CHEM, V274, P37233, DOI 10.1074/jbc.274.52.37233; Wang YL, 1998, FOLD DES, V3, P1, DOI 10.1016/S1359-0278(98)00003-0; WETSEL WC, 1992, J CELL BIOL, V117, P121, DOI 10.1083/jcb.117.1.121; Zeidman R, 1999, J CELL BIOL, V145, P713, DOI 10.1083/jcb.145.4.713	35	61	62	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY 29	2001	15	7					1634	+		10.1096/fj.00-0824fje	http://dx.doi.org/10.1096/fj.00-0824fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519CQ	11427510				2022-12-25	WOS:000173707700009
J	Singh, BB; Zheng, CY; Liu, XB; Lockwich, T; Liao, D; Zhu, MX; Birnbaumer, L; Ambudkar, IS				Singh, BB; Zheng, CY; Liu, XB; Lockwich, T; Liao, D; Zhu, MX; Birnbaumer, L; Ambudkar, IS			Trp1-dependent enhancement of salivary gland fluid secretion: role of store-operated calcium entry	FASEB JOURNAL			English	Article						store-operated calcium influx; calcium channel; fluid secretion; salivary glands; basolateral plasma membrane	INOSITOL 1,4,5-TRISPHOSPHATE RECEPTORS; TRP1; EXPRESSION; CHANNELS; ACETYLCHOLINE; MODULATION; DEPLETION; PROTEIN; CELLS	This study examined the involvement of store-operated Ca2+ entry in agonist-stimulation of salivary gland fluid secretion. A recombinant adenovirus (AdCMV-hTrp1) encoding the store-operated Ca2+ channel protein, human transient receptor potential 1 (hTrp1), was used to direct expression of HA (hemaglutinin)-tagged hTrp1 in vivo in rat submandibular glands (SMG) and in vitro in the human submandibular gland cell line (HSG). Studies with HSG cells demonstrated that AdCMV-hTrp1 was successful in directing the expression of functional hTrp1 and that it did not affect early Ca2+ signaling events. AdCMV-hTrp1-infected SMG displayed an increase in the level of Trp1 and a fivefold increase in pilocarpine-stimulated fluid secretion, compared with glands infected with a control adenovirus encoding luciferase (AdCMV-Luc). The expressed hTrp1 demonstrated polarized localization in the basolateral plasma membrane region of SMG acinar cells and was co-immunoprecipitated with IP(3)Rs. Further, acinar cells isolated from AdCMV-hTrp1-infected glands demonstrated a significant increase in carbachol- and Tg-stimulated Ca2+ entry compared with cells isolated from AdCMV-Luc-infected glands. We conclude that in vivo expression of Trp1 in SMG induces an enhancement of agonist-stimulated fluid secretion via increasing store-operated Ca2+ entry into acinar cells. These data suggest that store-operated Ca2+ entry has a role in agonist-stimulated fluid secretion from salivary glands.	Natl Inst Dent & Craniofacial Res, Secretory Physiol Sect, NIH, Bethesda, MD 20892 USA; Natl Inst Dent & Craniofacial Res, Gene Transfer Sect, Gene Therapy & Therapeut Branch, NIH, Bethesda, MD 20892 USA; Ohio State Univ, Neurobiotechnol Ctr, Columbus, OH 43210 USA; Univ Calif Los Angeles, Dept Anesthesiol, Los Angeles, CA 90095 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); University System of Ohio; Ohio State University; University of California System; University of California Los Angeles	Ambudkar, IS (corresponding author), Natl Inst Dent & Craniofacial Res, Secretory Physiol Sect, NIH, Bldg 10,Room 1N-113, Bethesda, MD 20892 USA.	ambudkar@yoda.nidcr.nih.gov		Singh, Brij/0000-0003-0535-5997	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000438] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000438] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Ambudkar IS, 2000, CRIT REV ORAL BIOL M, V11, P4, DOI 10.1177/10454411000110010301; Baum BJ, 1999, CRIT REV ORAL BIOL M, V10, P276, DOI 10.1177/10454411990100030201; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; Berridge MJ, 2000, SCIENCE, V287, P1604, DOI 10.1126/science.287.5458.1604; Birnbaumer L, 1996, P NATL ACAD SCI USA, V93, P15195, DOI 10.1073/pnas.93.26.15195; Boulay G, 1999, P NATL ACAD SCI USA, V96, P14955, DOI 10.1073/pnas.96.26.14955; Cook D. I., 1994, P1061; Delporte C, 1997, P NATL ACAD SCI USA, V94, P3268, DOI 10.1073/pnas.94.7.3268; DOUGLAS WW, 1963, J PHYSIOL-LONDON, V165, P528, DOI 10.1113/jphysiol.1963.sp007076; Evans RL, 1998, EUR J MORPHOL, V36, P142; FOSKETT JK, 1990, AM J PHYSIOL, V259, pC998; Hofmann T, 2000, J MOL MED, V78, P14, DOI 10.1007/s001090050378; Ishikawa Y, 1998, BIOCHEM BIOPH RES CO, V245, P835, DOI 10.1006/bbrc.1998.8395; Kiselyov K, 1999, MOL CELL, V4, P423, DOI 10.1016/S1097-2765(00)80344-5; Lee MG, 1997, J BIOL CHEM, V272, P15771, DOI 10.1074/jbc.272.25.15771; Liu XB, 1998, AM J PHYSIOL-CELL PH, V275, pC571, DOI 10.1152/ajpcell.1998.275.2.C571; Liu XB, 2000, J BIOL CHEM, V275, P3403, DOI 10.1074/jbc.275.5.3403; Lockwich TP, 2000, J BIOL CHEM, V275, P11934, DOI 10.1074/jbc.275.16.11934; PETERSEN OH, 1992, J PHYSIOL-LONDON, V448, P1; Petersen OH, 1999, EUR J CELL BIOL, V78, P221, DOI 10.1016/S0171-9335(99)80054-5; PUTNEY JW, 1986, ANNU REV PHYSIOL, V48, P75, DOI 10.1146/annurev.ph.48.030186.000451; Putney JW, 1999, P NATL ACAD SCI USA, V96, P14669, DOI 10.1073/pnas.96.26.14669; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/er.14.5.610; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; Rosado JA, 2000, BIOCHEM J, V350, P631, DOI 10.1042/0264-6021:3500631; Singh BB, 2000, J BIOL CHEM, V275, P36483, DOI 10.1074/jbc.C000529200; Wang SL, 1999, J ORAL PATHOL MED, V28, P145, DOI 10.1111/j.1600-0714.1999.tb02014.x; Wang WC, 1999, AM J PHYSIOL-CELL PH, V276, pC969, DOI 10.1152/ajpcell.1999.276.4.C969; Zhu X, 1998, NEWS PHYSIOL SCI, V13, P211	29	59	60	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY 29	2001	15	7					1652	+		10.1096/fj.00-0749fje	http://dx.doi.org/10.1096/fj.00-0749fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519CQ	11427516				2022-12-25	WOS:000173707700006
J	Oehler, MK; Norbury, C; Hague, S; Rees, MCP; Bicknell, R				Oehler, MK; Norbury, C; Hague, S; Rees, MCP; Bicknell, R			Adrenomedullin inhibits hypoxic cell death by upregulation of Bcl-2 in endometrial cancer cells: a possible promotion mechanism for tumour growth	ONCOGENE			English	Article						adrenomedullin; Bcl-2; hypoxia; apoptosis; cell death; survival	ANGIOGENIC FACTOR ADRENOMEDULLIN; GENE-RELATED PEPTIDE; BREAST-CANCER; IN-VIVO; PROTEIN FAMILY; APOPTOSIS; EXPRESSION; TAMOXIFEN; PREVENTION; INDUCTION	Regions of hypoxia are a common feature of solid tumours, When tumour cells are exposed to hypoxic stress, transcription of a battery of genes is initiated. The angiogenic factor adrenomedullin (ADM) is a hypoxia regulated gene, ADM is thought to act through the G protein-coupled receptor calcitonin receptor-like receptor (CRLR), with specificity being conferred by the receptor associated modifying protein 2 (RAMP2), Here we report for the! first time that ADM treated or stably transfected Ishikawa cells overexpressing ADM show increased resistance to hypoxia induced apoptosis, These cells also show an upregulation of the oncoprotein Bcl-2, which is protective against hypoxic cell death when transiently transfected into Ishikawa cells. Since Ishikawa cells express the putative ADM-receptor CRLR-RAMP2 the production and secretion of ADM with the consecutive upregulation of Bcl-2 could establish an autocrine/paracrine mechanism rescuing malignant cells from hypoxic cell death. These results, taken together with our previous findings that ADM is an angiogenic factor which is upregulated by the nonsteroidal antiestrogen tamoxifen (TAM) in endometrial cells, implicate this peptide as a promoter of tumour growth and a possible target for anticancer strategies. Oncogene (2001) 20, 2937-2945.	Univ Oxford, John Radcliffe Hosp, Inst Mol Med, Imperial Canc Res Fund,Mol Angiogenesis Lab, Oxford OX3 9DS, England; Univ Oxford, Cell Cycle Grp, Oxford OX3 9DS, England; Univ Oxford, Nuffield Dept Obstet & Gynaecol, Oxford OX3 9DU, England	University of Oxford; University of Oxford; University of Oxford	Bicknell, R (corresponding author), Univ Oxford, John Radcliffe Hosp, Inst Mol Med, Imperial Canc Res Fund,Mol Angiogenesis Lab, Oxford OX3 9DS, England.			Bicknell, Roy/0000-0002-0941-8919				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Alarcon RM, 1996, CANCER RES, V56, P4315; Barakat RR, 1996, CLIN OBSTET GYNECOL, V39, P629, DOI 10.1097/00003081-199609000-00012; Bergman L, 2000, LANCET, V356, P881, DOI 10.1016/S0140-6736(00)02677-5; Blancher C, 1998, CANCER METAST REV, V17, P187, DOI 10.1023/A:1006002419244; Caron KM, 2001, P NATL ACAD SCI USA, V98, P615, DOI 10.1073/pnas.021548898; Carthew P, 2000, CARCINOGENESIS, V21, P793, DOI 10.1093/carcin/21.4.793; Cormier-Regard S, 1998, J BIOL CHEM, V273, P17787, DOI 10.1074/jbc.273.28.17787; CORY S, 1999, CANCER RES, V59, P1685; Cuzick J, 2000, EUR J CANCER, V36, P1298, DOI 10.1016/S0959-8049(00)00106-4; Elkas J, 2000, OBSTET GYNECOL, V95, P697, DOI 10.1016/S0029-7844(99)00660-2; Evans SM, 1997, CANCER RES, V57, P5155; FURMAN E, 1992, J STEROID BIOCHEM, V43, P189, DOI 10.1016/0960-0760(92)90207-Y; Garayoa M, 2000, MOL ENDOCRINOL, V14, P848, DOI 10.1210/me.14.6.848; GLEADLE JM, 1995, AM J PHYSIOL-CELL PH, V268, pC1362, DOI 10.1152/ajpcell.1995.268.6.C1362; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Hague S, 2000, CLIN CANCER RES, V6, P2808; Hinson JP, 2000, ENDOCR REV, V21, P138, DOI 10.1210/er.21.2.138; Hockel M, 1999, CANCER RES, V59, P4525; Hofbauer KH, 2000, AM J PHYSIOL-REG I, V278, pR513, DOI 10.1152/ajpregu.2000.278.2.R513; ISHIMITSU T, 1994, BIOCHEM BIOPH RES CO, V203, P631, DOI 10.1006/bbrc.1994.2229; Jager R, 1997, ONCOGENE, V15, P1787, DOI 10.1038/sj.onc.1201353; Kamitani S, 1999, FEBS LETT, V448, P111, DOI 10.1016/S0014-5793(99)00358-0; Kato H, 1997, ENDOCRINOLOGY, V138, P2615, DOI 10.1210/en.138.6.2615; KITAMURA K, 1993, BIOCHEM BIOPH RES CO, V192, P553, DOI 10.1006/bbrc.1993.1451; McGill Gael, 1997, Frontiers in Bioscience (online), V2, pD353; McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666; Miller MJ, 1996, J BIOL CHEM, V271, P23345; Naik P, 1996, GENE DEV, V10, P2105, DOI 10.1101/gad.10.17.2105; Nakayama M, 1998, BIOCHEM BIOPH RES CO, V243, P514, DOI 10.1006/bbrc.1998.8131; Nguyen SV, 1999, BIOCHEM BIOPH RES CO, V265, P382, DOI 10.1006/bbrc.1999.1674; Nor JE, 1999, AM J PATHOL, V154, P375, DOI 10.1016/S0002-9440(10)65284-4; ONGKEKO W, 1995, J CELL SCI, V108, P2897; Parameswaran N, 1999, EUR J PHARMACOL, V372, P85, DOI 10.1016/S0014-2999(99)00022-9; Pellegrini M, 1999, J CLIN IMMUNOL, V19, P365, DOI 10.1023/A:1020598632068; PETERSEN NE, 1995, CLIN CHEM, V41, P1605; Ricca A, 2000, INT J CANCER, V86, P188, DOI 10.1002/(SICI)1097-0215(20000415)86:2<188::AID-IJC7>3.3.CO;2-N; Sakuragi N, 1998, INT J CANCER, V79, P153, DOI 10.1002/(SICI)1097-0215(19980417)79:2<153::AID-IJC10>3.0.CO;2-B; Shichiri M, 1999, MOL ENDOCRINOL, V13, P1353, DOI 10.1210/me.13.8.1353; Shimizu S, 1996, CANCER RES, V56, P2161; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; THOMLINSON R, 1995, BRIT J CANCER, V9, P539; Vaupel Peter W., 1993, P53; Wimalawansa SJ, 1997, CRIT REV NEUROBIOL, V11, P167, DOI 10.1615/CritRevNeurobiol.v11.i2-3.40; Yamabe K, 1998, BIOCHEM BIOPH RES CO, V243, P217, DOI 10.1006/bbrc.1997.7925; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zhao Y, 1998, ONCOGENE, V16, P409, DOI 10.1038/sj.onc.1201768	47	100	112	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 24	2001	20	23					2937	2945		10.1038/sj.onc.1204422	http://dx.doi.org/10.1038/sj.onc.1204422			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	435VA	11420706				2022-12-25	WOS:000168901800009
J	Bentires-Alj, M; Dejardin, E; Viatour, P; Van Lint, C; Froesch, B; Reed, JC; Merville, MP; Bours, V				Bentires-Alj, M; Dejardin, E; Viatour, P; Van Lint, C; Froesch, B; Reed, JC; Merville, MP; Bours, V			Inhibition of the NF-kappa B transcription factor increases Bax expression in cancer cell lines	ONCOGENE			English	Article						Bax; apoptosis; cancer; transcription factors.; NF-kappa B	NECROSIS-FACTOR-ALPHA; CREB-BINDING PROTEIN; TUMOR-SUPPRESSOR PROTEIN; BCL-X EXPRESSION; VIRUS TYPE-1 TAX; INDUCED APOPTOSIS; BREAST-CANCER; IN-VIVO; P53; GENE	The NF-kappaB transcription factor has been shown to inhibit apoptosis in several experimental systems. We therefore investigated whether the expression of the Bax proapoptotic protein could be influenced by NF-kappaB activity. Increased Bax protein expression was detected in HCT116, OVCAR-3 and MCF7 cells stably expressing a mutated unresponsive I kappaB-alpha inhibitory protein that blocks NF-kappaB activity. Northern blots showed that bax mRNA expression was increased as a consequence of mutated I kappaB-alpha expression in HCT116 cells. A careful examination of the human bax gene promoter sequence showed three putative binding sites for NF-kappaB, and the kappa B2 site at position -687 could indeed bind NF-kappaB complexes in vitro. Transient transfection of a bax promoter luciferase construct in HCT116 cells showed that NF-kappaB proteins could partially inhibit the transactivation of the bax promoter by p53, Mutations or deletions of the kappaB sites, including kappa B2, indicated that this NF-kappaB-dependent inhibitory effect did not require NF-kappaB DNA-binding, and was thus an indirect effect. However, cotransfection of expression vectors for several known cofactors failed to identify a competition between p53 and NF-kappaB for a transcription coactivator. Our findings thus demonstrate for the first time that NF-kappaB regulates, through an indirect pathway, the bax gene expression.	Univ Liege, CHU B35, Lab Med Chem & Med Oncol, B-4000 Liege, Belgium; Free Univ Brussels, Dept Mol Biol, Biol Chem Lab, Brussels, Belgium; Burnham Inst, La Jolla, CA 92037 USA	University of Liege; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Sanford Burnham Prebys Medical Discovery Institute	Bours, V (corresponding author), Univ Liege, CHU B35, Lab Med Chem & Med Oncol, B-4000 Liege, Belgium.		Dejardin, Emmanuel/AAE-9076-2021; Mohamed, Bentires-Alj/F-4484-2015	Mohamed, Bentires-Alj/0000-0001-6344-1127				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bentires-Alj M, 1999, CANCER RES, V59, P811; Bonizzi G, 1996, EUR J BIOCHEM, V242, P544, DOI 10.1111/j.1432-1033.1996.0544r.x; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BRACH MA, 1991, J CLIN INVEST, V88, P691, DOI 10.1172/JCI115354; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Cai ZZ, 1997, J BIOL CHEM, V272, P96; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Chariot A, 1999, J BIOL CHEM, V274, P5318, DOI 10.1074/jbc.274.9.5318; Chen F, 1999, J BIOL CHEM, V274, P35591, DOI 10.1074/jbc.274.50.35591; Das KC, 1997, J BIOL CHEM, V272, P14914, DOI 10.1074/jbc.272.23.14914; Dejardin E, 1999, ONCOGENE, V18, P2567, DOI 10.1038/sj.onc.1202599; DEJARDIN E, 1995, ONCOGENE, V11, P1835; Farmer G, 1996, MOL CELL BIOL, V16, P4295; Ferreira V, 1998, J BIOL CHEM, V273, P592, DOI 10.1074/jbc.273.1.592; Friess H, 1998, GUT, V43, P414, DOI 10.1136/gut.43.3.414; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Hellin AC, 1998, ONCOGENE, V16, P1187, DOI 10.1038/sj.onc.1201638; Jayaraman L, 1998, GENE DEV, V12, P462, DOI 10.1101/gad.12.4.462; Jones PL, 1997, MOL CELL BIOL, V17, P6970, DOI 10.1128/MCB.17.12.6970; KRIKOS A, 1992, J BIOL CHEM, V267, P17971; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MIYASHITA T, 1994, CANCER RES, V54, P3131; Na SY, 1998, J BIOL CHEM, V273, P10831, DOI 10.1074/jbc.273.18.10831; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Perera PY, 1996, INFECT IMMUN, V64, P878, DOI 10.1128/IAI.64.3.878-884.1996; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Piret B, 1996, NUCLEIC ACIDS RES, V24, P4242, DOI 10.1093/nar/24.21.4242; Pise-Masison CA, 2000, MOL CELL BIOL, V20, P3377, DOI 10.1128/MCB.20.10.3377-3386.2000; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Ravi R, 1998, CANCER RES, V58, P4531; Reed JC, 1999, J CLIN ONCOL, V17, P2941, DOI 10.1200/JCO.1999.17.9.2941; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Schmidt T, 1999, CELL DEATH DIFFER, V6, P873, DOI 10.1038/sj.cdd.4400562; SCHMITZ ML, 1995, J BIOL CHEM, V270, P7219, DOI 10.1074/jbc.270.13.7219; Scolnick DM, 1997, CANCER RES, V57, P3693; Sheppard KA, 1999, MOL CELL BIOL, V19, P6367; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; Steegenga WT, 1999, MOL CELL BIOL, V19, P3885; Stehlik C, 1998, J EXP MED, V188, P211, DOI 10.1084/jem.188.1.211; Tai YT, 1998, J CLIN ONCOL, V16, P2583, DOI 10.1200/JCO.1998.16.8.2583; Tamatani M, 1999, J BIOL CHEM, V274, P8531, DOI 10.1074/jbc.274.13.8531; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; Tsukahara T, 1999, J VIROL, V73, P7981, DOI 10.1128/JVI.73.10.7981-7987.1999; VAN AD, 1996, SCIENCE, V274, P787; Wadgaonkar R, 1999, J BIOL CHEM, V274, P1879, DOI 10.1074/jbc.274.4.1879; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Webster GA, 1999, MOL CELL BIOL, V19, P3485; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; ZHAN QM, 1994, ONCOGENE, V9, P3743; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	64	103	106	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 17	2001	20	22					2805	2813		10.1038/sj.onc.1204343	http://dx.doi.org/10.1038/sj.onc.1204343			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	432TP	11420692				2022-12-25	WOS:000168712000008
J	Curtin, JC; Dragnev, KH; Sekula, D; Christie, AJ; Dmitrovsky, E; Spinella, MJ				Curtin, JC; Dragnev, KH; Sekula, D; Christie, AJ; Dmitrovsky, E; Spinella, MJ			Retinoic acid activates p53 in human embryonal carcinoma through retinoid receptor-dependent stimulation of p53 transactivation function	ONCOGENE			English	Article						retinoic acid; differentiation; embryonal carcinoma; teratocarcinoma; p53	GERM-CELL TUMORS; CISPLATIN-INDUCED APOPTOSIS; DNA-DAMAGE; HUMAN TERATOCARCINOMAS; TESTICULAR-TUMORS; GENE-EXPRESSION; DOWN-REGULATION; DIFFERENTIATION; CANCER; PROTEIN	Although retinoids are known to regulate gene transcription by activating retinoid receptors, the targets of retinoid receptors are largely unknown. This study indicates effective all-trans retinoic acid (RA)-induced differentiation of human embryonal carcinoma cells engages p53, Unexpectedly, RA has been found to activate the transactivation function of p53 in the human embryonal carcinoma cell line, NT2/D1, in a retinoid receptor-dependent manner. A derived RA-resistant line, NT2/D1-R1, is deficient in this activity and is co-resistant to cisplatin, This indicates that RA and cisplatin responses may share a common pathway involving p53 in embryonal carcinomas. RA has no effect on p53 steady-state protein levels in either line. RA enhances endogenous p53 transactivation activity in NT2/D1 but not NT2/D1-R1 cells. In addition, RA induces transactivation activity of a gal4-p53 fusion protein, suggesting that RA activates p53 independent of increasing p53 levels or sequence-specific DNA binding. This activity is absent in retinoic acid receptor gamma (RAR gamma)-deficient NT2/D1-R1 cells but can be restored upon co-transfection with specific RARs. Transient transfection of a dominant-negative p53 construct in NT2/D1 cells blocks the RA-mediated transcriptional decline of a differentiation-sensitive reporter plasmid and enhances survival of NT2/D1 cells following cisplatin treatment. Taken together, these findings indicate that RA activates the intrinsic activation function of p53 by a novel mechanism independent of effects on p53 stability or DNA binding and that this activation may be a general mechanism that contributes to RA-mediated G1 arrest.	Dartmouth Coll, Sch Med, Dept Pharmacol & Toxicol, Hanover, NH 03755 USA; Dartmouth Coll, Hitchcock Med Ctr, Dept Med, Lebanon, NH 03756 USA; Dartmouth Coll, Hitchcock Med Ctr, Norris Cotton Canc Ctr, Lebanon, NH 03756 USA	Dartmouth College; Dartmouth College; Dartmouth College; Norris Cotton Cancer Center	Spinella, MJ (corresponding author), Dartmouth Coll, Sch Med, Dept Pharmacol & Toxicol, 7650 Remsen, Hanover, NH 03755 USA.		Spinella, Michael/B-7210-2014		NCI NIH HHS [R01 CA54494, CA75154, R01 CA87546] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K01CA075154, R01CA054494, R01CA087546] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allemand I, 1999, ONCOGENE, V18, P6521, DOI 10.1038/sj.onc.1203052; Andrews PW, 1998, APMIS, V106, P158, DOI 10.1111/j.1699-0463.1998.tb01331.x; Armstrong Robert B., 1994, P545; Arriola EL, 1999, ONCOGENE, V18, P1457, DOI 10.1038/sj.onc.1202420; Boersma AWM, 1997, CYTOMETRY, V27, P275, DOI 10.1002/(SICI)1097-0320(19970301)27:3<275::AID-CYTO10>3.0.CO;2-Q; Boyle JO, 2001, CLIN CANCER RES, V7, P259; Burger H, 1999, INT J CANCER, V81, P620, DOI 10.1002/(SICI)1097-0215(19990517)81:4<620::AID-IJC19>3.3.CO;2-J; Burger H, 1997, INT J CANCER, V73, P592, DOI 10.1002/(SICI)1097-0215(19971114)73:4<592::AID-IJC22>3.0.CO;2-A; Chaganti RSK, 2000, CANCER RES, V60, P1475; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Choi J, 1999, CELL MOL LIFE SCI, V55, P38, DOI 10.1007/s000180050268; Chresta CM, 1996, CANCER RES, V56, P1834; Collins MD, 1999, ANNU REV PHARMACOL, V39, P399, DOI 10.1146/annurev.pharmtox.39.1.399; DMITROVSKY E, 1990, CANCER SURV, V9, P369; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; GUCHELAAR HL, 1993, INT J CANCER, V55, P442, DOI 10.1002/ijc.2910550320; HALL PA, 1997, CURR BIOL, V7, P144; Hall SR, 1996, NUCLEIC ACIDS RES, V24, P1119, DOI 10.1093/nar/24.6.1119; HARVEY M, 1993, FASEB J, V7, P938, DOI 10.1096/fasebj.7.10.8344491; Hecker D, 1996, ONCOGENE, V12, P953; HEIMDAL K, 1993, GENE CHROMOSOME CANC, V6, P92, DOI 10.1002/gcc.2870060205; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; HONG WK, 1977, CANCER, V40, P2987, DOI 10.1002/1097-0142(197712)40:6<2987::AID-CNCR2820400634>3.0.CO;2-A; Houldsworth J, 1998, ONCOGENE, V16, P2345, DOI 10.1038/sj.onc.1201770; Hussain SP, 1998, CANCER RES, V58, P4023; JETTEN AM, 1979, NATURE, V278, P180, DOI 10.1038/278180a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liu M, 1996, J BIOL CHEM, V271, P31723, DOI 10.1074/jbc.271.49.31723; Lutzker SG, 1998, APMIS, V106, P85, DOI 10.1111/j.1699-0463.1998.tb01323.x; Lutzker SG, 1996, NAT MED, V2, P804, DOI 10.1038/nm0796-804; Maerz WJ, 1998, ONCOGENE, V17, P761, DOI 10.1038/sj.onc.1201992; Mangelsdorf David J., 1994, P319; Matin A, 1998, APMIS, V106, P174, DOI 10.1111/j.1699-0463.1998.tb01333.x; Meek DW, 1999, ONCOGENE, V18, P7666, DOI 10.1038/sj.onc.1202951; MILLER WH, 1994, DIFFERENTIATION, V55, P145, DOI 10.1046/j.1432-0436.1994.5520145.x; MILLER WH, 1990, ONCOGENE, V5, P511; MOASSER MM, 1994, ONCOGENE, V9, P833; MOASSER MM, 1995, ONCOGENE, V10, P1537; Moasser MM, 1996, DIFFERENTIATION, V60, P251, DOI 10.1046/j.1432-0436.1996.6040251.x; NASONBURCHENAL K, 1999, RETINOIDS HDB EXPT P, P301; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Ossovskaya VS, 1996, P NATL ACAD SCI USA, V93, P10309, DOI 10.1073/pnas.93.19.10309; PENG HQ, 1993, CANCER RES, V53, P3574; PERA MF, 1990, CANCER SURV, V9, P243; Rapley E, 1998, APMIS, V106, P64; RIOU G, 1995, MOL CARCINOGEN, V12, P124, DOI 10.1002/mc.2940120303; SCHOTTENFELD D, 1980, AM J EPIDEMIOL, V112, P232, DOI 10.1093/oxfordjournals.aje.a112989; Schwartz D, 1999, CELL GROWTH DIFFER, V10, P665; Shang YF, 1999, J BIOL CHEM, V274, P18005, DOI 10.1074/jbc.274.25.18005; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Shin DM, 1997, CLIN CANCER RES, V3, P875; Shin DM, 2000, J NATL CANCER I, V92, P69, DOI 10.1093/jnci/92.1.69; Spinella MJ, 1999, J BIOL CHEM, V274, P22013, DOI 10.1074/jbc.274.31.22013; Spinella MJ, 1998, ONCOGENE, V16, P3471, DOI 10.1038/sj.onc.1201876; Wadgaonkar R, 1999, J BIOL CHEM, V274, P13760, DOI 10.1074/jbc.274.20.13760; YUAN HB, 1995, GENE DEV, V9, P2635, DOI 10.1101/gad.9.21.2635; Zamble DB, 1998, P NATL ACAD SCI USA, V95, P6163, DOI 10.1073/pnas.95.11.6163; ZAUBERMAN A, 1995, NUCLEIC ACIDS RES, V23, P2584, DOI 10.1093/nar/23.14.2584	59	48	48	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 3	2001	20	20					2559	2569		10.1038/sj.onc.1204370	http://dx.doi.org/10.1038/sj.onc.1204370			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	431VM	11420666				2022-12-25	WOS:000168652500007
J	Howard, JC; Li, Q; Chu, W; Zochodne, B; Kapoor, M; Ung, Y; Rosen, K; Ben-David, Y				Howard, JC; Li, Q; Chu, W; Zochodne, B; Kapoor, M; Ung, Y; Rosen, K; Ben-David, Y			Bcl-2 expression in F-MuLV-induced erythroleukemias: a role for the anti-apoptotic action of Bcl-2 during tumor progression	ONCOGENE			English	Article						Friend erythroleukemia; Bcl-2; p53; tumor progression	VIRUS-INDUCED ERYTHROLEUKEMIA; CELLULAR P53 GENE; CHROMOSOMAL BREAKPOINT; TOPOISOMERASE-II; IN-VITRO; C-MYC; X-L; CELLS; GROWTH; ERYTHROPOIETIN	Erythroleukemias induced by various strains of Friend virus are multistage malignancies that result from the accumulation of genetic mutations, including the activation of proto-oncogenes and the inactivation of tumor suppressor genes. in this study, we demonstrate that Bcl-2 expression is activated in the majority of F-MuLV-induced erythroleukemia cell lines. In contrast, Bcl-2 was not expressed in any of the FV-P-induced erythroleukemia cell lines and protein levels were low or negligible in FV-A-induced erythroleukemia cell lines examined. In vivo, Bcl-2 expression levels gradually increased in F-MuLV-induced erythroleukemic cells prior to adaptation to culture. High expression of Bcl-2 in F-MuLV-induced erythroleukemic cells was shown to proceed the emergence of p53 mutation suggesting that Bcl-2 expression may delay p53 mutation in the leukemic cells, This is further supported by the demonstration that the majority of F-MuLV-induced erythroleukemia cell lines established from primary tumors induced in p53 mutant mice express low to negligible levels of Bcl-2, We have shown that the high levels of Bcl-2 expression in FV-P-induced erythroleukemic cells inhibited apoptosis induced by etoposide, low serum and p53 expression. Similarly, ectopic Bcl-2 expression within these cells also provided protection from apoptosis induced by etoposide and growth in low serum. These results suggest that the anti-apoptotic action of Bcl-2 may confer a selective in vivo and in vitro growth advantage to F-MuLV-induced erythroleukemic cells, which is not shared by FV-P/ FV-A-induced erythroleukemic cells. The observed induction of Bcl-2 expression in vivo constitutes a novel but late oncogenic event associated with the progression of F-MuLV-induced erythroleukemias.	Univ Toronto, Sunnybrook & Womens Coll, Hlth Sci Ctr, Dept Med Biophys,Div Canc Biol, Toronto, ON M4N 3M5, Canada; Toronto Sunnybrook Reg Canc Ctr, Toronto, ON M4N 3M5, Canada	University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Ben-David, Y (corresponding author), Univ Toronto, Sunnybrook & Womens Coll, Hlth Sci Ctr, Dept Med Biophys,Div Canc Biol, 2075 Bayview Ave,Room S216, Toronto, ON M4N 3M5, Canada.			Rosen, Kirill/0000-0002-4317-9907				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BELARDELLI F, 1995, APMIS, V103, P161, DOI 10.1111/j.1699-0463.1995.tb01092.x; BEN-DAVID Y, 1990, New Biologist, V2, P1015; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BENDAVID Y, 1990, P NATL ACAD SCI USA, V87, P1332, DOI 10.1073/pnas.87.4.1332; Benito A, 1996, BLOOD, V87, P3837, DOI 10.1182/blood.V87.9.3837.bloodjournal8793837; Brimmell M, 1998, ONCOGENE, V16, P1803, DOI 10.1038/sj.onc.1201704; CHOW V, 1987, J VIROL, V61, P2777, DOI 10.1128/JVI.61.9.2777-2781.1987; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; DAVID YB, 1988, ONCOGENE, V3, P179; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DIFFLEY JFX, 1992, NATURE, V357, P169, DOI 10.1038/357169a0; DOLE M, 1994, CANCER RES, V54, P3253; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; FRIEND C, 1957, J EXP MED, V105, P307, DOI 10.1084/jem.105.4.307; GOEBL MG, 1990, CELL, V61, P1165, DOI 10.1016/0092-8674(90)90676-6; Gregoli PA, 1997, BLOOD, V90, P630, DOI 10.1182/blood.V90.2.630.630_630_640; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Herzog CE, 1995, CLIN CANCER RES, V1, P1391; Howard J, 1996, CELL GROWTH DIFFER, V7, P1651; HOWARD JC, 1993, ONCOGENE, V8, P2721; Howard JC, 1996, ONCOGENE, V12, P1405; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; Jonkers J, 1996, BBA-REV CANCER, V1287, P29, DOI 10.1016/0304-419X(95)00020-G; KABAT D, 1989, CURR TOP MICROBIOL, V148, P1; KAMESAKI S, 1993, CANCER RES, V53, P4251; Lacronique V, 1997, BLOOD, V90, P3050, DOI 10.1182/blood.V90.8.3050; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; LIN YP, 1995, MOL CELL BIOL, V15, P6045; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MAJNO G, 1995, AM J PATHOL, V146, P3; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MITCHELL T, 1993, J VIROL, V67, P3665, DOI 10.1128/JVI.67.6.3665-3670.1993; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MIYASHITA T, 1994, CANCER RES, V54, P3131; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; MUNROE DG, 1990, MOL CELL BIOL, V10, P3307, DOI 10.1128/MCB.10.7.3307; OLIFF A, 1981, BLOOD, V58, P244; Packham G, 1998, GENE DEV, V12, P2475, DOI 10.1101/gad.12.16.2475; Reed JC, 1995, TOXICOL LETT, V82-3, P155, DOI 10.1016/0378-4274(95)03551-6; RYAN JJ, 1994, P NATL ACAD SCI USA, V91, P5878, DOI 10.1073/pnas.91.13.5878; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; SCHWARZE MMK, 1995, CANCER RES, V55, P2262; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; SHIBUYA T, 1983, P NATL ACAD SCI-BIOL, V80, P3721, DOI 10.1073/pnas.80.12.3721; Silva M, 1996, BLOOD, V88, P1576, DOI 10.1182/blood.V88.5.1576.1576; SILVER J, 1986, J VIROL, V57, P526, DOI 10.1128/JVI.57.2.526-533.1986; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Wong KS, 1999, ONCOGENE, V18, P5525, DOI 10.1038/sj.onc.1202938; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602	60	11	11	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 26	2001	20	18					2291	2300		10.1038/sj.onc.1204348	http://dx.doi.org/10.1038/sj.onc.1204348			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	427KZ	11402324				2022-12-25	WOS:000168404500011
J	Lee, S; Furuya, T; Kiyota, T; Takami, N; Murata, K; Niidome, Y; Bredesen, DE; Ellerby, HM; Sugihara, G				Lee, S; Furuya, T; Kiyota, T; Takami, N; Murata, K; Niidome, Y; Bredesen, DE; Ellerby, HM; Sugihara, G			De novo-designed peptide transforms Golgi-specific lipids into Golgi-like nanotubules.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROPHOBIC-HYDROPHILIC BALANCE; MEMBRANE DYNAMICS; VESICULATION	Cellular organelles, such as the Golgi apparatus and the endoplasmic reticulum, adopt characteristic structures depending on their function. While the tubular shapes of these structures result from complex protein-lipid interactions that are not fully understood, some fundamental machinery must be required. We show here that a de novo-designed 18-mer amphipathic a-helical peptide, Hel 13-5, transforms spherical liposomes made from a Golgi-specific phospholipid mixture into nanotubules on the scale of and resembling the shape of the nanotubules that form the Golgi apparatus. Furthermore, we show that that the size and the shape of such nanotubules depend on lipid composition and peptide properties such as length and the ratio of hydrophobic to hydrophilic amino acids. Although the question of precisely how nature engineers organellar membranes remains unknown, our simple novel system provides a basic set of tools to begin addressing this question.	Fukuoka Univ, Sch Med, Dept Chem, Fac Sci, Fukuoka 8140180, Japan; Fukuoka Univ, Sch Med, Radioisotope Ctr, Fukuoka 8140180, Japan; Fukuoka Univ, Sch Med, Cent Lab Infect Dis, Fukuoka 8140180, Japan; Kyushu Univ, Dept Mat Phys & Chem, Grad Sch Engn, Fukuoka 8128581, Japan; Buck Inst Age Res, Novato, CA 94945 USA	Fukuoka University; Fukuoka University; Fukuoka University; Kyushu University; Buck Institute for Research on Aging	Lee, S (corresponding author), Fukuoka Univ, Sch Med, Dept Chem, Fac Sci, Fukuoka 8140180, Japan.		Niidome, Yasuro/C-8516-2009	Niidome, Yasuro/0000-0002-1086-8036	NCI NIH HHS [1RO1CA/AG84262-01A1] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA084262] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBERTS B, 1994, MOL BIOL CELL, P601; COCHRANE CG, 1991, SCIENCE, V254, P566, DOI 10.1126/science.1948032; Kitamura A, 1999, BIOPHYS J, V76, P1457, DOI 10.1016/S0006-3495(99)77306-6; Kiyota T, 1996, BIOCHEMISTRY-US, V35, P13196, DOI 10.1021/bi961289t; MAYER LD, 1986, BIOCHIM BIOPHYS ACTA, V858, P161, DOI 10.1016/0005-2736(86)90302-0; MIYATA H, 1992, P NATL ACAD SCI USA, V89, P11547, DOI 10.1073/pnas.89.23.11547; Perez-Gil J, 1998, BBA-MOL BASIS DIS, V1408, P203, DOI 10.1016/S0925-4439(98)00068-4; Presley JF, 1998, MOL BIOL CELL, V9, P1617, DOI 10.1091/mbc.9.7.1617; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Sweitzer SM, 1998, CELL, V93, P1021, DOI 10.1016/S0092-8674(00)81207-6; Takei K, 1999, NAT CELL BIOL, V1, P33, DOI 10.1038/9004; WEIDMAN P, 1993, CELL, V75, P123, DOI 10.1016/S0092-8674(05)80089-3	13	42	42	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					41224	41228		10.1074/jbc.M104705200	http://dx.doi.org/10.1074/jbc.M104705200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11406635	hybrid			2022-12-25	WOS:000171925600113
J	Ueno, N; Murakami, M; Tanioka, T; Fujimori, K; Tanabe, T; Urade, Y; Kudo, I				Ueno, N; Murakami, M; Tanioka, T; Fujimori, K; Tanabe, T; Urade, Y; Kudo, I			Coupling between cyclooxygenase, terminal prostanoid synthase, and phospholipase A(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTAGLANDIN D-2 GENERATION; ENDOPEROXIDE-H SYNTHASE-1; ARACHIDONIC-ACID RELEASE; MAST-CELLS; PROSTACYCLIN SYNTHASE; ENDOTHELIAL-CELLS; MOLECULAR-CLONING; E-2 BIOSYNTHESIS; GENE DISRUPTION; DELAYED PHASE	We have recently shown that two distinct prostaglandin (PG) E-2 synthases show preferential functional coupling with upstream cyclooxygenase (COX)-1 and COX-2 in PGE(2) biosynthesis. To investigate whether other lineage-specific PG synthases also show preferential coupling with either COX isozyme, we introduced these enzymes alone or in combination into 293 cells to reconstitute their functional interrelationship. As did the membrane-bound PGE2 synthase, the perinuclear enzymes thromboxane synthase and PGI(2) synthase generated their respective products via COX-2 in preference to COX-1 in both the A23187-induced immediate and interleukin-1-induced delayed responses. Hematopoietic PGD(2) synthase preferentially used COX-1 and COX-2 in the A23187-induced immediate and interleukin-1-induced delayed PGD(2)-biosynthetic responses, respectively. This enzyme underwent stimulus-dependent translocation from the cytosol to perinuclear compartments, where COX-1 or COX-2 exists. COX selectivity of these lineage-specific PG synthases was also significantly affected by the concentrations of arachidonate, which was added exogenously to the cells or supplied endogenously by the action of cytosolic or secretory phospholipase A(2). Collectively, the efficiency of coupling between COXs and specific PG synthases may be crucially influenced by their spatial and temporal compartmentalization and by the amount of arachidonate supplied by PLA(2)s at a moment when PG production takes place.	Showa Univ, Sch Pharmaceut Sci, Dept Hlth Chem, Shinagawa Ku, Tokyo 1428555, Japan; Japan Sci & Technol Corp, CREST, Osaka Biosci Inst, Osaka 5650874, Japan; Natl Cardiovasc Ctr, Res Inst, Dept Pharmacol, Osaka 5658565, Japan	Showa University; Japan Science & Technology Agency (JST); National Cerebral & Cardiovascular Center - Japan	Murakami, M (corresponding author), Showa Univ, Sch Pharmaceut Sci, Dept Hlth Chem, Shinagawa Ku, 1-5-8 Hatanodai, Tokyo 1428555, Japan.		Fujimori, Ko/AAD-5428-2021	Fujimori, Ko/0000-0002-2506-0769				Balsinde J, 2000, J IMMUNOL, V164, P5398, DOI 10.4049/jimmunol.164.10.5398; Balsinde J, 1999, J BIOL CHEM, V274, P25967, DOI 10.1074/jbc.274.37.25967; Beuckmann CT, 2000, NEUROCHEM RES, V25, P733, DOI 10.1023/A:1007579507804; Bezzine S, 2000, J BIOL CHEM, V275, P3179, DOI 10.1074/jbc.275.5.3179; Bingham CO, 1996, J BIOL CHEM, V271, P25936, DOI 10.1074/jbc.271.42.25936; Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; Brock TG, 1999, J BIOL CHEM, V274, P11660, DOI 10.1074/jbc.274.17.11660; CAPDEVILA JH, 1996, J BIOL CHEM, V271, P30041; Chen QR, 1997, J BIOL CHEM, V272, P5952, DOI 10.1074/jbc.272.9.5952; Clancy R, 2000, J IMMUNOL, V165, P1582, DOI 10.4049/jimmunol.165.3.1582; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; DIXON RAF, 1990, NATURE, V343, P282, DOI 10.1038/343282a0; Gross GA, 1998, P NATL ACAD SCI USA, V95, P11875, DOI 10.1073/pnas.95.20.11875; Hammarberg T, 2000, J BIOL CHEM, V275, P38787, DOI 10.1074/jbc.M006136200; Han SK, 1999, J BIOL CHEM, V274, P11881, DOI 10.1074/jbc.274.17.11881; Hanasaki K, 1999, J BIOL CHEM, V274, P34203, DOI 10.1074/jbc.274.48.34203; HARA S, 1994, J BIOL CHEM, V269, P19897; Harada Y, 1996, PROSTAG OTH LIPID M, V51, P19, DOI 10.1016/0090-6980(95)00168-9; Healy AM, 1999, J BIOL CHEM, V274, P29812, DOI 10.1074/jbc.274.42.29812; Hirabayashi T, 1999, J BIOL CHEM, V274, P5163, DOI 10.1074/jbc.274.8.5163; Jakobsson PJ, 1999, P NATL ACAD SCI USA, V96, P7220, DOI 10.1073/pnas.96.13.7220; Kanaoka Y, 1997, CELL, V90, P1085, DOI 10.1016/S0092-8674(00)80374-8; KULMACZ RJ, 1995, J BIOL CHEM, V270, P24019, DOI 10.1074/jbc.270.41.24019; Kuwata H, 1998, J BIOL CHEM, V273, P1733, DOI 10.1074/jbc.273.3.1733; LANGENBACH R, 1995, CELL, V83, P483, DOI 10.1016/0092-8674(95)90126-4; Lim H, 1997, CELL, V91, P197, DOI 10.1016/S0092-8674(00)80402-X; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; Lin YZ, 1998, ARCH BIOCHEM BIOPHYS, V352, P78, DOI 10.1006/abbi.1998.0599; Liou JY, 2000, J BIOL CHEM, V275, P15314, DOI 10.1074/jbc.275.20.15314; Marnett LJ, 2000, J BIOL CHEM, V275, P13427, DOI 10.1074/jbc.275.18.13427; McAdam BF, 1999, P NATL ACAD SCI USA, V96, P272, DOI 10.1073/pnas.96.1.272; MIYATA A, 1994, BIOCHEM BIOPH RES CO, V200, P1728, DOI 10.1006/bbrc.1994.1652; MORHAM SG, 1995, CELL, V83, P473, DOI 10.1016/0092-8674(95)90125-6; MORITA I, 1995, J BIOL CHEM, V270, P10902, DOI 10.1074/jbc.270.18.10902; Murakami M, 1999, J BIOL CHEM, V274, P3103, DOI 10.1074/jbc.274.5.3103; Murakami M, 1999, J BIOL CHEM, V274, P31435, DOI 10.1074/jbc.274.44.31435; MURAKAMI M, 1995, J IMMUNOL, V155, P4445; Murakami M, 1997, J BIOL CHEM, V272, P19891, DOI 10.1074/jbc.272.32.19891; MURAKAMI M, 1993, J BIOL CHEM, V268, P839; MURAKAMI M, 1994, J BIOL CHEM, V269, P22269; Murakami M, 2000, J BIOL CHEM, V275, P32783, DOI 10.1074/jbc.M003505200; MURAKAMI M, 1995, J BIOL CHEM, V270, P3239, DOI 10.1074/jbc.270.7.3239; Murakami M, 2001, J BIOL CHEM, V276, P10083, DOI 10.1074/jbc.M007877200; Murakami M, 1999, J BIOL CHEM, V274, P29927, DOI 10.1074/jbc.274.42.29927; Murakami M, 1998, J BIOL CHEM, V273, P14411, DOI 10.1074/jbc.273.23.14411; MURAKAMI M, 1988, J BIOCHEM-TOKYO, V104, P884, DOI 10.1093/oxfordjournals.jbchem.a122577; NAGATA A, 1991, P NATL ACAD SCI USA, V88, P4020, DOI 10.1073/pnas.88.9.4020; Nakatani Y, 2000, J BIOL CHEM, V275, P1161, DOI 10.1074/jbc.275.2.1161; Naraba H, 1998, J IMMUNOL, V160, P2974; OHASHI K, 1992, J BIOL CHEM, V267, P789; Penglis PS, 2000, J IMMUNOL, V165, P1605, DOI 10.4049/jimmunol.165.3.1605; Pinzar E, 2000, J BIOL CHEM, V275, P31239, DOI 10.1074/jbc.M000750200; REDDY ST, 1994, J BIOL CHEM, V269, P15473; Reddy ST, 1997, J BIOL CHEM, V272, P3231, DOI 10.1074/jbc.272.6.3231; Reddy ST, 1997, J BIOL CHEM, V272, P13591, DOI 10.1074/jbc.272.21.13591; Schievella AR, 1995, J BIOL CHEM, V270, P30749, DOI 10.1074/jbc.270.51.30749; Shinohara H, 1999, J BIOL CHEM, V274, P12263, DOI 10.1074/jbc.274.18.12263; Shitashige M, 1998, BBA-LIPID LIPID MET, V1389, P57, DOI 10.1016/S0005-2760(97)00129-X; Spencer AG, 1998, J BIOL CHEM, V273, P9886, DOI 10.1074/jbc.273.16.9886; Suzuki T, 1999, J BIOL CHEM, V274, P241, DOI 10.1074/jbc.274.1.241; Tada K, 1998, J IMMUNOL, V161, P5008; Tanioka T, 2000, J BIOL CHEM, V275, P32775, DOI 10.1074/jbc.M003504200; Thoren S, 2000, EUR J BIOCHEM, V267, P6428, DOI 10.1046/j.1432-1327.2000.01735.x; Uozumi N, 1997, NATURE, V390, P618, DOI 10.1038/37622; WATANABE K, 1985, J BIOL CHEM, V260, P7035	65	159	160	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					34918	34927		10.1074/jbc.M100429200	http://dx.doi.org/10.1074/jbc.M100429200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11418589	hybrid			2022-12-25	WOS:000171024600077
J	Bishop, B; Koay, DC; Sartorelli, AC; Regan, L				Bishop, B; Koay, DC; Sartorelli, AC; Regan, L			Reengineering granulocyte colony-stimulating factor for enhanced stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPO RECEPTOR COMPLEX; HYDROPHOBIC CORE; 4-HELIX-BUNDLE PROTEIN; ALANINE SUBSTITUTIONS; PEPTIDE; DESIGN; DIFFERENTIATION; BINDING; HELICES; GLYCINE	Granulocyte colony-stimulating factor is a long-chain cytokine that has both biological and therapeutic applications. It is involved in the production and maturation of neutrophilic progenitor cells and neutrophils and is administered to stimulate the production of white blood cells to reduce the risk of serious infection in immunocompromised patients. We have reengineered granulocyte colony-stimulating factor to improve the thermodynamic stability of the protein, focusing on enhancing the alpha-helix propensity of residues in the antiparallel 4-helix bundle of the protein. These redesigns resulted in proteins with substantially enhanced stability while retaining wild-type levels of biological activity, measured as the ability of the reengineered proteins to stimulate the proliferation of murine myeloid cells transfected with the granulocyte colony-stimulating factor receptor.	Yale Univ, Dept Chem, New Haven, CT 06520 USA; Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Yale Univ, Sch Med, Ctr Canc, Dept Pharmacol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Ctr Canc, Dev Therapeut Program, New Haven, CT 06520 USA	Yale University; Yale University; Yale University; Yale University	Regan, L (corresponding author), Yale Univ, Dept Chem, 225 Prospect St, New Haven, CT 06520 USA.		Khanikaev, Alexander B/F-5438-2010	Khanikaev, Alexander B/0000-0002-7689-216X				Aritomi M, 1999, NATURE, V401, P713, DOI 10.1038/44394; AUSUBEL FM, 1989, SHORT PROTOCOLS MOL, P3; BABIOR BM, 1994, HEMATOLOGY PATHOPHYS, P279; Baldwin E, 1996, J MOL BIOL, V259, P542, DOI 10.1006/jmbi.1996.0338; Ballinger MD, 1999, NAT BIOTECHNOL, V17, P1199, DOI 10.1038/70746; BLABER M, 1995, J MOL BIOL, V246, P317, DOI 10.1006/jmbi.1994.0087; Chaiken IM, 1996, TRENDS BIOTECHNOL, V14, P369, DOI 10.1016/0167-7799(96)10050-0; CHAKRABARTTY A, 1995, ADV PROTEIN CHEM, V46, P141, DOI 10.1016/S0065-3233(08)60334-4; CHAKRABARTTY A, 1991, NATURE, V351, P586, DOI 10.1038/351586a0; DEMETRI GD, 1991, BLOOD, V78, P2791; Domingues H, 1999, NAT STRUCT BIOL, V6, P652; DONG F, 1993, MOL CELL BIOL, V13, P7774, DOI 10.1128/MCB.13.12.7774; GANTER C, 1990, BIOCHEMISTRY-US, V29, P9395, DOI 10.1021/bi00492a013; GRANT SGN, 1990, P NATL ACAD SCI USA, V87, P4645, DOI 10.1073/pnas.87.12.4645; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; Harbury PB, 1998, SCIENCE, V282, P1462, DOI 10.1126/science.282.5393.1462; HARBURY PB, 1995, P NATL ACAD SCI U S, V92, P3408; HECHT M H, 1986, Proteins Structure Function and Genetics, V1, P43, DOI 10.1002/prot.340010108; KITA Y, 1994, BIOCHEMISTRY-US, V33, P15178, DOI 10.1021/bi00254a029; Koay DC, 1999, BLOOD, V93, P3774, DOI 10.1182/blood.V93.11.3774.411a31_3774_3784; Kolvenbach CG, 1997, J PEPT RES, V50, P310; Lauffenburger DA, 1998, CHEM BIOL, V5, pR257, DOI 10.1016/S1074-5521(98)90110-7; LEE KH, 1991, J EXP MED, V173, P1257, DOI 10.1084/jem.173.5.1257; LI JM, 1993, J CELL BIOL, V120, P1481, DOI 10.1083/jcb.120.6.1481; LIM WA, 1992, BIOCHEMISTRY-US, V31, P4324, DOI 10.1021/bi00132a025; LIM WA, 1989, NATURE, V339, P31, DOI 10.1038/339031a0; LIM WA, 1991, J MOL BIOL, V219, P359, DOI 10.1016/0022-2836(91)90570-V; LIM WA, 1994, P NATL ACAD SCI USA, V91, P423, DOI 10.1073/pnas.91.1.423; Livnah O, 1996, SCIENCE, V273, P464, DOI 10.1126/science.273.5274.464; Livnah O, 1998, NAT STRUCT BIOL, V5, P993, DOI 10.1038/2965; Lucast LJ, 2001, BIOTECHNIQUES, V30, P544, DOI 10.2144/01303st06; MARGARIT I, 1992, PROTEIN ENG, V5, P543, DOI 10.1093/protein/5.6.543; MARQUSEE S, 1991, Current Biology, V1, P207, DOI 10.1016/0960-9822(91)90057-4; MOTT HR, 1995, CURR OPIN STRUC BIOL, V5, P114, DOI 10.1016/0959-440X(95)80016-T; MUNOZ V, 1994, PROTEINS, V20, P301, DOI 10.1002/prot.340200403; MUNSON M, 1994, PROTEIN SCI, V3, P2015, DOI 10.1002/pro.5560031114; Munson M, 1996, PROTEIN SCI, V5, P1584, DOI 10.1002/pro.5560050813; Nagi AD, 1997, FOLD DES, V2, P67, DOI 10.1016/S1359-0278(97)00007-2; Pace CN, 1998, BIOPHYS J, V75, P422, DOI 10.1016/S0006-3495(98)77529-0; PREDKI PF, 1995, CELL, V80, P41, DOI 10.1016/0092-8674(95)90449-2; Predki PF, 1996, NAT STRUCT BIOL, V3, P54, DOI 10.1038/nsb0196-54; Quan C, 1998, BIOPOLYMERS, V47, P265, DOI 10.1002/(SICI)1097-0282(1998)47:4<265::AID-BIP2>3.0.CO;2-K; ReidhaarOlson JF, 1996, BIOCHEMISTRY-US, V35, P9034, DOI 10.1021/bi952705x; Rohl CA, 1999, P NATL ACAD SCI USA, V96, P3682, DOI 10.1073/pnas.96.7.3682; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; Wells JA, 1996, ANNU REV BIOCHEM, V65, P609, DOI 10.1146/annurev.bi.65.070196.003141; Young DC, 1997, PROTEIN SCI, V6, P1228, DOI 10.1002/pro.5560060611; ZINK T, 1994, BIOCHEMISTRY-US, V33, P8453, DOI 10.1021/bi00194a009; [No title captured]	50	48	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33465	33470		10.1074/jbc.M104494200	http://dx.doi.org/10.1074/jbc.M104494200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11406632	hybrid			2022-12-25	WOS:000170910200025
J	Farzaneh-Far, A; Davies, JD; Braam, LA; Spronk, HM; Proudfoot, D; Chan, SW; O'Shaughnessy, KM; Weissberg, PL; Vermeer, C; Shanahan, CM				Farzaneh-Far, A; Davies, JD; Braam, LA; Spronk, HM; Proudfoot, D; Chan, SW; O'Shaughnessy, KM; Weissberg, PL; Vermeer, C; Shanahan, CM			A polymorphism of the human matrix gamma-carboxyglutamic acid protein promoter alters binding of an activating protein-1 complex and is associated with altered transcription and serum levels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; GLA PROTEIN; C-FOS; VASCULAR CALCIFICATION; MOUSE KERATINOCYTES; REGULATING PROTEINS; EXPRESSION; GENE; CALCIUM; JUN	Matrix gamma -carboxyglutamic acid protein (MGP) is a mineral-binding extracellular matrix protein synthesized by vascular smooth muscle cells (VSMCs) and chondrocytes that is thought to be a key regulator of tissue calcification. In this study, we identified four polymorphisms in the promoter region of the human MGP gene. Transfection studies showed that the G-7A and T-138C polymorphisms have an important impact on in vitro promoter activity when transiently transfected into VSMCs. We found that one of these polymorphisms (T-138C) is significantly correlated with serum MGP levels in human subjects. Promoter deletion analysis showed that this polymorphism lies in a region of the promoter critical for transcription in VSMCs. This region contains a potential activating protein-1 (AP-1) binding element located between -142 and -136. We have demonstrated that the T-138C polymorphism results in altered binding of an AP-1 complex to this region. The -138T allelic variant binds AP-1 complexes consisting primarily of c-Jun, JunB and its partners Fra-1 and Fra-2 in rat VSMC. Furthermore, the -138T variant form of the promoter was induced following phorbol 12-myristate 13-acetate treatment, while the -138C variant was refractive to phorbol 12-myristate 13-acetate treatment, confirming that AP-1 factors preferentially bind to the -138T variant. This study therefore suggests that a common polymorphism of the MGP promoter influences binding of the AP-1 complex, which may lead to altered transcription and serum levels. This could have important implications for diseases such as atherosclerosis and aortic valve stenosis, since it strongly suggests a genetic basis for regulation of tissue calcification.	Univ Cambridge, Addenbrookes Hosp, Div Cardiovasc Med, Cambridge CB2 2QQ, England; Univ Cambridge, Addenbrookes Hosp, Clin Pharmacol Unit, Cambridge CB2 2QQ, England; Univ Maastricht, Dept Biochem, NL-6200 MD Maastricht, Netherlands; Univ Maastricht, Cardiovasc Res Inst, NL-6200 MD Maastricht, Netherlands	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Maastricht University; Maastricht University	Farzaneh-Far, A (corresponding author), Univ Cambridge, Addenbrookes Hosp, Div Cardiovasc Med, ACCI Level 6,Hills Rd, Cambridge CB2 2QQ, England.			Spronk, Henri/0000-0002-3858-334X				Braam LAJLM, 2000, ARTERIOSCL THROM VAS, V20, P1257, DOI 10.1161/01.ATV.20.5.1257; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Farzaneh-Far A, 2000, BIOCHEM BIOPH RES CO, V277, P736, DOI 10.1006/bbrc.2000.3747; Farzaneh-Far A, 2001, Z Kardiol, V90 Suppl 3, P38; Farzaneh-Far A, 2001, HEART, V85, P13, DOI 10.1136/heart.85.1.13; GRAINGER DJ, 1991, BIOCHEM J, V277, P145, DOI 10.1042/bj2770145; Herrmann SM, 2000, ARTERIOSCL THROM VAS, V20, P2386, DOI 10.1161/01.ATV.20.11.2386; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KERPPOLA TK, 1994, ONCOGENE, V9, P3149; Kirfel J, 1997, P NATL ACAD SCI USA, V94, P2227, DOI 10.1073/pnas.94.6.2227; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; Luo GB, 1997, NATURE, V386, P78, DOI 10.1038/386078a0; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Mohler ER, 2000, LANCET, V356, P524, DOI 10.1016/S0140-6736(00)02572-1; Neuman W.F., 1980, FUNDAMENTAL CLIN BON; Ng DC, 2000, J BIOL CHEM, V275, P24080, DOI 10.1074/jbc.M002508200; PRICE PA, 1985, J BIOL CHEM, V260, P4971; Proudfoot D, 1998, ARTERIOSCL THROM VAS, V18, P379, DOI 10.1161/01.ATV.18.3.379; Rutberg SE, 1997, ONCOGENE, V15, P1337, DOI 10.1038/sj.onc.1201293; Rutberg SE, 1996, ONCOGENE, V13, P167; Schinke T, 1999, NAT GENET, V21, P150, DOI 10.1038/5928; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; Shanahan CM, 1999, CIRCULATION, V100, P2168, DOI 10.1161/01.CIR.100.21.2168; Shanahan CM, 1998, CRIT REV EUKAR GENE, V8, P357, DOI 10.1615/CritRevEukarGeneExpr.v8.i3-4.60; SHANAHAN CM, 1994, J CLIN INVEST, V93, P2393, DOI 10.1172/JCI117246; SHANAHAN CM, 1993, CIRC RES, V73, P193, DOI 10.1161/01.RES.73.1.193; SUZUKI T, 1991, NUCLEIC ACIDS RES, V19, P5537, DOI 10.1093/nar/19.20.5537; Szabowski A, 2000, CELL, V103, P745, DOI 10.1016/S0092-8674(00)00178-1; Venugopal R, 1996, P NATL ACAD SCI USA, V93, P14960, DOI 10.1073/pnas.93.25.14960; Wexler L, 1996, CIRCULATION, V94, P1175, DOI 10.1161/01.CIR.94.5.1175; Wingender E, 2000, NUCLEIC ACIDS RES, V28, P316, DOI 10.1093/nar/28.1.316	32	92	96	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					32466	32473		10.1074/jbc.M104909200	http://dx.doi.org/10.1074/jbc.M104909200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11425864	hybrid			2022-12-25	WOS:000170746000014
J	Adachi, J; Mori, Y; Matsui, S; Takigami, H; Fujino, J; Kitagawa, H; Miller, CA; Kato, T; Saeki, K; Matsuda, T				Adachi, J; Mori, Y; Matsui, S; Takigami, H; Fujino, J; Kitagawa, H; Miller, CA; Kato, T; Saeki, K; Matsuda, T			Indirubin and indigo are potent aryl hydrocarbon receptor ligands present in human urine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AH RECEPTOR; CELL-CYCLE; RETINOBLASTOMA PROTEIN; HEPATOMA-CELLS; INDUCTION; CYP1A1; CYTOCHROME-P450; TRANSCRIPTION	Aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor that regulates genes involved in xenobiotic metabolism, cellular proliferation, and differentiation. Numerous xenobiotic and biological compounds are known to interact with AhR, but it remains an orphan receptor, because its physiological ligand is unknown. We identified AhR ligands in human urine using a yeast AhR signaling assay and then characterized their properties. Two ligands, indirubin and indigo, were both present at average concentrations of similar to0.2 ml in the urine of normal donors. Indirubin was also detected in fetal bovine serum and contributed half of the total AhR ligand activity. The activities of indirubin and indigo were comparable with or more potent than that of the archetypal ligand, 2,3,7,8-tetrachlorodibenzo-p-dioxin, in yeast AhR activation assays. We suggest that the endogenous levels and potencies of indirubin and indigo are such that they activate AhR-mediated signaling mechanisms in vivo.	Kyoto Univ, Res Ctr Environm Qual Control, Otsu, Shiga 5200811, Japan; Kyoto Univ, Dept Environm Engn, Sakyo Ku, Yoshida Honmachi, Kyoto 6068501, Japan; Tulane Univ, Sch Publ Hlth & Trop Med, Dept Environm Hlth Sci, New Orleans, LA 70112 USA; Tulane Univ, Sch Publ Hlth & Trop Med, Tulane Xavier Ctr Bioenvironm Res, New Orleans, LA 70112 USA; Nagoya City Univ, Fac Pharmaceut Sci, Nagoya, Aichi 4678603, Japan	Kyoto University; Kyoto University; Tulane University; Tulane University; Xavier University of Louisiana; Nagoya City University	Matsuda, T (corresponding author), Kyoto Univ, Res Ctr Environm Qual Control, 1-2 Yumihama, Otsu, Shiga 5200811, Japan.		Miller, Charles A/I-3978-2019; Adachi, Jun/H-2813-2014	Miller, Charles A/0000-0003-0644-7455; Adachi, Jun/0000-0003-1220-3246	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R29ES009055] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES09055] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BLANZ J, 1989, RES COMMUN CHEM PATH, V64, P145; CHEN YH, 1995, J BIOL CHEM, V270, P22548, DOI 10.1074/jbc.270.38.22548; Ge NL, 1998, J BIOL CHEM, V273, P22708, DOI 10.1074/jbc.273.35.22708; Gillam EMJ, 2000, BIOCHEMISTRY-US, V39, P13817, DOI 10.1021/bi001229u; Gillam EMJ, 1999, BIOCHEM BIOPH RES CO, V265, P469, DOI 10.1006/bbrc.1999.1702; Gonzalez FJ, 1998, DRUG METAB DISPOS, V26, P1194; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307; HAYATSU H, 1992, J CHROMATOGR, V597, P37, DOI 10.1016/0021-9673(92)80095-C; Hoessel R, 1999, NAT CELL BIOL, V1, P60, DOI 10.1038/9035; HUFF J, 1994, ANNU REV PHARMACOL, V34, P343; JACKSON AH, 1988, CLIN CHIM ACTA, V172, P245, DOI 10.1016/0009-8981(88)90330-0; Kolluri SK, 1999, GENE DEV, V13, P1742, DOI 10.1101/gad.13.13.1742; Miller CA, 1999, TOXICOL APPL PHARM, V160, P297, DOI 10.1006/taap.1999.8769; MILLER CA, 1997, J BIOL CHEM, V272, P32834; OKEY AB, 1994, TRENDS PHARMACOL SCI, V15, P226, DOI 10.1016/0165-6147(94)90316-6; POHJANVIRTA R, 1994, PHARMACOL REV, V46, P483; Puga A, 2000, J BIOL CHEM, V275, P2943, DOI 10.1074/jbc.275.4.2943; Reiners JJ, 1999, CARCINOGENESIS, V20, P1561, DOI 10.1093/carcin/20.8.1561; RENNUG U, 1992, MUTAT RES, V282, P219; SAPIRA JD, 1971, METABOLISM, V20, P474, DOI 10.1016/0026-0495(71)90123-5; Savouret JF, 2001, J BIOL CHEM, V276, P3054, DOI 10.1074/jbc.M005988200; Schaldach CM, 1999, BIOCHEMISTRY-US, V38, P7594, DOI 10.1021/bi982861e; Sinal CJ, 1997, MOL PHARMACOL, V52, P590, DOI 10.1124/mol.52.4.590; Sogawa K, 1997, J BIOCHEM, V122, P1075; Wei YD, 1998, CHEM-BIOL INTERACT, V110, P39, DOI 10.1016/S0009-2797(97)00111-7	25	306	326	1	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					31475	31478		10.1074/jbc.C100238200	http://dx.doi.org/10.1074/jbc.C100238200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11425848	hybrid			2022-12-25	WOS:000170613500001
J	Boettiger, D; Lynch, L; Blystone, S; Huber, F				Boettiger, D; Lynch, L; Blystone, S; Huber, F			Distinct ligand-binding modes for integrin alpha(v)beta(3)-mediated adhesion to fibronectin versus vitronectin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; CYCLIC RGD PEPTIDES; CELL-ADHESION; CYTOPLASMIC DOMAIN; AFFINITY; ALPHA-5-BETA-1; ALPHA-V-BETA-3; RECEPTOR; CYTOSKELETON; ACTIVATION	Cell surface integrins can adopt distinct conformations in response to ligand binding and intracellular signals. Several integrins including alpha (v)beta (3). can bind to multiple ligands. The binding of alpha (v)beta (3) to fibronectin and vitronectin was used as a model to determine whether the same or distinct forms of the receptor were utilized in strong binding to the two different ligands. A spinning-dise device was used to measure the relative strength of the alpha (v)beta (3)-ligand bonds. The initial binding reaction for both ligands occurred in the absence of metabolic energy and resulted in a strong adhesion to fibronectin but a weak adhesion to vitronectin. Increases in the strength of the alpha (v)beta (3)-vitronectin bond required phosphorylation of the 13, cytoplasmic domain, intracellular signals, and the binding of cytoskeletal proteins to cytoplasmic domains of beta (3) controlled by Tyr-747 and Tyr-759. In contrast, alpha (v)beta (3)-mediated adhesion to fibronectin was unaffected by phorbol 12-myristate 13-acetate, mutations of Tyr-747 and Tyr-759 to phenylalanine, or availability of metabolic energy. This suggests that strong adhesion to fibronectin used the initial binding conformation, whereas strong binding to vitronectin required signaling-induced changes in the conformation of alpha (v)beta (3).	Univ Penn, Dept Microbiol, Philadelphia, PA 19104 USA; SUNY Syracuse, Upstate Med Univ, Dept Cell & Dev Biol, Syracuse, NY USA	University of Pennsylvania; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Boettiger, D (corresponding author), Univ Penn, Dept Microbiol, Philadelphia, PA 19104 USA.		Huber, Francois/G-6245-2011		NATIONAL CANCER INSTITUTE [R01CA016502] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057388] Funding Source: NIH RePORTER; NCI NIH HHS [CA16502] Funding Source: Medline; NIGMS NIH HHS [GM57388] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barillari G, 1999, BLOOD, V94, P663; Bennett JS, 1999, J BIOL CHEM, V274, P25301, DOI 10.1074/jbc.274.36.25301; Blystone SD, 1996, J BIOL CHEM, V271, P31458, DOI 10.1074/jbc.271.49.31458; Blystone SD, 1997, J BIOL CHEM, V272, P28757, DOI 10.1074/jbc.272.45.28757; Blystone SD, 1999, J CELL BIOL, V145, P889, DOI 10.1083/jcb.145.4.889; BLYSTONE SD, 1995, J CELL BIOL, V130, P745, DOI 10.1083/jcb.130.3.745; Boettiger D, 2001, MOL BIOL CELL, V12, P1227, DOI 10.1091/mbc.12.5.1227; Calderwood DA, 2000, J BIOL CHEM, V275, P22607, DOI 10.1074/jbc.R900037199; CHARO IF, 1990, J CELL BIOL, V111, P2795, DOI 10.1083/jcb.111.6.2795; Choquet D, 1997, CELL, V88, P39, DOI 10.1016/S0092-8674(00)81856-5; Dechantsreiter MA, 1999, J MED CHEM, V42, P3033, DOI 10.1021/jm970832g; DENIS C, 1993, BLOOD, V82, P3622; ENOMOTOIWAMOTO M, 1993, CELL ADHES COMMUN, V1, P191, DOI 10.3109/15419069309097253; FAULL RJ, 1993, J CELL BIOL, V121, P155, DOI 10.1083/jcb.121.1.155; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; Garcia AJ, 1999, BIOMATERIALS, V20, P2427, DOI 10.1016/S0142-9612(99)00170-2; Garcia AJ, 1998, J BIOL CHEM, V273, P34710, DOI 10.1074/jbc.273.52.34710; Garcia AJ, 1997, BIOMATERIALS, V18, P1091, DOI 10.1016/S0142-9612(97)00042-2; Garcia AJ, 1998, J BIOL CHEM, V273, P10988, DOI 10.1074/jbc.273.18.10988; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; HUGHES PE, 1995, J BIOL CHEM, V270, P12411, DOI 10.1074/jbc.270.21.12411; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Krutzsch HC, 1999, J BIOL CHEM, V274, P24080, DOI 10.1074/jbc.274.34.24080; Locardi E, 1999, J PEPT SCI, V5, P491, DOI 10.1002/(SICI)1099-1387(199911)5:11<491::AID-PSC218>3.0.CO;2-8; LOTZ MM, 1989, J CELL BIOL, V109, P1795, DOI 10.1083/jcb.109.4.1795; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; Nath D, 1999, J CELL SCI, V112, P579; Neff S, 1998, J VIROL, V72, P3587, DOI 10.1128/JVI.72.5.3587-3594.1998; OTOOLE TE, 1995, J BIOL CHEM, V270, P8553, DOI 10.1074/jbc.270.15.8553; PFAFF M, 1994, J BIOL CHEM, V269, P20233; Rusnati M, 1997, MOL BIOL CELL, V8, P2449, DOI 10.1091/mbc.8.12.2449; Schaffner-Reckinger E, 1998, J BIOL CHEM, V273, P12623, DOI 10.1074/jbc.273.20.12623; Schoenwaelder SM, 1999, CURR OPIN CELL BIOL, V11, P274, DOI 10.1016/S0955-0674(99)80037-4; SIMS PJ, 1991, J BIOL CHEM, V266, P7345; Sonnenberg A, 1993, Curr Top Microbiol Immunol, V184, P7; Triantafilou K, 2000, J VIROL, V74, P5856, DOI 10.1128/JVI.74.13.5856-5862.2000; WICKHAM TJ, 1993, CELL, V73, P309, DOI 10.1016/0092-8674(93)90231-E; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281	38	49	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					31684	31690		10.1074/jbc.M103997200	http://dx.doi.org/10.1074/jbc.M103997200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11423542	hybrid			2022-12-25	WOS:000170613500030
J	Ciaffoni, F; Salvioli, R; Tatti, M; Arancia, G; Crateri, P; Vaccaro, AM				Ciaffoni, F; Salvioli, R; Tatti, M; Arancia, G; Crateri, P; Vaccaro, AM			Saposin D solubilizes anionic phospholipid-containing membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN A-I; L-ALPHA-DIMYRISTOYLPHOSPHATIDYLCHOLINE; ACTIVATOR PROTEIN-DEFICIENCY; PROSAPOSIN; COMPLEXES; VESICLES; DISEASE; GLUCOSYLCERAMIDASE; RECONSTITUTION; PATIENT	Saposin (Sap) D is a late endosomal/lysosomal small protein, generated together with three other similar proteins, Sap A, B, and C, from the common precursor, prosaposin. Although the functions of saposins such as Sap B and C are well known (Sap B promotes the hydrolysis of sulfatides and Sap C that of glucosylceramide), neither the physiological function nor the mechanism of action of Sap D are yet fully understood. We previously found that a dramatic increase of Sap D superficial hydrophobicity, occurring at the low pH values characteristic of the late endosomal/lysosomal environment, triggers the interaction of the saposin with anionic phospholipid-containing vesicles. We have presently found that, upon lipid binding, Sap D solubilizes the membranes, as shown by the clearance of the vesicles turbidity. The results of gel filtration, density gradient centrifugation, and negative staining electron microscopy demonstrate that this effect is due to the transformation of large vesicles to smaller particles. The solubilizing effect of Sap D is highly dependent on pH, the lipid/saposin ratio, and the presence of anionic phospholipids; small variations in each of these conditions markedly influences the activity of Sap D. The present study documents the interaction of Sap D with membranes as a complex process. Anionic phospholipids attract Sap D from the medium; when the concentration of the saposin on the lipid surface reaches a critical value, the membrane breaks down into recombinant small particles enriched in anionic phospholipids. Our results suggest that the role played by Sap D is more general than promoting sphingolipid degradation, e.g. the saposin might also be a key mediator of the solubilization of intralysosomal/late endosomal anionic phospholipidcontaining membranes.	Ist Super Sanita, Dept Metab & Pathol Biochem, I-00161 Rome, Italy; Ist Super Sanita, Dept Ultrastruct, I-00161 Rome, Italy	Istituto Superiore di Sanita (ISS); Istituto Superiore di Sanita (ISS)	Vaccaro, AM (corresponding author), Ist Super Sanita, Dept Metab & Pathol Biochem, Viale Regina Elena 299, I-00161 Rome, Italy.		tatti, Massimo/N-1382-2017					AZUMA N, 1994, ARCH BIOCHEM BIOPHYS, V311, P354, DOI 10.1006/abbi.1994.1248; BRADOVA V, 1993, HUM GENET, V92, P143, DOI 10.1007/BF00219682; CHRISTOMANOU H, 1989, KLIN WOCHENSCHR, V67, P999, DOI 10.1007/BF01716064; FURST W, 1992, BIOCHIM BIOPHYS ACTA, V1126, P1, DOI 10.1016/0005-2760(92)90210-M; HARZER K, 1989, EUR J PEDIATR, V149, P31, DOI 10.1007/BF02024331; HIRAIWA M, 1992, P NATL ACAD SCI USA, V89, P11254, DOI 10.1073/pnas.89.23.11254; JONAS A, 1981, J BIOL CHEM, V256, P2420; JONAS A, 1980, J BIOL CHEM, V255, P2183; JONAS A, 1980, J BIOL CHEM, V255, P2190; KISHIMOTO Y, 1992, J LIPID RES, V33, P1255; KLEIN A, 1994, BIOCHEM BIOPH RES CO, V200, P1440, DOI 10.1006/bbrc.1994.1612; Kobayashi T, 1998, NATURE, V392, P193, DOI 10.1038/32440; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Linke T, 2001, J BIOL CHEM, V276, P5760, DOI 10.1074/jbc.M006846200; MORIMOTO S, 1988, BIOCHEM BIOPH RES CO, V156, P403, DOI 10.1016/S0006-291X(88)80855-6; MUNFORD RS, 1995, J LIPID RES, V36, P1653; OBRIEN JS, 1995, FASEB J, V9, P681, DOI 10.1096/fasebj.9.8.7768361; OBRIEN JS, 1991, FASEB J, V5, P301, DOI 10.1096/fasebj.5.3.2001789; Salvioi R, 2000, FEBS LETT, V472, P17, DOI 10.1016/S0014-5793(00)01417-4; SANDHOFF K, 1995, METABOLIC MOL BASES, P2427; SCHLOTE W, 1991, EUR J PEDIATR, V150, P584, DOI 10.1007/BF02072213; SCHNABEL D, 1992, J BIOL CHEM, V267, P3312; SUREWICZ WK, 1986, J BIOL CHEM, V261, P6191; SWANEY JB, 1980, J BIOL CHEM, V255, P877; Tatti M, 1999, EUR J BIOCHEM, V263, P486, DOI 10.1046/j.1432-1327.1999.00521.x; VACCARO AM, 1994, FEBS LETT, V349, P181, DOI 10.1016/0014-5793(94)00659-8; Vaccaro AM, 1999, NEUROCHEM RES, V24, P307, DOI 10.1023/A:1022530508763; VACCARO AM, 1993, FEBS LETT, V336, P159, DOI 10.1016/0014-5793(93)81631-9; Vaccaro AM, 1995, J BIOL CHEM, V270, P30576, DOI 10.1074/jbc.270.51.30576; Vaccaro AM, 1997, J BIOL CHEM, V272, P16862, DOI 10.1074/jbc.272.27.16862; VACCARO AM, 1995, J BIOL CHEM, V270, P9953, DOI 10.1074/jbc.270.17.9953; VANDEURS B, 1993, EUR J CELL BIOL, V61, P208; WENGER DA, 1989, AM J MED GENET, V33, P255, DOI 10.1002/ajmg.1320330223	33	32	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					31583	31589		10.1074/jbc.M102736200	http://dx.doi.org/10.1074/jbc.M102736200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11406625	hybrid			2022-12-25	WOS:000170613500017
J	Saparov, SM; Kozono, D; Rothe, U; Agre, P; Pohl, P				Saparov, SM; Kozono, D; Rothe, U; Agre, P; Pohl, P			Water and ion permeation of aquaporin-1 in planar lipid bilayers - Major differences in structural determinants and stoichiometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL CHIP28 PROTEIN; HUMAN RED-CELLS; UNSTIRRED LAYERS; XENOPUS OOCYTES; PH PROFILES; CHANNEL; PERMEABILITY; TRANSPORT; MEMBRANE; EXPRESSION	The aquaporin-1 (AQP1) water channel protein is known to facilitate the rapid movement of water across cell membranes, but a proposed secondary role as an ion channel is still unsettled. Here we describe a method to simultaneously measure water permeability and ion conductance of purified human AQP1 after reconstitution into planar lipid bilayers. Water permeability was determined by measuring Na+ concentrations adjacent to the membrane. Comparisons with the known single channel water permeability of AQP1 indicate that the planar lipid bilayers contain from 10(6) to 10(7) water channels. Addition of cGMP induced ion conductance in planar bilayers containing AQP1, whereas cAMP was without effect. The number of water channels exceeded the number of active ion channels by approximately 1 million-fold, yet p-chloromethylbenzenesulfonate inhibited the water permeability but not ion conductance. Identical ion channel parameters were achieved with AQP1 purified from human red blood cells or AQP1 heterologously expressed in Saccharomyces cerevisae and affinity purified with either N- or C-terminal poly-histidine tags. Rp-8-Br-cGMP inhibited all of the observed conductance levels of the cation selective channel (2, 6, and 10 pS in 100 mM Na+ or K+). Deletion of the putative cGMP binding motif at the C terminus by introduction of a stop codon at position 237 yielded a truncated AQP1 protein that was still permeated by water but not by ions. Our studies demonstrate a method for simultaneously measuring water permeability and ion conductance of AQP1 reconstituted into planar lipid bilayers. The ion conductance occurs (i) through a pathway distinct from the aqueous pathway, (ii) when stimulated directly by cGMP, and (iii) in only an exceedingly small fraction of AQP1 molecules.	Forschungsinst Mol Pharmakol, Nachwuchsgrp Biophys, D-13125 Berlin, Germany; Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; Univ Halle Wittenberg, Fak Med, Inst Physiol Chem, D-06097 Halle, Germany	Johns Hopkins University; Johns Hopkins University; Martin Luther University Halle Wittenberg	Agre, P (corresponding author), Forschungsinst Mol Pharmakol, Nachwuchsgrp Biophys, Robert Rossle Str 10, D-13125 Berlin, Germany.	pagre@bs.jhmi.edu; pohl@fmp-berlin.de	Pohl, Peter/A-5361-2008	Pohl, Peter/0000-0002-1792-2314	NEI NIH HHS [EY11239] Funding Source: Medline; NHLBI NIH HHS [HL48268, HL33991] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY011239] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033991, R01HL048268, R37HL048268] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Agre P, 1997, SCIENCE, V275, P1490, DOI 10.1126/science.275.5305.1490; Agre P, 1999, Methods Enzymol, V294, P550; Amman D., 1986, ION SELECTIVE MICROE; Anthony TL, 2000, MOL PHARMACOL, V57, P576, DOI 10.1124/mol.57.3.576; ANTONENKO YN, 1993, BIOPHYS J, V64, P1701, DOI 10.1016/S0006-3495(93)81542-X; Cho MR, 1999, BIOPHYS J, V76, P1136, DOI 10.1016/S0006-3495(99)77278-4; Coury LA, 1998, AM J PHYSIOL-RENAL, V274, pF34, DOI 10.1152/ajprenal.1998.274.1.F34; DAINTY J, 1966, J PHYSIOL-LONDON, V182, P66, DOI 10.1113/jphysiol.1966.sp007809; DEAMER DW, 1986, CHEM PHYS LIPIDS, V40, P167, DOI 10.1016/0009-3084(86)90069-1; Duquette PP, 2001, P NATL ACAD SCI USA, V98, P3796, DOI 10.1073/pnas.071245198; FETTIPLACE R, 1980, PHYSIOL REV, V60, P510, DOI 10.1152/physrev.1980.60.2.510; Finkelstein A., 1987, WATER MOVEMENT LIPID; Firsov D, 1996, P NATL ACAD SCI USA, V93, P15370, DOI 10.1073/pnas.93.26.15370; Fu DX, 2000, SCIENCE, V290, P481, DOI 10.1126/science.290.5491.481; HANAI T, 1966, J THEOR BIOL, V11, P370, DOI 10.1016/0022-5193(66)90099-3; Hill AE, 1995, INT REV CYTOL, V163, P1, DOI 10.1016/S0074-7696(08)62208-1; JANSEN M, 1995, BIOPHYS J, V68, P997, DOI 10.1016/S0006-3495(95)80275-4; Jovov B, 1999, J BIOL CHEM, V274, P37845, DOI 10.1074/jbc.274.53.37845; JUNG JS, 1994, J BIOL CHEM, V269, P14648; King LS, 2001, NEW ENGL J MED, V345, P175, DOI 10.1056/NEJM200107193450304; Lear JD, 1997, J AM CHEM SOC, V119, P3212, DOI 10.1021/ja9629672; Loo DDF, 1996, P NATL ACAD SCI USA, V93, P13367, DOI 10.1073/pnas.93.23.13367; Loo DDF, 1999, J PHYSIOL-LONDON, V518, P195, DOI 10.1111/j.1469-7793.1999.0195r.x; MACDONALD RC, 1991, BIOCHIM BIOPHYS ACTA, V1061, P297, DOI 10.1016/0005-2736(91)90295-J; MACEY RI, 1970, BIOCHIM BIOPHYS ACTA, V211, P104, DOI 10.1016/0005-2736(70)90130-6; Miller C, 1997, NATURE, V389, P328, DOI 10.1038/38599; MONTAL M, 1972, P NATL ACAD SCI USA, V69, P3561, DOI 10.1073/pnas.69.12.3561; Murata K, 2000, NATURE, V407, P599, DOI 10.1038/35036519; NIELSEN S, 1993, J CELL BIOL, V120, P371, DOI 10.1083/jcb.120.2.371; PATTUS F, 1978, BIOCHIM BIOPHYS ACTA, V507, P62, DOI 10.1016/0005-2736(78)90374-7; Pohl P, 1997, BIOPHYS J, V72, P1711, DOI 10.1016/S0006-3495(97)78817-9; POHL P, 1993, BIOCHIM BIOPHYS ACTA, V1152, P155, DOI 10.1016/0005-2736(93)90242-R; Pohl P, 2000, BIOPHYS J, V78, P2426, DOI 10.1016/S0006-3495(00)76786-5; Pohl P, 1998, BIOPHYS J, V75, P1403, DOI 10.1016/S0006-3495(98)74058-5; POHL P, 2001, IN PRESS P NATL ACAD; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; PRESTON GM, 1993, J BIOL CHEM, V268, P17; Saparov SM, 2000, BIOPHYS J, V79, P2526, DOI 10.1016/S0006-3495(00)76493-9; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SCHINDLER H, 1989, METHOD ENZYMOL, V171, P225; SCHINDLER H, 1979, BIOCHIM BIOPHYS ACTA, V555, P316, DOI 10.1016/0005-2736(79)90171-8; SMITH BL, 1991, J BIOL CHEM, V266, P6407; Spring KR, 1999, NEWS PHYSIOL SCI, V14, P92; Sui HX, 2000, ACTA CRYSTALLOGR D, V56, P1198, DOI 10.1107/S0907444900008143; Unger VM, 2000, NAT STRUCT BIOL, V7, P1082, DOI 10.1038/81914; Vallon V, 2000, AM J PHYSIOL-RENAL, V278, pF1030, DOI 10.1152/ajprenal.2000.278.6.F1030; WALZ T, 1994, J BIOL CHEM, V269, P1583; Yang BX, 1997, J BIOL CHEM, V272, P16140, DOI 10.1074/jbc.272.26.16140; Yasui M, 1999, NATURE, V402, P184, DOI 10.1038/46045; Yool AJ, 1996, SCIENCE, V273, P1216, DOI 10.1126/science.273.5279.1216; ZEIDEL ML, 1992, BIOCHEMISTRY-US, V31, P7436, DOI 10.1021/bi00148a002	51	95	102	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					31515	31520		10.1074/jbc.M104267200	http://dx.doi.org/10.1074/jbc.M104267200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11410596	hybrid			2022-12-25	WOS:000170613500008
J	Smith, ER; Smedberg, JL; Rula, ME; Hamilton, TC; Xu, XX				Smith, ER; Smedberg, JL; Rula, ME; Hamilton, TC; Xu, XX			Disassociation of MAPK activation and c-Fos expression in F9 embryonic carcinoma cells following retinoic acid-induced endoderm differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OVARIAN ADENOCARCINOMA CELLS; GROWTH-FACTOR; TARGETED DISRUPTION; PROTEIN PHOSPHATASE; SIGNAL-TRANSDUCTION; PARIETAL ENDODERM; TRANSCRIPTION; KINASE; GENE; DOMAIN	Retinoic, acid induces cell differentiation and suppresses cell growth in a wide spectrum of cell lines, and down-regulation of activator protein-1 activity by retinoic acid contributes to these effects. In embryonic stem cell-like F9 teratocarcinoma cells, which are widely used to study retinoic acid actions on gene regulation and early embryonic differentiation, retinoic acid treatment for 4 days resulted in suppression of cell growth and differentiation into primitive and then visceral endoderm-like cells, accompanied by a suppression of serum-induced c-Fos expression. The ALAPK (ERK) pathway was involved in mitogenic signaling in F9 cells stimulated with serum. Surprisingly, although c-Fos expression was reduced, the MAPK activity was not decreased by retinoic acid treatment. We found that retinoic acid treatment inhibited the phosphorylation of Elk-1, a target of activated MAPK required for c-Fos transcription. In F9 cells, the MAPK/MEK inhibitor PD98059 suppressed Elk-1 phosphorylation and c-Fos expression, indicating that MAPK activity is required for Elk-1 phosphorylation/activation. Phosphoprotein phosphatase 2B (calcineurin), the major phosphatase for activated Elk-1, is not the target in the disassociation of MAPK activation and c-Fos expression since its inhibition by cyclosporin A or activation by ionomycin had no significant effects on serum-stimulated c-Fos expression and Elk-1 phosphorylation. Thus, we conclude that retinoic acid treatment to induce F9 cell differentiation uncouples Ras/MAPK activation from c-Fos expression by reduction of Elk-1 phosphorylation through a mechanism not involving the activation of phosphoprotein phosphatase 2B.	Fox Chase Canc Ctr, Div Med Sci, Ovarian Canc Program, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Xu, XX (corresponding author), Fox Chase Canc Ctr, Div Med Sci, Ovarian Canc Program, 7701 Burholme Ave, Philadelphia, PA 19111 USA.	X_XU@fccc.edu			NATIONAL CANCER INSTITUTE [R01CA079716, P50CA083638, R01CA075389] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA83638, R01 CA79716, CA75389] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; Arteaga CL, 1996, CANCER RES, V56, P1098; Brown JR, 1998, MOL CELL BIOL, V18, P5609, DOI 10.1128/MCB.18.9.5609; Burdon T, 1999, DEV BIOL, V210, P30, DOI 10.1006/dbio.1999.9265; Chen YC, 1999, ONCOGENE, V18, P139, DOI 10.1038/sj.onc.1202272; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; Cho SY, 1999, MOL CELLS, V9, P179; Clements D, 2001, INT REV CYTOL, V203, P383; Crabtree GR, 1999, CELL, V96, P611, DOI 10.1016/S0092-8674(00)80571-1; Cruzalegui FH, 1999, ONCOGENE, V18, P7948, DOI 10.1038/sj.onc.1203362; CURRAN T, 1985, CANCER SURV, V4, P655; DE LUCA LM, 1991, FASEB J, V5, P2924; EDWARDS SA, 1988, DEV BIOL, V129, P91, DOI 10.1016/0012-1606(88)90164-9; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; Faria TN, 1998, MOL CELL ENDOCRINOL, V143, P155, DOI 10.1016/S0303-7207(98)00127-0; Faria TN, 1999, J BIOL CHEM, V274, P26783, DOI 10.1074/jbc.274.38.26783; Fazili Z, 1999, ONCOGENE, V18, P3104, DOI 10.1038/sj.onc.1202649; Gajovic S, 1998, EXP CELL RES, V242, P138, DOI 10.1006/excr.1998.4058; GREEN JBA, 1990, BIOESSAYS, V12, P437, DOI 10.1002/bies.950120907; GUDAS LJ, 1994, J BIOL CHEM, V269, P15399; Han GR, 1997, J BIOL CHEM, V272, P13711, DOI 10.1074/jbc.272.21.13711; HE J, 2001, IN PRESS J BIOL CHEM, V276; Hemenway Charles S., 1999, Cell Biochemistry and Biophysics, V30, P115, DOI 10.1007/BF02737887; HOGAN BLM, 1981, NATURE, V291, P235, DOI 10.1038/291235a0; Holt J, 1992, Cancer Treat Res, V63, P301; HU ED, 1994, EMBO J, V13, P3094, DOI 10.1002/j.1460-2075.1994.tb06608.x; Iwata A, 2001, J NEUROCHEM, V77, P239, DOI 10.1046/j.1471-4159.2001.t01-1-00232.x; JAFFEY P, 1992, CANCER RES, V52, P2384; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Koutsourakis M, 1999, DEVELOPMENT, V126, P723; LEVI BZ, 1988, CELL DIFFER DEV, V25, P95, DOI 10.1016/0922-3371(88)90105-0; Lin F, 2000, CANCER RES, V60, P3271; LOCKETT TJ, 1987, EXP CELL RES, V173, P370, DOI 10.1016/0014-4827(87)90277-1; Maden M, 1999, BIOESSAYS, V21, P809, DOI 10.1002/(SICI)1521-1878(199910)21:10<809::AID-BIES2>3.0.CO;2-0; MARTIN CA, 1990, MOL CELL ENDOCRINOL, V71, P27, DOI 10.1016/0303-7207(90)90071-F; MASON I, 1985, DIFFERENTIATION, V30, P76, DOI 10.1111/j.1432-0436.1985.tb00516.x; Matsuda S, 2000, IMMUNOPHARMACOLOGY, V47, P119, DOI 10.1016/S0162-3109(00)00192-2; McCaffery P, 2000, CYTOKINE GROWTH F R, V11, P233, DOI 10.1016/S1359-6101(00)00002-2; Minucci S, 1996, CURR OPIN GENET DEV, V6, P567, DOI 10.1016/S0959-437X(96)80085-2; Mok SC, 1998, ONCOGENE, V16, P2381, DOI 10.1038/sj.onc.1201769; Morrisey EE, 1998, GENE DEV, V12, P3579, DOI 10.1101/gad.12.22.3579; Morrisey EE, 2000, J BIOL CHEM, V275, P19949, DOI 10.1074/jbc.M001331200; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; MULLER R, 1984, NATURE, V311, P438, DOI 10.1038/311438a0; MULLER R, 1985, BIOCHIM BIOPHYS ACTA, V823, P207; Ozeki A, 1999, BBA-MOL CELL RES, V1450, P308, DOI 10.1016/S0167-4889(99)00063-4; PAWSON T, 1993, DEV GENET, V14, P333, DOI 10.1002/dvg.1020140502; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Ross SA, 2000, PHYSIOL REV, V80, P1021, DOI 10.1152/physrev.2000.80.3.1021; RUTHER U, 1985, EMBO J, V4, P1775, DOI 10.1002/j.1460-2075.1985.tb03850.x; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; Sheng ZJ, 2000, ONCOGENE, V19, P4847, DOI 10.1038/sj.onc.1203853; SHERMAN MI, 1978, DEV BIOL, V63, P27, DOI 10.1016/0012-1606(78)90110-0; Soprano DR, 1996, ONCOGENE, V12, P577; Sugimoto T, 1997, J BIOL CHEM, V272, P29415, DOI 10.1074/jbc.272.47.29415; Sugimoto T, 1998, EMBO J, V17, P1717, DOI 10.1093/emboj/17.6.1717; TANAKA S, 1993, J BIOL CHEM, V268, P8862; Tian JM, 1999, J BIOL CHEM, V274, P15173, DOI 10.1074/jbc.274.21.15173; VASIOS GW, 1989, P NATL ACAD SCI USA, V86, P9099, DOI 10.1073/pnas.86.23.9099; Verheijen MHG, 1999, J BIOL CHEM, V274, P1487, DOI 10.1074/jbc.274.3.1487; Wells JM, 1999, ANNU REV CELL DEV BI, V15, P393, DOI 10.1146/annurev.cellbio.15.1.393; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Wu SJ, 1997, EXP CELL RES, V232, P277, DOI 10.1006/excr.1997.3495; XU XX, 1995, J BIOL CHEM, V270, P14184, DOI 10.1074/jbc.270.23.14184; Xu XX, 1998, ONCOGENE, V16, P1561, DOI 10.1038/sj.onc.1201678; Yang SH, 1999, EMBO J, V18, P5666, DOI 10.1093/emboj/18.20.5666; Yang SH, 1998, MOL CELL BIOL, V18, P710, DOI 10.1128/MCB.18.2.710; YANG-YEN H-F, 1990, New Biologist, V2, P351; Zhao CM, 1999, J BIOL CHEM, V274, P19649, DOI 10.1074/jbc.274.28.19649	71	26	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					32094	32100		10.1074/jbc.M105009200	http://dx.doi.org/10.1074/jbc.M105009200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11402055	hybrid			2022-12-25	WOS:000170613500085
J	Davey, GE; Murmann, P; Heizmann, CW				Davey, GE; Murmann, P; Heizmann, CW			Intracellular Ca2+ and Zn2+ levels regulate the alternative cell density-dependent secretion of S100B in human glioblastoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEINS; GLYCATION END-PRODUCTS; IN-VITRO; CULTURED ASTROCYTES; S100-BETA PROTEIN; NEURITE EXTENSION; RECEPTOR; SURVIVAL; PHOSPHORYLATION; PROLIFERATION	In recent years, protein translocation has been implicated as the mechanism that controls assembly of signaling complexes and induction of signaling cascades. Several members of the multifunctional Ca2+ (Zn2+ - and Cu2+)-binding S100 proteins appear to translocate upon cellular stimulation, and some are even secreted from cells, exerting extracellular functions. We transfected cells with S100B-green fluorescent fusion proteins and followed the relocation in real time. A small number of cells underwent translocation spontaneously. However, the addition of thapsigargin, which increases Ca2+ levels, intensified ongoing translocation and secretion or induced these processes in resting cells. On the other hand, EGTA or BAPTA (1,2-bis(2-aminophenoxy)ethane-N,N,N ' ,N ' -tetraacetic acid), the Ca2+-chelating agents, inhibited these processes. In contrast, relocation of S100B seemed to be negatively dependent on Zn2+ levels. Treatment of cells with TPEN (NNN ' ,N ' -tetrakis(2-pyridylmethyl)ethylenediamine), a Zn2+-binding drug, resulted in a dramatic redistribution and translocation of S100B. Secretion of S100B, when measured by ELISA, was dependent on cell density. As cells reached confluence the secretion drastically declined. However, an increase in Ca2+ levels, and even more so, a decrease in Zn2+ concentration, reactivated secretion of S100B. On the other hand, secretion did not decrease by treatment with brefeldin A, supporting the view that this process is independent of the endoplasmic reticulum-Golgi classical secretion pathway.	Univ Zurich, Dept Pediat, Div Clin Chem & Biochem, CH-8032 Zurich, Switzerland	University of Zurich	Heizmann, CW (corresponding author), Univ Zurich, Dept Pediat, Div Clin Chem & Biochem, Steinwiesstr 75, CH-8032 Zurich, Switzerland.	heizmann@kispi.unizh.ch						Alexanian AR, 1999, FASEB J, V13, P1611, DOI 10.1096/fasebj.13.12.1611; Barber KR, 1999, J BIOL CHEM, V274, P1502, DOI 10.1074/jbc.274.3.1502; BARGER SW, 1992, J BIOL CHEM, V267, P9689; BAUDIER J, 1986, J BIOL CHEM, V261, P8192; BHATTACHARYYA A, 1992, J NEUROBIOL, V23, P451, DOI 10.1002/neu.480230410; Camby I, 1996, NEUROPEPTIDES, V30, P433, DOI 10.1016/S0143-4179(96)90006-2; CARON JM, 1985, NATURE, V317, P648, DOI 10.1038/317648a0; Carreira CM, 1998, J BIOL CHEM, V273, P22224, DOI 10.1074/jbc.273.35.22224; Curry BJ, 1999, MELANOMA RES, V9, P557, DOI 10.1097/00008390-199912000-00004; Davey GE, 2000, BBA-MOL CELL RES, V1498, P220, DOI 10.1016/S0167-4889(00)00098-7; De Hauwer C, 1998, J NEUROBIOL, V37, P373, DOI 10.1002/(SICI)1097-4695(19981115)37:3<373::AID-NEU3>3.0.CO;2-H; DeHauwer C, 1997, BIOCHEM BIOPH RES CO, V232, P267, DOI 10.1006/bbrc.1997.6291; Deloulme JC, 2000, J BIOL CHEM, V275, P35302, DOI 10.1074/jbc.M003943200; Delphin C, 1999, J BIOL CHEM, V274, P10539, DOI 10.1074/jbc.274.15.10539; DIARRA A, 1992, PFLUG ARCH EUR J PHY, V422, P40, DOI 10.1007/BF00381511; Donato R, 1999, BBA-MOL CELL RES, V1450, P191, DOI 10.1016/S0167-4889(99)00058-0; DONATO R, 1986, CELL CALCIUM, V7, P123, DOI 10.1016/0143-4160(86)90017-5; Drohat AC, 1998, BIOCHEMISTRY-US, V37, P2729, DOI 10.1021/bi972635p; Frosch M, 2000, ARTHRITIS RHEUM-US, V43, P628, DOI 10.1002/1529-0131(200003)43:3<628::AID-ANR20>3.0.CO;2-X; Gattaz WF, 2000, SCHIZOPHR RES, V43, P91, DOI 10.1016/S0920-9964(99)00146-2; Giaume C, 1998, GLIA, V24, P50, DOI 10.1002/(SICI)1098-1136(199809)24:1<50::AID-GLIA6>3.0.CO;2-4; Goncalves DS, 2000, NEUROREPORT, V11, P807, DOI 10.1097/00001756-200003200-00030; Griffin WST, 1998, NEUROBIOL AGING, V19, P401, DOI 10.1016/S0197-4580(98)00074-8; GROMADA J, 1995, FEBS LETT, V360, P303, DOI 10.1016/0014-5793(95)00131-R; Hack NJ, 2000, J NEUROSCI METH, V95, P177, DOI 10.1016/S0165-0270(99)00178-8; Hauschild A, 1999, MELANOMA RES, V9, P155, DOI 10.1097/00008390-199904000-00008; Heizmann CW, 1998, BIOMETALS, V11, P383, DOI 10.1023/A:1009212521172; Hofmann MA, 1999, CELL, V97, P889, DOI 10.1016/S0092-8674(00)80801-6; Hu JR, 1996, BBA-MOL CELL RES, V1313, P239, DOI 10.1016/0167-4889(96)00095-X; Hu JR, 1999, BRAIN RES, V842, P46, DOI 10.1016/S0006-8993(99)01804-1; Huttunen HJ, 2000, J BIOL CHEM, V275, P40096, DOI 10.1074/jbc.M006993200; Ikura M, 2000, NAT STRUCT BIOL, V7, P525, DOI 10.1038/76721; Ilg EC, 1996, INT J CANCER, V68, P325, DOI 10.1002/(SICI)1097-0215(19961104)68:3<325::AID-IJC10>3.0.CO;2-7; Jareb M, 1997, J NEUROSCI, V17, P8955; Kilby PM, 1997, PROTEIN SCI, V6, P2494; Kimura K, 2000, INT J ONCOL, V16, P1125; KISS R, 1995, CYTOMETRY, V20, P118, DOI 10.1002/cyto.990200204; KLIGMAN D, 1985, P NATL ACAD SCI USA, V82, P7136, DOI 10.1073/pnas.82.20.7136; Kursula P, 2000, MOL BRAIN RES, V76, P407, DOI 10.1016/S0169-328X(00)00018-8; Landriscina M, 2000, J BIOL CHEM, V275, P32753, DOI 10.1074/jbc.M002336200; Li YK, 2000, J NEUROCHEM, V74, P143; Li YK, 1998, J NEUROCHEM, V71, P1421; LIN LH, 1994, MOL BRAIN RES, V25, P297, DOI 10.1016/0169-328X(94)90165-1; Mandinova A, 1998, J CELL SCI, V111, P2043; McAdory BS, 1998, BRAIN RES, V813, P211, DOI 10.1016/S0006-8993(98)01014-2; Meplan C, 2000, ONCOGENE, V19, P5227, DOI 10.1038/sj.onc.1203907; Meyer T, 2000, TRENDS CELL BIOL, V10, P238, DOI 10.1016/S0962-8924(00)01764-5; Mueller A, 1999, HISTOCHEM CELL BIOL, V111, P453, DOI 10.1007/s004180050381; Passey RJ, 1999, J LEUKOCYTE BIOL, V66, P549, DOI 10.1002/jlb.66.4.549; Petrova TV, 2000, BRAIN RES, V853, P74, DOI 10.1016/S0006-8993(99)02251-9; Platt-Higgins AM, 2000, INT J CANCER, V89, P198, DOI 10.1002/(SICI)1097-0215(20000320)89:2<198::AID-IJC16>3.0.CO;2-L; Rammes A, 1997, J BIOL CHEM, V272, P9496; Schmidt AM, 2000, BBA-MOL CELL RES, V1498, P99, DOI 10.1016/S0167-4889(00)00087-2; Scotto C, 1999, MOL CELL BIOL, V19, P7168; SELINFREUND RH, 1991, P NATL ACAD SCI USA, V88, P3554, DOI 10.1073/pnas.88.9.3554; SHENG JG, 1994, J NEUROSCI RES, V39, P398, DOI 10.1002/jnr.490390406; Sheng JG, 2000, J NEUROCHEM, V74, P295, DOI 10.1046/j.1471-4159.2000.0740295.x; Shishibori T, 1999, BIOCHEM J, V338, P583, DOI 10.1042/0264-6021:3380583; Sohnle PG, 2000, J INFECT DIS, V182, P1272, DOI 10.1086/315810; Sorci G, 2000, NEUROSCIENCE, V99, P773, DOI 10.1016/S0306-4522(00)00238-4; Steinhoff BJ, 1999, EPILEPSY RES, V36, P75, DOI 10.1016/S0920-1211(99)00026-1; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; VANELDIK LJ, 1987, BRAIN RES, V436, P367, DOI 10.1016/0006-8993(87)91681-7; VANELDIK LJ, 1994, BBA-MOL CELL RES, V1223, P398, DOI 10.1016/0167-4889(94)90101-5; VANELDIK LJ, 1991, BRAIN RES, V542, P280, DOI 10.1016/0006-8993(91)91579-P; Wang GZ, 2000, J BIOL CHEM, V275, P11141, DOI 10.1074/jbc.275.15.11141; Wang HJ, 2000, J CELL BIOL, V150, P1489, DOI 10.1083/jcb.150.6.1489; WINNINGHAMMAJOR F, 1989, J CELL BIOL, V109, P3063, DOI 10.1083/jcb.109.6.3063; Xiong ZG, 2000, EXP CELL RES, V257, P281, DOI 10.1006/excr.2000.4902; Zhang WD, 2000, J CEREBR BLOOD F MET, V20, P967, DOI 10.1097/00004647-200006000-00009; Zhang ZY, 1999, J BIOL CHEM, V274, P25093, DOI 10.1074/jbc.274.35.25093; ZHU XY, 1999, CRC METH SIG TRANS, P129	72	81	81	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					30819	30826		10.1074/jbc.M103541200	http://dx.doi.org/10.1074/jbc.M103541200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11402046	hybrid			2022-12-25	WOS:000170472900033
J	Hohl, M; Christensen, O; Kunz, C; Naegeli, H; Fleck, O				Hohl, M; Christensen, O; Kunz, C; Naegeli, H; Fleck, O			Binding and repair of mismatched DNA mediated by Rhp14, the fission yeast homologue of human XPA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-EXCISION-REPAIR; SCHIZOSACCHAROMYCES-POMBE; DAMAGE-RECOGNITION; GENE; PROTEIN; MUTATIONS; ADDUCTS; RECOMBINATION; INVOLVEMENT; NUCLEASE	Rhp14 of Schizosaccharomyces pombe is homologous to human XPA and Saccharomyces cerevisiae Rad14, which act in nucleotide excision repair of DNA damages induced by ultraviolet light and chemical agents. Cells with disrupted rhp14 were highly sensitive to ultraviolet light, and epistasis analysis with swi10 (nucleotide excision repair) and rad2 (Uve1-dependent ultraviolet light damage repair pathway) revealed that Rhp14 is an important component of nucleotide excision repair for ultraviolet light-induced damages. Moreover, defective rhp14 caused instability of a GT repeat, similar to swi10 and synergistically with msh2 and exo10. Recombinant Rhp14 with an N-terminal hexahistidine tag was purified from Escherichia coli. Complementation studies with a rhp14 mutant demonstrated that the tagged Rhp14 is functional in repair of ultraviolet radiation-induced damages and in mitotic mutation avoidance. In bandshift assays, Rhp14 showed a preference to substrates with mismatched and unpaired nucleotides. Similarly, XPA bound more efficiently to C/C, A/C, and T/C mismatches than to homoduplex DNA. Our data show that mismatches and loops in DNA are substrates of nucleotide excision repair. Rhp14 is likely part of the recognition complex but alone is not sufficient for the high discrimination of nucleotide excision repair for modified DNA.	Univ Bern, Inst Cell Biol, CH-3012 Bern, Switzerland; Univ Zurich, Inst Pharmacol & Toxicol, Tierspital, CH-8008 Zurich, Switzerland	University of Bern; University of Zurich	Fleck, O (corresponding author), Univ Bern, Inst Cell Biol, Baltzerstr 4, CH-3012 Bern, Switzerland.	fleck@izb.unibe.ch		Fleck, Oliver/0000-0003-0550-6513; Kunz, Christophe/0000-0002-0511-3915				Alleva JL, 2000, BIOCHEMISTRY-US, V39, P2659, DOI 10.1021/bi992751n; Bahler J, 1998, YEAST, V14, P943, DOI 10.1002/(SICI)1097-0061(199807)14:10<943::AID-YEA292>3.0.CO;2-Y; BASI G, 1993, GENE, V123, P131, DOI 10.1016/0378-1119(93)90552-E; Batty DP, 2000, GENE, V241, P193, DOI 10.1016/S0378-1119(99)00489-8; Bhui-Kaur A, 1998, MOL CELL BIOL, V18, P1436, DOI 10.1128/MCB.18.3.1436; Burns JL, 1996, J BIOL CHEM, V271, P11607, DOI 10.1074/jbc.271.20.11607; Buschta-Hedayat N, 1999, P NATL ACAD SCI USA, V96, P6090, DOI 10.1073/pnas.96.11.6090; CARPENTER ATC, 1982, P NATL ACAD SCI-BIOL, V79, P5961, DOI 10.1073/pnas.79.19.5961; Fleck O, 1999, NAT GENET, V21, P314, DOI 10.1038/6838; FLECK O, 1994, NUCLEIC ACIDS RES, V22, P5289, DOI 10.1093/nar/22.24.5289; Fleck O, 1998, J BIOL CHEM, V273, P30398, DOI 10.1074/jbc.273.46.30398; Greene CN, 1997, MOL CELL BIOL, V17, P2844, DOI 10.1128/MCB.17.5.2844; Gunz D, 1996, J BIOL CHEM, V271, P25089, DOI 10.1074/jbc.271.41.25089; Gutz H., 1974, HDB GENETICS, V1, P395; HE ZG, 1995, NATURE, V374, P566, DOI 10.1038/374566a0; Hess MT, 1997, P NATL ACAD SCI USA, V94, P6664, DOI 10.1073/pnas.94.13.6664; Hess MT, 1997, MOL CELL BIOL, V17, P7069, DOI 10.1128/MCB.17.12.7069; HUANG JC, 1994, P NATL ACAD SCI USA, V91, P12213, DOI 10.1073/pnas.91.25.12213; JONES CJ, 1993, BIOCHEMISTRY-US, V32, P12096, DOI 10.1021/bi00096a021; LEA DE, 1949, J GENET, V49, P264, DOI 10.1007/BF02986080; Lehmann AR, 1996, MUTAT RES-DNA REPAIR, V363, P147, DOI 10.1016/0921-8777(96)00017-1; Mansour AA, 2001, GENETICS, V158, P77; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; Moggs JG, 1997, NUCLEIC ACIDS RES, V25, P480, DOI 10.1093/nar/25.3.480; MONTELONE BA, 1994, YEAST, V10, P13, DOI 10.1002/yea.320100103; MONTELONE BA, 1992, MUTAT RES, V267, P55, DOI 10.1016/0027-5107(92)90110-N; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Mu D, 1997, MOL CELL BIOL, V17, P760, DOI 10.1128/MCB.17.2.760; MURRAY JM, 1994, MOL CELL BIOL, V14, P4878, DOI 10.1128/MCB.14.7.4878; Petit C, 1999, BIOCHIMIE, V81, P15, DOI 10.1016/S0300-9084(99)80034-0; Reardon JT, 1996, J BIOL CHEM, V271, P19451, DOI 10.1074/jbc.271.32.19451; ROBINS P, 1991, EMBO J, V10, P3913, DOI 10.1002/j.1460-2075.1991.tb04961.x; RODEL C, 1992, NUCLEIC ACIDS RES, V20, P6347, DOI 10.1093/nar/20.23.6347; Rudolph C, 1998, CURR GENET, V34, P343, DOI 10.1007/s002940050405; Rudolph C, 1999, MOL CELL BIOL, V19, P241; Sancar A, 1999, NAT GENET, V21, P247, DOI 10.1038/6753; SCHAR P, 1993, GENETICS, V133, P825; Schar P, 1997, GENETICS, V146, P1275; SEKELSKY JJ, 1995, GENETICS, V141, P619; Sia EA, 1997, MUTAT RES-DNA REPAIR, V383, P61, DOI 10.1016/S0921-8777(96)00046-8; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; Sugasawa K, 1998, MOL CELL, V2, P223, DOI 10.1016/S1097-2765(00)80132-X; SZANKASI P, 1995, SCIENCE, V267, P1166, DOI 10.1126/science.7855597; Tornier C, 2001, GENETICS, V158, P65; Umar A, 1996, EUR J BIOCHEM, V238, P297, DOI 10.1111/j.1432-1033.1996.0297z.x; Wakasugi M, 1999, J BIOL CHEM, V274, P18759, DOI 10.1074/jbc.274.26.18759; Wakasugi M, 1998, P NATL ACAD SCI USA, V95, P6669, DOI 10.1073/pnas.95.12.6669; Wood RD, 1999, BIOCHIMIE, V81, P39, DOI 10.1016/S0300-9084(99)80036-4; Yonemasu R, 1997, NUCLEIC ACIDS RES, V25, P1553, DOI 10.1093/nar/25.8.1553	49	12	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					30766	30772		10.1074/jbc.M104039200	http://dx.doi.org/10.1074/jbc.M104039200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11408483	Green Accepted, hybrid			2022-12-25	WOS:000170472900026
J	Koglin, M; Vehse, K; Budaeus, L; Scholz, H; Behrends, S				Koglin, M; Vehse, K; Budaeus, L; Scholz, H; Behrends, S			Nitric oxide activates the beta(2) subunit of soluble guanylyl cyclase in the absence of a second subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; ACTIVITY REQUIRES; ALPHA(2) SUBUNIT; ENZYME SUBUNITS; RAT-KIDNEY; EXPRESSION; ADENYLYL; CONTAINS; FORM	Previously characterized mammalian soluble guanylyl cyclases form alpha/beta heterodimers that can be activated by the gaseous messenger, nitric oxide, and the novel guanylyl cyclase modulator YC-1. Four mammalian subunits have been cloned named alpha (1), beta (1), alpha (2), and beta (2). The alpha (1)/beta (1) and alpha (2)/beta (1) heterodimeric enzyme isoforms have been rigorously characterized. The role of the beta (2) subunit has remained elusive. Here we isolate a novel variant of this subunit and show that the beta (2) subunit does not need to form heterodimers for catalytic activity because enzyme activity can be measured when it is expressed alone in Sf9 cells. In analogy to the beta (3) subunit recently isolated from the insect Manduca sexta, activity was dependent on the presence of 4 mm free Mn2+. The EC50 values for the NO-donor diethylamine/NO were shifted to the left by I order of magnitude as compared with the alpha (1)/beta (1) heterodimeric form. In the presence of the detergent Tween, NO sensitivity of beta (2) was abolished, but the enzyme could be activated by protoporphyrin IX, indicating removal of a prosthetic heme group and exchange for the heme precursor. We suggest that the beta (2) subunit is the first mammalian NO-sensitive guanylyl cyclase lacking a heterodimeric structure.	Univ Hamburg, Inst Expt & Klin Pharmacol, D-20251 Hamburg, Germany	University of Hamburg	Behrends, S (corresponding author), Univ Hamburg, Inst Expt & Klin Pharmacol, Martinistr 52, D-20251 Hamburg, Germany.		Behrends, Sönke/A-2551-2010	Behrends, Sönke/0000-0002-9068-0729				Behrends S, 2000, BIOCHEM BIOPH RES CO, V271, P64, DOI 10.1006/bbrc.2000.2596; BEHRENDS S, 1995, J BIOL CHEM, V270, P21109, DOI 10.1074/jbc.270.36.21109; BUECHLER WA, 1991, BIOCHEM BIOPH RES CO, V174, P351, DOI 10.1016/0006-291X(91)90527-E; Denninger JW, 1999, BBA-BIOENERGETICS, V1411, P334, DOI 10.1016/S0005-2728(99)00024-9; DREWETT JG, 1994, ENDOCR REV, V15, P135, DOI 10.1210/er.15.2.135; Foerster J, 1996, EUR J BIOCHEM, V240, P380, DOI 10.1111/j.1432-1033.1996.0380h.x; Friebe A, 1997, BIOCHEMISTRY-US, V36, P1194, DOI 10.1021/bi962047w; GIUILI G, 1992, FEBS LETT, V304, P83, DOI 10.1016/0014-5793(92)80594-7; Gupta G, 1997, J CLIN INVEST, V100, P1488, DOI 10.1172/JCI119670; HARTENECK C, 1991, FEBS LETT, V292, P217, DOI 10.1016/0014-5793(91)80871-Y; HARTENECK C, 1990, FEBS LETT, V272, P221, DOI 10.1016/0014-5793(90)80489-6; Koesling D, 1999, Rev Physiol Biochem Pharmacol, V135, P41, DOI 10.1007/BFb0033669; Koglin M, 2000, BBA-GENE STRUCT EXPR, V1494, P286, DOI 10.1016/S0167-4781(00)00211-6; Lee YC, 2000, P NATL ACAD SCI USA, V97, P10763, DOI 10.1073/pnas.190333697; Liu Y, 1997, P NATL ACAD SCI USA, V94, P13414, DOI 10.1073/pnas.94.25.13414; MUNDEL P, 1995, HISTOCHEM CELL BIOL, V103, P75, DOI 10.1007/BF01464478; Nighorn A, 1999, J BIOL CHEM, V274, P2525, DOI 10.1074/jbc.274.4.2525; Russwurm M, 1998, BIOCHEM J, V335, P125, DOI 10.1042/bj3350125; WEDEL B, 1995, J BIOL CHEM, V270, P24871, DOI 10.1074/jbc.270.42.24871; Wedel BJ, 1997, P NATL ACAD SCI USA, V94, P459, DOI 10.1073/pnas.94.2.459; YUEN PST, 1990, BIOCHEMISTRY-US, V29, P10872, DOI 10.1021/bi00501a002; Zhang GY, 1997, NATURE, V386, P247, DOI 10.1038/386247a0	22	72	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					30737	30743		10.1074/jbc.M102549200	http://dx.doi.org/10.1074/jbc.M102549200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11406623	hybrid			2022-12-25	WOS:000170472900022
J	Naka, M; Ozaki, T; Takada, N; Takahashi, M; Shishikura, T; Sakiyama, S; Tada, M; Todo, S; Nakagawara, A				Naka, M; Ozaki, T; Takada, N; Takahashi, M; Shishikura, T; Sakiyama, S; Tada, M; Todo, S; Nakagawara, A			Functional characterization of naturally occurring mutants (P405R and P425L) of p73 alpha and p73 beta found in neuroblastoma and lung cancer	ONCOGENE			English	Article						growth suppression; missense mutation; p73; transcriptional activity	KINASE C-ABL; APOPTOTIC RESPONSE; TERMINAL REGION; P73 FUNCTION; P53; INDUCTION; VARIANTS; IDENTIFICATION; CELLS	The novel candidate tumor suppressor p73, a structural and functional homolog of p53, activates various p53 responsive promoters and induces tumor cell apoptosis, Although p73 is infrequently mutated in human cancers, we ha, e previously found two types of p73 mutation with amino acid substitution (P405R and P425L) in primary neuroblastoma and lung cancer. Here we report generations of the p73 mutants with either P405R or P425L substitution and functional analysis of these naturally occurring mutants, Indirect immunofluorescence staining revealed that nuclear accumulation of p73 alpha or p73 beta was not affected by these mutations. The P425L substitution reduced the ability of p73a to transactivate various p53 responsive promoters (p21(Waf1), Mdm2, and Bax), Moreover, this down-regulation was correlated with the reduced capability of p73 alpha (P425L) to suppress cell growth in p53-deficient SAOS-2 cells. In contrast, p73 beta (P425L) was as effective as wild-type p73 beta in transactivation and growth inhibition. On the other hand, the P405R substitution had no significant effect on both the transcriptional activity and the growth-suppressive ability of p73 alpha or p73 beta. These results suggested that, at least, one of the naturally occurring p73 mutants, p73 alpha (P425L), was a functionally defective mutant of p73.	Chiba Canc Ctr, Res Inst, Div Biochem, Chiba 2608717, Japan; Inst Canc Res, Div Cell Biol, Ciba 2608717, Japan; Hokkaido Univ, Sch Med, Dept Surg 1, Sapporo, Hokkaido 0608638, Japan	Chiba Cancer Center; Hokkaido University	Nakagawara, A (corresponding author), Chiba Canc Ctr, Res Inst, Div Biochem, 666-2 Nitona, Chiba 2608717, Japan.							Agami R, 1999, NATURE, V399, P809; Anderson ME, 1997, MOL CELL BIOL, V17, P6255, DOI 10.1128/MCB.17.11.6255; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; De Laurenzi V, 2000, J BIOL CHEM, V275, P15226, DOI 10.1074/jbc.275.20.15226; De Laurenzi V, 1999, CELL DEATH DIFFER, V6, P389, DOI 10.1038/sj.cdd.4400521; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; Dickman S, 1997, SCIENCE, V277, P1605, DOI 10.1126/science.277.5332.1605; Fang L, 1999, J CELL BIOL, V147, P823, DOI 10.1083/jcb.147.4.823; FRIEND S, 1994, SCIENCE, V265, P334, DOI 10.1126/science.8023155; Gong JG, 1999, NATURE, V399, P806; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Ichimiya S, 1999, ONCOGENE, V18, P1061, DOI 10.1038/sj.onc.1202390; Ikawa S, 1999, CELL DEATH DIFFER, V6, P1154, DOI 10.1038/sj.cdd.4400631; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaelin WG, 1999, ONCOGENE, V18, P7701, DOI 10.1038/sj.onc.1202955; Kaelin WG, 1999, J NATL CANCER I, V91, P594, DOI 10.1093/jnci/91.7.594; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kim AL, 1999, J BIOL CHEM, V274, P34924, DOI 10.1074/jbc.274.49.34924; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Ozaki T, 1999, CANCER RES, V59, P5902; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; Takada N, 1999, CANCER RES, V59, P2810; Ueda Y, 1999, ONCOGENE, V18, P4993, DOI 10.1038/sj.onc.1202817; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zeng XY, 1999, MOL CELL BIOL, V19, P3257	27	12	12	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 14	2001	20	27					3568	3572		10.1038/sj.onc.1204470	http://dx.doi.org/10.1038/sj.onc.1204470			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	445VB	11429704				2022-12-25	WOS:000169478300013
J	Kimura, SH; Ikawa, M; Ito, A; Okabe, M; Nojima, H				Kimura, SH; Ikawa, M; Ito, A; Okabe, M; Nojima, H			Cyclin G1 is involved in G2/M arrest in response to DNA damage and in growth control after damage recovery	ONCOGENE			English	Article						cyclin G1; cyclin G1-disrupted mouse; p53; G2/M arrest	CELL-CYCLE; CHROMOSOMAL LOCALIZATION; P53-MEDIATED APOPTOSIS; GENOMIC INTEGRITY; GENE-TRANSFER; P53; EXPRESSION; PROTEIN; RNA; MICE	Cyclin G1 is one of the target genes of the transcription factor p53, and is induced in a p53-dependent manner in response to DNA damage. Although cyclin G1 has been implicated in a range of biological phenomena, its precise function remains unclear. Here we present an analysis of the physiological role of cyclin Ct using mice homozygous for a targeted disruption of the cyclin G1 gene. In order to clarify the role of cyclin G1 in the p53 pathway, downstream events such as apoptosis, cell growth and cell cycle checkpoint control were analysed in thymocytes and embryonic fibroblasts derived from cyclin G1-disrupted mice. No difference was detected in induction of apoptosis between mouse embryo fibroblasts (MEFs) derived from cyclin G1(+/+) and cyclin G1(-/-) mice. Following irradiation, cyclin G1(-/-) MEFs proliferated more slowly and reached lower cell densities in culture dishes than cyclin G1(+/+) MEFs, Analysis of cell survival showed that cyclin G1(-/-) MEFs were about twice as sensitive as cyclin G1(+/+) MEFs to gamma radiation or UV radiation. Cyclin G1(-/-) mice were more sensitive to gamma radiation than wild-type mice. Flow cytometeric analysis revealed that the number of cyclin G1(-/-) MEFs in G2/M phase after irradiation was reduced by 50% relative to cyclin G1(+/+) MEFs, Our results demonstrate that cyclin ct plays roles in G2/M arrest, damage recovery and growth promotion after cellular stress.	Osaka Univ, Res Inst Microbial Dis, Dept Mol Genet, Suita, Osaka 5650871, Japan; Osaka Univ, Genome Informat Res Ctr, Suita, Osaka 5650871, Japan; Osaka Univ, Sch Med, Dept Pathol, Suita, Osaka 5650871, Japan	Osaka University; Osaka University; Osaka University	Nojima, H (corresponding author), Osaka Univ, Res Inst Microbial Dis, Dept Mol Genet, 3-1 Yamadaoka, Suita, Osaka 5650871, Japan.		ikawa, masahito/A-5315-2009; Okabe, Masaru/B-6917-2015	ikawa, masahito/0000-0001-9859-6217; Okabe, Masaru/0000-0002-0803-9044				Amundson SA, 1998, ONCOGENE, V17, P3287, DOI 10.1038/sj.onc.1202576; Asahina H, 1999, MUTAT RES-DNA REPAIR, V435, P255, DOI 10.1016/S0921-8777(99)00051-8; Attardi LD, 1996, EMBO J, V15, P3693, DOI 10.1002/j.1460-2075.1996.tb00739.x; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Bates S, 1996, ONCOGENE, V13, P1103; Bates S, 1999, CELL MOL LIFE SCI, V55, P28, DOI 10.1007/s000180050267; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Ding HF, 1998, CRIT REV ONCOGENESIS, V9, P83, DOI 10.1615/CritRevOncog.v9.i1.60; Edwards MC, 1998, MOL CELL BIOL, V18, P4291, DOI 10.1128/MCB.18.7.4291; El-Deiry WS, 1998, CURR TOP MICROBIOL, V227, P121; FANTES P, 1993, CELL CYCLE PRACTICAL, P6; Fu TJ, 1999, J BIOL CHEM, V274, P34527, DOI 10.1074/jbc.274.49.34527; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Horne MC, 1997, J BIOL CHEM, V272, P12650, DOI 10.1074/jbc.272.19.12650; Horne MC, 1996, J BIOL CHEM, V271, P6050, DOI 10.1074/jbc.271.11.6050; Hunt T, 1991, Semin Cell Biol, V2, P213; Ikawa M, 1997, NATURE, V387, P607, DOI 10.1038/42484; Janus F, 1999, CELL MOL LIFE SCI, V55, P12, DOI 10.1007/s000180050266; Jayaraman L, 1999, CELL MOL LIFE SCI, V55, P76, DOI 10.1007/s000180050271; Kanaoka Y, 1997, FEBS LETT, V402, P73, DOI 10.1016/S0014-5793(96)01484-6; KEMP CJ, 1994, NAT GENET, V8, P66, DOI 10.1038/ng0994-66; Kimura SH, 1997, GENOMICS, V46, P483, DOI 10.1006/geno.1997.5034; Kimura SH, 1997, GENOMICS, V44, P179, DOI 10.1006/geno.1997.4873; Kong M, 2000, EMBO J, V19, P1378, DOI 10.1093/emboj/19.6.1378; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MIYASHITA T, 1995, CELL, V80, P293; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Morita N, 1996, J NEUROSCI, V16, P5961; NAKAMURA T, 1995, EXP CELL RES, V221, P534, DOI 10.1006/excr.1995.1406; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; Okamoto K, 1999, ONCOGENE, V18, P4606, DOI 10.1038/sj.onc.1202821; Okamoto K, 1996, MOL CELL BIOL, V16, P6593; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PINES J, 1991, CELL GROWTH DIFFER, V2, P305; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; Reimers L, 1999, J BIOL CHEM, V274, P11022, DOI 10.1074/jbc.274.16.11022; Robertson E, 1987, TERATOCARCINOMAS EMB; ROSSI CC, 1998, TOXICOL LETT, V102, P491; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; Sambrook J., 2002, MOL CLONING LAB MANU; Shimizu A, 1998, BIOCHEM BIOPH RES CO, V242, P529, DOI 10.1006/bbrc.1997.8004; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; SKOTZKO M, 1995, CANCER RES, V55, P5493; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Smith ML, 1997, EXP CELL RES, V230, P61, DOI 10.1006/excr.1996.3402; TAMURA K, 1993, ONCOGENE, V8, P2113; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; ZAUBERMAN A, 1995, ONCOGENE, V10, P2361	53	116	126	1	6	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 31	2001	20	25					3290	3300		10.1038/sj.onc.1204270	http://dx.doi.org/10.1038/sj.onc.1204270			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	440ET	11423978				2022-12-25	WOS:000169163500012
J	Tinhofer, I; Bernhard, D; Senfter, M; Anether, G; Loeffler, M; Kroemer, G; Kofler, R; Csordas, A; Greil, R				Tinhofer, I; Bernhard, D; Senfter, M; Anether, G; Loeffler, M; Kroemer, G; Kofler, R; Csordas, A; Greil, R			Resveratrol, a tumor-suppressive compound from grapes, induces apoptosis via a novel mitochondrial pathway controlled by Bcl-2	FASEB JOURNAL			English	Article						cell death; antioxidant; cytochrome c-independent; lymphoblastic leukemia	INDEPENDENT APOPTOSIS; CYTOCHROME-C; PERMEABILITY TRANSITION; NUCLEAR TRANSLOCATION; CYCLOSPORINE-A; RED WINE; MEMBRANE; EXPRESSION; PROTEIN; CANCER	We report that resveratrol (3,5,4'-trihydroxy-trans-stilbene), a phytoalexin found in grapes and other plant food, induced a breakdown of the mitochondrial transmembrane potential (DeltaPsi(m)) in T-acute lymphoblastic leukemia cells and swelling of isolated rat mitochondria. The breakdown of DeltaPsi(m) was accompanied by the production of reactive oxygen species (ROS), and preceded phosphatidylserine exposure and DNA fragmentation. Breakdown of DeltaPsi(m) was not caused by the activation of caspase-8 or Bid, as no significant cleavage of these proteins could be detected in the induction phase of resveratrol-induced apoptosis. Though loss of DeltaPsi(m) was not followed by cytochrome c translocation to the cytosol, the mitochondrial changes triggered significant activation of caspase-9, -2, -3, and -6. Inhibition of DeltaPsi(m) breakdown and of ROS generation by N-acetylcysteine, or by overexpression of Bcl-2 protein, prevented apoptosis induction by resveratrol. The Bcl-2 expression status of tumor cells should therefore be considered relevant for potential clinical application of resveratrol as anticancer agent.	Univ Innsbruck, Dept Internal Med, Lab Mol Cytol, A-6020 Innsbruck, Austria; Univ Innsbruck, Tyrolean Canc Res Inst, A-6020 Innsbruck, Austria; Univ Innsbruck, Inst Gen & Expt Pathol, A-6020 Innsbruck, Austria; Inst Gustave Roussy, CNRS, UMR 1599, F-94805 Villejuif, France; Univ Innsbruck, Inst Med Chem & Biochem, A-6020 Innsbruck, Austria	University of Innsbruck; University of Innsbruck; University of Innsbruck; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; University of Innsbruck	Greil, R (corresponding author), Univ Innsbruck, Dept Internal Med, Lab Mol Cytol, Anichstr 35, A-6020 Innsbruck, Austria.	Richard.Greil@uibk.ac.at	Kroemer, Guido/AAY-9859-2020; Greil, Richard F/C-7673-2017; KROEMER, Guido/B-4263-2013	Greil, Richard F/0000-0002-4462-3694; KROEMER, Guido/0000-0002-9334-4405; Bernhard, David/0000-0002-2383-6607; Tinhofer, Ingeborg/0000-0002-0512-549X				Bernhard D, 2000, CELL DEATH DIFFER, V7, P834, DOI 10.1038/sj.cdd.4400719; Bossy Wetzel E, 1998, EMBO J, V17, P37; Brenner C, 2000, ONCOGENE, V19, P329, DOI 10.1038/sj.onc.1203298; BROEKEMEIER KM, 1989, J BIOL CHEM, V264, P7826; Chun YJ, 1999, BIOCHEM BIOPH RES CO, V262, P20, DOI 10.1006/bbrc.1999.1152; Clement MV, 1998, BLOOD, V92, P996; COSTANTINI P, 1995, TOXICOLOGY, V99, P77, DOI 10.1016/0300-483X(94)02997-9; Daugas E, 2000, FASEB J, V14, P729, DOI 10.1096/fasebj.14.5.729; Della Ragione F, 1998, BIOCHEM BIOPH RES CO, V250, P53, DOI 10.1006/bbrc.1998.9263; El-Mowafy AM, 1999, FEBS LETT, V451, P63, DOI 10.1016/S0014-5793(99)00541-4; Fauconneau B, 1997, LIFE SCI, V61, P2103, DOI 10.1016/S0024-3205(97)00883-7; Fontecave M, 1998, FEBS LETT, V421, P277, DOI 10.1016/S0014-5793(97)01572-X; Fukuhara K, 1998, BIOORG MED CHEM LETT, V8, P3187, DOI 10.1016/S0960-894X(98)00585-X; Geley S, 1997, ONCOGENE, V15, P2429, DOI 10.1038/sj.onc.1201399; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Gross A, 2000, MOL CELL BIOL, V20, P3125, DOI 10.1128/MCB.20.9.3125-3136.2000; Hartmann BL, 1999, ONCOGENE, V18, P713, DOI 10.1038/sj.onc.1202339; HENNET T, 1993, CANCER RES, V53, P1456; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Hsieh TC, 1999, EXP CELL RES, V249, P109, DOI 10.1006/excr.1999.4471; Hsieh TC, 1999, CANCER RES, V59, P2596; Huang CS, 1999, CARCINOGENESIS, V20, P237, DOI 10.1093/carcin/20.2.237; Iordanov MS, 2000, CANCER RES, V60, P1983; Jang MS, 1997, SCIENCE, V275, P218, DOI 10.1126/science.275.5297.218; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; Krajewski S, 1999, P NATL ACAD SCI USA, V96, P5752, DOI 10.1073/pnas.96.10.5752; KROEMER G, 1995, FASEB J, V9, P1277, DOI 10.1096/fasebj.9.13.7557017; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Li PF, 1999, EMBO J, V18, P6027, DOI 10.1093/emboj/18.21.6027; Mgbonyebi OP, 1998, INT J ONCOL, V12, P865; Olas B, 1999, ACTA BIOCHIM POL, V46, P961, DOI 10.18388/abp.1999_4119; PACEASCIAK CR, 1995, CLIN CHIM ACTA, V235, P207, DOI 10.1016/0009-8981(95)06045-1; Petit PX, 1998, FEBS LETT, V426, P111, DOI 10.1016/S0014-5793(98)00318-4; PETIT PX, 1995, J CELL BIOL, V130, P157, DOI 10.1083/jcb.130.1.157; Reed JC, 1996, J CELL BIOCHEM, V60, P23, DOI 10.1002/(SICI)1097-4644(19960101)60:1<23::AID-JCB5>3.3.CO;2-3; Salvioli S, 1997, FEBS LETT, V411, P77, DOI 10.1016/S0014-5793(97)00669-8; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; SHARMA S, 1994, CANCER RES, V54, P5848; SHIKAMA Y, 2001, KEYST S MOL MECH AP; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Subbaramaiah K, 1998, J BIOL CHEM, V273, P21875, DOI 10.1074/jbc.273.34.21875; Surh YJ, 1999, CANCER LETT, V140, P1, DOI 10.1016/S0304-3835(99)00039-7; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; Tsan MF, 2000, BRIT J HAEMATOL, V109, P405, DOI 10.1046/j.1365-2141.2000.01980.x; Uenobe F, 1997, MUTAT RES-FUND MOL M, V373, P197, DOI 10.1016/S0027-5107(96)00191-1; WALTON MI, 1993, CANCER RES, V53, P1853; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661; Zheng JB, 1999, BIOCHEM BIOPH RES CO, V261, P499, DOI 10.1006/bbrc.1999.1063; Zini R, 1999, DRUG EXP CLIN RES, V25, P87; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	54	171	185	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY 29	2001	15	7					1613	+		10.1096/fj.00-0675fje	http://dx.doi.org/10.1096/fj.00-0675fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519CQ	11427503				2022-12-25	WOS:000173707700016
J	Jang, SJ; Chiba, I; Hirai, A; Hong, WK; Mao, L				Jang, SJ; Chiba, I; Hirai, A; Hong, WK; Mao, L			Multiple oral squamous epithelial lesions: are they genetically related?	ONCOGENE			English	Article						multiple oral lesion; microsatellite alteration; clonality	COMMON CLONAL ORIGIN; ANDROGEN-RECEPTOR GENE; CELL LUNG-CANCER; NECK-CANCER; MICROSATELLITE ALTERATIONS; FIELD CANCERIZATION; PRIMARY TUMORS; CHROMOSOME 3P; PRIMARY HEAD; CARCINOMA	The development of second primary tumors (SPTs) in patients with head and neck squamous cell carcinoma (HNSCC) has become an increasingly important factor in clinical treatment decison, Currently, clinical and histologic parameters are used to determine whether or not SPT is present. Recent studies suggest that many SPTs in the upper aerodigestive tract have a common clonal origin, challenging the longstanding multiclonal origin concept, To determine genetic relationships among multiple oral cancerous and precancerous lesions (MOCP), we analysed 100 lesions from 26 Japanese patients, Lesion development was synchronous and metachronous. We looked for patterns of microsatellite alterations (MA) using seven markers at chromosomes 3p14, 9p21, and 17p13, where MA occurs early in oral carcinogenesis. Loss of heterozygosity (LOH) was found in 52.6% (41/78), 62.5% (60/96), and 59.3% (32/54) of informative MOCP at 3p14, 9p21, and 17p13, respectively, Microsatellite instability (MI) was observed in II, 26 and 13% of the samples at 3p14, 9p21, and 17p13 markers, respectively. Patterns of MA were concordant in only nine (14%) of 63 lesions from four (18%) of 22 patients who initially presented with noninvasive lesions. However, two of four patients with invasive cancer as indexed lesion showed 16 (43%) clonally related MOCP among 37 lesions (P=0.003). The results suggest that the majority of MOCP arise from clonally independent cells affected by field cancerization. However, the probability of mucosal spread of clonal malignant or premalignant cells may increase along with malignant progression.	Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Mol Biol Lab, Houston, TX 77030 USA; Hokkaido Univ, Sch Dent, Sapporo, Hokkaido 060, Japan	University of Texas System; UTMD Anderson Cancer Center; Hokkaido University	Mao, L (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Mol Biol Lab, 1515 Holcombe Blvd, Houston, TX 77030 USA.		Mao, Li/C-7570-2011	Mao, Li/0000-0001-7263-3358	NATIONAL CANCER INSTITUTE [P01CA052051] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA52051] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLEN RC, 1992, AM J HUM GENET, V51, P1229; Bedi GC, 1996, CANCER RES, V56, P2484; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BOYLE J, 1998, CANCER RES, V58, P4477; Buller RE, 1998, AM J OBSTET GYNECOL, V178, P641, DOI 10.1016/S0002-9378(98)70473-9; Califano J, 1996, CANCER RES, V56, P2488; CHUNG KY, 1993, CANCER RES, V53, P1676; Cianfriglia F, 1999, ORAL ONCOL, V35, P157, DOI 10.1016/S1368-8375(98)00105-5; EINHORN J, 1967, CANCER, V20, P2184, DOI DOI 10.1038/NRC1477; ELNAGGAR AK, 1995, CANCER RES, V55, P2656; Field JK, 1996, ANTICANCER RES, V16, P2421; HUNG J, 1995, JAMA-J AM MED ASSOC, V273, P558, DOI 10.1001/jama.273.7.558; Jang SJ, 2000, CANCER RES, V60, P864; JONES AS, 1995, CANCER, V75, P1343, DOI 10.1002/1097-0142(19950315)75:6<1343::AID-CNCR2820750617>3.0.CO;2-T; Kim SK, 1997, CANCER RES, V57, P400; LI XH, 1994, J NATL CANCER I, V86, P1524, DOI 10.1093/jnci/86.20.1524; Lydiatt WM, 1998, CANCER, V82, P1376, DOI 10.1002/(SICI)1097-0142(19980401)82:7<1376::AID-CNCR22>3.0.CO;2-2; MAO L, 1994, P NATL ACAD SCI USA, V91, P9871, DOI 10.1073/pnas.91.21.9871; Mao L, 1998, J NATL CANCER I, V90, P1545, DOI 10.1093/jnci/90.20.1545; Mao L, 1996, NAT MED, V2, P682, DOI 10.1038/nm0696-682; NAWROZ H, 1994, CANCER RES, V54, P1152; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; Prevo LJ, 1999, CANCER RES, V59, P4784; Roz L, 1996, CANCER RES, V56, P1228; Scholes AGM, 1998, CANCER RES, V58, P2003; SCHWARTZ LH, 1994, CANCER, V74, P1933, DOI 10.1002/1097-0142(19941001)74:7<1933::AID-CNCR2820740718>3.0.CO;2-X; SIDRANSKY D, 1992, NEW ENGL J MED, V326, P737, DOI 10.1056/NEJM199203123261104; SILVERMAN S, 1984, CANCER, V53, P563; SLAUGHTER DP, 1953, CANCER, V6, P963, DOI 10.1002/1097-0142(195309)6:5<963::AID-CNCR2820060515>3.0.CO;2-Q; SOZZI G, 1995, CANCER RES, V55, P135; Tseng JE, 1999, CANCER RES, V59, P4798; VANDERRIET P, 1994, CANCER RES, V54, P1156; VOKES EE, 1993, NEW ENGL J MED, V328, P184, DOI 10.1056/NEJM199301213280306; WORSHAM MJ, 1995, HUM PATHOL, V26, P251, DOI 10.1016/0046-8177(95)90054-3	34	74	80	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 26	2001	20	18					2235	2242		10.1038/sj.onc.1204311	http://dx.doi.org/10.1038/sj.onc.1204311			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	427KZ	11402318				2022-12-25	WOS:000168404500005
J	Hotta, K; Funahashi, T; Matsukawa, Y; Takahashi, M; Nishizawa, H; Kishida, K; Matsuda, M; Kuriyama, H; Kihara, S; Nakamura, T; Tochino, Y; Bodkin, NL; Hansen, BC; Matsuzawa, Y				Hotta, K; Funahashi, T; Matsukawa, Y; Takahashi, M; Nishizawa, H; Kishida, K; Matsuda, M; Kuriyama, H; Kihara, S; Nakamura, T; Tochino, Y; Bodkin, NL; Hansen, BC; Matsuzawa, Y			Galectin-12, an adipose-expressed galectin-like molecule possessing apoptosis-inducing activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GALACTOSIDE-BINDING LECTIN; MESSENGER-RNA; INSULIN SENSITIVITY; DIABETES-MELLITUS; GENE-EXPRESSION; PROTEIN GENE; BODY-WEIGHT; T-CELLS; CLONING; FAMILY	Galectins constitute a family of proteins that bind to beta -galactoside residues and have diverse physiological functions. Here we report on the identification of a galectin-like molecule, galectin-12, in a human adipose tissue cDNA library. The protein contained two potential carbohydrate-recognition domains with the second carbohydrate-recognition domain being less conserved compared with other galectins. In vitro translated galectin-12 bound to a lactosyl-agarose column far less efficiently than galectin-8. Galectin-12 mRNA was predominantly expressed in adipose tissue of human and mouse and in differentiated 3T3-L1 adipocytes. Caloric restriction and treatment of obese animals with troglitazone increased galectin-12 mRNA levels and decreased the average size of the cells in adipose tissue. The induction of galectin-12 expression by the thiazolidinedione, troglitazone, was paralleled by an increase in the number of apoptotic cells in adipose tissue. Immunocytochemical analysis revealed that galectin-12 was localized in the nucleus of adipocytes, and transfection with galectin-12 cDNA induced apoptosis of COS-1 cells. These results suggest that galectin-12, an adipose-expressed galectin-like molecule, may participate in the apoptosis of adipocytes.	Osaka Univ, Grad Sch Med, Dept Internal Med & Mol Sci, Suita, Osaka 5650871, Japan; Univ Maryland, Sch Med, Obes & Diabet Res Ctr, Baltimore, MD 21201 USA	Osaka University; University System of Maryland; University of Maryland Baltimore	Funahashi, T (corresponding author), Osaka Univ, Grad Sch Med, Dept Internal Med & Mol Sci, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	tohru@imed2.med.osaka-u.ac.jp	Hansen, Barbara C/J-8723-2012	Hansen, Barbara C/0000-0001-9646-3525; Hotta, Kikuko/0000-0003-2427-6354	NIA NIH HHS [AG62100] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Akahani S, 1997, CANCER RES, V57, P5272; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; BARONDES SH, 1994, CELL, V76, P597, DOI 10.1016/0092-8674(94)90498-7; BARONDES SH, 1994, J BIOL CHEM, V269, P20807; Bernerd F, 1999, P NATL ACAD SCI USA, V96, P11329, DOI 10.1073/pnas.96.20.11329; BODKIN NL, 1989, AM J PHYSIOL, V256, pE676, DOI 10.1152/ajpendo.1989.256.5.E676; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CHERAYIL BJ, 1990, P NATL ACAD SCI USA, V87, P7324, DOI 10.1073/pnas.87.18.7324; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; Chung CD, 2000, J IMMUNOL, V165, P3722, DOI 10.4049/jimmunol.165.7.3722; Clarke SL, 1997, BIOCHEM BIOPH RES CO, V240, P99, DOI 10.1006/bbrc.1997.7627; Colnot C, 1998, IMMUNOLOGY, V94, P290, DOI 10.1046/j.1365-2567.1998.00517.x; Dunphy JL, 2000, J BIOL CHEM, V275, P32106, DOI 10.1074/jbc.M003739200; Dyer KD, 1997, GENOMICS, V40, P217, DOI 10.1006/geno.1996.4590; Gavin JR, 1997, DIABETES CARE, V20, P1183; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Gitt MA, 1998, J BIOL CHEM, V273, P2961, DOI 10.1074/jbc.273.5.2961; GITT MA, 1986, P NATL ACAD SCI USA, V83, P7603, DOI 10.1073/pnas.83.20.7603; GITT MA, 1992, J BIOL CHEM, V267, P10601; GITT MA, 1995, J BIOL CHEM, V270, P5032, DOI 10.1074/jbc.270.10.5032; Hadari YR, 2000, J CELL SCI, V113, P2385; HADARI YR, 1995, J BIOL CHEM, V270, P3447, DOI 10.1074/jbc.270.7.3447; HANSEN BC, 1990, AM J PHYSIOL, V259, pR612, DOI 10.1152/ajpregu.1990.259.3.R612; HANSEN BC, 1993, DIABETES, V42, P1809, DOI 10.2337/diabetes.42.12.1809; HANSEN BC, 1986, DIABETOLOGIA, V29, P713, DOI 10.1007/BF00870281; HANSEN BC, 1995, OBES RES, V3, pS199, DOI 10.1002/j.1550-8528.1995.tb00464.x; Hansen BC, 1999, TOXICOL SCI, V52, P56, DOI 10.1093/toxsci/52.suppl_1.56; HE YF, 1995, J BIOL CHEM, V270, P28887, DOI 10.1074/jbc.270.48.28887; HERRERA R, 1989, MOL CELL BIOL, V9, P5331, DOI 10.1128/MCB.9.12.5331; Hotta K, 1996, J BIOL CHEM, V271, P25327, DOI 10.1074/jbc.271.41.25327; Huflejt ME, 1997, J BIOL CHEM, V272, P14294, DOI 10.1074/jbc.272.22.14294; JOHNSON PF, 1993, MOL CELL BIOL, V13, P6919, DOI 10.1128/MCB.13.11.6919; Kishida K, 2000, J BIOL CHEM, V275, P20896, DOI 10.1074/jbc.M001119200; Kuriyama H, 1997, BIOCHEM BIOPH RES CO, V241, P53, DOI 10.1006/bbrc.1997.7769; MADSEN P, 1995, J BIOL CHEM, V270, P5823, DOI 10.1074/jbc.270.11.5823; Maeda K, 1997, GENE, V190, P227, DOI 10.1016/S0378-1119(96)00730-5; Maeda K, 1996, BIOCHEM BIOPH RES CO, V221, P286, DOI 10.1006/bbrc.1996.0587; Magun R, 1998, DIABETES, V47, P1948, DOI 10.2337/diabetes.47.12.1948; Menon RP, 1999, EUR J BIOCHEM, V264, P569, DOI 10.1046/j.1432-1327.1999.00671.x; Miner JL, 2001, OBES RES, V9, P129, DOI 10.1038/oby.2001.16; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; OKUBO K, 1992, NAT GENET, V2, P173, DOI 10.1038/ng1192-173; Okuno A, 1998, J CLIN INVEST, V101, P1354, DOI 10.1172/JCI1235; Pace KE, 1999, J IMMUNOL, V163, P3801; Pace KE, 2000, J IMMUNOL, V165, P2331, DOI 10.4049/jimmunol.165.5.2331; PERILLO NL, 1995, NATURE, V378, P736, DOI 10.1038/378736a0; Qian H, 1998, ENDOCRINOLOGY, V139, P791, DOI 10.1210/en.139.2.791; Rabinovich GA, 2000, CELL DEATH DIFFER, V7, P747, DOI 10.1038/sj.cdd.4400708; RUBIN CS, 1978, J BIOL CHEM, V253, P7570; SABATH DE, 1990, GENE, V91, P185, DOI 10.1016/0378-1119(90)90087-8; Seetharaman J, 1998, J BIOL CHEM, V273, P13047, DOI 10.1074/jbc.273.21.13047; Sorisky A, 2000, INT J OBESITY, V24, pS3, DOI 10.1038/sj.ijo.0801491; Su ZZ, 1996, P NATL ACAD SCI USA, V93, P7252, DOI 10.1073/pnas.93.14.7252; THIESEN HJ, 1990, NUCLEIC ACIDS RES, V18, P3203, DOI 10.1093/nar/18.11.3203; Tureci O, 1997, J BIOL CHEM, V272, P6416, DOI 10.1074/jbc.272.10.6416; Wada J, 1997, J CLIN INVEST, V99, P2452, DOI 10.1172/JCI119429; Wada J, 1997, J BIOL CHEM, V272, P6078, DOI 10.1074/jbc.272.9.6078; WADE R, 1990, DEV BIOL, V142, P270, DOI 10.1016/0012-1606(90)90348-M; Yang RY, 1996, P NATL ACAD SCI USA, V93, P6737, DOI 10.1073/pnas.93.13.6737; Yang RY, 2001, J BIOL CHEM, V276, P20252, DOI 10.1074/jbc.M010914200	60	89	96	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					34089	34097		10.1074/jbc.M105097200	http://dx.doi.org/10.1074/jbc.M105097200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11435439	hybrid			2022-12-25	WOS:000170910200107
J	Kretsovali, A; Spilianakis, C; Dimakopoulos, A; Makatounakis, T; Papamatheakis, J				Kretsovali, A; Spilianakis, C; Dimakopoulos, A; Makatounakis, T; Papamatheakis, J			Self-association of class II transactivator correlates with its intracellular localization and transactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BARE LYMPHOCYTE SYNDROME; CREB BINDING-PROTEIN; NF-KAPPA-B; NUCLEAR-LOCALIZATION; CIITA INTERACTS; GTP-BINDING; EXPRESSION; TRANSCRIPTION; COACTIVATOR; ACTIVATION	Class II transactivator (CIITA) is the master regulator of major histocompatibility complex class II genes that regulates both B lymphocyte-specific and interferon gamma -inducible expression. Here we identify protein regions and examine mechanisms that determine the intracellular distribution of CIITA. We show that two separate regions of CIITA mediate nuclear export: amino acids 1-114 and 408-550. Both regions interact with the export receptor CRM-1. The CIITA region spanning amino acids 408-550 of CIITA also determines its ability for homotypic self-association as well as heterotypic interactions with other regions residing at the amino and carboxyl termini of the protein. These observations are in line with data demonstrating that co-expression of amino- and carboxyl-terminal parts of CIITA promote subcellular relocalization and, remarkably, rescue transcriptional activation by individually inert molecules. CIITA point mutations that impair nuclear import and abolish its activation function show reduced self-association. We propose that the concerted action of homo- and heterotypic interactions of CIITA determine proper protein configuration that in turn controls its nucleocytoplasmic trafficking.	Fdn Res & Technol Hellas, Inst Mol Biol & Biotechnol, Iraklion 71110, Crete, Greece; Univ Crete, Dept Biol, Iraklion 71110, Crete, Greece	Foundation for Research & Technology - Hellas (FORTH); University of Crete	Kretsovali, A (corresponding author), Fdn Res & Technol Hellas, Inst Mol Biol & Biotechnol, POB 1527, Iraklion 71110, Crete, Greece.	kretsova@imbb.forth.gr; papamath@imbb.forth.gr	Spilianakis, Charalampos G/C-9893-2011	Spilianakis, Charalampos G/0000-0003-0921-1923				BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; Bontron S, 1997, MOL CELL BIOL, V17, P4249, DOI 10.1128/MCB.17.8.4249; Brown JA, 1998, NUCLEIC ACIDS RES, V26, P4128, DOI 10.1093/nar/26.18.4128; CHANG CH, 1994, J EXP MED, V180, P1367, DOI 10.1084/jem.180.4.1367; Cressman DE, 1999, IMMUNITY, V10, P163, DOI 10.1016/S1074-7613(00)80017-5; CRESSWELL P, 1994, CURR BIOL, V4, P541, DOI 10.1016/S0960-9822(00)00119-6; Fontes JD, 1997, NUCLEIC ACIDS RES, V25, P2522, DOI 10.1093/nar/25.12.2522; Fontes JD, 1999, MOL CELL BIOL, V19, P941; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Gourley TS, 2001, J IMMUNOL, V166, P2917, DOI 10.4049/jimmunol.166.5.2917; Hake SB, 2000, MOL CELL BIOL, V20, P7716, DOI 10.1128/MCB.20.20.7716-7725.2000; Harton JA, 1999, SCIENCE, V285, P1402, DOI 10.1126/science.285.5432.1402; Inohara N, 2000, J BIOL CHEM, V275, P27823; Inohara N, 1999, J BIOL CHEM, V274, P14560, DOI 10.1074/jbc.274.21.14560; Kim HJ, 1999, MOL CELL BIOL, V19, P6323; Kretsovali A, 1998, MOL CELL BIOL, V18, P6777, DOI 10.1128/MCB.18.11.6777; Kumar KP, 2000, MOL CELL BIOL, V20, P4159, DOI 10.1128/MCB.20.11.4159-4168.2000; Lin RT, 1999, MOL CELL BIOL, V19, P2465; Linhoff MW, 2001, MOL CELL BIOL, V21, P3001, DOI 10.1128/MCB.21.9.3001-3011.2001; MACHOVEC GS, 1996, ONLINE LIB MICROCOMP, V14, P1; Mahanta SK, 1997, P NATL ACAD SCI USA, V94, P6324, DOI 10.1073/pnas.94.12.6324; Masternak K, 2000, GENE DEV, V14, P1156; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Quan V, 1999, IMMUNOGENETICS, V49, P957, DOI 10.1007/s002510050579; Reith W, 2001, ANNU REV IMMUNOL, V19, P331, DOI 10.1146/annurev.immunol.19.1.331; Scholl T, 1997, P NATL ACAD SCI USA, V94, P6330, DOI 10.1073/pnas.94.12.6330; Sisk TJ, 2001, MOL CELL BIOL, V21, P4919, DOI 10.1128/MCB.21.15.4919-4928.2001; Sisk TJ, 2000, J IMMUNOL, V165, P2511, DOI 10.4049/jimmunol.165.5.2511; Soutoglou E, 2000, MOL CELL, V5, P745, DOI 10.1016/S1097-2765(00)80253-1; Spilianakis C, 2000, MOL CELL BIOL, V20, P8489, DOI 10.1128/MCB.20.22.8489-8498.2000; STEIMLE V, 1993, CELL, V75, P135, DOI 10.1016/0092-8674(93)90685-J; STEIMLE V, 1994, SCIENCE, V265, P106, DOI 10.1126/science.8016643; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Yun S, 1997, INT IMMUNOL, V9, P1545, DOI 10.1093/intimm/9.10.1545; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x; Zhou H, 1997, J IMMUNOL, V158, P4741; Zhu JY, 1999, NATURE, V398, P256, DOI 10.1038/18473; Zhu XS, 2000, MOL CELL BIOL, V20, P6051, DOI 10.1128/MCB.20.16.6051-6061.2000	39	36	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					32191	32197		10.1074/jbc.M103164200	http://dx.doi.org/10.1074/jbc.M103164200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11413136	hybrid			2022-12-25	WOS:000170613500098
J	Wulff, H; Gutman, GA; Cahalan, MD; Chandy, KG				Wulff, H; Gutman, GA; Cahalan, MD; Chandy, KG			Delineation of the clotrimazole/TRAM-34 binding site on the intermediate conductance calcium-activated potassium channel, IKCa1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+-ACTIVATED K+ CHANNELS; HUMAN T-LYMPHOCYTES; CHLORIDE SECRETION; EPITHELIAL-CELLS; CA CHANNEL; GENE; PROLIFERATION; INHIBITION; EFFICACY; ROLES	Selective and potent triarylmethane blockers of the intermediate conductance calcium-activated potassium channel, IKCa1, have therapeutic use in sickle cell disease and secretory diarrhea and as immunosuppressants. Clotrimazole, a membrane-permeant triarylmethane, blocked IKCa1 with equal affinity when applied externally or internally, whereas a membrane-impermeant derivative TRAM-30 blocked the channel only when applied to the cytoplasmic side, indicating an internal drug-binding site. Introduction of the S5-P-S6 region of the triarylmethane-insensitive small conductance calcium-activated potassium channel SKCa3 into IKCa1 rendered the channel resistant to triarylmethanes. Replacement of Thr(250) or Val(275) in IKCa1 with the cot-responding SKCa3 residues selectively abolished triarylmethane sensitivity without affecting the affinity of the channel for tetraethylammonium, charybdotoxin, and nifedipine. Introduction of these two residues into SKCa3 rendered the channel sensitive to triarylmethanes. In a molecular model of IKCa1, Thr(250) and Val(275) line a water-filled cavity just below the selectivity filter. Structure-activity studies suggest that the side chain methyl groups of Thr(250) and Val(275) may lock the triarylmethanes in place via hydrophobic interactions with the pi -electron clouds of the phenyl rings. The heterocyclic moiety may project into the selectivity filter and obstruct the ion-conducting pathway from the inside.	Univ Calif Irvine, Sch Med, Dept Physiol & Biophys, Irvine, CA 92697 USA; Univ Calif Irvine, Sch Med, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA	University of California System; University of California Irvine; University of California System; University of California Irvine	Chandy, KG (corresponding author), Univ Calif Irvine, Sch Med, Dept Physiol & Biophys, Room 291,Joan Irvine Smith Hall, Irvine, CA 92697 USA.		wulff, Heike/Z-2056-2019		NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH059222] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS014609, R01NS014609] Funding Source: NIH RePORTER; NIMH NIH HHS [MH59222] Funding Source: Medline; NINDS NIH HHS [NS14609] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Brugnara C, 1997, Curr Opin Hematol, V4, P122; Brugnara C, 1996, J CLIN INVEST, V97, P1227, DOI 10.1172/JCI118537; Chandy KG, 1998, MOL PSYCHIATR, V3, P32, DOI 10.1038/sj.mp.4000353; COGHLAN MJ, 2001, J MED CHEM, V44, P1; Devor DC, 1999, J GEN PHYSIOL, V113, P743, DOI 10.1085/jgp.113.5.743; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Dunn PM, 1998, J MEMBRANE BIOL, V165, P133, DOI 10.1007/s002329900427; Fanger CM, 1999, J BIOL CHEM, V274, P5746, DOI 10.1074/jbc.274.9.5746; Fanger CM, 2001, J BIOL CHEM, V276, P12249, DOI 10.1074/jbc.M011342200; Ghanshani S, 1998, GENOMICS, V51, P160, DOI 10.1006/geno.1998.5333; Ghanshani S, 2000, J BIOL CHEM, V275, P37137, DOI 10.1074/jbc.M003941200; Ishii TM, 1997, P NATL ACAD SCI USA, V94, P11651, DOI 10.1073/pnas.94.21.11651; Jensen BS, 1999, P NATL ACAD SCI USA, V96, P10917, DOI 10.1073/pnas.96.19.10917; Khanna R, 1999, J BIOL CHEM, V274, P14838, DOI 10.1074/jbc.274.21.14838; Logsdon NJ, 1997, J BIOL CHEM, V272, P32723, DOI 10.1074/jbc.272.52.32723; Rauer H, 2000, J BIOL CHEM, V275, P1201, DOI 10.1074/jbc.275.2.1201; Rufo PA, 1996, J CLIN INVEST, V98, P2066, DOI 10.1172/JCI119012; Rufo PA, 1997, J CLIN INVEST, V100, P3111, DOI 10.1172/JCI119866; Sato C, 2001, NATURE, V409, P1047, DOI 10.1038/35059098; SAWYER PR, 1975, DRUGS, V9, P424, DOI 10.2165/00003495-197509060-00003; Vandorpe DH, 1998, J BIOL CHEM, V273, P21542, DOI 10.1074/jbc.273.34.21542; Wulff H, 2000, P NATL ACAD SCI USA, V97, P8151, DOI 10.1073/pnas.97.14.8151	22	111	123	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					32040	32045		10.1074/jbc.M105231200	http://dx.doi.org/10.1074/jbc.M105231200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11425865	hybrid			2022-12-25	WOS:000170613500078
J	Yuan, PX; Huang, LD; Jiang, YM; Gutkind, JS; Manji, HK; Chen, G				Yuan, PX; Huang, LD; Jiang, YM; Gutkind, JS; Manji, HK; Chen, G			The mood stabilizer valproic acid activates mitogen-activated protein kinases and promotes neurite growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBGENUAL PREFRONTAL CORTEX; HUMAN NEUROBLASTOMA-CELLS; DNA-BINDING ACTIVITY; OUTGROWTH IN-VITRO; C-JUN; TRANSCRIPTION FACTOR; TYROSINE-HYDROXYLASE; GENE-EXPRESSION; MAP KINASE; PC12 CELLS	The mood-stabilizing agents lithium and valproic acid (VPA) increase DNA binding activity and transactivation activity of AP-1 transcription factors, as wen as the expression of genes regulated by AP-1, in cultured cells and brain regions involved in mood regulation. In the present study, we found that VPA activated extracellular signal-regulated kinase (ERK), a kinase known to regulate AP-1 function and utilized by neurotrophins to mediate their diverse effects, including neuronal differentiation, neuronal survival, long term neuroplasticity, and potentially learning and memory. VPA-induced activation of ERK was blocked by the mitogen-activated protein kinase/ERK kinase inhibitor PD098059 and dominant-negative Ras and Raf mutants but not by dominant-negative stress-activated protein kinase/ERK kinase and mitogen-activated protein kinase kinase 6 mutants. VPA also increased the expression of genes regulated by the ERK pathway, including growth cone-associated protein 43 and Bcl-2, promoted neurite growth and cell survival, and enhanced norepinephrine uptake and release. These data demonstrate that VPA is an ERK pathway activator and produces neurotrophic effects.	NIMH, Unit Mol Neurotherapeut, Mol Pathophysiol Lab, NIH, Bethesda, MD 20892 USA; Wayne State Univ, Sch Med, Mol Pathophysiol Lab, Dept Psychiat & Behav Neurosci, Detroit, MI 48201 USA; NIDCR, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); Wayne State University; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Chen, G (corresponding author), NIMH, Unit Mol Neurotherapeut, Mol Pathophysiol Lab, NIH, Bldg 49,Rm B1EE16,49 Convert Dr, MSC 4405, Bethesda, MD 20892 USA.		Gutkind, J. Silvio/A-1053-2009; Chen, Guang/A-2570-2017; Gutkind, J. Silvio/J-1201-2016	Gutkind, J. Silvio/0000-0002-5150-4482	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000551] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000551] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH057743] Funding Source: NIH RePORTER; NIMH NIH HHS [MH57743] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Asghari V, 1998, MOL BRAIN RES, V58, P95, DOI 10.1016/S0169-328X(98)00107-7; Bassa BV, 1999, AM J PHYSIOL-RENAL, V277, pF328, DOI 10.1152/ajprenal.1999.277.3.F328; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOWDEN CL, 1994, JAMA-J AM MED ASSOC, V271, P918, DOI 10.1001/jama.271.12.918; Chen DF, 1997, NATURE, V385, P434, DOI 10.1038/385434a0; Chen G, 1998, J NEUROCHEM, V70, P1768; Chen G, 2000, J NEUROCHEM, V75, P1729, DOI 10.1046/j.1471-4159.2000.0751729.x; Chen G, 1999, J NEUROCHEM, V72, P879, DOI 10.1046/j.1471-4159.1999.720879.x; CHEN G, 1994, J NEUROCHEM, V63, P2361; Chen G, 1997, NEUROPSYCHOPHARMACOL, V16, P238; Chen G, 1999, MOL BRAIN RES, V64, P52, DOI 10.1016/S0169-328X(98)00303-9; Cieslik K, 2001, J BIOL CHEM, V276, P1211, DOI 10.1074/jbc.M005305200; Drevets WC, 1997, NATURE, V386, P824, DOI 10.1038/386824a0; Encinas M, 1999, J NEUROCHEM, V73, P1409, DOI 10.1046/j.1471-4159.1999.0731409.x; Finkbeiner S, 2000, NEURON, V25, P11, DOI 10.1016/S0896-6273(00)80866-1; Fryer RH, 1997, EXP NEUROL, V148, P616, DOI 10.1006/exnr.1997.6699; FUKUDA M, 1995, ONCOGENE, V11, P239; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; HANADA M, 1993, CANCER RES, V53, P4978; Ji L, 1996, J BIOL CHEM, V271, P22687, DOI 10.1074/jbc.271.37.22687; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Katoh S, 1996, BIOCHEM BIOPH RES CO, V229, P653, DOI 10.1006/bbrc.1996.1859; Kim B, 1997, J BIOL CHEM, V272, P21268, DOI 10.1074/jbc.272.34.21268; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Leppa S, 1998, EMBO J, V17, P4404, DOI 10.1093/emboj/17.15.4404; Liu YZ, 1999, NUCLEIC ACIDS RES, V27, P2086, DOI 10.1093/nar/27.10.2086; Marinissen MJ, 1999, MOL CELL BIOL, V19, P4289; MCELROY SL, 1995, TXB PSYCHOPHARMACOLO, P351; Merry DE, 1997, ANNU REV NEUROSCI, V20, P245, DOI 10.1146/annurev.neuro.20.1.245; Moore GJ, 2000, LANCET, V356, P1241, DOI 10.1016/S0140-6736(00)02793-8; Moore GJ, 2000, BIOL PSYCHIAT, V48, P1, DOI 10.1016/S0006-3223(00)00252-3; MURPHY NP, 1991, J NEUROCHEM, V56, P1810, DOI 10.1111/j.1471-4159.1991.tb02085.x; NILSSON M, 1990, NEUROCHEM RES, V15, P763, DOI 10.1007/BF00968551; Ongur D, 1998, P NATL ACAD SCI USA, V95, P13290, DOI 10.1073/pnas.95.22.13290; Ozaki N, 1997, J NEUROCHEM, V69, P2336; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; POST RM, 2000, COMPREHENSIVE TXB PS, V1, P1385; Pugazhenthi S, 1999, J BIOL CHEM, V274, P27529, DOI 10.1074/jbc.274.39.27529; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; PULVERER BJ, 1993, ONCOGENE, V8, P407; Rajkowska G, 2000, BIOL PSYCHIAT, V48, P766, DOI 10.1016/S0006-3223(00)00950-1; Rajkowska G, 1999, BIOL PSYCHIAT, V45, P1085, DOI 10.1016/S0006-3223(99)00041-4; RECIOPINTO E, 1984, BRAIN RES, V302, P323, DOI 10.1016/0006-8993(84)90246-4; Riccio A, 1999, SCIENCE, V286, P2358, DOI 10.1126/science.286.5448.2358; Sands SA, 2000, NEUROPSYCHOPHARMACOL, V22, P27, DOI 10.1016/S0893-133X(99)00072-X; SATO N, 1994, J NEUROBIOL, V25, P1227, DOI 10.1002/neu.480251005; Siafaka-Kapadai A, 1998, BIOCHEM PHARMACOL, V56, P207, DOI 10.1016/S0006-2952(98)00148-8; SKENE JHP, 1989, ANNU REV NEUROSCI, V12, P127, DOI 10.1146/annurev.ne.12.030189.001015; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; Wilson BE, 1996, MOL CELL BIOL, V16, P5546; Wlodarczyk BC, 1996, TERATOLOGY, V54, P284, DOI 10.1002/(SICI)1096-9926(199612)54:6<284::AID-TERA3>3.3.CO;2-J; XU I, 1997, STRATEGIES, V10, P1; Yuan PX, 1999, J NEUROCHEM, V73, P2299, DOI 10.1046/j.1471-4159.1999.0732299.x; Yuan PX, 1998, MOL BRAIN RES, V58, P225, DOI 10.1016/S0169-328X(98)00114-4; Zhang KZ, 1996, P NATL ACAD SCI USA, V93, P4504, DOI 10.1073/pnas.93.9.4504; Zigova T, 1999, EXP NEUROL, V157, P251, DOI 10.1006/exnr.1999.7054	57	279	291	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					31674	31683		10.1074/jbc.M104309200	http://dx.doi.org/10.1074/jbc.M104309200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11418608	hybrid			2022-12-25	WOS:000170613500029
J	Chang, C; Gonzalez, F; Rothermel, B; Sun, LP; Johnston, SA; Kodadek, T				Chang, C; Gonzalez, F; Rothermel, B; Sun, LP; Johnston, SA; Kodadek, T			The Gal4 activation domain binds Sug2 protein, a proteasome component, in vivo and in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; UBIQUITIN-MEDIATED PROTEOLYSIS; SACCHAROMYCES-CEREVISIAE; REGULATORY PARTICLE; CROSS-LINKING; IN-VIVO; TRANSCRIPTIONAL ACTIVATION; ESCHERICHIA-COLI; 2-HYBRID SYSTEM; YEAST	An in vivo protein interaction assay was used to search a yeast cDNA library for proteins that bind to the acidic activation domain (AD) of the yeast Ga14 protein. Sug2 protein, a component of the 19 S regulatory particle of the 26 S proteasome, was one of seven proteins identified in this screen. In vitro binding assays confirm a direct interaction between these proteins. SUG2 and SUG1, another 19 S component, were originally discovered as a mutation able to suppress the phenotype of a Gal4 truncation mutant (Gal4(D)p) lacking much of its AD. Sug1p has previously been shown to bind the Gal4 AD in vitro. Taken together, these genetic and biochemical data suggest a biologically significant interaction between the Gal4 protein and the 19 S regulatory particle of the proteasome. Indeed, it is demonstrated here that the Gal4 AD interacts specifically with immunopurified 19 S complex. The proteasome regulatory particle has been shown recently to play a direct role in RNA polymerase II transcription and the activator-19 S interaction could be important in recruiting this large complex to transcriptionally active GAL genes.	Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA; Stratagene Inc, La Jolla, CA 92037 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Chang, C (corresponding author), Univ Texas, SW Med Ctr, Dept Internal Med, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.			Kodadek, Thomas/0000-0003-1930-4795				Aronheim A, 1997, MOL CELL BIOL, V17, P3094, DOI 10.1128/MCB.17.6.3094; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Blau J, 1996, MOL CELL BIOL, V16, P2044; Braun BC, 1999, NAT CELL BIOL, V1, P221, DOI 10.1038/12043; CAREY M, 1989, J MOL BIOL, V209, P423, DOI 10.1016/0022-2836(89)90007-7; CHASMAN DI, 1990, MOL CELL BIOL, V10, P2916, DOI 10.1128/MCB.10.6.2916; CHUPING M, 1994, J BIOL CHEM, V369, P3539; COHEN S, 1981, NATURE, V294, P182, DOI 10.1038/294182a0; CONFALONIERI F, 1995, BIOESSAYS, V17, P639, DOI 10.1002/bies.950170710; ESTOJAK J, 1995, MOL CELL BIOL, V15, P5820; Fancy DA, 1998, BIOCHEM BIOPH RES CO, V247, P420, DOI 10.1006/bbrc.1998.8558; Fancy DA, 1999, P NATL ACAD SCI USA, V96, P6020, DOI 10.1073/pnas.96.11.6020; Fancy DA, 1996, CHEM BIOL, V3, P551, DOI 10.1016/S1074-5521(96)90146-5; FASSLER JS, 1989, MOL CELL BIOL, V9, P5602, DOI 10.1128/MCB.9.12.5602; Ferdous A, 2001, MOL CELL, V7, P981, DOI 10.1016/S1097-2765(01)00250-7; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FISCHER JA, 1988, NATURE, V332, P853, DOI 10.1038/332853a0; FRANKEL A, 1989, MOL CELL BIOL, V9, P415, DOI 10.1128/MCB.9.2.415; GIMBLE FS, 1989, J MOL BIOL, V206, P29, DOI 10.1016/0022-2836(89)90521-4; Glickman MH, 1998, MOL CELL BIOL, V18, P3149, DOI 10.1128/MCB.18.6.3149; Glickman MH, 1999, MOL BIOL REP, V26, P21, DOI 10.1023/A:1006928316738; Hays LB, 2000, BIOTECHNIQUES, V29, P288, DOI 10.2144/00292st04; Hendil KB, 1998, BIOCHEM J, V332, P749, DOI 10.1042/bj3320749; Horwich AL, 1999, P NATL ACAD SCI USA, V96, P11033, DOI 10.1073/pnas.96.20.11033; Huang WD, 2001, BIOTECHNIQUES, V30, P94, DOI 10.2144/01301st06; JOHNSTON SA, 1982, P NATL ACAD SCI-BIOL, V79, P6971, DOI 10.1073/pnas.79.22.6971; JOHNSTON SA, 1987, CELL, V50, P143, DOI 10.1016/0092-8674(87)90671-4; KIRCHHAUSEN T, 1990, MOL CELL BIOL, V10, P6089, DOI 10.1128/MCB.10.11.6089; KODADEK T, 1990, BIOCHEM BIOPH RES CO, V172, P804, DOI 10.1016/0006-291X(90)90746-A; Koh SS, 1998, MOL CELL, V1, P895, DOI 10.1016/S1097-2765(00)80088-X; Kuras L, 1999, NATURE, V399, P609, DOI 10.1038/21239; Laser H, 2000, P NATL ACAD SCI USA, V97, P13732, DOI 10.1073/pnas.250400997; Lee YC, 1999, MOL CELL BIOL, V19, P2967; LEUTHER KK, 1992, SCIENCE, V256, P1333, DOI 10.1126/science.1598579; Li XY, 1999, NATURE, V399, P605, DOI 10.1038/21232; LOHR D, 1995, FASEB J, V9, P777, DOI 10.1096/fasebj.9.9.7601342; LONG RM, 1991, MOL CELL BIOL, V11, P2311, DOI 10.1128/MCB.11.4.2311; MA J, 1987, CELL, V50, P137, DOI 10.1016/0092-8674(87)90670-2; Marsolier MC, 1997, J MOL BIOL, V268, P243, DOI 10.1006/jmbi.1997.0979; MCNABB DS, 1995, GENE DEV, V9, P47, DOI 10.1101/gad.9.1.47; Melcher K, 2000, J MOL BIOL, V301, P1097, DOI 10.1006/jmbi.2000.4034; MELCHER K, 1995, MOL CELL BIOL, V15, P2839; Michel B, 1998, MOL CELL, V2, P663, DOI 10.1016/S1097-2765(00)80164-1; Molinari E, 1999, EMBO J, V18, P6439, DOI 10.1093/emboj/18.22.6439; Moqtaderi Z, 1996, NATURE, V383, P188, DOI 10.1038/383188a0; Orphanides G, 1999, NATURE, V400, P284, DOI 10.1038/22350; PARTHUN MR, 1992, MOL CELL BIOL, V12, P4981, DOI 10.1128/MCB.12.11.4981; Platt A, 1998, EMBO J, V17, P4086, DOI 10.1093/emboj/17.14.4086; POON D, 1993, J BIOL CHEM, V268, P15325; Rubin DM, 1996, NATURE, V379, P655, DOI 10.1038/379655a0; Russell SJ, 1999, J BIOL CHEM, V274, P21943, DOI 10.1074/jbc.274.31.21943; Russell SJ, 1996, J BIOL CHEM, V271, P32810, DOI 10.1074/jbc.271.51.32810; Russell SJ, 2001, J BIOL CHEM, V276, P9825, DOI 10.1074/jbc.M010889200; SAKURAI H, 1993, P NATL ACAD SCI USA, V90, P8382, DOI 10.1073/pnas.90.18.8382; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Salghetti SE, 2000, P NATL ACAD SCI USA, V97, P3118, DOI 10.1073/pnas.050007597; Sil AK, 1999, MOL CELL BIOL, V19, P7828; Sterner DE, 1999, MOL CELL BIOL, V19, P86; SWAFFIELD JC, 1995, NATURE, V374, P88, DOI 10.1038/374088a0; SWAFFIELD JC, 1992, NATURE, V357, P698, DOI 10.1038/357698a0; Verma R, 2000, MOL BIOL CELL, V11, P3425, DOI 10.1091/mbc.11.10.3425; Walker SS, 1996, NATURE, V383, P185, DOI 10.1038/383185a0; WEBSTER N, 1988, CELL, V52, P169, DOI 10.1016/0092-8674(88)90505-3; Wu YB, 1996, EMBO J, V15, P3951, DOI 10.1002/j.1460-2075.1996.tb00769.x; YANKULOV K, 1994, CELL, V77, P749, DOI 10.1016/0092-8674(94)90058-2	65	40	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					30956	30963		10.1074/jbc.M102254200	http://dx.doi.org/10.1074/jbc.M102254200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11418596	hybrid			2022-12-25	WOS:000170472900050
J	Liang, XQ; Nazarian, A; Erdjument-Bromage, H; Bornmann, W; Tempst, P; Resh, MD				Liang, XQ; Nazarian, A; Erdjument-Bromage, H; Bornmann, W; Tempst, P; Resh, MD			Heterogeneous fatty acylation of Src family kinases with polyunsaturated fatty acids regulates raft localization and signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GPI-ANCHORED PROTEINS; T-CELL-RECEPTOR; ALPHA-SUBUNITS; PALMITOYLATION; P59(FYN); MYRISTOYLATION; ARACHIDONATE; TERMINUS; LAT	Fatty acylation of Src family kinases is essential for localization of the modified proteins to the plasma membrane and to plasma membrane rafts. It has been suggested that the presence of saturated fatty acyl chains on proteins is conducive for their insertion into liquid ordered lipid domains present in rafts. The ability of unsaturated dietary fatty acids to be attached to Src family kinases has not been investigated. Here we demonstrate that heterogeneous fatty acylation of Src family kinases occurs and that the nature of the attached fatty acid influences raft-mediated signal transduction. By using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry, we show that in addition to 14:0 (myristate), 14:1 and 14:2 fatty acids can be attached to the N-terminal glycine of the Src family kinase Fyn when the growth media are supplemented with these dietary fatty acids. Moreover, we synthesized novel iodinated analogs of oleate and stearate, and we showed that heterogeneous S-acylation can occur on cysteine residues within Fyn as well as G alpha, GAP43, and Ras. Modification of Fyn with unsaturated or polyunsaturated fatty acids reduced its raft localization and resulted in decreased T cell signal transduction. These studies establish that heterogeneous fatty acylation is a widespread occurrence that serves to regulate signal transduction by membrane-bound proteins.	Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Organ Synth Core Lab, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Resh, MD (corresponding author), Sloan Kettering Inst Canc Res, Cell Biol Program, 1275 York Ave,Box 143, New York, NY 10021 USA.	m-resh@ski.mskcc.org		Erdjument-Bromage, Hediye/0000-0003-0224-3594; Tempst, Paul/0000-0002-6680-3987; Resh, Marilyn/0000-0001-6118-9466	NATIONAL CANCER INSTITUTE [P01CA029502, P30CA029502] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057966] Funding Source: NIH RePORTER; NCI NIH HHS [CA29502] Funding Source: Medline; NIGMS NIH HHS [GM57966] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLAND L, 1994, J BIOL CHEM, V269, P16701; BERTHIAUME L, 1995, J BIOL CHEM, V270, P22399, DOI 10.1074/jbc.270.38.22399; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Brown DA, 1998, J MEMBRANE BIOL, V164, P103, DOI 10.1007/s002329900397; DeMar JC, 1997, J BIOL CHEM, V272, P31362, DOI 10.1074/jbc.272.50.31362; DIZHOOR AM, 1992, J BIOL CHEM, V267, P16033; Dunphy JT, 1996, J BIOL CHEM, V271, P7154, DOI 10.1074/jbc.271.12.7154; Erdjument-Bromage H, 1998, J CHROMATOGR A, V826, P167, DOI 10.1016/S0021-9673(98)00705-5; FUJIMOTO T, 1993, J BIOL CHEM, V268, P11394; HALLAK H, 1994, J BIOL CHEM, V269, P4713; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; JOHNSON DR, 1994, ANNU REV BIOCHEM, V63, P869, DOI 10.1146/annurev.bi.63.070194.004253; KOKAME K, 1992, NATURE, V359, P749, DOI 10.1038/359749a0; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; LIU YC, 1993, BIOCHEMISTRY-US, V32, P10714, DOI 10.1021/bi00091a023; Manes S, 1999, EMBO J, V18, P6211, DOI 10.1093/emboj/18.22.6211; Moffett S, 2000, J BIOL CHEM, V275, P2191, DOI 10.1074/jbc.275.3.2191; Montixi C, 1998, EMBO J, V17, P5334, DOI 10.1093/emboj/17.18.5334; MUSZBEK L, 1993, J BIOL CHEM, V268, P18243; Muszbek L, 1999, LIPIDS, V34, pS331, DOI 10.1007/BF02562334; PARENTI M, 1993, BIOCHEM J, V291, P349, DOI 10.1042/bj2910349; PESECKIS SM, 1994, J BIOL CHEM, V269, P30888; ROBBINS SM, 1995, MOL CELL BIOL, V15, P3507; SCHROEDER R, 1994, P NATL ACAD SCI USA, V91, P12130, DOI 10.1073/pnas.91.25.12130; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; SHENOYSCARIA AM, 1994, J CELL BIOL, V126, P353, DOI 10.1083/jcb.126.2.353; Stulnig TM, 1998, J CELL BIOL, V143, P637, DOI 10.1083/jcb.143.3.637; vantHof W, 1997, J CELL BIOL, V136, P1023, DOI 10.1083/jcb.136.5.1023; Webb Y, 2000, J BIOL CHEM, V275, P261, DOI 10.1074/jbc.275.1.261; Wolven A, 1997, MOL BIOL CELL, V8, P1159, DOI 10.1091/mbc.8.6.1159; Xavier R, 1998, IMMUNITY, V8, P723, DOI 10.1016/S1074-7613(00)80577-4; ZENG FY, 1995, J BIOL CHEM, V270, P21382, DOI 10.1074/jbc.270.36.21382; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0	34	173	179	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					30987	30994		10.1074/jbc.M104018200	http://dx.doi.org/10.1074/jbc.M104018200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11423543	hybrid			2022-12-25	WOS:000170472900054
J	Rodrigues, S; Nguyen, QD; Faivre, S; Bruyneel, E; Thim, L; Westley, B; May, F; Flatau, G; Mareel, M; Gespach, C; Emami, S				Rodrigues, S; Nguyen, QD; Faivre, S; Bruyneel, E; Thim, L; Westley, B; May, F; Flatau, G; Mareel, M; Gespach, C; Emami, S			Activation of cellular invasion by trefoil peptides and src is mediated by cyclooxygenase- and thromboxane A2 receptor-dependent signaling pathways	FASEB JOURNAL			English	Article						inflammation; cancer progression; heterotrimeric G-proteins; Rho-like GTPases; phospholipase C	FAMILIAL ADENOMATOUS POLYPOSIS; COLON-CANCER CELLS; BREAST-CANCER; SPASMOLYTIC POLYPEPTIDE; COLORECTAL ADENOMAS; EPITHELIAL-CELLS; NORMAL STOMACH; I COLLAGEN; G-PROTEINS; EXPRESSION	We have investigated the possible functional relationships between cellular invasion pathways induced by trefoil factors (TFFs), src, and the cyclooxygenases COX-1 and COX-2. Pharmacological inhibitors of the Rho small GTPase (C3 exoenzyme), phospholipase C (U-73122), cyclooxygenases (SC-560, NS-398), and the thromboxane A2 receptor (TXA2-R) antagonist SQ-295 completely abolished invasion induced by intestinal trefoil factor, pS2, and src in kidney and colonic epithelial cells MDCKts.src and PCmsrc. In contrast, invasion was induced by the TXA2-R mimetic U-46619, constitutively activated forms of the heterotrimeric G-proteins G alphaq (AG alphaq), G alpha 12, G alpha 13 (AG alpha 12/13), which are signaling elements downstream of TXA2-R. Ectopic overexpression of pS2 cDNA and protein in MDCKts.src-pS2 cells and human colorectal cancer cells HCT8/S11-pS2 initiate distinct invasion signals that are Rho independent and COX and TXA2-R dependent. We detected a marked induction of COX-2 protein and accumulation of the stable PGH2/TXA2 metabolite TXB2 in the conditioned medium from cells transformed by src. This led to activation of the TXA2R-dependent invasion pathway, which is monitored via a Rho- and G alpha 12/G alpha 13-independent mechanism using the G alphaq/PKC signaling cascade. These findings identify a new intracrine/paracrine loop that can be monitored by TFFs and src in inflammatory diseases and progression of colorectal cancers.	Hop St Antoine, INSERM, U482, Unite Signal Transduct & Cellular Funct Diabet &, F-75571 Paris 12, France; State Univ Ghent Hosp, Expt Cancerol Lab, B-9000 Ghent, Belgium; Novo Nordisk AS, DK-2880 Bagsvaerd, Denmark; Univ Newcastle Upon Tyne, Dept Pathol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England; UFR Med, INSERM, U452, Unite Biol Cellulaire & Mol Microorganismes Patho, F-06107 Nice, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Ghent University; Ghent University Hospital; Novo Nordisk; Newcastle University - UK; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	Gespach, C (corresponding author), Hop St Antoine, INSERM, U482, Unite Signal Transduct & Cellular Funct Diabet &, F-75571 Paris 12, France.	gespach@st-antoine.inserm.fr		Faivre, Sandrine/0000-0002-1590-485X				Attoub S, 2000, FASEB J, V14, P2329, DOI 10.1096/fj.00-0162; Babyatsky MW, 1996, GASTROENTEROLOGY, V110, P489, DOI 10.1053/gast.1996.v110.pm8566596; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; Benbow U, 1999, J BIOL CHEM, V274, P25371, DOI 10.1074/jbc.274.36.25371; Chadwick MP, 1997, BIOCHEM J, V327, P117, DOI 10.1042/bj3270117; Chapple KS, 2000, AM J PATHOL, V156, P545, DOI 10.1016/S0002-9440(10)64759-1; Coffey RJ, 1997, P NATL ACAD SCI USA, V94, P657, DOI 10.1073/pnas.94.2.657; DUBOIS RN, 1994, AM J PHYSIOL, V266, P822; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; Emami S, 2001, FASEB J, V15, P351, DOI 10.1096/fj.00-0355com; Empereur S, 1997, BRIT J CANCER, V75, P241, DOI 10.1038/bjc.1997.40; FLETCHER BS, 1992, J BIOL CHEM, V267, P4338; FLETCHER BS, 1991, J BIOL CHEM, V266, P14511; GESPACH C, 1988, CANCER RES, V48, P5079; GIARDIELLO FM, 1993, NEW ENGL J MED, V328, P1313, DOI 10.1056/NEJM199305063281805; GIOVANNUCCI E, 1995, NEW ENGL J MED, V333, P609, DOI 10.1056/NEJM199509073331001; Gupta S, 2000, PROSTATE, V42, P73, DOI 10.1002/(SICI)1097-0045(20000101)42:1<73::AID-PROS9>3.0.CO;2-G; HANBY AM, 1993, GASTROENTEROLOGY, V105, P1110, DOI 10.1016/0016-5085(93)90956-D; HIRATA M, 1991, NATURE, V349, P617, DOI 10.1038/349617a0; Jacoby RF, 1996, CANCER RES, V56, P710; Jones MK, 1999, FASEB J, V13, P2186, DOI 10.1096/fasebj.13.15.2186; KARGMAN SL, 1995, CANCER RES, V55, P2556; LABAYLE D, 1991, GASTROENTEROLOGY, V101, P635, DOI 10.1016/0016-5085(91)90519-Q; LEVINE PH, 1985, JNCI-J NATL CANCER I, V74, P291; LIU X, 1995, J CELL BIOL, V130, P227, DOI 10.1083/jcb.130.1.227; Mao JH, 1998, J BIOL CHEM, V273, P27118, DOI 10.1074/jbc.273.42.27118; Mashimo H, 1996, SCIENCE, V274, P262, DOI 10.1126/science.274.5285.262; MASIAKOWSKI P, 1982, NUCLEIC ACIDS RES, V10, P7895, DOI 10.1093/nar/10.24.7895; MORROW JD, 1994, J BIOL CHEM, V269, P4317; Narko K, 1997, J BIOL CHEM, V272, P21455, DOI 10.1074/jbc.272.34.21455; Newton JL, 2000, GUT, V46, P312, DOI 10.1136/gut.46.3.312; Noe V, 2001, J CELL SCI, V114, P111; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; OUELLET M, 1995, BIOCHEM J, V306, P247, DOI 10.1042/bj3060247; Playford RJ, 1996, P NATL ACAD SCI USA, V93, P2137, DOI 10.1073/pnas.93.5.2137; PODOLSKY DK, 1993, J BIOL CHEM, V268, P6694; Poulsen SS, 1999, GUT, V45, P516, DOI 10.1136/gut.45.4.516; Pratico D, 1996, J BIOL CHEM, V271, P8919, DOI 10.1074/jbc.271.15.8919; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Probst JC, 1996, FASEB J, V10, P1518, DOI 10.1096/fasebj.10.13.8940297; RAO CV, 1995, CANCER RES, V55, P1464; RAYCHOWDHURY MK, 1994, J BIOL CHEM, V269, P19256; Riehl T, 2000, GASTROENTEROLOGY, V118, P1106, DOI 10.1016/S0016-5085(00)70363-5; RIO MC, 1991, GASTROENTEROLOGY, V100, P375, DOI 10.1016/0016-5085(91)90205-Y; RIO MC, 1988, SCIENCE, V241, P705, DOI 10.1126/science.3041593; ROSAM AC, 1986, NATURE, V319, P54, DOI 10.1038/319054a0; RUDOLPH U, 1995, NAT GENET, V10, P143, DOI 10.1038/ng0695-143; SAITO Y, 1997, BACTERIAL TOXINS TOO, P85; Shao JY, 2000, J BIOL CHEM, V275, P33951, DOI 10.1074/jbc.M002324200; Shattuck-Brandt RL, 2000, GASTROENTEROLOGY, V118, P337, DOI 10.1016/S0016-5085(00)70216-2; SIMMONS DL, 1989, P NATL ACAD SCI USA, V86, P1178, DOI 10.1073/pnas.86.4.1178; Smith CJ, 1998, P NATL ACAD SCI USA, V95, P13313, DOI 10.1073/pnas.95.22.13313; Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603; SUEMORI S, 1991, P NATL ACAD SCI USA, V88, P11017, DOI 10.1073/pnas.88.24.11017; THIM L, 1995, BIOCHEMISTRY-US, V34, P4757, DOI 10.1021/bi00014a033; THIM L, 1989, FEBS LETT, V250, P85, DOI 10.1016/0014-5793(89)80690-8; Tomasetto C, 2000, GASTROENTEROLOGY, V118, P70, DOI 10.1016/S0016-5085(00)70415-X; Tran CP, 1999, GUT, V44, P636, DOI 10.1136/gut.44.5.636; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; Van Hoorde L, 2000, Prog Mol Subcell Biol, V25, P105; VERMEULEN SJ, 1995, CANCER RES, V55, P4722; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; Wilde C, 2000, J BIOL CHEM, V275, P16478, DOI 10.1074/jbc.M910362199; Williams CS, 1996, GASTROENTEROLOGY, V111, P1134, DOI 10.1016/S0016-5085(96)70083-5; Williams CS, 1999, ONCOGENE, V18, P7908, DOI 10.1038/sj.onc.1203286; Wong WM, 1999, GUT, V44, P890, DOI 10.1136/gut.44.6.890; WRIGHT NA, 1993, GASTROENTEROLOGY, V104, P12, DOI 10.1016/0016-5085(93)90830-6; XIE WL, 1994, MOL CELL BIOL, V14, P6531, DOI 10.1128/MCB.14.10.6531; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741; Zhang F, 1998, J BIOL CHEM, V273, P2424, DOI 10.1074/jbc.273.4.2424	72	68	73	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2001	15	9					1517	1528		10.1096/fj.00-0802com	http://dx.doi.org/10.1096/fj.00-0802com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	460PV	11427483				2022-12-25	WOS:000170318500003
J	Landriscina, M; Soldi, R; Bagala, C; Micucci, I; Bellum, S; Tarantini, F; Prudovsky, I; Maciag, T				Landriscina, M; Soldi, R; Bagala, C; Micucci, I; Bellum, S; Tarantini, F; Prudovsky, I; Maciag, T			S100A13 participates in the release of fibroblast growth factor 1 in response to heat shock in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; CALCIUM-BINDING PROTEINS; DISTINCT ANTIALLERGIC DRUGS; CELL-GROWTH; SUBCELLULAR-LOCALIZATION; CHEMOTACTIC PROTEIN; T-PA; SYNAPTOTAGMIN-1; AMLEXANOX; FAMILY	S100A13, a member of the S100 gene family of Ca2+-binding proteins has been previously characterized as a component of a brain-derived heparin-binding multiprotein aggregate/complex containing fibroblast growth factor 1 (FGF1). We report that while expression of S100A13 in NIH 3T3 cells results in the constitutive release of S100A13 into the extracellular compartment at 37 degreesC, co expression of S100A13 with FGF1 represses the constitutive release of S100A13 and enables NIH 3T3 cells to release S100A13 in response to temperature stress. S100A13 release in response to stress occurs with kinetics similar to that observed for the stress-induced release of FGF1, but S100A13 expression is able to reverse the sensitivity of FGF1 release to inhibitors of transcription and translation. The release of FGF1 and S100A13 in response to heat shock, results in the solubility of FGF1 at 100% (w/v) ammonium sulfate saturation, and the expression of a S100A13 deletion mutant lacking its novel basic residue-rich domain acts as a dominant negative effector of FGF1 release in vitro. Surprisingly, the expression of S100A13 also results in the stress-induced release of a Cys-free FGF1 mutant, which is normally not released from NM: 3T3 cells in response to heat shock. These data suggest that S100A13 may be a component of the pathway for the release of the signal peptide-less polypeptide, FGF1, and may involve a role for S100A13 in the formation of a noncovalent FGF1 homodimer.	Maine Med Ctr, Res Inst, Ctr Mol Med, Scarborough, ME 04074 USA	Maine Medical Center	Maciag, T (corresponding author), Maine Med Ctr, Res Inst, Ctr Mol Med, 81 Res Dr, Scarborough, ME 04074 USA.	maciat@mmc.org	Landriscina, Matteo/K-1092-2016; Bagalà, Cinzia/AAB-8981-2019; Tarantini, Francesca/I-6332-2012; Prudovsky, Igor/GVU-1521-2022	TARANTINI, FRANCESCA/0000-0002-1390-2965; Landriscina, Matteo/0000-0003-0591-9799	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032348] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL32348] Funding Source: Medline; NIA NIH HHS [AG98503] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Andrejevic S, 1997, INT J NEUROSCI, V89, P153, DOI 10.3109/00207459708988471; BENNETT MK, 1994, ANNU REV BIOCHEM, V63, P63, DOI 10.1146/annurev.bi.63.070194.000431; BENNETT MK, 1993, J NEUROSCI, V13, P1701; Bergmeyer H.U., 1965, METHODS ENZYMATIC AN, P736, DOI [10.1016/b978-0-12-395630-9.50134-1, DOI 10.1016/B978-0-12-395630-9.50134-1]; Bevers EM, 1996, LUPUS, V5, P480, DOI 10.1177/096120339600500531; Blaber M, 1996, BIOCHEMISTRY-US, V35, P2086, DOI 10.1021/bi9521755; BURGESS WH, 1985, J BIOL CHEM, V260, P1389; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; Carreira CM, 1998, J BIOL CHEM, V273, P22224, DOI 10.1074/jbc.273.35.22224; CARREIRA CM, 2001, IN PRESS GROWTH FACT; CESARMAN GM, 1994, J BIOL CHEM, V269, P21198; Chapman ER, 1998, J BIOL CHEM, V273, P13995, DOI 10.1074/jbc.273.22.13995; Damer CK, 1996, J NEUROCHEM, V67, P1661; DAS BK, 1992, BIOCHEM INT, V28, P775; Dinarello C A, 1998, Int Rev Immunol, V16, P457, DOI 10.3109/08830189809043005; Donato R, 1999, BBA-MOL CELL RES, V1450, P191, DOI 10.1016/S0167-4889(99)00058-0; Duarte WR, 1998, J DENT RES, V77, P1694, DOI 10.1177/00220345980770090501; ENGLEKA KA, 1992, J BIOL CHEM, V267, P11307; Friesel R, 1999, THROMB HAEMOSTASIS, V82, P748; Geczy C, 1996, BBA-MOL CELL RES, V1313, P246, DOI 10.1016/0167-4889(96)00096-1; Hajjar KA, 1999, TRENDS CARDIOVAS MED, V9, P128, DOI 10.1016/S1050-1738(99)00020-1; Heizmann CW, 1998, BIOMETALS, V11, P383, DOI 10.1023/A:1009212521172; Hou XE, 1998, J NEUROCYTOL, V27, P441, DOI 10.1023/A:1006988528655; Hoyaux D, 2000, BRAIN RES, V867, P280, DOI 10.1016/S0006-8993(00)02393-3; HUANG B, 1988, J CELL BIOL, V107, P121, DOI 10.1083/jcb.107.1.121; JACKSON A, 1995, J BIOL CHEM, V270, P33, DOI 10.1074/jbc.270.1.33; JACKSON A, 1992, P NATL ACAD SCI USA, V89, P10691, DOI 10.1073/pnas.89.22.10691; Kang HM, 1997, BIOCHEMISTRY-US, V36, P2041, DOI 10.1021/bi962569b; Kassam G, 1998, BIOCHEMISTRY-US, V37, P16958, DOI 10.1021/bi981713l; Landriscina M, 2000, J BIOL CHEM, V275, P32753, DOI 10.1074/jbc.M002336200; Lang T, 2000, BIOPHYS J, V78, P2863, DOI 10.1016/S0006-3495(00)76828-7; LaVallee TM, 1998, J BIOL CHEM, V273, P22217, DOI 10.1074/jbc.273.35.22217; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; MACIAG T, 1979, P NATL ACAD SCI USA, V76, P5674, DOI 10.1073/pnas.76.11.5674; Mailliard WS, 1996, J BIOL CHEM, V271, P719, DOI 10.1074/jbc.271.2.719; Mandinova A, 1998, J CELL SCI, V111, P2043; Marqueze B, 2000, BIOCHIMIE, V82, P409, DOI 10.1016/S0300-9084(00)00220-0; Mehta AD, 1999, NATURE, V400, P590, DOI 10.1038/23072; Nishikawa T, 1997, J BIOL CHEM, V272, P23037, DOI 10.1074/jbc.272.37.23037; Oyama Y, 1997, BIOCHEM BIOPH RES CO, V240, P341, DOI 10.1006/bbrc.1997.7476; Porta AR, 1996, MOL BRAIN RES, V41, P81; Rammes A, 1997, J BIOL CHEM, V272, P9496; Ridinger K, 2000, J BIOL CHEM, V275, P8686, DOI 10.1074/jbc.275.12.8686; SANO H, 1990, J CELL BIOL, V110, P1417, DOI 10.1083/jcb.110.4.1417; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; Schafer BW, 2000, J BIOL CHEM, V275, P30623, DOI 10.1074/jbc.M002260200; Seemann J, 1996, BIOCHEM J, V319, P123, DOI 10.1042/bj3190123; SHASHOUA VE, 1984, J NEUROCHEM, V42, P1536, DOI 10.1111/j.1471-4159.1984.tb12739.x; Shin JT, 1996, BBA-MOL CELL RES, V1312, P27, DOI 10.1016/0167-4889(96)00013-4; Shishibori T, 1999, BIOCHEM J, V338, P583, DOI 10.1042/0264-6021:3380583; Smith DE, 2000, J BIOL CHEM, V275, P1169, DOI 10.1074/jbc.275.2.1169; SPECTOR I, 1989, CELL MOTIL CYTOSKEL, V13, P127, DOI 10.1002/cm.970130302; STASIA MJ, 1989, BIOCHEMISTRY-US, V28, P9659, DOI 10.1021/bi00451a018; Tarantini F, 1998, J BIOL CHEM, V273, P22209, DOI 10.1074/jbc.273.35.22209; TARANTINI F, 1995, J BIOL CHEM, V270, P29039, DOI 10.1074/jbc.270.49.29039; Tarantini F, 2001, J BIOL CHEM, V276, P5147, DOI 10.1074/jbc.C000714200; THOMAS KA, 1985, P NATL ACAD SCI USA, V82, P6409, DOI 10.1073/pnas.82.19.6409; VANELDIK LJ, 1987, BRAIN RES, V436, P367, DOI 10.1016/0006-8993(87)91681-7; Wicki R, 1996, BIOCHEM BIOPH RES CO, V227, P594, DOI 10.1006/bbrc.1996.1551; Yen T, 1997, BLOOD, V90, P4812, DOI 10.1182/blood.V90.12.4812.4812_4812_4821; ZHANG JD, 1991, P NATL ACAD SCI USA, V88, P3446, DOI 10.1073/pnas.88.8.3446	61	71	74	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22544	22552		10.1074/jbc.M100546200	http://dx.doi.org/10.1074/jbc.M100546200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11410600	hybrid			2022-12-25	WOS:000169412700077
J	Ronchetti, D; Greco, A; Compasso, S; Colombo, G; Dell'Era, P; Otsuki, T; Lombardi, L; Neri, A				Ronchetti, D; Greco, A; Compasso, S; Colombo, G; Dell'Era, P; Otsuki, T; Lombardi, L; Neri, A			Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations	ONCOGENE			English	Article						FGFR3 mutations; multiple myeloma; t(4;14)	GROWTH-FACTOR RECEPTOR-3; T(4/14)(P16.3,Q32) CHROMOSOMAL TRANSLOCATION; LETHAL SKELETAL DYSPLASIA; CHONDROCYTE PROLIFERATION; ACTIVATING MUTATIONS; GENE; TRANSMEMBRANE; TRANSFORMATION; EXPRESSION; REGION	The t(4;14)(p16.3;q32) chromosomal translocation occurs in approximately 20%, of multiple myelomas (MM) and leads to the apparent deregulation of two genes located on 4p16.3: the fibroblast growth factor receptor 3 (FGFR3) and the putative transcription factor WHSC1/ MMSET, Interestingly, FGFR3 mutations known to be associated with autosomal dominant human skeletal disorders have also been found in some MM cell lines with t(4;14) but their pathogenetic role in MM is still controversial, Since cell lines may represent useful models for investigating the effects of deregulated FGFR3 mutants in MM, we analysed the expression, activation, signaling pathways and oncogenic potential of three mutants identified so far: the Y373C and K650E in the KMS-11 and OPM-2 cell lines respectively, and the novel G384D mutation here identified in the KMS-18 cell line, All of the cell lines present a heterozygous FGFR3 gene mutation and transcribe the mutated allele; unlike KMS-11 and OPM-2 (which express the IIIc isoform), the KMS-18 cell line expresses prevalently the isoform IIIb, We demonstrated that, under serum-starved conditions, KMS-11 and OPM-2 cells express appreciable levels of phosphorylated FGFR3 mutants indicating a constitutive activation of the Y373C and K650E receptors; the addition of the aFGF ligand further increased the level of receptor phosphorylation, Conversely, the FGFR3 mutant in KMS-18 does not seem to be constitutively activated since it was phosphorylated only in the presence of the ligand, In all three MM cell lines, ligand-stimulated FGFR3 mutants activated the MAP kinase signaling pathway but did not apparently involve either the STAT1 or STAT3 cascades, However, when transfected in 293T cells, G384D, like Y373C and K650E, was capable of activating MAPK, STAT1 and STAT3 under serum-starved condition, Finally, a focus formation assay of NIH3T3 cells transfected with FGFR3-expressing plasmid vectors showed that Y373C and K650E (albeit at different levels) but not G384D or the wild-type receptor, can induce transformed foci, Overall, our results support the idea that FGFR3 mutations are graded in terms of their activation capability, thus suggesting that they may play a critical role in the tumor progression of MM patients with t(4;14).	Univ Milan, Dipartimento Sci Med, Osped Maggiore, IRCCS,Serv Ematol, I-20122 Milan, Italy; Ist Nazl Tumori, I-20133 Milan, Italy; Osped Maggiore, IRCCS, Div Internal Med 3, Milan, Italy; Univ Brescia, Sch Med, Dept Biomed Sci & Biotechnol, Brescia, Italy; Kawasaki Med Sch, Dept Hyg, Okayama, Japan	IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Brescia; Kawasaki Medical School	Neri, A (corresponding author), Univ Milan, Dipartimento Sci Med, Osped Maggiore, IRCCS,Serv Ematol, Via Francesco Sforza 35, I-20122 Milan, Italy.		Dell'Era, Patrizia/N-6964-2019; Colombo, Gualtiero I./B-4737-2010; Neri, Antonino/I-9690-2014; Dell'Era, Patrizia/G-5294-2010; Greco, Angela/C-1953-2017; Dell'Era, Patrizia/ABD-5848-2020	Colombo, Gualtiero I./0000-0002-7348-1939; Neri, Antonino/0000-0001-9047-5912; Dell'Era, Patrizia/0000-0001-6682-6321; Greco, Angela/0000-0003-2994-0349; RONCHETTI, Domenica/0000-0002-4824-3445				BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Cappellen D, 1999, NAT GENET, V23, P18, DOI 10.1038/12615; CATLETTFALCONE R, 1999, IMMUNITY, V16, P2647; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chesi M, 1998, BLOOD, V92, P3025, DOI 10.1182/blood.V92.9.3025.421k53_3025_3034; Chesi M, 1997, NAT GENET, V16, P260, DOI 10.1038/ng0797-260; d'Avis PY, 1998, CELL GROWTH DIFFER, V9, P71; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; Finelli P, 1999, BLOOD, V94, P724, DOI 10.1182/blood.V94.2.724.414k05_724_732; Fracchiolla NS, 1998, BLOOD, V92, P2987, DOI 10.1182/blood.V92.8.2987; Francomano C. A., 1996, American Journal of Human Genetics, V59, pA25; GRECO A, 1995, MOL CELL BIOL, V15, P6118; Hart KC, 2000, ONCOGENE, V19, P3309, DOI 10.1038/sj.onc.1203650; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; Johnson MR, 1998, ONCOGENE, V16, P2647, DOI 10.1038/sj.onc.1201789; Johnston CL, 1995, J BIOL CHEM, V270, P30643, DOI 10.1074/jbc.270.51.30643; Kanai M, 1997, J BIOL CHEM, V272, P6621, DOI 10.1074/jbc.272.10.6621; Kannan K, 2000, IUBMB LIFE, V49, P197; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; Legeai-Mallet L, 1998, J BIOL CHEM, V273, P13007, DOI 10.1074/jbc.273.21.13007; Li Y, 1997, ONCOGENE, V14, P1397, DOI 10.1038/sj.onc.1200983; Li ZH, 1998, BLOOD, V92, p383A; LOFTS FJ, 1993, ONCOGENE, V8, P2813; LOMBARDI L, 1987, CELL, V49, P161, DOI 10.1016/0092-8674(87)90556-3; Malgeri U, 2000, CANCER RES, V60, P4058; MUENKE M, 1997, TIG, V11, P308; MURGUE B, 1994, CANCER RES, V54, P5206; NAMBA M, 1989, IN VITRO CELL DEV B, V25, P723; Naski MC, 1996, NAT GENET, V13, P233, DOI 10.1038/ng0696-233; Otsuki T, 1998, INT J ONCOL, V12, P545; Plowright EE, 2000, BLOOD, V95, P992, DOI 10.1182/blood.V95.3.992.003k29_992_998; Raffioni S, 1998, J BIOL CHEM, V273, P35250, DOI 10.1074/jbc.273.52.35250; Richelda R, 1997, BLOOD, V90, P4062, DOI 10.1182/blood.V90.10.4062; RONCHETTI D, 2001, IN PRESS LEUKEMIA; Rousseau F, 1996, HUM MOL GENET, V5, P509, DOI 10.1093/hmg/5.4.509; Sahni M, 1999, GENE DEV, V13, P1361, DOI 10.1101/gad.13.11.1361; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Stec I, 1998, HUM MOL GENET, V7, P1071, DOI 10.1093/hmg/7.7.1071; STERNBERG MJE, 1990, PROTEIN ENG, V3, P245, DOI 10.1093/protein/3.4.245; TAVORMINA PL, 1995, NAT GENET, V9, P321, DOI 10.1038/ng0395-321; THOMPSON LM, 1991, GENOMICS, V11, P1133, DOI 10.1016/0888-7543(91)90041-C; Webster MK, 1997, MOL CELL BIOL, V17, P5739, DOI 10.1128/MCB.17.10.5739; Webster MK, 1997, TRENDS GENET, V13, P178, DOI 10.1016/S0168-9525(97)01131-1; Webster MK, 1996, MOL CELL BIOL, V16, P4081	45	88	114	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 14	2001	20	27					3553	3562		10.1038/sj.onc.1204465	http://dx.doi.org/10.1038/sj.onc.1204465			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	445VB	11429702				2022-12-25	WOS:000169478300011
J	Dauphinot, L; De Oliveira, C; Melot, T; Sevenet, N; Thomas, V; Weissman, BE; Delattre, O				Dauphinot, L; De Oliveira, C; Melot, T; Sevenet, N; Thomas, V; Weissman, BE; Delattre, O			Analysis of the expression of cell cycle regulators in Ewing cell lines: EWS-FLI-1 modulates p57(KIP2) and c-Myc expression	ONCOGENE			English	Article						Ewing tumour; cell cycle; EWS-FLI-1; c-Myc; p57(KIP2)	DEPENDENT KINASE INHIBITOR; GROWTH-FACTOR-BETA; DNA-BINDING; P53 MUTATIONS; GENE; FUSION; DOMAIN; PROTEIN; TRANSLOCATION; ONCOPROTEINS	Ewing tumour is characterized by specific chromosome translocations which fuse EU'S to a subset of genes encoding ETS transcription factors, most frequently FLI-1. We report the analysis of the expression of various cell cycle regulators both in Ewing tumour derived cell lines and in different cellular models with either inducible or constitutive EWS-FLI-1 cDNA expression. In Ewing cell lines, cyclin D1, CDK4, Rb, p27(KIP1) and c-Myc were consistently highly expressed whereas p57(KIP2), p15(INK4B) and p14(ARF) demonstrated undetectable or low expression levels. The amount of p16(INK4A), p21(CIP1), p18(INKAC) and CDK6 was variable from one cell line to the other, The inducible expression of EWS-FLI-1 led to a strong upregulation of c-MSc and a considerable downregulation of p57(KIP2). Other proteins did not show evident modification. High c-Myc and very low p57(KIP2) expression levels were also observed in neuroblastoma NGP cells constitutively expressing EWS-FLI-1 as compared to parental cells. Analysis of the p57(KIP2) promoter indicated that EWS-FLI-1 downregulates, possibly through an indirect mechanism, the transcription of this gene, Finally, we show that ectopic expression of p57(KIP2) in Ewing cells blocks proliferation through a complete G1 arrest. These results suggest that the modulation of p57(KIP2) expression by EWS-FLI-1 is a fundamental step in Ewing tumorigenesis.	Inst Curie, Lab Pathol Mol Canc, INSERM U509, F-75248 Paris 05, France; Univ N Carolina, Lineberger Canc Ctr 345, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; University of North Carolina; University of North Carolina Chapel Hill	Delattre, O (corresponding author), Inst Curie, Lab Pathol Mol Canc, INSERM U509, 26 Rue Ulm, F-75248 Paris 05, France.			delattre, olivier/0000-0002-8730-2276				ALEXANDROW MG, 1995, CANCER RES, V55, P1452; Arvand A, 1998, ONCOGENE, V17, P2039, DOI 10.1038/sj.onc.1202129; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; de Medina SGD, 1998, HUM PATHOL, V29, P1005, DOI 10.1016/S0046-8177(98)90208-8; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Feinberg AP, 1999, CANCER RES, V59, p1743S; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Hahm KB, 1999, NAT GENET, V23, P222, DOI 10.1038/13854; HAMELIN R, 1994, INT J CANCER, V57, P336, DOI 10.1002/ijc.2910570308; Hashimoto Y, 1998, J BIOL CHEM, V273, P16544, DOI 10.1074/jbc.273.26.16544; Hatada I, 1996, NAT GENET, V14, P171, DOI 10.1038/ng1096-171; Hatada I, 1996, HUM MOL GENET, V5, P783, DOI 10.1093/hmg/5.6.783; Hermeking H, 2000, P NATL ACAD SCI USA, V97, P2229, DOI 10.1073/pnas.050586197; Im YH, 2000, CANCER RES, V60, P1536; Jaishankar S, 1999, ONCOGENE, V18, P5592, DOI 10.1038/sj.onc.1202940; KOMURO H, 1993, CANCER RES, V53, P5284; KOVAR H, 1993, ONCOGENE, V8, P2683; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; LESSNICK SL, 1995, ONCOGENE, V10, P423; Lin JY, 1996, MOL CELL BIOL, V16, P1786; MAO XH, 1994, J BIOL CHEM, V269, P18216; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; Matsuoka S, 1996, P NATL ACAD SCI USA, V93, P3026, DOI 10.1073/pnas.93.7.3026; May WA, 1997, NAT GENET, V17, P495, DOI 10.1038/ng1297-495; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; Melot T, 1997, HYBRIDOMA, V16, P457, DOI 10.1089/hyb.1997.16.457; PETER M, 1995, BRIT J CANCER, V72, P96, DOI 10.1038/bjc.1995.283; Reid LH, 1996, CANCER RES, V56, P1214; REMVIKOS Y, 1991, BRIT J CANCER, V64, P501, DOI 10.1038/bjc.1991.338; Reynaud EG, 1999, MOL CELL BIOL, V19, P7621; Sumarsono SH, 1996, NATURE, V379, P534, DOI 10.1038/379534a0; Thompson AD, 1996, ONCOGENE, V13, P2649; Tokino T, 1996, HUM GENET, V97, P625, DOI 10.1007/s004390050106; Xing EP, 1999, CLIN CANCER RES, V5, P2704	35	130	138	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 31	2001	20	25					3258	3265		10.1038/sj.onc.1204437	http://dx.doi.org/10.1038/sj.onc.1204437			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	440ET	11423975				2022-12-25	WOS:000169163500009
J	Niederberger, E; Tegeder, I; Vetter, G; Schmidtko, A; Schmidt, H; Euchenhofer, C; Brautigam, L; Grosch, S; Geisslinger, G				Niederberger, E; Tegeder, I; Vetter, G; Schmidtko, A; Schmidt, H; Euchenhofer, C; Brautigam, L; Grosch, S; Geisslinger, G			Celecoxib loses its anti-inflammatory efficacy at high doses through activation of NF-kappa B	FASEB JOURNAL			English	Article						arthritis; cyclooxygenase inhibitor; Celebrex (R)	NECROSIS-FACTOR-ALPHA; RHEUMATOID SYNOVIAL FIBROBLASTS; NITRIC-OXIDE SYNTHASE; CYCLOOXYGENASE-2 INHIBITOR; SELECTIVE-INHIBITION; COLON CARCINOGENESIS; ENDOTHELIAL-CELLS; CONTROLLED TRIAL; CANCER CELLS; SPINAL-CORD	Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, has recently been approved for the symptomatic treatment of arthritis. In some clinical studies, doses of 400 and 800 mg/day provided somewhat less efficacy compared with 200 mg/day, which suggests an early ceiling effect. Using the zymosan-induced inflammation model in rats, we show that celecoxib significantly reduces paw swelling at 50 mg/kg but completely loses its anti-inflammatory efficacy at doses greater than or equal to100 mg/kg. To evaluate the underlying mechanisms, we used rat renal mesangial cells as a cell culture model. In these cells, celecoxib (50 muM) increased the interleukin Ibeta stimulated nuclear translocation and DNA binding of NF-kappaB and facilitated the degradation of I-kappaB. Consequently, COX-2 and tumor necrosis factor alpha (TNF-alpha) expression were increased. The up-regulation of COX-2 and TNF-alpha also occurred in the spinal cord of rats treated with celecoxib (greater than or equal to100 mg/kg), indicating that in vitro mechanisms were relevant in vivo. Clinically, the overexpression. of COX-2 might be less important because celecoxib inhibits COX-2 enzymatically. However, the up-regulation of TNF-alpha and possibly other NF-kappaB regulated proinflammatory genes might worsen the pathophysiological processes underlying chronic arthritis.	Univ Frankfurt Klinikum, Inst Klin Pharmakol, Pharmazentrum Frankfurt, D-60590 Frankfurt, Germany	Goethe University Frankfurt; Goethe University Frankfurt Hospital	Geisslinger, G (corresponding author), Univ Frankfurt Klinikum, Inst Klin Pharmakol, Pharmazentrum Frankfurt, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	geisslinger@em.uni-frankfurt.de	Groesch, Sabine/H-4251-2018; Schmidtko, Achim/AAB-2122-2019; Tegeder, Irmgard/AAM-2246-2020; Tegeder, Irmgard/AAM-2266-2020	Groesch, Sabine/0000-0002-7262-6307; Tegeder, Irmgard/0000-0001-7524-8025; Tegeder, Irmgard/0000-0001-7524-8025; Schmidtko, Achim/0000-0001-7270-5075				Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Beiche F, 1998, INFLAMM RES, V47, P482, DOI 10.1007/s000110050362; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; Cusack JC, 2000, CANCER RES, V60, P2323; DeWitt DL, 1999, MOL PHARMACOL, V55, P625; DEWITT DL, 1993, ARCH BIOCHEM BIOPHYS, V306, P94, DOI 10.1006/abbi.1993.1485; Emery P, 1999, LANCET, V354, P2106, DOI 10.1016/S0140-6736(99)02332-6; Fort J, 1999, Am J Orthop (Belle Mead NJ), V28, P13; Fujisawa K, 1996, ARTHRITIS RHEUM-US, V39, P197, DOI 10.1002/art.1780390205; GEGEDER I, 2001, FASEB J, V15, P2; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P522, DOI 10.1073/pnas.90.2.522; Gierse JK, 1999, BIOCHEM J, V339, P607, DOI 10.1042/0264-6021:3390607; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Gupta RA, 2000, NAT MED, V6, P974, DOI 10.1038/79664; Han SY, 2000, BIOL PHARM BULL, V23, P420; Hanemaaijer R, 1997, J BIOL CHEM, V272, P31504, DOI 10.1074/jbc.272.50.31504; Jones MK, 1999, NAT MED, V5, P1418; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; Maihofner C, 2000, NEUROSCI LETT, V290, P71, DOI 10.1016/S0304-3940(00)01302-1; MASFERRER JL, 1994, P NATL ACAD SCI USA, V91, P3228, DOI 10.1073/pnas.91.8.3228; Matroule JY, 1999, PHOTOCHEM PHOTOBIOL, V70, P540, DOI 10.1111/j.1751-1097.1999.tb08249.x; McCarthy Denis M., 1999, American Journal of Medicine, V107, p37S; McCarthy DM, 1999, AM J MED, V107, p46S; Meller S T, 1997, Eur J Pain, V1, P43, DOI 10.1016/S1090-3801(97)90052-5; Moreland LW, 1999, ANN INTERN MED, V130, P478, DOI 10.7326/0003-4819-130-6-199903160-00004; Pahl HL, 1999, PHYSIOL REV, V79, P683, DOI 10.1152/physrev.1999.79.3.683; Penning TD, 1997, J MED CHEM, V40, P1347, DOI 10.1021/jm960803q; RADEKE HH, 1992, CLIN INVESTIGATOR, V70, P825; RAO CV, 1995, CANCER RES, V55, P1464; Reddy BS, 1996, CANCER RES, V56, P4566; Rose MJ, 2000, J CHROMATOGR B, V738, P377, DOI 10.1016/S0378-4347(99)00552-6; Sakurada S, 1996, INT IMMUNOL, V8, P1483, DOI 10.1093/intimm/8.10.1483; SCHLONDORFF D, 1987, FASEB J, V1, P272, DOI 10.1096/fasebj.1.4.3308611; SEIBERT K, 1994, P NATL ACAD SCI USA, V91, P12013, DOI 10.1073/pnas.91.25.12013; Simon LS, 1999, JAMA-J AM MED ASSOC, V282, P1921, DOI 10.1001/jama.282.20.1921; Simon LS, 1998, ARTHRITIS RHEUM-US, V41, P1591, DOI 10.1002/1529-0131(199809)41:9<1591::AID-ART9>3.0.CO;2-J; Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603; Stuhlmeier KM, 1999, BIOCHEM PHARMACOL, V57, P313, DOI 10.1016/S0006-2952(98)00301-3; VANE J, 1994, NATURE, V367, P215, DOI 10.1038/367215a0; WEBER C, 1995, CIRCULATION, V91, P1914, DOI 10.1161/01.CIR.91.7.1914; Weinblatt ME, 1999, NEW ENGL J MED, V340, P253, DOI 10.1056/NEJM199901283400401; Williams CS, 1996, AM J PHYSIOL, V270, P393; XIE QW, 1993, T ASSOC AM PHYSICIAN, V106, P1; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315; Zhao SZ, 1999, PHARMACOTHERAPY, V19, P1269, DOI 10.1592/phco.19.16.1269.30879	45	131	135	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY 29	2001	15	7					1622	+		10.1096/fj.00-0716fje	http://dx.doi.org/10.1096/fj.00-0716fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519CQ	11427506				2022-12-25	WOS:000173707700010
J	Nishiyama, H; Gill, JH; Pitt, E; Kennedy, W; Knowles, MA				Nishiyama, H; Gill, JH; Pitt, E; Kennedy, W; Knowles, MA			Negative regulation of G(1)/S transition by the candidate bladder tumour suppressor gene DBCCR1	ONCOGENE			English	Article						transitional cell carcinoma; DBCCR1; cell cycle	CELL-CYCLE; TGF-BETA; CANCER; DELETION; PROTEIN; LOCUS; RETINOBLASTOMA; METHYLATION; 9Q32-Q33; REGION	Deletion of all or part of chromosome 9q is the most common genetic alteration in all stages and grades of bladder cancer. DBCCR1 (deleted in bladder cancer chromosome region candidate I) maps to the chromosome region 9q32-33, a candidate tumour suppressor locus for bladder cancer, Although no mutations of DBCCR1 have been detected in bladder tumours, expression of DBCCR1 is silenced by promoter hypermethylation in 50% of bladder cancer cell lines analysed. Here we sought to provide functional evidence to authenticate DBCCR1 as a tumour suppressor using gene-transfer methods. Exogenous expression of DBCCR1 protein or an HA epitope-tagged fusion protein, HA-DBCCR1 in NIH3T3 cells and human bladder tumour cell lines resulted in suppression of proliferation. Cell cycle analyses in NIH3T3 cells revealed that DBCCR1-mediated growth inhibition,vas due to an increase in the number of cells in the G(1) phase of the cell cycle, The levels of apoptosis were not altered. These results demonstrate a role for DBCCR1 in cell cycle control, thereby supporting the hypothesis that this is the tumour suppressor gene targeted by 9q32-33 deletion in bladder cancer. Oncogene (2001) 20, 2956-2964.	St Jamess Univ Hosp, Imperial Canc Res Fund, Ctr Clin, Leeds LS9 7TF, W Yorkshire, England	Saint James's University Hospital; University of Leeds	Knowles, MA (corresponding author), St Jamess Univ Hosp, Imperial Canc Res Fund, Ctr Clin, Beckett St, Leeds LS9 7TF, W Yorkshire, England.			Knowles, Margaret/0000-0002-9363-8657; Gill, Jason/0000-0002-7564-7787				CAIRNS P, 1993, ONCOGENE, V8, P1083; DALBAGNI G, 1993, LANCET, V342, P469, DOI 10.1016/0140-6736(93)91595-D; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; HABUCHI T, 1995, ONCOGENE, V11, P1671; Habuchi T, 1998, GENOMICS, V48, P277, DOI 10.1006/geno.1997.5165; Habuchi T, 1997, HUM MOL GENET, V6, P913, DOI 10.1093/hmg/6.6.913; HABUCHI T, 2001, IN PRESS ONCOGENE; Hartmann A, 1999, AM J PATHOL, V154, P721, DOI 10.1016/S0002-9440(10)65318-7; Higashitsuji H, 2000, NAT MED, V6, P96, DOI 10.1038/71600; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; NIMAN HL, 1983, P NATL ACAD SCI-BIOL, V80, P4949, DOI 10.1073/pnas.80.16.4949; Nishiyama H, 1999, GENE CHROMOSOME CANC, V26, P171, DOI 10.1002/(SICI)1098-2264(199910)26:2<171::AID-GCC10>3.3.CO;2-2; Nishiyama H, 1997, J CELL BIOL, V137, P899, DOI 10.1083/jcb.137.4.899; Nishiyama H, 1999, GENOMICS, V59, P335, DOI 10.1006/geno.1999.5891; *OFF NAT STAT, 1996, MB1961 ONS; OLUMI AF, 1990, CANCER RES, V50, P7081; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; Pestov DG, 1999, BIOTECHNIQUES, V26, P102, DOI 10.2144/99261st04; Ravitz MJ, 1997, ADV CANCER RES, V71, P165, DOI 10.1016/S0065-230X(08)60099-8; Roussel MF, 1999, ONCOGENE, V18, P5311, DOI 10.1038/sj.onc.1202998; Salem C, 2000, CANCER RES, V60, P2473; Simoneau M, 1999, ONCOGENE, V18, P157, DOI 10.1038/sj.onc.1202277; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; WILLIAMSON MP, 1995, HUM MOL GENET, V4, P1569, DOI 10.1093/hmg/4.9.1569; WU SQ, 1991, CANCER RES, V51, P3323	28	49	53	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 24	2001	20	23					2956	2964		10.1038/sj.onc.1204432	http://dx.doi.org/10.1038/sj.onc.1204432			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	435VA	11420708				2022-12-25	WOS:000168901800011
J	Yasui, Y; Goto, H; Matsui, S; Manser, E; Lim, L; Nagata, K; Inagaki, M				Yasui, Y; Goto, H; Matsui, S; Manser, E; Lim, L; Nagata, K; Inagaki, M			Protein kinases required for segregation of vimentin filaments in mitotic process	ONCOGENE			English	Article						mitosis; vimentin; phosphorylation; Rho-kinase; protein kinase C (PKC); vimentin-Ser72 kinase	RHO-ASSOCIATED KINASE; CELL-CYCLE CONTROL; POLO-LIKE KINASES; INTERMEDIATE-FILAMENTS; CLEAVAGE FURROW; PHOSPHORYLATION; CYTOKINESIS; MITOSIS; SITE; CYTOSKELETON	Vimentin, one of type III intermediate filament (IF) proteins, is expressed not only in mesenchymal cells but also in most types of tumor cells. In the present study, rye introduced several types of vimentin mutated at putative phosphorylation sites in its amino-terminal head domain into type III IF-negative T24 cells. Site-specific mutation induced the formation of an unusually long bridge-like IF structure between the unseparated daughter cells, although these mutants formed the filament network similar to wild type in interphase cells. Together with sites phosphorylated by Rho-kinase and protein kinase C (PKC), vimentin-Ser72, which can not be phosphorylated by any known vimentin kinase, was one of the mutation sites essential for this phenotype, We further demonstrated that vimentin-Ser72 was phosphorylated specifically at the cleavage furrow during cytokinesis. These observations suggest the existence of a novel protein kinase responsible for vimentin filament separation through the cleavage furrow-specific vimentin phosphorylation, We propose that Rho-kinase, PKC, and an unidentified vimentin-Ser72 kinase may play important roles in vimentin filament separation during cytokinesis, Oncogene (2001) 20, 3868-2876.	Aichi Canc Ctr, Res Inst, Div Biochem, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Glaxo IMCB Grp, Inst Mol & Cell Biol, Singapore 117609, Singapore; Nagoya City Univ, Fac Pharmaceut Sci, Dept Biol Chem, Nagoya, Aichi 4678603, Japan; UCL, Inst Neurol, London WC1N 1PJ, England	Aichi Cancer Center; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); GlaxoSmithKline; Nagoya City University; University of London; University College London	Inagaki, M (corresponding author), Aichi Canc Ctr, Res Inst, Div Biochem, Chikusa Ku, Nagoya, Aichi 4648681, Japan.		Inagaki, Masaki/B-9920-2016; Manser, Edward/ABD-2301-2020	Goto, Hidemasa/0000-0002-6796-4467				Bischoff JR, 1999, TRENDS CELL BIOL, V9, P454, DOI 10.1016/S0962-8924(99)01658-X; CELIS JE, 1983, J CELL BIOL, V97, P1429, DOI 10.1083/jcb.97.5.1429; CHOU YH, 1990, CELL, V62, P1063, DOI 10.1016/0092-8674(90)90384-Q; Chung CY, 1999, J CELL BIOL, V147, P559, DOI 10.1083/jcb.147.3.559; ERIKSSON J E, 1992, Current Opinion in Cell Biology, V4, P99, DOI 10.1016/0955-0674(92)90065-K; EVANS RM, 1984, J BIOL CHEM, V259, P5372; EVANS RM, 1982, CELL, V29, P43, DOI 10.1016/0092-8674(82)90088-5; Foisner R, 1997, BIOESSAYS, V19, P297, DOI 10.1002/bies.950190407; FRANKE WW, 1982, CELL, V30, P103, DOI 10.1016/0092-8674(82)90016-2; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; GOSS VL, 1994, J BIOL CHEM, V269, P19074; Goto H, 1998, J BIOL CHEM, V273, P11728, DOI 10.1074/jbc.273.19.11728; Goto H, 2000, MICROSC RES TECHNIQ, V49, P173, DOI 10.1002/(SICI)1097-0029(20000415)49:2<173::AID-JEMT10>3.0.CO;2-A; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Holly SP, 1999, J CELL BIOL, V147, P845, DOI 10.1083/jcb.147.4.845; Inada H, 1999, J BIOL CHEM, V274, P34932, DOI 10.1074/jbc.274.49.34932; INAGAKI M, 1987, NATURE, V328, P649, DOI 10.1038/328649a0; Inagaki M, 1997, J BIOCHEM, V121, P407; Inagaki M, 1996, BIOESSAYS, V18, P481, DOI 10.1002/bies.950180610; Inagaki N, 1997, J BIOL CHEM, V272, P25195, DOI 10.1074/jbc.272.40.25195; INAGAKI N, 1994, TRENDS BIOCHEM SCI, V19, P448, DOI 10.1016/0968-0004(94)90128-7; Kosako H, 1999, ONCOGENE, V18, P2783, DOI 10.1038/sj.onc.1202633; Kosako H, 1997, J BIOL CHEM, V272, P10333; Ku NO, 1996, CANCER METAST REV, V15, P429, DOI 10.1007/BF00054011; Lane HA, 1997, TRENDS CELL BIOL, V7, P63, DOI 10.1016/S0962-8924(96)10051-9; Livneh E, 1997, EUR J BIOCHEM, V248, P1, DOI 10.1111/j.1432-1033.1997.t01-4-00001.x; Madaule P, 1998, NATURE, V394, P491, DOI 10.1038/28873; MATSUOKA Y, 1992, EMBO J, V11, P2895, DOI 10.1002/j.1460-2075.1992.tb05358.x; Nigg EA, 1998, CURR OPIN CELL BIOL, V10, P776, DOI 10.1016/S0955-0674(98)80121-X; NISHIZAWA K, 1991, J BIOL CHEM, V266, P3074; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OGAWARA M, 1995, J CELL BIOL, V131, P1055, DOI 10.1083/jcb.131.4.1055; Passalacqua M, 1999, FEBS LETT, V453, P249, DOI 10.1016/S0014-5793(99)00729-2; Prokopenko SN, 2000, J CELL BIOL, V148, P843, DOI 10.1083/jcb.148.5.843; Schumacher JM, 1998, J CELL BIOL, V143, P1635, DOI 10.1083/jcb.143.6.1635; Sekimata M, 1996, J CELL BIOL, V132, P635, DOI 10.1083/jcb.132.4.635; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; Takai Y, 1996, J CELL BIOL, V133, P141, DOI 10.1083/jcb.133.1.141; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; Terada Y, 1998, EMBO J, V17, P667, DOI 10.1093/emboj/17.3.667; Thompson LJ, 1996, J BIOL CHEM, V271, P15045, DOI 10.1074/jbc.271.25.15045; TSUJIMURA K, 1994, J BIOL CHEM, V269, P31097; Yasui Y, 1998, J CELL BIOL, V143, P1249, DOI 10.1083/jcb.143.5.1249	43	76	80	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 24	2001	20	23					2868	2876		10.1038/sj.onc.1204407	http://dx.doi.org/10.1038/sj.onc.1204407			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	435VA	11420699				2022-12-25	WOS:000168901800002
J	Hammond, DE; Urbe, S; Woude, GFV; Clague, MJ				Hammond, DE; Urbe, S; Woude, GFV; Clague, MJ			Down-regulation of MET, the receptor for hepatocyte growth factor	ONCOGENE			English	Article						Met; hepatocyte growth factor; endocytosis; proteasome	LIGAND-INDUCED INTERNALIZATION; TYROSINE KINASE RECEPTOR; FACTOR SCATTER FACTOR; FACTOR BETA-RECEPTOR; UBIQUITIN; PROTEIN; DEGRADATION; ENDOCYTOSIS; POLYUBIQUITINATION; IDENTIFICATION	The ligand-dependent degradation of activated tyrosine kinase receptors provides a means by which mitogenic signalling can be attenuated. In many cell types the ligand-dependent degradation of the tyrosine kinase receptor Met is completely dependent on the activity of the 26S proteasome (Jeffers et al,, 1997b), We now show that degradation also requires trafficking to late endosomal compartments and the activity of acid dependent proteases as determined by the effects of a dominant negative form of dynamin (K44A) and a vacuolar-ATPase inhibitor, concanamycin, We show that in the presence of the proteasome inhibitor lactacystin, Met fails to redistribute from the plasma membrane to intracellular compartments. This observation is most consistent with the interpretation that proteasome activity is required for Met internalization and only indirectly for its degradation.	Univ Liverpool, Physiol Lab, Liverpool L69 3BX, Merseyside, England; Van Andel Res Inst, Grand Rapids, MI 49503 USA	University of Liverpool; Van Andel Institute	Clague, MJ (corresponding author), Univ Liverpool, Physiol Lab, Crown St, Liverpool L69 3BX, Merseyside, England.		Clague, Michael J/A-7199-2008	Clague, Michael J/0000-0003-3355-9479; Hammond, Dean/0000-0002-6326-8739; Urbe, Sylvie/0000-0003-4735-9814				Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; Clague MJ, 1998, BIOCHEM J, V336, P271, DOI 10.1042/bj3360271; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; Di Fiore PP, 1999, CURR OPIN CELL BIOL, V11, P483, DOI 10.1016/S0955-0674(99)80069-6; GalchevaGargova Z, 1995, ONCOGENE, V11, P2649; GIORDANO S, 1989, ONCOGENE, V4, P1383; Govers R, 1999, EMBO J, V18, P28, DOI 10.1093/emboj/18.1.28; Govers R, 1997, EMBO J, V16, P4851, DOI 10.1093/emboj/16.16.4851; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; Hicke L, 1999, TRENDS CELL BIOL, V9, P107, DOI 10.1016/S0962-8924(98)01491-3; HOU D, 1994, J BIOL CHEM, V269, P14244; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; Jeffers M, 1997, MOL CELL BIOL, V17, P799, DOI 10.1128/MCB.17.2.799; Jeffers M, 1996, J MOL MED-JMM, V74, P505, DOI 10.1007/BF00204976; Kobayashi T, 1998, NATURE, V392, P193, DOI 10.1038/32440; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; MIYAZAWA K, 1994, BLOOD, V83, P137; MORI S, 1992, J BIOL CHEM, V267, P6429; MORI S, 1995, J BIOL CHEM, V270, P29447, DOI 10.1074/jbc.270.49.29447; MORI S, 1995, BIOCHEM BIOPH RES CO, V217, P224, DOI 10.1006/bbrc.1995.2767; MU FT, 1995, J BIOL CHEM, V270, P13503, DOI 10.1074/jbc.270.22.13503; NALDINI L, 1992, EMBO J, V11, P4825, DOI 10.1002/j.1460-2075.1992.tb05588.x; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; RONG S, 1993, CELL GROWTH DIFFER, V4, P563; RUBIN JS, 1993, BIOCHIM BIOPHYS ACTA, V1155, P357, DOI 10.1016/0304-419X(93)90015-5; Terrell J, 1998, MOL CELL, V1, P193, DOI 10.1016/S1097-2765(00)80020-9; van der Voort R, 2000, ADV CANCER RES, V79, P39, DOI 10.1016/S0065-230X(00)79002-6; van Kerkhof P, 2000, J BIOL CHEM, V275, P1575, DOI 10.1074/jbc.275.3.1575; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; YOSHIMORI T, 1991, J BIOL CHEM, V266, P17707	38	134	137	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 17	2001	20	22					2761	2770		10.1038/sj.onc.1204475	http://dx.doi.org/10.1038/sj.onc.1204475			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	432TP	11420688				2022-12-25	WOS:000168712000004
J	Makino, K; Yu, DH; Hung, MC				Makino, K; Yu, DH; Hung, MC			Transcriptional upregulation and activation of p55Cdc via p34(cdc2) in Taxol-induced apoptosis	ONCOGENE			English	Article						cDNA array; Taxol; p55Cdc; p34(cdc2); apoptosis	GENE-EXPRESSION PATTERNS; DNA MICROARRAY; MITOTIC BLOCK; MYELOID CELLS; KINASE; PROTEIN; PHOSPHORYLATION; OVEREXPRESSION; MECHANISM; COMPLEX	Paclitaxel (Taxol) is a potent and highly effective antineoplastic agent for the treatment of advanced, drug-refractory, metastatic breast cancers. Taxol not only induces tubulin polymerization, stabilizes microtubules, blocks cell cycle progression, and induces apoptosis, but it also alters gene expression. Here, we have identified that Taxol can upregulate expression of the gene encoding the cell cycle protein p55Cdc by using cDNA array technique. Taxol induced p55Cdc mRNA expression through activation of the p55Cdc promoter, which led to increase p55Cdc protein expression. Taxol also activated p55Cdc-associated kinase, In addition, overexpression of the p55Cdc gene resulted in cell death in both HeLa cells and NIH3T3 cells in a dose-dependent manner. A dominant-negative mutant of p34(cdc2) blocked Taxol-induced p55Cdc activation and inhibited p55Cdc-induced and Taxol-induced cell death. Our data suggest that transcriptional upregulation of p55Cdc and activation of p55Cdc by Taxol-mediated p34(cdc2) activation play a critical role in Taxol-induced cell death.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Hung, MC (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Box 108,1515 Holcombe Blvd, Houston, TX 77030 USA.		Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740; Yu, Dihua/0000-0001-6231-9381	NATIONAL CANCER INSTITUTE [P50CA083639, R01CA058880] Funding Source: NIH RePORTER; NCI NIH HHS [CA58880, P50 CA83639] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOGDAN C, 1992, J LEUKOCYTE BIOL, V52, P119, DOI 10.1002/jlb.52.1.119; CHOI WJ, 1990, BIOCHEM BIOPH RES CO, V172, P1324, DOI 10.1016/0006-291X(90)91594-I; DeRisi J, 1996, NAT GENET, V14, P457; DING AH, 1990, SCIENCE, V248, P370, DOI 10.1126/science.1970196; Farruggio DC, 1999, P NATL ACAD SCI USA, V96, P7306, DOI 10.1073/pnas.96.13.7306; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; Heller RA, 1997, P NATL ACAD SCI USA, V94, P2150, DOI 10.1073/pnas.94.6.2150; Jordan MA, 1996, CANCER RES, V56, P816; JORDAN MA, 1993, P NATL ACAD SCI USA, V90, P9552, DOI 10.1073/pnas.90.20.9552; Kao CT, 1996, ONCOGENE, V13, P1221; Kotani S, 1999, J CELL BIOL, V146, P791, DOI 10.1083/jcb.146.4.791; Kramer ER, 1998, CURR BIOL, V8, P1207, DOI 10.1016/S0960-9822(07)00510-6; KUMAR N, 1981, J BIOL CHEM, V256, P435; Lin M, 1998, EXP HEMATOL, V26, P1000; Lu K P, 1995, Prog Cell Cycle Res, V1, P187; MEIKRANTZ W, 1994, P NATL ACAD SCI USA, V91, P3754, DOI 10.1073/pnas.91.9.3754; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; SCHIFF PB, 1980, P NATL ACAD SCI-BIOL, V77, P1561, DOI 10.1073/pnas.77.3.1561; Shalon D, 1996, GENOME RES, V6, P639, DOI 10.1101/gr.6.7.639; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; Shteinberg M, 1999, BIOCHEM BIOPH RES CO, V260, P193, DOI 10.1006/bbrc.1999.0884; WANI MC, 1971, J AM CHEM SOC, V93, P2325, DOI 10.1021/ja00738a045; Weinstein J, 1997, J BIOL CHEM, V272, P28501, DOI 10.1074/jbc.272.45.28501; WEINSTEIN J, 1994, MOL CELL BIOL, V14, P3350, DOI 10.1128/MCB.14.5.3350; Weinstein J, 1998, MOL GENET METAB, V64, P52, DOI 10.1006/mgme.1998.2698; Yu DH, 1998, MOL CELL, V2, P581, DOI 10.1016/S1097-2765(00)80157-4; Yu DH, 1996, ONCOGENE, V13, P1359	29	18	21	2	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 3	2001	20	20					2537	2543		10.1038/sj.onc.1204366	http://dx.doi.org/10.1038/sj.onc.1204366			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	431VM	11420663	Bronze			2022-12-25	WOS:000168652500004
J	Spencer, VA; Davie, JR				Spencer, VA; Davie, JR			Dynamically acetylated histone association with transcriptionally active and competent genes in the avian adult beta-globin gene domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHICKEN ERYTHROCYTES; NUCLEAR MATRIX; NUCLEOTIDE-SEQUENCE; CHROMATIN; IMMATURE; HYPERACETYLATION; SOLUBILITY; CELLS; RATES; RNA	In chicken immature erythrocytes, class 1 acetylated histones are rapidly tri- and tetra-acetylated and rapidly deacetylated. Class 2 acetylated H3 and H4 are rapidly acetylated to mono- and di-acetylated isoforms and slowly deacetylated. Our previous studies suggested that class 1 acetylated histones were primarily associated with transcriptionally active DNA (beta (A)-globin) but not competent DNA (epsilon -globin). Chromatin salt solubility (chromatin fiber oligomerization) is directly influenced by hyperacetylation. In this study we investigated the association of class 1 histones with beta (A)- and epsilon -globin DNA by measuring their loss of solubility rates in 150 mM NaCl and 3 mM MgCl2 as a function of hyperacetylated histone deacetylation. Expressed and competent chromatin was associated with class I acetylated histones. As most active chromatin and hyperacetylated histones are associated with the low salt-insoluble residual nuclear material containing the nuclear matrix, we investigated whether hyperacetylated histones are bound to the beta (A)- and epsilon -globin DNA in this fraction. In chromatin. immunoprecipitation assays, we found that the beta (A)- and epsilon -globin coding regions are bound to hyperacetylated H3 and H4. Our observations are consistent with a model in which nuclear matrix-associated histone acetyltransferases and deacetylases mediate a dynamic attachment between active and competent chromatin and the nuclear matrix.	Univ Manitoba, Manitoba Inst Cell Biol, Winnipeg, MB R3E 0V9, Canada	University of Manitoba	Davie, JR (corresponding author), Univ Manitoba, Manitoba Inst Cell Biol, 675 McDermot Ave, Winnipeg, MB R3E 0V9, Canada.	Davie@cc.umaritoba.ca		Davie, James/0000-0002-0420-6888				ALONSO WR, 1987, NUCLEIC ACIDS RES, V15, P9325, DOI 10.1093/nar/15.22.9325; Davie JR, 1999, J CELL BIOCHEM, P141; DELCUVE GP, 1989, BIOCHEM J, V263, P179, DOI 10.1042/bj2630179; DODGSON JB, 1983, J BIOL CHEM, V258, P2685; DOLAN M, 1983, J BIOL CHEM, V258, P3983; FERENZ CR, 1985, NUCLEIC ACIDS RES, V13, P1977, DOI 10.1093/nar/13.6.1977; HEBBES TR, 1994, EMBO J, V13, P1823, DOI 10.1002/j.1460-2075.1994.tb06451.x; HENDZEL MJ, 1994, J BIOL CHEM, V269, P22894; HENDZEL MJ, 1991, J BIOL CHEM, V266, P21936; Misteli T, 2000, NATURE, V408, P877, DOI 10.1038/35048610; Nickerson JA, 1997, P NATL ACAD SCI USA, V94, P4446, DOI 10.1073/pnas.94.9.4446; RIDSDALE JA, 1990, J BIOL CHEM, V265, P5150; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Tse C, 1998, MOL CELL BIOL, V18, P4629, DOI 10.1128/MCB.18.8.4629; Walia H, 1998, J BIOL CHEM, V273, P14516, DOI 10.1074/jbc.273.23.14516; Wang XY, 2001, J BIOL CHEM, V276, P12764, DOI 10.1074/jbc.M100501200; ZHANG DE, 1988, BIOCHEM J, V250, P241, DOI 10.1042/bj2500241; ZHANG DE, 1988, BIOCHEM J, V250, P233, DOI 10.1042/bj2500233; ZHANG DE, 1986, BIOCHEM J, V240, P857, DOI 10.1042/bj2400857	19	25	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					34810	34815		10.1074/jbc.M104886200	http://dx.doi.org/10.1074/jbc.M104886200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11435438	hybrid			2022-12-25	WOS:000171024600063
J	Li, B; Trueb, B				Li, B; Trueb, B			Analysis of the alpha-actinin/zyxin interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL CONTACT PROTEIN; ZYXIN-RELATED PROTEIN; DOMAIN; BINDING; IDENTIFICATION; ACTIN; PDZ; PURIFICATION; ADHESION; CRP1	The yeast two-hybrid system was used to search for interaction partners of human zyxin. Screening of two different cDNA libraries, one prepared from human placenta, the other from human heart, yielded several positive clones that occurred in both searches, including clones coding for cyclophilin, nebulette, and a-actinin. The zyxin/alpha -actinin interaction was analyzed in detail. By site-directed mutagenesis, a linear motif of 6 amino acids (Phe-Gly-Pro-Val-Val-Ala) present at the N terminus of zyxin was found to play a critical role. Replacement of a single amino acid within this motif abolished binding to a-actinin in blot overlays as well as in living cells. On the other hand, the interaction site in a-actinin was mapped to a conformational. determinant present in the center of the protein as demonstrated by a fragment deletion analysis. This binding site involved a tandem array of two complete spectrin-like domains. Only fragments that were able to dimerize in yeast also bound to zyxin, suggesting that dimerization of ix-actinin is essential for zyxin binding.	Univ Bern, ME Muller Inst Biomech, CH-3010 Bern, Switzerland	University of Bern	Trueb, B (corresponding author), Univ Bern, ME Muller Inst Biomech, POB 30, CH-3010 Bern, Switzerland.	trueb@mem.unibe.ch	Trueb, Beat/AAL-9621-2020	Trueb, Beat/0000-0001-8684-6856				Cameron LA, 2000, NAT REV MOL CELL BIO, V1, P110, DOI 10.1038/35040061; COSTA GL, 1995, STRATAGENE STRATEGIE, V8, P6; CRAWFORD AW, 1991, J BIOL CHEM, V266, P5847; CRAWFORD AW, 1992, J CELL BIOL, V116, P1381, DOI 10.1083/jcb.116.6.1381; CRITCHLEY DR, 1999, GUIDEBOOK EXTRACELLU, P17; Djinovic-Carugo K, 1999, CELL, V98, P537, DOI 10.1016/S0092-8674(00)81981-9; Drees B, 2000, J BIOL CHEM, V275, P22503, DOI 10.1074/jbc.M001698200; Drees BE, 1999, J CELL BIOL, V147, P1549, DOI 10.1083/jcb.147.7.1549; DRESS BE, 1999, GUIDEBOOK EXTRACELLU, P95; Faulkner G, 1999, J CELL BIOL, V146, P465, DOI 10.1083/jcb.146.2.465; Golsteyn RM, 1997, J CELL SCI, V110, P1893; Hobert O, 1996, ONCOGENE, V12, P1577; Leinweber BD, 1999, BIOCHEM J, V344, P117, DOI 10.1042/0264-6021:3440117; LI B, 1993, FASEB J, V7, P957, DOI 10.1096/fasebj.7.10.8344494; Macalma T, 1996, J BIOL CHEM, V271, P31470, DOI 10.1074/jbc.271.49.31470; MILLAKE DB, 1989, NUCLEIC ACIDS RES, V17, P6725, DOI 10.1093/nar/17.16.6725; Mukai H, 1997, J BIOL CHEM, V272, P4740, DOI 10.1074/jbc.272.8.4740; Murthy KK, 1999, J BIOL CHEM, V274, P20679, DOI 10.1074/jbc.274.29.20679; Niebuhr K, 1997, EMBO J, V16, P5433, DOI 10.1093/emboj/16.17.5433; Nieset JE, 1997, J CELL SCI, V110, P1013; Nix DA, 1997, J CELL BIOL, V138, P1139, DOI 10.1083/jcb.138.5.1139; Petit MMR, 1996, GENOMICS, V36, P118, DOI 10.1006/geno.1996.0432; Pomies P, 1997, J CELL BIOL, V139, P157, DOI 10.1083/jcb.139.1.157; REINHARD M, 1995, P NATL ACAD SCI USA, V92, P7956, DOI 10.1073/pnas.92.17.7956; Reinhard M, 1999, J BIOL CHEM, V274, P13410, DOI 10.1074/jbc.274.19.13410; SADLER I, 1992, J CELL BIOL, V119, P1573, DOI 10.1083/jcb.119.6.1573; Schenker T, 2000, BBA-GENE STRUCT EXPR, V1493, P255, DOI 10.1016/S0167-4781(00)00167-6; Schmeichel KL, 1998, BIOCHEM J, V331, P885, DOI 10.1042/bj3310885; Schultz J, 2000, NUCLEIC ACIDS RES, V28, P231, DOI 10.1093/nar/28.1.231; Vallenius T, 2000, J BIOL CHEM, V275, P11100, DOI 10.1074/jbc.275.15.11100; WILLIMANN TE, 1994, J BIOL CHEM, V269, P332; Wyszynski M, 1997, NATURE, V385, P439, DOI 10.1038/385439a0; Xia HH, 1997, J CELL BIOL, V139, P507, DOI 10.1083/jcb.139.2.507; Young P, 1998, EMBO J, V17, P1614, DOI 10.1093/emboj/17.6.1614; Zumbrunn J, 1996, EUR J BIOCHEM, V241, P657, DOI 10.1111/j.1432-1033.1996.00657.x	35	39	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33328	33335		10.1074/jbc.M100789200	http://dx.doi.org/10.1074/jbc.M100789200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11423549	hybrid			2022-12-25	WOS:000170910200008
J	Torrents, E; Eliasson, R; Wolpher, H; Graslund, A; Reichard, P				Torrents, E; Eliasson, R; Wolpher, H; Graslund, A; Reichard, P			The anaerobic ribonucleotide reductase from Lactococcus lactis - Interactions between the two proteins NrdD and NrdG	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR CENTER; ELECTRON-PARAMAGNETIC-RESONANCE; PYRUVATE FORMATE-LYASE; ESCHERICHIA-COLI; LYSINE 2,3-AMINOMUTASE; BIOTIN SYNTHASE; ENZYME; EVOLUTION; CLUSTERS; 2FE-2S	Deoxyribonucleotide synthesis by anaerobic class III ribonucleotide reductases requires two proteins, NrdD and NrdG. NrdD contains catalytic and allosteric sites and, in its active form, a stable glycyl radical. This radical is generated by NrdG with its [4Fe-4S](+) cluster and S-adenosylmethionine. We now find that. NrdD and NrdG from Lactobacillus lactis anaerobically form a tight alpha (2)beta (2) complex, suggesting that radical generation by NrdG and radical transfer to the specific glycine residue of NrdD occurs within the complex. Activated NrdD was separated from NrdG by anaerobic affinity chromatography on dATP-Sepharose without loss of its glycyl radical NrdD alone then catalyzed the reduction of CTP with formate, as the electron donor and ATP as the allosteric effector. The reaction required Mg2+ and was stimulated by K+ but not by dithiothreitol. Thus NrdD is the actual reductase, and NrdG is an activase, making class III reductases highly similar to pyruvate formate lyase and its activase and suggesting a common root for the two anaerobic enzymes during early evolution. Our results further support the contention that ribonucleotide reduction during transition from an RNA world to a DNA world started with a class III-like enzyme from which other reductases evolved when oxygen appeared on earth.	Karolinska Inst, MBB, Med Nobel Inst, Dept Biochem, SE-17177 Stockholm, Sweden; Univ Autonoma Barcelona, Bacterial Mol Genet Inst Biotecnol & Biomed, E-08193 Bellaterra, Spain; Univ Stockholm, Dept Biochem & Biophys, SE-10691 Stockholm, Sweden	Karolinska Institutet; Autonomous University of Barcelona; Stockholm University	Reichard, P (corresponding author), Karolinska Inst, Dept Biochem 1, SE-17177 Stockholm, Sweden.	peter.reichard@mbb.ki.se	Torrents, Eduard/C-7184-2008	Torrents, Eduard/0000-0002-3010-1609				Becker A, 1999, NAT STRUCT BIOL, V6, P969; BIANCHI V, 1993, BIOCHEM BIOPH RES CO, V197, P792, DOI 10.1006/bbrc.1993.2548; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cosper NJ, 2000, BIOCHEMISTRY-US, V39, P15668, DOI 10.1021/bi0022184; Duin EC, 1997, BIOCHEMISTRY-US, V36, P11811, DOI 10.1021/bi9706430; FISH WW, 1988, METHOD ENZYMOL, V158, P357, DOI 10.1016/0076-6879(88)58067-9; FONTECAVE M, 1992, ADV ENZYMOL RAMB, V65, P147; FONTECAVE M, 1989, P NATL ACAD SCI USA, V86, P2147, DOI 10.1073/pnas.86.7.2147; Freeland SJ, 1999, SCIENCE, V286, P690, DOI 10.1126/science.286.5440.690; Jordan A, 1996, J BIOL CHEM, V271, P8779, DOI 10.1074/jbc.271.15.8779; Jordan A, 1998, ANNU REV BIOCHEM, V67, P71, DOI 10.1146/annurev.biochem.67.1.71; KESSLER D, 1996, ESCHERICHIA COLI SAL, P1999; KING TE, 1976, METHOD ENZYMOL, V110, P634; Krieger CJ, 2001, J BIOL CHEM, V276, P12924, DOI 10.1074/jbc.M009453200; Lieder KW, 1998, BIOCHEMISTRY-US, V37, P2578, DOI 10.1021/bi972417w; Liu A, 2000, J BIOL CHEM, V275, P12367, DOI 10.1074/jbc.275.17.12367; Logan DT, 1999, SCIENCE, V283, P1499, DOI 10.1126/science.283.5407.1499; Magnusson OT, 1999, J AM CHEM SOC, V121, P9764, DOI 10.1021/ja9925507; Miller JR, 2000, BIOCHEMISTRY-US, V39, P15166, DOI 10.1021/bi002060n; MULLIEZ E, 1995, P NATL ACAD SCI USA, V92, P8759, DOI 10.1073/pnas.92.19.8759; Ollagnier S, 1996, J BIOL CHEM, V271, P9410, DOI 10.1074/jbc.271.16.9410; Ollagnier S, 1999, J AM CHEM SOC, V121, P6344, DOI 10.1021/ja990073m; Ollagnier S, 1997, J BIOL CHEM, V272, P24216, DOI 10.1074/jbc.272.39.24216; Ollagnier-de Choudens S, 2000, BIOCHEMISTRY-US, V39, P4165, DOI 10.1021/bi992090u; Reichard P, 1997, TRENDS BIOCHEM SCI, V22, P81, DOI 10.1016/S0968-0004(97)01003-7; REICHARD P, 1993, J BIOL CHEM, V268, P8383; REICHARD P, 1993, SCIENCE, V260, P1773, DOI 10.1126/science.8511586; Sofia HJ, 2001, NUCLEIC ACIDS RES, V29, P1097, DOI 10.1093/nar/29.5.1097; Stuber F, 1998, PROD PLAN CONTROL, V9, P705, DOI 10.1080/095372898233713; Tamarit J, 1999, J BIOL CHEM, V274, P31291, DOI 10.1074/jbc.274.44.31291; Torrents E, 2000, J BIOL CHEM, V275, P2463, DOI 10.1074/jbc.275.4.2463; WAGNER AFV, 1992, P NATL ACAD SCI USA, V89, P996, DOI 10.1073/pnas.89.3.996	32	28	29	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33488	33494		10.1074/jbc.M103743200	http://dx.doi.org/10.1074/jbc.M103743200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11427536	hybrid			2022-12-25	WOS:000170910200028
J	Church, WB; Inglis, AS; Tseng, A; Duell, R; Lei, PW; Bryant, KJ; Scott, KF				Church, WB; Inglis, AS; Tseng, A; Duell, R; Lei, PW; Bryant, KJ; Scott, KF			A novel approach to the design of inhibitors of human secreted phospholipase A(2) based on native peptide inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHEUMATOID-ARTHRITIS; DISEASE-ACTIVITY; RATIONAL DESIGN; SEPTIC SHOCK; MAST-CELLS; EXPRESSION; PROTEIN; POTENT; INFLAMMATION; PATHWAYS	Human Type IIA secreted phospholipase A(2) (sPIA(2)-IIA) is an important modulator of cytokine-dependent inflammatory responses and a member of a growing superfamily of structurally related phospholipases. We have previously shown that sPLA(2)-IIA is inhibited by a pentapeptide sequence comprising residues 70-74 of the native sPLA2-IIA protein and that peptides derived from the equivalent region of different sPLA(2)-IIA species specifically inhibit the enzyme from which they are derived. We have now used an analogue screen of the human pentapeptide (70)FLSyK(74) in which side-chain residues were substituted, together with molecular docking approaches that modeled low-energy conformations of (FLSYK74)-F-70 bound to human sPLA(2)-IIA, to generate inhibitors with improved potency. Importantly, the modeling studies showed a close association between the NH2 and COOH termini of the peptide, predicting significant enhancement of the potency of inhibition by cyclization. Cyclic compounds were synthesized and indeed showed 5-50-fold increased potency over the linear peptide in an Escherichia coli membrane assay. Furthermore, the potency of inhibition correlated with steady-state binding of the cyclic peptides to sPIA2-IIA as determined by surface plasmon resonance studies. Two potential peptide interaction sites were identified on sPLA(2)-IIA from the modeling studies, one in the NH2-terminal helix and the other in the beta -wing region, and in vitro association assays support the potential for interaction of the peptides with these sites. The inhibitors were effective at nanomolar concentrations in blocking sPLA(2)-IIA-mediated amplification of cytokine-induced prostaglandin synthesis in human rheumatoid synoviocytes in culture. These studies provide an example where native peptide sequences can be used for the development of potent and selective inhibitors of enzyme function.	Univ New S Wales, St Vincents Hosp, Sch Clin, Dept Med, Sydney, NSW 2010, Australia; Univ New S Wales, St Vincents Hosp, Garvan Inst Med Res, Arthrit & Inflammat Res Programme, Sydney, NSW 2010, Australia	St Vincents Hospital Sydney; University of New South Wales Sydney; Garvan Institute of Medical Research; St Vincents Hospital Sydney; University of New South Wales Sydney	Scott, KF (corresponding author), Univ New S Wales, St Vincents Hosp, Sch Clin, Dept Med, L10 Garvan Bldg,384 Victoria St, Sydney, NSW 2010, Australia.		Bryant, Katherine/E-8574-2010; Church, William/H-6040-2013	Bryant, Katherine/0000-0002-8686-623X; Church, William/0000-0002-8033-5518; Scott, Kieran/0000-0002-6012-4107				ANDERSEN S, 1994, INFLAMMATION, V18, P1, DOI 10.1007/BF01534593; Balboa MA, 1996, J BIOL CHEM, V271, P32381, DOI 10.1074/jbc.271.50.32381; BAYBURT T, 1993, BIOCHEMISTRY-US, V32, P573, DOI 10.1021/bi00053a024; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; Bidgood MJ, 2000, J IMMUNOL, V165, P2790, DOI 10.4049/jimmunol.165.5.2790; BOMALASKI JS, 1991, J IMMUNOL, V146, P3904; Bowton DL, 1997, AM J RESP CRIT CARE, V155, P421, DOI 10.1164/ajrccm.155.2.9032172; CIRINO G, 1994, J RHEUMATOL, V21, P824; DIJKSTRA BW, 1981, J MOL BIOL, V147, P97, DOI 10.1016/0022-2836(81)90081-4; Gelb MH, 2000, J BIOL CHEM, V275, P39823, DOI 10.1074/jbc.C000671200; GREEN JA, 1991, INFLAMMATION, V15, P355, DOI 10.1007/BF00917352; Jamal OS, 1998, ANN RHEUM DIS, V57, P550, DOI 10.1136/ard.57.9.550; KIM DK, 1995, AM J PHYSIOL, V269, P109; Kim KP, 2001, J BIOL CHEM, V276, P11126, DOI 10.1074/jbc.M004604200; LAM PYS, 1994, SCIENCE, V263, P380, DOI 10.1126/science.8278812; Lin MKS, 1996, J RHEUMATOL, V23, P1162; MINAMI T, 1994, GUT, V35, P1593, DOI 10.1136/gut.35.11.1593; *MOL SIM INC, 1995, INS 2 DISC US GUID V; MONTGOMERY JA, 1993, J MED CHEM, V36, P55, DOI 10.1021/jm00053a008; Murakami M, 1999, J BIOL CHEM, V274, P3103, DOI 10.1074/jbc.274.5.3103; Murakami M, 2001, J BIOL CHEM, V276, P10083, DOI 10.1074/jbc.M007877200; PRUZANSKI W, 1988, J RHEUMATOL, V15, P1351; Reddy ST, 1997, J BIOL CHEM, V272, P13591, DOI 10.1074/jbc.272.21.13591; REICH SH, 1992, J MED CHEM, V35, P847, DOI 10.1021/jm00083a007; RICE GE, 1992, EICOSANOIDS, V5, P9; Sawada H, 1999, EUR J BIOCHEM, V263, P826, DOI 10.1046/j.1432-1327.1999.00565.x; SCHEVITZ RW, 1995, NAT STRUCT BIOL, V2, P458, DOI 10.1038/nsb0695-458; SCOTT DL, 1991, SCIENCE, V254, P1007, DOI 10.1126/science.1948070; Scott KF, 1999, J LEUKOCYTE BIOL, V66, P535, DOI 10.1002/jlb.66.4.535; Shen BJ, 1996, EUR J BIOCHEM, V240, P252, DOI 10.1111/j.1432-1033.1996.0252h.x; SMITH GM, 1992, BRIT J RHEUMATOL, V31, P175; Suzuki N, 2000, J BIOL CHEM, V275, P5785, DOI 10.1074/jbc.275.8.5785; Tada K, 1998, J IMMUNOL, V161, P5008; Tseng A, 1996, J BIOL CHEM, V271, P23992, DOI 10.1074/jbc.271.39.23992; VADAS P, 1984, J LAB CLIN MED, V104, P873; Valentin E, 1999, J BIOL CHEM, V274, P31195, DOI 10.1074/jbc.274.44.31195; Valentin E, 1999, J BIOL CHEM, V274, P19152, DOI 10.1074/jbc.274.27.19152; Valentin E, 2000, J BIOL CHEM, V275, P7492, DOI 10.1074/jbc.275.11.7492; VONITZSTEIN M, 1993, NATURE, V363, P418, DOI 10.1038/363418a0	39	38	42	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					33156	33164		10.1074/jbc.M101272200	http://dx.doi.org/10.1074/jbc.M101272200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11427527	hybrid			2022-12-25	WOS:000170746000102
J	Senga, T; Iwamoto, T; Kitamura, T; Miyake, Y; Hamaguchi, M				Senga, T; Iwamoto, T; Kitamura, T; Miyake, Y; Hamaguchi, M			JAK/STAT3-dependent activation of the RalGDS/Ral pathway in M1 mouse myeloid leukemia cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOKINE RECEPTOR GP130; RAS; STAT3; SIGNALS; FAMILY; EXPRESSION; EFFECTOR; CLONING; ROLES; GENE	The Ras-related GTPase (Ral) is converted to the GTP-bound form by Ral guanine nucleotide dissociation stimulator (RalGDS), a putative effector protein of Ras. Recently, it was proven that Ral regulates c-Src activity and subsequent phosphorylation of its substrate, STAT3. Here, we show that STAT3 inversely regulates activation of Ral through induction of expression of RalGDS. To identify new leukemia inhibitory factor-induced genes, we have performed representational difference analysis using M1 mouse myeloid leukemia cells and cloned RalGDS. The expression of RalGDS and subsequent activation of RalA were clearly suppressed by a dominant negative form of STAT3 and a JAK inhibitor, JAB/SOCS1/SSI-1, indicating that RalGDS/RalA signaling requires the activation of the JAK/STAT3 pathway. An experiment using a Ras inhibitor demonstrated that full activation of RalA also requires activation of Ras. These results suggest a novel cross-talk between JAW STAT3 and the Ras/RalGDS/Ral signaling pathways through gp130.	Nagoya Univ, Sch Med, Radioisotope Res Ctr, Div Med,Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Sch Med, Dept Ophthalmol, Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Sch Med, Dept Mol Pathogenesis, Showa Ku, Nagoya, Aichi 4668550, Japan; Univ Tokyo, Inst Med Sci, Dept Hematopoiet Factors, Minato Ku, Tokyo 1088639, Japan	Nagoya University; Nagoya University; Nagoya University; University of Tokyo	Iwamoto, T (corresponding author), Nagoya Univ, Sch Med, Radioisotope Res Ctr, Div Med,Showa Ku, 65 Tsurumai cho, Nagoya, Aichi 4668550, Japan.	iwamoto@med.nagoya-u.ac.jp	Kitamura, Toshio/AAA-2071-2021					ALBRIGHT CF, 1993, EMBO J, V12, P339, DOI 10.1002/j.1460-2075.1993.tb05662.x; Bellido T, 1998, J BIOL CHEM, V273, P21137, DOI 10.1074/jbc.273.33.21137; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; CHARDIN P, 1986, EMBO J, V5, P2203, DOI 10.1002/j.1460-2075.1986.tb04485.x; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Feig LA, 1996, TRENDS BIOCHEM SCI, V21, P438, DOI 10.1016/S0968-0004(96)10058-X; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Fukada T, 1998, EMBO J, V17, P6670, DOI 10.1093/emboj/17.22.6670; Goi T, 2000, EMBO J, V19, P623, DOI 10.1093/emboj/19.4.623; Goi T, 1999, MOL CELL BIOL, V19, P1731; Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551; HOFER F, 1994, P NATL ACAD SCI USA, V91, P4578; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; Ihara S, 1997, EMBO J, V16, P5345, DOI 10.1093/emboj/16.17.5345; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; Kitamura T, 2000, METH MOL B, V134, P143; LERNER EC, 1995, J BIOL CHEM, V270, P26802, DOI 10.1074/jbc.270.45.26802; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; Masuhara M, 1997, BIOCHEM BIOPH RES CO, V239, P439, DOI 10.1006/bbrc.1997.7484; Matsubara K, 1999, ONCOGENE, V18, P1303, DOI 10.1038/sj.onc.1202425; Nakashima S, 1999, EMBO J, V18, P3629, DOI 10.1093/emboj/18.13.3629; O'Farrell AM, 2000, J IMMUNOL, V164, P4607, DOI 10.4049/jimmunol.164.9.4607; Park SH, 1995, ONCOGENE, V11, P2349; Shirogane T, 1999, IMMUNITY, V11, P709, DOI 10.1016/S1074-7613(00)80145-4; Takahashi-Tezuka M, 1998, MOL CELL BIOL, V18, P4109, DOI 10.1128/MCB.18.7.4109; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; Wolthuis RMF, 1999, CURR OPIN GENET DEV, V9, P112, DOI 10.1016/S0959-437X(99)80016-1; Wolthuis RMF, 1998, MOL CELL BIOL, V18, P2486, DOI 10.1128/MCB.18.5.2486; Wolthuis RMF, 1996, ONCOGENE, V13, P353	31	16	16	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					32678	32681		10.1074/jbc.M105749200	http://dx.doi.org/10.1074/jbc.M105749200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11432872	hybrid			2022-12-25	WOS:000170746000041
J	Wu, MM; Grabe, M; Adams, S; Tsien, RY; Moore, HPH; Machen, TE				Wu, MM; Grabe, M; Adams, S; Tsien, RY; Moore, HPH; Machen, TE			Mechanisms of pH regulation in the regulated secretory pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; GREEN FLUORESCENT PROTEINS; LIVING CELLS; SYNAPTIC VESICLES; SECRETOGRANIN-II; MEMBRANE; ACIDIFICATION; GRANULE; COMPLEX; INSULIN	A precise pH gradient between organelles of the regulated secretory pathway is required for sorting and processing of prohormones. We studied pH regulation in live endocrine cells by targeting biotin-based pH indicators to cellular organelles expressing avidin-chimera proteins. In AtT-20 cells, we found that steady-state pH decreased from the endoplasmic reticulum (ER) (pH(ER) = 7.4 +/- 0.2, mean +/- S.D.) to Golgi (pH(G) = 6.2 +/- 0.4) to mature secretory granules (MSGs) (pH(MSG) = 5.5 +/- 0.4). Golgi and MSGs required active H+ v-ATPases for acidification. ER, Golgi, and MSG steady-state pH values were also dependent upon the different H+ leak rates across each membrane. However, neither steady-state pH(MSG) nor rates of passive H+ leak were affected by Cl--free solutions or valinomycin, indicating that MSG membrane potential was small and not a determinant of pH(MSG). Therefore, our data do not support earlier suggestions that organelle acidification is primarily regulated by Cl- conductances. Measurements of H+ leak rates, buffer capacities, and estimates of surface areas and volumes of these organelles were applied to a mathematical model to determine the H+ permeability (PH+) of each organelle membrane. We found that PH+ decreased progressively from ER to Golgi to MSGs, and proper acidification of Golgi and MSGs required gradual decreases in PH+ and successive increases in the active H+ pump density.	Univ Calif Berkeley, Dept Cell & Mol Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Phys, Berkeley, CA 94720 USA; Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92093 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego	Machen, TE (corresponding author), Univ Calif Berkeley, Dept Cell & Mol Biol, 231 Life Sci Addit, Berkeley, CA 94720 USA.		Grabe, Michael/B-3705-2009		NCRR NIH HHS [R24RR14891] Funding Source: Medline; NIDDK NIH HHS [DK51799] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051799] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALAWQATI Q, 1986, ANNU REV CELL BIOL, V2, P179, DOI 10.1146/annurev.cellbio.2.1.179; ANDERSON RGW, 1985, CELL, V40, P635, DOI 10.1016/0092-8674(85)90212-0; Arvan P, 1998, BIOCHEM J, V332, P593, DOI 10.1042/bj3320593; BARASCH J, 1988, J CELL BIOL, V107, P2137, DOI 10.1083/jcb.107.6.2137; CAIN CC, 1989, P NATL ACAD SCI USA, V86, P544, DOI 10.1073/pnas.86.2.544; CHANAT E, 1991, J CELL BIOL, V115, P1505, DOI 10.1083/jcb.115.6.1505; CHAVEZ RA, 1994, METHOD CELL BIOL, V43, P263; CHEGE NW, 1990, J CELL BIOL, V111, P893, DOI 10.1083/jcb.111.3.893; Colomer V, 1996, J BIOL CHEM, V271, P48, DOI 10.1074/jbc.271.1.48; Demaurex N, 1998, J BIOL CHEM, V273, P2044, DOI 10.1074/jbc.273.4.2044; Farinas J, 1999, J BIOL CHEM, V274, P7603, DOI 10.1074/jbc.274.12.7603; FUCHS R, 1989, P NATL ACAD SCI USA, V86, P539, DOI 10.1073/pnas.86.2.539; GERDES HH, 1989, J BIOL CHEM, V264, P12009; Grabe M, 2001, J GEN PHYSIOL, V117, P329, DOI 10.1085/jgp.117.4.329; GROTE E, 1995, CELL, V81, P581, DOI 10.1016/0092-8674(95)90079-9; GUMBINER B, 1981, P NATL ACAD SCI-BIOL, V78, P318, DOI 10.1073/pnas.78.1.318; HARTMANN T, 1990, BIOPHYS J, V58, P391, DOI 10.1016/S0006-3495(90)82385-7; HUTTON JC, 1982, BIOCHEM J, V204, P171, DOI 10.1042/bj2040171; Kim JH, 1996, J CELL BIOL, V134, P1387, DOI 10.1083/jcb.134.6.1387; Kim JH, 1998, P NATL ACAD SCI USA, V95, P2997, DOI 10.1073/pnas.95.6.2997; LANGRIDGESMITH JE, 1986, J MEMBRANE BIOL, V94, P197, DOI 10.1007/BF01869715; Llopis J, 1998, P NATL ACAD SCI USA, V95, P6803, DOI 10.1073/pnas.95.12.6803; MAYCOX PR, 1988, J BIOL CHEM, V263, P15423; MCNEIL PL, 1984, J CELL BIOL, V98, P1556, DOI 10.1083/jcb.98.4.1556; Miesenbock G, 1998, NATURE, V394, P192, DOI 10.1038/28190; ORCI L, 1987, CELL, V49, P865, DOI 10.1016/0092-8674(87)90624-6; ORCI L, 1994, J CELL BIOL, V126, P1149, DOI 10.1083/jcb.126.5.1149; ORCI L, 1986, J CELL BIOL, V103, P2273, DOI 10.1083/jcb.103.6.2273; Paula S, 1996, BIOPHYS J, V70, P339, DOI 10.1016/S0006-3495(96)79575-9; ROOS A, 1981, PHYSIOL REV, V61, P296, DOI 10.1152/physrev.1981.61.2.296; Schapiro FB, 2000, J BIOL CHEM, V275, P21025, DOI 10.1074/jbc.M002386200; SCHMIDT WK, 1995, MOL BIOL CELL, V6, P1271, DOI 10.1091/mbc.6.10.1271; SCHWARTZ AL, 1985, EMBO J, V4, P899, DOI 10.1002/j.1460-2075.1985.tb03716.x; SEKSEK O, 1995, J BIOL CHEM, V270, P4967, DOI 10.1074/jbc.270.10.4967; Stobrawa SM, 2001, NEURON, V29, P185, DOI 10.1016/S0896-6273(01)00189-1; TAGA R, 1993, ARCH HISTOL CYTOL, V58, P517; TAYLOR JR, 1982, INTRO ERROR ANAL, P141; Teter K, 1998, J BIOL CHEM, V273, P19625, DOI 10.1074/jbc.273.31.19625; Urbe S, 1997, BIOCHEM J, V321, P65, DOI 10.1042/bj3210065; Wu MM, 2000, CHEM BIOL, V7, P197, DOI 10.1016/S1074-5521(00)00088-0	40	205	206	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					33027	33035		10.1074/jbc.M103917200	http://dx.doi.org/10.1074/jbc.M103917200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11402049	hybrid			2022-12-25	WOS:000170746000087
J	Dan, C; Kelly, A; Bernard, O; Minden, A				Dan, C; Kelly, A; Bernard, O; Minden, A			Cytoskeletal changes regulated by the PAK4 serine/threonine kinase are mediated by LIM kinase 1 and cofilin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASES; ACTIN STRESS FIBERS; P21-ACTIVATED KINASE; FOCAL COMPLEXES; JUN KINASE; RHO; RAC; GTPASES; CDC42; PHOSPHORYLATION	PAK4 is the most recently identified member of the PAR family of serine/threonine kinases. PAK4 differs from other members of the PAK family in sequence and in many of its functions. Previously, we have shown that an important function of this kinase is to mediate the induction of filopodia in response to the Rho GTPase Cdc42. Here we show that PAR4 also regulates the activity of the protein kinase LIM kinase 1 (LIMK1). PAK4 was shown to interact specifically with LIMK1 in binding assays. Immune complex kinase assays revealed that both wild-type and constitutively active PAK4 phosphorylated LIMK1 even more strongly than PAK1, and activated PAK4 stimulated LIMK1's ability to phosphorylate cofilin. Immunofluorescence experiments revealed that PAK4 and LIMK1 cooperate to induce cytoskeletal changes in C2C12 cells. Furthermore, dominant negative LIMK1 and a mutant cofilin inhibited the specific cytoskeletal and cell shape changes that were induced in response to a recently characterized constitutively activated PAK4 mutant.	Columbia Univ, Sherman Fairchild Ctr, Dept Biol Sci, New York, NY 10027 USA; Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Mol Neurobiol Lab, Melbourne, Vic 3050, Australia	Columbia University; Royal Melbourne Hospital; Walter & Eliza Hall Institute	Minden, A (corresponding author), Columbia Univ, Sherman Fairchild Ctr, Dept Biol Sci, Biol Sci MC 2460,Rm 813,1212 Amsterdam Ave, New York, NY 10027 USA.		Bernard, Olivier/J-1133-2014	Bernard, Olivier/0000-0003-2539-9014; Dan, Chuntao/0000-0002-8951-4248	NCI NIH HHS [R01 CA76342] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076342] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abo A, 1998, EMBO J, V17, P6527, DOI 10.1093/emboj/17.22.6527; Arber S, 1998, NATURE, V393, P805, DOI 10.1038/31729; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; Bagrodia S, 1999, TRENDS CELL BIOL, V9, P350, DOI 10.1016/S0962-8924(99)01618-9; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Brown JL, 1996, CURR BIOL, V6, P598, DOI 10.1016/S0960-9822(02)00546-8; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Dutartre H, 1996, J CELL SCI, V109, P367; Edwards DC, 1999, NAT CELL BIOL, V1, P253, DOI 10.1038/12963; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; Joneson T, 1996, SCIENCE, V274, P1374, DOI 10.1126/science.274.5291.1374; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; MOON A, 1995, MOL BIOL CELL, V6, P1423, DOI 10.1091/mbc.6.11.1423; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NUNOUE K, 1995, ONCOGENE, V11, P701; Ohashi K, 2000, J BIOL CHEM, V275, P3577, DOI 10.1074/jbc.275.5.3577; Qu J, 2001, MOL CELL BIOL, V21, P3523, DOI 10.1128/MCB.21.10.3523-3533.2001; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Roberts AW, 1999, IMMUNITY, V10, P183, DOI 10.1016/S1074-7613(00)80019-9; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Sanders LC, 1999, SCIENCE, V283, P2083, DOI 10.1126/science.283.5410.2083; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; Stanyon CA, 1999, INT J BIOCHEM CELL B, V31, P389, DOI 10.1016/S1357-2725(98)00116-2; Sumi T, 1999, J CELL BIOL, V147, P1519, DOI 10.1083/jcb.147.7.1519; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; Yang N, 1998, NATURE, V393, P809, DOI 10.1038/31735; Yang XL, 1998, SCIENCE, V281, P1355, DOI 10.1126/science.281.5381.1355; Zeng Q, 2000, J CELL SCI, V113, P471; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	43	210	224	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					32115	32121		10.1074/jbc.M100871200	http://dx.doi.org/10.1074/jbc.M100871200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11413130	hybrid			2022-12-25	WOS:000170613500088
J	Orsi, A; Sparvoli, F; Ceriotti, A				Orsi, A; Sparvoli, F; Ceriotti, A			Role of individual disulfide bonds in the structural maturation of a low molecular weight glutenin subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WHEAT STORAGE PROTEINS; 11S SEED GLOBULINS; ENDOPLASMIC-RETICULUM; XENOPUS-OOCYTES; INFLUENZA HEMAGGLUTININ; HETEROTYPIC AGGREGATION; CONSERVED CYSTEINES; SECRETORY PROTEINS; MEMBRANE-PROTEINS; ESCHERICHIA-COLI	Gliadins and glutenins are the major storage proteins that accumulate in wheat endosperm cells during seed development. Although gliadins are mainly monomeric, glutenins consist of very large disulfide-linked polymers made up of high molecular weight and low molecular weight subunits. These polymers are among the largest protein molecules known in nature and are the most important determinants of the viscoelastic properties of gluten. As a first step toward the elucidation of the folding and assembly pathways that lead to glutenin polymer formation, we have exploited an in vitro system composed of wheat germ extract and bean microsomes to examine the role of disulfide bonds in the structural maturation of a low molecular weight glutenin subunit. When conditions allowing the formation of disulfide bonds were established, the in vitro synthesized low molecular weight glutenin subunit was recovered in monomeric form containing intrachain disulfide bonds. Conversely, synthesis under conditions that did not favor the formation of disulfide bonds led to the production of large aggregates from which the polypeptides could not be rescued by the post-translational generation of a more oxidizing environment. These results indicate that disulfide bond formation is essential for the conformational maturation of the low molecular weight glutenin subunit and suggest that early folding steps may play an important role in this process, allowing the timely pairing of critical cysteine residues. To determine which cysteines were important to maintain the protein in monomeric form, we prepared a set of mutants containing selected cysteine to serine substitutions. Our results show that two conserved cysteine residues form a critical disulfide bond that is essential in preventing the exposure of adhesive domains and the consequent formation of aberrant aggregates.	CNR, Ist Biosintesi Vegetali, Via Bassini 15, I-20133 Milan, Italy	Consiglio Nazionale delle Ricerche (CNR)	Ceriotti, A (corresponding author), CNR, Ist Biosintesi Vegetali, Via Bassini 15, I-20133 Milan, Italy.	aldo.ceriotti@ibv.mi.cnr.it	Ceriotti, Aldo/A-1448-2016; Sparvoli, Francesca/G-8372-2015	Ceriotti, Aldo/0000-0002-8230-8863; Orsi, Andrea/0000-0003-2839-1640; Sparvoli, Francesca/0000-0002-3304-7548				ALTSCHULER Y, 1994, J BIOL CHEM, V269, P6677; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BRAAKMAN I, 1991, J CELL BIOL, V114, P401, DOI 10.1083/jcb.114.3.401; BULLEID NJ, 1988, NATURE, V335, P649, DOI 10.1038/335649a0; BULLEID NJ, 1988, BIOCHEM J, V254, P805, DOI 10.1042/bj2540805; CERIOTTI A, 1991, EUR J BIOCHEM, V202, P959, DOI 10.1111/j.1432-1033.1991.tb16456.x; Ceriotti A, 1995, METHOD CELL BIOL, V50, P295, DOI 10.1016/S0091-679X(08)61038-9; CERIOTTI A, 1990, J CELL BIOL, V111, P409, DOI 10.1083/jcb.111.2.409; DICKINSON CD, 1987, P NATL ACAD SCI USA, V84, P5525, DOI 10.1073/pnas.84.16.5525; DOvidio R, 1997, THEOR APPL GENET, V95, P1119, DOI 10.1007/s001220050671; DOvidio R, 1997, J CEREAL SCI, V25, P1, DOI 10.1006/jcrs.1996.0065; Egorov TA, 1996, FEBS LETT, V396, P285, DOI 10.1016/0014-5793(96)01117-9; Elliott JG, 1997, J BIOL CHEM, V272, P13849, DOI 10.1074/jbc.272.21.13849; Frand AR, 2000, TRENDS CELL BIOL, V10, P203, DOI 10.1016/S0962-8924(00)01745-1; Galili G, 1998, PLANT MOL BIOL, V38, P1, DOI 10.1023/A:1006011919671; Galili G, 1996, PLANT PHYSIOL BIOCH, V34, P245; HILLE A, 1989, J BIOL CHEM, V264, P13460; Jung R, 1997, PLANT CELL, V9, P2037, DOI 10.1105/tpc.9.11.2037; Jung R, 1998, PLANT CELL, V10, P343, DOI 10.1105/tpc.10.3.343; KECK B, 1995, Z LEBENSM UNTERS FOR, V200, P432, DOI 10.1007/BF01193253; KOHLER P, 1993, Z LEBENSM UNTERS FOR, V196, P239, DOI 10.1007/BF01202740; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVANONY H, 1992, J CELL BIOL, V119, P1117, DOI 10.1083/jcb.119.5.1117; Lupattelli F, 1997, PLANT CELL, V9, P597, DOI 10.1105/tpc.9.4.597; MARQUARDT T, 1992, J CELL BIOL, V117, P505, DOI 10.1083/jcb.117.3.505; MARQUARDT T, 1993, J BIOL CHEM, V268, P19618; MARTY I, 1991, PLANT MOL BIOL, V17, P143, DOI 10.1007/BF00036817; Muller S, 1998, J CEREAL SCI, V27, P23, DOI 10.1006/jcrs.1997.0146; Muller S, 1998, J CEREAL SCI, V27, P109, DOI 10.1006/jcrs.1997.0158; MULLER S, 1995, J CEREAL SCI, V22, P21, DOI 10.1016/S0733-5210(05)80004-9; Muller S, 1997, J CEREAL SCI, V26, P169, DOI 10.1006/S0733-5210(97)90100-4; Nam YW, 1997, PLANT PHYSIOL, V115, P1629, DOI 10.1104/pp.115.4.1629; Netzer WJ, 1997, NATURE, V388, P343, DOI 10.1038/41024; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; OKITA TW, 1985, J BIOL CHEM, V260, P8203; PHAM DQD, 1992, GENE, V122, P345, DOI 10.1016/0378-1119(92)90224-D; RIVERAMADRID R, 1995, P NATL ACAD SCI USA, V92, P5620, DOI 10.1073/pnas.92.12.5620; ROBINSON R, 1989, BIOCHEM J, V263, P497, DOI 10.1042/bj2630497; SAWYER JT, 1994, J BIOL CHEM, V269, P22440; SCHEELE G, 1982, J BIOL CHEM, V257, P2277; SHANI N, 1994, J BIOL CHEM, V269, P8924; Shewry PR, 1997, J CEREAL SCI, V25, P207, DOI 10.1006/jcrs.1996.0100; Shimoni Y, 1996, J BIOL CHEM, V271, P18869, DOI 10.1074/jbc.271.31.18869; Sparvoli R, 2000, PLANT J, V24, P825, DOI 10.1046/j.1365-313x.2000.00933.x; Stewart EJ, 1998, EMBO J, V17, P5543, DOI 10.1093/emboj/17.19.5543; THOMPSON S, 1994, J AGR FOOD CHEM, V42, P426, DOI 10.1021/jf00038a035; YILLA M, 1992, J CELL BIOL, V118, P245, DOI 10.1083/jcb.118.2.245	48	31	34	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					32322	32329		10.1074/jbc.M103833200	http://dx.doi.org/10.1074/jbc.M103833200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11418605	hybrid			2022-12-25	WOS:000170613500114
J	Tsang, WY; Sayles, LC; Grad, LI; Pilgrim, DB; Lemire, BD				Tsang, WY; Sayles, LC; Grad, LI; Pilgrim, DB; Lemire, BD			Mitochondrial respiratory chain deficiency in Caenorhabditis elegans results in developmental arrest and increased life span	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL GENOMIC ANALYSIS; COMPLEX-I; C-ELEGANS; UBIQUINONE OXIDOREDUCTASE; SACCHAROMYCES-CEREVISIAE; RNA INTERFERENCE; OXIDATIVE STRESS; REVERSE GENETICS; ATP SYNTHASE; DISEASES	The growth and development of Caenorhabditis elegans are energy-dependent and rely on the mitochondrial respiratory chain (MRC) as the major source of ATP. The MRC is composed of similar to 70 nuclear, and 12 mitochondrial gene products. Complexes I and V are multisubunit proteins of the MRC. The nuo-1 gene encodes the NADH- and FAIN-binding subunit of complex I, the NADH-ubiquinone oxidoreductase. The atp-2 gene en. codes the active-site subunit of complex V, the ATP synthase. The nuo-1 (ua1) and atp-2(ua2) mutations are both lethal. They result in developmental arrest at the third larval stage (L3), arrest of gonad development at the second larval stage (L2), and impaired mobility, pharyngeal pumping, and defecation. Surprisingly, the nuo-1 and atp-2 mutations significantly lengthen the life spans of the arrested animals. When MRC biogenesis is blocked by chloramphenicol or doxycycline (inhibitors of mitochondrial translation), a quantitative and homogeneous developmental arrest as L3 larvae also results. The common phenotype induced by the mutations and drugs suggests that the L3-to-L4 transition may involve an energy-sensing developmental checkpoint. Since similar to 200 gene products are needed for MRC assembly and mtDNA replication, transcription, and translation, we predict that L3 arrest will be characteristic of mutations in these genes.	Univ Alberta, Dept Biochem, Canadian Inst Hlth, Res Grp Mol Biol Membrane Prot, Edmonton, AB T6G 2H7, Canada; Univ Alberta, Dept Sci Biol, Edmonton, AB T6G 2E9, Canada	University of Alberta; University of Alberta	Lemire, BD (corresponding author), Univ Alberta, Dept Biochem, Canadian Inst Hlth, Res Grp Mol Biol Membrane Prot, Edmonton, AB T6G 2H7, Canada.	bernard.lemire@ualberta.ca	Pilgrim, David B/A-2676-2014	Pilgrim, David B/0000-0001-7820-7915; Tsang, William/0000-0002-1584-616X				Aboobaker AA, 2000, ANN MED, V32, P23, DOI 10.3109/07853890008995906; ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Anderson P, 1995, METHOD CELL BIOL, V48, P31; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; AVERY L, 1997, C ELEGANS, V2, P679, DOI [10.1101/087969532.33.679, DOI 10.1101/087969532.33.679]; BEAL MF, 1995, ANN NEUROL, V38, P357, DOI 10.1002/ana.410380304; Bosher JM, 2000, NAT CELL BIOL, V2, pE31, DOI 10.1038/35000102; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Claros MG, 1996, EUR J BIOCHEM, V241, P779, DOI 10.1111/j.1432-1033.1996.00779.x; Culetto E, 2000, HUM MOL GENET, V9, P869, DOI 10.1093/hmg/9.6.869; CULOTTI JG, 1978, GENETICS, V90, P243; Dibrov E, 1998, J BIOL CHEM, V273, P32042, DOI 10.1074/jbc.273.48.32042; DiMauro S, 2000, BRAIN PATHOL, V10, P431; FECKE W, 1994, EUR J BIOCHEM, V220, P551, DOI 10.1111/j.1432-1033.1994.tb18655.x; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Fraser AG, 2000, NATURE, V408, P325, DOI 10.1038/35042517; Gonczy P, 2000, NATURE, V408, P331, DOI 10.1038/35042526; Hill AA, 2000, SCIENCE, V290, P809, DOI 10.1126/science.290.5492.809; Houstek J, 1999, HUM MOL GENET, V8, P1967; Inoue K, 2000, NAT GENET, V26, P176, DOI 10.1038/82826; Ishii N, 1998, NATURE, V394, P694, DOI 10.1038/29331; Jansen G, 1997, NAT GENET, V17, P119, DOI 10.1038/ng0997-119; Jenuth JP, 1996, NAT GENET, V14, P146, DOI 10.1038/ng1096-146; Kayser EB, 1999, ANESTHESIOLOGY, V90, P545, DOI 10.1097/00000542-199902000-00031; Kayser EB, 2001, J BIOL CHEM, V276, P20551, DOI 10.1074/jbc.M011066200; Lakowski B, 1998, P NATL ACAD SCI USA, V95, P13091, DOI 10.1073/pnas.95.22.13091; Larsson NG, 1998, NAT GENET, V18, P231, DOI 10.1038/ng0398-231; Lewis JA, 1995, METHOD CELL BIOL, V48, P3; Li K, 2000, CELL, V101, P389, DOI 10.1016/S0092-8674(00)80849-1; Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126; LUFT R, 1995, J INTERN MED, V238, P405, DOI 10.1111/j.1365-2796.1995.tb01218.x; Morris AAM, 1996, ANN NEUROL, V40, P25, DOI 10.1002/ana.410400107; MURFITT RR, 1976, COMP BIOCHEM PHYS B, V53, P423, DOI 10.1016/0305-0491(76)90191-7; Nijtmans LGJ, 1995, BBA-MOL BASIS DIS, V1272, P190, DOI 10.1016/0925-4439(95)00087-9; Ohnishi T, 1998, BBA-BIOENERGETICS, V1364, P186, DOI 10.1016/S0005-2728(98)00027-9; OKIMOTO R, 1992, GENETICS, V130, P471; PIKO L, 1973, J CELL BIOL, V58, P357, DOI 10.1083/jcb.58.2.357; Plasterk RHA, 1995, METHOD CELL BIOL, V48, P59; Robinson BH, 1998, BBA-BIOENERGETICS, V1364, P271, DOI 10.1016/S0005-2728(98)00033-4; Rubio-Gozalbo ME, 2000, HUM MUTAT, V15, P522, DOI 10.1002/1098-1004(200006)15:6<522::AID-HUMU4>3.0.CO;2-Y; SCHEDL T, 1997, C ELEGANS, V2, P241; Schuelke M, 1999, NAT GENET, V21, P260, DOI 10.1038/6772; Smeitink J, 1999, AM J HUM GENET, V64, P1505, DOI 10.1086/302432; Sue CM, 2000, BRAIN PATHOL, V10, P442; SULSTON J, 1988, NEMATODE CAENORHABDI, P123; Tabara H, 1998, SCIENCE, V282, P430, DOI 10.1126/science.282.5388.430; Timmons L, 1998, NATURE, V395, P854, DOI 10.1038/27579; Tissenbaum HA, 2000, P NATL ACAD SCI USA, V97, P460, DOI 10.1073/pnas.97.1.460; Troemel ER, 1999, BIOESSAYS, V21, P1011, DOI 10.1002/(SICI)1521-1878(199912)22:1&lt;1011::AID-BIES5&gt;3.0.CO;2-V; Vanfleteren JR, 1996, J EXP ZOOL, V274, P93, DOI 10.1002/(SICI)1097-010X(19960201)274:2&lt;93::AID-JEZ2&gt;3.0.CO;2-8; WALKER JE, 1992, Q REV BIOPHYS, V25, P253, DOI 10.1017/S003358350000425X; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; Wood WB, 1988, NEMATODE CAENORHABDI, P1; Zeviani M, 1997, MOL HUM REPROD, V3, P133, DOI 10.1093/molehr/3.2.133	55	113	124	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					32240	32246		10.1074/jbc.M103999200	http://dx.doi.org/10.1074/jbc.M103999200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11410594	hybrid			2022-12-25	WOS:000170613500104
J	Abrami, L; Fivaz, M; Kobayashi, T; Kinoshita, T; Parton, RG; van der Goot, FG				Abrami, L; Fivaz, M; Kobayashi, T; Kinoshita, T; Parton, RG; van der Goot, FG			Cross-talk between caveolae and glycosylphosphatidylinositol-rich domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORE-FORMING TOXIN; GPI-ANCHORED PROTEINS; CELL-SURFACE; DEPENDENT RETENTION; MEMBRANE-PROTEIN; MAMMALIAN-CELLS; PLASMA-MEMBRANE; LIPID RAFTS; CHOLESTEROL; BIOSYNTHESIS	Most mammalian cells have in their plasma membrane at least two types of lipid microdomains, non-invaginated lipid rafts and caveolae. Glycosylphosphatidylinositol (GPI)-anchored proteins constitute a class of proteins that are enriched in rafts but not caveolae at steady state. We have analyzed the effects of abolishing GPI biosynthesis on rafts, caveolae, and cholesterol levels. GPI-deficient cells were obtained by screening for resistance to the pore-forming toxin aerolysin, which uses this class of proteins as receptors. Despite the absence of GPI-anchored proteins, mutant cells still contained lipid rafts, indicating that GPI-anchored proteins are not crucial structural elements of these domains. Interestingly, the caveolae-specific membrane proteins, caveolin-1 and 2, were up-regulated in GPI-deficient cells, in contrast to flotillin-I and GM1, which were expressed at normal levels. Additionally, the number of surface caveolae was increased. This effect was specific since recovery of GPI biosynthesis by gene recomplementation restored caveolin expression and the number of surface caveolae to wild type levels. The inverse correlation between the expression of GPI-anchored proteins and caveolin-1 was confirmed by the observation that overexpression of caveolin-1 in wild type cells led to a decrease in the expression of GPI-anchored proteins. In cells lacking caveolae, the absence of GPI-anchored proteins caused an increase in cholesterol levels, suggesting a possible role of GPI-anchored proteins in cholesterol homeostasis, which in some cells, such as Chinese hamster ovary cells, can be compensated by caveolin up-regulation.	Univ Geneva, Dept Biochem, CH-1211 Geneva 4, Switzerland; RIKEN, Frontier Res Syst, Supramol Syst Res Grp, Wako, Saitama 3510198, Japan; Osaka Univ, Dept Immunoregulat, Microbial Dis Res Inst, Suita, Osaka 5650871, Japan; Univ Queensland, Inst Mol Biosci, Ctr Microscopy & Microanal, Brisbane, Qld 1072, Australia; Univ Queensland, Inst Mol Biosci, Ctr Microscopy & Microanal, Brisbane, Qld 1072, Australia; Univ Queensland, Dept Physiol & Pharmacol, Brisbane, Qld 1072, Australia	University of Geneva; RIKEN; Osaka University; University of Queensland; University of Queensland; University of Queensland	van der Goot, FG (corresponding author), Univ Geneva, Dept Biochem, 30 Quai E Ansermet, CH-1211 Geneva 4, Switzerland.	gisou.vandergoot@biochem.unige.ch	Parton, Robert G/C-5673-2009; van der Goot, Gisou G/B-2279-2012; Kinoshita, Taroh/C-7353-2009; KOBAYASHI, TOSHIHIDE/S-8313-2019; Kobayashi, Toshihide/B-6298-2015	Parton, Robert G/0000-0002-7494-5248; van der Goot, Gisou G/0000-0002-8522-274X; KOBAYASHI, TOSHIHIDE/0000-0002-4811-7270; Kobayashi, Toshihide/0000-0002-4811-7270; Fivaz, Marc/0000-0003-1003-7934; ABRAMI, laurence/0000-0002-1774-0481				Abrami L, 2000, TRENDS MICROBIOL, V8, P168, DOI 10.1016/S0966-842X(00)01722-4; Abrami L, 1998, J BIOL CHEM, V273, P32656, DOI 10.1074/jbc.273.49.32656; Abrami L, 1998, J CELL BIOL, V140, P525, DOI 10.1083/jcb.140.3.525; Aniento F, 1996, J CELL BIOL, V133, P29, DOI 10.1083/jcb.133.1.29; Bagnoli M, 2000, ONCOGENE, V19, P4754, DOI 10.1038/sj.onc.1203839; Baumann NA, 2000, J BIOL CHEM, V275, P7378, DOI 10.1074/jbc.275.10.7378; Bickel PE, 1997, J BIOL CHEM, V272, P13793, DOI 10.1074/jbc.272.21.13793; Brodsky RA, 1999, BLOOD, V93, P1749, DOI 10.1182/blood.V93.5.1749.405k09_1749_1756; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; BUCKLEY JT, 1990, BIOCHEM CELL BIOL, V68, P221, DOI 10.1139/o90-029; Chatterjee S, 2001, EMBO J, V20, P1583, DOI 10.1093/emboj/20.7.1583; Diep DB, 1998, J BIOL CHEM, V273, P2355, DOI 10.1074/jbc.273.4.2355; Ferguson MAJ, 1999, J CELL SCI, V112, P2799; Fielding CJ, 1997, J LIPID RES, V38, P1503; Fivaz M, 2000, ELECTROPHORESIS, V21, P3351, DOI 10.1002/1522-2683(20001001)21:16<3351::AID-ELPS3351>3.3.CO;2-B; Fivaz M, 1999, TRENDS CELL BIOL, V9, P212, DOI 10.1016/S0962-8924(99)01567-6; FRA AM, 1995, P NATL ACAD SCI USA, V92, P8655, DOI 10.1073/pnas.92.19.8655; FRA AM, 1994, J BIOL CHEM, V269, P30745; Galbiati F, 1998, EMBO J, V17, P6633, DOI 10.1093/emboj/17.22.6633; Gordon VM, 1999, J BIOL CHEM, V274, P27274, DOI 10.1074/jbc.274.38.27274; GRAHAM FL, 1973, VIROLOGY, V54, P536, DOI 10.1016/0042-6822(73)90163-3; Hailstones D, 1998, J LIPID RES, V39, P369; Harder T, 2000, J CELL BIOL, V151, P199, DOI 10.1083/jcb.151.2.199; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; Ikonen E, 2000, TRAFFIC, V1, P212, DOI 10.1034/j.1600-0854.2000.010303.x; Janes PW, 2000, SEMIN IMMUNOL, V12, P23, DOI 10.1006/smim.2000.0204; Kasahara K, 2000, J BIOL CHEM, V275, P34701, DOI 10.1074/jbc.M003163200; Kinoshita T, 1997, J BIOCHEM-TOKYO, V122, P251; Kirchhausen T, 2000, NAT REV MOL CELL BIO, V1, P187, DOI 10.1038/35043117; Kreis TE, 1995, ANNU REV CELL DEV BI, V11, P677, DOI 10.1146/annurev.cb.11.110195.003333; KUGE O, 1985, P NATL ACAD SCI USA, V82, P1926, DOI 10.1073/pnas.82.7.1926; KURZCHALIA TV, 1992, J CELL BIOL, V118, P1003, DOI 10.1083/jcb.118.5.1003; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lang DM, 1998, J NEUROBIOL, V37, P502, DOI 10.1002/(SICI)1097-4695(199812)37:4<502::AID-NEU2>3.0.CO;2-S; Lee SJ, 1998, NAT MED, V4, P730, DOI 10.1038/nm0698-730; Lipardi C, 1998, J CELL BIOL, V140, P617, DOI 10.1083/jcb.140.3.617; London E, 2000, BBA-BIOMEMBRANES, V1508, P182, DOI 10.1016/S0304-4157(00)00007-1; Maeda Y, 1998, EMBO J, V17, P4920, DOI 10.1093/emboj/17.17.4920; Maxfield FR, 1997, ADV EXP MED BIOL, V419, P355; Mayor S, 1998, EMBO J, V17, P4626, DOI 10.1093/emboj/17.16.4626; Muniz M, 2001, CELL, V104, P313, DOI 10.1016/S0092-8674(01)00215-X; Muniz M, 2000, EMBO J, V19, P10, DOI 10.1093/emboj/19.1.10; Nakamura N, 1997, J BIOL CHEM, V272, P15834, DOI 10.1074/jbc.272.25.15834; Nelson KL, 1997, J BIOL CHEM, V272, P12170, DOI 10.1074/jbc.272.18.12170; Nichols BJ, 2001, J CELL BIOL, V153, P529, DOI 10.1083/jcb.153.3.529; Nozaki M, 1999, LAB INVEST, V79, P293; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Parton RG, 1996, CURR OPIN CELL BIOL, V8, P542, DOI 10.1016/S0955-0674(96)80033-0; Pasquali C, 1997, ELECTROPHORESIS, V18, P2573, DOI 10.1002/elps.1150181413; Rojo M, 1997, J CELL BIOL, V139, P1119, DOI 10.1083/jcb.139.5.1119; Samuel BU, 2001, J BIOL CHEM, V276, P29319, DOI 10.1074/jbc.M101268200; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; Schlegel A, 2000, FRONT BIOSCI-LANDMRK, V5, pD929, DOI 10.2741/schlegel; SCHNITZER JE, 1995, SCIENCE, V269, P1435, DOI 10.1126/science.7660128; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Simons M, 1998, P NATL ACAD SCI USA, V95, P6460, DOI 10.1073/pnas.95.11.6460; STEVENS VL, 1995, BIOCHEM J, V310, P361, DOI 10.1042/bj3100361; Stevens VL, 1996, BIOCHEM J, V313, P253, DOI 10.1042/bj3130253; SUGIYAMA E, 1991, J BIOL CHEM, V266, P12119; Tarutani M, 1997, P NATL ACAD SCI USA, V94, P7400, DOI 10.1073/pnas.94.14.7400; van der Goot FG, 2001, SEMIN IMMUNOL, V13, P89, DOI 10.1006/smim.2000.0300; VANDERGOOT FG, 1994, J BIOL CHEM, V269, P30496; VANTHOF W, 1995, J BIOL CHEM, V270, P24150; Vogel U, 1998, J CELL SCI, V111, P825; Volonte D, 1999, J BIOL CHEM, V274, P12702, DOI 10.1074/jbc.274.18.12702; Watanabe R, 2000, EMBO J, V19, P4402, DOI 10.1093/emboj/19.16.4402; Yang CPH, 1998, FEBS LETT, V439, P368, DOI 10.1016/S0014-5793(98)01354-4; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	68	79	84	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					30729	30736		10.1074/jbc.M102039200	http://dx.doi.org/10.1074/jbc.M102039200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11406621	hybrid			2022-12-25	WOS:000170472900021
J	Awasthi, S; Palmer, R; Castro, M; Mobarak, CD; Ruby, SW				Awasthi, S; Palmer, R; Castro, M; Mobarak, CD; Ruby, SW			New roles for the Snp1 and Exo84 proteins in yeast pre-mRNA splicing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							SMALL NUCLEAR RIBONUCLEOPROTEIN; U1 SNRNP PROTEIN; SACCHAROMYCES-CEREVISIAE; 2-HYBRID SYSTEM; REQUIRES ATP; CELL-SURFACE; PRP8 PROTEIN; 70K PROTEIN; SPLICEOSOME; IDENTIFICATION	The mammalian 70K protein, a component of the U1 small nuclear ribonucleoprotein involved in pre-mRNA splicing, interacts with a number of proteins important for regulating constitutive and alternative splicing. Similar proteins that interact with the yeast homolog of the 70K protein, Snp1p, have yet to be identified. We used the two-hybrid system to find four (U) under bar1-(S) under bar np1 (a) under bar ssociating (Usa) proteins. Two of these proteins physically associate with Snp1p as assayed by coimmunoprecipitation. One is Prp8p, a known, essential spliceosomal component. This interaction suggests some novel functions for Snp1p and the U1 small nuclear ribonucleoprotein late in spliceosome development. The other, Exo84p, is a conserved subunit of the exocyst, an eight-protein complex functioning in secretion. We show here that Exo84p is also involved in pre-mRNA splicing. A temperature-sensitive exo84 mutation caused increased ratios of pre-mRNA to mRNA for the Rp130 and actin transcripts in cells incubated at the non-permissive temperature. The mutation also led to a defect in splicing and prespliceosome formation in vitro; an indication that Exo84p has a direct role in splicing. The results elucidate a surprising link between splicing and secretion.	Univ New Mexico, Hlth Sci Ctr, Dept Mol Genet & Microbiol, Canc Res & Treatment Ctr, Albuquerque, NM 87131 USA	University of New Mexico; University of New Mexico's Health Sciences Center	Ruby, SW (corresponding author), Univ New Mexico, Hlth Sci Ctr, Dept Mol Genet & Microbiol, Canc Res & Treatment Ctr, 900 Camino Salud NE, Albuquerque, NM 87131 USA.	sruby@unm.edu						Abovich N, 1997, CELL, V89, P403, DOI 10.1016/S0092-8674(00)80221-4; ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; Alexieva KI, 1999, INT J BIOCHEM CELL B, V31, P903, DOI 10.1016/S1357-2725(99)00044-8; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; [Anonymous], 1991, Methods Enzymol, V194, P1; Ast G, 1997, RNA, V3, P371; BECKER DM, 1991, METHOD ENZYMOL, V194, P182; Beggs JD, 1995, J CELL SCI, P101; Berglund JA, 1998, GENE DEV, V12, P858, DOI 10.1101/gad.12.6.858; Bousquet-Antonelli C, 2000, CELL, V102, P765, DOI 10.1016/S0092-8674(00)00065-9; BROWN JD, 1992, EMBO J, V11, P3721, DOI 10.1002/j.1460-2075.1992.tb05457.x; CABIB E, 1989, J CELL BIOL, V108, P1665, DOI 10.1083/jcb.108.5.1665; Cao WH, 1998, J BIOL CHEM, V273, P20629, DOI 10.1074/jbc.273.32.20629; CHANG TH, 1988, MOL CELL BIOL, V8, P2379, DOI 10.1128/MCB.8.6.2379; Chen EJ, 1998, MOL CELL BIOL, V18, P7139, DOI 10.1128/MCB.18.12.7139; Chen JYF, 2001, MOL CELL, V7, P227, DOI 10.1016/S1097-2765(01)00170-8; CHENG SC, 1986, P NATL ACAD SCI USA, V83, P2387, DOI 10.1073/pnas.83.8.2387; Cherry JM, 1998, NUCLEIC ACIDS RES, V26, P73, DOI 10.1093/nar/26.1.73; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; Cody R.P., 1991, APPL STAT SAS PROGRA; Collins CA, 2000, NAT STRUCT BIOL, V7, P850; DECKER CJ, 1994, TRENDS BIOCHEM SCI, V19, P336, DOI 10.1016/0968-0004(94)90073-6; ELBLE R, 1992, BIOTECHNIQUES, V13, P18; ENTIAN KD, 1999, MOL GEN GENET, V262; FABRIZIO P, 1990, SCIENCE, V250, P404, DOI 10.1126/science.2145630; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FIELDS S, 1994, TRENDS GENET, V10, P286, DOI 10.1016/0168-9525(90)90012-U; Finger FP, 1998, J CELL BIOL, V142, P609, DOI 10.1083/jcb.142.3.609; Fortes P, 1999, GENE DEV, V13, P2425, DOI 10.1101/gad.13.18.2425; FromontRacine M, 1997, NAT GENET, V16, P277, DOI 10.1038/ng0797-277; FU XD, 1995, RNA, V1, P663; *GEN COMP GROUP, 1999, WISC PACK VERS 10; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Guo W, 1999, J BIOL CHEM, V274, P23558, DOI 10.1074/jbc.274.33.23558; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; HEINRICHS V, 1990, SCIENCE, V247, P69, DOI 10.1126/science.2136774; HILLEREN PJ, 1995, MOL CELL BIOL, V15, P6341; HODGES PE, 1995, YEAST, V11, P337; Hofmann K, 1999, NUCLEIC ACIDS RES, V27, P215, DOI 10.1093/nar/27.1.215; Jans DA, 2000, BIOESSAYS, V22, P532, DOI 10.1002/(SICI)1521-1878(200006)22:6<532::AID-BIES6>3.0.CO;2-O; JONES JS, 1990, YEAST, V6, P363, DOI 10.1002/yea.320060502; KAO HY, 1992, NUCLEIC ACIDS RES, V20, P4009, DOI 10.1093/nar/20.15.4009; Kramer A, 1996, ANNU REV BIOCHEM, V65, P367, DOI 10.1146/annurev.biochem.65.1.367; Kuhn AN, 2000, GENETICS, V155, P1667; Kuhn AN, 1999, MOL CELL, V3, P65, DOI 10.1016/S1097-2765(00)80175-6; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; Lee MS, 1996, GENE DEV, V10, P1233, DOI 10.1101/gad.10.10.1233; LEGRAIN P, 1993, SCIENCE, V262, P108, DOI 10.1126/science.8211114; LEGRAIN P, 1994, NUCLEIC ACIDS RES, V22, P3241, DOI 10.1093/nar/22.15.3241; LESSER CF, 1993, GENETICS, V133, P851; Luo HBR, 1999, RNA, V5, P893, DOI 10.1017/S1355838299990520; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; Lussier M, 1997, GENETICS, V147, P435; LUSTIG AJ, 1986, CELL, V47, P953, DOI 10.1016/0092-8674(86)90810-X; Lybarger S, 1999, MOL CELL BIOL, V19, P577; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; MATTAJ IW, 1988, STRUCTURE FUNCTION M, P100; Misteli T, 1999, CURR BIOL, V9, pR198, DOI 10.1016/S0960-9822(99)80128-6; Mizuta K, 1998, NUCLEIC ACIDS RES, V26, P1063, DOI 10.1093/nar/26.4.1063; MIZUTA K, 1994, MOL CELL BIOL, V14, P2493, DOI 10.1128/MCB.14.4.2493; Nanduri J, 1999, J BIOL CHEM, V274, P33785, DOI 10.1074/jbc.274.47.33785; Neubauer G, 1997, P NATL ACAD SCI USA, V94, P385, DOI 10.1073/pnas.94.2.385; NEWMAN AJ, 1994, CURR OPIN GENET DEV, V4, P298, DOI 10.1016/S0959-437X(05)80057-7; ODay CL, 1996, J BIOL CHEM, V271, P33261, DOI 10.1074/jbc.271.52.33261; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Proudfoot N, 2000, TRENDS BIOCHEM SCI, V25, P290, DOI 10.1016/S0968-0004(00)01591-7; Pruyne D, 2000, J CELL SCI, V113, P365; Raghunathan PL, 1998, CURR BIOL, V8, P847, DOI 10.1016/S0960-9822(07)00345-4; ROMAC JMJ, 1995, GENE DEV, V9, P1400, DOI 10.1101/gad.9.11.1400; ROMAC JMJ, 1994, MOL CELL BIOL, V14, P4662, DOI 10.1128/MCB.14.7.4662; ROSBASH M, 1991, TRENDS BIOCHEM SCI, V16, P187, DOI 10.1016/0968-0004(91)90073-5; Rose MD., 1990, METHODS YEAST GENETI; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; RUBY SW, 1991, TRENDS GENET, V7, P79; Ruby SW, 1997, J BIOL CHEM, V272, P17333, DOI 10.1074/jbc.272.28.17333; RUBY SW, 1993, GENE DEV, V7, P1909, DOI 10.1101/gad.7.10.1909; RUBY SW, 1985, MOL CELL BIOL, V5, P75, DOI 10.1128/MCB.5.1.75; Ruby SW, 1999, METH MOL B, V118, P365; Ruby SW, 1999, METH MOL B, V118, P323; RUBY SW, 1988, SCIENCE, V242, P1028, DOI 10.1126/science.2973660; RYMOND BC, 1990, METHOD ENZYMOL, V181, P122; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schwer B, 1996, RNA, V2, P574; Sidrauski C, 1998, TRENDS CELL BIOL, V8, P245, DOI 10.1016/S0962-8924(98)01267-7; SIKORSKI RS, 1989, GENETICS, V122, P19; SMITH V, 1991, EMBO J, V10, P2627, DOI 10.1002/j.1460-2075.1991.tb07805.x; Staley JP, 1999, MOL CELL, V3, P55, DOI 10.1016/S1097-2765(00)80174-4; Staley JP, 1998, CELL, V92, P315, DOI 10.1016/S0092-8674(00)80925-3; STRAUSS EJ, 1991, GENE DEV, V5, P629, DOI 10.1101/gad.5.4.629; Tacke R, 1999, P SOC EXP BIOL MED, V220, P59, DOI 10.1046/j.1525-1373.1999.d01-10.x; TODA T, 1987, MOL CELL BIOL, V7, P1371, DOI 10.1128/MCB.7.4.1371; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; Warner JR, 1999, TRENDS BIOCHEM SCI, V24, P437, DOI 10.1016/S0968-0004(99)01460-7; Wiest DK, 1996, J BIOL CHEM, V271, P33268, DOI 10.1074/jbc.271.52.33268; Winer B.J., 1991, STAT PRINCIPLES EXPT; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; WOPPMANN A, 1993, NUCLEIC ACIDS RES, V21, P2815, DOI 10.1093/nar/21.12.2815; WU JY, 1993, CELL, V75, P1061, DOI 10.1016/0092-8674(93)90316-I; Xiao SH, 1998, EMBO J, V17, P6359, DOI 10.1093/emboj/17.21.6359; Xie JY, 2001, NATURE, V410, P936, DOI 10.1038/35073593; Yun CY, 2000, J CELL BIOL, V150, P707, DOI 10.1083/jcb.150.4.707; Zhang D, 1999, GENE DEV, V13, P581, DOI 10.1101/gad.13.5.581; Zhang WJ, 1998, MOL CELL BIOL, V18, P676, DOI 10.1128/MCB.18.2.676	104	26	29	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					31004	31015		10.1074/jbc.M100022200	http://dx.doi.org/10.1074/jbc.M100022200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11425851	hybrid			2022-12-25	WOS:000170472900056
J	Beuning, PJ; Musier-Forsyth, K				Beuning, PJ; Musier-Forsyth, K			Species-specific differences in amino acid editing by class II prolyl-tRNA synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; ESCHERICHIA-COLI; MOLECULAR RECOGNITION; PROTEIN-SYNTHESIS; CRYSTAL-STRUCTURE; DISCRIMINATION; AMINOACYLATION; ISOLEUCINE; YEAST; SIEVE	Aminoacyl-tRNA synthetases are a family of enzymes responsible for ensuring the accuracy of the genetic code by specifically attaching a particular amino acid to their cognate tRNA substrates. Through primary sequence alignments, prolyl-tRNA synthetases (ProRSs) have been divided into two phylogenetically divergent groups. We have been interested in understanding whether the unusual evolutionary pattern of ProRSs corresponds to functional differences as well. Previously, we showed that some features of tRNA recognition and aminoacylation are indeed group-specific. Here, we examine the species-specific differences in another enzymatic activity, namely amino acid editing. Proofreading or editing provides a mechanism by which incorrectly activated amino acids are hydrolyzed and thus prevented from misincorporation into proteins. "Prokaryotic-like" Escherichia coli ProRS has recently been shown to be capable of misactivating alanine and possesses both pretransfer and post-transfer hydrolytic editing activity against this noncognate amino acid. We now find that two ProRSs belonging to the "eukaryotic-like" group exhibit differences in their hydrolytic editing activity. Whereas ProRS from Methanococcus jannaschii is similar to E. coli in its ability to hydrolyze misactivated alanine via both pretransfer and post-transfer editing pathways, human ProRS lacks these activities. These results have implications for the selection or design of antibiotics that specifically target the editing active site of the prokaryotic-like group of ProRSs.	Univ Minnesota, Dept Chem, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Musier-Forsyth, K (corresponding author), Univ Minnesota, Dept Chem, 207 Pleasant St SE, Minneapolis, MN 55455 USA.				NIGMS NIH HHS [GM49928] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM049928, R01GM049928, R55GM049928] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAN C, 1991, MOL CELL BIOCHEM, V130, P149; BALDWIN AN, 1966, J BIOL CHEM, V241, P839; Beuning PJ, 2000, P NATL ACAD SCI USA, V97, P8916, DOI 10.1073/pnas.97.16.8916; Burke B, 2000, BIOCHEMISTRY-US, V39, P15540, DOI 10.1021/bi001835p; BURKE B, 2001, J BIOL CHEM, V276; Chen JF, 2000, BIOCHEMISTRY-US, V39, P6726, DOI 10.1021/bi000108r; Cusack S, 1998, STRUCTURE, V6, P101, DOI 10.1016/S0969-2126(98)00011-2; DEPOUPLANA LR, IN PRESS J MOL ECOL; Dock-Bregeon AC, 2000, CELL, V103, P877, DOI 10.1016/S0092-8674(00)00191-4; ELDRED EW, 1972, J BIOL CHEM, V247, P2961; ENGLISCH S, 1986, NUCLEIC ACIDS RES, V14, P7529, DOI 10.1093/nar/14.19.7529; FERSHT AR, 1981, PROC R SOC SER B-BIO, V212, P351, DOI 10.1098/rspb.1981.0044; FERSHT AR, 1979, BIOCHEMISTRY-US, V18, P1238, DOI 10.1021/bi00574a019; FERSHT AR, 1976, BIOCHEMISTRY-US, V15, P3342, DOI 10.1021/bi00660a026; FERSHT AR, 1979, BIOCHEMISTRY-US, V18, P2627, DOI 10.1021/bi00579a030; FOWDEN L, 1963, BIOCHIM BIOPHYS ACTA, V71, P459, DOI 10.1016/0006-3002(63)91104-1; FREIST W, 1985, BIOCHEMISTRY-US, V24, P7014, DOI 10.1021/bi00345a040; FREIST W, 1994, EUR J BIOCHEM, V220, P745, DOI 10.1111/j.1432-1033.1994.tb18675.x; Freist W, 1998, J THEOR BIOL, V193, P19, DOI 10.1006/jtbi.1998.0672; Fukai S, 2000, CELL, V103, P793, DOI 10.1016/S0092-8674(00)00182-3; GABIUS HJ, 1983, BIOCHEMISTRY-US, V22, P2331, DOI 10.1021/bi00279a005; Hamann CS, 1999, J BACTERIOL, V181, P5880, DOI 10.1128/JB.181.18.5880-5884.1999; Heacock D, 1996, BIOORG CHEM, V24, P273, DOI 10.1006/bioo.1996.0025; Hendrickson TL, 2000, BIOCHEMISTRY-US, V39, P8180, DOI 10.1021/bi0004798; HOU YM, 1988, NATURE, V333, P140, DOI 10.1038/333140a0; Ibba M, 2000, ANNU REV BIOCHEM, V69, P617, DOI 10.1146/annurev.biochem.69.1.617; IGLOI GL, 1978, BIOCHEMISTRY-US, V17, P3459, DOI 10.1021/bi00610a006; JAKUBOWSKI H, 1980, BIOCHEMISTRY-US, V19, P5071, DOI 10.1021/bi00563a021; JAKUBOWSKI H, 1992, MICROBIOL REV, V56, P412, DOI 10.1128/MMBR.56.3.412-429.1992; Lin L, 1996, BIOCHEMISTRY-US, V35, P5596, DOI 10.1021/bi960011y; Lin L, 1996, NATURE, V384, P33, DOI 10.1038/384033b0; LINCECUM TL, 2000, SAAS B BIOCH BIOTECH, V13, P25; Lipman RSA, 2000, BIOCHEMISTRY-US, V39, P7792, DOI 10.1021/bi0004955; Liu HJ, 1996, J AM CHEM SOC, V118, P2523, DOI 10.1021/ja954062e; LIU HJ, 1995, NUCLEIC ACIDS RES, V23, P165, DOI 10.1093/nar/23.1.165; LIU HJ, 1994, BIOCHEMISTRY-US, V33, P12708, DOI 10.1021/bi00208a023; MCCLAIN WH, 1988, SCIENCE, V242, P1681, DOI 10.1126/science.2462282; Mursinna RS, 2001, BIOCHEMISTRY-US, V40, P5376, DOI 10.1021/bi002915w; Musier-Forsyth K, 1999, ACCOUNTS CHEM RES, V32, P368, DOI 10.1021/ar970148w; MUSIERFORSYTH K, 1991, P NATL ACAD SCI USA, V88, P209, DOI 10.1073/pnas.88.1.209; Nureki O, 1998, SCIENCE, V280, P578, DOI 10.1126/science.280.5363.578; PROENZA AM, 1995, LIFE SCI, V57, P1589; RABINOVITZ M, 1969, J BACTERIOL, V99, P336, DOI 10.1128/JB.99.1.336-338.1969; RAUHUT R, 1985, J BIOL CHEM, V260, P182; RAUNIO R, 1970, ACTA CHEM SCAND, V24, P2737, DOI 10.3891/acta.chem.scand.24-2737; Sankaranarayanan R, 2000, NAT STRUCT BIOL, V7, P461; Schimmel P, 1998, FASEB J, V12, P1599, DOI 10.1096/fasebj.12.15.1599; SCHMIDT E, 1995, BIOCHEMISTRY-US, V34, P11204, DOI 10.1021/bi00035a028; SCHMIDT E, 1994, SCIENCE, V264, P265, DOI 10.1126/science.8146659; Silvian LF, 1999, SCIENCE, V285, P1074, DOI 10.1126/science.285.5430.1074; Stathopoulos C, 2000, SCIENCE, V287, P479, DOI 10.1126/science.287.5452.479; Stathopoulos C, 2001, BIOCHEMISTRY-US, V40, P46, DOI 10.1021/bi002108x; Stehlin C, 1998, BIOCHEMISTRY-US, V37, P8605, DOI 10.1021/bi980364s; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Yaremchuk A, 2000, EMBO J, V19, P4745, DOI 10.1093/emboj/19.17.4745; YARUS M, 1972, P NATL ACAD SCI USA, V69, P1915, DOI 10.1073/pnas.69.7.1915; Zhang H, 2000, PROTEINS, V40, P86, DOI 10.1002/(SICI)1097-0134(20000701)40:1<86::AID-PROT100>3.0.CO;2-Y	57	68	71	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					30779	30785		10.1074/jbc.M104761200	http://dx.doi.org/10.1074/jbc.M104761200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11408489	hybrid			2022-12-25	WOS:000170472900028
J	Lee, L; Sadowski, PD				Lee, L; Sadowski, PD			Directional resolution of synthetic Holliday structures by the Cre recombinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC RECOMBINATION; INTEGRASE FAMILY; FLP PROTEIN; IN-VITRO; DNA; SIMILARITIES; INTERMEDIATE; JUNCTIONS; PRODUCTS; SYNAPSE	The Cre recombinase of bacteriophage P1 cleaves its target site, loxP, in a defined order. Recombination is initiated on one pair of strands to form a Holliday intermediate, which is then resolved by cleavage and exchange of the other pair of strands to yield recombinant products. To investigate the influence of the loxP sequence on the directionality of resolution, we constructed synthetic Holliday (chi) structures containing either wild-type or mutant lox sites. We found that Cre preferentially resolved the synthetic wild-type chi structures on a particular pair of strands. The bias in the direction of resolution was dictated by the asymmetric loxP sequence since the resolution bias was abolished with symmetric lox sites. Systematic substitutions of the loxP site revealed that the bases immediately 5 ' to the scissile phosphodiester bonds were primarily responsible for the directionality of resolution. Interchanging these base pairs was sufficient to reverse the resolution bias. The Cre-lox co-crystal structures show that Lys(86) makes a base-specific contact with guanine immediately 5 ' to one of the scissile phosphates. Substituting Lys(86) with alanine resulted in a reduction of the resolution bias, indicating that this amino acid is important for establishing the bias in resolution.	Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada	University of Toronto	Sadowski, PD (corresponding author), Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada.							ABREMSKI K, 1983, CELL, V32, P1301, DOI 10.1016/0092-8674(83)90311-2; ARCISZEWSKA LK, 1995, EMBO J, V14, P2112, DOI 10.1002/j.1460-2075.1995.tb07203.x; ARGOS P, 1986, EMBO J, V5, P433, DOI 10.1002/j.1460-2075.1986.tb04229.x; AUSTIN S, 1981, CELL, V25, P729, DOI 10.1016/0092-8674(81)90180-X; Azaro MA, 1997, EMBO J, V16, P3744, DOI 10.1093/emboj/16.12.3744; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Colloms SD, 1996, EMBO J, V15, P1172, DOI 10.1002/j.1460-2075.1996.tb00456.x; DIXON JE, 1993, J MOL BIOL, V234, P522, DOI 10.1006/jmbi.1993.1608; Gopaul DN, 1998, EMBO J, V17, P4175, DOI 10.1093/emboj/17.14.4175; Guo F, 1999, P NATL ACAD SCI USA, V96, P7143, DOI 10.1073/pnas.96.13.7143; Guo F, 1997, NATURE, V389, P40, DOI 10.1038/37925; Hallet B, 1999, MOL CELL, V4, P949, DOI 10.1016/S1097-2765(00)80224-5; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HOESS R, 1987, P NATL ACAD SCI USA, V84, P6840, DOI 10.1073/pnas.84.19.6840; HOESS RH, 1982, P NATL ACAD SCI-BIOL, V79, P3398, DOI 10.1073/pnas.79.11.3398; HOESS RH, 1990, STRUCTURE METHODS, V1, P203; HOLLIDAY R, 1964, GENET RES, V5, P282, DOI 10.1017/S0016672300001233; JAYARAM M, 1988, P NATL ACAD SCI USA, V85, P7902, DOI 10.1073/pnas.85.21.7902; KITTS PA, 1987, NATURE, V329, P346, DOI 10.1038/329346a0; KITTS PA, 1988, NUCLEIC ACIDS RES, V16, P6839, DOI 10.1093/nar/16.14.6839; KITTS PA, 1988, J MOL BIOL, V204, P95, DOI 10.1016/0022-2836(88)90602-X; LANDY A, 1989, ANNU REV BIOCHEM, V58, P913, DOI 10.1146/annurev.biochem.58.1.913; Lee G, 1998, GENE, V216, P55, DOI 10.1016/S0378-1119(98)00325-4; MEYERLEON L, 1988, MOL CELL BIOL, V8, P3784, DOI 10.1128/MCB.8.9.3784; Nunes-Duby SE, 1998, NUCLEIC ACIDS RES, V26, P391, DOI 10.1093/nar/26.2.391; NUNESDUBY SE, 1987, CELL, V50, P779, DOI 10.1016/0092-8674(87)90336-9; Recchia GD, 1999, EMBO J, V18, P5724, DOI 10.1093/emboj/18.20.5724; SADOWSKI PD, 1995, PROG NUCLEIC ACID RE, V51, P53, DOI 10.1016/S0079-6603(08)60876-4; Sambrook J., 2002, MOL CLONING LAB MANU; Shaikh AC, 1997, J BIOL CHEM, V272, P5695, DOI 10.1074/jbc.272.9.5695; SHERRATT DJ, 1995, PHILOS T ROY SOC B, V347, P37, DOI 10.1098/rstb.1995.0006; Tribble G, 2000, J BIOL CHEM, V275, P22255, DOI 10.1074/jbc.M908261199; WIERZBICKI A, 1987, J MOL BIOL, V195, P785, DOI 10.1016/0022-2836(87)90484-0; Zerbib D, 1997, J MOL BIOL, V270, P663, DOI 10.1006/jmbi.1997.1157	34	26	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					31092	31098		10.1074/jbc.M103739200	http://dx.doi.org/10.1074/jbc.M103739200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11406627	hybrid			2022-12-25	WOS:000170472900067
J	Verkhusha, VV; Otsuna, H; Awasaki, T; Oda, H; Tsukita, S; Ito, K				Verkhusha, VV; Otsuna, H; Awasaki, T; Oda, H; Tsukita, S; Ito, K			An enhanced mutant of red fluorescent protein DsRed for double labeling and developmental timer of neural fiber bundle formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DROSOPHILA MUSHROOM BODIES; MELANOGASTER; NEURONS; CORAL; CHROMOPHORE; EXPRESSION; CELLS; BODY	We developed a new variant of coral-derived red fluorescent protein, DsRed S197Y, which is brighter and essentially free from secondary fluorescence peak. This makes it an ideal reporter for double labeling with green fluorescent protein (GFP). Though purified protein shows only 20% stronger fluorescence emission, culture cells that express DsRed S197Y exhibit a 3-3.5 times higher level of fluorescence than the cells that express wild-type DsRed. The much slower fluorescence maturation of DsRed than that of GFP is a beneficial feature for a fluorescent developmental timer application. When GFP and DsRed S197Y are expressed simultaneously, emissions start at different latency. This provides information about the time after the onset of expression. It reflects the order of cell differentiation if the expression is activated upon differentiation of certain types of cells. We applied this system to the developing brain of Drosophila and visualized, for the first time, the formation order of neural fibers within a large bundle. Our results showed that newly extending fibers of the mushroom body neurons mainly run into the core rather than to the periphery of the existing bundle. DsRed-based timer thus presents an indispensable tool for developmental biology and genetics of model organisms.	Japan Sci & Technol Corp, Exploratory Res Adv Technol, Tsukita Cell Axis Project, Kyoto 600813, Japan; Natl Inst Basic Biol, Okazaki, Aichi 4448585, Japan; Nagoya Univ, Div Biol Sci, Nagoya, Aichi 4648602, Japan; Kyoto Univ, Fac Med, Dept Cell Biol, Kyoto 6068501, Japan; JST, Precursory Res Embryon Sci & Technol, Okazaki, Aichi 4448585, Japan	Japan Science & Technology Agency (JST); National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); Nagoya University; Kyoto University; Japan Science & Technology Agency (JST)	Verkhusha, VV (corresponding author), Japan Sci & Technol Corp, Exploratory Res Adv Technol, Tsukita Cell Axis Project, Kyoto Res Pk, Kyoto 600813, Japan.		AWASAKI, Takeshi/AAO-7579-2021; Verkhusha, Vladislav/AAU-7784-2020; Oda, Hiroki/AAC-2559-2019	AWASAKI, Takeshi/0000-0003-2662-6389; Verkhusha, Vladislav/0000-0002-2083-8121; 				Baird GS, 2000, P NATL ACAD SCI USA, V97, P11984, DOI 10.1073/pnas.97.22.11984; BRAND AH, 1993, DEVELOPMENT, V118, P401; Crameri A, 1996, NAT BIOTECHNOL, V14, P315, DOI 10.1038/nbt0396-315; Crittenden JR, 1998, LEARN MEMORY, V5, P38; Cubitt AB, 1999, METHOD CELL BIOL, V58, P19; Estes PS, 2000, J NEUROGENET, V13, P233, DOI 10.3109/01677060009084496; Fradkov AF, 2000, FEBS LETT, V479, P127, DOI 10.1016/S0014-5793(00)01895-0; Freeman M, 1996, CELL, V87, P651, DOI 10.1016/S0092-8674(00)81385-9; Fukuda H, 2000, BIOCHEMISTRY-US, V39, P12025, DOI 10.1021/bi000543l; Gross LA, 2000, P NATL ACAD SCI USA, V97, P11990, DOI 10.1073/pnas.97.22.11990; Hinke W., 1961, Zeitschrift fuer Morphologie und Oekologie der Tiere Berlin, V50, P81, DOI 10.1007/BF00407351; Ito K, 1998, LEARN MEMORY, V5, P52; Ito K, 1997, DEVELOPMENT, V124, P761; ITO K, 1992, DEV BIOL, V149, P134, DOI 10.1016/0012-1606(92)90270-Q; Lee T, 1999, DEVELOPMENT, V126, P4065; Matz MV, 1999, NAT BIOTECHNOL, V17, P969, DOI 10.1038/13657; ODA H, 1994, DEV BIOL, V165, P716, DOI 10.1006/dbio.1994.1287; Reid BG, 1997, BIOCHEMISTRY-US, V36, P6786, DOI 10.1021/bi970281w; Ritzenthaler S, 2000, NAT NEUROSCI, V3, P1012, DOI 10.1038/79833; ROBERTSON HM, 1988, GENETICS, V118, P461; Rorth P, 1998, MECH DEVELOP, V78, P113, DOI 10.1016/S0925-4773(98)00157-9; Terskikh A, 2000, SCIENCE, V290, P1585, DOI 10.1126/science.290.5496.1585; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; Verkhusha VV, 1999, FEBS LETT, V445, P395, DOI 10.1016/S0014-5793(99)00124-6; Vrzheshch PV, 2000, FEBS LETT, V487, P203, DOI 10.1016/S0014-5793(00)02344-9; Wachter RM, 1998, STRUCTURE, V6, P1267, DOI 10.1016/S0969-2126(98)00127-0; WOLFF T, 1993, DEV DROSOPHILA MELAN, V2, P1277; YANG MY, 1995, NEURON, V15, P45	28	88	99	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					29621	29624		10.1074/jbc.C100200200	http://dx.doi.org/10.1074/jbc.C100200200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11408473	hybrid			2022-12-25	WOS:000170558000004
J	Landberg, G; Ostlund, H; Nielsen, NH; Roos, G; Emdin, S; Burger, AM; Seth, A				Landberg, G; Ostlund, H; Nielsen, NH; Roos, G; Emdin, S; Burger, AM; Seth, A			Downregulation of the potential suppressor gene IGFBP-rP1 in human breast cancer is associated with inactivation of the retinoblastoma protein, cyclin E overexpression and increased proliferation in estrogen receptor negative tumors	ONCOGENE			English	Article						IGFBP; breast cancer; proliferation; cell cycle; estrogen receptor	TISSUE MICROARRAY ANALYSIS; EXPRESSION; AMPLIFICATION; MAC25; D1	The complex insulin-like growth factor network of ligands, receptors and binding proteins has been shown to be disturbed in breast cancer, In addition to defects in proteins controling cell cycle checkpoints, this type of aberrations could affect tumor growth and survival thereby influencing both tumor aggressiveness and potential response to treatments, We have previously identified the T1A12/mac25 protein, which is identical to the IGFBP-rP1, as a differentially expressed gene product in breast cancer cells compared with normal cells, Here we compare the expression of IGFBP-rP1 in 106 tumor samples with known status of cell cycle aberrations and other clinicopathological data, This was done using a tumor tissue section array system that allows for simultaneous immunohistochemical staining of ail samples in parallel, Cytoplasmic staining of variable intensity was observed in most tumors, 15% Lacked IGFBP-rP1 staining completely, 20% had weak staining, 32% intermediate and 33% showed strong staining, Low IGFBP-rP1 was associated with high cyclin E protein content, retinoblastoma protein (pRb) inactivation, low bcl-2 protein, poorly differentiated tumors and higher stage, There was a significantly impaired prognosis for patients with low IGFBP-rP1 protein tumors, Interestingly, IGFBP-rP1 showed an inverse association with proliferation (Ki-67%) in estrogen receptor negative tumors as well as in cyclin E high tumors suggesting a separate cell cycle regulatory function for IGFBP-rP1 independent of interaction with the estrogen receptor or the pRb pathway.	Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada; Sunnbrook & Womens Coll, Hlth Sci Ctr, Toronto, ON, Canada; Univ Freiburg, Tumor Biol Ctr, Freiburg, Germany; Umea Univ, Dept Surg & Perioperat Sci, S-90187 Umea, Sweden; Umea Univ, Dept Med Biosci Pathol, S-90187 Umea, Sweden; Lund Univ, Malmo Univ Hosp, Dept Lab Med, Div Pathol, Malmo, Sweden	University of Toronto; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Freiburg; Umea University; Umea University; Lund University; Skane University Hospital	Seth, A (corresponding author), Univ Toronto, Dept Lab Med & Pathobiol, 76 Greenville St, Toronto, ON, Canada.							Burger AM, 1998, ONCOGENE, V16, P2459, DOI 10.1038/sj.onc.1201772; DEGEORGES A, 1998, CANCER RES, V50, P2787; Ellis MJ, 1998, BREAST CANCER RES TR, V52, P175, DOI 10.1023/A:1006127621512; Kato MV, 1996, ONCOGENE, V12, P1361; Komatsu S, 2000, BIOCHEM BIOPH RES CO, V267, P109, DOI 10.1006/bbrc.1999.1937; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Landberg G, 1997, APMIS, V105, P575, DOI 10.1111/j.1699-0463.1997.tb05056.x; Loden M, 1999, ONCOGENE, V18, P2557, DOI 10.1038/sj.onc.1202488; LUKAS J, 1995, CANCER RES, V55, P4818; Martin JL, 1999, J BIOL CHEM, V274, P16407, DOI 10.1074/jbc.274.23.16407; Moch H, 1999, AM J PATHOL, V154, P981, DOI 10.1016/S0002-9440(10)65349-7; Nielsen NH, 1996, BRIT J CANCER, V74, P874, DOI 10.1038/bjc.1996.451; Nielsen NH, 1999, BREAST CANCER RES TR, V56, P105; Nielsen NH, 1997, ONCOGENE, V14, P295, DOI 10.1038/sj.onc.1200833; Nielsen NH, 1998, ANAL CELL PATHOL, V17, P177, DOI 10.1155/1998/659712; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PAGE DL, 1995, AM J CLIN PATHOL, V103, P123; Richter J, 2000, AM J PATHOL, V157, P787, DOI 10.1016/S0002-9440(10)64592-0; Roos G, 1998, INT J CANCER, V79, P343, DOI 10.1002/(SICI)1097-0215(19980821)79:4<343::AID-IJC6>3.0.CO;2-V; Schraml P, 1999, CLIN CANCER RES, V5, P1966; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sprenger CC, 1999, CANCER RES, V59, P2370; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; SWISSHELM K, 1995, P NATL ACAD SCI USA, V92, P4472, DOI 10.1073/pnas.92.10.4472; Wilson EM, 1997, J CLIN ENDOCR METAB, V82, P1301, DOI 10.1210/jc.82.4.1301	25	71	76	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 14	2001	20	27					3497	3505		10.1038/sj.onc.1204471	http://dx.doi.org/10.1038/sj.onc.1204471			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	445VB	11429696				2022-12-25	WOS:000169478300005
J	Munro, J; Steeghs, K; Morrison, V; Ireland, H; Parkinson, EK				Munro, J; Steeghs, K; Morrison, V; Ireland, H; Parkinson, EK			Human fibroblast replicative senescence can occur in the absence of extensive cell division and short telomeres	ONCOGENE			English	Article						telomerase; telomeres; senescence; cell division; cell cycle inhibitors	HUMAN-DIPLOID FIBROBLASTS; TUMOR-SUPPRESSOR; LIFE-SPAN; STOCHASTIC MECHANISM; EPITHELIAL-CELLS; CDK-INHIBITOR; P53 PROTEIN; IN-VIVO; EXPRESSION; ARREST	Ectopic expression of telomerase blocks both telomeric attrition and senescence, suggesting that telomeric attrition is a mitotic counting mechanism that culminates in replicative senescence, By holding human fibroblast cultures confluent for up to 12 weeks at a time, we confirmed previous observations and showed that telomeric attrition requires cell division and also, that senescence occurs at a constant average telomere length, not at a constant time point. However, on resuming cell division, these long-term confluent (LTC) cultures completed 15-25 fewer mean population doublings (MPDs) than the controls prior to senescence. These lost divisions were mainly accounted for by slow cell turnover of the LTC cultures and by permanent cell cycle exit of 94% of the LTC cells, which resulted in many cell divisions being unmeasured by the MPD method, In the LTC cultures, p27(KIPI) accumulated and pRb became under-phosphorylated and under-expressed. Also, coincident with permanent cell cycle exit and before 1 MPD was completed, the LTC cultures upregulated the cell cycle inhibitors p21(WAF) and p16(INK4A) but not p14(ARF) developed other markers of senescence. We then tested the relationship between cell cycle re-entry and the cell cycle-inhibitory proteins following subculture of the LTC cultures. Tn these cultures, the downregulation of p27(KIPI) and the phosphorylation of pRb preceded the complete resumption of normal proliferation rate, which was accompanied by the down-regulation of p16(INK4A). Our results show that most normal human fibroblasts can accumulate p16(INK4A), p21(WAF) and p27(KIPI) and senesce by cell division-independent mechanism(s). Furthermore, this form of senescence likely requires p16(INK4A) and perhaps p27(KIPI).	CRC, Beatson Labs, Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland	Beatson Institute	Parkinson, EK (corresponding author), CRC, Beatson Labs, Beatson Inst Canc Res, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.							Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; ALLSOPP RC, 1995, EXP CELL RES, V220, P194, DOI 10.1006/excr.1995.1306; ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; BURNS JE, 1993, BRIT J CANCER, V67, P1274, DOI 10.1038/bjc.1993.238; Collado M, 2000, J BIOL CHEM, V275, P21960, DOI 10.1074/jbc.M000759200; CRISTOFALO VJ, 1993, PHYSIOL REV, V73, P617, DOI 10.1152/physrev.1993.73.3.617; Dietrich C, 1997, EXP CELL RES, V232, P72, DOI 10.1006/excr.1997.3507; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Durand B, 1998, CURR BIOL, V8, P431, DOI 10.1016/S0960-9822(98)70177-0; Durand B, 1997, EMBO J, V16, P306, DOI 10.1093/emboj/16.2.306; GOLDSTEIN S, 1974, EXP CELL RES, V88, P359, DOI 10.1016/0014-4827(74)90252-3; Hara E, 1996, MOL CELL BIOL, V16, P859; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; Holliday R, 1996, BIOESSAYS, V18, P3, DOI 10.1002/bies.950180103; Jiang XR, 1999, NAT GENET, V21, P111, DOI 10.1038/5056; Jones CJ, 2000, MOL CELL BIOL, V20, P5690, DOI 10.1128/MCB.20.15.5690-5699.2000; Kamijo T, 1999, CANCER RES, V59, P2464; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; KIPLING D, 1990, NATURE, V347, P400, DOI 10.1038/347400a0; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; Makarov VL, 1997, CELL, V88, P657, DOI 10.1016/S0092-8674(00)81908-X; Mazars GR, 1997, P NATL ACAD SCI USA, V94, P151, DOI 10.1073/pnas.94.1.151; McConnell BB, 1998, CURR BIOL, V8, P351, DOI 10.1016/S0960-9822(98)70137-X; Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063; OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Robles SJ, 1998, ONCOGENE, V16, P1113, DOI 10.1038/sj.onc.1201862; Rubelj I, 1999, J THEOR BIOL, V197, P425, DOI 10.1006/jtbi.1998.0886; SCHOR SL, 1987, BIOESSAYS, V7, P200, DOI 10.1002/bies.950070503; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Shelton DN, 1999, CURR BIOL, V9, P939, DOI 10.1016/S0960-9822(99)80420-5; Sitte N, 1998, FREE RADICAL BIO MED, V24, P885, DOI 10.1016/S0891-5849(97)00363-8; SMITH JR, 1980, SCIENCE, V207, P82; STEIN GH, 1995, BIOESSAYS, V17, P537, DOI 10.1002/bies.950170610; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Takuwa N, 1997, MOL CELL BIOL, V17, P5348, DOI 10.1128/MCB.17.9.5348; Tresini M, 1998, CANCER RES, V58, P1; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; Vaziri H, 1997, EMBO J, V16, P6018, DOI 10.1093/emboj/16.19.6018; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; VONZGLINICKI T, 1995, EXP CELL RES, V220, P186, DOI 10.1006/excr.1995.1305; Wong H, 1996, EXP GERONTOL, V31, P311, DOI 10.1016/0531-5565(95)00025-9; Wright WE, 1996, EMBO J, V15, P1734, DOI 10.1002/j.1460-2075.1996.tb00519.x; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178	49	61	62	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 14	2001	20	27					3541	3552		10.1038/sj.onc.1204460	http://dx.doi.org/10.1038/sj.onc.1204460			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	445VB	11429701				2022-12-25	WOS:000169478300010
J	Lara-Pezzi, E; Roche, S; Andrisani, OM; Sanchez-Madrid, F; Lopez-Cabrera, M				Lara-Pezzi, E; Roche, S; Andrisani, OM; Sanchez-Madrid, F; Lopez-Cabrera, M			The hepatitis B virus HBx protein induces adherens junction disruption in a src-dependent manner	ONCOGENE			English	Article						cadherin; catenin; HCC; metastasis; tyrosine phosphorylation	HUMAN HEPATOCELLULAR CARCINOMAS; E-CADHERIN; X-PROTEIN; TRANSGENIC MICE; BETA-CATENIN; CELL-ADHESION; MEDIATED ADHESION; TYROSINE KINASES; GENE-EXPRESSION; LIVER-CANCER	Chronic hepatitis B virus infection is strongly associated with the development of hepatocellular carcinoma (HCC). Epithelial tumors are frequently characterized by loss of cadherin expression or function. Cadherin-dependent adhesion prevents the acquisition of a migratory and invasive phenotype, and loss of its function is itself enough for the progression from adenoma to carcinoma, The HBx protein of hepatitis B virus is thought to contribute to the development of the carcinoma, however, its role in the oncogenic and metastatic processes is far from being fully understood. We report herein the ability of HBx to disrupt intercellular adhesion in three different cell lines stably transfected with an inducible HBx expression vector. The linkage between the actin cytoskeleton and cadherin complex, which is essential for its function, is disrupted in the presence of HBx, as indicated by detergent solubility and immunoprecipitation experiments, In addition, beta -catenin was tyrosine phosphorylated in HBx-expressing cells, Inhibition of the src family of tyrosine kinases resulted in the prevention of the disruption of adherens junctions. These results suggest that HBx is able to disrupt intercellular adhesion in a src-dependent manner, and provide a novel mechanism by which HBx may contribute to the development of HCC.	Hosp Univ Princesa, Unidad Biol Mol, Madrid 28006, Spain; Hosp Univ Princesa, Serv Inmunol, Madrid 28006, Spain; Ctr Rech Biochem Macromol, CNRS, UPR 1086, F-34293 Montpellier 5, France; Purdue Univ, Dept Basic Med Sci, W Lafayette, IN 47907 USA	Hospital de La Princesa; Hospital de La Princesa; Centre National de la Recherche Scientifique (CNRS); Purdue University System; Purdue University; Purdue University West Lafayette Campus	Lopez-Cabrera, M (corresponding author), Hosp Univ Princesa, Unidad Biol Mol, Diego de Leon 62, Madrid 28006, Spain.		Lara-Pezzi, Enrique/E-2350-2015; Sanchez-Madrid, Francisco/M-7889-2016; Cabrera, Manuel López/AAA-5463-2019	Lara-Pezzi, Enrique/0000-0002-2743-1033; Sanchez-Madrid, Francisco/0000-0001-5303-0762; roche, serge/0000-0003-3413-3859; Lopez Cabrera, Manuel/0000-0002-0976-9719; Andrisani, Ourania/0000-0002-6230-0303				Balsamo J, 1996, J CELL BIOL, V134, P801, DOI 10.1083/jcb.134.3.801; Baptista M, 1999, HEPATOLOGY, V29, P946, DOI 10.1002/hep.510290336; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; Chisari FV, 2000, AM J PATHOL, V156, P1117, DOI 10.1016/S0002-9440(10)64980-2; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Feitelson MA, 1997, AM J PATHOL, V150, P1141; GEIGER B, 1992, ANNU REV CELL BIOL, V8, P307, DOI 10.1146/annurev.cb.08.110192.001515; Gottlob K, 1998, CANCER RES, V58, P3566; Gottlob K, 1998, J BIOL CHEM, V273, P33347, DOI 10.1074/jbc.273.50.33347; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Haviv I, 1998, MOL CELL BIOL, V18, P1562, DOI 10.1128/MCB.18.3.1562; Hazan RB, 1998, J BIOL CHEM, V273, P9078, DOI 10.1074/jbc.273.15.9078; KEKULE AS, 1993, NATURE, V361, P742, DOI 10.1038/361742a0; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; Klein NP, 1997, MOL CELL BIOL, V17, P6427, DOI 10.1128/MCB.17.11.6427; KOIKE K, 1994, J CLIN INVEST, V94, P44, DOI 10.1172/JCI117343; Kozyraki R, 1996, GASTROENTEROLOGY, V110, P1137, DOI 10.1053/gast.1996.v110.pm8613003; Lara-Pezzi E, 2001, J HEPATOL, V34, P409, DOI 10.1016/S0168-8278(00)00090-8; Lara-Pezzi E, 1998, EMBO J, V17, P7066, DOI 10.1093/emboj/17.23.7066; LARAPEZZI E, 2001, IN PRESS HEPATOLOGY; LEE TH, 1995, J VIROL, V69, P1107, DOI 10.1128/JVI.69.2.1107-1114.1995; LUDUENA MA, 1977, J CELL PHYSIOL, V91, P119, DOI 10.1002/jcp.1040910112; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; Masaki T, 1998, HEPATOLOGY, V27, P1257, DOI 10.1002/hep.510270511; Muller T, 1999, J BIOL CHEM, V274, P10173, DOI 10.1074/jbc.274.15.10173; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Poussin K, 1999, INT J CANCER, V80, P497, DOI 10.1002/(SICI)1097-0215(19990209)80:4<497::AID-IJC3>3.0.CO;2-8; Provost E, 1999, CURR OPIN CELL BIOL, V11, P567, DOI 10.1016/S0955-0674(99)00015-0; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; Schafer DF, 1999, LANCET, V353, P1253, DOI 10.1016/S0140-6736(98)09148-X; Sirma H, 1999, ONCOGENE, V18, P4848, DOI 10.1038/sj.onc.1202867; Slagle BL, 1996, MOL CARCINOGEN, V15, P261, DOI 10.1002/(SICI)1098-2744(199604)15:4<261::AID-MC3>3.0.CO;2-J; SLAGLE BL, 1993, HEPATOLOGY, V18, P757, DOI 10.1002/hep.1840180402; Tarn C, 1999, J BIOL CHEM, V274, P2327, DOI 10.1074/jbc.274.4.2327; Terradillos O, 1997, ONCOGENE, V14, P395, DOI 10.1038/sj.onc.1200850; Tlsty TD, 1998, CURR OPIN CELL BIOL, V10, P647, DOI 10.1016/S0955-0674(98)80041-0; Tsukita Shoichiro, 1992, Current Opinion in Cell Biology, V4, P834, DOI 10.1016/0955-0674(92)90108-O; UEDA H, 1995, NAT GENET, V9, P41, DOI 10.1038/ng0195-41; Van Nhieu JT, 1999, AM J PATHOL, V155, P703, DOI 10.1016/S0002-9440(10)65168-1; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Yu DY, 1999, J HEPATOL, V31, P123, DOI 10.1016/S0168-8278(99)80172-X; Zondervan PE, 2000, J PATHOL, V192, P207, DOI 10.1002/1096-9896(2000)9999:9999&lt;::AID-PATH690&gt;3.0.CO;2-#	43	68	73	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 7	2001	20	26					3323	3331		10.1038/sj.onc.1204451	http://dx.doi.org/10.1038/sj.onc.1204451			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	441UW	11423982				2022-12-25	WOS:000169248800002
J	Zhu, L; Zilbering, A; Wu, XD; Mahadev, K; Joseph, JI; Jabbour, S; Deeb, W; Goldstein, BJ				Zhu, L; Zilbering, A; Wu, XD; Mahadev, K; Joseph, JI; Jabbour, S; Deeb, W; Goldstein, BJ			Use of an anaerobic environment to preserve the endogenous activity of protein-tyrosine phosphatases isolated from intact cells	FASEB JOURNAL			English	Article						signal transduction; redox; cysteine; thiol; protein-tyrosine phosphatase 1B	EPIDERMAL GROWTH-FACTOR; SIGNAL-TRANSDUCTION; REDOX REGULATION; REVERSIBLE INACTIVATION; INSULIN SENSITIVITY; RECEPTOR; 1B; CATALYSIS; ROLES; MECHANISM	Protein-tyrosine phosphatases (PTPases) have a common cysteine residue whose reduced state is integral to their phosphocysteine-mediated reaction mechanism. The catalytic cysteine thiol can be oxidized or conjugated during cellular redox reactions, which provides an important means of PTPase regulation in vivo. Because exposure to air can artifactually oxidize this reactive thiol, PTPase assays have typically used potent reducing agents such as dithiothreitol to reactivate the enzymes present. However, this approach does not allow for the measurement of endogenous PTPase activity as directly isolated from the in vivo cellular environment. Here we show that sample processing and assay in an anaerobic chamber by using deoxygenated buffers can preserve the overall activity of PTPases in subcellular fractions of 3T3-L1 adipocytes, HepG2 hepatoma cells, and human adipose tissue, as well as with PTP1B, specifically isolated by immunoprecipitation. Cell lysis into air reduced the PTPase activity to as low as 20% of the level observed with sample handling in the anaerobic environment, which was variably restored towards the activity in the anaerobic samples by treatment with dithiothreitol. The approach reported here provides a new framework for characterizing the activity of PTPases as isolated from the intracellular milieu, which more closely reflects the endogenous reactivity and potential impact of these PTPases on signal transduction pathways involving reversible protein-tyrosine phosphorylation.	Thomas Jefferson Univ, Jefferson Med Coll, Div Endocrinol & Metab Dis, Dept Med,Dorrance H Hamilton Res Labs, Philadelphia, PA 19107 USA	Jefferson University	Goldstein, BJ (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Div Endocrinol & Metab Dis, Dept Med,Dorrance H Hamilton Res Labs, Room 349 Alumni Hall,1020 Locust St, Philadelphia, PA 19107 USA.	Barry.Goldstein@mail.tju.edu						AHMAD F, 1995, J BIOL CHEM, V270, P20503, DOI 10.1074/jbc.270.35.20503; Bae YS, 2000, J BIOL CHEM, V275, P10527, DOI 10.1074/jbc.275.14.10527; Barford D, 1998, ANNU REV BIOPH BIOM, V27, P133, DOI 10.1146/annurev.biophys.27.1.133; Barrett WC, 1999, J BIOL CHEM, V274, P34543, DOI 10.1074/jbc.274.49.34543; Barrett WC, 1999, BIOCHEMISTRY-US, V38, P6699, DOI 10.1021/bi990240v; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen H, 1997, J BIOL CHEM, V272, P8026, DOI 10.1074/jbc.272.12.8026; Claiborne A, 1999, BIOCHEMISTRY-US, V38, P15407, DOI 10.1021/bi992025k; CZECH MP, 1974, J BIOL CHEM, V249, P1001; Denu JM, 1998, BIOCHEMISTRY-US, V37, P5633, DOI 10.1021/bi973035t; Denu JM, 1998, CURR OPIN CHEM BIOL, V2, P633, DOI 10.1016/S1367-5931(98)80095-1; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; GOLDSTEIN BJ, 2000, DIABETES MELLITUS FU, P206; GOLDSTEIN BJ, 1998, PROTEIN PROFILE; HASHIMOTO N, 1992, J BIOL CHEM, V267, P13811; HEFFETZ D, 1990, J BIOL CHEM, V265, P2896; Herrlich P, 2000, BIOCHEM PHARMACOL, V59, P35, DOI 10.1016/S0006-2952(99)00298-1; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Huyer G, 1997, J BIOL CHEM, V272, P843, DOI 10.1074/jbc.272.2.843; Kenner KA, 1996, J BIOL CHEM, V271, P19810, DOI 10.1074/jbc.271.33.19810; Klaman LD, 2000, MOL CELL BIOL, V20, P5479, DOI 10.1128/MCB.20.15.5479-5489.2000; KOLACZYNSKI JW, 1994, INT J OBESITY, V18, P161; Lee SR, 1998, J BIOL CHEM, V273, P15366, DOI 10.1074/jbc.273.25.15366; Lohse DL, 1997, BIOCHEMISTRY-US, V36, P4568, DOI 10.1021/bi963094r; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; PIKE LJ, 1984, J BIOL CHEM, V259, P9913; POT DA, 1991, J BIOL CHEM, V266, P19688; Rudich A, 1999, DIABETOLOGIA, V42, P949, DOI 10.1007/s001250051253; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Seely BL, 1996, DIABETES, V45, P1379, DOI 10.2337/diabetes.45.10.1379; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; TONKS NK, 1991, METHOD ENZYMOL, V201, P442; Zhang ZY, 1998, CRIT REV BIOCHEM MOL, V33, P1, DOI 10.1080/10409239891204161	34	14	15	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY 29	2001	15	7					1637	+		10.1096/fj.00-0795fje	http://dx.doi.org/10.1096/fj.00-0795fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519CQ	11427511				2022-12-25	WOS:000173707700012
J	Kim, H; You, SK; Kim, IJ; Foster, LK; Farris, J; Ambady, S; de Leon, FAP; Foster, DN				Kim, H; You, SK; Kim, IJ; Foster, LK; Farris, J; Ambady, S; de Leon, FAP; Foster, DN			Alterations in p53 and E2F-1 function common to immortalized chicken embryo fibroblasts	ONCOGENE			English	Article						chicken embryo fibroblast; immortalization; p53; E2F-1; telomerase	HUMAN-CELLS; SACCHAROMYCES-CEREVISIAE; CELLULAR SENESCENCE; TELOMERASE ACTIVITY; TUMOR-CELLS; GENE; DEGRADATION; EXPRESSION; MECHANISM; PATTERNS	A number of non-virally and non-chemically immortalized chicken embryo fibroblast (CEF) cells have been established recently in continuous cell culture. All immortal CEF cells tested showed common genetic alterations in the expression patterns of p53 and E2F-1 mRNA and protein which were down- and up-regulated, respectively, The biological effects of differentially regulated p53 and E2F-1 were determined by reporter gene transcriptional activity assays, DNA binding assays, and Northern blot analysis of the expression patterns of down-stream genes, In addition, expression of most of the cyclin genes was up-regulated in immortal CEF cells, which may be associated with the rapid cell division rates and serum-independent growth patterns seen in immortal CEF cells. The telomeric lengths and chromosome integrity were maintained in all immortal CEF cell lines without detectable telomerase activity. Although the functional inactivations of the p53 and Rb regulatory pathways are known to be common events for cellular immortalization, the genetic changes leading to alteration of p53 and E2F-1 function through transcriptional and post-transcriptional regulation seem to be unique in immortal CEF cells.	Univ Minnesota, Dept Anim Sci, St Paul, MN 55108 USA; Seoul Natl Univ, Sch Agr Biotechnol, Suwon 441744, South Korea	University of Minnesota System; University of Minnesota Twin Cities; Seoul National University (SNU)	Foster, DN (corresponding author), 495 AnSci VetMed, 1988 Fitch AVe, St Paul, MN 55108 USA.		Kim, Hyunggee/F-2673-2013; Kang, Phil Jun/F-4716-2013; You, Seungkwon/H-3067-2015	Kim, Hyunggee/0000-0002-4738-0990; Ponce de Leon, Federico/0000-0001-8645-553X				ATADJA P, 1995, P NATL ACAD SCI USA, V92, P8348, DOI 10.1073/pnas.92.18.8348; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Boulton SJ, 1996, NUCLEIC ACIDS RES, V24, P4639, DOI 10.1093/nar/24.23.4639; Bryan TM, 1997, HUM MOL GENET, V6, P921, DOI 10.1093/hmg/6.6.921; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; CHEN XB, 1993, GENE DEV, V7, P1837, DOI 10.1101/gad.7.10.1837; DELEON FAP, 1992, J HERED, V83, P36, DOI 10.1093/oxfordjournals.jhered.a111154; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; GREENWELL PW, 1995, CELL, V82, P823, DOI 10.1016/0092-8674(95)90479-4; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; Himly M, 1998, VIROLOGY, V248, P295, DOI 10.1006/viro.1998.9290; Jha KK, 1998, EXP CELL RES, V245, P1, DOI 10.1006/excr.1998.4272; Kaelin WG, 1999, BIOESSAYS, V21, P950, DOI 10.1002/(SICI)1521-1878(199911)21:11<950::AID-BIES7>3.0.CO;2-D; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; McEachern MJ, 1996, GENE DEV, V10, P1822, DOI 10.1101/gad.10.14.1822; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Meyyappan M, 1998, MOL CELL BIOL, V18, P3163, DOI 10.1128/MCB.18.6.3163; Robertson KD, 1998, MOL CELL BIOL, V18, P6457, DOI 10.1128/MCB.18.11.6457; RUBELJ I, 1994, EXP CELL RES, V211, P82, DOI 10.1006/excr.1994.1062; Schaefer-Klein J, 1998, VIROLOGY, V248, P305, DOI 10.1006/viro.1998.9291; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Sedivy JM, 1998, P NATL ACAD SCI USA, V95, P9078, DOI 10.1073/pnas.95.16.9078; SEGAWA K, 1993, ONCOGENE, V8, P543; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Venkatesan RN, 1998, P NATL ACAD SCI USA, V95, P14763, DOI 10.1073/pnas.95.25.14763; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; Zhang HS, 1999, CELL, V97, P53, DOI 10.1016/S0092-8674(00)80714-X	36	35	43	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 10	2001	20	21					2671	2682		10.1038/sj.onc.1204378	http://dx.doi.org/10.1038/sj.onc.1204378			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	431VN	11420679				2022-12-25	WOS:000168652600008
J	Zhang, DW; Cole, SPC; Deeley, RG				Zhang, DW; Cole, SPC; Deeley, RG			Identification of a nonconserved amino acid residue in multidrug resistance protein 1 important for determining substrate specificity - Evidence for functional interaction between transmembrane helices 14 and 17	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN P-GLYCOPROTEIN; PLASMA-MEMBRANE VESICLES; PHARMACOLOGICAL CHARACTERIZATION; VINCRISTINE TRANSPORT; MEDIATED TRANSPORT; LEUKOTRIENE C-4; MRP; GLUTATHIONE; CELLS; MURINE	Murine multidrug resistance protein 1 (mrp1), differs from its human ortholog (MRP1) in that it fails to confer anthracycline resistance and transports the MRP1 substrate, 17 beta -estradiol 17-(beta -D-glucuronide) (E(2)17 betaG), very poorly. By mutating variant residues in mrp1 to those present in MRP1, we identified Glu(1089) of MRP1 as being critical for anthracycline resistance. However, Glu(1089) mutations had no effect on E(2)17 betaG transport. We have now identified a nonconserved amino acid within the highly conserved COOH-proximal transmembrane helix of MRP1/mrp1 that is important for transport of the conjugated estrogen. Converting Ala(1239) in mrp1 to Thr, as in the corresponding position (1242) in MRP1, increased E(2)17 betaG transport 3-fold. Any mutation of mrp1 Ala(1239), including substitution with Thr, decreased resistance to vincristine and VP-16 without altering anthracycline resistance. However, introduction of a second murine to human mutation, Q1086E, which alone selectively increases anthracycline resistance, into mrp1A1239T restored resistance to both vincristine and VP-16. To confirm the importance of MRP1 Thr(1242) for E(2)17 betaG transport and drug resistance, we mutated this residue to Ala, Cys, Ser, Leu, and Lys. These mutations decreased E(2)17 betaG transport 2-fold. Conversion to Asp eliminated transport of the estrogen conjugate and also decreased leukotriene C-4 transport similar to2-fold. The mutations also reduced the ability of MRP1 to confer resistance to all drugs tested. As with mrp1, introduction of a second mutation based on the murine sequence to create MRP1E1089Q/ T1242A restored resistance to vincristine and VP-16, but not anthracyclines, without affecting transport of leukotriene C-4 and E(2)17 betaG. These results demonstrate the important role of Thr(1242) for E(2)17 betaG transport. They also reveal a highly specific functional relationship between nonconserved amino acids in TM helices 14 and 17 of both mrp1 and MRP1 that enables both proteins to confer similar levels of resistance to vincristine and VP-16.	Queens Univ, Canc Res Labs, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Pathol, Kingston, ON K7L 3N6, Canada	Queens University - Canada; Queens University - Canada	Deeley, RG (corresponding author), Queens Univ, Canc Res Labs, Botterell Hall, Kingston, ON K7L 3N6, Canada.		Deeley, Roger/J-4828-2012; Cole, Susan P.C./I-6389-2017; Zhang, Dawei/ABD-8990-2022	Cole, Susan P.C./0000-0001-6571-6884; Zhang, Dawei/0000-0001-8279-8041				Bakos E, 1996, J BIOL CHEM, V271, P12322, DOI 10.1074/jbc.271.21.12322; Borst P, 1999, BBA-BIOMEMBRANES, V1461, P347, DOI 10.1016/S0005-2736(99)00167-4; COLE SPC, 1994, CANCER RES, V54, P5902; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; Daoud R, 2001, J BIOL CHEM, V276, P12324, DOI 10.1074/jbc.M009782200; Deeley RG, 1997, SEMIN CANCER BIOL, V8, P193, DOI 10.1006/scbi.1997.0070; Ding GY, 1999, ANTICANCER RES, V19, P3243; GRANT CE, 1994, CANCER RES, V54, P357; Hafkemeyer P, 1998, BIOCHEMISTRY-US, V37, P16400, DOI 10.1021/bi980871+; Higgins CF, 1997, SEMIN CANCER BIOL, V8, P135, DOI 10.1006/scbi.1997.0067; Hipfner DR, 1997, J BIOL CHEM, V272, P23623, DOI 10.1074/jbc.272.38.23623; Hipfner DR, 1998, BRIT J CANCER, V78, P1134, DOI 10.1038/bjc.1998.642; Hipfner DR, 1996, CANCER RES, V56, P3307; Hipfner DR, 1999, BBA-BIOMEMBRANES, V1461, P359, DOI 10.1016/S0005-2736(99)00168-6; Ito K, 2001, MOL PHARMACOL, V59, P1077, DOI 10.1124/mol.59.5.1077; Ito K, 2001, J BIOL CHEM, V276, P15616, DOI 10.1074/jbc.M011246200; Jedlitschky G, 1996, CANCER RES, V56, P988; Keppler D, 1999, ADV ENZYME REGUL, V39, P237, DOI 10.1016/S0065-2571(98)00015-6; Leslie EM, 2001, J BIOL CHEM, V276, P27846, DOI 10.1074/jbc.M102453200; Loe DW, 1996, J BIOL CHEM, V271, P9683, DOI 10.1074/jbc.271.16.9683; Loe DW, 1998, CANCER RES, V58, P5130; Loe DW, 1996, J BIOL CHEM, V271, P9675, DOI 10.1074/jbc.271.16.9675; Loo TW, 1997, J BIOL CHEM, V272, P20986, DOI 10.1074/jbc.272.34.20986; Loo TW, 1997, J BIOL CHEM, V272, P31945, DOI 10.1074/jbc.272.51.31945; LOO TW, 1993, J BIOL CHEM, V268, P19965; Mao QC, 2000, J BIOL CHEM, V275, P34166, DOI 10.1074/jbc.M004584200; Qian YM, 2001, J BIOL CHEM, V276, P6404, DOI 10.1074/jbc.M008251200; Renes J, 1999, BRIT J PHARMACOL, V126, P681, DOI 10.1038/sj.bjp.0702360; Robbiani DF, 2000, CELL, V103, P757, DOI 10.1016/S0092-8674(00)00179-3; Ryu S, 2000, J BIOL CHEM, V275, P39617, DOI 10.1074/jbc.M005149200; Sakamoto H, 1999, CANCER LETT, V135, P113; Schinkel AH, 1997, SEMIN CANCER BIOL, V8, P161, DOI 10.1006/scbi.1997.0068; SCHLEMMER SR, 1994, J BIOL CHEM, V269, P31059; Seelig A, 2000, INT J CLIN PHARM TH, V38, P111; Sharom FJ, 1999, BBA-BIOMEMBRANES, V1461, P327, DOI 10.1016/S0005-2736(99)00166-2; Stride BD, 1999, J BIOL CHEM, V274, P22877, DOI 10.1074/jbc.274.32.22877; Stride BD, 1997, MOL PHARMACOL, V52, P344, DOI 10.1124/mol.52.3.344; Stride BD, 1996, MOL PHARMACOL, V49, P962; Wijnholds J, 1997, NAT MED, V3, P1275, DOI 10.1038/nm1197-1275; WILSON GM, 1995, PLASMID, V33, P198, DOI 10.1006/plas.1995.1021; Zhang DW, 2001, J BIOL CHEM, V276, P13231, DOI 10.1074/jbc.M010008200	41	64	69	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					34966	34974		10.1074/jbc.M105063200	http://dx.doi.org/10.1074/jbc.M105063200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11429411	hybrid			2022-12-25	WOS:000171024600083
J	Baulande, S; Lasnier, F; Lucas, M; Pairault, J				Baulande, S; Lasnier, F; Lucas, M; Pairault, J			Adiponutrin, a transmembrane protein corresponding to a novel dietary- and obesity-linked mRNA specifically expressed in the adipose lineage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENZYME GENE-EXPRESSION; ADIPOCYTE DIFFERENTIATION; RIBONUCLEIC-ACID; MESSENGER-RNA; CELL-LINE; SENSITIVITY; INSULIN; PREADIPOCYTE; CONVERSION; INVITRO	We have used a mRNA differential display technique to identify new genes involved in the reprogramming of gene expression during the adipose conversion of mouse 3T3 preadipocyte, cell lines. We report here on the identification and cloning of a novel adipose-specific cDNA encoding a predicted membrane protein of 413 amino acids. The level of the corresponding 3.2-kilobase mRNA is tremendously increased during 3T3-L1 and 3T3-F442A differentiation into adipocytes. A single, very abundant 3.2-kilobase transcript is also found in inguinal and epididymal white adipose tissues and in interscapular brown adipose tissue but not in any other tissues examined. Its expression in adipose tissue is under tight nutritional regulation. The level of this novel 3.2-kilobase transcript becomes virtually nondetectable during fasting but is dramatically increased when fasted mice are refed a high carbohydrate diet. Based on its adipose specificity and dietary regulation, the novel gene product; has been designated adiponutrin. The expression of adiponutrin mRNA is also 50-fold elevated in genetically obese fa/fa rats, indicating a link between adiponutrin and obesity. Western blot and confocal imagery analyses with epitope-tagged protein transiently expressed in 3T3-L1 adipocytes, and COS cells show that adiponutrin strictly localizes to membranes and is absent from. the cytosol. Sequence analysis reveals homologies with several other members of related eukaryotic proteins, including a human paralog, which has been recently described in vesicular transport mechanisms. This leads us to suggest that adiponutrin could be involved in vesicular targeting and protein transport restricted to the adipocyte function.	Univ Paris 06, CNRS, UMR Physiol & Physiopathol, F-75270 Paris 06, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite	Pairault, J (corresponding author), Univ Paris 06, CNRS, UMR Physiol & Physiopathol, 15 Rue Ecole Med, F-75270 Paris 06, France.			BAULANDE, Sylvain/0000-0003-3104-1684				CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLARKE SD, 1990, J NUTR, V120, P218, DOI 10.1093/jn/120.2.218; CORNELIUS P, 1994, ANNU REV NUTR, V14, P99, DOI 10.1146/annurev.nu.14.070194.000531; COUPE C, 1990, AM J PHYSIOL, V258, pE126, DOI 10.1152/ajpendo.1990.258.1.E126; ElHadri K, 1996, EUR J PHARMACOL, V297, P107, DOI 10.1016/0014-2999(95)00723-7; FOUFELLE F, 1992, J BIOL CHEM, V267, P20543; Frohman Michael A., 1995, P381; GIRARD J, 1994, FASEB J, V8, P36, DOI 10.1096/fasebj.8.1.7905448; GREEN H, 1976, CELL, V7, P105, DOI 10.1016/0092-8674(76)90260-9; GREEN H, 1979, J CELL PHYSIOL, V101, P169, DOI 10.1002/jcp.1041010119; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; GREEN H, 1975, CELL, V5, P19, DOI 10.1016/0092-8674(75)90087-2; Gregoire FM, 1998, PHYSIOL REV, V78, P783, DOI 10.1152/physrev.1998.78.3.783; Guo XM, 2000, GENE, V251, P45, DOI 10.1016/S0378-1119(00)00192-X; Jones BH, 1998, BIOCHEM J, V335, P405, DOI 10.1042/bj3350405; JUMP DB, 1985, ENDOCRINOLOGY, V117, P2259, DOI 10.1210/endo-117-6-2259; KELLER A, 1981, J NEUROCHEM, V36, P1389, DOI 10.1111/j.1471-4159.1981.tb00577.x; Kim JB, 1998, J CLIN INVEST, V101, P1, DOI 10.1172/JCI1411; Kim KH, 2001, J BIOL CHEM, V276, P11252, DOI 10.1074/jbc.C100028200; Kim S, 2000, J NUTR, V130, p3110S; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; Rosen ED, 2000, ANNU REV CELL DEV BI, V16, P145, DOI 10.1146/annurev.cellbio.16.1.145; RUBIN CS, 1978, J BIOL CHEM, V253, P7570; RUBIN CS, 1977, J BIOL CHEM, V252, P3554; SADOWSKI HB, 1992, J BIOL CHEM, V267, P4722; Sambrook J., 2002, MOL CLONING LAB MANU; Tatusov RL, 2001, NUCLEIC ACIDS RES, V29, P22, DOI 10.1093/nar/29.1.22; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WATERS KM, 1994, J BIOL CHEM, V269, P27773; WELSH J, 1992, NUCLEIC ACIDS RES, V20, P4965, DOI 10.1093/nar/20.19.4965; [No title captured]	33	193	206	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33336	33344		10.1074/jbc.M105193200	http://dx.doi.org/10.1074/jbc.M105193200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11431482	hybrid			2022-12-25	WOS:000170910200009
J	Lin, L; Schmidt, B; Teckman, J; Perlmutter, DH				Lin, L; Schmidt, B; Teckman, J; Perlmutter, DH			A naturally occurring nonpolymerogenic mutant of alpha 1-antitrypsin characterized by prolonged retention in the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA(1)-ANTITRYPSIN DEFICIENCY; MUTATION; LIVER; VARIANTS; DEGRADATION; SECRETION; REQUIRES; DISEASE; DEFECT; GENE	The classical form of alphal-antitrypsin (alphal-AT) deficiency is associated with a mutant alpha1-ATZ molecule that polymerizes in the endoplasmic reticulum (ER) of liver cells. A subgroup of individuals homozygous for the protease inhibitor (PI) Z allele develop chronic liver injury and are predisposed to hepatocellular carcinoma. In this study we evaluated the primary structure of alphal-AT in a family in which three affected members had severe liver disease associated with alphal-AT deficiency. We discovered that one sibling was a compound heterozygote with one PI Z allele and a second allele, the PI Z + saar allele, bearing the mutation that characterizes alphal-ATZ as well as the mutation that characterizes alphal-AT Saarbrucken (alphal-AT saar). The mutation in PI saar introduces a premature termination codon resulting in an alphal-AT protein truncated for 19 amino acids at its carboxyl terminus. Studies of a second sib with severe liver disease and other living family members did not reveal the presence of the alphal-AT saar mutation and therefore do not substantiate a role for this mutation in the liver disease phenotype of this family. However, studies of alphal-AT saar and alphal-ATZ + saar expressed in heterologous cells show that there is prolonged intracellular retention of these mutants even though they do not have polymerogenic properties. These results therefore have important implications for further understanding the fate of mutant alphal-AT molecules, the mechanism of ER retention, and the pathogenesis of liver injury in alphal-AT deficiency.	Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; St Louis Childrens Hosp, Div Gastroenterol & Nutr, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL)	Perlmutter, DH (corresponding author), Univ Pittsburgh, Childrens Hosp Pittsburgh, Sch Med, Dept Pediat, 3705 5th Ave, Pittsburgh, PA 15213 USA.			Schmidt, Bela Z/0000-0003-1085-9372; Teckman, Jeffrey/0000-0002-4870-2621				Brantly M, 1997, AM J RESP CELL MOL, V16, P225, DOI 10.1165/ajrcmb.16.3.9070606; BRODBECK RM, 1992, J BIOL CHEM, V267, P294; Carrell R, 1997, ADV EXP MED BIOL, V425, P207; Carrell RW, 1997, LANCET, V350, P134, DOI 10.1016/S0140-6736(97)02073-4; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Dul JL, 2001, J CELL BIOL, V152, P705, DOI 10.1083/jcb.152.4.705; FOREMAN RC, 1984, FEBS LETT, V169, P84; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JEPPSSON JO, 1976, FEBS LETT, V65, P195, DOI 10.1016/0014-5793(76)80478-4; Kang HA, 1997, J BIOL CHEM, V272, P510; KIDD VJ, 1983, NATURE, V304, P230, DOI 10.1038/304230a0; KIM JH, 1995, J BIOL CHEM, V270, P8597, DOI 10.1074/jbc.270.15.8597; Knight K R, 1997, Respirology, V2, P91, DOI 10.1111/j.1440-1843.1997.tb00060.x; LOMAS DA, 1992, NATURE, V357, P605, DOI 10.1038/357605a0; MCELVANEY NG, 1997, LUNG SCI FDN, P2537; OWEN MC, 1976, FEBS LETT, V79, P247; PERLMUTTER DH, 1985, P NATL ACAD SCI USA, V82, P6918, DOI 10.1073/pnas.82.20.6918; PERLMUTTER DH, 1999, SCHIFFS DIS LIVER, P1131; PERLMUTTER DH, 2001, IN PRESS LIVER BIOL; Qu DF, 1996, J BIOL CHEM, V271, P22791, DOI 10.1074/jbc.271.37.22791; SIDHAR SK, 1995, J BIOL CHEM, V270, P8393, DOI 10.1074/jbc.270.15.8393; SIFERS RN, 1988, J BIOL CHEM, V263, P7330; SVEGER T, 1995, HEPATOLOGY, V22, P514, DOI 10.1002/hep.1840220221; SVEGER T, 1978, PEDIATRICS, V62, P22; WU Y, 1994, P NATL ACAD SCI USA, V91, P9014, DOI 10.1073/pnas.91.19.9014	25	45	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33893	33898		10.1074/jbc.M105226200	http://dx.doi.org/10.1074/jbc.M105226200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11427540	hybrid			2022-12-25	WOS:000170910200082
J	Muhlenhoff, M; Manegold, A; Windfuhr, M; Gotza, B; Gerardy-Schahn, R				Muhlenhoff, M; Manegold, A; Windfuhr, M; Gotza, B; Gerardy-Schahn, R			The impact of N-glycosylation on the functions of polysialyltransferases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE; DEVELOPMENTALLY-REGULATED MEMBER; POLYSIALIC ACID SYNTHASE; CENTRAL-NERVOUS-SYSTEM; ALPHA-MANNOSIDASE-II; 2 POLYSIALYLTRANSFERASES; OLFACTORY-BULB; ADULT-RAT; EXPRESSION; POLYSIALYLATION	Poly-alpha -2,8-sialic acid (polysialic acid) is a post-translational modification of the neural cell adhesion molecule (NCAM) and an important regulator of neuronal cell-cell interactions. The synthesis of polysialic acid depends on the two polysialyltransferases ST8SiaII and ST8SiaIV. Understanding the catalytic mechanisms of the polysialyltransferases is critical toward the aim of influencing physiological and pathophysiological functions mediated by polysialic acid. We recently demonstrated that polysialyltransferases are bifunctional enzymes exhibiting auto- and NCAM polysialylation activity. Autopolysialylation occurs on N-glycans of the enzymes, and glycosylation variants lacking sialic acid and galactose were found to be inactive for both auto- and NCAM polysialylation. In the present study, we have analyzed the number and functional importance of N-linked oligosaccharides present on polysialyltransferases. We demonstrate that autopolysialylation depends on specific N-glycans attached to Asn(74) in ST8SiaIV and Asn(89) and Asn(219) in ST8SiaII. Deletion of polysialic acid acceptor sites by site-directed mutagenesis rendered the polysialyltransferases inactive in vitro and in vivo. The inactivity of autopolysialylation-negative polysialyltransferases in vivo was not caused by the absence or default targeting of the enzymes. The data presented in this study clearly show that active polysialyltransferases are competent to perform autopolysialylation and provide strong evidence for a tight functional link between the two catalytic functions.	Hannover Med Sch, Inst Physiol Chem, D-30625 Hannover, Germany	Hannover Medical School	Gerardy-Schahn, R (corresponding author), Hannover Med Sch, Inst Physiol Chem, Carl Neuberg Str 1, D-30625 Hannover, Germany.	gerardy-schahn.rita@mh-hannover.de						Angata K, 1998, J BIOL CHEM, V273, P28524, DOI 10.1074/jbc.273.43.28524; Angata K, 2000, J BIOL CHEM, V275, P18594, DOI 10.1074/jbc.M910204199; Angata K, 2001, J BIOL CHEM, V276, P15369, DOI 10.1074/jbc.M100576200; Baboval T, 2000, BBA-GEN SUBJECTS, V1475, P383, DOI 10.1016/S0304-4165(00)00094-5; BONFANTI L, 1992, NEUROSCIENCE, V49, P419, DOI 10.1016/0306-4522(92)90107-D; Breton C, 1998, GLYCOBIOLOGY, V8, P87, DOI 10.1093/glycob/8.1.87; BRISSON JR, 1992, BIOCHEMISTRY-US, V31, P4996, DOI 10.1021/bi00136a012; Chen C, 2000, GLYCOBIOLOGY, V10, P531, DOI 10.1093/glycob/10.5.531; Christensen LL, 2000, GLYCOBIOLOGY, V10, P931, DOI 10.1093/glycob/10.9.931; Close BE, 2000, J BIOL CHEM, V275, P4484, DOI 10.1074/jbc.275.6.4484; Close BE, 1998, J BIOL CHEM, V273, P34586, DOI 10.1074/jbc.273.51.34586; Daniel L, 2000, CANCER RES, V60, P80; ECKHARDT M, 1995, NATURE, V373, P715, DOI 10.1038/373715a0; Eckhardt M, 2000, J NEUROSCI, V20, P5234, DOI 10.1523/JNEUROSCI.20-14-05234.2000; FINNE J, 1985, J BIOL CHEM, V260, P1265; FROSCH M, 1985, P NATL ACAD SCI USA, V82, P1194, DOI 10.1073/pnas.82.4.1194; Fukuda M, 1996, CANCER RES, V56, P2237; GERARDYSCHAHN R, 1995, MOL MICROBIOL, V16, P441, DOI 10.1111/j.1365-2958.1995.tb02409.x; GERARDYSCHAHN R, 1994, INT J CANCER, P38; Gluer S, 1998, BRIT J CANCER, V78, P106, DOI 10.1038/bjc.1998.450; HARAGUCHI M, 1995, BIOCHEM J, V312, P273, DOI 10.1042/bj3120273; Hildebrandt H, 1998, J NEUROCHEM, V71, P2339; Hu HY, 1996, NEURON, V16, P735, DOI 10.1016/S0896-6273(00)80094-X; Inoue S, 2000, J BIOL CHEM, V275, P29968, DOI 10.1074/jbc.M004150200; Kojima N, 1997, J BIOCHEM-TOKYO, V122, P1265; KOJIMA N, 1995, FEBS LETT, V373, P119, DOI 10.1016/0014-5793(95)01024-9; Kurosawa N, 1997, J NEUROCHEM, V69, P494; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIVINGSTON BD, 1993, J BIOL CHEM, V268, P11504; LIVINGSTON BD, 1988, J BIOL CHEM, V263, P9443; MIRAGALL F, 1990, J NEUROCYTOL, V19, P899, DOI 10.1007/BF01186818; MOREMEN KW, 1991, J BIOL CHEM, V266, P16876; Muhlenhoff M, 1996, EMBO J, V15, P6943, DOI 10.1002/j.1460-2075.1996.tb01086.x; Muhlenhoff M, 1998, CURR OPIN STRUC BIOL, V8, P558, DOI 10.1016/S0959-440X(98)80144-9; Muhlenhoff M, 1996, CURR BIOL, V6, P1188, DOI 10.1016/S0960-9822(02)70687-8; Murakami S, 2000, J COMP NEUROL, V420, P171; Nakayama J, 1996, J BIOL CHEM, V271, P1829, DOI 10.1074/jbc.271.4.1829; NELSON RW, 1995, J BIOL CHEM, V270, P17171, DOI 10.1074/jbc.270.29.17171; Ong E, 1998, GLYCOBIOLOGY, V8, P415, DOI 10.1093/glycob/8.4.415; Rutishauser U, 1996, TRENDS NEUROSCI, V19, P422; Rutishauser U, 1996, CURR OPIN CELL BIOL, V8, P679, DOI 10.1016/S0955-0674(96)80109-8; SANCHEZLOPEZ R, 1988, J BIOL CHEM, V263, P11892; SCHNEIDEGGER EP, 1994, LAB INVEST, V70, P95; Seidenfaden R, 2000, EUR J CELL BIOL, V79, P680, DOI 10.1078/0171-9335-00093; SEKI T, 1991, NEUROSCI RES, V12, P503, DOI 10.1016/S0168-0102(09)80003-5; THEODOSIS DT, 1991, P NATL ACAD SCI USA, V88, P5494, DOI 10.1073/pnas.88.13.5494; VELASCO A, 1993, J CELL BIOL, V122, P39, DOI 10.1083/jcb.122.1.39; Windfuhr M, 2000, J BIOL CHEM, V275, P32861, DOI 10.1074/jbc.M003507200; YANG PF, 1994, J BIOL CHEM, V269, P23039	49	41	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					34066	34073		10.1074/jbc.M101022200	http://dx.doi.org/10.1074/jbc.M101022200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11418591	hybrid			2022-12-25	WOS:000170910200104
J	Calugaru, SV; Swanson, R; Olson, ST				Calugaru, SV; Swanson, R; Olson, ST			The pH dependence of serpin-proteinase complex dissociation reveals a mechanism of complex stabilization involving inactive and active conformational states of the proteinase which are perturbable by calcium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REACTIVE CENTER LOOP; INCREASED STRUCTURAL FLEXIBILITY; HUMAN ANTITHROMBIN-III; BOVINE BETA-TRYPSIN; ALPHA(1)-PROTEINASE INHIBITOR; KINETIC CHARACTERIZATION; ALPHA-CHYMOTRYPSIN; PLASMINOGEN-ACTIVATOR; TARGET PROTEINASES; SERINE PROTEASES	Serpin family protein proteinase inhibitors trap proteinases at the acyl-intermediate stage of cleavage of the serpin as a proteinase substrate by undergoing a dramatic conformational change, which is thought to distort the proteinase active site and slow deacylation. To investigate the extent to which proteinase catalytic function I. Ls defective in the serpin-proteinase complex, we compared the pH dependence of dissociation of several serpin-proteinase acyl-complexes with that of normal guanidinobenzoyl-proteinase acyl-intermediate complexes. Whereas the apparent rate constant for dissociation of guanidinobenzoyl-proteinase complexes (k(diss, app)) showed a pH dependence characteristic of His-57 catalysis of complex deacylation, the pH dependence of k(diss, app) for the serpin-proteinase complexes showed no evidence for His-57 involvement in complex deacylation and was instead characteristic of a hydroxide-mediated deacylation similar to that observed for the hydrolysis of tosylarginine methyl ester. Hydroxylamine enhanced the rate of serpin-proteinase complex dissociation but with a rate constant for nucleophilic attack on the acyl bond several orders of magnitude slower than that of hydroxide, implying limited accessibility of the acyl bond in the complex. The addition of 10-100 mm Ca2+ ions stimulated up to 80-fold the dissociation rate constant of several serpin-trypsin complexes in a saturable manner at neutral pH and altered the pH dependence to a pattern characteristic of His-57-catalyzed complex deacylation. These results support a mechanism of kinetic stabilization of serpin-proteinase complexes wherein the complex is trapped as an acyl-intermediate by a serpin conformational change-induced inactivation of the proteinase catalytic function, but suggest that the inactive proteinase conformation in the complex is in equilibrium with an active proteinase conformation that can be stabilized by the preferential binding of an allosteric ligand such as Ca2+.	Univ Illinois, Coll Dent, Ctr Mol Biol Oral Dis, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Olson, ST (corresponding author), Univ Illinois, Coll Dent, Ctr Mol Biol Oral Dis, Rm 530E,Dent MC 860,801 S Paulina St, Chicago, IL 60612 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL064013] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01-HL-64013] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASCENZI P, 1982, BIOCHEMISTRY-US, V21, P2483, DOI 10.1021/bi00539a030; BJORK I, 1992, J BIOL CHEM, V267, P19047; BJORK I, 1993, BIOCHEMISTRY-US, V32, P6501; BLOOM JW, 1978, J BIOL CHEM, V253, P547; BOCK PE, 1989, ARCH BIOCHEM BIOPHYS, V273, P375, DOI 10.1016/0003-9861(89)90496-7; BODE W, 1976, FEBS LETT, V68, P231, DOI 10.1016/0014-5793(76)80443-7; BODE W, 1975, FEBS LETT, V56, P139, DOI 10.1016/0014-5793(75)80128-1; ChaillanHuntington CE, 1997, BIOCHEMISTRY-US, V36, P9562, DOI 10.1021/bi970651g; CHASE T, 1969, BIOCHEMISTRY-US, V8, P2212, DOI 10.1021/bi00833a063; Chuang YJ, 2001, J BIOL CHEM, V276, P14961, DOI 10.1074/jbc.M011550200; Chuang YJ, 2001, BIOCHEMISTRY-US, V40, P6670, DOI 10.1021/bi002933d; CHURCH FC, 1997, CHEM BIOL SERPINS; COREY DR, 1992, J AM CHEM SOC, V114, P1784, DOI 10.1021/ja00031a037; CRAIG PA, 1989, J BIOL CHEM, V264, P5452; DANIELSSON A, 1983, BIOCHEM J, V213, P345, DOI 10.1042/bj2130345; DEJERSEY J, 1980, ARCH BIOCHEM BIOPHYS, V205, P536, DOI 10.1016/0003-9861(80)90136-8; DICERA E, 1991, BIOCHEMISTRY-US, V30, P7913, DOI 10.1021/bi00246a007; Egelund R, 1998, BIOCHEMISTRY-US, V37, P6375, DOI 10.1021/bi973043+; Egelund R, 2001, EUR J BIOCHEM, V268, P673, DOI 10.1046/j.1432-1327.2001.01921.x; ERSDALBADJU E, 1995, BIOCHEM J, V310, P323, DOI 10.1042/bj3100323; Fa M, 2000, STRUCT FOLD DES, V8, P397, DOI 10.1016/S0969-2126(00)00121-0; FERSHT AR, 1973, BIOCHEMISTRY-US, V12, P2035, DOI 10.1021/bi00735a002; FERSHT AR, 1974, BIOCHEMISTRY-US, V13, P1416, DOI 10.1021/bi00704a016; Futamura A, 1998, BIOCHEMISTRY-US, V37, P13110, DOI 10.1021/bi981234m; GERTLER A, 1974, BIOCHEMISTRY-US, V13, P1302, DOI 10.1021/bi00703a038; Gettins P.G.W., 1996, SERPINS STRUCTURE FU; Han JH, 1998, BIOCHEMISTRY-US, V37, P3203, DOI 10.1021/bi9722195; HERVE M, 1991, ARCH BIOCHEM BIOPHYS, V285, P142, DOI 10.1016/0003-9861(91)90341-F; HUBER R, 1978, ACCOUNTS CHEM RES, V11, P114, DOI 10.1021/ar50123a006; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; Kaslik G, 1999, ARCH BIOCHEM BIOPHYS, V362, P254, DOI 10.1006/abbi.1998.1035; KASLIK G, 1995, FEBS LETT, V370, P179, DOI 10.1016/0014-5793(95)00816-R; Kaslik G, 1997, BIOCHEMISTRY-US, V36, P5455, DOI 10.1021/bi962931m; KAY J, 1971, J BIOL CHEM, V246, P6661; Kvassman JO, 1998, BIOCHEMISTRY-US, V37, P15491, DOI 10.1021/bi9814787; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LATALLO ZS, 1986, THROMB RES, V43, P507, DOI 10.1016/0049-3848(86)90071-X; LAWRENCE DA, 1995, J BIOL CHEM, V270, P25309, DOI 10.1074/jbc.270.43.25309; MANGEL WF, 1990, BIOCHEMISTRY-US, V29, P8351, DOI 10.1021/bi00488a022; MELHADO LL, 1982, J AM CHEM SOC, V104, P7299, DOI 10.1021/ja00389a065; NORDENMAN B, 1977, EUR J BIOCHEM, V78, P195, DOI 10.1111/j.1432-1033.1977.tb11730.x; O'Malley KM, 2001, J BIOL CHEM, V276, P6631, DOI 10.1074/jbc.M008478200; OLSON ST, 1995, J BIOL CHEM, V270, P30007; OLSON ST, 1982, J BIOL CHEM, V257, P4891; OLSON ST, 1995, J BIOL CHEM, V270, P9717, DOI 10.1074/jbc.270.17.9717; OLSON ST, 1993, BIOCHEMISTRY-US, V32, P12136, DOI 10.1021/bi00096a026; Olson ST, 1997, J BIOL CHEM, V272, P13338, DOI 10.1074/jbc.272.20.13338; OLSON ST, 1993, METHOD ENZYMOL, V222, P525; Peterson FC, 2001, BIOCHEMISTRY-US, V40, P6284, DOI 10.1021/bi010100x; Plotnick MI, 1997, BIOCHEMISTRY-US, V36, P14601, DOI 10.1021/bi971530j; Plotnick MI, 1996, BIOCHEMISTRY-US, V35, P7586, DOI 10.1021/bi960233w; Polgar L, 1990, Mechanisms in Protease Action; REZAIE AR, 1994, J BIOL CHEM, V269, P21495; SHORE JD, 1995, J BIOL CHEM, V270, P5395, DOI 10.1074/jbc.270.10.5395; Stavridi ES, 1996, BIOCHEMISTRY-US, V35, P10608, DOI 10.1021/bi9605806; Stone SR, 1997, J MOL BIOL, V265, P344, DOI 10.1006/jmbi.1996.0727; Stratikos E, 1998, J BIOL CHEM, V273, P15582, DOI 10.1074/jbc.273.25.15582; Stratikos E, 1999, P NATL ACAD SCI USA, V96, P4808, DOI 10.1073/pnas.96.9.4808; WILCZYNSKA M, 1995, J BIOL CHEM, V270, P29652; WRIGHT HT, 1995, PROTEINS, V22, P210, DOI 10.1002/prot.340220303; YUNG BY, 1975, BIOCHEM BIOPH RES CO, V65, P927, DOI 10.1016/S0006-291X(75)80474-8	61	50	51	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					32446	32455		10.1074/jbc.M104731200	http://dx.doi.org/10.1074/jbc.M104731200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11404362	hybrid			2022-12-25	WOS:000170746000012
J	De Angelis, E; Brummendorf, T; Cheng, L; Lemmon, V; Kenwrick, S				De Angelis, E; Brummendorf, T; Cheng, L; Lemmon, V; Kenwrick, S			Alternative use of a mini exon of the L1 gene affects L1 binding to neural ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE; NEURITE OUTGROWTH; CRYSTAL-STRUCTURE; GROWTH CONE; AXONIN-1; EXPRESSION; PROMOTION; MUTATIONS; ISOFORMS; DOMAINS	Neural cell adhesion molecule Ll is a cell surface glycoprotein required for the correct development of the nervous system. Ll exists as two isoforms encoded by mRNA species that either collectively incorporate or exclude exons 2 and 27. Neurons utilize only the full-length isoform, whereas Schwann cells, kidney cells, and blood lymphocytes only express the short form of L1. Still other cells, oligodendrocytes, regulate Ll isoform expression in a maturation-dependent manner. The RSLE motif encoded by exon 27 is known to have a role in clathrin-mediated endocytosis of L1, but the function of the exon 2-encoded motif (YEGHHV) is unknown. Here we show that this motif is required for the optimal binding of Ll to several neural ligands and is likely to be important for nervous system development. Thus, alternative use of exon 2 is a mechanism for regulating ligand interactions with L1.	Wellcome Trust Ctr Mol Mechanisms Dis, Cambridge CB2 2XY, England; Univ Cambridge, Addenbrookes Hosp, Dept Med, Cambridge CB2 2XY, England; Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany; Case Western Reserve Univ, Dept Neurosci, Cleveland, OH 44106 USA	University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Case Western Reserve University	De Angelis, E (corresponding author), Wellcome Trust Ctr Mol Mechanisms Dis, Hills Rd, Cambridge CB2 2XY, England.		Lemmon, Vance/A-7410-2010; Lemmon, Vance/A-2565-2008	Lemmon, Vance/0000-0003-3550-7576; 	NEI NIH HHS [R01 EY005285, R01 EY005285-23, EY05285, EY11373] Funding Source: Medline; NATIONAL EYE INSTITUTE [P30EY011373, R01EY005285] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Brummendorf T, 1998, CURR OPIN NEUROBIOL, V8, P87, DOI 10.1016/S0959-4388(98)80012-3; BRUMMENDORF T, 1993, NEURON, V10, P711; Buchstaller A, 1996, J CELL BIOL, V135, P1593, DOI 10.1083/jcb.135.6.1593; Coutelle O, 1998, GENE, V208, P7, DOI 10.1016/S0378-1119(97)00614-8; De Angelis E, 1999, EMBO J, V18, P4744, DOI 10.1093/emboj/18.17.4744; DEPPERT W, 1981, J VIROL, V37, P478, DOI 10.1128/JVI.37.1.478-482.1981; Freigang J, 2000, CELL, V101, P425, DOI 10.1016/S0092-8674(00)80852-1; Haspel J, 2000, J NEUROBIOL, V42, P287, DOI 10.1002/(SICI)1097-4695(20000215)42:3<287::AID-NEU1>3.3.CO;2-O; Itoh K, 2000, J NEUROSCI RES, V60, P579; JOUET M, 1995, MOL BRAIN RES, V30, P378, DOI 10.1016/0169-328X(95)00027-P; Kamiguchi H, 1998, J NEUROSCI, V18, P5311, DOI 10.1523/JNEUROSCI.18-14-05311.1998; Kamiguchi H, 1997, J NEUROSCI RES, V49, P1, DOI 10.1002/(SICI)1097-4547(19970701)49:1<1::AID-JNR1>3.0.CO;2-H; Kamiguchi H, 1998, J NEUROSCI, V18, P3749, DOI 10.1523/jneurosci.18-10-03749.1998; Kenwrick S, 2000, HUM MOL GENET, V9, P879, DOI 10.1093/hmg/9.6.879; Kunz S, 1998, J CELL BIOL, V143, P1673, DOI 10.1083/jcb.143.6.1673; MIURA M, 1991, FEBS LETT, V289, P91, DOI 10.1016/0014-5793(91)80915-P; Oleszewski M, 2000, J BIOL CHEM, V275, P34478, DOI 10.1074/jbc.M004147200; REID RA, 1992, J MOL NEUROSCI, V3, P127, DOI 10.1007/BF02919404; Su XD, 1998, SCIENCE, V281, P991, DOI 10.1126/science.281.5379.991; Takeda Y, 1996, J NEUROCHEM, V66, P2338; Treubert U, 1998, J NEUROSCI, V18, P1795; Volkmer H, 1998, J CELL BIOL, V142, P1083, DOI 10.1083/jcb.142.4.1083; WOLFF JM, 1988, J BIOL CHEM, V263, P11943	23	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					32738	32742		10.1074/jbc.M105156200	http://dx.doi.org/10.1074/jbc.M105156200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11435440	hybrid			2022-12-25	WOS:000170746000049
J	Lang, SE; McMahon, SB; Cole, MD; Hearing, P				Lang, SE; McMahon, SB; Cole, MD; Hearing, P			E2F transcriptional activation requires TRRAP and GCN5 cofactors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-PHASE ENTRY; SUSCEPTIBILITY GENE-PRODUCT; TATA-BINDING PROTEIN; CELL-CYCLE ARREST; RETINOBLASTOMA PROTEIN; HISTONE ACETYLTRANSFERASE; FAMILY MEMBERS; C-MYC; REPRESSES TRANSCRIPTION; NUCLEAR-LOCALIZATION	The E2F family of transcription factors regulates the temporal transcription of genes involved in cell cycle progression and DNA synthesis. E2F transactivation is antagonized by retinoblastoma protein (pRb), which recruits chromatin-remodeling proteins such as histone deacetylases and SWI.SNF complexes to the promoter to repress transcription. We hypothesized that E2F proteins must reverse the pRb-imposed chromatin structure to stimulate transcription. If this is true, E2F proteins should recruit proteins capable of histone acetylation. Here we map the E2F-4 transactivation domain and show that E2F-1 and E2F-4 transactivation domains bind the acetyltransferase GCN5 and cofactor TRRAP in vivo. TRRAP and GCN5 co-expression stimulated E2F-mediated transactivation, and e-Myc repressed E2F transactivation dependent on an intact TRRAP/GCN5 binding motif. The transactivation domain of E2F-4 recruited proteins with significant histone acetyltransferase activity in vivo, and this activity required catalytically active GCN5. E2F-4 proteins with subtle mutations in the transactivation domain exhibited a positive correlation among transcriptional activation and GCN5 and TRRAP binding capacity and associated acetyltransferase activity. We conclude that E2F stimulates transcription by recruiting acetyltransferase activity and the essential cofactors GCN5 and TRRAP. These results provide a mechanism for E2F transcription factors to overcome pRb-mediated dominant repression of transcription.	SUNY Stony Brook, Sch Med, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA; Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Princeton University	Hearing, P (corresponding author), SUNY Stony Brook, Sch Med, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA.			McMahon, Steven/0000-0002-3405-1768	NATIONAL CANCER INSTITUTE [R01CA055248, T32CA009176, P01CA028146] Funding Source: NIH RePORTER; NCI NIH HHS [CA09176, CA28146, CA55248] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADNANE J, 1995, J BIOL CHEM, V270, P8837, DOI 10.1074/jbc.270.15.8837; Allen KE, 1997, J CELL SCI, V110, P2819; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Berger SL, 1999, CURR OPIN CELL BIOL, V11, P336, DOI 10.1016/S0955-0674(99)80046-5; Blau J, 1996, MOL CELL BIOL, V16, P2044; Brand M, 1999, J BIOL CHEM, V274, P18285, DOI 10.1074/jbc.274.26.18285; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; BROUGH DE, 1995, MOL CELL BIOL, V15, P1536; Brown CE, 2000, TRENDS BIOCHEM SCI, V25, P15, DOI 10.1016/S0968-0004(99)01516-9; BROWNELL JE, 1995, P NATL ACAD SCI USA, V92, P6364, DOI 10.1073/pnas.92.14.6364; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; EMILI A, 1995, J BIOL CHEM, V270, P13674, DOI 10.1074/jbc.270.23.13674; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; Ferreira R, 1998, P NATL ACAD SCI USA, V95, P10493, DOI 10.1073/pnas.95.18.10493; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; Grant PA, 1999, SEMIN CELL DEV BIOL, V10, P169, DOI 10.1006/scdb.1999.0298; HAGEMEIER C, 1993, NUCLEIC ACIDS RES, V21, P4998, DOI 10.1093/nar/21.22.4998; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; Lee CW, 1998, ONCOGENE, V16, P2695, DOI 10.1038/sj.onc.1201818; Lin SY, 1996, MOL CELL BIOL, V16, P1668; Lin YX, 1999, NATURE, V400, P86, DOI 10.1038/21922; Lukas J, 1996, MOL CELL BIOL, V16, P1047; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magae J, 1996, J CELL SCI, V109, P1717; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Marti A, 1999, NAT CELL BIOL, V1, P14, DOI 10.1038/8984; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Marzio G, 2000, J BIOL CHEM, V275, P10887, DOI 10.1074/jbc.275.15.10887; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; McMahon SB, 2000, MOL CELL BIOL, V20, P556, DOI 10.1128/MCB.20.2.556-562.2000; Morris L, 2000, NAT CELL BIOL, V2, P232, DOI 10.1038/35008660; Muller H, 1997, MOL CELL BIOL, V17, P5508; MULLER H, 2000, BIOCHIM BIOPHYS ACTA, V1470, P1; MURTHY SCS, 1985, P NATL ACAD SCI USA, V82, P2230, DOI 10.1073/pnas.82.8.2230; Nevels M, 1997, P NATL ACAD SCI USA, V94, P1206, DOI 10.1073/pnas.94.4.1206; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; OBERT S, 1994, MOL CELL BIOL, V14, P1333, DOI 10.1128/MCB.14.2.1333; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Pearson A, 1997, ONCOGENE, V15, P2643, DOI 10.1038/sj.onc.1201451; Pierce AM, 1998, MOL CARCINOGEN, V22, P190, DOI 10.1002/(SICI)1098-2744(199807)22:3<190::AID-MC7>3.0.CO;2-P; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Reed Michael, 1993, Gene Expression, V3, P95; Ross JF, 1999, MOL CELL, V3, P195, DOI 10.1016/S1097-2765(00)80310-X; Saleh A, 1998, J BIOL CHEM, V273, P26559, DOI 10.1074/jbc.273.41.26559; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; Snowden AW, 1998, BIOCHEM PHARMACOL, V55, P1947, DOI 10.1016/S0006-2952(98)00020-3; SOMMER A, 1998, J BIOL CHEM, V273, P6642; Trouche D, 1996, NUCLEIC ACIDS RES, V24, P4139, DOI 10.1093/nar/24.21.4139; Trouche D, 1997, P NATL ACAD SCI USA, V94, P11268, DOI 10.1073/pnas.94.21.11268; Trouche D, 1996, P NATL ACAD SCI USA, V93, P1439, DOI 10.1073/pnas.93.4.1439; Verona R, 1997, MOL CELL BIOL, V17, P7268, DOI 10.1128/MCB.17.12.7268; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; WONG KK, 1995, MOL CELL BIOL, V15, P6535; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X	73	97	100	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					32627	32634		10.1074/jbc.M102067200	http://dx.doi.org/10.1074/jbc.M102067200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11418595	hybrid			2022-12-25	WOS:000170746000034
J	Palma, M; Shannon, O; Quezada, HC; Berg, A; Flock, JI				Palma, M; Shannon, O; Quezada, HC; Berg, A; Flock, JI			Extracellular fibrinogen-binding protein, Efb, from Staphylococcus aureus blocks platelet aggregation due to its binding to the alpha-chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLUMPING FACTOR; NUCLEOTIDE-SEQUENCE; FRAGMENT-D; RECEPTOR; GENE; THROMBOSPONDIN; IDENTIFICATION; SPECIFICITY; VIRULENCE; CLONING	Extracellular fibrinogen-binding protein (Efb) secreted by Staphylococcus aureus has previously been shown to contribute to pathogenesis in a rat wound infection model. Also antibodies against Efb exhibited a protective effect in a mouse mastitis model. The interaction between Efb and fibrinogen is divalent, with one binding site within the N-terminal repeat region in Efb and one at the C terminus. In this study we show that the distal D domain of fibrinogen contains at least one of the binding domains recognized by Efb. Efb stimulates fibrinogen binding to ADP-activated platelets. Furthermore, Efb inhibits ADP-induced, fibrinogen-dependent platelet aggregation in a concentration-dependent manner. This implies that Efb modifies platelet function by amplifying a non-functional interaction between fibrinogen and platelets. Efb recognizes the A alpha -chain of the D fragment of fibrinogen. The RGD sequence on the A alpha -chain is located close to the region recognized by Efb and contains a putative binding site for the platelet integrin GPIIb/IIIa receptor complex involved in platelet aggregation.	Huddinge Univ Hosp, Dept Microbiol Pathol & Immunol, Karolinska Inst, S-14186 Huddinge, Sweden; Huddinge Univ Hosp, Dept Med, Karolinska Inst, S-14186 Huddinge, Sweden; Huddinge Univ Hosp, Dept Clin Chem, C1 74, Karolinska Inst, S-14186 Huddinge, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet	Flock, JI (corresponding author), Huddinge Univ Hosp, Dept Microbiol Pathol & Immunol, Karolinska Inst, F 82, S-14186 Huddinge, Sweden.		Palma, Marco/AAX-8408-2020	Palma, Marco/0000-0001-8910-994X; Shannon, Oonagh/0000-0001-8291-8189				BACONBAGULEY T, 1990, J BIOL CHEM, V265, P2317; BODEN MK, 1992, MICROB PATHOGENESIS, V12, P289, DOI 10.1016/0882-4010(92)90047-R; BODEN MK, 1994, MOL MICROBIOL, V12, P599, DOI 10.1111/j.1365-2958.1994.tb01046.x; BOUMA H, 1978, THROMB RES, V13, P557, DOI 10.1016/0049-3848(78)90142-1; CHEUNG AI, 1995, INFECT IMMUN, V63, P1914, DOI 10.1128/IAI.63.5.1914-1920.1995; COLLEN D, 1975, J BIOL CHEM, V250, P5808; Colque-Navarro P, 2000, CLIN DIAGN LAB IMMUN, V7, P14, DOI 10.1128/CDLI.7.1.14-20.2000; DOOLITTLE RF, 1984, ANNU REV BIOCHEM, V53, P195, DOI 10.1146/annurev.bi.53.070184.001211; HAWIGER J, 1989, BIOCHEMISTRY-US, V28, P2909, DOI 10.1021/bi00433a024; JONSSON K, 1995, J BIOL CHEM, V270, P21457, DOI 10.1074/jbc.270.37.21457; KAIDA S, 1987, J BIOCHEM, V102, P1177, DOI 10.1093/oxfordjournals.jbchem.a122156; MAMO W, 1994, FEMS IMMUNOL MED MIC, V10, P47, DOI 10.1111/j.1574-695X.1994.tb00010.x; McDevitt D, 1997, EUR J BIOCHEM, V247, P416, DOI 10.1111/j.1432-1033.1997.00416.x; MCDEVITT D, 1995, MOL MICROBIOL, V16, P895, DOI 10.1111/j.1365-2958.1995.tb02316.x; MCDEVITT D, 1994, MOL MICROBIOL, V11, P237, DOI 10.1111/j.1365-2958.1994.tb00304.x; MCGAVIN MH, 1993, INFECT IMMUN, V61, P2479, DOI 10.1128/IAI.61.6.2479-2485.1993; NEIDHIN D, 1999, MOL MICROBIOL, V30, P245; Nilsson M, 1998, INFECT IMMUN, V66, P2666, DOI 10.1128/IAI.66.6.2666-2673.1998; Palma M, 1996, INFECT IMMUN, V64, P5284, DOI 10.1128/IAI.64.12.5284-5289.1996; Palma M, 1999, J BACTERIOL, V181, P2840, DOI 10.1128/JB.181.9.2840-2845.1999; Palma M, 1998, J BIOL CHEM, V273, P13177, DOI 10.1074/jbc.273.21.13177; Pei L, 1999, INFECT IMMUN, V67, P4525, DOI 10.1128/IAI.67.9.4525-4530.1999; PHONIMDAENG P, 1990, MOL MICROBIOL, V4, P393, DOI 10.1111/j.1365-2958.1990.tb00606.x; Spraggon G, 1997, NATURE, V389, P455, DOI 10.1038/38947; TUSZYNSKI GP, 1985, J BIOL CHEM, V260, P2240; VOSKUILEN M, 1987, J BIOL CHEM, V262, P5944	26	51	56	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					31691	31697		10.1074/jbc.M104554200	http://dx.doi.org/10.1074/jbc.M104554200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11418620	hybrid			2022-12-25	WOS:000170613500031
J	Roe, MW; Mooret, AL; Lidofsky, SD				Roe, MW; Mooret, AL; Lidofsky, SD			Purinergic-independent calcium signaling mediates recovery from hepatocellular swelling - Implications for volume regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; INCREASES INOSITOL 1,4,5-TRISPHOSPHATE; ISOLATED GUINEA-PIG; RAT-LIVER CELLS; INTRACELLULAR CALCIUM; ATP RELEASE; HUMAN HEPATOCYTES; EPITHELIAL-CELLS; PHOSPHOLIPASE-C; RHO-KINASE	Swelling of hepatocytes and other epithelia activates volume-sensitive ion channels that facilitate fluid and electrolyte efflux to restore cell volume, but the responsible signaling pathways are incompletely defined. Previous work in model HTC rat hepatoma cells has indicated that swelling elicits ATP release, which stimulates P2 receptors and activates Cl- channels, and that this mechanism is essential for hepatocellular volume recovery. Since P2 receptors are generally coupled to Ca2+ signaling pathways, we determined whether hepatocellular swelling affected cytosolic [Ca2+], and if this involved a purinergic mechanism. Exposure of HTC cells to hypotonic media evoked an increase in cytosolic [Ca2+], which was followed by activation of K+ and Cl- currents. Maneuvers that interfered with swelling-induced increases in cytosolic [Ca2+], including extracellular Ca2+ removal and intracellular Ca2+ store depletion with thapsigargin, inhibited activation of membrane currents and volume recovery. However, the swelling-induced increases in cytosolic [Ca2+] were unaffected by either extracellular ATP depletion with apyrase or blockade of P2 receptors with suramin. These findings indicate that swelling elicits an increase in hepatocellular Ca2+, which is essential for ion channel activation and volume recovery, but that this increase does not stem from activation of volume-sensitive P2 receptors. Collectively, these observations imply that regulatory responses to hepatocellular swelling involve a dual requirement for a purinergic-independent Ca2+ signaling cascade and a Ca2+-independent purinergic signaling pathway.	Univ Vermont, Coll Med, Dept Med, Burlington, VT 05401 USA; Univ Vermont, Coll Med, Dept Pharmacol, Burlington, VT 05401 USA	University of Vermont; University of Vermont	Roe, MW (corresponding author), Univ Vermont, Coll Med, Dept Med, Burgess 414 MFU, Burlington, VT 05401 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK047849] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK47849] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAQUET A, 1991, FEBS LETT, V278, P103, DOI 10.1016/0014-5793(91)80094-J; BEAR CE, 1990, AM J PHYSIOL, V258, pC421, DOI 10.1152/ajpcell.1990.258.3.C421; BEAR CE, 1987, PFLUG ARCH EUR J PHY, V410, P342, DOI 10.1007/BF00580288; Bodily K, 1997, HEPATOLOGY, V25, P403; Borgdorff AJ, 2000, J NEUROPHYSIOL, V83, P81, DOI 10.1152/jn.2000.83.1.81; Communi D, 1997, J BIOL CHEM, V272, P31969, DOI 10.1074/jbc.272.51.31969; CORASANTI JG, 1990, AM J PHYSIOL, V258, pG260; Crepel V, 1998, J NEUROSCI, V18, P1196; Dixon CJ, 2000, BRIT J PHARMACOL, V129, P764, DOI 10.1038/sj.bjp.0703103; Errington RJ, 1999, METH MOL B, V122, P315; Felix JA, 1996, AM J RESP CELL MOL, V14, P296, DOI 10.1165/ajrcmb.14.3.8845181; Feranchak AP, 2000, J HEPATOL, V33, P174, DOI 10.1016/S0168-8278(00)80357-8; Feranchak AP, 1998, J BIOL CHEM, V273, P14906, DOI 10.1074/jbc.273.24.14906; FITZ JG, 1994, AM J PHYSIOL, V266, pG677, DOI 10.1152/ajpgi.1994.266.4.G677; GLENNON MC, 1992, J BIOL CHEM, V267, P8230; HADDAD P, 1991, AM J PHYSIOL, V261, pG340, DOI 10.1152/ajpgi.1991.261.2.G340; Haussinger D, 1996, Prog Liver Dis, V14, P29; Jena M, 1997, AM J PHYSIOL-CELL PH, V273, pC316, DOI 10.1152/ajpcell.1997.273.1.C316; KHALBUSS WE, 1991, HEPATOLOGY, V13, P962, DOI 10.1016/0270-9139(91)90271-V; KOUMI SI, 1994, J GEN PHYSIOL, V104, P357, DOI 10.1085/jgp.104.2.357; LIDOFSKY DS, 1997, AM J PHYSIOL, V273, pG849; MCCARTY NA, 1992, PHYSIOL REV, V72, P1037, DOI 10.1152/physrev.1992.72.4.1037; Meng XJ, 1996, AM J PHYSIOL-CELL PH, V271, pC112, DOI 10.1152/ajpcell.1996.271.1.C112; Missiaen L, 1996, J BIOL CHEM, V271, P4601; Neary JT, 1999, J NEUROSCI, V19, P4211, DOI 10.1523/jneurosci.19-11-04211.1999; Nguyen TD, 2001, AM J PHYSIOL-GASTR L, V280, pG795, DOI 10.1152/ajpgi.2001.280.5.G795; Nilius B, 1999, J PHYSIOL-LONDON, V516, P67, DOI 10.1111/j.1469-7793.1999.067aa.x; NOVAK EJ, 1994, CYTOMETRY, V17, P135, DOI 10.1002/cyto.990170205; O'Neill WC, 1999, AM J PHYSIOL-CELL PH, V276, pC995, DOI 10.1152/ajpcell.1999.276.5.C995; Ralevic V, 1998, PHARMACOL REV, V50, P413; Roman RM, 1997, J BIOL CHEM, V272, P21970, DOI 10.1074/jbc.272.35.21970; Roman RM, 1999, GASTROENTEROLOGY, V116, P964, DOI 10.1016/S0016-5085(99)70081-8; Roman RM, 1998, HEPATOLOGY, V28, P1073, DOI 10.1002/hep.510280423; SANDFORD CA, 1992, J PHYSIOL-LONDON, V447, P133, DOI 10.1113/jphysiol.1992.sp018995; Sauzeau V, 2000, AM J PHYSIOL-HEART C, V278, pH1751, DOI 10.1152/ajpheart.2000.278.6.H1751; Schofl C, 1999, AM J PHYSIOL-GASTR L, V276, pG164, DOI 10.1152/ajpgi.1999.276.1.G164; SCHREIBER R, 1995, BIOCHEM J, V309, P19, DOI 10.1042/bj3090019; Tilly BC, 1996, MOL BIOL CELL, V7, P1419, DOI 10.1091/mbc.7.9.1419; Wang Y, 1996, P NATL ACAD SCI USA, V93, P12020, DOI 10.1073/pnas.93.21.12020; Wu X, 1997, J MEMBRANE BIOL, V158, P127, DOI 10.1007/s002329900250; Yano M, 1996, J BIOL CHEM, V271, P6702, DOI 10.1074/jbc.271.12.6702	41	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					30871	30877		10.1074/jbc.M102362200	http://dx.doi.org/10.1074/jbc.M102362200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11413133	hybrid			2022-12-25	WOS:000170472900039
J	Baoutina, A; Dean, RT; Jessup, W				Baoutina, A; Dean, RT; Jessup, W			Trans-plasma membrane electron transport induces macrophage-mediated low-density lipoprotein oxidation	FASEB JOURNAL			English	Article						LDL oxidation; plasma membrane electron transport; ascorbate; macrophage; atherosclerosis	VITAMIN-C; ALPHA-TOCOPHEROL; ASCORBIC-ACID; ATHEROSCLEROTIC LESIONS; DEHYDROASCORBIC ACID; LIPID-PEROXIDATION; OXIDIZED LIPIDS; LDL OXIDATION; FOAM CELLS; IRON	Oxidation of low-density lipoprotein (LDL) in the arterial intima has been implicated in atherogenesis. The exact mechanism of this oxidation, however, remains unclear. In the present study we investigated the role of the trans-plasma membrane electron transport (TPMET) system of macrophages in cell-mediated LDL oxidation. We demonstrated that TPMET of mouse and human macrophages, measured as reduction of the impermeable oxidant ferricyanide (FEC), was enhanced strongly by loading macrophages with ascorbate (Asc). This appoach also enhanced the ability of cells to oxidize LDL in Ham's F-10 medium. The stimulatory effect of Asc-enrichment of macrophages on both processes was not due to release of Asc or other reductants into the medium, as demonstrated by the lack of the effects of ascorbate oxidase and the inhibitors of cellular Asc-recycling on these processes. This conclusion is also supported by experiments in which we analyzed the amounts of Asc and DHA secreted by cells and tested their effect of LDL oxidation, and also measured the ability of cell-conditioned medium from control and Asc-enriched cells to reduce FEC. We conclude that TPMET is largely responsible for macrophage-mediated LDL oxidation by means of its capacity to reduce extracellular transition metals.	Heart Res Inst, Cell Biol Grp, Camperdown, NSW 2050, Australia	University of Sydney; Heart Research Institute	Baoutina, A (corresponding author), Heart Res Inst, Cell Biol Grp, 145 Missenden Rd, Camperdown, NSW 2050, Australia.	a.baoutina@hri.org.au		Dean, Roger Thornton/0000-0002-8859-8902				ABDALLA DSP, 1992, ATHEROSCLEROSIS, V97, P149, DOI 10.1016/0021-9150(92)90128-4; AVRON M, 1963, ANAL BIOCHEM, V6, P549, DOI 10.1016/0003-2697(63)90149-0; BALLA G, 1991, ARTERIOSCLER THROMB, V11, P1700, DOI 10.1161/01.ATV.11.6.1700; Baoutina A, 2000, J BIOL CHEM, V275, P1635, DOI 10.1074/jbc.275.3.1635; Baoutina A, 1998, J LIPID RES, V39, P114; Baoutina A, 2000, REDOX REP, V5, P85, DOI 10.1179/135100000101535591; Berliner JA, 1996, FREE RADICAL BIO MED, V20, P707, DOI 10.1016/0891-5849(95)02173-6; Camejo G, 1998, J LIPID RES, V39, P755; Carr A, 1999, FASEB J, V13, P1007, DOI 10.1096/fasebj.13.9.1007; Chisolm GM, 1999, J BIOL CHEM, V274, P25959, DOI 10.1074/jbc.274.37.25959; Dai LI, 1996, BBA-LIPID LIPID MET, V1304, P223, DOI 10.1016/S0005-2760(96)00121-X; EHRENWALD E, 1994, J CLIN INVEST, V93, P1493, DOI 10.1172/JCI117127; FREI B, 1989, P NATL ACAD SCI USA, V86, P6377, DOI 10.1073/pnas.86.16.6377; Garner B, 1997, J BIOL CHEM, V272, P6927, DOI 10.1074/jbc.272.11.6927; Garner B, 1996, REDOX REP, V2, P97, DOI 10.1080/13510002.1996.11747035; Halliwell B, 1999, TRENDS BIOCHEM SCI, V24, P255, DOI 10.1016/S0968-0004(99)01418-8; HUNTER GC, 1991, P SOC EXP BIOL MED, V196, P273; ITABE H, 1994, J BIOL CHEM, V269, P15274; KRITHARIDES L, 1995, ARCH BIOCHEM BIOPHYS, V323, P127, DOI 10.1006/abbi.1995.0018; LAMB DJ, 1995, FEBS LETT, V374, P12, DOI 10.1016/0014-5793(95)01068-P; Lee FY, 1998, ATHEROSCLEROSIS, V138, P281, DOI 10.1016/S0021-9150(98)00033-1; Martin A, 1997, ARTERIOSCL THROM VAS, V17, P1583, DOI 10.1161/01.ATV.17.8.1583; May JM, 1999, FASEB J, V13, P995, DOI 10.1096/fasebj.13.9.995; May JM, 2000, BIOCHEM BIOPH RES CO, V267, P118, DOI 10.1006/bbrc.1999.1906; May JM, 1999, FREE RADICAL BIO MED, V26, P1513, DOI 10.1016/S0891-5849(99)00017-9; MAY JM, 1995, BBA-BIOMEMBRANES, V1238, P127, DOI 10.1016/0005-2736(95)00120-R; Medina MA, 1997, BIOESSAYS, V19, P977, DOI 10.1002/bies.950191107; Merker MP, 1998, AM J PHYSIOL-LUNG C, V274, pL685; Mohr D., 1996, FREE RADICALS PRACTI, P271; Niu XW, 1999, ARTERIOSCL THROM VAS, V19, P1708, DOI 10.1161/01.ATV.19.7.1708; ORRINGER EP, 1979, J CLIN INVEST, V63, P53, DOI 10.1172/JCI109277; Otero P, 1997, FREE RADICAL RES, V27, P619, DOI 10.3109/10715769709097865; RETSKY KL, 1995, BBA-LIPID LIPID MET, V1257, P279, DOI 10.1016/0005-2760(95)00089-U; RICEEVANS C, 1993, FEBS LETT, V326, P177, DOI 10.1016/0014-5793(93)81786-Y; Rumsey SC, 2000, J BIOL CHEM, V275, P28246; SCHIPFER W, 1985, INT J BIOCHEM, V17, P819, DOI 10.1016/0020-711X(85)90270-8; SMITH C, 1992, BIOCHEM J, V286, P901, DOI 10.1042/bj2860901; Stait SE, 1996, BIOCHEM J, V320, P373; STAIT SE, 1994, FEBS LETT, V341, P263, DOI 10.1016/0014-5793(94)80469-9; SUARNA C, 1995, ARTERIOSCL THROM VAS, V15, P1616, DOI 10.1161/01.ATV.15.10.1616; THORSTENSEN K, 1990, BIOCHIM BIOPHYS ACTA, V1052, P29, DOI 10.1016/0167-4889(90)90053-G; Van Duijn MM, 1998, J BIOL CHEM, V273, P13415, DOI 10.1074/jbc.273.22.13415; VanDuijn MM, 2000, J BIOL CHEM, V275, P27720; VERA JC, 1993, NATURE, V364, P79, DOI 10.1038/364079a0; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; Wood JL, 1999, FREE RADICAL RES, V31, P367, DOI 10.1080/10715769900300941; Xing XY, 1998, J LIPID RES, V39, P2201; Yuan XM, 1999, FREE RADICAL RES, V30, P221, DOI 10.1080/10715769900300241; Yuan XM, 1996, ATHEROSCLEROSIS, V124, P61, DOI 10.1016/0021-9150(96)05817-0	50	18	18	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY 29	2001	15	7					1580	+		10.1096/fj.00-0704fje	http://dx.doi.org/10.1096/fj.00-0704fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519CQ	11427492				2022-12-25	WOS:000173707700030
J	Yin, XY; Grove, LE; Prochownik, EV				Yin, XY; Grove, LE; Prochownik, EV			Mmip-2/Rnf-17 enhances c-Myc function and regulates some target genes in common with glucocorticoid hormones	ONCOGENE			English	Article						RING finger proteins; Mad; Max; apoptosis; ornithine decarboxylase; gamma-interferon	TRANSCRIPTION FACTOR NETWORK; CELL-CYCLE PROGRESSION; RING-FINGER DOMAIN; DNA-BINDING; ONCOGENIC ACTIVITY; LEUCINE-ZIPPER; MAX; PROTEIN; GROWTH; DIFFERENTIATION	Members of the Mad family of basic-helix-loop-helix-leucine zipper proteins inhibit the transcriptional activity of the c-Myc oncoprotein. Mmip-2/Rnf-17 is a RING-finger protein that interacts with all four known Mad proteins, redistributes them to the cytoplasm, and thus enhances c-Myc function, We generated cell lines in in which Mmip-2/Rnf-17 was rendered glucocorticoid (GC)-inducible, Stable expression of Mmip-/Rnf-17 resulted in the expected transport of the most abundant endogenous mad protein, Mxi1, to the cytoplasm, Compensatory increases in Mxi1 and Mad3 transcripts, similar to those previously described in Mad1 null hematopoietic cells, genes were also seen, Mmip-2/Rnf-17 also sensitized cells to several different pro-apoptotic stimuli and regulated a subset of c-Myc target genes, Unexpectedly, some of these genes were also found to be modulated solely by GCs, Thus, the inhibition of Mad proteins by Mmip-2/Rnf-17 modulates c-Myc function by enhancing its ability to regulate a subset of its potential target genes, Our results also identify a previously unrecognized overlap between genes regulated by c-Myc- and GCs and provide a potential molecular basis for their regulation of common cellular functions. Oncogene (2001) 20, 2908-2917.	Childrens Hosp Pittsburgh, Hematol Oncol Sect, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Med Ctr, Dept Mol Genet & Biochem, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Inst Canc, Program Mol Genet, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Prochownik, EV (corresponding author), Childrens Hosp Pittsburgh, Hematol Oncol Sect, 3705 5th Ave, Pittsburgh, PA 15213 USA.				NATIONAL CANCER INSTITUTE [R33CA083219] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033741] Funding Source: NIH RePORTER; NCI NIH HHS [CA83219] Funding Source: Medline; NHLBI NIH HHS [HL33741] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; ASKEW DS, 1991, ONCOGENE, V6, P1915; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; Billin AN, 1999, J BIOL CHEM, V274, P36344, DOI 10.1074/jbc.274.51.36344; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Boyd SD, 2000, NAT CELL BIOL, V2, P563, DOI 10.1038/35023500; Cato ACB, 1996, BIOESSAYS, V18, P371, DOI 10.1002/bies.950180507; Claassen GF, 1999, ONCOGENE, V18, P2925, DOI 10.1038/sj.onc.1202747; Claassen GF, 2000, P NATL ACAD SCI USA, V97, P9498, DOI 10.1073/pnas.150006697; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; Dang CV, 1999, MOL CELL BIOL, V19, P1; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; Foley KP, 1998, EMBO J, V17, P774, DOI 10.1093/emboj/17.3.774; FORSTHOEFEL AM, 1987, MOL ENDOCRINOL, V1, P899, DOI 10.1210/mend-1-12-899; Geley S, 1996, REV PHYSIOL BIOCH P, V128, P1; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; GOLDE DW, 1976, J CLIN INVEST, V57, P57, DOI 10.1172/JCI108269; Gupta K, 1998, ONCOGENE, V16, P1149, DOI 10.1038/sj.onc.1201634; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Hurlin PJ, 1999, EMBO J, V18, P7019, DOI 10.1093/emboj/18.24.7019; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; Hurlin PJ, 1995, ONCOGENE, V11, P2487; Hurlin PJ, 1997, GENE DEV, V11, P44, DOI 10.1101/gad.11.1.44; HURLIN PJ, 1994, COLD SPRING HARB SYM, V59, P109, DOI 10.1101/SQB.1994.059.01.014; Iritani BM, 1999, P NATL ACAD SCI USA, V96, P13180, DOI 10.1073/pnas.96.23.13180; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Landay M, 2000, CELL DEATH DIFFER, V7, P697, DOI 10.1038/sj.cdd.4400701; LONGENECKER JP, 1984, J CELL BIOL, V98, P534, DOI 10.1083/jcb.98.2.534; Luscher B, 1999, ONCOGENE, V18, P2955, DOI 10.1038/sj.onc.1202750; MACDOUGALD OA, 1995, ANNU REV BIOCHEM, V64, P345, DOI 10.1146/annurev.bi.64.070195.002021; McMahon SB, 2000, MOL CELL BIOL, V20, P556, DOI 10.1128/MCB.20.2.556-562.2000; Meroni G, 2000, ONCOGENE, V19, P3266, DOI 10.1038/sj.onc.1203634; Nesbit CE, 1998, CELL GROWTH DIFFER, V9, P731; Nesbit CE, 2000, ONCOGENE, V19, P3200, DOI 10.1038/sj.onc.1203636; O'Hagan RC, 2000, NAT GENET, V24, P113, DOI 10.1038/72761; Obaya AJ, 1999, ONCOGENE, V18, P2934, DOI 10.1038/sj.onc.1202749; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PROCHOWNIK EV, 1986, NATURE, V322, P848, DOI 10.1038/322848a0; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; RHEE K, 1995, CANCER RES, V55, P4188; Sakamuro D, 1999, ONCOGENE, V18, P2942, DOI 10.1038/sj.onc.1202725; SCHER W, 1978, P NATL ACAD SCI USA, V75, P3851, DOI 10.1073/pnas.75.8.3851; Schmidt EV, 1999, ONCOGENE, V18, P2988, DOI 10.1038/sj.onc.1202751; Schreiber-Agus N, 1998, NATURE, V393, P483, DOI 10.1038/31008; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; SKLAR MD, 1991, MOL CELL BIOL, V11, P3699, DOI 10.1128/MCB.11.7.3699; SMITH MJ, 1990, MOL CELL BIOL, V10, P5333, DOI 10.1128/MCB.10.10.5333; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; Thompson EB, 1998, ANNU REV PHYSIOL, V60, P575, DOI 10.1146/annurev.physiol.60.1.575; THULASI R, 1993, J BIOL CHEM, V268, P18306; von Lindern M, 1999, BLOOD, V94, P550, DOI 10.1182/blood.V94.2.550.414k39_550_559; Yin XY, 1999, ONCOGENE, V18, P1177, DOI 10.1038/sj.onc.1202410; Yin XY, 1999, ONCOGENE, V18, P6621, DOI 10.1038/sj.onc.1203097; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; Zhang H, 1997, J BIOL CHEM, V272, P17416, DOI 10.1074/jbc.272.28.17416	68	15	19	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 24	2001	20	23					2908	2917		10.1038/sj.onc.1204417	http://dx.doi.org/10.1038/sj.onc.1204417			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	435VA	11420703				2022-12-25	WOS:000168901800006
J	An, XL; Takakuwa, Y; Manno, S; Han, BG; Gascard, P; Mohandas, N				An, XL; Takakuwa, Y; Manno, S; Han, BG; Gascard, P; Mohandas, N			Structural and functional characterization of protein 4.1R-phosphatidylserine interaction - Potential role in 4.1R sorting within cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPECTRIN-ACTIN BINDING; ERYTHROCYTE-MEMBRANE; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; TERNARY COMPLEX; GLYCOPHORIN-C; BANDS 2.1; CALMODULIN; SITE; DOMAIN; IDENTIFICATION	Erythrocyte protein 4.1R is a multifunctional protein that binds to various membrane proteins and to phosphatidylserine. In the present study, we report two important observations concerning 4.1R-phosphatidylserine interaction. Biochemically, a major finding of the present study is that 4.1R binding to phosphatidylserine appears to be a two-step process in which 4.1R first interacts with serine head group of phosphatidylserine through the positively charged amino acids YKRS and subsequently forms a tight hydrophobic interaction with fatty acid moieties. 4.1R failed to dissociate from phosphatidylserine liposomes under high ionic strength but could be released specifically by phospholipase A(2) but not by phospholipase C or D. Biochemical analyses showed that acyl chains were associated with 4.1R released by phospholipase A(2). Importantly, the association of acyl chains with 4.1R impaired its ability to interact with calmodulin, band 3, and glycophorin C. Removal of acyl chains restored 4.1R binding. These data indicate that acyl chains of phosphatidylserine play an important role in its interaction with 4.1R and on 4.1R function. In terms of biological significance, we have obtained evidence that 4.1R-phosphatidylserine interaction may play an important role in cellular sorting of 4.1R.	Univ Calif Berkeley, Lawrence Berkeley Natl Lab, Div Life Sci, Berkeley, CA 94720 USA; Tokyo Womens Med Univ, Dept Biochem, Sch Med, Shinjuku Ku, Tokyo 1628666, Japan	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; Tokyo Women's Medical University	Mohandas, N (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Natl Lab, Div Life Sci, Mail Stop 74hy157,1 Cyclotron Rd, Berkeley, CA 94720 USA.		Han, Bong-Gyoon/J-9120-2012	Gascard, Philippe/0000-0001-5912-5228	NIDDK NIH HHS [DK 32094, DK 56355, DK 26263] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK026263, R01DK026263, R01DK056355, P01DK032094] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		An XL, 1996, J BIOL CHEM, V271, P33187, DOI 10.1074/jbc.271.52.33187; ANDERSON JP, 1987, J BIOL CHEM, V262, P6365; Barret C, 2000, J CELL BIOL, V151, P1067, DOI 10.1083/jcb.151.5.1067; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BROCKMAN JL, 1991, J BIOL CHEM, V266, P2508; COHEN AM, 1988, BIOCHEMISTRY-US, V27, P614, DOI 10.1021/bi00402a018; CONBOY JG, 1993, SEMIN HEMATOL, V30, P58; CORREAS I, 1986, J BIOL CHEM, V261, P3362; CORREAS I, 1986, J BIOL CHEM, V261, P3310; DANILOV YN, 1990, J BIOL CHEM, V265, P2556; DISHER DE, 1993, J BIOL CHEM, V268, P7186; DISHER DE, 1995, J CELL BIOL, V130, P897; Fabbri M, 1999, EMBO J, V18, P4915, DOI 10.1093/emboj/18.18.4915; Gascard P, 1998, BLOOD, V92, P4404, DOI 10.1182/blood.V92.11.4404.423k50_4404_4414; GOLDMANN WH, 1992, BIOCHEMISTRY-US, V31, P7665, DOI 10.1021/bi00148a030; Han BG, 2000, NAT STRUCT BIOL, V7, P871; HORNE WC, 1993, BLOOD, V82, P2558; JONS T, 1992, EMBO J, V11, P2863, DOI 10.1002/j.1460-2075.1992.tb05354.x; KAUFMANN S, 1992, FEBS LETT, V314, P203, DOI 10.1016/0014-5793(92)80975-M; LETO TL, 1984, J BIOL CHEM, V259, P4603; LI Y, 1997, J CELL BIOL, V137, P1191; LOMBARDO CR, 1994, BBA-BIOMEMBRANES, V1196, P139, DOI 10.1016/0005-2736(94)00233-9; MARFATIA SM, 1994, J BIOL CHEM, V269, P8631; Mattagajasingh SN, 1999, J CELL BIOL, V145, P29, DOI 10.1083/jcb.145.1.29; Mattagajasingh SN, 2000, J BIOL CHEM, V275, P30573, DOI 10.1074/jbc.M004578200; MISCHE SM, 1987, J CELL BIOL, V105, P2837, DOI 10.1083/jcb.105.6.2837; Nunomura W, 2000, J BIOL CHEM, V275, P24540, DOI 10.1074/jbc.M002492200; Nunomura W, 2000, J BIOL CHEM, V275, P6360, DOI 10.1074/jbc.275.9.6360; Nunomura W, 1997, J BIOL CHEM, V272, P30322, DOI 10.1074/jbc.272.48.30322; Parra M, 2000, J BIOL CHEM, V275, P3247, DOI 10.1074/jbc.275.5.3247; RYBICKI AC, 1988, J CLIN INVEST, V81, P255, DOI 10.1172/JCI113303; SATO SB, 1983, EUR J BIOCHEM, V130, P19; SCHISCHMANOFF PO, 1995, J BIOL CHEM, V270, P21243, DOI 10.1074/jbc.270.36.21243; Shea TB, 1997, J NEUROSCI RES, V50, P114, DOI 10.1002/(SICI)1097-4547(19971001)50:1<114::AID-JNR12>3.0.CO;2-B; TAKAKUWA Y, 1986, J CLIN INVEST, V78, P80, DOI 10.1172/JCI112577; Takakuwa Y, 2000, INT J HEMATOL, V72, P298; TAKASHI N, 1995, J BIOL CHEM, V270, P12147; TANAKA T, 1991, J BIOL CHEM, V266, P1134; TEHERNIA G, 1981, J CLIN INVEST, V68, P454; TUMA PL, 1993, J BIOL CHEM, V268, P17240; TYLER JM, 1980, J BIOL CHEM, V255, P7034; TYLER JM, 1979, P NATL ACAD SCI USA, V76, P5192, DOI 10.1073/pnas.76.10.5192; Walensky LD, 1998, J CELL BIOL, V141, P143, DOI 10.1083/jcb.141.1.143	43	43	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35778	35785		10.1074/jbc.M101364200	http://dx.doi.org/10.1074/jbc.M101364200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11423550	hybrid			2022-12-25	WOS:000171109300075
J	Song, MS; Pham, PT; Olson, M; Carter, JR; Franden, MA; Schaaper, RM; McHenry, CS				Song, MS; Pham, PT; Olson, M; Carter, JR; Franden, MA; Schaaper, RM; McHenry, CS			The delta and delta ' subunits of the DNA polymerase III holoenzyme are essential for initiation complex formation and processive elongation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMOSOMAL REPLICATION MACHINE; ESCHERICHIA-COLI; SLIDING CLAMPS; GAMMA-SUBUNIT; ACCESSORY PROTEINS; LAGGING-STRAND; READING FRAME; BETA-SUBUNIT; PRIMED DNA; TAU	delta and delta' are required for assembly of the processivity factor beta (2) onto primed DNA in the DNA polymerase III holoenzyme-catalyzed reaction. We developed protocols for generating highly purified preparations of delta and delta'. In holoenzyme reconstitution assays, delta' could not be replaced by delta, tau, or gamma, even when either of the latter were present at a 10,000-fold molar excess. Likewise, delta could not be replaced by delta', tau, or gamma. Bacterial strains bearing chromosomal knockouts of either the holA(delta) or holB(delta') genes were not viable, demonstrating that both delta and delta' are essential. Western blots of isolated initiation complexes demonstrated the presence of both delta and delta'. However, in the absence of chi psi and single-stranded DNA-binding protein, a stable initiation complex lacking delta delta' was isolated by gel filtration. Lack of delta-delta' decreased the rate of elongation about 3-fold, and the extent of processive replication was significantly decreased. Adding back delta-delta' but not chi psi, delta, or delta' alone restored the diminished activity, indicating that in addition to being key components required for the beta loading activity of the DnaX complex, delta delta' is present in initiation complex and is required for processive elongation.	Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, Denver, CO 80262 USA; NIEHS, Genet Mol Lab, NIH, Res Triangle Pk, NC 27709 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	McHenry, CS (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, 4200 E 9th Ave, Denver, CO 80262 USA.		Schaaper, Roel M/E-6680-2019	Schaaper, Roel M/0000-0003-1344-3196	NIGMS NIH HHS [GM35695] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES065086, Z01ES065086] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035695] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLINKOWA AL, 1990, NUCLEIC ACIDS RES, V18, P1725, DOI 10.1093/nar/18.7.1725; BURGERS PMJ, 1982, J BIOL CHEM, V257, P1468; CARTER JR, 1992, J BACTERIOL, V174, P7013, DOI 10.1128/JB.174.21.7013-7025.1992; CARTER JR, 1993, J BACTERIOL, V175, P3812, DOI 10.1128/JB.175.12.3812-3822.1993; CULL MG, 1995, PURIFICATION ESCHERI, P22; DALLMANN HG, 1995, J BIOL CHEM, V270, P29555, DOI 10.1074/jbc.270.49.29555; DONG ZM, 1993, J BIOL CHEM, V268, P11758; FAY PJ, 1981, J BIOL CHEM, V256, P976; FLOWER AM, 1990, P NATL ACAD SCI USA, V87, P3713, DOI 10.1073/pnas.87.10.3713; Gao DX, 2001, J BIOL CHEM, V276, P4447, DOI 10.1074/jbc.M009827200; Glover BP, 2000, J BIOL CHEM, V275, P3017, DOI 10.1074/jbc.275.5.3017; Glover BP, 1998, J BIOL CHEM, V273, P23476, DOI 10.1074/jbc.273.36.23476; GRIEP MA, 1989, J BIOL CHEM, V264, P11294; Guenther B, 1997, CELL, V91, P335, DOI 10.1016/S0092-8674(00)80417-1; JARVIS TC, 1989, J BIOL CHEM, V264, P12709; JOHANSON KO, 1982, J BIOL CHEM, V257, P2310; JOHANSON KO, 1986, J BIOL CHEM, V261, P1460; JOHANSON KO, 1984, J BIOL CHEM, V259, P4589; JOHANSON KO, 1981, STRUCTURE DNA PROTEI, P425; Kelman Z, 1998, EMBO J, V17, P2436, DOI 10.1093/emboj/17.8.2436; KELMAN Z, 1995, ANNU REV BIOCHEM, V64, P171, DOI 10.1146/annurev.bi.64.070195.001131; Kim DR, 1996, J BIOL CHEM, V271, P20681, DOI 10.1074/jbc.271.34.20681; Kim SS, 1996, CELL, V84, P643, DOI 10.1016/S0092-8674(00)81039-9; Kornberg A., 1992, DNA REPLICATION; LEE SH, 1991, J BIOL CHEM, V266, P594; Link AJ, 1997, J BACTERIOL, V179, P6228, DOI 10.1128/jb.179.20.6228-6237.1997; MAKI S, 1988, J BIOL CHEM, V263, P6561; MCHENRY CS, 1991, J BIOL CHEM, V266, P19127; MCHENRY CS, 1988, ANNU REV BIOCHEM, V57, P519; MCHENRY CS, 1979, J BIOL CHEM, V254, P1748; MCHENRY CS, 1989, MOL MECH DNA REPLICA, P115; MOK M, 1987, J BIOL CHEM, V262, P16644; NAKTINIS V, 1995, J BIOL CHEM, V270, P13358, DOI 10.1074/jbc.270.22.13358; OLSON MW, 1995, J BIOL CHEM, V270, P29570, DOI 10.1074/jbc.270.49.29570; ONRUST R, 1993, J BIOL CHEM, V268, P11766; ONRUST R, 1991, J BIOL CHEM, V266, P21681; ONRUST R, 1995, J BIOL CHEM, V270, P13348, DOI 10.1074/jbc.270.22.13348; Pritchard AE, 2000, EMBO J, V19, P6536, DOI 10.1093/emboj/19.23.6536; Pritchard AE, 1996, J BIOL CHEM, V271, P10291, DOI 10.1074/jbc.271.17.10291; REEMS JA, 1995, J BIOL CHEM, V270, P5606, DOI 10.1074/jbc.270.10.5606; REEMS JA, 1994, J BIOL CHEM, V269, P33091; SCHAAPER RM, 1985, GENE, V39, P181, DOI 10.1016/0378-1119(85)90312-9; STUKENBERG PT, 1995, J BIOL CHEM, V270, P13384, DOI 10.1074/jbc.270.22.13384; TSUCHIHASHI Z, 1990, P NATL ACAD SCI USA, V87, P2516, DOI 10.1073/pnas.87.7.2516; TURNER J, 1997, FASEB J, V11, P1; Uhlmann F, 1997, J BIOL CHEM, V272, P10065; VANWEZENBEEK PMGF, 1980, GENE, V11, P129, DOI 10.1016/0378-1119(80)90093-1; WICKNER S, 1976, P NATL ACAD SCI USA, V73, P3511, DOI 10.1073/pnas.73.10.3511; WU CA, 1992, J BIOL CHEM, V267, P4030; XIAO H, 1993, J BIOL CHEM, V268, P11773	50	21	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					35165	35175		10.1074/jbc.M100389200	http://dx.doi.org/10.1074/jbc.M100389200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11432857	hybrid			2022-12-25	WOS:000171024600107
J	Chiarugi, P; Fiaschi, T; Taddei, ML; Talini, D; Giannoni, E; Raugei, G; Ramponi, G				Chiarugi, P; Fiaschi, T; Taddei, ML; Talini, D; Giannoni, E; Raugei, G; Ramponi, G			Two vicinal cysteines confer a peculiar redox regulation to low molecular weight protein tyrosine phosphatase in response to platelet-derived growth factor receptor stimulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROGEN-PEROXIDE; REVERSIBLE INACTIVATION; NADPH OXIDASE; MECHANISM; ACTIVATION; H2O2; SRC; PHOSPHORYLATION; KINASE; CELLS	Low molecular weight protein tyrosine phosphatase (LMW-PTP) is an enzyme involved in platelet-derived growth factor (PDGF)-induced mitogenesis and cytoskeleton rearrangement because it is able to bind and dephosphorylate the activated receptor. LMW-PTP presents two cysteines in positions 12 and 17, both belonging to the catalytic pocket; this is a unique feature of LMW-PTP among all protein tyrosine phosphatases. Our previous results demonstrated that in vitro LMW-PTP is oxidized by either H2O2 or nitric oxide with the formation of a disulfide bond between Cys-12 and Cys-17. This oxidation leads to reversible enzyme inactivation because treatment with reductants permits catalytic activity rescue. In the present study we investigated the in vivo inactivation of LMW-PTP by either extracellularly or intracellularly generated H2O2, evaluating its action directly on its natural substrate, PDGF receptor. LMW-PTP is oxidized and inactivated by exogenous oxidative stress and recovers its activity after oxidant removal. LMW-PTP is oxidized also during PDGF signaling, very likely upon PDGF-induced H2O2 production, and recovers its activity within 40 min. Our results strongly suggest that reversibility of in vivo LMW-PTP oxidation is glutathione-dependent. In addition, we propose an intriguing and peculiar role of Cys-17 in the formation of a S-S intramolecular bond, which protects the catalytic Cys-12 from further and irreversible, oxidation. On the basis of our results we propose that the presence of an additional cysteine near the catalytic cysteine could confer to LMW-PTP the ability to rapidly recover its activity and finely regulate PDGF receptor activation during both extracellularly and intracellularly generated oxidative stress.	Univ Studi Firenze, Dipartimento Sci Biochim, I-50134 Florence, Italy	University of Florence	Ramponi, G (corresponding author), Univ Studi Firenze, Dipartimento Sci Biochim, Viale Morgagni 50, I-50134 Florence, Italy.	raugei@scibio.unifi.it	Giannoni, Elisa/AAE-2092-2020; Chiarugi, Paola/CDD-7988-2022	raugei, giovanni/0000-0003-1294-786X; Chiarugi, Paola/0000-0001-7655-2969; Giannoni, Elisa/0000-0001-7136-1098				Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Bae GU, 1999, J BIOL CHEM, V274, P32596, DOI 10.1074/jbc.274.46.32596; Bae YS, 2000, J BIOL CHEM, V275, P10527, DOI 10.1074/jbc.275.14.10527; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Barrett WC, 1999, BIOCHEMISTRY-US, V38, P6699, DOI 10.1021/bi990240v; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; Biaglow JE, 2000, ANAL BIOCHEM, V281, P77, DOI 10.1006/abio.2000.4533; Bucciantini M, 1999, FEBS LETT, V456, P73, DOI 10.1016/S0014-5793(99)00828-5; CAMICI G, 1989, J BIOL CHEM, V264, P2560; Carballo M, 1999, J BIOL CHEM, V274, P17580, DOI 10.1074/jbc.274.25.17580; Caselli A, 1998, J BIOL CHEM, V273, P32554, DOI 10.1074/jbc.273.49.32554; CASELLI A, 1995, FEBS LETT, V374, P249, DOI 10.1016/0014-5793(95)01120-4; Chiarugi P, 1998, J BIOL CHEM, V273, P6776, DOI 10.1074/jbc.273.12.6776; Chiarugi P, 2000, J BIOL CHEM, V275, P4640, DOI 10.1074/jbc.275.7.4640; CHIARUGI P, 1995, FEBS LETT, V372, P49, DOI 10.1016/0014-5793(95)00947-8; Cirri P, 1996, J BIOL CHEM, V271, P2604, DOI 10.1074/jbc.271.5.2604; CIRRI P, 1993, EUR J BIOCHEM, V214, P647, DOI 10.1111/j.1432-1033.1993.tb17965.x; Cirri P, 1998, J BIOL CHEM, V273, P32522, DOI 10.1074/jbc.273.49.32522; Claiborne A, 1999, BIOCHEMISTRY-US, V38, P15407, DOI 10.1021/bi992025k; DAVIS JP, 1994, J BIOL CHEM, V269, P8734; Delaunay A, 2000, EMBO J, V19, P5157, DOI 10.1093/emboj/19.19.5157; Denu JM, 1998, BIOCHEMISTRY-US, V37, P5633, DOI 10.1021/bi973035t; Fauman EB, 1996, TRENDS BIOCHEM SCI, V21, P413, DOI 10.1016/S0968-0004(96)10059-1; Gross S, 1999, J BIOL CHEM, V274, P26378, DOI 10.1074/jbc.274.37.26378; HECHT D, 1992, BIOCHEM BIOPH RES CO, V188, P773, DOI 10.1016/0006-291X(92)91123-8; Huyer G, 1997, J BIOL CHEM, V272, P843, DOI 10.1074/jbc.272.2.843; Kamata H, 1999, CELL SIGNAL, V11, P1, DOI 10.1016/S0898-6568(98)00037-0; Lee SR, 1998, J BIOL CHEM, V273, P15366, DOI 10.1074/jbc.273.25.15366; Mustacich D, 2000, BIOCHEM J, V346, P1, DOI 10.1042/0264-6021:3460001; Pagano PJ, 1997, P NATL ACAD SCI USA, V94, P14483, DOI 10.1073/pnas.94.26.14483; RAMPONI G, 1994, ADV PROT PHOSPHATASE, V8, P1; Rigacci S, 1996, J BIOL CHEM, V271, P1278, DOI 10.1074/jbc.271.3.1278; Sun XG, 2000, J BIOL CHEM, V275, P17237, DOI 10.1074/jbc.C000099200; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Tailor P, 1997, J BIOL CHEM, V272, P5371, DOI 10.1074/jbc.272.9.5371; Tirosh A, 1999, J BIOL CHEM, V274, P10595, DOI 10.1074/jbc.274.15.10595; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Waldron RT, 2000, J BIOL CHEM, V275, P17114, DOI 10.1074/jbc.M908959199; Wu YL, 1998, FEBS LETT, V440, P111, DOI 10.1016/S0014-5793(98)01415-X; ZHANG ZY, 1994, ADV ENZYMOL RAMB, V68, P1; ZHANG ZY, 1992, BIOCHEMISTRY-US, V31, P1701, DOI 10.1021/bi00121a018	41	162	166	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33478	33487		10.1074/jbc.M102302200	http://dx.doi.org/10.1074/jbc.M102302200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11429404	hybrid			2022-12-25	WOS:000170910200027
J	Chohan, KK; Jones, M; Grossmann, JG; Frerman, FE; Scrutton, NS; Sutcliffe, MJ				Chohan, KK; Jones, M; Grossmann, JG; Frerman, FE; Scrutton, NS; Sutcliffe, MJ			Protein dynamics enhance electronic coupling in electron transfer complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A DEHYDROGENASE; ACYL-COA DEHYDROGENASE; X-RAY-SCATTERING; TRANSFER FLAVOPROTEIN; TRIMETHYLAMINE DEHYDROGENASE; PARACOCCUS-DENITRIFICANS; CRYSTAL-STRUCTURES; WILD-TYPE; PURIFICATION; RESOLUTION	Electron-transferring flavoproteins (ETFs) from human and Paracoccus denitrificans have been analyzed by small angle x-ray scattering, showing that neither molecule exists in a rigid conformation in solution. Both ETFs sample a range of conformations corresponding to a large rotation of domain II with respect to domains I and III. A model of the human ETF-medium chain acyl-CoA dehydrogenase complex, consistent with x-ray scattering data, indicates that optimal electron transfer requires domain Il of ETF to rotate by similar to 30 to 50 degrees toward domain I relative to its position in the x-ray structure. Domain motion establishes a new "robust engineering principle" for electron transfer complexes, tolerating multiple configurations of the complex while retaining efficient electron transfer.	Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England; Univ Leicester, Dept Chem, Leicester LE1 7RH, Leics, England; Res Councils Daresbury Lab, Cent Lab, Warrington WA4 4AD, Cheshire, England; Univ Colorado, Sch Med, Dept Pediat, Denver, CO 80262 USA	University of Leicester; University of Leicester; STFC Daresbury Laboratory; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Sutcliffe, MJ (corresponding author), Univ Leicester, Dept Biochem, Univ Rd, Leicester LE1 7RH, Leics, England.	nss@le.ac.uk; sjm@le.ac.uk		Sutcliffe, Mike/0000-0003-0414-1700				Basran J, 2000, BIOCHEMISTRY-US, V39, P9188, DOI 10.1021/bi0006868; Beinert H., 1963, ENZYMES, P447; BERATAN DN, 1991, SCIENCE, V252, P1285, DOI 10.1126/science.1656523; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Chohan KK, 1998, PROTEIN PEPTIDE LETT, V5, P231; Dwyer TM, 1999, BBA-PROTEIN STRUCT M, V1433, P139, DOI 10.1016/S0167-4838(99)00139-9; Feigin L.A., 1987, STRUCTURE ANAL SMALL; Griffin KJ, 1997, BIOCHEMISTRY-US, V36, P4194, DOI 10.1021/bi962572v; Grossmann JG, 1998, J MOL BIOL, V279, P461, DOI 10.1006/jmbi.1998.1787; Gruez A, 2000, J MOL BIOL, V299, P199, DOI 10.1006/jmbi.2000.3748; HOLZENBURG A, 2000, SUBCELLULAR BIOCH EN, V35; HUBBARD SJ, 1993, NACCESS DEPT CHEM MO; HUSAIN M, 1985, J BACTERIOL, V163, P709, DOI 10.1128/JB.163.2.709-715.1985; IKEDA Y, 1983, J BIOL CHEM, V258, P9477; JOHNSON BD, 1993, BIOCHEMISTRY-US, V32, P10779, DOI 10.1021/bi00091a032; Jones CL, 1996, NEPHROLOGY, V2, P13, DOI 10.1111/j.1440-1797.1996.tb00061.x; Jones M, 2000, J BIOL CHEM, V275, P21349, DOI 10.1074/jbc.M001564200; Lee HJ, 1996, BIOCHEMISTRY-US, V35, P12412, DOI 10.1021/bi9607867; LEWIS R, 1994, J SYNCHROTRON RADIAT, V1, P43, DOI 10.1107/S090904959400693X; Muller JJ, 2001, J BIOL CHEM, V276, P2786, DOI 10.1074/jbc.M008501200; Page CC, 1999, NATURE, V402, P47, DOI 10.1038/46972; POROD G, 1951, KOLLOID Z Z POLYM, V124, P83, DOI 10.1007/BF01512792; REGAN JJ, 1993, PATHWAYS, pR2; Roberts DL, 1999, BIOCHEMISTRY-US, V38, P1977, DOI 10.1021/bi9820917; Roberts DL, 1996, P NATL ACAD SCI USA, V93, P14355, DOI 10.1073/pnas.93.25.14355; Salazar D, 1997, J BIOL CHEM, V272, P26425, DOI 10.1074/jbc.272.42.26425; SEMENYUK AV, 1991, J APPL CRYSTALLOGR, V24, P537, DOI 10.1107/S002188989100081X; Sharp RE, 1999, BBA-PROTEIN STRUCT M, V1432, P143, DOI 10.1016/S0167-4838(99)00109-0; STEENKAMP DJ, 1978, J BIOL CHEM, V253, P4086; STUHRMAN.HB, 1970, ACTA CRYSTALL A-CRYS, VA 26, P297, DOI 10.1107/S0567739470000748; Svergun D, 1995, J APPL CRYSTALLOGR, V28, P768, DOI 10.1107/S0021889895007047; Svergun DI, 1997, J APPL CRYSTALLOGR, V30, P798, DOI 10.1107/S0021889897001714; SWENSON RP, 1996, FLAVINS FLAVOPROTEIN, P515; THORPE C, 1979, BIOCHEMISTRY-US, V18, P331, DOI 10.1021/bi00569a016; Thorpe C, 1991, CHEM BIOCH FLAVOENZY, P471; TOWNSANDREWS E, 1989, REV SCI INSTRUM, V60, P2346, DOI 10.1063/1.1140765; Vakser IA, 1996, BIOPOLYMERS, V39, P455, DOI 10.1002/(SICI)1097-0282(199609)39:3<455::AID-BIP16>3.3.CO;2-8; WATMOUGH NJ, 1992, EUR J BIOCHEM, V205, P1089, DOI 10.1111/j.1432-1033.1992.tb16877.x; Weidenhaupt M, 1996, ARCH MICROBIOL, V165, P169, DOI 10.1007/s002030050312; WHITFIELD CD, 1974, J BIOL CHEM, V249, P2801; Wilson EK, 1997, BIOCHEMISTRY-US, V36, P41, DOI 10.1021/bi961224q; XIA ZX, 1990, J MOL BIOL, V212, P837, DOI 10.1016/0022-2836(90)90240-M; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612	43	34	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					34142	34147		10.1074/jbc.M101341200	http://dx.doi.org/10.1074/jbc.M101341200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11429403	hybrid			2022-12-25	WOS:000170910200113
J	Kataoka, K; Handa, H; Nishizawa, M				Kataoka, K; Handa, H; Nishizawa, M			Induction of cellular antioxidative stress genes through heterodimeric transcription factor Nrf2/small Maf by antirheumatic gold(I) compounds	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE STRESS; PERITONEAL-MACROPHAGES; RHEUMATOID-ARTHRITIS; RESPONSIVE ELEMENTS; NUCLEAR ONCOPROTEIN; RADICAL GENERATION; SODIUM THIOMALATE; METAL-COMPOUNDS; HEME OXYGENASE; MESSENGER-RNA	Gold(I)-containing compounds have long been used in the treatment of rheumatoid arthritis (RA), but the molecular mechanism of their action has remained largely unknown. In this paper we have demonstrated that gold(I) drugs selectively activate the DNA binding of a heterodimer consisting of the basic-leucine zipper transcription factors Nrf2 and small Maf. Once bound to its recognition DNA sequence termed antioxidant-responsive element or Maf-recognition element, Nrf2/small Maf induces a set of antioxidative stress genes, including heme oxygenase-1 and gamma -glutamylcysteine synthetase, whose products have been demonstrated to contribute to the scavenging of reactive oxygen species and to exhibit anti-inflammatory effects. Our findings suggest that stimulation of antioxidative stress response through activation of Nrf2/small Maf may be a pharmacologically important part of the actions of gold(I) drugs for the treatment of rheumatoid arthritis. Alternatively, activation of Nrf2/small Maf may be a protective response of cells against toxic effects of the drugs.	Tokyo Inst Technol, Frontier Collaborat Res Ctr, Midori Ku, Yokohama, Kanagawa 2268503, Japan; Scripps Res Inst, Dept Mol Med, La Jolla, CA 92037 USA	Tokyo Institute of Technology; Scripps Research Institute	Kataoka, K (corresponding author), Tokyo Inst Technol, Frontier Collaborat Res Ctr, Midori Ku, 4259 Nagatsuta, Yokohama, Kanagawa 2268503, Japan.							Aaseth J, 1998, ANALYST, V123, P3, DOI 10.1039/a704840h; Alam J, 1999, J BIOL CHEM, V274, P26071, DOI 10.1074/jbc.274.37.26071; Bondeson J, 1995, BIOCHEM PHARMACOL, V50, P1753, DOI 10.1016/0006-2952(95)02030-6; Chan JY, 2000, BBA-GENE STRUCT EXPR, V1517, P19, DOI 10.1016/S0167-4781(00)00238-4; DAVIS P, 1983, ARTHRITIS RHEUM, V26, P82, DOI 10.1002/art.1780260114; Ferris CD, 1999, NAT CELL BIOL, V1, P152, DOI 10.1038/11072; HANDEL ML, 1995, P NATL ACAD SCI USA, V92, P4497, DOI 10.1073/pnas.92.10.4497; HARTH M, 1983, J RHEUMATOL, V10, P701; Hayes JD, 2000, BIOCHEM SOC T, V28, P33, DOI 10.1042/bst0280033; HIRAI H, 1994, P NATL ACAD SCI USA, V91, P3584, DOI 10.1073/pnas.91.9.3584; IGARASHI K, 1995, P NATL ACAD SCI USA, V92, P7445, DOI 10.1073/pnas.92.16.7445; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; Ishii T, 2000, J BIOL CHEM, V275, P16023, DOI 10.1074/jbc.275.21.16023; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; ITOH K, 1995, MOL CELL BIOL, V15, P4184, DOI 10.1128/mcb.15.8.4184; Jeon KI, 2000, J IMMUNOL, V164, P5981, DOI 10.4049/jimmunol.164.11.5981; Jeyapaul J, 2000, BIOCHEM PHARMACOL, V59, P1433, DOI 10.1016/S0006-2952(00)00256-2; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; KATAOKA K, 1994, MOL CELL BIOL, V14, P7581, DOI 10.1128/MCB.14.11.7581; KATAOKA K, 1995, MOL CELL BIOL, V15, P2180; Kataoka K, 2001, J BIOL CHEM, V276, P819, DOI 10.1074/jbc.M007643200; Kataoka K, 1996, ONCOGENE, V12, P53; Kean WF, 1997, BRIT J RHEUMATOL, V36, P560; KERPPOLA TK, 1994, ONCOGENE, V9, P675; Kobayashi A, 1999, J BIOL CHEM, V274, P6443, DOI 10.1074/jbc.274.10.6443; Moinova HR, 1999, BIOCHEM BIOPH RES CO, V261, P661, DOI 10.1006/bbrc.1999.1109; Otterbein LE, 2000, NAT MED, V6, P422, DOI 10.1038/74680; Oyake T, 1996, MOL CELL BIOL, V16, P6083; SATO H, 1995, BIOCHEM PHARMACOL, V49, P1453, DOI 10.1016/0006-2952(95)00033-V; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; TAKEDA K, 1994, J BIOL CHEM, V269, P22858; TREJO J, 1992, MOL CELL BIOL, V12, P4742, DOI 10.1128/MCB.12.10.4742; Tsuji Y, 2000, MOL CELL BIOL, V20, P5818, DOI 10.1128/MCB.20.16.5818-5827.2000; Venugopal R, 1998, ONCOGENE, V17, P3145, DOI 10.1038/sj.onc.1202237; Wasserman WW, 1997, P NATL ACAD SCI USA, V94, P5361, DOI 10.1073/pnas.94.10.5361; Willis D, 1996, NAT MED, V2, P87, DOI 10.1038/nm0196-87; Yachie A, 1999, J CLIN INVEST, V103, P129, DOI 10.1172/JCI4165; Yamashita M, 1999, EUR J PHARMACOL, V368, P251, DOI 10.1016/S0014-2999(99)00053-9; Yoshida S, 1999, INT IMMUNOL, V11, P151, DOI 10.1093/intimm/11.2.151	40	110	115	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					34074	34081		10.1074/jbc.M105383200	http://dx.doi.org/10.1074/jbc.M105383200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11429414	hybrid			2022-12-25	WOS:000170910200105
J	Wong, ST; Baker, LP; Trinh, K; Hetman, M; Suzuki, LA; Storm, DR; Bornfeldt, KE				Wong, ST; Baker, LP; Trinh, K; Hetman, M; Suzuki, LA; Storm, DR; Bornfeldt, KE			Adenylyl cyclase 3 mediates prostaglandin E-2-induced growth inhibition in arterial smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-A; IN-VIVO; DIFFERENTIAL REGULATION; SIGNALING PATHWAYS; ANGIOTENSIN-II; WHOLE CELLS; CYCLIC-AMP; PROLIFERATION; CAMP; CALCIUM	Arterial smooth muscle cell (SMC) proliferation contributes to a number of vascular pathologies. Prostaglandin E-2 (PGE(2)), produced by the endothelium and by SMCs themselves, acts as a potent SMC growth inhibitor. The growth-inhibitory effects of PGE2 are mediated through activation of G-protein-coupled membrane receptors, activation of adenylyl cyclases (ACs), formation of cAMP, and subsequent inhibition of mitogenic signal transduction pathways in SMCs. Of the 10 different mammalian AC isoforms known today, seven isoforms (AC2-7 and AC9) are expressed in SMCs from various species. We show that, despite the presence of several different AG isoforms, the principal AC isoform activated by PGE(2) in human arterial SMCs is a calmodulin kinase II-inhibited AC with characteristics similar to those of AC3. AC3 is expressed in isolated human arterial SMCs and in intact aorta. We further show that arterial SMCs isolated from AC3-deficient mice are resistant to PGE(2)-induced growth inhibition. In summary, AC3 is the principal AC isoform activated by PGE(2) in arterial SMCs, and AC3 mediates the growth-inhibitory effects of PGE(2). Because AC3 activity is inhibited by intracellular calcium through calmodulin kinase II, AC3 may serve as an important integrator of growth-inhibitory signals that stimulate cAMP formation and growth factors that increase intracellular calcium.	Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98195 USA; Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Bornfeldt, KE (corresponding author), Univ Washington, Sch Med, Dept Pathol, Box 357470, Seattle, WA 98195 USA.		Bornfeldt, Karin/AAI-2241-2019	Bornfeldt, Karin/0000-0001-9208-6523	NHLBI NIH HHS [HL62887] Funding Source: Medline; NICHD NIH HHS [HD00836] Funding Source: Medline; NINDS NIH HHS [NS357056] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R24HD000836] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD000836] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062887] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANTONI FA, 1995, J BIOL CHEM, V270, P28055; ASSENDER JW, 1992, BIOCHEM J, V288, P527, DOI 10.1042/bj2880527; BERK BC, 1991, BIOCHEM J, V274, P799, DOI 10.1042/bj2740799; Boie Y, 1997, EUR J PHARMACOL, V340, P227, DOI 10.1016/S0014-2999(97)01383-6; Bornfeldt KE, 1999, CELL SIGNAL, V11, P465, DOI 10.1016/S0898-6568(99)00020-0; BORNFELDT KE, 1994, J CLIN INVEST, V93, P1266, DOI 10.1172/JCI117081; CALI JJ, 1994, J BIOL CHEM, V269, P12190; CHOI EJ, 1992, J BIOL CHEM, V267, P12440; CHOI EJ, 1993, BIOCHEMISTRY-US, V32, P1891, DOI 10.1021/bi00059a001; Cospedal R, 1999, BIOCHEM J, V342, P407, DOI 10.1042/0264-6021:3420407; Defer N, 2000, AM J PHYSIOL-RENAL, V279, pF400, DOI 10.1152/ajprenal.2000.279.3.F400; Fukumoto S, 1999, CIRC RES, V85, P985; Glass CK, 2001, CELL, V104, P503, DOI 10.1016/S0092-8674(01)00238-0; Grant SL, 2000, MOL PHARMACOL, V57, P460, DOI 10.1124/mol.57.3.460; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; GRAVES LM, 1995, P NATL ACAD SCI USA, V92, P7222, DOI 10.1073/pnas.92.16.7222; Guldemeester A, 1999, AM J PHYSIOL-LUNG C, V276, pL1010, DOI 10.1152/ajplung.1999.276.6.L1010; Guldemeester HA, 1998, CHEST, V114, p38S, DOI 10.1378/chest.114.1_Supplement.38S; Hainaud P, 2001, ATHEROSCLEROSIS, V154, P301, DOI 10.1016/S0021-9150(00)00487-1; Hirata A, 2000, BRIT J PHARMACOL, V131, P1521, DOI 10.1038/sj.bjp.0703730; Hurley JH, 1998, CURR OPIN STRUC BIOL, V8, P770, DOI 10.1016/S0959-440X(98)80097-3; Indolfi C, 1997, NAT MED, V3, P775, DOI 10.1038/nm0797-775; Indolfi C, 2000, J AM COLL CARDIOL, V36, P288, DOI 10.1016/S0735-1097(00)00679-3; IWAMI G, 1995, J BIOL CHEM, V270, P12481, DOI 10.1074/jbc.270.21.12481; JACOBOWITZ O, 1993, J BIOL CHEM, V268, P3829; Kim S, 2001, J BIOL CHEM, V276, P12864, DOI 10.1074/jbc.M001492200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lipskaia L, 1998, J CELL PHYSIOL, V176, P50, DOI 10.1002/(SICI)1097-4652(199807)176:1<50::AID-JCP6>3.0.CO;2-7; Lipskaia L, 1997, FEBS LETT, V415, P275, DOI 10.1016/S0014-5793(97)01001-6; MagnierGaubil C, 1996, J BIOL CHEM, V271, P27788, DOI 10.1074/jbc.271.44.27788; Nielsen MD, 1996, J BIOL CHEM, V271, P33308, DOI 10.1074/jbc.271.52.33308; Plevin R, 1997, CELL SIGNAL, V9, P323, DOI 10.1016/S0898-6568(96)00193-3; Price SA, 2000, J ENDOCRINOL, V164, P21, DOI 10.1677/joe.0.1640021; REDDY R, 1995, J BIOL CHEM, V270, P14340, DOI 10.1074/jbc.270.24.14340; ROE MW, 1989, J CELL PHYSIOL, V139, P100, DOI 10.1002/jcp.1041390115; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Ross R., 1980, HDB PHYSL CARDIOVA 2, P69; Rybalkin SD, 1997, J CLIN INVEST, V100, P2611, DOI 10.1172/JCI119805; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SHORT AD, 1993, P NATL ACAD SCI USA, V90, P4986, DOI 10.1073/pnas.90.11.4986; Sinnarajah S, 2001, NATURE, V409, P1051, DOI 10.1038/35059104; Smit MJ, 1998, P NATL ACAD SCI USA, V95, P15084, DOI 10.1073/pnas.95.25.15084; Soler M, 2000, CIRC RES, V87, P504; SOUTHGATE K, 1990, ATHEROSCLEROSIS, V82, P113, DOI 10.1016/0021-9150(90)90150-H; Suzuki LA, 2001, DIABETES, V50, P851, DOI 10.2337/diabetes.50.4.851; TANG WJ, 1992, CELL, V70, P869, DOI 10.1016/0092-8674(92)90236-6; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TANG WJ, 1991, J BIOL CHEM, V266, P8595; TAUSSIG R, 1995, J BIOL CHEM, V270, P1, DOI 10.1074/jbc.270.1.1; Wang CY, 2000, CIRC RES, V86, P982, DOI 10.1161/01.RES.86.9.982; WAYMAN GA, 1995, J BIOL CHEM, V270, P21480, DOI 10.1074/jbc.270.37.21480; Wayman GA, 1996, MOL CELL BIOL, V16, P6075; Wei J, 1998, NEURON, V21, P495, DOI 10.1016/S0896-6273(00)80561-9; Wei J, 1996, J BIOL CHEM, V271, P24231, DOI 10.1074/jbc.271.39.24231; Wong ST, 2000, NEURON, V27, P487, DOI 10.1016/S0896-6273(00)00060-X; XIA ZG, 1993, J NEUROCHEM, V60, P305, DOI 10.1111/j.1471-4159.1993.tb05852.x; XIA ZG, 1992, NEUROSCI LETT, V144, P169, DOI 10.1016/0304-3940(92)90742-P; YOSHIMURA M, 1993, J BIOL CHEM, V268, P4604; Zhang JH, 1997, AM J PHYSIOL-HEART C, V273, pH971, DOI 10.1152/ajpheart.1997.273.2.H971	59	33	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					34206	34212		10.1074/jbc.M103923200	http://dx.doi.org/10.1074/jbc.M103923200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11432866	hybrid			2022-12-25	WOS:000170910200122
J	Yan, RQ; Munzner, JB; Shuck, ME; Bienkowski, MJ				Yan, RQ; Munzner, JB; Shuck, ME; Bienkowski, MJ			BACE2 functions as an alternative alpha-secretase in cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; ALZHEIMERS BETA-SECRETASE; ASPARTYL PROTEASE; ASP1 BACE2; CLEAVAGE; DISEASE; SITE; IDENTIFICATION; MATURATION; ENZYME	BACE1 and BACE2 define a new subfamily of membrane-anchored aspartyl proteases. Both endoproteases share similar structural organization including a prodomain, a catalytic domain formed via DTG and DSG active site motifs, a single transmembrane domain, and a short C-terminal tail. BACE1 has been identified as the Alzheimer's beta -secretase, whereas BACE2 was mapped to the Down's critical region of human chromosome 21. Herein we show that purified BACE2 can be autoactivated in vitro. Purified BACE2 cleaves human amyloid precursor protein (APP) sequences at the beta -secretase site, and near the alpha -secretase site, mainly at A beta -Phe(20) down arrow Ala(21) and also at A beta -Phe(19) down arrow Phe(20). Alternatively, in cells BACE2 has a limited effect on the beta -secretase site but efficiently cleaves the sequences near the a-secretase site. The in vitro specificity of APP processing by BACE2 is distinct from that observed in cells. BACE2 localizes in the endoplasmic reticulum, Golgi, trans-Golgi network, endosomes, and plasma membrane, and its cellular localization patterns depend on the presence of its transmembrane domain. BACE2 chimeras that increase localization of BACE2 in the trans-Golgi network do not change its APP processing patterns. Thus, BACE2 can be distinguished from BACE1 on the basis of autoprocessing of the prosegment, APP processing specificity, and subcellular localization patterns.	Pharmacia Corp, Dept Cell & Mol Biol, Kalamazoo, MI 49007 USA	Pfizer	Yan, RQ (corresponding author), Pharmacia Corp, Dept Cell & Mol Biol, 301 Henrietta St, Kalamazoo, MI 49007 USA.	ryan@pharmacia.com		Yan, Riqiang/0000-0001-7195-7617				Acquati F, 2000, FEBS LETT, V468, P59, DOI 10.1016/S0014-5793(00)01192-3; Bennett BD, 2000, J BIOL CHEM, V275, P20647, DOI 10.1074/jbc.M002688200; Bennett BD, 2000, J BIOL CHEM, V275, P37712, DOI 10.1074/jbc.M005339200; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; Cai HB, 2001, NAT NEUROSCI, V4, P233, DOI 10.1038/85064; Capell A, 2000, J BIOL CHEM, V275, P30849, DOI 10.1074/jbc.M003202200; Charlwood J, 2001, J BIOL CHEM, V276, P16739, DOI 10.1074/jbc.M009361200; Creemers JWM, 2001, J BIOL CHEM, V276, P4211, DOI 10.1074/jbc.M006947200; Dominguez DI, 2001, AMYLOID, V8, P124, DOI 10.3109/13506120109007356; Farzan M, 2000, P NATL ACAD SCI USA, V97, P9712, DOI 10.1073/pnas.160115697; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V122, P1131, DOI 10.1016/0006-291X(84)91209-9; Gruninger-Leitch F, 2000, NAT BIOTECHNOL, V18, P66, DOI 10.1038/71944; Hardy J, 1997, TRENDS NEUROSCI, V20, P154, DOI 10.1016/S0166-2236(96)01030-2; Huse JT, 2000, J BIOL CHEM, V275, P33729, DOI 10.1074/jbc.M004175200; Hussain I, 2000, MOL CELL NEUROSCI, V16, P609, DOI 10.1006/mcne.2000.0884; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; Hussain I, 2001, J BIOL CHEM, V276, P23322, DOI 10.1074/jbc.M101069200; Koike H, 1999, BIOCHEM J, V343, P371, DOI 10.1042/0264-6021:3430371; LADROR US, 1994, J BIOL CHEM, V269, P18422; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; Lin XL, 2000, P NATL ACAD SCI USA, V97, P1456, DOI 10.1073/pnas.97.4.1456; Luo Y, 2001, NAT NEUROSCI, V4, P231, DOI 10.1038/85059; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; Roberds SL, 2001, HUM MOL GENET, V10, P1317, DOI 10.1093/hmg/10.12.1317; Saftig P, 1996, J BIOL CHEM, V271, P27241, DOI 10.1074/jbc.271.44.27241; SAUNDERS AJ, 1999, SCIENCE, V286, P1225; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; Shi XP, 2001, J BIOL CHEM, V276, P10366, DOI 10.1074/jbc.M009200200; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; Solans A, 2000, CYTOGENET CELL GENET, V89, P177, DOI 10.1159/000015608; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Walter J, 2001, J BIOL CHEM, V276, P14634, DOI 10.1074/jbc.M011116200; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Youkin S. G., 1998, J PHYSIOL-LONDON, V92, P289	35	135	146	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					34019	34027		10.1074/jbc.M105583200	http://dx.doi.org/10.1074/jbc.M105583200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11423558	hybrid			2022-12-25	WOS:000170910200098
J	Rey, O; Young, SH; Cantrell, D; Rozengurt, E				Rey, O; Young, SH; Cantrell, D; Rozengurt, E			Rapid protein kinase D translocation in response to G protein-coupled receptor activation - Dependence on protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; PLECKSTRIN HOMOLOGY DOMAIN; CYSTEINE-RICH MOTIFS; PHORBOL ESTERS; INTACT-CELLS; IN-VIVO; D PKD; MOLECULAR-CLONING; 58-KDA PROTEIN; MU	Protein kinase D (PKD)/protein kinase C (PKC) mu is a serine/threonine protein kinase that can be activated by physiological stimuli like growth factors, antigen-receptor engagement and G protein-coupled receptor (GPCR) agonists via a phosphorylation-dependent mechanism that requires PKC activity. In order to investigate the dynamic mechanisms associated with GPCR signaling, the intracellular translocation of a green fluorescent protein-tagged PKD was analyzed by real-time visualization in fibroblasts and epithelial cells stimulated with bombesin, a GPCR agonist. We found that bombesin induced a rapidly reversible plasma membrane translocation of green fluorescent protein-tagged PKD, an event that can be divided into two distinct mechanistic steps. The first step, which is exclusively mediated by the cysteine-rich domain in the N terminus of PKD, involved its translocation from the cytosol to the plasma membrane. The second step, i.e. the rapid reverse translocation of PKD from the plasma membrane to the cytosol, required its catalytic domain and surprisingly PKC activity. These findings provide evidence for a novel mechanism by which PKC coordinates the translocation and activation of PKD in response to bombesin-induced GPCR activation.	Univ Calif Los Angeles, Sch Med, Dept Med,Div Digest Dis, Unit Signal Transduct & Gastrointestinal Canc, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, CURE Digest Dis Res Ctr, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; Imperial Canc Res Fund, Lymphocyte Activat Lab, London WC2A 3PX, England	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Cancer Research UK	Rozengurt, E (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Med,Div Digest Dis, Unit Signal Transduct & Gastrointestinal Canc, 900 Vet Ave,Warren Hall,Rm 11-124, Los Angeles, CA 90095 USA.			Rey, Osvaldo/0000-0003-1575-9864				Abedi H, 1998, FEBS LETT, V427, P209, DOI 10.1016/S0014-5793(98)00427-X; Bagowski CP, 1999, EMBO J, V18, P5567, DOI 10.1093/emboj/18.20.5567; BLOOM GS, 1989, J BIOL CHEM, V264, P16083; CELIS JE, 1994, CELL BIOL LAB HDB; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; Exton JH, 1996, ANNU REV PHARMACOL, V36, P481, DOI 10.1146/annurev.pa.36.040196.002405; Feng X, 2000, J BIOL CHEM, V275, P17024, DOI 10.1074/jbc.275.22.17024; Gao YS, 1998, J BIOL CHEM, V273, P33825, DOI 10.1074/jbc.273.50.33825; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; Haworth RS, 1999, AM J PHYSIOL-CELL PH, V277, pC1202, DOI 10.1152/ajpcell.1999.277.6.C1202; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; Iglesias T, 1999, FEBS LETT, V454, P53, DOI 10.1016/S0014-5793(99)00772-3; Iglesias T, 1998, J BIOL CHEM, V273, P410, DOI 10.1074/jbc.273.1.410; Iglesias T, 1998, FEBS LETT, V437, P19, DOI 10.1016/S0014-5793(98)01189-2; Iglesias T, 1998, J BIOL CHEM, V273, P27662, DOI 10.1074/jbc.273.42.27662; Jamora C, 1999, CELL, V98, P59, DOI 10.1016/S0092-8674(00)80606-6; Johannes FJ, 1999, FEBS LETT, V461, P68, DOI 10.1016/S0014-5793(99)01424-6; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; Liljedahl M, 2001, CELL, V104, P409, DOI 10.1016/S0092-8674(01)00228-8; Matthews S, 1999, FEBS LETT, V457, P515, DOI 10.1016/S0014-5793(99)01090-X; Matthews SA, 2000, EMBO J, V19, P2935, DOI 10.1093/emboj/19.12.2935; Matthews SA, 1997, J BIOL CHEM, V272, P20245, DOI 10.1074/jbc.272.32.20245; Matthews SA, 1999, J BIOL CHEM, V274, P26543, DOI 10.1074/jbc.274.37.26543; Matz MV, 1999, NAT BIOTECHNOL, V17, P969, DOI 10.1038/13657; Mikoshiba K, 1997, CURR OPIN NEUROBIOL, V7, P339, DOI 10.1016/S0959-4388(97)80061-X; MILLIGAN G, 1992, SIGNAL TRANSDUCTION; Nakhost A, 1999, J BIOL CHEM, V274, P28944, DOI 10.1074/jbc.274.41.28944; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1989, CANCER, V63, P1892, DOI 10.1002/1097-0142(19890515)63:10<1892::AID-CNCR2820631005>3.0.CO;2-Z; Oancea E, 1998, J CELL BIOL, V140, P485, DOI 10.1083/jcb.140.3.485; Paolucci L, 1999, CANCER RES, V59, P572; PETTITT TR, 1993, BIOCHEM J, V289, P487, DOI 10.1042/bj2890487; Prestle J, 1996, J CELL BIOL, V134, P1401, DOI 10.1083/jcb.134.6.1401; Rozengurt E, 1997, BIOCHEM SOC T, V25, P565, DOI 10.1042/bst0250565; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; Sidorenko SP, 1996, IMMUNITY, V5, P353, DOI 10.1016/S1074-7613(00)80261-7; Storz P, 2000, J BIOL CHEM, V275, P24601, DOI 10.1074/jbc.M002964200; Teruel MN, 2000, CELL, V103, P181, DOI 10.1016/S0092-8674(00)00109-4; Toker Alex, 1998, Frontiers in Bioscience, V3, pD1134; VALVERDE AM, 1994, P NATL ACAD SCI USA, V91, P8572, DOI 10.1073/pnas.91.18.8572; Van Lint J, 1998, J BIOL CHEM, V273, P7038, DOI 10.1074/jbc.273.12.7038; VANLINT J, 1995, J BIOL CHEM, V270, P1455, DOI 10.1074/jbc.270.3.1455; Waldron RT, 2000, J BIOL CHEM, V275, P17114, DOI 10.1074/jbc.M908959199; Waldron RT, 1999, J BIOL CHEM, V274, P9224, DOI 10.1074/jbc.274.14.9224; Waldron RT, 2001, J BIOL CHEM, V276, P32606, DOI 10.1074/jbc.M101648200; Yuan JZ, 2000, J BIOL CHEM, V275, P2157, DOI 10.1074/jbc.275.3.2157; Zugaza JL, 1996, EMBO J, V15, P6220, DOI 10.1002/j.1460-2075.1996.tb01012.x; Zugaza JL, 1997, J BIOL CHEM, V272, P23952, DOI 10.1074/jbc.272.38.23952	51	90	90	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					32616	32626		10.1074/jbc.M101649200	http://dx.doi.org/10.1074/jbc.M101649200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11410587	hybrid			2022-12-25	WOS:000170746000033
J	Gurvitz, A; Hiltunen, JK; Erdmann, R; Hamilton, B; Hartig, A; Ruis, H; Rottensteiner, H				Gurvitz, A; Hiltunen, JK; Erdmann, R; Hamilton, B; Hartig, A; Ruis, H; Rottensteiner, H			Saccharomyces cerevisiae Adr1p governs fatty acid beta-oxidation and peroxisome proliferation by regulating POX1 and PEX11	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UPSTREAM ACTIVATING SEQUENCE; TRANSCRIPTION FACTORS PIP2P; 2,4-DIENOYL-COA REDUCTASE; 3-OXOACYL-COA THIOLASE; GLYCEROL KINASE; OLEIC ACID; GENE SPS19; PROTEIN; YEAST; MUTANTS	Saccharomyces cerevisiae Adr1p is essential for fatty acid degradation and peroxisome proliferation. Here, the role of Adr1p was examined with respect to the transcriptional regulation of the Pip2p-Oaf1p dependent genes POX1 and PEX11. POX1 encodes the rate-limiting enzyme of peroxisomal beta -oxidation, acyl-CoA oxidase. The POX1 promoter was shown to contain a canonical Adr1p element (UAS1), within which the oleate response element (ORE) was nested. PEX11 codes for a peroxin that is critical for normal peroxisome proliferation, and its promoter was shown similarly to contain a UAS1-like element overlapping the ORE. Northern analysis demonstrated that transcriptional up-regulation of both POX1 and PEX11 was abolished in adr1 Delta mutant cells, and immunoblotting confirmed that the abundance of their gene products was dramatically reduced. Studies of an overlapping ORE/UAS1 arrangement in the CTA1 promoter revealed synergy between these elements. We conclude that overlapping ORE and UAS1 elements in conjunction with their binding factors Pip2p-Oaf1p and Adr1p coordinate the carbon flux through beta -oxidation with peroxisome proliferation.	Univ Vienna, Inst Biochem & Mol Zellbiol, A-1030 Vienna, Austria; Univ Oulu, Dept Biochem, Bioctr, FIN-90570 Oulu, Finland; Free Univ Berlin, FB Biol Chem Pharm, D-14195 Berlin, Germany; Vianna Bioctr, Ludwig Boltzmann Forschungsstelle Biochem, A-1030 Vienna, Austria	University of Vienna; Finland National Institute for Health & Welfare; University of Oulu; Free University of Berlin; Ludwig Boltzmann Institute	Gurvitz, A (corresponding author), Univ Vienna, Inst Biochem & Mol Zellbiol, Dr Bohrgasse 9, A-1030 Vienna, Austria.			Hartig, Andreas/0000-0003-3334-2763				Baumgartner U, 1999, J BIOL CHEM, V274, P22208, DOI 10.1074/jbc.274.32.22208; BEERS RF, 1952, J BIOL CHEM, V195, P133; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chang CC, 1999, J CELL SCI, V112, P1579; CHENG C, 1994, MOL CELL BIOL, V14, P3842, DOI 10.1128/MCB.14.6.3842; CIRIACY M, 1975, MOL GEN GENET, V138, P157, DOI 10.1007/BF02428119; DMOCHOWSKA A, 1990, GENE, V88, P247, DOI 10.1016/0378-1119(90)90038-S; EINERHAND AWC, 1991, EUR J BIOCHEM, V200, P113, DOI 10.1111/j.1432-1033.1991.tb21056.x; EINERHAND AWC, 1993, EUR J BIOCHEM, V214, P323, DOI 10.1111/j.1432-1033.1993.tb17927.x; EISEN A, 1988, MOL CELL BIOL, V8, P4552, DOI 10.1128/MCB.8.10.4552; ERDMANN R, 1994, YEAST, V10, P1173, DOI 10.1002/yea.320100905; ERDMANN R, 1995, J CELL BIOL, V128, P509, DOI 10.1083/jcb.128.4.509; FILIPITS M, 1993, GENE, V132, P49, DOI 10.1016/0378-1119(93)90513-3; Grauslund M, 1999, NUCLEIC ACIDS RES, V27, P4391, DOI 10.1093/nar/27.22.4391; Gurvitz A, 1997, MOL MICROBIOL, V26, P675, DOI 10.1046/j.1365-2958.1997.5931969.x; Gurvitz A, 1997, J BIOL CHEM, V272, P22140, DOI 10.1074/jbc.272.35.22140; Gurvitz A, 1999, MOL GEN GENET, V262, P481; Gurvitz Aner, 2000, Molecular Cell Biology Research Communications, V4, P81, DOI 10.1006/mcbr.2000.0261; HILTUNEN JK, 1992, J BIOL CHEM, V267, P6646; IGUAL JC, 1991, YEAST, V7, P379, DOI 10.1002/yea.320070408; Igual JC, 1996, MOL GEN GENET, V252, P446, DOI 10.1007/s004380050249; JONES EW, 1977, GENETICS, V85, P23; Kunau WH, 1995, PROG LIPID RES, V34, P267, DOI 10.1016/0163-7827(95)00011-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZAROW PB, 1995, J NEUROPATH EXP NEUR, V54, P720, DOI 10.1097/00005072-199509000-00015; Luo Y, 1996, J BIOL CHEM, V271, P12068, DOI 10.1074/jbc.271.20.12068; MARSHALL PA, 1995, J CELL BIOL, V129, P345, DOI 10.1083/jcb.129.2.345; Merika M, 2001, CURR OPIN GENET DEV, V11, P205, DOI 10.1016/S0959-437X(00)00180-5; Miller JH., 1972, EXPT MOL GENETICS; MOSER HW, 1991, CLIN BIOCHEM, V24, P343, DOI 10.1016/0009-9120(91)80009-R; PALOSAARI PM, 1990, J BIOL CHEM, V265, P3347; PAVLIK P, 1993, CURR GENET, V24, P21, DOI 10.1007/BF00324660; RICHTER K, 1980, J BIOL CHEM, V255, P8019; Rottensteiner H, 1997, EUR J BIOCHEM, V247, P776, DOI 10.1111/j.1432-1033.1997.00776.x; Rottensteiner H, 1996, EMBO J, V15, P2924, DOI 10.1002/j.1460-2075.1996.tb00655.x; Sambrook J., 2002, MOL CLONING LAB MANU; SIMON M, 1991, MOL CELL BIOL, V11, P699, DOI 10.1128/MCB.11.2.699; SIMON M, 1992, YEAST, V8, P303, DOI 10.1002/yea.320080407; SIMON MM, 1995, MOL GEN GENET, V249, P289, DOI 10.1007/BF00290529; van Roermund CWT, 2000, J CELL BIOL, V150, P489, DOI 10.1083/jcb.150.3.489; VEENHUIS M, 1987, YEAST, V3, P77, DOI 10.1002/yea.320030204; YAFFE MP, 1984, P NATL ACAD SCI-BIOL, V81, P4819, DOI 10.1073/pnas.81.15.4819	42	49	50	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					31825	31830		10.1074/jbc.M105989200	http://dx.doi.org/10.1074/jbc.M105989200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11431484	hybrid			2022-12-25	WOS:000170613500049
J	Kumar, NV; Bernstein, LR				Kumar, NV; Bernstein, LR			Ten ERK-related proteins in three distinct classes associate with AP-1 proteins and/or AP-1 DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL DOMAIN; RNA-POLYMERASE-II; SODIUM DODECYL-SULFATE; TRANSCRIPTION FACTOR; BINDING ACTIVITY; CELL-CYCLE; MAP KINASE; INDUCED TRANSFORMATION; ACTIVATION DOMAIN; TUMOR PROMOTION	We have identified seven ERK-related proteins ("ERPs"), including ERK2, that are stably associated in vivo with AP-1 dimers composed of diverse Jun and Fos family proteins. These complexes have kinase activity. We designate them as "class I ERPs." We originally hypothesized that these ERPs associate with DNA along with AP-1 proteins. We devised a DNA affinity chromatography-based analytical assay for DNA binding, the "nucleotide affinity preincubation specificity test recognition" (NAPSTER) assay. In this assay, class I ERPs do not associate with AP-1 DNA. However, several new "class II" ERPs do associate with DNA. p41 and p44 are ERK1/2-related ERPs that lack kinase activity and associate along with AP-1 proteins with AP-1 DNA. Class I ER-Ps and their associated kinase activity thus appear to bind AP-1 dimers when they are not bound to DNA and then disengage and are replaced by class II ERPs to form higher order complexes when AP-1 dimers bind DNA p97 is a class HI ERP, related to ERK3, that associates with AP-1 DNA without AP-1 proteins. With the exception of ERK2, none of the 10 ERPs appear to be known mitogen-activated protein kinase superfamily members.	Texas A&M Univ, Hlth Sci Ctr, Dept Pathol & Lab Med, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Bernstein, LR (corresponding author), Texas A&M Univ, Hlth Sci Ctr, Dept Pathol & Lab Med, College Stn, TX 77843 USA.			Nandicoori, Vinay/0000-0002-5682-4178	NCI NIH HHS [R29 CA73783] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA073783] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abe J, 1996, J BIOL CHEM, V271, P16586, DOI 10.1074/jbc.271.28.16586; Abe MK, 1999, MOL CELL BIOL, V19, P1301; Albanese C, 1999, J BIOL CHEM, V274, P34186, DOI 10.1074/jbc.274.48.34186; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Aronheim A, 1997, MOL CELL BIOL, V17, P3094, DOI 10.1128/MCB.17.6.3094; Baranger AM, 1998, CURR OPIN CHEM BIOL, V2, P18, DOI 10.1016/S1367-5931(98)80031-8; BERNSTEIN LR, 1994, J BIOL CHEM, V269, P9401; Bernstein LR, 1999, BBA-GENE STRUCT EXPR, V1489, P263, DOI 10.1016/S0167-4781(99)00191-8; BERNSTEIN LR, 1989, SCIENCE, V244, P566, DOI 10.1126/science.2541502; Bonnet F, 1999, NUCLEIC ACIDS RES, V27, P4399, DOI 10.1093/nar/27.22.4399; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; Chakraborti S, 1998, CELL SIGNAL, V10, P675, DOI 10.1016/S0898-6568(98)00014-X; Chen L, 1998, NATURE, V392, P42, DOI 10.1038/32100; Cheng M, 1996, J BIOL CHEM, V271, P8951, DOI 10.1074/jbc.271.15.8951; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DAI TN, 1995, ONCOGENE, V10, P849; Denhardt DT, 1996, CRIT REV ONCOGENESIS, V7, P261, DOI 10.1615/CritRevOncog.v7.i3-4.70; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DONG ZG, 1994, P NATL ACAD SCI USA, V91, P609, DOI 10.1073/pnas.91.2.609; DUBOIS MF, 1994, EMBO J, V13, P4787, DOI 10.1002/j.1460-2075.1994.tb06804.x; English J, 1999, EXP CELL RES, V253, P255, DOI 10.1006/excr.1999.4687; FRAME MC, 1991, ONCOGENE, V6, P205; FROST JA, 1994, P NATL ACAD SCI USA, V91, P3844, DOI 10.1073/pnas.91.9.3844; GARDNER K, 1994, J BIOL CHEM, V269, P32963; GRUDA MC, 1994, ONCOGENE, V9, P2537; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Huang CS, 1999, J BIOL CHEM, V274, P29672, DOI 10.1074/jbc.274.42.29672; HURST HC, 1995, PROTEIN PROFILE, V2, P105; Janulis M, 2001, MOL CELL BIOL, V21, P2235, DOI 10.1128/MCB.21.6.2235-2247.2001; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kasler HG, 2000, MOL CELL BIOL, V20, P8382, DOI 10.1128/MCB.20.22.8382-8389.2000; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; L'Allemain Gilles, 1994, Progress in Growth Factor Research, V5, P291, DOI 10.1016/0955-2235(94)90011-6; Lechner C, 1996, P NATL ACAD SCI USA, V93, P4355, DOI 10.1073/pnas.93.9.4355; LEE JD, 1995, BIOCHEM BIOPH RES CO, V213, P715, DOI 10.1006/bbrc.1995.2189; Lee SK, 2000, MOL ENDOCRINOL, V14, P915, DOI 10.1210/me.14.6.915; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; MARKOWITZ RB, 1995, BIOCHEM BIOPH RES CO, V207, P1051, DOI 10.1006/bbrc.1995.1291; May GHW, 1998, J BIOL CHEM, V273, P33429, DOI 10.1074/jbc.273.50.33429; Naumann M, 1999, J BIOL CHEM, V274, P35297, DOI 10.1074/jbc.274.50.35297; Nead MA, 1998, EMBO J, V17, P2342, DOI 10.1093/emboj/17.8.2342; Peng X, 1996, J NEUROCHEM, V66, P1191; Pennypacker K R, 1995, J Fla Med Assoc, V82, P551; PETERSON SR, 1992, GENE DEV, V6, P426, DOI 10.1101/gad.6.3.426; Powers C, 1996, J BIOL CHEM, V271, P30089, DOI 10.1074/jbc.271.47.30089; Rosenberger SF, 1999, J BIOL CHEM, V274, P1124, DOI 10.1074/jbc.274.2.1124; SANGHERA JS, 1992, MOL BIOL CELL, V3, P775, DOI 10.1091/mbc.3.7.775; Watts RG, 1998, ONCOGENE, V17, P3493, DOI 10.1038/sj.onc.1202259; WATTS RG, 1995, MOL CARCINOGEN, V13, P27, DOI 10.1002/mc.2940130106; Wisdom R, 1999, EXP CELL RES, V253, P180, DOI 10.1006/excr.1999.4685; Xiao L, 2000, CANCER RES, V60, P400; Yang CC, 1998, NUCLEIC ACIDS RES, V26, P4771, DOI 10.1093/nar/26.20.4771; Young MR, 1999, P NATL ACAD SCI USA, V96, P9827, DOI 10.1073/pnas.96.17.9827; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665; ZHU AX, 1994, MOL CELL BIOL, V14, P8202, DOI 10.1128/MCB.14.12.8202	64	11	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					32362	32372		10.1074/jbc.M103677200	http://dx.doi.org/10.1074/jbc.M103677200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11431474	hybrid			2022-12-25	WOS:000170613500119
J	Perrin, MH; Fischer, WH; Kunitake, KS; Craig, AG; Koerber, SC; Cervini, LA; Rivier, JE; Groppe, JC; Greenwald, J; Nielsen, SM; Vale, WW				Perrin, MH; Fischer, WH; Kunitake, KS; Craig, AG; Koerber, SC; Cervini, LA; Rivier, JE; Groppe, JC; Greenwald, J; Nielsen, SM; Vale, WW			Expression, purification, and characterization of a soluble form of the first extracellular domain of the human type 1 corticotropin releasing factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; HIGH-AFFINITY; TERMINAL FRAGMENT; BINDING DOMAINS; XENOPUS-LAEVIS; IDENTIFICATION; UROCORTIN; CLONING; PITUITARY; SUBTYPE	The first extracellular domain (ECD-1) of the corticotropin releasing factor (CRF) type 1 receptor, (CRFR1), is important for binding of CRY ligands. A soluble protein, mNT-CRFR1, produced by COS M6 cells transfected with a cDNA encoding amino acids 1-119 of human CRFR1 and modified to include epitope tags, binds a CRF antagonist, astressin, in a radioreceptor assay using [I-125-D-Tyr(0)]astressin. N-terminal sequencing of mNT-CRFR1 showed the absence of the first 23 amino acids of human CRFR1. This result suggests that the CRFR1 protein is processed to cleave a putative signal peptide corresponding to amino acids 1-23. A cDNA encoding amino acids 24-119 followed by a FLAG tag, was expressed as a thioredoxin fusion protein in Escherichia coli. Following thrombin cleavage, the purified protein (bNT-CRFR1) binds astressin and the agonist urocortin with high affinity. Reduced, alkylated bNT-CRFR1 does not bind [I-125-D-Tyr(0)]astressin. Mass spectrometric analysis of photoaffinity labeled bNT-CRFR1 yielded a 1:1 complex with ligand. Analysis of the disulfide arrangement of bNT-CRFR1 revealed bonds between Cys(30) and Cys(54), Cys(44) and Cys(87), and Cys(68) and Cys(102). This arrangement is similar to that of the ECD-1 of the parathyroid hormone receptor (PTHR), suggesting a conserved structural motif in the N-terminal domain of this family of receptors.	Salk Inst Biol Studies, Peptide Biol Lab, Clayton Fdn, La Jolla, CA 92037 USA; Lundbeck A S, DK-2500 Valby, Denmark; Salk Inst Biol Studies, Struct Biol Lab, La Jolla, CA 92037 USA	Salk Institute; Lundbeck Corporation; Salk Institute	Perrin, MH (corresponding author), Salk Inst Biol Studies, Peptide Biol Lab, Clayton Fdn, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	perrin@salk.edu			NIDDK NIH HHS [DK 26741] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK026741] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arai M, 2001, ENDOCRINOLOGY, V142, P446, DOI 10.1210/en.142.1.446; Bale TL, 2000, NAT GENET, V24, P410, DOI 10.1038/74263; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; BOHM G, 1992, PROTEIN ENG, V5, P191, DOI 10.1093/protein/5.3.191; CAO YJ, 1995, BIOCHEM BIOPH RES CO, V212, P673, DOI 10.1006/bbrc.1995.2021; CHANG CP, 1993, NEURON, V11, P1187, DOI 10.1016/0896-6273(93)90230-O; CHEN RP, 1993, P NATL ACAD SCI USA, V90, P8967, DOI 10.1073/pnas.90.19.8967; Dautzenberg FM, 1997, J NEUROCHEM, V69, P1640; Dautzenberg FM, 1998, P NATL ACAD SCI USA, V95, P4941, DOI 10.1073/pnas.95.9.4941; Dautzenberg FM, 1999, J NEUROCHEM, V73, P821, DOI 10.1046/j.1471-4159.1999.0730821.x; Donaldson CJ, 1996, ENDOCRINOLOGY, V137, P3896, DOI 10.1210/endo.137.9.8756563; Farzan M, 2000, J BIOL CHEM, V275, P33516, DOI 10.1074/jbc.M007228200; Fischer WH, 1999, J PROTEIN CHEM, V18, P437, DOI 10.1023/A:1020640725959; Gershengorn MC, 2001, ENDOCRINOLOGY, V142, P2, DOI 10.1210/en.142.1.2; Goldsmith PK, 1999, J BIOL CHEM, V274, P11303, DOI 10.1074/jbc.274.16.11303; Grauschopf U, 2000, BIOCHEMISTRY-US, V39, P8878, DOI 10.1021/bi0001426; GULYAS J, 1995, P NATL ACAD SCI USA, V92, P10575, DOI 10.1073/pnas.92.23.10575; Hsu SY, 2001, NAT MED, V7, P605, DOI 10.1038/87936; KISHIMOTO T, 1995, P NATL ACAD SCI USA, V92, P1108, DOI 10.1073/pnas.92.4.1108; Kunishima N, 2000, NATURE, V407, P971, DOI 10.1038/35039564; Lewis K, 2001, P NATL ACAD SCI USA, V98, P7570, DOI 10.1073/pnas.121165198; Liaw CW, 1997, MOL ENDOCRINOL, V11, P980, DOI 10.1210/me.11.7.980; Liaw CW, 1997, MOL ENDOCRINOL, V11, P2048, DOI 10.1210/me.11.13.2048; LOVENBERG TW, 1995, P NATL ACAD SCI USA, V92, P836, DOI 10.1073/pnas.92.3.836; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MORODER L, 1993, BIOCHEMISTRY-US, V32, P13551, DOI 10.1021/bi00212a022; Nielsen SM, 2000, P NATL ACAD SCI USA, V97, P10277, DOI 10.1073/pnas.97.18.10277; Okamoto T, 1998, J BIOL CHEM, V273, P13089, DOI 10.1074/jbc.273.21.13089; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; PERRIN M, 1995, P NATL ACAD SCI USA, V92, P2969, DOI 10.1073/pnas.92.7.2969; Perrin MH, 1999, ANN NY ACAD SCI, V885, P312, DOI 10.1111/j.1749-6632.1999.tb08687.x; Perrin MH, 1998, ENDOCRINOLOGY, V139, P566, DOI 10.1210/en.139.2.566; PERRIN MH, 1986, ENDOCRINOLOGY, V118, P1171, DOI 10.1210/endo-118-3-1171; Perrin MH, 1999, J PHARMACOL EXP THER, V288, P729; Qi LJ, 1997, BIOCHEMISTRY-US, V36, P12442, DOI 10.1021/bi970997r; Remy JJ, 2001, J BIOL CHEM, V276, P1681, DOI 10.1074/jbc.M005206200; Reyes TM, 2001, P NATL ACAD SCI USA, V98, P2843, DOI 10.1073/pnas.051626398; Schmidt A, 2001, J BIOL CHEM, V276, P23373, DOI 10.1074/jbc.M100057200; SINGER SJ, 1990, ANNU REV CELL BIOL, V6, P247, DOI 10.1146/annurev.cb.06.110190.001335; Smith GW, 1998, NEURON, V20, P1093, DOI 10.1016/S0896-6273(00)80491-2; Spiess J, 1998, TRENDS ENDOCRIN MET, V9, P140, DOI 10.1016/S1043-2760(98)00037-X; STENZEL P, 1995, MOL ENDOCRINOL, V9, P637, DOI 10.1210/me.9.5.637; SUTTON SW, 1995, ENDOCRINOLOGY, V136, P1097, DOI 10.1210/en.136.3.1097; Sydow S, 1997, MOL BRAIN RES, V52, P182, DOI 10.1016/S0169-328X(97)00256-8; Sydow S, 1999, EUR J BIOCHEM, V259, P55, DOI 10.1046/j.1432-1327.1999.00007.x; Tsuji Y, 2000, J BIOL CHEM, V275, P28144; VAUGHAN J, 1995, NATURE, V378, P287, DOI 10.1038/378287a0; VITA N, 1993, FEBS LETT, V335, P1, DOI 10.1016/0014-5793(93)80427-V; WALLIN E, 1995, PROTEIN ENG, V8, P693, DOI 10.1093/protein/8.7.693; Wille S, 1999, J NEUROCHEM, V72, P388, DOI 10.1046/j.1471-4159.1999.0720388.x; Wilmen A, 1996, FEBS LETT, V398, P43, DOI 10.1016/S0014-5793(96)01214-8; Yu JX, 1996, ENDOCRINOLOGY, V137, P192, DOI 10.1210/en.137.1.192	52	76	84	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					31528	31534		10.1074/jbc.M101838200	http://dx.doi.org/10.1074/jbc.M101838200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11425856	hybrid			2022-12-25	WOS:000170613500010
J	Segall, L; Daly, SE; Blostein, R				Segall, L; Daly, SE; Blostein, R			Mechanistic basis for kinetic differences between the rat alpha 1, alpha 2, and alpha 3 isoforms of the Na,K-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-PUMP REGULATION; NA+-K+ PUMP; PLASMA-MEMBRANE; FUNCTIONAL CONSEQUENCES; ION-TRANSPORT; SUBUNIT; ATPASE; EXPRESSION; CELLS; NA+,K+-ATPASE	Previous studies showed that the alpha1, alpha2, and alpha3 isoforms of the catalytic subunit of the Na,K-ATPase differ in their apparent affinities for the ligands ATP, Na+, and K+. For the rat isoforms transfected into HeLa cells, K ' (ATP) for ATP binding at its low affinity site is lower for a2 and a3 compared with al; relative to al and a2, a3 has a higher K ' (Na) and lower K ' (K) (Jewell, E. A., and Lingrel, J. B (1991) J. Biol. Chem. 266, 16925-16930; Munzer, J. S., Daly, S. E., Jewell-Motz, E. A., Lingrel, J. B, and Blostein, R. (1994) J. Biol. Chem. 269, 16668-16676). The experiments described in the present study provide insight into the mechanistic basis for these differences. The results show that a2 differs from al primarily by a shift in the E-1 reversible arrow E-2 equilibrium in favor of E-1 form(s) as evidenced by (i) a similar to 20-fold increase in IC50 for vanadate, (ii) decreased catalytic turnover, and (iii) notable stability of Na,K-ATPase activity at acidic pH. In contrast, despite its lower K ' (ATP) compared with alpha (1) the E-1 <----> E-2 poise of A is not shifted toward E-1. Distinct intrinsic interactions with Na+ ions are underscored by the marked selectivity for Na+ over Li+ of alpha3 compared with either al or a2 and higher K ' (Na) for cytoplasmic Na+, which persists over a 100-fold range in proton concentration, independent of the presence of K+. The kinetic analysis also suggests alpha3-specific differences in relative rates of partial reactions, which impact this isoform's distinct apparent affinities for both Na+ and K+.	McGill Univ, Dept Biochem & Med, Montreal, PQ H3G 1A4, Canada	McGill University	Segall, L (corresponding author), Montreal Gen Hosp, 1650 Cedar Ave, Montreal, PQ H3G 1A4, Canada.							Ambesi A, 2000, J BIOL CHEM, V275, P20545, DOI 10.1074/jbc.M001682200; Balshaw DM, 2000, BIOPHYS J, V79, P853, DOI 10.1016/S0006-3495(00)76341-7; BERREBIBERTRAND I, 1994, FEBS LETT, V348, P55, DOI 10.1016/0014-5793(94)00550-8; BERREBIBERTRAND I, 1990, BIOCHIM BIOPHYS ACTA, V1021, P148, DOI 10.1016/0005-2736(90)90027-L; Blanco G, 1998, AM J PHYSIOL-RENAL, V275, pF633, DOI 10.1152/ajprenal.1998.275.5.F633; BLOSTEIN R, 1988, METHOD ENZYMOL, V156, P171; BLOSTEIN R, 1979, NA K ATPASE STRUCTUR, P233; Boxenbaum N, 1998, J BIOL CHEM, V273, P23086, DOI 10.1074/jbc.273.36.23086; Buch-Pedersen MJ, 2000, J BIOL CHEM, V275, P39167, DOI 10.1074/jbc.M007537200; CANTLEY LC, 1978, J BIOL CHEM, V253, P7361; Crambert G, 2000, J BIOL CHEM, V275, P1976, DOI 10.1074/jbc.275.3.1976; DALY SE, 1994, J BIOL CHEM, V269, P23944; Daly SE, 1997, J BIOL CHEM, V272, P6341, DOI 10.1074/jbc.272.10.6341; Daly SE, 1996, J BIOL CHEM, V271, P23683, DOI 10.1074/jbc.271.39.23683; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; DUNHAM PB, 1977, P NATL ACAD SCI USA, V74, P3099, DOI 10.1073/pnas.74.7.3099; Forbush B 3rd, 1991, Soc Gen Physiol Ser, V46, P210; GARAY RP, 1973, J PHYSIOL-LONDON, V231, P297, DOI 10.1113/jphysiol.1973.sp010234; James PF, 1999, MOL CELL, V3, P555, DOI 10.1016/S1097-2765(00)80349-4; JEWELL EA, 1992, ANN NY ACAD SCI, V671, P120, DOI 10.1111/j.1749-6632.1992.tb43790.x; JEWELL EA, 1991, J BIOL CHEM, V266, P16925; Juel C, 2000, AM J PHYSIOL-REG I, V278, pR1107, DOI 10.1152/ajpregu.2000.278.4.R1107; Kometiani P, 2001, AM J PHYSIOL-HEART C, V280, pH1415, DOI 10.1152/ajpheart.2001.280.3.H1415; LANE LK, 1993, J BIOL CHEM, V268, P17930; LINGREL JB, 1990, PROG NUCLEIC ACID RE, V38, P37; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; LUCCHESI PA, 1991, J BIOL CHEM, V266, P9327; Markwell M A, 1981, Methods Enzymol, V72, P296; MERCER RW, 1993, J CELL BIOL, V121, P579, DOI 10.1083/jcb.121.3.579; MUNZER JS, 1994, J BIOL CHEM, V269, P16668; POST RL, 1972, J BIOL CHEM, V247, P6530; SACHS JR, 1977, J PHYSIOL-LONDON, V264, P449, DOI 10.1113/jphysiol.1977.sp011677; SHANI M, 1987, BIOCHIM BIOPHYS ACTA, V904, P13, DOI 10.1016/0005-2736(87)90081-2; SWEADNER KJ, 1989, BIOCHIM BIOPHYS ACTA, V988, P185, DOI 10.1016/0304-4157(89)90019-1; Therien AG, 1999, AM J PHYSIOL-CELL PH, V277, pC891, DOI 10.1152/ajpcell.1999.277.5.C891; Therien AG, 1996, J BIOL CHEM, V271, P7104, DOI 10.1074/jbc.271.12.7104; Therien AG, 1999, J BIOL CHEM, V274, P12252, DOI 10.1074/jbc.274.18.12252; Therien AG, 2000, AM J PHYSIOL-CELL PH, V279, pC541, DOI 10.1152/ajpcell.2000.279.3.C541; Tsakiridis T, 1996, J APPL PHYSIOL, V80, P699, DOI 10.1152/jappl.1996.80.2.699; Woo AL, 2000, J BIOL CHEM, V275, P20693, DOI 10.1074/jbc.M002323200; Woo AL, 1999, J MEMBRANE BIOL, V169, P39, DOI 10.1007/PL00005899	41	45	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					31535	31541		10.1074/jbc.M103720200	http://dx.doi.org/10.1074/jbc.M103720200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11427535	hybrid			2022-12-25	WOS:000170613500011
J	Brandvold, KA; Ewert, DL; Kent, SC; Neiman, P; Ruddell, A				Brandvold, KA; Ewert, DL; Kent, SC; Neiman, P; Ruddell, A			Blocked B cell differentiation and emigration support the early growth of Myc-induced lymphomas	ONCOGENE			English	Article						Myc; lymphoma; retrovirus; B cell differentiation	AVIAN-LEUKOSIS VIRUS; C-MYC; TRANSGENIC MICE; STEM-CELLS; EXPRESSION; APOPTOSIS; FABRICIUS; BURSA; INDUCTION; PROTEIN	Avian leukosis virus induces lymphoma in chickens after proviral integration within the c-Myc gene, and subsequent expansion of Myc-overexpressing lymphocytes within transformed bursal follicles, The clonal expansion of these follicles allowed us to examine how Myc influences cell differentiation, growth, and apoptosis in lymphoid progenitors soon after the onset of Myc overexpression, Immunohistochemical analysis of developmental markers established that Myc overexpression consistently blocks lymphocyte differentiation at a late embryonic stage. Myc-transformed follicles also grow much more rapidly than normal follicles, This rapid growth is not mediated by suppression of apoptosis, as normal and Myc-transformed follicles showed similar rates of cell death by TUNEL immunohistochemical analyis of cells undergoing DNA degradation. Measurements of DNA synthesis and mitotic index showed modest effects of Myc to increase lymphocyte proliferation, as normal lymphocytes already divide rapidly. The major mechanism mediating rapid growth of transformed follicles instead involved failure of myc-overexpressing lymphocytes to emigrate from transformed follicles, while normal lymphocytes actively emigrate after hatching, as measured by BrdU pulse-chase labeling and immunohistochemical measurements. This failure to undergo the normal program of differentiation and subsequent bursal retention of lymphocytes accounts for most of the growth of transformed follicles, while Myc-induced proliferation makes a smaller contribution.	Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA; Wistar Inst Anat & Biol, Philadelphia, PA USA; Harvard Univ, Brigham & Womens Hosp, Inst Med, Ctr Neurol Dis, Boston, MA 02115 USA; Univ Washington, Dept Med, Washington, DC USA; Univ Washington, Dept Pathol, Seattle, WA 98195 USA	Fred Hutchinson Cancer Center; The Wistar Institute; Harvard University; Brigham & Women's Hospital; University of Washington; University of Washington; University of Washington Seattle	Ruddell, A (corresponding author), Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave N,Mailstop C2-023,POB 19024, Seattle, WA 98109 USA.			Ruddell, Alanna/0000-0002-0195-5576	NCI NIH HHS [R01 CA20068, R01 CA68328] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA020068, R01CA068328] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Blyth K, 2000, ONCOGENE, V19, P773, DOI 10.1038/sj.onc.1203321; Brabletz T, 2000, AM J PATHOL, V156, P865, DOI 10.1016/S0002-9440(10)64955-3; Brandvold KA, 2000, ONCOGENE, V19, P2780, DOI 10.1038/sj.onc.1203589; COOPER MD, 1968, JNCI-J NATL CANCER I, V41, P373; EWERT DL, 1988, ADV VET SCI COMP MED, V32, P37; Felsher DW, 1999, MOL CELL, V4, P199, DOI 10.1016/S1097-2765(00)80367-6; Felsher DW, 1999, P NATL ACAD SCI USA, V96, P3940, DOI 10.1073/pnas.96.7.3940; Flenghi L, 1996, AM J PATHOL, V148, P1543; Gandarillas A, 1997, GENE DEV, V11, P2869, DOI 10.1101/gad.11.21.2869; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Gong M, 1998, J VIROL, V72, P5517, DOI 10.1128/JVI.72.7.5517-5525.1998; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; HENRIKSSON M, 1996, ADV CANCER RES, V68, P110; Hermeking H, 2000, P NATL ACAD SCI USA, V97, P2229, DOI 10.1073/pnas.050586197; Iritani BM, 1999, P NATL ACAD SCI USA, V96, P13180, DOI 10.1073/pnas.96.23.13180; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; Johnston LA, 1999, CELL, V98, P779, DOI 10.1016/S0092-8674(00)81512-3; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; MAAS HJL, 1982, AVIAN PATHOL, V11, P309, DOI 10.1080/03079458208436103; MASTELLER EL, 1995, DEVELOPMENT, V121, P1657; MASTELLER EL, 1995, J IMMUNOL, V155, P5550; NATH P, 1987, EXP CELL RES, V169, P215, DOI 10.1016/0014-4827(87)90239-4; NEIMAN PE, 1991, P NATL ACAD SCI USA, V88, P5857, DOI 10.1073/pnas.88.13.5857; NEIMAN PE, 1988, CURR TOP MICROBIOL, V141, P67; NEIMAN PE, 1994, COLD SPRING HARB SYM, V59, P509, DOI 10.1101/SQB.1994.059.01.056; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Ngo CV, 2000, CELL GROWTH DIFFER, V11, P201; OLSON WC, 1990, HYBRIDOMA, V9, P331, DOI 10.1089/hyb.1990.9.331; PARAMITHIOTIS E, 1995, J EXP MED, V181, P105, DOI 10.1084/jem.181.1.105; PARAMITHIOTIS E, 1994, EUR J IMMUNOL, V24, P458, DOI 10.1002/eji.1830240229; Pelengaris S, 1999, MOL CELL, V3, P565, DOI 10.1016/S1097-2765(00)80350-0; Prasad VS, 1997, MOL CARCINOGEN, V18, P66, DOI 10.1002/(SICI)1098-2744(199702)18:2<66::AID-MC2>3.0.CO;2-O; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; RATCLIFFE MJH, 1985, IMMUNOL TODAY, V6, P223, DOI 10.1016/0167-5699(85)90039-8; Schmidt EV, 1999, ONCOGENE, V18, P2988, DOI 10.1038/sj.onc.1202751; SCHOENWOLF GC, 1981, J MORPHOL, V167, P35, DOI 10.1002/jmor.1051670104; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	38	14	15	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 31	2001	20	25					3226	3234		10.1038/sj.onc.1204431	http://dx.doi.org/10.1038/sj.onc.1204431			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	440ET	11423972				2022-12-25	WOS:000169163500006
J	Friedrich, K; Wieder, T; Von Haefen, C; Radetzki, S; Janicke, R; Schulze-Osthoff, K; Dorken, B; Daniel, PT				Friedrich, K; Wieder, T; Von Haefen, C; Radetzki, S; Janicke, R; Schulze-Osthoff, K; Dorken, B; Daniel, PT			Overexpression of caspase-3 restores sensitivity for drug-induced apoptosis in breast cancer cell lines with acquired drug resistance	ONCOGENE			English	Article						caspase-3; chemotherapeutics; apoptosis; drug resistance; MCF-7 cells	GENE BAX-ALPHA; CYTOCHROME-C; THYMOCYTE APOPTOSIS; PROTEASE ACTIVITY; ANTICANCER DRUGS; TUMOR-GROWTH; HL-60 CELLS; IN-VIVO; DEATH; EXPRESSION	In this study, we asked whether overexpression of caspase-3, a central downstream executioner of apoptotic pathways, might sensitize breast cancer cells with acquired drug resistance (MT1/ADR) to drug-induced apoptosis, As control, we employed caspase-3 negative and caspase-3-transfected MCF-7 cells, Whereas mock-transfected MCF-7 cells were resistent to epirubicin, etoposide and paclitaxel (taxol), the same drugs led to breakdown of nuclear DNA in caspase-3-transfected MCF-7 cells, MT1/ADR cells express low levels of wild type caspase-3 but show defective caspase activation and apoptosis upon drug exposure. These cells also display a Less efficient activation of the mitochondrial permeability transition. Caspase-3-transfected MT1/ADR clones showed a 2.8-fold increase in the protein level and a 3.7-fold higher specific enzyme activity. Procaspase-3 overexpression was not toxic and did not affect background apoptosis, Interestingly, procaspase-3-transfected MT1/ADR cells were more sensitive to cytotoxic drags as compared with vector-transfected controls and DNA fragmentation nearly reached the levels of the original drug sensitive MT1 cells. Thus, overexpression of caspase-3 enhances chemosensitivity especially in situations where activation of the mitochondrial apoptosome is disturbed.	Humboldt Univ, Med Ctr Charite, Dept Hematol Oncol & Tumor Immunol, D-13125 Berlin, Germany; Univ Munster, Dept Immunol & Cell Biol, D-48149 Munster, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Munster	Daniel, PT (corresponding author), Humboldt Univ, Med Ctr Charite, Dept Hematol Oncol & Tumor Immunol, Lindenberger Weg 80,Campus Berlin Buch, D-13125 Berlin, Germany.		Schulze-Osthoff, Klaus/N-9025-2013	Schulze-Osthoff, Klaus/0000-0003-1443-2720				Bargou RC, 1996, J CLIN INVEST, V97, P2651, DOI 10.1172/JCI118715; BARGOU RC, 1995, INT J CANCER, V60, P854, DOI 10.1002/ijc.2910600622; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; COSSET FL, 1995, J VIROL, V69, P7430, DOI 10.1128/JVI.69.12.7430-7436.1995; Daniel PT, 1999, BLOOD, V94, P1100, DOI 10.1182/blood.V94.3.1100.415a16_1100_1107; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; Essmann F, 2000, BIOCHEM J, V346, P777, DOI 10.1042/0264-6021:3460777; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; Hannun YA, 1997, BLOOD, V89, P1845, DOI 10.1182/blood.V89.6.1845; Hiwasa T, 1998, ANTI-CANCER DRUG, V9, P82, DOI 10.1097/00001813-199801000-00010; Ibrado AM, 1996, CELL GROWTH DIFFER, V7, P1087; Ibrado AM, 1996, CANCER RES, V56, P4743; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Janicke RU, 1998, J BIOL CHEM, V273, P15540, DOI 10.1074/jbc.273.25.15540; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KRAJEWSKI S, 1995, CANCER RES, V55, P4471; KRAMMER PH, 1994, CURR OPIN IMMUNOL, V6, P279, DOI 10.1016/0952-7915(94)90102-3; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; LOTEM J, 1993, CELL GROWTH DIFFER, V4, P41; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MILLER AD, 1989, BIOTECHNIQUES, V7, P984; MILLER AD, 1989, BIOTECHNIQUES, V7, P989; MIYASHITA T, 1993, BLOOD, V81, P151; NAUNDORF H, 1992, BREAST CANCER RES TR, V23, P87, DOI 10.1007/BF01831480; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Perkins C, 1998, CANCER RES, V58, P4561; Prokop A, 2000, LEUKEMIA, V14, P1606, DOI 10.1038/sj.leu.2401866; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Slee EA, 2000, CELL DEATH DIFFER, V7, P556, DOI 10.1038/sj.cdd.4400689; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Stein U, 1997, INT J CANCER, V72, P885, DOI 10.1002/(SICI)1097-0215(19970904)72:5<885::AID-IJC28>3.0.CO;2-6; Sturm I, 2000, INT J CANCER, V87, P517, DOI 10.1002/1097-0215(20000815)87:4<517::AID-IJC9>3.0.CO;2-B; Sturm I, 1999, J CLIN ONCOL, V17, P1364, DOI 10.1200/JCO.1999.17.5.1364; Suzuki A, 1998, EUR J PHARMACOL, V343, P87, DOI 10.1016/S0014-2999(97)01520-3; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Uckert W, 1998, HUM GENE THER, V9, P2619, DOI 10.1089/10430349850019454; Wagener C, 1996, INT J CANCER, V67, P138, DOI 10.1002/(SICI)1097-0215(19960703)67:1<138::AID-IJC22>3.0.CO;2-9; Wesselborg S, 1999, BLOOD, V93, P3053, DOI 10.1182/blood.V93.9.3053; Wieder T, 1998, J BIOL CHEM, V273, P11025, DOI 10.1074/jbc.273.18.11025; WIEDER T, 1994, FEBS LETT, V345, P207, DOI 10.1016/0014-5793(94)00433-1; Wieder T, 2001, BLOOD, V97, P1378, DOI 10.1182/blood.V97.5.1378; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	48	105	115	0	7	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 17	2001	20	22					2749	2760		10.1038/sj.onc.1204342	http://dx.doi.org/10.1038/sj.onc.1204342			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	432TP	11420687				2022-12-25	WOS:000168712000003
J	Tobias, ES; Hurlstone, AFL; MacKenzie, E; McFarlane, R; Black, DM				Tobias, ES; Hurlstone, AFL; MacKenzie, E; McFarlane, R; Black, DM			The TES gene at 7q31,1 is methylated in tumours and encodes a novel growth-suppressing LIM domain protein	ONCOGENE			English	Article						LIM domain; TSG; methylation; chromosome 7	HUMAN GASTRIC CARCINOMAS; PRIMARY BREAST-CANCER; FREQUENT LOSS; LONG ARM; PROMOTER HYPERMETHYLATION; OVARIAN CARCINOMAS; CHROMOSOME 7Q; SQUAMOUS-CELL; ALLELIC LOSS; HETEROZYGOSITY	Many studies suggest that a multi-tissue tumour suppressor gene is located at human chromosome 7q31.1, We have cloned and characterized a novel gene at this locus. The TES gene lies within the minimal region of overlap of several LOH studies and appears to possess the properties of a tumour suppressor. TES is widely expressed and is predicted to encode a protein of 421 amino acids, with three C-terminal LIM domains. Mutation analysis of the coding TES exons in 21 human tumour-derived cell lines revealed the presence of a frameshift mutation in one allele in the breast cancer cell line ZR-75, Methylation of the CpG island at the 5 ' end of TES appears to be a remarkably frequent finding, occurring in seven out of 10 ovarian carcinomas and in each of the 30 tumour-derived cell lines tested, Moreover, forced expression of TES in HeLa or OVCAR5 cells, resulted in a profound reduction in growth potential, as determined by the colony formation assay. We believe that TES is a tumour suppressor gene that is inactivated primarily by transcriptional silencing resulting from CpG island methylation.	Beatson Inst Canc Res, CRC, Beatson Labs, Glasgow G61 1BD, Lanark, Scotland; Univ Utrecht Hosp, Dept Immunol, NL-3584 CX Utrecht, Netherlands	Beatson Institute; Utrecht University; Utrecht University Medical Center	Black, DM (corresponding author), Beatson Inst Canc Res, CRC, Beatson Labs, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.		Tobias, Edward/D-4246-2009	Tobias, Edward/0000-0003-2649-7695; Hurlstone, Adam/0000-0001-5260-9457				Achille A, 1996, CANCER RES, V56, P3808; ATKIN NB, 1993, CANCER GENET CYTOGEN, V67, P123, DOI 10.1016/0165-4608(93)90164-H; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; BIECHE I, 1992, LANCET, V339, P139, DOI 10.1016/0140-6736(92)90208-K; Costanzi-Strauss E, 1998, EXP CELL RES, V238, P51, DOI 10.1006/excr.1997.3810; DIVECHA N, 1995, GENE, V156, P283, DOI 10.1016/0378-1119(95)00088-N; Dreyer SD, 1998, NAT GENET, V19, P47, DOI 10.1038/ng0598-47; Edelson MI, 1997, ONCOGENE, V14, P2979, DOI 10.1038/sj.onc.1201271; Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564; Fleisher AS, 1999, CANCER RES, V59, P1090; HERMAN JG, 1995, CANCER RES, V55, P4525; Hobert O, 2000, TRENDS GENET, V16, P75, DOI 10.1016/S0168-9525(99)01883-1; Hobert O, 1996, ONCOGENE, V12, P1577; Hurlstone AFL, 1999, ONCOGENE, V18, P1881, DOI 10.1038/sj.onc.1202491; Kerr J, 1996, ONCOGENE, V13, P1815; Koike M, 1997, GENE CHROMOSOME CANC, V19, P1, DOI 10.1002/(SICI)1098-2264(199705)19:1<1::AID-GCC1>3.0.CO;2-3; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; KUNIYASU H, 1994, INT J CANCER, V59, P597, DOI 10.1002/ijc.2910590504; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; Maniatis T, MOL CLONING LAB MANU; Matsuya M, 1998, J BIOL CHEM, V273, P1003, DOI 10.1074/jbc.273.2.1003; Murthy KK, 1999, J BIOL CHEM, V274, P20679, DOI 10.1074/jbc.274.29.20679; Nishiya N, 1998, NUCLEIC ACIDS RES, V26, P4267, DOI 10.1093/nar/26.18.4267; OGATA T, 1993, MOL CELL BIOL, V13, P6036, DOI 10.1128/MCB.13.10.6036; PEDERSEN B, 1994, CANCER GENET CYTOGEN, V78, P181, DOI 10.1016/0165-4608(94)90088-4; PEREZALVARADO GC, 1994, NAT STRUCT BIOL, V1, P388, DOI 10.1038/nsb0694-388; SCHMEICHEL KL, 1994, CELL, V79, P211, DOI 10.1016/0092-8674(94)90191-0; Shibanuma M, 1997, MOL CELL BIOL, V17, P1224, DOI 10.1128/MCB.17.3.1224; SHIBANUMA M, 1994, J BIOL CHEM, V269, P26767; Shridhar V, 1997, ONCOGENE, V15, P2727, DOI 10.1038/sj.onc.1201448; Tamura G, 2000, J NATL CANCER I, V92, P569, DOI 10.1093/jnci/92.7.569; Veigl ML, 1998, P NATL ACAD SCI USA, V95, P8698, DOI 10.1073/pnas.95.15.8698; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; WU RY, 1994, J BIOL CHEM, V269, P25085; Wu RY, 1996, J BIOL CHEM, V271, P15934, DOI 10.1074/jbc.271.27.15934; ZENKLUSEN JC, 1994, ONCOGENE, V9, P2817; Zenklusen JC, 1996, MOL CARCINOGEN, V15, P167; ZENKLUSEN JC, 1995, ONCOGENE, V11, P359; ZENKLUSEN JC, 1994, CANCER RES, V54, P6370; ZENKLUSEN JC, 1994, P NATL ACAD SCI USA, V91, P12155, DOI 10.1073/pnas.91.25.12155; ZENKLUSEN JC, 1995, CANCER RES, V55, P1347; Zenklusen JC, 1996, GENOME RES, V6, P1070, DOI 10.1101/gr.6.11.1070	43	81	89	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 17	2001	20	22					2844	2853		10.1038/sj.onc.1204433	http://dx.doi.org/10.1038/sj.onc.1204433			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	432TP	11420696	Bronze			2022-12-25	WOS:000168712000012
J	Hohenstein, P; Kielman, MF; Breukel, C; Bennett, LM; Wiseman, R; Krimpenfort, P; Cornelisse, G; van Ommen, GJ; Devilee, P; Fodde, R				Hohenstein, P; Kielman, MF; Breukel, C; Bennett, LM; Wiseman, R; Krimpenfort, P; Cornelisse, G; van Ommen, GJ; Devilee, P; Fodde, R			A targeted mouse Brca1 mutation removing the last BRCT repeat results in apoptosis and embryonic lethality at the headfold stage	ONCOGENE			English	Article						Brca1(1700T); mouse model; hereditary breast cancer; p53; genotype-phenotype correlation; DNA damage	DNA-DAMAGE; BREAST-CANCER; TRANSCRIPTIONAL ACTIVATION; GENETIC INSTABILITY; TUMOR SPECTRUM; MEIOTIC CELLS; MODEL; EXPRESSION; REPAIR; MICE	A mouse model with a targeted mutation in the 3' end of the endogenous Brca1 gene, Brca1(1700T), was generated to compare the phenotypic consequences of truncated SI cal proteins with other mutant Brca1 models reported in the literature to date. Mice heterozygous for the Brca1(1700T) mutation do not show any predisposition to tumorigenesis, Treatment of these mice with ionizing radiation or breeding with Ape, Msh-2 or Tp53 mutant mouse models did not show any change in the tumor phenotype, Like other Brca1 mouse models, the Brca1(1700T) mutation is embryonic lethal in homozygous state, However, homozygous Brca1(1700T) embryos reach the headfold stage but are delayed in their development and fail to turn. Thus, in contrast to Brca1(null) models, the mutant embryos do not undergo growth arrest leading to a developmental block at 6.5 dpc, but continue to proliferate and differentiate until 9.5 dpc. Homozygous embryos die between 9.5-10.5 dpc due to massive apoptosis throughout the embryo. These results indicate that a C-terminal truncating Brca1 mutation removing the last BRCT repeat has a different effect on normal cell function than does the complete absence of Brca1.	Leiden Univ, Med Ctr, Dept Human & Clin Genet, NL-2300 RA Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Pathol, NL-2300 RA Leiden, Netherlands; NIEHS, Res Triangle Pk, NC 27709 USA; Netherlands Canc Inst, Div Mol Genet, NL-1066 CX Amsterdam, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Netherlands Cancer Institute	Fodde, R (corresponding author), Leiden Univ, Med Ctr, Dept Human & Clin Genet, POB 9503, NL-2300 RA Leiden, Netherlands.		Fodde, Riccardo/AAW-9394-2021; DEVILEE, PETER/ABR-2140-2022; Hohenstein, Peter/Y-2428-2018	Fodde, Riccardo/0000-0001-9839-4324; Hohenstein, Peter/0000-0001-8548-4734	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES023000] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BENNETT LM, 1995, GENOMICS, V29, P576, DOI 10.1006/geno.1995.9963; Blaszyk H, 2000, INT J CANCER, V89, P32, DOI 10.1002/(SICI)1097-0215(20000120)89:1<32::AID-IJC6>3.0.CO;2-G; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Chandler J, 2001, GENESIS, V29, P72, DOI 10.1002/1526-968X(200102)29:2<72::AID-GENE1007>3.0.CO;2-B; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen JJ, 1998, MOL CELL, V2, P317, DOI 10.1016/S1097-2765(00)80276-2; FODDE R, 1994, P NATL ACAD SCI USA, V91, P8969, DOI 10.1073/pnas.91.19.8969; GAYTHER SA, 1995, NAT GENET, V11, P428, DOI 10.1038/ng1295-428; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Grade K, 1997, J CANCER RES CLIN, V123, P69, DOI 10.1007/BF01212618; Hakem R, 1997, NAT GENET, V16, P298, DOI 10.1038/ng0797-298; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; SAH VP, 1995, NAT GENET, V10, P175, DOI 10.1038/ng0695-175; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Shen SX, 1998, ONCOGENE, V17, P3115, DOI 10.1038/sj.onc.1202243; Smits R, 2000, GENE CHROMOSOME CANC, V29, P229, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1033>3.0.CO;2-R; Smits R, 1998, GASTROENTEROLOGY, V114, P275, DOI 10.1016/S0016-5085(98)70478-0; Smits R, 1999, GENE DEV, V13, P1309, DOI 10.1101/gad.13.10.1309; Sobol A, 1996, CANCER RES, V56, P3216; Sobol H, 1997, INT J ONCOL, V10, P349; Thakur S, 1997, MOL CELL BIOL, V17, P444, DOI 10.1128/MCB.17.1.444; van Oordt CWVH, 1999, GENE CHROMOSOME CANC, V24, P191; vanOordt CWV, 1997, CARCINOGENESIS, V18, P2197, DOI 10.1093/carcin/18.11.2197; Wang Y, 2000, GENE DEV, V14, P927; WILKINSON DG, 1990, NATURE, V343, P657, DOI 10.1038/343657a0; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; Wilson CA, 1997, ONCOGENE, V14, P1, DOI 10.1038/sj.onc.1200924; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Yu VPCC, 2000, GENE DEV, V14, P1400; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	43	46	47	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 3	2001	20	20					2544	2550		10.1038/sj.onc.1204363	http://dx.doi.org/10.1038/sj.onc.1204363			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	431VM	11420664				2022-12-25	WOS:000168652500005
J	Lozano, RM; Redondo-Horcajo, M; Jimenez, MA; Zilberberg, L; Cuevas, P; Bikfalvi, A; Rico, M; Gimenez-Gallego, G				Lozano, RM; Redondo-Horcajo, M; Jimenez, MA; Zilberberg, L; Cuevas, P; Bikfalvi, A; Rico, M; Gimenez-Gallego, G			Solution structure and interaction with basic and acidic fibroblast growth factor of a 3-kDa human platelet factor-4 fragment with antiangiogenic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; IN-VITRO ANGIOGENESIS; CHEMICAL-SHIFTS; FACTOR-IV; CRYSTAL-STRUCTURE; BIOLOGICAL MACROMOLECULES; SECONDARY STRUCTURE; COUPLING-CONSTANTS; ENDOTHELIAL-CELL; MURINE MELANOMA	Platelet factor-4 is a protein belonging to the family of ELR-negative CXC chemokines which binds to fibroblast growth factor and inhibits its mitogenic activity. Platelet factor-4 also inhibits tumor growth by mechanisms involving antiangiogenesis. Antiangiogenic activity in vitro has also been shown for the 24-residue C-terminal fragment of the protein, which decreases the affinity between basic fibroblast growth factor and its cell-surface receptor. In this study, the preferential conformation of this fragment in solution has been determined and has been found to be composed of two helical subdomains. In addition, we show that the fragment forms a specific 1:1 complex with acidic and basic fibroblast growth factors and that both subdomains are probably required for inhibition of fibroblast growth factor-driven mitogenesis. Finally, we show that the binding of the fragment alters the structure of the fibroblast growth factors, although some of such alterations do not seem related with the inhibition of mitogenic activity. Since this fragment has recently been shown to inhibit fibroblast growth factor-induced angiogenesis in vivo when injected intraperitoneally, these results are relevant for developing new antiangiogenic treatments.	CSIC, Ctr Invest Biol, E-28006 Madrid, Spain; CSIC, Inst Estructura Mat, E-28006 Madrid, Spain; Univ Bordeaux, Growth Factor & Cell Differentiat Lab, F-33405 Talence, France; Univ Madrid, Hosp Ramon y Cajal, Serv Histol, Madrid 28034, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Estructura de la Materia (IEM); UDICE-French Research Universities; Universite de Bordeaux; Hospital Universitario Ramon y Cajal	Gimenez-Gallego, G (corresponding author), CSIC, Ctr Invest Biol, Velazquez 144, E-28006 Madrid, Spain.		Jimenez, M. Angeles/C-7193-2008	Jimenez, M. Angeles/0000-0001-6835-5850; Lozano, Rosa Maria/0000-0003-2762-6938				ABRAHAM JA, 1986, EMBO J, V5, P2523, DOI 10.1002/j.1460-2075.1986.tb04530.x; ARAKAWA T, 1993, PROTEIN ENG, V6, P541, DOI 10.1093/protein/6.5.541; AUE WP, 1976, J CHEM PHYS, V64, P2229, DOI 10.1063/1.432450; BAIRD A, 1990, HDB EXPT PHARM, V95, P369; BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; Bikfalvi A, 1997, ENDOCR REV, V18, P26, DOI 10.1210/er.18.1.26; Blaber M, 1996, BIOCHEMISTRY-US, V35, P2086, DOI 10.1021/bi9521755; BLANCO FJ, 1993, J AM CHEM SOC, V115, P5887, DOI 10.1021/ja00066a092; BODENHAUSEN G, 1980, CHEM PHYS LETT, V69, P185, DOI 10.1016/0009-2614(80)80041-8; BROWN KJ, 1994, BIOCHEMISTRY-US, V33, P13918, DOI 10.1021/bi00250a047; CASE DA, 1994, METHOD ENZYMOL, V239, P392; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; COPELAND RA, 1991, ARCH BIOCHEM BIOPHYS, V289, P53, DOI 10.1016/0003-9861(91)90441-K; Coulier F, 1997, J MOL EVOL, V44, P43, DOI 10.1007/PL00006120; Cuevas P, 1997, GROWTH FACTORS, V15, P29, DOI 10.3109/08977199709002110; Culajay JF, 2000, BIOCHEMISTRY-US, V39, P7153, DOI 10.1021/bi9927742; DEUEL TF, 1977, P NATL ACAD SCI USA, V74, P2256, DOI 10.1073/pnas.74.6.2256; DIDONATO A, 1993, ANAL BIOCHEM, V212, P291, DOI 10.1006/abio.1993.1328; Ferrara N, 1999, J MOL MED, V77, P527, DOI 10.1007/s001099900019; GIMENEZGALLEGO G, 1986, BIOCHEM BIOPH RES CO, V138, P611, DOI 10.1016/S0006-291X(86)80540-X; GIMENEZGALLEGO G, 1986, BIOCHEM BIOPH RES CO, V135, P541, DOI 10.1016/0006-291X(86)90028-8; GIMENEZGALLEGO G, 1994, NEUROL RES, V16, P313; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; GUNTERT P, 1991, J MOL BIOL, V217, P517, DOI 10.1016/0022-2836(91)90754-T; GUPTA SK, 1994, J CELL BIOL, V127, P1121, DOI 10.1083/jcb.127.4.1121; GUPTA SK, 1995, P NATL ACAD SCI USA, V92, P7799, DOI 10.1073/pnas.92.17.7799; Hagedorn M, 2001, FASEB J, V15, P550; HANSELL P, 1995, AM J PHYSIOL, V269, P829; HUTCHINSON EG, 1994, PROTEIN SCI, V3, P2207, DOI 10.1002/pro.5560031206; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; JIMENEZ MA, 1994, J MOL BIOL, V242, P487; Jonca F, 1997, J BIOL CHEM, V272, P24203, DOI 10.1074/jbc.272.39.24203; Jouan V, 1999, BLOOD, V94, P984, DOI 10.1182/blood.V94.3.984.415k31_984_993; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KOLBER DL, 1995, J NATL CANCER I, V87, P304, DOI 10.1093/jnci/87.4.304; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; Laue T.M., 1992, ANAL ULTRACENTRIFUGA; LOSCALZO J, 1985, ARCH BIOCHEM BIOPHYS, V240, P446, DOI 10.1016/0003-9861(85)90049-9; Lozano RM, 1998, J MOL BIOL, V281, P899, DOI 10.1006/jmbi.1998.1977; Lozano RM, 2000, BIOCHEMISTRY-US, V39, P4982, DOI 10.1021/bi992544n; MAIONE TE, 1991, CANCER RES, V51, P2077; MAIONE TE, 1990, SCIENCE, V247, P77, DOI 10.1126/science.1688470; Mandriota SJ, 1997, J CELL SCI, V110, P2293; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; MARION D, 1989, BIOCHEMISTRY-US, V28, P6150, DOI 10.1021/bi00441a004; MATOUSCHEK A, 1992, J MOL BIOL, V224, P819, DOI 10.1016/0022-2836(92)90564-Z; MINTON AP, 1994, MODERN ANAL ULTRACEN; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; Munoz V, 1997, BIOPOLYMERS, V41, P495, DOI 10.1002/(SICI)1097-0282(19970415)41:5<495::AID-BIP2>3.3.CO;2-6; MUNOZ V, 1995, NAT STRUCT BIOL, V2, P380, DOI 10.1038/nsb0595-380; NIEWIAROWSKI S, 1976, LAB CLIN MED, V87, P720; Nishimura T, 1999, BBA-GENE STRUCT EXPR, V1444, P148, DOI 10.1016/S0167-4781(98)00255-3; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; ORTEGA S, 1991, J BIOL CHEM, V266, P5842; Pace C N, 1986, Methods Enzymol, V131, P266; Pellegrini L, 2000, NATURE, V407, P1029, DOI 10.1038/35039551; Perollet C, 1998, BLOOD, V91, P3289, DOI 10.1182/blood.V91.9.3289.3289_3289_3299; PESSEN H, 1985, METHOD ENZYMOL, V117, P219; Philo JS, 1997, BIOPHYS J, V72, P435, DOI 10.1016/S0006-3495(97)78684-3; PinedaLucena A, 1996, J MOL BIOL, V264, P162, DOI 10.1006/jmbi.1996.0631; PINEDALUCENA A, 1994, J MOL BIOL, V242, P81, DOI 10.1006/jmbi.1994.1558; PINEDALUCENA A, 1994, EUR J BIOCHEM, V222, P425, DOI 10.1111/j.1432-1033.1994.tb18881.x; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Romero A, 1996, EUR J BIOCHEM, V241, P453, DOI 10.1111/j.1432-1033.1996.00453.x; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; SHARPE RJ, 1990, JNCI-J NATL CANCER I, V82, P848, DOI 10.1093/jnci/82.10.848; SONNICHSEN FD, 1992, BIOCHEMISTRY-US, V31, P8790, DOI 10.1021/bi00152a015; STAFFORD WF, 1978, BIOCHEMISTRY-US, V17, P607, DOI 10.1021/bi00597a008; SZILAGYI L, 1995, PROG NUCL MAG RES SP, V27, P325, DOI 10.1016/0079-6565(95)01011-2; Tanaka T, 1997, NAT MED, V3, P437, DOI 10.1038/nm0497-437; TANFORD C, 1974, BIOCHEMISTRY-US, V13, P2369, DOI 10.1021/bi00708a021; THOMAS KA, 1986, TRENDS BIOCHEM SCI, V11, P1; VANHOLDE KE, 1986, PHYSICAL BIOCH; VOLKIN DB, 1993, ARCH BIOCHEM BIOPHYS, V300, P30, DOI 10.1006/abbi.1993.1005; WATSON JB, 1994, J CLIN INVEST, V94, P261, DOI 10.1172/JCI117316; WAXMAN E, 1993, BIOCHEMISTRY-US, V32, P3005, DOI 10.1021/bi00063a011; WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777; WISHART DS, 1994, METHOD ENZYMOL, V239, P363; WISHART DS, 1995, J BIOMOL NMR, V5, P67, DOI 10.1007/BF00227471; WUTHRICH K, 1984, J MOL BIOL, V180, P715, DOI 10.1016/0022-2836(84)90034-2; Wuthrich K, 1986, NMR PROTEINS NUCL AC; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; ZAZO M, 1992, GENE, V113, P231, DOI 10.1016/0378-1119(92)90400-J; ZHANG XH, 1994, BIOCHEMISTRY-US, V33, P8361, DOI 10.1021/bi00193a025; ZHU X, 1991, SCIENCE, V251, P90, DOI 10.1126/science.1702556	86	32	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35723	35734		10.1074/jbc.M101565200	http://dx.doi.org/10.1074/jbc.M101565200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11423536	Green Published, hybrid			2022-12-25	WOS:000171109300069
J	Demmers, JAA; van Duijn, E; Haverkamp, J; Greathouse, DV; Koeppe, RE; Heck, AJR; Killian, JA				Demmers, JAA; van Duijn, E; Haverkamp, J; Greathouse, DV; Koeppe, RE; Heck, AJR; Killian, JA			Interfacial positioning and stability of transmembrane peptides in lipid bilayers studied by combining hydrogen/deuterium exchange and mass spectrometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-HELICAL PEPTIDES; MEMBRANE-PROTEINS; HYDROPHOBIC MISMATCH; CHAIN-LENGTH; GRAMICIDIN-A; TRYPTOPHAN; RESIDUES; PHOSPHOLIPIDS; ASSOCIATION; THICKNESS	Nano-electrospray ionization mass spectrometry (ESI-MS) was used to analyze hydrogen/deuterium (RID) exchange properties of transmembrane peptides with varying length and composition. Synthetic transmembrane peptides were used with a general acetyl-GW(2)(LA)(n)LW(2)A-ethanolamine sequence. These peptides were incorporated in large unilamellar vesicles of 1,2-dimyristoyl-sn-glycero-3-phosphocholine. The vesicles were diluted in buffered deuterium oxide, and the H/D exchange after different incubation times was directly analyzed by means of ESI-MS. First, the influence of the length of the hydrophobic Leu.-Ala sequence on exchange behavior was investigated. It was shown that longer peptide analogs are more protected from H/D exchange than expected on the basis of their length with respect to bilayer thickness. This is explained by an increased protection from the bilayer environment, be. cause of stretching of the lipid acyl chains and/or tilting of the longer peptides. Next, the role of the flanking tryptophan residues was investigated. The length of the transmembrane part that shows very slow H/D exchange was found to depend on the exact position of the tryptophans in the peptide sequence, suggesting that tryptophan acts as a strong determinant for positioning of proteins at the membrane/water interface. Finally, the influence of putative helix breakers was studied. It was shown that the presence of Pro in the transmembrane segment results in much higher exchange rates as compared with Gly or Leu, suggesting a destabilization of the alpha -helix. Tandem MS measurements suggested that the increased exchange takes place over the entire transmembrane segment. The results show that ESI-MS is a convenient technique to gain detailed insight into properties of peptides in lipid bilayers by monitoring H/D exchange kinetics.	Univ Utrecht, Ctr Biomembranes & Lipid Enzymol, Biomembrane Inst, Dept Biochem Membranes, NL-3584 CH Utrecht, Netherlands; Univ Utrecht, Bijvoet Ctr Biomol Res, Dept Biomol Mass Spect, NL-3584 CA Utrecht, Netherlands; Univ Utrecht, Utrecht Inst Pharmaceut Sci, NL-3584 CA Utrecht, Netherlands; Univ Arkansas, Dept Chem & Biochem, Fayetteville, AR 72701 USA	Utrecht University; Utrecht University; Utrecht University; University of Arkansas System; University of Arkansas Fayetteville	Killian, JA (corresponding author), Univ Utrecht, Ctr Biomembranes & Lipid Enzymol, Biomembrane Inst, Dept Biochem Membranes, Padualaan 8, NL-3584 CH Utrecht, Netherlands.		Heck, Albert/D-7098-2011; Killian, J. Antoinette/I-3001-2016; Demmers, Jeroen AA/F-4046-2016	Heck, Albert/0000-0002-2405-4404; Demmers, Jeroen AA/0000-0002-8757-9611; Koeppe, Roger/0000-0003-0676-6413; Killian, J. Antoinette/0000-0001-8010-3816	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034968] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-34968] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLUME A, 1983, BIOCHEMISTRY-US, V22, P5436, DOI 10.1021/bi00292a027; Braun P, 1999, BIOCHEMISTRY-US, V38, P9778, DOI 10.1021/bi990923a; de Planque MRR, 1999, J BIOL CHEM, V274, P20839, DOI 10.1074/jbc.274.30.20839; de Planque MRR, 1998, BIOCHEMISTRY-US, V37, P9333, DOI 10.1021/bi980233r; de Planque MRR, 2001, BIOCHEMISTRY-US, V40, P5000, DOI 10.1021/bi000804r; Demmers JAA, 2000, P NATL ACAD SCI USA, V97, P3189, DOI 10.1073/pnas.050444797; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Eilers M, 2000, P NATL ACAD SCI USA, V97, P5796, DOI 10.1073/pnas.97.11.5796; Eyles SJ, 2000, J MOL BIOL, V301, P737, DOI 10.1006/jmbi.2000.4002; Greathouse DV, 2001, J PEPT RES, V57, P519, DOI 10.1034/j.1399-3011.2001.00849.x; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; JANSEN M, 1995, BIOPHYS J, V68, P997, DOI 10.1016/S0006-3495(95)80275-4; Javadpour MM, 1999, BIOPHYS J, V77, P1609, DOI 10.1016/S0006-3495(99)77009-8; Killian JA, 2000, TRENDS BIOCHEM SCI, V25, P429, DOI 10.1016/S0968-0004(00)01626-1; Killian JA, 1996, BIOCHEMISTRY-US, V35, P1037, DOI 10.1021/bi9519258; Killian JA, 1998, BBA-REV BIOMEMBRANES, V1376, P401, DOI 10.1016/S0304-4157(98)00017-3; Kovacs F, 1999, P NATL ACAD SCI USA, V96, P7910, DOI 10.1073/pnas.96.14.7910; LANDOLTMARTICORENA C, 1993, J MOL BIOL, V229, P602, DOI 10.1006/jmbi.1993.1066; LEWIS BA, 1983, J MOL BIOL, V166, P211, DOI 10.1016/S0022-2836(83)80007-2; LI SC, 1992, FEBS LETT, V311, P217, DOI 10.1016/0014-5793(92)81106-V; Persson S, 1998, BIOPHYS J, V75, P1365, DOI 10.1016/S0006-3495(98)74054-8; Ridder ANJA, 2000, BIOCHEMISTRY-US, V39, P6521, DOI 10.1021/bi000073v; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; Russ WP, 2000, J MOL BIOL, V296, P911, DOI 10.1006/jmbi.1999.3489; SCHIFFER M, 1995, J MOL BIOL, V252, P472, DOI 10.1006/jmbi.1995.0512; Wimley WC, 1996, NAT STRUCT BIOL, V3, P842, DOI 10.1038/nsb1096-842; Yau WM, 1998, BIOCHEMISTRY-US, V37, P14713, DOI 10.1021/bi980809c	27	67	67	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					34501	34508		10.1074/jbc.M101401200	http://dx.doi.org/10.1074/jbc.M101401200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11435420	hybrid			2022-12-25	WOS:000171024600022
J	Gomes, XV; Schmidt, SLG; Burgers, PMJ				Gomes, XV; Schmidt, SLG; Burgers, PMJ			ATP utilization by yeast replication factor C II. Multiple stepwise ATP binding events are required to load proliferating cell nuclear antigen onto primed DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-DELTA; PROTEIN COMPLEX; SLIDING CLAMP; LARGE SUBUNIT; IN-VITRO; RECOGNITION; ALPHA; OVERPRODUCTION; PURIFICATION; INITIATION	Binding of adenosine (3-thiotriphosphate) (ATP gammaS), a nonhydrolyzable analog of ATP, to replication factor C with a N-terminal truncation (Delta2-273) of the Rfc1 subunit (RFC) was studied by filter binding. RFC alone bound 1.8 ATP gammaS molecules. However, when either PCNA or primer-template DNA were also present 2.6 or 2.7 ATP gammaS molecules, respectively, were bound. When both PCNA and DNA were present 3.6 ATP gammaS molecules were bound per RFC. Order of addition experiments using surface plasmon resonance indicate that RFC forms an ATP-mediated binary complex with PCNA prior to formation of a ternary DNA.PCNA.RFC complex. An ATP-mediated complex between RFC and DNA was not competent for binding PCNA, and the RFC.DNA complex dissociated with hydrolysis of ATP. Based on these experiments a model is proposed in which: (i) RFC binds two ATPs (RFC.ATP(2)); (ii) this complex binds PCNA (PCNA.RFC.ATP(2)), which goes through a conformational change to reveal a binding site for one additional ATP (PCNA.RFC.ATP(3)); (iii) this complex can bind DNA to yield DNA.PCNA.RFC.ATP(3); (iv) a conformational change in the latter complex reveals a fourth binding site for ATP; and (v) the DNA.PCNA.RFC.ATP(4) complex is finally competent for completion of PCNA loading and release of RFC upon hydrolysis of ATP.	Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA	Washington University (WUSTL)	Burgers, PMJ (corresponding author), Washington Univ, Sch Med, Dept Biochem & Mol Biophys, 660 S Euclid Ave, St Louis, MO 63110 USA.	burgers@biochem.wustl.edu	Burgers, Peter M/AAW-6621-2021		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032431] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32431, R01 GM032431] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen BL, 1998, NUCLEIC ACIDS RES, V26, P3877, DOI 10.1093/nar/26.17.3877; BURGERS PMJ, 1991, J BIOL CHEM, V266, P22698; Burgers PMJ, 1999, METHODS, V18, P349, DOI 10.1006/meth.1999.0796; ECKSTEIN F, 1985, ANNU REV BIOCHEM, V54, P367, DOI 10.1146/annurev.bi.54.070185.002055; Fotedar R, 1996, EMBO J, V15, P4423, DOI 10.1002/j.1460-2075.1996.tb00815.x; Gerik KJ, 1997, J BIOL CHEM, V272, P1256, DOI 10.1074/jbc.272.2.1256; Gomes XV, 2001, J BIOL CHEM, V276, P34768, DOI 10.1074/jbc.M011631200; Gomes XV, 2000, J BIOL CHEM, V275, P14541, DOI 10.1074/jbc.275.19.14541; Green CM, 2000, CURR BIOL, V10, P39, DOI 10.1016/S0960-9822(99)00263-8; Hingorani MM, 1999, EMBO J, V18, P5131, DOI 10.1093/emboj/18.18.5131; KOUPRINA N, 1994, GENETICS, V138, P1067; Latham GJ, 1996, J MOL BIOL, V264, P426, DOI 10.1006/jmbi.1996.0651; LEE SH, 1990, P NATL ACAD SCI USA, V87, P5672, DOI 10.1073/pnas.87.15.5672; LEE SH, 1991, J BIOL CHEM, V266, P594; Maga G, 2000, J MOL BIOL, V295, P791, DOI 10.1006/jmbi.1999.3394; Mossi R, 2000, J MOL BIOL, V295, P803, DOI 10.1006/jmbi.1999.3395; PODUST LM, 1995, MOL CELL BIOL, V15, P3072; Sexton DJ, 1998, BIOCHEMISTRY-US, V37, P7749, DOI 10.1021/bi980088h; TSURIMOTO T, 1990, NATURE, V346, P534, DOI 10.1038/346534a0; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1961; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; Turner J, 1999, EMBO J, V18, P771, DOI 10.1093/emboj/18.3.771; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; Waga S, 1998, MOL CELL BIOL, V18, P4177, DOI 10.1128/MCB.18.7.4177; YODER BL, 1991, J BIOL CHEM, V266, P22689; Yuzhakov A, 1999, EMBO J, V18, P6189, DOI 10.1093/emboj/18.21.6189	26	86	86	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					34776	34783		10.1074/jbc.M011743200	http://dx.doi.org/10.1074/jbc.M011743200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11432856	hybrid			2022-12-25	WOS:000171024600059
J	Gray, J; Haran, MM; Schneider, K; Vesce, S; Ray, AM; Owen, D; White, IR; Cutler, P; Davis, JB				Gray, J; Haran, MM; Schneider, K; Vesce, S; Ray, AM; Owen, D; White, IR; Cutler, P; Davis, JB			Evidence that inhibition of cathepsin-B contributes to the neuroprotective properties of caspase inhibitor Tyr-Val-Ala-Asp-chloromethyl ketone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL DEATH; APOPTOSIS; GLUTAMATE; PROTEASES; IDENTIFICATION; EXPRESSION; ISCHEMIA; PROTEINS; TOXICITY; CULTURES	During the use of tetrapeptide and other proprietary caspase inhibitors in the study of neurodegeneration, we had concluded that mechanisms other than the inhibition of caspases contributed to the protective effects of certain caspase inhibitors. Here we report our studies to identify a target for and hence a mechanism by which the tetrapeptide inhibitor tyrosine-valine-alanine-aspartate-chloromethyl ketone (Ac-YVAD-cmk) is able to rescue neuronal cell cultures from cell death. Ac-YVAD-cmk rescued neuronal cells from cell death in response to oxidative stress and oxygen/glucose deprivation. Affinity labeling with biotinylated YVAD-cmk demonstrated distinct binding proteins for the inhibitor in cells from the central nervous system versus Jurkat cells. Binding to the novel target protein was displaced by class-specific protease inhibitors and suggested that the target is a cysteine protease. Affinity purification and sequencing identified the target as cathepsin-B. Cathepsin-B inhibitors competed with biotinylated YVAD-cmk for the target protein. The availability of the target for binding was reduced in cells that had been rescued by unlabeled inhibitor. Cathepsin-D inhibitors rescue hippocampal slices from cell death induced by oxygen/glucose deprivation. These data provide evidence to support a role for cathepsin-B in neuronal cell death, particularly that following ischemia.	GlaxoSmithKline, Neurosci Res, Harlow CM19 5AW, Essex, England; GlaxoSmithKline, Analyt Sci, Harlow CM19 5AW, Essex, England; GlaxoSmithKline, Computat & Struct Sci, Harlow CM19 5AW, Essex, England	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline	Davis, JB (corresponding author), GlaxoSmithKline, Neurosci H17, 3rd Ave, Harlow CM19 5AW, Essex, England.		Schneider, Klaus/N-6604-2014; Jansen, Heiko T./A-5770-2008	Schneider, Klaus/0000-0002-3068-8681; Jansen, Heiko T./0000-0003-0178-396X				ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; Chevallet M, 1997, ANAL BIOCHEM, V251, P69, DOI 10.1006/abio.1997.2206; CHIBBER R, 1983, EUR J BIOCHEM, V136, P383, DOI 10.1111/j.1432-1033.1983.tb07753.x; Choi DW, 1996, CURR OPIN NEUROBIOL, V6, P667, DOI 10.1016/S0959-4388(96)80101-2; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Faleiro L, 1997, EMBO J, V16, P2271, DOI 10.1093/emboj/16.9.2271; GORG A, 1995, ELECTROPHORESIS, V16, P1079, DOI 10.1002/elps.11501601183; Guicciardi ME, 2000, J CLIN INVEST, V106, P1127, DOI 10.1172/JCI9914; GULLICK WJ, 1986, PRACTICAL PROTEIN CH, P207; HANSEN M, 1991, J IMMUNOL METHODS, V119, P203; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; Hill IE, 1997, BRAIN RES, V751, P206, DOI 10.1016/S0006-8993(96)01403-5; Isahara K, 1999, NEUROSCIENCE, V91, P233, DOI 10.1016/S0306-4522(98)00566-1; Johnson DE, 2000, LEUKEMIA, V14, P1695, DOI 10.1038/sj.leu.2401879; Kohda Y, 1996, BIOCHEM BIOPH RES CO, V228, P616, DOI 10.1006/bbrc.1996.1706; Levy-Strumpf N, 1998, ONCOGENE, V17, P3331, DOI 10.1038/sj.onc.1202588; Maher P, 1996, J NEUROSCI, V16, P6394; MANN M, 1994, ANAL CHEM, V66, P4390, DOI 10.1021/ac00096a002; MORIMOTO BH, 1990, NEURON, V5, P875, DOI 10.1016/0896-6273(90)90347-I; NEWELL DW, 1995, J NEUROSCI, V15, P7702; PILKINGTON SJ, 1991, BIOCHEMISTRY-US, V30, P2166, DOI 10.1021/bi00222a021; Schotte P, 1998, BIOCHEM BIOPH RES CO, V251, P379, DOI 10.1006/bbrc.1998.9425; Seyfried D, 1997, J NEUROSURG, V87, P716, DOI 10.3171/jns.1997.87.5.0716; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tsuchiya K, 1999, EXP NEUROL, V155, P187, DOI 10.1006/exnr.1998.6988; WILKIN GP, 1976, BRAIN RES, V115, P181, DOI 10.1016/0006-8993(76)90506-0; Yamashima T, 2000, PROG NEUROBIOL, V62, P273, DOI 10.1016/S0301-0082(00)00006-X	29	47	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					32750	32755		10.1074/jbc.M103150200	http://dx.doi.org/10.1074/jbc.M103150200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11427531	hybrid			2022-12-25	WOS:000170746000051
J	Bosc, C; Frank, R; Denarier, E; Ronjat, M; Schweitzer, A; Wehland, J; Jot, D				Bosc, C; Frank, R; Denarier, E; Ronjat, M; Schweitzer, A; Wehland, J; Jot, D			Identification of novel bifunctional calmodulin-binding and microtubule-stabilizing motifs in STOP proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLD-STABLE MICROTUBULES; POSTTRANSLATIONAL MODIFICATION; LISTERIA-MONOCYTOGENES; SPOT-SYNTHESIS; LIVING CELLS; DYNAMICS; BEHAVIOR; MOUSE; PURIFICATION; FIBROBLASTS	Although microtubules are intrinsically labile tubulin assemblies, many cell types contain stable polymers, resisting depolymerizing conditions such as exposure to the cold or the drug nocodazole. This microtubule stabilization is largely due to polymer association with STOP proteins. There are several STOP variants, some with capacity to induce microtubule resistance to both the cold and nocodazole, others with microtubule cold stabilizing activity only. These microtubule-stabilizing effects of STOP proteins are inhibited by calmodulin and we now demonstrate that they are determined by two distinct kinds of repeated modular sequences (Mn and Me), both containing a calmodulin-binding peptide, but displaying different microtubule stabilizing activities. Mn modules induce microtubule resistance to both the cold and nocodazole when expressed in cells. Me modules, which correspond to the STOP central repeats, have microtubule cold stabilizing activity only. Mouse neuronal STOPs, which induce both cold and drug resistance in cellular microtubules, contain three Mn modules and four Me modules. Compared with neuronal STOPs, the non-neuronal F-STOP lacks multiple Mn modules and this corresponds with an inability to induce nocodazole resistance. STOP modules represent novel bifunctional calmodulin-binding and microtubule-stabilizing sequences that may be essential for the generation of the different patterns of microtubule stabilization observed in cells.	CEA, Lab Cytosquelette, Dept Biol Mol & Struct Cytosquelette, INSERM,U366, F-38054 Grenoble 9, France; GBF, AG Mol Recognit, D-38124 Braunschweig, Germany; CEA, Lab Canaux Ion & Signalisat, Dept Biol Mol & Struct, INSERM,EMI 9931, F-38054 Grenoble 9, France; Gesell Biotechnol Forsch GmbH, Dept Cell Biol, D-38124 Braunschweig, Germany	CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); Helmholtz Association; Helmholtz-Center for Infection Research; CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); Gesellschaft fur Biotechnologische Forschung mbH	Bosc, C (corresponding author), CEA, Lab Cytosquelette, Dept Biol Mol & Struct Cytosquelette, INSERM,U366, 17 Rue Martyrs, F-38054 Grenoble 9, France.		Denarier, Eric/H-3555-2017; Denarier, Eric/X-6137-2019; Bosc, Christophe/P-3401-2017; Bosc, Christophe/Q-8877-2019	Denarier, Eric/0000-0002-4169-397X; Denarier, Eric/0000-0002-4169-397X; Bosc, Christophe/0000-0002-3195-6692; Bosc, Christophe/0000-0002-3195-6692; Ronjat, Michel/0000-0002-9728-6425				BAAS PW, 1986, J CELL BIOL, V103, P917, DOI 10.1083/jcb.103.3.917; BAAS PW, 1994, J CELL SCI, V107, P135; BERSHADSKY AD, 1979, CELL BIOL INT REP, V3, P45, DOI 10.1016/0309-1651(79)90067-5; Bosc C, 1996, P NATL ACAD SCI USA, V93, P2125, DOI 10.1073/pnas.93.5.2125; BULINSKI JC, 1991, BIOESSAYS, V13, P285, DOI 10.1002/bies.950130605; Chin D, 2000, TRENDS CELL BIOL, V10, P322, DOI 10.1016/S0962-8924(00)01800-6; CRIVICI A, 1995, ANNU REV BIOPH BIOM, V24, P85, DOI 10.1146/annurev.bb.24.060195.000505; Darji A, 1996, INFECT IMMUN, V64, P2356, DOI 10.1128/IAI.64.6.2356-2358.1996; Denarier E, 1998, P NATL ACAD SCI USA, V95, P6055, DOI 10.1073/pnas.95.11.6055; Denarier E, 1998, BIOCHEM BIOPH RES CO, V243, P791, DOI 10.1006/bbrc.1998.8179; DOMANN E, 1992, EMBO J, V11, P1981, DOI 10.1002/j.1460-2075.1992.tb05252.x; Dustin P., 1984, MICROTUBULES; FARRELL KW, 1987, J CELL BIOL, V104, P1035, DOI 10.1083/jcb.104.4.1035; Frank R, 1996, Methods Mol Biol, V66, P149; FRANK R, 1992, TETRAHEDRON, V48, P9217, DOI 10.1016/S0040-4020(01)85612-X; GREEN KJ, 1990, J BIOL CHEM, V265, P2603; Guillaud L, 1998, J CELL BIOL, V142, P167, DOI 10.1083/jcb.142.1.167; HANLEY RM, 1987, SCIENCE, V237, P293, DOI 10.1126/science.3037704; JOB D, 1982, BIOCHEMISTRY-US, V21, P509, DOI 10.1021/bi00532a015; JOB D, 1981, P NATL ACAD SCI-BIOL, V78, P4679, DOI 10.1073/pnas.78.8.4679; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LEWIS SA, 1988, SCIENCE, V242, P936, DOI 10.1126/science.3142041; LIEUVIN A, 1994, J CELL BIOL, V124, P985, DOI 10.1083/jcb.124.6.985; Llanos R, 1999, BIOCHEMISTRY-US, V38, P15712, DOI 10.1021/bi990895w; MARGOLIS RL, 1986, P NATL ACAD SCI USA, V83, P639, DOI 10.1073/pnas.83.3.639; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; MOSKALEWSKI S, 1980, CELL TISSUE RES, V210, P403; Niebuhr K, 1997, EMBO J, V16, P5433, DOI 10.1093/emboj/16.17.5433; Niebuhr Kirsten, 1997, P797; PIROLLET F, 1989, BIOCHEMISTRY-US, V28, P835, DOI 10.1021/bi00428a064; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; Ritco-Vonsovici M, 2000, J MOL BIOL, V304, P81, DOI 10.1006/jmbi.2000.4177; SAMMAK PJ, 1988, NATURE, V332, P724, DOI 10.1038/332724a0; SCHULZE E, 1987, J CELL BIOL, V105, P2167, DOI 10.1083/jcb.105.5.2167; SCHULZE E, 1988, NATURE, V334, P356, DOI 10.1038/334356a0; SHELDEN E, 1993, J CELL BIOL, V120, P935, DOI 10.1083/jcb.120.4.935; Suzuki Mikiko, 1998, Journal of Medical and Dental Sciences, V45, P123; WEST RR, 1991, J BIOL CHEM, V266, P21886	38	31	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					30904	30913		10.1074/jbc.M011614200	http://dx.doi.org/10.1074/jbc.M011614200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11413126	hybrid			2022-12-25	WOS:000170472900044
J	Inagaki, N; Maitra, R; Satoh, K; Pakrasi, HB				Inagaki, N; Maitra, R; Satoh, K; Pakrasi, HB			Amino acid residues that are critical for in vivo catalytic activity of CtpA, the carboxyl-terminal processing protease for the D1 protein of photosystem II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOSYNTHETIC OXYGEN EVOLUTION; SYNECHOCYSTIS SP PCC-6803; SCENEDESMUS-OBLIQUUS; PRECURSOR PROTEIN; MUTANT STRAIN; COMPLEX; IDENTIFICATION; MANGANESE; SPINACH; CLONING	CtpA, a carboxyl-terminal processing protease, is a member of a novel family of endoproteases that includes a tail-specific protease from Escherichia coli. In oxygenic photosynthetic organisms, CtpA catalyzes C-terminal processing of the D1 protein of photosystem II, an essential event for the assembly of a manganese cluster and consequent light-mediated water oxidation. We introduced site-specific mutations at 14 conserved residues of CtpA in the cyanobacterium Synechocystis sp. PCC 6803 to examine their functional roles. Analysis of the photoautotrophic growth capabilities of these mutants, their ability to process precursor D1 protein and hence evolve oxygen, along with an estimation of the protease content in the mutants revealed that five of these residues are critical for in vivo activity of CtpA. Recent x-ray crystal structure analysis of CtpA from the eukaryotic alga Scenedesmus obliquus (Liao, D.-I., Qian, J., Chisholm, D. A., Jordan, D. B. and Diner, B. A. (2000) Nat. Struct. Biol. 7, 749-753) has shown that the residues equivalent to Ser-313 and Lys-338, two of the five residues mentioned above, form the catalytic center of this enzyme. Our in vivo analysis demonstrates that the three other residues, Asp-253, Arg-255, and Glu-316, are also important determinants of the catalytic activity of CtpA.	Washington Univ, Dept Biol, St Louis, MO 63130 USA; Okayama Univ, Dept Biol, Okayama 7008530, Japan; Natl Inst Basic Biol, Okazaki, Aichi 4448585, Japan	Washington University (WUSTL); Okayama University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB)	Pakrasi, HB (corresponding author), Washington Univ, Dept Biol, Box 1137,1 Brookings Dr, St Louis, MO 63130 USA.			Inagaki, Noritoshi/0000-0001-8738-6636	NIGMS NIH HHS [GM 45797] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045797] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN MM, 1968, J PHYCOL, V4, P1, DOI 10.1111/j.1529-8817.1968.tb04667.x; ANBUDURAI PR, 1994, P NATL ACAD SCI USA, V91, P8082, DOI 10.1073/pnas.91.17.8082; BARTSEVICH VV, 1995, EMBO J, V14, P1845, DOI 10.1002/j.1460-2075.1995.tb07176.x; BOWYER JR, 1992, J BIOL CHEM, V267, P5424; DINER BA, 1988, J BIOL CHEM, V263, P8972; DZELZKALNS VA, 1988, EMBO J, V7, P333, DOI 10.1002/j.1460-2075.1988.tb02817.x; FUJITA S, 1995, PLANT CELL PHYSIOL, V36, P1169; Inagaki N, 1996, PLANT MOL BIOL, V30, P39, DOI 10.1007/BF00017801; Ivleva NB, 2000, PLANT PHYSIOL, V124, P1403, DOI 10.1104/pp.124.3.1403; KEILER KC, 1995, J BIOL CHEM, V270, P28864, DOI 10.1074/jbc.270.48.28864; KEILER KC, 1998, HDB PROTEOLYTIC ENZY, P460; Keller K.C., 1996, SCIENCE, V271, P990; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liao DI, 2000, NAT STRUCT BIOL, V7, P749, DOI 10.1038/78973; LICHTENTHALER HK, 1987, METHOD ENZYMOL, V148, P350; MANNAN RM, 1993, PLANT PHYSIOL, V103, P971, DOI 10.1104/pp.103.3.971; NANBA O, 1987, P NATL ACAD SCI USA, V84, P109, DOI 10.1073/pnas.84.1.109; NIXON PJ, 1992, BIOCHEMISTRY-US, V31, P10859, DOI 10.1021/bi00159a029; Oelmuller R, 1996, J BIOL CHEM, V271, P21848, DOI 10.1074/jbc.271.36.21848; Paetzel M, 1998, NATURE, V396, P186, DOI 10.1038/24196; Paetzel M, 1997, TRENDS BIOCHEM SCI, V22, P28, DOI 10.1016/S0968-0004(96)10065-7; Pakrasi HB, 1995, ANNU REV GENET, V29, P755; PICARD V, 1994, NUCLEIC ACIDS RES, V22, P2587, DOI 10.1093/nar/22.13.2587; Sambrook J., 2002, MOL CLONING LAB MANU; SATOH K, 1998, HDB PROTEOLYTIC ENZY, P463; SHESTAKOV SV, 1994, J BIOL CHEM, V269, P19354; SILBER KR, 1992, P NATL ACAD SCI USA, V89, P295, DOI 10.1073/pnas.89.1.295; Yamamoto Y, 2001, J BIOL CHEM, V276, P7518, DOI 10.1074/jbc.M008877200; Zhang LX, 1999, J BIOL CHEM, V274, P16062, DOI 10.1074/jbc.274.23.16062; Zouni A, 2001, NATURE, V409, P739, DOI 10.1038/35055589	30	23	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30099	30105		10.1074/jbc.M102600200	http://dx.doi.org/10.1074/jbc.M102600200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11408480	hybrid			2022-12-25	WOS:000170558000067
J	Maurici, D; Monti, P; Campomenosi, P; North, S; Frebourg, T; Fronza, G; Hainaut, P				Maurici, D; Monti, P; Campomenosi, P; North, S; Frebourg, T; Fronza, G; Hainaut, P			Amifostine (WR2721) restores transcriptional activity of specific p53 mutant proteins in a yeast functional assay	ONCOGENE			English	Article						amifostine; p53; yeast functional assay	TUMOR-SUPPRESSOR P53; DNA-BINDING; CELL-CYCLE; GENE-EXPRESSION; IN-VITRO; IDENTIFICATION; MUTATIONS; APOPTOSIS; SPECTRUM; LINES	Many p53 mutants found in human cancer have an altered ability to bind DNA and transactivate gene expression. Re-expression of functional p53 in cells in which the endogenous TP53 gene is inactivated has been demonstrated to restore a non-tumorigenic phenotype, Pharmacological modulation of p53 mutant conformation may therefore represent a mechanism to reactivate p53 function and consequently improve response to radio- and chemotherapy, We have recently reported that the radio- and chemoprotector Amifostine (WR2721, Ethyol(H)) activates wild-type p53 in cultured mammalian cells. In the present study, we have used a yeast functional assay to investigate the effect of WR2721 on the transcriptional activity of p53. WR2721 restored this activity in a temperature-sensitive mutant V272M (valine to methionine at codon 272) expressed at the nonpermissive temperature and it also partially restored the transcriptional activity of several other conformationally flexible p53 mutants. The results indicate that the yeast functional assay may be used to identify compounds that modulate p53 activity, with potential therapeutic implications.	Int Agcy Res Canc, Grp Mol Carcinogenesis, F-69372 Lyon, France; Natl Canc Inst, Mutagenesis Lab, IST, I-16132 Genoa, Italy; Fac Med & Pharm, INSERM EPI, F-76183 Rouen, France	World Health Organization; International Agency for Research on Cancer (IARC); Institut National de la Sante et de la Recherche Medicale (Inserm)	Hainaut, P (corresponding author), Int Agcy Res Canc, Grp Mol Carcinogenesis, 150 Cours Albert Thomas, F-69372 Lyon, France.		Monti, Paola/Y-1118-2019; Fronza, Gilberto/AAG-8735-2019; Campomenosi, Paola/C-9729-2011; Hainaut, Pierre/B-6018-2012; Frebourg, Thierry/AAK-8390-2020	Monti, Paola/0000-0002-1978-4998; Fronza, Gilberto/0000-0003-3722-553X; Campomenosi, Paola/0000-0002-8853-1134; Hainaut, Pierre/0000-0002-1303-1610; 				Barnas C, 1997, INT J CANCER, V71, P79, DOI 10.1002/(SICI)1097-0215(19970328)71:1<79::AID-IJC14>3.0.CO;2-4; CALABROJONES PM, 1985, INT J RADIAT BIOL, V47, P23, DOI 10.1080/09553008514550041; Capizzi RL, 1999, SEMIN ONCOL, V26, P72; Capizzi RL, 1999, SEMIN ONCOL, V26, P1; Capizzi RL, 1999, SEMIN ONCOL, V26, P3; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Di Como CJ, 1998, ONCOGENE, V16, P2527; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Flaman JM, 1998, ONCOGENE, V16, P1369, DOI 10.1038/sj.onc.1201889; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; GRDINA DJ, 1995, CARCINOGENESIS, V16, P767, DOI 10.1093/carcin/16.4.767; Hainaut P, 2000, ADV CANCER RES, V77, P81; HAINAUT P, 1993, CANCER RES, V53, P4469; Inga A, 1997, CARCINOGENESIS, V18, P2019, DOI 10.1093/carcin/18.10.2019; Inga A, 1999, CANCER RES, V59, P689; Inga A, 1998, CARCINOGENESIS, V19, P741, DOI 10.1093/carcin/19.5.741; ISHIOKA C, 1993, NAT GENET, V5, P124, DOI 10.1038/ng1093-124; Jia LQ, 1997, MOL CARCINOGEN, V19, P243, DOI 10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D; Kelly JD, 1999, J BIOL CHEM, V274, P18327, DOI 10.1074/jbc.274.26.18327; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Kramer DL, 1998, BIOCHEM SOC T, V26, P609, DOI 10.1042/bst0260609; Kramer DL, 1999, CANCER RES, V59, P1278; Lang D, 1998, ONCOGENE, V16, P1593, DOI 10.1038/sj.onc.1201665; Li L, 1999, AM J PHYSIOL-CELL PH, V276, pC946, DOI 10.1152/ajpcell.1999.276.4.C946; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; Marzatico F, 2000, CANCER CHEMOTH PHARM, V45, P172, DOI 10.1007/s002800050026; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; North S, 2000, ONCOGENE, V19, P1206, DOI 10.1038/sj.onc.1203413; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Oren M, 1999, CELL MOL LIFE SCI, V55, P9, DOI 10.1007/s000180050265; PEGG AE, 1988, CANCER RES, V48, P759; Pollard KJ, 1999, EMBO J, V18, P5622, DOI 10.1093/emboj/18.20.5622; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; RAINWATER R, 1995, MOL CELL BIOL, V15, P3892; Robert V, 2000, CARCINOGENESIS, V21, P563, DOI 10.1093/carcin/21.4.563; ROLLEY N, 1995, ONCOGENE, V11, P763; Roth JA, 1996, NAT MED, V2, P985, DOI 10.1038/nm0996-985; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; Ryan KM, 1998, MOL CELL BIOL, V18, P3692, DOI 10.1128/MCB.18.7.3692; SHIGEMATSU N, 1994, MUTAGENESIS, V9, P355, DOI 10.1093/mutage/9.4.355; Verhaegh GW, 1997, MOL CELL BIOL, V17, P5699, DOI 10.1128/MCB.17.10.5699	44	46	48	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 14	2001	20	27					3533	3540		10.1038/sj.onc.1204428	http://dx.doi.org/10.1038/sj.onc.1204428			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	445VB	11429700				2022-12-25	WOS:000169478300009
J	Mahyar-Roemer, M; Roemer, K				Mahyar-Roemer, M; Roemer, K			p21 Waf1/Cip1 can protect human colon carcinoma cells against p53-dependent and p53-independent apoptosis induced by natural chemopreventive and therapeutic agents	ONCOGENE			English	Article						p21; p53; colon cancer; butyrate; chemotherapy	CHAIN FATTY-ACIDS; NITRIC-OXIDE SYNTHASE; DIETARY FIBER; CYCLE ARREST; CANCER-CELLS; P53; BUTYRATE; GROWTH; P21(WAF1/CIP1); DEATH	The molecular basis for the sensitivity of tumor cells to chemopreventive natural food compounds and commonly used chemotherapeutic agents is not well understood, not least because studies are frequently confounded by the diversity among cell lines or rely on experimental protein overexpression. Here we investigated the effects of n-butyrate, a cancer-preventive short-chain fatty acid produced by anaerobic bacteria in the gastrointestinal tract, on the human wild-type p53 and p21 expressing HCT116 colon carcinoma cell line and on HCT116 cells with either p53 or p21 alleles inactivated by homologous recombination. The effects of n-butyrate were then compared with those elicited by cytotoxic drugs and the natural chemopreventive phytoalexin of wine and grapes, resveratrol. We document that physiological concentrations of n-butyrate stimulate p21 expression and induce apoptosis independently of p53, and that the absence of p21 increases apoptosis drastically. The apoptosis is mediated through the mitochondria and is accompanied by mitochondrial proliferation and membrane potential changes. Adriamycin, etoposide, cisplatinum, colcemid and resveratrol induce distinct cellular responses; however, absence of p21 favors apoptosis-induction by adriamycin, etoposide and colcemid. Thus, control of p21 expression may support chemoprevention and certain tumor therapies.	Univ Saarland, Sch Med, Dept Virol, D-66421 Homburg, Germany	Saarland University	Roemer, K (corresponding author), Univ Saarland, Sch Med, Dept Virol, Bldg 47, D-66421 Homburg, Germany.							Archer SY, 1998, P NATL ACAD SCI USA, V95, P6791, DOI 10.1073/pnas.95.12.6791; Attardi LD, 2000, GENE DEV, V14, P704; Atz J, 2000, J CELL BIOCHEM, V76, P572, DOI 10.1002/(SICI)1097-4644(20000315)76:4<572::AID-JCB6>3.0.CO;2-6; BARNES PJ, 1994, CL ALLER IM, V4, P501; Barshishat M, 2000, BRIT J CANCER, V82, P195; Blandino G, 1999, ONCOGENE, V18, P477, DOI 10.1038/sj.onc.1202314; BOFFA LC, 1992, CANCER RES, V52, P5906; Brown JM, 1999, CANCER RES, V59, P1391; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; CUMMINGS JH, 1981, GUT, V22, P763, DOI 10.1136/gut.22.9.763; CUPLER EJ, 1995, ACTA NEUROPATHOL, V90, P1; Fan SJ, 1997, ONCOGENE, V14, P2127, DOI 10.1038/sj.onc.1201052; Gorospe M, 1996, MOL CELL BIOL, V16, P6654; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HEERDT BG, 1994, CANCER RES, V54, P3288; Hodin RA, 1996, CELL GROWTH DIFFER, V7, P647; Hsieh TC, 1999, CANCER RES, V59, P2596; Huang CS, 1999, CARCINOGENESIS, V20, P237, DOI 10.1093/carcin/20.2.237; Huang YQ, 2000, J BIOL CHEM, V275, P6462, DOI 10.1074/jbc.275.9.6462; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; Jimenez GS, 1999, ONCOGENE, V18, P7656, DOI 10.1038/sj.onc.1203013; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Li PF, 1999, EMBO J, V18, P6027, DOI 10.1093/emboj/18.21.6027; Lin YP, 2000, NAT GENET, V26, P122, DOI 10.1038/79102; Litvak DA, 1998, SURGERY, V124, P161, DOI 10.1067/msy.1998.90365; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; Mancini M, 1997, J CELL BIOL, V138, P449, DOI 10.1083/jcb.138.2.449; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; McBain JA, 1997, BIOCHEM PHARMACOL, V53, P1357, DOI 10.1016/S0006-2952(96)00904-5; MCINTYRE A, 1993, GUT, V34, P386, DOI 10.1136/gut.34.3.386; MIYASHITA T, 1995, CELL, V80, P293; Mortensen K, 1999, J BIOL CHEM, V274, P37679, DOI 10.1074/jbc.274.53.37679; Nakano K, 1997, J BIOL CHEM, V272, P22199, DOI 10.1074/jbc.272.35.22199; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; REIPERT S, 1995, EXP CELL RES, V221, P281, DOI 10.1006/excr.1995.1376; SCHWARTZ B, 1992, INT J CANCER, V52, P60, DOI 10.1002/ijc.2910520113; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Tian H, 2000, CANCER RES, V60, P679; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Waldman T, 1997, NAT MED, V3, P1034, DOI 10.1038/nm0997-1034; WALDMAN T, 1995, CANCER RES, V55, P5187; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang H, 1999, J CELL PHYSIOL, V178, P173, DOI 10.1002/(SICI)1097-4652(199902)178:2<173::AID-JCP6>3.3.CO;2-H; Wang YC, 1999, ONCOGENE, V18, P2643, DOI 10.1038/sj.onc.1202632; Weinstein JN, 1997, SCIENCE, V275, P343, DOI 10.1126/science.275.5298.343; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Yin YX, 1998, NATURE, V391, P707, DOI 10.1038/35648	57	155	161	0	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 7	2001	20	26					3387	3398		10.1038/sj.onc.1204440	http://dx.doi.org/10.1038/sj.onc.1204440			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	441UW	11423989				2022-12-25	WOS:000169248800009
J	Manos, EJ; Kim, MLH; Kassis, J; Chang, PY; Wells, A; Jones, DA				Manos, EJ; Kim, MLH; Kassis, J; Chang, PY; Wells, A; Jones, DA			Dolichol-phosphate-mannose-3 (DPM3)/prostin-1 is a novel phospholipase C-gamma regulated gene negatively associated with prostate tumor invasion	ONCOGENE			English	Article						prostate; invasion; metastasis; phospholipase; EGF receptor; microarray	EPIDERMAL GROWTH-FACTOR; IN-VITRO INVASIVENESS; EGF RECEPTOR; PLASMINOGEN-ACTIVATOR; FIBROBLAST MIGRATION; CARCINOMA-CELLS; CANCER-CELLS; EXPRESSION; MOTILITY; KINASE	The most ominous development in tumor progression is the transition to an invasive and metastatic phenotype, Little is known, however, about the molecular alterations that cause a tumor to become invasive, in view of this, we have used microarray expression analysis to evaluate the expression profiles of a unique panel of human DU145 prostate cancer sublines that vary in their invasive potential, The three DU145 sublines expressed epidermal growth factor (EGF) receptors that differed in their ability to activate phospholipase C-gamma (PLC gamma). Three-way analyses yielded 11 genes out of 4608 genes screened that associated directly or inversely with invasive potential, The gene whose expression correlated most strongly with lack of invasion was identified as a potential invasion suppressor and called prostin-1. Pharmacological inhibition of PLC gamma (U73122) confirmed that PLC gamma, signaling suppressed prostin-1 in that U73122 treatment caused induction of prostin-1 in PLC gamma, competent cells, The prostin-l gene, conserved through phylogeny, is induced by androgen in LNCaP cells acid encodes a 92 amino acid protein, The protein shares no extensive homologies with other known genes, yet was recently identified as a small stabilizer subunit of the dolichol-phosphate-mannose (DPM) synthase complex, That DPM3/prostin-1 might suppress tumor progression was supported by the finding that exogenous expression in COS cells leads to apoptosis, These findings support the use of model cell lines to identify putative tumor suppressors and promoters.	Univ Utah, Huntsman Canc Inst, Div Mol Pharmacol, Salt Lake City, UT 84112 USA; Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15260 USA; Univ Wisconsin, Mol & Cellular Pharmacol Program, Madison, WI 53706 USA; Pittsburgh VAMC, Pittsburgh, PA 15260 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Wisconsin System; University of Wisconsin Madison; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Jones, DA (corresponding author), Univ Utah, Huntsman Canc Inst, Div Mol Pharmacol, 2000 Circle Hope,Rm 5242, Salt Lake City, UT 84112 USA.			Wells, Alan/0000-0002-1637-8150				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; Barrack ER, 1997, PROSTATE, V31, P61; BAUER J, 1992, J CELL PHYSIOL, V153, P437, DOI 10.1002/jcp.1041530302; Bornfeldt KE, 1995, ANN NY ACAD SCI, V766, P416, DOI 10.1111/j.1749-6632.1995.tb26691.x; BOROS P, 1995, LANCET, V345, P293, DOI 10.1016/S0140-6736(95)90279-1; Chen P, 1996, MOL BIOL CELL, V7, P871, DOI 10.1091/mbc.7.6.871; CHEN P, 1994, J CELL BIOL, V127, P847, DOI 10.1083/jcb.127.3.847; CHEN P, 1994, J CELL BIOL, V124, P547, DOI 10.1083/jcb.124.4.547; David M, 1996, J BIOL CHEM, V271, P9185, DOI 10.1074/jbc.271.16.9185; Glading A, 2000, J BIOL CHEM, V275, P2390, DOI 10.1074/jbc.275.4.2390; GORDON SR, 1990, CELL MOTIL CYTOSKEL, V16, P47, DOI 10.1002/cm.970160107; Heller RA, 1997, P NATL ACAD SCI USA, V94, P2150, DOI 10.1073/pnas.94.6.2150; Jacobs W, 1997, J NEURO-ONCOL, V32, P93, DOI 10.1023/A:1005777711567; Kameyama T, 1996, BIOCHEM BIOPH RES CO, V226, P396, DOI 10.1006/bbrc.1996.1367; Karpf AR, 1999, P NATL ACAD SCI USA, V96, P14007, DOI 10.1073/pnas.96.24.14007; Kim HG, 1999, HISTOL HISTOPATHOL, V14, P1175, DOI 10.14670/HH-14.1175; KINDRA V, 1994, ONCOGENE, V9, P1429; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; Kustikova O, 1998, MOL CELL BIOL, V18, P7095, DOI 10.1128/MCB.18.12.7095; Lal A, 1999, CANCER RES, V59, P5403; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Maeda Y, 2000, EMBO J, V19, P2475, DOI 10.1093/emboj/19.11.2475; Maheshwari G, 1999, BIOPHYS J, V76, P2814, DOI 10.1016/S0006-3495(99)77435-7; Malliri A, 1998, J CELL BIOL, V143, P1087, DOI 10.1083/jcb.143.4.1087; METTLIN C, 1993, CA-CANCER J CLIN, V43, P83, DOI 10.3322/canjclin.43.2.83; MOUL JW, 1996, FED PRACT, V13, P3; Nguyen DHD, 1998, J BIOL CHEM, V273, P8502, DOI 10.1074/jbc.273.14.8502; Reuning U, 1998, INT J ONCOL, V13, P893; Rochefort H, 1998, J STEROID BIOCHEM, V65, P163, DOI 10.1016/S0960-0760(98)00010-7; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Schena M, 1996, P NATL ACAD SCI USA, V93, P10614, DOI 10.1073/pnas.93.20.10614; Schmitt M, 1995, J Obstet Gynaecol (Tokyo 1995), V21, P151; SHULTZ MJ, 1996, FED PRACT, V13, P14; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; Takaoka A, 1998, ONCOGENE, V16, P1443, DOI 10.1038/sj.onc.1201648; Turner T, 1997, CLIN CANCER RES, V3, P2275; Turner T, 1996, CLIN EXP METASTAS, V14, P409, DOI 10.1007/BF00123400; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Ware MF, 1998, J CELL SCI, V111, P2423; Wells A, 1998, MICROSC RES TECHNIQ, V43, P395, DOI 10.1002/(SICI)1097-0029(19981201)43:5<395::AID-JEMT6>3.0.CO;2-T; WENNSTROM S, 1994, ONCOGENE, V9, P651; WHITTEMORE AS, 1991, J NATL CANCER I, V83, P1231, DOI 10.1093/jnci/83.17.1231; Winberg ML, 1998, CELL, V95, P903, DOI 10.1016/S0092-8674(00)81715-8; XIE H, 1995, CLIN EXP METASTAS, V13, P407, DOI 10.1007/BF00118180; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	47	24	26	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 17	2001	20	22					2781	2790		10.1038/sj.onc.1204379	http://dx.doi.org/10.1038/sj.onc.1204379			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	432TP	11420690				2022-12-25	WOS:000168712000006
J	Singaraja, RR; Bocher, V; James, ER; Clee, SM; Zhang, LH; Leavitt, BR; Tan, B; Brooks-Wilson, A; Kwok, A; Bissada, N; Yang, YZ; Liu, GQ; Tafuri, SR; Fievet, C; Wellington, CL; Staels, B; Hayden, MR				Singaraja, RR; Bocher, V; James, ER; Clee, SM; Zhang, LH; Leavitt, BR; Tan, B; Brooks-Wilson, A; Kwok, A; Bissada, N; Yang, YZ; Liu, GQ; Tafuri, SR; Fievet, C; Wellington, CL; Staels, B; Hayden, MR			Human ABCA1 BAC transgenic mice show increased high density lipoprotein cholesterol and apoAI-dependent efflux stimulated by an internal promoter containing liver X receptor response elements in intron 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-BINDING CASSETTE; APOLIPOPROTEIN-A-I; PRE-MESSENGER-RNA; TANGIER-DISEASE; ATHEROGENIC DIET; NUCLEAR RECEPTOR; CELLULAR CHOLESTEROL; STRAINS C57BL/6; GENE-EXPRESSION; INBRED STRAINS	By using BAC transgenic mice, we have shown that increased human ABCA1 protein expression results in a significant increase in cholesterol efflux in different tissues and marked elevation in high density lipoprotein (HDL)-cholesterol levels associated with increases in apoAI and apoAII. Three novel ABCA1 transcripts containing three different transcription initiation sites that utilize sequences in intron I have been identified. In BAC transgenic mice there is an increased expression of ABCA1 protein, but the distribution of the ABCA1 product in different cells remains similar to wild type mice. An internal promoter in human intron I containing liver X response elements is functional in vivo and directly contributes to regulation of the human ABCA1 gene in multiple tissues and to raised HDL cholesterol, apoAI, and apoAII levels. A highly significant relationship between raised protein levels, increased efflux, and level of HDL elevation is evident. These data provide proof of the principle that increased human ABCA1 efflux activity is associated with an increase in HDL levels in vivo.	Univ British Columbia, Ctr Mol Med & Therapeut, Dept Med Genet, Vancouver, BC V5Z 4H4, Canada; Univ British Columbia, Womens & Childrens Hosp, Vancouver, BC V5Z 4H4, Canada; Inst Pasteur, F-59019 Lille, France; Univ Lille 2, Fac Pharm, U545, F-59019 Lille, France; Xenon Genet Inc, Vancouver, BC V5Z 1Z3, Canada; Pfizer Global Res & Dev, Cardiovasc Mol Sci & Technol, Ann Arbor, MI 48105 USA	University of British Columbia; University of British Columbia; Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille - ISITE; Universite de Lille; Pfizer	Hayden, MR (corresponding author), Univ British Columbia, Ctr Mol Med & Therapeut, Dept Med Genet, 980 W 28th Ave, Vancouver, BC V5Z 4H4, Canada.	mrh@cmmt.ubc.ca	Clee, Susanne/AAC-4278-2020; Leavitt, Blair R/G-1934-2012; Brooks-Wilson, Angela/E-9399-2012; Clee, Susanne/F-7312-2010; James, Erick R/D-4725-2012; Staels, Bart/N-9497-2016; Hayden, Michael R/D-8581-2011	Brooks-Wilson, Angela/0000-0003-1009-6408; Clee, Susanne/0000-0001-7946-688X; Staels, Bart/0000-0002-3784-1503; Hayden, Michael R/0000-0001-5159-1419; Singaraja, Roshni/0000-0002-3418-3867				Adams MD, 1996, CURR OPIN CELL BIOL, V8, P331, DOI 10.1016/S0955-0674(96)80006-8; Aebersold R, 2000, Ann N Y Acad Sci, V919, P33; Albers JJ, 1999, J LIPID RES, V40, P295; Attie AD, 2000, CIRCULATION, V102, P312; Berthou L, 1996, J CLIN INVEST, V97, P2408, DOI 10.1172/JCI118687; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; BOGGS RT, 1987, CELL, V50, P739, DOI 10.1016/0092-8674(87)90332-1; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; BRUENING W, 1992, NAT GENET, V1, P144, DOI 10.1038/ng0592-144; Cavelier LB, 2001, J BIOL CHEM, V276, P18046, DOI 10.1074/jbc.M100565200; Chawla A, 2001, MOL CELL, V7, P161, DOI 10.1016/S1097-2765(01)00164-2; Christiansen-Weber TA, 2000, AM J PATHOL, V157, P1017, DOI 10.1016/S0002-9440(10)64614-7; Clee SM, 2000, J CLIN INVEST, V106, P1263, DOI 10.1172/JCI10727; Costet P, 2000, J BIOL CHEM, V275, P28240; Delerive P, 2000, FEBS LETT, V471, P34, DOI 10.1016/S0014-5793(00)01364-8; Fatyol K, 1999, MOL GEN GENET, V261, P337, DOI 10.1007/s004380050974; FRANCIS GA, 1995, J CLIN INVEST, V96, P78, DOI 10.1172/JCI118082; Gu LJ, 1999, ARTERIOSCL THROM VAS, V19, P442, DOI 10.1161/01.ATV.19.2.442; Gygi SP, 1999, MOL CELL BIOL, V19, P1720, DOI 10.1128/mcb.19.3.1720; Hedrick CC, 2000, ARTERIOSCL THROM VAS, V20, P1946, DOI 10.1161/01.ATV.20.8.1946; ISHIDA BY, 1991, J LIPID RES, V32, P559; ISHIDA BY, 1989, GENETIC FACTORS ATHE; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; Langmann T, 1999, BIOCHEM BIOPH RES CO, V257, P29, DOI 10.1006/bbrc.1999.0406; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; Lejeune F, 2001, J BIOL CHEM, V276, P7850, DOI 10.1074/jbc.M009510200; LIU MS, 1994, J BIOL CHEM, V269, P11417; Lopez AJ, 1998, ANNU REV GENET, V32, P279, DOI 10.1146/annurev.genet.32.1.279; Machleder D, 1997, J CLIN INVEST, V99, P1406, DOI 10.1172/JCI119300; Marcil M, 1999, LANCET, V354, P1341, DOI 10.1016/S0140-6736(99)07026-9; Marcil M, 1999, ARTERIOSCL THROM VAS, V19, P159, DOI 10.1161/01.ATV.19.1.159; McNeish J, 2000, P NATL ACAD SCI USA, V97, P4245, DOI 10.1073/pnas.97.8.4245; McQueen KL, 2001, IMMUNOGENETICS, V52, P212; Mehrabian M, 2000, J LIPID RES, V41, P1936; NISHINA PM, 1993, LIPIDS, V28, P599, DOI 10.1007/BF02536053; NISHINA PM, 1990, J LIPID RES, V31, P859; PAIGEN B, 1987, ATHEROSCLEROSIS, V64, P215, DOI 10.1016/0021-9150(87)90249-8; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; Pullinger CR, 2000, BIOCHEM BIOPH RES CO, V271, P451, DOI 10.1006/bbrc.2000.2652; PURCELLHUYNH DA, 1995, J CLIN INVEST, V96, P1845, DOI 10.1172/JCI118230; ROGLER G, 1995, ARTERIOSCL THROM VAS, V15, P683, DOI 10.1161/01.ATV.15.5.683; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Santamarina-Fojo S, 2000, P NATL ACAD SCI USA, V97, P7987, DOI 10.1073/pnas.97.14.7987; Schwartz K, 2000, BIOCHEM BIOPH RES CO, V274, P794, DOI 10.1006/bbrc.2000.3243; SRIVASTAVA RAK, 1992, BIOCHIM BIOPHYS ACTA, V1125, P251, DOI 10.1016/0005-2760(92)90053-X; Vu-Dac N, 1998, J BIOL CHEM, V273, P25713, DOI 10.1074/jbc.273.40.25713; WILLY PJ, 1995, GENE DEV, V9, P1033, DOI 10.1101/gad.9.9.1033	49	163	174	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33969	33979		10.1074/jbc.M102503200	http://dx.doi.org/10.1074/jbc.M102503200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11423537	hybrid			2022-12-25	WOS:000170910200092
J	Stenmark, P; Grunler, J; Mattsson, J; Sindelar, PJ; Nordlund, P; Berthold, DA				Stenmark, P; Grunler, J; Mattsson, J; Sindelar, PJ; Nordlund, P; Berthold, DA			A new member of the family of di-iron carboxylate proteins - Coq7 (clk-1), a membrane-bound hydroxylase involved in ubiquinone biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-Q BIOSYNTHESIS; TIMING GENE CLK-1; ESCHERICHIA-COLI; ALTERNATIVE OXIDASE; SITE; CONSERVATION; MUTATIONS; SEQUENCE; MODEL; MOUSE	Ubiquinone (UQ) is an essential cofactor for respiratory metabolism. In yeast, mutation of the COQ7 gene results in the absence of UQ biosynthesis and demonstrates a role for this gene in the step leading to the hydroxylation of 5-demethoxyubiquinone. Intriguingly, the disruption of the corresponding gene in Caenorhabditis elegans, clk-1, results in a prolonged life span and a slowing of development. Because of the pleiotropic effect of this disruption, the small size of the protein, and the lack of obvious homology to other known hydroxylases, it has been suggested that Coq7 may be a regulatory or structural component in UQ biosynthesis, rather than acting as the hydroxylase per se. Here we identify Coq7 as belonging to a family of a di-iron containing oxidases/hydroxylases based on a conserved sequence motif for the iron ligands, supporting a direct function of Coq7 as a hydroxylase. We have cloned COQ7 from Pseudomonas aeruginosa and Thiobacillus ferrooxidans and show that indeed this gene complements an Escherichia coli mutant that lacks an unrelated 5-demethoxyubiquinone hydroxylase. Based on the similarities to other well studied di-iron carboxylate proteins, we propose a structural model for Coq7 as an interfacial integral membrane protein.	Univ Stockholm, Dept Biochem & Biophys, S-10691 Stockholm, Sweden	Stockholm University	Nordlund, P (corresponding author), Univ Stockholm, Dept Biochem & Biophys, Svante Arrhenius Vag 12, S-10691 Stockholm, Sweden.			Stenmark, Pal/0000-0003-4777-3417				ABERG F, 1992, ARCH BIOCHEM BIOPHYS, V295, P230, DOI 10.1016/0003-9861(92)90511-T; ALEXANDER K, 1978, BIOCHEMISTRY-US, V17, P4750, DOI 10.1021/bi00615a024; Andersson ME, 1999, FEBS LETT, V449, P17, DOI 10.1016/S0014-5793(99)00376-2; Andersson SGE, 1998, NATURE, V396, P133, DOI 10.1038/24094; Asaumi S, 1999, GENOMICS, V58, P293, DOI 10.1006/geno.1999.5838; Berthold DA, 2000, BBA-BIOENERGETICS, V1460, P241, DOI 10.1016/S0005-2728(00)00149-3; Clarke CF, 2000, PROTOPLASMA, V213, P134, DOI 10.1007/BF01282151; Ewbank JJ, 1997, SCIENCE, V275, P980, DOI 10.1126/science.275.5302.980; FELTON J, 1980, J BACTERIOL, V142, P221, DOI 10.1128/JB.142.1.221-228.1980; FROLOW F, 1994, NAT STRUCT BIOL, V1, P453, DOI 10.1038/nsb0794-453; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HALLBERG KB, 1994, MICROBIOL-SGM, V140, P3451, DOI 10.1099/13500872-140-12-3451; Jonassen T, 1996, ARCH BIOCHEM BIOPHYS, V330, P285, DOI 10.1006/abbi.1996.0255; Jonassen T, 2001, P NATL ACAD SCI USA, V98, P421, DOI 10.1073/pnas.021337498; Jonassen T, 1998, J BIOL CHEM, V273, P3351, DOI 10.1074/jbc.273.6.3351; Josse EM, 2000, PLANT PHYSIOL, V123, P1427, DOI 10.1104/pp.123.4.1427; Kwon O, 2000, FEMS MICROBIOL LETT, V186, P157, DOI 10.1016/S0378-1097(00)00134-8; Liu QH, 2000, METHOD ENZYMOL, V328, P530, DOI 10.1016/S0076-6879(00)28417-6; Logan DT, 1998, BIOCHEMISTRY-US, V37, P10798, DOI 10.1021/bi9806403; Marbois BN, 1996, J BIOL CHEM, V271, P2995, DOI 10.1074/jbc.271.6.2995; MATSUSHITA K, 1980, J BACTERIOL, V141, P389, DOI 10.1128/JB.141.1.389-392.1980; Meganathan R., 1996, ESCHERICHIA COLI SAL, P642; Miyadera H, 2001, J BIOL CHEM, V276, P7713, DOI 10.1074/jbc.C000889200; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; Solomon EI, 2000, CHEM REV, V100, P235, DOI 10.1021/cr9900275; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Vajo Z, 1999, MAMM GENOME, V10, P1000, DOI 10.1007/s003359901147; WALLACE BJ, 1977, BIOCHIM BIOPHYS ACTA, V461, P75, DOI 10.1016/0005-2728(77)90070-6; Wendt KU, 1999, J MOL BIOL, V286, P175, DOI 10.1006/jmbi.1998.2470; WONG A, 1995, GENETICS, V139, P1247; Yao Z, 1992, PCR Methods Appl, V1, P205; YOUNG IG, 1971, J BACTERIOL, V105, P769, DOI 10.1128/JB.105.3.769-778.1971	32	98	101	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33297	33300		10.1074/jbc.C100346200	http://dx.doi.org/10.1074/jbc.C100346200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11435415	hybrid			2022-12-25	WOS:000170910200002
J	Sturzenbaum, SR; Winters, C; Galay, M; Morgan, AJ; Kille, P				Sturzenbaum, SR; Winters, C; Galay, M; Morgan, AJ; Kille, P			Metal ion trafficking in earthworms - Identification of a cadmium-specific metallothionein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING; SEQUESTRATION; COPPER; PROTEINS; CLONING; CD	Exposure to cadmium poses a considerable risk to human health and environmental safety. Earthworms reside in the most contaminated sites on earth, displaying a phenomenal tolerance to toxic heavy metals. They exhibit a distinct metabolic pathway that allows the bio-accumulation of cadmium to yield body burdens in excess of 1/1000th of total dry body weight, a most impressive figure by any standard. However, the precise molecular mechanism underlying this phenomenon remains to be unraveled. This study meets this challenge by fully characterizing the major metal-binding protein in earthworms, namely the two isoforms of metallothionein. Chemical analysis of recombinant protein showed that although both isoforms bind equimolar amounts of cadmium (6 mol), wMT-2 is more stable during proton competition. Furthermore, isoform-specific transcript analysis demonstrated that only wMT-2 is responsive to cadmium in a dose and temporal manner. The specific sequestration of cadmium to wMT-2 protein was confirmed in situ using polyclonal antisera. The latter also provided the means for mapping the cellular and intracellular distribution of metallothionein, thus yielding a holistic insight into its involvement in cadmium transit during absorption, storage, and excretion. The structure-function relationship of wMT-2 and its role in cadmium detoxification through sequestration and compartmentalization is discussed.	Cardiff Univ, Sch Biosci, Cardiff CF1 3US, S Glam, Wales	Cardiff University	Sturzenbaum, SR (corresponding author), Cardiff Univ, Sch Biosci, POB 911, Cardiff CF10 3US, S Glam, Wales.	SturzenbaumSR@Carcliff.ac.uk	Kille, Peter/A-4337-2010; Morgan, Andrew J/A-4508-2010	Kille, Peter/0000-0001-6023-5221; 				BROWN MW, 1987, COMP BIOCHEM PHYS C, V87, P65, DOI 10.1016/0742-8413(87)90182-4; Dallinger R, 1997, NATURE, V388, P237, DOI 10.1038/40785; Darwin C., 1881, FORMATION VEGETABLE, DOI DOI 10.1017/CBO9780511703850; Gruber C, 2000, EUR J BIOCHEM, V267, P573, DOI 10.1046/j.1432-1327.2000.01035.x; HEILMAIER HE, 1987, TOXICOL LETT, V38, P205, DOI 10.1016/0378-4274(87)90001-4; Hensbergen PJ, 1999, EUR J BIOCHEM, V259, P197, DOI 10.1046/j.1432-1327.1999.00016.x; Jacob ST, 1999, GENE EXPRESSION, V7, P301; KILLE P, 1992, J BIOL CHEM, V267, P8042; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARET W, 1994, P NATL ACAD SCI USA, V91, P237, DOI 10.1073/pnas.91.1.237; Marino F, 1998, COMP BIOCHEM PHYS C, V120, P217, DOI 10.1016/S0742-8413(98)00043-7; MORGAN AJ, 1993, SETAC SP P, P333; Morgan AJ, 1999, INVERTEBR REPROD DEV, V36, P17, DOI 10.1080/07924259.1999.9652673; Morgan AJ, 1999, METH MOL B, V117, P245; MORGAN JE, 1989, COMP BIOCHEM PHYS C, V92, P15, DOI 10.1016/0742-8413(89)90195-3; Morris CA, 1999, METALLOTHIONEIN IV, P621; RHEE IK, 1990, PROTEIN ENG, V3, P205, DOI 10.1093/protein/3.3.205; SLICE LW, 1990, J BIOL CHEM, V265, P256; STILLMAN MJ, 1987, J BIOL CHEM, V262, P4538; Sturzenbaum SR, 1998, FEBS LETT, V431, P437, DOI 10.1016/S0014-5793(98)00809-6; TOKUYASU KT, 1985, J CELL BIOL, V100, P1157, DOI 10.1083/jcb.100.4.1157; TOMMEY AM, 1991, FEBS LETT, V292, P48, DOI 10.1016/0014-5793(91)80831-M; Webster P, 1999, METH MOL B, V117, P49; WINGE DR, 1982, J BIOL CHEM, V257, P3471; Winters C, 1997, HISTOCHEM J, V29, P301, DOI 10.1023/A:1026474531060	25	121	126	0	32	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					34013	34018		10.1074/jbc.M103605200	http://dx.doi.org/10.1074/jbc.M103605200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11418603	hybrid			2022-12-25	WOS:000170910200097
J	Jannatipour, M; Dion, P; Khan, S; Jindal, H; Fan, XP; Laganiere, J; Chishti, AH; Rouleau, GA				Jannatipour, M; Dion, P; Khan, S; Jindal, H; Fan, XP; Laganiere, J; Chishti, AH; Rouleau, GA			Schwannomin isoform-1 interacts with syntenin via PDZ domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROFIBROMATOSIS-2 TUMOR-SUPPRESSOR; PROTEIN-PROTEIN INTERACTIONS; TYPE-2 GENE-PRODUCT; BASOLATERAL MEMBRANE; EPITHELIAL-CELLS; ERM PROTEINS; MERLIN; EZRIN; FAMILY; CYTOSKELETON	The neurofibromatosis type 2 gene (NF2) is involved in the pathogenesis of benign tumors of the human nervous system. The NF2 protein, called schwannomin or merlin, is inactivated in virtually all schwannomas and meningiomas. The molecular mechanisms by which schwannomin functions as a tumor suppressor is unknown but believed to involve plasma membrane-cytoskeletal interactions. Two major alternatively spliced isoforms of schwannomin differing in their C termini have been reported. Using the yeast two-hybrid system, we have identified syntenin as a binding partner for schwannomin isoform-1 (sch-1). Syntenin is an adapter protein that couples transmembrane proteoglycans to cytoskeletal components and is involved in intracellular vesicle transport. The C terminus 25 amino acids of sch-1 and the two PDZ domains of syntenin mediate their binding, and mutations introduced within the VAFFEEL region of sch-1 defined a sequence crucial for syntenin recognition. We have showed that the two proteins interacted in vitro and in vivo and localized underneath the plasma membrane. Fibroblast cells expressing heterologous antisense syntenin display alterations in the subcellular distribution of sch-1. Together, these results provide the first functional clue to the existence of schwannomin isoforms and could unravel novel pathways for the transport and subcellular localization of schwannomin in vivo.	McGill Univ, Ctr Res Neurosci, Montreal, PQ H3G 1A4, Canada; Montreal Gen Hosp, Montreal, PQ H3G 1A4, Canada; Tufts Univ, Sch Med, Sect Hematol Oncol Res, St Elizabeths Med Ctr, Boston, MA 02135 USA	McGill University; McGill University; St. Elizabeth's Medical Center; Tufts University	Rouleau, GA (corresponding author), McGill Univ, Ctr Res Neurosci, 1650 Cedar Ave, Montreal, PQ H3G 1A4, Canada.			Fan, Xueping/0000-0002-3715-6864	NCI NIH HHS [CA66263] Funding Source: Medline; NHLBI NIH HHS [HL60755] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA066263] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060755] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARPIN M, 1994, CURR OPIN CELL BIOL, V6, P136, DOI 10.1016/0955-0674(94)90127-9; BIANCHI AB, 1994, NAT GENET, V6, P185, DOI 10.1038/ng0294-185; Brault E, 2001, J CELL SCI, V114, P1901; Bretscher A, 1999, CURR OPIN CELL BIOL, V11, P109, DOI 10.1016/S0955-0674(99)80013-1; Bretscher A, 2000, ANNU REV CELL DEV BI, V16, P113, DOI 10.1146/annurev.cellbio.16.1.113; Cohen AR, 1998, J CELL BIOL, V142, P129, DOI 10.1083/jcb.142.1.129; Cowburn D, 1997, CURR OPIN STRUC BIOL, V7, P835, DOI 10.1016/S0959-440X(97)80155-8; Daniels DL, 1998, NAT STRUCT BIOL, V5, P317, DOI 10.1038/nsb0498-317; Dobrosotskaya I, 1997, J BIOL CHEM, V272, P31589, DOI 10.1074/jbc.272.50.31589; Fanning AS, 1996, CURR BIOL, V6, P1385, DOI 10.1016/S0960-9822(96)00737-3; Fanning AS, 1998, CURR TOP MICROBIOL, V228, P209; Fernandez-Larrea J, 1999, MOL CELL, V3, P423, DOI 10.1016/S1097-2765(00)80470-0; Fialka I, 1999, J BIOL CHEM, V274, P26233, DOI 10.1074/jbc.274.37.26233; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GonzalezAgosti C, 1996, ONCOGENE, V13, P1239; Gronholm M, 1999, J CELL SCI, V112, P895; Grootjans JJ, 1997, P NATL ACAD SCI USA, V94, P13683, DOI 10.1073/pnas.94.25.13683; GUTMANN DH, 1995, HUM MOL GENET, V4, P471, DOI 10.1093/hmg/4.3.471; Gutmann DH, 1999, HUM MOL GENET, V8, P267, DOI 10.1093/hmg/8.2.267; Hillier BJ, 1999, SCIENCE, V284, P812, DOI 10.1126/science.284.5415.812; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; Huynh DP, 1996, ONCOGENE, V13, P73; JINDAL HK, 1998, AM SOC HEM M ABSTR N, pA6; Kachinsky AM, 1999, J CELL BIOL, V145, P391, DOI 10.1083/jcb.145.2.391; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Koroll M, 2001, J BIOL CHEM, V276, P10646, DOI 10.1074/jbc.M010647200; Lamb RF, 1997, CURR BIOL, V7, P682, DOI 10.1016/S0960-9822(06)00295-8; Lin D, 1999, J BIOL CHEM, V274, P3726, DOI 10.1074/jbc.274.6.3726; LOUIS DN, 1995, BRAIN PATHOL, V5, P163, DOI 10.1111/j.1750-3639.1995.tb00590.x; LUTCHMAN M, 1995, CANCER RES, V55, P2270; Maekawa K, 1999, BIOCHEM J, V337, P179, DOI 10.1042/0264-6021:3370179; Meng JJ, 2000, J NEUROSCI RES, V62, P491, DOI 10.1002/1097-4547(20001115)62:4<491::AID-JNR3>3.0.CO;2-D; Obremski VJ, 1998, J NEUROBIOL, V37, P487, DOI 10.1002/(SICI)1097-4695(199812)37:4<487::AID-NEU1>3.3.CO;2-2; Pearson MA, 2000, CELL, V101, P259, DOI 10.1016/S0092-8674(00)80836-3; Ponting CP, 1997, BIOESSAYS, V19, P469, DOI 10.1002/bies.950190606; PYKETT MJ, 1994, HUM MOL GENET, V3, P559, DOI 10.1093/hmg/3.4.559; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; Sainio M, 1997, J CELL SCI, V110, P2249; Saoncella S, 1999, P NATL ACAD SCI USA, V96, P2805, DOI 10.1073/pnas.96.6.2805; Scherer SS, 1996, J NEUROSCI RES, V46, P595, DOI 10.1002/(SICI)1097-4547(19961201)46:5<595::AID-JNR8>3.3.CO;2-2; Scoles DR, 1998, NAT GENET, V18, P354, DOI 10.1038/ng0498-354; Shaw RJ, 1998, J BIOL CHEM, V273, P7757, DOI 10.1074/jbc.273.13.7757; Sherman L, 1997, ONCOGENE, V15, P2505, DOI 10.1038/sj.onc.1201418; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; THOMAS G, 1994, EUR J CANCER, V30A, P1981, DOI 10.1016/0959-8049(94)00390-Q; Torres R, 1998, NEURON, V21, P1453, DOI 10.1016/S0896-6273(00)80663-7; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; Vaheri A, 1997, CURR OPIN CELL BIOL, V9, P659, DOI 10.1016/S0955-0674(97)80119-6; Xu HM, 1998, J NEUROSCI RES, V51, P403, DOI 10.1002/(SICI)1097-4547(19980201)51:3<403::AID-JNR13>3.0.CO;2-7; Yonemura S, 1998, J CELL BIOL, V140, P885, DOI 10.1083/jcb.140.4.885	52	60	64	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					33093	33100		10.1074/jbc.M105792200	http://dx.doi.org/10.1074/jbc.M105792200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11432873	hybrid			2022-12-25	WOS:000170746000095
J	Wang, XL; Hu, B; Zimmermann, B; Kilimann, MW				Wang, XL; Hu, B; Zimmermann, B; Kilimann, MW			Rim1 and rabphilin-3 bind Rab3-GTP by composite determinants partially related through N-terminal alpha-helix motifs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC VESICLES; PROTEIN RAB3A; EFFECTOR; DOMAIN; EXOCYTOSIS; CHROMAFFIN; SECRETION; MEMBRANES; POTENTIATION; MECHANISM	Rim1 is a protein of the presynaptic active zone, the area of the plasma membrane specialized for neurotransmitter exocytosis, and interacts with Rab3, a small GTPase implicated in neurotransmitter vesicle dynamics. Here, we have studied the molecular determinants of Rim1 that are responsible for Rab3 binding, employing surface plasmon resonance and recombinant, bacterially expressed Rab3 and Rim1 proteins. A site that binds GTP- but not GDP-saturated Rab3 was localized to a short alpha -helical sequence near the Rim1 N terminus (amino acids 19-55). Rab3 isoforms A, C, and D were bound with similar affinities (K-d = 1-2 mum). Low affinity binding of Rab6A-GTP was also observed (K-d = 16 mum), whereas Rab1B, -5, -7, -8, or -11A did not bind. Adjacent sequences up to amino acid 387, encompassing differentially spliced sequences, the zinc finger module, and the SGAWFF motif of Rim1, did not significantly contribute to the strength or the specificity of Rab3 binding, whereas a point mutation within the helix (R33G) abolished binding. This Rab3 binding site of Rim1 is reminiscent of the N-terminal alpha -helix that is part of the Rab3-binding region of rabphilin-3, and indeed we observed low affinity, specific binding of Rab3A (K-d on the order of magnitude of 10-100 mum) to this region of rabphilin-3 alone (amino acids 40-88), whereas additional sequences up to amino acid 178 are needed for high affinity Rab3A binding to rabphilin-3 (K-d = 10-20 nm). In contrast, an N-terminal alpha -helix motif in aczonin, with sequence similarity to the Rab3-binding site of Rim1, did not bind Rab3A, -C, or -D or several other Rah proteins. These results were qualitatively confirmed in pull-down experiments with native, prenylated Rab3 from brain lysate in Triton X-100. Munc13 bound to the zinc finger domain of Rim1 but not to the rabphilin-3 or aczonin zinc fingers. Pull-down experiments from brain lysate in the presence of cholate as detergent detected binding to downstream Rim1 sequences, between amino acids 56 and 387, of syntaxin and of Rab3. The latter, however, was inhibited rather than stimulated by GTP.	Ruhr Univ Bochum, Inst Physiol Chem, D-44780 Bochum, Germany; Ruhr Univ Bochum, Biaffin GmbH & Co KG, D-44780 Bochum, Germany	Ruhr University Bochum; Ruhr University Bochum	Kilimann, MW (corresponding author), Ruhr Univ Bochum, Inst Physiol Chem, D-44780 Bochum, Germany.	manfred.kilimann@ruhr-uni-bochum.de						Abdul-Ghani M, 2001, J BIOL CHEM, V276, P6225, DOI 10.1074/jbc.M009073200; Arribas M, 1997, EUR J CELL BIOL, V74, P209; Bean AJ, 1997, NEURON, V19, P751, DOI 10.1016/S0896-6273(00)80957-5; Betz A, 2001, NEURON, V30, P183, DOI 10.1016/S0896-6273(01)00272-0; Betz A, 1997, J BIOL CHEM, V272, P2520; Castillo PE, 1997, NATURE, V388, P590, DOI 10.1038/41574; Chavrier P, 1999, CURR OPIN CELL BIOL, V11, P466, DOI 10.1016/S0955-0674(99)80067-2; Chung SH, 1999, J BIOL CHEM, V274, P18113, DOI 10.1074/jbc.274.25.18113; CHUNG SH, 1995, J BIOL CHEM, V270, P16714, DOI 10.1074/jbc.270.28.16714; Coppola T, 1999, EMBO J, V18, P5885, DOI 10.1093/emboj/18.21.5885; Fenster SD, 2000, NEURON, V25, P203, DOI 10.1016/S0896-6273(00)80883-1; FISCHER V, 1991, NATURE, V349, P79; Fitzgerald ML, 1999, BIOCHEM J, V342, P353, DOI 10.1042/0264-6021:3420353; GEPPERT M, 1994, NATURE, V369, P493, DOI 10.1038/369493a0; Geppert M, 1997, NATURE, V387, P810, DOI 10.1038/42954; GIEDROC DP, 1986, P NATL ACAD SCI USA, V83, P8452, DOI 10.1073/pnas.83.22.8452; Haynes LP, 2001, J BIOL CHEM, V276, P9726, DOI 10.1074/jbc.M006959200; Joberty G, 1999, J CELL SCI, V112, P3579; Kotake K, 1997, J BIOL CHEM, V272, P29407, DOI 10.1074/jbc.272.47.29407; Kuhlmann J, 1997, BIOCHEMISTRY-US, V36, P12027, DOI 10.1021/bi970524k; Lenzen C, 1998, BIOCHEMISTRY-US, V37, P7420, DOI 10.1021/bi972621j; LI C, 1994, NEURON, V13, P885, DOI 10.1016/0896-6273(94)90254-2; LIDA H, 1997, AM J PHYSIOL, V41, pC1594; Martincic I, 1997, J BIOL CHEM, V272, P26991, DOI 10.1074/jbc.272.43.26991; McKiernan CJ, 1996, MOL CELL BIOL, V16, P4985; MIZOGUCHI A, 1990, J BIOL CHEM, V265, P11872; Novick P, 1997, CURR OPIN CELL BIOL, V9, P496, DOI 10.1016/S0955-0674(97)80025-7; Ostermeier C, 1999, CELL, V96, P363, DOI 10.1016/S0092-8674(00)80549-8; Ozaki N, 2000, NAT CELL BIOL, V2, P805, DOI 10.1038/35041046; Rudolph MG, 1998, J BIOL CHEM, V273, P18067, DOI 10.1074/jbc.273.29.18067; Schimmoller F, 1998, J BIOL CHEM, V273, P22161, DOI 10.1074/jbc.273.35.22161; Schluter OM, 1999, J NEUROSCI, V19, P5834, DOI 10.1523/JNEUROSCI.19-14-05834.1999; STAHL B, 1994, J BIOL CHEM, V269, P24770; Stahl B, 1996, EMBO J, V15, P1799, DOI 10.1002/j.1460-2075.1996.tb00529.x; Sun L, 2001, J BIOL CHEM, V276, P12911, DOI 10.1074/jbc.M011110200; Sydor JR, 1998, BIOCHEMISTRY-US, V37, P14292, DOI 10.1021/bi980764f; TIXIERVIDAL A, 1993, J CELL SCI, V105, P935; VONMOLLARD GF, 1994, J BIOL CHEM, V269, P10971; Wada M, 1997, J BIOL CHEM, V272, P3875, DOI 10.1074/jbc.272.7.3875; Wang XL, 1999, J CELL BIOL, V147, P151, DOI 10.1083/jcb.147.1.151; Wang Y, 1997, NATURE, V388, P593, DOI 10.1038/41580; Wang Y, 2000, J BIOL CHEM, V275, P20033, DOI 10.1074/jbc.M909008199; White J, 1999, J CELL BIOL, V147, P743, DOI 10.1083/jcb.147.4.743	43	49	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					32480	32488		10.1074/jbc.M103337200	http://dx.doi.org/10.1074/jbc.M103337200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11431472	hybrid			2022-12-25	WOS:000170746000016
J	Alexander, JJ; Hack, BK; Cunningham, PN; Quigg, RJ				Alexander, JJ; Hack, BK; Cunningham, PN; Quigg, RJ			A protein with characteristics of factor H is present on rodent platelets and functions as the immune adherence receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENT FACTOR-H; DECAY-ACCELERATING FACTOR; HUMAN POLYMORPHONUCLEAR LEUKOCYTES; BINDING-SITES; MONOCLONAL-ANTIBODIES; NEISSERIA-GONORRHOEAE; REGULATORY PROTEINS; TISSUE DISTRIBUTION; MOLECULAR-CLONING; SERUM RESISTANCE	Complement-coated particles interact with specific immune adherence receptors JAR). In primates, this function is served by complement receptor 1 (CR1) on erythrocytes. In contrast, rodent platelets bear LAR distinct from CR1, the identity of which was studied here. A 150-kDa C3b-binding protein was isolated from rat platelets, which had immunochemical and biochemical identity to plasma factor H. Immunofluorescence microscopy and flow cytometry demonstrated that factor H was present on the surface of rat and mouse platelets, which could be removed by treatment with neuraminidase. Sheep erythrocytes bearing C3b underwent immune adherence with rat and mouse platelets, which was blocked with anti-factor H F(ab ')(2) antibodies, but not with antibodies binding to the complement regulator, Crry, on the platelet surface. By reverse transcription-polymerase chain reaction using rat platelet RNA and primers designed from mouse factor H, a 472-base pair product was generated that was identical in sequence to that produced from rat liver RNA. The translated protein product was 85% similar to mouse liver factor H. The 3 ' -nucleotide sequence from platelets predicted a soluble factor H protein. By Northern analysis, liver and platelets had identically sized factor H mRNA. Thus, rat and mouse platelets have a membrane protein with characteristics of factor H that is linked via sialic acid residues and functions as the LAR. Whether platelet factor H is acquired by passive adsorption from sera and/or is produced by platelets remains to be determined.	Univ Chicago, Nephrol Sect, Dept Med, Chicago, IL 60637 USA	University of Chicago	Alexander, JJ (corresponding author), Univ Chicago, Nephrol Sect, Dept Med, 5841 S Maryland Ave,MC5100, Chicago, IL 60637 USA.	jalexand@medicine.uchicago.edu	Alexander, Jessy/ABA-7664-2020		NIDDK NIH HHS [T32DK07510, R01DK55357, R01DK48173] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055357, T32DK007510] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHEARN JM, 1989, ADV IMMUNOL, V46, P183, DOI 10.1016/S0065-2776(08)60654-9; Alexander JJ, 1999, IMMUNOPHARMACOLOGY, V42, P245, DOI 10.1016/S0162-3109(99)00010-7; Ault BH, 1997, J BIOL CHEM, V272, P25168, DOI 10.1074/jbc.272.40.25168; AVERY VM, 1993, J IMMUNOL, V151, P5545; CAMPBELL RD, 1988, ANNU REV IMMUNOL, V6, P161, DOI 10.1146/annurev.iy.06.040188.001113; CHEVALIER J, 1989, J IMMUNOL, V142, P2031; Chittum HS, 1998, BIOCHEMISTRY-US, V37, P10866, DOI 10.1021/bi981042r; DEVINE DV, 1987, P NATL ACAD SCI USA, V84, P5873, DOI 10.1073/pnas.84.16.5873; DEVINE DV, 1987, J CLIN INVEST, V79, P131, DOI 10.1172/JCI112773; Diaz A, 1997, J IMMUNOL, V158, P3779; DiScipio RG, 1998, J IMMUNOL, V160, P4057; EDBERG JC, 1989, CLIN IMMUNOL IMMUNOP, V51, P118, DOI 10.1016/0090-1229(89)90212-2; FEARON DT, 1979, P NATL ACAD SCI USA, V76, P5867, DOI 10.1073/pnas.76.11.5867; FISCHETTI VA, 1995, INFECT IMMUN, V63, P149, DOI 10.1128/IAI.63.1.149-153.1995; He C, 1997, ARCH BIOCHEM BIOPHYS, V341, P347, DOI 10.1006/abbi.1997.9989; HEBERT LA, 1991, AM J KIDNEY DIS, V17, P352; HELLWAGE J, 2000, J BIOL CHEM; HENSON PM, 1969, IMMUNOLOGY, V16, P107; Hinchliffe SJ, 1998, J IMMUNOL, V161, P5695; HOLERS VM, 1995, PRINCIPLES PRACTICES, P363; HOURCADE D, 1989, ADV IMMUNOL, V45, P381, DOI 10.1016/S0065-2776(08)60697-5; Jokiranta TS, 2000, J BIOL CHEM, V275, P27657; Junnikkala S, 2000, J IMMUNOL, V164, P6075, DOI 10.4049/jimmunol.164.11.6075; KAZATCHKINE MD, 1982, J CLIN INVEST, V69, P900, DOI 10.1172/JCI110529; KENNEY DM, 1981, CLIN IMMUNOL IMMUNOP, V21, P351, DOI 10.1016/0090-1229(81)90224-5; KINGSMORE SF, 1989, J EXP MED, V169, P1479, DOI 10.1084/jem.169.4.1479; KINOSHITA T, 1988, J IMMUNOL, V140, P3066; KINOSHITA T, 1985, J IMMUNOL, V134, P2564; KRISTENSEN T, 1986, P NATL ACAD SCI USA, V83, P3963, DOI 10.1073/pnas.83.11.3963; KURTZ CB, 1990, J IMMUNOL, V144, P3581; LI B, 1993, J IMMUNOL, V151, P4295; LUBLIN DM, 1986, J BIOL CHEM, V261, P5736; MALHOTRA V, 1985, EUR J IMMUNOL, V15, P935, DOI 10.1002/eji.1830150913; MANTHEI U, 1988, J IMMUNOL, V140, P1228; McKenzie SE, 1999, J IMMUNOL, V162, P4311; McRae JL, 2001, J BIOL CHEM, V276, P6747, DOI 10.1074/jbc.M007495200; MOLINA H, 1990, J IMMUNOL, V145, P2974; MOLINA H, 1994, J IMMUNOL, V153, P789; Morgan H.C, 1999, COMPLEMENT REGULATOR, P41; Nabil K, 1997, BIOCHEM J, V326, P377, DOI 10.1042/bj3260377; NELSON DS, 1963, ADV IMMUNOL, V3, P131, DOI 10.1016/S0065-2776(08)60812-3; NELSON RA, 1953, SCIENCE, V118, P733, DOI 10.1126/science.118.3077.733; OKUDA T, 1984, DEV COMP IMMUNOL, V8, P461, DOI 10.1016/0145-305X(84)90053-3; PANGBURN MK, 1991, J BIOL CHEM, V266, P16847; Quigg RJ, 1997, J IMMUNOL, V159, P2438; QUIGG RJ, 1994, J AM SOC NEPHROL, V4, P1912; QUIGG RJ, 1995, IMMUNOGENETICS, V42, P362, DOI 10.1007/BF00179397; Quigg RJ, 2000, IMMUNOLOGY, V99, P46, DOI 10.1046/j.1365-2567.2000.00945.x; QUIGG RJ, 1993, KIDNEY INT, V43, P730, DOI 10.1038/ki.1993.104; QUIGG RJ, 1995, J IMMUNOL, V155, P1481; Ram S, 1998, J EXP MED, V187, P743, DOI 10.1084/jem.187.5.743; Ram S, 1998, J EXP MED, V188, P671, DOI 10.1084/jem.188.4.671; RODRIGUEZ DC, 1985, J EXP MED, V161, P1189; SADLON TA, 1994, IMMUNOL CELL BIOL, V72, P461, DOI 10.1038/icb.1994.70; SCHIFFERLI JA, 1989, KIDNEY INT, V35, P993, DOI 10.1038/ki.1989.83; Schiller B, 1998, J EXP MED, V188, P1353, DOI 10.1084/jem.188.7.1353; Sharma AK, 1996, P NATL ACAD SCI USA, V93, P10996, DOI 10.1073/pnas.93.20.10996; Sharma AK, 1997, INFECT IMMUN, V65, P484, DOI 10.1128/IAI.65.2.484-487.1997; SIM RB, 1982, BIOCHEM J, V205, P285, DOI 10.1042/bj2050285; Soames CJ, 1997, BIOCHEM J, V326, P553, DOI 10.1042/bj3260553; SPICER AP, 1995, J IMMUNOL, V155, P3079; Spiller OB, 1999, IMMUNOLOGY, V97, P374; TAYLOR RP, 1985, J IMMUNOL, V134, P2550; Zipfel PF, 1999, MOL IMMUNOL, V36, P241, DOI 10.1016/S0161-5890(99)00038-3; Zipfel PF, 1999, IMMUNOPHARMACOLOGY, V42, P53, DOI 10.1016/S0162-3109(99)00015-6	65	51	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					32129	32135		10.1074/jbc.M101299200	http://dx.doi.org/10.1074/jbc.M101299200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11406620	hybrid			2022-12-25	WOS:000170613500090
J	Langosch, D; Brosig, B; Pipkorn, R				Langosch, D; Brosig, B; Pipkorn, R			Peptide mimics of the vesicular stomatitis virus G-protein transmembrane segment drive membrane fusion in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANCHORED INFLUENZA HEMAGGLUTININ; ALPHA-HELICAL PEPTIDES; AMINO-ACIDS; HEMIFUSION INTERMEDIATE; ENVELOPE GLYCOPROTEIN; SPANNING DOMAIN; ENVIRONMENTS; PROPENSITIES; ORIENTATION; MECHANISM	The efficiency of cell-cell fusion mediated by heterologously expressed vesicular stomatitis virus G-protein has previously been shown to be affected by mutating its transmembrane segment. Here, we show that a synthetic peptide modeled after this transmembrane segment drives liposome-liposome fusion. Addition of millimolar Ca2+ concentrations strongly potentiated the effect of the peptides suggesting that Ca2+-mediated liposome aggregation supports the activity of the peptide. Peptide-driven fusion was suppressed by lysolipid, an established inhibitor of natural membrane fusion, and involved inner and outer leaflets of the liposomal bilayer. Thus, transmembrane segment peptide-driven liposome fusion exhibits important hallmarks characteristic of natural membrane fusion. Importantly, the mutations previously shown to attenuate the function of full-length G-protein in cell-cell fusion also attenuated the fusogenicity of the peptide, albeit in a less pronounced fashion. Therefore, the function of the peptide mimic is dependent on its primary structure, similar to full-length G-protein. Together, our data suggest that the G-protein transmembrane segment is an autonomous functional domain. We propose that it acts at a late step in membrane fusion elicited by vesicular stomatitis virus.	Univ Heidelberg, Inst Neurobiol, Dept Neurobiol, D-69120 Heidelberg, Germany; German Canc Res Ctr, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ)	Langosch, D (corresponding author), Univ Heidelberg, Inst Neurobiol, Dept Neurobiol, Neuenheimer Feld 364, D-69120 Heidelberg, Germany.							Armstrong RT, 2000, J CELL BIOL, V151, P425, DOI 10.1083/jcb.151.2.425; Bottcher CJF, 1961, ANAL CHIM ACTA, V24, P203; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; CHERNOMORDIK L, 1995, J MEMBRANE BIOL, V146, P1; CHERNOMORDIK LV, 1993, FEBS LETT, V318, P71, DOI 10.1016/0014-5793(93)81330-3; Cleverley DZ, 1998, P NATL ACAD SCI USA, V95, P3425, DOI 10.1073/pnas.95.7.3425; de Planque MRR, 1999, J BIOL CHEM, V274, P20839, DOI 10.1074/jbc.274.30.20839; DURELL SR, 1997, MOL MEMBR BIOL, V14, P97; DUZGUNES N, 1987, BIOCHEMISTRY-US, V26, P8435, DOI 10.1021/bi00399a061; Gurezka R, 1999, J BIOL CHEM, V274, P9265, DOI 10.1074/jbc.274.14.9265; Hernandez LD, 1996, ANNU REV CELL DEV BI, V12, P627, DOI 10.1146/annurev.cellbio.12.1.627; HOEKSTRA D, 1993, METHOD ENZYMOL, V220, P15, DOI 10.1016/0076-6879(93)20070-J; HUSCHILT JC, 1989, BIOCHIM BIOPHYS ACTA, V979, P139, DOI 10.1016/0005-2736(89)90534-8; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; KEMBLE GW, 1994, CELL, V76, P383, DOI 10.1016/0092-8674(94)90344-1; KOZERSKI G, 2000, J VIROL, V74, P395; Lentz BR, 2000, CURR OPIN STRUC BIOL, V10, P607, DOI 10.1016/S0959-440X(00)00138-X; LI SC, 1994, NAT STRUCT BIOL, V1, P368, DOI 10.1038/nsb0694-368; LI SC, 1992, INT J PEPT PROT RES, V40, P243; Liu LP, 1998, J BIOL CHEM, V273, P23645, DOI 10.1074/jbc.273.37.23645; Liu LP, 1997, BIOCHEMISTRY-US, V36, P5476, DOI 10.1021/bi970030n; Markosyan RM, 2000, MOL BIOL CELL, V11, P1143, DOI 10.1091/mbc.11.4.1143; Melikyan GB, 2000, MOL BIOL CELL, V11, P3765, DOI 10.1091/mbc.11.11.3765; Melikyan GB, 1999, MOL BIOL CELL, V10, P1821, DOI 10.1091/mbc.10.6.1821; Nussler F, 1997, BIOPHYS J, V73, P2280; Odell D, 1997, J VIROL, V71, P7996, DOI 10.1128/JVI.71.10.7996-8000.1997; OWENS RJ, 1994, J VIROL, V68, P570, DOI 10.1128/JVI.68.1.570-574.1994; PAPAHADJOPOULOS D, 1990, J BIOENERG BIOMEMBR, V22, P157, DOI 10.1007/BF00762944; Pecheur EI, 1999, J MEMBRANE BIOL, V167, P1, DOI 10.1007/s002329900466; SMITH CK, 1994, BIOCHEMISTRY-US, V33, P5510, DOI 10.1021/bi00184a020; Street AG, 1999, P NATL ACAD SCI USA, V96, P9074, DOI 10.1073/pnas.96.16.9074; STRUCK DK, 1981, BIOCHEMISTRY-US, V20, P4093, DOI 10.1021/bi00517a023; Tatulian SA, 2000, BIOCHEMISTRY-US, V39, P496, DOI 10.1021/bi991594p; Taylor GM, 1999, MOL BIOL CELL, V10, P2803, DOI 10.1091/mbc.10.9.2803; Webb RJ, 1998, BIOCHEMISTRY-US, V37, P673, DOI 10.1021/bi972441+; WILK T, 1996, VIROLOGY, V76, P539	36	41	41	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					32016	32021		10.1074/jbc.M102579200	http://dx.doi.org/10.1074/jbc.M102579200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11418597	hybrid			2022-12-25	WOS:000170613500075
J	Peiretti, F; Lopez, S; Deprez-Beauclair, P; Bonardo, B; Juhan-Vague, I; Nalbone, G				Peiretti, F; Lopez, S; Deprez-Beauclair, P; Bonardo, B; Juhan-Vague, I; Nalbone, G			Inhibition of p70(S6) kinase during transforming growth factor-beta 1/vitamin D-3-induced monocyte differentiation of HL-60 cells allows tumor necrosis factor-alpha to stimulate plasminogen activator inhibitor-1 synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; MESSENGER-RNA TRANSLATION; P70 S6 KINASE; GENE-EXPRESSION; HL60 CELLS; NEOINTIMA FORMATION; RAPAMYCIN; PROLIFERATION; RECEPTOR; SUPPRESSES	We investigated intracellular mechanisms involved in the up-regulation of plasminogen activator inhibitor I (PAI-1) synthesis by human recombinant tumor necrosis factor-a (TNF) during monocyte differentiation of HL-60 cells triggered by the transforming growth factor-beta1/ vitamin D-3 (TGF/D3) mixture. TGF/D3-treated cells expressed surface monocytic markers and produced noticeable amounts of PAI-1 but stopped to proliferate. A reduced p70 S6 kinase (p70(S6K)) phosphorylation was also observed and, in this situation, TNF dramatically enhanced PAI-1 synthesis. Similarly, TNF significantly up-regulated PAI-1 synthesis when p70(S6K) phosphorylation was inhibited by rapamycin. This phenomenon was not due to a general decrease in protein synthesis but involved the activation of gene transcription rather than PAI-1 mRNA stabilization. The level of the transcriptional regulator factor E2F1, a repressor of PAI-1 gene expression, was shown to be down-modulated in TGF/D3- as well as in rapamycin-treated cells. Furthermore, the apoptotic effect of TNF in HL-60 cells appeared to be prevented by the addition of either TGF/D3 or rapamycin. In conclusion, these results indicate that inhibition of p70(S6K) phosphorylation during TGF/D3-induced monocyte differentiation of HL-60 cells is a determinant factor that allows TNF to exert its up-regulating effect on PAI-1 synthesis while protecting cells from apoptosis.	Fac Med Marseille, Hematol Lab, EPI 99 36, F-13385 Marseille 5, France	UDICE-French Research Universities; Aix-Marseille Universite	Peiretti, F (corresponding author), Fac Med Marseille, Hematol Lab, EPI 99 36, 27 Bd Jean Moulin, F-13385 Marseille 5, France.	Franck.Peiretti@medecine.univ-mrs.fr	Peiretti, Franck/GLV-3378-2022; LOPEZ, SOPHIE/R-1917-2016; peiretti, franck/L-2718-2017	Peiretti, Franck/0000-0001-7198-0534; LOPEZ, SOPHIE/0000-0002-5009-5533; peiretti, franck/0000-0001-7198-0534				ANDREASEN PA, 1990, MOL CELL ENDOCRINOL, V68, P1, DOI 10.1016/0303-7207(90)90164-4; Carmeliet P, 1997, CIRCULATION, V96, P3180, DOI 10.1161/01.CIR.96.9.3180; Carmeliet P, 1997, J CLIN INVEST, V99, P200, DOI 10.1172/JCI119148; Chapman HA, 1997, CURR OPIN CELL BIOL, V9, P714, DOI 10.1016/S0955-0674(97)80126-3; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; Edelmann HML, 1996, J BIOL CHEM, V271, P963, DOI 10.1074/jbc.271.2.963; Gallo R, 1999, CIRCULATION, V99, P2164, DOI 10.1161/01.CIR.99.16.2164; Hardwick JS, 1999, P NATL ACAD SCI USA, V96, P14866, DOI 10.1073/pnas.96.26.14866; HORIGUCHIYAMADA J, 1994, MOL CELL BIOCHEM, V132, P31, DOI 10.1007/BF00925672; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; JENO P, 1988, P NATL ACAD SCI USA, V85, P406, DOI 10.1073/pnas.85.2.406; Johnson KL, 1999, IMMUNOL CELL BIOL, V77, P242, DOI 10.1046/j.1440-1711.1999.00821.x; JUHANVAGUE I, 1993, THROMB HAEMOSTASIS, V70, P138; Kanatani Y, 1996, CELL GROWTH DIFFER, V7, P187; Kanayasu-Toyoda T, 1999, J BIOL CHEM, V274, P25471, DOI 10.1074/jbc.274.36.25471; Kirkham PA, 1998, J IMMUNOL, V161, P1630; Koziczak M, 2000, MOL CELL BIOL, V20, P2014, DOI 10.1128/MCB.20.6.2014-2022.2000; Krichevsky AM, 1999, J BIOL CHEM, V274, P14295, DOI 10.1074/jbc.274.20.14295; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; LODISH HF, 1974, NATURE, V251, P385, DOI 10.1038/251385a0; Lopez S, 1999, THROMB HAEMOSTASIS, V81, P415, DOI 10.1055/s-0037-1614488; Lopez S, 2000, J BIOL CHEM, V275, P3081, DOI 10.1074/jbc.275.5.3081; Loscalzo Joseph, 1996, Seminars in Thrombosis and Hemostasis, V22, P503, DOI 10.1055/s-2007-999051; LUNDGREN CH, 1994, CIRCULATION, V90, P1927, DOI 10.1161/01.CIR.90.4.1927; MARX SO, 1995, CIRC RES, V76, P412, DOI 10.1161/01.RES.76.3.412; MCCARTHY DM, 1983, LEUKEMIA RES, V7, P51, DOI 10.1016/0145-2126(83)90057-7; MORIKAWA M, 1990, IN VITRO CELL DEV B, V26, P682; Murakami T, 1996, CURR OPIN LIPIDOL, V7, P320, DOI 10.1097/00041433-199610000-00010; NING YM, 1993, J BIOL CHEM, V268, P6073; NOVAKHOFER I, 1984, J BIOL CHEM, V259, P5995; OKABEKADO J, 1991, ANTICANCER RES, V11, P181; Peiretti F, 1997, ARTERIOSCL THROM VAS, V17, P1550, DOI 10.1161/01.ATV.17.8.1550; Plenz G, 1998, EUR CYTOKINE NETW, V9, P701; Plow Edward F., 1999, Thrombosis and Haemostasis, V82, P4; Poon M, 1996, J CLIN INVEST, V98, P2277, DOI 10.1172/JCI119038; Preissner KT, 1997, THROMB HAEMOSTASIS, V78, P88; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; ROUIS M, 1990, ARTERIOSCLEROSIS, V10, P246, DOI 10.1161/01.ATV.10.2.246; Saunders NA, 1998, CANCER RES, V58, P1646; SCHWARTZ CJ, 1986, SEMIN THROMB HEMOST, V12, P79, DOI 10.1055/s-2007-1003539; SEHGAL SN, 1995, THER DRUG MONIT, V17, P660, DOI 10.1097/00007691-199512000-00019; SHI YF, 1995, CANCER RES, V55, P1982; Shiffman D, 2000, J BIOL CHEM, V275, P37324, DOI 10.1074/jbc.M004732200; Suzuki T, 2000, BLOOD, V96, P2584; Tamayo P, 1999, P NATL ACAD SCI USA, V96, P2907, DOI 10.1073/pnas.96.6.2907; TESTA U, 1993, J IMMUNOL, V150, P2418; Trayner ID, 1998, LEUKEMIA RES, V22, P537, DOI 10.1016/S0145-2126(98)00041-1; Valentinis B, 2000, J BIOL CHEM, V275, P25451, DOI 10.1074/jbc.M002271200; Volarevic S, 2001, PROG NUCLEIC ACID RE, V65, P101; Wang QM, 2000, J CELL PHYSIOL, V183, P238, DOI 10.1002/(SICI)1097-4652(200005)183:2<238::AID-JCP10>3.3.CO;2-T; Weng QP, 1998, J BIOL CHEM, V273, P16621, DOI 10.1074/jbc.273.26.16621; YANAGISAWASHIOTA F, 1995, ANTICANCER RES, V15, P259	55	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					32214	32219		10.1074/jbc.M103357200	http://dx.doi.org/10.1074/jbc.M103357200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11402043	hybrid			2022-12-25	WOS:000170613500101
J	Zimmer, G; Budz, L; Herrler, G				Zimmer, G; Budz, L; Herrler, G			Proteolytic activation of respiratory syncytial virus fusion protein - Cleavage at two furin consensus sequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT VACCINIA VIRUS; CELL-CELL FUSION; INFLUENZA HEMAGGLUTININ; MEMBRANE-FUSION; F-PROTEIN; SH GENE; GLYCOPROTEIN; EXPRESSION; RSV; ATTACHMENT	The F (fusion) protein of the respiratory syncytial viruses is synthesized as an inactive precursor F-0 that is proteolytically processed at the multibasic sequence KKRKRR136 into the subunits F-1 and F-2 by the cellular protease furin. This maturation process is essential for the F protein to gain fusion competence. We observed that proteolytic cleavage additionally occurs at another basic motif, RARR(109), that also meets the requirements for furin recognition. Cleavage at both sites leads to the removal from. the polypeptide chain of a glycosylated peptide of 27 amino acids. When the sequence RARR(109) was changed to NANR(109) or to RANN(109) by site-directed mutagenesis, cleavage by furin was completely prevented. Although the mutants were still processed at position Arg(136). they did not show any syncytia formation. Proteolytic cleavage of the modified motifs was achieved by treatment of transfected cells with trypsin converting the F mutants into their fusogenic forms. Our findings indicate that both furin consensus sequences have to be cleaved in order to activate the fusion protein.	Tierarztl Hsch Hannover, Inst Virol, D-30559 Hannover, Germany	University of Veterinary Medicine Hannover, Foundation	Herrler, G (corresponding author), Tierarztl Hsch Hannover, Inst Virol, Bunteweg 17, D-30559 Hannover, Germany.			Zimmer, Gert/0000-0002-2708-2507				BAKER JC, 1991, VET QUART, V13, P47, DOI 10.1080/01652176.1991.9694284; BAKER JC, 1986, AM J VET RES, V47, P240; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; Blumenthal R, 1996, J CELL BIOL, V135, P63, DOI 10.1083/jcb.135.1.63; Bolt G, 2000, VIRUS RES, V68, P25, DOI 10.1016/S0168-1702(00)00149-0; BOSCH V, 1990, J VIROL, V64, P2337, DOI 10.1128/JVI.64.5.2337-2344.1990; Buchholz UJ, 1999, J VIROL, V73, P251, DOI 10.1128/JVI.73.1.251-259.1999; Bukreyev A, 1997, J VIROL, V71, P8973, DOI 10.1128/JVI.71.12.8973-8982.1997; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; Carr CM, 1997, P NATL ACAD SCI USA, V94, P14306, DOI 10.1073/pnas.94.26.14306; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; CHAMBERS P, 1992, J GEN VIROL, V73, P1717, DOI 10.1099/0022-1317-73-7-1717; Chen J, 1998, CELL, V95, P409, DOI 10.1016/S0092-8674(00)81771-7; COLLINS PL, 1995, P NATL ACAD SCI USA, V92, P11563, DOI 10.1073/pnas.92.25.11563; COLLINS PL, 1991, J GEN VIROL, V72, P3095, DOI 10.1099/0022-1317-72-12-3095; Collins PL, 1996, FIELDS VIROLOGY, P1313; CONNORS M, 1991, J VIROL, V65, P1634, DOI 10.1128/JVI.65.3.1634-1637.1991; Dimitrov DS, 1997, CELL, V91, P721, DOI 10.1016/S0092-8674(00)80460-2; Feldman SA, 2000, J VIROL, V74, P6442, DOI 10.1128/JVI.74.14.6442-6447.2000; Feldman SA, 1999, J VIROL, V73, P6610, DOI 10.1128/JVI.73.8.6610-6617.1999; GRUBER C, 1985, J GEN VIROL, V66, P1241, DOI 10.1099/0022-1317-66-6-1241; Hallak LK, 2000, VIROLOGY, V271, P264, DOI 10.1006/viro.2000.0293; Hallak LK, 2000, J VIROL, V74, P10508, DOI 10.1128/JVI.74.22.10508-10513.2000; HEMINWAY BR, 1994, VIROLOGY, V200, P801, DOI 10.1006/viro.1994.1245; Hernandez LD, 1996, ANNU REV CELL DEV BI, V12, P627, DOI 10.1146/annurev.cellbio.12.1.627; Huovila APJ, 1996, CURR OPIN CELL BIOL, V8, P692, DOI 10.1016/S0955-0674(96)80111-6; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; Karron RA, 1997, P NATL ACAD SCI USA, V94, P13961, DOI 10.1073/pnas.94.25.13961; KAWAOKA Y, 1984, VIROLOGY, V139, P303, DOI 10.1016/0042-6822(84)90376-3; KIMMAN TG, 1990, ARCH VIROL, V112, P1, DOI 10.1007/BF01348982; Klenk Hans-Dieter, 1994, Trends in Microbiology, V2, P39, DOI 10.1016/0966-842X(94)90123-6; KLENK HD, 1994, MONOGRAPH, V28, P241; Krusat T, 1997, ARCH VIROL, V142, P1247, DOI 10.1007/s007050050156; Krysan DJ, 1999, J BIOL CHEM, V274, P23229, DOI 10.1074/jbc.274.33.23229; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LEBIVIC A, 1989, P NATL ACAD SCI USA, V86, P9313; LOPEZ JA, 1988, VIRUS RES, V10, P249, DOI 10.1016/0168-1702(88)90020-2; Maisner A, 2000, J GEN VIROL, V81, P441, DOI 10.1099/0022-1317-81-2-441; Martinez I, 2000, J GEN VIROL, V81, P2715, DOI 10.1099/0022-1317-81-11-2715; Melikyan GB, 1997, TRENDS MICROBIOL, V5, P349, DOI 10.1016/S0966-842X(97)01107-4; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; OLMSTED RA, 1986, P NATL ACAD SCI USA, V83, P7462, DOI 10.1073/pnas.83.19.7462; Pastey MK, 1997, J GEN VIROL, V78, P1885, DOI 10.1099/0022-1317-78-8-1885; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; STOTT EJ, 1985, ARCH VIROL, V84, P1, DOI 10.1007/BF01310552; SUTTER G, 1995, FEBS LETT, V371, P9, DOI 10.1016/0014-5793(95)00843-X; TASHIRO M, 1987, J GEN VIROL, V68, P2039, DOI 10.1099/0022-1317-68-7-2039; TASHIRO M, 1987, NATURE, V325, P536, DOI 10.1038/325536a0; WERTZ GW, 1987, J VIROL, V61, P293, DOI 10.1128/JVI.61.2.293-301.1987; WHITE JM, 1994, MONOGRAPH, V28, P281; Whitehead SS, 1999, J VIROL, V73, P3438, DOI 10.1128/JVI.73.4.3438-3442.1999; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0; Wolfsberg TG, 1996, DEV BIOL, V180, P389, DOI 10.1006/dbio.1996.0313; YU Q, 1991, J GEN VIROL, V72, P75, DOI 10.1099/0022-1317-72-1-75; Zimmer G, 2001, J VIROL, V75, P4744, DOI 10.1128/JVI.75.10.4744-4751.2001	56	98	110	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					31642	31650		10.1074/jbc.M102633200	http://dx.doi.org/10.1074/jbc.M102633200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11418598	hybrid			2022-12-25	WOS:000170613500025
J	Bakillah, A; Hussain, MM				Bakillah, A; Hussain, MM			Binding of microsomal trigrlyceride transfer protein to lipids results in increased affinity for apolipoprotein B - Evidence for stable microsomal MTP-lipid complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	72nd Annual Scientific Session of the American-Heart-Association	NOV 07-10, 1999	ATLANTA, GA	Amer Heart Assoc			TRIGLYCERIDE TRANSFER PROTEIN; TERMINALLY TRUNCATED FORMS; CONTAINING LIPOPROTEINS; INTRACELLULAR DEGRADATION; MONOCLONAL-ANTIBODIES; HEPATOMA-CELLS; CACO-2 CELLS; SECRETION; EXPRESSION; DENSITY	Apolipoprotein B (apoll) and microsomal triglyceride transfer protein (MTP) are known to interact with each other. We evaluated the effect of different lipids on the protein-protein interactions between MTP and apoB100 or its C-terminally truncated forms. Negatively charged lipids decreased protein-protein interactions between apoB and MTP. In contrast, zwitterionic phospholipids enhanced (2-4-fold) the binding of apoB100 to MTP by increasing affinity (1.5-3-fold) between these proteins without affecting the number of binding sites. Similarly, phospholipids augmented (1.5-4-fold) the binding of various C-terminally truncated apoB peptides to MTP. The increased binding was greater for apoll peptides containing lipid-binding domains, such as apoB28 and apoB42. Surprisingly, preincubation of apoB28 with lipid vesicles had no effect on MTP binding. In contrast, incubation of MTP with lipid vesicles resulted in a stable association of MTP with vesicles, and MTP-lipid vesicles bound better (5-fold increase) to LDL than did lipid-free MTP. To determine whether MTP exists stably associated with lipids in cells, microsomal contents from COS cells expressing MTP, HepG2 cells, and mouse liver were ultracentrifuged, and MTP was visualized in different density fractions. MTP was found associated and unassociated with lipids. In contrast, apoB17 and apoB:270-570 were present unassociated with lipids in COS cells. These studies show that the binding of MTP to lipids results in increased affinity for apoB and that stable MTP-lipid complexes exist in the lumen of the endoplasmic reticulum. Protein-protein interactions between apoll and MTP may juxtapose lipids associated with MTP to lipid-binding domains of apoB and facilitate hydrophobic interactions leading to enhance affinity. We speculate that MTP-lipid complexes may serve as nuclei to form "primordial lipoproteins" and may also play a role in the bulk addition of lipids during the "core expansion" of these lipoproteins.	Suny Downstate Med Ctr, Dept Anat, Brooklyn, NY 11203 USA; Suny Downstate Med Ctr, Dept Cell Biol, Brooklyn, NY 11203 USA; Suny Downstate Med Ctr, Dept Pediat, Brooklyn, NY 11203 USA; MCP Hahnemann Univ, Dept Biochem, Philadelphia, PA 19129 USA	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; Drexel University	Hussain, MM (corresponding author), Suny Downstate Med Ctr, Dept Anat, 450 Clarkson Ave,Box 5, Brooklyn, NY 11203 USA.	mahmoodhussain@netmail.hscbklyn.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064272] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046900, R29DK046900] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-64272] Funding Source: Medline; NIDDK NIH HHS [DK-46900] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALEXANDER CA, 1976, J CELL BIOL, V69, P241, DOI 10.1083/jcb.69.2.241; ATZEL A, 1993, BIOCHEMISTRY-US, V32, P10444, DOI 10.1021/bi00090a021; ATZEL A, 1994, BIOCHEMISTRY-US, V33, P15382, DOI 10.1021/bi00255a019; Bakillah A, 1998, BIOCHEMISTRY-US, V37, P3727, DOI 10.1021/bi972629t; Bakillah A, 1999, CIRCULATION, V100, P745; Bakillah A, 2000, BIOCHEMISTRY-US, V39, P4892, DOI 10.1021/bi9924009; Bakillah A, 1997, LIPIDS, V32, P1113, DOI 10.1007/s11745-997-0143-8; Benoist F, 1997, J BIOL CHEM, V272, P20435, DOI 10.1074/jbc.272.33.20435; Bradbury P, 1999, J BIOL CHEM, V274, P3159, DOI 10.1074/jbc.274.5.3159; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chang BHJ, 1999, J BIOL CHEM, V274, P6051, DOI 10.1074/jbc.274.10.6051; Davis RA, 1999, BBA-MOL CELL BIOL L, V1440, P1, DOI 10.1016/S1388-1981(99)00083-9; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; Ginsberg HN, 1997, CLIN EXP PHARMACOL P, V24, pA29, DOI 10.1111/j.1440-1681.1997.tb03051.x; Gordon DA, 2000, BBA-MOL CELL BIOL L, V1486, P72, DOI 10.1016/S1388-1981(00)00049-4; GORDON DA, 1994, P NATL ACAD SCI USA, V91, P7628, DOI 10.1073/pnas.91.16.7628; Haghpassand M, 1996, J LIPID RES, V37, P1468; Hussain MM, 2000, ATHEROSCLEROSIS, V148, P1; Hussain MM, 1998, J BIOL CHEM, V273, P25612, DOI 10.1074/jbc.273.40.25612; Hussain MM, 1997, BIOCHEMISTRY-US, V36, P13060, DOI 10.1021/bi971395a; Hussain MM, 1996, BBA-LIPID LIPID MET, V1300, P151, DOI 10.1016/0005-2760(96)00041-0; HUSSAIN MM, 1995, ARTERIOSCL THROM VAS, V15, P485, DOI 10.1161/01.ATV.15.4.485; Hussain MM, 2001, FRONT BIOSCI, V6, pD320, DOI 10.2741/Hussain; Innerarity TL, 1996, J BIOL CHEM, V271, P2353, DOI 10.1074/jbc.271.5.2353; JAMIL H, 1995, J BIOL CHEM, V270, P6549, DOI 10.1074/jbc.270.12.6549; Jamil H, 1996, P NATL ACAD SCI USA, V93, P11991, DOI 10.1073/pnas.93.21.11991; Kim E, 1998, J LIPID RES, V39, P703; Leung GK, 2000, J BIOL CHEM, V275, P7515, DOI 10.1074/jbc.275.11.7515; Liao W, 1999, BIOCHEMISTRY-US, V38, P7532, DOI 10.1021/bi9904196; Lu B, 2000, J BIOL CHEM, V275, P20775, DOI 10.1074/jbc.M003508200; Luchoomun J, 1999, J BIOL CHEM, V274, P19565, DOI 10.1074/jbc.274.28.19565; Luchoomun J, 1997, ARTERIOSCL THROM VAS, V17, P2955, DOI 10.1161/01.ATV.17.11.2955; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; Mann CJ, 1999, J MOL BIOL, V285, P391, DOI 10.1006/jmbi.1998.2298; MILNE RW, 1983, ARTERIOSCLEROSIS, V3, P23, DOI 10.1161/01.ATV.3.1.23; Patel SB, 1996, J BIOL CHEM, V271, P18686, DOI 10.1074/jbc.271.31.18686; PEASE RJ, 1990, J BIOL CHEM, V265, P553; Raabe M, 1999, J CLIN INVEST, V103, P1287, DOI 10.1172/JCI6576; Read J, 2000, J BIOL CHEM, V275, P30372, DOI 10.1074/jbc.C000364200; Segrest JP, 1998, J LIPID RES, V39, P85; Segrest JP, 1999, J LIPID RES, V40, P1401; SEGREST JP, 1994, ARTERIOSCLER THROMB, V14, P1674, DOI 10.1161/01.ATV.14.10.1674; SHARP D, 1993, NATURE, V365, P65, DOI 10.1038/365065a0; SHOULDERS CC, 1993, HUM MOL GENET, V2, P2109, DOI 10.1093/hmg/2.12.2109; Tietge UJF, 1999, J LIPID RES, V40, P2134; WANG HX, 1994, J BIOL CHEM, V269, P18514; WETTERAU JR, 1992, SCIENCE, V258, P999; Wetterau JR, 1998, SCIENCE, V282, P751, DOI 10.1126/science.282.5389.751; Wu XJ, 1996, J BIOL CHEM, V271, P10277, DOI 10.1074/jbc.271.17.10277; YAO ZM, 1988, J BIOL CHEM, V263, P2998; YAO ZM, 1991, J BIOL CHEM, V266, P3300; Yao ZM, 1997, J LIPID RES, V38, P1937; Zhou ZY, 1998, BBA-LIPID LIPID MET, V1391, P13, DOI 10.1016/S0005-2760(97)00200-2	53	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					31466	31473		10.1074/jbc.M100390200	http://dx.doi.org/10.1074/jbc.M100390200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology	463JG	11427523	hybrid			2022-12-25	WOS:000170472900113
J	Yang, HP; Huang, ZZ; Wang, JH; Lu, SC				Yang, HP; Huang, ZZ; Wang, JH; Lu, SC			The role of c-Myb and Sp1 in the up-regulation of methionine adenosyltransferase 2A gene expression in human hepatocellular carcinoma	FASEB JOURNAL			English	Article						methionine adenosyltransferase; transcriptional regulation; HCC; S-adenosylmethionine	S-ADENOSYLMETHIONINE SYNTHETASE; FUNCTIONAL-CHARACTERIZATION; 5'-FLANKING REGION; LIVER; CLONING; RAT; DIFFERENTIATION; ACTIVATION; SUBUNIT; FAMILY	Liver-specific and non-liver-specific methionine adenosyltransferase (MAT) are products of two genes, MAT1A and MAT2A, respectively, that catalyze the formation of S-adenosylmethionine. We showed a switch from MAT1A to MAT2A expression at the transcriptional level in human hepatocellular carcinoma (HCC) that facilitates cancer cell growth. The purpose of the present study was to better understand the molecular mechanism of increased MAT2A expression in HCC. In vitro DNase I footprinting analysis revealed two protected sites (-354 to -312 and -73 to -28) using nuclear proteins from HCC and HepG2 cells, but not normal liver. These sites are also protected in HepG2 cells on in vivo DNase I footprinting analysis. These protected sites contain consensus binding sites for c-Myb and Sp1. In HCC, the mRNA levels of c-myb and Sp1 and binding to their respective sites increased. Mutation of the c-Myb or Sp1 site reduced MAT2A promoter activity by 67% and 50%, respectively. The importance of these cis-acting elements and trans-activating factors was confirmed using heterologous promoter and expression vectors. Increased expression of c-Myb and Sp1 and binding to the MAT2A promoter contribute to transcriptional up-regulation of MAT2A in HCC.	Univ So Calif, Keck Sch Med, USC UCLA Res Ctr Alcohol Liver & Pancreat Dis, Liver Dis Res Ctr,Div Gastroenterol & Liver Dis, Los Angeles, CA 90033 USA	University of Southern California	Lu, SC (corresponding author), Univ So Calif, Sch Med, Dept Med, Div Gastrointestinal & Liver Dis, HMR Bldg 415,2011 Zonal Ave, Los Angeles, CA 90033 USA.	shellylu@hsc.usc.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK048522] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK48522] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALVAREZ L, 1993, BIOCHEM J, V293, P481, DOI 10.1042/bj2930481; Cai JX, 1998, CANCER RES, V58, P1444; Cai JX, 1996, HEPATOLOGY, V24, P1090; Cai JX, 1997, BIOCHEM J, V326, P167, DOI 10.1042/bj3260167; Chalkley GE, 1999, EMBO J, V18, P4835, DOI 10.1093/emboj/18.17.4835; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DELAROSA J, 1995, J BIOL CHEM, V270, P21860; FINKELSTEIN JD, 1990, J NUTR BIOCHEM, V1, P228, DOI 10.1016/0955-2863(90)90070-2; GARRITY PA, 1992, P NATL ACAD SCI USA, V89, P1021, DOI 10.1073/pnas.89.3.1021; Gil B, 1996, HEPATOLOGY, V24, P876; HORIKAWA S, 1993, FEBS LETT, V330, P307, DOI 10.1016/0014-5793(93)80894-Z; HORIKAWA S, 1992, FEBS LETT, V312, P37, DOI 10.1016/0014-5793(92)81405-B; Hromas R, 1996, CURR TOP MICROBIOL, V211, P159; Huang ZZ, 1999, HEPATOLOGY, V29, P1471, DOI 10.1002/hep.510290525; Huang ZZ, 1998, AM J PHYSIOL-GASTR L, V275, pG14, DOI 10.1152/ajpgi.1998.275.1.G14; Kitada T, 1997, HEPATOLOGY, V26, P1506; Kotb M, 1997, TRENDS GENET, V13, P51, DOI 10.1016/S0168-9525(97)01013-5; Lu SC, 2000, INT J BIOCHEM CELL B, V32, P391, DOI 10.1016/S1357-2725(99)00139-9; MAJELLO B, 1986, P NATL ACAD SCI USA, V83, P9636, DOI 10.1073/pnas.83.24.9636; Mao ZB, 1998, BIOCHEM BIOPH RES CO, V248, P479, DOI 10.1006/bbrc.1998.8965; Mato JM, 1997, PHARMACOL THERAPEUT, V73, P265, DOI 10.1016/S0163-7258(96)00197-0; MCCLINTON D, 1990, MOL CELL BIOL, V10, P705, DOI 10.1128/MCB.10.2.705; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; Ohtaka-Maruyama C, 1998, NUCLEIC ACIDS RES, V26, P407, DOI 10.1093/nar/26.2.407; Ruiz IG, 2000, DNA CELL BIOL, V19, P167, DOI 10.1089/104454900314555; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Tobena R, 1996, BIOCHEM J, V319, P929, DOI 10.1042/bj3190929; TUGORES A, 1994, J BIOL CHEM, V269, P30789; Yang HP, 2001, AM J PHYSIOL-GASTR L, V280, pG184; Yang J, 1997, NUCLEIC ACIDS RES, V25, P2213, DOI 10.1093/nar/25.11.2213; Zeng ZH, 2000, BIOCHEM J, V346, P475, DOI 10.1042/0264-6021:3460475	31	55	59	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2001	15	9					1507	1516		10.1096/fj.01-0040com	http://dx.doi.org/10.1096/fj.01-0040com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	460PV	11427482				2022-12-25	WOS:000170318500002
J	Ahrens, T; Sleeman, JP; Schempp, CM; Howells, N; Hofmann, M; Ponta, H; Herrlich, P; Simon, JC				Ahrens, T; Sleeman, JP; Schempp, CM; Howells, N; Hofmann, M; Ponta, H; Herrlich, P; Simon, JC			Soluble CD44 inhibits melanoma tumor growth by blocking cell surface CD44 binding to hyaluronic acid	ONCOGENE			English	Article						malignant melanoma; hyaluronic acid; CD44; shedding	MAMMARY-CARCINOMA CELLS; HUMAN BREAST-CANCER; MATRIX REORGANIZATION; EXTRACELLULAR DOMAIN; METASTASIS FORMATION; SPLICE VARIANTS; L-SELECTIN; ADHESION; EXPRESSION; MIGRATION	Proteolytic cleavage of the extracellular domain of CD44 from the surface of cells has been observed recently in different cell types, In cell culture supernatants of human melanoma cell lines a 70 kDa soluble CD44 protein (soICD44) was detected at concentrations of 250-300 ng/ml. Protease inhibitor studies revealed that serine proteases and metalloproteases are involved in the cleavage of CD44 from the surface of melanoma cells. To analyse a possible function of soluble CD44 a human malignant melanoma cell line was stably transfected with cDNAs encoding either wild type soluble CD44s or mutated forms with defective HA binding properties (CD44sR41A and CD44sR150A/R154A). Soluble CD44s almost completely inhibited hyaluronic acid binding by melanoma cells, whereas soluble CD44 mutated in the HA binding domain had no effect, When cultivated on hyaluronic acid, melanoma cell proliferation was induced by 30% for both the parental and the control transfected cells. This increase in proliferation was blocked completely in solCD44s-secreting transfectants, whereas solCD44sR41A and solCD44sR150A/R154A-secreting cells again showed hyaluronic acid-induced cell proliferation, These cell lines were subcutaneously injected into MF1 nu/nu mice to compare their growth as tumors in vivo. Compared to tumors derived from parental and control transfected cells, we observed a dramatic reduction of primary tumor growth with solCD44s expressing MM cells. Transfectants expressing solCD44s mutated in the HA binding domain in contrast developed fast-growing primary tumors. These results provide strong evidence that direct solCD44 interactions with hyaluronic acid interfere competively with processes induced by hyaluronic acid binding to surface CD44, Autocrine, or drug-induced secretion of solCD44 by human melanoma cells may thus exert potent antitumoral effects in vivo.	Univ Freiburg, Dept Dermatol, D-79104 Freiburg, Germany; Forschungszentrum Karlsruhe, Genet Inst, D-76021 Karlsruhe, Germany; Lion Biosci AG, D-69120 Heidelberg, Germany	University of Freiburg; Helmholtz Association; Karlsruhe Institute of Technology	Simon, JC (corresponding author), Univ Freiburg, Dept Dermatol, Hauptstr 7, D-79104 Freiburg, Germany.		Sleeman, Jonathan P/H-2515-2013; Hofmann-Apitius, Martin/E-6123-2018	Sleeman, Jonathan P/0000-0003-1718-7687; Hofmann-Apitius, Martin/0000-0001-9012-6720				Ahrens T, 2001, J INVEST DERMATOL, V116, P93, DOI 10.1046/j.1523-1747.2001.00236.x; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; Bajorath J, 1998, J BIOL CHEM, V273, P338, DOI 10.1074/jbc.273.1.338; Banerji S, 1999, J CELL BIOL, V144, P789, DOI 10.1083/jcb.144.4.789; BARTOLAZZI A, 1995, J CELL SCI, V108, P1723; BARTOLAZZI A, 1994, J EXP MED, V180, P53, DOI 10.1084/jem.180.1.53; BAZIL V, 1992, J IMMUNOL, V149, P747; BAZIL V, 1995, IMMUNOL TODAY, V16, P135, DOI 10.1016/0167-5699(95)80130-8; BAZIL V, 1994, J IMMUNOL, V152, P1314; Champagne B, 1998, J IMMUNOL, V161, P6398; CHEN AJ, 1995, J EXP MED, V182, P519, DOI 10.1084/jem.182.2.519; Dietrich A, 1997, EUR J CANCER, V33, P926, DOI 10.1016/S0959-8049(96)00512-6; Fichtner I, 1997, ANTICANCER RES, V17, P3633; Friedl P, 1997, CANCER RES, V57, P2061; GALANDRINI R, 1994, J IMMUNOL, V153, P21; Goebeler M, 1996, J CELL SCI, V109, P1957; Greco RM, 1998, J CELL PHYSIOL, V177, P465, DOI 10.1002/(SICI)1097-4652(199812)177:3<465::AID-JCP9>3.0.CO;2-5; Gunthert AR, 1996, J CELL BIOL, V134, P1089, DOI 10.1083/jcb.134.4.1089; GUO YJ, 1994, CANCER RES, V54, P422; HAMANN KJ, 1995, J IMMUNOL, V154, P4073; Ichikawa T, 1999, J INVEST DERMATOL, V113, P935, DOI 10.1046/j.1523-1747.1999.00804.x; Itano N, 1999, CANCER RES, V59, P2499; Kaya G, 1997, GENE DEV, V11, P996, DOI 10.1101/gad.11.8.996; Kosaki R, 1999, CANCER RES, V59, P1141; Lackner C, 1998, BREAST CANCER RES TR, V47, P29, DOI 10.1023/A:1005913514376; LECA G, 1995, J IMMUNOL, V154, P1069; LIAO HX, 1995, J IMMUNOL, V155, P3938; Maaser K, 1999, MOL BIOL CELL, V10, P3067, DOI 10.1091/mbc.10.10.3067; Martin S, 1997, INT J CANCER, V74, P443, DOI 10.1002/(SICI)1097-0215(19970822)74:4<443::AID-IJC14>3.3.CO;2-1; Naor D, 1997, ADV CANCER RES, V71, P241, DOI 10.1016/S0065-230X(08)60101-3; Okamoto I, 1999, ONCOGENE, V18, P1435, DOI 10.1038/sj.onc.1202447; PEACH RJ, 1993, J CELL BIOL, V122, P257, DOI 10.1083/jcb.122.1.257; Peterson RM, 2000, AM J PATHOL, V156, P2159, DOI 10.1016/S0002-9440(10)65086-9; Rafi A, 1997, BLOOD, V89, P2901, DOI 10.1182/blood.V89.8.2901; Ropponen K, 1998, CANCER RES, V58, P342; Schaider H, 1997, J AM ACAD DERMATOL, V36, P209, DOI 10.1016/S0190-9622(97)70282-2; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; Simon JC, 1996, EUR J CANCER, V32A, P1394, DOI 10.1016/0959-8049(96)00196-7; Sleeman JP, 1996, CANCER RES, V56, P3134; STAMENKOVIC I, 1991, EMBO J, V10, P343, DOI 10.1002/j.1460-2075.1991.tb07955.x; SY MS, 1991, J EXP MED, V174, P859, DOI 10.1084/jem.174.4.859; SY MS, 1992, J EXP MED, V176, P623, DOI 10.1084/jem.176.2.623; THOMAS L, 1992, J CELL BIOL, V118, P971, DOI 10.1083/jcb.118.4.971; TURLEY EA, 1987, BIOCHEMISTRY-US, V26, P2997, DOI 10.1021/bi00385a007; Victor R, 1999, INT J CANCER, V82, P77, DOI 10.1002/(SICI)1097-0215(19990702)82:1<77::AID-IJC14>3.0.CO;2-Q; WEST DC, 1989, EXP CELL RES, V183, P179, DOI 10.1016/0014-4827(89)90428-X; YANG BH, 1994, EMBO J, V13, P286, DOI 10.1002/j.1460-2075.1994.tb06261.x; Yu Q, 1997, J EXP MED, V186, P1985, DOI 10.1084/jem.186.12.1985; Zawadzki V, 1998, INT J CANCER, V75, P919, DOI 10.1002/(SICI)1097-0215(19980316)75:6<919::AID-IJC15>3.3.CO;2-V; Zeimet AG, 1997, BRIT J CANCER, V76, P1646, DOI 10.1038/bjc.1997.611; ZHANG LR, 1995, CANCER RES, V55, P428	51	118	126	1	16	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 7	2001	20	26					3399	3408		10.1038/sj.onc.1204435	http://dx.doi.org/10.1038/sj.onc.1204435			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	441UW	11423990				2022-12-25	WOS:000169248800010
J	Xue, LY; Chiu, SM; Oleinick, NL				Xue, LY; Chiu, SM; Oleinick, NL			Photochemical destruction of the Bcl-2 oncoprotein during photodynamic therapy with the phthalocyanine photosensitizer Pc 4	ONCOGENE			English	Article						Bcl-2; apoptosis; photodynamic therapy; Pc 4	PROSTATE-CANCER CELLS; CYTOCHROME-C; INDUCED APOPTOSIS; CASPASE ACTIVATION; TYROSINE KINASE; SINGLET OXYGEN; RELEASE; DEATH; MITOCHONDRIA; CLEAVAGE	Photodynamic therapy (PDT), utilizing a photosensitizer and visible light, causes localized oxidative damage. With the mitochondrial photosensitizer Pc 4, PDT induces apoptosis, yet its molecular targets are not known, Here, the anti-apoptotic protein Bcl-2 is shown to be highly sensitive to PDT, as judged on Western blots by the disappearance of anti-Bcl-2-reactive material from the position of the native 26 kDa protein. The loss of Bcl-2 was PDT dose dependent and was observed for both endogenous and overexpressed Bcl-2 in several cell lines, immediately after PDT, and with chilled cells. It was accompanied by a trace of a 23-kDa cleavage product as well as high-molecular weight products that may result from photochemical crosslinking. PDT-induced Bcl-2 loss occurred in MCF-7 cells that do not express caspase-3 or in the presence of protease inhibitors, but was prevented, along with the induction of apoptosis, by the singlet oxygen scavenger L-histidine. Loss of FLAG-Bcl-2 was observed with both anti-FLAG and anti-Bcl-2 antibodies, indicating loss of native protein rather than simple BCL-2-epitope destruction. Photochemical damage was not observed in Bcl-x(L), Bax, Bad, the voltage-dependent anion channel, or the adenine nucleotide translocator. Therefore, Bcl-2 is one target of PDT with Pc 4, and PDT damage to Bcl-2 contributes to its efficient induction of apoptosis.	Case Western Reserve Univ, Sch Med, Dept Radiat Oncol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, CWRU Ireland Comprehens Canc Ctr, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Oleinick, NL (corresponding author), Case Western Reserve Univ, Sch Med, Dept Radiat Oncol, BRB-324,10900 Euclid Ave, Cleveland, OH 44106 USA.				NATIONAL CANCER INSTITUTE [P30CA043703, P01CA048735, R01CA083917] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA48735, R01 CA83917, P30 CA43703] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGARWAL R, 1991, CANCER LETT, V56, P125, DOI 10.1016/0304-3835(91)90086-W; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; Carthy CM, 1999, LAB INVEST, V79, P953; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Colussi VC, 1999, PHOTOCHEM PHOTOBIOL, V69, P236, DOI 10.1562/0031-8655(1999)069<0236:PPTOHO>2.3.CO;2; EGUCHI Y, 1992, NUCLEIC ACIDS RES, V20, P4187, DOI 10.1093/nar/20.16.4187; Fadeel B, 1999, LEUKEMIA, V13, P719, DOI 10.1038/sj.leu.2401411; Fujita N, 1998, BIOCHEM BIOPH RES CO, V246, P484, DOI 10.1006/bbrc.1998.8587; Grandgirard D, 1998, EMBO J, V17, P1268, DOI 10.1093/emboj/17.5.1268; Granville DJ, 1999, BRIT J CANCER, V79, P95, DOI 10.1038/sj.bjc.6690017; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Haldar S, 1996, CANCER RES, V56, P1253; HALLIWELL B, 1989, FREE RADICAL BIO MED, P66; He HL, 1998, J BIOL CHEM, V273, P25015, DOI 10.1074/jbc.273.39.25015; He J, 1997, PHOTOCHEM PHOTOBIOL, V65, P581; He J, 1996, PHOTOCHEM PHOTOBIOL, V64, P845, DOI 10.1111/j.1751-1097.1996.tb01845.x; HENDERSON BW, 1992, PHOTOCHEM PHOTOBIOL, V55, P145, DOI 10.1111/j.1751-1097.1992.tb04222.x; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Jacobson MD, 1996, J CELL BIOL, V133, P1041, DOI 10.1083/jcb.133.5.1041; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Kessel D, 1999, CELL DEATH DIFFER, V6, P28, DOI 10.1038/sj.cdd.4400446; Kim HRC, 1999, CANCER RES, V59, P3429; Kirsch DG, 1999, J BIOL CHEM, V274, P21155, DOI 10.1074/jbc.274.30.21155; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KORSMEYER SJ, 1999, CANCER RES, V59, P1693; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; Lavie G, 1999, BRIT J CANCER, V79, P423, DOI 10.1038/sj.bjc.6690066; MOAN J, 1992, PHOTOCHEM PHOTOBIOL, V55, P931, DOI 10.1111/j.1751-1097.1992.tb08541.x; Oleinick NL, 1998, RADIAT RES, V150, pS146, DOI 10.2307/3579816; OLEINICK NL, 1993, PHOTOCHEM PHOTOBIOL, V57, P242, DOI 10.1111/j.1751-1097.1993.tb02282.x; Qiu Y, 1998, P NATL ACAD SCI USA, V95, P3644, DOI 10.1073/pnas.95.7.3644; Reed JC, 1998, BBA-BIOENERGETICS, V1366, P127, DOI 10.1016/S0005-2728(98)00108-X; Susin SA, 1999, J EXP MED, V189, P381, DOI 10.1084/jem.189.2.381; Trivedi NS, 2000, PHOTOCHEM PHOTOBIOL, V71, P634, DOI 10.1562/0031-8655(2000)071<0634:QAOPLI>2.0.CO;2; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; Tudor G, 2000, CELL DEATH DIFFER, V7, P574, DOI 10.1038/sj.cdd.4400688; Varnes ME, 1999, BIOCHEM BIOPH RES CO, V255, P673, DOI 10.1006/bbrc.1999.0261; WEISHAUPT KR, 1976, CANCER RES, V36, P2326; Wuerzberger SM, 1998, CANCER RES, V58, P1876; Xue LY, 2001, EXP CELL RES, V263, P145, DOI 10.1006/excr.2000.5108; Xue LY, 1999, ONCOGENE, V18, P3391, DOI 10.1038/sj.onc.1202687; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zhang WG, 1999, PHOTOCHEM PHOTOBIOL, V69, P582, DOI 10.1562/0031-8655(1999)069<0582:ABRVIT>2.3.CO;2	44	179	197	1	18	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 7	2001	20	26					3420	3427		10.1038/sj.onc.1204441	http://dx.doi.org/10.1038/sj.onc.1204441			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	441UW	11423992				2022-12-25	WOS:000169248800012
J	Gunther, C; Schmidt, U; Rudolph, R; Bohm, G				Gunther, C; Schmidt, U; Rudolph, R; Bohm, G			Protein and peptide delivery via engineered polyomavirus-like particles	FASEB JOURNAL			English	Article						drug delivery; in vitro assembly; VP1; WW domain	MURINE POLYOMAVIRUS; WW DOMAIN; BINDING; VP1; DNA; PSEUDOCAPSIDS; COMPLEX; CELLS; SITE	Recent advances in molecular biology have led to the development of new therapeutics to address genetic disorders. The developments in the production and availability of recombinant proteins are likely to have a substantial impact on many diseases in the short term. A major limit for the use of recombinant proteins in clinical applications is their inability to enter cells and be targeted to the appropriate intracellular site. Here, we describe a novel system for the intracellular delivery of peptides and proteins using recombinantly expressed polyomavirus-like particles as universal carriers. The inner surface of the particles was modified by the fusion of a WW domain, which was derived from the mouse formin binding protein 11 (FBP11) to the viral coat protein in order to bind specifically to proline-rich ligands. Physicochemical characterization of the fusion protein demonstrated that the functional units of the VP1-WW protein remained intact. Assembly of the particles in the presence of proline-rich ligands resulted in an efficient encapsidation of the ligands into the particles. Fluorescence-labeled peptides and the green fluorescent protein were used as model ligands. The delivery of the ligands into cultured eukaryotic cells could be demonstrated with confocal laser-scanning microscopy.	Univ Halle Wittenberg, Inst Biotechnol, D-06120 Halle An Der Saale, Germany; ACGT ProGenom AG, D-06120 Halle An Der Saale, Germany	Martin Luther University Halle Wittenberg	Gunther, C (corresponding author), Univ Halle Wittenberg, Inst Biotechnol, Kurt Mothes Str 3, D-06120 Halle An Der Saale, Germany.	constanze.guenther@biochemtech.uni-halle.de						Bedford MT, 1997, EMBO J, V16, P2376, DOI 10.1093/emboj/16.9.2376; BOHM G, 1992, PROTEIN ENG, V5, P191, DOI 10.1093/protein/5.3.191; BORK P, 1994, TRENDS BIOCHEM SCI, V19, P531, DOI 10.1016/0968-0004(94)90053-1; Braun H, 1999, BIOTECHNOL APPL BIOC, V29, P31; CHANG DC, 1993, J VIROL, V67, P6327, DOI 10.1128/JVI.67.10.6327-6331.1993; Chang YJ, 1996, J ENHANC HEAT TRANSF, V3, P15, DOI 10.1615/JEnhHeatTransf.v3.i1.20; Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7; FORSTOVA J, 1995, HUM GENE THER, V6, P297, DOI 10.1089/hum.1995.6.3-297; Koepf EK, 1999, PROTEIN SCI, V8, P841, DOI 10.1110/ps.8.4.841; Koepf EK, 1999, BIOCHEMISTRY-US, V38, P14338, DOI 10.1021/bi991105l; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEAVITT AD, 1985, J BIOL CHEM, V23, P12803; Macias MJ, 2000, NAT STRUCT BIOL, V7, P375, DOI 10.1038/75144; Macias MJ, 1996, NATURE, V382, P646, DOI 10.1038/382646a0; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Russell CS, 1999, CLIN GENET, V55, P389, DOI 10.1034/j.1399-0004.1999.550601.x; SAHLI R, 1993, VIROLOGY, V192, P142, DOI 10.1006/viro.1993.1016; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SALUNKE DM, 1989, BIOPHYS J, V56, P887, DOI 10.1016/S0006-3495(89)82735-3; SALUNKE DM, 1986, CELL, V46, P895, DOI 10.1016/0092-8674(86)90071-1; Schmidt U, 1999, BIOL CHEM, V380, P397, DOI 10.1515/BC.1999.053; Schmidt U, 2000, J VIROL, V74, P1658, DOI 10.1128/JVI.74.4.1658-1662.2000; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Scott MD, 1998, CURR PHARM DESIGN, V4, P423; Soeda E, 1998, GENE THER, V5, P1410, DOI 10.1038/sj.gt.3300748; Stehle T, 1996, STRUCTURE, V4, P183, DOI 10.1016/S0969-2126(96)00021-4; Stehle T, 1997, EMBO J, V16, P5139, DOI 10.1093/emboj/16.16.5139; STEHLE T, 1994, NATURE, V369, P160, DOI 10.1038/369160a0; Stubenrauch K, 2000, J CHROMATOGR B, V737, P77, DOI 10.1016/S0378-4347(99)00392-8; SUDOL M, 1995, J BIOL CHEM, V270, P14733, DOI 10.1074/jbc.270.24.14733; Yang F, 1996, NAT BIOTECHNOL, V14, P1246, DOI 10.1038/nbt1096-1246	31	22	26	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY 29	2001	15	7					1646	+		10.1096/fj.00-0645fje	http://dx.doi.org/10.1096/fj.00-0645fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519CQ	11427514				2022-12-25	WOS:000173707700022
J	Yung, S; Woods, A; Chan, TM; Davies, M; Williams, JD; Couchman, JR				Yung, S; Woods, A; Chan, TM; Davies, M; Williams, JD; Couchman, JR			Syndecan-4 up-regulation in proliferative renal disease is related to microfilament organization	FASEB JOURNAL			English	Article						proteoglycans; heparan sulfate; actin; alpha-actinin	HEPARAN-SULFATE PROTEOGLYCAN; CYTOPLASMIC DOMAIN; BASEMENT-MEMBRANE; MESANGIAL CELLS; PROTEIN; EXPRESSION; FAMILY; CYTOSKELETON; CASK/LIN-2; MORPHOLOGY	Syndecan-4 is a transmembrane heparan sulfate proteoglycan (HSPG) expressed widely in mammalian cells. It has been implicated in growth-factor binding, cell-extracellular matrix adhesion, and tissue damage responses. Although several HSPGs are present within kidney mesangium and glomerular basement membranes, no data are available on the synthesis of syndecan-4 by mesangial cells or its expression in human renal disease. We examined renal biopsy specimens from normal controls, nonproliferative disease (thin-membrane disease), and progressive proliferative disease (IgA nephropathy). By using RT-PCR and immunohistochemical staining, we identified an increase in both gene expression (IgA nephropathy vs. thin membrane disease, P = 0.0004) and synthesis of syndecan-4 in progressive proliferative disease. Syndecan-4 increased within both mesangium and tubulo-interstitium, as did alpha-actinin, a microfilament cytoskeletal component. Syndecan-4 was a focal adhesion component in human mesangial cells, colocalizing with vinculin and alpha-actinin, and was present in the cortical, submembraneous myosin sheath as seen for alpha-actinin. Both syndecan-4 and alpha-actinin were retained selectively in detergent-resistant cytoskeleton-matrix preparations, emphasizing their close association in cell-matrix adhesion. Syndecan-4 may be important in the adhesion, migration, and proliferation of HMC, and its up-regulation could indicate proliferative disease.	Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA; Cardiff Univ, Inst Nephrol, Cardiff CF4 4XN, S Glam, Wales; Univ Hong Kong, Dept Med, Div Nephrol, Hong Kong, Hong Kong, Peoples R China	University of Alabama System; University of Alabama Birmingham; Cardiff University; University of Hong Kong	Couchman, JR (corresponding author), Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA.	jrcouchman@cellbio.bhs.uab.edu	Chan, Daniel Tak Mao/C-4202-2009; Yung, Susan Sou Ying/C-4468-2009					ASUNDI VK, 1995, J BIOL CHEM, V270, P26404, DOI 10.1074/jbc.270.44.26404; BACIU PC, 1995, MOL BIOL CELL, V6, P1503, DOI 10.1091/mbc.6.11.1503; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BORDER WA, 1991, CIBA F SYMP, V157, P178; BRENNER BM, 1980, NEW ENGL J MED, V307, P652; CAREY DJ, 1994, J CELL BIOL, V124, P161, DOI 10.1083/jcb.124.1.161; Carey DJ, 1997, BIOCHEM J, V327, P1; CizmeciSmith G, 1997, ARTERIOSCL THROM VAS, V17, P172, DOI 10.1161/01.ATV.17.1.172; CLARKSON AR, 1977, CLIN NEPHROL, V8, P459; Cohen AR, 1998, J CELL BIOL, V142, P129, DOI 10.1083/jcb.142.1.129; Couchman JR, 1999, J CELL SCI, V112, P3415; DAMICO G, 1986, Q J MED, V59, P363; DAVID G, 1992, J CELL BIOL, V118, P961, DOI 10.1083/jcb.118.4.961; Echtermeyer F, 1999, J CELL SCI, V112, P3433; ENG E, 1994, KIDNEY INT, V45, pS45; Ferrario F, 1999, ANN MED INTERNE, V150, P108; FIORETTO P, 1994, DIABETES, V43, P1358, DOI 10.2337/diabetes.43.11.1358; Fuki IV, 1997, J CLIN INVEST, V100, P1611, DOI 10.1172/JCI119685; Gallo R, 1996, J INVEST DERMATOL, V107, P676, DOI 10.1111/1523-1747.ep12365571; GALLO RL, 1994, P NATL ACAD SCI USA, V91, P11035, DOI 10.1073/pnas.91.23.11035; Greene DK, 2000, MOL BIOL CELL, V11, p394A; Grootjans JJ, 1997, P NATL ACAD SCI USA, V94, P13683, DOI 10.1073/pnas.94.25.13683; Hillis GS, 1997, NEPHROL DIAL TRANSPL, V12, P1137, DOI 10.1093/ndt/12.6.1137; Horowitz A, 1998, J BIOL CHEM, V273, P10914, DOI 10.1074/jbc.273.18.10914; Hsueh YP, 1998, J CELL BIOL, V142, P139, DOI 10.1083/jcb.142.1.139; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; Jin DK, 1996, J AM SOC NEPHROL, V7, P2636; KASHGARIAN M, 1992, KIDNEY INT, V41, P524, DOI 10.1038/ki.1992.74; KIM CW, 1994, MOL BIOL CELL, V5, P797, DOI 10.1091/mbc.5.7.797; KOJIMA T, 1992, J BIOL CHEM, V267, P4859; Longley RL, 1999, J CELL SCI, V112, P3421; LYON M, 1991, BIOCHEM J, V273, P415, DOI 10.1042/bj2730415; MAUER SM, 1984, J CLIN INVEST, V74, P1143, DOI 10.1172/JCI111523; NAMIE S, 1995, NEPHROL DIAL TRANSPL, V10, P1342; NOONAN DM, 1991, J BIOL CHEM, V266, P22939; ODONNELL MP, 1988, FASEB J, V2, P2339, DOI 10.1096/fasebj.2.8.3282959; Oh ES, 1997, J BIOL CHEM, V272, P11805, DOI 10.1074/jbc.272.18.11805; Oh ES, 1998, J BIOL CHEM, V273, P10624, DOI 10.1074/jbc.273.17.10624; Rapraeger AC, 1998, CURR OPIN CELL BIOL, V10, P620, DOI 10.1016/S0955-0674(98)80038-0; Roskams T, 1998, J PATHOL, V185, P290, DOI 10.1002/(SICI)1096-9896(199807)185:3<290::AID-PATH91>3.0.CO;2-I; Saoncella S, 1999, P NATL ACAD SCI USA, V96, P2805, DOI 10.1073/pnas.96.6.2805; SEAQUIST ER, 1989, NEW ENGL J MED, V320, P1161, DOI 10.1056/NEJM198905043201801; THOMAS GJ, 1990, ARCH BIOCHEM BIOPHYS, V278, P11, DOI 10.1016/0003-9861(90)90224-M; THOMAS GJ, 1991, BIOCHEM J, V277, P81, DOI 10.1042/bj2770081; THOMAS GJ, 1995, KIDNEY INT, V48, P1278, DOI 10.1038/ki.1995.412; Vleming LJ, 1998, CLIN NEPHROL, V49, P337; Wada T, 1997, KIDNEY INT, pS182; Woods A, 2000, J BIOL CHEM, V275, P24233, DOI 10.1074/jbc.R000001200; WOODS A, 1994, MOL BIOL CELL, V5, P183, DOI 10.1091/mbc.5.2.183; Woods A, 2000, ARCH BIOCHEM BIOPHYS, V374, P66, DOI 10.1006/abbi.1999.1607; WOODS A, 1985, J BIOL CHEM, V260, P872; YOSHIOKA K, 1995, HISTOL HISTOPATHOL, V10, P203; YUNG S, 1995, AM J PATHOL, V146, P520; Zhang YF, 1999, J BIOL CHEM, V274, P14786, DOI 10.1074/jbc.274.21.14786; ZIGMOND SH, 1979, EXP CELL RES, V119, P205, DOI 10.1016/0014-4827(79)90349-5; Zimmerman M, 1999, MED PSYCHIATRY, V13, P1	57	42	44	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY 29	2001	15	7					1631	+		10.1096/fj.00-0794fje	http://dx.doi.org/10.1096/fj.00-0794fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519CQ	11427509				2022-12-25	WOS:000173707700013
J	Chan, TL; Yuen, ST; Ho, JWC; Chan, ASY; Kwan, KD; Chung, LP; Lam, PWY; Tse, CW; Leung, SY				Chan, TL; Yuen, ST; Ho, JWC; Chan, ASY; Kwan, KD; Chung, LP; Lam, PWY; Tse, CW; Leung, SY			A novel germline 1.8-kb deletion of hMLH1 mimicking alternative splicing: a founder mutation in the Chinese population	ONCOGENE			English	Article						hMLH1; germline mutation; intragenic deletion; alternative splicing; HNPCC syndrome	NONPOLYPOSIS COLORECTAL-CANCER; DNA MISMATCH REPAIR; HEREDITARY COLON-CANCER; MLH1 MESSENGER-RNA; MICROSATELLITE INSTABILITY; GENE-MUTATIONS; YOUNG-PATIENTS; HMSH2; MSH2; FAMILIES	We have previously reported that there is a high incidence of microsatellite instability (MSI) and germline mismatch repair gene mutation in colorectal cancer arising from young Hong Kong Chinese, Most of the germline mutations involve hMSH2, which is different from the mutation spectrum in the Western population. It is well known that alternative splicing is common in hMLH1, which complicates RNA based mutation detection methods. In contrast, large deletions in hMLH1, commonly observed in some ethnic groups, tend to escape detection by exon-by-exon direct DNA sequencing. Here we report the detection of a novel germline 1.8 kb deletion involving exon 11 of hMLH1 in a local hereditary non-polyposis colorectal cancer family. This mutation generates a mRNA transcript with deletion of exons 10-11, which is indistinguishable from one of the most common and predominant hMLH1 splice variants, A diagnostic test based on PCR of the breakpoint region led to the identification of an additional young colorectal cancer patient with this mutation. Haplotype analysis suggests that they may share a common ancestral mutation. Our results caution investigators in the interpretation of alternative splicing and have important implications for the design of hMLH1 mutation detection strategy in the Chinese population. Oncogene (2001) 20, 2976-2981.	Univ Hong Kong, Queen Mary Hosp, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Queen Mary Hosp, Hereditary Gastrointestinal Canc Registry, Hong Kong, Hong Kong, Peoples R China; Queen Elizabeth Hosp, Dept Surg, Kowloon, Hong Kong, Peoples R China; Queen Elizabeth Hosp, Dept Pathol, Kowloon, Hong Kong, Peoples R China	University of Hong Kong; University of Hong Kong	Leung, SY (corresponding author), Univ Hong Kong, Queen Mary Hosp, Dept Pathol, Pokfulam Rd, Hong Kong, Hong Kong, Peoples R China.		Leung, Suet Yi/C-4340-2009; Chung, Lap Ping/C-4258-2009; Yuen, Siu/K-6311-2014; Leung, Suet Yi/T-9620-2019	Leung, Suet Yi/0000-0001-8614-4619				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Akiyama Y, 1997, CANCER RES, V57, P3920; Bapat BV, 1999, HUM GENET, V104, P167, DOI 10.1007/s004390050931; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; BUERSTEDDE JM, 1995, J MED GENET, V32, P909, DOI 10.1136/jmg.32.11.909; Chan TL, 1999, JNCI-J NATL CANCER I, V91, P1221, DOI 10.1093/jnci/91.14.1221; Charbonnier F, 2000, CANCER RES, V60, P2760; CHARBONNIER F, 1995, CANCER RES, V55, P1839; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; Farrington SM, 1998, AM J HUM GENET, V63, P749, DOI 10.1086/301996; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; Froggatt NJ, 1996, J MED GENET, V33, P726, DOI 10.1136/jmg.33.9.726; Ho JWC, 2000, INT J CANCER, V89, P356, DOI 10.1002/1097-0215(20000720)89:4<356::AID-IJC7>3.0.CO;2-J; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; KohonenCorish M, 1996, AM J HUM GENET, V59, P818; Lamberti C, 1999, GUT, V44, P839, DOI 10.1136/gut.44.6.839; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; Leung SY, 1998, AM J PATHOL, V153, P1181, DOI 10.1016/S0002-9440(10)65662-3; Leung SY, 1999, CANCER RES, V59, P159; Liu B, 1996, NAT MED, V2, P169, DOI 10.1038/nm0296-169; LIU B, 1995, NAT MED, V1, P348, DOI 10.1038/nm0495-348; Mauillon JL, 1996, CANCER RES, V56, P5728; MIYAKI M, 1995, J MOL MED-JMM, V73, P515; Miyaki M, 1997, NAT GENET, V17, P271, DOI 10.1038/ng1197-271; Moslein G, 1996, HUM MOL GENET, V5, P1245, DOI 10.1093/hmg/5.9.1245; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; NYSTROMLAHTI M, 1995, NAT MED, V1, P1203, DOI 10.1038/nm1195-1203; NystromLahti M, 1996, HUM MOL GENET, V5, P763, DOI 10.1093/hmg/5.6.763; Palmer E, 1998, CHEM BRIT, V34, P27; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; Peltomaki P, 1997, GASTROENTEROLOGY, V113, P1146, DOI 10.1053/gast.1997.v113.pm9322509; Schuelke M, 2000, NAT BIOTECHNOL, V18, P233, DOI 10.1038/72708; Stelter A, 2000, INT FED INFO PROC, V51, P43; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Viel A, 1997, GENE CHROMOSOME CANC, V18, P8, DOI 10.1002/(SICI)1098-2264(199701)18:1<8::AID-GCC2>3.0.CO;2-7; Weber TK, 1997, CANCER RES, V57, P3798; WIJNEN J, 1995, AM J HUM GENET, V56, P1060; Wijnen J, 1998, NAT GENET, V20, P326, DOI 10.1038/3795; Wijnen J, 1996, AM J HUM GENET, V58, P300; Yuen ST, 1997, BRIT J CANCER, V76, P1610, DOI 10.1038/bjc.1997.605	41	32	33	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 24	2001	20	23					2976	2981		10.1038/sj.onc.1204376	http://dx.doi.org/10.1038/sj.onc.1204376			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	435VA	11420710				2022-12-25	WOS:000168901800013
J	Nagasawa, M; Gelfand, EW; Lucas, JJ				Nagasawa, M; Gelfand, EW; Lucas, JJ			Accumulation of high levels of the p53 and p130 growth-suppressing proteins in cell lines stably over-expressing cyclin-dependent kinase 6 (cdk6)	ONCOGENE			English	Article						cyclin-dependent kinase 6; growth control; p53 protein; p130 protein	CDK-ACTIVATING KINASE; DIFFERENTIAL REGULATION; RETINOBLASTOMA-PROTEIN; G1 PHASE; PHOSPHORYLATION; PROGRESSION; POLYMERASE; IDENTIFICATION; MECHANISMS; INHIBITION	Cyclin-dependent kinase 6(cdk6) is present in randomly proliferating cultures of 3T3 cells but has little detectable enzymatic activity, Significant activity is detected only during a short period in early G1 phase. To examine the possible functions of cdk6 in 3T3 cells, lines stably over-expressing cdk6 were constructed and compared to normal 3T3 cells or cell lines with reduced cdk6 levels due to expression of a dominant-negative form of the protein, Over-expression of cdk6 in cells, which led to high levels of activity even in proliferating cultures, had dramatic effects, Cell lines stably over-expressing wild-type cdk6 had a markedly reduced growth rate compared to parental 3T3 cells or lines expressing a dominant-negative form of cdk6. They also over-produced the p53 and p130 proteins and had increased sensitivity to UV-irradiation. Irradiation resulted in accumulation of the Bas protein and rapid cell death, Levels of p53 and p130 proteins were downregulated and the growth rate of the cells was increased by introduction of the dominant-negative form of cdk6 into cells over-expressing cdk6, indicating that cdk6 is involved in the overproduction of p53 and p130. The results suggest that cdk6, through regulation of growth suppressing molecules, may play a role in halting cellular growth when proliferation is inappropriate. Oncogene, (2001) 20, 2889-2899.	Natl Jewish Med& Res Ctr, Dept Pediat, Div Basic Sci, Denver, CO 80206 USA	National Jewish Health	Lucas, JJ (corresponding author), Natl Jewish Med& Res Ctr, Dept Pediat, Div Basic Sci, 1400 Jackson St, Denver, CO 80206 USA.		Nagasawa, Masayuki/CAI-8101-2022; Nagasawa, Masayuki/AAX-1734-2020	Nagasawa, Masayuki/0000-0002-8085-4940	NATIONAL CANCER INSTITUTE [P30CA046934] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036577] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI042246, R01AI042246] Funding Source: NIH RePORTER; NCI NIH HHS [CA46934] Funding Source: Medline; NHLBI NIH HHS [HL-36577] Funding Source: Medline; NIAID NIH HHS [AI-42246] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bagella L, 1998, J CELL PHYSIOL, V177, P206, DOI 10.1002/(SICI)1097-4652(199811)177:2<206::AID-JCP2>3.3.CO;2-W; BATES S, 1994, ONCOGENE, V9, P71; De Falco G, 1998, J CELL PHYSIOL, V177, P501, DOI 10.1002/(SICI)1097-4652(199812)177:4<501::AID-JCP1>3.0.CO;2-4; DeLuca A, 1997, J BIOL CHEM, V272, P20971, DOI 10.1074/jbc.272.34.20971; Dong F, 1998, J BIOL CHEM, V273, P6190, DOI 10.1074/jbc.273.11.6190; Edwards MC, 1998, MOL CELL BIOL, V18, P4291, DOI 10.1128/MCB.18.7.4291; ELDIERY WS, 1993, CELL, V75, P917; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; Fujinaga K, 1998, J VIROL, V72, P7154, DOI 10.1128/JVI.72.9.7154-7159.1998; Garriga J, 1998, BIOCHEM J, V333, P645, DOI 10.1042/bj3330645; Grossel MJ, 1999, J BIOL CHEM, V274, P29960, DOI 10.1074/jbc.274.42.29960; Haapajarvi T, 1997, MOL CELL BIOL, V17, P3074, DOI 10.1128/MCB.17.6.3074; HANKS SK, 1987, P NATL ACAD SCI USA, V84, P388, DOI 10.1073/pnas.84.2.388; Hengstschlager M, 1999, MUTAT RES-REV MUTAT, V436, P1, DOI 10.1016/S1383-5742(98)00022-2; Hiyama H, 1997, ONCOGENE, V14, P2533, DOI 10.1038/sj.onc.1201080; Howard CM, 2000, CANCER RES, V60, P2737; Hsieh FF, 2000, BLOOD, V96, P2746, DOI 10.1182/blood.V96.8.2746.h8002746_2746_2754; Jiang H, 1998, MOL CELL BIOL, V18, P5284, DOI 10.1128/MCB.18.9.5284; Kapoor M, 1998, P NATL ACAD SCI USA, V95, P2834, DOI 10.1073/pnas.95.6.2834; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LeCouter JE, 1996, ONCOGENE, V12, P1433; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; LUCAS JJ, 1995, J IMMUNOL, V154, P6275; LUCAS JJ, 1995, BLOOD, V86, P2268, DOI 10.1182/blood.V86.6.2268.bloodjournal8662268; LUCAS JJ, 1995, J CELL PHYSIOL, V165, P406, DOI 10.1002/jcp.1041650222; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MacLachlan TK, 1998, J CELL BIOCHEM, V71, P467, DOI 10.1002/(SICI)1097-4644(19981215)71:4<467::AID-JCB2>3.3.CO;2-7; Martinez JD, 1997, ONCOGENE, V14, P2511, DOI 10.1038/sj.onc.1201095; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; Matushansky I, 2000, BLOOD, V96, P2755, DOI 10.1182/blood.V96.8.2755.h8002755_2755_2764; Matushansky I, 2000, P NATL ACAD SCI USA, V97, P14317, DOI 10.1073/pnas.250488697; Mayol X, 1996, ONCOGENE, V13, P237; MAYOL X, 1995, ONCOGENE, V11, P801; MAYOL X, 1998, FRONT BIOSCI, V3, P11; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; MERCER WE, 1985, EXP CELL RES, V160, P31, DOI 10.1016/0014-4827(85)90233-2; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MIYASHITA T, 1995, CELL, V80, P293; Moberg K, 1996, MOL CELL BIOL, V16, P1436; Nagasawa M, 1997, J IMMUNOL, V158, P5146; Nigg EA, 1993, CURR OPIN CELL BIOL, V5, P187, DOI 10.1016/0955-0674(93)90101-U; Ojala PM, 2000, NAT CELL BIOL, V2, P819, DOI 10.1038/35041064; Ojala PM, 1999, CANCER RES, V59, P4984; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PINES J, 1990, New Biologist, V2, P389; PINES J, 1994, SEMIN CELL BIOL, V5, P339; Rane SG, 1999, NAT GENET, V22, P44, DOI 10.1038/8751; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; Rickert P, 1996, ONCOGENE, V12, P2631; Sergere JC, 2000, BIOCHEM BIOPH RES CO, V276, P271, DOI 10.1006/bbrc.2000.3395; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Smith EJ, 1998, CELL GROWTH DIFFER, V9, P297; Smith EJ, 1996, MOL CELL BIOL, V16, P6965; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; SZEPESI A, 1994, BLOOD, V84, P3413; Tang D, 1996, Prog Cell Cycle Res, V2, P205; TASSAN JP, 1995, P NATL ACAD SCI USA, V92, P8871, DOI 10.1073/pnas.92.19.8871; TERADA N, 1991, J IMMUNOL, V147, P698; TERADA N, 1993, J CELL PHYSIOL, V154, P7, DOI 10.1002/jcp.1041540103; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Tsutsui T, 1999, MOL CELL BIOL, V19, P7011; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WINSTON JT, 1993, MOL BIOL CELL, V4, P1133, DOI 10.1091/mbc.4.11.1133; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; Zhang Q, 1997, DEV BIOL, V183, P222, DOI 10.1006/dbio.1996.8494	76	18	18	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 24	2001	20	23					2889	2899		10.1038/sj.onc.1204396	http://dx.doi.org/10.1038/sj.onc.1204396			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	435VA	11420701				2022-12-25	WOS:000168901800004
J	Bouscary, D; Lecoq-Lafon, C; Chretien, S; Zompi, S; Fichelson, S; Muller, O; Porteu, F; Dusanter-Fourt, I; Gisselbrecht, S; Mayeux, P; Lacombe, C				Bouscary, D; Lecoq-Lafon, C; Chretien, S; Zompi, S; Fichelson, S; Muller, O; Porteu, F; Dusanter-Fourt, I; Gisselbrecht, S; Mayeux, P; Lacombe, C			Role of Gab proteins in phosphatidylinositol 3-kinase activation by thrombopoietin (Tpo)	ONCOGENE			English	Article						Gab proteins; phosphatidylinositol 3-kinase; Akt; thrombopoietin; cytokines; signal transduction	C-MPL LIGAND; PLECKSTRIN HOMOLOGY DOMAIN; GROWTH-FACTOR RECEPTOR; INDUCED MEGAKARYOCYTIC DIFFERENTIATION; PHOSPHOTYROSINE-BINDING DOMAIN; TYROSINE PHOSPHORYLATION; CYTOPLASMIC DOMAIN; INSULIN-RECEPTOR; EPITHELIAL MORPHOGENESIS; SHC PHOSPHORYLATION	In this study, we show that upon thrombopoietin (Tpo) stimulation the two adapter proteins Gab1 and Gab2 are strongly tyrosine phosphorylated and associated with Shc, SHP2, PI 3-kinase and Grb2 in mpl-expressing UT7 cells. Although Gab1 and Gab2 seem to mediate overlapping biological signals in many cells, only Gab1 is expressed and phosphorylated in response to Tpo in primary human megakaryocytic progenitors; furthermore, it associates with the same proteins. Although a Low level of tyrosine phosphorylated IRS-2 protein is also detected in PI 3-kinase immunoprecipitates, cab proteins are the essential proteins associated with PI 3-kinase after Tpo stimulation. We demonstrate that, albeit no association is detected between the Tpo receptor mpl and Gab proteins, Y112 located in the C-terminal cytoplasmic domain of mpl is required for Gab1/2 tyrosine phosphorylation, Gab proteins are not tyrosine phosphorylated after Tpo stimulation of UT-7 and Ba/F3 cells expressing a mpl mutant lacking Y112. Moreover, no activation of the PI 3-kinase/Akt pathway is observed in cells expressing this mpl mutant. Finally, we show that this mutant does not allow cell proliferation, thereby confirming that PI 3-kinase activation is required for Tpo-induced cell proliferation.	Univ Paris 05, Hop Cochin, ICGM, INSERM,U363, F-75014 Paris, France; AP HP, Hop Cochin, Serv Hematol, Paris, France; Hop Cochin, Lab Rech Hemobiol, F-75014 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Universite de Montpellier; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite	Lacombe, C (corresponding author), Univ Paris 05, Hop Cochin, ICGM, INSERM,U363, 27 Rue Faubourg St Jacques, F-75014 Paris, France.		Chretien, Stany/M-5166-2018; PORTEU, Françoise/I-8445-2016; Dusanter-Fourt, Isabelle/P-4558-2017	PORTEU, Françoise/0000-0002-2403-4163; Dusanter-Fourt, Isabelle/0000-0002-9286-1021; Bouscary, Didier/0000-0003-3654-5064				Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Alexander WS, 1996, EMBO J, V15, P6531, DOI 10.1002/j.1460-2075.1996.tb01044.x; Bardelli A, 1997, ONCOGENE, V15, P3103, DOI 10.1038/sj.onc.1201561; BARTLEY TD, 1994, CELL, V77, P1117, DOI 10.1016/0092-8674(94)90450-2; BENIT L, 1994, J VIROL, V68, P5270; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; CASE RD, 1994, J BIOL CHEM, V269, P10467; DAMEN JE, 1993, BLOOD, V82, P2296; Debili N, 1996, BLOOD, V88, P1284, DOI 10.1182/blood.V88.4.1284.bloodjournal8841284; DESAUVAGE FJ, 1994, NATURE, V369, P533, DOI 10.1038/369533a0; DRACHMAN JG, 1995, J BIOL CHEM, V270, P4979, DOI 10.1074/jbc.270.10.4979; Drachman JG, 1997, P NATL ACAD SCI USA, V94, P2350, DOI 10.1073/pnas.94.6.2350; DUSANTERFOURT I, 1992, J BIOL CHEM, V267, P10670; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Geltz NR, 1998, BLOOD, V91, P930, DOI 10.1182/blood.V91.3.930.930_930_939; Gu HH, 2000, MOL CELL BIOL, V20, P7109, DOI 10.1128/MCB.20.19.7109-7120.2000; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; GURNEY AL, 1995, P NATL ACAD SCI USA, V92, P5292, DOI 10.1073/pnas.92.12.5292; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; HolgadoMadruga M, 1997, P NATL ACAD SCI USA, V94, P12419, DOI 10.1073/pnas.94.23.12419; Ingham RJ, 1998, J BIOL CHEM, V273, P30630, DOI 10.1074/jbc.273.46.30630; Itoh M, 2000, MOL CELL BIOL, V20, P3695, DOI 10.1128/MCB.20.10.3695-3704.2000; KAUSHANSKY K, 1994, NATURE, V369, P568, DOI 10.1038/369568a0; Korhonen JM, 1999, J BIOL CHEM, V274, P37307, DOI 10.1074/jbc.274.52.37307; Laminet AA, 1996, J BIOL CHEM, V271, P264, DOI 10.1074/jbc.271.1.264; Lecoq-Lafon C, 1999, BLOOD, V93, P2578, DOI 10.1182/blood.V93.8.2578.408k24_2578_2585; Lock LS, 2000, J BIOL CHEM, V275, P31536, DOI 10.1074/jbc.M003597200; Maroun CR, 1999, MOL CELL BIOL, V19, P1784; Matsumura I, 1998, MOL CELL BIOL, V18, P4282, DOI 10.1128/MCB.18.7.4282; Miyakawa Y, 2001, J BIOL CHEM, V276, P2494, DOI 10.1074/jbc.M002633200; Nishida K, 1999, BLOOD, V93, P1809, DOI 10.1182/blood.V93.6.1809.406k35_1809_1816; PALLARD C, 1995, EMBO J, V14, P2847, DOI 10.1002/j.1460-2075.1995.tb07284.x; Porteu F, 1996, MOL CELL BIOL, V16, P2473; Raabe T, 1996, CELL, V85, P911, DOI 10.1016/S0092-8674(00)81274-X; Rodrigues GA, 2000, MOL CELL BIOL, V20, P1448, DOI 10.1128/MCB.20.4.1448-1459.2000; Rouyez MC, 1997, MOL CELL BIOL, V17, P4991, DOI 10.1128/MCB.17.9.4991; Sattler M, 1997, J CELL PHYSIOL, V171, P28; SATTLER M, 1995, EXP HEMATOL, V23, P1040; Shi ZQ, 2000, MOL CELL BIOL, V20, P1526, DOI 10.1128/MCB.20.5.1526-1536.2000; Takahashi-Tezuka M, 1998, MOL CELL BIOL, V18, P4109, DOI 10.1128/MCB.18.7.4109; vanderGeer P, 1996, P NATL ACAD SCI USA, V93, P963, DOI 10.1073/pnas.93.3.963; VIGON I, 1993, ONCOGENE, V8, P2607; VIGON I, 1992, P NATL ACAD SCI USA, V89, P5640, DOI 10.1073/pnas.89.12.5640; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; WENDLING F, 1994, NATURE, V369, P571, DOI 10.1038/369571a0; Wickrema A, 1999, J BIOL CHEM, V274, P24469, DOI 10.1074/jbc.274.35.24469; Yenush L, 1996, J BIOL CHEM, V271, P24300, DOI 10.1074/jbc.271.39.24300; Zhao CM, 1999, J BIOL CHEM, V274, P19649, DOI 10.1074/jbc.274.28.19649; ZHOU SY, 1995, TRENDS BIOCHEM SCI, V20, P470; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	50	37	47	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 26	2001	20	18					2197	2204		10.1038/sj.onc.1204317	http://dx.doi.org/10.1038/sj.onc.1204317			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	427KZ	11402314				2022-12-25	WOS:000168404500001
J	Hedstrand, H; Ekwall, O; Olsson, MJ; Landgren, E; Kemp, EH; Weetman, AP; Perheentupa, J; Husebye, E; Gustafsson, J; Betterle, C; Kampe, O; Rorsman, F				Hedstrand, H; Ekwall, O; Olsson, MJ; Landgren, E; Kemp, EH; Weetman, AP; Perheentupa, J; Husebye, E; Gustafsson, J; Betterle, C; Kampe, O; Rorsman, F			The transcription factors SOX9 and SOX10 are vitiligo autoantigens in autoimmune polyendocrine syndrome type I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID DECARBOXYLASE; MELANIN-PRODUCING CELLS; AUTOSOMAL SEX REVERSAL; SRY-RELATED GENE; ADDISONS-DISEASE; CYTOCHROME-P450 ENZYMES; POLYGLANDULAR SYNDROME; CAMPOMELIC DYSPLASIA; HAIR-FOLLICLES; HMG PROTEINS	Vitiligo is common in the hereditary disorder autoimmune polyendocrine syndrome type I (APS I). Patients with APS I are known to have high titer autoantibodies directed against various tissue-specific antigens. Using sera from APS I patients for immunoscreening of a cDNA library from human scalp, we identified the transcription factors SOX9 and SOX10 as novel autoantigens related to this syndrome. Immunoreactivity against SOX9 was found in 14 (15%) and against SOX10 in 20 (22%) of the 91 APS I sera studied. All patients reacting with SOX9 displayed reactivity against SOX10, suggesting shared epitopes. Among the 19 patients with vitiligo, 12 (63%) were positive for SOX10 (p < 0.0001). Furthermore, three of 93 sera from patients with vitiligo, unrelated to APS I showed strong reactivity against SOX10 which may indicate a more general role of SOX10 as an autoantigen in vitiligo.	Univ Uppsala Hosp, Dept Med Sci, SE-75185 Uppsala, Sweden; No Gen Hosp, Dept Clin Sci, Sheffield S5 7AU, S Yorkshire, England; Univ Helsinki, Hosp Children & Adolescents, FIN-00014 Helsinki, Finland; Haukeland Hosp, Inst Med, Div Endocrinol, NO-5021 Bergen, Norway; Univ Uppsala Hosp, Dept Womens & Childrens Hlth, S-75185 Uppsala, Sweden; Univ Padua, Inst Med Semeiot, I-35128 Padua, Italy	Uppsala University; Uppsala University Hospital; Northern General Hospital; University of Helsinki; University of Bergen; Haukeland University Hospital; Uppsala University; Uppsala University Hospital; University of Padua	Hedstrand, H (corresponding author), Univ Uppsala Hosp, Dept Med Sci, SE-75185 Uppsala, Sweden.		Kemp, Elizabeth Helen/D-1665-2011	Kemp, Elizabeth Helen/0000-0002-0313-8916; Ekwall, Olov/0000-0002-4506-9955; Kampe, Olle/0000-0001-6091-9914				Aaltonen J, 1997, NAT GENET, V17, P399, DOI 10.1038/ng1297-399; AHONEN P, 1990, NEW ENGL J MED, V322, P1829, DOI 10.1056/NEJM199006283222601; AYER LM, 1994, ARTHRITIS RHEUM, V37, P98, DOI 10.1002/art.1780370115; Betterle C, 1998, J CLIN ENDOCR METAB, V83, P1049, DOI 10.1210/jc.83.4.1049; BETTERLE C, 1985, DERMATOLOGICA, V171, P419, DOI 10.1159/000249466; BETTERLE C, 1984, LANCET, V1, P159; BETTERLE C, 1992, ARCH DERMATOL, V128, P123, DOI 10.1001/archderm.128.1.123; Bondurand N, 1998, FEBS LETT, V432, P168, DOI 10.1016/S0014-5793(98)00843-6; BUSTIN M, 1982, SCIENCE, V215, P1245, DOI 10.1126/science.6460317; Chen S, 1996, J CLIN ENDOCR METAB, V81, P1871, DOI 10.1210/jc.81.5.1871; CUI J, 1992, J INVEST DERMATOL, V98, P162, DOI 10.1111/1523-1747.ep12555773; CUNLIFFE WJ, 1968, BRIT J DERMATOL, V80, P135, DOI 10.1111/j.1365-2133.1968.tb12282.x; Ekwall O, 1998, LANCET, V352, P279, DOI 10.1016/S0140-6736(97)11050-9; FOSTER JW, 1994, NATURE, V372, P525, DOI 10.1038/372525a0; GALBRAITH GMP, 1988, CLIN IMMUNOL IMMUNOP, V48, P317, DOI 10.1016/0090-1229(88)90025-6; GebreMedhin G, 1997, FEBS LETT, V412, P439, DOI 10.1016/S0014-5793(97)00797-7; Goding CR, 2000, GENE DEV, V14, P1712; GOULD IM, 1985, BRIT J DERMATOL, V113, P153, DOI 10.1111/j.1365-2133.1985.tb02057.x; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; GRUNNET I, 1970, ARCH DERMATOL, V101, P82, DOI 10.1001/archderm.101.1.82; Gure AO, 2000, P NATL ACAD SCI USA, V97, P4198, DOI 10.1073/pnas.97.8.4198; Hedstrand H, 1999, J INVEST DERMATOL, V113, P1054, DOI 10.1046/j.1523-1747.1999.00778.x; Hedstrand H, 2000, BIOCHEM BIOPH RES CO, V267, P456, DOI 10.1006/bbrc.1999.1945; HERTZ KC, 1977, NEW ENGL J MED, V297, P634, DOI 10.1056/NEJM197709222971204; HOWITZ J, 1971, LANCET, V1, P1331; Husebye ES, 1997, J CLIN ENDOCR METAB, V82, P147, DOI 10.1210/jc.82.1.147; KAMPE O, 1989, DIABETES, V38, P1326, DOI 10.2337/diabetes.38.10.1326; Kasimiotis H, 2000, DIABETES, V49, P555, DOI 10.2337/diabetes.49.4.555; Kemp EH, 1998, BRIT J DERMATOL, V139, P798; Kemp EH, 1997, J INVEST DERMATOL, V109, P69, DOI 10.1111/1523-1747.ep12276556; Kemp EH, 1998, CLIN EXP IMMUNOL, V114, P333; Kuhlbrodt K, 1998, J NEUROSCI, V18, P237, DOI 10.1523/jneurosci.18-01-00237.1998; Lee M, 2000, J BIOL CHEM, V275, P37978, DOI 10.1074/jbc.M003816200; LERNER AB, 1971, AM J MED, V51, P141, DOI 10.1016/0002-9343(71)90232-4; Mackay IR, 2000, IMMUNOL REV, V174, P226, DOI 10.1034/j.1600-0528.2002.017410.x; Mirakian R, 1998, LANCET, V352, P255, DOI 10.1016/S0140-6736(05)60257-7; Morse JH, 1996, CLIN EXP IMMUNOL, V106, P389, DOI 10.1046/j.1365-2249.1996.d01-848.x; MUHLEN CV, 1995, SEMIN ARTHRITIS RHEU, V5, P323; Nagamine K, 1997, NAT GENET, V17, P393, DOI 10.1038/ng1297-393; NAUGHTON GK, 1983, J EXP MED, V158, P246, DOI 10.1084/jem.158.1.246; NEUER G, 1992, ARTHRITIS RHEUM, V35, P472, DOI 10.1002/art.1780350418; Neufeld M, 1980, Pediatr Ann, V9, P154; OLSSON MJ, 1994, ACTA DERM-VENEREOL, V74, P226; OLSSON MJ, 1993, ACTA DERM-VENEREOL, V73, P49; Pingault V, 1998, NAT GENET, V18, P171, DOI 10.1038/ng0298-171; Prior HM, 1996, MOL MED, V2, P405, DOI 10.1007/BF03401900; RORSMAN F, 1995, P NATL ACAD SCI USA, V92, P8626, DOI 10.1073/pnas.92.19.8626; SCHALLREUTER KU, 1994, DERMATOLOGY, V188, P269, DOI 10.1159/000247164; SONG YH, 1994, LANCET, V344, P1049, DOI 10.1016/S0140-6736(94)91709-4; Southard-Smith EM, 1998, NAT GENET, V18, P60, DOI 10.1038/ng0198-60; Tobin DJ, 1996, PIGM CELL RES, V9, P304, DOI 10.1111/j.1600-0749.1996.tb00122.x; Tuomi T, 1996, J CLIN ENDOCR METAB, V81, P1488, DOI 10.1210/jc.81.4.1488; UIBO R, 1994, J CLIN ENDOCR METAB, V78, P323, DOI 10.1210/jc.78.2.323; VELLOSO LA, 1994, DIABETOLOGIA, V37, P61; WAGNER T, 1994, CELL, V79, P1111, DOI 10.1016/0092-8674(94)90041-8; WANG SJ, 1994, AM J MED GENET, V51, P234, DOI 10.1002/ajmg.1320510313; Wegner M, 1999, NUCLEIC ACIDS RES, V27, P1409, DOI 10.1093/nar/27.6.1409; WINQVIST O, 1993, J CLIN INVEST, V92, P2377, DOI 10.1172/JCI116843; Winqvist O, 1996, MOL MED TODAY, V2, P282, DOI 10.1016/1357-4310(96)10024-1	59	89	98	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35390	35395		10.1074/jbc.M102391200	http://dx.doi.org/10.1074/jbc.M102391200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11423552	hybrid			2022-12-25	WOS:000171109300026
J	Reddy, SK; Kamireddi, M; Dhanireddy, K; Young, L; Davis, A; Reddy, PT				Reddy, SK; Kamireddi, M; Dhanireddy, K; Young, L; Davis, A; Reddy, PT			Eukaryotic-like adenylyl cyclases in Mycobacterium tuberculosis H37Rv - Cloning and characterization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-PRODUCTS; CYCLIC-AMP; PROTEIN; EXPRESSION; RESISTANCE; HEMOLYSIN; APOPTOSIS; INFECTION; SEQUENCE; DOMAINS	Screening the Mycobacterium tuberculosis H37Rv genomic library for complementation of catabolic defect for cAMP-dependent expression of maltose operon produced the adenylyl cyclase gene (Mtb cya, GenBank(TM) accession no. AF017731 (1997)) annotated later as Rv1625c (Cole, S. T., Brosch, R., Parkhill, J., Garnier, T., Churcher, C., Harris, D., Gordon, S. V., Eiglmeier, K., Gas, S., Barry, C. E., III, et al. (1998) Nature 393, 537-544). The deduced amino acid (aa) sequence (443 aa) encoded by Mtb cya contains a single hydrophobic domain of six transmembrane helices (152 aa) in the amino-terminal half of the protein. Flanking this domain are an arginine-rich (17%) amino-terminal cytoplasmic tail (46 aa) and a carboxyl-terminal cytoplasmic domain (245 aa) with extensive homology to the catalytic core of eukaryotic adenylyl cyclases. Site-directed mutagenesis of Arg(43) and Arg(44) to alanine/glycine showed a loss of adenylyl cyclase activity, whereas mutagenesis to lysine restored the activity. Hence it is proposed that the formation of the catalytic site in Mtb adenylyl cyclase requires an interaction between Arg(43) and Arg(44) residues in the distal cytoplasmic tail and the carboxyl-terminal cytoplasmic domain. Mtb adenylyl cyclase activity at the physiological concentration of ATP (1 mm) was 475 nmol of cAMP/min/mg of membrane protein in the presence of Mn2+ but only 10 nmol of cAMP/min/mg of membrane protein in the presence of Mg2+. The physiological significance of the activation of Mtb adenylyl cyclase by Mn2+ is discussed in view of the presence of manganese transporter protein in mycobacteria and macrophages wherein mycobacteria reside.	NIST, Chem Sci & Technol Lab, Div Biotechnol, DNA Technol Grp, Gaithersburg, MD 20899 USA	National Institute of Standards & Technology (NIST) - USA	Reddy, PT (corresponding author), NIST, Chem Sci & Technol Lab, Div Biotechnol, DNA Technol Grp, Bldg 227,Rm B244,Mail Stop 831-1,100 Bur Dr, Gaithersburg, MD 20899 USA.							Av-Gay Y., 1997, MICROB COMP GENOMICS, V2, P63, DOI DOI 10.1089/OMI.1.1997.2.63; Bernard H U, 1979, Methods Enzymol, V68, P482; Buck J, 1999, P NATL ACAD SCI USA, V96, P79, DOI 10.1073/pnas.96.1.79; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Coudart-Cavalli MP, 1997, BIOCHIMIE, V79, P757, DOI 10.1016/S0300-9084(97)86934-9; DOLIN PJ, 1994, B WORLD HEALTH ORGAN, V72, P213; Gueirard P, 1998, INFECT IMMUN, V66, P1718, DOI 10.1128/IAI.66.4.1718-1725.1998; HARWOOD JP, 1975, J BIOL CHEM, V250, P4656; Kamireddi M, 1997, Indian J Clin Biochem, V12, P63, DOI 10.1007/BF02873063; KHELEF N, 1993, INFECT IMMUN, V61, P4064, DOI 10.1128/IAI.61.10.4064-4071.1993; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; LEPPLA SH, 1982, P NATL ACAD SCI-BIOL, V79, P3162, DOI 10.1073/pnas.79.10.3162; LOWRIE DB, 1975, NATURE, V254, P600, DOI 10.1038/254600a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MASURE HR, 1987, MICROBIOL REV, V51, P60, DOI 10.1128/MMBR.51.1.60-65.1987; PADH H, 1976, INDIAN J BIOCHEM BIO, V13, P413; PADH H, 1980, MICROBIOS, V27, P69; PADH H, 1977, MICROBIOS, V16, P183; REDDY P, 1989, NUCLEIC ACIDS RES, V17, P10473, DOI 10.1093/nar/17.24.10473; ROY A, 1982, MOL GEN GENET, V188, P465, DOI 10.1007/BF00330050; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; Sambrook J., 2002, MOL CLONING LAB MANU; SEGREST JP, 1990, PROTEINS, V8, P103, DOI 10.1002/prot.340080202; SHAH S, 1991, J BACTERIOL, V173, P3238, DOI 10.1128/JB.173.10.3238-3242.1991; Supek F, 1996, P NATL ACAD SCI USA, V93, P5105, DOI 10.1073/pnas.93.10.5105; TANG WJ, 1995, SCIENCE, V268, P1769, DOI 10.1126/science.7792604; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; VIDAL SM, 1993, CELL, V73, P469, DOI 10.1016/0092-8674(93)90135-D; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; Whisnant RE, 1996, P NATL ACAD SCI USA, V93, P6621, DOI 10.1073/pnas.93.13.6621; Wolff J, 1980, P NATL ACAD SCI USA, V77, P3840; Zhang GY, 1997, NATURE, V386, P247, DOI 10.1038/386247a0; ZUBER M, 1987, P NATL ACAD SCI USA, V84, P4514, DOI 10.1073/pnas.84.13.4514	35	43	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					35141	35149		10.1074/jbc.M104108200	http://dx.doi.org/10.1074/jbc.M104108200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11431477	hybrid			2022-12-25	WOS:000171024600104
J	Aalfs, JD; Narlikar, GJ; Kingston, RE				Aalfs, JD; Narlikar, GJ; Kingston, RE			Functional differences between the human ATP-dependent nucleosome remodeling proteins BRG1 and SNF2H	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SWI/SNF COMPLEX; HUMAN SWI-SNF; HISTONE OCTAMER; SACCHAROMYCES-CEREVISIAE; IN-VITRO; HO GENE; CHROMATIN; ISWI; TRANSCRIPTION; BINDING	ATP-dependent nucleosome remodeling complexes can be grouped into several classes that may differ in their biochemical remodeling activities and biological roles. Although there are a number of biochemical studies of each class of remodeler, there are very little data directly comparing the biochemical activities of remodelers from different classes. We have purified two ATP-hydrolyzing proteins, SNF2H and BRG1, which are members of complexes from two different classes of remodelers. Consistent with previous reports, these two homogeneous proteins can perform remodeling functions. We show significant functional differences between SNF2H and BRG1 in vitro; although both SNF2H and BRG1 hydrolyze ATP and remodel linear arrays of nucleosomes, only BRG1 can remodel mononucleosomes. Also, only BRG1 can alter the topology of nucleosomal plasmids. We propose that these functional differences reflect significant mechanistic differences between the two remodeler classes that will impact their biological roles.	Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Kingston, RE (corresponding author), Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.							AALFS J, 2001, BIOCH COMP HUMAN ATP; Aihara T, 1998, CYTOGENET CELL GENET, V81, P191, DOI 10.1159/000015027; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; Bochar DA, 2000, P NATL ACAD SCI USA, V97, P1038, DOI 10.1073/pnas.97.3.1038; Cairns BR, 1996, CELL, V87, P1249, DOI 10.1016/S0092-8674(00)81820-6; CAIRNS BR, 1994, P NATL ACAD SCI USA, V91, P1950, DOI 10.1073/pnas.91.5.1950; Corona DFV, 1999, MOL CELL, V3, P239, DOI 10.1016/S1097-2765(00)80314-7; Cosma MP, 1999, CELL, V97, P299, DOI 10.1016/S0092-8674(00)80740-0; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; ELFRING LK, 1994, MOL CELL BIOL, V14, P2225, DOI 10.1128/MCB.14.4.2225; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; Gavin I, 2001, MOL CELL, V7, P97, DOI 10.1016/S1097-2765(01)00158-7; Georgel PT, 1997, EMBO J, V16, P4717, DOI 10.1093/emboj/16.15.4717; Guyon JR, 1999, MOL CELL BIOL, V19, P2088; Hamiche A, 1999, CELL, V97, P833, DOI 10.1016/S0092-8674(00)80796-5; Havas K, 2000, CELL, V103, P1133, DOI 10.1016/S0092-8674(00)00215-4; Imbalzano AN, 1996, J BIOL CHEM, V271, P20726, DOI 10.1074/jbc.271.34.20726; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; Ito T, 1999, GENE DEV, V13, P1529, DOI 10.1101/gad.13.12.1529; Ito T, 1997, CELL, V90, P145, DOI 10.1016/S0092-8674(00)80321-9; Jeanmougin F, 1997, TRENDS BIOCHEM SCI, V22, P151, DOI 10.1016/S0968-0004(97)01042-6; Krebs JE, 1999, GENE DEV, V13, P1412, DOI 10.1101/gad.13.11.1412; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; Langst G, 1999, CELL, V97, P843, DOI 10.1016/S0092-8674(00)80797-7; LeRoy G, 1998, SCIENCE, V282, P1900, DOI 10.1126/science.282.5395.1900; Logie C, 1997, EMBO J, V16, P6772, DOI 10.1093/emboj/16.22.6772; Lorch Y, 1999, CELL, V96, P389, DOI 10.1016/S0092-8674(00)80551-6; Lorch Y, 1998, CELL, V94, P29, DOI 10.1016/S0092-8674(00)81218-0; MORSE RH, 1989, EMBO J, V8, P2343, DOI 10.1002/j.1460-2075.1989.tb08362.x; NACHEVA GA, 1989, CELL, V58, P27, DOI 10.1016/0092-8674(89)90399-1; NEIGEBORN L, 1984, GENETICS, V108, P845; Papoulas O, 1998, DEVELOPMENT, V125, P3955; Phelan ML, 2000, MOL CELL BIOL, V20, P6380, DOI 10.1128/MCB.20.17.6380-6389.2000; Phelan ML, 1999, MOL CELL, V3, P247, DOI 10.1016/S1097-2765(00)80315-9; Poot RA, 2000, EMBO J, V19, P3377, DOI 10.1093/emboj/19.13.3377; ROUGVIE AE, 1988, CELL, V54, P795, DOI 10.1016/S0092-8674(88)91087-2; Schnitzler G, 1998, CELL, V94, P17, DOI 10.1016/S0092-8674(00)81217-9; SHRADER TE, 1989, P NATL ACAD SCI USA, V86, P7418, DOI 10.1073/pnas.86.19.7418; Sif S, 1998, GENE DEV, V12, P2842, DOI 10.1101/gad.12.18.2842; Steger DJ, 1998, P NATL ACAD SCI USA, V95, P12924, DOI 10.1073/pnas.95.22.12924; STERN M, 1984, J MOL BIOL, V178, P853, DOI 10.1016/0022-2836(84)90315-2; Sudarsanam P, 1999, EMBO J, V18, P3101, DOI 10.1093/emboj/18.11.3101; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; Tsukiyama T, 1999, GENE DEV, V13, P686, DOI 10.1101/gad.13.6.686; VargaWeisz PD, 1997, NATURE, V388, P598, DOI 10.1038/41587; Wade PA, 1998, CURR BIOL, V8, P843, DOI 10.1016/S0960-9822(98)70328-8; Wang WD, 1996, GENE DEV, V10, P2117, DOI 10.1101/gad.10.17.2117; WONG I, 1993, P NATL ACAD SCI USA, V90, P5428, DOI 10.1073/pnas.90.12.5428; WORKMAN JL, 1991, METHOD CELL BIOL, V35, P419; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3	51	70	71	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					34270	34278		10.1074/jbc.M104163200	http://dx.doi.org/10.1074/jbc.M104163200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11435432	hybrid			2022-12-25	WOS:000170910200130
J	Wang, DS; Canaff, L; Davidson, D; Corluka, A; Liu, HL; Hendy, GN; Henderson, JE				Wang, DS; Canaff, L; Davidson, D; Corluka, A; Liu, HL; Hendy, GN; Henderson, JE			Alterations in the sensing and transport of phosphate and calcium by differentiating chondrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-RELATED PEPTIDE; FAMILIAL HYPOCALCIURIC HYPERCALCEMIA; NEONATAL SEVERE HYPERPARATHYROIDISM; GROWTH-FACTOR RECEPTOR-3; CONVOLUTED TUBULE CELLS; II COLLAGEN GENE; PARATHYROID-HORMONE; MATRIX VESICLES; IN-VITRO; METAPHYSEAL CHONDRODYSPLASIA	During endochondral bone formation and fracture healing, cells committed to chondrogenesis undergo a temporally restricted program of differentiation that is characterized by sequential changes in their phenotype and gene expression. This results in the manufacture, remodeling, and mineralization of a cartilage template on which bone is laid down. Articular chondrocytes undergo a similar but restricted differentiation program that does not proceed to mineralization, except in pathologic conditions such as osteoarthritis. The pathogenesis of disorders of cartilage development and metabolism, including osteochondrodysplasia, fracture non-union, and osteoarthritis remain poorly defined. We used the CFK2 model to examine the potential roles of phosphate and calcium ions in the regulatory pathways that mediate chondrogenesis and cartilage maturation. Differentiation was monitored over a 4-week period using a combination of morphological, biochemical, and molecular markers that have been characterized in vivo and in vitro. CFK2 cells expressed the type III sodium-dependent phosphate transporters Glvr-1 and Ram-1, as well as a calcium-sensing mechanism. Regulated expression and activity of Glvr-1 by extracellular phosphate and parathyroid hormone-related protein was restricted to an early stage of CFK2 differentiation, as evidenced by expression of type II collagen, proteoglycan, and Ihh. On the other hand, regulated expression and activity of a calcium-sensing receptor by extracellular calcium was most evident after 2 weeks of differentiation, concomitant with an increase in type X collagen expression, alkaline phosphatase activity and parathyroid hormone/parathyroid hormone-related protein receptor expression. On the basis of these temporally restricted changes in the sensing and transport of phosphate and calcium, we predict that extracellular phosphate plays a role in the commitment of chondrogenic cells to differentiation, whereas extracellular calcium plays a role at a later stage in their differentiation program.	McGill Univ, Dept Med, Lady Davis Inst Med Res, Sir Mortimer B Davis Jewish Gen Hosp, Montreal, PQ H3T 1E2, Canada; Royal Victoria Hosp, Calcium Res Lab, Montreal, PQ H3A 1A1, Canada	Lady Davis Institute; McGill University; McGill University; Royal Victoria Hospital	Henderson, JE (corresponding author), McGill Univ, Dept Med, Lady Davis Inst Med Res, Sir Mortimer B Davis Jewish Gen Hosp, Rm 602,3755 Cote St Catherine Rd, Montreal, PQ H3T 1E2, Canada.							Aarts MM, 1999, J BONE MINER RES, V14, P1493, DOI 10.1359/jbmr.1999.14.9.1493; Aarts MM, 1999, J BIOL CHEM, V274, P4832, DOI 10.1074/jbc.274.8.4832; Alini M, 1996, J BONE MINER RES, V11, P105; Amizuka N, 1999, J BONE MINER RES, V14, pS435; AMIZUKA N, 1994, J CELL BIOL, V126, P1611, DOI 10.1083/jcb.126.6.1611; Amizuka N, 1996, ENDOCRINOLOGY, V137, P5055, DOI 10.1210/en.137.11.5055; ANDERSON HC, 1995, CLIN ORTHOP RELAT R, P266; ANDERSON HC, 1969, J CELL BIOL, V41, P59, DOI 10.1083/jcb.41.1.59; Bai M, 1997, J CLIN INVEST, V99, P1917, DOI 10.1172/JCI119359; Bapty BW, 1998, KIDNEY INT, V53, P583, DOI 10.1046/j.1523-1755.1998.00790.x; BERNIER SM, 1993, J BONE MINER RES, V8, P475; Bernier SM, 1996, ANN NY ACAD SCI, V785, P212, DOI 10.1111/j.1749-6632.1996.tb56264.x; BERNIER SM, 1990, J CELL PHYSIOL, V145, P274, DOI 10.1002/jcp.1041450212; BICKLE DD, 1996, J CLIN INVEST, V97, P1085; Billinghurst RC, 1997, J CLIN INVEST, V99, P1534, DOI 10.1172/JCI119316; BINGHAM PJ, 1974, CALC TISS RES, V14, P31, DOI 10.1007/BF02060281; BOSKEY AL, 1992, BONE MINER, V16, P11, DOI 10.1016/0169-6009(92)90819-Y; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; Caverzasio J, 1996, KIDNEY INT, V49, P975, DOI 10.1038/ki.1996.138; Chang WH, 1999, ENDOCRINOLOGY, V140, P1911, DOI 10.1210/en.140.4.1911; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; GERSTENFELD LC, 1991, J CELL BIOL, V112, P501, DOI 10.1083/jcb.112.3.501; GLASER JH, 1981, J BIOL CHEM, V256, P2607; GLORIEUX FH, 1972, NEW ENGL J MED, V287, P481, DOI 10.1056/NEJM197209072871003; GOLUB EE, 1983, J BIOL CHEM, V258, P616; Guicheux J, 2000, BONE, V27, P69, DOI 10.1016/S8756-3282(00)00302-1; Guo J, 2001, ENDOCRINOLOGY, V142, P1260, DOI 10.1210/en.142.3.1260; Henderson JE, 1996, J CELL PHYSIOL, V169, P33, DOI 10.1002/(SICI)1097-4652(199610)169:1<33::AID-JCP4>3.0.CO;2-F; HENDERSON JE, 1995, MOL CELL BIOL, V15, P4064; Henderson JE, 2000, J BONE MINER RES, V15, P155, DOI 10.1359/jbmr.2000.15.1.155; HENDERSON JE, 2000, OSTEOPOROSIS PRIMER, P113; Hendy GN, 2000, HUM MUTAT, V16, P281, DOI 10.1002/1098-1004(200010)16:4<281::AID-HUMU1>3.0.CO;2-A; HOWELL DS, 1968, J CLIN INVEST, V47, P1121, DOI 10.1172/JCI105801; IKEDA K, 1989, BIOCHEM BIOPH RES CO, V162, P108, DOI 10.1016/0006-291X(89)91969-4; JEE WSS, 1983, HISTOLOGY CELL TISSU, V5, P200; JIKKO A, 1993, DEV BIOL, V156, P372, DOI 10.1006/dbio.1993.1084; Johnson K, 1999, ARTHRITIS RHEUM-US, V42, P1986, DOI 10.1002/1529-0131(199909)42:9<1986::AID-ANR26>3.0.CO;2-O; KAKUTA S, 1985, CALCIFIED TISSUE INT, V37, P293, DOI 10.1007/BF02554877; KARAPLIS AC, 1994, GENE DEV, V8, P277, DOI 10.1101/gad.8.3.277; Karp SJ, 2000, DEVELOPMENT, V127, P543; Kavanaugh MP, 1996, KIDNEY INT, V49, P959, DOI 10.1038/ki.1996.135; KAVANAUGH MP, 1994, P NATL ACAD SCI USA, V91, P7071, DOI 10.1073/pnas.91.15.7071; Kirsch T, 1997, J CELL BIOL, V137, P1149, DOI 10.1083/jcb.137.5.1149; Krebsbach PH, 1996, J BIOL CHEM, V271, P4298, DOI 10.1074/jbc.271.8.4298; LIPMAN ML, 1994, J IMMUNOL, V152, P5120; Lipman ML, 1998, J BIOL CHEM, V273, P13729, DOI 10.1074/jbc.273.22.13729; Mansfield K, 2001, BONE, V28, P1, DOI 10.1016/S8756-3282(00)00409-9; MARIE PJ, 1981, J CLIN INVEST, V67, P911, DOI 10.1172/JCI110110; McEwen DG, 1999, J BIOL CHEM, V274, P30934, DOI 10.1074/jbc.274.43.30934; METSARANTA M, 1991, J BIOL CHEM, V266, P16862; MONTESSUIT C, 1991, J BIOL CHEM, V266, P17791; MONTESSUIT C, 1995, J BONE MINER RES, V10, P625; Nielsen LB, 2001, BONE, V28, P160, DOI 10.1016/S8756-3282(00)00418-X; Palmer G, 2000, GENE, V244, P35, DOI 10.1016/S0378-1119(00)00010-X; Palmer G, 1999, BONE, V24, P1, DOI 10.1016/S8756-3282(98)00151-3; Papaioannou S, 1999, BBA-MOL CELL RES, V1449, P284, DOI 10.1016/S0167-4889(99)00025-7; Pi M, 2000, J BIOL CHEM, V275, P3256, DOI 10.1074/jbc.275.5.3256; POOLE AR, 1991, CARTILAGE MOL ASPECT, P179; POOLE AR, 2000, OSTEOPOROSIS PRIMER, P3; Richardson C, 1996, MOL CELL BIOL, V16, P4240; Ryan Lawrence M., 1993, P1835; SCHIPANI E, 1995, SCIENCE, V268, P98, DOI 10.1126/science.7701349; Shukunami C, 1997, J BONE MINER RES, V12, P1174, DOI 10.1359/jbmr.1997.12.8.1174; Shukunami C, 1996, J CELL BIOL, V133, P457, DOI 10.1083/jcb.133.2.457; SIMMONS DJ, 1970, CLIN ORTHOP RELAT R, V68, P252; TAKIGAWA M, 1980, P NATL ACAD SCI-BIOL, V77, P1481, DOI 10.1073/pnas.77.3.1481; TAKUWA N, 1987, J BIOL CHEM, V262, P182; TAVORMINA PL, 1995, NAT GENET, V9, P321, DOI 10.1038/ng0395-321; Tenenhouse HS, 1997, J BONE MINER RES, V12, P159, DOI 10.1359/jbmr.1997.12.2.159; Tenenhouse HS, 1998, J BONE MINER RES, V13, P590, DOI 10.1359/jbmr.1998.13.4.590; Terkeltaub R, 1998, ARTHRITIS RHEUM-US, V41, P2152, DOI 10.1002/1529-0131(199812)41:12<2152::AID-ART10>3.3.CO;2-O; Valentini RP, 1997, J BIOL CHEM, V272, P8466, DOI 10.1074/jbc.272.13.8466; Vortkamp A, 1996, SCIENCE, V273, P613, DOI 10.1126/science.273.5275.613; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; WARMAN ML, 1993, NAT GENET, V5, P79, DOI 10.1038/ng0993-79; Windahl SH, 1999, J CLIN INVEST, V104, P895, DOI 10.1172/JCI6730; WINDAHL SH, 2001, IN PRESS J BONE MINE; Yamaguchi T, 2000, ADV PHARMACOL, V47, P209; YANG T, 1997, AM J PHYSIOL, V272, P751; Yao J, 1998, DEV GROWTH DIFFER, V40, P133	80	59	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33995	34005		10.1074/jbc.M007757200	http://dx.doi.org/10.1074/jbc.M007757200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11404353	hybrid			2022-12-25	WOS:000170910200095
J	Krimbou, L; Marcil, M; Davignon, J; Genest, J				Krimbou, L; Marcil, M; Davignon, J; Genest, J			Interaction of lecithin : cholesterol acyltransferase (LCAT)center dot alpha(2)-macroglobulin complex with low density lipoprotein receptor-related protein (LRP) - Evidence for an alpha(2)-macroglobulin/LRP receptor-mediated system participating in LCAT clearance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESTER TRANSFER PROTEIN; APOLIPOPROTEIN-A-I; HUMAN PLASMA; BINDING; BETA; LOCALIZATION; EXPRESSION; MUTANTS; LPE	The reaction of lecithin:cholesterol acyltransferase (LCAT) with high density lipoproteins (RDL) is of critical importance in reverse cholesterol transport, but the structural and functional pathways involved in the regulation of LCAT have not been established. We present evidence for the direct binding of LCAT to alpha (2)-macroglobulin (alpha M-2) in human plasma to form a complex 18.5 nm in diameter. Forty percent of plasma LCAT-HDL was associated with a2M; moreover, most of the LCAT in cerebrospinal fluid and in the medium of cultured human hepatoma cell line was associated with alpha M-2. Purified recombinant human LCAT (rLCAT) labeled with I-125 bound to native and methylamine-activated alpha M-2 (alpha M-2-MA) in vitro in a time- and concentration-dependent manner, and this binding did not depend on the presence of lipid. rLCAT bound to alpha 2M-MA with greater affinity than to alpha 2M. Furthermore, rLCAT did not activate alpha 2M as phosphatidylcholine-specific phospholipase C does. Reconstituted HDL particles (LpA-I) inhibited the binding of rLCAT to alpha M-2 more efficiently than native HDL3 did. LCAT associated with alpha M-2 was enzymatically inactive under both endogenous and exogenous assay conditions. Purified rLCAT alone did not bind to low density lipoprotein receptor-related protein (LRP) as lipoprotein lipase (LPL) does; however, when rLCAT was combined with alpha 2M-MA to form a complex, binding, internalization, and degradation of rLCAT took place in LRPexpressing cells (LRP (+/+)) but not in cells deficient in LRP (LRP (-/-)). It is concluded that the binding of LCAT to alpha 2M inhibits its enzymatic activity. Furthermore, the finding supports the possibility that the LRP receptor can act in vivo to mediate clearance of the LCAT-alpha M-2 complex and may significantly influence the bioavailability of LCAT.	McGill Univ, Royal Victoria Hosp, Ctr Hlth, Cardiovasc Genet Lab,Cardiol Div, Montreal, PQ H3A 1A1, Canada; Clin Res Inst Montreal, Hyperlipidemia & Atherosclerosis Res Grp, Montreal, PQ H2W 1R7, Canada	McGill University; Royal Victoria Hospital; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal	Genest, J (corresponding author), McGill Univ, Royal Victoria Hosp, Ctr Hlth, Cardiovasc Genet Lab,Cardiol Div, M4-76,687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.							Adimoolam S, 1998, J BIOL CHEM, V273, P32561, DOI 10.1074/jbc.273.49.32561; BOLIN DJ, 1994, J BIOL CHEM, V269, P7429; BONELLI FS, 1989, J BIOL CHEM, V264, P14723; BORTH W, 1994, ANN NY ACAD SCI, V737, P267, DOI 10.1111/j.1749-6632.1994.tb44317.x; CHEUNG MC, 1986, J LIPID RES, V27, P1135; Chisholm JW, 1999, J LIPID RES, V40, P1512; Collet X, 1999, BIOCHEM BIOPH RES CO, V258, P73, DOI 10.1006/bbrc.1999.0601; CROOKSTON KP, 1994, J BIOL CHEM, V269, P1533; Du YS, 1997, J NEUROCHEM, V69, P299; FIELDING CJ, 1995, J LIPID RES, V36, P211; FRANCONE OL, 1989, J BIOL CHEM, V264, P7066; GLOMSET JA, 1968, J LIPID RES, V9, P155; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GONIAS SL, 1994, ANN NY ACAD SCI, V737, P273, DOI 10.1111/j.1749-6632.1994.tb44318.x; HILL JS, 1990, CLIN CHEM, V36, P1871; ILLINGWORTH D R, 1970, Biochimica et Biophysica Acta, V220, P610, DOI 10.1016/0005-2744(70)90292-5; JENSEN PH, 1989, FEBS LETT, V255, P275, DOI 10.1016/0014-5793(89)81105-6; Jin LH, 1999, BIOCHEMISTRY-US, V38, P15659, DOI 10.1021/bi9916729; Krimbou L, 1997, J LIPID RES, V38, P35; Krimbou L, 1998, J LIPID RES, V39, P861; Krimbou L, 1998, J LIPID RES, V39, P2373; MARCIL M, 1995, ARTERIOSCL THROM VAS, V15, P1015, DOI 10.1161/01.ATV.15.8.1015; MATZ CE, 1982, J BIOL CHEM, V257, P4535; MCLEAN J, 1986, P NATL ACAD SCI USA, V83, P2335, DOI 10.1073/pnas.83.8.2335; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; QU SJ, 1995, J LIPID RES, V36, P967; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; SALACINSKI PRP, 1981, ANAL BIOCHEM, V117, P136, DOI 10.1016/0003-2697(81)90703-X; SMITH KM, 1990, J LIPID RES, V31, P995; Sottrup-Jensen L, 1987, PLASMA PROTEINS STRU, V5, P192; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P11539; Starkey P. M., 1977, PROTEINASES MAMMALIA, P663; TALL AR, 1993, J LIPID RES, V34, P1255; VLAICU R, 1985, ATHEROSCLEROSIS, V55, P35, DOI 10.1016/0021-9150(85)90164-9; Vohl MC, 1999, BIOCHEMISTRY-US, V38, P5976, DOI 10.1021/bi982258w; WANG CY, 1995, CANCER RES, V55, P5101; WEEB DJ, 1994, J BIOL CHEM, V269, P30402	37	30	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					33241	33248		10.1074/jbc.M100326200	http://dx.doi.org/10.1074/jbc.M100326200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11435418	hybrid			2022-12-25	WOS:000170746000110
J	Bechoua, S; Daniel, LW				Bechoua, S; Daniel, LW			Phospholipase D is required in the signaling pathway leading to p38 MAPK activation in neutrophil-like HL-60 cells, stimulated by N-formyl-methionyl-leucyl-phenylalanine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; PROTEIN-KINASE ACTIVATION; TRANSDUCTION PATHWAYS; PHOSPHATIDIC-ACID; GENE-EXPRESSION; BINDING-PROTEIN; TNF-ALPHA; GM-CSF; PHOSPHORYLATION; MECHANISMS	Human acute myelogenous leukemia cells (HL-60 Cells) can be induced to differentiate to neutrophils by exposure to dibutyryl-cyclic AMP. The differentiation of HL-60 cells allowed the mitogen-activated protein kinases p38 and p44/p42 to be rapidly and transiently activated upon stimulation with N-formyl-methionyl-leucyl-phenylalanine (fMLP). Western blot analysis using phosphospecific p38 and p44/p42 mitogen-activated protein kinase antibodies showed that increasing concentrations of ethanol or 1-butanol but not 2-butanol (0.05-0.5%) inhibited fMLP-induced p38 activation but did not inhibit p44/p42 activation. These data indicated that activation of phospholipase D (PLD) was required for activation of p38 but not p44/p42. We compared the effect of fMLP with those of tumor necrosis factor a (TNF alpha) and granulocyte-macrophage colony-stimulating factor (GAT-CSF). We found that ethanol did not inhibit p38 phosphorylation upon stimulation with either GM-CSF or TNF alpha. These results suggested that in cells stimulated with RULP, PLD was upstream of p38. To further test the involvement of PLD, we used antisense inhibition of human PLD1 expression. Treatment with antisense oligonueleotides inhibited p38 but not p44/p42 phosphorylation. These data supported a role for human PLD1 in fMLP-induced p38-activation in neutrophil-like HL-60 cells. In addition, the results obtained with TNF alpha and GM-CSF demonstrated that p38 activation occurred independently of PLD activation.	Wake Forest Univ, Sch Med, Dept Biochem, Winston Salem, NC 27157 USA	Wake Forest University	Daniel, LW (corresponding author), Wake Forest Univ, Sch Med, Dept Biochem, Winston Salem, NC 27157 USA.				NCI NIH HHS [CA-72730, CA-12197] Funding Source: Medline; NIAID NIH HHS [AI-38949] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA012197, R01CA072730] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038949, P01AI138949] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABST JJ, 1980, J EXP MED, V151, P101; AGWU DE, 1989, J BIOL CHEM, V264, P1405; ARAI KI, 1988, ANNU REV BIOCHEM, V59, P783; BAULDRY SA, 1991, J BIOL CHEM, V266, P4173; BAULDRY SA, 1991, J IMMUNOL, V146, P1277; BLIGH DG, 1959, CAN J BIOCH PHYSL, V123, P64; BOURGOIN S, 1990, J EXP MED, V172, P767, DOI 10.1084/jem.172.3.767; BOURGOIN S, 1992, CELL SIGNAL, V4, P487; BUHL AM, 1994, P NATL ACAD SCI USA, V91, P9190, DOI 10.1073/pnas.91.19.9190; CHAO W, 1993, BIOCHEM J, V292, P617, DOI 10.1042/bj2920617; CHIANG MY, 1991, J BIOL CHEM, V266, P18162; Colley WC, 1997, BIOCHEM J, V326, P745, DOI 10.1042/bj3260745; COLLINS SJ, 1987, BLOOD, V70, P1233; DARBY C, 1990, BLOOD, V75, P2396; Denhardt DT, 1996, BIOCHEM J, V318, P729, DOI 10.1042/bj3180729; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DOLNICK BJ, 1990, BIOCHEM PHARMACOL, V40, P671, DOI 10.1016/0006-2952(90)90300-A; Downey GP, 1996, J BIOL CHEM, V271, P21005, DOI 10.1074/jbc.271.35.21005; ElBenna J, 1996, ARCH BIOCHEM BIOPHYS, V334, P395; Exton JH, 1997, J BIOL CHEM, V272, P15579, DOI 10.1074/jbc.272.25.15579; Exton JH, 1997, PHYSIOL REV, V77, P303, DOI 10.1152/physrev.1997.77.2.303; Fensome A, 1998, J BIOL CHEM, V273, P13157, DOI 10.1074/jbc.273.21.13157; Foey AD, 1998, J IMMUNOL, V160, P920; Frasch SC, 1998, J BIOL CHEM, V273, P8389, DOI 10.1074/jbc.273.14.8389; GERARD C, 1994, CURR OPIN IMMUNOL, V6, P140, DOI 10.1016/0952-7915(94)90045-0; GOMEZCAMBRONERO J, 1991, ADV EXP MED BIOL, V314, P35; GUTHRIE LA, 1984, J EXP MED, V160, P1656, DOI 10.1084/jem.160.6.1656; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; HASLETT C, 1989, CURR OPIN IMMUNOL, V2, P10, DOI 10.1016/0952-7915(89)90091-5; Hayes TS, 1999, CELL SIGNAL, V11, P195, DOI 10.1016/S0898-6568(98)00066-7; HELENE C, 1990, BIOCHIM BIOPHYS ACTA, V1049, P99, DOI 10.1016/0167-4781(90)90031-V; Krump E, 1997, J BIOL CHEM, V272, P937, DOI 10.1074/jbc.272.2.937; Lee JC, 1996, J LEUKOCYTE BIOL, V59, P152, DOI 10.1002/jlb.59.2.152; Lee TG, 1997, BBA-LIPID LIPID MET, V1347, P199, DOI 10.1016/S0005-2760(97)00083-0; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; Martin A, 1997, BIOCHEM SOC T, V25, P1157, DOI 10.1042/bst0251157; Muthalif MM, 2000, J PHARMACOL EXP THER, V293, P268; Nahas N, 1996, BIOCHEM J, V318, P247, DOI 10.1042/bj3180247; Nixon AB, 1999, J BIOL CHEM, V274, P5469, DOI 10.1074/jbc.274.9.5469; OFlaherty JT, 1996, J BIOL CHEM, V271, P17821, DOI 10.1074/jbc.271.30.17821; Ohguchi K, 1997, J BIOL CHEM, V272, P1990, DOI 10.1074/jbc.272.3.1990; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Rane MJ, 1997, J IMMUNOL, V159, P5070; ROTHSTEIN JL, 1988, P NATL ACAD SCI USA, V85, P607, DOI 10.1073/pnas.85.2.607; Saqib KM, 1997, BIOCHEM SOC T, V25, pS586, DOI 10.1042/bst025s586; Schnyder B, 1998, BIOCHEM J, V331, P489, DOI 10.1042/bj3310489; Singer WD, 1997, ANNU REV BIOCHEM, V66, P475, DOI 10.1146/annurev.biochem.66.1.475; STEIN CA, 1988, CANCER RES, V48, P2659; STRUM JC, 1993, BIOCHIM BIOPHYS ACTA, V1169, P25, DOI 10.1016/0005-2760(93)90077-M; TYAGI SR, 1989, FEBS LETT, V257, P188, DOI 10.1016/0014-5793(89)81817-4; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; WORTHEN GS, 1994, J CLIN INVEST, V94, P815, DOI 10.1172/JCI117401; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; ZON G, 1988, PHARM RES-DORDR, V5, P539, DOI 10.1023/A:1015985728434; Zu YL, 1998, J IMMUNOL, V160, P1982	59	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					31752	31759		10.1074/jbc.M101265200	http://dx.doi.org/10.1074/jbc.M101265200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11427526	hybrid			2022-12-25	WOS:000170613500039
J	Song, M; Helguera, G; Eghbali, M; Zhu, N; Zarei, MM; Olcese, R; Toro, L; Stefani, E				Song, M; Helguera, G; Eghbali, M; Zhu, N; Zarei, MM; Olcese, R; Toro, L; Stefani, E			Remodeling of Kv4.3 potassium channel gene expression under the control of sex hormones	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSIENT OUTWARD CURRENT; SMOOTH-MUSCLE CELLS; K+ CHANNEL; ALPHA-SUBUNIT; I-TO; MYOCARDIAL-INFARCTION; VENTRICULAR MUSCLE; RAT; CLONING; MYOMETRIUM	Kv4.3 channels are important molecular components of transient K+ currents (Ito currents) in brain and heart. They are involved in setting the frequency of neuronal firing and heart pacing. Altered Kv4.3 channel expression has been demonstrated under pathological conditions like heart failure indicating their critical role in heart function. Thyroid hormone studies suggest that their expression in the heart may be hormonally regulated. To explore the possibility that sex hormones control Kv4.3 expression, we investigated whether its expression changes in the pregnant uterus. This organ represents a unique model to study Ito currents, because it possesses this type of K+ current and undergoes dramatic changes in function and excitability during pregnancy. We cloned Kv4.3 channel from myometrium and found that its protein and transcript expression is greatly diminished during pregnancy. Experiments in ovariectomized rats demonstrate that estrogen is one mechanism responsible for the dramatic reduction in Kv4.3 expression and function prior to parturition. Furthermore, the reduction of plasma membrane Kv4.3 protein is accompanied by a perinuclear localization suggesting that cell trafficking is also controlled by sex hormones. Thus, estrogen remodels the expression of Kv4.3 in myometrium by directly diminishing its transcription and, indirectly, by altering Kv4.3 delivery to the plasma membrane.	Univ Calif Los Angeles, Sch Med, Dept Anesthesiol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Physiol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Brain Res Inst, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Stefani, E (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Anesthesiol, BH-509A CHS,Box 957115, Los Angeles, CA 90095 USA.			Helguera, Gustavo/0000-0003-1509-3564	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054970] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL54970] Funding Source: Medline; NIGMS NIH HHS [GM52203] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEXANDROVA M, 1980, ENDOCRINOLOGY, V106, P730, DOI 10.1210/endo-106-3-730; An WF, 2000, NATURE, V403, P553, DOI 10.1038/35000592; ANWER K, 1993, AM J PHYSIOL, V265, pC976, DOI 10.1152/ajpcell.1993.265.4.C976; Barry DM, 1998, CIRC RES, V83, P560, DOI 10.1161/01.RES.83.5.560; Benkusky NA, 2000, J BIOL CHEM, V275, P27712; Brahmajothi MV, 1999, J GEN PHYSIOL, V113, P581, DOI 10.1085/jgp.113.4.581; Challis John R. G., 1994, P985; Dixon JE, 1996, CIRC RES, V79, P659, DOI 10.1161/01.RES.79.4.659; DIXON JE, 1994, CIRC RES, V75, P252, DOI 10.1161/01.RES.75.2.252; Eghbali M, 2001, BIOPHYS J, V80, p444A; GidhJain M, 1996, CIRC RES, V79, P669, DOI 10.1161/01.RES.79.4.669; GORDIENKO DV, 1994, AM J PHYSIOL, V266, pF325, DOI 10.1152/ajprenal.1994.266.2.F325; Grammer JB, 2000, J CARDIOVASC ELECTR, V11, P626, DOI 10.1111/j.1540-8167.2000.tb00024.x; Hoppe UC, 2000, J CLIN INVEST, V105, P1077, DOI 10.1172/JCI8757; Isbrandt D, 2000, GENOMICS, V64, P144, DOI 10.1006/geno.2000.6117; Kaab S, 1998, CIRCULATION, V98, P1383, DOI 10.1161/01.CIR.98.14.1383; Koh SD, 1999, J PHYSIOL-LONDON, V515, P475, DOI 10.1111/j.1469-7793.1999.475ac.x; LAPOLT PS, 1986, BIOL REPROD, V35, P1131, DOI 10.1095/biolreprod35.5.1131; Martina M, 1998, J NEUROSCI, V18, P8111; Ohya S, 1997, FEBS LETT, V420, P47, DOI 10.1016/S0014-5793(97)01483-X; Pongs O, 1999, ANN NY ACAD SCI, V868, P344, DOI 10.1111/j.1749-6632.1999.tb11296.x; RENTERIA EP, 1991, AM J PHYSIOL, V261, pC278; Ririe KM, 1997, ANAL BIOCHEM, V245, P154, DOI 10.1006/abio.1996.9916; Sanguinetti MC, 1997, MOL PHARMACOL, V51, P491; Satoh H, 1996, GEN PHARMACOL, V27, P455, DOI 10.1016/0306-3623(95)02067-5; Serodio P, 1996, J NEUROPHYSIOL, V75, P2174, DOI 10.1152/jn.1996.75.5.2174; Shih TM, 1998, METHOD ENZYMOL, V293, P529; Song M, 1999, FEBS LETT, V460, P427, DOI 10.1016/S0014-5793(99)01394-0; STEFANI E, 1994, BIOPHYS J, V66, P996, DOI 10.1016/S0006-3495(94)80881-1; Tsaur ML, 1997, FEBS LETT, V400, P215, DOI 10.1016/S0014-5793(96)01388-9; Wang SY, 1998, J GEN PHYSIOL, V112, P737, DOI 10.1085/jgp.112.6.737; Wang ZG, 1999, CIRC RES, V84, P551, DOI 10.1161/01.RES.84.5.551; Wible BA, 1998, J BIOL CHEM, V273, P11745, DOI 10.1074/jbc.273.19.11745; Wickenden AD, 2000, AM J PHYSIOL-HEART C, V278, pH1105, DOI 10.1152/ajpheart.2000.278.4.H1105; Xu HD, 1999, J GEN PHYSIOL, V113, P661, DOI 10.1085/jgp.113.5.661; YUAN XJ, 1995, AM J PHYSIOL-CELL PH, V268, pC259, DOI 10.1152/ajpcell.1995.268.1.C259	36	103	108	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					31883	31890		10.1074/jbc.M101058200	http://dx.doi.org/10.1074/jbc.M101058200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11427525	hybrid			2022-12-25	WOS:000170613500058
J	Migita, K; Haines, WR; Voigt, MM; Egan, TM				Migita, K; Haines, WR; Voigt, MM; Egan, TM			Polar residues of the second transmembrane domain influence cation permeability of the ATP-gated P2X(2) receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ION CHANNELS; ACETYLCHOLINE-RECEPTOR; STRUCTURAL MOTIF; SELECTIVITY; MICE; PROTEIN; PAIN; PORE	P2X receptors are simple polypeptide channels that mediate fast purinergic depolarizations in both nerve and muscle. Although the depolarization results mainly from the influx of Na+, these channels also conduct a significant Ca2+ current that is large enough to evoke transmitter release from presynaptic neurons. We sought to determine the molecular basis of this Ca2+ conductance by a mutational analysis of recombinant P2X(2) receptors. Wild type and 31 mutant P2X(2) receptors were expressed in HEK-293 cells and studied under voltage-clamp. We found that the relative Ca2+ permeability measured from the reversal potentials of ATP-gated currents was unaffected by neutralizing fixed charge (Asp(315), Asp(349)) near the mouths of the channel pore. By contrast, mutations that changed the character or side chain volume of three polar residues (Thr(336), Thr(339), Ser(340)) within the pore led to significant changes in P-Ca/P-Cs. The largest changes occurred when Thr339 and Ser340 were replaced with tyrosine; these mutations almost completely abolished Ca2+ permeability, reduced P-Li/P-Cs by about one-half, and shifted the relative permeability sequence of Cs+, Rb+, K+, and Na+ to their relative mobility in water. Our results suggest that the permeability sequence of the P2X(2) receptor arises in part from interactions of permeating cations with the polar side chains of three amino acids located in a short stretch of the second transmembrane domain.	St Louis Univ, Sch Med, Dept Pharmacol & Physiol Sci, St Louis, MO 63104 USA	Saint Louis University	Egan, TM (corresponding author), St Louis Univ, Sch Med, Dept Pharmacol & Physiol Sci, 1402 S Grand Blvd, St Louis, MO 63104 USA.		Migita, Keisuke/E-8274-2013	Egan, Terrance/0000-0002-7249-3161	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056236] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035534] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL56236] Funding Source: Medline; NINDS NIH HHS [NS35534] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AIDLEY DJ, 1996, ION CHANNELS MOL MOT; BRAKE AJ, 1994, NATURE, V371, P519, DOI 10.1038/371519a0; CHOTHIA C, 1975, NATURE, V254, P304, DOI 10.1038/254304a0; Cockayne DA, 2000, NATURE, V407, P1011, DOI 10.1038/35039519; Ding SH, 1999, J GEN PHYSIOL, V113, P695, DOI 10.1085/jgp.113.5.695; Egan TM, 1998, J NEUROSCI, V18, P2350; Evans RJ, 1996, J PHYSIOL-LONDON, V497, P413, DOI 10.1113/jphysiol.1996.sp021777; HAINES WR, 2001, IN PRESS J NEUROSCI; HEINEMANN SH, 1992, NATURE, V356, P441, DOI 10.1038/356441a0; Hille B., 1992, IONIC CHANNELS EXCIT; HORN R, 1992, METHOD ENZYMOL, V207, P149; IMOTO K, 1993, FEBS LETT, V325, P100, DOI 10.1016/0014-5793(93)81422-V; IMOTO K, 1993, ANN NY ACAD SCI, V707, P38, DOI 10.1111/j.1749-6632.1993.tb38040.x; Khakh BS, 1999, NEURON, V23, P653, DOI 10.1016/S0896-6273(01)80025-8; Khakh BS, 2001, NAT REV NEUROSCI, V2, P165, DOI 10.1038/35058521; Khakh BS, 1999, NAT NEUROSCI, V2, P322, DOI 10.1038/7233; Khakh BS, 2001, PHARMACOL REV, V53, P107; Kim M, 1997, BIOCHEM BIOPH RES CO, V240, P618, DOI 10.1006/bbrc.1997.7713; KONNO T, 1991, P ROY SOC B-BIOL SCI, V244, P69, DOI 10.1098/rspb.1991.0053; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Miyazawa A, 1999, J MOL BIOL, V288, P765, DOI 10.1006/jmbi.1999.2721; Moore DD, 1995, GLOB MOB SURV; MULLINS LJ, 1961, ANN NY ACAD SCI, V94, P390, DOI 10.1111/j.1749-6632.1961.tb35553.x; Mulryan K, 2000, NATURE, V403, P86, DOI 10.1038/47495; Nakazawa K, 1998, EUR J PHARMACOL, V347, P141, DOI 10.1016/S0014-2999(98)00207-6; Nakazawa K, 1998, BIOCHEM BIOPH RES CO, V244, P599, DOI 10.1006/bbrc.1998.8312; Nicke A, 1998, EMBO J, V17, P3016, DOI 10.1093/emboj/17.11.3016; North RA, 2000, ANNU REV PHARMACOL, V40, P563, DOI 10.1146/annurev.pharmtox.40.1.563; Rassendren F, 1997, EMBO J, V16, P3446, DOI 10.1093/emboj/16.12.3446; Solle M, 2001, J BIOL CHEM, V276, P125, DOI 10.1074/jbc.M006781200; Souslova V, 2000, NATURE, V407, P1015, DOI 10.1038/35039526; Torres GE, 1998, FEBS LETT, V425, P19, DOI 10.1016/S0014-5793(98)00179-3; Torres GE, 1999, J BIOL CHEM, V274, P6653, DOI 10.1074/jbc.274.10.6653; Virginio C, 1998, J PHYSIOL-LONDON, V510, P27, DOI 10.1111/j.1469-7793.1998.027bz.x; Virginio C, 1999, NAT NEUROSCI, V2, P315, DOI 10.1038/7225	35	78	78	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					30934	30941		10.1074/jbc.M103366200	http://dx.doi.org/10.1074/jbc.M103366200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11402044	hybrid			2022-12-25	WOS:000170472900047
J	Toshima, J; Toshima, JY; Takeuchi, K; Mori, R; Mizuno, K				Toshima, J; Toshima, JY; Takeuchi, K; Mori, R; Mizuno, K			Cofilin phosphorylation and actin reorganization activities of testicular protein kinase 2 and its predominant expression in testicular Sertoli cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TESTIS-SPECIFIC PROTEIN-KINASE-1; LIM-KINASE; CYTOSKELETAL DYNAMICS; ACTIVATION LOOP; ALPHA-PAK; IDENTIFICATION; RHO; FAMILY; TESK1; LIM-KINASE-1	We previously identified testicular protein kinase 1 (TESK1), which phosphorylates cofilin and induces actin cytoskeletal reorganization. We now report identification and characterization of another member of a TESK family, testicular protein kinase 2 (TESK2), with 48% amino acid identity with TESK1. Like TESK1, TESK2 phosphorylated cofilin specifically at Ser-3 and induced formation of actin stress fibers and focal adhesions. Both TESK1 and TESK2 are highly expressed in the testis, but in contrast to TESK1, which is predominantly expressed in testicular germ cells, TESK2 is expressed predominantly in nongerminal Sertoli cells. Thus, TESK1 and TESK2 seem to play distinct roles in spermatogenesis. In HeLa cells, TESK1 was localized mainly in the cytoplasm, whereas TESK2 was localized mainly in the nucleus, which means that TESK1 and TESK2 likely have distinct cellular functions. Because the kinase-inactive mutant of TESK2 was localized in the cytoplasm, nuclear/cytoplasmic localization of TESK2 depends on its kinase activity. A TESK2 mutant lacking the C-terminal noncatalytic region had about a 10-fold higher kinase activity in vitro and, when expressed in HeLa cells, induced punctate actin aggregates in the cytoplasm and unusual condensation and fragmentation of nuclei, followed by apoptosis. Thus, we propose that the C-terminal region plays important roles in regulating the kinase activity and cellular functions of TESK2.	Tohoku Univ, Grad Sch Life Sci, Dept Biomol Sci, Sendai, Miyagi 9808578, Japan	Tohoku University	Mizuno, K (corresponding author), Tohoku Univ, Grad Sch Life Sci, Dept Biomol Sci, Sendai, Miyagi 9808578, Japan.	kmizuno@biology.tohoku.ac.jp	Mizuno, Kensaku/G-8631-2015; 純子, 十島 Y/GRS-7321-2022					AGNEW BJ, 1995, J BIOL CHEM, V270, P17582, DOI 10.1074/jbc.270.29.17582; Amano T, 2001, BIOCHEM J, V354, P149, DOI 10.1042/0264-6021:3540149; Arber S, 1998, NATURE, V393, P805, DOI 10.1038/31729; BAMBURG JR, 1999, ANNU REV CELL DEV BI, V14, P305; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Edwards DC, 1999, NAT CELL BIOL, V1, P253, DOI 10.1038/12963; Frost JA, 1998, J BIOL CHEM, V273, P28191, DOI 10.1074/jbc.273.43.28191; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; Ishizaki T, 1997, FEBS LETT, V404, P118, DOI 10.1016/S0014-5793(97)00107-5; Koji T, 1996, J ELECTRON MICROSC, V45, P119, DOI 10.1093/oxfordjournals.jmicro.a023420; Lee N, 1997, P NATL ACAD SCI USA, V94, P13642, DOI 10.1073/pnas.94.25.13642; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; MIZUNO K, 1994, ONCOGENE, V9, P1605; MOON A, 1995, MOL BIOL CELL, V6, P1423, DOI 10.1091/mbc.6.11.1423; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; NUNOUE K, 1995, ONCOGENE, V11, P701; Ohashi K, 2000, J BIOL CHEM, V275, P3577, DOI 10.1074/jbc.275.5.3577; Okano I, 1995, J BIOL CHEM, V270, P31321, DOI 10.1074/jbc.270.52.31321; Rosok O, 1999, GENOMICS, V61, P44, DOI 10.1006/geno.1999.5922; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Santolini E, 1999, EXP CELL RES, V253, P186, DOI 10.1006/excr.1999.4694; Sumi T, 1999, J CELL BIOL, V147, P1519, DOI 10.1083/jcb.147.7.1519; Sumi T, 2001, J BIOL CHEM, V276, P670, DOI 10.1074/jbc.M007074200; Theriot JA, 1997, J CELL BIOL, V136, P1165, DOI 10.1083/jcb.136.6.1165; Toshima J, 1998, BIOCHEM BIOPH RES CO, V249, P107, DOI 10.1006/bbrc.1998.9099; Toshima J, 1995, J BIOL CHEM, V270, P31331, DOI 10.1074/jbc.270.52.31331; Toshima J, 1998, GENE, V206, P237, DOI 10.1016/S0378-1119(97)00591-X; Toshima J, 2001, MOL BIOL CELL, V12, P1131, DOI 10.1091/mbc.12.4.1131; Toshima J, 1999, J BIOL CHEM, V274, P12171, DOI 10.1074/jbc.274.17.12171; Yang N, 1998, NATURE, V393, P809, DOI 10.1038/31735; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153; ZHENGWEI Y, 1990, BIOL REPROD, V43, P629, DOI 10.1095/biolreprod43.4.629	34	109	120	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					31449	31458		10.1074/jbc.M102988200	http://dx.doi.org/10.1074/jbc.M102988200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11418599	hybrid			2022-12-25	WOS:000170472900111
J	Kozak, KR; Prusakiewicz, JJ; Rowlinson, SW; Schneider, C; Marnett, LJ				Kozak, KR; Prusakiewicz, JJ; Rowlinson, SW; Schneider, C; Marnett, LJ			Amino acid determinants in cyclooxygenase-2 oxygenation of the endocannabinoid 2-arachidonylglycerol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; PROSTAGLANDIN G/H SYNTHASE-2; ENDOPEROXIDE-H SYNTHASE-1; ACTIVE-SITE; ARACHIDONIC-ACID; SELECTIVE-INHIBITION; CRYSTAL-STRUCTURE; BINDING-SITE; H-2 SYNTHASE; ASPIRIN	The endocannabinoid, 2-arachiclonylglycerol (2-AG), is an endogenous ligand for the central (CBI) and peripheral (CB2) cannabinoid receptors and has been shown to be efficiently and selectively oxygenated by cyclooxygenase (COX)-2. We have investigated 2-AG/COX-2 interactions through site-directed mutagenesis. An evaluation of more than 20 site-directed mutants of murine COX-2 has allowed for the development of a model of 2-AG binding within the COX-2 active site. Most strikingly, these studies have identified Arg-513 as a critical determinant in the ability of COX-2 to efficiently generate prostaglandin Hz glycerol ester, explaining, in part, the observed isoform selectivity for this substrate. Mutational analysis of Leu-531, an amino acid located directly across from Arg-513 in the COX-2 active site, suggests that 2-AG is shifted in the active site away from this hydrophobic residue and toward Arg-513 relative to arachidonic acid. Despite this difference, aspirin-treated COX-2 oxygenates 2-AG to afford 15-hydroxyeicosatetraenoic acid glycerol ester in a reaction analogous to the C-15 oxygenation of arachidonic acid observed with acetylated COX-2. Finally, the differences in substrate binding do not alter the stereospecificity of the cyclooxygenase reaction; 2-AG-derived and arachidonic acid-derived products share identical stereochemistry.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Chem, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Ctr Mol Toxicol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Div Clin Pharmacol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Marnett, LJ (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA.				NATIONAL CANCER INSTITUTE [R01CA089450, P01CA068484] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007347] Funding Source: NIH RePORTER; NCI NIH HHS [CA68484, CA89450] Funding Source: Medline; NIEHS NIH HHS [ES00267] Funding Source: Medline; NIGMS NIH HHS [GM07347] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALAPURE AK, 1989, BIOCHEM PHARMACOL, V38, P2875; Bhattacharyya DK, 1996, J BIOL CHEM, V271, P2179, DOI 10.1074/jbc.271.4.2179; EVETT GE, 1993, ARCH BIOCHEM BIOPHYS, V306, P169, DOI 10.1006/abbi.1993.1496; Gierse JK, 1996, J BIOL CHEM, V271, P15810, DOI 10.1074/jbc.271.26.15810; Greig GM, 1997, MOL PHARMACOL, V52, P829, DOI 10.1124/mol.52.5.829; Guo QP, 1996, J BIOL CHEM, V271, P19134, DOI 10.1074/jbc.271.32.19134; HAMBERG M, 1973, P NATL ACAD SCI USA, V70, P899, DOI 10.1073/pnas.70.3.899; HANASAKI K, 1990, J BIOL CHEM, V265, P4871; HERSCHMAN HR, 1995, BIOESSAYS, V17, P1031, DOI 10.1002/bies.950171207; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; KALGUTKAR AS, 1994, BIOCHEMISTRY-US, V33, P8625, DOI 10.1021/bi00195a002; KENNEDY BP, 1993, BIOCHEM BIOPH RES CO, V197, P494, DOI 10.1006/bbrc.1993.2506; Kiefer JR, 2000, NATURE, V405, P97, DOI 10.1038/35011103; Kozak KR, 2000, J BIOL CHEM, V275, P33744, DOI 10.1074/jbc.M007088200; Kurumbail RG, 1996, NATURE, V384, P644, DOI 10.1038/384644a0; LECOMTE M, 1994, J BIOL CHEM, V269, P13207; Loll PJ, 1996, BIOCHEMISTRY-US, V35, P7330, DOI 10.1021/bi952776w; LOLL PJ, 1995, NAT STRUCT BIOL, V2, P637, DOI 10.1038/nsb0895-637; Luong C, 1996, NAT STRUCT BIOL, V3, P927, DOI 10.1038/nsb1196-927; Malkowski MG, 2000, SCIENCE, V289, P1933, DOI 10.1126/science.289.5486.1933; Mancini JA, 1997, MOL PHARMACOL, V51, P52, DOI 10.1124/mol.51.1.52; MASFERRER JL, 1994, P NATL ACAD SCI USA, V91, P3228, DOI 10.1073/pnas.91.8.3228; MEADE EA, 1993, J BIOL CHEM, V268, P6610; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; Rowlinson SW, 2000, J BIOL CHEM, V275, P6586, DOI 10.1074/jbc.275.9.6586; Rowlinson SW, 1999, J BIOL CHEM, V274, P23305, DOI 10.1074/jbc.274.33.23305; Schneider C, 2000, ANAL BIOCHEM, V287, P186, DOI 10.1006/abio.2000.4847; Schneider C, 2000, J BIOL CHEM, V275, P4743, DOI 10.1074/jbc.275.7.4743; Serhan CN, 1999, ADV EXP MED BIOL, V469, P287; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Smith WL, 1996, ADV IMMUNOL, V62, P167, DOI 10.1016/S0065-2776(08)60430-7; Thuresson ED, 2001, J BIOL CHEM, V276, P10347, DOI 10.1074/jbc.M009377200; VANE JR, 1994, P NATL ACAD SCI USA, V91, P2046, DOI 10.1073/pnas.91.6.2046; Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97; Xiao GS, 1997, BIOCHEMISTRY-US, V36, P1836, DOI 10.1021/bi962476u; YU K, 1995, J BIOL CHEM, V270, P23975, DOI 10.1074/jbc.270.41.23975; Yu M, 1997, J BIOL CHEM, V272, P21181, DOI 10.1074/jbc.272.34.21181; Zhang VV, 1996, BIOCHEM BIOPH RES CO, V227, P499, DOI 10.1006/bbrc.1996.1536	39	54	55	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30072	30077		10.1074/jbc.M104467200	http://dx.doi.org/10.1074/jbc.M104467200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11402053	hybrid			2022-12-25	WOS:000170558000063
J	Montagnani, M; Chen, H; Barr, VA; Quon, MJ				Montagnani, M; Chen, H; Barr, VA; Quon, MJ			Insulin-stimulated activation of eNOS is independent of Ca2+ but requires phosphorylation by Akt at Ser(1179)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; RAT ADIPOSE-CELLS; ENDOTHELIAL GROWTH-FACTOR; PROTEIN-KINASE-B; LYSOPHOSPHATIDIC ACID; MICE LACKING; CA2+-INDEPENDENT ACTIVATION; THYMIDINE INCORPORATION; RECEPTOR SUBSTRATE-1; TRANSLOCATION	Vasodilator actions of insulin are mediated by activation of endothelial nitric-oxide synthase (eNOS) and subsequent production of NO. Phosphatidylinositol 3-kinase and Akt play important roles in insulin-signaling pathways leading to production of NO in vascular endothelium. Here we dissected mechanisms whereby insulin activates eNOS by using the fluorescent dye DAF-2 to directly measure NO production in single cells. Insulin caused a rapid increase in intracellular NO in NIH-3T3(IR) cells transiently transfected with eNOS.. The stimulation of NO production by lysophosphatidic, acid (LPA) was abrogated by pretreatment of cells with the calcium chelator 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid. Remarkably, in the same cells, insulin-stimulated production of NO was unaffected. However, cells expressing the eNOS-S1179A mutant (disrupted Akt phosphorylation site) did not produce detectable NO in response to insulin, whereas the response to LPA was Similar to that observed in cells expressing wild-type eNOS. Moreover, production of NO in response to insulin was blocked by coexpression. of an inhibitory mutant of Akt, whereas the response to LPA was unaffected. Phosphorylation of eNOS at Ser(1179) was observed only in response to treatment with insulin, but not with LPA. Interestingly, platelet-derived growth factor treatment of cells activated Akt but not eNOS. Results from human vascular endothelial cells were qualitatively similar to those obtained in transfected NIH-3T3(IR) cells, although the magnitude of the responses was smaller. We conclude that insulin regulates eNOS activity using a Ca2+-independent mechanism requiring phosphorylation. of eNOS by Akt. Importantly, phosphorylation-dependent mechanisms that enhance eNOS activity can operate independently from Ca2+-dependent mechanisms.	NHLBI, Cardiol Branch, NIH, Bethesda, MD 20892 USA; NIDDK, Diabet Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Quon, MJ (corresponding author), NHLBI, Cardiol Branch, NIH, Bldg 10,Rm 8C-218,10 Ctr Dr,MSC 1755, Bethesda, MD 20892 USA.		Quon, Michael/B-1970-2008; Montagnani, Monica/AAV-2057-2020	Montagnani, Monica/0000-0002-5697-8185; Quon, Michael/0000-0002-9601-9915; QUON, MICHAEL/0000-0002-5289-3707	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [Z01AT000001, Z02AT000001, ZIAAT000001] Funding Source: NIH RePORTER; National Center for Complementary & Integrative Health [ZIFAT000001] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL003607] Funding Source: NIH RePORTER	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abe H, 1998, J CLIN INVEST, V101, P1784, DOI 10.1172/JCI1594; Ahmad F, 2000, J IMMUNOL, V164, P4678, DOI 10.4049/jimmunol.164.9.4678; Aspinwall CA, 2000, J BIOL CHEM, V275, P22331, DOI 10.1074/jbc.M909647199; Bernier SG, 2000, J BIOL CHEM, V275, P30707, DOI 10.1074/jbc.M005116200; Butt E, 2000, J BIOL CHEM, V275, P5179, DOI 10.1074/jbc.275.7.5179; CaulinGlaser T, 1997, CIRC RES, V81, P885; Chen ZP, 1999, FEBS LETT, V443, P285, DOI 10.1016/S0014-5793(98)01705-0; CHOI T, 1991, MOL CELL BIOL, V11, P3070, DOI 10.1128/MCB.11.6.3070; Cong LN, 1997, MOL ENDOCRINOL, V11, P1881, DOI 10.1210/me.11.13.1881; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Fang XJ, 2000, BIOCHEM J, V352, P135, DOI 10.1042/0264-6021:3520135; Feron O, 1998, J BIOL CHEM, V273, P3125, DOI 10.1074/jbc.273.6.3125; Fleming I, 1998, CIRC RES, V82, P686, DOI 10.1161/01.RES.82.6.686; Fleming I, 1999, CARDIOVASC RES, V43, P532, DOI 10.1016/S0008-6363(99)00094-2; Fleming I, 1999, P NATL ACAD SCI USA, V96, P1123, DOI 10.1073/pnas.96.3.1123; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Goetz RM, 1999, P NATL ACAD SCI USA, V96, P2788, DOI 10.1073/pnas.96.6.2788; Gratton JP, 2000, J BIOL CHEM, V275, P22268, DOI 10.1074/jbc.M001644200; He H, 1999, J BIOL CHEM, V274, P25130, DOI 10.1074/jbc.274.35.25130; Hisamoto K, 2001, J BIOL CHEM, V276, P3459, DOI 10.1074/jbc.M005036200; HUANG PL, 1995, NATURE, V377, P239, DOI 10.1038/377239a0; Igarashi J, 1999, P NATL ACAD SCI USA, V96, P12583, DOI 10.1073/pnas.96.22.12583; Igarashi J, 2001, J BIOL CHEM, V276, P12420, DOI 10.1074/jbc.M008375200; JALINK K, 1990, J BIOL CHEM, V265, P12232; Jonas EA, 1997, NATURE, V385, P343, DOI 10.1038/385343a0; Kojima H, 1998, ANAL CHEM, V70, P2446, DOI 10.1021/ac9801723; McCabe TJ, 2000, J BIOL CHEM, V275, P6123, DOI 10.1074/jbc.275.9.6123; Michel JB, 1997, J BIOL CHEM, V272, P25907, DOI 10.1074/jbc.272.41.25907; Michel JB, 1997, J BIOL CHEM, V272, P15583, DOI 10.1074/jbc.272.25.15583; Michel T, 1997, J CLIN INVEST, V100, P2146, DOI 10.1172/JCI119750; Michell BJ, 1999, CURR BIOL, V9, P845, DOI 10.1016/S0960-9822(99)80371-6; Mombouli JV, 1999, J MOL CELL CARDIOL, V31, P61, DOI 10.1006/jmcc.1998.0844; Montagnani M, 2000, DIABETES OBES METAB, V2, P285, DOI 10.1046/j.1463-1326.2000.00092.x; Nakatsubo N, 1998, FEBS LETT, V427, P263, DOI 10.1016/S0014-5793(98)00440-2; Nystrom FH, 1999, CELL SIGNAL, V11, P563, DOI 10.1016/S0898-6568(99)00025-X; Papapetropoulos A, 1997, J CLIN INVEST, V100, P3131, DOI 10.1172/JCI119868; QUON MJ, 1994, P NATL ACAD SCI USA, V91, P5587, DOI 10.1073/pnas.91.12.5587; Quon MJ, 1996, BIOCHEM BIOPH RES CO, V226, P587, DOI 10.1006/bbrc.1996.1400; QUON MJ, 1995, MOL CELL BIOL, V15, P5403; QUON MJ, 1992, BIOCHEMISTRY-US, V31, P9947, DOI 10.1021/bi00156a013; SCHERRER U, 1994, J CLIN INVEST, V94, P2511, DOI 10.1172/JCI117621; Shankar RR, 2000, DIABETES, V49, P684, DOI 10.2337/diabetes.49.5.684; Shesely EG, 1996, P NATL ACAD SCI USA, V93, P13176, DOI 10.1073/pnas.93.23.13176; STEINBERG HO, 1994, J CLIN INVEST, V94, P1172, DOI 10.1172/JCI117433; Stuehr DJ, 1999, BBA-BIOENERGETICS, V1411, P217, DOI 10.1016/S0005-2728(99)00016-X; TSUKAHARA H, 1994, KIDNEY INT, V45, P598, DOI 10.1038/ki.1994.78; Weiner JA, 1999, P NATL ACAD SCI USA, V96, P5233, DOI 10.1073/pnas.96.9.5233; Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147; Zeng GY, 1996, J CLIN INVEST, V98, P894, DOI 10.1172/JCI118871; Zeng GY, 2000, CIRCULATION, V101, P1539, DOI 10.1161/01.CIR.101.13.1539	50	427	447	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30392	30398		10.1074/jbc.M103702200	http://dx.doi.org/10.1074/jbc.M103702200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11402048	hybrid			2022-12-25	WOS:000170558000103
J	Landriscina, M; Bagala, C; Mandinova, A; Soldi, R; Micucci, I; Bellum, S; Prudovsky, I; Maciag, T				Landriscina, M; Bagala, C; Mandinova, A; Soldi, R; Micucci, I; Bellum, S; Prudovsky, I; Maciag, T			Copper induces the assembly of a multiprotein aggregate implicated in the release of fibroblast growth factor 1 in response to stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEINS; FACTOR-I; ENDOTHELIAL-CELLS; TERMINAL DOMAIN; S100 PROTEINS; SYNAPTOTAGMIN-1; FAMILY; SHOCK; TETRATHIOMOLYBDATE; PROLIFERATION	Fibroblast growth factor (FGF) 1 is known to be released in response to stress conditions as a component of a multiprotein aggregate containing the p40 extravescicular domain of p65 synaptotagmin (Syt) 1 and S100A13, Since FGF1 is a Cu2+-binding protein and Cu2+ is known to induce its dimerization, we evaluated the capacity of recombinant FGF1, p40 Syt1, and S100A13 to interact in a cell-free system and the role of Cu2+ in this interaction. We report that FGF1, p40 Syt1, and S100A13 are able to bind Cu2+ With Similar affinity and to interact in the presence of Cu2+ to form a multiprotein aggregate which is resistant to low concentrations of SDS and sensitive to reducing conditions and ultracentrifugation, The formation of this aggregate in the presence of Cu2+ is dependent on the presence of S100A13 and is mediated by cysteine-independent interactions between S100A13 and either FGF1 or p40 Syt1, Interestingly, S100A13 is also able to interact in the presence of Cu2+ with Cys-free FGF1 and this observation may account for the ability of S100A13 to export Cys-free FGF1 in response to stress. Lastly, tetrathiomolybdate, a Cu2+ chelator, significantly represses in a dose-dependent manner the heat shock-induced release of FGF1 and S100A13, These data suggest that S100A13 may be involved in the assembly of the multiprotein aggregate required for the release of FGF1 and that Cu2+ oxidation may be an essential post-translational intracellular modifier of this process.	Maine Med Ctr, Res Inst, Ctr Mol Med, Scarborough, ME 04074 USA; Univ Maine, Ctr Biophys Sci, Orono, ME 04469 USA	Maine Medical Center; University of Maine System; University of Maine Orono	Maciag, T (corresponding author), Maine Med Ctr, Res Inst, Ctr Mol Med, 81 Res Dr, Scarborough, ME 04074 USA.		Bagalà, Cinzia/AAB-8981-2019; Landriscina, Matteo/K-1092-2016; Prudovsky, Igor/GVU-1521-2022	Landriscina, Matteo/0000-0003-0591-9799	NHLBI NIH HHS [HL32348] Funding Source: Medline; NIA NIH HHS [AG98503] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032348] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bergmeyer H.U., 1965, METHODS ENZYMATIC AN, P736, DOI [10.1016/b978-0-12-395630-9.50134-1, DOI 10.1016/B978-0-12-395630-9.50134-1]; Blaber M, 1996, BIOCHEMISTRY-US, V35, P2086, DOI 10.1021/bi9521755; Brem, 1999, Cancer Control, V6, P436; Brewer GJ, 2000, CLIN CANCER RES, V6, P1; Brewer GJ, 1996, ARCH NEUROL-CHICAGO, V53, P1017, DOI 10.1001/archneur.1996.00550100103019; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; Carreira CM, 1998, J BIOL CHEM, V273, P22224, DOI 10.1074/jbc.273.35.22224; CARREIRA CM, 2001, IN PRESS GROWTH FACT; Cox DW, 1999, BRIT MED BULL, V55, P544, DOI 10.1258/0007142991902619; Donato R, 1999, BBA-MOL CELL RES, V1450, P191, DOI 10.1016/S0167-4889(99)00058-0; ENGLEKA KA, 1992, J BIOL CHEM, V267, P11307; FOROUGH R, 1991, BIOCHIM BIOPHYS ACTA, V1090, P293, DOI 10.1016/0167-4781(91)90192-O; Friesel R, 1999, THROMB HAEMOSTASIS, V82, P748; HANNAN GN, 1982, J CELL PHYSIOL, V111, P207, DOI 10.1002/jcp.1041110213; Heizmann CW, 1998, BIOMETALS, V11, P383, DOI 10.1023/A:1009212521172; Hu GF, 1998, J CELL BIOCHEM, V69, P326, DOI 10.1002/(SICI)1097-4644(19980601)69:3<326::AID-JCB10>3.0.CO;2-A; JACKSON A, 1995, J BIOL CHEM, V270, P33, DOI 10.1074/jbc.270.1.33; JACKSON A, 1992, P NATL ACAD SCI USA, V89, P10691, DOI 10.1073/pnas.89.22.10691; Kang HM, 1997, BIOCHEMISTRY-US, V36, P2041, DOI 10.1021/bi962569b; Landriscina M, 2001, J BIOL CHEM, V276, P22544, DOI 10.1074/jbc.M100546200; LANE TF, 1994, J CELL BIOL, V125, P929, DOI 10.1083/jcb.125.4.929; LaVallee TM, 1998, J BIOL CHEM, V273, P22217, DOI 10.1074/jbc.273.35.22217; Lum H, 2001, AM J PHYSIOL-CELL PH, V280, pC719; Mailliard WS, 1996, J BIOL CHEM, V271, P719, DOI 10.1074/jbc.271.2.719; Marqueze B, 2000, BIOCHIMIE, V82, P409, DOI 10.1016/S0300-9084(00)00220-0; MATSUBARA T, 1989, J CLIN INVEST, V83, P158, DOI 10.1172/JCI113853; Nishikawa T, 1997, J BIOL CHEM, V272, P23037, DOI 10.1074/jbc.272.37.23037; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; RUCKER RB, 1988, FASEB J, V2, P2252, DOI 10.1096/fasebj.2.7.3127264; SANO H, 1990, J CELL BIOL, V110, P1417, DOI 10.1083/jcb.110.4.1417; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; Schafer BW, 2000, J BIOL CHEM, V275, P30623, DOI 10.1074/jbc.M002260200; Seemann J, 1996, BIOCHEM J, V319, P123, DOI 10.1042/bj3190123; Shi JP, 1997, J BIOL CHEM, V272, P1142, DOI 10.1074/jbc.272.2.1142; Shin JT, 1996, BBA-MOL CELL RES, V1312, P27, DOI 10.1016/0167-4889(96)00013-4; Soncin F, 1997, BIOCHEM BIOPH RES CO, V236, P604, DOI 10.1006/bbrc.1997.7018; Tarantini F, 1998, J BIOL CHEM, V273, P22209, DOI 10.1074/jbc.273.35.22209; TARANTINI F, 1995, J BIOL CHEM, V270, P29039, DOI 10.1074/jbc.270.49.29039	38	103	106	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25549	25557		10.1074/jbc.M102925200	http://dx.doi.org/10.1074/jbc.M102925200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11432880	hybrid			2022-12-25	WOS:000169800700146
J	Brabender, J; Usadel, H; Danenberg, KD; Metzger, R; Schneider, PM; Lord, RV; Wickramasinghe, K; Lum, CE; Park, J; Salonga, D; Singer, J; Sidransky, D; Holscher, AH; Meltzer, SJ; Danenberg, PV				Brabender, J; Usadel, H; Danenberg, KD; Metzger, R; Schneider, PM; Lord, RV; Wickramasinghe, K; Lum, CE; Park, J; Salonga, D; Singer, J; Sidransky, D; Holscher, AH; Meltzer, SJ; Danenberg, PV			Adenomatous polyposis coli gene promoter hypermethylation in non-small cell lung cancer is associated with survival	ONCOGENE			English	Article						APC; methylation; neoplasia; NSCLC	CHI-SQUARE STATISTICS; DNA; METHYLATION	Methylation of 5 ' CpG islands in promoter and upstream coding regions has been identified as a mechanism for transcriptional inactivation of tumor suppressor genes. The purpose of this study was to determine whether hypermethylation of the adenomatous polyposis coli (APC) gene promoter occurs in primary non-small cell lung cancer (NSCLC), and whether hypermethylated APC has any relationship with survival. APC promoter 1A methylation was determined in normal and corresponding tumor tissue from 91 NSCLC patients and in a control group of 10 patients without cancer, using a quantitative fluorogenic real-time PCR (Taqman((R))) system. APC promoter methylation was detectable in 86 (95%) of 91 tumor samples, but also in 80 (88%) of 91 normal samples of NSCLC patients, and in only two (20%) of 10 normal lung tissues of the control group. The median level of APC promoter methylation was 4.75 in tumor compared to 1.57 in normal lung tissue (P < 0.001), Patients with low methylation status showed significantly longer survival than did patients with high methylation status (P = 0.041), In a multivariate analysis of prognostic factors, APC methylation was a significant independent prognostic factor (P = 0.044), as were pT (P = 0.050) and pN (P < 0.001) classifications. This investigation shows that APC gene promoter methylation occurs in the majority of primary NSCLCs, High APC promoter methylation is significantly associated with inferior survival, showing promise as a biomarker of biologically aggressive disease in NSCLC.	Univ So Calif, Norris Comprehens Canc Ctr, Los Angeles, CA 90033 USA; Univ So Calif, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA; Univ So Calif, Dept Pathol, Los Angeles, CA 90033 USA; Univ Cologne, Dept Visual & Vasc Surg, D-50931 Cologne, Germany; Johns Hopkins Univ, Div Head & Neck Canc Res, Baltimore, MD 21231 USA; Univ Maryland, Sch Med, Greenebaum Canc Ctr, Dept Med, Baltimore, MD 21201 USA; Baltimore VA Hosp, Baltimore, MD 21201 USA	University of Southern California; University of Southern California; University of Southern California; University of Cologne; Johns Hopkins University; University System of Maryland; University of Maryland Baltimore	Brabender, J (corresponding author), Univ So Calif, Norris Comprehens Canc Ctr, NOR 5318,1441 Eastlake Ave, Los Angeles, CA 90033 USA.			Lord, Reginald V N/0000-0001-7475-492X	NCI NIH HHS [CA78843, R01 CA71716, CA85069, CA77057] Funding Source: Medline; NIDDK NIH HHS [DK47717, DK53620] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077057, R01CA078843, U01CA085069, R01CA071716] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053620, R01DK047717] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baylin SB, 1998, ADV CANCER RES, V72, P141; Eads CA, 1999, CANCER RES, V59, P2302; Eads CA, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e32; EGUICHI K, 1997, CANCER RES, V57, P4913; Esteller M, 2000, CANCER RES, V60, P4366; Esteller M, 1999, CANCER RES, V59, P67; Ginsberg Robert J., 1997, P858; HALPERN J, 1982, BIOMETRICS, V38, P1017, DOI 10.2307/2529882; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Hiltunen MO, 1997, INT J CANCER, V70, P644, DOI 10.1002/(SICI)1097-0215(19970317)70:6<644::AID-IJC3>3.3.CO;2-2; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Kawakami K, 2000, J NATL CANCER I, V92, P1805, DOI 10.1093/jnci/92.22.1805; Landis SH, 1998, CA-CANCER J CLIN, V48, P6, DOI 10.3322/canjclin.48.1.6; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MILLER R, 1982, BIOMETRICS, V38, P1011, DOI 10.2307/2529881; Olek A, 1996, NUCLEIC ACIDS RES, V24, P5064, DOI 10.1093/nar/24.24.5064; PIKE MC, 1972, J R STAT SOC A, V135, P210; Tang XM, 2000, JNCI-J NATL CANCER I, V92, P1511, DOI 10.1093/jnci/92.18.1511; Tsuchiya T, 2000, ONCOGENE, V19, P3642, DOI 10.1038/sj.onc.1203704	19	112	122	2	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 14	2001	20	27					3528	3532		10.1038/sj.onc.1204455	http://dx.doi.org/10.1038/sj.onc.1204455			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	445VB	11429699				2022-12-25	WOS:000169478300008
J	Bessa, M; Saville, MK; Watson, RJ				Bessa, M; Saville, MK; Watson, RJ			Inhibition of cyclin A/Cdk2 phosphorylation impairs B-Myb transactivation function without affecting interactions with DNA or the CBP coactivator	ONCOGENE			English	Article						B-Myb; cyclin A; phosphorylation; CBP; transcriptional regulation	NEGATIVE REGULATORY DOMAIN; TERMINAL CONSERVED DOMAIN; HUMAN C-MYB; CELL-CYCLE; A-MYB; TRANSCRIPTIONAL COACTIVATOR; HEMATOPOIETIC-CELLS; BINDING ACTIVITY; GENE-PRODUCT; ACTIVATION	Expression of the B-Myb transcription factor is directed by an E2F-dependent transcriptional mechanism to late G1 and S phases of the cell cycle, where its transactivation properties are enhanced post-translationally by cyclin A/Cdk2-mediated phosphorylation, Other experiments have shown that removal of the B-Myb C-terminus constitutively activates both transactivation and DNA-binding activities, suggesting that autoregulation by this inhibitory domain is counteracted by phosphorylation. We report here on further experiments to examine this hypothesis. The importance of this We report here on further experiments to examine this hypothesis. The importance of this modification was first emphasized by showing that co-transfected dominant-negative Cdk2 (Cdk2DN) substantially reduced B-Myb transactivation activity. We then attempted to map the autoregulatory domain by analysing a series of progressively deleted C-terminal B-Myb mutants. Removal of just 29 C-terminal aa increased transactivation appreciably, however, maximal activity required removal of 143 amino acids (as in B-Myb+561). Enhanced B-Myb+561 function correlated with the acquisition of DNA binding activity to a single Myb binding site (MBS) oligonucleotide as determined by bandshift assays, however, further assays showed that even wt B-Myb could bind a DNA fragment containing three MBS. Although transactivation by B-Myb was severely dependent on hyperphosphorylation, neither inhibiting this activity by co-transfecting Cdk2DN nor augmenting it with cyclin A resulted in significant effects on DNA-binding. We also found that B-Myb could synergize with the CBP coactivator and that this cooperativity was cyclin A/Cdk2-dependent. Despite this, the physical association between these proteins was not influenced by the B-Myb phosphorylation status. We discuss these findings in relation to the autoregulation of B-Myb by the C-terminal domain.	Imperial Coll Sch Med, Sect Virol & Cell Biol, London W2 1PG, England; Imperial Coll Sch Med, Ludwig Inst Canc Res, London W2 1PG, England	Imperial College London; Imperial College London; Ludwig Institute for Cancer Research	Watson, RJ (corresponding author), Imperial Coll Sch Med, Sect Virol & Cell Biol, Norfolk Pl,St Marys Campus, London W2 1PG, England.							Ansieau S, 1997, J MOL MED-JMM, V75, P815, DOI 10.1007/s001090050170; ARSURA M, 1992, BLOOD, V79, P2708; Bartsch O, 1999, EUR J BIOCHEM, V260, P384, DOI 10.1046/j.1432-1327.1999.00191.x; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; Bies J, 1996, ONCOGENE, V12, P355; Cervellera MN, 2000, J BIOL CHEM, V275, P10692, DOI 10.1074/jbc.275.14.10692; Charrasse S, 2000, ONCOGENE, V19, P2986, DOI 10.1038/sj.onc.1203618; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; Dash AB, 1996, GENE DEV, V10, P1858, DOI 10.1101/gad.10.15.1858; De Falco G, 2000, ONCOGENE, V19, P373, DOI 10.1038/sj.onc.1203305; DUBENDORFF JW, 1992, GENE DEV, V6, P2524, DOI 10.1101/gad.6.12b.2524; Facchinetti V, 1997, BIOCHEM J, V324, P729, DOI 10.1042/bj3240729; GOLAY J, 1991, BLOOD, V77, P149; Horstmann S, 2000, ONCOGENE, V19, P298, DOI 10.1038/sj.onc.1203302; HOWE KM, 1990, EMBO J, V9, P161, DOI 10.1002/j.1460-2075.1990.tb08092.x; HU YL, 1991, ONCOGENE, V6, P1549; Humbert-Lan G, 1999, J BIOL CHEM, V274, P10293, DOI 10.1074/jbc.274.15.10293; Johnson TK, 1999, J BIOL CHEM, V274, P36741, DOI 10.1074/jbc.274.51.36741; KALKBRENNER F, 1990, ONCOGENE, V5, P657; Kamano H, 1995, ONCOGENE, V11, P2575; KANEIISHII C, 1992, P NATL ACAD SCI USA, V89, P3088, DOI 10.1073/pnas.89.7.3088; LAM EWF, 1994, EMBO J, V13, P871, DOI 10.1002/j.1460-2075.1994.tb06330.x; LAM EWF, 1995, GENE, V160, P277, DOI 10.1016/0378-1119(95)00184-8; LAM EWF, 1992, ONCOGENE, V7, P1885; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; Lane S, 1997, ONCOGENE, V14, P2445, DOI 10.1038/sj.onc.1201086; Miglarese MR, 1996, J BIOL CHEM, V271, P22697, DOI 10.1074/jbc.271.37.22697; Morris L, 2000, NAT CELL BIOL, V2, P232, DOI 10.1038/35008660; NAKAGOSHI H, 1993, J BIOL CHEM, V268, P14161; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; Oelgeschlager M, 1996, EMBO J, V15, P2771, DOI 10.1002/j.1460-2075.1996.tb00637.x; RAMSAY RG, 1991, ONCOGENE, V6, P1875; RASCHELLA G, 1995, J BIOL CHEM, V270, P8540, DOI 10.1074/jbc.270.15.8540; REISS K, 1991, J CELL PHYSIOL, V148, P338, DOI 10.1002/jcp.1041480303; Robinson C, 1996, ONCOGENE, V12, P1855; Sala A, 1999, ONCOGENE, V18, P1333, DOI 10.1038/sj.onc.1202421; SALA A, 1992, P NATL ACAD SCI USA, V89, P10415, DOI 10.1073/pnas.89.21.10415; Sala A, 1997, P NATL ACAD SCI USA, V94, P532, DOI 10.1073/pnas.94.2.532; Sala A, 1996, J BIOL CHEM, V271, P28738, DOI 10.1074/jbc.271.46.28738; Sano Y, 2001, J BIOL CHEM, V276, P3674, DOI 10.1074/jbc.M006896200; Saville MK, 1998, ONCOGENE, V17, P2679, DOI 10.1038/sj.onc.1202503; Sitzmann J, 1996, ONCOGENE, V12, P1889; TAKAHASHI T, 1995, FEBS LETT, V358, P89, DOI 10.1016/0014-5793(94)01402-M; Tanaka Y, 1999, J BIOL CHEM, V274, P28067, DOI 10.1074/jbc.274.40.28067; TASHIRO S, 1995, ONCOGENE, V10, P1699; Tomita A, 2000, ONCOGENE, V19, P444, DOI 10.1038/sj.onc.1203329; Vorbrueggen G, 1996, BIOL CHEM, V377, P721, DOI 10.1515/bchm3.1996.377.11.721; WATSON RJ, 1993, NUCLEIC ACIDS RES, V21, P267, DOI 10.1093/nar/21.2.267; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Ziebold U, 1997, CURR BIOL, V7, P253, DOI 10.1016/S0960-9822(06)00121-7; Ziebold U, 1997, ONCOGENE, V15, P1011, DOI 10.1038/sj.onc.1201282	53	35	35	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 7	2001	20	26					3376	3386		10.1038/sj.onc.1204439	http://dx.doi.org/10.1038/sj.onc.1204439			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	441UW	11423988				2022-12-25	WOS:000169248800008
J	Park, JS; Qiao, L; Su, ZZ; Hinman, D; Willoughby, K; McKinstry, R; Yacoub, A; Duigou, GJ; Young, CSH; Grant, S; Hagan, MP; Ellis, E; Fisher, PB; Dent, P				Park, JS; Qiao, L; Su, ZZ; Hinman, D; Willoughby, K; McKinstry, R; Yacoub, A; Duigou, GJ; Young, CSH; Grant, S; Hagan, MP; Ellis, E; Fisher, PB; Dent, P			Ionizing radiation modulates vascular endothelial growth factor (VEGF) expression through multiple mitogen activated protein kinase dependent pathways	ONCOGENE			English	Article						ionizing radiation; MAPK; JNK; AP-1; VEGF; PEG-3; apoptosis	SQUAMOUS CARCINOMA-CELLS; BREAST-CANCER CELLS; FACTOR-ALPHA; GLIOBLASTOMA-MULTIFORME; SIGNALING PATHWAY; ESTROGEN-RECEPTOR; GENE-EXPRESSION; A431 CELLS; FACTOR-I; INHIBITION	We investigated the role of radiation-induced mitogen activated protein kinase (MAPK) pathway activity in the regulation of proliferation, cell survival and vascular endothelial growth factor (VEGF) production in primary astrocytes and in To and RT2 glioblastoma cells derived from Fisher 344 rats, In these cells, ionizing radiation (2 Gy) caused activation of the MAPK pathway which was blocked by specific inhibitor drugs, Blunting of radiation-induced MAPK activity weakly enhanced radiation-induced apoptosis 24 h after exposure in RT2 cells, Furthermore, blunting of MAPK activation weakly enhanced the ability of radiation to reduce RT2 cell growth in clonogenic growth assays, These findings argue that inhibition of MAPK signaling reduces proliferation and enhances cell killing by ionizing radiation in transformed astrocytes, Proliferation and survival of cancer cells has been linked in vivo to enhanced expression of angiogenic growth factors, Recently we demonstrated that the gene product of a novel rodent radiation-responsive gene, progression elevated gene 3 (PEG-3), could enhance vascular endothelial growth factor (VEGF) promoter activity in rodent fibroblasts, leading to increased VEGF protein levels and tumorigenic behavior in vivo. Thus PEG-3 and VEGF expression could be expected to directly correlate with the oncogenic potential of transformed cells, RT2 cells expressed more PEG-3 and VEGF protein than To cells, and were more tumorigenic in vivo than To cells, Radiation activated the PEG-3 promoter via MAPK signaling and ectopic over-expression of PEG-3 enhanced both basal MARK activity and basal VEGF promoter activity, Basal MAPK activity partially correlated with basal VEGF promoter activity and VEGF protein levels in primary astrocytes, T9 and RT2 cells, Radiation increased the activity of the VEGF promoter and VEGF protein levels in primary astrocytes, T9 and RT2 cells which were dependent upon MAPK function, Furthermore, inhibition of AP-1 transcription factor signaling by dominant negative c-Jun (TAM67) also significantly reduced basal, and to a lesser extent radiation-induced, VEGF promoter function in RT2 cells, Collectively, our data demonstrate that radiation-induced MAPK signaling can both protect cells: from radiation-induced cell death as well as enhance protein levels of pro-angiogenic factors such as VEGF, Enhanced VEGF expression in RT2 cells may be mediated via MAPK and JNK pathway signaling which converges upon the AP-1 transcription factor complex.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Radiat Oncol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Physiol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA; Columbia Univ Coll Phys & Surg, Dept Urol & Pathol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Microbiol, New York, NY 10032 USA	Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University; Columbia University; Columbia University	Dent, P (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Radiat Oncol, 401 Coll St, Richmond, VA 23298 USA.				NCI NIH HHS [CA35675] Funding Source: Medline; NIDDK NIH HHS [DK52875] Funding Source: Medline; NIGMS NIH HHS [GM31452] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA035675] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031452] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abbott DW, 1999, J BIOL CHEM, V274, P2732, DOI 10.1074/jbc.274.5.2732; Ahmed SM, 2000, J NEUROCHEM, V74, P1951, DOI 10.1046/j.1471-4159.2000.741951000000000.x; Auer KL, 1998, MOL BIOL CELL, V9, P561, DOI 10.1091/mbc.9.3.561; Balaban N, 1996, BBA-MOL CELL RES, V1314, P147, DOI 10.1016/S0167-4889(96)00068-7; Barth RF, 1998, J NEURO-ONCOL, V36, P91, DOI 10.1023/A:1005805203044; Baselga J, 1996, J BIOL CHEM, V271, P3279, DOI 10.1074/jbc.271.6.3279; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; Cartee L, 2000, INT J ONCOL, V16, P413; Carter S, 1998, ONCOGENE, V16, P2787, DOI 10.1038/sj.onc.1201802; Chen BK, 2000, P NATL ACAD SCI USA, V97, P10406, DOI 10.1073/pnas.180321497; Chmura SJ, 1997, CANCER RES, V57, P4340; Conrad PW, 1999, J BIOL CHEM, V274, P33709, DOI 10.1074/jbc.274.47.33709; Dent P, 1999, MOL BIOL CELL, V10, P2493, DOI 10.1091/mbc.10.8.2493; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Fisher PB, 1984, TUMOR PROMOTION COCA, P57; Gokhale PC, 1999, ANTISENSE NUCLEIC A, V9, P191, DOI 10.1089/oli.1.1999.9.191; Goldkorn T, 1997, BBA-MOL CELL RES, V1358, P289, DOI 10.1016/S0167-4889(97)00063-3; Gupta AK, 2000, RADIAT RES, V154, P64, DOI 10.1667/0033-7587(2000)154[0064:RMRRIN]2.0.CO;2; Hagan M, 2000, RADIAT RES, V153, P371, DOI 10.1667/0033-7587(2000)153[0371:IRIMAP]2.0.CO;2; Hossain MA, 2000, J BIOL CHEM, V275, P27874; Huhn SL, 1999, CLIN CANCER RES, V5, P1435; Kang DC, 1998, P NATL ACAD SCI USA, V95, P13788, DOI 10.1073/pnas.95.23.13788; Kavanagh BD, 1998, RADIAT RES, V149, P579, DOI 10.2307/3579904; Kraus JA, 2000, J NEUROL, V247, P455, DOI 10.1007/s004150070175; Levenson AS, 1998, BRIT J CANCER, V77, P1812, DOI 10.1038/bjc.1998.301; Li ZG, 2000, INT J ONCOL, V17, P453; Mazure NM, 1997, BLOOD, V90, P3322, DOI 10.1182/blood.V90.9.3322; Minet E, 1999, BIOCHEM BIOPH RES CO, V261, P534, DOI 10.1006/bbrc.1999.0995; Pages G, 2000, ANN NY ACAD SCI, V902, P187; Park JS, 1999, MOL BIOL CELL, V10, P4231, DOI 10.1091/mbc.10.12.4231; Park JS, 2000, MOL BIOL CELL, V11, P2915, DOI 10.1091/mbc.11.9.2915; Putz T, 1999, CANCER RES, V59, P227; Rak J, 2000, CANCER RES, V60, P490; Reardon DB, 1999, ONCOGENE, V18, P4756, DOI 10.1038/sj.onc.1202849; Ryuto M, 1996, J BIOL CHEM, V271, P28220, DOI 10.1074/jbc.271.45.28220; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; SCHMIDTULLRICH RK, 1992, INT J RADIAT BIOL, V61, P405, DOI 10.1080/09553009214551101; SchmidtUllrich RK, 1997, ONCOGENE, V15, P1191, DOI 10.1038/sj.onc.1201275; Slevin M, 2000, NEUROREPORT, V11, P2759, DOI 10.1097/00001756-200008210-00030; Su ZZ, 1997, P NATL ACAD SCI USA, V94, P9125, DOI 10.1073/pnas.94.17.9125; Su ZZ, 1999, P NATL ACAD SCI USA, V96, P15115, DOI 10.1073/pnas.96.26.15115; Su ZZ, 2000, ONCOGENE, V19, P3411, DOI 10.1038/sj.onc.1203666; Suy S, 1997, ONCOGENE, V15, P53, DOI 10.1038/sj.onc.1201165; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Zundel W, 2000, GENE DEV, V14, P391	46	114	122	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 31	2001	20	25					3266	3280		10.1038/sj.onc.1204258	http://dx.doi.org/10.1038/sj.onc.1204258			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	440ET	11423976				2022-12-25	WOS:000169163500010
J	Tarapore, P; Horn, HF; Tokuyama, Y; Fukasawa, K				Tarapore, P; Horn, HF; Tokuyama, Y; Fukasawa, K			Direct regulation of the centrosome duplication cycle by the p53-p21(Waf1/Cip1) pathway	ONCOGENE			English	Article						centrosome duplication; Waf1; p53; CDK2; cyclin E	CELL-CYCLE; MAMMALIAN-CELLS; CHROMOSOME INSTABILITY; GENOMIC INSTABILITY; DEPENDENT KINASES; PHASE-TRANSITION; PROTEIN-KINASE; P53; EXPRESSION; INHIBITOR	The function of the centrosomes to direct mitotic spindles is critical for accurate chromosome transmission to daughter cells. Since each daughter cell inherits one centrosome, each centrosome must duplicate prior to the next mitosis, and do so only once, Thus, there are control mechanism(s) that ensure the coordinated progression of centrosome duplication and other cell cycle events (i,e, DNA synthesis), and limit centrosome duplication to once per cell cycle, Deregulation of the centrosome duplication cycle results in abnormal amplification of centrosomes, leading to aberrant mitoses and increased chromosome transmission errors, This has been found to be the case for cells lacking functional p53 tumor suppressor protein. However, it had remained to be determined whether the deregulation of the centrosome duplication cycle is the direct or indirect effect of loss/mutational inactivation of p53, Here, we found that the normal centrosome duplication cycle is almost completely restored in p53(-/-) cells by re-introduction of wild-type p53 at a physiologically relevant level, demonstrating that p,53 is directly involved in the regulation of centrosome duplication, Since cyclin dependent kinase 2 (CDK2)/cyclin E triggers DNA synthesis as well as centrosome duplication, we tested whether Waf1, a CDK inhibitor and a major target of p53's transactivation function, is an effector of p,53-mediated regulation of centrosome duplication, We found that induced expression of Waf1 in p53(-/-) cells only partially restored the centrosome duplication control, suggesting that Waf1 comprises one of the multiple effector pathways of the p53-mediated regulation of the centrosome duplication cycle.	Univ Cincinnati, Coll Med, Dept Cell Biol Neurobiol & Anat, Vontz Ctr Mol Studies, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Fukasawa, K (corresponding author), Univ Cincinnati, Coll Med, Dept Cell Biol Neurobiol & Anat, Vontz Ctr Mol Studies, POB 670521, Cincinnati, OH 45267 USA.		Tarapore, Pheruza/A-8876-2013	Tarapore, Pheruza/0000-0003-0911-3661; Horn, Henning/0000-0002-5885-8996				BALCZON R, 1995, J CELL BIOL, V130, P105, DOI 10.1083/jcb.130.1.105; BORNENS M, 1992, CENTROSOME, V6, P1; BRINKLEY BR, 1985, ANNU REV CELL BIOL, V1, P145, DOI 10.1146/annurev.cellbio.1.1.145; Brinkley BR, 1998, CELL MOTIL CYTOSKEL, V41, P281, DOI 10.1002/(SICI)1097-0169(1998)41:4<281::AID-CM1>3.0.CO;2-C; Carroll PE, 1999, ONCOGENE, V18, P1935, DOI 10.1038/sj.onc.1202515; CHEN S, 1983, P NATL ACAD SCI-BIOL, V80, P5670, DOI 10.1073/pnas.80.18.5670; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fukasawa K, 1997, MOL CELL BIOL, V17, P506, DOI 10.1128/MCB.17.1.506; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Fukasawa K, 1997, ONCOGENE, V15, P1295, DOI 10.1038/sj.onc.1201482; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; GOTTLIEB MT, 1996, BIOCHIM BIOPHYS ACTA, V1287, P77; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HARPER JW, 1993, CELL, V75, P805; HEICHMAN KA, 1994, CELL, V79, P557, DOI 10.1016/0092-8674(94)90541-X; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; Hollander MC, 1999, NAT GENET, V23, P176, DOI 10.1038/13802; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hu T, 1999, MUTAT RES-FUND MOL M, V426, P51, DOI 10.1016/S0027-5107(99)00077-9; JOSHI HC, 1994, CURR OPIN CELL BIOL, V6, P55, DOI 10.1016/0955-0674(94)90116-3; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817; Lange BMH, 1996, TRENDS CELL BIOL, V6, P348, DOI 10.1016/0962-8924(96)10033-7; Lee HY, 1997, GENE, V184, P177, DOI 10.1016/S0378-1119(96)00592-6; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Lingle WL, 1998, P NATL ACAD SCI USA, V95, P2950, DOI 10.1073/pnas.95.6.2950; Mantel C, 1999, BLOOD, V93, P1390, DOI 10.1182/blood.V93.4.1390.404k25_1390_1398; Matsumoto Y, 1999, CURR BIOL, V9, P429, DOI 10.1016/S0960-9822(99)80191-2; MAZIA D, 1987, INT REV CYTOL, V100, P49; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; MORO F, 1995, CARCINOGENESIS, V16, P2435, DOI 10.1093/carcin/16.10.2435; Mussman JG, 2000, ONCOGENE, V19, P1635, DOI 10.1038/sj.onc.1203460; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Pihan GA, 1998, CANCER RES, V58, P3974; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Tournier Frederic, 1994, V13, P303; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Vandre D.D., 1989, MITOSIS MOL MECHANIS, P39; Wahl GM, 1997, CANCER SURV, V29, P183; Wang XJ, 1998, MOL CARCINOGEN, V23, P185, DOI 10.1002/(SICI)1098-2744(199811)23:3<185::AID-MC7>3.0.CO;2-5; Weber RG, 1998, CYTOGENET CELL GENET, V83, P266, DOI 10.1159/000015168; Winey M, 1996, CURR BIOL, V6, P962, DOI 10.1016/S0960-9822(02)00639-5; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9	52	120	122	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 31	2001	20	25					3173	3184		10.1038/sj.onc.1204424	http://dx.doi.org/10.1038/sj.onc.1204424			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	440ET	11423967				2022-12-25	WOS:000169163500001
J	Leonarduzzi, G; Sevanian, A; Sottero, B; Arkan, MC; Biasi, F; Chiarpotto, E; Basaga, H; Poli, G				Leonarduzzi, G; Sevanian, A; Sottero, B; Arkan, MC; Biasi, F; Chiarpotto, E; Basaga, H; Poli, G			Up-regulation of the fibrogenic cytokine TGF-beta 1 by oxysterols: a mechanistic link between cholesterol and atherosclerosis	FASEB JOURNAL			English	Article						7-ketocholesterol; atherogenesis; oxidized low-density lipoproteins	GROWTH-FACTOR-BETA; LOW-DENSITY-LIPOPROTEIN; OXIDATION-PRODUCTS; LIPID-PEROXIDATION; MASS-SPECTROMETRY; PLASMA; TISSUE; EXPRESSION; 7-BETA-HYDROXYCHOLESTEROL; 7-KETOCHOLESTEROL	Deposition of blood cholesterol in the subendothelial space of major arteries is a main feature of the fibrotic plaque as well as the key event in the progression of atherosclerosis. However, the mechanisms by which cholesterol triggers and sustains the fibrotic degeneration of blood arteries remain undefined. The results reported here indicate that a biologically representative mixture of oxysterols, 27-carbon products of cholesterol oxidation, rather than an individual oxysterol at the same concentration, exerts a strong profibrogenic effect when taken up by macrophages. Incubation of murine and human macrophages with such oxysterol mixture markedly promotes both expression and synthesis of one of the most potent proinflammatory and fibrogenic cytokines, transforming growth factor beta1 (TGF-beta1). By contrast, no effect on TGF-beta1 expression and synthesis was found with unoxidized cholesterol. Macrophage uptake of cholesterol and conversion to foam cells is a hallmark of early atherogenesis, but it appears that cholesterol oxidation products, as well as other low-density lipoprotein oxidation products, are required to generate a proper fibrogenic stimulus that is not fulfilled by cholesterol deposition alone.	Univ Turin, S Luigi Gonzaga Hosp, Dept Clin & Biol Sci, I-10043 Turin, Italy; Univ So Calif, Sch Pharm, Dept Mol Pharmacol & Toxicol, Los Angeles, CA 90033 USA; Sabanci Univ, Fac Engn & Nat Sci, Istanbul, Turkey; CNR, Ctr Immunogenet & Expt Oncol, I-10126 Turin, Italy	University of Turin; University of Southern California; Sabanci University; Consiglio Nazionale delle Ricerche (CNR)	Poli, G (corresponding author), Univ Turin, S Luigi Gonzaga Hosp, Dept Clin & Biol Sci, I-10043 Turin, Italy.	giuseppe.poli@unito.it	Leonarduzzi, Gabriella/AAA-6575-2019	LEONARDUZZI, Gabriella Marisa/0000-0002-3422-821X				ADDIS PB, 1989, FREE RADICAL BIO MED, V7, P179, DOI 10.1016/0891-5849(89)90011-7; BEDOSSA P, 1995, J HEPATOL, V22, P37; BJORKHEM I, 1988, J LIPID RES, V29, P1031; BORDER WA, 1994, NEW ENGL J MED, V331, P1286; Brooks C.J.W., 1983, BIOCHEM SOC T, V11, P700; Brown AJ, 1999, ATHEROSCLEROSIS, V142, P1, DOI 10.1016/S0021-9150(98)00196-8; Chang YH, 1997, FREE RADICAL BIO MED, V23, P202, DOI 10.1016/S0891-5849(96)00626-0; DZELETOVIC S, 1995, ANAL BIOCHEM, V225, P73, DOI 10.1006/abio.1995.1110; ESTERBAUER H, 1986, BIOCHIM BIOPHYS ACTA, V876, P154, DOI 10.1016/0005-2760(86)90329-2; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; Grande JP, 1997, P SOC EXP BIOL MED, V214, P27; GRAY MF, 1971, LIPIDS, V6, P836, DOI 10.1007/BF02531214; HODIS HN, 1991, ATHEROSCLEROSIS, V89, P117, DOI 10.1016/0021-9150(91)90051-4; HODIS HN, 1994, J LIPID RES, V35, P669; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; KOVACS EJ, 1991, IMMUNOL TODAY, V12, P17, DOI 10.1016/0167-5699(91)90107-5; KUDO K, 1989, J LIPID RES, V30, P1097; Lemaire S, 1998, FEBS LETT, V440, P434, DOI 10.1016/S0014-5793(98)01496-3; Leonarduzzi G, 1997, FASEB J, V11, P851, DOI 10.1096/fasebj.11.11.9285483; Liu Y, 1997, ARTERIOSCL THROM VAS, V17, P317, DOI 10.1161/01.ATV.17.2.317; Lizard G, 1997, FEBS LETT, V419, P276, DOI 10.1016/S0014-5793(97)01473-7; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Mol MJTM, 1997, ATHEROSCLEROSIS, V129, P169, DOI 10.1016/S0021-9150(96)06022-4; Napoli C, 1997, J CLIN INVEST, V100, P2680, DOI 10.1172/JCI119813; Poli G, 1997, FREE RADICAL BIO MED, V22, P287, DOI 10.1016/S0891-5849(96)00327-9; Poli Giuseppe, 2000, Molecular Aspects of Medicine, V21, P49, DOI 10.1016/S0098-2997(00)00004-2; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Schroepfer GJ, 2000, PHYSIOL REV, V80, P361, DOI 10.1152/physrev.2000.80.1.361; SEVANIAN A, 1994, FREE RADICAL BIO MED, V17, P397, DOI 10.1016/0891-5849(94)90166-X; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; Yuan XM, 2000, FREE RADICAL BIO MED, V28, P208, DOI 10.1016/S0891-5849(99)00220-8	31	62	63	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY 29	2001	15	7					1619	+		10.1096/fj.00-0668fje	http://dx.doi.org/10.1096/fj.00-0668fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519CQ	11427505				2022-12-25	WOS:000173707700024
J	Pifl, C; Zezula, R; Spittler, A; Kattinger, A; Reither, H; Caron, MG; Hornykiewicz, O				Pifl, C; Zezula, R; Spittler, A; Kattinger, A; Reither, H; Caron, MG; Hornykiewicz, O			Antiproliferative action of dopamine and norepinephrine in neuroblastoma cells expressing the human dopamine transporter	FASEB JOURNAL			English	Article						neurodegeneration; neuroprotection; cell differentiation; cell cycle; oxidative stress apoptosis; iron	PARKINSONS-DISEASE; NERVOUS-SYSTEM; MITOCHONDRIAL RESPIRATION; TYROSINE-HYDROXYLASE; HYDROGEN-PEROXIDE; SERUM DEPRIVATION; CORTICAL-NEURONS; OXIDATIVE STRESS; CEREBRAL-CORTEX; BRAIN DOPAMINE	The classical catecholamine transmitters dopamine and norepinephrine are also involved in neurodevelopment and neuron cell death. These effects are thought to be mediated by receptors coupled to intracellular second messengers and by oxidative stress, respectively. Using human SK-N-MC neuroblastoma cells stably transfected with the dopamine or norepinephrine transporter, we show that catecholamines have profound effects on cell viability not mediated by any of the above mechanisms. Low micromolar concentrations of dopamine or norepinephrine (1-10 muM) affected cell growth depending on the expression level of plasmalemmal transport. The growth inhibition was accompanied by a profound effect on the cell cycle profile with an arrest in G, as determined by flow cytometry measuring DNA content. In a proportion of cells, apoptosis was present. Various antioxidants did not prevent the catecholamine effect, and there was no indication of accumulation of reactive oxygen species (as determined by hydroethidine, dichlorofluorescein, and the inactivation-reactivation pattern of aconitase), ruling out involvement of oxidative stress. Reversal by FeCl3 and parallel effects of the iron-chelator deferoxamine suggest that the catecholamine action was related to intracellular iron chelation. This novel biological action of dopamine and norepinephrine unrelated to neurotransmitter receptors, second messengers, or oxidative stress may be important for cell differentiation during neurodevelopment and survival of differentiated neurons.	Univ Vienna, Inst Brain Res, Div Biochem & Mol Biol, A-1090 Vienna, Austria; Univ Vienna, Inst Pharmacol, A-1090 Vienna, Austria; Univ Vienna, Dept Surg, A-1090 Vienna, Austria; Duke Univ, Med Ctr, Dept Cell Biol, Howard Hughes Med Inst Labs, Durham, NC 27710 USA	University of Vienna; University of Vienna; University of Vienna; Duke University	Pifl, C (corresponding author), Univ Vienna, Inst Brain Res, Div Biochem & Mol Biol, Spitalgasse 4, A-1090 Vienna, Austria.	christian.pifl@univie.ac.at		Pifl, Christian/0000-0003-1456-4264; Spittler, Andreas/0000-0003-2657-6836				Alagarsamy S, 1997, DRUG ALCOHOL DEPEN, V48, P105, DOI 10.1016/S0376-8716(97)00118-X; BENSHACHAR D, 1995, J NEUROCHEM, V64, P718, DOI 10.1046/j.1471-4159.1995.64020718.x; BUCK KJ, 1994, P NATL ACAD SCI USA, V91, P12584, DOI 10.1073/pnas.91.26.12584; Burke WJ, 1997, BRAIN RES, V760, P290, DOI 10.1016/S0006-8993(97)00447-2; Cadet JL, 1998, NEUROCHEM INT, V32, P117, DOI 10.1016/S0197-0186(97)00031-4; CARTER WO, 1994, J LEUKOCYTE BIOL, V55, P253; COLBURN RW, 1965, NATURE, V208, P37, DOI 10.1038/208037a0; COYLE JT, 1972, J NEUROCHEM, V19, P1117, DOI 10.1111/j.1471-4159.1972.tb01431.x; CUBELLS JF, 1994, J NEUROSCI, V14, P2260, DOI 10.1523/jneurosci.14-04-02260.1994; DAWSON VL, 1993, J NEUROSCI, V13, P2651; DEXTER DT, 1989, J NEUROCHEM, V52, P381, DOI 10.1111/j.1471-4159.1989.tb09133.x; FAHN S, 1992, ANN NEUROL, V32, P804, DOI 10.1002/ana.410320616; Farinelli SE, 1996, J NEUROSCI, V16, P1150, DOI 10.1523/jneurosci.16-03-01150.1996; GARDNER PR, 1995, J BIOL CHEM, V270, P13399, DOI 10.1074/jbc.270.22.13399; GRAHAM DG, 1978, MOL PHARMACOL, V14, P644; Grilli M, 1996, SCIENCE, V274, P1383, DOI 10.1126/science.274.5291.1383; GROL CJ, 1979, NEUROBIOLOGY DOPAMIN, P7; HARTIKKA J, 1992, J NEUROSCI RES, V32, P190, DOI 10.1002/jnr.490320208; HASTINGS TG, 1995, J NEUROCHEM, V64, P919; Hastings TG, 1996, P NATL ACAD SCI USA, V93, P1956, DOI 10.1073/pnas.93.5.1956; HIRAMATSU M, 1994, FREE RADICAL BIO MED, V16, P201, DOI 10.1016/0891-5849(94)90144-9; HOWARD MK, 1993, J NEUROCHEM, V60, P1783, DOI 10.1111/j.1471-4159.1993.tb13404.x; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; Langston JW, 1996, NEUROLOGY, V47, pS153, DOI 10.1212/WNL.47.6_Suppl_3.153S; LAUDER JM, 1993, TRENDS NEUROSCI, V16, P233, DOI 10.1016/0166-2236(93)90162-F; LAUDER JM, 1988, PROG BRAIN RES, V73, P365; LaVoie MJ, 1999, J NEUROSCI, V19, P1484, DOI 10.1523/jneurosci.19-04-01484.1999; MAKER HS, 1981, J NEUROCHEM, V36, P589, DOI 10.1111/j.1471-4159.1981.tb01631.x; Masserano JM, 1996, MOL PHARMACOL, V50, P1309; MATTAMMAL MB, 1995, NEURODEGENERATION, V4, P271, DOI 10.1016/1055-8330(95)90016-0; Miller JW, 1996, FREE RADICAL BIO MED, V21, P241, DOI 10.1016/0891-5849(96)00033-0; Morikawa N, 1996, J NEUROCHEM, V66, P1174; MUSCHEL RJ, 1995, CANCER RES, V55, P995; NYHOLM S, 1993, J BIOL CHEM, V268, P26200; OFFEN D, 1995, BBA-MOL CELL RES, V1268, P171, DOI 10.1016/0167-4889(95)00075-4; Offen D, 1996, EXP NEUROL, V141, P32, DOI 10.1006/exnr.1996.0136; Park DS, 1997, J NEUROSCI, V17, P1256, DOI 10.1523/jneurosci.17-04-01256.1997; Patel M, 1996, NEURON, V16, P345, DOI 10.1016/S0896-6273(00)80052-5; PERRY TL, 1982, NEUROSCI LETT, V33, P305, DOI 10.1016/0304-3940(82)90390-1; PIERI C, 1994, LIFE SCI, V55, pPL271, DOI 10.1016/0024-3205(94)00666-0; Pifl C, 1996, J PHARMACOL EXP THER, V277, P1437; PIFL C, 1988, EUR J PHARMACOL, V153, P33, DOI 10.1016/0014-2999(88)90585-7; PIFL C, 1993, J NEUROSCI, V13, P4246, DOI 10.1523/jneurosci.13-10-04246.1993; RAJAN KS, 1971, J NEUROCHEM, V18, P345, DOI 10.1111/j.1471-4159.1971.tb11963.x; Ratan RR, 1996, NEUROCHEM INT, V29, P153, DOI 10.1016/0197-0186(95)00115-8; Richardson DR, 1997, CAN J PHYSIOL PHARM, V75, P1164, DOI 10.1139/cjpp-75-10-11-1164; RIEDERER P, 1989, J NEUROCHEM, V52, P515, DOI 10.1111/j.1471-4159.1989.tb09150.x; ROSENBERG PA, 1988, J NEUROSCI, V8, P2887, DOI 10.1523/jneurosci.08-08-02887.1988; Ross ME, 1996, TRENDS NEUROSCI, V19, P62, DOI 10.1016/0166-2236(96)89622-6; RUBIN LL, 1993, CURR BIOL, V3, P391, DOI 10.1016/0960-9822(93)90211-6; Simantov R, 1996, NEUROSCIENCE, V74, P39, DOI 10.1016/0306-4522(96)00102-9; TERADA N, 1991, J IMMUNOL, V147, P698; Thomaidou D, 1997, J NEUROSCI, V17, P1075, DOI 10.1523/jneurosci.17-03-01075.1997; VelezPardo C, 1997, PHARMACOL TOXICOL, V80, P76, DOI 10.1111/j.1600-0773.1997.tb00287.x; VYAS I, 1986, J NEUROCHEM, V46, P1501, DOI 10.1111/j.1471-4159.1986.tb01768.x; Yaginuma H, 1996, J NEUROSCI, V16, P3685; ZHOU QY, 1995, NATURE, V374, P640, DOI 10.1038/374640a0; ZIV I, 1994, NEUROSCI LETT, V170, P136, DOI 10.1016/0304-3940(94)90258-5	59	20	21	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY 29	2001	15	7					1607	+		10.1096/fj.00-0738fje	http://dx.doi.org/10.1096/fj.00-0738fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519CQ	11427501				2022-12-25	WOS:000173707700018
J	Savignac, M; Badou, A; Moreau, M; Leclerc, C; Guery, JC; Paulet, P; Druet, P; Ragab-Thomas, J; Pelletier, L				Savignac, M; Badou, A; Moreau, M; Leclerc, C; Guery, JC; Paulet, P; Druet, P; Ragab-Thomas, J; Pelletier, L			Protein kinase C-mediated calcium entry dependent upon dihydropyridine-sensitive channels: a T-cell receptor-coupled signaling pathway involved in interleukin 4 synthesis	FASEB JOURNAL			English	Article						interleukin 4; L-type calcium channels; T lymphocyte	ALTERED PEPTIDE LIGANDS; CYTOKINE PRODUCTION; IL-4 PRODUCTION; CA2+ CHANNELS; TRANSDUCTION PATHWAYS; DOWN-REGULATION; ACTIVATION; TH1; MODULATION; INDUCTION	Signaling events induced by T-cell receptor (TCR) engagement involve a cascade of tyrosine phosphorylation events leading to activation of several downstream pathways and resulting in cytokine production. TCR-dependent interferon gamma (IFN-gamma) production by Th1 cells has been shown to require tyrosine phosphorylation of numerous proteins, intracellular Ca2+ mobilization, and mitogen-activated protein kinase activation. In contrast, the signaling pathways responsible for TCR-dependent interleukin (IL) 4 production remain poorly understood. By using a T-cell hybridoma that displays a hierarchized production of IL-4 and IFN-gamma following TCR engagement (IL-4 being produced at a lower threshold of activation than IFN-gamma), we showed that IL-4 can be produced in spite of the absence of tyrosine phosphorylation of phospholipase Cgamma1. However, protein kinase C (PKC) was found to be translocated to the cell membrane, and an increase in intracellular Ca2+ concentration was observed. The PKC-dependent Ca2+ response and IL-4 expression were accounted for by a dihydropyridine-sensitive Ca2+ entry, which could occur through L-type calcium channels. This pathway was also functional in the D10G4.1 Th2 clone. The fact that this pathway, allowing IL-4 production, did not require optimal activation might explain why low doses of peptides or altered peptide ligands favor Th2 responses.	Hop Purpan, INSERM, U326, F-31059 Toulouse, France; Hop Purpan, Inst Federatif Rech IFR 30, F-31059 Toulouse, France; Univ Toulouse 3, CNRS, UMR 5547, F-31062 Toulouse, France	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Pelletier, L (corresponding author), Hop Purpan, INSERM, U28, Pl Dr Baylac, F-31059 Toulouse, France.	Lucette.Pelletier@purpan.inserm.fr	Savignac, Magali/K-1757-2014; Pelletier, Lucette/L-2956-2014; Leclerc, Catherine/O-6514-2015; GUERY, Jean-Charles/G-1452-2013	GUERY, Jean-Charles/0000-0003-4499-3270; Badou, Abdallah/0000-0003-4849-9085				ADORINI L, 1988, P NATL ACAD SCI USA, V85, P5181, DOI 10.1073/pnas.85.14.5181; Akha AAS, 1996, J BIOL CHEM, V271, P7297, DOI 10.1074/jbc.271.13.7297; Allal C, 2000, J BIOL CHEM, V275, P31001, DOI 10.1074/jbc.M005264200; AlRamadi BK, 1996, J IMMUNOL, V157, P4751; Badou A, 1997, J BIOL CHEM, V272, P32411, DOI 10.1074/jbc.272.51.32411; BORDIER C, 1981, J BIOL CHEM, V256, P1604; Boutin Y, 1997, J IMMUNOL, V159, P5802; Cantrell D, 1996, ANNU REV IMMUNOL, V14, P259, DOI 10.1146/annurev.immunol.14.1.259; Carballido JM, 1997, EUR J IMMUNOL, V27, P515, DOI 10.1002/eji.1830270224; Chau LA, 1999, J IMMUNOL, V163, P1853; Chau LA, 1998, J EXP MED, V187, P1699, DOI 10.1084/jem.187.10.1699; CHEN CS, 1993, J BIOL CHEM, V268, P15812; Chen YZ, 1998, EUR J IMMUNOL, V28, P3929, DOI 10.1002/(SICI)1521-4141(199812)28:12<3929::AID-IMMU3929>3.0.CO;2-8; CONSTANT S, 1995, J EXP MED, V182, P1591, DOI 10.1084/jem.182.5.1591; Constant SL, 1997, ANNU REV IMMUNOL, V15, P297, DOI 10.1146/annurev.immunol.15.1.297; Dumont FJ, 1998, J IMMUNOL, V160, P2579; Egerton M, 1996, EUR J IMMUNOL, V26, P2279, DOI 10.1002/eji.1830261002; EVAVOLD BD, 1991, SCIENCE, V252, P1308, DOI 10.1126/science.1833816; GAJEWSKI TF, 1990, J IMMUNOL, V144, P4110; GAJEWSKI TF, 1994, J EXP MED, V179, P481, DOI 10.1084/jem.179.2.481; Graef IA, 1999, NATURE, V401, P703, DOI 10.1038/44378; Guery JC, 1996, J EXP MED, V183, P485, DOI 10.1084/jem.183.2.485; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Harada Y, 1996, J ALLERGY CLIN IMMUN, V98, pS161, DOI 10.1016/S0091-6749(96)70063-5; Hartzell HC, 1996, AM J PHYSIOL-CELL PH, V270, pC1293; Janoshazi A, 1999, BIOCHEMISTRY-US, V38, P13316, DOI 10.1021/bi990427m; KNAUS HG, 1992, P NATL ACAD SCI USA, V89, P3586, DOI 10.1073/pnas.89.8.3586; KUBO M, 1994, J BIOL CHEM, V269, P19441; KUBO M, 1994, INT IMMUNOL, V6, P179, DOI 10.1093/intimm/6.2.179; KUBO RT, 1989, J IMMUNOL, V142, P2736; Kurosaki T, 2000, IMMUNITY, V12, P1, DOI 10.1016/S1074-7613(00)80153-3; LECLERC C, 1995, CELL CALCIUM, V17, P216, DOI 10.1016/0143-4160(95)90036-5; Legendre V, 1999, INT IMMUNOL, V11, P1731, DOI 10.1093/intimm/11.11.1731; LIBLAU RS, 1995, IMMUNOL TODAY, V16, P34, DOI 10.1016/0167-5699(95)80068-9; Liu YH, 2000, J BIOL CHEM, V275, P3603, DOI 10.1074/jbc.275.5.3603; Lombardi G, 1996, J IMMUNOL, V156, P2769; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; MOREAU M, 1994, P NATL ACAD SCI USA, V91, P12639, DOI 10.1073/pnas.91.26.12639; OPENSHAW P, 1995, J EXP MED, V182, P1357, DOI 10.1084/jem.182.5.1357; PEREZREYES E, 1990, J BIOL CHEM, V265, P20430; Poggi A, 1998, J BIOL CHEM, V273, P7205, DOI 10.1074/jbc.273.13.7205; Puri TS, 1997, BIOCHEMISTRY-US, V36, P9605, DOI 10.1021/bi970500d; Rabinowitz JD, 1996, IMMUNITY, V5, P125, DOI 10.1016/S1074-7613(00)80489-6; Ron D, 1999, J BIOL CHEM, V274, P19003, DOI 10.1074/jbc.274.27.19003; Salio M, 1997, EUR J IMMUNOL, V27, P1769, DOI 10.1002/eji.1830270726; SCOTT P, 1991, IMMUNOL TODAY, V12, P346, DOI 10.1016/0167-5699(91)90063-Y; Shistik E, 1998, J BIOL CHEM, V273, P17901, DOI 10.1074/jbc.273.28.17901; Singh RAK, 1999, J IMMUNOL, V163, P6393; SloanLancaster J, 1997, J IMMUNOL, V159, P1160; Striessnig J, 1999, CELL PHYSIOL BIOCHEM, V9, P242, DOI 10.1159/000016320; TAMURA T, 1993, J IMMUNOL, V151, P6051; TAMURA T, 1995, J IMMUNOL, V155, P4692; Tao X, 1997, J IMMUNOL, V158, P4237; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; VARADI G, 1995, TRENDS PHARMACOL SCI, V16, P43, DOI 10.1016/S0165-6147(00)88977-4; Viard P, 1999, FASEB J, V13, P685, DOI 10.1096/fasebj.13.6.685; Viola A, 1996, SCIENCE, V273, P104, DOI 10.1126/science.273.5271.104; Zocchi MR, 1998, J IMMUNOL, V161, P2938	58	47	49	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY 29	2001	15	7					1577	+		10.1096/fj.00-0733fje	http://dx.doi.org/10.1096/fj.00-0733fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519CQ	11427491				2022-12-25	WOS:000173707700031
J	Fattman, CL; Delach, SM; Dou, QP; Johnson, DE				Fattman, CL; Delach, SM; Dou, QP; Johnson, DE			Sequential two-step cleavage of the retinoblastoma protein by caspase-3/-7 during etoposide-induced apoptosis	ONCOGENE			English	Article						retinoblastoma; caspase; apoptosis; etoposide; cleavage	S-PHASE ENTRY; TRANSCRIPTION FACTOR; GENE-PRODUCT; CELL-CYCLE; P53-MEDIATED APOPTOSIS; SUSCEPTIBILITY GENE; CANCER-CELLS; RB; DEPHOSPHORYLATION; E2F-1	During cellular apoptosis, retinoblastoma protein (RB) is subjected to cleavage near the carboxyl terminus by a caspase-3-like protease, In addition, an heretofore unidentified protease cleaves RB internally, generating fragments of 68 and 48 kDa, Internal cleavage abrogates the ability of RB to associate with E2F, To investigate the mechanism of RB internal cleavage, we developed and employed an in vitro cleavage assay. Incubation of in vitro translated S-35-RB with apoptotic cell extracts led to RB cleavage at the C-terminus, followed by internal cleavage. The caspase peptide inhibitors z-VAD-FMK or z-DEVD-FMK blocked both cleavage events. Rapid C-terminal and internal cleavage were also observed when recombinant caspase-3 was added to S-35-RB. Moreover, when caspase-3 was added to nonapoptotic cell extract, efficient internal cleavage of cellular RB was observed. Caspase-mediated internal cleavage occurred following RB residue aspartate(349) in the sequence DSID349. This sequence is consistent with a DXXD recognition motif for caspase-3-like enzymes. Interestingly, ne also observed RB internal cleavage in caspase-3-deficient MCF-7 cells, indicating that other caspases are capable of cleaving RB internally. Indeed, caspase-7, a member of the caspase-3 subfamily, was found to cleave S-35-RB at both the carboxyl terminus, and following aspartate(349). By contrast, caspases that are not members of the caspase-3 subfamily failed to cleave RB. Taken together, our findings demonstrate that during apoptosis, a caspase-3-like protease is responsible for degradation and functional inactivation of RB by cleaving the protein internally following aspartate(349). Oncogene (2001) 20, 2918-2926.	Univ Pittsburgh, Sch Med, Dept Pharmacol, Div Hematol Oncol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15213 USA; Univ S Florida, H Lee Moffitt Canc Ctr, Dept Biochem & Mol Biol, Drug DIscovery Program, Tampa, FL 33612 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Johnson, DE (corresponding author), Univ Pittsburgh, Sch Med, Dept Pharmacol, Div Hematol Oncol, BST E1055,211 Lothrop St, Pittsburgh, PA 15213 USA.			Dou, Qingping/0000-0002-6465-1473	NATIONAL CANCER INSTITUTE [R29CA066044] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R55AG013300, R29AG013300] Funding Source: NIH RePORTER; NCI NIH HHS [CA66044] Funding Source: Medline; NIA NIH HHS [AG13300] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; An B, 1996, CANCER RES, V56, P438; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; Berry DE, 1996, ONCOGENE, V12, P1809; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; Chen WD, 1997, ONCOGENE, V14, P1243, DOI 10.1038/sj.onc.1201096; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; Dou QP, 1997, APOPTOSIS, V2, P5; Dou QP, 1997, J CELL BIOCHEM, V64, P586; Fattman CL, 1998, CANCER LETT, V130, P103, DOI 10.1016/S0304-3835(98)00121-9; Fattman CL, 1997, J CELL BIOCHEM, V67, P399; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; HASSKOGAN DA, 1995, EMBO J, V14, P461; HAUPT Y, 1995, ONCOGENE, V10, P1563; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Janicke RU, 1996, EMBO J, V15, P6969, DOI 10.1002/j.1460-2075.1996.tb01089.x; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Kranenburg O, 1996, EMBO J, V15, P46, DOI 10.1002/j.1460-2075.1996.tb00332.x; Kurokawa H, 1999, ONCOL REP, V6, P33; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; McConkey DJ, 1996, ONCOGENE, V13, P1693; MEIKRANTZ W, 1994, P NATL ACAD SCI USA, V91, P3754, DOI 10.1073/pnas.91.9.3754; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Shan B, 1996, CELL GROWTH DIFFER, V7, P689; Tan XQ, 1998, TRENDS CELL BIOL, V8, P116, DOI 10.1016/S0962-8924(97)01208-7; Tan XQ, 1997, J BIOL CHEM, V272, P9613; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4	38	46	49	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 24	2001	20	23					2918	2926		10.1038/sj.onc.1204414	http://dx.doi.org/10.1038/sj.onc.1204414			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	435VA	11420704				2022-12-25	WOS:000168901800007
J	Strauss, JG; Frank, S; Kratky, D; Hammerle, G; Hrzenjak, A; Knipping, G; von Eckardstein, A; Kostner, GM; Zechner, R				Strauss, JG; Frank, S; Kratky, D; Hammerle, G; Hrzenjak, A; Knipping, G; von Eckardstein, A; Kostner, GM; Zechner, R			Adenovirus-mediated rescue of lipoprotein lipase-deficient mice - Lipolysis of triglyceride-rich lipoproteins is essential for high density lipoprotein maturation in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING CASSETTE TRANSPORTER-1; PHOSPHOLIPID TRANSFER PROTEIN; APOLIPOPROTEIN-A-I; TANGIER-DISEASE; CHOLESTEROL LEVELS; TRANSGENIC MICE; ADIPOSE-TISSUE; KNOCKOUT MICE; GENE-TRANSFER; APOA-I	Lipoprotein lipase (LPL) is the rate-limiting enzyme for the hydrolysis of triglycerides and the subsequent uptake of free fatty acids in extrahepatic tissues. Deficiency of LPL in humans (Type I hyperlipoproteinemia) is associated with massive chylomicronemia, low high density lipoprotein (HDL) cholesterol levels, and recurrent attacks of pancreatitis when not controlled by a strict diet. In contrast to humans, homozygous LPL knock-out mice (L0) do not survive suckling and die between 18 and 24 h after birth. In this study, an adenovirus-based protocol was utilized for the transient expression of LPL during the suckling period in an effort to rescue L0 mice. After a single intraperitoneal injection of 5 x 10(9) plaque-forming units of LPL-expressing vir-us immediately after birth, more than 90% of L0 mice survived the first days of life. 3% of L0 mice survived the entire suckling period and lived for up to 20 months' although LPL activity in mouse tissues and postheparin plasma was undetectable in all animals after 6 weeks of age. Adult LPL-deficient mice were smaller than their littermates until 2-3 months of age and exhibited very high triglyceride levels in the fed (4997 +/- 1102 versus 113.4 +/- 18.7 mg/dl) and fasted state (2007 +/- 375 versus 65.5 +/- 7.4 mg/dl). Plasma total cholesterol levels, free fatty acids, and ketone bodies were elevated in L0 mice, whereas plasma glucose was normal. Most strikingly, L0 mice lacked apoA-I-containing pre beta -HDL particles as well as mature HDL resulting in undetectable HDL cholesterol and HDL-apoA-I levels. HDL deficiency in plasma was evident despite normal apoA-I mRNA levels in the liver and normal apoA-I protein levels in plasma, which were predominantly found in the chylomicron fraction. The absence of pre beta -HDL and mature HDL particles supports the concept that the lipolysis of triglyceride-rich lipoproteins is an essential step for HDL maturation.	Graz Univ, Rudolf Zechner Inst Mol Biol Biochem & Microbiol, A-8010 Graz, Austria; Graz Univ, Inst Med Biochem & Med Mol Biol, A-8010 Graz, Austria; Univ Munster, Inst Clin Chem & Lab Med, D-48149 Munster, Germany	University of Graz; University of Graz; University of Munster	Zechner, R (corresponding author), Graz Univ, Rudolf Zechner Inst Mol Biol Biochem & Microbiol, Heinrichstr 31 A, A-8010 Graz, Austria.		Kratky, Dagmar/ABF-5699-2021	Bogner-Strauss, Juliane/0000-0003-2459-0124; Zechner, Rudolf/0000-0001-5483-1182; Kratky, Dagmar/0000-0003-1357-7573				Barrans A, 1996, BBA-LIPID LIPID MET, V1300, P73, DOI 10.1016/0005-2760(95)00236-7; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; BRESLOW JL, 1993, ANN NY ACAD SCI, V676, P157; BRINTON EA, 1994, ARTERIOSCLER THROMB, V14, P707, DOI 10.1161/01.ATV.14.5.707; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Brunzell JD, 1989, METABOLIC BASIS INHE, P1165; CASTLE CK, 1991, J LIPID RES, V32, P439; Chang SF, 1998, J LIPID RES, V39, P2350; Clay MA, 1996, J LIPID RES, V37, P1722; Clay MA, 1999, BIOCHEM J, V337, P445, DOI 10.1042/0264-6021:3370445; COLEMAN T, 1995, J BIOL CHEM, V270, P12518, DOI 10.1074/jbc.270.21.12518; CRYER A, 1985, REPROD NUTR DEV, V25, P255, DOI 10.1051/rnd:19850216; EISENBERG S, 1984, J LIPID RES, V25, P1017; EISENBERG S, 1992, J CLIN INVEST, V90, P2013, DOI 10.1172/JCI116081; Excoffon KJDA, 1997, ARTERIOSCL THROM VAS, V17, P2532, DOI 10.1161/01.ATV.17.11.2532; FRIEDMAN G, 1991, BIOCHIM BIOPHYS ACTA, V666, P156; Ginzinger DG, 1999, EUR J CLIN INVEST, V29, P17, DOI 10.1046/j.1365-2362.1999.00435.x; Goldberg IJ, 1996, J LIPID RES, V37, P693; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAMILTON RL, 1986, J LIPID RES, V27, P967; Huuskonen J, 2000, CURR OPIN LIPIDOL, V11, P285, DOI 10.1097/00041433-200006000-00009; ITO Y, 1990, SCIENCE, V249, P790, DOI 10.1126/science.2167514; Jiang XC, 1999, J CLIN INVEST, V103, P907, DOI 10.1172/JCI5578; JONES LA, 1984, J LIPID RES, V25, P319; Kobayashi K, 1996, J BIOL CHEM, V271, P6852, DOI 10.1074/jbc.271.12.6852; KOSTNER G, 1972, BIOCHEMISTRY-US, V11, P3419, DOI 10.1021/bi00768a015; Lee M, 1999, ARTERIOSCL THROM VAS, V19, P1066, DOI 10.1161/01.ATV.19.4.1066; Levak-Frank S, 1999, P NATL ACAD SCI USA, V96, P3165, DOI 10.1073/pnas.96.6.3165; LevakFrank S, 1997, J BIOL CHEM, V272, P17182, DOI 10.1074/jbc.272.27.17182; LEVAKFRANK S, 1995, J CLIN INVEST, V96, P976, DOI 10.1172/JCI118145; LUTZ PE, 1908, J CLIN INVEST, V107, P1183; Marshall BA, 1999, J BIOL CHEM, V274, P27426, DOI 10.1074/jbc.274.39.27426; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; Merkel M, 1998, P NATL ACAD SCI USA, V95, P13841, DOI 10.1073/pnas.95.23.13841; Merkel M, 1998, J CLIN INVEST, V102, P893, DOI 10.1172/JCI2912; MIESENBOCK G, 1993, J CLIN INVEST, V91, P448, DOI 10.1172/JCI116222; MUSLINER TA, 1991, J LIPID RES, V32, P917; Olivecrona Thomas, 1993, Current Opinion in Lipidology, V4, P187, DOI 10.1097/00041433-199306000-00003; Oram JF, 2000, CURR OPIN LIPIDOL, V11, P253, DOI 10.1097/00041433-200006000-00005; Orso E, 2000, NAT GENET, V24, P192, DOI 10.1038/72869; PATERNITI JR, 1983, SCIENCE, V221, P167, DOI 10.1126/science.6857276; PEEVA E, 1992, INT J OBESITY, V16, P737; ROGERS MP, 1974, J LIPID RES, V15, P263; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Santamarina-Fojo S, 2000, CURR OPIN LIPIDOL, V11, P267, DOI 10.1097/00041433-200006000-00007; Sattler W, 1996, BIOCHEM J, V318, P15, DOI 10.1042/bj3180015; Savonen R, 1999, J LIPID RES, V40, P1336; SAXENA U, 1992, J CLIN INVEST, V89, P373, DOI 10.1172/JCI115595; SCHUMAKER VN, 1986, METHOD ENZYMOL, V128, P155; SINN HJ, 1988, ANAL BIOCHEM, V170, P186, DOI 10.1016/0003-2697(88)90107-8; TALL AR, 1993, J LIPID RES, V34, P1255; TENG BB, 1994, J BIOL CHEM, V269, P29395; TRABER MG, 1985, J CLIN INVEST, V75, P1729, DOI 10.1172/JCI111883; Weinstock PH, 1995, J CLIN INVEST, V96, P2555, DOI 10.1172/JCI118319; Weinstock PH, 1997, P NATL ACAD SCI USA, V94, P10261, DOI 10.1073/pnas.94.19.10261; WILSON DE, 1990, J CLIN INVEST, V86, P725; ZECHNER R, 1990, BIOCHIM BIOPHYS ACTA, V1044, P20, DOI 10.1016/0005-2760(90)90213-H; Zechner R, 1997, CURR OPIN LIPIDOL, V8, P77, DOI 10.1097/00041433-199704000-00005	60	77	78	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36083	36090		10.1074/jbc.M104430200	http://dx.doi.org/10.1074/jbc.M104430200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11432868	hybrid			2022-12-25	WOS:000171194500007
J	Botella, LM; Sanchez-Elsner, T; Rius, C; Corbi, A; Bernabeu, C				Botella, LM; Sanchez-Elsner, T; Rius, C; Corbi, A; Bernabeu, C			Identification of a critical Sp1 site within the endoglin promoter and its involvement in the transforming growth factor-beta stimulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEREDITARY HEMORRHAGIC TELANGIECTASIA; TRANSCRIPTION FACTOR SP1; SMAD-BINDING-ELEMENT; TGF-BETA; DNA-BINDING; ENDOTHELIAL-CELLS; FUNCTIONAL INTERACTIONS; EXPRESSION ANALYSIS; CELLULAR-RESPONSES; HEART DEVELOPMENT	Endoglin, a component of the transforming growth factor-beta (TGF-beta) receptor complex expressed on endothelial cells, is involved in cardiovascular morphogenesis and vascular remodeling, as exemplified by the fact that the endoglin gene is the target for the autosomal dominant disorder known as hereditary hemorrhagic telangiectasia type 1. Since haploinsufficiency is the underlying mechanism for hereditary hemorrhagic telangiectasia type 1, understanding the regulation of endoglin gene expression appears to be a crucial step to correct the disease. In this study we have identified an Sp1 site at -37 as a critical element for the basal transcription of the endoglin TATA-less promoter. Since endoglin promoter activity is stimulated by TGF-beta and this stimulation is located at the Spl-containing proximal region, we have investigated the possible involvement of Spl in the TGF-beta -mediated induction. Mutation of the Sp1-binding sequence, or addition of the Spl inhibitor WP631, abolished both the basal transcription activity and the TGF-beta responsiveness of the endoglin promoter. Binding of Sp1 and Smad3 to the proximal promoter region -50/-29 was evidenced by electrophoretic mobility shift assays and DNA affinity precipitation studies. Furthermore, synergistic cooperation on the promoter activity between Sp1 and TGF-beta or Smad3 could be demonstrated by co-transfection experiments of reporter promoter constructs. The molecular mechanism underlying this cooperation appears to involve a direct physical interaction between Sp1 and Smad3/Smad4.	CSIC, Ctr Invest Biol, E-28006 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)	Bernabeu, C (corresponding author), CSIC, Ctr Invest Biol, Velazquez 144, E-28006 Madrid, Spain.		Bernabeu, Carmelo/L-3226-2014; Corbí, Angel L./ABC-8146-2020; Bernabeu, Carmelo/P-4662-2019; Botella, Luisa M/L-1392-2014; Corbi, Angel/B-7194-2011	Bernabeu, Carmelo/0000-0002-1563-6162; Corbí, Angel L./0000-0003-1980-5733; Bernabeu, Carmelo/0000-0002-1563-6162; Corbi, Angel/0000-0003-1980-5733; Sanchez-Elsner, Tilman/0000-0003-1915-2410				Arthur HM, 2000, DEV BIOL, V217, P42, DOI 10.1006/dbio.1999.9534; Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; BAE HW, 1995, J BIOL CHEM, V270, P29460, DOI 10.1074/jbc.270.49.29460; Barbara NP, 1999, J BIOL CHEM, V274, P584, DOI 10.1074/jbc.274.2.584; BERG JM, 1992, P NATL ACAD SCI USA, V89, P11109, DOI 10.1073/pnas.89.23.11109; Bourdeau A, 1999, J CLIN INVEST, V104, P1343, DOI 10.1172/JCI8088; Brodin G, 2000, J BIOL CHEM, V275, P29023, DOI 10.1074/jbc.M002815200; CHEIFETZ S, 1992, J BIOL CHEM, V267, P19027; CHUNGFANG L, 2000, J BIOL CHEM, V275, P36400; Das P, 1999, GENES CELLS, V4, P123, DOI 10.1046/j.1365-2443.1999.00244.x; Datta PK, 2000, J BIOL CHEM, V275, P40014, DOI 10.1074/jbc.C000508200; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Feng XH, 2000, EMBO J, V19, P5178, DOI 10.1093/emboj/19.19.5178; Gallione CJ, 1998, HUM MUTAT, V11, P286, DOI 10.1002/(SICI)1098-1004(1998)11:4<286::AID-HUMU6>3.0.CO;2-B; Hata A, 2000, CELL, V100, P229, DOI 10.1016/S0092-8674(00)81561-5; Hirano F, 1998, MOL CELL BIOL, V18, P1266, DOI 10.1128/MCB.18.3.1266; HUMPHRIES DE, 1994, BIOCHEM BIOPH RES CO, V203, P1020, DOI 10.1006/bbrc.1994.2284; Iavarone A, 1997, NATURE, V387, P417; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kardassis D, 1999, J BIOL CHEM, V274, P29572, DOI 10.1074/jbc.274.41.29572; KIM SJ, 1989, J BIOL CHEM, V264, P402; Kim Y, 1998, J BIOL CHEM, V273, P33750, DOI 10.1074/jbc.273.50.33750; Kusanagi K, 2000, MOL BIOL CELL, V11, P555, DOI 10.1091/mbc.11.2.555; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; Lania L, 1997, INT J BIOCHEM CELL B, V29, P1313, DOI 10.1016/S1357-2725(97)00094-0; Lastres P, 1996, J CELL BIOL, V133, P1109, DOI 10.1083/jcb.133.5.1109; Lee JS, 1998, P NATL ACAD SCI USA, V95, P969, DOI 10.1073/pnas.95.3.969; LEE JS, 1993, P NATL ACAD SCI USA, V90, P6145, DOI 10.1073/pnas.90.13.6145; Letamendia A, 1998, J BIOL CHEM, V273, P33011, DOI 10.1074/jbc.273.49.33011; Li CG, 2000, FASEB J, V14, P55, DOI 10.1096/fasebj.14.1.55; Li DY, 1999, SCIENCE, V284, P1534, DOI 10.1126/science.284.5419.1534; LI JM, 1995, J BIOL CHEM, V270, P26750, DOI 10.1074/jbc.270.45.26750; Lin SY, 1996, MOL CELL BIOL, V16, P1668; Marin M, 1997, CELL, V89, P619, DOI 10.1016/S0092-8674(00)80243-3; Martin B, 1999, NUCLEIC ACIDS RES, V27, P3402, DOI 10.1093/nar/27.17.3402; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MCALLISTER KA, 1994, NAT GENET, V8, P345, DOI 10.1038/ng1294-345; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Naar AM, 1998, GENE DEV, V12, P3020, DOI 10.1101/gad.12.19.3020; Nagarajan RP, 1999, J BIOL CHEM, V274, P33412, DOI 10.1074/jbc.274.47.33412; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Pardali K, 2000, J BIOL CHEM, V275, P29244, DOI 10.1074/jbc.M909467199; Pece N, 1997, J CLIN INVEST, V100, P2568, DOI 10.1172/JCI119800; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; Qu R, 1998, CELL TISSUE RES, V292, P333, DOI 10.1007/s004410051064; Rius C, 1998, BLOOD, V92, P4677; Saluja D, 1998, MOL CELL BIOL, V18, P5734, DOI 10.1128/MCB.18.10.5734; Schmitt J, 1996, GENOMICS, V32, P358, DOI 10.1006/geno.1996.0130; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Shovlin CL, 1997, AM J HUM GENET, V61, P68, DOI 10.1086/513906; ten Dijke P, 2000, TRENDS BIOCHEM SCI, V25, P64, DOI 10.1016/S0968-0004(99)01519-4; UDVADIA AJ, 1995, P NATL ACAD SCI USA, V92, P3953, DOI 10.1073/pnas.92.9.3953; Vincent EB, 1998, DEV DYNAM, V213, P237, DOI 10.1002/(SICI)1097-0177(199811)213:3<237::AID-AJA1>3.0.CO;2-M; YAMASHITA H, 1994, J BIOL CHEM, V269, P1995; Yeo CY, 1999, J BIOL CHEM, V274, P26584, DOI 10.1074/jbc.274.37.26584; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814	60	64	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					34486	34494		10.1074/jbc.M011611200	http://dx.doi.org/10.1074/jbc.M011611200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11432852	hybrid, Green Published			2022-12-25	WOS:000171024600020
J	Nadanaka, S; Sato, C; Kitajima, K; Katagiri, K; Irie, S; Yamagata, T				Nadanaka, S; Sato, C; Kitajima, K; Katagiri, K; Irie, S; Yamagata, T			Occurrence of oligosialic acids on integrin alpha(5) subunit and their involvement in cell adhesion to fibronectin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYSIALIC ACID; BINDING ACTIVITY; RAINBOW-TROUT; RECEPTOR; GLYCOSYLATION; GLYCOPROTEINS; RESIDUES; ALPHA-5-BETA-1; BIOSYNTHESIS; MOLECULE	Integrin alpha (5)beta (1), a major fibronectin receptor, functions in a wide variety of biological phenomena. We have found that alpha2-8-linked oligosialic acids with 5:5 degree of polymerization (DP) less than or equal to 7 occur on integrin alpha (5) subunit of the human melanoma cell line G361. The integrin alpha (5) subunit immunoprecipitated with anti-integrin alpha (5) antibody reacted with the monoclonal antibody 12E3, which recognizes oligo/polysialic acid with DP greater than or equal to 5 but not with the polyclonal antibody H.46 recognizing oligo/polysialic acid with DP greater than or equal to 8. The occurrence of oligosialic acids was further demonstrated by fluorometric C-7/C-9 analysis on the immunopurified integrin alpha (5) subunit. Oligosialic acids were also found in the alpha (5) subunit of several other human cells such as foreskin fibroblast and chronic erythroleukemia K562 cells. These results suggest the ubiquitous modification with unique oligosialic acids occurs on the ar, subunit of integrin alpha (5)beta (1). The adhesion of human melanoma G361 cells to fibronectin was mainly mediated by integrin alpha (5)beta (1). Treatment of cells with sialidase from Arthrobacter ureafaciens cleaving alpha2-3-, alpha2-6-, and alpha2-8-linked sialic acids inhibited adhesion to fibronectin. On the other hand, N-acetyl-neuraminidase II, which cleaves alpha2-3 and alpha2-6 but not alpha2-8 linkages, showed no inhibitory activity. After the loss of oligosialic acids, integrin alpha (5)beta (1), failed to bind to fibronectin-conjugated Sepharose, indicating that the oligosialic acid on the a5 subunit of integrin alpha (5)beta (1) plays important roles in cell adhesion to fibronectin.	Kyoto Univ, Grad Sch Biostudies, Sakyo Ku, Kyoto 6068304, Japan; Nippi Res Inst Biomatrix, Adachi Ku, Tokyo 1208601, Japan; Nagoya Univ, Grad Sch Bioagr Sci, Dept Appl Mol Biosci, Nagoya, Aichi 4648601, Japan; Kyoto Univ, Bayer Chair Dept Mol Immunol & Allergy, Sakyo Ku, Kyoto 6068501, Japan; Japan Inst Leather Res, Div Glycobiol & Glycotechnol, Adachi Ku, Tokyo 1208601, Japan	Kyoto University; Nagoya University; Kyoto University	Nadanaka, S (corresponding author), Kyoto Univ, Grad Sch Biostudies, Sakyo Ku, 46-29 Yoshida Shimoadachi, Kyoto 6068304, Japan.		Naganawa, Shinji/I-1572-2012; SATO, Chihiro/B-7396-2014	Naganawa, Shinji/0000-0002-0214-613X; 				AKIYAMA SK, 1989, J BIOL CHEM, V264, P18011; AKIYAMA SK, 1987, J BIOL CHEM, V262, P17536; Angata K, 2000, J BIOL CHEM, V275, P18594, DOI 10.1074/jbc.M910204199; ARGRAVES WS, 1987, J CELL BIOL, V105, P1183, DOI 10.1083/jcb.105.3.1183; BREUSS JM, 1995, J CELL SCI, V108, P2241; CARTER WG, 1990, J CELL BIOL, V110, P1387, DOI 10.1083/jcb.110.4.1387; CHERESH DA, 1987, J CELL BIOL, V105, P1163, DOI 10.1083/jcb.105.3.1163; Eisenmann KM, 1999, NAT CELL BIOL, V1, P507, DOI 10.1038/70302; Funakoshi Y, 1997, GLYCOBIOLOGY, V7, P195, DOI 10.1093/glycob/7.2.195; Granovsky M, 2000, NAT MED, V6, P306; HALLENBECK PC, 1987, J BIOL CHEM, V262, P3553; INOUE S, 1978, BIOCHEM BIOPH RES CO, V83, P1018, DOI 10.1016/0006-291X(78)91497-3; Inoue S, 1996, J BIOL CHEM, V271, P24341, DOI 10.1074/jbc.271.40.24341; Ishiguro K, 2000, J BIOL CHEM, V275, P5249, DOI 10.1074/jbc.275.8.5249; KINASHI T, 1994, BLOOD, V83, P1033; KOYAMA T, 1992, J BIOL CHEM, V267, P25939; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPUGNANI MG, 1991, J CELL BIOL, V112, P479, DOI 10.1083/jcb.112.3.479; Mould AP, 1998, BIOCHEM J, V331, P821, DOI 10.1042/bj3310821; Nakagawa H, 1996, EUR J BIOCHEM, V237, P76, DOI 10.1111/j.1432-1033.1996.0076n.x; Nohara K, 1998, J BIOCHEM, V124, P194, DOI 10.1093/oxfordjournals.jbchem.a022079; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; ROHR TE, 1980, J BIOL CHEM, V255, P2332; Rutishauser U, 1998, J CELL BIOCHEM, V70, P304, DOI 10.1002/(SICI)1097-4644(19980901)70:3<304::AID-JCB3>3.0.CO;2-R; Rutishauser U, 1996, CURR OPIN CELL BIOL, V8, P679, DOI 10.1016/S0955-0674(96)80109-8; Saoncella S, 1999, P NATL ACAD SCI USA, V96, P2805, DOI 10.1073/pnas.96.6.2805; Sato C, 1998, ANAL BIOCHEM, V261, P191, DOI 10.1006/abio.1998.2718; Sato C, 1998, J BIOL CHEM, V273, P2575, DOI 10.1074/jbc.273.5.2575; Sato C, 2000, J BIOL CHEM, V275, P15422, DOI 10.1074/jbc.275.20.15422; Sato C, 1999, ANAL BIOCHEM, V266, P102, DOI 10.1006/abio.1998.2921; Sato C, 1999, GLYCOCONJUGATE J, V16, pS117; SMITH JC, 1990, DEVELOPMENT, V108, P229; SYMINGTON BE, 1989, J BIOL CHEM, V264, P13258; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TROY FA, 1996, BIOL SIALIC ACIDS, P95; VANDEWATER L, 1988, CANCER RES, V48, P5730; VANLENTEN L, 1971, J BIOL CHEM, V246, P1889; Wang XQ, 2001, J BIOL CHEM, V276, P8436, DOI 10.1074/jbc.M006097200; WATT FM, 1994, CURR BIOL, V4, P270, DOI 10.1016/S0960-9822(00)00063-4; YANG JT, 1993, DEVELOPMENT, V119, P1093; ZHENG MZ, 1994, J BIOL CHEM, V269, P12325; ZUBER C, 1992, J BIOL CHEM, V267, P9965	42	58	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33657	33664		10.1074/jbc.M011100200	http://dx.doi.org/10.1074/jbc.M011100200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11418585	hybrid			2022-12-25	WOS:000170910200051
J	Hatakeyama, S; Yada, M; Matsumoto, M; Ishida, N; Nakayama, KI				Hatakeyama, S; Yada, M; Matsumoto, M; Ishida, N; Nakayama, KI			U box proteins as a new family of ubiquitin-protein ligases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B-ALPHA; SIGNAL-INDUCED UBIQUITINATION; RING FINGER; MULTIUBIQUITIN CHAIN; BETA-CATENIN; SACCHAROMYCES-CEREVISIAE; C-CBL; DEGRADATION; COMPLEX; TRCP	The U box is a domain of similar to 70 amino acids that is present in proteins from yeast to humans. The prototype U box protein, yeast Ufd2, was identified as a ubiquitin chain assembly factor that cooperates with a ubiquitin-activating enzyme (EI), a ubiquitin-conjugating enzyme (E2), and a ubiquitin-protein ligase (E3) to catalyze ubiquitin chain formation on artificial substrates. E3 enzymes are thought to determine the substrate specificity of ubiquitination and have been classified into two families, the HECT and RING finger families. Six mammalian U box proteins have now been shown to mediate polyubiquitination in the presence of El and E2 and in the absence of E3. These U box proteins exhibited different specificities for E2 enzymes in this reaction. Deletion of the U box or mutation of conserved amino acids within it abolished ubiquitination activity. Some U box proteins catalyzed polyubiquitination by targeting lysine residues of ubiquitin other than lysine 48, which is utilized by HECT and RING finger E3 enzymes for polyubiquitination that serves as a signal for proteolysis by the 26 S proteasome. These data suggest that U box proteins constitute a third family of E3 enzymes and that E4 activity may reflect a specialized type of E3 activity.	Kyushu Univ, Med Inst Bioregulat, Dept Mol & Cellular Biol, Higashi Ku, Fukuoka 8128582, Japan; Japan Sci & Technol Corp, CREST, Kawaguchi, Saitama 3320012, Japan	Kyushu University; Japan Science & Technology Agency (JST)	Nakayama, KI (corresponding author), Kyushu Univ, Med Inst Bioregulat, Dept Mol & Cellular Biol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.		Hatakeyama, Shigetsugu/C-8333-2012	Hatakeyama, Shigetsugu/0000-0002-2150-9979				Aravind L, 2000, CURR BIOL, V10, pR132, DOI 10.1016/S0960-9822(00)00398-5; ARNASON T, 1994, MOL CELL BIOL, V14, P7876, DOI 10.1128/MCB.14.12.7876; Ballinger CA, 1999, MOL CELL BIOL, V19, P4535; Connell P, 2001, NAT CELL BIOL, V3, P93, DOI 10.1038/35050618; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Fisk HA, 1999, J CELL BIOL, V145, P1199, DOI 10.1083/jcb.145.6.1199; Freemont PS, 2000, CURR BIOL, V10, pR84, DOI 10.1016/S0960-9822(00)00287-6; Galan JM, 1997, EMBO J, V16, P5847, DOI 10.1093/emboj/16.19.5847; Gmachl M, 2000, P NATL ACAD SCI USA, V97, P8973, DOI 10.1073/pnas.97.16.8973; Hatakeyama S, 1997, J BIOL CHEM, V272, P15085, DOI 10.1074/jbc.272.24.15085; Hatakeyama S, 1999, P NATL ACAD SCI USA, V96, P3859, DOI 10.1073/pnas.96.7.3859; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; Honda R, 2000, ONCOGENE, V19, P1473, DOI 10.1038/sj.onc.1203464; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P5249, DOI 10.1073/pnas.92.11.5249-a; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; JOHNSON ES, 1995, J BIOL CHEM, V270, P17442, DOI 10.1074/jbc.270.29.17442; Kamura T, 1999, GENE DEV, V13, P2928, DOI 10.1101/gad.13.22.2928; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Koegl M, 1999, CELL, V96, P635, DOI 10.1016/S0092-8674(00)80574-7; Latres E, 1999, ONCOGENE, V18, P849, DOI 10.1038/sj.onc.1202653; Leverson JD, 2000, MOL BIOL CELL, V11, P2315, DOI 10.1091/mbc.11.7.2315; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Ohta T, 1999, MOL CELL, V3, P535, DOI 10.1016/S1097-2765(00)80482-7; Orian A, 2000, EMBO J, V19, P2580, DOI 10.1093/emboj/19.11.2580; Peters JM, 1998, CURR OPIN CELL BIOL, V10, P759, DOI 10.1016/S0955-0674(98)80119-1; Pickart CM, 2000, TRENDS BIOCHEM SCI, V25, P544, DOI 10.1016/S0968-0004(00)01681-9; Pickart CM, 1997, FASEB J, V11, P1055, DOI 10.1096/fasebj.11.13.9367341; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; Seol JH, 1999, GENE DEV, V13, P1614, DOI 10.1101/gad.13.12.1614; Skowyra D, 1999, SCIENCE, V284, P662, DOI 10.1126/science.284.5414.662; SPENCE J, 1995, MOL CELL BIOL, V15, P1265; Spence J, 2000, CELL, V102, P67, DOI 10.1016/S0092-8674(00)00011-8; Spencer E, 1999, GENE DEV, V13, P284, DOI 10.1101/gad.13.3.284; Staub O, 1997, EMBO J, V16, P6325, DOI 10.1093/emboj/16.21.6325; Tan PL, 1999, MOL CELL, V3, P527, DOI 10.1016/S1097-2765(00)80481-5; Wang BB, 1996, BIOCHEM J, V314, P313, DOI 10.1042/bj3140313; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; Weissman AM, 1997, IMMUNOL TODAY, V18, P189, DOI 10.1016/S0167-5699(97)84666-X; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Wu C, 1999, J BIOL CHEM, V274, P29591, DOI 10.1074/jbc.274.42.29591; Xie YM, 1999, EMBO J, V18, P6832, DOI 10.1093/emboj/18.23.6832; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159	50	442	477	8	38	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					33111	33120		10.1074/jbc.M102755200	http://dx.doi.org/10.1074/jbc.M102755200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11435423	hybrid			2022-12-25	WOS:000170746000097
J	Gibson, CW; Yuan, ZA; Hall, B; Longenecker, G; Chen, EH; Thyagarajan, T; Sreenath, T; Wright, JT; Decker, S; Piddington, R; Harrison, G; Kulkarni, AB				Gibson, CW; Yuan, ZA; Hall, B; Longenecker, G; Chen, EH; Thyagarajan, T; Sreenath, T; Wright, JT; Decker, S; Piddington, R; Harrison, G; Kulkarni, AB			Amelogenin-deficient mice display an amelogenesis imperfecta phenotype	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSENSE MUTATION; GENE AMGX; ENAMEL; PROTEINS; BIOMINERALIZATION; SEQUENCE; DEFECTS; CLONING; MATRIX; REGION	Dental enamel is the hardest tissue in the body and cannot be replaced or repaired, because the enamel secreting cells are lost at tooth eruption. X-linked amelogenesis imperfecta (MIM 301200), a phenotypically diverse hereditary disorder affecting enamel development, is caused by deletions or point mutations in the human X-chromosomal amelogenin gene. Although the precise functions of the amelogenin proteins in enamel formation are not well defined, these proteins constitute 90% of the enamel organic matrix. We have disrupted the amelogenin locus to generate amelogenin null mice, which display distinctly abnormal teeth as early as 2 weeks of age with chalky-white discoloration. Microradiography revealed broken tips of incisors and molars and scanning electron microscopy analysis indicated disorganized hypoplastic enamel. The amelogenin null phenotype reveals that the amelogenins are apparently not required for initiation of mineral crystal formation but rather for the organization of crystal pattern and regulation of enamel thickness. These null mice will be useful for understanding the functions of amelogenin proteins during enamel formation and for developing therapeutic approaches for treating this developmental defect that affects the enamel.	Univ Penn, Sch Dent Med, Dept Anat & Histol, Philadelphia, PA 19104 USA; Univ Penn, Sch Dent Med, Dept Biochem, Philadelphia, PA 19104 USA; NIDCR, Funct Genom Unit, NIH, Bethesda, MD 20892 USA; NIDCR, Gene Targeting Facil, NIH, Bethesda, MD 20892 USA; Univ N Carolina, Dept Pediat Dent, Chapel Hill, NC 27599 USA	University of Pennsylvania; University of Pennsylvania; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); University of North Carolina; University of North Carolina Chapel Hill	Gibson, CW (corresponding author), Univ Penn, Sch Dent Med, Dept Anat & Histol, 4010 Locust St, Philadelphia, PA 19104 USA.	gibson@biochem.dental.upenn.edu; akulkarni@dir.nidcr.nih.gov	Wright, John Timothy/AAX-5755-2020		NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE011089] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE010149, R01DE012879] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ALDRED MJ, 1992, HUM GENET, V90, P413; Bartlett JD, 1999, CRIT REV ORAL BIOL M, V10, P425, DOI 10.1177/10454411990100040101; Chen E, 1998, GENE, V216, P131, DOI 10.1016/S0378-1119(98)00300-X; Collier PM, 1997, ARCH ORAL BIOL, V42, P235, DOI 10.1016/S0003-9969(96)00099-4; DIEKWISCH T, 1993, DEVELOPMENT, V117, P471; FINCHAM AG, 1995, J STRUCT BIOL, V115, P50, DOI 10.1006/jsbi.1995.1029; FINCHAM AG, 1991, ARCH ORAL BIOL, V36, P305, DOI 10.1016/0003-9969(91)90101-Y; FINCHAM AG, 1991, CALCIFIED TISSUE INT, V48, P288, DOI 10.1007/BF02556382; GIBSON CW, 1992, CALCIFIED TISSUE INT, V51, P162, DOI 10.1007/BF00298506; Gibson CW, 1995, CONNECT TISSUE RES, V32, P109, DOI 10.3109/03008209509013711; Gibson CW, 1999, CRIT REV EUKAR GENE, V9, P45, DOI 10.1615/CritRevEukaryotGeneExpr.v9.i1.40; GLIMCHER MJ, 1964, BIOCHEM J, V93, P202, DOI 10.1042/bj0930202; HEROLD RC, 1987, ARCH ORAL BIOL, V32, P439, DOI 10.1016/0003-9969(87)90080-X; Hu CC, 1996, J DENT RES, V75, P1735, DOI 10.1177/00220345960750100501; Hu CC, 1997, J DENT RES, V76, P641, DOI 10.1177/00220345970760020401; LAGERSTROM M, 1991, GENOMICS, V10, P971, DOI 10.1016/0888-7543(91)90187-J; LAGERSTROMFERMER M, 1995, GENOMICS, V26, P159, DOI 10.1016/0888-7543(95)80097-6; LAU EC, 1989, GENOMICS, V4, P162, DOI 10.1016/0888-7543(89)90295-4; LENCH NJ, 1994, HUM MOL GENET, V3, P827, DOI 10.1093/hmg/3.5.827; LENCH NJ, 1995, HUM MUTAT, V5, P251, DOI 10.1002/humu.1380050310; LYNGSTADAAS SP, 1995, EMBO J, V14, P5224, DOI 10.1002/j.1460-2075.1995.tb00207.x; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; Moradian-Oldak J, 2000, J STRUCT BIOL, V131, P27, DOI 10.1006/jsbi.2000.4237; MORADIANOLDAK J, 1994, BIOPOLYMERS, V34, P1339, DOI 10.1002/bip.360341006; NAKAHORI Y, 1991, GENOMICS, V9, P264, DOI 10.1016/0888-7543(91)90251-9; Ohshima T, 1996, P NATL ACAD SCI USA, V93, P11173, DOI 10.1073/pnas.93.20.11173; Oida S, 1996, DNA SEQUENCE, V6, P307, DOI 10.3109/10425179609020879; Paine ML, 1997, J BONE MINER RES, V12, P221, DOI 10.1359/jbmr.1997.12.2.221; Paine ML, 2000, J STRUCT BIOL, V132, P191, DOI 10.1006/jsbi.2000.4324; Ravindranath RMH, 1999, J BIOL CHEM, V274, P2464, DOI 10.1074/jbc.274.4.2464; Robinson C, 1998, EUR J ORAL SCI, V106, P282, DOI 10.1111/j.1600-0722.1998.tb02188.x; SALIDO EC, 1992, AM J HUM GENET, V50, P303; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHROEDER HE, 1991, ORAL STRUCTURAL BIOL, P56; SIMMER JP, 1994, CALCIFIED TISSUE INT, V55, P302, DOI 10.1007/BF00310410; Smith CE, 1998, CRIT REV ORAL BIOL M, V9, P128, DOI 10.1177/10454411980090020101; SNEAD ML, 1985, BIOCHEM BIOPH RES CO, V129, P812, DOI 10.1016/0006-291X(85)91964-3; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; TERMINE JD, 1980, J BIOL CHEM, V255, P9760; Witkop CJ, 1976, ORAL FACIAL GENETICS, P151; Yuan ZA, 1996, ARCH ORAL BIOL, V41, P205, DOI 10.1016/0003-9969(95)00119-0	41	357	363	1	25	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					31871	31875		10.1074/jbc.M104624200	http://dx.doi.org/10.1074/jbc.M104624200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11406633	Green Published, hybrid			2022-12-25	WOS:000170613500056
J	Shi, CS; Kehrl, JH				Shi, CS; Kehrl, JH			PYK2 links G(q)alpha and G(13)alpha signaling to NF-kappa B activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE ACTIVITY; PHOSPHOINOSITIDE 3-KINASE; MARGINAL ZONE; TYROSINE KINASE; CELLS; REQUIREMENT; BRADYKININ; ABSENCE; AKT	Signaling via a variety of G-protein-coupled receptors (GPCRs) leads to activation of nuclear factor (NF)-kappaB. Evidence exists for a signaling pathway initiated by the B2 type bradykinin receptor via G(q) activation, which leads to the sequential stimulation of phosphoinositide 3-kinase (PI3K), the serine/threonine kinase Akt, I kappaB kinases, and finally nuclear factor NF-kappaB-dependent transcription. GPCR-mediated G(q)alpha or G(13)alpha activation also potently stimulates the tyrosine kinase PYK2. In this study we tested whether G(q)alpha- and/or G(13)alpha -induced PYK2 activation contributes to GPCR-mediated NF-kappaB activation. Among the GTPase-deficient forms of G alpha tested, G(13)alpha and G(q)alpha most potently stimulated an NF-kappaB-dependent reporter gene. PYK2 activated the same reporter gene and synergized with either G(q)alpha Q209L (QL) or G(13)alpha Q226L (QL). Placing PYK2 upstream of both PI3K and Akt activation, PYK2 activated Aht through a PI3K-dependent pathway, and either a dominant negative form of Aht or the PI3K inhibitor LY294002 blocked PYK2-stimulated NF-kappaB-dependent transcription. Placing PYK2 downstream of G-protein activation, a kinase-dead form of PYK2, PYK2 (KD), blocked NF-kappaB-dependent transcription triggered by signaling through the muscarinic receptor type 1 and either G(q)alpha QL or G(13)alpha QL. PYK2 (KD) also blocked Akt activation by the same stimuli. These results indicate that PYK2 can link G-protein activation through PI3K, Akt, and I kappaB kinase to NF-kappaB activation.	NIAID, Immunoregulat Lab, Cell Mol Immunol Sect B, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Kehrl, JH (corresponding author), NIAID, Immunoregulat Lab, Cell Mol Immunol Sect B, NIH, Bldg 10 Rm 11B08,10 Ctr DR MSC 1876, Bethesda, MD 20892 USA.	jkehrl@atlas.niaid.nih.gov	Kehrl, John/AAE-6292-2019	Kehrl, John/0000-0002-6526-159X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000739, ZIAAI000739] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Avraham H, 2000, CELL SIGNAL, V12, P123, DOI 10.1016/S0898-6568(99)00076-5; Cariappa A, 2000, J EXP MED, V192, P1175, DOI 10.1084/jem.192.8.1175; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Dikic I, 1998, J BIOL CHEM, V273, P14301, DOI 10.1074/jbc.273.23.14301; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Fruman DA, 1999, SCIENCE, V283, P393, DOI 10.1126/science.283.5400.393; Gallois C, 1998, J BIOL CHEM, V273, P23183, DOI 10.1074/jbc.273.36.23183; Guinamard R, 2000, NAT IMMUNOL, V1, P31, DOI 10.1038/76882; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Karin M, 2000, SEMIN IMMUNOL, V12, P85, DOI 10.1006/smim.2000.0210; Kehrl JH, 1998, IMMUNITY, V8, P1, DOI 10.1016/S1074-7613(00)80453-7; KRAVCHENKO VV, 1995, J BIOL CHEM, V270, P14928, DOI 10.1074/jbc.270.25.14928; Martin F, 2000, IMMUNOL REV, V175, P70, DOI 10.1034/j.1600-065X.2000.017515.x; Murasawa S, 1998, HYPERTENSION, V32, P668, DOI 10.1161/01.HYP.32.4.668; Okada T, 2000, IMMUNITY, V13, P817, DOI 10.1016/S1074-7613(00)00079-0; Ozes ON, 1999, NATURE, V401, P82; Pan ZK, 1999, J BIOL CHEM, V274, P9918, DOI 10.1074/jbc.274.15.9918; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; Sayed MR, 2000, J CELL PHYSIOL, V183, P314, DOI 10.1002/(SICI)1097-4652(200006)183:3<314::AID-JCP3>3.0.CO;2-J; Shahrestanifar M, 1999, J BIOL CHEM, V274, P3828, DOI 10.1074/jbc.274.6.3828; Shi CS, 2000, J BIOL CHEM, V275, P24470, DOI 10.1074/jbc.M908449199; Walker EH, 1999, NATURE, V402, P313, DOI 10.1038/46319; Xie P, 2000, J BIOL CHEM, V275, P24907, DOI 10.1074/jbc.M001051200	24	55	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					31845	31850		10.1074/jbc.M101043200	http://dx.doi.org/10.1074/jbc.M101043200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11435419	hybrid			2022-12-25	WOS:000170613500052
J	Snyders, S; Kohorn, BD				Snyders, S; Kohorn, BD			Disruption of thylakoid-associated kinase 1 leads to alteration of light harvesting in arabidopsis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PHOSPHORYLATION; CHLAMYDOMONAS-REINHARDTII; STATE TRANSITIONS; PHOTOSYSTEM-I; COMPLEX-II; MEMBRANES; CHLOROPLASTS; PLASTOQUINOL; BINDING; SITE	To survive fluctuations in quality and intensity of light, plants and algae are able to preferentially direct the absorption of light energy to either one of the two photosystems, PSI or PSII. This rapid process is referred to as a state transition and has been correlated with the phosphorylation and migration of the light-harvesting complex protein (LHCP) between PSII and PSI. We show here that thylakoid protein kinases (TAKs) are required for state transitions in Arabidopsis. Antisense TAK1 expression leads to a loss of LHCP phosphorylation and a reduction in state transitions. Preferential activation of PSII causes LHCP to accumulate with PSI, and TAK1. mutants disrupt this process. Finally, TAKs also influence the phosphorylation. of multiple thylakoid proteins.	Duke Univ, Dept Biol, DCMB, Durham, NC 27708 USA	Duke University	Kohorn, BD (corresponding author), Duke Univ, Dept Biol, DCMB, Rm B353 LSRC, Durham, NC 27708 USA.							ALLEN JF, 1992, BIOCHIM BIOPHYS ACTA, V1098, P275, DOI 10.1016/S0005-2728(09)91014-3; ANDERSSON B, 1994, ADV MOL CEL, V10, P1; BONAVENTURA C, 1969, BIOCHIM BIOPHYS ACTA, V189, P366, DOI 10.1016/0005-2728(69)90168-6; Chen WQ, 1996, PLANT J, V10, P955, DOI 10.1046/j.1365-313X.1996.10060955.x; ESCOUBAS JM, 1995, P NATL ACAD SCI USA, V92, P10237, DOI 10.1073/pnas.92.22.10237; Fleischmann MM, 1999, J BIOL CHEM, V274, P30987, DOI 10.1074/jbc.274.43.30987; FOYER CH, 1987, BIOCHEM J, V248, P103, DOI 10.1042/bj2480103; Gal A, 1997, PHYSIOL PLANTARUM, V100, P869, DOI 10.1034/j.1399-3054.1997.1000413.x; GEORGAKOPOULOS JH, 1994, BBA-BIOENERGETICS, V1188, P380, DOI 10.1016/0005-2728(94)90059-0; Havaux M, 2000, PLANT PHYSIOL, V124, P273, DOI 10.1104/pp.124.1.273; KOHORN BD, 1990, J BIOL CHEM, V265, P2118; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lunde C, 2000, NATURE, V408, P613, DOI 10.1038/35046121; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; MAYFIELD SP, 1995, ANNU REV PLANT PHYS, V46, P147, DOI 10.1146/annurev.pp.46.060195.001051; MINDRINOS M, 1994, CELL, V78, P1089, DOI 10.1016/0092-8674(94)90282-8; Rintamaki E, 1997, J BIOL CHEM, V272, P30476, DOI 10.1074/jbc.272.48.30476; Rintamaki E, 2000, P NATL ACAD SCI USA, V97, P11644, DOI 10.1073/pnas.180054297; Rintamaki E, 1996, J BIOL CHEM, V271, P14870, DOI 10.1074/jbc.271.25.14870; Rokka A, 2000, PLANT PHYSIOL, V123, P1525, DOI 10.1104/pp.123.4.1525; Sambrook J., 2002, MOL CLONING LAB MANU; SHAW CH, 1983, GENE, V23, P315, DOI 10.1016/0378-1119(83)90021-5; SILVERSTEIN T, 1993, FEBS LETT, V334, P101, DOI 10.1016/0014-5793(93)81690-2; SMITH TA, 1994, J CELL BIOL, V126, P365, DOI 10.1083/jcb.126.2.365; Snyders S, 1999, J BIOL CHEM, V274, P9137, DOI 10.1074/jbc.274.14.9137; SONOIKE K, 1995, PLANT CELL PHYSIOL, V36, P825, DOI 10.1093/oxfordjournals.pcp.a078827; VALLON O, 1991, P NATL ACAD SCI USA, V88, P8262, DOI 10.1073/pnas.88.18.8262; VanderVlugtBergmans CJB, 1997, PHYSIOL MOL PLANT P, V50, P1, DOI 10.1006/pmpp.1996.0067; Vener AV, 1998, CURR OPIN PLANT BIOL, V1, P217, DOI 10.1016/S1369-5266(98)80107-6; Vener AV, 1997, P NATL ACAD SCI USA, V94, P1585, DOI 10.1073/pnas.94.4.1585; Vener AV, 1999, BIOCHEMISTRY-US, V38, P14955, DOI 10.1021/bi990971v; VENER AV, 1995, J BIOL CHEM, V270, P25225, DOI 10.1074/jbc.270.42.25225; WOLLMAN FA, 1984, J CELL BIOL, V98, P1, DOI 10.1083/jcb.98.1.1; Zito F, 1999, EMBO J, V18, P2961, DOI 10.1093/emboj/18.11.2961	34	74	81	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					32169	32176		10.1074/jbc.M102539200	http://dx.doi.org/10.1074/jbc.M102539200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11423538	hybrid			2022-12-25	WOS:000170613500095
J	Biberstine-Kinkade, KJ; DeLeo, FR; Epstein, RI; LeRoy, BA; Nauseef, WM; Dinauer, MC				Biberstine-Kinkade, KJ; DeLeo, FR; Epstein, RI; LeRoy, BA; Nauseef, WM; Dinauer, MC			Heme-ligating histidines in flavocytochrome b(558)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; NEUTROPHIL CYTOCHROME-B; PHAGOCYTE NADPH OXIDASE; LIGHT-CHAIN; SUPEROXIDE; MUTATIONS; GENE; COMPONENT; IDENTIFICATION; GP91-PHOX	The phagocyte NADPH-dependent oxidase generates superoxide (O-2(.-)) by reducing molecular oxygen through flavocytochrome b(558) (flavocytochrome b), a heterodimeric oxidoreductase composed of gp91(phox) and p22(phox) subunits. Although each flavocytochrome b molecule contains two heme groups, their precise distribution within the heterodimer is unknown. Among functionally and/or structurally related oxidoreductases, histidines at codons 101, 111, 115, 119, 209, 210, and 222 of gp91(phox) are conserved and potential candidates to ligate heme, We compared biochemical and functional features of normal flavocytochrome b with those in cells expressing gp91(phox) harboring amino acid substitutions at each of these histidines. Surface expression of flavocytochrome b and heterodimer formation were relatively unaffected in cells expressing gp91(phox) H111L, H119L, or H210L. These mutations also had no effect on the flavocytochrome b heme spectrum, although NADPH oxidase activity was decreased in cells expressing gp91(phox) H119L or H210L. In contrast, gp65 was not processed to gp91(phox), heterodimers did not form, and flavocytochrome b was not expressed on the surface of cells expressing gp91(phox) H101L, H115L, H115L, H209C, H209Y, H222L, H222C, or H222R. Similarly, this subset of mutants lacked detectable O-2(.-)-generating activity, and flavocytochrome b purified from these cells contained little or no heme. These findings demonstrate that His(101), His(115), His(209), and His(222) of gp91(phox) are critical for heme binding and biosynthetic maturation of flavocytochrome b.	Indiana Univ, Sch Med, Riley Hosp Children, Wells Ctr Pediat Res,Dept Pediat Hematol Oncol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Riley Hosp Children, Wells Ctr Pediat Res,Dept Med & Mol Genet, Indianapolis, IN 46202 USA; Vet Adm Med Ctr, Inflammat Program, Iowa City, IA 52242 USA; Vet Adm Med Ctr, Dept Med, Iowa City, IA 52242 USA; Univ Iowa, Iowa City, IA 52242 USA	Indiana University System; Indiana University-Purdue University Indianapolis; James Whitcomb Riley Hospital Children; Indiana University System; Indiana University-Purdue University Indianapolis; James Whitcomb Riley Hospital Children; US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Iowa	Dinauer, MC (corresponding author), Wells Ctr Pediat Res, 1044 W Walnut St,R4,Rm 402A, Indianapolis, IN 46202 USA.	mdinauer@iupui.edu		DeLeo, Frank/0000-0003-3150-2516; Nauseef, William/0000-0003-4032-757X	NHLBI NIH HHS [P01 HL 53586, R01 HL 45635] Funding Source: Medline; NIAID NIH HHS [O1 AI 34879] Funding Source: Medline; NIDDK NIH HHS [P50 DK 49218] Funding Source: Medline; BLRD VA [I01 BX000513] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045635, P01HL053586] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI034879, R01AI034879] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK049218] Funding Source: NIH RePORTER; Veterans Affairs [I01BX000513] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); BLRD VA; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Veterans Affairs(US Department of Veterans Affairs)		Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; BOLSCHER BGJM, 1991, BLOOD, V77, P2482; BORREGAARD N, 1983, J CELL BIOL, V97, P52, DOI 10.1083/jcb.97.1.52; Burritt JB, 1998, J BIOL CHEM, V273, P24847, DOI 10.1074/jbc.273.38.24847; Burritt JB, 2000, EUR J HAEMATOL, V65, P407, DOI 10.1034/j.1600-0609.2000.065006407.x; Burritt JB, 2001, J BIOL CHEM, V276, P2053, DOI 10.1074/jbc.M006236200; BURRITT JB, 1995, J BIOL CHEM, V270, P16974, DOI 10.1074/jbc.270.28.16974; CROSS AR, 1995, J BIOL CHEM, V270, P6543, DOI 10.1074/jbc.270.12.6543; CROSS AR, 1995, J BIOL CHEM, V270, P17075, DOI 10.1074/jbc.270.29.17075; CURNUTTE JT, 2001, MOL BASIS PHAGOCYTE, P539; DeLeo FR, 2000, J BIOL CHEM, V275, P13986, DOI 10.1074/jbc.275.18.13986; DeLeo FR, 1998, J CLIN INVEST, V101, P455, DOI 10.1172/JCI949; DeLeo FR, 1996, J LEUKOCYTE BIOL, V60, P677, DOI 10.1002/jlb.60.6.677; DINAUER M, 1998, HEMATOLOGY INFANCY C, V1, P889; DINAUER MC, 1990, J CLIN INVEST, V86, P1729, DOI 10.1172/JCI114898; DINAUER MC, 1987, NATURE, V327, P717, DOI 10.1038/327717a0; Finegold AA, 1996, J BIOL CHEM, V271, P31021, DOI 10.1074/jbc.271.49.31021; Fujii H, 1995, FEBS LETT, V377, P345, DOI 10.1016/0014-5793(95)01372-5; HEYWORTH P, 1998, MOL CELLULAR BASIS I, P165; Heyworth PG, 2001, BLOOD CELL MOL DIS, V27, P16, DOI 10.1006/bcmd.2000.0347; HURST JK, 1991, J BIOL CHEM, V266, P1627; IMAJOHOHMI S, 1992, J BIOL CHEM, V267, P180; Ishibashi F, 2000, HUM GENET, V106, P473, DOI 10.1007/s004390000288; JESAITIS AJ, 1995, J IMMUNOL, V155, P3286; Kaneda M, 1999, BLOOD, V93, P2098, DOI 10.1182/blood.V93.6.2098.406k09_2098_2104; KOSHKIN V, 1993, FEBS LETT, V327, P57, DOI 10.1016/0014-5793(93)81039-3; KOSHKIN V, 1994, FEBS LETT, V338, P285, DOI 10.1016/0014-5793(94)80285-8; Kume A, 2000, J LAB CLIN MED, V135, P122, DOI 10.1067/mlc.2000.104458; Lambeth JD, 2000, TRENDS BIOCHEM SCI, V25, P459, DOI 10.1016/S0968-0004(00)01658-3; Malech HL, 1997, SEMIN HEMATOL, V34, P279; MALY FE, 1993, J EXP MED, V178, P2047, DOI 10.1084/jem.178.6.2047; Maniatis T., 1982, MOL CLONING LAB MANU; Metcalf Julia A., 1986, LAB MANUAL NEUTROPHI; Nauseef WM, 1999, P ASSOC AM PHYSICIAN, V111, P373, DOI 10.1111/paa.1999.111.5.373; PARKOS CA, 1989, BLOOD, V73, P1416; PARKOS CA, 1992, MOLECULAR BASIS OF OXIDATIVE DAMAGE BY LEUKOCYTES, P45; PARKOS CA, 1988, P NATL ACAD SCI USA, V85, P3319, DOI 10.1073/pnas.85.10.3319; QUINN MT, 1992, J BIOL CHEM, V267, P7303; Rae J, 1998, AM J HUM GENET, V62, P1320, DOI 10.1086/301874; ROBERTSON DE, 1994, NATURE, V368, P425, DOI 10.1038/368425a0; Roos D, 1999, PRIMARY IMMUNODEFICIENCY DISEASES, P353; Roos D, 1996, BLOOD, V87, P1663; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; ROYERPOKORA B, 1986, NATURE, V322, P32, DOI 10.1038/322032a0; SEGAL AW, 1987, NATURE, V326, P88, DOI 10.1038/326088a0; Shatwell KP, 1996, J BIOL CHEM, V271, P14240, DOI 10.1074/jbc.271.24.14240; TEAHAN C, 1987, NATURE, V327, P720, DOI 10.1038/327720a0; Tsuda M, 1998, HUM GENET, V103, P377, DOI 10.1007/s004390050836; UENO I, 1991, FEBS LETT, V281, P130, DOI 10.1016/0014-5793(91)80375-D; VERHOEVEN AJ, 1989, BLOOD, V73, P1686; Wallach TM, 1997, BIOCHEM J, V321, P583, DOI 10.1042/bj3210583; Yu LX, 1999, J BIOL CHEM, V274, P4364, DOI 10.1074/jbc.274.7.4364; Yu LX, 1997, J BIOL CHEM, V272, P27288, DOI 10.1074/jbc.272.43.27288; Yu LX, 1998, P NATL ACAD SCI USA, V95, P7993, DOI 10.1073/pnas.95.14.7993; ZHEN L, 1993, P NATL ACAD SCI USA, V90, P9832, DOI 10.1073/pnas.90.21.9832	55	86	86	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					31105	31112		10.1074/jbc.M103327200	http://dx.doi.org/10.1074/jbc.M103327200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11413138	hybrid			2022-12-25	WOS:000170472900069
J	De Fabiani, E; Mitro, N; Anzulovich, AC; Pinelli, A; Galli, G; Crestani, M				De Fabiani, E; Mitro, N; Anzulovich, AC; Pinelli, A; Galli, G; Crestani, M			The negative effects of bile acids and tumor necrosis factor-alpha on the transcription of cholesterol 7 alpha-hydroxylase gene (CYP7A1) converge to hepatic nuclear factor-4 - A novel mechanism of feedback regulation of bile acid synthesis mediated by nuclear receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; PROTEIN-KINASES; RESPONSE ELEMENT; EXPRESSION; PHOSPHORYLATION; ACTIVATION; IDENTIFICATION; INDUCTION; TNF; FXR	Bile acids regulate the cholesterol 7 alpha -hydroxylase gene (CYP7A1), which encodes the rate-limiting enzyme in the classical pathway of bile acid synthesis. Here we report a novel mechanism whereby bile acid feedback regulates CYP7A1 transcription through the nuclear receptor hepatocyte nuclear factor-4 (HNF-4), which binds to the bile acid response element (BARE) at nt -149/-118 relative to the transcription start site. Using transient transfection assays of HepG2 cells with Ga14-HNF-4 fusion proteins, we show that chenodeoxycholic acid (CDCA) dampened the transactivation potential of HNF-4. Overexpression of a constitutive active form of MEKK1, an upstream mitogen-activated protein kinase (MAPK) module triggered by stress signals, strongly repressed the promoter activity of CYP7A1 via the consensus sequence for HNF-4 embedded in the BARE. Similarly, MEEK1 inhibited the activity of HNF-4 in the Ga14-based assay. The involvement of the MEKK1-dependent pathway in the bile acid-mediated repression of CYP7A1 was confirmed by co-transfecting a dominant negative form of the stress-activated protein kinase kinase, SEK, which abolished the effect of CDCA upon CYP7A1 transcription. Treatment of transfected HepG2 cells with tumor necrosis factor a (TNF-alpha), an activator of the MEKK1 pathway, led to the repression of CYP7A1 via the HNF-4 site in the BARE. TNF-alpha also inhibited the transactivation potential of HNF-4. Collectively, our results demonstrate for the first time that HNF-4, in combination with a MAPK signaling pathway, acts as a bile acid sensor in the liver. Furthermore, the effects of CDCA and TNF-alpha converge to HNF-4, which binds to the BARE of CYP7A1, suggesting a link between the cascades elicited by bile acids and pro-inflammatory stimuli in the liver.	Univ Milan, Fac Farm, Dipartimento Sci Farmacol, I-20133 Milan, Italy	University of Milan	Crestani, M (corresponding author), Univ Milan, Fac Farm, Dipartimento Sci Farmacol, Via Balzaretti 9, I-20133 Milan, Italy.	Maurizio.Crestani@unimi.it	De Fabiani, Emma/B-6936-2015	De Fabiani, Emma/0000-0003-2406-1468; Crestani, Maurizio/0000-0001-9230-1078; Anzulovich, Ana/0000-0001-6989-7168; Mitro, Nico/0000-0002-5000-3619				Ait-Si-Ali S, 1999, BIOCHEM BIOPH RES CO, V262, P157, DOI 10.1006/bbrc.1999.1132; Auwerx J, 1999, CELL, V97, P161; Avdi NJ, 2001, J BIOL CHEM, V276, P2189, DOI 10.1074/jbc.M007527200; Baud V, 1999, GENE DEV, V13, P1297, DOI 10.1101/gad.13.10.1297; Chen NY, 1999, J BIOL CHEM, V274, P15389, DOI 10.1074/jbc.274.22.15389; CHIANG JYL, 1994, J BIOL CHEM, V269, P17502; Chiang JYL, 2000, J BIOL CHEM, V275, P10918, DOI 10.1074/jbc.275.15.10918; CRESTANI M, 1994, BIOCHEM BIOPH RES CO, V198, P546, DOI 10.1006/bbrc.1994.1080; Crestani M, 1996, BIOCHEM BIOPH RES CO, V225, P585, DOI 10.1006/bbrc.1996.1215; CRESTANI M, 1995, J LIPID RES, V36, P2419; Crestani M, 1998, J LIPID RES, V39, P2192; De Fabiani E, 2000, BIOCHEM J, V347, P147; del Castillo-Olivares A, 2000, NUCLEIC ACIDS RES, V28, P3587; Feingold KR, 1996, J LIPID RES, V37, P223; GERLIER D, 1986, J IMMUNOL METHODS, V94, P57, DOI 10.1016/0022-1759(86)90215-2; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Gupta S, 2001, J BIOL CHEM, V276, P15816, DOI 10.1074/jbc.M010878200; Hayhurst GP, 2001, MOL CELL BIOL, V21, P1393, DOI 10.1128/MCB.21.4.1393-1403.2001; Hsu HY, 2000, J BIOL CHEM, V275, P41035, DOI 10.1074/jbc.M003464200; Lee YK, 2000, MOL CELL BIOL, V20, P187, DOI 10.1128/MCB.20.1.187-195.2000; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; Miyake JH, 2000, J BIOL CHEM, V275, P21805, DOI 10.1074/jbc.C000275200; Moller DE, 2000, TRENDS ENDOCRIN MET, V11, P212, DOI 10.1016/S1043-2760(00)00272-1; Nitta M, 1999, P NATL ACAD SCI USA, V96, P6660, DOI 10.1073/pnas.96.12.6660; PANDAK WM, 1991, J BIOL CHEM, V266, P3416; Read MA, 1997, J BIOL CHEM, V272, P2753, DOI 10.1074/jbc.272.5.2753; Rowan BG, 2000, J BIOL CHEM, V275, P4475, DOI 10.1074/jbc.275.6.4475; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Sinal CJ, 2000, CELL, V102, P731, DOI 10.1016/S0092-8674(00)00062-3; Soutoglou E, 2000, MOL CELL, V5, P745, DOI 10.1016/S1097-2765(00)80253-1; STRAVITZ RT, 1993, J BIOL CHEM, V268, P13987; Stravitz RT, 1996, AM J PHYSIOL-GASTR L, V271, pG293, DOI 10.1152/ajpgi.1996.271.2.G293; STRAVITZ RT, 1999, P 15 INT BIL AC M BI; Stroup D, 2000, J LIPID RES, V41, P1; Stroup D, 1997, AM J PHYSIOL-GASTR L, V273, pG508, DOI 10.1152/ajpgi.1997.273.2.G508; Viollet B, 1997, MOL CELL BIOL, V17, P4208, DOI 10.1128/MCB.17.8.4208; Wang DP, 1996, J LIPID RES, V37, P1831; Yamagata K, 1996, NATURE, V384, P458, DOI 10.1038/384458a0; Yuan LW, 2000, J BIOL CHEM, V275, P40946, DOI 10.1074/jbc.M007832200	39	144	147	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					30708	30716		10.1074/jbc.M103270200	http://dx.doi.org/10.1074/jbc.M103270200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11402042	hybrid			2022-12-25	WOS:000170472900018
J	Fringer, J; Grinnell, F				Fringer, J; Grinnell, F			Fibroblast quiescence in floating or released collagen matrices	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; CELL-CYCLE PROGRESSION; SUSTAINED ACTIVATION; SIGNAL-TRANSDUCTION; DOWN-REGULATION; GROWTH-FACTORS; EXPRESSION; ADHESION; PHASE; PHOSPHORYLATION	Fibroblasts in attached collagen matrices proliferate, whereas cells in floating or released matrices become quiescent. Cells in attached matrices had prominent actin stress fibers, indicating that they were under isometric tension, whereas stress fibers were absent from fibroblasts in floating or released matrices. Compared with cells in attached matrices, cells in floating or released matrices showed downregulation of cyclin DI and up-regulation of p27(Kip1) cyclin-dependent kinase inhibitor, and similar changes occurred after the ERK signaling pathway was blocked by UO126 in cells in attached matrices. A different pattern of changes in cell cycle regulatory proteins occurred, however, after serum deprivation or actin cytoskeletal depolymerization by latrunculin B, which did not prevent signaling through the ERK pathway. Therefore, cell quiescence in floating or released collagen matrices could be explained by decreased signaling through the ERK pathway, but these changes were not accounted for by the absence of isometric tension in the cells.	Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Grinnell, F (corresponding author), Univ Texas, SW Med Ctr, Dept Cell Biol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	frederick.grinnell@utsouthwestern.edu			NIAMS NIH HHS [AR41940] Funding Source: Medline; NIGMS NIH HHS [GM31321] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR041940] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031321, R37GM031321] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aplin AE, 2001, J CELL BIOL, V153, P273, DOI 10.1083/jcb.153.2.273; Aplin AE, 1999, CURR OPIN CELL BIOL, V11, P737, DOI 10.1016/S0955-0674(99)00045-9; Assoian RK, 1997, CURR OPIN CELL BIOL, V9, P93, DOI 10.1016/S0955-0674(97)80157-3; Assoian RK, 2001, CURR OPIN GENET DEV, V11, P48, DOI 10.1016/S0959-437X(00)00155-6; BELL E, 1979, P NATL ACAD SCI USA, V76, P1274, DOI 10.1073/pnas.76.3.1274; Bohmer RM, 1996, MOL BIOL CELL, V7, P101; Bosch M, 1998, J BIOL CHEM, V273, P22145, DOI 10.1074/jbc.273.34.22145; Bottazzi ME, 1999, J CELL BIOL, V146, P1255, DOI 10.1083/jcb.146.6.1255; Burack WR, 2000, CURR OPIN CELL BIOL, V12, P211, DOI 10.1016/S0955-0674(99)00078-2; Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425; CHEN QM, 1994, J BIOL CHEM, V269, P26602; Danen EHJ, 2000, J CELL BIOL, V151, P1413, DOI 10.1083/jcb.151.7.1413; Desmouliere A, 1996, MOL CELLULAR BIOL WO, P391; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; ELSDALE T, 1972, J CELL BIOL, V54, P626, DOI 10.1083/jcb.54.3.626; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Fluck J, 1998, J INVEST DERMATOL, V110, P153, DOI 10.1046/j.1523-1747.1998.00095.x; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Grinnell F, 1999, EXP CELL RES, V248, P608, DOI 10.1006/excr.1999.4440; GULLBERG D, 1990, EXP CELL RES, V186, P264, DOI 10.1016/0014-4827(90)90305-T; HALLIDAY NL, 1995, EXP CELL RES, V217, P109, DOI 10.1006/excr.1995.1069; HARRIS AK, 1981, NATURE, V290, P249, DOI 10.1038/290249a0; Henriet P, 2000, P NATL ACAD SCI USA, V97, P10026, DOI 10.1073/pnas.170290997; Huang S, 1999, NAT CELL BIOL, V1, pE131, DOI 10.1038/13043; Huang S, 1998, MOL BIOL CELL, V9, P3179, DOI 10.1091/mbc.9.11.3179; Ingber DE, 1997, ANNU REV PHYSIOL, V59, P575, DOI 10.1146/annurev.physiol.59.1.575; KLEIN CE, 1991, J CELL BIOL, V115, P1427, DOI 10.1083/jcb.115.5.1427; Koyama H, 1996, CELL, V87, P1069, DOI 10.1016/S0092-8674(00)81801-2; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; MELOCHE S, 1992, MOL ENDOCRINOL, V6, P845, DOI 10.1210/me.6.5.845; MOCHITATE K, 1991, EXP CELL RES, V193, P198, DOI 10.1016/0014-4827(91)90556-A; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; Park H, 1998, J BIOL CHEM, V273, P32304, DOI 10.1074/jbc.273.48.32304; Rivard N, 1999, AM J PHYSIOL-CELL PH, V277, pC652, DOI 10.1152/ajpcell.1999.277.4.C652; Rizzo V, 1998, J BIOL CHEM, V273, P26323, DOI 10.1074/jbc.273.41.26323; Roovers K, 2000, BIOESSAYS, V22, P818, DOI 10.1002/1521-1878(200009)22:9<818::AID-BIES7>3.3.CO;2-Y; Rosenfeldt H, 2000, J BIOL CHEM, V275, P3088, DOI 10.1074/jbc.275.5.3088; SCHIRO JA, 1991, CELL, V67, P403, DOI 10.1016/0092-8674(91)90191-Z; Schwartz MA, 1999, CURR OPIN CELL BIOL, V11, P197, DOI 10.1016/S0955-0674(99)80026-X; Seufferlein T, 1996, MOL BIOL CELL, V7, P1865, DOI 10.1091/mbc.7.12.1865; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Somasundaram R, 1996, J BIOL CHEM, V271, P26884, DOI 10.1074/jbc.271.43.26884; SPECTOR I, 1989, CELL MOTIL CYTOSKEL, V13, P127, DOI 10.1002/cm.970130302; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391; ZHU XY, 1999, CRC METH SIG TRANS, P129	50	76	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					31047	31052		10.1074/jbc.M101898200	http://dx.doi.org/10.1074/jbc.M101898200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11410588	hybrid			2022-12-25	WOS:000170472900061
J	Izumi, M; Fujio, Y; Kunisada, K; Negoro, S; Tone, E; Funamoto, M; Osugi, T; Oshima, Y; Nakaoka, Y; Kishimoto, T; Yamauchi-Takihara, K; Hirota, H				Izumi, M; Fujio, Y; Kunisada, K; Negoro, S; Tone, E; Funamoto, M; Osugi, T; Oshima, Y; Nakaoka, Y; Kishimoto, T; Yamauchi-Takihara, K; Hirota, H			Bone morphogenetic protein-2 inhibits serum deprivation-induced apoptosis of neonatal cardiac myocytes through activation of the Smad1 pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE/THREONINE KINASE RECEPTORS; MYOCARDIAL-CELL HYPERTROPHY; ADULT VENTRICULAR MYOCYTES; GROWTH-FACTOR-I; GENE-EXPRESSION; BCL-X; HEART-FAILURE; ALPHA(1)-ADRENERGIC RECEPTOR; SIGNAL-TRANSDUCTION; PARACRINE MECHANISM	Bone morphogenetic protein (BMP)-2 has been shown to induce ectopic expression of cardiac transcription factors and beating cardiomyocytes in non-precardiac mesodermal cells, suggesting that BMP-2 is an inductive signaling molecule that participates in cardiac development. However, direct evidence of the effects of BMP-2 on cardiac myocytes has not been reported. To examine the role of BMP-2 and its receptors, we studied the ability of BMP-2 to promote survival of isolated neonatal rat cardiac myocytes. BMP receptors IA IB, and II and activin receptor I were found to be expressed in myocytes, and BMP-2 phosphorylated Smad1 and p38 MAPK. Interestingly, BMP-2 promoted survival and inhibited apoptosis of serum-deprived myocytes, although it did not strongly induce hypertrophic growth. To explore the mechanisms for this protective effect, an adenovirus-based vector system was used. Similar to BMP-2, Smad1 promoted survival that was repressed by Smad6. Moreover, BMP-2 and Smad1 enhanced the expression of the anti-apoptotic molecule Bcl-x(L). Antisense oligonucleotides to bcl-x(L) attenuated the survival effected by BMP-2. Overall, our findings suggest that BMP-2 prevents apoptosis of myocytes by induction of Bcl-x(L) via a Smad1 pathway and might be a novel survival factor without any hypertrophic effect on myocytes.	Osaka Univ, Grad Sch Med, Dept Mol Med, Suita, Osaka 5650871, Japan	Osaka University	Hirota, H (corresponding author), Osaka Univ, Grad Sch Med, Dept Mol Med, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.		Kishimoto, Tadamitsu/C-8470-2009; Fujio, Yasushi/H-3421-2017	Fujio, Yasushi/0000-0003-0828-2930				Ackermann EJ, 1999, J BIOL CHEM, V274, P11245, DOI 10.1074/jbc.274.16.11245; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; BERRIDGE MV, 1993, ARCH BIOCHEM BIOPHYS, V303, P474, DOI 10.1006/abbi.1993.1311; Bhatia M, 1999, J EXP MED, V189, P1139, DOI 10.1084/jem.189.7.1139; BOGOYEVITCH MA, 1994, J BIOL CHEM, V269, P1110; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BUERKE M, 1995, P NATL ACAD SCI USA, V92, P8031, DOI 10.1073/pnas.92.17.8031; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORY AH, 1991, CANCER COMMUN, V3, P207, DOI 10.3727/095535491820873191; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Fujii M, 1999, MOL BIOL CELL, V10, P3801, DOI 10.1091/mbc.10.11.3801; Fujio Y, 1997, J CLIN INVEST, V99, P2898, DOI 10.1172/JCI119484; GRAHAM A, 1994, NATURE, V372, P684, DOI 10.1038/372684a0; Haunstetter A, 1998, CIRC RES, V82, P1111, DOI 10.1161/01.RES.82.11.1111; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hirota H, 1999, CELL, V97, P189, DOI 10.1016/S0092-8674(00)80729-1; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Iantosca MR, 1999, J NEUROSCI RES, V56, P248; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; ITO H, 1991, CIRC RES, V69, P209, DOI 10.1161/01.RES.69.1.209; IWAKI K, 1990, J BIOL CHEM, V265, P13809; Iwasaki S, 1999, J BIOL CHEM, V274, P26503, DOI 10.1074/jbc.274.37.26503; IZUMO S, 1988, P NATL ACAD SCI USA, V85, P339, DOI 10.1073/pnas.85.2.339; Kajstura J, 1997, J MOL CELL CARDIOL, V29, P859, DOI 10.1006/jmcc.1996.0333; Kaye D, 1996, J CLIN INVEST, V97, P281, DOI 10.1172/JCI118414; Kimura N, 2000, J BIOL CHEM, V275, P17647, DOI 10.1074/jbc.M908622199; Kunisada K, 2000, P NATL ACAD SCI USA, V97, P315, DOI 10.1073/pnas.97.1.315; Kunisada K, 1996, CIRCULATION, V94, P2626, DOI 10.1161/01.CIR.94.10.2626; Le-Niculescu H, 1999, MOL CELL BIOL, V19, P751; Li Q, 1997, J CLIN INVEST, V100, P1991, DOI 10.1172/JCI119730; Massague J, 1996, CANCER SURV, V27, P41; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Mehler MF, 1997, TRENDS NEUROSCI, V20, P309, DOI 10.1016/S0166-2236(96)01046-6; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; Negoro S, 2001, CIRCULATION, V103, P555, DOI 10.1161/01.CIR.103.4.555; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; NOHNO T, 1995, J BIOL CHEM, V270, P22522, DOI 10.1074/jbc.270.38.22522; Oh H, 1998, J BIOL CHEM, V273, P9703, DOI 10.1074/jbc.273.16.9703; Ramirez MT, 1997, J BIOL CHEM, V272, P14057, DOI 10.1074/jbc.272.22.14057; REDDI AH, 1994, CURR OPIN GENET DEV, V4, P737, DOI 10.1016/0959-437X(94)90141-O; Roelen BAJ, 1997, INT J DEV BIOL, V41, P541; Rokosh DG, 1996, J BIOL CHEM, V271, P5839, DOI 10.1074/jbc.271.10.5839; ROSEN V, 1992, TRENDS GENET, V8, P97, DOI 10.1016/0168-9525(92)90063-A; ROSENZWEIG BL, 1995, P NATL ACAD SCI USA, V92, P7632, DOI 10.1073/pnas.92.17.7632; SADOSHIMA J, 1993, EMBO J, V12, P1681, DOI 10.1002/j.1460-2075.1993.tb05813.x; Sheng ZL, 1997, J BIOL CHEM, V272, P5783, DOI 10.1074/jbc.272.9.5783; Shiraiwa N, 1996, J BIOL CHEM, V271, P13258, DOI 10.1074/jbc.271.22.13258; Shirakabe K, 1997, J BIOL CHEM, V272, P8141, DOI 10.1074/jbc.272.13.8141; SHUBEITA HE, 1990, J BIOL CHEM, V265, P20555; Singh K, 1996, J BIOL CHEM, V271, P1111, DOI 10.1074/jbc.271.2.1111; tenDijke P, 1996, CURR OPIN CELL BIOL, V8, P139; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; Varley JE, 1996, EXP NEUROL, V140, P84, DOI 10.1006/exnr.1996.0118; WANG ZH, 1995, J IMMUNOL, V155, P3722; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yao ZB, 1999, J BIOL CHEM, V274, P2118, DOI 10.1074/jbc.274.4.2118; Yokouchi Y, 1996, DEVELOPMENT, V122, P3725; Zannad F, 2000, CIRCULATION, V102, P2700, DOI 10.1161/01.CIR.102.22.2700; Zhang D, 2000, NAT MED, V6, P556, DOI 10.1038/75037; Zhao YY, 1998, J BIOL CHEM, V273, P10261, DOI 10.1074/jbc.273.17.10261; Zou HY, 1996, SCIENCE, V272, P738, DOI 10.1126/science.272.5262.738	62	67	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					31133	31141		10.1074/jbc.M101463200	http://dx.doi.org/10.1074/jbc.M101463200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11408477	hybrid			2022-12-25	WOS:000170472900072
J	Li, Y; Foran, P; Lawrence, G; Mohammed, N; Chan-Kwo-Chion, CKN; Lisk, G; Aoki, R; Dolly, O				Li, Y; Foran, P; Lawrence, G; Mohammed, N; Chan-Kwo-Chion, CKN; Lisk, G; Aoki, R; Dolly, O			Recombinant forms of tetanus toxin engineered for examining and exploiting neuronal trafficking pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETROGRADE AXONAL-TRANSPORT; BOTULINUM NEUROTOXIN-A; CENTRAL-NERVOUS-SYSTEM; HEAVY-CHAIN; NEUROTRANSMITTER RELEASE; INTERCHAIN DISULFIDE; TRANSMITTER RELEASE; LIMITED PROTEOLYSIS; ESCHERICHIA-COLI; LIGHT-CHAIN	Tetanus toxin is a fascinating, multifunctional protein that binds to peripheral neurons, undergoes retrograde transport and trans-synaptic transfer to central inhibitory neurons where it blocks transmitter release, thereby, causing spastic paralysis. As a pre-requisite for exploiting its unique trafficking properties, a novel recombinant single chain was expressed at a high level in Eacherichia coli as a soluble, easily purifiable protein. It could be activated with enterokinase to produce a di-chain that matched native toxin in terms of proteolytic and neuroinhibitory activities, as well as induction of spastic paralysis in mice. Importantly, nicking was not essential for protease activity. Substitution of GIU234 by Ala created a protease-deficient atoxic form, which blocked the neuroparalytic action of tetanus toxin in vitro, with equal potency to its heavy chain; but, the mutant proved > 30-fold more potent in preventing tetanus in mice. This observation unveils differences between the intoxication processes resulting from retrograde transport of toxin in vivo and its local uptake into peripheral or central nerves in vitro, dispelling a popularly held belief that the heavy chain is the sole determinant for efficient trafficking. Thus, this innocuous mutant may be a useful vehicle, superior to the heavy chain, for drug delivery to central neurons.	Univ London Imperial Coll Sci Technol & Med, Dept Biochem, London SW7 2AZ, England; Allergan Pharmaceut Inc, Irvine, CA 92623 USA	Imperial College London; AbbVie; Allergan	Dolly, O (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Biochem, London SW7 2AZ, England.		Dolly, Oliver/G-1532-2012; Dolly, Oliver/ABH-6677-2020; Lawrence, Gary/F-3949-2012	Dolly, Oliver/0000-0002-0861-5320; Dolly, Oliver/0000-0002-0861-5320; 				BIZZINI B, 1977, J NEUROCHEM, V28, P529, DOI 10.1111/j.1471-4159.1977.tb10423.x; BIZZINI B, 1981, BRAIN RES, V210, P291, DOI 10.1016/0006-8993(81)90902-1; CAMBRAYDEAKIN MA, 1995, NEURAL CELL CULTURE, P3; Coen L, 1997, P NATL ACAD SCI USA, V94, P9400, DOI 10.1073/pnas.94.17.9400; DanielsHolgate PU, 1996, J NEUROSCI RES, V44, P263, DOI 10.1002/(SICI)1097-4547(19960501)44:3<263::AID-JNR7>3.0.CO;2-E; DEPAIVA A, 1993, J BIOL CHEM, V268, P20838; DEPAIVA A, 1993, J NEUROCHEM, V61, P2338, DOI 10.1111/j.1471-4159.1993.tb07482.x; Dolly J. O., 1990, NEUROMUSCULAR TRANSM, P107; DOLLY JO, 1994, SEMIN NEUROSCI, V6, P149; FAIRWEATHER NF, 1993, FEBS LETT, V323, P218, DOI 10.1016/0014-5793(93)81343-X; FIGUEIREDO D, 1995, INFECT IMMUN, V63, P3218, DOI 10.1128/IAI.63.8.3218-3221.1995; Figueiredo DM, 1997, EXP NEUROL, V145, P546, DOI 10.1006/exnr.1997.6490; FISHMAN PS, 1990, J NEUROL SCI, V98, P311, DOI 10.1016/0022-510X(90)90272-O; Fishman PS, 1999, NAT TOXINS, V7, P151, DOI 10.1002/(SICI)1522-7189(199907/08)7:4<151::AID-NT51>3.3.CO;2-B; FORAN P, 1994, BIOCHEMISTRY-US, V33, P15365, DOI 10.1021/bi00255a017; FRANCIS JW, 1995, J BIOL CHEM, V270, P15434, DOI 10.1074/jbc.270.25.15434; GALLO V, 1982, P NATL ACAD SCI-BIOL, V79, P7919, DOI 10.1073/pnas.79.24.7919; HABERMANN E, 1991, N-S ARCH PHARMACOL, V343, P323; HABIG WH, 1983, FRONTIERS BIOCH STUD, P463; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; Herreros J, 2000, J NEUROCHEM, V74, P1941, DOI 10.1046/j.1471-4159.2000.0741941.x; HOGY B, 1992, TOXICON, V30, P63, DOI 10.1016/0041-0101(92)90502-V; KRIEGLSTEIN KG, 1991, EUR J BIOCHEM, V202, P41, DOI 10.1111/j.1432-1033.1991.tb16342.x; Lacy DB, 1998, NAT STRUCT BIOL, V5, P898, DOI 10.1038/2338; Lalli G, 1999, J CELL SCI, V112, P2715; Li Y, 1999, J BIOCHEM, V125, P1200, DOI 10.1093/oxfordjournals.jbchem.a022404; LI Y, 1994, BIOCHEMISTRY-US, V33, P7014, DOI 10.1021/bi00188a034; LINK E, 1992, BIOCHEM BIOPH RES CO, V189, P1017, DOI 10.1016/0006-291X(92)92305-H; MAISEY EA, 1988, EUR J BIOCHEM, V177, P683, DOI 10.1111/j.1432-1033.1988.tb14423.x; MATSUDA M, 1982, BIOCHEM BIOPH RES CO, V104, P799, DOI 10.1016/0006-291X(82)90708-2; MONTECUCCO C, 1986, TRENDS BIOCHEM SCI, V11, P314, DOI 10.1016/0968-0004(86)90282-3; MONTECUCCO C, 1993, TRENDS BIOCHEM SCI, V18, P324, DOI 10.1016/0968-0004(93)90065-U; PRICE DL, 1975, SCIENCE, V188, P945, DOI 10.1126/science.49080; SCHIAVO G, 1990, INFECT IMMUN, V58, P4136, DOI 10.1128/IAI.58.12.4136-4141.1990; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; Schiavo G, 2000, PHYSIOL REV, V80, P717, DOI 10.1152/physrev.2000.80.2.717; SCHIAVO G, 1991, EUR J BIOCHEM, V199, P705, DOI 10.1111/j.1432-1033.1991.tb16174.x; SCHWAB ME, 1979, J CELL BIOL, V82, P798, DOI 10.1083/jcb.82.3.798; SIMPSON LL, 1986, ANNU REV PHARMACOL, V26, P427, DOI 10.1146/annurev.pa.26.040186.002235; STOCKEL K, 1975, BRAIN RES, V99, P1, DOI 10.1016/0006-8993(75)90604-6; Ugolini Gabriella, 1995, P293, DOI 10.1016/B978-012397570-6/50019-8; WELLER U, 1989, EUR J BIOCHEM, V182, P649, DOI 10.1111/j.1432-1033.1989.tb14874.x; [No title captured]	43	27	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					31394	31401		10.1074/jbc.M103517200	http://dx.doi.org/10.1074/jbc.M103517200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11402045	hybrid			2022-12-25	WOS:000170472900104
J	Ruiz-Echevarria, MJ; Munshi, R; Tomback, J; Kinzy, TG; Peltz, SW				Ruiz-Echevarria, MJ; Munshi, R; Tomback, J; Kinzy, TG; Peltz, SW			Characterization of a general stabilizer element that blocks deadenylation-dependent mRNA decay	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIS-ACTING SEQUENCES; BINDING PROTEIN; CODING REGION; YEAST; TRANSLATION; DEGRADATION; MFA2; TRANSCRIPTS; TURNOVER; SEGMENT	mRNA degradation is a regulated process that can play an important role in determining the level of expression of specific genes. The rate at which a specific mRNA is degraded depends largely on specific cis-acting sequences located throughout the transcript. cis-Acting destabilizer sequences that promote increased rates of decay have been identified in several short-lived mRNAs. However, little is known about elements that promote stability, known as stabilizer elements (STEs), and how they function. The work presented here describes the characterization of a STE in the PGK1 transcript. The PGK1 stabilizer element (P-STE) has been delineated to a 64-nucleotide sequence from the coding region that can stabilize a chimeric transcript containing the instability elements from the 3 ' -untranslated region of the MFA2 transcript. The P-STE is located within the PGK1 coding region and functions when located in the translated portion of the transcript and at a minimum distance from the W-untranslated region. These results further support the link between translation and mRNA degradation. A conserved sequence in the TEF1/2 transcript has been identified that also functions as a STE, suggesting that this sequence element maybe a general stability determinant found in other yeast mRNAs.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Mol Genet & Microbiol, Piscataway, NJ 08854 USA; Canc Inst New Jersey, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey	Kinzy, TG (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Mol Genet & Microbiol, 675 Hoes Ln, Piscataway, NJ 08854 USA.	kinzytg@umdnj.edu; peltz@umdnj.edu		Ruiz Echevarria, Maria Jesus/0000-0001-7133-9982; Kinzy, Terri/0000-0003-1394-9226	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058276, R01GM057483] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM58276, GM57483, R01 GM057483] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson JSJ, 1998, EMBO J, V17, P1497, DOI 10.1093/emboj/17.5.1497; AUSUBEL FM, 1992, CURRENT PROTOCOLS MO, V2; Barnes CA, 1998, NUCLEIC ACIDS RES, V26, P2433, DOI 10.1093/nar/26.10.2433; BARNES CA, 1993, EMBO J, V12, P3323, DOI 10.1002/j.1460-2075.1993.tb06002.x; BARNES CA, 1995, MOL GEN GENET, V246, P619, DOI 10.1007/BF00298969; BEELMAN CA, 1994, J BIOL CHEM, V269, P9687; BEELMAN CA, 1995, CELL, V81, P179, DOI 10.1016/0092-8674(95)90326-7; Caponigro G, 1996, NUCLEIC ACIDS RES, V24, P4304, DOI 10.1093/nar/24.21.4304; CAPONIGRO G, 1993, MOL CELL BIOL, V13, P5141, DOI 10.1128/MCB.13.9.5141; CEREGHINO GP, 1995, MOL BIOL CELL, V6, P1125, DOI 10.1091/mbc.6.9.1125; DECKER CJ, 1993, GENE DEV, V7, P1632, DOI 10.1101/gad.7.8.1632; Gonzalez CI, 1996, J BIOL CHEM, V271, P25801, DOI 10.1074/jbc.271.42.25801; Grosset C, 2000, CELL, V103, P29, DOI 10.1016/S0092-8674(00)00102-1; HAGAN KW, 1995, MOL CELL BIOL, V15, P809; HEATON B, 1992, NUCLEIC ACIDS RES, V20, P5365, DOI 10.1093/nar/20.20.5365; Hennigan AN, 1996, MOL CELL BIOL, V16, P3833; HERRICK D, 1992, GENE, V114, P35, DOI 10.1016/0378-1119(92)90704-S; HERRICK D, 1990, MOL CELL BIOL, V10, P2269, DOI 10.1128/MCB.10.5.2269; HERSKOWITZ I, 1991, METHOD ENZYMOL, V194, P132; Holcik M, 1997, P NATL ACAD SCI USA, V94, P2410, DOI 10.1073/pnas.94.6.2410; HSU CL, 1993, MOL CELL BIOL, V13, P4826, DOI 10.1128/MCB.13.8.4826; Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401; LaGrandeur T, 1999, RNA, V5, P420, DOI 10.1017/S1355838299981748; Linz B, 1997, J BIOL CHEM, V272, P9131; MUHLRAD D, 1992, GENE DEV, V6, P2100, DOI 10.1101/gad.6.11.2100; MUHLRAD D, 1994, GENE DEV, V8, P855, DOI 10.1101/gad.8.7.855; MUHLRAD D, 1994, NATURE, V370, P578, DOI 10.1038/370578a0; MYSLINSKI E, 1990, SCIENCE, V247, P1213, DOI 10.1126/science.1690452; PARKER R, 1990, P NATL ACAD SCI USA, V87, P2780, DOI 10.1073/pnas.87.7.2780; Paulding WR, 1999, J BIOL CHEM, V274, P2532, DOI 10.1074/jbc.274.4.2532; PELTZ SW, 1993, GENE DEV, V7, P1737, DOI 10.1101/gad.7.9.1737; PELTZ SW, 1993, CONTROL MRNA STABILI, P291; PRESUTTI C, 1995, EMBO J, V14, P4022, DOI 10.1002/j.1460-2075.1995.tb00073.x; Rose M. D., 1990, METHODS YEAST GENETI, P97; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; Ruiz-Echevarria MJ, 2000, CELL, V101, P741, DOI 10.1016/S0092-8674(00)80886-7; Ruiz-Echevarria MJ, 1998, EMBO J, V17, P575, DOI 10.1093/emboj/17.2.575; SAMBROOK J, 1989, MOL CLONINB LAB MANU; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; Stefanovic B, 1997, MOL CELL BIOL, V17, P5201, DOI 10.1128/MCB.17.9.5201; SUROSKY RT, 1992, MOL CELL BIOL, V12, P3948, DOI 10.1128/MCB.12.9.3948; THEODORAKIS NG, 1996, TRANSLATIONAL CONTRO, P631; VREKEN P, 1992, MOL CELL BIOL, V12, P2986, DOI 10.1128/MCB.12.7.2986; WANG XM, 1995, MOL CELL BIOL, V15, P1769; Wang ZR, 1999, MOL CELL BIOL, V19, P4552; WEISS IM, 1994, MOL CELL BIOL, V14, P8123, DOI 10.1128/MCB.14.12.8123; Zuk D, 1998, EMBO J, V17, P2914, DOI 10.1093/emboj/17.10.2914	47	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					30995	31003		10.1074/jbc.M010833200	http://dx.doi.org/10.1074/jbc.M010833200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11423548	hybrid			2022-12-25	WOS:000170472900055
J	Vabulas, RM; Ahmad-Nejad, P; da Costa, C; Miethke, T; Kirschning, CJ; Hacker, H; Wagner, H				Vabulas, RM; Ahmad-Nejad, P; da Costa, C; Miethke, T; Kirschning, CJ; Hacker, H; Wagner, H			Endocytosed HSP60s use toll-like receptor 2 (TLR2) and TLR4 to activate the Toll/interleukin-1 receptor signaling pathway in innate immune cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; NF-KAPPA-B; ANTIGEN-PRESENTING CELLS; GP96 INDUCES MATURATION; DENDRITIC CELLS; CUTTING EDGE; MEDIATED ENDOCYTOSIS; WALL COMPONENTS; CPG-DNA; ADAPTER	Heat shock proteins (HSPs) require no adjuvant to confer immunogenicity to bound peptides, as if they possessed an intrinsic "danger" signature. To understand the proinflammatory nature of HSP, we analyzed signaling induced by human and chlamydial HSP60. We show that both HSP60s activate the stress-activated protein kinases p38 and JNK1/2, the mitogen-activated protein kinases ERK1/2, and the I-kappaB kinase (IKK). Activation of JNK and IKK proceeds via the Toll/IL-1 receptor signaling pathway involving MyD88 and TRAF6. Human fibroblasts transfected with TLR2 or TLR4 plus MD-2 gain responsiveness to HSP60, while TLR2- or TLR4-defective cells display impaired responses. Initiation of signaling requires endocytosis of HSP60 that is effectively inhibited by serum component(s). The results revealed that adjuvanticity of HSP60 operates similar to that of classical pathogen-derived ligands.	Tech Univ Munich, Inst Med Microbiol Immunol & Hyg, D-81675 Munich, Germany	Technical University of Munich	Wagner, H (corresponding author), Tech Univ Munich, Inst Med Microbiol Immunol & Hyg, Trogerstr 9, D-81675 Munich, Germany.		Haecker, Hans/F-6826-2013; Vabulas, R. Martin/D-3506-2011	Haecker, Hans/0000-0001-5971-0451; 				Adachi O, 1998, IMMUNITY, V9, P143, DOI 10.1016/S1074-7613(00)80596-8; Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; ARNOLD D, 1995, J EXP MED, V182, P885, DOI 10.1084/jem.182.3.885; Arnold-Schild D, 1999, J IMMUNOL, V162, P3757; Asea A, 2000, NAT MED, V6, P435, DOI 10.1038/74697; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Basu S, 2000, INT IMMUNOL, V12, P1539, DOI 10.1093/intimm/12.11.1539; Binder RJ, 2000, J IMMUNOL, V165, P6029, DOI 10.4049/jimmunol.165.11.6029; Binder RJ, 2000, NAT IMMUNOL, V1, P151, DOI 10.1038/77835; Binder RJ, 2000, J IMMUNOL, V165, P2582, DOI 10.4049/jimmunol.165.5.2582; Blachere NE, 1997, J EXP MED, V186, P1315, DOI 10.1084/jem.186.8.1315; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Castellino F, 2000, J EXP MED, V191, P1957, DOI 10.1084/jem.191.11.1957; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen W, 1999, J IMMUNOL, V162, P3212; DAVIES PJA, 1980, NATURE, V283, P162, DOI 10.1038/283162a0; Gallucci S, 1999, NAT MED, V5, P1249, DOI 10.1038/15200; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Hacker H, 2000, J EXP MED, V192, P595, DOI 10.1084/jem.192.4.595; Hacker H, 1999, EMBO J, V18, P6973, DOI 10.1093/emboj/18.24.6973; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Hirschfeld M, 2000, J IMMUNOL, V165, P618, DOI 10.4049/jimmunol.165.2.618; Karin M, 2000, SEMIN IMMUNOL, V12, P85, DOI 10.1006/smim.2000.0210; Kashiwada M, 1998, J EXP MED, V187, P237, DOI 10.1084/jem.187.2.237; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; Kol A, 1998, CIRCULATION, V98, P300, DOI 10.1161/01.CIR.98.4.300; Kol A, 2000, J IMMUNOL, V164, P13, DOI 10.4049/jimmunol.164.1.13; Kol A, 1999, J CLIN INVEST, V103, P571, DOI 10.1172/JCI5310; Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015; Lutz MB, 1999, J IMMUNOL METHODS, V223, P77, DOI 10.1016/S0022-1759(98)00204-X; Medzhitov R, 1998, MOL CELL, V2, P253, DOI 10.1016/S1097-2765(00)80136-7; Moroi Y, 2000, P NATL ACAD SCI USA, V97, P3485, DOI 10.1073/pnas.070550797; Nieland TJF, 1996, P NATL ACAD SCI USA, V93, P6135, DOI 10.1073/pnas.93.12.6135; Ohashi K, 2000, J IMMUNOL, V164, P558, DOI 10.4049/jimmunol.164.2.558; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Riezman H, 1997, CELL, V91, P731, DOI 10.1016/S0092-8674(00)80461-4; Sauter B, 2000, J EXP MED, V191, P423, DOI 10.1084/jem.191.3.423; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406; Singh-Jasuja H, 2000, EUR J IMMUNOL, V30, P2211, DOI 10.1002/1521-4141(2000)30:8<2211::AID-IMMU2211>3.0.CO;2-0; Srivastava PK, 1998, IMMUNITY, V8, P657, DOI 10.1016/S1074-7613(00)80570-1; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Takeuchi O, 2000, INT IMMUNOL, V12, P113, DOI 10.1093/intimm/12.1.113; UDONO H, 1993, J EXP MED, V178, P1391, DOI 10.1084/jem.178.4.1391; WEINSTEIN SL, 1992, J BIOL CHEM, V267, P14955; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1	49	631	670	2	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					31332	31339		10.1074/jbc.M103217200	http://dx.doi.org/10.1074/jbc.M103217200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11402040	hybrid			2022-12-25	WOS:000170472900097
J	Vasiljeva, L; Valmu, L; Kaariainen, L; Merits, A				Vasiljeva, L; Valmu, L; Kaariainen, L; Merits, A			Site-specific protease activity of the carboxyl-terminal domain of semliki forest virus replicase protein nsP2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM DODECYL-SULFATE; STRAND RNA-SYNTHESIS; SINDBIS VIRUS; ENCODED PROTEINASES; MINUS-STRAND; NONSTRUCTURAL POLYPROTEINS; GEL-ELECTROPHORESIS; CRYSTAL-STRUCTURE; NS4A COFACTOR; NS3 PROTEASE	The virus-specific components (nsP1-nsP4) of Semliki Forest virus RNA polymerase are synthesized as a large polyprotein (P1234), which is cleaved by a virus-encoded protease. Based on mutagenesis studies, nsP2 has been implicated as the protease moiety of P1234. Here, we show that purified nsP2 (799 amino acids) and its C-terminal domain Pro39 (amino acids 459-799) specifically process P1234 and its cleavage intermediates. Analysis of cleavage products of in vitro synthesized P12, P23, and P34 revealed cleavages at sites 1/2,2/3, and 3/4. The cleavage regions of P1/2, P2/3, and P3/4 were expressed as thioredoxin fusion proteins (Trx12, Trx23, and Trx34), containing similar to 20 amino acids on each side of the cleavage sites. After exposure of these purified fusion proteins to nsP2 or Pro39, the reaction products were analyzed by SDS-polyacrylamide gel electrophoresis, mass spectrometry, and amino-terminal sequencing. The expected amino termini of nsP2, nsP3, and nsP4 were detected. The cleavage at 3/4 site was most efficient, whereas cleavage at 1/2 site required 5000-fold more of Pro39, and 2/3 site was almost resistant to cleavage. The activity of Pro39 was inhibited by N-ethylmaleimide, Zn2+, and Cu2+, but not by EDTA, phenylmethylsulfonyl fluoride, or pepstatin, in accordance with the thiol proteinase nature of nsP2.	Univ Helsinki, Bioctr Viikki, Inst Biotechnol, Program Cellular Biotechnol, FIN-00014 Helsinki, Finland	University of Helsinki	Kaariainen, L (corresponding author), Univ Helsinki, Bioctr Viikki, Inst Biotechnol, Program Cellular Biotechnol, POB 56, FIN-00014 Helsinki, Finland.	leevi.kaariainen@helsinki.fi	Vasilieva, Lidia/AAU-1473-2020; Merits, Andres/H-3125-2015	Merits, Andres/0000-0001-8193-0071; Vasiljeva, Lidia/0000-0002-1244-8772				Beynon R.J, 1989, PROTEOLYTIC ENZYMES, P83; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; de Cedron MG, 1999, FEBS LETT, V448, P19, DOI 10.1016/S0014-5793(99)00321-X; DING MX, 1989, VIROLOGY, V171, P280, DOI 10.1016/0042-6822(89)90539-4; FAILLA C, 1994, J VIROL, V68, P3753, DOI 10.1128/JVI.68.6.3753-3760.1994; Frey TK, 1999, ENCY VIROLOGY, P1592; GORBALENYA AE, 1991, FEBS LETT, V288, P201, DOI 10.1016/0014-5793(91)81034-6; HARDY WR, 1989, J VIROL, V63, P4653, DOI 10.1128/JVI.63.11.4653-4664.1989; KAARIAINEN L, 1987, J CELL SCI, P231; KALKKINEN N, 1981, VIROLOGY, V113, P188, DOI 10.1016/0042-6822(81)90147-1; KALKKINEN N, 1986, ADV METHODS PROTEIN, P194; KERANEN S, 1983, J VIROL, V47, P505; Kim JL, 1996, CELL, V87, P343, DOI 10.1016/S0092-8674(00)81351-3; Kujala P, 2001, J VIROL, V75, P3873, DOI 10.1128/JVI.75.8.3873-3884.2001; LAWSON MA, 1991, P NATL ACAD SCI USA, V88, P9919, DOI 10.1073/pnas.88.22.9919; LEMM JA, 1993, J VIROL, V67, P1905, DOI 10.1128/JVI.67.4.1905-1915.1993; LEMM JA, 1993, J VIROL, V67, P1916, DOI 10.1128/JVI.67.4.1916-1926.1993; LEMM JA, 1994, EMBO J, V13, P2925, DOI 10.1002/j.1460-2075.1994.tb06587.x; LIN C, 1995, P NATL ACAD SCI USA, V92, P7622, DOI 10.1073/pnas.92.17.7622; Love RA, 1996, CELL, V87, P331, DOI 10.1016/S0092-8674(00)81350-1; Merits A, 2001, J GEN VIROL, V82, P765, DOI 10.1099/0022-1317-82-4-765; Moini M, 1998, J AM SOC MASS SPECTR, V9, P977, DOI 10.1016/S1044-0305(98)00079-8; PERANEN J, 1990, J VIROL, V64, P1888; PERANEN J, 1993, J HISTOCHEM CYTOCHEM, V41, P447, DOI 10.1177/41.3.8429208; RIKKONEN M, 1992, VIROLOGY, V189, P462, DOI 10.1016/0042-6822(92)90570-F; Rikkonen M, 1996, VIROLOGY, V218, P352, DOI 10.1006/viro.1996.0204; RIKKONEN M, 1994, J VIROL, V68, P5804, DOI 10.1128/JVI.68.9.5804-5810.1994; Ryan MD, 1998, J GEN VIROL, V79, P947, DOI 10.1099/0022-1317-79-5-947; Ryan MD, 1997, J GEN VIROL, V78, P699, DOI 10.1099/0022-1317-78-4-699; SAWICKI DL, 1980, J VIROL, V34, P108, DOI 10.1128/JVI.34.1.108-118.1980; SAWICKI DL, 1985, VIROLOGY, V144, P20, DOI 10.1016/0042-6822(85)90301-0; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schlesinger MJ, 1999, ENCY VIROLOGY, P1656; Shimizu Y, 1996, J VIROL, V70, P127, DOI 10.1128/JVI.70.1.127-132.1996; SHIRAKO Y, 1990, VIROLOGY, V177, P54, DOI 10.1016/0042-6822(90)90459-5; SHIRAKO Y, 1994, J VIROL, V68, P1874, DOI 10.1128/JVI.68.3.1874-1885.1994; STRAUSS EG, 1992, VIROLOGY, V191, P932, DOI 10.1016/0042-6822(92)90268-T; STRAUSS JH, 1994, MICROBIOL REV, V58, P491, DOI 10.1128/MMBR.58.3.491-562.1994; Strauss JH, 1990, SEMIN VIROL, V1, P347; Suopanki J, 1998, J GEN VIROL, V79, P309, DOI 10.1099/0022-1317-79-2-309; ten Dam E, 1999, J GEN VIROL, V80, P1879, DOI 10.1099/0022-1317-80-8-1879; Vasiljeva L, 2000, J BIOL CHEM, V275, P17281, DOI 10.1074/jbc.M910340199; YU FS, 1991, VIROLOGY, V182, P615; Ziebuhr J, 2000, J GEN VIROL, V81, P853, DOI 10.1099/0022-1317-81-4-853	45	66	69	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					30786	30793		10.1074/jbc.M104786200	http://dx.doi.org/10.1074/jbc.M104786200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11410598	hybrid			2022-12-25	WOS:000170472900029
J	Zolman, BK; Monroe-Augustus, M; Thompson, B; Hawes, JW; Krukenberg, KA; Matsuda, SPT; Bartel, B				Zolman, BK; Monroe-Augustus, M; Thompson, B; Hawes, JW; Krukenberg, KA; Matsuda, SPT; Bartel, B			chy1, an Arabidopsis mutant with impaired beta-oxidation, is defective in a peroxisomal beta-hydroxyisobutyryl-CoA hydrolase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID DEGRADATION; MOLECULAR CHARACTERIZATION; INDOLE-3-BUTYRIC ACID; RESISTANT MUTANTS; PLANT; DEHYDROGENASE; PURIFICATION; COENZYME; CARBOXYLASE; METABOLISM	The Arabidopsis chy1 mutant is resistant to indole-3-butyric acid, a naturally occurring form of the plant hormone auxin. Because the mutant also has defects in peroxisomal beta -oxidation, this resistance presumably results from a reduced conversion of indole-3-butyric acid to indole-3-acetic acid. We have cloned CHY1, which appears to encode a peroxisomal protein 43% identical to a mammalian valine catabolic enzyme that hydrolyzes beta -hydroxyisobutyryl-CoA. We demonstrated that a human beta -hydroxyisobutyryl-CoA hydrolase functionally complements chy1 when redirected from the mitochondria to the peroxisomes. We expressed CHY1 as a glutathione S-transferase (GST) fusion protein and demonstrated that purified GST-CHY1 hydrolyzes beta -hydroxyisobutyryl-CoA. Mutagenesis studies showed that a glutamate that is catalytically essential in homologous enoyl-CoA hydratases was also essential in CHY1. Mutating a residue that is differentially conserved between hydrolases and hydratases established that this position is relevant to the catalytic distinction between the enzyme classes. It is likely, that CHY1 acts in peroxisomal valine catabolism and that accumulation of a toxic intermediate, methacrylyl-CoA, causes the altered beta -oxidation phenotypes of the chy1 mutant. Our results support the hypothesis that the energy-intensive sequence unique to valine catabolism, where an intermediate CoA ester is hydrolyzed and a new CoA ester is formed two steps later, avoids methacrylyl-CoA accumulation.	Rice Univ, Dept Biochem & Cell Biol, Houston, TX 77005 USA; Rice Univ, Dept Chem, Houston, TX 77005 USA; Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA	Rice University; Rice University; Indiana University System; Indiana University-Purdue University Indianapolis	Bartel, B (corresponding author), Rice Univ, Dept Biochem & Cell Biol, 6100 S Main St, Houston, TX 77005 USA.	bartel@rice.edu	Bartel, Bonnie/O-8119-2019; Bartel, Bonnie/D-3550-2011	Bartel, Bonnie/0000-0002-6367-346X; Bartel, Bonnie/0000-0002-6367-346X; Thompson, Beth/0000-0002-5358-0796				Anderson MD, 1998, PLANT PHYSIOL, V118, P1127, DOI 10.1104/pp.118.4.1127; Ausubel F., 1999, CURRENT PROTOCOLS MO; BALDET P, 1992, PLANT PHYSIOL, V99, P450, DOI 10.1104/pp.99.2.450; BELL CJ, 1994, GENOMICS, V19, P137, DOI 10.1006/geno.1994.1023; Belshaw PJ, 1999, SCIENCE, V284, P486, DOI 10.1126/science.284.5413.486; BEVAN M, 1984, NUCLEIC ACIDS RES, V12, P8711, DOI 10.1093/nar/12.22.8711; BROWN GK, 1982, PEDIATRICS, V70, P532; Brown JWS, 1996, PLANT MOL BIOL, V32, P531, DOI 10.1007/BF00019105; CELENZA JL, 1995, GENE DEV, V9, P2131, DOI 10.1101/gad.9.17.2131; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; COSTE J, 1990, TETRAHEDRON LETT, V31, P205, DOI 10.1016/S0040-4039(00)94371-5; Dansen TB, 2000, NAT CELL BIOL, V2, P51, DOI 10.1038/71375; Daschner K, 1999, PLANT MOL BIOL, V39, P1275; Davies Peter J., 1995, P1; Davies RT, 1999, PLANT CELL, V11, P365, DOI 10.1105/tpc.11.3.365; DEARFIELD KL, 1991, MUTAGENESIS, V6, P519, DOI 10.1093/mutage/6.6.519; DUNFORD R, 1990, PHYTOCHEMISTRY, V29, P41, DOI 10.1016/0031-9422(90)89006-U; Eastmond PJ, 2000, J BIOL CHEM, V275, P34375, DOI 10.1074/jbc.M004945200; Engel CK, 1998, J MOL BIOL, V275, P847, DOI 10.1006/jmbi.1997.1491; Faivre-Nitschke SE, 2001, EUR J BIOCHEM, V268, P1332, DOI 10.1046/j.1432-1327.2001.01999.x; FAWCETT CH, 1960, PROC R SOC SER B-BIO, V152, P231, DOI 10.1098/rspb.1960.0035; FELDMANN KA, 1991, PLANT J, V1, P71, DOI 10.1111/j.1365-313X.1991.00071.x; Fujiki Y, 2000, J BIOL CHEM, V275, P6007, DOI 10.1074/jbc.275.8.6007; GEHRING U, 1968, EUR J BIOCHEM, V6, P264, DOI 10.1111/j.1432-1033.1968.tb00446.x; Geisbrecht BV, 1998, J BIOL CHEM, V273, P33184, DOI 10.1074/jbc.273.50.33184; GERBLING H, 1989, PLANT PHYSIOL, V91, P1387, DOI 10.1104/pp.91.4.1387; GERBLING H, 1988, PLANT PHYSIOL, V88, P13, DOI 10.1104/pp.88.1.13; GERHARDT B, 1992, PROG LIPID RES, V31, P417, DOI 10.1016/0163-7827(92)90004-3; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; HAUGHN GW, 1986, MOL GEN GENET, V204, P430, DOI 10.1007/BF00331020; Hawes JW, 1996, J BIOL CHEM, V271, P26430, DOI 10.1074/jbc.271.42.26430; Hayashi M, 1998, PLANT CELL, V10, P183, DOI 10.1105/tpc.10.2.183; Hayashi M, 2000, EMBO J, V19, P5701, DOI 10.1093/emboj/19.21.5701; Hebsgaard SM, 1996, NUCLEIC ACIDS RES, V24, P3439, DOI 10.1093/nar/24.17.3439; Kaneko T, 1998, DNA Res, V5, P131, DOI 10.1093/dnares/5.2.131; KINDL H, 1993, BIOCHIMIE, V75, P225, DOI 10.1016/0300-9084(93)90080-C; KONIECZNY A, 1993, PLANT J, V4, P403, DOI 10.1046/j.1365-313X.1993.04020403.x; KOTANI H, 1998, DNA RES, V5, P243; Lazarow Paul B., 1993, Trends in Cell Biology, V3, P89, DOI 10.1016/0962-8924(93)90079-G; LECLERE S, 2001, IN PRESS PLANT MOL B; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Ludwig-Muller J, 2000, PLANT GROWTH REGUL, V32, P219, DOI 10.1023/A:1010746806891; MAZELIS M, 1980, BIOCH PLANTS, V5, P542; McKean AL, 2000, J BIOL CHEM, V275, P5582, DOI 10.1074/jbc.275.8.5582; MINET M, 1992, PLANT J, V2, P417; MULLERNEWEN G, 1995, EUR J BIOCHEM, V228, P68, DOI 10.1111/j.1432-1033.1995.tb20230.x; NAGY F, 1988, MOL BIOL MANUAL; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; Olsen LJ, 1998, PLANT MOL BIOL, V38, P163, DOI 10.1023/A:1006092830670; Reinard T, 2000, J BIOL CHEM, V275, P33738, DOI 10.1074/jbc.M004178200; Richmond TA, 1999, PLANT CELL, V11, P1911, DOI 10.1105/tpc.11.10.1911; SALAM WH, 1986, BIOCHIM BIOPHYS ACTA, V873, P321, DOI 10.1016/0167-4838(86)90079-8; Sato S, 2000, DNA RES, V7, P31, DOI 10.1093/dnares/7.1.31; Shimomura Y, 2000, METHOD ENZYMOL, V324, P229; SHIMOMURA Y, 1994, J BIOL CHEM, V269, P14248; Smith RF, 1996, GENOME RES, V6, P454, DOI 10.1101/gr.6.5.454; STASINOPOULOS TC, 1990, PLANT PHYSIOL, V93, P1365, DOI 10.1104/pp.93.4.1365; Swofford D.L., 2001, PAUP PHYLOGENETIC AN; Tabak HF, 1999, TRENDS CELL BIOL, V9, P447, DOI 10.1016/S0962-8924(99)01650-5; TRUSCOTT RJW, 1981, BIOMED MASS SPECTROM, V8, P99, DOI 10.1002/bms.1200080304; Zolman BK, 2000, GENETICS, V156, P1323	61	78	88	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					31037	31046		10.1074/jbc.M104679200	http://dx.doi.org/10.1074/jbc.M104679200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11404361	hybrid			2022-12-25	WOS:000170472900060
J	Louis, JM; Bewley, CA; Clore, GM				Louis, JM; Bewley, CA; Clore, GM			Design and properties of N-CCG-gp41, a chimeric gp41 molecule with nanomolar HIV fusion inhibitory activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMIAN IMMUNODEFICIENCY VIRUS; 44 KDA ECTODOMAIN; ENVELOPE GLYCOPROTEIN; COILED-COIL; INACTIVATING PROTEIN; SECONDARY STRUCTURE; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; ATOMIC-STRUCTURE; CYANOVIRIN-N	The design and characterization of a chimeric protein, termed N-CCG-gp41, derived from the ectodomain of human immunodeficiency virus (HIV), type I gp41 is described. N-CCG-gp41 features an exposed trimeric coiled-coil comprising the N-terminal helices of the gp41 ectodomain. The trimeric coiled-coil is stabilized both by fusion to a minimal thermostable ectodomain of gp41 and by engineered intersubunit disulfide bonds. N(CCG)gp41 is shown to inhibit HIV envelope-mediated cell fusion at nanomolar concentrations with an IC., of 16.1 +/- 2.8 nM. It is proposed that N-CCG-gp41 targets the exposed C-terminal region of the gp41 ectodomain in its pre-hairpin intermediate state, thereby preventing the formation of the fusogenic form of the gp41 ectodomain, which comprises a highly stable trimer of hairpins arranged in a six-helix bundle. N-CCG-gp41 has potential as a therapeutic agent for the direct inhibition of HIV cell entry, as an anti-HIV vaccine, and as a component of a rapid throughput assay for screening for small molecule inhibitors of HIV envelope-mediated cell fusion. It is anticipated that antibodies raised against N-CCG-gp41 may target the trimeric coiled-coil of N-terminal helices of the gp41 ectodomain that is exposed in the pre-hairpin intermediate state in a manner analogous to peptides derived from the C-terminal helix of gp41 that are currently in clinical trials.	NIDDK, Phys Chem Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Clore, GM (corresponding author), NIDDK, Phys Chem Lab, NIH, Bldg 5,Rm B1-301, Bethesda, MD 20892 USA.		Clore, G Marius/L-2546-2018; Clore, G. Marius/A-3511-2008	Clore, G Marius/0000-0003-3809-1027; Clore, G. Marius/0000-0003-3809-1027; Bewley, Carole/0000-0003-2203-0852; Louis, John M/0000-0002-0052-1899	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK032103, ZIADK032103] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALEXANDER WA, 1992, J VIROL, V66, P2934, DOI 10.1128/JVI.66.5.2934-2942.1992; ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; Bewley CA, 2001, J AM CHEM SOC, V123, P3892, DOI 10.1021/ja004040e; Boyd MR, 1997, ANTIMICROB AGENTS CH, V41, P1521, DOI 10.1128/AAC.41.7.1521; BRODER CC, 1995, P NATL ACAD SCI USA, V92, P9004, DOI 10.1073/pnas.92.19.9004; BRUNGER AT, 1993, X PLOR SYSTEM XRYA C; Caffrey M, 1998, EMBO J, V17, P4572, DOI 10.1093/emboj/17.16.4572; Caffrey M, 1997, J MOL BIOL, V271, P819, DOI 10.1006/jmbi.1997.1217; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Chan DC, 1998, P NATL ACAD SCI USA, V95, P15613, DOI 10.1073/pnas.95.26.15613; Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0; Eckert DM, 1999, CELL, V99, P103, DOI 10.1016/S0092-8674(00)80066-5; Farzan M, 1998, J VIROL, V72, P7620, DOI 10.1128/JVI.72.9.7620-7625.1998; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Ferrer M, 1999, NAT STRUCT BIOL, V6, P953; FREED EO, 1995, J BIOL CHEM, V270, P23883, DOI 10.1074/jbc.270.41.23883; Furuta RA, 1998, NAT STRUCT BIOL, V5, P276, DOI 10.1038/nsb0498-276; Kilby JM, 1998, NAT MED, V4, P1302, DOI 10.1038/3293; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; LOUIS JM, 1989, BIOCHEM BIOPH RES CO, V159, P87, DOI 10.1016/0006-291X(89)92408-X; LU M, 1995, NAT STRUCT BIOL, V2, P1075, DOI 10.1038/nsb1295-1075; Malashkevich VN, 1998, P NATL ACAD SCI USA, V95, P9134, DOI 10.1073/pnas.95.16.9134; McMichael AJ, 1999, NAT MED, V5, P612, DOI 10.1038/9455; Moore JP, 1997, CURR OPIN IMMUNOL, V9, P551, DOI 10.1016/S0952-7915(97)80110-0; PERKINS SJ, 1986, EUR J BIOCHEM, V157, P169, DOI 10.1111/j.1432-1033.1986.tb09653.x; Root MJ, 2001, SCIENCE, V291, P884, DOI 10.1126/science.1057453; Salzwedel K, 2000, J VIROL, V74, P326, DOI 10.1128/JVI.74.1.326-333.2000; Schwieters CD, 2001, J MAGN RESON, V149, P239, DOI 10.1006/jmre.2001.2300; Tan KM, 1997, P NATL ACAD SCI USA, V94, P12303, DOI 10.1073/pnas.94.23.12303; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; Weng YK, 1998, J VIROL, V72, P9676, DOI 10.1128/JVI.72.12.9676-9682.1998; WILD CT, 1994, P NATL ACAD SCI USA, V91, P9770, DOI 10.1073/pnas.91.21.9770; WILD CT, 1992, P NATL ACAD SCI USA, V99, P10537; Yang F, 1999, J MOL BIOL, V288, P403, DOI 10.1006/jmbi.1999.2693	34	94	117	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29485	29489		10.1074/jbc.C100317200	http://dx.doi.org/10.1074/jbc.C100317200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11418583	hybrid			2022-12-25	WOS:000170346000111
J	Alexakis, C; Guettoufi, A; Mestries, P; Strup, C; Mathe, D; Barbaud, C; Barritault, D; Caruelle, JP; Kern, P				Alexakis, C; Guettoufi, A; Mestries, P; Strup, C; Mathe, D; Barbaud, C; Barritault, D; Caruelle, JP; Kern, P			Heparan mimetic regulates collagen expression and TGF-beta 1 distribution in gamma-irradiated human intestinal smooth muscle cells	FASEB JOURNAL			English	Article						gamma radiation; intestinal fibrosis; collagen; transforming growth factor beta 1	GROWTH-FACTOR BETA-1; CHRONIC RADIATION ENTEROPATHY; CHEMICALLY-MODIFIED DEXTRANS; TRANSFORMING GROWTH-FACTOR-BETA-1; V COLLAGEN; INDUCED FIBROSIS; CROHNS-DISEASE; THERAPY; FIBROBLASTS; PHENOTYPE	Radiation-induced intestinal fibrosis is characterized by collagen accumulation, a process in which TGF-beta1 plays a key role. We analyzed the effects of gamma radiation on collagen expression and TGF-beta1 distribution in human intestinal smooth muscle cells (HISM). We investigated the activity of a carboxymethylated and sulfated dextran (RG-1503), exhibiting antifibrotic properties and promoting in vivo intestinal tissue repair, on irradiated HISM. After Co-60 irradiation (10 Gy), HISM were labeled with [H-3] proline (+/-RG-1503). Radiolabeled collagen I, III, and V were quantified by SDS-PAGE. TGF-beta1 was quantified by ELISA in culture medium, pericellular and intracellular compartments. Irradiation induced a specific 2.85-fold increase in collagen III production by HISM. Collagen V decreased by 80% 72 h after irradiation. Pericellular TGF-beta1 was increased (up to two-fold) in irradiated HISM. RG-1503 added before or after irradiation reversed both mRNA and protein levels of collagen III and V to control values. RG-1503 decreased the amount of TGF-beta1 in the cell layer below the control values. Irradiation of HISM induced the development of a fibrotic phenotype in terms of collagen production and TGF-beta1 distribution. The antifibrotic RG-1503 restored HISM physiological characteristics and may represent a promising therapeutic approach for radiation-induced intestinal fibrosis.	Univ Paris 12, Fac Sci Creteil, CRRET CNRS UPRESA 7053, F-94010 Creteil, France; Inst Protect & Surete Nucl, Dept Protect Sante Homme & Dosimetrie, Sect Autonome Radiobiol Appl Med, F-92265 Fontenay Aux Roses, France	Universite Paris-Est-Creteil-Val-de-Marne (UPEC)	Barritault, D (corresponding author), Univ Paris 12, Fac Sci Creteil, CRRET CNRS UPRESA 7053, Ave Gen de Gaulle, F-94010 Creteil, France.	Barritault@univ-paris12.fr						Aamiri A, 1995, NEUROSCI LETT, V201, P243, DOI 10.1016/0304-3940(95)12182-X; ADAMS MD, 1995, NATURE, V377, P3; ASSELOTCHAPEL C, 1995, BIOCHEM PHARMACOL, V49, P653, DOI 10.1016/0006-2952(94)00462-U; Becker JM, 1999, GASTROENTEROL CLIN N, V28, P371, DOI 10.1016/S0889-8553(05)70061-3; BENAZZOUG Y, 1995, BIOCHEM PHARMACOL, V49, P847, DOI 10.1016/0006-2952(94)00455-U; Benazzoug Y, 1998, EXP GERONTOL, V33, P445, DOI 10.1016/S0531-5565(98)00015-1; BIRK DE, 1990, J CELL SCI, V95, P649; Blanquaert F, 1999, J BIOMED MATER RES, V44, P63, DOI 10.1002/(SICI)1097-4636(199901)44:1<63::AID-JBM7>3.0.CO;2-S; Burger A, 1998, INT J RADIAT BIOL, V73, P401, DOI 10.1080/095530098142239; Ceol M, 2000, J AM SOC NEPHROL, V11, P2324, DOI 10.1681/ASN.V11122324; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHU ML, 1982, NUCLEIC ACIDS RES, V10, P5925, DOI 10.1093/nar/10.19.5925; CHU ML, 1985, J BIOL CHEM, V260, P4357; COIA LR, 1995, INT J RADIAT ONCOL, V31, P1213, DOI 10.1016/0360-3016(94)00419-L; DECROMBRUGGHE B, 1990, ANN NY ACAD SCI, V580, P88, DOI 10.1111/j.1749-6632.1990.tb17921.x; Ehrhart EJ, 1997, FASEB J, V11, P991, DOI 10.1096/fasebj.11.12.9337152; EIFEL PJ, 1995, INT J RADIAT ONCOL, V32, P1289, DOI 10.1016/0360-3016(95)00118-I; ELNABOUT R, 1989, MATRIX, V9, P411, DOI 10.1016/S0934-8832(89)80047-2; FOLLOWILL DS, 1995, RADIAT RES, V144, P318, DOI 10.2307/3578952; GRAHAM MF, 1984, P SOC EXP BIOL MED, V176, P503; GRAHAM MF, 1990, GASTROENTEROLOGY, V99, P447, DOI 10.1016/0016-5085(90)91028-5; Hauer-Jensen M, 1998, RADIAT RES, V150, P673, DOI 10.2307/3579890; Herskind C, 1998, STRAHLENTHER ONKOL, V174, P12; Lafont J, 1998, GROWTH FACTORS, V16, P23, DOI 10.3109/08977199809017489; LANDBERG CW, 1994, RADIOTHER ONCOL, V32, P29; LAWRENCE R, 1994, J BIOL CHEM, V269, P9603; Ledoux D, 2000, J BIOL CHEM, V275, P29383, DOI 10.1074/jbc.M000837200; Logeart D, 1996, J BIOMED MATER RES, V30, P501, DOI 10.1002/(SICI)1097-4636(199604)30:4<501::AID-JBM8>3.0.CO;2-T; Lyon M, 1997, J BIOL CHEM, V272, P18000, DOI 10.1074/jbc.272.29.18000; MAJACK RA, 1985, J CELL BIOL, V100, P613, DOI 10.1083/jcb.100.2.613; MARTIN N, 1997, HDB ORGANIC CONDUCTI, V1, P1; MCCAFFREY TA, 1992, J CELL PHYSIOL, V152, P430, DOI 10.1002/jcp.1041520226; MCCAFFREY TA, 1994, J CELL PHYSIOL, V159, P51, DOI 10.1002/jcp.1041590108; Meddahi A, 1996, J BIOMED MATER RES, V31, P293, DOI 10.1002/(SICI)1097-4636(199607)31:3<293::AID-JBM1>3.0.CO;2-H; MEDDAHI A, 1994, PATHOL RES PRACT, V190, P923; Mestries P, 1998, J BIOMED MATER RES, V42, P286, DOI 10.1002/(SICI)1097-4636(199811)42:2<286::AID-JBM14>3.3.CO;2-F; OKane S, 1997, INT J BIOCHEM CELL B, V29, P63, DOI 10.1016/S1357-2725(96)00120-3; Parekh TV, 1998, CELL GROWTH DIFFER, V9, P423; Pucilowska JB, 2000, AM J PHYSIOL-GASTR L, V279, pG653; RANDALL K, 1995, INT J RADIAT BIOL, V68, P301, DOI 10.1080/09553009514551231; REMY J, 1991, RADIAT RES, V125, P14, DOI 10.2307/3577976; Richter KK, 1997, INT J RADIAT ONCOL, V39, P187, DOI 10.1016/S0360-3016(97)00290-3; Rodemann HP, 1996, KIDNEY INT, V49, pS32; SCHMIDT A, 1995, EUR J CELL BIOL, V67, P130; STALLMACH A, 1992, GASTROENTEROLOGY, V102, P1920, DOI 10.1016/0016-5085(92)90314-O; Wang JR, 1998, AM J PATHOL, V153, P1531, DOI 10.1016/S0002-9440(10)65741-0; YEOH E, 1993, INT J RADIAT ONCOL, V26, P229, DOI 10.1016/0360-3016(93)90202-7	47	21	23	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2001	15	9					1546	1554		10.1096/fj.00-0756com	http://dx.doi.org/10.1096/fj.00-0756com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	460PV	11427486				2022-12-25	WOS:000170318500006
J	Gershenwald, JE; Sumner, W; Calderone, T; Wang, Z; Huang, SY; Bar-Eli, M				Gershenwald, JE; Sumner, W; Calderone, T; Wang, Z; Huang, SY; Bar-Eli, M			Dominant-negative transcription factor AP-2 augments SB-2 melanoma tumor growth in vivo	ONCOGENE			English	Article						melanoma; angiogenesis; metastasis; matrix metallaproteinase-2; transcriptional regulation	HUMAN-MALIGNANT MELANOMA; MMP-2 IMMUNOREACTIVE PROTEIN; PRIMARY CUTANEOUS MELANOMA; IV COLLAGENASE GENE; C-KIT EXPRESSION; DNA-BINDING; E-CADHERIN; MATRIX METALLOPROTEINASES; SIGNAL-TRANSDUCTION; RELATIVE EXPRESSION	We have previously demonstrated that the transition of melanoma to the metastatic phenotype is associated with a loss of expression of the transcription factor AP-2. To further investigate the role of AP-2 in the progression of human melanoma, we attempted to inactivate AP-2 in primary cutaneous SB-2 melanoma cells by using a dominant-negative AP-2, or AP-2B, gene, AP-2B is an alternatively spliced AP-2 variant capable of inhibiting AP-2 trans-activator function, Stable transfection of primary cutaneous melanoma SB-2 cells with the dominant-negative AP-2B gene was confirmed by RT-PCR and Northern blot analyses, Electromobility shift assay using nuclear extracts from these cell lines demonstrated decreased functional binding of AP-2B-transfected cells to the AP-2 consensus binding sequence compared with neo-transfected controls. In addition, CAT activity driven by a construct containing the AP-2 consensus binding sequence was downregulated in the AP-2B transfected cells, indicating AP-2 activity was quenched in the transfected cells, Orthotopic (subcutaneous) injection of the dominant-negative (AP-2B)-transfected cell lines into nude mice increased their tumorigenicity compared to control neo-transfected cells, The AP-2B-transfected cells displayed an increase in MMP-2 expression (by Northern blot) and MMP-2 activity (by zymography), which resulted in an increase in invasiveness through Matrigel-coated filters. The AP-2B-transfected tumors also displayed an increase in MMP-2 expression, microvessel density, and angiogenesis in vivo. These results demonstrate that inactivation of AP-2 contributes to the progression of melanoma, at least partially via deregulation of the MMP-2 gene.	Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Bar-Eli, M (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, 1515 Holcombe Blvd, Houston, TX 77030 USA.		Gershenwald, Jeff/AAX-4367-2020	Gershenwald, Jeff/0000-0003-4519-5369	NATIONAL CANCER INSTITUTE [T32CA009599, R01CA076098] Funding Source: NIH RePORTER; NCI NIH HHS [CA76098, T-32 CA09599] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ariizumi K, 1996, J DERMATOL SCI, V12, P147, DOI 10.1016/0923-1811(95)00474-2; Bar-Eli M, 1999, CANCER METAST REV, V18, P377, DOI 10.1023/A:1006377309524; BarEli M, 1997, J CELL PHYSIOL, V173, P275, DOI 10.1002/(SICI)1097-4652(199711)173:2<275::AID-JCP35>3.0.CO;2-C; BAUER R, 1994, NUCLEIC ACIDS RES, V22, P1413, DOI 10.1093/nar/22.8.1413; BLOOD CH, 1990, BIOCHIM BIOPHYS ACTA, V1032, P89, DOI 10.1016/0304-419X(90)90014-R; BOHM M, 1995, CELL GROWTH DIFFER, V6, P291; BOSHER JM, 1995, P NATL ACAD SCI USA, V92, P744, DOI 10.1073/pnas.92.3.744; BUETTNER R, 1993, MOL CELL BIOL, V13, P4174, DOI 10.1128/MCB.13.7.4174; COPEMAN MC, 1992, PATHOLOGY, V24, P307, DOI 10.3109/00313029209068886; DESCHEEMAEKER KA, 1992, J BIOL CHEM, V267, P15086; DUAN CM, 1995, J BIOL CHEM, V270, P24844, DOI 10.1074/jbc.270.42.24844; Fang D, 1999, BIOCHEM BIOPH RES CO, V256, P657, DOI 10.1006/bbrc.1999.0400; FIDLER IJ, 1990, CANCER RES, V50, P6130; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FRISCH SM, 1990, MOL CELL BIOL, V10, P6524, DOI 10.1128/MCB.10.12.6524; GAUBATZ S, 1995, EMBO J, V14, P1508, DOI 10.1002/j.1460-2075.1995.tb07137.x; GAYNOR RB, 1991, GENOMICS, V10, P1100, DOI 10.1016/0888-7543(91)90209-W; Goding CR, 2000, GENE DEV, V14, P1712; GretherBeck S, 1996, P NATL ACAD SCI USA, V93, P14586, DOI 10.1073/pnas.93.25.14586; HASLINGER A, 1985, P NATL ACAD SCI USA, V82, P8572, DOI 10.1073/pnas.82.24.8572; HEALY E, 1995, GENE CHROMOSOME CANC, V12, P152, DOI 10.1002/gcc.2870120211; Herbst RS, 2000, CLIN CANCER RES, V6, P790; Hofmann UB, 1999, BRIT J CANCER, V81, P774, DOI 10.1038/sj.bjc.6690763; HOLMAN CDJ, 1980, INT J CANCER, V25, P317, DOI 10.1002/ijc.2910250303; Huang S, 1998, EMBO J, V17, P4358, DOI 10.1093/emboj/17.15.4358; Huang S, 2000, CLIN CANCER RES, V6, P2573; Huang SY, 1996, ONCOGENE, V13, P2339; HUHTALA P, 1990, J BIOL CHEM, V265, P11077; HYMAN SE, 1989, MOL CELL BIOL, V9, P321, DOI 10.1128/MCB.9.1.321; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; Janknecht R, 1997, EMBO J, V16, P1620, DOI 10.1093/emboj/16.7.1620; Jean D, 2000, MOL CELL BIOCHEM, V212, P19, DOI 10.1023/A:1007128101751; Jean D, 1998, J BIOL CHEM, V273, P24884, DOI 10.1074/jbc.273.38.24884; Jean D, 1998, J BIOL CHEM, V273, P16501, DOI 10.1074/jbc.273.26.16501; Jean D, 2000, ONCOGENE, V19, P2721, DOI 10.1038/sj.onc.1203569; KANNAN F, 1994, GENE DEV, V8, P1258, DOI 10.1101/gad.8.11.1258; Kannan P, 1999, NUCLEIC ACIDS RES, V27, P866, DOI 10.1093/nar/27.3.866; KANNO M, 1989, EMBO J, V8, P4205, DOI 10.1002/j.1460-2075.1989.tb08606.x; KARELINA TV, 1995, J INVEST DERMATOL, V105, P411, DOI 10.1111/1523-1747.ep12321097; Karjalainen JM, 1998, J CLIN ONCOL, V16, P3584, DOI 10.1200/JCO.1998.16.11.3584; Karjalainen JM, 2000, BRIT J CANCER, V82, P2015; King R, 1999, AM J PATHOL, V155, P731, DOI 10.1016/S0002-9440(10)65172-3; Kuniyasu H, 1999, CLIN CANCER RES, V5, P25; Kuniyasu H, 2000, CLIN CANCER RES, V6, P2295; LASSAM N, 1992, ONCOGENE, V7, P51; LEASK A, 1991, P NATL ACAD SCI USA, V88, P7948, DOI 10.1073/pnas.88.18.7948; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LEHMANN JM, 1989, P NATL ACAD SCI USA, V86, P9891, DOI 10.1073/pnas.86.24.9891; LI LM, 1989, JNCI-J NATL CANCER I, V81, P1406, DOI 10.1093/jnci/81.18.1406; Liotta L A, 1990, Semin Cancer Biol, V1, P99; LIOTTA LA, 1980, NATURE, V284, P67, DOI 10.1038/284067a0; LIOTTA LA, 1986, CANCER RES, V46, P1; LUCA M, 1993, MELANOMA RES, V3, P35, DOI 10.1097/00008390-199304000-00006; Luca M, 1997, AM J PATHOL, V151, P1105; LUCA M, 1995, ONCOGENE, V11, P1399; LUSCHER B, 1989, GENE DEV, V3, P1507, DOI 10.1101/gad.3.10.1507; Maytin EV, 1999, DEV BIOL, V216, P164, DOI 10.1006/dbio.1999.9460; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; NYBORG JK, 1990, J BIOL CHEM, V265, P8230; PATHAK S, 1983, CYTOGENET CELL GENET, V36, P573, DOI 10.1159/000131975; Qin HW, 1999, J BIOL CHEM, V274, P29130, DOI 10.1074/jbc.274.41.29130; Real LM, 1998, INT J CANCER, V75, P317, DOI 10.1002/(SICI)1097-0215(19980119)75:2<317::AID-IJC23>3.0.CO;2-8; ROMERDAHL CA, 1988, CANCER RES, V48, P4007; Ropponen KM, 1999, BRIT J CANCER, V81, P133, DOI 10.1038/sj.bjc.6690662; RUTBERG SE, 1994, MOL CARCINOGEN, V10, P82, DOI 10.1002/mc.2940100205; Schmidt VA, 1996, J BIOL CHEM, V271, P9307, DOI 10.1074/jbc.271.16.9307; Schorle H, 1996, NATURE, V381, P235, DOI 10.1038/381235a0; SHIH IM, 1994, CANCER RES, V54, P2514; SINGH RK, 1995, CANCER RES, V55, P3669; Somasundaram K, 1996, P NATL ACAD SCI USA, V93, P3088, DOI 10.1073/pnas.93.7.3088; TRENT JM, 1989, CANCER RES, V49, P420; Vaisanen A, 1999, J PATHOL, V188, P56; Vaisanen A, 1998, J PATHOL, V186, P51; VERSCHRAEGEN CF, 1991, ANTICANCER RES, V11, P529; WELCH DR, 1994, ONCOGENE, V9, P255; WILLIAMS T, 1991, SCIENCE, V251, P1067, DOI 10.1126/science.1998122; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; Xie SH, 1997, CANCER RES, V57, P2295; Xie SH, 1997, ONCOGENE, V15, P2069, DOI 10.1038/sj.onc.1201358; ZAKUT R, 1993, ONCOGENE, V8, P2221; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78; ZHANG J, 1995, CANCER RES, V55, P4640; Zhang JA, 1996, NATURE, V381, P238, DOI 10.1038/381238a0	85	69	71	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 7	2001	20	26					3363	3375		10.1038/sj.onc.1204450	http://dx.doi.org/10.1038/sj.onc.1204450			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	441UW	11423987				2022-12-25	WOS:000169248800007
J	Gagliardi, M; Maynard, S; Bojovic, B; Bedard, PA				Gagliardi, M; Maynard, S; Bojovic, B; Bedard, PA			The constitutive activation of the CEF-4/9E3 chemokine gene depends on C/EBP beta in v-src transformed chicken embryo fibroblasts	ONCOGENE			English	Article						CEF-4/9E3 chemokine; C/EBP beta; pp60(v-src)	ROUS-SARCOMA VIRUS; NECROSIS-FACTOR-ALPHA; NF-KAPPA-B; ENDOTHELIAL GROWTH-FACTOR; EFII ENHANCER SEQUENCE; BINDING-PROTEIN-BETA; LONG TERMINAL REPEAT; KINASE-C SUBSTRATE; TRANSCRIPTION FACTOR; CELLULAR-TRANSFORMATION	The CEF-4/9E3 chemokine gene is expressed constitutively in chicken embryo fibroblasts (CEF) transformed by the Rous sarcoma virus (RSV), This aberrant induction is controlled at the transcriptional and posttranscriptional Levels. Transcriptional activation depends on multiple elements of the CEF-4 promoter composing a Src-responsive-Unit or SRU, The SRU includes a TPA responsive element, a PRDII/kappaB domain and a CAAT box. In this report, we identify C/EBP beta as a component of the trans-acting factor interacting with the CAAT box of the CEF-4 promoter. In addition, we show that CI EBP beta binds to a second element located in proximity of the TRE, A mutation of this distal CAAT box impaired the activation of the CEF-4 promoter by pp60(v-src) indicating that this element is also part of the SRU, Using the RCASBP retroviral vector, we expressed a dominant negative mutant of C/EBP beta (designated Delta 184-C/EBP beta) in RSV-transformed CEF, Delta 184-C/EBP beta decreased the accumulation of the CEF-4 mRNA and activation of the CEF-4 promoter by pp60(v-src). The induction of the Cox-2 gene (CEF-147) was also reduced by Delta 184-C/EBP beta. The effect of the dominant negative mutant was observed within 1 h of the activation of a thermolabile pp60(v-src) suggesting that C/EBP beta is an early target of v-src transformation. The dominant negative mutant did not inhibit the transformation of CEF by RSV and in fact accentuated the transformed cell phenotype, Therefore, the activation of C/EBP beta is important for the expression of v-src regulated genes but is not required for the in vitro transformation of CEF by pp60(v-src).	York Univ, Dept Biol, N York, ON M3J 1P3, Canada; McMaster Univ, Inst Mol Biol & Biotechnol, Hamilton, ON L8S 4K1, Canada	York University - Canada; McMaster University	Bedard, PA (corresponding author), York Univ, Dept Biol, 4700 Keele St, N York, ON M3J 1P3, Canada.			Maynard, Scott/0000-0001-5625-936X				Arenberg DA, 1996, J CLIN INVEST, V97, P2792, DOI 10.1172/JCI118734; BALENTIEN E, 1991, ONCOGENE, V6, P1115; BEDARD PA, 1987, MOL CELL BIOL, V7, P1450, DOI 10.1128/MCB.7.4.1450; BEDARD PA, 1987, P NATL ACAD SCI USA, V84, P6715, DOI 10.1073/pnas.84.19.6715; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; Buck M, 1999, MOL CELL, V4, P1087, DOI 10.1016/S1097-2765(00)80237-3; Cabannes E, 1997, ONCOGENE, V15, P29, DOI 10.1038/sj.onc.1201162; CALKHOVEN CF, 1994, NUCLEIC ACIDS RES, V22, P5540, DOI 10.1093/nar/22.25.5540; Calkhoven CF, 2000, GENE DEV, V14, P1920; Chang CJ, 1998, MOL CELL BIOL, V18, P5880, DOI 10.1128/MCB.18.10.5880; DEHBI M, 1992, BIOCHEM CELL BIOL, V70, P980, DOI 10.1139/o92-142; DEHBI M, 1992, MOL CELL BIOL, V12, P1490, DOI 10.1128/MCB.12.4.1490; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GILLET G, 1995, EMBO J, V14, P1372, DOI 10.1002/j.1460-2075.1995.tb07123.x; GRANGERSCHNARR M, 1992, P NATL ACAD SCI USA, V89, P4236, DOI 10.1073/pnas.89.10.4236; Greenbaum LE, 1998, J CLIN INVEST, V102, P996, DOI 10.1172/JCI3135; HSU W, 1994, MOL CELL BIOL, V14, P268, DOI 10.1128/MCB.14.1.268; Inoue H, 1998, J VIROL, V72, P2532, DOI 10.1128/JVI.72.3.2532-2537.1998; Johnson R, 1996, MOL CELL BIOL, V16, P4504; JOSEPH CK, 1992, J BIOL CHEM, V267, P1327; KATZ S, 1993, EMBO J, V12, P1321, DOI 10.1002/j.1460-2075.1993.tb05777.x; Kim S, 1999, MOL CELL BIOL, V19, P5718; Kim YS, 1998, J BIOL CHEM, V273, P27686, DOI 10.1074/jbc.273.42.27686; KLAMPFER L, 1994, MOL CELL BIOL, V14, P6561, DOI 10.1128/MCB.14.10.6561; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; Kowenz-Leutz E, 1999, MOL CELL, V4, P735, DOI 10.1016/S1097-2765(00)80384-6; KOWENZLEUTZ E, 1994, GENE DEV, V8, P2781, DOI 10.1101/gad.8.22.2781; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; Lin X, 1997, CANCER RES, V57, P3068; Lin XY, 1997, CANCER RES, V57, P2304; Lin XY, 1996, J BIOL CHEM, V271, P28430, DOI 10.1074/jbc.271.45.28430; Lin XY, 1998, CANCER RES, V58, P1770; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; Mangeney M, 1996, ONCOGENE, V13, P1441; MAO PL, 1993, J BIOL CHEM, V268, P8131; Martins-Green M., 1997, Cytokine and Growth Factor Reviews, V8, P221, DOI 10.1016/S1359-6101(97)00016-6; Martins-Green M, 1998, CYTOKINE, V10, P522, DOI 10.1006/cyto.1997.0311; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; Merika M, 1998, MOL CELL, V1, P277, DOI 10.1016/S1097-2765(00)80028-3; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; Muller C, 1999, P NATL ACAD SCI USA, V96, P7276, DOI 10.1073/pnas.96.13.7276; PETROPOULOS CJ, 1991, J VIROL, V65, P3728, DOI 10.1128/JVI.65.7.3728-3737.1991; Raught B, 1996, CANCER RES, V56, P4382; RICHMOND A, 1988, EMBO J, V7, P2025, DOI 10.1002/j.1460-2075.1988.tb03042.x; Robinson GW, 1998, GENE DEV, V12, P1907, DOI 10.1101/gad.12.12.1907; SCHADENDORF, 1994, J IMMUNOL, V153, P3360; SCHADENDORF D, 1993, J IMMUNOL, V151, P2667; Seagroves TN, 2000, MOL ENDOCRINOL, V14, P359, DOI 10.1210/me.14.3.359; SEARS RC, 1994, MOL CELL BIOL, V14, P4855, DOI 10.1128/MCB.14.7.4855; SEARS RC, 1994, MOL CELL BIOL, V14, P5617; SEARS RC, 1992, J VIROL, V66, P6338, DOI 10.1128/JVI.66.11.6338-6352.1992; SIMMONS DL, 1989, P NATL ACAD SCI USA, V86, P1178, DOI 10.1073/pnas.86.4.1178; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; STERNECK E, 1992, EMBO J, V11, P115, DOI 10.1002/j.1460-2075.1992.tb05034.x; SUGANO S, 1987, CELL, V49, P321, DOI 10.1016/0092-8674(87)90284-4; SUNDERKOTTER C, 1994, J LEUKOCYTE BIOL, V55, P410, DOI 10.1002/jlb.55.3.410; SUZUKI T, 1994, J VIROL, V68, P3527, DOI 10.1128/JVI.68.6.3527-3535.1994; Timchenko NA, 1999, NUCLEIC ACIDS RES, V27, P4517, DOI 10.1093/nar/27.22.4517; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; Topol LZ, 1997, MOL CELL BIOL, V17, P4801, DOI 10.1128/MCB.17.8.4801; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Wadleigh DJ, 2000, J BIOL CHEM, V275, P6259, DOI 10.1074/jbc.275.9.6259; Wakabayashi Y, 1995, JPN J CANCER RES, V86, P1189, DOI 10.1111/j.1349-7006.1995.tb03314.x; WASYLYK C, 1994, ONCOGENE, V9, P3665; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; XIE WL, 1994, MOL CELL BIOL, V14, P6531, DOI 10.1128/MCB.14.10.6531; Yoshida S, 1997, MOL CELL BIOL, V17, P4015, DOI 10.1128/MCB.17.7.4015; Zagariya A, 1998, MOL CELL BIOL, V18, P2815, DOI 10.1128/MCB.18.5.2815; Zhu SY, 1999, MOL CELL BIOL, V19, P7181	71	6	6	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 26	2001	20	18					2301	2313		10.1038/sj.onc.1204354	http://dx.doi.org/10.1038/sj.onc.1204354			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	427KZ	11402325				2022-12-25	WOS:000168404500012
J	Huai, Q; Xia, YH; Chen, YQ; Callahan, B; Li, N; Ke, HM				Huai, Q; Xia, YH; Chen, YQ; Callahan, B; Li, N; Ke, HM			Crystal structures of 1-aminocyclopropane-1-carboxylate (ACC) synthase in complex with aminoethoxyvinylglycine and pyridoxal-5 '-phosphate provide new insight into catalytic mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATE-DEPENDENT ENZYME; ASPARTATE-AMINOTRANSFERASE; ESCHERICHIA-COLI; EVOLUTIONARY RELATIONSHIPS; 3-DIMENSIONAL STRUCTURE; ORNITHINE-DECARBOXYLASE; ANGSTROM RESOLUTION; ACID SYNTHASE; KEY ENZYME; WILD-TYPE	The structures of tomato 1-aminocyclopropane-1-carboxylate synthase (ACS) in complex with either cofactor pyridoxal-5'-phosphate (PLP) or both PLP and inhibitor aminoethoxyvinylglycine have been determined by x-ray crystallography. The structures showed good conservation of the catalytic residues, suggesting a similar catalytic mechanism for ACS and other PLP-dependent enzymes. However, the proximity of Tyr(152) to the C-gamma -S bond of model substrate S-adenosylmethionine implies its critical role in the catalysis. The concerted accomplishment of catalysis by cofactor PLP and a protein residue, as proposed on the basis of the ACS structures in this paper, may represent a general scheme for the diversity of PLP-dependent catalyses. PLP-dependent enzymes have been categorized into four types of folds. A structural comparison revealed that a core fragment of ACS in fold type I is superimposable over tryptophan synthase beta subunit in fold type II and mouse ornithine decarboxylase in fold type III, thus suggesting a divergent evolution of PLP-dependent enzymes.	Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Hong Kong Univ Sci & Technol, Dept Biol, Kowloon, Hong Kong, Peoples R China	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Hong Kong University of Science & Technology	Ke, HM (corresponding author), Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA.	hke@med.unc.edu	Callahan, Brian/G-6491-2010	Callahan, Brian/0000-0003-4826-0162				ALEXANDER FW, 1994, EUR J BIOCHEM, V219, P953, DOI 10.1111/j.1432-1033.1994.tb18577.x; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BLEECKER AB, 1986, P NATL ACAD SCI USA, V83, P7755, DOI 10.1073/pnas.83.20.7755; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Capitani G, 1999, J MOL BIOL, V294, P745, DOI 10.1006/jmbi.1999.3255; Chook YM, 1998, ACTA CRYSTALLOGR D, V54, P822, DOI 10.1107/S0907444997020064; Clausen T, 1998, EMBO J, V17, P6827, DOI 10.1093/emboj/17.23.6827; Clausen T, 2000, P NATL ACAD SCI USA, V97, P3856, DOI 10.1073/pnas.97.8.3856; Clausen T, 1997, BIOCHEMISTRY-US, V36, P12633, DOI 10.1021/bi970630m; Eads JC, 1999, BIOCHEMISTRY-US, V38, P9840, DOI 10.1021/bi990018q; FORD GC, 1980, P NATL ACAD SCI-BIOL, V77, P2559, DOI 10.1073/pnas.77.5.2559; GRAY J, 1992, PLANT MOL BIOL, V19, P69, DOI 10.1007/BF00015607; HAYASHI H, 1995, J BIOCHEM-TOKYO, V118, P463, DOI 10.1093/oxfordjournals.jbchem.a124931; Hennig M, 1997, P NATL ACAD SCI USA, V94, P4866, DOI 10.1073/pnas.94.10.4866; Hester G, 1999, J MOL BIOL, V286, P829, DOI 10.1006/jmbi.1998.2506; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HYDE CC, 1988, J BIOL CHEM, V263, P17857; JAGER J, 1994, J MOL BIOL, V239, P285, DOI 10.1006/jmbi.1994.1368; Jansonius JN, 1998, CURR OPIN STRUC BIOL, V8, P759, DOI 10.1016/S0959-440X(98)80096-1; JOHN RA, 1995, BBA-PROTEIN STRUCT M, V1248, P81, DOI 10.1016/0167-4838(95)00025-P; JONES TA, 1982, COMPUTATIONAL CRYSTA, P303; Kack H, 1999, J MOL BIOL, V291, P857, DOI 10.1006/jmbi.1999.2997; Kaiser JT, 2000, J MOL BIOL, V297, P451, DOI 10.1006/jmbi.2000.3581; KENDE H, 1993, ANNU REV PLANT PHYS, V44, P283, DOI 10.1146/annurev.pp.44.060193.001435; Kern AD, 1999, STRUCTURE, V7, P567, DOI 10.1016/S0969-2126(99)80073-2; Krupka HI, 2000, EMBO J, V19, P3168, DOI 10.1093/emboj/19.13.3168; Li N, 1996, FEBS LETT, V378, P286, DOI 10.1016/0014-5793(95)01464-0; LI N, 1994, J BIOL CHEM, V269, P6908; Li YS, 1997, BIOCHEMISTRY-US, V36, P15477, DOI 10.1021/bi971625l; MEHTA PK, 1989, EUR J BIOCHEM, V186, P249, DOI 10.1111/j.1432-1033.1989.tb15202.x; MOMANY C, 1995, J MOL BIOL, V252, P643, DOI 10.1006/jmbi.1995.0526; Nakai T, 1999, BIOCHEMISTRY-US, V38, P2413, DOI 10.1021/bi9819881; Navaza J, 1997, METHOD ENZYMOL, V276, P581, DOI 10.1016/S0076-6879(97)76079-8; Okamoto A, 1996, J BIOCHEM-TOKYO, V119, P135; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; RAMALINGAM K, 1985, P NATL ACAD SCI USA, V82, P7820, DOI 10.1073/pnas.82.23.7820; Rhee S, 1997, J BIOL CHEM, V272, P17293, DOI 10.1074/jbc.272.28.17293; Rhee S, 1996, BIOCHEMISTRY-US, V35, P4211, DOI 10.1021/bi952506d; SATOH S, 1983, PHYSIOL PLANTARUM, V57, P521, DOI 10.1111/j.1399-3054.1983.tb02779.x; SATOH S, 1989, PLANT PHYSIOL, V91, P1036, DOI 10.1104/pp.91.3.1036; Stamper CGF, 1998, BIOCHEMISTRY-US, V37, P10438, DOI 10.1021/bi980692s; Storici P, 1999, J MOL BIOL, V285, P297, DOI 10.1006/jmbi.1998.2289; Storici P, 1999, BIOCHEMISTRY-US, V38, P8628, DOI 10.1021/bi990478j; SUGIO S, 1995, BIOCHEMISTRY-US, V34, P9661, DOI 10.1021/bi00030a002; Tarun AS, 1998, J BIOL CHEM, V273, P12509, DOI 10.1074/jbc.273.20.12509; Tarun AS, 1998, P NATL ACAD SCI USA, V95, P9796, DOI 10.1073/pnas.95.17.9796; THEOLOGIS A, 1992, CELL, V70, P181, DOI 10.1016/0092-8674(92)90093-R; TONEY MD, 1995, J MOL BIOL, V245, P151, DOI 10.1006/jmbi.1994.0014; WALSH C, 1979, ENZYMATIC REACTION M, P851; WHITE MF, 1994, P NATL ACAD SCI USA, V91, P12428, DOI 10.1073/pnas.91.26.12428; YANG SF, 1984, ANNU REV PLANT PHYS, V35, P155, DOI 10.1146/annurev.pp.35.060184.001103; YIP WK, 1991, PLANT PHYSIOL, V95, P251, DOI 10.1104/pp.95.1.251	52	60	66	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 12	2001	276	41					38210	38216						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	481NU	11431475				2022-12-25	WOS:000171526500066
J	Brosh, RM; Harmakar, P; Sommers, JA; Yang, Q; Wang, XW; Spillare, EA; Harris, CC; Bohr, VA				Brosh, RM; Harmakar, P; Sommers, JA; Yang, Q; Wang, XW; Spillare, EA; Harris, CC; Bohr, VA			p53 modulates the exonuclease activity of Werner syndrome protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOBLASTOID CELL-LINES; SINGLE-STRANDED-DNA; WILD-TYPE; P53-MEDIATED APOPTOSIS; HELICASE ACTIVITY; BINDING DOMAIN; GROWTH-CONTROL; SYNDROME GENE; WRN PROTEIN; MUTANT P53	Werner syndrome (WS) is characterized by the early onset of symptoms of premature aging, cancer, and genomic instability. The molecular basis of the defects is not understood but presumably relates to the DNA helicase and exonuclease activities of the protein encoded by the WRN gene that is mutated in the disease. The attenuation of p53-mediated apoptosis in WS cells and reported physical interaction between WRN and the tumor suppressor p53 suggest that p53 and WRN functionally interact in a pathway necessary for the normal cellular response. In this study, we have demonstrated that p53 inhibits the exonuclease activity of the purified full-length recombinant WRN protein. p53 did not have an effect on a truncated amino-terminal WRN fragment that retains exonuclease activity but lacks the physical interaction domain for p53 located in the carboxyl terminus. Two naturally occurring p53 mutants found in human cancer displayed a reduced ability to inhibit WRN exonuclease activity. In cells arrested in S phase with hydroxyurea, WRN exits the nucleolus and colocalizes with p53 in the nucleoplasm. The regulation of WRN function by p53 is likely to play an important role in the maintenance of genomic integrity and prevention of cancer and other clinical symptoms associated with WS.	NIA, Genet Mol Lab, NIH, Baltimore, MD 21224 USA; NCI, Human Carcinogenesis Lab, NIH, Bethesda, MD 21892 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Bohr, VA (corresponding author), NIA, Genet Mol Lab, NIH, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.		Bohr, Vilhelm/AAP-5931-2020; Wang, Xin Wei/B-6162-2009	Wang, Xin Wei/0000-0001-9735-606X	NATIONAL INSTITUTE ON AGING [ZIAAG000741, ZIAAG000726, Z01AG000741, Z01AG000726] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; Bennett MR, 1999, BIOCHEM PHARMACOL, V58, P1089; Blander G, 1999, J BIOL CHEM, V274, P29463, DOI 10.1074/jbc.274.41.29463; Brosh RM, 2000, J BIOL CHEM, V275, P23500, DOI 10.1074/jbc.M001557200; Brosh RM, 1999, J BIOL CHEM, V274, P18341, DOI 10.1074/jbc.274.26.18341; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Constantinou A, 2000, EMBO REP, V1, P80, DOI 10.1093/embo-reports/kvd004; Cooper MP, 2000, GENE DEV, V14, P907; COX LS, 1995, EMBO J, V14, P2099, DOI 10.1002/j.1460-2075.1995.tb07201.x; El-Deiry WS, 1998, CURR TOP MICROBIOL, V227, P121; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EPSTEIN CJ, 1966, MEDICINE, V45, P177, DOI 10.1097/00005792-196605000-00001; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; FRIEDMAN PN, 1990, P NATL ACAD SCI USA, V87, P9275, DOI 10.1073/pnas.87.23.9275; Goto M, 1996, CANCER EPIDEM BIOMAR, V5, P239; Gray MD, 1997, NAT GENET, V17, P100, DOI 10.1038/ng0997-100; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HANAOKA F, 1985, ADV EXP MED BIOL, V190, P439; Huang SR, 1998, NAT GENET, V20, P114, DOI 10.1038/2410; Huang SR, 2000, NUCLEIC ACIDS RES, V28, P2396, DOI 10.1093/nar/28.12.2396; Kamath-Loeb AS, 1998, J BIOL CHEM, V273, P34145, DOI 10.1074/jbc.273.51.34145; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1991, ONCOGENE, V6, P131; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KIENZLE H, 1989, EUR J BIOCHEM, V184, P181, DOI 10.1111/j.1432-1033.1989.tb15005.x; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Lebel M, 1999, J BIOL CHEM, V274, P37795, DOI 10.1074/jbc.274.53.37795; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lombard DB, 2000, MOL CELL BIOL, V20, P3286, DOI 10.1128/MCB.20.9.3286-3291.2000; Machwe A, 2000, NUCLEIC ACIDS RES, V28, P2762, DOI 10.1093/nar/28.14.2762; Marciniak RA, 1998, P NATL ACAD SCI USA, V95, P6887, DOI 10.1073/pnas.95.12.6887; MATSON SW, 1983, J BIOL CHEM, V258, P4009; Orren DK, 1999, NUCLEIC ACIDS RES, V27, P3557, DOI 10.1093/nar/27.17.3557; Orren DK, 2001, NUCLEIC ACIDS RES, V29, P1926, DOI 10.1093/nar/29.9.1926; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; POOT M, 1992, EXP CELL RES, V202, P267, DOI 10.1016/0014-4827(92)90074-I; Robles AI, 1999, ONCOGENE, V18, P4681, DOI 10.1038/sj.onc.1202862; SALK D, 1982, HUM GENET, V62, P1, DOI 10.1007/BF00295598; Shen JC, 1998, J BIOL CHEM, V273, P34139, DOI 10.1074/jbc.273.51.34139; Shen JC, 1998, NUCLEIC ACIDS RES, V26, P2879, DOI 10.1093/nar/26.12.2879; Spillare EA, 1999, GENE DEV, V13, P1355, DOI 10.1101/gad.13.11.1355; TAKEUCHI F, 1982, HUM GENET, V60, P365, DOI 10.1007/BF00569220; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; Yamabe Y, 1998, MOL CELL BIOL, V18, P6191, DOI 10.1128/MCB.18.11.6191; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258; Zhou XL, 1999, CANCER RES, V59, P843	50	80	84	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					35093	35102		10.1074/jbc.M103332200	http://dx.doi.org/10.1074/jbc.M103332200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11427532	hybrid			2022-12-25	WOS:000171024600099
J	Morimoto, T; Hasegawa, K; Wada, H; Kakita, T; Kaburagi, S; Yanazume, T; Sasayama, S				Morimoto, T; Hasegawa, K; Wada, H; Kakita, T; Kaburagi, S; Yanazume, T; Sasayama, S			Calcineurin-GATA4 pathway is involved in beta-adrenergic agonist-responsive endothelin-1 transcription in cardiac myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY-CHAIN GENE; HEART-FAILURE; RAT CARDIOMYOCYTES; HYPERTROPHY; EXPRESSION; MUSCLE; CELLS; INHIBITION; GATA-4; PROTEIN	Increases in the expression of endothelin-1 (ET-1) in cardiac myocytes play a critical role in the development of heart failure in vivo. Whereas norepinephrine (NE) is a potent inducer of ET-1 expression in cardiac myocytes, the signaling pathways that link NE to inducible cardiac ET-1 expression are unknown. Adrenergic stimulation results in an increase in intracellular calcium levels, which in turn activates calcineurin. Here, we have shown that stimulation with NE markedly increased the expression of the ET-1 gene in primary cardiac myocytes from neonatal rats. This increase was severely attenuated by a beta -adrenergic antagonist, metoprolol, but not by an alpha -adrenergic antagonist, prazosin. Consistent with these data, the beta -adrenergic agonist isoproterenol (ISO) activated the rat ET-1 promoter activity to an extent that was similar to NE. The ISO-stimulated increase in promoter activity was significantly inhibited by a Ca2+-antagonist, nifedipine, and an immunosuppressant, cyclosporin A, which blocks calcineurin. Mutation analysis indicated that the GATA4 binding site is required for ISO-responsive ET-1 transcription. Stimulation with ISO enhanced the interaction between NFATc and GATA4 in cardiac myocytes. Consistent with this interaction, overexpression of GATA4 and NFATc synergistically activated the ET-1 promoter. These findings demonstrate that NE-stimulated ET-1 expression in cardiac myocytes is mediated predominantly via a beta -adrenergic pathway, and that calcium-activated calcineurin-GATA4 plays a role in this process.	Kyoto Univ, Grad Sch Med, Dept Cardiovasc Med, Sakyo Ku, Kyoto 6068507, Japan	Kyoto University	Hasegawa, K (corresponding author), Kyoto Univ, Grad Sch Med, Dept Cardiovasc Med, Sakyo Ku, 54 Kawara Cho, Kyoto 6068507, Japan.			Wada, Hiromichi/0000-0002-8980-224X				ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; FRANCIS GS, 1993, CIRCULATION, V87, P140; GREPIN C, 1994, MOL CELL BIOL, V14, P3115, DOI 10.1128/MCB.14.5.3115; Harada M, 1997, CIRCULATION, V96, P3737; Hasegawa K, 1997, CIRCULATION, V96, P3943; Herzig TC, 1997, P NATL ACAD SCI USA, V94, P7543, DOI 10.1073/pnas.94.14.7543; Inada T, 1999, J AM COLL CARDIOL, V33, P565, DOI 10.1016/S0735-1097(98)00564-6; IP HS, 1994, MOL CELL BIOL, V14, P7517, DOI 10.1128/MCB.14.11.7517; ITO H, 1993, J CLIN INVEST, V92, P398, DOI 10.1172/JCI116579; ITO H, 1991, CIRC RES, V69, P209, DOI 10.1161/01.RES.69.1.209; Iwanaga Y, 1998, CIRCULATION, V98, P2065, DOI 10.1161/01.CIR.98.19.2065; JAMES AF, 1994, NATURE, V370, P297, DOI 10.1038/370297a0; Kaburagi S, 1999, CIRCULATION, V99, P292, DOI 10.1161/01.CIR.99.2.292; Kakita T, 1999, J BIOL CHEM, V274, P34096, DOI 10.1074/jbc.274.48.34096; KAWANA M, 1995, MOL CELL BIOL, V15, P4225; Lee JP, 1999, P NATL ACAD SCI USA, V96, P3251, DOI 10.1073/pnas.96.6.3251; McGrew MJ, 1996, MOL CELL BIOL, V16, P4524; MOLKENTIN JD, 1994, MOL CELL BIOL, V14, P4947, DOI 10.1128/MCB.14.7.4947; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Morimoto T, 1999, J BIOL CHEM, V274, P12811, DOI 10.1074/jbc.274.18.12811; Morimoto T, 2000, J BIOL CHEM, V275, P13721, DOI 10.1074/jbc.275.18.13721; PACKER M, 1992, J AM COLL CARDIOL, V20, P248, DOI 10.1016/0735-1097(92)90167-L; Pan S, 1997, BIOCHEM BIOPH RES CO, V240, P314, DOI 10.1006/bbrc.1997.7381; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; RUFF VA, 1995, J BIOL CHEM, V270, P22602, DOI 10.1074/jbc.270.38.22602; Sakai S, 1996, NATURE, V384, P353, DOI 10.1038/384353a0; SHAW KTY, 1995, P NATL ACAD SCI USA, V92, P11205, DOI 10.1073/pnas.92.24.11205; SHICHIRI M, 1991, J CLIN INVEST, V87, P1867, DOI 10.1172/JCI115210; SHUBEITA HE, 1990, J BIOL CHEM, V265, P20555; STEMMER PM, 1994, BIOCHEMISTRY-US, V33, P6859, DOI 10.1021/bi00188a015; Sussman MA, 1998, SCIENCE, V281, P1690, DOI 10.1126/science.281.5383.1690; Walsh RA, 1999, CIRC RES, V84, P741, DOI 10.1161/01.RES.84.6.741; WILSON DB, 1990, MOL CELL BIOL, V10, P4854, DOI 10.1128/MCB.10.9.4854; Yamazaki T, 1996, J BIOL CHEM, V271, P3221, DOI 10.1074/jbc.271.6.3221; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0	35	45	45	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					34983	34989		10.1074/jbc.M005498200	http://dx.doi.org/10.1074/jbc.M005498200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11435416	hybrid			2022-12-25	WOS:000171024600085
J	Ikeda, Y; Yamamoto, J; Okamura, M; Fujino, T; Takahashi, S; Takeuchi, K; Osborne, TF; Yamamoto, TT; Ito, S; Sakai, J				Ikeda, Y; Yamamoto, J; Okamura, M; Fujino, T; Takahashi, S; Takeuchi, K; Osborne, TF; Yamamoto, TT; Ito, S; Sakai, J			Transcriptional regulation of the murine acetyl-CoA synthetase 1 gene through multiple clustered binding sites for sterol regulatory element-binding proteins and a single neighboring site for Sp1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLEAVAGE-ACTIVATING PROTEIN; FATTY-ACID SYNTHASE; NUCLEAR FACTOR-Y; RECEPTOR GENE; SP-FAMILY; IN-VIVO; NF-Y; PROMOTER; EXPRESSION; SREBPS	Cytosolic acetyl-CoA synthetase (AceCS1) activates acetate to supply the cells with acetyl-CoA for lipid synthesis. The cDNA for the mammalian AceCS1 has been isolated recently, and the mRNA was shown to be negatively regulated by sterols in cultured cells. In the current study, we describe the molecular mechanisms directing the sterol-regulated expression of murine AceCS1 by cloning and functional studies of the 5 ' -flanking region of the AceCS1 gene. An AceCS1 promoter-reporter gene (similar to2.1 kilobase pairs) was negatively regulated when sterols were added to the medium of cultured cells, and the promoter was markedly induced by co-transfection of a plasmid that expresses the transcriptionally active nuclear form of either sterol regulatory element-binding protein (SREBP)-1a or -2 in HepG2 cells. Sequence analysis suggested that the AceCS1 promoter contains an E-box, two putative CCAAT-boxes, eight sterol regulatory element (SRE) motifs, and six GC-boxes. Gel shift assays demonstrated that all eight SRE motifs bound purified SREBP-1a in vitro with similar affinity. Luciferase reporter gene assays revealed that sterol regulation was critically dependent on three closely spaced SRE motifs and an adjacent GC-box. However, mutation of two putative upstream CCAAT-boxes did not affect SREBP dependent activation. Electrophoretic mobility "supershift" analyses confirmed that both Spl and Sp3 bound to the critical GC-box. In addition, transfection studies in Drosophila SL2 cells demonstrated that SREBP synergistically activated the AceCS1 promoter along with Sp1 or Sp3 but not with nuclear factor-Y.	Tohoku Univ, Grad Sch Med, Dept Med, Div Nephrol Endocrinol & Vasc Med, Sendai, Miyagi 9808574, Japan; Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92717 USA; Fukui Med Univ, Dept Internal Med 3, Fukui 9101193, Japan; Tohoku Univ, Ctr Gene Res, Sendai, Miyagi 9818555, Japan	Tohoku University; University of California System; University of California Irvine; University of Fukui; Tohoku University	Sakai, J (corresponding author), Tohoku Univ, Grad Sch Med, Dept Med, Div Nephrol Endocrinol & Vasc Med, Sendai, Miyagi 9808574, Japan.		Ito, Sadayoshi/A-3933-2015	Sakai, Juro/0000-0003-4043-1035; Ito, Sadayoshi/0000-0002-5092-3626				AssimacopoulosJeannet F, 1997, J BIOL CHEM, V272, P1659, DOI 10.1074/jbc.272.3.1659; Athanikar JN, 1997, MOL CELL BIOL, V17, P5193, DOI 10.1128/MCB.17.9.5193; BRIGGS MR, 1993, J BIOL CHEM, V268, P14490; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; DeBose-Boyd RA, 1999, CELL, V99, P703, DOI 10.1016/S0092-8674(00)81668-2; Dooley KA, 1998, J BIOL CHEM, V273, P1349, DOI 10.1074/jbc.273.3.1349; Ericsson J, 1996, J BIOL CHEM, V271, P24359, DOI 10.1074/jbc.271.40.24359; Foretz M, 1999, P NATL ACAD SCI USA, V96, P12737, DOI 10.1073/pnas.96.22.12737; Foretz M, 1999, MOL CELL BIOL, V19, P3760; Fujino T, 2001, J BIOL CHEM, V276, P11420, DOI 10.1074/jbc.M008782200; Guan GM, 1997, J BIOL CHEM, V272, P10295; Horton JD, 1998, P NATL ACAD SCI USA, V95, P5987, DOI 10.1073/pnas.95.11.5987; Ikeda Y, 2000, J BIOL CHEM, V275, P33142, DOI 10.1074/jbc.M002319200; JACKSON SM, 1995, J BIOL CHEM, V270, P21445, DOI 10.1074/jbc.270.37.21445; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; Lopez JM, 1996, P NATL ACAD SCI USA, V93, P1049, DOI 10.1073/pnas.93.3.1049; Luong A, 2000, J BIOL CHEM, V275, P26458, DOI 10.1074/jbc.M004160200; Magana MM, 1996, J BIOL CHEM, V271, P32689, DOI 10.1074/jbc.271.51.32689; Magana MM, 2000, J BIOL CHEM, V275, P4726, DOI 10.1074/jbc.275.7.4726; Moon YA, 2000, J BIOL CHEM, V275, P30280, DOI 10.1074/jbc.M001066200; Nohturfft A, 2000, CELL, V102, P315, DOI 10.1016/S0092-8674(00)00037-4; Pai JT, 1996, P NATL ACAD SCI USA, V93, P5437, DOI 10.1073/pnas.93.11.5437; Rawson RB, 1997, MOL CELL, V1, P47, DOI 10.1016/S1097-2765(00)80006-4; Repa JJ, 2000, J BIOL CHEM, V275, P39685, DOI 10.1074/jbc.M007653200; Sakai J, 1998, MOL CELL, V2, P505, DOI 10.1016/S1097-2765(00)80150-1; Sakai J, 1998, J BIOL CHEM, V273, P5785, DOI 10.1074/jbc.273.10.5785; Sakai J, 1996, CELL, V85, P1037, DOI 10.1016/S0092-8674(00)81304-5; Sakai J, 1997, J BIOL CHEM, V272, P20213, DOI 10.1074/jbc.272.32.20213; SANCHEZ HB, 1995, J BIOL CHEM, V270, P1161, DOI 10.1074/jbc.270.3.1161; Sato R, 2000, J BIOL CHEM, V275, P12497, DOI 10.1074/jbc.275.17.12497; Schultz JR, 2000, GENE DEV, V14, P2831, DOI 10.1101/gad.850400; Shimano H, 1999, J BIOL CHEM, V274, P35832, DOI 10.1074/jbc.274.50.35832; Shimomura I, 1997, J CLIN INVEST, V99, P838, DOI 10.1172/JCI119247; Shimomura L, 1999, P NATL ACAD SCI USA, V96, P13656, DOI 10.1073/pnas.96.24.13656; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; WOODNUTT G, 1986, COMP BIOCHEM PHYS B, V85, P487, DOI 10.1016/0305-0491(86)90033-7; Yamada K, 2000, J BIOL CHEM, V275, P18129, DOI 10.1074/jbc.M001543200	39	63	64	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					34259	34269		10.1074/jbc.M103848200	http://dx.doi.org/10.1074/jbc.M103848200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11435428	hybrid			2022-12-25	WOS:000170910200129
J	Aizawa, T; Hayakawa, Y; Ohnishi, A; Fujitani, N; Clark, KD; Strand, MR; Miura, K; Koganesawa, N; Kumaki, Y; Demura, M; Nitta, K; Kawano, K				Aizawa, T; Hayakawa, Y; Ohnishi, A; Fujitani, N; Clark, KD; Strand, MR; Miura, K; Koganesawa, N; Kumaki, Y; Demura, M; Nitta, K; Kawano, K			Structure and activity of the insect cytokine growth-blocking peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMATOCYTE-SPREADING PEPTIDE; SOLID-PHASE PEPTIDE; FACTOR-ALPHA; FACTOR RECEPTOR; MANDUCA-SEXTA; PSEUDOPLUSIA-INCLUDENS; PARALYTIC PEPTIDES; TGF-ALPHA; HEMOLYMPH; BINDING	Growth-blocking peptide (GBP) is a 25-amino acid insect cytokine found in Lepidopteran insects that possesses diverse biological activities such as larval growth regulation, cell proliferation, and stimulation of immune cells (plasmatocytes). The tertiary structure of GBP consists of a structured core that contains a disulfide bridge and a short antiparallel beta -sheet (Tyr(11)Arg(13) and Cys(19)-Pro(21)) and flexible N and C termini (Glu(1)-Gly(6) and Phe(23)-Gln(25)). In this study, deletion and point mutation analogs of GBP were synthesized to investigate the relationship between the structure of GBP and its mitogenic and plasmatocyte spreading activity. The results indicated that deletion of the N-terminal residue, Glu(1), eliminated all plasmatocyte spreading activity but did not reduce mitogenic activity. In contrast, deletion of Phe(23) along with the remainder of the C terminus destroyed all mitogenic activity but only slightly reduced plasmatocyte spreading activity. Therefore, the minimal structure of GBP containing mitogenic activity is 2-23 GBP, whereas that with plasmatocyte spreading activity is 1-22 GBP. NMR analysis indicated that these N- and C-terminal deletion mutants retained a similar core structure to wild-type GBP. Replacement of Asp(16) with either a Glu, Leu, or Asn residue similarly did not alter the core structure of GBP. However, these mutants had no mitogenic activity, although they retained about 50% of their plasmatocyte spreading activity. We conclude that specific residues in the unstructured and structured domains of GBP differentially affect the biological activities of GBP, which suggests the possibility that multifunctional properties of this peptide may be mediated by different forms of a GBP receptor.	Hokkaido Univ, Inst Low Temp Sci, Kita Ku, Sapporo, Hokkaido 0600819, Japan; Toyama Med & Pharmaceut Univ, Fac Pharmaceut Sci, Sugitani, Toyama 9300194, Japan; Hokkaido Univ, Grad Sch Sci, Div Biol Sci, Sapporo, Hokkaido 0600810, Japan; Univ Wisconsin, Dept Entomol, Madison, WI 53706 USA	Hokkaido University; University of Toyama; Hokkaido University; University of Wisconsin System; University of Wisconsin Madison	Hayakawa, Y (corresponding author), Hokkaido Univ, Inst Low Temp Sci, Kita Ku, Kita-19,Nishi-8, Sapporo, Hokkaido 0600819, Japan.		Demura, Makoto/F-5272-2011; Kawano, Keiichi/F-5265-2011; Aizawa, Tomoyasu/F-5278-2011; Clark, Kevin/GQA-9811-2022; Fujitani, Naoki/A-4072-2012	Demura, Makoto/0000-0003-0912-9284; Aizawa, Tomoyasu/0000-0001-9134-7576; Ohnishi, Atsushi/0000-0003-1213-4439; Fujitani, Naoki/0000-0002-4035-7317				Aizawa T, 1999, J BIOL CHEM, V274, P1887, DOI 10.1074/jbc.274.4.1887; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; Clark KD, 1997, J BIOL CHEM, V272, P23440, DOI 10.1074/jbc.272.37.23440; Clark KD, 2001, J BIOL CHEM, V276, P18491, DOI 10.1074/jbc.M100579200; FIELDS GB, 1990, INT J PEPT PROT RES, V35, P161, DOI 10.1111/j.1399-3011.1990.tb00939.x; Furuya K, 1999, PEPTIDES, V20, P53, DOI 10.1016/S0196-9781(98)00148-X; Ha SD, 1999, PEPTIDES, V20, P561, DOI 10.1016/S0196-9781(99)00008-X; Hayakawa Y, 1998, BIOCHEM BIOPH RES CO, V250, P194, DOI 10.1006/bbrc.1998.8959; HAYAKAWA Y, 1990, J BIOL CHEM, V265, P10813; HAYAKAWA Y, 1991, J BIOL CHEM, V266, P7982; HAYAKAWA Y, 1995, FEBS LETT, V376, P185, DOI 10.1016/0014-5793(95)01273-7; HAYAKAWA Y, 1994, J BIOCHEM-TOKYO, V115, P15, DOI 10.1093/oxfordjournals.jbchem.a124291; HAYAKAWA Y, 1993, INSECT BIOCHEM MOLEC, V23, P225, DOI 10.1016/0965-1748(93)90003-B; HEATH WF, 1986, P NATL ACAD SCI USA, V83, P6367, DOI 10.1073/pnas.83.17.6367; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; KRAMER RH, 1994, J BIOL CHEM, V269, P8708; MACURA S, 1981, J MAGN RESON, V43, P259, DOI 10.1016/0022-2364(81)90037-8; McInnes C, 1996, J BIOL CHEM, V271, P32204, DOI 10.1074/jbc.271.50.32204; McInnes C, 2000, PROTEIN ENG, V13, P143, DOI 10.1093/protein/13.3.143; NICOLAS E, 1989, TETRAHEDRON LETT, V30, P497, DOI 10.1016/S0040-4039(00)95238-9; Noguchi H, 1997, FEBS LETT, V413, P157, DOI 10.1016/S0014-5793(97)00848-X; Ohnishi A, 1995, INSECT BIOCHEM MOLEC, V25, P1121, DOI 10.1016/0965-1748(95)00054-2; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; RICHTER A, 1992, BIOCHEMISTRY-US, V31, P9546, DOI 10.1021/bi00155a006; RICHTER A, 1995, J BIOL CHEM, V270, P1612, DOI 10.1074/jbc.270.4.1612; Seino Atsushi, 1998, Journal of Sericultural Science of Japan, V67, P473; SKINNER WS, 1991, J BIOL CHEM, V266, P12873; SKINNER WS, 1993, COMP BIOCHEM PHYS C, V104, P133, DOI 10.1016/0742-8413(93)90124-4; Strand MR, 2000, J INSECT PHYSIOL, V46, P817, DOI 10.1016/S0022-1910(99)00171-7; TAM J P, 1988, Peptide Research, V1, P6; TAM JP, 1991, INT J PEPT PROT RES, V38, P204; Volkman BF, 1999, J BIOL CHEM, V274, P4493, DOI 10.1074/jbc.274.8.4493; Wang Y, 1999, INSECT BIOCHEM MOLEC, V29, P1075, DOI 10.1016/S0965-1748(99)00086-7; Yu XQ, 1999, J PEPT RES, V54, P256, DOI 10.1034/j.1399-3011.1999.00136.x; ZUIDERWEG ERP, 1986, J MAGN RESON, V70, P336, DOI 10.1016/0022-2364(86)90020-X	35	40	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					31813	31818		10.1074/jbc.M105251200	http://dx.doi.org/10.1074/jbc.M105251200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11429413	hybrid			2022-12-25	WOS:000170613500047
J	Wild, MK; Huang, MC; Schulze-Horsel, U; van der Merwe, PA; Vestweber, D				Wild, MK; Huang, MC; Schulze-Horsel, U; van der Merwe, PA; Vestweber, D			Affinity, kinetics, and thermodynamics of E-selectin binding to E-selectin ligand-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; PROTEIN-PROTEIN INTERACTIONS; HAMSTER OVARY CELLS; ROLLING IN-VIVO; SIALYL-LEWIS-X; P-SELECTIN; GLYCOPROTEIN LIGAND-1; IMMUNOGLOBULIN SUPERFAMILY; CARBOHYDRATE LIGANDS; LEUKOCYTE ADHESION	E-selectin is an endothelial adhesion molecule, which mediates the tethering and rolling of leukocytes on vascular endothelium. It recognizes the glycoprotein E-selectin ligand-1 (ESL-1) as a major binding partner on mouse myeloid cells. Using surface plasmon resonance, we measured the kinetics and affinity of binding of monomeric E-selectin to ESL-1 isolated from mouse bone marrow cells. E-selectin bound to ESL-1 with a fast dissociation rate constant of 4.6 s(-1) and a calculated association rate constant of 7.4 X 10(4) M-1. s(-1). We determined a dissociation constant (K-d) of 62 muM, which resembles the affinity of L-selectin binding to glycosylation-dependent cell adhesion molecule-1. The affinity of the E-selectin-ESL-1 interaction did not change significantly when the temperature was varied from 5 degreesC to 37 degreesC, indicating that the enthalpic contribution to the binding is small at physiological temperatures, and that, in contrast to typical protein-carbohydrate interactions, binding is driven primarily by favorable entropic changes. Interestingly, surface plasmon resonance experiments with recombinant ESL-1 from alpha1,3-fucosyltransferase IV-expressing Chinese hamster ovary cells showed a very similar K-d of 66 muM, suggesting that this fucosyltransferase is sufficient to produce fully functional recombinant ESL-1. Following the recent description of the affinity and kinetics of the selectin-ligand pairs L-selectin-glycosylation-dependent cell adhesion molecule-1 and P-selectin-P-selectin glycoprotein ligand-1, this is the first determination of the parameters of E-selectin binding to one of its naturally occurring ligands.	Univ Munster, Zentrum Molekularbiol Entzundung, Inst Cell Biol, D-48149 Munster, Germany; Max Planck Inst Physiol & Clin Res, D-61231 Bad Nauheim, Germany; Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England	University of Munster; Max Planck Society; University of Oxford	Vestweber, D (corresponding author), Univ Munster, Zentrum Molekularbiol Entzundung, Inst Cell Biol, Von Esmarch Str 56, D-48149 Munster, Germany.	vestweb@uni-muenster.de	van der Merwe, P. Anton/F-8539-2011	HUANG, MIN-CHUAN/0000-0002-0704-3447; Vestweber, Dietmar/0000-0002-3517-732X				Alon R, 1997, J CELL BIOL, V138, P1169, DOI 10.1083/jcb.138.5.1169; ALON R, 1995, NATURE, V374, P539, DOI 10.1038/374539a0; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Austrup F, 1997, NATURE, V385, P81, DOI 10.1038/385081a0; BEBBINGTON C R, 1991, Methods (Orlando), V2, P136, DOI 10.1016/S1046-2023(05)80214-2; Bebbington CR, 1987, DNA CLONING PRACTICA, VIII, P163; Borges E, 1997, J EXP MED, V185, P573, DOI 10.1084/jem.185.3.573; Borges E, 1997, J BIOL CHEM, V272, P28786, DOI 10.1074/jbc.272.45.28786; BOSSE R, 1994, EUR J IMMUNOL, V24, P3019, DOI 10.1002/eji.1830241215; BRANDLEY BK, 1993, GLYCOBIOLOGY, V3, P633, DOI 10.1093/glycob/3.6.633; Brown MH, 1998, J EXP MED, V188, P2083, DOI 10.1084/jem.188.11.2083; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; COOKE RM, 1994, BIOCHEMISTRY-US, V33, P10591, DOI 10.1021/bi00201a004; Davis SJ, 1998, IMMUNOL REV, V163, P217, DOI 10.1111/j.1600-065X.1998.tb01199.x; Dwir O, 1998, CELL ADHES COMMUN, V6, P349, DOI 10.3109/15419069809010793; Ebnet K, 1999, HISTOCHEM CELL BIOL, V112, P1, DOI 10.1007/s004180050387; FOXALL C, 1992, J CELL BIOL, V117, P895, DOI 10.1083/jcb.117.4.895; Frenette PS, 2000, J EXP MED, V191, P1413, DOI 10.1084/jem.191.8.1413; GONATAS JO, 1989, J BIOL CHEM, V264, P646; GONATAS JO, 1995, J CELL SCI, V108, P457; HAHNE M, 1993, J CELL BIOL, V121, P655, DOI 10.1083/jcb.121.3.655; HALLMANN R, 1995, SCAND J RHEUMATOL, P107; HENSLEY P, 1994, J BIOL CHEM, V269, P23949; Hirata T, 2000, J EXP MED, V192, P1669, DOI 10.1084/jem.192.11.1669; HONIG B, 1995, SCIENCE, V268, P1144, DOI 10.1126/science.7761829; Huang MC, 2000, J BIOL CHEM, V275, P31353, DOI 10.1074/jbc.M005449200; HUNT SV, 1981, CELL TISSUE KINET, V14, P445, DOI 10.1111/j.1365-2184.1981.tb00551.x; JACOB GS, 1995, BIOCHEMISTRY-US, V34, P1210, DOI 10.1021/bi00004a014; Kansas GS, 1996, BLOOD, V88, P3259, DOI 10.1182/blood.V88.9.3259.bloodjournal8893259; KELM S, 1994, CURR BIOL, V4, P965, DOI 10.1016/S0960-9822(00)00220-7; KIKUTA A, 1994, BLOOD, V84, P3766, DOI 10.1182/blood.V84.11.3766.bloodjournal84113766; Kunkel EJ, 1996, CIRC RES, V79, P1196, DOI 10.1161/01.RES.79.6.1196; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LENTER M, 1994, J CELL BIOL, V125, P471, DOI 10.1083/jcb.125.2.471; LEVINOVITZ A, 1993, J CELL BIOL, V121, P449, DOI 10.1083/jcb.121.2.449; LEWINSOHN DM, 1987, J IMMUNOL, V138, P4313; Maenaka K, 1999, J BIOL CHEM, V274, P28329, DOI 10.1074/jbc.274.40.28329; McEver RP, 1997, J CLIN INVEST, V100, P485, DOI 10.1172/JCI119556; Mehta P, 1998, J BIOL CHEM, V273, P32506, DOI 10.1074/jbc.273.49.32506; MOORE KL, 1992, J CELL BIOL, V118, P445, DOI 10.1083/jcb.118.2.445; MOORE KL, 1995, J CELL BIOL, V128, P661, DOI 10.1083/jcb.128.4.661; MOY VT, 1994, SCIENCE, V266, P257, DOI 10.1126/science.7939660; NELSON RM, 1993, J CLIN INVEST, V91, P1157, DOI 10.1172/JCI116275; Nicholson MW, 1998, J BIOL CHEM, V273, P763, DOI 10.1074/jbc.273.2.763; NORMAN KE, 1995, BLOOD, V86, P4417, DOI 10.1182/blood.V86.12.4417.bloodjournal86124417; Patel KD, 1995, J CELL BIOL, V131, P1893, DOI 10.1083/jcb.131.6.1893; Patel KD, 1997, J IMMUNOL, V159, P4555; PATEL TP, 1994, BIOCHEMISTRY-US, V33, P14815, DOI 10.1021/bi00253a021; PICKER LJ, 1991, CELL, V66, P921, DOI 10.1016/0092-8674(91)90438-5; Poppe L, 1997, J AM CHEM SOC, V119, P1727, DOI 10.1021/ja9610702; Ramos CL, 1997, BLOOD, V89, P3009, DOI 10.1182/blood.V89.8.3009; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; Schreiber G, 1996, NAT STRUCT BIOL, V3, P427, DOI 10.1038/nsb0596-427; Singer MS, 1996, J IMMUNOL METHODS, V196, P153, DOI 10.1016/0022-1759(96)00106-8; Somers WS, 2000, CELL, V103, P467, DOI 10.1016/S0092-8674(00)00138-0; Spertini O, 1996, J CELL BIOL, V135, P523, DOI 10.1083/jcb.135.2.523; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STANLEY P, 1975, CELL, V6, P121, DOI 10.1016/0092-8674(75)90002-1; Steegmaier M, 1997, J CELL SCI, V110, P687; STEEGMAIER M, 1995, NATURE, V373, P615, DOI 10.1038/373615a0; STIEBER A, 1995, EXP CELL RES, V219, P562, DOI 10.1006/excr.1995.1265; Stites WE, 1997, CHEM REV, V97, P1233, DOI 10.1021/cr960387h; TOONE EJ, 1994, CURR OPIN STRUC BIOL, V4, P719, DOI 10.1016/S0959-440X(94)90170-8; VACHINO G, 1995, J BIOL CHEM, V270, P21966, DOI 10.1074/jbc.270.37.21966; van der Merwe PA, 1999, CURR BIOL, V9, pR419; VANDERMERWE PA, 1993, EMBO J, V12, P4945, DOI 10.1002/j.1460-2075.1993.tb06188.x; vanderMerwe PA, 1997, J EXP MED, V185, P393, DOI 10.1084/jem.185.3.393; VANDERMERWE PA, 1994, TRENDS BIOCHEM SCI, V19, P354; vanderMerwe PA, 1996, J BIOL CHEM, V271, P9273, DOI 10.1074/jbc.271.16.9273; Varki A, 1997, J CLIN INVEST, V99, P158, DOI 10.1172/JCI119142; VARKI A, 1994, P NATL ACAD SCI USA, V91, P7390, DOI 10.1073/pnas.91.16.7390; Vestweber D, 1999, PHYSIOL REV, V79, P181, DOI 10.1152/physrev.1999.79.1.181; VONANDRIAN UH, 1995, CELL, V82, P989, DOI 10.1016/0092-8674(95)90278-3; WELLER A, 1992, J BIOL CHEM, V267, P15176; WILLIAMS AF, 1991, NATURE, V352, P473, DOI 10.1038/352473a0; Wojciak-Stothard B, 1999, J CELL BIOL, V145, P1293, DOI 10.1083/jcb.145.6.1293; Yang J, 1999, J EXP MED, V190, P1769, DOI 10.1084/jem.190.12.1769; YOO SH, 1995, BIOCHEMISTRY-US, V34, P632, DOI 10.1021/bi00002a030; Yoshida M, 1996, J CELL BIOL, V133, P445, DOI 10.1083/jcb.133.2.445; Zollner O, 1996, J BIOL CHEM, V271, P33002, DOI 10.1074/jbc.271.51.33002	81	74	77	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					31602	31612		10.1074/jbc.M104844200	http://dx.doi.org/10.1074/jbc.M104844200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11404363	hybrid			2022-12-25	WOS:000170613500020
J	Zhang, Y; Qiu, WJ; Liu, DX; Neo, SY; He, X; Lin, SC				Zhang, Y; Qiu, WJ; Liu, DX; Neo, SY; He, X; Lin, SC			Differential molecular assemblies underlie the dual function of axin in modulating the Wnt and JNK pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; TUMOR-SUPPRESSOR PROTEIN; APC GENE-PRODUCT; BETA-CATENIN; XENOPUS EMBRYOS; C-JUN; HEPATOCELLULAR CARCINOMAS; NEGATIVE REGULATOR; SIGNALING PATHWAY; DOWN-REGULATION	Axin is a multidomain scaffold protein that exerts a dual function in the Wnt signaling and MEKK1/JNK pathways. This raises a critical question as to whether Axin-based differential molecular assemblies exist and how these may act to coordinate the two separate pathways. Here we show that both wild-type glycogen synthase kinase-3 beta (GSK-3 beta) and kinase-dead GSK-3 beta -Y216F (capable of binding to Axin), but not GSK-3 beta -K85M (incapable of binding to Axin in mammalian cells), prevented MEKK1 binding to the Axin complex, thereby inhibiting JNK activation. We further show that casein kinase le also inhibited Axin-mediated JNK activation by competing against MEKK1 binding. In contrast,. beta -catenin and adenomatous polyposis coli binding did not affect MEKK1 binding to the same Axin complex. This suggests that even when Axin is "switched" to activate the JNK pathway, it is still capable of sequestering free beta -catenin, which is a critical aspect for cellular homeostasis. Our results clearly demonstrate that differential molecular assemblies underlie the duality of Axin functions in the negative regulation of Wnt signaling and activation of the JNK MAPK pathway.	Inst Mol & Cell Biol, Regulatory Biol Lab, Singapore 117609, Singapore; Harvard Univ, Sch Med, Childrens Hosp, Div Neurosci, Boston, MA 02115 USA	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); Harvard University; Boston Children's Hospital; Harvard Medical School	Lin, SC (corresponding author), Hong Kong Univ Sci & Technol, Dept Biochem, Kowloon, Hong Kong, Peoples R China.		QIU, WENJING/GZL-9992-2022; Lin, SC/G-4666-2010	Zhang, Yi/0000-0003-2785-1780	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057603] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01GM 57603] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Arias AM, 1999, CURR OPIN GENET DEV, V9, P447, DOI 10.1016/S0959-437X(99)80068-9; Barth AIM, 1997, J CELL BIOL, V136, P693, DOI 10.1083/jcb.136.3.693; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Bienz M, 1999, CURR OPIN GENET DEV, V9, P595, DOI 10.1016/S0959-437X(99)00016-7; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Clevers H, 2000, NAT GENET, V24, P206, DOI 10.1038/73396; Ding VW, 2000, J BIOL CHEM, V275, P32475, DOI 10.1074/jbc.M005342200; DOMINGUEZ I, 1995, P NATL ACAD SCI USA, V92, P8498, DOI 10.1073/pnas.92.18.8498; Fagotto F, 1999, J CELL BIOL, V145, P741, DOI 10.1083/jcb.145.4.741; Fang XJ, 2000, P NATL ACAD SCI USA, V97, P11960, DOI 10.1073/pnas.220413597; Gat U, 1998, CELL, V95, P605, DOI 10.1016/S0092-8674(00)81631-1; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; He X, 1997, SCIENCE, V275, P1652, DOI 10.1126/science.275.5306.1652; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; Hedgepeth CM, 1999, MOL CELL BIOL, V19, P7147; Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574; Hsu W, 1999, J BIOL CHEM, V274, P3439, DOI 10.1074/jbc.274.6.3439; HUGHES K, 1993, EMBO J, V12, P803, DOI 10.1002/j.1460-2075.1993.tb05715.x; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Kawahara K, 2000, J BIOL CHEM, V275, P8369, DOI 10.1074/jbc.275.12.8369; Leppa S, 1999, ONCOGENE, V18, P6158, DOI 10.1038/sj.onc.1203173; Liu CM, 1999, P NATL ACAD SCI USA, V96, P6273, DOI 10.1073/pnas.96.11.6273; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MUNEMITSU S, 1994, CANCER RES, V54, P3676; Munemitsu S, 1996, MOL CELL BIOL, V16, P4088; Nathke IS, 1996, J CELL BIOL, V134, P165, DOI 10.1083/jcb.134.1.165; Neo SY, 2000, BIOCHEM BIOPH RES CO, V272, P144, DOI 10.1006/bbrc.2000.2751; Palacios J, 1998, CANCER RES, V58, P1344; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Peters JM, 1999, NATURE, V401, P345, DOI 10.1038/43830; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; Reinacher-Schick A, 2001, J CELL BIOL, V152, P491, DOI 10.1083/jcb.152.3.491; Rosin-Arbesfeld R, 2000, NATURE, V406, P1009, DOI 10.1038/35023016; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Sakanaka C, 1999, P NATL ACAD SCI USA, V96, P12548, DOI 10.1073/pnas.96.22.12548; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Seeling JM, 1999, SCIENCE, V283, P2089, DOI 10.1126/science.283.5410.2089; Shih IM, 2000, CANCER RES, V60, P1671; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; van Weeren PC, 1998, J BIOL CHEM, V273, P13150, DOI 10.1074/jbc.273.21.13150; Voeller HJ, 1998, CANCER RES, V58, P2520; Willert K, 1999, GENE DEV, V13, P1768, DOI 10.1101/gad.13.14.1768; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; YANAGAWA SI, 1995, GENE DEV, V9, P1087, DOI 10.1101/gad.9.9.1087; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; Yujiri T, 1999, J BIOL CHEM, V274, P12605, DOI 10.1074/jbc.274.18.12605; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4; Zhang Y, 1999, J BIOL CHEM, V274, P35247, DOI 10.1074/jbc.274.49.35247; Zhang Y, 2000, J BIOL CHEM, V275, P25008, DOI 10.1074/jbc.M002491200	57	33	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					32152	32159		10.1074/jbc.M104451200	http://dx.doi.org/10.1074/jbc.M104451200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11408485	hybrid			2022-12-25	WOS:000170613500093
J	Oussatcheva, EA; Hashem, VI; Zou, Y; Sinden, RR; Potaman, VN				Oussatcheva, EA; Hashem, VI; Zou, Y; Sinden, RR; Potaman, VN			Involvement of the nucleotide excision repair protein UvrA in instability of CAG-CTG repeat sequences in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MISMATCH REPAIR; HETERODUPLEX DNA; HUMAN-DISEASE; GENETIC INSTABILITY; MAMMALIAN-CELLS; TRINUCLEOTIDE REPEATS; TRIPLET REPEATS; DUPLEX DNA; REPLICATION; RECOMBINATION	Several human genetic diseases have been associated with the genetic instability, specifically expansion, of trinucleotide repeat sequences such as (CTG)(n)(.)(CAG)(n). Molecular models of repeat instability imply replication slippage and the formation of loops and imperfect hairpins in single strands. Subsequently, these loops or hairpins may be recognized and processed by DNA repair systems. To evaluate the potential role of nucleotide excision repair in repeat instability, we measured the rates of repeat deletion in wild type and excision repair-deficient Escherichia coli strains (using a genetic assay for deletions). The rate of triplet repeat deletion decreased in an E. coli strain deficient in the damage recognition protein UvrA. Moreover, loops containing 23 CTG repeats were less efficiently excised from heteroduplex plasmids after their transformation into the uvrA(-) strain. As a result, an increased proportion of plasmids containing the full-length repeat were recovered after the replication of heteroduplex plasmids containing unrepaired loops. In biochemical experiments, UvrA bound to heteroduplex substrates containing repeat loops of 1, 2, or 17 CAG repeats with a Kd of about 10-20 nm, which is an affinity about 2 orders of magnitude higher than that of UvrA bound to the control substrates containing (CTG)(n)(.)(CAG)(n) in the linear form. These results suggest that UvrA is involved in triplet repeat instability in cells. Specifically, UvrA may bind to loops formed during replication slippage or in slipped strand DNA and initiate DNA repair events that result in repeat deletion. These results imply a more comprehensive role for UvrA, in addition to the recognition of DNA damage, in maintaining the integrity of the genome.	Texas A&M Univ Syst, Hlth Sci Ctr, Inst Biosci & Technol, Houston, TX 77030 USA; Univ Texas, Med Branch, Sealy Ctr Mol Sci, Galveston, TX 77555 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Medical Branch Galveston	Potaman, VN (corresponding author), Texas A&M Univ Syst, Hlth Sci Ctr, Inst Biosci & Technol, 2121 W Holcombe Blvd, Houston, TX 77030 USA.		Sinden, Richard/AAE-3086-2019; Zou, Yue/ABA-8429-2020		NIEHS NIH HHS [ES05508] Funding Source: Medline	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ahn BC, 1996, J BIOL CHEM, V271, P21462, DOI 10.1074/jbc.271.35.21462; ALTON NK, 1979, NATURE, V282, P864, DOI 10.1038/282864a0; AYARES D, 1987, MOL CELL BIOL, V7, P1656, DOI 10.1128/MCB.7.5.1656; BICHARA M, 1987, J BACTERIOL, V169, P423, DOI 10.1128/jb.169.1.423-426.1987; CAMPBELL CR, 1989, MUTAT RES, V211, P181, DOI 10.1016/0027-5107(89)90118-8; CARRAWAY M, 1993, J BACTERIOL, V175, P3972, DOI 10.1128/JB.175.13.3972-3980.1993; Connelly JC, 1998, P NATL ACAD SCI USA, V95, P7969, DOI 10.1073/pnas.95.14.7969; Cooper D. N., 1993, HUMAN GENE MUTATION; Corrette-Bennett SE, 1999, J BIOL CHEM, V274, P17605, DOI 10.1074/jbc.274.25.17605; Cox MM, 1998, GENES CELLS, V3, P65, DOI 10.1046/j.1365-2443.1998.00175.x; Cummings CJ, 2000, HUM MOL GENET, V9, P909, DOI 10.1093/hmg/9.6.909; Darlow JM, 1998, J MOL BIOL, V275, P3, DOI 10.1006/jmbi.1997.1453; Delagoutte E, 1997, J MOL BIOL, V266, P703, DOI 10.1006/jmbi.1996.0830; DOHET C, 1987, MOL GEN GENET, V206, P181, DOI 10.1007/BF00326556; DRAKE JW, 1991, P NATL ACAD SCI USA, V88, P7160, DOI 10.1073/pnas.88.16.7160; FISHEL R, 1989, J BACTERIOL, V171, P3046, DOI 10.1128/jb.171.6.3046-3052.1989; FISHEL RA, 1984, COLD SPRING HARB SYM, V49, P603, DOI 10.1101/SQB.1984.049.01.068; Genschel J, 1998, J BIOL CHEM, V273, P19895, DOI 10.1074/jbc.273.31.19895; Giovannucci E, 1997, P NATL ACAD SCI USA, V94, P3320, DOI 10.1073/pnas.94.7.3320; Haber JE, 1999, TRENDS BIOCHEM SCI, V24, P271, DOI 10.1016/S0968-0004(99)01413-9; HUSAIN I, 1988, P NATL ACAD SCI USA, V85, P2558, DOI 10.1073/pnas.85.8.2558; JAWORSKI A, 1995, P NATL ACAD SCI USA, V92, P11019, DOI 10.1073/pnas.92.24.11019; KANG S, 1995, NAT GENET, V10, P213, DOI 10.1038/ng0695-213; Kantoff P, 1998, BBA-REV CANCER, V1378, pC1; Kolodner RD, 1999, CURR OPIN GENET DEV, V9, P89, DOI 10.1016/S0959-437X(99)80013-6; Leach DRF, 1997, MOL MICROBIOL, V26, P597, DOI 10.1046/j.1365-2958.1997.6071957.x; LEACH DRF, 1994, BIOESSAYS, V16, P893, DOI 10.1002/bies.950161207; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; Littman SJ, 1999, J BIOL CHEM, V274, P7474, DOI 10.1074/jbc.274.11.7474; Lupski JR, 1998, TRENDS GENET, V14, P417, DOI 10.1016/S0168-9525(98)01555-8; Marians KJ, 2000, CURR OPIN GENET DEV, V10, P151, DOI 10.1016/S0959-437X(00)00059-9; MAZUR SJ, 1991, BIOCHEMISTRY-US, V30, P4432, DOI 10.1021/bi00232a009; Michel B, 2000, TRENDS BIOCHEM SCI, V25, P173, DOI 10.1016/S0968-0004(00)01560-7; Mitas M, 1997, NUCLEIC ACIDS RES, V25, P2245, DOI 10.1093/nar/25.12.2245; Modrich P, 1997, J BIOL CHEM, V272, P24727, DOI 10.1074/jbc.272.40.24727; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Moolenaar GF, 1998, J BIOL CHEM, V273, P34896, DOI 10.1074/jbc.273.52.34896; Oussatcheva EA, 1999, J MOL BIOL, V292, P75, DOI 10.1006/jmbi.1999.3043; PARKER BO, 1992, P NATL ACAD SCI USA, V89, P1730, DOI 10.1073/pnas.89.5.1730; Parniewski P, 2000, J MOL BIOL, V299, P865, DOI 10.1006/jmbi.2000.3796; Parniewski P, 1999, NUCLEIC ACIDS RES, V27, P616, DOI 10.1093/nar/27.2.616; Pearson CE, 1998, GENETIC INSTABILITIES AND HEREDITARY NEUROLOGICAL DISEASES, P585; Pearson CE, 1996, BIOCHEMISTRY-US, V35, P5041, DOI 10.1021/bi9601013; Pearson CE, 1998, CURR OPIN STRUC BIOL, V8, P321, DOI 10.1016/S0959-440X(98)80065-1; Richards RI, 1997, TRENDS BIOCHEM SCI, V22, P432, DOI 10.1016/S0968-0004(97)01108-0; Sambrook J., 2002, MOL CLONING LAB MANU; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; Schmidt KH, 2000, MOL MICROBIOL, V35, P463, DOI 10.1046/j.1365-2958.2000.01727.x; Schumacher S, 1998, J MOL BIOL, V279, P1101, DOI 10.1006/jmbi.1998.1827; Sinden Richard R., 1992, Current Opinion in Biotechnology, V3, P612, DOI 10.1016/0958-1669(92)90005-4; Tsao H, 1998, BIOCHEMISTRY-US, V37, P4993, DOI 10.1021/bi980291c; VANHOUTEN B, 1987, J BIOL CHEM, V262, P13180; Verhoeven EEA, 2000, J BIOL CHEM, V275, P5120, DOI 10.1074/jbc.275.7.5120; WEISS U, 1987, P NATL ACAD SCI USA, V84, P1619, DOI 10.1073/pnas.84.6.1619; Wells R.D., 1998, GENETIC INSTABILITIE; Wells RD, 1998, J BIOL CHEM, V273, P19532, DOI 10.1074/jbc.273.31.19532; Wells RD, 1996, J BIOL CHEM, V271, P2875, DOI 10.1074/jbc.271.6.2875; Zou Y, 1999, EMBO J, V18, P4889, DOI 10.1093/emboj/18.17.4889; ZOU Y, 1995, BIOCHEMISTRY-US, V34, P13582, DOI 10.1021/bi00041a038; Zou Y, 1997, J BIOL CHEM, V272, P4820, DOI 10.1074/jbc.272.8.4820	60	45	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					30878	30884		10.1074/jbc.M104697200	http://dx.doi.org/10.1074/jbc.M104697200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11413147	hybrid			2022-12-25	WOS:000170472900040
J	Yamazaki, H; Shimada, T; Martin, MV; Guengerich, FP				Yamazaki, H; Shimada, T; Martin, MV; Guengerich, FP			Stimulation of cytochrome P450 reactions by apo-cytochrome b(5) - Evidence against transfer of heme from cytochrome P450 3A4 to apo-cytochrome b5, or heme oxygenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER MICROSOMAL CYTOCHROME-P-450; PROTEIN-PROTEIN INTERACTIONS; OXIDATIVE DRUG-METABOLISM; ELECTRON-TRANSFER; RAT-LIVER; RECONSTITUTED SYSTEMS; GENETIC-POLYMORPHISM; CATALYTIC ACTIVITIES; ESCHERICHIA-COLI; FUSION PROTEIN	Many cytochrome P450 (P450)-dependent reactions have been shown to be stimulated by another microsomal protein, cytochrome b(5) (b(5)). Two major explanations are (i) direct electron transfer from b(5) and (ii) a conformational. effect in the absence of electron transfer. Some P450s (e.g. 3A4, 2C9, 17A, and 4A7) are stimulated by either b(5) or b(5) devoid of heme (apo-b(5)), indicating a lack of electron transfer, whereas other P450s (e.g. 2E1) are stimulated by b5 but not by apo-b(5). Recently, a proposal has been made by Guryev et al. (Biochemistry 40, 5018-5031, 2001) that the stimulation by apo-b5 can be explained only by transfer of heme from P450 preparations to apo-b(5), enabling electron transfer. We have repeated earlier findings of stimulation of catalytic activity of testosterone 6 beta -hydroxylation activities with four P450 preparations, in which nearly all of the heme was accounted for as P450. Spectral analysis of mixtures indicated that only similar to5% of the heme can be transferred to apo-b(5), which cannot account for the observed stimulation. The presence of the heme scavenger apomyoglobin did not inhibit the stimulation of P450 3A4-dependent testosterone or nifedipine oxidation activity. Further evidence against the presence of loosely bound P450 3A4 heme was provided in experiments with apo-heme oxygenase, in which only 3% of the P450 heme was converted to biliverdin. Finally, b(5) supported NADH-b(5) reductase/P450 3A4-dependent testosterone 6 beta -hydroxylation, but apo-b(5) did not. Thus, apo-b(5) can stimulate P450 3A4 reactions as well as b(5) in the absence of electron transfer, and heme transfer from P450 3A4 to apo-b(5) cannot be used to explain the catalytic stimulation.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Ctr Mol Toxicol, Nashville, TN 37232 USA; Osaka Prefectural Inst Publ Hlth, Osaka 5370025, Japan; Kanazawa Univ, Fac Pharmaceut Sci, Div Drug Metab, Kanazawa, Ishikawa 9200934, Japan	Vanderbilt University; Vanderbilt University; Osaka Prefectural Institute of Public Health; Kanazawa University	Guengerich, FP (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, 638 Robinson Res Bldg MRBI,23rd & Pierce Ave, Nashville, TN 37232 USA.	guengerich@toxicology.mc.vanderbilt.edu	Yamazaki, Hiroshi/A-6081-2011	Yamazaki, Hiroshi/0000-0002-1068-4261; Shimada, Tsutomu/0000-0003-2552-4348	NATIONAL CANCER INSTITUTE [R01CA090426, R35CA044353] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA90426, R35 CA44353] Funding Source: Medline; NIEHS NIH HHS [P30 ES00267] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Atkins WM, 2001, CHEM RES TOXICOL, V14, P338, DOI 10.1021/tx0002132; Auchus RJ, 1998, J BIOL CHEM, V273, P3158, DOI 10.1074/jbc.273.6.3158; Backes WL, 1998, BIOCHEMISTRY-US, V37, P12852, DOI 10.1021/bi980674a; BEAUNE PH, 1986, P NATL ACAD SCI USA, V83, P8064, DOI 10.1073/pnas.83.21.8064; BONKOVSKY HL, 1986, ANAL BIOCHEM, V155, P56, DOI 10.1016/0003-2697(86)90224-1; BOSTERLING B, 1982, J BIOL CHEM, V257, P4375; Bridges A, 1998, J BIOL CHEM, V273, P17036, DOI 10.1074/jbc.273.27.17036; de Montellano PR Ortiz, 1995, CYTOCHROME P450 STRU; Domanski TL, 1998, ARCH BIOCHEM BIOPHYS, V350, P223, DOI 10.1006/abbi.1997.0525; FALK JE, 1964, PORPHYRINS METALLOPO, P81; Falzone CJ, 2001, BIOCHEMISTRY-US, V40, P4879, DOI 10.1021/bi002681g; GILLAM EMJ, 1993, ARCH BIOCHEM BIOPHYS, V305, P123, DOI 10.1006/abbi.1993.1401; GUENGERICH FP, 1975, J BIOL CHEM, V250, P7405; Guengerich FP, 2001, CHEM RES TOXICOL, V14, P611, DOI 10.1021/tx0002583; GUENGERICH FP, 1986, J BIOL CHEM, V261, P5051; GUENGERICH FP, 1983, BIOCHEMISTRY-US, V22, P2811, DOI 10.1021/bi00281a007; GUENGERICH FP, 1978, BIOCHEMISTRY-US, V17, P3633, DOI 10.1021/bi00610a033; Guengerich FP, 1997, BIOCHEMISTRY-US, V36, P14741, DOI 10.1021/bi9719399; GUENGERICH FP, 1991, CHEM RES TOXICOL, V4, P391, DOI 10.1021/tx00022a001; Guryev OL, 2001, BIOCHEMISTRY-US, V40, P5018, DOI 10.1021/bi002305w; Hanna IH, 2000, ARCH BIOCHEM BIOPHYS, V376, P206, DOI 10.1006/abbi.2000.1708; Hanna IH, 1998, ARCH BIOCHEM BIOPHYS, V350, P324, DOI 10.1006/abbi.1997.0534; HASEMANN CA, 1995, STRUCTURE, V3, P41, DOI 10.1016/S0969-2126(01)00134-4; HILDEBRANDT A, 1971, ARCH BIOCHEM BIOPHYS, V143, P66, DOI 10.1016/0003-9861(71)90186-X; HONKAKOSKI P, 1992, BIOCHIM BIOPHYS ACTA, V1122, P6, DOI 10.1016/0167-4838(92)90120-3; Hosea NA, 2000, BIOCHEMISTRY-US, V39, P5929, DOI 10.1021/bi992765t; Hosea NA, 1998, ARCH BIOCHEM BIOPHYS, V353, P365, DOI 10.1006/abbi.1998.0659; IMAI Y, 1981, J BIOCHEM-TOKYO, V89, P351, DOI 10.1093/oxfordjournals.jbchem.a133209; IMAOKA S, 1992, BIOCHEMISTRY-US, V31, P6063, DOI 10.1021/bi00141a015; INGELMANSUNDBERG M, 1980, BIOCHEM BIOPH RES CO, V97, P582, DOI 10.1016/0006-291X(80)90303-4; Koley AP, 1997, BIOCHEM PHARMACOL, V53, P455, DOI 10.1016/S0006-2952(96)00836-2; KRASNY HC, 1977, MOL PHARMACOL, V13, P759; KUTTY RK, 1988, ARCH BIOCHEM BIOPHYS, V260, P638, DOI 10.1016/0003-9861(88)90492-4; LEWIS D.F.V, 1996, CYTOCHROMES P450 STR; Loughran PA, 2000, BIOCHEMISTRY-US, V39, P15110, DOI 10.1021/bi001522u; Loughran PA, 2001, ARCH BIOCHEM BIOPHYS, V385, P311, DOI 10.1006/abbi.2000.2136; MIHARA K, 1975, J BIOCHEM-TOKYO, V78, P1057, DOI 10.1093/oxfordjournals.jbchem.a130983; MIKI N, 1980, J BIOCHEM-TOKYO, V88, P307, DOI 10.1093/oxfordjournals.jbchem.a132976; NOSHIRO M, 1981, EUR J BIOCHEM, V116, P521, DOI 10.1111/j.1432-1033.1981.tb05367.x; NOSHIRO M, 1980, J BIOCHEM-TOKYO, V88, P1521, DOI 10.1093/oxfordjournals.jbchem.a133123; OMURA T, 1964, J BIOL CHEM, V239, P2370; PALMER G, 1992, J BIOL CHEM, V267, P665; Perret A, 1998, BIOCHEMISTRY-US, V37, P11412, DOI 10.1021/bi980908q; Peterson JA, 1986, CYTOCHROME P 450 STR, P89; POMPON D, 1984, J BIOL CHEM, V259, P5377; PORTER TD, 1991, J BIOL CHEM, V266, P13469; Rivera M, 1998, BIOCHEMISTRY-US, V37, P1485, DOI 10.1021/bi972390g; ROSENBERG DW, 1980, BIOCHEM J, V190, P465, DOI 10.1042/bj1900465; Schenkman JB, 1999, DRUG METAB REV, V31, P351, DOI 10.1081/DMR-100101923; Shaw PM, 1997, ARCH BIOCHEM BIOPHYS, V348, P107, DOI 10.1006/abbi.1997.0378; SHEN AL, 1989, J BIOL CHEM, V264, P7584; SHET MS, 1993, P NATL ACAD SCI USA, V90, P11748, DOI 10.1073/pnas.90.24.11748; SHIMADA T, 1986, J BIOL CHEM, V261, P909; Strittmatter P, 1978, Methods Enzymol, V52, P97; TAMBURINI PP, 1983, J BIOL CHEM, V258, P3444; TAMBURINI PP, 1985, J BIOL CHEM, V260, P4007; VELICK SF, 1956, J BIOL CHEM, V221, P265; WEST SB, 1974, BIOCHEM BIOPH RES CO, V58, P516, DOI 10.1016/0006-291X(74)90395-7; WILKS A, 1995, BIOCHEMISTRY-US, V34, P4421, DOI 10.1021/bi00013a034; YAMANO T, 1978, PHARMACOL THER PT A, V2, P673, DOI 10.1016/0362-5478(78)90010-4; Yamazaki H, 1999, DRUG METAB DISPOS, V27, P999; Yamazaki H, 1997, ARCH BIOCHEM BIOPHYS, V342, P329, DOI 10.1006/abbi.1997.0125; YAMAZAKI H, 1995, BIOCHEMISTRY-US, V34, P8380, DOI 10.1021/bi00026a020; Yamazaki H, 1996, ARCH BIOCHEM BIOPHYS, V325, P174, DOI 10.1006/abbi.1996.0022; Yamazaki H, 1996, BIOCHEM PHARMACOL, V52, P301, DOI 10.1016/0006-2952(96)00208-0; Yamazaki H, 1996, J BIOL CHEM, V271, P27438, DOI 10.1074/jbc.271.44.27438; Yano JK, 2000, J BIOL CHEM, V275, P31086, DOI 10.1074/jbc.M004281200	67	86	89	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					30885	30891		10.1074/jbc.M105011200	http://dx.doi.org/10.1074/jbc.M105011200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11413149	hybrid			2022-12-25	WOS:000170472900041
J	Mercalli, E; Ghizzoni, S; Arighi, E; Alberti, L; Sangregorio, R; Radice, MT; Gishizky, ML; Pierotti, MA; Borrello, MG				Mercalli, E; Ghizzoni, S; Arighi, E; Alberti, L; Sangregorio, R; Radice, MT; Gishizky, ML; Pierotti, MA; Borrello, MG			Key role of Shc signaling in the transforming pathway triggered by Ret/ptc2 oncoprotein	ONCOGENE			English	Article						Ret; Shc; oncogene; thyroid carcinoma	RECEPTOR TYROSINE KINASES; NEUROTROPHIC FACTOR; TRANSDUCTION PATHWAYS; PHOSPHORYLATION SITES; RET MUTATIONS; DOCKING SITE; PROTEIN; ACTIVATION; BINDING; DOMAIN	The RET/PTC oncogenes, generated by chromosomal rearrangements in papillary thyroid carcinomas, are constitutively activated versions of protoRET, a gene encoding two protein isoforms of a transmembrane tyrosine kinase receptor, By using Ret/ptc2 short isoform (iso9), we have previously demonstrated that Tyr586 (Tyr1062 of protoRet) is the docking site for both the PTB and the SH2 domains of Shc. To determine the relevance of this interaction for the transforming activity of Ret/ptc oncogenes, we have generated and characterized novel Ret/ptc mutants unable to activate Shc: Ret/ptc2 long isoform (iso51)-Y586F and both isoforms of Ret/ptc2-N583A, These mutants neither activate Shc nor transform NIH3T3 cells. Since Tyr1062 shows features of a multifunctional docking site, we have used a Shc mutant (Shc Y317F) to directly assess Shc role, We have demonstrated that in our cell syst-ern Shc Y317F behaves like a dominant interfering mutant on the activation of the Grb2-Sos pathway by endogenous Shc triggered by Ret/ptc2, A strong reduction of the transforming activity of Ret/ptc2 in presence of this mutant was also demonstrated. Our data suggest that Shc activation play a key role in the transforming pathways triggered by Ret/ptc oncoproteins. Moreover, we have shown that coexpression of the Shc-Y317F mutant with Ret/ptc2 specifically causes apoptosis, and that the surviving cells lose the long-term expression of one of the two genes.	Ist Nazl Tumori, Dept Expt Oncol, Res Unit 3, I-20133 Milan, Italy; SUGEN, San Francisco, CA 94080 USA	Fondazione IRCCS Istituto Nazionale Tumori Milan; Pfizer	Pierotti, MA (corresponding author), Ist Nazl Tumori, Dept Expt Oncol, Res Unit 3, Via G Venezian 1, I-20133 Milan, Italy.		Pierotti, Marco Alessandro/AAC-4728-2022; Borrello, Maria Grazia/C-3161-2017	Pierotti, Marco Alessandro/0000-0002-7431-8332; Borrello, Maria Grazia/0000-0002-6854-2848				Alberti L, 1998, ONCOGENE, V17, P1079, DOI 10.1038/sj.onc.1202046; Arighi E, 1997, ONCOGENE, V14, P773, DOI 10.1038/sj.onc.1200896; Asai N, 1996, J BIOL CHEM, V271, P17644, DOI 10.1074/jbc.271.30.17644; Besset V, 2000, J BIOL CHEM, V275, P39159, DOI 10.1074/jbc.M006908200; BONGARZONE I, 1989, ONCOGENE, V4, P1457; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; Bordeaux MC, 2000, EMBO J, V19, P4056, DOI 10.1093/emboj/19.15.4056; Borrello MG, 1996, MOL CELL BIOL, V16, P2151; BORRELLO MG, 1994, ONCOGENE, V9, P1661; Creedon DJ, 1997, P NATL ACAD SCI USA, V94, P7018, DOI 10.1073/pnas.94.13.7018; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; Durick K, 1998, MOL CELL BIOL, V18, P2298, DOI 10.1128/MCB.18.4.2298; DURICK K, 1995, J BIOL CHEM, V270, P24642, DOI 10.1074/jbc.270.42.24642; Durick K, 1996, J BIOL CHEM, V271, P12691, DOI 10.1074/jbc.271.22.12691; Fambrough D, 1999, CELL, V97, P727, DOI 10.1016/S0092-8674(00)80785-0; Fischer AH, 1998, AM J PATHOL, V153, P1443, DOI 10.1016/S0002-9440(10)65731-8; FIXMAN ED, 1995, ONCOGENE, V10, P237; Gotoh N, 1997, MOL CELL BIOL, V17, P1824, DOI 10.1128/MCB.17.4.1824; Guo M, 1999, CURR OPIN CELL BIOL, V11, P745, DOI 10.1016/S0955-0674(99)00046-0; Hayashi H, 2000, ONCOGENE, V19, P4469, DOI 10.1038/sj.onc.1203799; Hennige AM, 2000, MOL CELL ENDOCRINOL, V167, P69, DOI 10.1016/S0303-7207(00)00283-5; Hill RJ, 1996, CELL GROWTH DIFFER, V7, P1125; ISHIZAKA Y, 1989, ONCOGENE, V4, P789; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; Liu X, 1996, J BIOL CHEM, V271, P5309, DOI 10.1074/jbc.271.10.5309; Lorenzo MJ, 1997, ONCOGENE, V14, P763, DOI 10.1038/sj.onc.1200894; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; Migliaccio E, 1999, NATURE, V402, P309, DOI 10.1038/46311; Milbrandt J, 1998, NEURON, V20, P245, DOI 10.1016/S0896-6273(00)80453-5; Pandey A, 1996, J BIOL CHEM, V271, P10607, DOI 10.1074/jbc.271.18.10607; PANDEY A, 1995, J BIOL CHEM, V270, P21461, DOI 10.1074/jbc.270.37.21461; Pasini B, 1996, TRENDS GENET, V12, P138, DOI 10.1016/0168-9525(96)10012-3; PASINI B, 1995, NAT GENET, V10, P35, DOI 10.1038/ng0595-35; PELICCI G, 1995, ONCOGENE, V11, P899; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Pierotti MA, 1996, GENE CHROMOSOME CANC, V16, P1; Porter AC, 1998, ONCOGENE, V17, P1343, DOI 10.1038/sj.onc.1202171; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; Segouffin-Cariou C, 2000, J BIOL CHEM, V275, P3568, DOI 10.1074/jbc.275.5.3568; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; TAKAHASHI M, 1988, ONCOGENE, V3, P571; Thomas D, 1997, J BIOL CHEM, V272, P22293, DOI 10.1074/jbc.272.35.22293; TRUB T, 1995, J BIOL CHEM, V270, P18205; Trupp M, 1999, J BIOL CHEM, V274, P20885, DOI 10.1074/jbc.274.30.20885; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; vanWeering DHJ, 1997, J BIOL CHEM, V272, P249	50	21	21	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 14	2001	20	27					3475	3485		10.1038/sj.onc.1204462	http://dx.doi.org/10.1038/sj.onc.1204462			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	445VB	11429694				2022-12-25	WOS:000169478300003
J	Coelho, ALJ; De Freitas, MS; Mariano-Oliveira, A; Oliveira-Carvalho, AL; Zingali, RB; Barja-Fidalgo, C				Coelho, ALJ; De Freitas, MS; Mariano-Oliveira, A; Oliveira-Carvalho, AL; Zingali, RB; Barja-Fidalgo, C			Interaction of disintegrins with human neutrophils induces cytoskeleton reorganization, focal adhesion kinase activation, and extracellular-regulated kinase-2 nuclear translocation, interfering with the chemotactic function	FASEB JOURNAL			English	Article						disintegrins; neutrophils; chemotaxis; tyrosine kinase pathway; actin cytoskeleton	SNAKE-VENOM DISINTEGRIN; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; PROTEIN-KINASE; CELL-ADHESION; ACTIN CYTOSKELETON; BINDING PROTEIN; INTEGRIN; CONTORTROSTATIN; ECHISTATIN	We previously demonstrated that jarastatin (JT), a new disintegrin from Bothrops jararaca venom, altered actin dynamics in human polymorphonuclear neutrophils (PMNs) and inhibited cell migration in vivo and in vitro (14). In this study, we evaluated the effects of JT and two other monomeric disintegrins, kistrin (KR) and flavoridin (FL), on PMN chemotaxis and chemokinesis in vitro and on the activation of integrin-mediated pathways. Although JT, but not KR or FL, was chemotactic, only KR was chemokinetic to PMN. However, preincubation of PMN with any disintegrins inhibited chemotaxis for fMLP. Treatment of PMN with JT and KR increased actin polymerization, whereas FL reduced the content of F-actin. The effects of JT and KR on actin dynamics were inhibited (50%) by genistein, a tyrosine kinase inhibitor. Accordingly, JT and KR induced an increase in tyrosine phosphorylation, whereas FL had no effect. The three disintegrins were able to induce focal adhesion kinase activation. However, JT and KR promoted Erk-2 nuclear translocation, and FL inhibited Erk-2 activation. The data suggest that although the disintegrins JT and KR directly activate integrin-coupled signaling, FL may interact differently with integrins, triggering an inhibitory pathway modulated by focal adhesion kinase activation.	Univ Estado Rio de Janeiro, Inst Biol, Dept Farmacol, BR-20551030 Rio De Janeiro, Brazil; Univ Fed Rio de Janeiro, ICB, CCS, Dept Bioquim Med, Rio De Janeiro, Brazil	Universidade do Estado do Rio de Janeiro; Universidade Federal do Rio de Janeiro	Barja-Fidalgo, C (corresponding author), Univ Estado Rio de Janeiro, Inst Biol, Dept Farmacol, Av 28 Setembro 87,5th Floor,Vila Isabel, BR-20551030 Rio De Janeiro, Brazil.	barja-fidalgo@uerj.br	de Freitas, Marta Sampaio/AAE-8422-2021; Zingali, Russolina/G-4862-2012	Zingali, Russolina/0000-0003-3156-6923				ANDERSON NG, 1992, CELL SIGNAL, V4, P239, DOI 10.1016/0898-6568(92)90063-E; Aplin AE, 1998, PHARMACOL REV, V50, P197; Asthagiri AR, 1999, J BIOL CHEM, V274, P27119, DOI 10.1074/jbc.274.38.27119; Belisario MA, 2000, BBA-MOL CELL RES, V1497, P227, DOI 10.1016/S0167-4889(00)00061-6; BOGOMOLSKIYAHALOM V, 1995, BLOOD REV, V9, P183, DOI 10.1016/0268-960X(95)90024-1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN EJ, 1988, J EXP MED, V167, P777, DOI 10.1084/jem.167.3.777; BUHL AM, 1994, P NATL ACAD SCI USA, V91, P9190, DOI 10.1073/pnas.91.19.9190; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CARRENO MP, 1993, CLIN IMMUNOL IMMUNOP, V69, P43, DOI 10.1006/clin.1993.1148; CHEN QM, 1994, J BIOL CHEM, V269, P26602; Chicurel ME, 1998, NATURE, V392, P730, DOI 10.1038/33719; Coelho ALJ, 1999, EXP CELL RES, V251, P379, DOI 10.1006/excr.1999.4583; Danen EHJ, 1998, EXP CELL RES, V238, P188, DOI 10.1006/excr.1997.3821; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOOLEY DC, 1982, EXP HEMATOL, V10, P591; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; GOMEZCAMBRONERO J, 1992, P NATL ACAD SCI USA, V89, P7551, DOI 10.1073/pnas.89.16.7551; GRINSTEIN S, 1992, J BIOL CHEM, V267, P18122; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Juliano D, 1996, EXP CELL RES, V225, P132, DOI 10.1006/excr.1996.0164; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Knall C, 1996, J BIOL CHEM, V271, P2832, DOI 10.1074/jbc.271.5.2832; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE TH, 1989, CLIN SCI, V77, P195, DOI 10.1042/cs0770195; Lian JP, 1999, J IMMUNOL, V163, P4527; Lowell CA, 1999, J LEUKOCYTE BIOL, V65, P313, DOI 10.1002/jlb.65.3.313; McLane MA, 1998, P SOC EXP BIOL MED, V219, P109, DOI 10.3181/00379727-219-44322; McLane MA, 1996, FEBS LETT, V391, P139, DOI 10.1016/0014-5793(96)00716-8; Mocsai A, 2000, J IMMUNOL, V164, P4321, DOI 10.4049/jimmunol.164.8.4321; NIEWIAROWSKI S, 1994, SEMIN HEMATOL, V31, P289; Ritter MR, 2001, TOXICON, V39, P283, DOI 10.1016/S0041-0101(00)00126-4; Ritter MR, 2000, BIOCHEM BIOPH RES CO, V274, P142, DOI 10.1006/bbrc.2000.3111; Ritter MR, 2000, J CELL BIOCHEM, V79, P28, DOI 10.1002/1097-4644(2000)79:1<28::AID-JCB40>3.0.CO;2-Y; Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697; Sheikh S, 1997, BIOCHEM BIOPH RES CO, V238, P910, DOI 10.1006/bbrc.1997.7407; Staiano N, 1997, EUR J CELL BIOL, V73, P298; Stanton KJ, 1999, J LEUKOCYTE BIOL, V65, P515, DOI 10.1002/jlb.65.4.515; Williams MA, 1999, J LEUKOCYTE BIOL, V65, P725, DOI 10.1002/jlb.65.6.725; Zouki C, 2001, FASEB J, V15, P25	42	34	34	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY 29	2001	15	7					1643	+		10.1096/fj.00-0812fje	http://dx.doi.org/10.1096/fj.00-0812fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519CQ	11427513				2022-12-25	WOS:000173707700007
J	Elkin, M; Ilan, N; Ishai-Michaeli, R; Friedmann, Y; Papo, O; Pecker, I; Vlodavsky, I				Elkin, M; Ilan, N; Ishai-Michaeli, R; Friedmann, Y; Papo, O; Pecker, I; Vlodavsky, I			Heparanase as mediator of angiogenesis: mode of action	FASEB JOURNAL			English	Article						heparan sulfate proteoglycans; extracellular matrix; endothelial cells; basic fibroblast growth factor; wound healing	FIBROBLAST-GROWTH-FACTOR; EXTRACELLULAR-MATRIX; TUMOR-METASTASIS; SULFATE PROTEOGLYCANS; MAMMALIAN HEPARANASE; ENDOTHELIAL-CELLS; BASEMENT-MEMBRANE; RECEPTOR-BINDING; HEPARIN; EXPRESSION	Extracellular matrix (ECM) and basement membranes (BMs) present a physical barrier that requires enzymatic degradation during endothelial cell (EC) sprouting at early stages of angiogenesis. These multimolecular structures also serve as a storage depot for heparin-binding angiogenic factors. Heparan sulfate proteoglycans (HSPGs) are responsible for the self-assembly and integrity of the ECM and BM structure, as well as for sequestration of growth and differentiation factors. Recently, we reported the cloning of heparanase, an endo-beta-D-glucuronidase degrading heparan sulfate (HS), and provided direct evidence for its role in tumor metastasis. We now demonstrate that heparanase is intimately involved in angiogenesis and elucidate its mode of action. Apart from its direct involvement in ECM degradation and EC migration (vascular sprouting), heparanase releases active basic fibroblast growth factor (bFGF) from the subendothelial ECM, as well as bFGF-stimulating HS degradation fragments from the EC surface. Interestingly, ECM-derived HS fragments induced little or no potentiation of the growth-promoting activity of bFGF. The angiogenic effect of heparanase was demonstrated in vivo (via the Matrigel plug assay) by showing a three- to fourfold increase in neovascularization induced by murine T-lymphoma cells after stable transfection with the heparanase gene. Increased tissue vascularity was also observed in a mouse wound-healing model in response to topical administration of recombinant heparanase. Immunohistochemical staining of human colon carcinoma tissue revealed a high expression of the heparanase protein in the endothelium of sprouting capillaries and small vessels, but not of mature quiescent blood vessels. The ability of heparanase to promote tumor angiogenesis and its involvement in tumor metastasis make it a promising target for cancer therapy.	Hadassah Hebrew Univ Hosp, Dept Oncol, IL-91120 Jerusalem, Israel; Hadassah Hebrew Univ Hosp, Dept Pathol, IL-91120 Jerusalem, Israel; InSight, IL-76121 Rehovot, Israel	Hebrew University of Jerusalem; Hadassah University Medical Center; Hebrew University of Jerusalem; Hadassah University Medical Center	Vlodavsky, I (corresponding author), Hadassah Hebrew Univ Hosp, Dept Oncol, POB 12000, IL-91120 Jerusalem, Israel.	vlodavsk@cc.huji.ac.il						AIRBANKS MB, 1999, J BIOL CHEM, V274, P29587; AVIEZER D, 1994, CELL, V79, P1005, DOI 10.1016/0092-8674(94)90031-0; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Chang Z, 2000, FASEB J, V14, P137, DOI 10.1096/fasebj.14.1.137; Dempsey LA, 2000, TRENDS BIOCHEM SCI, V25, P349, DOI 10.1016/S0968-0004(00)01619-4; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; Friedmann Y, 2000, AM J PATHOL, V157, P1167, DOI 10.1016/S0002-9440(10)64632-9; GILAT D, 1995, J EXP MED, V181, P1929, DOI 10.1084/jem.181.5.1929; GODDER K, 1991, J CELL PHYSIOL, V148, P274, DOI 10.1002/jcp.1041480213; Goshen R, 1996, MOL HUM REPROD, V2, P679, DOI 10.1093/molehr/2.9.679; Hulett MD, 1999, NAT MED, V5, P803, DOI 10.1038/10525; Ilan N, 1999, J CELL SCI, V112, P3005; Iozzo RV, 1996, FASEB J, V10, P598, DOI 10.1096/fasebj.10.5.8621059; ISHAIMICHAELI R, 1992, BIOCHEMISTRY-US, V31, P2080, DOI 10.1021/bi00122a027; Kussie PH, 1999, BIOCHEM BIOPH RES CO, V261, P183, DOI 10.1006/bbrc.1999.0962; Miao HQ, 1997, J CLIN INVEST, V99, P1565, DOI 10.1172/JCI119319; NAKAJIMA M, 1988, J CELL BIOCHEM, V36, P157, DOI 10.1002/jcb.240360207; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; Parish CR, 1999, CANCER RES, V59, P3433; PARISH CR, 1987, INT J CANCER, V40, P511, DOI 10.1002/ijc.2910400414; PASSANITI A, 1992, LAB INVEST, V67, P519; Pillarisetti S, 1997, J BIOL CHEM, V272, P15753, DOI 10.1074/jbc.272.25.15753; Schweitzer KM, 1997, LAB INVEST, V76, P25; SLOANE BF, 1994, J CELL SCI, V107, P373; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; Stetler-Stevenson WG, 1999, J CLIN INVEST, V103, P1237, DOI 10.1172/JCI6870; Toyoshima M, 1999, J BIOL CHEM, V274, P24153, DOI 10.1074/jbc.274.34.24153; VLODAVSKY I, 1994, INVAS METAST, V14, P290; Vlodavsky I, 1999, NAT MED, V5, P793, DOI 10.1038/10518; Vlodavsky I, 1996, CANCER METAST REV, V15, P177, DOI 10.1007/BF00437470; VLODAVSKY I, 1993, BASEMENT MEMBRANES C, P327; VLODAVSKY I, 1999, CURRENT PROTOCOLS CE, V1; VUKICEVIC S, 1992, EXP CELL RES, V202, P1, DOI 10.1016/0014-4827(92)90397-Q	34	271	295	1	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY 29	2001	15	7					1661	+		10.1096/fj.00-0895fje	http://dx.doi.org/10.1096/fj.00-0895fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519CQ	11427519				2022-12-25	WOS:000173707700003
J	Yamane, K; Katayama, E; Tsuruo, T				Yamane, K; Katayama, E; Tsuruo, T			p53 contains a DNA break-binding motif similar to the functional part of BRCT-related region of Rb	ONCOGENE			English	Article						DNA damage; tumor suppressor; Nijmegen breakage syndrome; DNA double-strand breaks; DNA end binding	C-TERMINAL DOMAIN; OLIGOMERIZATION DOMAIN; LI-FRAUMENI; PROTEIN; CHECKPOINT; APOPTOSIS; DAMAGE; REPAIR; TRANSFORMATION; LOCALIZATION	The BRCT regions are two repeating structures at BRCA1 carboxyl-terminus and are ubiquitous in some proteins involved in DNA repair and cell cycle checkpoints. It was shown that BRCTs of TopBP1, BRCA1, and BRCT-Ws of Rb hound DNA ends and breaks. We indicate here that the C-terminus of p53 tumor suppressor contains a DNA binding motif (residues 327-333 in human), whose features are similar to those of the part of BRCT-W in Rb with DNA binding activity. The short motif was required for the gel retardation activity of DNA fragments, since residues 311-333 show cd the activity while residues 311-326 showed no activity. Significant numbers of total p53 and its fragments with the motif formed multimerizing complexes and associated with DNA ends and breaks, These results suggest the common presence of DNA binding motifs that can recognize DNA ends or damages in major tumor suppressors, Rb, BRCA1 and p53. The oncogenic activity of p53 C-terminus (residues 311-393) required both the DNA damage recognition motif and the repair enzyme-associating domain. Oncogene (2001) 20, 2859-2867.	Univ Tokyo, Inst Mol & Cellular Biosci, Biomed Res Lab, Bunkyo Ku, Tokyo 1130032, Japan; Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Toshima Ku, Tokyo 1708455, Japan; Japan Sci & Technol Corp, Div Biomol Imaging, Kawaguchi, Saitama 3320012, Japan; Univ Tokyo, Inst Med Sci, Minato Ku, Tokyo 1088639, Japan	University of Tokyo; Japanese Foundation for Cancer Research; Japan Science & Technology Agency (JST); University of Tokyo	Yamane, K (corresponding author), Mayo Clin & Mayo Fdn, Dept Oncol, Guggenheim Bldg,Room 1306,200 1st St SW, Rochester, MN 55905 USA.							Aurelio ON, 2000, MOL CELL BIOL, V20, P770, DOI 10.1128/MCB.20.3.770-778.2000; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Chai YL, 1999, ONCOGENE, V18, P263, DOI 10.1038/sj.onc.1202323; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; Cranston A, 1997, NAT GENET, V17, P114, DOI 10.1038/ng0997-114; Davison TS, 1998, ONCOGENE, V17, P651, DOI 10.1038/sj.onc.1202062; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Innocente SA, 1999, P NATL ACAD SCI USA, V96, P2147, DOI 10.1073/pnas.96.5.2147; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Lomax ME, 1998, ONCOGENE, V17, P643, DOI 10.1038/sj.onc.1201974; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MIMORI T, 1986, J BIOL CHEM, V261, P375; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; REED M, 1995, P NATL ACAD SCI USA, V92, P9455, DOI 10.1073/pnas.92.21.9455; Selivanova G, 1996, NUCLEIC ACIDS RES, V24, P3560, DOI 10.1093/nar/24.18.3560; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; THUKRAL SK, 1994, MOL CELL BIOL, V14, P8315, DOI 10.1128/MCB.14.12.8315; TYLER JM, 1980, J ULTRA MOL STRUCT R, V71, P95, DOI 10.1016/S0022-5320(80)90098-2; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; WANG P, 1994, MOL CELL BIOL, V14, P5182, DOI 10.1128/MCB.14.8.5182; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WU L, 1995, MOL CELL BIOL, V15, P497, DOI 10.1128/MCB.15.1.497; Yamane K, 1997, EUR J BIOCHEM, V250, P794, DOI 10.1111/j.1432-1033.1997.00794.x; Yamane K, 1999, ONCOGENE, V18, P5194, DOI 10.1038/sj.onc.1202922; Yamane K, 2000, ONCOGENE, V19, P1982, DOI 10.1038/sj.onc.1203528; Yamane K, 2000, BIOCHEM BIOPH RES CO, V279, P678, DOI 10.1006/bbrc.2000.3983; ZAKUTHOURI R, 1985, EMBO J, V4, P1251, DOI 10.1002/j.1460-2075.1985.tb03768.x	38	6	6	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 24	2001	20	23					2859	2867		10.1038/sj.onc.1204408	http://dx.doi.org/10.1038/sj.onc.1204408			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	435VA	11420698				2022-12-25	WOS:000168901800001
J	Frost, V; Al-Mehairi, S; Sinclair, AJ				Frost, V; Al-Mehairi, S; Sinclair, AJ			Exploitation of a non-apoptotic caspase to regulate the abundance of the cdkI p27(KIP1) in transformed lymphoid cells	ONCOGENE			English	Article						cell cycle; apoptosis; lymphoma; protease	DEPENDENT KINASE INHIBITOR; EPSTEIN-BARR-VIRUS; BREAST-CANCER CELLS; CYCLE ARREST; GROWTH ARREST; T-CELLS; MDM2 ONCOPROTEIN; GENE P27(KIP1); B-LYMPHOCYTES; MICE LACKING	Expression of the cyclin dependent kinase inhibitor p27(KIP1) is intimately linked to the control of proliferation, and is itself regulated by transcription, translation, phosphorylation, protein stability or sequestration, p27(KIP1) is also regulated during apoptosis; cleavage occurs at (DPSDS)-S-139 and ESQD(108)V, by a sub-set of z-VAD-fmk-sensitive caspases, We have identified related but distinct mechanism that regulates p27(KIP1) in proliferating lymphoid cell lines. In a B-lymphoid cell line (BJAB), the abundance of p27(KIP1) oscillates inversely to proliferation; loss of full-length p27(KIP1) correlates with the appearance of a truncated version corresponding to cleavage at (DPSDS)-S-139, A direct correlation exists between the appearance of truncated p27(KIP1) and the presence of an activity able to cleave peptides representing (DPSDS)-S-139 and a caspase-8 substrate (Ac-IETD-AMC) in vitro. This activity is inhibited by Ac-IETD-CHO but not Z-VAD-fmk in vitro, Furthermore a requirement for caspase-8 has been excluded. The activity differs from the apoptosis related p27(KIP1)-cleaving activity; indeed few cells undergoing apoptosis are present in the population of proliferating cells, The activity is further distinguished by its inability to cleave a peptide based on ESQD(108)V in vitro, together with the lack of a corresponding cleavage product in vivo. Inhibition of the caspase activity in vivo promotes an accumulation of full length p27(KIP1), as well as a decrease in cell proliferation. Together these studies highlight the importance of non-apoptotic caspases in regulating p27(KIP1) in transformed lymphoid cells.	Univ Sussex, Sch Biol Sci, Brighton BN1 9QG, E Sussex, England	University of Sussex	Sinclair, AJ (corresponding author), Univ Sussex, Sch Biol Sci, Brighton BN1 9QG, E Sussex, England.			Sinclair, Alison/0000-0001-8510-8691				Agrawal D, 1996, MOL CELL BIOL, V16, P4327; Akita K, 1997, J BIOL CHEM, V272, P26595, DOI 10.1074/jbc.272.42.26595; Alam A, 1999, J EXP MED, V190, P1879, DOI 10.1084/jem.190.12.1879; Barnouin K, 1999, ONCOGENE, V18, P6388, DOI 10.1038/sj.onc.1203162; Cannell EJ, 1998, FEBS LETT, V439, P297, DOI 10.1016/S0014-5793(98)01391-X; Cannell EJ, 1996, ONCOGENE, V13, P1413; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Chen LH, 1997, J BIOL CHEM, V272, P22966, DOI 10.1074/jbc.272.36.22966; CLEMENTS GB, 1975, INT J CANCER, V16, P125, DOI 10.1002/ijc.2910160114; Craig C, 1997, ONCOGENE, V14, P2283, DOI 10.1038/sj.onc.1201064; Ekert PG, 1999, CELL DEATH DIFFER, V6, P1081, DOI 10.1038/sj.cdd.4400594; Erhardt P, 1997, J BIOL CHEM, V272, P15049, DOI 10.1074/jbc.272.24.15049; Eymin B, 1999, ONCOGENE, V18, P4839, DOI 10.1038/sj.onc.1202860; Eymin B, 1999, ONCOGENE, V18, P1411, DOI 10.1038/sj.onc.1202437; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Fredersdorf S, 1997, P NATL ACAD SCI USA, V94, P6380, DOI 10.1073/pnas.94.12.6380; Frost V, 2000, ONCOGENE, V19, P3115, DOI 10.1038/sj.onc.1203657; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Harvey KJ, 2000, J CELL BIOL, V148, P59, DOI 10.1083/jcb.148.1.59; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Hiromura K, 1999, J CLIN INVEST, V103, P597, DOI 10.1172/JCI5461; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Kawamata S, 1998, BLOOD, V91, P561, DOI 10.1182/blood.V91.2.561.561_561_569; Kennedy NJ, 1999, J EXP MED, V190, P1891, DOI 10.1084/jem.190.12.1891; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Kwon TK, 1997, J IMMUNOL, V158, P5642; Kwon TK, 1996, GENE, V180, P113, DOI 10.1016/S0378-1119(96)00416-7; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; Loubat A, 1999, ONCOGENE, V18, P3324, DOI 10.1038/sj.onc.1202668; Luo Y, 1996, MOL CELL BIOL, V16, P6744; Millard SS, 1997, J BIOL CHEM, V272, P7093, DOI 10.1074/jbc.272.11.7093; Miossec C, 1997, J BIOL CHEM, V272, P13459, DOI 10.1074/jbc.272.21.13459; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; Morisaki H, 1997, BIOCHEM BIOPH RES CO, V240, P386, DOI 10.1006/bbrc.1997.7590; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Nguyen H, 1999, MOL CELL BIOL, V19, P1190; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Park DS, 1998, J CELL BIOL, V143, P457, DOI 10.1083/jcb.143.2.457; Pochampally R, 1999, J BIOL CHEM, V274, P15271, DOI 10.1074/jbc.274.21.15271; Pochampally R, 1998, ONCOGENE, V17, P2629, DOI 10.1038/sj.onc.1202206; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Schreiber M, 1999, ONCOGENE, V18, P1663, DOI 10.1038/sj.onc.1202466; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SINCLAIR AJ, 1994, EMBO J, V13, P3321, DOI 10.1002/j.1460-2075.1994.tb06634.x; Soos TJ, 1996, CELL GROWTH DIFFER, V7, P135; Spender LC, 1999, J VIROL, V73, P4678, DOI 10.1128/JVI.73.6.4678-4688.1999; Talanian RV, 1997, J BIOL CHEM, V272, P9677; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; Wang XT, 1997, ONCOGENE, V15, P2991, DOI 10.1038/sj.onc.1201450; Wilhelm S, 1998, EUR J IMMUNOL, V28, P891, DOI 10.1002/(SICI)1521-4141(199803)28:03<891::AID-IMMU891>3.3.CO;2-O; Wu DMH, 1999, J IMMUNOL, V162, P1287; Zeuner A, 1999, CELL DEATH DIFFER, V6, P1075, DOI 10.1038/sj.cdd.4400596; Zhang YJ, 1998, J BIOL CHEM, V273, P1144, DOI 10.1074/jbc.273.2.1144	66	26	26	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 17	2001	20	22					2737	2748		10.1038/sj.onc.1204367	http://dx.doi.org/10.1038/sj.onc.1204367			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	432TP	11420686				2022-12-25	WOS:000168712000002
J	Sutherland, LC; Lerman, M; Williams, GT; Miller, BA				Sutherland, LC; Lerman, M; Williams, GT; Miller, BA			LUCA-15 suppresses CD95-mediated apoptosis in Jurkat T cells	ONCOGENE			English	Article						LUCA-15; 3p21.3; apoptosis; CD95; staurosporine; Jurkat	CHEMOTHERAPY-INDUCED APOPTOSIS; MOLECULAR-GENETIC CHANGES; CYTOCHROME-C RELEASE; RNA-BINDING PROTEIN; LUNG-CANCER; HOMOZYGOUS DELETION; CHROMOSOME 3P21.3; TUMOR-GROWTH; EXPRESSION PATTERNS; MICROCELL HYBRIDS	The candidate tumour suppressor gene, LUCA-15, maps to the lung cancer tumour suppressor locus 3p21.3. Overexpression of an alternative RNA splice variant of LUCA-15 has been shown to retard human Jurkat T cell proliferation and to accelerate CD95-mediated apoptosis, An antisense cDNA to the 3'-UTR of this splice variant was able to suppress CD95-mediated apoptosis, Here, we report that overexpression of LUCA-15 itself suppresses CD95-mediated apoptosis in Jurkat cells. This suppression occurs Drier to the final execution stage of the CD95 signalling pathway, and is associated with upregulation of the apoptosis inhibitory protein Bcl-2, LUCA-15 overexpression is also able to inhibit apoptosis induced by the protein kinase inhibitor staurosporine, but is not able to significantly suppress apoptosis mediated by the topoisomerase II inhibitor etoposide, These findings suggest that LUCA-15 is a selective inhibitor of cell death, and confirm the importance of the LUCA-15 genetic locus in the control of apoptosis.	Sigfried & Janet Weis Ctr Res, Geisinger Clin, Henry Hood Res Program, Danville, PA 17822 USA; Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Pediat,Div Hematol Oncol, Hershey, PA 17033 USA; NCI, Immunobiol Lab, FCRDC, Frederick, MD 21702 USA; Univ Keele, Sch Life Sci, Keele ST5 5BG, Staffs, England	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Keele University	Sutherland, LC (corresponding author), Sigfried & Janet Weis Ctr Res, Geisinger Clin, Henry Hood Res Program, 100 N Acad Ave, Danville, PA 17822 USA.		Williams, Gwyn/GQY-7555-2022	Williams, Gwyn/0000-0003-4556-9930	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR010732] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046778, R56DK046778] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO056000] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-56000] Funding Source: Medline; NCRR NIH HHS [M01RR10732] Funding Source: Medline; NIDDK NIH HHS [DK46778] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aravind L, 1999, TRENDS BIOCHEM SCI, V24, P342, DOI 10.1016/S0968-0004(99)01437-1; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Chung GTY, 1995, ONCOGENE, V11, P2591; Daigo Y, 1999, CANCER RES, V59, P1966; DALY MC, 1993, ONCOGENE, V8, P1721; DOLE M, 1994, CANCER RES, V54, P3253; Drabkin HA, 1999, ONCOGENE, V18, P2589, DOI 10.1038/sj.onc.1202601; Frederick A, 1998, ONCOGENE, V16, P153, DOI 10.1038/sj.onc.1201537; GAZDAR AF, 1994, COLD SPRING HARB SYM, V59, P565, DOI 10.1101/SQB.1994.059.01.063; GRAY DA, 1995, ONCOGENE, V10, P2179; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Imreh S, 1997, GENE CHROMOSOME CANC, V20, P224; Inoue A, 1996, NUCLEIC ACIDS RES, V24, P2990, DOI 10.1093/nar/24.15.2990; Jackers P, 1996, ONCOGENE, V13, P495; Jensen DE, 1998, ONCOGENE, V16, P1097, DOI 10.1038/sj.onc.1201861; Johnson DE, 2000, CANCER RES, V60, P1818; KAMESAKI S, 1993, CANCER RES, V53, P4251; KASHUBA VI, 1995, CANCER GENET CYTOGEN, V81, P144, DOI 10.1016/0165-4608(94)00215-W; Kashuba VI, 1997, FEBS LETT, V419, P181, DOI 10.1016/S0014-5793(97)01449-X; Kholodnyuk I, 1997, GENE CHROMOSOME CANC, V18, P200, DOI 10.1002/(SICI)1098-2264(199703)18:3<200::AID-GCC6>3.0.CO;2-5; KOK K, 1994, CANCER RES, V54, P4183; Kok K, 1997, ADV CANCER RES, V71, P27, DOI 10.1016/S0065-230X(08)60096-2; Latif F, 1997, HUM GENET, V99, P334, DOI 10.1007/s004390050368; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Lock RB, 1996, CANCER RES, V56, P4006; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MIYASHITA T, 1993, BLOOD, V81, P151; Oh JJ, 1999, NUCLEIC ACIDS RES, V27, P4008, DOI 10.1093/nar/27.20.4008; OSHEROFF N, 1989, BIOCHEMISTRY-US, V28, P6157, DOI 10.1021/bi00441a005; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Sekido Y, 1998, ONCOGENE, V16, P3151, DOI 10.1038/sj.onc.1201858; Sekido Y, 1996, P NATL ACAD SCI USA, V93, P4120, DOI 10.1073/pnas.93.9.4120; Shaham S, 1996, CELL, V86, P201, DOI 10.1016/S0092-8674(00)80092-6; Shriver SP, 1998, MUTAT RES-GENOMICS, V406, P9, DOI 10.1016/S1383-5726(98)00006-5; Sithanandam G, 1996, MOL CELL BIOL, V16, P868; Slee EA, 2000, CELL DEATH DIFFER, V7, P556, DOI 10.1038/sj.cdd.4400689; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; Sutherland LC, 2000, ONCOGENE, V19, P3774, DOI 10.1038/sj.onc.1203720; Sutherland LC, 1997, J IMMUNOL METHODS, V207, P179, DOI 10.1016/S0022-1759(97)00118-X; Szeles A, 1997, GENE CHROMOSOME CANC, V20, P329; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; Tang DM, 2000, J BIOL CHEM, V275, P9303, DOI 10.1074/jbc.275.13.9303; Timmer T, 1999, EUR J HUM GENET, V7, P478, DOI 10.1038/sj.ejhg.5200334; Todd MC, 1996, ONCOGENE, V13, P2387; Uchida K, 1997, CYTOGENET CELL GENET, V78, P209, DOI 10.1159/000134658; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; Wei MH, 1996, CANCER RES, V56, P1487; Wyllie AH, 1997, EUR J CELL BIOL, V73, P189; YAMAKAWA K, 1993, ONCOGENE, V8, P327; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X	50	33	34	1	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 10	2001	20	21					2713	2719		10.1038/sj.onc.1204371	http://dx.doi.org/10.1038/sj.onc.1204371			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	431VN	11420683				2022-12-25	WOS:000168652600012
J	D'Orso, I; Frasch, ACC				D'Orso, I; Frasch, ACC			TcUBP-1, a developmentally regulated U-rich RNA-binding protein involved in selective mRNA destabilization in trypanosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; 3'-UNTRANSLATED REGION; POLYPYRIMIDINE TRACT; UNTRANSLATED REGION; CRUZI GENOME; ELEMENTS; GENE; EXPRESSION; BRUCEI; DEGRADATION	Developmental stages of the trypanosome life cycle differ in their morphology, biology, and biochemical properties. Consequently, several proteins have to be tightly regulated in their expression to allow trypanosomes to adapt rapidly to sudden environmental changes, a process that might be of central importance for parasite survival. However, in contrast to higher eukaryotic cells, trypanosomes do not seem to regulate gene expression through regulation of transcription initiation. These parasites make use of post-transcriptional regulatory mechanisms and modification of mRNA half-life is a relevant one. Trans-acting factors binding to cis-elements that affect mRNA stability of mature transcripts have not been identified in these cells. In this work, a novel U-rich RNA-binding protein (TcUBP-1) from Trypanosoma cruzi, the agent of Chagas disease, was identified. Its structure includes an RNA recognition motif, a nuclear export signal, and auxiliary domains with glycine- and glutamine-rich regions. TcUBP-1 recognizes the 44-nucleotide AU-rich RNA instability element located in the W-untranslated region of mucin SMUG mRNAs (Di Noia, J. M., D'Orso, I., Sanchez, D. O., and Frasch, A. C. (2000) J. Biol. Chem. 275, 10218-10227) as well as GU-rich sequences. Over-expression of TcUBP-1 in trypanosomes decreases the half-life of SMUG mucin mRNAs in vivo but does not affect the stability of other parasite mRNAs. Because TcUBP-1 is developmentally regulated, it might have a relevant role in regulating protein expression during trypanosome differentiation, allowing a correct expression pattern of U-rich-containing mRNAs.	Unv Nacl Gen SAn Martin, INTI, Inst Invest Biotechnol,Inst Tecnol Chascomus, CONICET, RA-1650 San Martin, Buenos Aires, Argentina	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Instituto Nacional de Tecnologia Industrial (INTI)	Frasch, ACC (corresponding author), Unv Nacl Gen San Martin, INTI, Inst Invest Biotechnol,Inst Tecnol Chascomus, CONICET, Av Gral Paz S-N,Edificio 24,Casilla de Correo 30, RA-1650 San Martin, Buenos Aires, Argentina.			Frasch, Alberto Carlos/0000-0001-7532-653X				Aguero F, 2000, GENOME RES, V10, P1996, DOI 10.1101/gr.GR-1463R; AMADO R, 1984, METHOD ENZYMOL, V107, P377; BEELMAN CA, 1995, CELL, V81, P179, DOI 10.1016/0092-8674(95)90326-7; BENAMAR MF, 1991, NUCLEIC ACIDS RES, V19, P5857, DOI 10.1093/nar/19.21.5857; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CAPPA SMG, 1981, MEDICINA-BUENOS AIRE, V41, P119; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; Charest H, 1996, J BIOL CHEM, V271, P17081, DOI 10.1074/jbc.271.29.17081; Chen CY, 1998, SCIENCE, V280, P1945, DOI 10.1126/science.280.5371.1945; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Coughlin BC, 2000, J BIOL CHEM, V275, P12051, DOI 10.1074/jbc.275.16.12051; D'Orso I, 2001, J BIOL CHEM, V276, P15783, DOI 10.1074/jbc.M010959200; Di Noia JM, 2000, J BIOL CHEM, V275, P10218, DOI 10.1074/jbc.275.14.10218; Di Noia JM, 1998, J BIOL CHEM, V273, P10843, DOI 10.1074/jbc.273.18.10843; DONELSON JE, 1995, J BIOL CHEM, V270, P7783, DOI 10.1074/jbc.270.14.7783; DRAGON EA, 1987, MOL CELL BIOL, V7, P1271, DOI 10.1128/MCB.7.3.1271; Dreyfuss G, 1996, CELL, V85, P963, DOI 10.1016/S0092-8674(00)81298-2; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; FOURNEY RM, 1978, FOCUS, V10, P5; Frasch ACC, 2000, PARASITOL TODAY, V16, P282, DOI 10.1016/S0169-4758(00)01698-7; Furger A, 1997, MOL CELL BIOL, V17, P4372, DOI 10.1128/MCB.17.8.4372; Gao FB, 1996, J CELL SCI, V109, P579; Gilinger G, 2001, NUCLEIC ACIDS RES, V29, P1556, DOI 10.1093/nar/29.7.1556; Golightly LM, 2000, MOL BIOCHEM PARASIT, V105, P61, DOI 10.1016/S0166-6851(99)00165-6; GOOD PJ, 1995, P NATL ACAD SCI USA, V92, P4557, DOI 10.1073/pnas.92.10.4557; Greene JAL, 1996, J BIOL CHEM, V271, P26762, DOI 10.1074/jbc.271.43.26762; HAMILTON BJ, 1993, J BIOL CHEM, V268, P8881; Handa N, 1999, NATURE, V398, P579, DOI 10.1038/19242; Hotz HR, 1997, NUCLEIC ACIDS RES, V25, P3017, DOI 10.1093/nar/25.15.3017; Ismaili N, 2000, MOL BIOCHEM PARASIT, V106, P109, DOI 10.1016/S0166-6851(99)00205-4; IZAURRALDE E, 1995, CELL, V81, P153, DOI 10.1016/0092-8674(95)90323-2; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; KIM YJ, 1993, J NEUROSCI, V13, P1045; KIM YJ, 1993, MOL CELL BIOL, V13, P174, DOI 10.1128/MCB.13.1.174; Kishore R, 1999, J IMMUNOL, V162, P2457; Kontoyiannis D, 1999, IMMUNITY, V10, P387, DOI 10.1016/S1074-7613(00)80038-2; Lee MGS, 1996, MOL CELL BIOL, V16, P1220; Loflin P, 1999, GENE DEV, V13, P1884, DOI 10.1101/gad.13.14.1884; MartinezCalvillo S, 1997, GENE, V199, P71, DOI 10.1016/S0378-1119(97)00348-X; MATTHEWS KR, 1994, GENE DEV, V8, P491, DOI 10.1101/gad.8.4.491; Merendino L, 1999, NATURE, V402, P838, DOI 10.1038/45602; Myer VE, 1997, EMBO J, V16, P2130, DOI 10.1093/emboj/16.8.2130; MYER VE, 1995, RNA, V1, P171; NAGY E, 1995, J BIOL CHEM, V270, P2755, DOI 10.1074/jbc.270.6.2755; NAKAGAWA J, 1995, P NATL ACAD SCI USA, V92, P2051, DOI 10.1073/pnas.92.6.2051; Nakielny S, 1997, ANNU REV NEUROSCI, V20, P269, DOI 10.1146/annurev.neuro.20.1.269; Nozaki T, 1995, MOL BIOCHEM PARASIT, V75, P55, DOI 10.1016/0166-6851(95)02512-X; PAIK W, 1984, METHOD ENZYMOL, V106, P3; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; Pollevick GD, 2000, J BIOL CHEM, V275, P27671; Roditi I, 1998, MOL BIOCHEM PARASIT, V91, P117, DOI 10.1016/S0166-6851(97)00195-3; Sambrook J., 2002, MOL CLONING LAB MANU; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SINGH R, 1995, SCIENCE, V268, P1173, DOI 10.1126/science.7761834; SIOMI H, 1995, J CELL BIOL, V129, P551, DOI 10.1083/jcb.129.3.551; Sokolowski M, 1997, ONCOGENE, V15, P2303, DOI 10.1038/sj.onc.1201415; STOECKLIN G, 1994, J BIOL CHEM, V269, P28591; Stuart K, 1998, Verh K Acad Geneeskd Belg, V60, P63; TEIXEIRA SMR, 1995, J BIOL CHEM, V270, P22586, DOI 10.1074/jbc.270.38.22586; Weston D, 1999, MOL BIOCHEM PARASIT, V102, P53, DOI 10.1016/S0166-6851(99)00079-1; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652; Zingales B, 1997, ACTA TROP, V68, P159, DOI 10.1016/S0001-706X(97)00088-0	63	68	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					34801	34809		10.1074/jbc.M102120200	http://dx.doi.org/10.1074/jbc.M102120200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11435421	hybrid			2022-12-25	WOS:000171024600062
J	Kulkarni, AA; Abul-Hamd, AT; Rai, R; El Berry, H; Cooper, TG				Kulkarni, AA; Abul-Hamd, AT; Rai, R; El Berry, H; Cooper, TG			Gln3p nuclear localization and interaction with Ure2p in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITROGEN CATABOLITE REPRESSION; DNA-BINDING DOMAIN; GENE-EXPRESSION; TRANSCRIPTIONAL ACTIVATION; DEVELOPING HEART; PROTEIN; YEAST; PRION; TOR; PHOSPHORYLATION	Gln3p is one of two well characterized GATA family transcriptional activation factors whose function is regulated by the nitrogen supply of the cell. When nitrogen is limiting, Gln3p and Gat1p are concentrated in the nucleus where they bind GATA sequences upstream of nitrogen catabolite repression (NCR)-sensitive genes and activate their transcription. Conversely, in excess nitrogen, these GATA sequences are unoccupied by Gln3p and Gat1p because these transcription activators are excluded from the nucleus. Ure2p binds to Gln3p and Gat1p and is required for NCR-sensitive transcription to be repressed and for nuclear exclusion of these transcription factors. Here we show the following. (i) Gln3p residues 344-365 are required for nuclear localization. (ii) Replacing Ser-344, Ser-347, and Ser-355 with alanines has minimal effects on GFP-Gln3p localization. However, replacing Gln3p Ser-344, Ser-347, and Ser-355 with aspartates results in significant loss of its ability to be concentrated in the nucleus. (iii) N and C termini of the Gln3p region required for it to complex with Ure2p and be excluded from the nucleus are between residues 1-103 and 301-365, respectively. (iv) N and C termini of the Ure2p region required for it to interact with Gln3p are situated between residues 101-151 and 330-346, respectively. (v) Loss of Ure2p residues participating in either dimer or prion formation diminishes its ability to carry out NCR-sensitive regulation of Gln3p activity.	Univ Tennessee, Dept Mol Sci, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	Cooper, TG (corresponding author), Univ Tennessee, Dept Mol Sci, Memphis, TN 38163 USA.	tcooper@utmem.edu		Cooper, Terrance G./0000-0002-7651-9963	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035642] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-35642, R01 GM035642-13, R01 GM035642] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Azuma Y, 1997, BIOCHIMIE, V79, P247, DOI 10.1016/S0300-9084(97)83512-2; Beck T, 1999, NATURE, V402, P689, DOI 10.1038/45287; Bertram PG, 2000, J BIOL CHEM, V275, P35727, DOI 10.1074/jbc.M004235200; Blinder D, 1996, J BACTERIOL, V178, P4734, DOI 10.1128/jb.178.15.4734-4736.1996; Bousset L, 2001, STRUCTURE, V9, P39, DOI 10.1016/S0969-2126(00)00553-0; Cardenas ME, 1999, GENE DEV, V13, P3271, DOI 10.1101/gad.13.24.3271; CHISHOLM G, 1982, MOL CELL BIOL, V2, P1088, DOI 10.1128/MCB.2.9.1088; Coffman JA, 1996, MOL CELL BIOL, V16, P847; COFFMAN JA, 1994, J BACTERIOL, V176, P7476, DOI 10.1128/JB.176.24.7476-7483.1994; Cokol M, 2000, EMBO REP, V1, P411, DOI 10.1093/embo-reports/kvd092; COOPER TG, 1990, J BACTERIOL, V172, P1014, DOI 10.1128/jb.172.2.1014-1018.1990; Cooper TG, 1996, MYCOTA, V3, P139; Cox KH, 1999, YEAST, V15, P703, DOI 10.1002/(SICI)1097-0061(19990615)15:8<703::AID-YEA413>3.0.CO;2-Z; Cox KH, 2000, J BIOL CHEM, V275, P17611, DOI 10.1074/jbc.M001648200; CUNNINGHAM TS, 1993, J BACTERIOL, V175, P5851, DOI 10.1128/JB.175.18.5851-5861.1993; CUNNINGHAM TS, 1994, J BACTERIOL, V176, P4718, DOI 10.1128/JB.176.15.4718-4725.1994; Cunningham TS, 1996, J BACTERIOL, V178, P3470, DOI 10.1128/jb.178.12.3470-3479.1996; Cunningham TS, 2000, J BIOL CHEM, V275, P14408, DOI 10.1074/jbc.275.19.14408; DAUGHERTY JR, 1993, J BACTERIOL, V175, P64, DOI 10.1128/JB.175.1.64-73.1993; Distler M, 2001, J BACTERIOL, V183, P4636, DOI 10.1128/JB.183.15.4636-4642.2001; DRILLIEN R, 1972, J BACTERIOL, V109, P203, DOI 10.1128/JB.109.1.203-208.1972; DRILLIEN R, 1973, BIOCHEM BIOPH RES CO, V53, P367, DOI 10.1016/0006-291X(73)90671-2; Edskes HK, 1999, P NATL ACAD SCI USA, V96, P1498, DOI 10.1073/pnas.96.4.1498; Fernandez-Bellot E, 1999, BIOCHEM J, V338, P403, DOI 10.1042/0264-6021:3380403; Ferrigno P, 1998, EMBO J, V17, P5606, DOI 10.1093/emboj/17.19.5606; Hardwick JS, 1999, P NATL ACAD SCI USA, V96, P14866, DOI 10.1073/pnas.96.26.14866; Hofman-Bang J, 1999, MOL BIOTECHNOL, V12, P35, DOI 10.1385/MB:12:1:35; JANS DA, 1995, J BIOL CHEM, V270, P17064, DOI 10.1074/jbc.270.29.17064; Jans DA, 1996, PHYSIOL REV, V76, P651, DOI 10.1152/physrev.1996.76.3.651; KELLEY C, 1993, DEVELOPMENT, V118, P817; LAVERRIERE AC, 1994, J BIOL CHEM, V269, P23177; Maddelein ML, 1999, MOL CELL BIOL, V19, P4516; MASISON DC, 1995, SCIENCE, V270, P93, DOI 10.1126/science.270.5233.93; Masison DC, 1997, P NATL ACAD SCI USA, V94, P12503, DOI 10.1073/pnas.94.23.12503; MINEHART PL, 1991, MOL CELL BIOL, V11, P6216, DOI 10.1128/MCB.11.12.6216; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; OMICHINSKI JG, 1993, SCIENCE, V261, P438, DOI 10.1126/science.8332909; RAI R, 1989, MOL CELL BIOL, V9, P602, DOI 10.1128/MCB.9.2.602; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Scott S, 2000, J BIOL CHEM, V275, P7198, DOI 10.1074/jbc.275.10.7198; Scott S, 2000, J BIOL CHEM, V275, P30886, DOI 10.1074/jbc.M005624200; Smart WC, 1996, MOL CELL BIOL, V16, P5876; Svetlov V, 1997, J BACTERIOL, V179, P7644, DOI 10.1128/jb.179.24.7644-7652.1997; Svetlov VV, 1998, J BACTERIOL, V180, P5682, DOI 10.1128/JB.180.21.5682-5688.1998; ter Schure EG, 2000, FEMS MICROBIOL REV, V24, P67, DOI 10.1016/S0168-6445(99)00030-3; Thual C, 2001, BIOCHEMISTRY-US, V40, P1764, DOI 10.1021/bi001916l; Umland TC, 2001, P NATL ACAD SCI USA, V98, P1459, DOI 10.1073/pnas.041607898; VANVUUREN HJJ, 1991, J BACTERIOL, V173, P7186, DOI 10.1128/jb.173.22.7186-7195.1991; WEISS MJ, 1995, EXP HEMATOL, V23, P99; Wickner RB, 2000, J STRUCT BIOL, V130, P310, DOI 10.1006/jsbi.2000.4250; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170; Young MR, 1997, GENES CELLS, V2, P631, DOI 10.1046/j.1365-2443.1997.1510349.x	52	70	73	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					32136	32144		10.1074/jbc.M104580200	http://dx.doi.org/10.1074/jbc.M104580200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11408486	Green Accepted, hybrid			2022-12-25	WOS:000170613500091
J	Melhuish, TA; Gallo, CM; Wotton, D				Melhuish, TA; Gallo, CM; Wotton, D			TGIF2 interacts with histone deacetylase I and represses transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; HOMEOBOX GENE; HOMEODOMAIN PROTEINS; SMAD PROTEINS; TUMOR-SUPPRESSOR; TALE SUPERCLASS; COREPRESSOR; COMPLEXES; DOMAIN; HOX	TG-interacting factor (TGIF) is a transcriptional repressor, which represses transcription by binding directly to DNA or interacts with transforming growth factor beta (TGF beta)-activated Smads, thereby repressing TGF beta -responsive gene expression. Mutation of TGIF in humans causes holoprosencephaly, a severe genetic disorder affecting craniofacial development. Searching human expressed sequence tag data bases revealed the presence of clones encoding a TGIF-related protein (TGIF2), which contains two regions of high sequence identity with TGIF. Here we show that, like TGIF, TGIF2 recruits histone deacetylase, but in contrast to TGIF, is unable to interact with the corepressor CtBP. TGIF2 and TGIF have very similar DNA-binding homeodomains, and TGIF2 represses transcription when bound to DNA via a TGIF binding site. TGIF2 interacts with TGF beta -activated Smads and represses TGF beta -responsive transcription. TGIF2 appears to be a context-independent transcriptional repressor, which can perform similar functions to TGIF and may play a role in processes, which, when disrupted by mutations in TGIF, cause holoprosencephaly.	Univ Virginia, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA; Univ Virginia, Ctr Cell Signaling, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia	Wotton, D (corresponding author), Univ Virginia, Hosp W, Ctr Cell Signaling, Box 800577 HSC, Charlottesville, VA 22908 USA.			Wotton, David/0000-0002-4652-5350				Asahara H, 1999, MOL CELL BIOL, V19, P8219; Berthelsen J, 1998, EMBO J, V17, P1423, DOI 10.1093/emboj/17.5.1423; Berthelsen J, 1998, EMBO J, V17, P1434, DOI 10.1093/emboj/17.5.1434; Bertolino E, 1995, J BIOL CHEM, V270, P31178, DOI 10.1074/jbc.270.52.31178; Bertolino E, 1996, DEV DYNAM, V205, P410, DOI 10.1002/(SICI)1097-0177(199604)205:4<410::AID-AJA5>3.0.CO;2-L; Burglin TR, 1997, NUCLEIC ACIDS RES, V25, P4173, DOI 10.1093/nar/25.21.4173; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.biochem.63.1.487; Golden JA, 1998, J NEUROPATH EXP NEUR, V57, P991, DOI 10.1097/00005072-199811000-00001; GRAFF JM, 1994, CELL, V79, P169, DOI 10.1016/0092-8674(94)90409-X; Gripp KW, 2000, NAT GENET, V25, P205, DOI 10.1038/76074; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; Imoto I, 2000, BIOCHEM BIOPH RES CO, V276, P264, DOI 10.1006/bbrc.2000.3449; Jacobs Y, 1999, MOL CELL BIOL, V19, P5134, DOI 10.1128/mcb.19.7.5134; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; Liu B, 1999, MOL CELL BIOL, V19, P424; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Lo RS, 2001, EMBO J, V20, P128, DOI 10.1093/emboj/20.1.128; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 1997, TRENDS CELL BIOL, V7, P187, DOI 10.1016/S0962-8924(97)01036-2; MCGINNIS W, 1984, NATURE, V308, P428, DOI 10.1038/308428a0; MCGINNIS W, 1984, CELL, V37, P403, DOI 10.1016/0092-8674(84)90370-2; Melhuish TA, 2000, J BIOL CHEM, V275, P39762, DOI 10.1074/jbc.C000416200; MOSKOW JJ, 1995, MOL CELL BIOL, V15, P5434; Muenke M, 2000, CURR OPIN GENET DEV, V10, P262, DOI 10.1016/S0959-437X(00)00084-8; Nanni L, 1999, HUM MOL GENET, V8, P2479, DOI 10.1093/hmg/8.13.2479; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; OVERHAUSER J, 1995, AM J HUM GENET, V57, P1080; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; Roessler E, 1998, J INHERIT METAB DIS, V21, P481, DOI 10.1023/A:1005406719292; SCHAEPER U, 1995, P NATL ACAD SCI USA, V92, P10467, DOI 10.1073/pnas.92.23.10467; Stroschein SL, 1999, SCIENCE, V286, P771, DOI 10.1126/science.286.5440.771; Sun Y, 1999, P NATL ACAD SCI USA, V96, P12442, DOI 10.1073/pnas.96.22.12442; Sun Y, 1999, MOL CELL, V4, P499, DOI 10.1016/S1097-2765(00)80201-4; Wallis DE, 1999, MOL GENET METAB, V68, P126, DOI 10.1006/mgme.1999.2895; Wotton D, 1999, J BIOL CHEM, V274, P37105, DOI 10.1074/jbc.274.52.37105; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6; Wotton D, 2001, CURR TOP MICROBIOL, V254, P145; Yang WM, 1997, J BIOL CHEM, V272, P28001, DOI 10.1074/jbc.272.44.28001; Yang Y, 2000, J BIOL CHEM, V275, P20734, DOI 10.1074/jbc.M908382199; Zhang Y, 1999, TRENDS CELL BIOL, V9, P274, DOI 10.1016/S0962-8924(99)01579-2; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	49	97	105	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					32109	32114		10.1074/jbc.M103377200	http://dx.doi.org/10.1074/jbc.M103377200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11427533	hybrid			2022-12-25	WOS:000170613500087
J	Yoshiike, Y; Tanemura, K; Murayama, O; Akagi, T; Murayama, M; Sato, S; Sun, XY; Tanaka, N; Takashima, A				Yoshiike, Y; Tanemura, K; Murayama, O; Akagi, T; Murayama, M; Sato, S; Sun, XY; Tanaka, N; Takashima, A			New insights on how metals disrupt amyloid beta-aggregation and their effects on amyloid-beta cytotoxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMER A-BETA; MITOCHONDRIAL SUCCINATE-DEHYDROGENASE; CONGO RED; PHYSIOLOGICAL CONCENTRATIONS; PRECURSOR PROTEIN; DEPENDENT BINDING; FIBRIL FORMATION; THIOFLAVINE-T; IN-VITRO; DISEASE	Amyloid-beta protein (A beta) aggregates in the brain to form senile plaques. By using thioflavin T, a dye that specifically binds to fibrillar structures, we found that metals such as Zn(ll) and Cu(II) normally inhibit amyloid beta -aggregation. Another method for detecting A beta, which does not distinguish the types of aggregates, showed that these metals induce a non-beta -sheeted aggregation, as reported previously. Secondary structural analysis and microscopic studies revealed that metals induced A beta to make non-fibrillar aggregates by disrupting beta -sheet formation. These non-fibrillar A beta aggregates displayed much weaker Congo Red birefringence, and in separate cell culture experiments, were less toxic than self beta -aggregates, as demonstrated by 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide assay. The toxicity of soluble A beta was enhanced in the presence of Cu(Il), which suggests the previously hypothesized role of A beta in generating oxidative stress. Finally, under an acidic condition, similar to that in the inflammation associated with senile plaques, beta -aggregation was robustly facilitated at one specific concentration of Zn(ll) in the presence of heparin. However, because a higher concentration of Zn(II) virtually abolished this abnormal phenomenon, and at normal pH any concentrations strongly inhibit beta -aggregation and its associated cytotoxicity, including its anti-oxidative nature we suggest that Zn(II) has an overall protective effect against beta -amyloid toxicity.	RIKEN, Brain Sci Inst, Lab Alzheimers Dis, Wako, Saitama 3510198, Japan; Tokyo Inst Technol, Dept Life Sci, Yokohama, Kanagawa 2268503, Japan; Azabu Univ, Grad Sch Environm Hlth Sci, Sagamihara, Kanagawa 2298501, Japan; RIKEN, Brain Sci Inst, Lab Neural Architecture, Wako, Saitama 3510198, Japan	RIKEN; Tokyo Institute of Technology; Azabu University; RIKEN	Takashima, A (corresponding author), RIKEN, Brain Sci Inst, Lab Alzheimers Dis, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	kenneth@brain.riken.go.jp						Abe K, 1998, NEUROSCI RES, V31, P295, DOI 10.1016/S0168-0102(98)00055-8; Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Atwood CS, 1998, J BIOL CHEM, V273, P12817, DOI 10.1074/jbc.273.21.12817; Bondy SC, 1998, BRAIN RES, V799, P91, DOI 10.1016/S0006-8993(98)00461-2; Brown AM, 1997, J NEUROCHEM, V69, P1204; BRUNDEN KR, 1993, J NEUROCHEM, V61, P2147, DOI 10.1111/j.1471-4159.1993.tb07453.x; BUSH AI, 1994, J BIOL CHEM, V269, P12152; BUSH AI, 1994, SCIENCE, V265, P1464, DOI 10.1126/science.8073293; Carter DB, 1998, NEUROBIOL AGING, V19, P37, DOI 10.1016/S0197-4580(97)00164-4; Castillo GM, 1997, J NEUROCHEM, V69, P2452; Chaney MO, 1998, PROTEIN ENG, V11, P761, DOI 10.1093/protein/11.9.761; Cherny RA, 1999, J BIOL CHEM, V274, P23223, DOI 10.1074/jbc.274.33.23223; CONNOR JR, 1992, J NEUROSCI RES, V31, P327, DOI 10.1002/jnr.490310214; Cuajungco MP, 2000, J BIOL CHEM, V275, P19439, DOI 10.1074/jbc.C000165200; Curtain CC, 2001, J BIOL CHEM, V276, P20466, DOI 10.1074/jbc.M100175200; DAVIES IJT, 1968, J CLIN PATHOL, V21, P359, DOI 10.1136/jcp.21.3.359; DYRKS T, 1992, J BIOL CHEM, V267, P18210; Esler WP, 1996, J NEUROCHEM, V66, P723; FRASER PE, 1992, J NEUROCHEM, V59, P1531, DOI 10.1111/j.1471-4159.1992.tb08470.x; FREDERICKSON CJ, 1989, INT REV NEUROBIOL, V31, P145; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Huang XD, 1999, BIOCHEMISTRY-US, V38, P7609, DOI 10.1021/bi990438f; Huang XD, 1999, J BIOL CHEM, V274, P37111, DOI 10.1074/jbc.274.52.37111; Huang XD, 2000, J NUTR, V130, p1488S, DOI 10.1093/jn/130.5.1488S; Irizarry MC, 1997, J NEUROSCI, V17, P7053; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; KANEKO I, 1995, J NEUROCHEM, V65, P2585; KISILEVSKY R, 1995, NAT MED, V1, P143, DOI 10.1038/nm0295-143; Kisilevsky R, 1997, ANN NY ACAD SCI, V826, P117, DOI 10.1111/j.1749-6632.1997.tb48465.x; KLUNK WE, 1989, J HISTOCHEM CYTOCHEM, V37, P1273, DOI 10.1177/37.8.2666510; Lee JY, 1999, J NEUROSCI, V19, DOI 10.1523/jneurosci.19-11-j0002.1999; LEVINE H, 1993, PROTEIN SCI, V2, P404, DOI 10.1002/pro.5560020312; Liu ST, 1999, BIOCHEMISTRY-US, V38, P9373, DOI 10.1021/bi990205o; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; Lovell MA, 1999, BRAIN RES, V823, P88, DOI 10.1016/S0006-8993(99)01114-2; Malinchik SB, 1998, BIOPHYS J, V74, P537, DOI 10.1016/S0006-3495(98)77812-9; MANTYH PW, 1993, J NEUROCHEM, V61, P1171, DOI 10.1111/j.1471-4159.1993.tb03639.x; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MCLACHLAN JC, 1991, LANCET, V337, P742, DOI 10.1016/0140-6736(91)90336-N; Miura T, 2000, BIOCHEMISTRY-US, V39, P7024, DOI 10.1021/bi0002479; Moir RD, 1999, BIOCHEMISTRY-US, V38, P4595, DOI 10.1021/bi982437d; NAIKI H, 1989, ANAL BIOCHEM, V177, P244, DOI 10.1016/0003-2697(89)90046-8; Perczel A., 1996, CIRCULAR DICHROISM C, P285; Pereira C, 1998, NEUROREPORT, V9, P1749, DOI 10.1097/00001756-199806010-00015; PIKE CJ, 1991, BRAIN RES, V563, P311, DOI 10.1016/0006-8993(91)91553-D; PIKE CJ, 1993, J NEUROSCI, V13, P1676; POTEMPA LA, 1985, J BIOL CHEM, V260, P2142; Roher AE, 1996, J BIOL CHEM, V271, P20631, DOI 10.1074/jbc.271.34.20631; SIMMONS LK, 1994, MOL PHARMACOL, V45, P373; SNOW AD, 1994, NEURON, V12, P219, DOI 10.1016/0896-6273(94)90165-1; SNOW AD, 1988, AM J PATHOL, V133, P456; Suh SW, 2000, BRAIN RES, V852, P274, DOI 10.1016/S0006-8993(99)02096-X; UEDA K, 1994, BRAIN RES, V639, P240, DOI 10.1016/0006-8993(94)91736-1; WOOD SJ, 1995, BIOCHEMISTRY-US, V34, P724, DOI 10.1021/bi00003a003; Wood SJ, 1996, J MOL BIOL, V256, P870, DOI 10.1006/jmbi.1996.0133; YATES CM, 1990, J NEUROCHEM, V55, P1624, DOI 10.1111/j.1471-4159.1990.tb04948.x; YOUNG ID, 1989, ACTA NEUROPATHOL, V78, P202, DOI 10.1007/BF00688210	59	220	230	0	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					32293	32299		10.1074/jbc.M010706200	http://dx.doi.org/10.1074/jbc.M010706200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11423547	hybrid			2022-12-25	WOS:000170613500111
J	Boule, JB; Rougeon, F; Papanicolaou, C				Boule, JB; Rougeon, F; Papanicolaou, C			Terminal deoxynucleotidyl transferase indiscriminately incorporates ribonucleotides and deoxyribonucleotides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE-BETA; FAMILY-X POLYMERASES; NUCLEOTIDYLTRANSFERASE SUPERFAMILY; REVERSE-TRANSCRIPTASE; V(D)J RECOMBINATION; MUTATIONAL ANALYSIS; CATALYTIC DOMAIN; POOL IMBALANCE; N-REGIONS; BINDING	Terminal deoxynucleotidyl transferase (TdT) catalyzes the condensation of deoxyribonucleotides on 3 ' -hydroxyl ends of DNA strands in a template-independent manner and adds N-regions to gene segment junctions during V(D)J recombination. Although TdT is able to incorporate a few ribonucleotides in vitro, TdT discrimination between ribo- and deoxyribonucleotides has never been studied. We found that TdT shows only a minor preference for incorporation of deoxyribonucleotides over ribonucleotides on DNA strands. However, incorporation of ribonucleotides alone or in the presence of deoxyribonucleotides generally leads to premature chain termination, reflecting an impeded accommodation of ribo- or mixed ribo/deoxyribonucleic acid substrates by TdT. An essential catalytic aspartate in TdT was identified, which is a first step toward understanding the apparent lack of sugar discrimination by TdT.	Inst Pasteur, CNRS, URA 1960, Unite Genet & Biochim Dev, F-75015 Paris, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Papanicolaou, C (corresponding author), Inst Pasteur, CNRS, URA 1960, Unite Genet & Biochim Dev, 25 Rue Dr Roux, F-75015 Paris, France.		Boulé, Jean-Baptiste/M-8200-2017	Boulé, Jean-Baptiste/0000-0002-0994-5831				Aravind L, 1999, NUCLEIC ACIDS RES, V27, P1609, DOI 10.1093/nar/27.7.1609; Astatke M, 1998, P NATL ACAD SCI USA, V95, P3402, DOI 10.1073/pnas.95.7.3402; Aw TY, 2000, INT REV CYTOL, V192, P223; Bambara RA, 1995, METHOD ENZYMOL, V262, P270; BENTOLILA LA, 1995, EMBO J, V14, P4221, DOI 10.1002/j.1460-2075.1995.tb00096.x; Blackburn MR, 1998, J BIOL CHEM, V273, P5093, DOI 10.1074/jbc.273.9.5093; BOLLUM JF, 1974, ENZYMES, V10, P145; Bonnin A, 1999, J MOL BIOL, V290, P241, DOI 10.1006/jmbi.1999.2900; Boule JB, 2000, J BIOL CHEM, V275, P28984, DOI 10.1074/jbc.M005544200; Boule LB, 1998, MOL BIOTECHNOL, V10, P199, DOI 10.1007/BF02740839; Cases-Gonzalez CE, 2000, J BIOL CHEM, V275, P19759, DOI 10.1074/jbc.M910361199; CHANG LMS, 1971, BIOCHEMISTRY-US, V10, P536, DOI 10.1021/bi00779a029; DEIBEL MR, 1980, J BIOL CHEM, V255, P4206; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; Fersht AR., 1977, ENZYME STRUCTURE MEC; Gangi-Peterson L, 1999, J CLIN INVEST, V103, P833, DOI 10.1172/JCI4320; Gao GX, 1997, P NATL ACAD SCI USA, V94, P407, DOI 10.1073/pnas.94.2.407; GILFILLAN S, 1993, SCIENCE, V261, P1175, DOI 10.1126/science.8356452; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P345, DOI 10.1016/S0968-0004(00)89071-4; Huang Y, 1997, BIOCHEMISTRY-US, V36, P13718, DOI 10.1021/bi971609o; ITO J, 1991, NUCLEIC ACIDS RES, V19, P4045, DOI 10.1093/nar/19.15.4045; Joyce CM, 1997, P NATL ACAD SCI USA, V94, P1619, DOI 10.1073/pnas.94.5.1619; JOYCE CM, 1995, J BACTERIOL, V177, P6321, DOI 10.1128/jb.177.22.6321-6329.1995; KALLENBACH S, 1992, P NATL ACAD SCI USA, V89, P2799, DOI 10.1073/pnas.89.7.2799; KATO KI, 1967, J BIOL CHEM, V242, P2780; Kepler TB, 1996, J IMMUNOL, V157, P4451; Kirk BW, 1999, BIOCHEMISTRY-US, V38, P7727, DOI 10.1021/bi990247c; KOMORI T, 1993, SCIENCE, V261, P1171, DOI 10.1126/science.8356451; Kornberg A., 1991, DNA REPLICATION; Kornberg Arthur, 1974, DNA SYNTHESIS; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Martin G, 1996, EMBO J, V15, P2593, DOI 10.1002/j.1460-2075.1996.tb00617.x; Menge KL, 1995, BIOCHEMISTRY-US, V34, P15934, DOI 10.1021/bi00049a008; MEUTH M, 1984, MUTAT RES, V126, P107, DOI 10.1016/0027-5107(84)90051-4; NINIO J, 1987, P NATL ACAD SCI USA, V84, P663, DOI 10.1073/pnas.84.3.663; Pelletier H, 1996, BIOCHEMISTRY-US, V35, P12762, DOI 10.1021/bi9529566; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; Ramsden DA, 1997, NATURE, V388, P488, DOI 10.1038/41351; RICCHETTI M, 1993, EMBO J, V12, P387, DOI 10.1002/j.1460-2075.1993.tb05670.x; ROYCHOUDHURY R, 1972, J BIOL CHEM, V247, P3910; SAWAYA MR, 1994, SCIENCE, V264, P1930, DOI 10.1126/science.7516581; SOUSA R, 1995, EMBO J, V14, P4609, DOI 10.1002/j.1460-2075.1995.tb00140.x; Steitz TA, 1999, J BIOL CHEM, V274, P17395, DOI 10.1074/jbc.274.25.17395; Sukumar N, 2000, ACTA CRYSTALLOGR D, V56, P1662, DOI 10.1107/S090744490001297X; TABOR S, 1989, P NATL ACAD SCI USA, V86, P4076, DOI 10.1073/pnas.86.11.4076; YANG BL, 1994, J BIOL CHEM, V269, P11859; Yue DX, 1996, RNA, V2, P895	47	82	90	4	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					31388	31393		10.1074/jbc.M105272200	http://dx.doi.org/10.1074/jbc.M105272200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11406636	hybrid			2022-12-25	WOS:000170472900103
J	Dominguez, JM; Martin, JJ				Dominguez, JM; Martin, JJ			Identification of a putative sordarin binding site in Candida albicans elongation factor 2 by photoaffinity labeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNGAL PROTEIN-SYNTHESIS; CONFORMATIONAL-CHANGES; FACTOR EEF-2; EF-G; THERMUS-THERMOPHILUS; SELECTIVE-INHIBITION; ADENYLIC NUCLEOTIDES; SEQUENCE ALIGNMENT; GTP HYDROLYSIS; RIBOSOMAL-RNA	Candida albicans EF-2 binds sordarin to a single class of binding sites with K-d = 1.26 mum. Equimolar mixtures of EF-2 and ribosomes, in the presence of a non-hydrolyzable GTP analog, reveal two classes of high affinity sordarin binding sites with K-d = 0.7 and 41.5 nm, probably due to the existence of two ribosome populations. Photoaffinity labeling of C. albicans EF-2 in the absence of ribosomes has been performed with [C-14]GM258383, a photoactivatable sordarin derivative. Labeling is saturable and can be considered specific, because it can be prevented with another sordarin analog. The fragment GIn(224)-LYS232 has been identified as the modified peptide within the EF-2 sequence, Lys(228) being the residue to which the photoprobe was linked. This fragment is included within the G " -subdomain of EF-2. These results are discussed in the light of the high sordarin specificity toward fungal systems.	GlaxoSmithKline S A PTM, Dept Res, Madrid 28760, Spain	GlaxoSmithKline	Dominguez, JM (corresponding author), GlaxoSmithKline S A PTM, Dept Res, C-Severo Ochoa 2, Madrid 28760, Spain.	juan_m_dominguez@gsk.com	Dominguez, Juan Manuel/I-9993-2019	Dominguez, Juan Manuel/0000-0001-9472-6969				Aevarsson A, 1995, J MOL EVOL, V41, P1096; AEVARSSON A, 1994, EMBO J, V13, P3669, DOI 10.1002/j.1460-2075.1994.tb06676.x; Agrawal RK, 1998, P NATL ACAD SCI USA, V95, P6134, DOI 10.1073/pnas.95.11.6134; Agrawal RK, 1999, NAT STRUCT BIOL, V6, P643, DOI 10.1038/10695; Aviles P, 2000, ANTIMICROB AGENTS CH, V44, P2333, DOI 10.1128/AAC.44.9.2333-2340.2000; Ban N, 1999, NATURE, V400, P841, DOI 10.1038/23641; Briones C, 2000, NUCLEIC ACIDS RES, V28, P4497, DOI 10.1093/nar/28.22.4497; Capa L, 1998, ANTIMICROB AGENTS CH, V42, P2694, DOI 10.1128/AAC.42.10.2694; CHOWDHRY V, 1979, ANNU REV BIOCHEM, V48, P293, DOI 10.1146/annurev.bi.48.070179.001453; Cook ND, 1996, DRUG DISCOV TODAY, V1, P287, DOI 10.1016/1359-6446(96)10026-X; CZWORKOWSKI J, 1994, EMBO J, V13, P3661, DOI 10.1002/j.1460-2075.1994.tb06675.x; Dominguez JM, 1999, J BIOL CHEM, V274, P22423, DOI 10.1074/jbc.274.32.22423; Dominguez JM, 1998, ANTIMICROB AGENTS CH, V42, P2279, DOI 10.1128/AAC.42.9.2279; Dominguez JM, 1998, ANTIMICROB AGENTS CH, V42, P2274, DOI 10.1128/AAC.42.9.2274; Gargallo-Viola, 1999, CURR OPIN ANTIINFECT, V1, P297; Gomez-Lorenzo MG, 1998, J BIOL CHEM, V273, P25041, DOI 10.1074/jbc.273.39.25041; Gonzalo P, 2000, BIOCHEMISTRY-US, V39, P13558, DOI 10.1021/bi000896k; Green R, 2000, CURR BIOL, V10, pR369, DOI 10.1016/S0960-9822(00)00481-4; GUILLOT D, 1993, J BIOL CHEM, V268, P26082; IGLEWSKI WJ, 1990, ADP RIBOSYLATING TOX, P511; Justice MC, 1998, J BIOL CHEM, V273, P3148, DOI 10.1074/jbc.273.6.3148; KING SM, 1991, METHOD ENZYMOL, V196, P449; KOTZYBAHIBERT F, 1995, ANGEW CHEM INT EDIT, V34, P1296, DOI 10.1002/anie.199512961; LOTTSPEICH F, 1994, MICROCHARACTERIZATIO, P11; Martemyanov KA, 2000, J BIOL CHEM, V275, P35820, DOI 10.1074/jbc.M002656200; Odds FC, 2001, EXPERT OPIN THER PAT, V11, P283, DOI 10.1517/13543776.11.2.283; Peske F, 2000, MOL CELL, V6, P501, DOI 10.1016/S1097-2765(00)00049-6; Rodnina MV, 1997, NATURE, V385, P37, DOI 10.1038/385037a0; RYAZANOV AG, 1988, NATURE, V334, P170, DOI 10.1038/334170a0; Shastry M, 2001, MICROBIOL-UK, V147, P383, DOI 10.1099/00221287-147-2-383; SONTAG B, 1993, BIOCHEMISTRY-US, V32, P1976, DOI 10.1021/bi00059a014; SPEDDING G, 1990, RIBOSOMES PROTEIN SY, P1; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VanLoock MS, 2000, J MOL BIOL, V304, P507, DOI 10.1006/jmbi.2000.4213; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Wilson KS, 1998, CELL, V92, P131, DOI 10.1016/S0092-8674(00)80905-8	36	4	4	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					31402	31407		10.1074/jbc.M104183200	http://dx.doi.org/10.1074/jbc.M104183200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11402051	hybrid			2022-12-25	WOS:000170472900105
J	Arron, JR; Vologodskaia, M; Wong, BR; Naramura, M; Kim, N; Gu, H; Choi, Y				Arron, JR; Vologodskaia, M; Wong, BR; Naramura, M; Kim, N; Gu, H; Choi, Y			A positive regulatory role for Cbl family proteins in tumor necrosis factor-related activation-induced cytokine (TRANCE) and CD40L-mediated Akt activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; KAPPA-B ACTIVATION; N-TERMINAL KINASE; TYROSINE PHOSPHORYLATION; DENDRITIC CELLS; RING FINGER; PHOSPHATIDYLINOSITOL-3 KINASE; NEGATIVE REGULATION; UBIQUITIN LIGASE; P85 SUBUNIT	Tumor necrosis factor (TNF)-related activation-induced cytokine (TRANCE) is a TNF family member essential for osteoclast differentiation, and it induces the activation and survival of osteoclasts and mature dendritic cells. We recently demonstrated that TRANCE activates Akt via a mechanism involving TRANCE receptor (TRANCE-R)/RANK, TRAF6, and c-Src. Here, we show that TRANCE-R and CD40 recruit TRAF6, Cbl family-scaffolding proteins, and the phospholipid kinase phosphatidylinositol 3-kinase in a ligand-dependent manner. The recruitment of Cbl-b and c-Cbl to TRANCE-R, is dependent upon the activity of Src-family kinases. TRANCE and CD40L-mediated Akt activation is defective in Cbl-b -/- dendritic cells, and CD40L-mediated Akt activation is defective in c-Cbl -/- B cells. These findings implicate Cbl family proteins as not only negative regulators of signaling but as positive modulators of TNF receptor superfamily signaling as well.	Rockefeller Univ, Immunol Lab, New York, NY 10021 USA; Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA; NIAID, Immunol Lab, NIH, Rockville, MD 20852 USA	Rockefeller University; Howard Hughes Medical Institute; Rockefeller University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Choi, Y (corresponding author), Rockefeller Univ, Immunol Lab, New York, NY 10021 USA.	ychoi3@mail.med.upenn.edu		Naramura, Mayumi/0000-0003-3658-0767; Arron, Joseph/0000-0001-7677-9979	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044264] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-44264] Funding Source: Medline; NIGMS NIH HHS [GM-07739] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; Bachmaier K, 2000, NATURE, V403, P211, DOI 10.1038/35003228; Baker SJ, 1998, ONCOGENE, V17, P3261, DOI 10.1038/sj.onc.1202568; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; BLAKE TJ, 1991, ONCOGENE, V6, P653; Bustelo XR, 1997, ONCOGENE, V15, P2511, DOI 10.1038/sj.onc.1201430; Chiang YPJ, 2000, NATURE, V403, P216, DOI 10.1038/35003235; DeSmedt T, 1996, J EXP MED, V184, P1413, DOI 10.1084/jem.184.4.1413; Elly C, 1999, ONCOGENE, V18, P1147, DOI 10.1038/sj.onc.1202411; Ettenberg SA, 1999, ONCOGENE, V18, P1855, DOI 10.1038/sj.onc.1202499; Fang D, 2001, J BIOL CHEM, V276, P4872, DOI 10.1074/jbc.M008901200; Harris KF, 1999, P NATL ACAD SCI USA, V96, P13738, DOI 10.1073/pnas.96.24.13738; HARTLEY D, 1995, J BIOL CHEM, V270, P18260, DOI 10.1074/jbc.270.31.18260; Hunter S, 1999, J BIOL CHEM, V274, P2097, DOI 10.1074/jbc.274.4.2097; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; Josien R, 2000, J EXP MED, V191, P495, DOI 10.1084/jem.191.3.495; Josien R, 1999, J IMMUNOL, V162, P2562; Kanagasundaram V, 1996, BIOCHEM J, V320, P69, DOI 10.1042/bj3200069; KEANE MM, 1995, ONCOGENE, V10, P2367; Kim D, 2000, J EXP MED, V192, P1467, DOI 10.1084/jem.192.10.1467; Lee PSW, 1999, EMBO J, V18, P3616, DOI 10.1093/emboj/18.13.3616; Lee SY, 1997, IMMUNITY, V7, P703, DOI 10.1016/S1074-7613(00)80390-8; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Liu YC, 1997, J BIOL CHEM, V272, P9979, DOI 10.1074/jbc.272.15.9979; Lupher ML, 1999, IMMUNOL TODAY, V20, P375, DOI 10.1016/S0167-5699(99)01484-X; Meili R, 1999, EMBO J, V18, P2092, DOI 10.1093/emboj/18.8.2092; Moodycliffe AM, 2000, J EXP MED, V191, P2011, DOI 10.1084/jem.191.11.2011; Naramura M, 1998, P NATL ACAD SCI USA, V95, P15547, DOI 10.1073/pnas.95.26.15547; Ota S, 2000, J BIOL CHEM, V275, P414, DOI 10.1074/jbc.275.1.414; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; Rudd CE, 2000, CURR BIOL, V10, pR344, DOI 10.1016/S0960-9822(00)00463-2; Sanjay A, 2001, J CELL BIOL, V152, P181, DOI 10.1083/jcb.152.1.181; Shishido T, 2000, P NATL ACAD SCI USA, V97, P6439, DOI 10.1073/pnas.060030697; Takayanagi H, 2000, NATURE, V408, P600, DOI 10.1038/35046102; Wani MR, 1999, ENDOCRINOLOGY, V140, P1927, DOI 10.1210/en.140.4.1927; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190; Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097-2765(00)80232-4; Wong BR, 1998, J BIOL CHEM, V273, P28355, DOI 10.1074/jbc.273.43.28355; Wong BR, 1999, J LEUKOCYTE BIOL, V65, P715, DOI 10.1002/jlb.65.6.715; Wong BR, 1997, J EXP MED, V186, P2075, DOI 10.1084/jem.186.12.2075; Wouters FS, 1999, CURR BIOL, V9, P1127, DOI 10.1016/S0960-9822(99)80484-9; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707	45	106	110	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30011	30017		10.1074/jbc.M100414200	http://dx.doi.org/10.1074/jbc.M100414200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11406619	hybrid			2022-12-25	WOS:000170558000054
J	Murphy, PJM; Kanelakis, KC; Galigniana, MD; Morishima, Y; Pratt, WB				Murphy, PJM; Kanelakis, KC; Galigniana, MD; Morishima, Y; Pratt, WB			Stoichiometry, abundance, and functional significance of the hsp90/hsp70-based multiprotein chaperone machinery in reticulocyte lysate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; GLUCOCORTICOID-RECEPTOR; MOLECULAR CHAPERONE; HORMONE-BINDING; PROGESTERONE-RECEPTOR; NEUROSPORA-CRASSA; HSP90; HETEROCOMPLEX; HSP70; DOMAIN	Rabbit reticulocyte lysate contains a multiprotein chaperone system that assembles the glucocorticoid receptor (GR) into a complex with hsp90 and converts the hormone binding domain of the receptor to its high affinity steroid binding state. This system has been resolved into five proteins, with hsp90 and hsp70 being essential and Hop, hsp40, and p23 acting as co-chaperones that optimize assembly. Hop binds independently to hsp70 and hsp90 to form an hsp90(.)Hop(.)hsp70 complex that acts as a machinery to open up the GR steroid binding site. Because purified hsp90 and hsp70 are sufficient for some activation of GR steroid binding activity, some investigators have rejected any role for Hop in GR(.)hsp90 heterocomplex assembly. Here, we counter that impression by showing that all of the Hop in reticulocyte lysate is present in an hsp90(.)Hop(.)hsp70 complex with a stoichiometry of 2:1.1. The complex accounts for similar to 30% of the hsp90 and similar to9% of the hsp70 in lysate, and upon Sephacryl S-300 chromatography the GR(.)hsp90 assembly activity resides in the peak containing Hop-bound hsp90. Consistent with the notion that the two essential chaperones cooperate with each other to open up the steroid binding site, we also show that purified hsp90 and hsp70 interact directly with each other to form weak hsp90-hsp70 complexes with a stoichiometry of 2:1.	Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Murphy, PJM (corresponding author), Univ Michigan, Sch Med, Dept Pharmacol, 1301 Med Sci Res Bldg 3, Ann Arbor, MI 48109 USA.	pjmurphy@umich.edu		GALIGNIANA, MARIO/0000-0002-9130-8574	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031573, R37DK031573] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK31573] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Azem A, 1997, J BIOL CHEM, V272, P20901, DOI 10.1074/jbc.272.33.20901; Benaroudj N, 1997, J BIOL CHEM, V272, P8744, DOI 10.1074/jbc.272.13.8744; Bose S, 1996, SCIENCE, V274, P1715, DOI 10.1126/science.274.5293.1715; BRESNICK EH, 1989, J BIOL CHEM, V264, P4992; CAPLAN AJ, 1992, J BIOL CHEM, V267, P18890; Carrello A, 1999, J BIOL CHEM, V274, P2682, DOI 10.1074/jbc.274.5.2682; Chang HCJ, 1997, MOL CELL BIOL, V17, P318, DOI 10.1128/MCB.17.1.318; CHANG HCJ, 1994, J BIOL CHEM, V269, P24983; CHEN S, 1998, J BIOL CHEM, V3, P118; Chen SY, 1996, MOL ENDOCRINOL, V10, P682, DOI 10.1210/me.10.6.682; CZAR MJ, 1994, J BIOL CHEM, V269, P11155; Demand J, 1998, MOL CELL BIOL, V18, P2023, DOI 10.1128/MCB.18.4.2023; Dittmar KD, 1997, J BIOL CHEM, V272, P13047, DOI 10.1074/jbc.272.20.13047; Dittmar KD, 1998, J BIOL CHEM, V273, P7358, DOI 10.1074/jbc.273.13.7358; Dittmar KD, 1996, J BIOL CHEM, V271, P12833, DOI 10.1074/jbc.271.22.12833; Dittmar KD, 1997, J BIOL CHEM, V272, P21213, DOI 10.1074/jbc.272.34.21213; Freeman BC, 1996, SCIENCE, V274, P1718, DOI 10.1126/science.274.5293.1718; Freitag DG, 1997, BIOCHEMISTRY-US, V36, P10221, DOI 10.1021/bi963030g; Giannoukos G, 1999, J BIOL CHEM, V274, P36527, DOI 10.1074/jbc.274.51.36527; Grenert JP, 1999, J BIOL CHEM, V274, P17525, DOI 10.1074/jbc.274.25.17525; HONORE B, 1992, J BIOL CHEM, V267, P8485; HUTCHISON KA, 1995, J BIOL CHEM, V270, P18841, DOI 10.1074/jbc.270.32.18841; HUTCHISON KA, 1994, J BIOL CHEM, V269, P27894; HUTCHISON KA, 1992, J BIOL CHEM, V267, P14047; HUTCHISON KA, 1994, J BIOL CHEM, V269, P5043; JOHNSON JL, 1994, J BIOL CHEM, V269, P24989; Kosano H, 1998, J BIOL CHEM, V273, P32973, DOI 10.1074/jbc.273.49.32973; Lassle M, 1997, J BIOL CHEM, V272, P1876, DOI 10.1074/jbc.272.3.1876; MINAMI Y, 1994, MOL CELL BIOL, V14, P1459, DOI 10.1128/MCB.14.2.1459; Morishima Y, 2000, J BIOL CHEM, V275, P18054, DOI 10.1074/jbc.M000434200; Morishima Y, 2000, J BIOL CHEM, V275, P6894, DOI 10.1074/jbc.275.10.6894; Morishima Y, 2001, BIOCHEMISTRY-US, V40, P1109, DOI 10.1021/bi002399+; NICOLET CM, 1989, MOL CELL BIOL, V9, P3638, DOI 10.1128/MCB.9.9.3638; Ouimet PM, 1998, BIOCHEM CELL BIOL, V76, P97, DOI 10.1139/bcb-76-1-97; Pratt WB, 2001, TRENDS PLANT SCI, V6, P54, DOI 10.1016/S1360-1385(00)01843-4; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Prodromou C, 1999, EMBO J, V18, P754, DOI 10.1093/emboj/18.3.754; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Rajapandi T, 2000, J BIOL CHEM, V275, P22597, DOI 10.1074/jbc.M002035200; SCHERRER LC, 1992, BIOCHEMISTRY-US, V31, P7325, DOI 10.1021/bi00147a017; SCHERRER LC, 1990, J BIOL CHEM, V265, P21397; Scheufler C, 2000, CELL, V101, P199, DOI 10.1016/S0092-8674(00)80830-2; SCHONFELD HJ, 1995, J BIOL CHEM, V270, P2183, DOI 10.1074/jbc.270.5.2183; Silverstein AM, 1999, J BIOL CHEM, V274, P36980, DOI 10.1074/jbc.274.52.36980; SMITH DF, 1990, MOL ENDOCRINOL, V4, P1704, DOI 10.1210/mend-4-11-1704; SMITH DF, 1993, MOL CELL BIOL, V13, P869, DOI 10.1128/MCB.13.2.869; Stancato LF, 1996, J BIOL CHEM, V271, P8831, DOI 10.1074/jbc.271.15.8831; Sullivan W, 1997, J BIOL CHEM, V272, P8007, DOI 10.1074/jbc.272.12.8007; Xu M, 1998, J BIOL CHEM, V273, P13918, DOI 10.1074/jbc.273.22.13918; Young JC, 1998, J BIOL CHEM, V273, P18007, DOI 10.1074/jbc.273.29.18007	50	65	67	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30092	30098		10.1074/jbc.M103773200	http://dx.doi.org/10.1074/jbc.M103773200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11404358	hybrid			2022-12-25	WOS:000170558000066
J	Inga, A; Resnick, MA				Inga, A; Resnick, MA			Novel human p53 mutations that are toxic to yeast can enhance transactivation of specific promoters and reactivate tumor p53 mutants	ONCOGENE			English	Article						p53; yeast functional assays; p53 toxic mutants; enhanced transactivation; p53 mutants reactivation	CELL-CYCLE ARREST; DNA-BINDING SITES; FUNCTIONAL ASSAY; GENE-EXPRESSION; SEQUENCE-SPECIFICITY; SUPPRESSOR PROTEIN; TERMINAL DOMAIN; GROWTH ARREST; CANCER-CELLS; TARGET GENE	Since highly expressed human p53 can inhibit human and yeast cell growth, we predicted that p53 mutants could be generated with increased growth inhibition of the yeast Saccharomyces cerevisiae and that these would be useful for characterizing p53 functions and tumor p53 mutants. A random mutagenesis screen led to the isolation of mutations in the DIVA binding domain that result in p53 being lethal even at moderate expression levels in yeast. Three independent mutants had an alanine change at the evolutionary invariant V122 in the L1 loop. The other toxic mutations affected codons 277 (C277R, C277W) and 279 (G279R). This latter amino acid change was also reported in tumors, while all the other mutations are novel. A recently developed rheostatable GALI promoter system that provides graded increases in expression of p53 was used to examine the transactivation function of the toxic mutations when expression was greatly reduced and cells were viable. At low expression levels the toxic mutants lacked transactivation from a 3xRGC responsive element (RE). Surprisingly some exhibited enhanced transactivation with p21 and bax REs. The V122A mutant was able to re-activate transactivation of various p53 tumor mutants and retained growth inhibition when co-expressed with dominant-negative tumor mutations. Upon expression in human Saos-2 cells the V122A p53 mutant caused growth suppression, was capable of transactivation and exhibited higher than wild type activity with the bax promoter in luciferase assays. A non-functional p53 tumor mutant was partially reactivated by V122A for both transactivation and growth suppression. Thus, the screen for toxic p53 mutants in yeast can identify novel p53 variants that may be useful in dissecting p53 regulated cellular responses and in developing p53-based cancer therapies.	NIEHS, Genet Mol Lab, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Resnick, MA (corresponding author), NIEHS, Genet Mol Lab, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.		Inga, Alberto/AAC-3815-2022; resnick, Michael/F-1668-2019	Inga, Alberto/0000-0002-8767-1637; resnick, Michael/0000-0002-8473-7506	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES065079, Z01ES065079] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ashcroft M, 1999, ONCOGENE, V18, P7637, DOI 10.1038/sj.onc.1203012; Aurelio ON, 2000, MOL CELL BIOL, V20, P770, DOI 10.1128/MCB.20.3.770-778.2000; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BISCHOFF JR, 1992, MOL CELL BIOL, V12, P1405, DOI 10.1128/MCB.12.4.1405; Brachmann RK, 1996, P NATL ACAD SCI USA, V93, P4091, DOI 10.1073/pnas.93.9.4091; Brachmann RK, 1998, EMBO J, V17, P1847, DOI 10.1093/emboj/17.7.1847; Chappuis PO, 1999, INT J CANCER, V84, P587, DOI 10.1002/(SICI)1097-0215(19991222)84:6<587::AID-IJC8>3.0.CO;2-8; Chene P, 1999, BIOCHEM BIOPH RES CO, V263, P1, DOI 10.1006/bbrc.1999.1294; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Clayman GL, 1998, J CLIN ONCOL, V16, P2221, DOI 10.1200/JCO.1998.16.6.2221; Cortes U, 2000, MOL CARCINOGEN, V27, P57, DOI 10.1002/(SICI)1098-2744(200002)27:2<57::AID-MC1>3.3.CO;2-9; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Flaman JM, 1998, ONCOGENE, V16, P1369, DOI 10.1038/sj.onc.1201889; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; Frazier MW, 1998, MOL CELL BIOL, V18, P3735, DOI 10.1128/MCB.18.7.3735; FREEMAN J, 1994, EMBO J, V13, P5393, DOI 10.1002/j.1460-2075.1994.tb06874.x; Gagnebin J, 1998, ONCOGENE, V16, P685, DOI 10.1038/sj.onc.1201568; Gallagher WM, 1999, ANN ONCOL, V10, P139, DOI 10.1023/A:1008368500557; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Guardavaccaro D, 2000, MOL CELL BIOL, V20, P1797, DOI 10.1128/MCB.20.5.1797-1815.2000; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Hernandez-Boussard T, 1999, HUM MUTAT, V14, P1; Inga A, 1997, CARCINOGENESIS, V18, P2019, DOI 10.1093/carcin/18.10.2019; Inga A, 1997, ONCOGENE, V14, P1307, DOI 10.1038/sj.onc.1200952; Inga A, 2001, ONCOGENE, V20, P501, DOI 10.1038/sj.onc.1204116; ISHIOKA C, 1995, ONCOGENE, V10, P1485; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; LIN JY, 1995, ONCOGENE, V10, P2387; LinGoerke JL, 1997, BIOTECHNIQUES, V23, P409, DOI 10.2144/97233bm12; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; McLure KG, 1998, EMBO J, V17, P3342, DOI 10.1093/emboj/17.12.3342; Meek DW, 1998, INT J RADIAT BIOL, V74, P729, DOI 10.1080/095530098141005; NIGRO JM, 1992, MOL CELL BIOL, V12, P1357, DOI 10.1128/MCB.12.3.1357; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Ohki R, 2000, J BIOL CHEM, V275, P22627, DOI 10.1074/jbc.C000235200; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Prives C, 1999, J PATHOL, V187, P112; Resnick-Silverman L, 1998, GENE DEV, V12, P2102, DOI 10.1101/gad.12.14.2102; Robert V, 2000, CARCINOGENESIS, V21, P563, DOI 10.1093/carcin/21.4.563; ROLLEY N, 1995, ONCOGENE, V11, P763; Saller E, 1999, EMBO J, V18, P4424, DOI 10.1093/emboj/18.16.4424; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; Selivanova G, 1999, MOL CELL BIOL, V19, P3395; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Soussi T, 1996, J MOL BIOL, V260, P623, DOI 10.1006/jmbi.1996.0425; Swisher SG, 1999, J NATL CANCER I, V91, P763, DOI 10.1093/jnci/91.9.763; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; Thornborrow EC, 1999, J BIOL CHEM, V274, P33747, DOI 10.1074/jbc.274.47.33747; THUKRAL SK, 1995, MOL CELL BIOL, V15, P5196; Velasco-Miguel S, 1999, ONCOGENE, V18, P127, DOI 10.1038/sj.onc.1202274; Vinyals A, 1999, GENE THER, V6, P22, DOI 10.1038/sj.gt.3300786; Walker DR, 1999, ONCOGENE, V18, P211, DOI 10.1038/sj.onc.1202298; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; Wieczorek AM, 1996, NAT MED, V2, P1143, DOI 10.1038/nm1096-1143; Wolf JK, 1999, GYNECOL ONCOL, V75, P261, DOI 10.1006/gyno.1999.5565; Wong KB, 1999, P NATL ACAD SCI USA, V96, P8438, DOI 10.1073/pnas.96.15.8438; Zhu JH, 2000, MOL CELL BIOL, V20, P5602, DOI 10.1128/MCB.20.15.5602-5618.2000	62	42	44	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 7	2001	20	26					3409	3419		10.1038/sj.onc.1204457	http://dx.doi.org/10.1038/sj.onc.1204457			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	441UW	11423991				2022-12-25	WOS:000169248800011
J	Kwek, SSS; Derry, J; Tyner, AL; Shen, ZY; Gudkov, AV				Kwek, SSS; Derry, J; Tyner, AL; Shen, ZY; Gudkov, AV			Functional analysis and intracellular localization of p53 modified by SUMO-1	ONCOGENE			English	Article						SUMO-1; p53; transactivation; cellular localization	UBIQUITIN-LIKE PROTEIN; NUCLEAR-PORE COMPLEX; CELL-CYCLE PROGRESSION; TUMOR-SUPPRESSOR P53; DNA-DAMAGE; COVALENT MODIFICATION; ADENOVIRUS TYPE-5; IN-VITRO; MDM2; CONJUGATION	p53 tumor suppressor is a subject of several posttranslational modifications, including phosphorylation, ubiquitination and acetylation, which regulate p53 function. A new covalent modification of p53 at lysine 386 by SUMO-1 was recently identified. To elucidate the function of sumoylated p53, we compared the properties of wild type p53 and sumoylation-deficient p53 mutant, K386R, No differences were found between wild type p53 and K386R mutant of p53 in transactivation or growth suppression assays. Moreover, overexpression of SUMO-1 has no effect on p53-regulated transcription. Biochemical fractionation showed that sumoylated p53 is localized in the nucleus and is tightly bound to chromatin structures. p53 and SUMO-1 colocalized in PML nuclear bodies in 293 cells and the nucleoli in MCF7 and HT1080 cells. However, sumoylation-deficient p53 mutant showed a similar pattern of intranuclear localization, suggesting that SUMO-1 does not target p53 to subnuclear structures. These data indicate that SUMO-1 modification of p53 at lysine 386 may not be essential for p53's cellular localization, transcriptional activation, or growth regulation.	Univ Illinois, Coll Med, Dept Mol Genet, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Gudkov, AV (corresponding author), Univ Illinois, Coll Med, Dept Mol Genet, 900 S Ashland Ave, Chicago, IL 60607 USA.			Shen, Zhiyuan/0000-0003-2834-0309; Gudkov, Andrei/0000-0003-2548-0154; Tyner, Angela/0000-0001-7448-8625	NATIONAL CANCER INSTITUTE [R01CA075179] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056283] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008353, R29ES008353] Funding Source: NIH RePORTER; NCI NIH HHS [CA75179] Funding Source: Medline; NIDDK NIH HHS [R01 DK056283] Funding Source: Medline; NIEHS NIH HHS [ES08353] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Blattner C, 1999, ONCOGENE, V18, P1723, DOI 10.1038/sj.onc.1202480; Boddy MN, 1996, ONCOGENE, V13, P971; Buschmann T, 2000, CELL, V101, P753, DOI 10.1016/S0092-8674(00)80887-9; CARTER T, 1987, CANCER RES, V47, P803; Chehab NH, 2000, GENE DEV, V14, P278; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Desterro JMP, 1997, FEBS LETT, V417, P297, DOI 10.1016/S0014-5793(97)01305-7; FINLEY RL, 1995, DNA CLONING EXPRESSI, P169; FISCELLA M, 1993, ONCOGENE, V8, P1519; FUCHS B, 1995, ONCOGENE, V10, P789; GERACE L, 1982, J CELL BIOL, V95, P826, DOI 10.1083/jcb.95.3.826; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gong LM, 2000, J BIOL CHEM, V275, P3355, DOI 10.1074/jbc.275.5.3355; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GRAHAM JM, 1997, SUBCELLULAR FRACTION, P71; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hollstein M, 1996, NUCLEIC ACIDS RES, V24, P141, DOI 10.1093/nar/24.1.141; HOLTZ D, 1989, CELL, V59, P969, DOI 10.1016/0092-8674(89)90753-8; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Johnson ES, 1997, J BIOL CHEM, V272, P26799, DOI 10.1074/jbc.272.43.26799; Johnson ES, 1997, EMBO J, V16, P5509, DOI 10.1093/emboj/16.18.5509; Kamitani T, 1998, J BIOL CHEM, V273, P26675, DOI 10.1074/jbc.273.41.26675; Kamitani T, 1997, J BIOL CHEM, V272, P14001, DOI 10.1074/jbc.272.22.14001; KAY RR, 1972, EUR J BIOCHEM, V30, P145, DOI 10.1111/j.1432-1033.1972.tb02081.x; Kim YH, 1999, P NATL ACAD SCI USA, V96, P12350, DOI 10.1073/pnas.96.22.12350; Kirsch DG, 1998, J CLIN ONCOL, V16, P3158, DOI 10.1200/JCO.1998.16.9.3158; Kondratov R. V., 1996, Molekulyarnaya Biologiya (Moscow), V30, P613; Kubbutat MHG, 1998, MOL MED TODAY, V4, P250, DOI 10.1016/S1357-4310(98)01260-X; Lain S, 1999, EXP CELL RES, V248, P457, DOI 10.1006/excr.1999.4433; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Leppard KN, 1999, J GEN VIROL, V80, P997, DOI 10.1099/0022-1317-80-4-997; Li SJ, 1999, NATURE, V398, P246, DOI 10.1038/18457; Li WH, 2000, NUCLEIC ACIDS RES, V28, P1145, DOI 10.1093/nar/28.5.1145; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Lindstrom MS, 2000, EXP CELL RES, V256, P400, DOI 10.1006/excr.2000.4854; Liu L, 1999, MOL CELL BIOL, V19, P1202; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Mao Y, 2000, P NATL ACAD SCI USA, V97, P4046, DOI 10.1073/pnas.080536597; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; MELUH PB, 1995, MOL BIOL CELL, V6, P793, DOI 10.1091/mbc.6.7.793; Minty A, 2000, J BIOL CHEM, V275, P36316, DOI 10.1074/jbc.M004293200; Momand J, 2000, GENE, V242, P15, DOI 10.1016/S0378-1119(99)00487-4; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Okuma T, 1999, BIOCHEM BIOPH RES CO, V254, P693, DOI 10.1006/bbrc.1998.9995; Okura T, 1996, J IMMUNOL, V157, P4277; Piette J, 1997, ONCOGENE, V15, P1001, DOI 10.1038/sj.onc.1201432; REIMER G, 1987, ARTHRITIS RHEUM, V30, P793, DOI 10.1002/art.1780300709; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Rubbi CP, 2000, ONCOGENE, V19, P85, DOI 10.1038/sj.onc.1203378; Saitoh H, 1997, TRENDS BIOCHEM SCI, V22, P374, DOI 10.1016/S0968-0004(97)01102-X; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; Shen ZY, 1996, GENOMICS, V37, P183, DOI 10.1006/geno.1996.0540; Shieh SY, 2000, GENE DEV, V14, P289; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; SNOW CM, 1987, J CELL BIOL, V104, P1143, DOI 10.1083/jcb.104.5.1143; Sternsdorf T, 1999, J BIOL CHEM, V274, P12555, DOI 10.1074/jbc.274.18.12555; Sternsdorf T, 1997, J CELL BIOL, V139, P1621, DOI 10.1083/jcb.139.7.1621; Suzuki T, 1999, J BIOL CHEM, V274, P31131, DOI 10.1074/jbc.274.44.31131; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2	69	110	116	0	9	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 3	2001	20	20					2587	2599		10.1038/sj.onc.1204362	http://dx.doi.org/10.1038/sj.onc.1204362			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	431VM	11420669				2022-12-25	WOS:000168652500010
J	Tomita, T; Watabiki, T; Takikawa, R; Morohashi, Y; Takasugi, N; Kopan, R; De Strooper, B; Iwatsubo, T				Tomita, T; Watabiki, T; Takikawa, R; Morohashi, Y; Takasugi, N; Kopan, R; De Strooper, B; Iwatsubo, T			The first proline of PALP motif at the C terminus of presenilins is obligatory for stabilization, complex formation, and gamma-secretase activities of presenilins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID-BETA-PROTEIN; DISEASE-ASSOCIATED PRESENILIN-1; ALZHEIMERS-DISEASE; CAENORHABDITIS-ELEGANS; PROTEOLYTIC RELEASE; MUTANT; NOTCH; ENDOPROTEOLYSIS; CLEAVAGE; MUTATION	Mutations in presenilin (PS) genes cause early-onset familial Alzheimer's disease by increasing production of the amyloidogenic form of amyloid beta peptides ending at residue 42 (A beta 42). PS is an evolutionarily conserved multipass transmembrane protein, and all known PS proteins contain a proline-alanine-leucine-proline (PALP) motif starting at proline (P) 414 (amino acid numbering based on human PS2) at the C terminus. Furthermore, missense mutations that replace the first proline of PALP with leucine (P414L) lead to a loss-of-function of PS in Drosophila melanogaster and Caenorhabditis elegans. To elucidate the roles of the PALP motif in PS structure and function, we analyzed neuro2a as well as PS1/2 null fibroblast cell lines transfected with human PS harboring mutations at the PALP motif. P414L mutation in PS2 (and its equivalent in PS1) abrogated stabilization, high molecular weight complex formation, and entry to Golgi/trans-Golgi network of PS proteins, resulting in failure of A beta 42 overproduction on familial Alzheimer's disease mutant basis as well as of site-3 cleavage of Notch. These data suggest that the first proline of the PALP motif plays a crucial role in the stabilization and formation of the high molecular weight complex of PS, the latter being the active form with intramembrane proteolytic activities.	Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Neuropathol & Neurosci, Bunkyo Ku, Tokyo 1130033, Japan; Washington Univ, Div Dermatol, St Louis, MO 63110 USA; Washington Univ, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Katholieke Univ Leuven, Neuronal Cell Biol Lab, B-3000 Louvain, Belgium; Flanders Interuniv Inst Biotechnol, B-3000 Louvain, Belgium	University of Tokyo; Washington University (WUSTL); Washington University (WUSTL); KU Leuven	Iwatsubo, T (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Neuropathol & Neurosci, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	iwatsubo@mol.f.u-tokyo.ac.jp	de+Strooper, Bart/Z-1638-2019; Tomita, Taisuke/L-5427-2015; Kopan, Raphael/AFG-3275-2022; De Strooper, Bart/F-6507-2012; Kopan, Raphael/AAF-1357-2022	Tomita, Taisuke/0000-0002-0075-5943; De Strooper, Bart/0000-0001-5455-5819; Watabiki, Tomonari/0000-0003-4289-8659; Kopan, Raphael/0000-0002-0350-2730; TAKASUGI, NOBUMASA/0000-0002-6059-2082				ARAI H, 1987, BIOCHEMISTRY-US, V26, P6632, DOI 10.1021/bi00395a011; Arduengo PM, 1998, J CELL SCI, V111, P3645; Capell A, 1998, J BIOL CHEM, V273, P3205, DOI 10.1074/jbc.273.6.3205; Citron M, 1998, NEUROBIOL DIS, V5, P107, DOI 10.1006/nbdi.1998.0183; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Donoviel DB, 1999, GENE DEV, V13, P2801, DOI 10.1101/gad.13.21.2801; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; Fukumoto H, 1999, NEUROREPORT, V10, P2965, DOI 10.1097/00001756-199909290-00017; Guo YQ, 1999, J NEUROSCI, V19, P8435; Herreman A, 2000, NAT CELL BIOL, V2, P461, DOI 10.1038/35017105; Herreman A, 1999, P NATL ACAD SCI USA, V96, P11872, DOI 10.1073/pnas.96.21.11872; Iwata H, 2001, J BIOL CHEM, V276, P21678, DOI 10.1074/jbc.M007989200; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; IWATSUBO T, 1995, ANN NEUROL, V37, P294, DOI 10.1002/ana.410370305; Jacobsen H, 1999, J BIOL CHEM, V274, P35233, DOI 10.1074/jbc.274.49.35233; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Kopan R, 2000, GENE DEV, V14, P2799, DOI 10.1101/gad.836900; Kulic L, 2000, P NATL ACAD SCI USA, V97, P5913, DOI 10.1073/pnas.100049897; LEVITAN D, 1995, NATURE, V377, P351, DOI 10.1038/377351a0; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Naruse S, 1998, NEURON, V21, P1213, DOI 10.1016/S0896-6273(00)80637-6; Okochi M, 2000, J BIOL CHEM, V275, P40925, DOI 10.1074/jbc.M005254200; Palmer ME, 1999, RAPID COMMUN MASS SP, V13, P256, DOI 10.1002/(SICI)1097-0231(19990228)13:4<256::AID-RCM459>3.0.CO;2-S; Ratovitski T, 1997, J BIOL CHEM, V272, P24536, DOI 10.1074/jbc.272.39.24536; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Seeger M, 1997, P NATL ACAD SCI USA, V94, P5090, DOI 10.1073/pnas.94.10.5090; Seiffert D, 2000, J BIOL CHEM, V275, P34086, DOI 10.1074/jbc.M005430200; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; Shirotani K, 2000, J BIOL CHEM, V275, P3681, DOI 10.1074/jbc.275.5.3681; Song WH, 1999, P NATL ACAD SCI USA, V96, P6959, DOI 10.1073/pnas.96.12.6959; Steiner H, 2000, NAT CELL BIOL, V2, P848, DOI 10.1038/35041097; Steiner H, 1999, BIOCHEMISTRY-US, V38, P14600, DOI 10.1021/bi9914210; Steiner H, 1998, J BIOL CHEM, V273, P32322, DOI 10.1074/jbc.273.48.32322; Steiner H, 1999, J BIOL CHEM, V274, P28669, DOI 10.1074/jbc.274.40.28669; Struhl G, 2000, MOL CELL, V6, P625, DOI 10.1016/S1097-2765(00)00061-7; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Taddei K, 1998, NEUROREPORT, V9, P3335, DOI 10.1097/00001756-199810050-00034; Thinakaran G, 1997, J BIOL CHEM, V272, P28415, DOI 10.1074/jbc.272.45.28415; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Tomita T, 1999, J NEUROSCI, V19, P10627, DOI 10.1523/JNEUROSCI.19-24-10627.1999; Tomita T, 1998, J BIOL CHEM, V273, P21153, DOI 10.1074/jbc.273.33.21153; Tomita T, 1997, P NATL ACAD SCI USA, V94, P2025, DOI 10.1073/pnas.94.5.2025; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Xia WM, 1998, BIOCHEMISTRY-US, V37, P16465, DOI 10.1021/bi9816195; Yu G, 2000, J BIOL CHEM, V275, P27348; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Yu G, 1998, J BIOL CHEM, V273, P16470, DOI 10.1074/jbc.273.26.16470; Zhang ZH, 2000, NAT CELL BIOL, V2, P463, DOI 10.1038/35017108	53	77	79	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					33273	33281		10.1074/jbc.M011152200	http://dx.doi.org/10.1074/jbc.M011152200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11432849	hybrid			2022-12-25	WOS:000170746000114
J	Fujimoto, I; Bruses, JL; Rutishauser, U				Fujimoto, I; Bruses, JL; Rutishauser, U			Regulation of cell adhesion by polysialic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULE N-CAM; HOMOPHILIC BINDING; NEURITE OUTGROWTH; NEURAL ADHESION; NERVOUS-SYSTEM; NCAM; L1; POLYSIALYLATION; IDENTIFICATION; DETERMINANTS	The polysialylation of neural cell adhesion molecule (NCAM) evolved in vertebrates to carry out biological functions related to changes in cell position and morphology. Many of these effects involve the attenuation of cell interactions that are not mediated through NCAM's own adhesion properties. A proposed mechanism for this global effect on cell interaction is the steric inhibition of membrane-membrane apposition based solely on polysialic acid (PSA) biophysical properties. However, it remains possible that the intrinsic binding or signaling properties of the NCAM polypeptide are also involved. To help resolve this issue, this study uses a quantitative cell detachment assay together with cells engineered to display different adhesion receptors together with a variety of polysialylated NCAM polypeptide isoforms and functional domain deletion mutations. The results obtained indicate that regulation by PSA occurs with adhesion receptors as diverse as an IgCAM, a cadherin and an integrin, and does not require NCAM functional domains other than those minimally required for polysialylation. These findings are most consistent with the cell apposition mechanism for PSA action, as this model predicts that the inhibitory effects of PSA-NCAM on cell adhesion should be independent of the nature of the adhesion system and of any intrinsic binding or signalling properties of the NCAM polypeptide itself.	Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Rutishauser, U (corresponding author), Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, 1275 York Ave, New York, NY 10021 USA.			Fujimoto, Ichiro/0000-0001-7088-6407				ACHESON A, 1991, J CELL BIOL, V114, P143, DOI 10.1083/jcb.114.1.143; Beggs HE, 1997, J BIOL CHEM, V272, P8310, DOI 10.1074/jbc.272.13.8310; Brieher WM, 1996, J CELL BIOL, V135, P487, DOI 10.1083/jcb.135.2.487; COLE GJ, 1989, NEURON, V2, P1157, DOI 10.1016/0896-6273(89)90182-7; CREMER H, 1994, NATURE, V367, P455, DOI 10.1038/367455a0; DEDHAR S, 1989, J BIOL CHEM, V264, P4832; DEDHAR S, 1990, J CELL BIOL, V110, P2185, DOI 10.1083/jcb.110.6.2185; Felding-Habermann B, 1997, J CELL BIOL, V139, P1567, DOI 10.1083/jcb.139.6.1567; FINNE J, 1985, TRENDS BIOCHEM SCI, V10, P129, DOI 10.1016/0968-0004(85)90274-9; Fransen E, 1998, HUM MOL GENET, V7, P999, DOI 10.1093/hmg/7.6.999; FRELINGER AL, 1986, J CELL BIOL, V103, P1729, DOI 10.1083/jcb.103.5.1729; HALLENBECK PC, 1987, J BIOL CHEM, V262, P3553; HOFFMAN S, 1984, ADV EXP MED BIOL, V181, P147; HORSTKORTE R, 1993, J CELL BIOL, V121, P1409, DOI 10.1083/jcb.121.6.1409; KADMON G, 1990, J CELL BIOL, V110, P209, DOI 10.1083/jcb.110.1.209; KADMON G, 1990, J CELL BIOL, V110, P193, DOI 10.1083/jcb.110.1.193; Kolkova K, 2000, J NEUROSCI, V20, P2238; Muhlenhoff M, 1996, CURR BIOL, V6, P1188, DOI 10.1016/S0960-9822(02)70687-8; Muller D, 2000, P NATL ACAD SCI USA, V97, P4315, DOI 10.1073/pnas.070022697; Nakayama J, 1996, J BIOL CHEM, V271, P1829, DOI 10.1074/jbc.271.4.1829; NELSON RW, 1995, J BIOL CHEM, V270, P17171, DOI 10.1074/jbc.270.29.17171; OKA S, 1995, J BIOL CHEM, V270, P19357, DOI 10.1074/jbc.270.33.19357; POLLERBERG GE, 1986, NATURE, V324, P462, DOI 10.1038/324462a0; POLLERBERG GE, 1987, CELL TISSUE RES, V250, P227, DOI 10.1007/BF00214676; RAO Y, 1993, J BIOL CHEM, V268, P20630; RAO Y, 1992, J CELL BIOL, V118, P937, DOI 10.1083/jcb.118.4.937; Rutishauser U, 1996, TRENDS NEUROSCI, V19, P422; RUTISHAUSER U, 1988, SCIENCE, V240, P53, DOI 10.1126/science.3281256; Saffell JL, 1997, NEURON, V18, P231, DOI 10.1016/S0896-6273(00)80264-0; Seki T, 1998, J NEUROSCI, V18, P3757; Storms SD, 1998, J BIOL CHEM, V273, P27124, DOI 10.1074/jbc.273.42.27124; TANG JC, 1994, NEURON, V13, P405, DOI 10.1016/0896-6273(94)90356-5; TOMASIEWICZ H, 1993, NEURON, V11, P1163, DOI 10.1016/0896-6273(93)90228-J; YANG PF, 1992, J CELL BIOL, V116, P1487, DOI 10.1083/jcb.116.6.1487; YANG PF, 1994, J BIOL CHEM, V269, P23039; Yap AS, 1997, CURR BIOL, V7, P308, DOI 10.1016/S0960-9822(06)00154-0	36	129	132	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					31745	31751		10.1074/jbc.M104525200	http://dx.doi.org/10.1074/jbc.M104525200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11425861	hybrid			2022-12-25	WOS:000170613500038
J	Lim, C; Gwack, Y; Hwang, S; Kim, S; Choe, J				Lim, C; Gwack, Y; Hwang, S; Kim, S; Choe, J			The transcriptional activity of cAMP response element-binding protein-binding protein is modulated by the latency associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPSTEIN-BARR-VIRUS; DNA-SEQUENCES; HUMAN-HERPESVIRUS-8 BINDS; MULTIPLE DOMAINS; COACTIVATOR CBP; CREB; P300; ACTIVATION; INTERACTS; KSHV	A multifunctional transcription co-activator, cAMP response element-binding protein-binding protein (CBP) interacts with a number of cellular factors and participates in cell growth, transformation, and development. It is also targeted by many viral proteins for their transcriptional activity or for the regulation of cellular processes. Here, we report that the C/H3 region of CBP is targeted by the latency associated nuclear antigen (LANA) of Kaposi's sarcoma-associated herpesvirus (KSHV). LANA interferes with the interaction between CBP and c-Fos, a representative C/H3 region binding, cellular transcription factor, in vivo and in vitro. In addition, we found that LANA inhibits the transcriptional activity and the in vitro histone acetyltransferase activity of CBP, suggesting that LANA modulates the global transcriptional activities of infected cells through the interaction with CBP. These results indicate that KSHV follows one of the conserved strategies, which other viruses utilize for influencing the cellular processes.	Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea	Korea Advanced Institute of Science & Technology (KAIST)	Choe, J (corresponding author), Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea.		Lim, Chunghun/AAB-1253-2020; Choe, Joonho/F-3066-2011	Lim, Chunghun/0000-0001-8473-9272; Hwang, Seungmin/0000-0003-0846-5462				Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Ballestas ME, 1999, SCIENCE, V284, P641, DOI 10.1126/science.284.5414.641; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Cotter MA, 1999, VIROLOGY, V264, P254, DOI 10.1006/viro.1999.9999; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Eckner R, 1996, MOL CELL BIOL, V16, P3454; Friborg J, 1999, NATURE, V402, P889, DOI 10.1038/47266; Ganem D, 1997, CELL, V91, P157, DOI 10.1016/S0092-8674(00)80398-0; Gao SJ, 1996, NAT MED, V2, P925, DOI 10.1038/nm0896-925; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Goodman RH, 2000, GENE DEV, V14, P1553; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Gwack Y, 2001, J VIROL, V75, P1909, DOI 10.1128/JVI.75.4.1909-1917.2001; Hotttiger MO, 1998, J VIROL, V72, P8252, DOI 10.1128/JVI.72.10.8252-8256.1998; Jayachandra S, 1999, P NATL ACAD SCI USA, V96, P11566, DOI 10.1073/pnas.96.20.11566; Kedes DH, 1996, NAT MED, V2, P918, DOI 10.1038/nm0896-918; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Krithivas A, 2000, J VIROL, V74, P9637, DOI 10.1128/JVI.74.20.9637-9645.2000; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0; Lee D, 2000, J BIOL CHEM, V275, P7045, DOI 10.1074/jbc.275.10.7045; Liang GS, 1997, J BIOL CHEM, V272, P24088, DOI 10.1074/jbc.272.38.24088; Lim C, 2000, J GEN VIROL, V81, P2645, DOI 10.1099/0022-1317-81-11-2645; Lukac DM, 1998, VIROLOGY, V252, P304, DOI 10.1006/viro.1998.9486; Lukac DM, 1999, J VIROL, V73, P9348, DOI 10.1128/JVI.73.11.9348-9361.1999; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; Martinez-Balbas MA, 1998, EMBO J, V17, P2886, DOI 10.1093/emboj/17.10.2886; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; Patel D, 1999, EMBO J, V18, P5061, DOI 10.1093/emboj/18.18.5061; Platt GM, 1999, J VIROL, V73, P9789, DOI 10.1128/JVI.73.12.9789-9795.1999; Rainbow L, 1997, J VIROL, V71, P5915, DOI 10.1128/JVI.71.8.5915-5921.1997; Renne R, 2001, J VIROL, V75, P458, DOI 10.1128/JVI.75.1.458-468.2001; Russo JJ, 1996, P NATL ACAD SCI USA, V93, P14862, DOI 10.1073/pnas.93.25.14862; Sarid R, 1998, J VIROL, V72, P1005, DOI 10.1128/JVI.72.2.1005-1012.1998; Schwam DR, 2000, J VIROL, V74, P8532, DOI 10.1128/JVI.74.18.8532-8540.2000; Seo T, 2000, BIOCHEM BIOPH RES CO, V270, P23, DOI 10.1006/bbrc.2000.2393; Sun R, 1998, P NATL ACAD SCI USA, V95, P10866, DOI 10.1073/pnas.95.18.10866; Swope DL, 1996, J BIOL CHEM, V271, P28138, DOI 10.1074/jbc.271.45.28138; Van Orden K, 1999, J BIOL CHEM, V274, P26321, DOI 10.1074/jbc.274.37.26321; Wang L, 2000, P NATL ACAD SCI USA, V97, P430, DOI 10.1073/pnas.97.1.430; Zerby D, 1999, MOL CELL BIOL, V19, P1617	46	100	102	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					31016	31022		10.1074/jbc.M102431200	http://dx.doi.org/10.1074/jbc.M102431200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11425857	hybrid			2022-12-25	WOS:000170472900057
J	Nakayama, K; Puchkaev, A; Pikuleva, IA				Nakayama, K; Puchkaev, A; Pikuleva, IA			Membrane binding and substrate access merge in cytochrome P4507Al, a key enzyme in degradation of cholesterol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; EXPRESSION; PURIFICATION; 7-ALPHA-HYDROXYLASE; HYDROXYLATION; SEQUENCES; PROTEINS	To study membrane topology and mechanism for substrate specificity, we truncated residues 2-24 in microsomal cytochrome P450 7A1 (P450 7A1) and introduced conservative and nonconservative substitutions at positions 214-227. Heterologous expression in Escherichia coli was followed by investigation of the subcellular distribution of the mutant P450s and determination of the kinetic and substrate binding parameters for cholesterol. The results indicate that a hydrophobic region, comprising residues 214-227, forms a secondary site of attachment to the membrane in P450 7A1 in addition to the NH2-terminal signal-anchor sequence. There are two groups of residues at this enzyme-membrane interface. The first are those whose mutation results in more cytosolic P450 (Val-214, His-225, and Met-226). The second group are those whose mutation leads to more membrane-bound P450 (Phe-215, Leu-218, Ile-224, and Phe227). In addition, the V214A, V214L, V214T, F215A, F215L, F215Y, L218I, L218V, V219T, and M226A mutants showed a 5-12-fold increased K-m for cholesterol. The k(cat) of the V214A, V214L, V219T, and M226A mutants was increased up to 1.8-fold, and that of the V214T, F215A, F215L, F215Y, L218I, and L218V mutants was decreased 3-10.5-fold. Based on analysis of these mutations we suggest that cholesterol enters P450 7A1 through the membrane, and Val-214, Phe-215, and Leu-218 are the residues located near the point of cholesterol entry. The results provide an understanding of both the P450 7A1membrane interactions and the mechanism for substrate specificity.	Univ Texas, Med Branch, Dept Pharmacol & Toxicol, Galveston, TX 77555 USA; Byelarussian Acad Sci, Inst Bioorgan Chem, Minsk 220141, BELARUS	University of Texas System; University of Texas Medical Branch Galveston; National Academy of Sciences of Belarus (NASB); Institute of Bioorganic Chemistry of the National Academy of Sciences of Belarus	Pikuleva, IA (corresponding author), Univ Texas, Med Branch, Dept Pharmacol & Toxicol, 301 Univ Blvd, Galveston, TX 77555 USA.	irpikule@utmb.edu		Pikuleva, Irina/0000-0001-9742-6232	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006676] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062882] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES06676] Funding Source: Medline; NIGMS NIH HHS [GM62882-01] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHRISTOU M, 1992, BIOCHEMISTRY-US, V31, P2835, DOI 10.1021/bi00125a027; Cosme J, 2000, J BIOL CHEM, V275, P2545, DOI 10.1074/jbc.275.4.2545; CUPPVICKERY JR, 1995, NAT STRUCT BIOL, V2, P144, DOI 10.1038/nsb0295-144; DELEMOSCHIARANDINI C, 1987, J CELL BIOL, V104, P209, DOI 10.1083/jcb.104.2.209; DEPREZ E, 1994, BIOCHEMISTRY-US, V33, P14464, DOI 10.1021/bi00252a012; Dong MS, 1996, BIOCHEMISTRY-US, V35, P10031, DOI 10.1021/bi960873z; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; Graham SE, 1999, ARCH BIOCHEM BIOPHYS, V369, P24, DOI 10.1006/abbi.1999.1350; GrahamLorence S, 1997, J BIOL CHEM, V272, P1127, DOI 10.1074/jbc.272.2.1127; GRAHAMLORENCE S, 1995, PROTEIN SCI, V4, P1065, DOI 10.1002/pro.5560040605; Hanna IH, 1998, ARCH BIOCHEM BIOPHYS, V350, P324, DOI 10.1006/abbi.1997.0534; HASEMANN CA, 1994, J MOL BIOL, V236, P1169, DOI 10.1016/0022-2836(94)90019-1; Hoch U, 2000, J BIOL CHEM, V275, P26952; KARAM WG, 1994, J LIPID RES, V35, P1222; KARAM WG, 1992, BIOCHEM BIOPH RES CO, V185, P588, DOI 10.1016/0006-291X(92)91665-D; KEMPF AC, 1995, ARCH BIOCHEM BIOPHYS, V321, P277, DOI 10.1006/abbi.1995.1396; KOMINAMI S, 1986, J BIOL CHEM, V261, P2077; KORZEKWA KR, 1993, PHARMACOGENETICS, V3, P1, DOI 10.1097/00008571-199302000-00001; Kusano K, 1999, ARCH BIOCHEM BIOPHYS, V367, P129, DOI 10.1006/abbi.1999.1248; LI YC, 1991, J BIOL CHEM, V266, P19186; LISCUM L, 1992, J LIPID RES, V33, P1239; MUELLER EJ, 1995, CYTOCHROME P450 STRU, P183; MYANT NB, 1977, J LIPID RES, V18, P135; Nelson DR, 1996, PHARMACOGENETICS, V6, P1, DOI 10.1097/00008571-199602000-00002; Oliver CF, 1997, BIOCHEM J, V327, P537; OMURA T, 1964, J BIOL CHEM, V239, P2370; Pace CN, 1998, BIOPHYS J, V75, P422, DOI 10.1016/S0006-3495(98)77529-0; Park SY, 1997, NAT STRUCT BIOL, V4, P827, DOI 10.1038/nsb1097-827; PERNECKY SJ, 1993, P NATL ACAD SCI USA, V90, P2651, DOI 10.1073/pnas.90.7.2651; Pikuleva IA, 1997, ARCH BIOCHEM BIOPHYS, V343, P123, DOI 10.1006/abbi.1997.0142; Pikuleva IA, 2001, BIOCHEMISTRY-US, V40, P7621, DOI 10.1021/bi010193i; Podust LM, 2001, P NATL ACAD SCI USA, V98, P3068, DOI 10.1073/pnas.061562898; POULOS TL, 1987, J MOL BIOL, V195, P687, DOI 10.1016/0022-2836(87)90190-2; POULOS TL, 1986, BIOCHEMISTRY-US, V25, P5314, DOI 10.1021/bi00366a049; RAVICHANDRAN KG, 1993, SCIENCE, V261, P731, DOI 10.1126/science.8342039; RUSSELL DW, 1992, BIOCHEMISTRY-US, V31, P4737, DOI 10.1021/bi00135a001; SAGARA Y, 1993, ARCH BIOCHEM BIOPHYS, V304, P272, DOI 10.1006/abbi.1993.1349; VOET D, 1990, BIOCHEMISTRY-US, P337; vonWachenfeldt C, 1997, ARCH BIOCHEM BIOPHYS, V339, P107, DOI 10.1006/abbi.1996.9859; WACHENFELDT C, 1995, CYTOCHROME P450 STRU, P183; WELLS AV, 1992, BIOCHEMISTRY-US, V31, P4384, DOI 10.1021/bi00133a002; Williams PA, 2000, MOL CELL, V5, P121, DOI 10.1016/S1097-2765(00)80408-6; Yano JK, 2000, J BIOL CHEM, V275, P31086, DOI 10.1074/jbc.M004281200; Zamyatnin A A, 1972, Prog Biophys Mol Biol, V24, P107, DOI 10.1016/0079-6107(72)90005-3	44	36	38	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					31459	31465		10.1074/jbc.M103943200	http://dx.doi.org/10.1074/jbc.M103943200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11423554	hybrid			2022-12-25	WOS:000170472900112
J	Simonovic, M; Volz, K				Simonovic, M; Volz, K			A distinct meta-active conformation in the 1.1-angstrom resolution structure of wild-type apoCheY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPONSE REGULATOR PROTEIN; BACTERIAL CHEMOTAXIS; UNCOUPLED PHOSPHORYLATION; SIGNAL-TRANSDUCTION; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; CHEY; REFINEMENT; ACTIVATION; ASPARTATE	CheY is the best characterized member of the response regulator superfamily, and as such it has become the principal model for understanding the initial molecular mechanisms of signaling in two-component systems. Normal signaling by response regulators requires phosphorylation, in combination with an activation mechanism whose conformational effects are not completely understood. CheY activation involves three events, phosphorylation, a conformational. change in the beta (4)-alpha (4) loop, and a rotational restriction of the side chain of tyrosine 106. An outstanding question concerns the nature of an active conformation in the apoCheY population. The details of this 1.08-Angstrom resolution crystal structure of wild-type apoCheY shows the beta (4)-alpha (4) loop in two distinctly different conformations that sterically correlate with the two rotameric positions of the tyrosine 106 side chain. One of these conformational states of CheY is the inactive form, and we propose that the other is a meta-active form, responsible for the active properties seen in apoCheY.	Univ Illinois, Coll Med, Dept Microbiol & Immunol, Chicago, IL 60612 USA; Univ Illinois, Dept Biochem & Mol Biol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Volz, K (corresponding author), Univ Illinois, Coll Med, Dept Microbiol & Immunol, Chicago, IL 60612 USA.			Simonovic, Miljan/0000-0002-1576-2222	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047522] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47522] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARAK R, 1992, BIOCHEMISTRY-US, V31, P1821, DOI 10.1021/bi00121a034; Birck C, 1999, STRUCTURE, V7, P1505, DOI 10.1016/S0969-2126(00)88341-0; Cho HS, 2000, J MOL BIOL, V297, P543, DOI 10.1006/jmbi.2000.3595; Feher VA, 1999, NATURE, V400, P289, DOI 10.1038/22357; FINZEL BC, 1987, J APPL CRYSTALLOGR, V20, P53, DOI 10.1107/S0021889887087144; GANGULI S, 1995, J BIOL CHEM, V270, P17386, DOI 10.1074/jbc.270.29.17386; Gouet P, 2001, ACTA CRYSTALLOGR D, V57, P44, DOI 10.1107/S090744490001492X; Halkides CJ, 2000, BIOCHEMISTRY-US, V39, P5280, DOI 10.1021/bi9925524; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; Hoch JA, 1995, 2 COMPONENT SIGNAL T; Jiang MY, 1997, J BIOL CHEM, V272, P11850, DOI 10.1074/jbc.272.18.11850; Kern D, 1999, NATURE, V402, P894, DOI 10.1038/47273; Lee SY, 2001, NAT STRUCT BIOL, V8, P52; Lewis RJ, 1999, J MOL BIOL, V294, P9, DOI 10.1006/jmbi.1999.3261; LUKAT GS, 1991, J BIOL CHEM, V266, P8348; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; McEvoy MM, 1998, P NATL ACAD SCI USA, V95, P7333, DOI 10.1073/pnas.95.13.7333; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; ROMAN SJ, 1992, J BACTERIOL, V174, P6247, DOI 10.1128/JB.174.19.6247-6255.1992; SANDERS DA, 1989, J BIOL CHEM, V264, P21770; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; Volkman BF, 2001, SCIENCE, V291, P2429, DOI 10.1126/science.291.5512.2429; VOLZ K, 1991, J BIOL CHEM, V266, P15511; Volz K., 1995, 2 COMPONENT SIGNAL T, P53; Welch M, 1998, NAT STRUCT BIOL, V5, P25, DOI 10.1038/nsb0198-25; Zhu XY, 1996, J BACTERIOL, V178, P4208, DOI 10.1128/jb.178.14.4208-4215.1996; Zhu XY, 1997, J BIOL CHEM, V272, P23758, DOI 10.1074/jbc.272.38.23758; Zhu XY, 1997, J BIOL CHEM, V272, P5000, DOI 10.1074/jbc.272.8.5000	28	61	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					28637	28640		10.1074/jbc.C100295200	http://dx.doi.org/10.1074/jbc.C100295200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11410584	hybrid			2022-12-25	WOS:000170346000002
J	Larcher, F; Del Rio, M; Serrano, F; Segovia, JC; Ramirez, A; Meana, A; Page, A; Abad, JL; Gonzalez, MA; Bueren, J; Bernad, A; Jorcano, JL				Larcher, F; Del Rio, M; Serrano, F; Segovia, JC; Ramirez, A; Meana, A; Page, A; Abad, JL; Gonzalez, MA; Bueren, J; Bernad, A; Jorcano, JL			A cutaneous gene therapy approach to human leptin deficiencies: correction of the murine ob/ob phenotype using leptin-targeted keratinocyte grafts	FASEB JOURNAL			English	Article						skin; lipodistrophy; diabetes; leptin replacement	GENETICALLY-OBESE MICE; HUMAN EPIDERMAL-CELLS; TRANSGENIC MICE; STEM-CELLS; GROWTH-HORMONE; INSULIN SENSITIVITY; DIABETES-MELLITUS; HEMOPHILIA-B; IN-VITRO; EXPRESSION	Leptin deficiency produces a phenotype of obesity, diabetes, and infertility in the ob/ob mouse. In humans, leptin deficiency occurs in some cases of congenital obesity and in lipodystrophic disorders characterized by reduced adipose tissue and insulin resistance. Cutaneous gene therapy is considered an attractive potential method to correct circulating protein deficiencies, since gene-transferred human keratinocytes can produce and secrete gene products with systemic action. However, no studies showing correction of a systemic defect have been reported. We report the successful correction of leptin deficiency using cutaneous gene therapy in the ob/ob mouse model. As a feasibility approach, skin explants from transgenic mice overexpressing leptin were grafted on immunodeficient ob/ob mice. One month later, recipient mice reached body weight values of lean animals. Other biochemical and clinical parameters were also normalized. In a second human gene therapy approach, a retroviral vector encoding both leptin and EGFP cDNAs was used to transduce HK and, epithelial grafts enriched in high leptin-producing HK were transplanted to immunosuppressed ob/ob mice. HK-derived leptin induced body weight reduction after a drop in blood glucose and food intake. Leptin replacement through genetically engineered HK grafts provides a valuable therapeutic alternative for permanent treatment of human leptin deficiency conditions.	CIEMAT, Project Cell & Mol Biol & Gene Therapy, E-28040 Madrid, Spain; Fdn Marcelino Botin Gene Therapy, Madrid, Spain; Ctr Nacl Biotecnol, Dept Immunol & Oncol, Madrid, Spain; Ctr Transfus Principado Asturias, Oviedo, Spain	Centro de Investigaciones Energeticas, Medioambientales Tecnologicas; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Larcher, F (corresponding author), CIEMAT, Project Cell & Mol Biol & Gene Therapy, Ave Complutense 22 Edificio 7, E-28040 Madrid, Spain.	Fernando.larcher@ciemat.es	Bueren, Juan/L-6112-2014; Segovia, Jose Carlos/L-2922-2014; Meana, Alvaro/D-9710-2019; Bernad, Antonio/P-8573-2017; Gonzalez, Manuel A/A-3404-2013; Ramirez, Angel/A-4800-2018; Larcher, Fernando/J-1527-2016; DEL RIO, MARCELA/H-2796-2015	Bueren, Juan/0000-0002-3228-7013; Segovia, Jose Carlos/0000-0003-4101-6124; Meana, Alvaro/0000-0001-9434-6042; Ramirez, Angel/0000-0001-7745-5108; Larcher, Fernando/0000-0002-6771-3561; DEL RIO, MARCELA/0000-0003-2910-7189; Page, Angustias/0000-0002-0231-8536; Bernad, Antonio/0000-0003-0620-9668				Ahima RS, 2000, ANNU REV PHYSIOL, V62, P413, DOI 10.1146/annurev.physiol.62.1.413; Albella B, 1999, TRANSPLANTATION, V67, P1348, DOI 10.1097/00007890-199905270-00010; ALEXANDER MY, 1995, HUM MOL GENET, V4, P993, DOI 10.1093/hmg/4.6.993; BARRANDON Y, 1988, J INVEST DERMATOL, V91, P315, DOI 10.1111/1523-1747.ep12475646; Bouloumie A, 1998, CIRC RES, V83, P1059, DOI 10.1161/01.RES.83.10.1059; COLEMAN DL, 1978, DIABETOLOGIA, V14, P141, DOI 10.1007/BF00429772; Compton Carolyn C., 1994, Journal of Burn Care and Rehabilitation, V15, P393, DOI 10.1097/00004630-199409000-00002; Del Rio M, 1999, GENE THER, V6, P1734, DOI 10.1038/sj.gt.3300986; DeLuca M, 1997, GENE THER, V4, P381, DOI 10.1038/sj.gt.3300434; Deng H, 1998, BIOTECHNIQUES, V25, P274, DOI 10.2144/98252gt02; Deng H, 1997, NAT BIOTECHNOL, V15, P1388, DOI 10.1038/nbt1297-1388; DiGiovanni J, 2000, CANCER RES, V60, P1561; Ducy P, 2000, CELL, V100, P197, DOI 10.1016/S0092-8674(00)81558-5; Ebihara K, 2000, DIABETES, V49, pA210; Fakharzadeh SS, 2000, BLOOD, V95, P2799, DOI 10.1182/blood.V95.9.2799.009k23_2799_2805; Farooqi IS, 1999, NEW ENGL J MED, V341, P879, DOI 10.1056/NEJM199909163411204; FENJVES ES, 1994, HUM GENE THER, V5, P1241, DOI 10.1089/hum.1994.5.10-1241; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; GALLICO GG, 1984, NEW ENGL J MED, V311, P448, DOI 10.1056/NEJM198408163110706; GERRARD AJ, 1993, NAT GENET, V3, P180, DOI 10.1038/ng0293-180; Guerra L, 2000, ARCH DERMATOL, V136, P1380, DOI 10.1001/archderm.136.11.1380; Ioffe E, 1998, P NATL ACAD SCI USA, V95, P11852, DOI 10.1073/pnas.95.20.11852; Kim YB, 2000, ENDOCRINOLOGY, V141, P2328, DOI 10.1210/en.141.7.2328; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; Kolodka TM, 1998, P NATL ACAD SCI USA, V95, P4356, DOI 10.1073/pnas.95.8.4356; LEITER EH, 1992, JAX NOTES, V451; Mathor MB, 1996, P NATL ACAD SCI USA, V93, P10371, DOI 10.1073/pnas.93.19.10371; Meana A, 1998, BURNS, V24, P621, DOI 10.1016/S0305-4179(98)00107-7; Meng XM, 1998, J CLIN INVEST, V101, P1462, DOI 10.1172/JCI1031; Moitra J, 1998, GENE DEV, V12, P3168, DOI 10.1101/gad.12.20.3168; Montague CT, 1997, NATURE, V387, P903, DOI 10.1038/43185; MORGAN JR, 1987, SCIENCE, V237, P1476; Morsy MA, 1998, GENE THER, V5, P8, DOI 10.1038/sj.gt.3300565; MURILLAS R, 1995, EMBO J, V14, P5216, DOI 10.1002/j.1460-2075.1995.tb00206.x; Murphy JE, 1997, P NATL ACAD SCI USA, V94, P13921, DOI 10.1073/pnas.94.25.13921; Muzzin P, 1996, P NATL ACAD SCI USA, V93, P14804, DOI 10.1073/pnas.93.25.14804; Namae M, 1998, LAB ANIM SCI, V48, P103; Ogawa Y, 1999, DIABETES, V48, P1822, DOI 10.2337/diabetes.48.9.1822; Pardini VC, 1998, J CLIN ENDOCR METAB, V83, P503, DOI 10.1210/jc.83.2.503; Pellegrini G, 1998, MED BIOL ENG COMPUT, V36, P778, DOI 10.1007/BF02518885; Pfutzner W, 1999, HUM GENE THER, V10, P2811, DOI 10.1089/10430349950016546; RAMIREZ A, 1994, DIFFERENTIATION, V58, P53, DOI 10.1007/s002580050065; Robles AI, 1996, P NATL ACAD SCI USA, V93, P7634, DOI 10.1073/pnas.93.15.7634; SEIP M, 1996, ACTA PEDIAT S, V13, P2; Shimomura I, 1998, GENE DEV, V12, P3182, DOI 10.1101/gad.12.20.3182; Shimomura I, 1999, NATURE, V401, P73, DOI 10.1038/43448; Sierra-Honigmann MR, 1998, SCIENCE, V281, P1683, DOI 10.1126/science.281.5383.1683; Strobel A, 1998, NAT GENET, V18, P213, DOI 10.1038/ng0398-213; TAICHMAN LB, 1994, KERATINOCYTE HDB, P543; TEUMER J, 1990, FASEB J, V4, P3245, DOI 10.1096/fasebj.4.14.2227214; Wang MY, 1998, P NATL ACAD SCI USA, V95, P714, DOI 10.1073/pnas.95.2.714; Wang XM, 1997, P NATL ACAD SCI USA, V94, P219, DOI 10.1073/pnas.94.1.219; Yang SL, 1999, HUM GENE THER, V10, P123, DOI 10.1089/10430349950019255	53	53	57	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2001	15	9					1529	1538		10.1096/fj.01-0082com	http://dx.doi.org/10.1096/fj.01-0082com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	460PV	11427484				2022-12-25	WOS:000170318500004
J	Abe, K; Hirai, M; Mizuno, K; Higashi, N; Sekimoto, T; Miki, T; Hirano, T; Nakajima, K				Abe, K; Hirai, M; Mizuno, K; Higashi, N; Sekimoto, T; Miki, T; Hirano, T; Nakajima, K			The YXXQ motif in gp 130 is crucial for STAT3 phosphorylation at Ser727 through an H7-sensitive kinase pathway	ONCOGENE			English	Article						STAT3; ser phosphorylation; IL-6; gp 130; YXXQ motif; transcription	TRANSCRIPTIONALLY ACTIVE STAT1; CYTOKINE RECEPTOR GP130; IL-6 RESPONSE ELEMENT; CRE-LIKE SITE; SERINE PHOSPHORYLATION; TYROSINE PHOSPHORYLATION; PROTEIN-KINASE; SIGNAL-TRANSDUCTION; JUNB PROMOTER; GROWTH ARREST	The signal transducer and activator of transcription (STAT) 3 is essential for mediating signals from the receptors for a variety of cytokines and growth factors, including IL-6 and EGF, and from cytoplasmic tyrosine kinases, Upon stimulation, STAT3 is phosphorylated at Ser727 and Tyr705, However, the role of phosphorylation at Ser727, and the kinase pathways responsible for this phosphorylation in IL-6 signaling remain obscure. Here we show that IL-6 activates at least two distinct STAT3 serine kinase pathways and that an H7-sensitive pathway is dominant over a PD98059-sensitive one in HepG2 cells stimulated with a low concentration of IL-6, The analysis, using a series of chimeric receptors containing the extracellular domain of the G-CSF receptor, the truncated form of gp 130, and additional short peptides at the gp 130 carboxy-terminus, shelved that the YXXQ motif of gp 130 was sufficient for the H7-sensitive STAT3 Ser727 phosphorylation, This YXXQ-mediated pathway does not involve Erk, p38, JNK, or PKC delta, and requires a site in the region from 533 to 711 of STAT3 for phosphorylation in vivo. Moreover, we show that Ser727 is required for full transcriptional activity of STAT3 for two different response elements, Thus, the YXXQ motif regulates STAT3 activities in two ways in response to even a low concentration of IL-6: it recruits STAT3 to the receptor for tyrosine phosphorylation, and activates an unidentified H7-sensitive pathway leading to the serine phosphorylation of STAT3.	Osaka City Univ, Grad Sch Med, Dept Immunol, Abeno Ku, Osaka 5458585, Japan; Osaka City Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Osaka 5458585, Japan; Osaka City Univ, Grad Sch Med, Dept Mol Oncol, Osaka 5458585, Japan	Osaka Metropolitan University; Osaka Metropolitan University; Osaka Metropolitan University	Nakajima, K (corresponding author), Osaka City Univ, Grad Sch Med, Dept Immunol, Abeno Ku, 1-4-3 Asahi Machi, Osaka 5458585, Japan.		Hirano, Toshio/C-8194-2009					AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; Beadling C, 1996, EMBO J, V15, P1902, DOI 10.1002/j.1460-2075.1996.tb00541.x; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; BOULTON TG, 1994, J BIOL CHEM, V269, P11648; BOULTON TG, 1995, P NATL ACAD SCI USA, V92, P6915, DOI 10.1073/pnas.92.15.6915; Bromberg JF, 1996, P NATL ACAD SCI USA, V93, P7673, DOI 10.1073/pnas.93.15.7673; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Chakraborty A, 1999, BLOOD, V93, P15, DOI 10.1182/blood.V93.1.15.401a46_15_24; Cho SS, 1996, J IMMUNOL, V157, P4781; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; COFFER P, 1995, ONCOGENE, V10, P985; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; FUJITANI Y, 1994, BIOCHEM BIOPH RES CO, V202, P1181, DOI 10.1006/bbrc.1994.2053; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; Hirano Toshio, 1997, Cytokine and Growth Factor Reviews, V8, P241, DOI 10.1016/S1359-6101(98)80005-1; Horvath CM, 1996, J VIROL, V70, P647, DOI 10.1128/JVI.70.1.647-650.1996; Ichiba M, 1998, J BIOL CHEM, V273, P6132, DOI 10.1074/jbc.273.11.6132; Ihara S, 1997, EMBO J, V16, P5345, DOI 10.1093/emboj/16.17.5345; Jain N, 1999, J BIOL CHEM, V274, P24392, DOI 10.1074/jbc.274.34.24392; Jain N, 1998, ONCOGENE, V17, P3157, DOI 10.1038/sj.onc.1202238; Kiuchi N, 1999, J EXP MED, V189, P63, DOI 10.1084/jem.189.1.63; Kojima H, 1996, ONCOGENE, V12, P547; Lim CP, 1999, J BIOL CHEM, V274, P31055, DOI 10.1074/jbc.274.43.31055; LUTTICKEN C, 1995, FEBS LETT, V360, P137, DOI 10.1016/0014-5793(95)00076-L; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MATSUDA T, 1988, EUR J IMMUNOL, V18, P951, DOI 10.1002/eji.1830180618; Minami M, 1996, P NATL ACAD SCI USA, V93, P3963, DOI 10.1073/pnas.93.9.3963; NAKAJIMA K, 1991, MOL CELL BIOL, V11, P1409, DOI 10.1128/MCB.11.3.1409; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Nakajima K, 1995, ANN NY ACAD SCI, V762, P55; NAKAJIMA K, 1993, MOL CELL BIOL, V13, P3027, DOI 10.1128/MCB.13.5.3027; Narimatsu M, 1997, BIOCHEM BIOPH RES CO, V238, P764, DOI 10.1006/bbrc.1997.7387; O'Farrell AM, 2000, J IMMUNOL, V164, P4607, DOI 10.4049/jimmunol.164.9.4607; Schaefer LK, 1999, BIOCHEM BIOPH RES CO, V266, P481, DOI 10.1006/bbrc.1999.1853; Schuringa JJ, 2000, BIOCHEM J, V347, P89, DOI 10.1042/0264-6021:3470089; Sengupta TK, 1998, P NATL ACAD SCI USA, V95, P11107, DOI 10.1073/pnas.95.19.11107; Shirogane T, 1999, IMMUNITY, V11, P709, DOI 10.1016/S1074-7613(00)80145-4; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; STAHL N, 1994, SCIENCE, V263, P91; SZALLASI Z, 1994, MOL PHARMACOL, V46, P840; Takahashi-Tezuka M, 1998, MOL CELL BIOL, V18, P4109, DOI 10.1128/MCB.18.7.4109; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; Turkson J, 1999, MOL CELL BIOL, V19, P7519; Uddin S, 1997, J IMMUNOL, V158, P2390; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Wen ZL, 1997, NUCLEIC ACIDS RES, V25, P2062, DOI 10.1093/nar/25.11.2062; Yamanaka Y, 1996, EMBO J, V15, P1557, DOI 10.1002/j.1460-2075.1996.tb00500.x; Yokogami K, 2000, CURR BIOL, V10, P47, DOI 10.1016/S0960-9822(99)00268-7; YUAN JP, 1994, MOL CELL BIOL, V14, P1657, DOI 10.1128/MCB.14.3.1657; Zhang JJ, 1998, EMBO J, V17, P6963, DOI 10.1093/emboj/17.23.6963; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; Zhu XJ, 1997, MOL CELL BIOL, V17, P6618, DOI 10.1128/MCB.17.11.6618	55	56	59	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 14	2001	20	27					3464	3474		10.1038/sj.onc.1204461	http://dx.doi.org/10.1038/sj.onc.1204461			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	445VB	11429693				2022-12-25	WOS:000169478300002
J	Gu, JJ; Rubin, RM; Yuan, ZM				Gu, JJ; Rubin, RM; Yuan, ZM			A sequence element of p53 that determines its susceptibility to viral oncoprotein-targeted degradation	ONCOGENE			English	Article						p53 degradation; HPV16 E6; E1B55k/E4 34k; p73; p53; chimeras	HUMAN PAPILLOMAVIRUS TYPE-16; E6 ONCOPROTEIN; P73; MDM2; PROTEIN; INACTIVATION; ASSOCIATION; APOPTOSIS; PROMOTES; CANCER	The molecular basis that the viral oncoproteins, including HPV16 E6 and E1B55k/E4 34k complex, differentially target p53 but not its homolog p73 for degradation remains elusive, Using a series of p53/p73 chimeras, we demonstrated that despite binding to the different regions of p53, both HPV16 E6 and E1B55k/E4 34k required a very same p53 sequence, amino acid residues 92 to 112 [p53(aa.92-112)], previously identified as a necessity for Mdm2-mediated degradation, to target p53 for degradation. Removal of the p53(aa.92-112) by either substitution or deletion resulted in a p53 protein that was no longer degradable hy the viral proteins. More significantly, swapping the oncoprotein-binding motif and the p53(aa.92-112) rendered p73 susceptible to oncoprotein-mediated degradation. Collectively, our data supports a model in which the p53(aa.92-112) functions as a determinant for p53 stability while the binding of the oncoproteins directs p53 into the specific pathway for proteolysis.	Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	Yuan, ZM (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, 665 Huntington Ave,Bldg 1,Room 209, Boston, MA 02115 USA.							ARMSTRONG JF, 1995, CURR BIOL, V5, P931, DOI 10.1016/S0960-9822(95)00183-7; Balint E, 1999, ONCOGENE, V18, P3923, DOI 10.1038/sj.onc.1202781; Crook T, 1996, VIROLOGY, V217, P285, DOI 10.1006/viro.1996.0115; Dobbelstein M, 1998, J GEN VIROL, V79, P3079, DOI 10.1099/0022-1317-79-12-3079; Dobbelstein M, 1999, ONCOGENE, V18, P2101, DOI 10.1038/sj.onc.1202512; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Donehower LA, 1996, SEMIN CANCER BIOL, V7, P269, DOI 10.1006/scbi.1996.0035; Gu JJ, 2000, MOL CELL BIOL, V20, P1243, DOI 10.1128/MCB.20.4.1243-1253.2000; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KAO CC, 1990, VIROLOGY, V179, P806, DOI 10.1016/0042-6822(90)90148-K; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li XQ, 1996, J VIROL, V70, P4509, DOI 10.1128/JVI.70.7.4509-4516.1996; Li XQ, 1996, J BIOL CHEM, V271, P4447; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; MARSTON NJ, 1995, ONCOGENE, V10, P1709; Prabhu NS, 1998, INT J ONCOL, V13, P5; Querido E, 1997, J VIROL, V71, P3788, DOI 10.1128/JVI.71.5.3788-3798.1997; Roth J, 1998, J VIROL, V72, P8510, DOI 10.1128/JVI.72.11.8510-8516.1998; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Steegenga WT, 1999, MOL CELL BIOL, V19, P3885; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; Zeng XY, 1999, MOL CELL BIOL, V19, P3257	27	16	16	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 14	2001	20	27					3519	3527		10.1038/sj.onc.1204454	http://dx.doi.org/10.1038/sj.onc.1204454			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	445VB	11429698				2022-12-25	WOS:000169478300007
J	Jimenez, B; Volpert, OV; Reiher, F; Chang, LF; Munoz, A; Karin, M; Bouck, N				Jimenez, B; Volpert, OV; Reiher, F; Chang, LF; Munoz, A; Karin, M; Bouck, N			c-Jun N-terminal kinase activation is required for the inhibition of neovascularization by thrombospondin-1	ONCOGENE			English	Article						thrombospondin; anti-angiogenic signalling; CD36; tumor angiogenesis; JNK	ENDOTHELIAL GROWTH-FACTOR; PROTEIN-KINASE; IN-VITRO; ANGIOGENESIS; APOPTOSIS; CELLS; JNK2; MECHANISMS; INDUCTION; SURVIVIN	Thrombospondin-1 (TSP-1) is a potent inhibitor of angiogenesis that acts directly on endothelial cells via the CD36 surface receptor molecule to halt their migration, proliferation, and morphogenesis in vitro and to block neovascularization in vivo. Here we show that inhibitory signals elicited by TSP-1 did not alter the ability of inducers of angiogenesis to activate p42 and p44 mitogen-activated protein kinase (MAPK). Rather, TSP-1 induced a rapid and transient activation of c-Jun N-terminal kinases (JNK). JNK activation by TSP-1 required engagement of CD36, as it was blocked by antagonistic CD36 antibodies and stimulated by short anti-angiogenic peptides derived from TSP-1 that act exclusively via CD36. TSP-1 inhibition of corneal neovascularization induced by bFGF was severely impaired in mice null for JNK-1, pointing to a critical role for this stress-activated kinase in the inhibition of neovascularization by TSP-1.	Univ Autonoma Madrid, CSIC, Inst Invest Biomed, Madrid 28029, Spain; Northwestern Univ, Sch Med, Dept Immunol Microbiol, Chicago, IL USA; Northwestern Univ, Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL USA; Univ Autonoma Madrid, Fac Med, Dept Bioquim, Madrid, Spain; Univ Calif San Diego, Dept Pharmacol, Lab Gene Regulat & Signal Transduct, La Jolla, CA 92093 USA	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Northwestern University; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; Autonomous University of Madrid; University of California System; University of California San Diego	Jimenez, B (corresponding author), Univ Autonoma Madrid, CSIC, Inst Invest Biomed, Arturo Duperier 4, Madrid 28029, Spain.		Munoz, Alberto/O-6393-2014; Cuenca, Benilde Jimenez/K-9959-2014	Munoz, Alberto/0000-0003-3890-4251; Volpert, Olga/0000-0003-1381-5543; Jimenez Cuenca, Benilde/0000-0002-1806-6636	NCI NIH HHS [CA52750, CA64239] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064239] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BORNSTEIN P, 1994, METHOD ENZYMOL, V245, P62; Bouck N, 1996, ADV CANCER RES, V69, P135, DOI 10.1016/S0065-230X(08)60862-3; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Chu WM, 1999, IMMUNITY, V11, P721, DOI 10.1016/S1074-7613(00)80146-6; Claesson-Welsh L, 1998, P NATL ACAD SCI USA, V95, P5579, DOI 10.1073/pnas.95.10.5579; DANGELO G, 1995, P NATL ACAD SCI USA, V92, P6374, DOI 10.1073/pnas.92.14.6374; Dawson DW, 1997, J CELL BIOL, V138, P707, DOI 10.1083/jcb.138.3.707; Dhanabal M, 1999, J BIOL CHEM, V274, P11721, DOI 10.1074/jbc.274.17.11721; Dong C, 1998, SCIENCE, V282, P2092, DOI 10.1126/science.282.5396.2092; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Fujio Y, 1999, J BIOL CHEM, V274, P16349, DOI 10.1074/jbc.274.23.16349; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; Kamphaus GD, 2000, J BIOL CHEM, V275, P1209, DOI 10.1074/jbc.275.2.1209; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; LOO D, 1994, CELL BIOL LAB HDB, P45; Lucas R, 1998, BLOOD, V92, P4730; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Modur V, 1996, J BIOL CHEM, V271, P13094, DOI 10.1074/jbc.271.22.13094; Nor JE, 1999, AM J PATHOL, V154, P375, DOI 10.1016/S0002-9440(10)65284-4; O'Connor DS, 2000, AM J PATHOL, V156, P393, DOI 10.1016/S0002-9440(10)64742-6; Pedram A, 1998, J BIOL CHEM, V273, P26722, DOI 10.1074/jbc.273.41.26722; Roberts DD, 1996, FASEB J, V10, P1183, DOI 10.1096/fasebj.10.10.8751720; Sabapathy K, 1999, MECH DEVELOP, V89, P115, DOI 10.1016/S0925-4773(99)00213-0; Sabapathy K, 1999, CURR BIOL, V9, P116, DOI 10.1016/S0960-9822(99)80065-7; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497; Tran J, 1999, BIOCHEM BIOPH RES CO, V264, P781, DOI 10.1006/bbrc.1999.1589; Volpert OV, 1998, P NATL ACAD SCI USA, V95, P6343, DOI 10.1073/pnas.95.11.6343; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; Yang DD, 1998, IMMUNITY, V9, P575, DOI 10.1016/S1074-7613(00)80640-8; Yeh CH, 1998, BLOOD, V92, P3268, DOI 10.1182/blood.V92.9.3268.421k41_3268_3276; Yue TL, 1997, MOL PHARMACOL, V51, P951, DOI 10.1124/mol.51.6.951	33	65	72	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 7	2001	20	26					3443	3448		10.1038/sj.onc.1204464	http://dx.doi.org/10.1038/sj.onc.1204464			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	441UW	11423995				2022-12-25	WOS:000169248800015
J	Yount, GL; Afshar, G; Ries, S; Korn, M; Shalev, N; Basila, D; McCormick, F; Haas-Kogan, DA				Yount, GL; Afshar, G; Ries, S; Korn, M; Shalev, N; Basila, D; McCormick, F; Haas-Kogan, DA			Transcriptional activation of TRADD mediates p53-independent radiation-induced apoptosis of glioma cells	ONCOGENE			English	Article						TRADD; glioma; radiation; apoptosis; cDNA array; gene therapy	DRUG-INDUCED APOPTOSIS; NF-KAPPA-B; APO-1/FAS RECEPTOR/LIGAND SYSTEM; MYC-INDUCED APOPTOSIS; IONIZING-RADIATION; BRAIN-TUMORS; C-MYC; CYCLIN-A; DEATH; EXPRESSION	Survival of patients with Glioblastoma Multiforme (GM), a highly malignant brain tumor, remains poor despite concerted efforts to improve therapy. The median survival of patients with GM has remained approximately 1 year regardless of the therapeutic approach, Since radiation therapy is the most effective adjuvant therapy for GM and nearly half of GM tumors harbor p53 mutations, we sought to identify genes that mediate p53-independent apoptosis of GM cells in response to ionizing radiation. Using broad-scale gene expression analysis we found that following radiation treatment, TRADD expression was induced in a uniquely radiosensitive GM cell line but not in radioresistant GM cell lines. TRADD over-expression killed GM cells and activated NF-kappaB, We found that blocking the TRADD-mediated pathway using a dominant-negative mutant of FADD (FADD-DN) enhanced radiation resistance of GM cells, as reflected in both susceptibility to apoptosis and clonogenic survival following irradiation, Conversely stable expression of exogenous TRADD enhanced radiation-induced apoptosis of GM cell lines, reflecting the biological significance of TRADD regulation in p53-independent apoptosis, These findings generate interest in utilizing TRADD in gene therapy for GM tumors, particularly in light of its dual function of directly inducing rapid apoptosis and sensitizing GM cells to standard anti-neoplastic therapy.	Univ Calif San Francisco, Dept Radiat Oncol, San Francisco, CA 94143 USA; Calif Pacific Med Ctr, Complementary Med Res Inst, San Francisco, CA 94115 USA; Univ Calif San Francisco, Canc Res Inst, San Francisco, CA 94115 USA	University of California System; University of California San Francisco; California Pacific Medical Center; California Pacific Medical Center Research Institute; University of California System; University of California San Francisco	Haas-Kogan, DA (corresponding author), Univ Calif San Francisco, Dept Radiat Oncol, 505 Parnassus Ave, San Francisco, CA 94143 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR001271] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR01271] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AKASHI M, 1995, J BIOL CHEM, V270, P19181, DOI 10.1074/jbc.270.32.19181; ALBRIGHT N, 1987, RADIAT RES, V112, P331, DOI 10.2307/3577260; Baker SJ, 1998, ONCOGENE, V17, P3261, DOI 10.1038/sj.onc.1202568; BARR PJ, 1994, BIO-TECHNOL, V12, P487, DOI 10.1038/nbt0594-487; Baumler CB, 1996, BLOOD, V88, P1741; Brown JM, 1999, CANCER RES, V59, P1391; CHEN PC, 1995, CANCER GENET CYTOGEN, V82, P106, DOI 10.1016/0165-4608(94)00213-U; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; DATTA R, 1992, CELL GROWTH DIFFER, V3, P637; DeNardo GL, 1999, CLIN CANCER RES, V5, p3219S; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; FERRER I, 1992, BRAIN RES, V588, P351, DOI 10.1016/0006-8993(92)91599-A; FERRER I, 1995, INT J DEV NEUROSCI, V13, P21, DOI 10.1016/0736-5748(94)00064-A; FERTIL B, 1985, INT J RADIAT ONCOL, V11, P1699, DOI 10.1016/0360-3016(85)90223-8; French LE, 1999, NAT MED, V5, P146, DOI 10.1038/5505; Frenkel J, 1999, ONCOGENE, V18, P2901, DOI 10.1038/sj.onc.1202518; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Fulda S, 1997, CANCER RES, V57, P3823; Gallagher WM, 1999, ANN ONCOL, V10, P139, DOI 10.1023/A:1008368500557; Goswami PC, 1996, MOL CELL BIOL, V16, P1500; Guo N, 2000, J BIOL CHEM, V275, P1715, DOI 10.1074/jbc.275.3.1715; Gura T, 1997, SCIENCE, V277, P768, DOI 10.1126/science.277.5327.768; Haas-Kogan D A, 1996, Cancer J Sci Am, V2, P114; HaasKogan DA, 1996, INT J RADIAT ONCOL, V36, P95, DOI 10.1016/S0360-3016(96)00244-1; Hagiyama H, 1999, ONCOGENE, V18, P4091, DOI 10.1038/sj.onc.1202772; Herr I, 1997, EMBO J, V16, P6200, DOI 10.1093/emboj/16.20.6200; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; ITOH N, 1993, J BIOL CHEM, V268, P10932; Joneson T, 1999, MOL CELL BIOL, V19, P5892; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Klefstrom J, 1997, EMBO J, V16, P7382, DOI 10.1093/emboj/16.24.7382; Knudsen KE, 1999, J BIOL CHEM, V274, P27632, DOI 10.1074/jbc.274.39.27632; Kolbus A, 2000, MOL CELL BIOL, V20, P575, DOI 10.1128/MCB.20.2.575-582.2000; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; LUDGATE CM, 1988, INT J RADIAT ONCOL, V15, P1091, DOI 10.1016/0360-3016(88)90189-7; Merritt AJ, 1997, ONCOGENE, V14, P2759, DOI 10.1038/sj.onc.1201126; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; Murphy S, 1990, METHODS NEUROSCIENCE, V2, P33; MUSCHEL RJ, 1991, CANCER RES, V51, P5113; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Prados MD, 1998, INT J RADIAT ONCOL, V40, P57, DOI 10.1016/S0360-3016(97)00566-X; SARKAR A, 1993, CANCER CHEMOTH PHARM, V32, P477, DOI 10.1007/BF00685893; SHELINE GE, 1977, CANCER, V39, P873, DOI 10.1002/1097-0142(197702)39:2+<873::AID-CNCR2820390725>3.0.CO;2-Y; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; TAGHIAN A, 1992, INT J RADIAT ONCOL, V23, P55, DOI 10.1016/0360-3016(92)90543-Q; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; Trudel M, 1997, J EXP MED, V186, P1873, DOI 10.1084/jem.186.11.1873; Uberti D, 1999, EXP CELL RES, V252, P123, DOI 10.1006/excr.1999.4606; Villa R, 1996, INT J CANCER, V66, P104, DOI 10.1002/(SICI)1097-0215(19960328)66:1<104::AID-IJC18>3.0.CO;2-D; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Weinstein J, 1997, J BIOL CHEM, V272, P28501, DOI 10.1074/jbc.272.45.28501; Weinstein J, 1998, MOL GENET METAB, V64, P52, DOI 10.1006/mgme.1998.2698; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Yuan ZM, 1998, ONCOGENE, V16, P1643, DOI 10.1038/sj.onc.1201698	59	26	27	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 17	2001	20	22					2826	2835		10.1038/sj.onc.1204393	http://dx.doi.org/10.1038/sj.onc.1204393			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	432TP	11420694				2022-12-25	WOS:000168712000010
J	Verrecchia, F; Tacheau, C; Schorpp-Kistner, M; Angel, P; Mauviel, A				Verrecchia, F; Tacheau, C; Schorpp-Kistner, M; Angel, P; Mauviel, A			Induction of the AP-1 members c-Jun and JunB by TGF-beta/Smad suppresses early Smad-driven gene activation	ONCOGENE			English	Article						TGF-zeta; signaling; Smad; AP-1; Jun; gene expression	GROWTH-FACTOR-BETA; TRANSCRIPTIONAL ACTIVATION; COACTIVATOR P300; BINDING SEQUENCE; COL7A1 PROMOTER; DNA-BINDING; FOS; EXPRESSION; COMPLEX; IDENTIFICATION	Smad proteins transduce signals from TGF-beta receptors and regulate transcription of target genes, Among the latter are c-jun and junB, which encode members of the AP-I family of transcription factors. In this study, we have investigated the functional interactions of the Smad and AP-1 transcription factors in the context of Smad-specific gene transactivation in both fibroblasts and keratinocytes. We demonstrate that overexpression of either junB or c-jun prevents TGF-beta- or Smad3-induced transactivation of the Smad-specific promoter construct (SBE)(4)-Lux. Inversely, Smad-driven promoter transactivation by TGF-beta /Smad is significantly enhanced when c-jun expression is abolished in HaCaT keratinocytes, and when junB expression is prevented in fibroblasts, consistent with the cell-type specific induction of jun members by TGF-beta, We also demonstrate that Smad-specific gene transactivation in junB(-/-) mouse embryonic fibroblasts is significantly higher than in embryonic fibroblasts from the control parental mouse line, and that this difference is abolished by rescuing junB expression in junB(-/-) cells. Finally, we have determined that off-DNA interactions between Smad3 and both c-jun and JunB result in the reduction of Smad3/ DNA interactions, From these results, we provide a model in which jun expression in response to the initial Smad cascade represents a negative feed-back mechanism counteracting Smad-driven gene transactivation.	Hop St Louis, INSERM, U532, F-75010 Paris, France; Deutsch Krebsforschungszentrum, Div Signal Transduct & Growth Control, D-69120 Heidelberg, Germany	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Helmholtz Association; German Cancer Research Center (DKFZ)	Mauviel, A (corresponding author), Hop St Louis, Inst Rech Peau, INSERM, U532, Pavillon Bazin,1 Ave Claude Vellefaux, F-75475 Paris 10, France.		MAUVIEL, Alain/F-6251-2013; Verrecchia, Franck/G-5535-2018	Verrecchia, Franck/0000-0003-4920-2554; Mauviel, Alain/0000-0002-0438-2793				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; Chung KY, 1996, J BIOL CHEM, V271, P3272, DOI 10.1074/jbc.271.6.3272; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Hottiger MO, 1998, EMBO J, V17, P3124, DOI 10.1093/emboj/17.11.3124; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; Lee JS, 1996, MOL CELL BIOL, V16, P4312; Letterio JJ, 1997, CLIN IMMUNOL IMMUNOP, V84, P244, DOI 10.1006/clin.1997.4409; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; Maggirwar SB, 2000, J NEUROCHEM, V74, P527, DOI 10.1046/j.1471-4159.2000.740527.x; MARINKOVICH MP, 1993, DEV DYNAM, V197, P255, DOI 10.1002/aja.1001970404; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, GENE DEV, V14, P627; MAUVIEL A, 1993, CURR BIOL, V3, P822, DOI 10.1016/0960-9822(93)90216-B; Mauviel A, 1996, J BIOL CHEM, V271, P10917, DOI 10.1074/jbc.271.18.10917; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; Schorpp-Kistner M, 1999, EMBO J, V18, P934, DOI 10.1093/emboj/18.4.934; SCHREIBER M, 1995, EMBO J, V14, P5338, DOI 10.1002/j.1460-2075.1995.tb00218.x; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; Shen X, 1998, MOL BIOL CELL, V9, P3309, DOI 10.1091/mbc.9.12.3309; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Szabowski A, 2000, CELL, V103, P745, DOI 10.1016/S0092-8674(00)00178-1; Tang WL, 1998, J BIOL CHEM, V273, P5506, DOI 10.1074/jbc.273.10.5506; Verrecchia F, 2000, J BIOL CHEM, V275, P30226, DOI 10.1074/jbc.M005310200; Vindevoghel L, 1998, J BIOL CHEM, V273, P13053, DOI 10.1074/jbc.273.21.13053; Vindevoghel L, 1998, P NATL ACAD SCI USA, V95, P14769, DOI 10.1073/pnas.95.25.14769; Wong C, 1999, MOL CELL BIOL, V19, P1821; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814	39	85	87	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 26	2001	20	18					2205	2211		10.1038/sj.onc.1204347	http://dx.doi.org/10.1038/sj.onc.1204347			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	427KZ	11402315				2022-12-25	WOS:000168404500002
J	Aguilaniu, H; Gustafsson, L; Rigoulet, M; Nystrom, T				Aguilaniu, H; Gustafsson, L; Rigoulet, M; Nystrom, T			Protein oxidation in G(0) cells of Saccharomyces cerevisiae depends on the state rather than rate of respiration and is enhanced in pos9 but not yap1 mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUPEROXIDE-DISMUTASE; ESCHERICHIA-COLI; STATIONARY-PHASE; STRESS-RESPONSE; LIFE-SPAN; YEAST; OXYGEN; MITOCHONDRIA; SENESCENCE; EXTENSION	Immunodetection of protein carbonyl groups demonstrates that growth arrest elicited by carbon or nitrogen starvation causes an increased oxidation of proteins in Saccharomyces cerevisiae. Mutant analysis suggests that the response regulator Pos9p is involved in mitigating self-inflicted oxidative damages in G(0) cells, whereas Yap1p is primarily required in growing cells. The data also suggest that oxidation of target proteins is not a priori an effect of arrest of cell division or nutrient depletion and cannot be explained by the respiratory activity alone nor a high ratio of catabolic/anabolic activity in G(0) cells. Instead, we observed that starvation elicits a transition in the respiratory state (from phosphorylating to nonphosphorylating respiration) and that this transition is associated with a stepwise increase in protein oxidation. During carbon starvation, this transition and increase in oxidation occurs immediately as the carbon source is depleted, growth is arrested, and the respiratory rate falls drastically. In contrast, during nitrogen starvation and excess carbon the respiratory state transition and stepwise increase in protein oxidation are markedly delayed and occur long after the nitrogen source has been depleted and division and growth-arrested. Oxidation in G(0) cells could be enhanced by treating cells with low concentrations of antimycin A and attenuated with myxothiazol, indicating that protein oxidation is intimately linked to reactive oxygen species generated by semiquinones of the Q-cycle. Thus, the work presented suggests that the degree of coupling in the mitochondrial respiratory apparatus rather then the overall rate of respiration affects the degree of protein oxidation in nondividing yeast cells.	Univ Gothenburg, Dept Cell & Mol Biol Microbiol, SE-40530 Gothenburg, Sweden; Chalmers Univ Technol, Dept Mol Biotechnol, SE-40530 Gothenburg, Sweden; Univ Bordeaux 2, CNRS, Inst Biochim & Genet Cellulaires, F-33077 Bordeaux, France	University of Gothenburg; Chalmers University of Technology; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux	Nystrom, T (corresponding author), Univ Gothenburg, Dept Cell & Mol Biol Microbiol, Box 462, SE-40530 Gothenburg, Sweden.							Barker MG, 1999, FEMS MICROBIOL LETT, V177, P199, DOI 10.1016/S0378-1097(99)00308-0; Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; Beckmann K. B., 1997, OXIDATIVE STRESS MOL, P201; BENOV L, 1995, ARCH BIOCHEM BIOPHYS, V322, P291, DOI 10.1006/abbi.1995.1465; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; CAIN K, 1977, BIOCHEM J, V162, P575, DOI 10.1042/bj1620575; CHANCE B, 1956, ADV ENZYMOL REL S BI, V17, P65; CHRISTENSEN LH, 1995, CHEM ENG SCI, V50, P2601, DOI 10.1016/0009-2509(95)00108-H; Dukan S, 1999, J BIOL CHEM, V274, P26027, DOI 10.1074/jbc.274.37.26027; Dukan S, 1998, GENE DEV, V12, P3431, DOI 10.1101/gad.12.21.3431; Eisenstark A, 1996, FREE RADICAL BIO MED, V21, P975, DOI 10.1016/S0891-5849(96)00154-2; FITTON V, 1994, BIOCHEMISTRY-US, V33, P9692, DOI 10.1021/bi00198a039; HALLER T, 1994, ANAL BIOCHEM, V218, P338, DOI 10.1006/abio.1994.1188; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; HARSHMAN KD, 1988, CELL, V53, P321, DOI 10.1016/0092-8674(88)90393-5; Jakubowski W, 2000, FREE RADICAL BIO MED, V28, P659, DOI 10.1016/S0891-5849(99)00266-X; JI LL, 1991, AM J PHYSIOL, V261, pR386, DOI 10.1152/ajpregu.1991.261.2.R386; Korshunov SS, 1997, FEBS LETT, V416, P15, DOI 10.1016/S0014-5793(97)01159-9; KREMS B, 1995, CURR GENET, V27, P427, DOI 10.1007/BF00311211; LARSEN D P, 1991, Lake and Reservoir Management, V7, P1; Lee J, 1999, J BIOL CHEM, V274, P16040, DOI 10.1074/jbc.274.23.16040; LEVINE RL, 1994, METHOD ENZYMOL, V233, P346; Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126; Longo VD, 1996, J BIOL CHEM, V271, P12275, DOI 10.1074/jbc.271.21.12275; Longo VD, 1999, ARCH BIOCHEM BIOPHYS, V365, P131, DOI 10.1006/abbi.1999.1158; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; Morgan BA, 1997, EMBO J, V16, P1035, DOI 10.1093/emboj/16.5.1035; MOYEROWLEY WS, 1988, COLD SPRING HARB SYM, V53, P711, DOI 10.1101/SQB.1988.053.01.081; Nystrom T, 1996, J BACTERIOL, V178, P927, DOI 10.1128/jb.178.3.927-930.1996; OLZ R, 1993, J BACTERIOL, V175, P2205, DOI 10.1128/JB.175.8.2205-2213.1993; ORR WC, 1994, SCIENCE, V263, P1128, DOI 10.1126/science.8108730; Papa S, 1997, MOL CELL BIOCHEM, V174, P305, DOI 10.1023/A:1006873518427; PEARL R, 1928, RATE LIVING, P183; RUBNER M, 1908, PROBLEM LEBENSDAUER, P150; SCHNELL N, 1991, EUR J BIOCHEM, V200, P487, DOI 10.1111/j.1432-1033.1991.tb16209.x; SIEBENLIST KR, 1983, BIOCHEMISTRY-US, V22, P4642, DOI 10.1021/bi00289a005; Sinclair DA, 1997, CELL, V91, P1033, DOI 10.1016/S0092-8674(00)80493-6; Skulachev VP, 1996, Q REV BIOPHYS, V29, P169, DOI 10.1017/S0033583500005795; SOHAL RS, 1976, GERONTOLOGY, V22, P317, DOI 10.1159/000212146; SOHAL RS, 1995, MECH AGEING DEV, V81, P15, DOI 10.1016/0047-6374(94)01578-A; TRUMPOWER BL, 1990, J BIOL CHEM, V265, P11409	42	51	52	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35396	35404		10.1074/jbc.M101796200	http://dx.doi.org/10.1074/jbc.M101796200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11431467	hybrid			2022-12-25	WOS:000171109300027
J	Boncela, J; Papiewska, I; Fijalkowska, I; Walkowiak, B; Cierniewski, CS				Boncela, J; Papiewska, I; Fijalkowska, I; Walkowiak, B; Cierniewski, CS			Acute phase protein alpha(1)-acid glycoprotein interacts with plasminogen activator inhibitor type 1 and stabilizes its inhibitory activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR SMOOTH-MUSCLE; HUMAN ALPHA-1-ACID GLYCOPROTEIN; HUMAN-PLASMA; STRUCTURAL REQUIREMENTS; COMPLEX-FORMATION; BINDING-SITE; VITRONECTIN; EXPRESSION; DOMAIN; PAI-1	alpha (1)-Acid glycoprotein, one of the major acute phase proteins, was found to interact with plasminogen activator inhibitor type 1 (PAI-1) and to stabilize its inhibitory activity toward plasminogen activators. This conclusion is based on the following observations: (a) alpha (1)-acid glycoprotein was identified to bind PAI-1 by a yeast two-hybrid system. Three of 10 positive clones identified by this method to interact with PAI-1 contained almost the entire sequence of alpha (1)-acid glycoprotein; (b) this protein formed complexes with PAI-1 that could be immunoprecipitated from both the incubation mixtures and blood plasma by specific antibodies to either PAI-1 or alpha (1)-acid glycoprotein. Such complexes could be also detected by a solid phase binding assay; and (c) the real-time bimolecular interactions monitored by surface plasmon resonance indicated that the complex of alpha (1)-acid glycoprotein with PAI-1 is less stable than that formed by vitronectin with PAI-1, but in both cases, the apparent KD values were in the range of strong interactions (4.51 + 1.33 and 0.58 + 0.07 nm, respectively). The on rate for binding of PAI-1 to ai-glycoprotein or vitronectin differed by 2-fold, indicating much faster complex formation by vitronectin than by alpha (1)-acid glycoprotein. On the other hand, dissociation of PAI-1 bound to vitronectin was much slower than that from the alpha (1)-acid glycoprotein, as indicated by 4-fold lower k(off) values. Furthermore, the PAI-1 activity toward urokinase-type plasminogen activator and tissue-type plasminogen activator was significantly prolonged in the presence of alpha (1)-acid glycoprotein. These observations suggest that the complex of PAI-1 with alpha (1)-acid glycoprotein can play a role as an alternative reservoir of the physiologically active form of the inhibitor, particularly during inflammation or other acute phase reactions.	Med Univ Lodz, Dept Biophys, PL-90131 Lodz, Poland; Polish Acad Sci, Ctr Microbiol & Virol, PL-93232 Lodz, Poland; Tech Univ Lodz, Dept Biophys, PL-90537 Lodz, Poland	Medical University Lodz; Polish Academy of Sciences; Lodz University of Technology	Cierniewski, CS (corresponding author), Med Univ Lodz, Dept Biophys, 3 Lindleya St, PL-90131 Lodz, Poland.	cc0604@psk2.am.lodz.pl	Boncela, Joanna/AAU-4481-2020	Boncela, Joanna/0000-0001-8419-7012; Walkowiak, Bogdan/0000-0003-4867-5456				BERK BC, 1990, J BIOL CHEM, V265, P17334; BJORQUIST P, 1994, BBA-PROTEIN STRUCT M, V1209, P191, DOI 10.1016/0167-4838(94)90184-8; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; DECLERCK PJ, 1988, BLOOD, V71, P220; DECLERCK PJ, 1988, J BIOL CHEM, V263, P15454; Deng G, 1996, J BIOL CHEM, V271, P12716, DOI 10.1074/jbc.271.22.12716; DENTE L, 1988, GENE DEV, V2, P259, DOI 10.1101/gad.2.2.259; EHRLICH HJ, 1992, J BIOL CHEM, V267, P11606; FEY GH, 1987, MOL BIOL MED, V4, P323; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Fournier T, 2000, BBA-PROTEIN STRUCT M, V1482, P157, DOI 10.1016/S0167-4838(00)00153-9; GEBBINK RK, 1993, BIOCHEMISTRY-US, V32, P1675, DOI 10.1021/bi00057a035; KIRKPATRICK J, 1993, BLOOD, V81, P1290; KOST C, 1992, J BIOL CHEM, V267, P12098; KREMER JMH, 1988, PHARMACOL REV, V40, P1; KRUITHOF EKO, 1987, BLOOD, V70, P1645; KUSHNER I, 1982, ANN NY ACAD SCI, V389, P39, DOI 10.1111/j.1749-6632.1982.tb22124.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBERS JWJ, 1987, J BIOL CHEM, V262, P17492; LARENCE DA, 1995, MOL BASIS THROMBOSIS, P517; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LAWRENCE DA, 1994, BIOCHEMISTRY-US, V33, P3643, DOI 10.1021/bi00178a022; LAWRENCE DA, 1995, J BIOL CHEM, V270, P25309, DOI 10.1074/jbc.270.43.25309; Lawrence DA, 1997, NAT STRUCT BIOL, V4, P339, DOI 10.1038/nsb0597-339; LAWRENCE DA, 1986, BIOCHEMISTRY-US, V25, P6351, DOI 10.1021/bi00369a001; LAWRENCE DA, 1994, J BIOL CHEM, V269, P15223; Lawrence DA, 1997, J BIOL CHEM, V272, P7676, DOI 10.1074/jbc.272.12.7676; LEWIS ML, 1991, THROMB RES, V64, P223, DOI 10.1016/0049-3848(91)90121-C; Lijnen HR, 1996, INT J CLIN LAB RES, V26, P1, DOI 10.1007/BF02644767; LINDAHL TL, 1989, THROMB HAEMOSTASIS, V62, P748; LOSKUTOFF DJ, 1989, PROG HEMOST THROMB, V9, P87; MIMURO J, 1989, J BIOL CHEM, V264, P936; MIMURO J, 1993, BIOCHEMISTRY-US, V32, P2314, DOI 10.1021/bi00060a024; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; NODAHEINY H, 1993, CIRC RES, V72, P36, DOI 10.1161/01.RES.72.1.36; PANNEKOEK H, 1986, EMBO J, V5, P2539, DOI 10.1002/j.1460-2075.1986.tb04532.x; Podor TJ, 2000, J BIOL CHEM, V275, P19788, DOI 10.1074/jbc.M908079199; Podor TJ, 2000, J BIOL CHEM, V275, P25402, DOI 10.1074/jbc.M000362200; PREISSNER KT, 1990, J BIOL CHEM, V265, P18490; PREISSNER KT, 1989, BLOOD, V74, P1989; SAKSELA O, 1988, ANNU REV CELL BIOL, V4, P93, DOI 10.1146/annurev.cb.04.110188.000521; SALONEN EM, 1989, J BIOL CHEM, V264, P6339; SCHMID K, 1977, BIOCHIM BIOPHYS ACTA, V492, P291, DOI 10.1016/0005-2795(77)90080-0; SEIFFERT D, 1991, J BIOL CHEM, V266, P2824; SEIFFERT D, 1997, J BIOL CHEM, V272, P29644; SHIBATA Y, 1984, MICROBIOL IMMUNOL, V28, P99, DOI 10.1111/j.1348-0421.1984.tb02950.x; SIGURDARDOTTIR O, 1990, BIOCHIM BIOPHYS ACTA, V1035, P56, DOI 10.1016/0304-4165(90)90173-T; Sorensson J, 1999, AM J PHYSIOL-HEART C, V276, pH530, DOI 10.1152/ajpheart.1999.276.2.H530; SPRENGERS ED, 1986, THROMB HAEMOSTASIS, V55, P325; Stefansson S, 1996, NATURE, V383, P441, DOI 10.1038/383441a0; Stefansson S, 1998, J BIOL CHEM, V273, P6358, DOI 10.1074/jbc.273.11.6358; STRANDBERG L, 1991, J BIOL CHEM, V266, P13852; STRINGER HAR, 1995, J BIOL CHEM, V270, P11205, DOI 10.1074/jbc.270.19.11205; TAUBMAN MB, 1993, AM J CARDIOL, V72, pC55, DOI 10.1016/0002-9149(93)90256-C; Tonner E, 2000, ADV EXP MED BIOL, V480, P45; VANMEIJER M, 1994, FEBS LETT, V352, P342, DOI 10.1016/0014-5793(94)00990-2; WAGNER OF, 1989, J CLIN INVEST, V84, P647, DOI 10.1172/JCI114211; Williams JP, 1997, AM J PHYSIOL-GASTR L, V273, pG1031, DOI 10.1152/ajpgi.1997.273.5.G1031; WOJTA J, 1993, THROMB HAEMOSTASIS, V70, P469; YOSHIMA H, 1981, J BIOL CHEM, V256, P8476	60	40	41	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35305	35311		10.1074/jbc.M104028200	http://dx.doi.org/10.1074/jbc.M104028200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11418606	hybrid			2022-12-25	WOS:000171109300015
J	Lindemann, S; Tolley, ND; Eyre, JR; Kraiss, LW; Mahoney, TM; Weyrich, AS				Lindemann, S; Tolley, ND; Eyre, JR; Kraiss, LW; Mahoney, TM; Weyrich, AS			Integrins regulate the intracellular distribution of eukaryotic initiation factor 4E in platelets - A checkpoint for translational control	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANCHORAGE-DEPENDENT FIBROBLASTS; ACTIVATED HUMAN PLATELETS; HUMAN-BLOOD PLATELETS; MESSENGER-RNA; MEMBRANE SKELETON; PROTEIN-SYNTHESIS; CYTOSKELETON; RIBOSOMES	Recent evidence from our laboratory demonstrates that platelets synthesize numerous proteins in a signal-dependent fashion (Pabla, R., Weyrich, A. S., Dixon, D. A., Bray, P. F., McIntyre, T. M., Prescott, S. M., and Zimmerman, G. A. (1999) J. Cell Biol. 144, 175-184; Weyrich, A. S., Dixon, D. A., Pabla, R., Elstad, M. R., McIntyre, T. M., Prescott, S. M., and Zimmerman, G. A. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 5556-5561). Protein synthesis in platelets is controlled at the translational level; however, the mechanisms of regulation are not known. Here we demonstrate that translation initiation factors are redistributed to mRNA-rich areas in aggregated platelets, an event that induces protein synthesis. Interrogation of cDNA arrays revealed that platelet-derived mRNAs are primarily associated with the cytoskeletal core. In contrast, eukaryotic initiation factor 4E (eIF4E), the essential mRNA cap-binding protein that controls global translation rates, is localized in the membrane skeleton and soluble fraction of platelets, physically separated from most mRNAs. Platelet activation redistributes eIF4E to the cytoskeleton and increases interactions of eIF4E with mRNA cap structures. Redistribution of eIF4E to the mRNA-rich cytoskeleton coincides with a marked increase in protein synthesis, a process that is blocked when intracellular actin is disrupted. Additional studies demonstrated that ss (3) integrins are the primary membrane receptor that distributes eIF4E within the cell. These results imply that integrins link receptor-mediated pathways with mRNA-rich cytoskeletal domains and thereby modulate the organization of intracellular translational complexes. They also indicate that the functional status of eIF4E is regulated by its intracellular distribution.	Univ Utah, Sch Med, Eccles Program Human Biol & Genet, Salt Lake City, UT 84112 USA; Univ Utah, Sch Med, Dept Internal Med, Salt Lake City, UT 84112 USA; Univ Utah, Sch Med, Dept Surg, Salt Lake City, UT 84112 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Weyrich, AS (corresponding author), Univ Utah, Sch Med, Eccles Program Human Biol & Genet, Biol 533,Rm 4220, Salt Lake City, UT 84112 USA.		Lindemann, Stephan/AAH-3888-2020	Weyrich, Andrew/0000-0001-9622-4647	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL056713, K08HL004151] Funding Source: NIH RePORTER; NHLBI NIH HHS [KO8 HL 04151, HL 56713] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bassell G, 1997, CURR OPIN CELL BIOL, V9, P109, DOI 10.1016/S0955-0674(97)80159-7; BENECKE BJ, 1978, CELL, V14, P931, DOI 10.1016/0092-8674(78)90347-1; BOOYSE FM, 1968, BIOCHIM BIOPHYS ACTA, V157, P660, DOI 10.1016/0005-2787(68)90172-X; BOOYSE FM, 1971, THROMB DIATH HAEMOST, V26, P167; Chicurel ME, 1998, NATURE, V392, P730, DOI 10.1038/33719; FARMER SR, 1978, CELL, V15, P627, DOI 10.1016/0092-8674(78)90031-4; FOX JEB, 1993, ADV EXP MED BIOL, V344, P175; FOX JEB, 1988, J CELL BIOL, V106, P1525, DOI 10.1083/jcb.106.5.1525; FOX JEB, 1993, J BIOL CHEM, V268, P25973; FOX JEB, 1996, PRACT APPROACH SER, P217; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Hovland R, 1996, INT J BIOCHEM CELL B, V28, P1089, DOI 10.1016/1357-2725(96)00059-3; KIEFFER N, 1987, EUR J BIOCHEM, V164, P189, DOI 10.1111/j.1432-1033.1987.tb11010.x; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; LINDEMANN S, 2001, IN PRESS J CELL BIOL; LUDANY A, 1988, CLIN BIOCHEM, V21, P107, DOI 10.1016/S0009-9120(88)80097-3; Pabla R, 1999, J CELL BIOL, V144, P175, DOI 10.1083/jcb.144.1.175; Rosenwald IB, 2001, THROMB HAEMOSTASIS, V85, P142; ROTH GJ, 1989, BIOCHEM BIOPH RES CO, V160, P705, DOI 10.1016/0006-291X(89)92490-X; Shattil SJ, 1997, J CLIN INVEST, V100, pS91; Sonenberg N, 1998, CURR OPIN CELL BIOL, V10, P268, DOI 10.1016/S0955-0674(98)80150-6; TSAO CH, 1971, SCAND J HAEMATOL, V8, P134; Weyrich AS, 1996, J CLIN INVEST, V97, P1525, DOI 10.1172/JCI118575; Weyrich AS, 1998, P NATL ACAD SCI USA, V95, P5556, DOI 10.1073/pnas.95.10.5556; WEYRICH AS, 1995, J CLIN INVEST, V95, P2297, DOI 10.1172/JCI117921	25	92	95	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33947	33951		10.1074/jbc.M104281200	http://dx.doi.org/10.1074/jbc.M104281200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11431478	hybrid			2022-12-25	WOS:000170910200089
J	Alvarez, I; Sesma, L; Marcilla, M; Ramos, M; Marti, M; Camafeita, E; de Castro, JAL				Alvarez, I; Sesma, L; Marcilla, M; Ramos, M; Marti, M; Camafeita, E; de Castro, JAL			Identification of novel HLA-B27 ligands derived from polymorphic regions of its own or other class I molecules based on direct generation by 20 S proteasome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL CLONE; HL-A 27; ANKYLOSING-SPONDYLITIS; ENDOPLASMIC-RETICULUM; ANTIGENIC PEPTIDES; CTL EPITOPE; PROTEOLYTIC ACTIVITIES; INTERFERON-GAMMA; BINDING PEPTIDES; BRANCHED-CHAIN	HLA-B27 is strongly associated with ankylosing spondylitis. Natural HLA-B27 ligands derived from polymorphic regions of its own or other class I HILA molecules might be involved in autoimmunity or provide diversity among HLA-B27-bound peptide repertoires from individuals. In particular, an 11-mer spanning HLA-B27 residues 169-179 is a natural HLA-B27 ligand with homology to proteins from Gram-negative bacteria. Proteasomal digestion of synthetic substrates demonstrated direct generation of the B27(169-179) ligand. Cleavage after residue 181 generated a B27(169-181) 13-mer that was subsequently found as a natural ligand of B*2705 and B*2704. Its binding to HLA-B27 subtypes in vivo correlated better than B27-(169-179) with association to spondyloarthropathy. Proteasomal cleavage generated also a peptide spanning B*2705 residues 150-158. This region is polymorphic among HLA-B27 subtypes and class I HLA antigens. The peptide was a natural B*2704 ligand. Since this subtype differs from B*2705 at residue 152, it was concluded that the ligand arose from HLA-B*3503, synthesized in the cells used as a source for B*2704-bound peptides. Thus, polymorphic HLA-B27 ligands derived from HLA-B27 or other class I molecules are directly produced by the 20 S proteasome in vitro, and this can be used for identification of such ligands in the constitutive HLA-B27-bound peptide pool.	Univ Autonoma Madrid, Fac Ciencias, Ctr Biol Mol Severo Ochoa, CSIC, E-28049 Madrid, Spain; Ctr Nacl Biotecnol, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	de Castro, JAL (corresponding author), Univ Autonoma Madrid, Fac Ciencias, Ctr Biol Mol Severo Ochoa, CSIC, E-28049 Madrid, Spain.	aldecastro@cbm.uam.es	Ramos, Manuel/F-5076-2016; Alvarez, Iñaki/A-6684-2011; Marcilla, Miguel/B-8430-2013; Martí, Mercè/I-2164-2015	Ramos, Manuel/0000-0002-0404-7936; Alvarez, Iñaki/0000-0001-9484-0868; Marcilla, Miguel/0000-0001-9171-5076; Martí, Mercè/0000-0002-1846-0043				Allen RL, 1999, IMMUNOGENETICS, V50, P220, DOI 10.1007/s002510050596; BARNSTABLE CJ, 1978, CELL, V14, P9, DOI 10.1016/0092-8674(78)90296-9; Beninga J, 1998, J BIOL CHEM, V273, P18734, DOI 10.1074/jbc.273.30.18734; BENJAMIN R, 1990, IMMUNOL TODAY, V11, P137, DOI 10.1016/0167-5699(90)90051-A; Boisgerault F, 1996, J CLIN INVEST, V98, P2764, DOI 10.1172/JCI119102; BREWERTON DA, 1973, LANCET, V2, P996, DOI 10.1016/S0140-6736(73)91091-X; BREWERTON DA, 1973, LANCET, V1, P904; BURMESTER GR, 1995, ANNU REV IMMUNOL, V13, P229, DOI 10.1146/annurev.iy.13.040195.001305; Colbert RA, 2000, MOL MED TODAY, V6, P224, DOI 10.1016/S1357-4310(00)01699-3; Cresswell P, 1999, IMMUNOL REV, V172, P21, DOI 10.1111/j.1600-065X.1999.tb01353.x; DAMATO M, 1995, EUR J IMMUNOL, V25, P3199, DOI 10.1002/eji.1830251133; DEL VM, 1991, CELL, V66, P1145; DELPORTO P, 1994, J IMMUNOL, V153, P3093; DEMARTINO GN, 1994, J BIOL CHEM, V269, P20878; DICK LR, 1994, J IMMUNOL, V152, P3884; Dick TP, 1996, CELL, V86, P253, DOI 10.1016/S0092-8674(00)80097-5; DUBIEL W, 1992, J BIOL CHEM, V267, P22369; Edwards JCW, 2000, IMMUNOL TODAY, V21, P256, DOI 10.1016/S0167-5699(00)01625-X; EGGERS M, 1995, J EXP MED, V182, P1865, DOI 10.1084/jem.182.6.1865; Ehring B, 1996, EUR J BIOCHEM, V235, P404, DOI 10.1111/j.1432-1033.1996.00404.x; ELLIOTT T, 1995, J EXP MED, V181, P1481, DOI 10.1084/jem.181.4.1481; ENGELHARD VH, 1994, ANNU REV IMMUNOL, V12, P181, DOI 10.1146/annurev.iy.12.040194.001145; Galocha B, 1996, TISSUE ANTIGENS, V48, P509, DOI 10.1111/j.1399-0039.1996.tb02664.x; Garcia F, 1997, TISSUE ANTIGENS, V49, P23, DOI 10.1111/j.1399-0039.1997.tb02705.x; GonzalezRoces S, 1997, TISSUE ANTIGENS, V49, P116, DOI 10.1111/j.1399-0039.1997.tb02724.x; Griffin TA, 1998, J EXP MED, V187, P97, DOI 10.1084/jem.187.1.97; Groettrup M, 1996, NATURE, V381, P166, DOI 10.1038/381166a0; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; Heinemeyer W, 1997, J BIOL CHEM, V272, P25200, DOI 10.1074/jbc.272.40.25200; Hughes EA, 1996, J EXP MED, V183, P1569, DOI 10.1084/jem.183.4.1569; Hughes EA, 1997, P NATL ACAD SCI USA, V94, P1896, DOI 10.1073/pnas.94.5.1896; Kessler JH, 2001, J EXP MED, V193, P73, DOI 10.1084/jem.193.1.73; Khan MA, 2000, CURR OPIN RHEUMATOL, V12, P235, DOI 10.1097/00002281-200007000-00001; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; Lamas JR, 1999, ARTHRITIS RHEUM-US, V42, P1975, DOI 10.1002/1529-0131(199909)42:9<1975::AID-ANR25>3.0.CO;2-V; LOPEZLARREA C, 1995, TISSUE ANTIGENS, V45, P169, DOI 10.1111/j.1399-0039.1995.tb02436.x; Lucchiari-Hartz M, 2000, J EXP MED, V191, P239, DOI 10.1084/jem.191.2.239; Luckey CJ, 1998, J IMMUNOL, V161, P112; MA CP, 1994, J BIOL CHEM, V269, P3539; Marina A, 1999, J MASS SPECTROM, V34, P17, DOI 10.1002/(SICI)1096-9888(199901)34:1<17::AID-JMS746>3.3.CO;2-Y; McCormack TA, 1998, BIOCHEMISTRY-US, V37, P7792, DOI 10.1021/bi980097q; Mear JP, 1999, J IMMUNOL, V163, P6665; Mo XY, 1999, J IMMUNOL, V163, P5851; Nasution AR, 1997, J RHEUMATOL, V24, P1111; NIEDERMANN G, 1995, IMMUNITY, V2, P289, DOI 10.1016/1074-7613(95)90053-5; Niedermann G, 1997, J EXP MED, V186, P209, DOI 10.1084/jem.186.2.209; ORLOWSKI M, 1993, BIOCHEMISTRY-US, V32, P1563, DOI 10.1021/bi00057a022; Ossendorp F, 1996, IMMUNITY, V5, P115, DOI 10.1016/S1074-7613(00)80488-4; Paradela A, 2000, J IMMUNOL, V164, P329, DOI 10.4049/jimmunol.164.1.329; Paradela A, 1998, J IMMUNOL, V161, P5481; PARHAM P, 1995, IMMUNOL REV, V143, P141, DOI 10.1111/j.1600-065X.1995.tb00674.x; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; Ren EC, 1997, TISSUE ANTIGENS, V49, P67, DOI 10.1111/j.1399-0039.1997.tb02713.x; Rock KL, 1999, ANNU REV IMMUNOL, V17, P739, DOI 10.1146/annurev.immunol.17.1.739; ROELSE J, 1994, J EXP MED, V180, P1591, DOI 10.1084/jem.180.5.1591; SCOFIELD RH, 1995, LANCET, V345, P1542, DOI 10.1016/S0140-6736(95)91089-1; Shimbara N, 1997, GENES CELLS, V2, P785, DOI 10.1046/j.1365-2443.1997.1610359.x; SNYDER HL, 1994, J EXP MED, V180, P2389, DOI 10.1084/jem.180.6.2389; Stoltze L, 1998, EUR J IMMUNOL, V28, P4029, DOI 10.1002/(SICI)1521-4141(199812)28:12<4029::AID-IMMU4029>3.0.CO;2-N; VEGA MA, 1986, J IMMUNOL, V137, P3557; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; Wordsworth P, 1998, RHEUM DIS CLIN N AM, V24, P845, DOI 10.1016/S0889-857X(05)70045-4; Wuorela M, 1998, AM J MED SCI, V316, P264, DOI 10.1097/00000441-199810000-00007; Yague J, 2000, J EXP MED, V191, P2083, DOI 10.1084/jem.191.12.2083; Yague J, 1998, TISSUE ANTIGENS, V52, P416, DOI 10.1111/j.1399-0039.1998.tb03067.x; YellenShaw AJ, 1997, J IMMUNOL, V158, P3227; ZEMMOUR J, 1992, J IMMUNOL, V148, P1941	68	23	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					32729	32737		10.1074/jbc.M104663200	http://dx.doi.org/10.1074/jbc.M104663200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11435436	hybrid			2022-12-25	WOS:000170746000048
J	Nguyen, MHH; Ho, JMY; Beattie, BK; Barber, DL				Nguyen, MHH; Ho, JMY; Beattie, BK; Barber, DL			TEL-JAK2 mediates constitutive activation of the phosphatidylinositol 3-kinase/protein kinase B signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORMED HEMATOPOIETIC-CELLS; COLONY-STIMULATING FACTOR; DNA-BINDING ACTIVITY; BCR-ABL ONCOGENE; TYROSINE PHOSPHORYLATION; LYMPHOPROLIFERATIVE DISEASE; MOLECULAR-CLONING; STAT PROTEINS; SH2 DOMAINS; C-AKT	A subset of chromosomal translocations that participate in leukemia involve activated tyrosine kinases. The ets transcription factor, TEL, undergoes translocations with several distinct tyrosine kinases including JAK2. TEL-JAK2 transforms cell lines to factor independence, and constitutive tyrosine kinase activity results in the phosphorylation of several substrates including STAT1, STAT3, and STAT5. In this study we have shown that TEL-JAK2 can constitutively activate the phosphatidylinositol 3'-kinase (PI 3'-kinase) signaling pathway. The regulatory subunit of PI 3'-kinase, p85, associates with TEL-JAK2 in immunoprecipitations, and this was shown to be mediated by the amino-terminal SH2 domain of p85 but independent of a putative p85-binding motif within TEL-JAK2. The scaffolding protein Gab2 can also mediate the association of p85. TEL-JAK2 constitutively phosphorylates the downstream substrate protein kinase B/AKT. Importantly, the pharmacologic PI 3'-kinase inhibitor, LY294002, blocked TEL-JAK2 factor-independent growth and phosphorylation of protein kinase B. However, LY294002 did not alter STAT5 tyrosine phosphorylation, indicating that STAT5 and protein kinase B activation mediated by TEL-JAK2 are independent signaling pathways. Therefore, activation of the PI 3'-kinase signaling pathway is an important event mediated by TEL-JAK2 chromosomal translocations.	Univ Hlth Network, Ontario Canc Inst, Div Cell & Mol Biol, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5G 2M9, Canada; Univ Hlth Network, Toronto Gen Hosp, Dept Lab Med & Pathobiol, Toronto, ON M5G 2M9, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital	Barber, DL (corresponding author), Univ Hlth Network, Ontario Canc Inst, Div Cell & Mol Biol, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.	dbarber@oci.utoronto.ca		Barber, Dwayne/0000-0001-5528-8150				AmaranteMendes GP, 1997, CELL DEATH DIFFER, V4, P548, DOI 10.1038/sj.cdd.4400276; ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; Bai RY, 2000, BLOOD, V96, P4319, DOI 10.1182/blood.V96.13.4319; BARBER DL, 1994, MOL CELL BIOL, V14, P2257, DOI 10.1128/MCB.14.4.2257; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; Brennan P, 1997, IMMUNITY, V7, P679, DOI 10.1016/S1074-7613(00)80388-X; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Carron C, 2000, BLOOD, V95, P3891; Cazzaniga G, 1999, BLOOD, V94, P4370, DOI 10.1182/blood.V94.12.4370.424k34_4370_4373; Coffer PJ, 1998, BIOCHEM J, V335, P1; Craddock BL, 1999, J BIOL CHEM, V274, P10633, DOI 10.1074/jbc.274.15.10633; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DAMEN JE, 1995, J BIOL CHEM, V270, P23402, DOI 10.1074/jbc.270.40.23402; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEJONG R, 1995, J BIOL CHEM, V270, P21468, DOI 10.1074/jbc.270.37.21468; DEL PL, 1997, SCIENCE, V278, P687; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Eguchi M, 1999, BLOOD, V93, P1355, DOI 10.1182/blood.V93.4.1355; Frank DA, 1996, LEUKEMIA, V10, P1724; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Fruman DA, 1996, GENOMICS, V37, P113, DOI 10.1006/geno.1996.0527; GILLILAND DG, 1998, LEUKEMIA S1, V12, P7; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; GOLD MR, 1994, J BIOL CHEM, V269, P5403; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Golub TR, 1996, MOL CELL BIOL, V16, P4107; Gu HH, 2000, MOL CELL BIOL, V20, P7109, DOI 10.1128/MCB.20.19.7109-7120.2000; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; HARRISONFINDIK D, 1995, ONCOGENE, V10, P1385; Ho JMY, 1999, BLOOD, V93, P4354, DOI 10.1182/blood.V93.12.4354.412k30_4354_4364; HolgadoMadruga M, 1997, P NATL ACAD SCI USA, V94, P12419, DOI 10.1073/pnas.94.23.12419; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; Jain SK, 1996, BLOOD, V88, P1542; Jain SK, 1997, ONCOGENE, V14, P2217, DOI 10.1038/sj.onc.1201049; JANSSEN JWG, 1995, BRIT J HAEMATOL, V90, P222, DOI 10.1111/j.1365-2141.1995.tb03407.x; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; Knezevich SR, 1998, NAT GENET, V18, P184, DOI 10.1038/ng0298-184; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; Liu QR, 1999, GENE DEV, V13, P786, DOI 10.1101/gad.13.7.786; MATSUGUCHI T, 1994, J BIOL CHEM, V269, P5016; Neshat MS, 2000, MOL CELL BIOL, V20, P1179, DOI 10.1128/MCB.20.4.1179-1186.2000; Odai H, 1997, BLOOD, V89, P2745, DOI 10.1182/blood.V89.8.2745; Ormerod MG, 1998, LEUKEMIA, V12, P1013, DOI 10.1038/sj.leu.2401061; Peeters P, 1997, CANCER RES, V57, P564; Peeters P, 1997, BLOOD, V90, P2535, DOI 10.1182/blood.V90.7.2535.2535_2535_2540; PICCIONE E, 1993, BIOCHEMISTRY-US, V32, P3197, DOI 10.1021/bi00064a001; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; RORDORFNIKOLIC T, 1995, J BIOL CHEM, V270, P3662, DOI 10.1074/jbc.270.8.3662; Salgia R, 1996, EXP HEMATOL, V24, P310; Sattler M, 1999, MOL CELL BIOL, V19, P7473; SAWYERS CL, 1995, J EXP MED, V181, P307, DOI 10.1084/jem.181.1.307; Sawyers CL, 1999, NEW ENGL J MED, V340, P1330, DOI 10.1056/NEJM199904293401706; Scheid MP, 1998, P NATL ACAD SCI USA, V95, P7439, DOI 10.1073/pnas.95.13.7439; SCHEID MP, 1995, BIOCHEM J, V312, P159, DOI 10.1042/bj3120159; Schwaller J, 1998, EMBO J, V17, P5321, DOI 10.1093/emboj/17.18.5321; Schwaller J, 2000, MOL CELL, V6, P693, DOI 10.1016/S1097-2765(00)00067-8; Senechal K, 1998, MOL CELL BIOL, V18, P5082, DOI 10.1128/MCB.18.9.5082; Shuai K, 1996, ONCOGENE, V13, P247; SKORSKI T, 1995, BLOOD, V86, P726, DOI 10.1182/blood.V86.2.726.bloodjournal862726; Skorski T, 1998, P NATL ACAD SCI USA, V95, P11858, DOI 10.1073/pnas.95.20.11858; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; TAUCHI T, 1994, J BIOL CHEM, V269, P15381; TAUCHI T, 1994, J EXP MED, V179, P167, DOI 10.1084/jem.179.1.167; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Yenush L, 1997, BIOESSAYS, V19, P491, DOI 10.1002/bies.950190608; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	82	54	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					32704	32713		10.1074/jbc.M103100200	http://dx.doi.org/10.1074/jbc.M103100200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11435425	hybrid			2022-12-25	WOS:000170746000045
J	Bauer, B; Krumbock, N; Fresser, F; Hochholdinger, F; Spitaler, M; Simm, A; Uberall, F; Schraven, B; Baier, G				Bauer, B; Krumbock, N; Fresser, F; Hochholdinger, F; Spitaler, M; Simm, A; Uberall, F; Schraven, B; Baier, G			Complex formation and cooperation of protein kinase C theta and Akt1/protein kinase B alpha in the NF-kappa B transactivation cascade in Jurkat T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PKC-THETA; PHOSPHOINOSITIDE 3-KINASE; REGULATORY DOMAIN; IL-2 PROMOTER; ACTIVATION; VAV; TRANSLOCATION; LYMPHOCYTES; APOPTOSIS; MEMBRANE	Protein kinase C theta (PKC theta) is known to induce NF-kappaB, an essential transcriptional element in T cell receptor/ CD28-mediated interleukin-2 production but also T cell survival. Here we provide evidence that PKC theta is physically and functionally coupled to Akt1 in this signaling pathway. First, T cell receptor/CD3 ligation was sufficient to induce activation as well as plasma membrane recruitment of PKC theta. Second, PKC theta selectively cooperated with Akt1, known to act downstream of CD28 coreceptor signaling, in activating a NF-kappaB reporter in T cells. Third, Akt1 function was shown to be required for PKC theta -mediated NF-kappaB transactivation. Fourth, PKC theta co-immunoprecipitated with Akt1 however, neither Akt1 nor PKC theta served as a prominent substrate for each other in vitro as well as in intact T cells. Finally, plasma membrane targeting of PKC theta and Akt1 exerted synergistic transactivation of the I-kappaB kinase beta /inhibitor of NF-kappaB/NF-kappaB signaling cascade independent of T cell activation. Taken together, these findings suggest a direct cross-talk between PKC theta and Akt1 in Jurkat T cells.	Univ Innsbruck, Dept Med Biol & Human Genet, A-6020 Innsbruck, Austria; Univ Innsbruck, Dept Med Chem & Biochem, A-6020 Innsbruck, Austria; Univ Wurzburg, Dept Clin Biochem, D-97078 Wurzburg, Germany; Otto Von Guericke Univ, Inst Immunol, D-39120 Magdeburg, Germany	University of Innsbruck; University of Innsbruck; University of Wurzburg; Otto von Guericke University	Baier, G (corresponding author), Univ Innsbruck, Inst Med Biol & Human Genet, Schoepfstr 41, A-6020 Innsbruck, Austria.	Gottfried.Baier@uibk.ac.at	Baier, Gottfried/E-8755-2012	Spitaler, Martin/0000-0002-8833-638X; Baier, Gottfried/0000-0002-2085-8325				Altman A, 2000, IMMUNOL TODAY, V21, P567, DOI 10.1016/S0167-5699(00)01749-7; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; BaierBitterlich G, 1996, MOL CELL BIOL, V16, P1842; Bauer B, 2000, EUR J IMMUNOL, V30, P3645, DOI 10.1002/1521-4141(200012)30:12<3645::AID-IMMU3645>3.0.CO;2-#; Bertolotto C, 2000, J BIOL CHEM, V275, P37246, DOI 10.1074/jbc.M007732200; Bi K, 2001, NAT IMMUNOL, V2, P556, DOI 10.1038/88765; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; Coudronniere N, 2000, P NATL ACAD SCI USA, V97, P3394, DOI 10.1073/pnas.060028097; Datta R, 1997, J BIOL CHEM, V272, P20317, DOI 10.1074/jbc.272.33.20317; Fischer KD, 1998, SEMIN IMMUNOL, V10, P317, DOI 10.1006/smim.1998.0124; Genot EM, 2000, MOL CELL BIOL, V20, P5469, DOI 10.1128/MCB.20.15.5469-5478.2000; GENOT EM, 1995, J BIOL CHEM, V270, P9833, DOI 10.1074/jbc.270.17.9833; Ghaffari-Tabrizi N, 1999, EUR J IMMUNOL, V29, P132; Hochholdinger F, 1999, MOL CELL BIOL, V19, P8052; Holsinger LJ, 1998, CURR BIOL, V8, P563, DOI 10.1016/S0960-9822(98)70225-8; JAMES G, 1992, J CELL BIOL, V116, P863, DOI 10.1083/jcb.116.4.863; Jones RG, 2000, J EXP MED, V191, P1721, DOI 10.1084/jem.191.10.1721; Kane LP, 2001, NAT IMMUNOL, V2, P37, DOI 10.1038/83144; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Khoshnan A, 2000, J IMMUNOL, V165, P6933, DOI 10.4049/jimmunol.165.12.6933; Kong YY, 1998, J EXP MED, V188, P2099, DOI 10.1084/jem.188.11.2099; KONISHI H, 1994, BIOCHEM BIOPH RES CO, V205, P1770, DOI 10.1006/bbrc.1994.2874; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Lin X, 2000, MOL CELL BIOL, V20, P2933, DOI 10.1128/MCB.20.8.2933-2940.2000; Meller N, 1996, MOL CELL BIOL, V16, P5782; Mok CL, 1999, J EXP MED, V189, P575, DOI 10.1084/jem.189.3.575; Monks CRF, 1998, NATURE, V395, P82, DOI 10.1038/25764; Monks CRF, 1997, NATURE, V385, P83, DOI 10.1038/385083a0; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Parry RV, 1997, EUR J IMMUNOL, V27, P2495, DOI 10.1002/eji.1830271006; Shan XC, 2000, MOL CELL BIOL, V20, P6945, DOI 10.1128/MCB.20.18.6945-6957.2000; Stempka L, 1999, J BIOL CHEM, V274, P8886, DOI 10.1074/jbc.274.13.8886; Sun ZM, 2000, NATURE, V404, P402, DOI 10.1038/35006090; Villalba M, 2000, IMMUNITY, V12, P151, DOI 10.1016/S1074-7613(00)80168-5; Villalba M, 1999, J IMMUNOL, V163, P5813; Werlen G, 1998, EMBO J, V17, P3101, DOI 10.1093/emboj/17.11.3101	38	69	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					31627	31634		10.1074/jbc.M103098200	http://dx.doi.org/10.1074/jbc.M103098200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11410591	hybrid			2022-12-25	WOS:000170613500023
J	Takahashi, K; Baba, S; Koyanagi, Y; Yamamoto, N; Takaku, H; Kawai, G				Takahashi, K; Baba, S; Koyanagi, Y; Yamamoto, N; Takaku, H; Kawai, G			Two basic regions of NCp7 are sufficient for conformational conversion of HIV-1 dimerization initiation site from kissing-loop dimer to extended-duplex dimer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; MURINE LEUKEMIA-VIRUS; NUCLEOCAPSID PROTEIN NCP10; STRANDED PENTANUCLEOTIDE D(ACGCC); RNA ANNEALING ACTIVITIES; IN-VITRO; GENOMIC RNA; ZINC-FINGER; NMR STRUCTURE; VIRAL-RNA	Nucleocapsid (NC) protein possesses nucleotide-annealing activities, which are used in various processes in retroviral life cycle. As conserved characters, the NC proteins have one or two zinc fingers of CX2CX4HX4C motif surrounded by basic amino acid sequences. Requirement of the zinc fingers for the annealing activities of NC protein remains controversial. In this study, we focused the requirement in the process of maturation of dimeric viral RNA. Discrimination between immature and mature dimers of synthetic RNA corresponding to the dimerization initiation site of human immunodeficiency virus type 1 (HIV-1) genomic RNA was performed based on their Mg2+-dependent stability in gel electrophoreses and on their distinct signal pattern from NMR analysis of imino protons. Chaperoning activity of the HIV-1 NC protein, NCp7, and its fragments for maturation of dimeric RNA was investigated using these experimental systems. We found that the two basic regions flanking the N-terminal zinc finger of NCp7, which are connected by two glycine residues instead of the zinc finger, were sufficient, although about 10 times the amounts of peptide were needed in comparison with intact NCp7. Further, it was found that the amount of basic residues rather than the amino acid sequence itself is important for the activity. The zinc fingers may involve the binding affinity and/or such a possible specific binding of NCp7 to dimerization initiation site dimer that leads to the maturation reaction.	Chiba Inst Technol, Dept Ind Chem, Narashino, Chiba 2758588, Japan; Tohoku Univ, Sch Med, Dept Virol, Aobu Ku, Sendai, Miyagi 9808575, Japan; Tokyo Med & Dent Univ, Fac Med, Dept Mol Virol, Bunkyo Ku, Tokyo 1138519, Japan	Chiba Institute of Technology; Tohoku University; Tokyo Medical & Dental University (TMDU)	Kawai, G (corresponding author), Chiba Inst Technol, Dept Ind Chem, 2-17-1 Tsudanuma, Narashino, Chiba 2758588, Japan.							BERKOWITZ RD, 1994, VIROLOGY, V202, P233, DOI 10.1006/viro.1994.1339; Berthoux L, 1997, J VIROL, V71, P6973, DOI 10.1128/JVI.71.9.6973-6981.1997; Cimarelli A, 2000, J VIROL, V74, P3046, DOI 10.1128/JVI.74.7.3046-3057.2000; DANNULL J, 1994, EMBO J, V13, P1525, DOI 10.1002/j.1460-2075.1994.tb06414.x; DARLIX JL, 1995, J MOL BIOL, V254, P523, DOI 10.1006/jmbi.1995.0635; De Guzman RN, 1998, SCIENCE, V279, P384, DOI 10.1126/science.279.5349.384; DEMENE H, 1994, J BIOMOL NMR, V4, P153, DOI 10.1007/BF00175244; DEMENE H, 1994, BIOCHEMISTRY-US, V33, P11707, DOI 10.1021/bi00205a006; DEROCQUIGNY H, 1993, NUCLEIC ACIDS RES, V21, P823; DEROCQUIGNY H, 1992, P NATL ACAD SCI USA, V89, P6472, DOI 10.1073/pnas.89.14.6472; Ennifar E, 1999, STRUCTURE, V7, P1439, DOI 10.1016/S0969-2126(00)80033-7; FENG YX, 1995, J VIROL, V69, P2486, DOI 10.1128/JVI.69.4.2486-2490.1995; Feng YX, 1996, P NATL ACAD SCI USA, V93, P7577, DOI 10.1073/pnas.93.15.7577; FU W, 1994, J VIROL, V68, P5013, DOI 10.1128/JVI.68.8.5013-5018.1994; FU W, 1993, J VIROL, V67, P5443, DOI 10.1128/JVI.67.9.5443-5449.1993; FU XD, 1988, J BIOL CHEM, V263, P2140; Gao Y, 1998, PROTEIN SCI, V7, P2265, DOI 10.1002/pro.5560071104; Girard F, 1999, J BIOMOL STRUCT DYN, V16, P1145, DOI 10.1080/07391102.1999.10508323; GORELICK RJ, 1993, J VIROL, V67, P4027, DOI 10.1128/JVI.67.7.4027-4036.1993; HOUSSET V, 1993, J VIROL, V67, P2537, DOI 10.1128/JVI.67.5.2537-2545.1993; Hsu M, 2000, NUCLEIC ACIDS RES, V28, P1724, DOI 10.1093/nar/28.8.1724; Klein DJ, 2000, BIOCHEMISTRY-US, V39, P1604, DOI 10.1021/bi9922493; Kodera Y, 1998, BIOCHEMISTRY-US, V37, P17704, DOI 10.1021/bi981818o; LAPADATTAPOLSKY M, 1995, NUCLEIC ACIDS RES, V23, P2434, DOI 10.1093/nar/23.13.2434; LAUGHREA M, 1994, BIOCHEMISTRY-US, V33, P13464, DOI 10.1021/bi00249a035; Laughrea M, 1996, BIOCHEMISTRY-US, V35, P1589, DOI 10.1021/bi951838f; MORELLET N, 1992, EMBO J, V11, P3059, DOI 10.1002/j.1460-2075.1992.tb05377.x; MORELLET N, 1994, J MOL BIOL, V235, P287, DOI 10.1016/S0022-2836(05)80033-6; Morellet N, 1998, J MOL BIOL, V283, P419, DOI 10.1006/jmbi.1998.2098; Mujeeb A, 1999, FEBS LETT, V458, P387, DOI 10.1016/S0014-5793(99)01183-7; Mujeeb A, 1998, NAT STRUCT BIOL, V5, P432, DOI 10.1038/nsb0698-432; Muriaux D, 1996, J BIOL CHEM, V271, P33686, DOI 10.1074/jbc.271.52.33686; Muriaux D, 1996, BIOCHEMISTRY-US, V35, P5075, DOI 10.1021/bi952822s; OTTMANN M, 1995, J VIROL, V69, P1778, DOI 10.1128/JVI.69.3.1778-1784.1995; PLATEAU P, 1982, J AM CHEM SOC, V104, P7310, DOI 10.1021/ja00389a067; PRATS AC, 1991, NUCLEIC ACIDS RES, V19, P3533, DOI 10.1093/nar/19.13.3533; Rein A, 1998, TRENDS BIOCHEM SCI, V23, P297, DOI 10.1016/S0968-0004(98)01256-0; Remy E, 1998, J BIOL CHEM, V273, P4819, DOI 10.1074/jbc.273.9.4819; Rong LW, 1998, J VIROL, V72, P9353, DOI 10.1128/JVI.72.11.9353-9358.1998; Schmalzbauer E, 1996, J VIROL, V70, P771, DOI 10.1128/JVI.70.2.771-777.1996; Schuler W, 1999, BIOCHEMISTRY-US, V38, P12984, DOI 10.1021/bi990378d; SKRIPKIN E, 1994, P NATL ACAD SCI USA, V91, P4945, DOI 10.1073/pnas.91.11.4945; Takahashi K, 2000, J BIOCHEM-TOKYO, V127, P681, DOI 10.1093/oxfordjournals.jbchem.a022657; Takahashi KI, 2000, RNA, V6, P96, DOI 10.1017/S1355838200991635; Wu WX, 1996, J VIROL, V70, P7132, DOI 10.1128/JVI.70.10.7132-7142.1996	45	32	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					31274	31278		10.1074/jbc.M104577200	http://dx.doi.org/10.1074/jbc.M104577200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11418609	hybrid			2022-12-25	WOS:000170472900090
J	Wada, T; Nakagawa, K; Watanabe, T; Nishitai, G; Seo, JW; Kishimoto, H; Kitagawa, D; Sasaki, T; Penninger, JM; Nishina, H; Katada, T				Wada, T; Nakagawa, K; Watanabe, T; Nishitai, G; Seo, JW; Kishimoto, H; Kitagawa, D; Sasaki, T; Penninger, JM; Nishina, H; Katada, T			Impaired synergistic activation of stress-activated protein kinase SAPK/JNK in mouse embryonic stem cells lacking SEK1/MKK4 - Different contribution of SEK2/MKK7 isoforms to the synergistic activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUN NH2-TERMINAL KINASE; N-TERMINAL KINASE; IN-VITRO; MKK7; JNK; INHIBITION; SAPK1/JNK; APOPTOSIS	Stress-activated protein kinase/c-Jun NH2-terminal kinase (SAPK/JNK), which is a member of the mitogen-activated protein kinase (MAPK) family, plays an important role in a stress-induced signaling cascade. SAPK/JNK activation requires the phosphorylation of Thr and Tyr residues in its Thr-Pro-Tyr motif, and SEK1 (MKK4) and MKK7 (SEK2) have been identified as the upstream MAPK kinases. Here we examined the activation and phosphorylation sites of SAPK/JNK and differentiated the contribution of SEK1 and MKK7 alpha1, -gamma1, and -gamma2 isoforms to the MAPK activation. In SEK1-deficient mouse embryonic stem cells, stress-induced SAPK/JNK activation was markedly impaired, and this defect was accompanied with a decreased level of the Tyr phosphorylation. Analysis in HeLa cells co-transfected with the two MAPK kinases revealed that the Thr and Tyr of SAPK/JNK were independently phosphorylated in response to heat shock by MKK7 gamma1 and SEK1, respectively. However, MKK7 alpha1 failed to phosphorylate the Thr of SAPK/JNK unless its Tyr residue was phosphorylated by SEK1. In contrast, MKK7 gamma2 had the ability to phosphorylate both Thr and Tyr residues. In all cases, the dual phosphorylation of the Thr and Tyr residues was essentially required for the fall activation of SAPK/JNK. These data provide the first evidence that synergistic activation of SAPK/JNK requires both phosphorylation at the Thr and Tyr residues in living cells and that the preference for the Thr and Tyr phosphorylation was different among the members of MAPK kinases.	Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Physiol Chem, Bunkyo Ku, Tokyo 1130033, Japan; Univ Toronto, Ontario Canc Inst, Amgen Inst, Toronto, ON M5G 2C1, Canada; Univ Toronto, Dept Med Biophys & Immunol, Toronto, ON M5G 2C1, Canada	University of Tokyo; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto	Nishina, H (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Physiol Chem, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.		Penninger, Josef M/I-6860-2013	Penninger, Josef M/0000-0002-8194-3777; Sasaki, Takehiko/0000-0003-1837-3748				Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Dong C, 2000, NATURE, V405, P91, DOI 10.1038/35011091; Fleming Y, 2000, BIOCHEM J, V352, P145, DOI 10.1042/0264-6021:3520145; Ganiatsas S, 1998, P NATL ACAD SCI USA, V95, P6881, DOI 10.1073/pnas.95.12.6881; Holland PM, 1997, J BIOL CHEM, V272, P24994, DOI 10.1074/jbc.272.40.24994; Lawler S, 1997, FEBS LETT, V414, P153, DOI 10.1016/S0014-5793(97)00990-3; Lawler S, 1998, CURR BIOL, V8, P1387, DOI 10.1016/S0960-9822(98)00019-0; Lisnock J, 2000, BIOCHEMISTRY-US, V39, P3141, DOI 10.1021/bi992410+; Lu XH, 1997, J BIOL CHEM, V272, P24751, DOI 10.1074/jbc.272.40.24751; Meriin AB, 1999, MOL CELL BIOL, V19, P2547; Moriguchi T, 1997, EMBO J, V16, P7045, DOI 10.1093/emboj/16.23.7045; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; Nishina H, 1997, J EXP MED, V186, P941, DOI 10.1084/jem.186.6.941; Nishina H, 1999, DEVELOPMENT, V126, P505; Tournier C, 1999, MOL CELL BIOL, V19, P1569; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; Wu ZG, 1997, MOL CELL BIOL, V17, P7407, DOI 10.1128/MCB.17.12.7407; Yamauchi J, 1999, J BIOL CHEM, V274, P1957, DOI 10.1074/jbc.274.4.1957; Yang D, 1997, P NATL ACAD SCI USA, V94, P3004, DOI 10.1073/pnas.94.7.3004; Yao ZB, 1997, J BIOL CHEM, V272, P32378, DOI 10.1074/jbc.272.51.32378	20	56	56	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					30892	30897		10.1074/jbc.M011780200	http://dx.doi.org/10.1074/jbc.M011780200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11418587	hybrid			2022-12-25	WOS:000170472900042
J	Umata, T; Hirata, M; Takahashi, T; Ryu, F; Shida, S; Takahashi, Y; Tsuneoka, M; Miura, Y; Masuda, M; Horiguchi, Y; Mekada, E				Umata, T; Hirata, M; Takahashi, T; Ryu, F; Shida, S; Takahashi, Y; Tsuneoka, M; Miura, Y; Masuda, M; Horiguchi, Y; Mekada, E			A dual signaling cascade that regulates the ectodomain shedding of heparin-binding epidermal growth factor-like growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; DIPHTHERIA-TOXIN RECEPTOR; EGF RECEPTOR; MEMBRANE-PROTEIN; TYROSINE KINASE; CELL-ADHESION; RHO FAMILY; PKC-DELTA; ACTIVATION; CLEAVAGE	Ectodomain shedding is an important mechanism to regulate the biological activities of membrane proteins. We focus here on the signaling mechanism of the ectodomain shedding of heparin-binding epidermal growth factor (EGF)-like growth factor (pro HB-EGF). Lysophosphatidic acid (LPA), a ligand for seven-transmembrane G protein-coupled receptors, stimulates the shedding of pro HB-EGF, which constitutes a G protein-coupled receptor-mediated transactivation of the EGF receptor. Experiments using a series of inhibitors and overexpression of mutant forms of signaling molecules revealed that the Ras-Raf-MEK signal is essential for the LPA-induced shedding. In addition, the small GTPase Rac is involved in the LPA-induced shedding, possibly to promote MEK activation. 12-O-Tetradecanoylphorbol-13-acetate is another potent inducer of pro HB-EGF shedding. We also demonstrate that the LPA-induced pathway is distinct from the 12-O-tetradecanoylphorbol-13-acetate-induced pathway and that these pathways constitute a dual signaling cascade that regulates the shedding of pro HB-EGF.	Kurume Univ, Inst Life Sci, Kurume, Fukuoka 8390861, Japan; Osaka Univ, Res Inst Microbial Dis, Dept Cell Biol, Suita, Osaka 5650871, Japan; Osaka Univ, Res Inst Microbial Dis, Dept Bacterial Toxinol, Suita, Osaka 5650871, Japan	Kurume University; Osaka University; Osaka University	Mekada, E (corresponding author), Kurume Univ, Inst Life Sci, Kurume, Fukuoka 8390861, Japan.		Miura, Yoshiki/U-8875-2019	Miura, Yoshiki/0000-0002-7596-0482; Mekada, Eisuke/0000-0001-8858-4781				Aicher B, 1997, J CELL BIOL, V138, P681, DOI 10.1083/jcb.138.3.681; Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Besser D, 1995, ONCOGENE, V11, P2383; Blobel CP, 1997, CELL, V90, P589, DOI 10.1016/S0092-8674(00)80519-X; Burstein ES, 1998, ONCOGENE, V17, P1617, DOI 10.1038/sj.onc.1202067; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; Eguchi S, 1998, J BIOL CHEM, V273, P8890, DOI 10.1074/jbc.273.15.8890; Eguchi S, 2001, J BIOL CHEM, V276, P7957, DOI 10.1074/jbc.M008570200; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; Fan HZ, 1999, EMBO J, V18, P6962, DOI 10.1093/emboj/18.24.6962; Feehan C, 1996, J BIOL CHEM, V271, P7019, DOI 10.1074/jbc.271.12.7019; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; Foschi M, 1997, EMBO J, V16, P6439, DOI 10.1093/emboj/16.21.6439; Fukata M, 1999, J BIOL CHEM, V274, P26044, DOI 10.1074/jbc.274.37.26044; Gechtman Z, 1999, J BIOL CHEM, V274, P28828, DOI 10.1074/jbc.274.40.28828; GOISHI K, 1995, MOL BIOL CELL, V6, P967, DOI 10.1091/mbc.6.8.967; Golembo M, 1996, DEVELOPMENT, V122, P3363; Hackel PO, 1999, CURR OPIN CELL BIOL, V11, P184, DOI 10.1016/S0955-0674(99)80024-6; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HIGASHIYAMA S, 1995, J CELL BIOL, V128, P929, DOI 10.1083/jcb.128.5.929; HIRAI S, 1994, EMBO J, V13, P2331, DOI 10.1002/j.1460-2075.1994.tb06517.x; Hirata M, 2001, BIOCHEM BIOPH RES CO, V283, P915, DOI 10.1006/bbrc.2001.4879; IWAMOTO R, 1994, EMBO J, V13, P2322, DOI 10.1002/j.1460-2075.1994.tb06516.x; Iwamoto R, 1999, J BIOL CHEM, V274, P25906, DOI 10.1074/jbc.274.36.25906; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; Kawano Y, 2000, J BIOL CHEM, V275, P29628, DOI 10.1074/jbc.M002440200; Kjoller L, 1999, EXP CELL RES, V253, P166, DOI 10.1006/excr.1999.4674; Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; Masuda M, 2000, EMBO J, V19, P521, DOI 10.1093/emboj/19.4.521; Moolenaar WH, 1999, EXP CELL RES, V253, P230, DOI 10.1006/excr.1999.4702; NAKAMURA K, 1995, J CELL BIOL, V129, P1691, DOI 10.1083/jcb.129.6.1691; OGOROCHI T, 1989, BIOCHEM BIOPH RES CO, V163, P1175, DOI 10.1016/0006-291X(89)92344-9; OHASHI Y, 1987, J BIOL CHEM, V262, P1430; OHNO S, 1994, J BIOL CHEM, V269, P17495; PANDIELLA A, 1991, P NATL ACAD SCI USA, V88, P1726, DOI 10.1073/pnas.88.5.1726; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; ROSEJOHN S, 1994, BIOCHEM J, V300, P281, DOI 10.1042/bj3000281; Roudabush FL, 2000, J BIOL CHEM, V275, P22583, DOI 10.1074/jbc.M002915200; Royal I, 2000, MOL BIOL CELL, V11, P1709, DOI 10.1091/mbc.11.5.1709; Subramanian SV, 1997, J BIOL CHEM, V272, P14713, DOI 10.1074/jbc.272.23.14713; Sugai M, 1999, INFECT IMMUN, V67, P6550; Vecchi M, 1996, J BIOL CHEM, V271, P18989, DOI 10.1074/jbc.271.31.18989; Wasserman JD, 1997, TRENDS CELL BIOL, V7, P431, DOI 10.1016/S0962-8924(97)01143-4; Werb Z, 1998, SCIENCE, V282, P1279, DOI 10.1126/science.282.5392.1279	51	83	86	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30475	30482		10.1074/jbc.M103673200	http://dx.doi.org/10.1074/jbc.M103673200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11402047	hybrid			2022-12-25	WOS:000170558000114
J	Khurana, R; Uversky, VN; Nielsen, L; Fink, AL				Khurana, R; Uversky, VN; Nielsen, L; Fink, AL			Is Congo red an amyloid-specific dye?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-SCATTERING; PARALLEL BETA-HELIX; MOLTEN GLOBULE; CIBACRON BLUE; THIOFLAVINE-T; PROTEIN; BINDING; APOMYOGLOBIN; FIBRILS; INTERMEDIATE	Congo red (CR) binding, monitored by characteristic yellow-green birefringence under crossed polarization has been used as a diagnostic test for the presence of amyloid in tissue sections for several decades. This assay is also widely used for the characterization of in vitro amyloid fibrils, In order to probe the structural specificity of Congo red binding to amyloid fibrils we have used an induced circular dichroism (CD) assay. Amyloid fibrils from insulin and the variable domain of Ig light chain demonstrate induced CD spectra upon binding to Congo red. Surprisingly, the native conformations of insulin and Ig light chain also induced Congo red circular dichroism, but with different spectral shapes than those from fibrils, In fact, a wide variety of native proteins exhibited induced CR circular dichroism indicating that CR bound to representative proteins from different classes of secondary structure such as alpha (citrate synthase), alpha + beta (lysozyme), beta (concavaIin A), and parallel beta -helical proteins (pectate lyase), Partially folded intermediates of apomyoglobin induced different Congo red CD bands than the corresponding native conformation, however, no induced CD bands were observed with unfolded protein. Congo red was also found to induce oligomerization of native proteins, as demonstrated by covalent cross-linking and small angle x-ray scattering. Our data suggest that Congo red is sandwiched between two protein molecules causing protein oligomerization, The fact that Congo red binds to native, partially folded conformations and amyloid fibrils of several proteins shows that it must be used with caution as a diagnostic test for the presence of amyloid fibrils in vitro.	Univ Calif Santa Cruz, Dept Chem & Biochem, Santa Cruz, CA 95064 USA	University of California System; University of California Santa Cruz	Fink, AL (corresponding author), Univ Calif Santa Cruz, Dept Chem & Biochem, Santa Cruz, CA 95064 USA.		Uversky, Vladimir N./F-4515-2011	Uversky, Vladimir N./0000-0002-4037-5857				Ashburn TT, 1996, CHEM BIOL, V3, P351, DOI 10.1016/S1074-5521(96)90118-0; ATTWOOD TK, 1990, LIQ CRYST, V7, P657, DOI 10.1080/02678299008036749; BARRICK D, 1993, BIOCHEMISTRY-US, V32, P3790, DOI 10.1021/bi00065a035; BENDITT EP, 1970, P NATL ACAD SCI USA, V66, P1044, DOI 10.1073/pnas.66.4.1044; BENHOLD H, 1922, MUENCHEN MED WOCHENS, V69, P1537; CAUGHEY B, 1994, J VIROL, V68, P2135, DOI 10.1128/JVI.68.4.2135-2141.1994; CAUGHEY B, 1993, J VIROL, V67, P6270, DOI 10.1128/JVI.67.10.6270-6272.1993; Cotton A.A., 1896, ANN CHIM PHYS, V8, P347; Demaimay R, 1998, J NEUROCHEM, V71, P2534; DIVRY PAUL, 1927, JOUR NEUROL ET PSYCHIATR, V27, P643; DONIACH S, 1995, J MOL BIOL, V254, P960, DOI 10.1006/jmbi.1995.0668; EDWARDS RA, 1979, BIOCHEMISTRY-US, V18, P5197, DOI 10.1021/bi00590a026; EDWARDS RA, 1977, BIOCHEM BIOPH RES CO, V79, P470, DOI 10.1016/0006-291X(77)90181-4; ELGHETANY MT, 1988, STAIN TECHNOL, V63, P201, DOI 10.3109/10520298809107185; ELIEZER D, 1993, BIOPHYS J, V65, P912, DOI 10.1016/S0006-3495(93)81124-X; GAST K, 1994, EUR BIOPHYS J BIOPHY, V23, P297, DOI 10.1007/BF00213579; Glatter O., 1982, SMALL ANGLE X RAY SC; GLENNER GG, 1972, J HISTOCHEM CYTOCHEM, V20, P821, DOI 10.1177/20.10.821; GOTO Y, 1990, J MOL BIOL, V214, P803, DOI 10.1016/0022-2836(90)90334-I; GRIKO YV, 1988, J MOL BIOL, V202, P127, DOI 10.1016/0022-2836(88)90525-6; Heegaard NHH, 2000, J CHROMATOGR A, V894, P319, DOI 10.1016/S0021-9673(00)00579-3; Inouye H, 2000, AMYLOID, V7, P179, DOI 10.3109/13506120009146832; KAGAN HM, 1973, BIOCHIM BIOPHYS ACTA, V322, P258, DOI 10.1016/0005-2795(73)90302-4; KATAOKA M, 1993, J MOL BIOL, V229, P591, DOI 10.1006/jmbi.1993.1064; Khurana R, 2000, BIOPHYS J, V78, P994, DOI 10.1016/S0006-3495(00)76657-4; KLUNK WE, 1989, J HISTOCHEM CYTOCHEM, V37, P1273, DOI 10.1177/37.8.2666510; KLUNK WE, 1989, J HISTOCHEM CYTOCHEM, V37, P1293, DOI 10.1177/37.8.2666512; Kuciel R, 1997, ACTA BIOCHIM POL, V44, P645, DOI 10.18388/abp.1997_4367; KUMOSINSKI TF, 1985, METHOD ENZYMOL, V117, P154; LEVINE H, 1993, PROTEIN SCI, V2, P404, DOI 10.1002/pro.5560020312; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; LUZATTI V, 1961, J MOL BIOL, V3, P367; NAIKI H, 1989, ANAL BIOCHEM, V177, P244, DOI 10.1016/0003-2697(89)90046-8; Piekarska B, 1999, ACTA BIOCHIM POL, V46, P841, DOI 10.18388/abp.1999_4105; PUCHTLER H, 1962, J HISTOCHEM CYTOCHEM, V10, P355, DOI 10.1177/10.3.355; RAETZ CRH, 1995, SCIENCE, V270, P997, DOI 10.1126/science.270.5238.997; Roterman I, 1998, COMPUT CHEM, V22, P61, DOI 10.1016/S0097-8485(97)00014-4; Semisotnov GV, 1996, J MOL BIOL, V262, P559, DOI 10.1006/jmbi.1996.0535; Shi L, 1996, BIOCHEMISTRY-US, V35, P3297, DOI 10.1021/bi951984l; STEINBACHER S, 1994, SCIENCE, V265, P383, DOI 10.1126/science.8023158; STEVENS PW, 1995, PROTEIN SCI, V4, P421; Stopa B, 1998, BIOCHIMIE, V80, P963, DOI 10.1016/S0300-9084(99)80001-7; Stopa B, 1997, BIOCHIMIE, V79, P23, DOI 10.1016/S0300-9084(97)87621-3; STRYER LUBERT, 1965, J MOL BIOL, V13, P482; TAKASHI R, 1977, P NATL ACAD SCI USA, V74, P2334, DOI 10.1073/pnas.74.6.2334; Tanford C, 1968, Adv Protein Chem, V23, P121, DOI 10.1016/S0065-3233(08)60401-5; TAYLOR DL, 1974, J HISTOCHEM CYTOCHEM, V22, P1105, DOI 10.1177/22.12.1105; TURNELL WG, 1992, J MOL BIOL, V227, P1205, DOI 10.1016/0022-2836(92)90532-O; UVERSKY VN, 1993, BIOCHEMISTRY-US, V32, P13288, DOI 10.1021/bi00211a042; Westermark GT, 1999, METHOD ENZYMOL, V309, P3; WOODY AYM, 1981, BIOCHIM BIOPHYS ACTA, V655, P82, DOI 10.1016/0005-2787(81)90069-1; YODER MD, 1993, SCIENCE, V260, P1503, DOI 10.1126/science.8502994	53	244	252	1	49	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22715	22721		10.1074/jbc.M011499200	http://dx.doi.org/10.1074/jbc.M011499200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11410601	hybrid			2022-12-25	WOS:000169412700099
J	Jopling, CL; Willis, AE				Jopling, CL; Willis, AE			N-myc translation is initiated via an internal ribosome entry segment that displays enhanced activity in neuronal cells	ONCOGENE			English	Article						N-myc; translation initiation; IRES; neuronal	FACTOR MESSENGER-RNA; HUMAN NEUROBLASTOMA-CELLS; C-MYC; ALTERNATIVE TRANSLATION; MURINE DEVELOPMENT; RETINOIC ACID; SITE; EXPRESSION; GROWTH; PROTEIN	Eukaryotic translation can be initiated either by a cap-dependent mechanism or by internal ribosome entry, a process by which ribosomes are directly recruited to structured regions of mRNA upstream of the initiation codon, We analysed the 5' untranslated region (UTR) of the proto-oncogene N-myc, and demonstrated by transfections in a dicistronic vector system that it contains a potent internal ribosome entry segment (IRES), The IRES is similar in length to the c-myc [RES and the activities of these IRESs are comparable in non-neuronal cells. Transfections were also carried out in cell lines derived from neuroblastomas, in which N-myc is expressed, and in a neuronal precursor cell line. In these cells the N-myc IRES is up to seven times more active than that of c-myc, suggesting that neuronal-specific non-canonical trans-acting factors are used by the N-myc but not the c-myc IRES, N-myc expression is increased by gene amplification in many neuroblastomas, but this is the first example of a translational mechanism by which N-myc expression could be further increased. The discovery of an IRES that displays enhanced activity in neuronal cell lines has important potential as a tool for protein expression in neural tissue.	Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England	University of Leicester	Willis, AE (corresponding author), Univ Leicester, Dept Biochem, Univ Rd, Leicester LE1 7RH, Leics, England.			Jopling, Catherine/0000-0001-6046-1456; Willis, Anne/0000-0002-1470-8531				Akiri G, 1998, ONCOGENE, V17, P227, DOI 10.1038/sj.onc.1202019; Bernstein J, 1997, J BIOL CHEM, V272, P9356; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; Chagnovich D, 1996, J BIOL CHEM, V271, P33580, DOI 10.1074/jbc.271.52.33580; Coldwell MJ, 2000, ONCOGENE, V19, P899, DOI 10.1038/sj.onc.1203407; Cornelis S, 2000, MOL CELL, V5, P597, DOI 10.1016/S1097-2765(00)80239-7; Creancier L, 2000, J CELL BIOL, V150, P275, DOI 10.1083/jcb.150.1.275; Dang CV, 1999, MOL CELL BIOL, V19, P1; Derrington EA, 1999, HUM GENE THER, V10, P1129, DOI 10.1089/10430349950018120; Henis-Korenblit S, 2000, MOL CELL BIOL, V20, P496, DOI 10.1128/MCB.20.2.496-506.2000; Holcik M, 1999, NAT CELL BIOL, V1, P190, DOI 10.1038/11109; Huez I, 1998, MOL CELL BIOL, V18, P6178, DOI 10.1128/MCB.18.11.6178; IBSON JM, 1988, ONCOGENE, V2, P399; Jackson RJ, 1995, CURR TOP MICROBIOL, V203, P1; KATOH K, 1988, NUCLEIC ACIDS RES, V16, P3589, DOI 10.1093/nar/16.8.3589; KOHL NE, 1986, NATURE, V319, P73, DOI 10.1038/319073a0; Lutz W, 1998, ONCOGENE, V17, P339, DOI 10.1038/sj.onc.1200201; Lutz W, 1996, ONCOGENE, V13, P803; Malynn BA, 2000, GENE DEV, V14, P1390; Miller DL, 1998, FEBS LETT, V434, P417, DOI 10.1016/S0014-5793(98)01025-4; Nanbru C, 1997, J BIOL CHEM, V272, P32061, DOI 10.1074/jbc.272.51.32061; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Pilipenko EV, 2000, GENE DEV, V14, P2028; Pozner A, 2000, MOL CELL BIOL, V20, P2297, DOI 10.1128/MCB.20.7.2297-2307.2000; Pyronnet S, 2000, MOL CELL, V5, P607, DOI 10.1016/S1097-2765(00)80240-3; SAITO H, 1983, P NATL ACAD SCI-BIOL, V80, P7476, DOI 10.1073/pnas.80.24.7476; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SHEA TB, 1994, NEUROREPORT, V5, P797, DOI 10.1097/00001756-199403000-00015; Sivak LE, 1999, MOL CELL BIOL, V19, P155; STANTON BR, 1992, GENE DEV, V6, P2235, DOI 10.1101/gad.6.12a.2235; Stein I, 1998, MOL CELL BIOL, V18, P3112, DOI 10.1128/MCB.18.6.3112; Stoneley M, 2000, MOL CELL BIOL, V20, P1162, DOI 10.1128/MCB.20.4.1162-1169.2000; Stoneley M, 2000, NUCLEIC ACIDS RES, V28, P687, DOI 10.1093/nar/28.3.687; Stoneley M, 1998, ONCOGENE, V16, P423, DOI 10.1038/sj.onc.1201763; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; SUGIYAMA A, 1991, ONCOGENE, V6, P2027; THIELE CJ, 1985, NATURE, V313, P404, DOI 10.1038/313404a0; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	40	56	57	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 10	2001	20	21					2664	2670		10.1038/sj.onc.1204404	http://dx.doi.org/10.1038/sj.onc.1204404			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	431VN	11420678				2022-12-25	WOS:000168652600007
J	Demoor-Fossard, M; Galera, P; Santra, M; Iozzo, RV; Pujol, JP; Redini, F				Demoor-Fossard, M; Galera, P; Santra, M; Iozzo, RV; Pujol, JP; Redini, F			A composite element binding the vitamin D receptor and the retinoic X receptor alpha mediates the transforming growth factor-beta inhibition of decorin gene expression in articular chondrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN OSTEOARTHRITIC CARTILAGE; MESSENGER-RNA LEVELS; PHENOTYPIC MODULATION; PROTEOGLYCAN DECORIN; HUMAN-FIBROBLASTS; MAMMALIAN-CELLS; DOWN-REGULATION; ALGINATE BEADS; PROTEIN CORE; FACTOR-A	Decorin, a small leucine-rich proteoglycan may play an important role in the attempt of cartilage repair initiated by chondrocytes in early stages of osteoarthritis, through its ability to bind collagen fibrils and growth factors such as transforming growth factor-beta (TGF-beta). We previously demonstrated that TGF-beta decreased decorin mRNA steady state levels in articular chondrocytes (Demoor, M., Redini, F., Boittin, M., and Pujol, J.-P. (1998) Biochim. Biophys. Acta 1398, 179-191). Here, we investigated the effect of TGF-beta on decorin gene expression in both primary cultures of articular chondrocytes and chondrocytes dedifferentiated by serial passages. Transient transfection of cells with plasmid constructs of the decorin promoter linked to the luciferase reporter gene revealed transcriptional repression by TGF-beta, in fully differentiated as well as dedifferentiated chondrocytes. Experiments with 5'-deleted constructs allowed characterization of a TGF-beta -responsive element in the shortest construct (base pairs (bp) -155/+269). DNase I footprinting analysis delineated a negative TGF-beta -responsive region between -140 and -111 bp in the decorin proximal promoter. Get retardation assays demonstrated that TGF-beta modulates decorin gene expression through transcription factors, the nature and mode of action of which depend on the differentiation state of the chondrocytes; two DNA-protein complexes were formed in the region -1441-127 bp with nuclear extracts from primary chondrocytes, whereas a higher mobility complex was observed in the -127/-111 bp region for dedifferentiated cells. Antibodies against vitamin D and retinoic acid receptors used in supershift experiments showed that these nuclear receptors are involved in the regulation of decorin gene expression in articular chondrocytes.	Fac Med, Lab Biochim Tissu Conjonctif, F-14032 Caen, France; Thomas Jefferson Univ, Jefferson Med Coll, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Jefferson Med Coll, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA	Universite de Caen Normandie; Jefferson University; Jefferson University	Redini, F (corresponding author), Fac Med EE 99 01, Lab Physiopathol Resorpt Ossense, 1 Rue Gaston Veil, F-44035 Nantes 01, France.		REDINI, Francoise/K-7981-2015; Iozzo, Renato/AAS-1980-2020	Iozzo, Renato/0000-0002-5908-5112	NATIONAL CANCER INSTITUTE [R01CA039481] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA-39481] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAM F, 1999, ENDOCRINOLOGY, V140, P63; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ARCHER CW, 1990, J CELL SCI, V97, P361; BENYA PD, 1977, BIOCHEMISTRY-US, V16, P865, DOI 10.1021/bi00624a009; BENYA PD, 1978, CELL, V15, P1313, DOI 10.1016/0092-8674(78)90056-9; BONAVENTURE J, 1994, EXP CELL RES, V212, P97, DOI 10.1006/excr.1994.1123; BRUCKNER P, 1994, MICROSC RES TECHNIQ, V28, P378, DOI 10.1002/jemt.1070280504; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Csordas G, 2000, J BIOL CHEM, V275, P32879, DOI 10.1074/jbc.M005609200; CsSzabo G, 1997, ARTHRITIS RHEUM, V40, P1037, DOI 10.1002/art.1780400607; CSSZABO G, 1995, ARTHRITIS RHEUM, V38, P660, DOI 10.1002/art.1780380514; DANIELSON KG, 1993, GENOMICS, V15, P146, DOI 10.1006/geno.1993.1022; DELRIOTSONIS K, 1994, BIOCHEM BIOPH RES CO, V204, P975, DOI 10.1006/bbrc.1994.2556; DEMAY MB, 1990, P NATL ACAD SCI USA, V87, P369, DOI 10.1073/pnas.87.1.369; Demoor-Fossard M, 1998, BBA-GENE STRUCT EXPR, V1398, P179, DOI 10.1016/S0167-4781(98)00044-X; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EDWARDS DR, 1987, EMBO J, V6, P1899, DOI 10.1002/j.1460-2075.1987.tb02449.x; EIKENBERRY EF, 1992, ARTICULAR CARTILAGE AND OSTEOARTHRITIS, P133; ELLINGSWORTH LR, 1986, J BIOL CHEM, V261, P2362; FRAZER A, 1991, BIOCHEM BIOPH RES CO, V180, P602, DOI 10.1016/S0006-291X(05)81108-8; GALERA P, 1992, EXP CELL RES, V200, P379, DOI 10.1016/0014-4827(92)90186-C; Gallagher JT, 1989, CURR OPIN CELL BIOL, V1, P1201, DOI 10.1016/S0955-0674(89)80072-9; GLOSSL J, 1983, BIOCHEM J, V215, P295; GOLDWASSER M, 1982, CLIN ORTHOP RELAT R, P296; Hagg R, 1998, J CELL BIOL, V142, P285, DOI 10.1083/jcb.142.1.285; HAUSELMANN HJ, 1994, J CELL SCI, V107, P17; Haussler MR, 1998, J BONE MINER RES, V13, P325, DOI 10.1359/jbmr.1998.13.3.325; HILDEBRAND A, 1994, BIOCHEM J, V302, P527, DOI 10.1042/bj3020527; IOZZO RV, 1993, EXPERIENTIA, V49, P447, DOI 10.1007/BF01923588; Iozzo RV, 1999, PROG NUCLEIC ACID RE, V62, P19; Iozzo RV, 1999, J BIOL CHEM, V274, P18843, DOI 10.1074/jbc.274.27.18843; Iozzo RV, 1999, J BIOL CHEM, V274, P4489, DOI 10.1074/jbc.274.8.4489; Iozzo RV, 1996, FASEB J, V10, P598, DOI 10.1096/fasebj.10.5.8621059; KAHARI VM, 1991, J BIOL CHEM, V266, P10608; KERNER SA, 1989, P NATL ACAD SCI USA, V86, P4455, DOI 10.1073/pnas.86.12.4455; KRESSE H, 1993, EXPERIENTIA, V49, P403, DOI 10.1007/BF01923585; KUETTNER KE, 1982, J CELL BIOL, V93, P751, DOI 10.1083/jcb.93.3.751; LIU JM, 1991, VIROLOGY, V182, P361, DOI 10.1016/0042-6822(91)90682-2; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Malemud C J, 1994, Osteoarthritis Cartilage, V2, P29, DOI 10.1016/S1063-4584(05)80004-4; Mauviel A, 1996, J BIOL CHEM, V271, P24824, DOI 10.1074/jbc.271.40.24824; MAUVIEL A, 1995, J BIOL CHEM, V270, P11692, DOI 10.1074/jbc.270.19.11692; Maxam A M, 1980, Methods Enzymol, V65, P499; MEIJER D, 1990, NUCLEIC ACIDS RES, V18, P7357, DOI 10.1093/nar/18.24.7357; NIMNI M, 1973, SCIENCE, V181, P751, DOI 10.1126/science.181.4101.751; Pedrozo HA, 1999, CALCIFIED TISSUE INT, V64, P50, DOI 10.1007/s002239900578; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; RASCLE A, 1994, ONCOGENE, V9, P2853; REDINI F, 1988, FEBS LETT, V234, P172, DOI 10.1016/0014-5793(88)81327-9; REGINATO AM, 1994, ARTHRITIS RHEUM, V37, P1338, DOI 10.1002/art.1780370912; ROUGHLEY PJ, 1993, BIOCHEM J, V295, P421, DOI 10.1042/bj2950421; SANTRA M, 1994, J BIOL CHEM, V269, P579; Santra M, 1997, J CLIN INVEST, V100, P149, DOI 10.1172/JCI119507; SANTRA M, 1995, P NATL ACAD SCI USA, V92, P7016, DOI 10.1073/pnas.92.15.7016; Santra M, 2000, J BIOL CHEM, V275, P35153, DOI 10.1074/jbc.M006821200; SCHMIDT G, 1987, J CELL BIOL, V104, P1683, DOI 10.1083/jcb.104.6.1683; SCHOLZEN T, 1994, J BIOL CHEM, V269, P28270; SCOTT JE, 1992, FASEB J, V6, P2639, DOI 10.1096/fasebj.6.9.1612287; SEYEDIN SM, 1986, J BIOL CHEM, V261, P5693; TAKEUCHI Y, 1994, J BIOL CHEM, V269, P32634; vanderKraan PM, 1997, J RHEUMATOL, V24, P543; VONDERMARK K, 1992, ARTHRITIS RHEUM-US, V35, P806, DOI 10.1002/art.1780350715; WINNEMOLLER M, 1992, EUR J CELL BIOL, V59, P47; YAMAGUCHI Y, 1988, NATURE, V336, P244, DOI 10.1038/336244a0; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0; Yanagi Y, 1999, J BIOL CHEM, V274, P12971, DOI 10.1074/jbc.274.19.12971; Yanagisawa J, 1999, SCIENCE, V283, P1317, DOI 10.1126/science.283.5406.1317; Yoshizawa T, 1997, NAT GENET, V16, P391, DOI 10.1038/ng0897-391	68	24	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					36983	36992		10.1074/jbc.M011442200	http://dx.doi.org/10.1074/jbc.M011442200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11406617	hybrid			2022-12-25	WOS:000171375700018
J	Balakrishnan, M; Fay, PJ; Bambara, RA				Balakrishnan, M; Fay, PJ; Bambara, RA			The kissing hairpin sequence promotes recombination within the HIV-I 5 ' leader region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; MURINE LEUKEMIA-VIRUS; STRAND DNA-SYNTHESIS; ROUS-SARCOMA VIRUS; RNASE-H-FUNCTION; REVERSE-TRANSCRIPTASE; RETROVIRAL RECOMBINATION; GENOMIC RNA; GENETIC-RECOMBINATION; NUCLEOCAPSID PROTEIN	The role of RNA-RNA template interactions in facilitating recombination during reverse transcription of minus strand DNA has been examined. The tested hypothesis is that template switching by reverse transcriptase is promoted at sites where homologous regions of two RNAs are brought in close proximity via stable intertemplate interactions. Frequency and distribution of template switching between homologous donor and acceptor RNAs were examined within the human immunodeficiency virus type 1 (HIV-1) 5 ' -untranslated region (UTR) containing the dimer initiation sequence (DIS). Results were compared with control nondimerizing templates from the pol region. The dimerizing UTR templates displayed a 4-fold higher transfer efficiency than the control. A striking 53% of transfers in the UTR mapped near the DIS, of which two-thirds occurred immediately 5 ' to this sequence. In the UTR template, deletion of the DIS hairpin disrupted template dimerization and caused a 4-fold drop in transfer efficiency. Insertion of the DIS within the pol template increased both dimerization and transfer efficiency. Transfer distributions revealed that in both sets of templates, DIS-induced dimerization increased the efficiency of transfers across the whole template, with the transfers peaking around the dimerization site. Overall, these results suggest that template dimerization facilitated by the unique geometry of the DIS-promoted kissing interactions effectively promotes recombination within the HIV-1 5 ' -UTR.	Univ Rochester, Med Ctr, Dept Biochem & Biophys, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Ctr Canc, Rochester, NY 14642 USA	University of Rochester; University of Rochester	Bambara, RA (corresponding author), Univ Rochester, Med Ctr, Dept Biochem & Biophys, Box 712,601 Elmwood Ave, Rochester, NY 14642 USA.				NIGMS NIH HHS [GM 49573] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049573] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson JA, 1998, J VIROL, V72, P1186, DOI 10.1128/JVI.72.2.1186-1194.1998; AWANG G, 1993, BIOCHEMISTRY-US, V32, P11453, DOI 10.1021/bi00093a024; BAUDIN F, 1993, J MOL BIOL, V229, P382, DOI 10.1006/jmbi.1993.1041; Berkhout B, 1996, PROG NUCLEIC ACID RE, V54, P1, DOI 10.1016/S0079-6603(08)60359-1; Berkhout B, 1996, J VIROL, V70, P6723, DOI 10.1128/JVI.70.10.6723-6732.1996; Berkhout B, 2000, RNA, V6, P282, DOI 10.1017/S1355838200991684; BIETH E, 1990, NUCLEIC ACIDS RES, V18, P119, DOI 10.1093/nar/18.1.119; BLAIR DG, 1977, VIROLOGY, V77, P534, DOI 10.1016/0042-6822(77)90479-2; BURNS DPW, 1994, J VIROL, V68, P4196, DOI 10.1128/JVI.68.7.4196-4203.1994; CLAVEL F, 1989, J VIROL, V63, P1455, DOI 10.1128/JVI.63.3.1455-1459.1989; Clever JL, 1996, J VIROL, V70, P5902, DOI 10.1128/JVI.70.9.5902-5908.1996; COFFIN J, 1996, AIDS S, V10, P75; COFFIN JM, 1979, J GEN VIROL, V42, P1, DOI 10.1099/0022-1317-42-1-1; COLICELLI J, 1987, VIROLOGY, V160, P518, DOI 10.1016/0042-6822(87)90030-4; DARLIX JL, 1990, J MOL BIOL, V216, P689, DOI 10.1016/0022-2836(90)90392-Y; DEROCQUIGNY H, 1992, P NATL ACAD SCI USA, V89, P6472, DOI 10.1073/pnas.89.14.6472; DESTEFANO JJ, 1994, J BIOL CHEM, V269, P161; DESTEFANO JJ, 1992, J VIROL, V66, P6370, DOI 10.1128/JVI.66.11.6370-6378.1992; DeStefano JJ, 1997, ARCH VIROL, V142, P1797, DOI 10.1007/s007050050198; DESTEFANO JJ, 1994, BBA-GENE STRUCT EXPR, V1219, P380, DOI 10.1016/0167-4781(94)90062-0; Diaz L, 1996, NUCLEIC ACIDS RES, V24, P3086, DOI 10.1093/nar/24.15.3086; DIAZ RS, 1995, J VIROL, V69, P3273, DOI 10.1128/JVI.69.6.3273-3281.1995; DIFRONZO NL, 1993, J VIROL, V67, P3763, DOI 10.1128/JVI.67.7.3763-3770.1993; Feng YX, 1996, P NATL ACAD SCI USA, V93, P7577, DOI 10.1073/pnas.93.15.7577; FU W, 1994, J VIROL, V68, P5013, DOI 10.1128/JVI.68.8.5013-5018.1994; FU W, 1993, J VIROL, V67, P5443, DOI 10.1128/JVI.67.9.5443-5449.1993; GILBOA E, 1979, CELL, V18, P93, DOI 10.1016/0092-8674(79)90357-X; GIRARD PM, 1995, BIOCHEMISTRY-US, V34, P9785, DOI 10.1021/bi00030a016; GOODENOW M, 1989, J ACQ IMMUN DEF SYND, V2, P344; GOODRICH DW, 1990, P NATL ACAD SCI USA, V87, P2052, DOI 10.1073/pnas.87.6.2052; GU ZX, 1995, ANTIMICROB AGENTS CH, V39, P1888, DOI 10.1128/AAC.39.8.1888; Harrison GP, 1998, NUCLEIC ACIDS RES, V26, P3433, DOI 10.1093/nar/26.14.3433; HU WS, 1992, J VIROL, V66, P4457, DOI 10.1128/JVI.66.7.4457-4463.1992; HU WS, 1990, SCIENCE, V250, P1227, DOI 10.1126/science.1700865; Hunter E, 1978, Curr Top Microbiol Immunol, V79, P295; JAEGER JA, 1989, P NATL ACAD SCI USA, V86, P7706, DOI 10.1073/pnas.86.20.7706; Jetzt AE, 2000, J VIROL, V74, P1234, DOI 10.1128/JVI.74.3.1234-1240.2000; KAWAI S, 1972, VIROLOGY, V49, P37, DOI 10.1016/S0042-6822(72)80005-9; KELLAM P, 1995, J VIROL, V69, P669, DOI 10.1128/JVI.69.2.669-674.1995; Kim JK, 1997, J BIOL CHEM, V272, P16769, DOI 10.1074/jbc.272.27.16769; LAUGHREA M, 1994, BIOCHEMISTRY-US, V33, P13464, DOI 10.1021/bi00249a035; LINIAL M, 1979, J VIROL, V31, P257, DOI 10.1128/JVI.31.1.257-260.1979; Lund AH, 1999, J VIROL, V73, P9614, DOI 10.1128/JVI.73.11.9614-9618.1999; LUO G, 1990, J VIROL, V64, P4321, DOI 10.1128/JVI.64.9.4321-4328.1990; Mikkelsen JG, 1998, J VIROL, V72, P6967, DOI 10.1128/JVI.72.9.6967-6978.1998; Mikkelsen JG, 1996, J VIROL, V70, P1439, DOI 10.1128/JVI.70.3.1439-1447.1996; Mikkelsen JG, 2000, J VIROL, V74, P600, DOI 10.1128/JVI.74.2.600-610.2000; Mujeeb A, 1998, NAT STRUCT BIOL, V5, P432, DOI 10.1038/nsb0698-432; MURIAUX D, 1995, J BIOL CHEM, V270, P8209, DOI 10.1074/jbc.270.14.8209; Negroni M, 2001, NAT REV MOL CELL BIO, V2, P151, DOI 10.1038/35052098; PAILLART JC, 1994, J BIOL CHEM, V269, P27486; Paillart JC, 1996, J VIROL, V70, P8348, DOI 10.1128/JVI.70.12.8348-8354.1996; Palaniappan C, 1996, J BIOL CHEM, V271, P22331, DOI 10.1074/jbc.271.37.22331; PANGANIBAN AT, 1988, SCIENCE, V241, P1064, DOI 10.1126/science.2457948; PATHAK VK, 1990, P NATL ACAD SCI USA, V87, P6019, DOI 10.1073/pnas.87.16.6019; PELISKA JA, 1992, SCIENCE, V258, P1112, DOI 10.1126/science.1279806; REIN A, 1994, J VIROL, V68, P6124, DOI 10.1128/JVI.68.9.6124-6129.1994; ROBERTSON DL, 1995, NATURE, V374, P124, DOI 10.1038/374124b0; Salminen MO, 1997, J VIROL, V71, P2647, DOI 10.1128/JVI.71.4.2647-2655.1997; SCHATZ O, 1989, FEBS LETT, V257, P311, DOI 10.1016/0014-5793(89)81559-5; SCHWARTZBERG P, 1985, J VIROL, V53, P719, DOI 10.1128/JVI.53.3.719-726.1985; SKALKA AM, 1982, J CELL BIOCHEM, V19, P293, DOI 10.1002/jcb.240190311; SKRIPKIN E, 1994, P NATL ACAD SCI USA, V91, P4945, DOI 10.1073/pnas.91.11.4945; STUHLMANN H, 1992, J VIROL, V66, P2378, DOI 10.1128/JVI.66.4.2378-2388.1992; Suo ZC, 1997, BIOCHEMISTRY-US, V36, P14778, DOI 10.1021/bi971963m; TANESE N, 1991, J VIROL, V65, P4387, DOI 10.1128/JVI.65.8.4387-4397.1991; VOGT PK, 1971, VIROLOGY, V46, P947, DOI 10.1016/0042-6822(71)90093-6; WAINHOBSON S, 1992, CURR TOP MICROBIOL, V176, P181; WEISS RA, 1973, VIROLOGY, V52, P535, DOI 10.1016/0042-6822(73)90349-8; Wooley DP, 1998, VIROLOGY, V243, P229, DOI 10.1006/viro.1998.9052; WU WM, 1995, J BIOL CHEM, V270, P325, DOI 10.1074/jbc.270.1.263; XU H, 1987, P NATL ACAD SCI USA, V84, P8553, DOI 10.1073/pnas.84.23.8553; Yu H, 1998, J BIOL CHEM, V273, P28384, DOI 10.1074/jbc.273.43.28384; Zhang JY, 2000, J VIROL, V74, P2313, DOI 10.1128/JVI.74.5.2313-2322.2000	74	70	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36482	36492		10.1074/jbc.M102860200	http://dx.doi.org/10.1074/jbc.M102860200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11432862	hybrid			2022-12-25	WOS:000171194500059
J	Allegrin, S; Sealoni, A; Ferrara, L; Pesi, R; Pinna, P; Sgarrella, F; Camici, M; Eriksson, S; Tozzi, MG				Allegrin, S; Sealoni, A; Ferrara, L; Pesi, R; Pinna, P; Sgarrella, F; Camici, M; Eriksson, S; Tozzi, MG			Bovine cytosolic 5 '-nucleotidase acts through the formation of an aspartate 52-phosphoenzyme intermediate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROCYTE PYRIMIDINE 5'-NUCLEOTIDASE; WOODWARDS-REAGENT-K; ESCHERICHIA-COLI; NUCLEOSIDE PHOSPHOTRANSFERASE; CLONING; CELLS; EXPRESSION; DEFICIENCY; MECHANISM; HISTIDINE	Cytosolic; 5'-nucleotidase/phosphotransferase (cN-II), specific for purine monophosphates and their deoxyderivatives, acts through the formation of a phosphoenzyme intermediate. Phosphate may either be released leading to 5'-mononucleotide hydrolysis or be transferred to an appropriate nucleoside acceptor, giving rise to a mononucleotide interconversion. Chemical reagents specifically modifying aspartate and glutamate residues inhibit the enzyme, and this inhibition is partially prevented by cN-II substrates and physiological inhibitors. Peptide mapping experiments with the phosphoenzyme previously treated with tritiated borohydride allowed isolation of a radiolabeled peptide. Sequence analysis demonstrated that radioactivity was associated with a hydroxymethyl derivative that resulted from reduction of the Asp-52-phosphate intermediate. Site-directed mutagenesis experiments confirmed the essential role of Asp-52 in the catalytic machinery of the enzyme and suggested also that Asp-54 assists in the formation of the acyl phosphate species. From sequence alignments we conclude that cytosolic 5'-nucleotidase, along with other nucleotidases, belong to a large superfamily of hydrolases with different substrate specificities and functional roles.	Univ Sassari, Dipartimento Sci Farmaco, I-07100 Sassari, Italy; Natl Lab Natl Inst Biostruct & Biosyst, Osilo, Sassari, Italy; Inst Ric Adattamento Bouini & Bufali Ambiente Mez, Ctr Serv Spettrometria Massa, I-80147 Naples, Italy; Univ Pisa, Dipartimento Fisiol & Biochim, I-56100 Pisa, Italy; Swedish Univ Agr Sci, Ctr Biomed, Dept Vet Med Chem, S-75123 Uppsala, Sweden	University of Sassari; University of Pisa; Swedish University of Agricultural Sciences	Tozzi, MG (corresponding author), Univ Sassari, Dipartimento Sci Farmaco, Via Muroni 23-A, I-07100 Sassari, Italy.		Tozzi, Maria Grazia/A-6018-2016; Pesi, Rossana/AAQ-3102-2020; Allegrini, Simone/F-9192-2010	Tozzi, Maria Grazia/0000-0002-1075-7096; Allegrini, Simone/0000-0002-7005-654X; Scaloni, Andrea/0000-0001-9362-8515; Pesi, Rossana/0000-0003-4785-7282				Allegrini S, 1997, BIOCHEM J, V328, P483, DOI 10.1042/bj3280483; Amici A, 2000, BLOOD, V96, P1596, DOI 10.1182/blood.V96.4.1596.h8001596_1596_1598; Amici A, 1997, FEBS LETT, V419, P263, DOI 10.1016/S0014-5793(97)01464-6; Aravind L, 1998, TRENDS BIOCHEM SCI, V23, P127, DOI 10.1016/S0968-0004(98)01189-X; Baiocchi C, 1996, BIOCHEM J, V317, P797, DOI 10.1042/bj3170797; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bustos P, 1996, J PROTEIN CHEM, V15, P467, DOI 10.1007/BF01886854; Collet JF, 1998, J BIOL CHEM, V273, P14107, DOI 10.1074/jbc.273.23.14107; Collet JF, 1997, FEBS LETT, V408, P281, DOI 10.1016/S0014-5793(97)00438-9; DEGANI C, 1973, J BIOL CHEM, V248, P8222; EKICI AB, 1997, TECHNICAL TIPS ONLIN; HIRONO A, 1987, BRIT J HAEMATOL, V65, P35, DOI 10.1111/j.1365-2141.1987.tb06132.x; HOGLUND L, 1990, J BIOL CHEM, V265, P6589; Hunsucker SA, 2001, J BIOL CHEM, V276, P10498, DOI 10.1074/jbc.M011218200; ITOH R, 1992, COMP BIOCHEM PHYS B, V103, P153, DOI 10.1016/0305-0491(92)90427-S; KERESZTESSY Z, 1994, ARCH BIOCHEM BIOPHYS, V314, P142, DOI 10.1006/abbi.1994.1422; KOMMISAROV AA, 1995, J BIOL CHEM, V270, P10050; LLAMAS K, 1986, J AM CHEM SOC, V108, P5543, DOI 10.1021/ja00278a030; MARALIHALLI GB, 1993, J PROTEIN CHEM, V12, P451, DOI 10.1007/BF01025045; Marsich E, 2001, EUR J BIOCHEM, V268, P139, DOI 10.1046/j.1432-1327.2001.01860.x; Page T, 1997, P NATL ACAD SCI USA, V94, P11601, DOI 10.1073/pnas.94.21.11601; PESI R, 1994, ARCH BIOCHEM BIOPHYS, V312, P75, DOI 10.1006/abbi.1994.1282; Pesi R, 2000, NEUROREPORT, V11, P1827, DOI 10.1097/00001756-200006260-00006; Pirard M, 1997, FEBS LETT, V411, P251, DOI 10.1016/S0014-5793(97)00704-7; Rampazzo C, 2000, J BIOL CHEM, V275, P5409, DOI 10.1074/jbc.275.8.5409; Rampazzo C, 2000, P NATL ACAD SCI USA, V97, P8239, DOI 10.1073/pnas.97.15.8239; Sala-Newby GB, 1999, J BIOL CHEM, V274, P17789, DOI 10.1074/jbc.274.25.17789; SHINA U, 1985, ANAL BIOCHEM, V151, P327; TESORIERE G, 1984, BIOCHIM BIOPHYS ACTA, V786, P231, DOI 10.1016/0167-4838(84)90093-1; TOZZI MG, 1991, ARCH BIOCHEM BIOPHYS, V291, P212, DOI 10.1016/0003-9861(91)90125-3; VALENTINE WN, 1974, J CLIN INVEST, V54, P866, DOI 10.1172/JCI107826; VANDEKERCKHOVE J, 1993, METHODS IN PROTEIN SEQUENCE ANALYSIS, P11; Wang WR, 2001, STRUCTURE, V9, P65, DOI 10.1016/S0969-2126(00)00558-X; WORKU Y, 1982, BIOCHEM J, V205, P503, DOI 10.1042/bj2050503; ZIMMERMANN H, 1992, BIOCHEM J, V285, P345, DOI 10.1042/bj2850345	35	60	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33526	33532		10.1074/jbc.M104088200	http://dx.doi.org/10.1074/jbc.M104088200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11432867	hybrid			2022-12-25	WOS:000170910200033
J	Suetsugu, S; Miki, H; Takenawa, T				Suetsugu, S; Miki, H; Takenawa, T			Identification of another actin-related protein (Arp) 2/3 complex binding site in neural Wiskott-Aldrich syndrome protein (N-WASP) that complements actin polymerization induced by the Arp2/3 complex activating (VCA) domain of N-WASP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; DEPOLYMERIZING PROTEIN; MICROSPIKE FORMATION; SHIGELLA-FLEXNERI; MOTILITY; NUCLEATION; CDC42; INDUCTION; LISTERIA; SIGNALS	Neural Wiskott-Aldrich syndrome protein (N-WASP) is an essential regulator of actin cytoskeleton formation via its association with the actin-related protein (Arp) 2/3 complex. It is believed that the C-terminal Arp2/3 complex-activating domain (verprolin homology, cofilin homology, and acidic (VCA) or C-terminal region of WASP family proteins domain) of N-WASP is usually kept masked (autoinhibition) but is opened upon cooperative binding of upstream regulators such as Cdc42 and phosphatidylinositol 4,5-bisphosphate (PIP2). However, the mechanisms of autoinhibition and association with Arp2/3 complex are still unclear. We focused on the acidic region of N-WASP because it is thought to interact with Arp2/3 complex and may be involved in autoinhibition. Partial deletion of acidic residues from the VCA portion alone greatly reduced actin polymerization activity, demonstrating that the acidic region contributes to Arp2/3 complex-mediated actin polymerization. Surprisingly, the same partial deletion of the acidic region in full-length N-WASP led to constitutive activity comparable with the activity seen with the VCA portion. Therefore, the acidic region in full-length N-WASP plays an indispensable role in the formation of the autoinhibited structure. This mutant contains WASP-homology (WH) I domain with weak affinity to the Arp2/3 complex, leading to activity in the absence of part of the acidic region. Furthermore, the actin comet formed by the DeltaW'H1 mutant of N-WASP was much smaller than that of wild-type N-WASP. Partial deletion of acidic residues did not affect actin comet size, indicating the importance of the WH1 domain in actin structure formation. Collectively, the acidic region of N-WASP plays an essential role in Arp2/3 complex activation as well as in the formation of the autoinhibited structure, whereas the WH1 domain complements the activation of the Arp2/3 complex achieved through the VCA portion.	Univ Tokyo, Inst Med Sci, Dept Biochem, Minato Ku, Tokyo 1088639, Japan	University of Tokyo	Takenawa, T (corresponding author), Univ Tokyo, Inst Med Sci, Dept Biochem, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.		Suetsugu, Shiro/B-3300-2010; Suetsugu, Shiro/AAF-4427-2019; Suetsugu, Shiro/ABB-6033-2020	Suetsugu, Shiro/0000-0002-4612-0628; Suetsugu, Shiro/0000-0002-4612-0628; 				Blanchoin L, 2000, NATURE, V404, P1007, DOI 10.1038/35010008; Cameron LA, 1999, P NATL ACAD SCI USA, V96, P4908, DOI 10.1073/pnas.96.9.4908; DERRY JMJ, 1994, CELL, V78, P635, DOI 10.1016/0092-8674(94)90528-2; Egile C, 1999, J CELL BIOL, V146, P1319, DOI 10.1083/jcb.146.6.1319; Higgs HN, 2000, J CELL BIOL, V150, P1311, DOI 10.1083/jcb.150.6.1311; Kim AS, 2000, NATURE, V404, P151, DOI 10.1038/35004513; Loisel TP, 1999, NATURE, V401, P613, DOI 10.1038/44183; Machesky LM, 1999, P NATL ACAD SCI USA, V96, P3739, DOI 10.1073/pnas.96.7.3739; Marchand JB, 2001, NAT CELL BIOL, V3, P76, DOI 10.1038/35050590; Miki H, 1998, EMBO J, V17, P6932, DOI 10.1093/emboj/17.23.6932; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; Miki H, 1996, EMBO J, V15, P5326, DOI 10.1002/j.1460-2075.1996.tb00917.x; Moreau V, 2000, NAT CELL BIOL, V2, P441, DOI 10.1038/35017080; Pantaloni D, 2000, NAT CELL BIOL, V2, P385, DOI 10.1038/35017011; Prehoda KE, 2000, SCIENCE, V290, P801, DOI 10.1126/science.290.5492.801; Ramesh N, 1997, P NATL ACAD SCI USA, V94, P14671, DOI 10.1073/pnas.94.26.14671; Rohatgi R, 2000, J CELL BIOL, V150, P1299, DOI 10.1083/jcb.150.6.1299; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Rozelle AL, 2000, CURR BIOL, V10, P311, DOI 10.1016/S0960-9822(00)00384-5; Suetsugu S, 1999, BIOCHEM BIOPH RES CO, V260, P296, DOI 10.1006/bbrc.1999.0894; Suetsugu S, 1998, EMBO J, V17, P6516, DOI 10.1093/emboj/17.22.6516; Suetsugu S, 2001, BIOCHEM BIOPH RES CO, V282, P739, DOI 10.1006/bbrc.2001.4619; Suzuki T, 1998, EMBO J, V17, P2767, DOI 10.1093/emboj/17.10.2767; Taunton J, 2000, J CELL BIOL, V148, P519, DOI 10.1083/jcb.148.3.519; Theriot JA, 1998, METHOD ENZYMOL, V298, P114, DOI 10.1016/S0076-6879(98)98013-2; Yamaguchi H, 2000, P NATL ACAD SCI USA, V97, P12631, DOI 10.1073/pnas.190351397; Yarar D, 1999, CURR BIOL, V9, P555, DOI 10.1016/S0960-9822(99)80243-7	27	43	43	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					33175	33180		10.1074/jbc.M102866200	http://dx.doi.org/10.1074/jbc.M102866200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11432863	hybrid			2022-12-25	WOS:000170746000104
J	Cocco, R; Stenberg, G; Dragani, B; Principe, DR; Paludi, D; Mannervik, B; Aceto, A				Cocco, R; Stenberg, G; Dragani, B; Principe, DR; Paludi, D; Mannervik, B; Aceto, A			The folding and stability of human alpha class glutathione transferase A1-1 depend on distinct roles of a conserved N-capping box and hydrophobic staple motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-TRANSFERASE; TRANSITION-STATE; CHYMOTRYPSIN INHIBITOR-2; 3-DIMENSIONAL STRUCTURE; IDENTIFICATION; ISOENZYMES; RESIDUES; NUCLEUS; P1-1; MECHANISMS	An N-capping box and a hydrophobic staple motif are strictly conserved in the core of all known glutathione S-transferases (GST). In the present work, mutations of hGSTA1-1 enzyme residues forming these motifs have been generated. The analysis of S154A, D157A, and S154A/D157A capping mutants indicate that the removal of this local signal destabilizes the protein. The fact that the third helical residue D157A mutation (N-3) was much more destabilizing than the first helical residue S154A mutation (N-cap) suggests that the appropriate conformation of the conserved substructure formed by the alpha6-helix and preceding loop (GST motif II) is crucial for the overall protein stability. The refolding study of GSTAI-1 variants supports the prediction that this subdomain could represent a nucleation site of refolding. The analysis of L153A, I158A, L153G, and L153A/I158A hydrophobic staple mutants indicate that the removal of this motif destabilizes the GSTA1-1 structure as well as its refolding transition state. The hydrophobic staple interaction favors essential inter-domain contacts and, thereby, in contrast to capping interactions, accelerates the enzyme reactivation. Its strict conservation in the GST system supports the suggestion that this local signal could represent an evolutionarily conserved determinant for rapid folding.	Univ G DAnnunzio, Dipartimento Sci Biochim, I-66100 Chieti, Italy; Univ G DAnnunzio, Dipartimento Sci Farmaco, I-66100 Chieti, Italy; Uppsala Univ, Dept Biochem, Biomed Ctr, S-75123 Uppsala, Sweden	G d'Annunzio University of Chieti-Pescara; G d'Annunzio University of Chieti-Pescara; Uppsala University	Aceto, A (corresponding author), Univ G DAnnunzio, Dipartimento Sci Biochim, Via Vestini 31, I-66100 Chieti, Italy.							ABKEVICH VI, 1994, BIOCHEMISTRY-US, V33, P10026, DOI 10.1021/bi00199a029; ACETO A, 1990, CARCINOGENESIS, V11, P2267, DOI 10.1093/carcin/11.12.2267; Aceto A, 1997, BIOCHEM J, V322, P229, DOI 10.1042/bj3220229; ACETO A, 1992, BIOCHEM J, V285, P241, DOI 10.1042/bj2850241; Aurora R, 1998, PROTEIN SCI, V7, P21, DOI 10.1002/pro.5560070103; DANIELSON UH, 1985, BIOCHEM J, V231, P263, DOI 10.1042/bj2310263; Dragani B, 1997, J BIOL CHEM, V272, P25518, DOI 10.1074/jbc.272.41.25518; Fersht AR, 1997, CURR OPIN STRUC BIOL, V7, P3, DOI 10.1016/S0959-440X(97)80002-4; Gustafsson A, 1999, J MOL BIOL, V288, P787, DOI 10.1006/jmbi.1999.2712; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; JACKSON SE, 1993, BIOCHEMISTRY-US, V32, P11270, DOI 10.1021/bi00093a002; JI XH, 1992, BIOCHEMISTRY-US, V31, P10169, DOI 10.1021/bi00157a004; KOONIN EV, 1994, PROTEIN SCI, V3, P2045, DOI 10.1002/pro.5560031117; MANNERVIK B, 1985, P NATL ACAD SCI USA, V82, P7202, DOI 10.1073/pnas.82.21.7202; MUNOZ V, 1995, BIOCHEMISTRY-US, V34, P15301, DOI 10.1021/bi00046a039; MUNOZ V, 1995, NAT STRUCT BIOL, V2, P380, DOI 10.1038/nsb0595-380; OTZEN DE, 1994, P NATL ACAD SCI USA, V91, P10422, DOI 10.1073/pnas.91.22.10422; PRESTA LG, 1988, SCIENCE, V240, P1632, DOI 10.1126/science.2837824; Ptitsyn OB, 1999, J MOL BIOL, V291, P671, DOI 10.1006/jmbi.1999.2920; Ptitsyn OB, 1996, FASEB J, V10, P3, DOI 10.1096/fasebj.10.1.8566544; Ptitsyn OB, 1998, J MOL BIOL, V278, P655, DOI 10.1006/jmbi.1997.1620; REINEMER P, 1991, EMBO J, V10, P1997, DOI 10.1002/j.1460-2075.1991.tb07729.x; RICHARDSON JS, 1988, SCIENCE, V240, P1648, DOI 10.1126/science.3381086; Rossjohn J, 2000, J MOL BIOL, V302, P295, DOI 10.1006/jmbi.2000.4054; SEALE JW, 1994, PROTEIN SCI, V3, P1741, DOI 10.1002/pro.5560031014; Shakhnovich E, 1996, NATURE, V379, P96, DOI 10.1038/379096a0; SINNING I, 1993, J MOL BIOL, V232, P192, DOI 10.1006/jmbi.1993.1376; Stenberg G, 2000, J BIOL CHEM, V275, P10421, DOI 10.1074/jbc.275.14.10421; STENBERG G, 1992, PROTEIN EXPRES PURIF, V3, P80, DOI 10.1016/1046-5928(92)90060-A; TAHIR MK, 1986, J BIOL CHEM, V261, P1048; WILCE MCJ, 1995, EMBO J, V14, P2133, DOI 10.1002/j.1460-2075.1995.tb07207.x	31	41	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					32177	32183		10.1074/jbc.M104057200	http://dx.doi.org/10.1074/jbc.M104057200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11423556	hybrid			2022-12-25	WOS:000170613500096
J	Fotinou, C; Emsley, P; Black, I; Ando, H; Ishida, H; Kiso, M; Sinha, KA; Fairweather, NF; Isaacs, NW				Fotinou, C; Emsley, P; Black, I; Ando, H; Ishida, H; Kiso, M; Sinha, KA; Fairweather, NF; Isaacs, NW			The crystal structure of tetanus toxin Hc fragment complexed with a synthetic GT1b analogue suggests cross-linking between ganglioside receptors and the toxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOTULINUM NEUROTOXIN; CHOLERA-TOXIN; C FRAGMENT; BINDING; IDENTIFICATION; REFINEMENT; MEMBRANES; DOMAIN	Tetanus toxin, a member of the family of Clostridial neurotoxins, is one of the most potent toxins known. The crystal structure of the complex of the COOH-terminal fragment of the heavy chain with an analogue of its ganglioside receptor, GT1b, provides the first direct identification and characterization of the ganglioside-binding sites. The ganglioside induces cross-linking by binding to two distinct sites on the Hc molecule. The structure sheds new light on the binding of Clostridial neurotoxins to receptors on neuronal cells and provides important information relevant to the design of antitetanus and anti-botulism therapeutic agents.	Univ Glasgow, Dept Chem, Glasgow G12 8QQ, Lanark, Scotland; Gifu Univ, Dept Appl Bioorgan Chem, Gifu 5011193, Japan; Univ London Imperial Coll Sci Technol & Med, Dept Biochem, London SW7 2AZ, England	University of Glasgow; Gifu University; Imperial College London	Isaacs, NW (corresponding author), Univ Glasgow, Dept Chem, Glasgow G12 8QQ, Lanark, Scotland.	neil@chem.gla.ac.uk	Ando, Hiromune/J-8294-2017	Ando, Hiromune/0000-0002-0551-0830				ACQUOTTI D, 1991, CHEM PHYS LIPIDS, V59, P107, DOI 10.1016/0009-3084(91)90001-R; ANGSTROM J, 1994, P NATL ACAD SCI USA, V91, P11859, DOI 10.1073/pnas.91.25.11859; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BAKRY N, 1991, J PHARMACOL EXP THER, V258, P613; Bohne A, 1998, J MOL MODEL, V4, P33, DOI 10.1007/s008940050068; Emsley P, 2000, J BIOL CHEM, V275, P8889, DOI 10.1074/jbc.275.12.8889; Evans P. R., 1993, P CCP4 STUD WEEK DAT, P114; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FIGUEIREDO D, 1995, INFECT IMMUN, V63, P3218, DOI 10.1128/IAI.63.8.3218-3221.1995; FISHMAN PH, 1982, J MEMBRANE BIOL, V69, P85, DOI 10.1007/BF01872268; HALPERN JL, 1993, J BIOL CHEM, V268, P11188; Halpern JL, 1995, CURR TOP MICROBIOL, V195, P221; Herreros J, 2000, BIOCHEM J, V347, P199, DOI 10.1042/0264-6021:3470199; Herreros J, 2000, J NEUROCHEM, V74, P1941, DOI 10.1046/j.1471-4159.2000.0741941.x; HERREROS J, 1999, COMPREHENSIVE SOURCE, P202; HOLMGREN J, 1980, EUR J BIOCHEM, V106, P371, DOI 10.1111/j.1432-1033.1980.tb04583.x; ISHIDA HK, 1994, TETRAHEDRON-ASYMMETR, V5, P2493, DOI 10.1016/S0957-4166(00)80396-1; Janshoff A, 1997, EUR BIOPHYS J BIOPHY, V26, P261, DOI 10.1007/s002490050079; Johnson EA, 1999, ANNU REV MICROBIOL, V53, P551, DOI 10.1146/annurev.micro.53.1.551; Kamata Y, 1997, TOXICON, V35, P1337, DOI 10.1016/S0041-0101(97)00027-5; Karlsson KA, 1998, ACTA BIOCHIM POL, V45, P429, DOI 10.18388/abp.1998_4237; Kitamura M, 1999, BBA-MOL CELL BIOL L, V1441, P1, DOI 10.1016/S1388-1981(99)00140-7; Kozaki S, 1998, MICROB PATHOGENESIS, V25, P91, DOI 10.1006/mpat.1998.0214; Kubota T, 1997, APPL ENVIRON MICROB, V63, P1214, DOI 10.1128/AEM.63.4.1214-1218.1997; Lacy DB, 1998, NAT STRUCT BIOL, V5, P898, DOI 10.1038/2338; Lalli G, 1999, J CELL SCI, V112, P2715; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Li L, 1998, J NAT TOXINS, V7, P215; MERRITT EA, 1994, PROTEIN SCI, V3, P166; MONTECUCCO C, 1986, TRENDS BIOCHEM SCI, V11, P314, DOI 10.1016/0968-0004(86)90282-3; MONTECUCCO C, 1994, MOL MICROBIOL, V13, P1, DOI 10.1111/j.1365-2958.1994.tb00396.x; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NISHIKI T, 1994, J BIOL CHEM, V269, P10498; PIERCE EJ, 1986, BIOCHEM J, V236, P845, DOI 10.1042/bj2360845; RINI JM, 1995, ANNU REV BIOPH BIOM, V24, P551, DOI 10.1146/annurev.biophys.24.1.551; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; Shapiro RE, 1997, J BIOL CHEM, V272, P30380, DOI 10.1074/jbc.272.48.30380; SIMPSON LL, 1971, J NEUROCHEM, V18, P1341, DOI 10.1111/j.1471-4159.1971.tb00235.x; Sinha K, 2000, MOL MICROBIOL, V37, P1041, DOI 10.1046/j.1365-2958.2000.02091.x; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Stehle T, 1997, EMBO J, V16, P5139, DOI 10.1093/emboj/16.16.5139; Sutton JM, 2001, FEBS LETT, V493, P45, DOI 10.1016/S0014-5793(01)02273-6; Swaminathan S, 2000, NAT STRUCT BIOL, V7, P693, DOI 10.1038/78005; Umland TC, 1997, NAT STRUCT BIOL, V4, P788, DOI 10.1038/nsb1097-788; VANHEYNI.WE, 1974, NATURE, V249, P415, DOI 10.1038/249415a0; VANHEYNINGEN W, 1961, J GEN MICROBIOL, V24, P107, DOI 10.1099/00221287-24-1-107; VELURAJA K, 1984, CARBOHYD POLYM, V4, P357, DOI 10.1016/0144-8617(84)90050-X; Weis WI, 1996, ANNU REV BIOCHEM, V65, P441, DOI 10.1146/annurev.bi.65.070196.002301; Williamson LC, 1999, J BIOL CHEM, V274, P25173, DOI 10.1074/jbc.274.35.25173	52	145	156	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					32274	32281		10.1074/jbc.M103285200	http://dx.doi.org/10.1074/jbc.M103285200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11418600	hybrid			2022-12-25	WOS:000170613500108
J	Maul, J; Siems, WE; Hoehe, MR; Grecksch, G; Bader, M; Walther, T				Maul, J; Siems, WE; Hoehe, MR; Grecksch, G; Bader, M; Walther, T			Alcohol consumption is controlled by angiotensin II	FASEB JOURNAL			English	Article						transgenic mice; ACE inhibition; spirapril	CONVERTING ENZYME-INHIBITORS; ETHANOL-CONSUMPTION; DEFICIENT MICE; MECHANISMS; RECEPTORS; HUMANS; RATS	Pharmacological manipulation of the renin-angiotensin system (RAS) appears to alter voluntary alcohol consumption in animals. We have now addressed the role of angiotensin II (AII) in alcohol intake by comparing the alcohol-drinking behavior of mice lacking or overexpressing the angiotensinogen gene in a two-bottle choice paradigm. We found that alcohol consumption was directly related to AII levels. Animals harboring a rat angiotensinogen transgene consumed significantly more of the alcoholic beverage than did controls. This effect could be remarkably reduced by spirapril, an inhibitor of the angiotensin-converting enzyme (ACE). However, mice lacking the angiotensinogen gene exhibited a markedly reduced alcohol intake. These results indicate a role for the angiotensinogen gene in alcohol consumption via modulation of AII.	Inst Mol Pharmacol, D-13125 Berlin, Germany; Max Delbruck Ctr Mol Med, Berlin, Germany; Univ Magdeburg, Inst Pharmacol & Toxicol, D-39106 Magdeburg, Germany; Free Univ Berlin, Univ Hosp, Dept Cardiol & Pneumol, D-1000 Berlin, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Otto von Guericke University; Free University of Berlin	Maul, J (corresponding author), Inst Mol Pharmacol, Robert Roessle Str 10, D-13125 Berlin, Germany.	maul@fmp-berlin.de	Bader, Michael/K-2124-2013	Bader, Michael/0000-0003-4780-4164				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CRABBE JC, 1996, NAT GENET, V14, P89; Daubert DL, 1999, BRAIN RES, V816, P8, DOI 10.1016/S0006-8993(98)00930-5; FITTS DA, 1993, PHARMACOL BIOCHEM BE, V45, P35, DOI 10.1016/0091-3057(93)90082-5; FRIEDLAND J, 1976, AM J CLIN PATHOL, V66, P416; FUXE K, 1980, NEURAL PEPTIDES NEUR, P37; GARRIB A, 1998, BIOCHEM SOC T, V26, P136; Grupp LA, 1997, ALCOHOL, V14, P71, DOI 10.1016/S0741-8329(96)00109-7; GRUPP LA, 1988, PHARMACOL BIOCHEM BE, V31, P813, DOI 10.1016/0091-3057(88)90389-9; GRUPP LA, 1988, PHARMACOL BIOCHEM BE, V29, P479, DOI 10.1016/0091-3057(88)90007-X; GRUPP LA, 1993, NIAAA RES MONOGRAPH, V23, P37; HUBBELL CL, 1992, ALCOHOL, V9, P53, DOI 10.1016/0741-8329(92)90010-8; HULME EC, 1992, RECEPTOR LIGAND INTE, P177; Jenkins TA, 1997, BRAIN RES, V748, P137, DOI 10.1016/S0006-8993(96)01276-0; Kiefer SW, 1998, ALCOHOL CLIN EXP RES, V22, P1146, DOI 10.1097/00000374-199808000-00025; Kihara M, 1998, KIDNEY INT, V53, P548, DOI 10.1046/j.1523-1755.1998.00801.x; KIMURA S, 1992, EMBO J, V11, P821, DOI 10.1002/j.1460-2075.1992.tb05119.x; LINGHAM T, 1990, ALCOHOL CLIN EXP RES, V14, P92, DOI 10.1111/j.1530-0277.1990.tb00453.x; Phillips TJ, 1998, NAT NEUROSCI, V1, P610, DOI 10.1038/2843; ROACH MK, 1968, CLIN CHIM ACTA, V21, P275, DOI 10.1016/0009-8981(68)90138-1; SPINOSA G, 1988, ALCOHOL CLIN EXP RES, V12, P65, DOI 10.1111/j.1530-0277.1988.tb00134.x; SYBERTZ EJ, 1987, J CARDIOVASCULAR S7, V10, P105; TANIMOTO K, 1994, J BIOL CHEM, V269, P31334; TERDAL ES, 1994, ALCOHOL CLIN EXP RES, V18, P542, DOI 10.1111/j.1530-0277.1994.tb00907.x; Thiele TE, 1998, NATURE, V396, P366, DOI 10.1038/24614; Urata H, 1995, EUR HEART J, V16, P79, DOI 10.1093/eurheartj/16.suppl_N.79; Walther T, 1999, BEHAV BRAIN RES, V100, P1, DOI 10.1016/S0166-4328(98)00078-3; Weisinger RS, 1999, AM J PHYSIOL-REG I, V277, pR162; Weisinger RS, 1999, PHYSIOL BEHAV, V67, P369, DOI 10.1016/S0031-9384(99)00085-2	29	30	34	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY 29	2001	15	7					1640	+		10.1096/fj.00-097fje	http://dx.doi.org/10.1096/fj.00-097fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519CQ	11427512				2022-12-25	WOS:000173707700008
J	Reichel, M; Gillert, E; Angermuller, S; Hensel, JP; Heidel, F; Lode, M; Leis, T; Biondi, A; Haas, OA; Strehl, S; Panzer-Grumayer, ER; Griesinger, F; Beck, JD; Greil, J; Fey, GH; Uckun, FM; Marschalek, R				Reichel, M; Gillert, E; Angermuller, S; Hensel, JP; Heidel, F; Lode, M; Leis, T; Biondi, A; Haas, OA; Strehl, S; Panzer-Grumayer, ER; Griesinger, F; Beck, JD; Greil, J; Fey, GH; Uckun, FM; Marschalek, R			Biased distribution of chromosomal breakpoints involving the MLL gene in infants versus children and adults with t(4;11) ALL	ONCOGENE			English	Article						chromosomal translocation t(4;11); ALL-1/MLL/HRX gene; AF4 gene	ACUTE-LEUKEMIA; CLUSTER REGION; TRANSLOCATION T(4-11); EXON/INTRON STRUCTURE; SEQUENCE-ANALYSIS; 11Q23; IDENTIFICATION; CLEAVAGE	Derivative chromosomes of 40 patients diagnosed with t(4;11) acute lymphoblastic leukemia (ALL),were analysed on the genomic DNA level. Chromosomal breakpoints were identified in most cases within the known breakpoint cluster regions of the involved MLL and AF4 genes, Due to our current knowledge of the primary DNA sequences of both breakpoint cluster regions, specific features were identified at the chromosomal fusion sites, including deletions, inversions and duplications of parental DNA sequences, After separation of all t(4;11) leukemia patients into two age classes (below and above 1 year of age), the analysis of chromosomal fusion sites revealed significant differences in the distribution of chromosomal breakpoints and led to the definition of two hotspot areas within the MLL breakpoint cluster region, This may point to the possibility of different age-linked mechanisms that sere leading to t(4;11) chromosomal translocations. Oncogene (2001) 20, 2900-2907.	Univ Frankfurt, Bioctr, Inst Pharmaceut Biol, D-60439 Frankfurt, Germany; Univ Erlangen Nurnberg, Chair Genet, D-91058 Erlangen, Germany; Univ Erlangen Nurnberg, Dept Pediat, D-91054 Erlangen, Germany; Osped S Gerardo, Ctr Ric M Tettamanti, I-20052 Monza, MI, Italy; St Anna Kinderspital, CCRI, A-1090 Vienna, Austria; Univ Hosp Gottingen, Div Haematol Oncol, D-37075 Gottingen, Germany; Parker Hughes Canc Ctr, St Paul, MN 55113 USA; Parker Hughes Inst, Childrens Canc Grp, ALL Biol Reference Lab, St Paul, MN 55113 USA	Goethe University Frankfurt; University of Erlangen Nuremberg; University of Erlangen Nuremberg; San Gerardo Hospital; Saint Anna Children's Hospital; University of Gottingen	Marschalek, R (corresponding author), Univ Frankfurt, Bioctr, Inst Pharmaceut Biol, N230,303 Marie-Curie Str 9, D-60439 Frankfurt, Germany.		Biondi, Andrea/AAX-1865-2020; Haas, Oskar/AAM-5794-2020; Biondi, Andrea/K-9997-2016; Marschalek, Rolf/D-3404-2011	Biondi, Andrea/0000-0002-6757-6173; Marschalek, Rolf/0000-0003-4870-3445; Heidel, Florian/0000-0003-2438-1955; Reichel, Martin/0000-0001-7886-2784; Strehl, Sabine/0000-0002-0179-0628; Uckun, Fatih M./0000-0001-9334-183X				BERNARD OA, 1995, GENE CHROMOSOME CANC, V13, P75, DOI 10.1002/gcc.2870130202; Cimino G, 1997, CANCER RES, V57, P2879; Cimino G, 1998, HAEMATOLOGICA, V83, P350; Felix CA, 1997, BLOOD, V90, P4679, DOI 10.1182/blood.V90.12.4679.4679_4679_4686; Gillert E, 1999, ONCOGENE, V18, P4663, DOI 10.1038/sj.onc.1202842; GU Y, 1994, CANCER RES, V54, P2327; Leis T, 1998, LEUKEMIA, V12, P758, DOI 10.1038/sj.leu.2401006; Marschalek R, 1997, LEUKEMIA LYMPHOMA, V27, P417, DOI 10.3109/10428199709058308; MARSCHALEK R, 1995, BRIT J HAEMATOL, V90, P308, DOI 10.1111/j.1365-2141.1995.tb05151.x; Nilson I, 1996, BRIT J HAEMATOL, V93, P966, DOI 10.1046/j.1365-2141.1996.d01-1748.x; Nilson I, 1997, BRIT J HAEMATOL, V98, P157, DOI 10.1046/j.1365-2141.1997.1522966.x; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; Reichel M, 1999, CANCER RES, V59, P3357; Reichel M, 1998, ONCOGENE, V17, P3035, DOI 10.1038/sj.onc.1202229; Stanulla M, 1997, MOL CELL BIOL, V17, P4070, DOI 10.1128/MCB.17.7.4070; Strissel Gbroeker Pamela L., 1996, Blood, V87, P1912; Strissel PL, 1998, BLOOD, V92, P3793, DOI 10.1182/blood.V92.10.3793.422a24_3793_3803; Super HG, 1997, GENE CHROMOSOME CANC, V20, P185, DOI 10.1002/(SICI)1098-2264(199710)20:2<185::AID-GCC9>3.0.CO;2-#; ZIEMINVANDERPOEL S, 1991, P NATL ACAD SCI USA, V88, P10735, DOI 10.1073/pnas.88.23.10735	19	64	68	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 24	2001	20	23					2900	2907		10.1038/sj.onc.1204401	http://dx.doi.org/10.1038/sj.onc.1204401			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	435VA	11420702				2022-12-25	WOS:000168901800005
J	Rodier, A; Rochard, P; Berthet, C; Rouault, JP; Casas, F; Daury, L; Busson, M; Magaud, JP; Wrutniak-Cabello, C; Cabello, G				Rodier, A; Rochard, P; Berthet, C; Rouault, JP; Casas, F; Daury, L; Busson, M; Magaud, JP; Wrutniak-Cabello, C; Cabello, G			Identification of functional domains involved in BTG1 cell localization	ONCOGENE			English	Article						BTG1; NLS; NES; myoblast; cell localization	TRANSCRIPTIONAL REGULATORY COMPLEX; NUCLEAR EXPORT SIGNAL; ARGININE N-METHYLTRANSFERASE; MOLECULAR-CLONING; MESSENGER-RNA; PROTEIN BTG1; LEPTOMYCIN-B; GENE; CRM1; TRANSLOCATION	We have previously shown that BTG1 stimulates myoblast differentiation, In addition, this protein displays a major nuclear localization in confluent myoblasts, decreasing during the early steps of differentiation, and is essentially detected in the cytoplasm of mature myotubes. To identify the domains involved in the cellular trafficking of BTG1, we observed the localization of several BTG1 sequences fused to beta Galactosidase. The highly conserved B box among all members of the BTG family induces a significant nuclear localization of the beta Gal moiety, enhanced by presence of the BTG1 carboxy-terminal sequence. In addition, a functional Nuclear Export Signal (NES) overlaps the B box. Moreover, presence of the first 43 NH2-terminal amino acids reduced the nuclear localization of each chimeric protein tested. Last, the BTG1 amino-terminal domain hears an LxxLL, motif favouring nuclear accumulation, and another region encompassing the A box inhibiting nuclear localization. In contrast to a BTG1 mutant exclusively localized in the cytoplasm, transient expression of a mutant displaying a nuclear Localization enhanced myoblasts withdrawal from the cell cycle and terminal differentiation, thus mimicking the myogenic influence of BTG1, In conclusion, several regions of BTG1 are implicated in its cellular localization, and BTG1 myogenic activity is induced at the nuclear level.	Univ Montpellier 2, ENSAM, INRA,Unite Endocrinol Cellulaire, UMR Differenciat Cellulaire & Croissance, F-34060 Montpellier 1, France; Ctr Leon Berard, INSERM, U453, F-69373 Lyon, France	Arts et Metiers Institute of Technology; INRAE; Institut Agro; Montpellier SupAgro; Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard	Cabello, G (corresponding author), Univ Montpellier 2, ENSAM, INRA,Unite Endocrinol Cellulaire, UMR Differenciat Cellulaire & Croissance, 2 Pl Viala, F-34060 Montpellier 1, France.		berthet, cyril/T-4842-2017	berthet, cyril/0000-0003-3166-3141; Daury, Laetitia/0000-0002-1296-7150; Francois, Casas/0000-0002-5535-8195				ANTIN PB, 1991, DEV BIOL, V143, P111, DOI 10.1016/0012-1606(91)90058-B; Bogdan JA, 1998, BIOCHEM J, V336, P471, DOI 10.1042/bj3360471; BRADBURY A, 1991, P NATL ACAD SCI USA, V88, P3353, DOI 10.1073/pnas.88.8.3353; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Chen PJ, 2000, DEV BIOL, V217, P77, DOI 10.1006/dbio.1999.9521; DINGWALL C, 1982, CELL, V30, P449, DOI 10.1016/0092-8674(82)90242-2; DRAPER MP, 1995, MOL CELL BIOL, V15, P3487; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; FLETCHER BS, 1991, J BIOL CHEM, V266, P14511; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fukuda M, 1996, J BIOL CHEM, V271, P20024, DOI 10.1074/jbc.271.33.20024; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; GHOSH SK, 1988, J BIOL CHEM, V263, P19024; Guardavaccaro D, 2000, MOL CELL BIOL, V20, P1797, DOI 10.1128/MCB.20.5.1797-1815.2000; Guehenneux F, 1997, LEUKEMIA, V11, P370, DOI 10.1038/sj.leu.2400599; GUIOCHONMANTEL A, 1994, P NATL ACAD SCI USA, V91, P7179, DOI 10.1073/pnas.91.15.7179; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Iacopetti P, 1999, P NATL ACAD SCI USA, V96, P4639, DOI 10.1073/pnas.96.8.4639; Ikematsu N, 1999, ONCOGENE, V18, P7432, DOI 10.1038/sj.onc.1203193; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Kudo N, 1997, J BIOL CHEM, V272, P29742, DOI 10.1074/jbc.272.47.29742; Lin WJ, 1996, J BIOL CHEM, V271, P15034, DOI 10.1074/jbc.271.25.15034; MARCHAL S, 1993, BIOL CELL, V78, P191, DOI 10.1016/0248-4900(93)90129-3; MARCHAL S, 1995, EXP CELL RES, V220, P1, DOI 10.1006/excr.1995.1285; Matsuda S, 1996, ONCOGENE, V12, P705; Montagnoli A, 1996, CELL GROWTH DIFFER, V7, P1327; NEWMEYER DD, 1988, CELL, V52, P641, DOI 10.1016/0092-8674(88)90402-3; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Prevot D, 2000, J BIOL CHEM, V275, P147, DOI 10.1074/jbc.275.1.147; RAJPUROHIT R, 1994, J BIOL CHEM, V269, P1075; RIMOKH R, 1991, GENE CHROMOSOME CANC, V3, P24, DOI 10.1002/gcc.2870030106; Rodier A, 1999, EXP CELL RES, V249, P337, DOI 10.1006/excr.1999.4486; Rouault JP, 1998, J BIOL CHEM, V273, P22563, DOI 10.1074/jbc.273.35.22563; ROUAULT JP, 1992, EMBO J, V11, P1663, DOI 10.1002/j.1460-2075.1992.tb05213.x; Saka Y, 2000, MECH DEVELOP, V93, P27, DOI 10.1016/S0925-4773(00)00260-4; Snedecor G.W., 1961, STAT METHODS; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X	41	22	26	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 10	2001	20	21					2691	2703		10.1038/sj.onc.1204398	http://dx.doi.org/10.1038/sj.onc.1204398			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	431VN	11420681				2022-12-25	WOS:000168652600010
J	Giambartolomei, S; Covone, F; Levrero, M; Balsano, C				Giambartolomei, S; Covone, F; Levrero, M; Balsano, C			Sustained activation of the Raf/MEK/Erk pathway in response to EGF in stable cell lines expressing the Hepatitis C Virus (HCV) core protein	ONCOGENE			English	Article						HCV; core; Raf; Erk1/2; EGF; HCC	HUMAN HEPATOCELLULAR-CARCINOMA; B VIRUS; TRANSCRIPTION FACTORS; RNA HELICASE; HBX PROTEIN; KINASES; RAS; HEPATOCARCINOGENESIS; INTERACTS; CIRRHOSIS	Chronic hepatitis C virus (HCV) infection is a leading cause of liver cirrhosis and hepatocellular carcinoma (HCC) worldwide. The HCV capside core is a multifunctional protein with regulatory functions that affects transcription and cell growth in vitro and in vivo. Here, we show that both HCV genotype 1a and 3 core proteins activate MEK1 and Erk1/2 MAP kinases and that the costitutive expression of the HCV core results in a high basal activity of Raf1 and MAP/kinase/ kinase, as determined by endogenous Raf1 in vitro kinase assay and immunodetection of hyperphosphorylated Erk1 and Erk2 even after a serum starvation. Moreover, the activation of both Erk1/2 and the downstream transcription factor Elk-l in response to the mitogenic stimulus EGF is significantly prolonged. The sustained response to EGF in cells expressing the HCV core occurs despite a normal induction of the MAP phosphatases MKP regulatory feedback and is likely due to the costitutive activation of Raf-l activity. The ability of HCV core proteins to directly activate the MAP kinase cascade and to prolong its activity in response to mitogenic stimuli may contribute to the neoplastic transformation of HCV infected liver cells.	Univ Rome La Sapienza, Fdn Andrea Cesalpino, Gene Express Lab, Rome, Italy; Univ Aquila, Dept Internal Med, I-67100 Laquila, Italy; Univ Cagliari, Dept Internal Med, Cagliari, Italy	Sapienza University Rome; University of L'Aquila; University of Cagliari	Balsano, C (corresponding author), Policlin Umberto I, Med Clin 1, Fdn A Cesalpino, Viale Policlin 155, I-001612 Rome, Italy.		Balsano, Clara/AAK-9870-2020; Levrero, Massimo/G-5680-2016	Balsano, Clara/0000-0002-9615-7031; Levrero, Massimo/0000-0002-4978-0875				Aoki H, 2000, J VIROL, V74, P1736, DOI 10.1128/JVI.74.4.1736-1741.2000; Barba G, 1997, P NATL ACAD SCI USA, V94, P1200, DOI 10.1073/pnas.94.4.1200; Brondello JM, 1999, SCIENCE, V286, P2514, DOI 10.1126/science.286.5449.2514; Bruno S, 1997, HEPATOLOGY, V25, P754, DOI 10.1002/hep.510250344; Cacciola I, 1999, NEW ENGL J MED, V341, P22, DOI 10.1056/NEJM199907013410104; Colombo M, 1999, J HEPATOL, V31, P25, DOI 10.1016/S0168-8278(99)80370-5; De Francesco R, 1999, J HEPATOL, V31, P47, DOI 10.1016/S0168-8278(99)80374-2; Donato F, 1998, INT J CANCER, V75, P347, DOI 10.1002/(SICI)1097-0215(19980130)75:3&lt;347::AID-IJC4&gt;3.0.CO;2-2; DORIA M, 1995, EMBO J, V14, P4747, DOI 10.1002/j.1460-2075.1995.tb00156.x; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Hayashi J, 2000, HEPATOLOGY, V32, P958, DOI 10.1053/jhep.2000.19343; Hayashi J, 1999, INTERVIROLOGY, V42, P205, DOI 10.1159/000024962; Ito Y, 1998, HEPATOLOGY, V27, P951, DOI 10.1002/hep.510270409; Jin DY, 2000, EMBO J, V19, P729, DOI 10.1093/emboj/19.4.729; Kalkuhl A, 1998, HEPATOLOGY, V27, P1081, DOI 10.1002/hep.510270425; Klein NP, 1997, MOL CELL BIOL, V17, P6427, DOI 10.1128/MCB.17.11.6427; Lu W, 1999, VIROLOGY, V264, P134, DOI 10.1006/viro.1999.9979; Mamiya N, 1999, J BIOL CHEM, V274, P15751, DOI 10.1074/jbc.274.22.15751; McKillop IH, 1997, HEPATOLOGY, V26, P1484; Moriya K, 1997, J GEN VIROL, V78, P1527, DOI 10.1099/0022-1317-78-7-1527; Moriya K, 1998, NAT MED, V4, P1065, DOI 10.1038/2053; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; NATOLI G, 1994, ONCOGENE, V9, P2837; Ray RB, 2000, VIROLOGY, V271, P197, DOI 10.1006/viro.2000.0295; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Schmidt CM, 1997, BIOCHEM BIOPH RES CO, V236, P54, DOI 10.1006/bbrc.1997.6840; Shibata Y, 1999, INT J ONCOL, V14, P1153; Shrivastava A, 1998, J VIROL, V72, P9722, DOI 10.1128/JVI.72.12.9722-9728.1998; Tamori A, 1999, HEPATOLOGY, V29, P1429, DOI 10.1002/hep.510290520; Tsuchihara K, 1999, VIROLOGY, V258, P100, DOI 10.1006/viro.1999.9694; You LR, 1999, J VIROL, V73, P2841, DOI 10.1128/JVI.73.4.2841-2853.1999	31	117	122	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 3	2001	20	20					2606	2610		10.1038/sj.onc.1204372	http://dx.doi.org/10.1038/sj.onc.1204372			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	431VM	11420671				2022-12-25	WOS:000168652500012
J	Ahmad, N; Kalka, K; Mukhtar, H				Ahmad, N; Kalka, K; Mukhtar, H			In vitro and in vivo inhibition of epidermal growth factor receptor-tyrosine kinase pathway by photodynamic therapy	ONCOGENE			English	Article						PDT; EGFR; Shc; cell cycle; apoptosis	ACTIVATED PROTEIN-KINASE; MEDIATED APOPTOSIS; INDUCED ABLATION; CARCINOMA-CELLS; MOUSE SKIN; HELA-CELLS; TUMORS; A431; INVOLVEMENT; PROGRESSION	PDT, a new therapeutic procedure for the management of many malignant conditions including skin cancer, involves the administration of a photosensitizing compound followed by illumination of the lesion with visible light, We earlier showed an involvement of: (i) WAF1/ p21-cyclins (D1 and E)-cdk (2 and 6) network; and (ii) Rb/E2F-DP machinery during silicon phthalocyanine (Pc4)-PDT-mediated cell cycle dysregulation and apoptosis of human epidermoid carcinoma (A431) cells, Here, we investigated the involvement of EGFR-pathway during antiproliferative responses of Pc4-PDT in A431 cells and during ablation of murine skin papillomas. Pc4-PDT of A431 cells was found to result in a time-dependent down-modulation of the protein expression and phosphorylation of EGFR and Shc (an immediate downstream molecule in EGFR-pathway), during progressive increase in apoptotic response. To establish the relevance of these in vitro findings to in vivo situations, we subjected chemically- as well as ultraviolet B radiation-induced squamous papillomas in SENCAR and SKH-1 hairless mice, respectively, to Pc4-PDT, and assessed its effect on EGFR-pathway during ablation of these tumors. Pc4-PDT was found to result in a time-dependent: (i) inhibition of protein expressions of EGFR; and (ii) tyrosine phosphorylation of EGFR and Shc; and (iii) induction of apoptosis, during the regression of these tumors, These data suggest the involvement of EGFR-pathway during the antiproliferative effects of PDT, It is tempting to speculate that inhibitors of EGFR could enhance the therapeutic efficacy of PDT.	Case Western Reserve Univ, Dept Dermatol, Cleveland, OH 44106 USA	Case Western Reserve University	Mukhtar, H (corresponding author), Case Western Reserve Univ, Dept Dermatol, 11100 Euclid Ave, Cleveland, OH 44106 USA.				NATIONAL CANCER INSTITUTE [R01CA051802, P30CA043703, P01CA048735] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR039750] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA 48735, P30 CA 43703, R01 CA 51802] Funding Source: Medline; NIAMS NIH HHS [P30 AR 39750] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Agarwal R, 1996, PHOTOCHEM PHOTOBIOL, V63, P547, DOI 10.1111/j.1751-1097.1996.tb03082.x; Ahmad N, 1999, ONCOGENE, V18, P1891, DOI 10.1038/sj.onc.1202493; Ahmad N, 1998, P NATL ACAD SCI USA, V95, P6977, DOI 10.1073/pnas.95.12.6977; Ahmad N, 1998, BIOCHEM BIOPH RES CO, V247, P294, DOI 10.1006/bbrc.1998.8748; Ahmad N, 2000, J INVEST DERMATOL, V115, P1041, DOI 10.1046/j.1523-1747.2000.00147.x; Assefa Z, 1999, J BIOL CHEM, V274, P8788, DOI 10.1074/jbc.274.13.8788; Chiu SM, 2000, INT J ONCOL, V16, P423; Colussi VC, 1999, PHOTOCHEM PHOTOBIOL, V69, P236, DOI 10.1562/0031-8655(1999)069<0236:PPTOHO>2.3.CO;2; Dougherty TJ, 1998, JNCI-J NATL CANCER I, V90, P889, DOI 10.1093/jnci/90.12.889; Engbrecht BW, 1999, CANCER RES, V59, P4334; Fry DW, 1999, PHARMACOL THERAPEUT, V82, P207, DOI 10.1016/S0163-7258(98)00050-3; Graness A, 2000, BIOCHEM J, V347, P441, DOI 10.1042/0264-6021:3470441; Granville DJ, 1998, FEBS LETT, V437, P5, DOI 10.1016/S0014-5793(98)01193-4; Granville DJ, 1998, FEBS LETT, V422, P151, DOI 10.1016/S0014-5793(97)01616-5; Gupta S, 1998, CANCER RES, V58, P1785; Hansen LA, 2000, CANCER RES, V60, P3328; Kalka K, 2000, CANCER RES, V60, P5984; Kalka K, 2000, J AM ACAD DERMATOL, V42, P389, DOI 10.1016/S0190-9622(00)90209-3; Kawaguchi T, 2000, BRIT J CANCER, V82, P418; Kessler JJ, 1998, LAND DEGRAD DEV, V9, P95, DOI 10.1002/(SICI)1099-145X(199803/04)9:2<95::AID-LDR289>3.0.CO;2-Y; Kim HRC, 1999, CANCER RES, V59, P3429; Mukhtar H, 1996, PHOTOCHEM PHOTOBIOL, V63, P355, DOI 10.1111/j.1751-1097.1996.tb03040.x; Nakamura T, 1996, ONCOGENE, V13, P1111; Oleinick NL, 1998, RADIAT RES, V150, pS146, DOI 10.2307/3579816; OLEINICK NL, 1993, PHOTOCHEM PHOTOBIOL, V57, P242, DOI 10.1111/j.1751-1097.1993.tb02282.x; SchmidtUllrich RK, 1997, ONCOGENE, V15, P1191, DOI 10.1038/sj.onc.1201275; Tajiri H, 1998, CANCER LETT, V128, P205, DOI 10.1016/S0304-3835(98)00066-4; Varnes ME, 1999, BIOCHEM BIOPH RES CO, V255, P673, DOI 10.1006/bbrc.1999.0261; Whitacre CM, 2000, CLIN CANCER RES, V6, P2021; Woodburn JR, 1999, PHARMACOL THERAPEUT, V82, P241, DOI 10.1016/S0163-7258(98)00045-X; ZAIDI SIA, 1993, PHOTOCHEM PHOTOBIOL, V58, P771, DOI 10.1111/j.1751-1097.1993.tb04969.x; Zhang WG, 1999, CANCER LETT, V138, P189, DOI 10.1016/S0304-3835(99)00013-0	33	54	57	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 26	2001	20	18					2314	2317		10.1038/sj.onc.1204313	http://dx.doi.org/10.1038/sj.onc.1204313			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	427KZ	11402326				2022-12-25	WOS:000168404500013
J	Goetz, F; Tzeng, YJ; Guhl, E; Merker, J; Graessmann, M; Graessmann, A				Goetz, F; Tzeng, YJ; Guhl, E; Merker, J; Graessmann, M; Graessmann, A			The SV40 small t-antigen prevents mammary gland differentiation and induces breast cancer formation in transgenic mice; truncated large T-antigen molecules harboring the intact p53 and pRb binding region do not have this effect	ONCOGENE			English	Article						SV40 small t-antigen; transgenic animals; cyclin D1; mammary gland differentiation; breast cancer	PROTEIN PHOSPHATASE 2A; CELL-GROWTH; TRANSFORMATION; P21(WAF1/CIP1); INVOLUTION; APOPTOSIS; CARCINOMA; MUTATION; ANIMALS	We report here for the first time, that the SV40 small t-antigen inhibits mammary gland differentiation during mid-pregnancy and that about. 10% of multiparous WAP-SVt transgenic animals develop breast tumors with latencies ranging from 10-17 months, Cyclin D1 is deregulated and over expressed in the small t-antigen positive mammary gland epithelial cells (ME-cells) and in the breast tumor cells, SV40 small t-antigen immortalized ME-cells (t-ME-cells) exhibit a strong intranuclear cyclin D1 staining, also in the absence of external growth factors and the cells continue to divide for several days without serum. In addition, the expression rate of cyclin E acid p21(Waf1) but not of p53 is increased, Coimmunoprecipitation experiments revealed that p21(Waf1) is mainly associated with the cyclin D/CDK4 but not with the cyclin E/CDK2 complex, WAP-SVT transgenic animals exhibit an almost regular mammary gland development until late pregnancy but the majority of the ME-cells are eliminated by apoptosis during the early lactation period. Tumor formation is delayed and less efficient than in T/t-antigen positive animals, Sequestration of p53 and pRb by the N-terminal truncated T-antigen molecules (T1-antigen and T2-antigen) does not affect mammary gland differentiation and the transgenic animals (WAP-SVBst-Bam) do not develop breast tumors.	Free Univ Berlin, Inst Mol Biol & Biochem, D-14195 Berlin, Germany; Tzu Chi Univ, Grad Inst Mol & Cell Biol, Hualien 970, Taiwan; Free Univ Berlin, Inst Anat, D-14195 Berlin, Germany	Free University of Berlin; Tzu Chi University; Free University of Berlin	Graessmann, A (corresponding author), Free Univ Berlin, Inst Mol Biol & Biochem, Arnimallee 22, D-14195 Berlin, Germany.							CICALA C, 1994, J VIROL, V68, P3138, DOI 10.1128/JVI.68.5.3138-3144.1994; DeCaprio JA, 1999, BIOLOGICALS, V27, P23, DOI 10.1006/biol.1998.0173; Dotto GP, 2000, BBA-REV CANCER, V1471, pM43, DOI 10.1016/S0304-419X(00)00019-6; EUL J, 1995, EMBO J, V14, P3226, DOI 10.1002/j.1460-2075.1995.tb07325.x; Garcia A, 2000, J BIOL CHEM, V275, P9385, DOI 10.1074/jbc.275.13.9385; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Kohlhoff S, 2000, FREE RADICAL BIO MED, V29, P497, DOI 10.1016/S0891-5849(00)00340-3; Li ML, 2000, ONCOGENE, V19, P1010, DOI 10.1038/sj.onc.1203271; MARTIN RG, 1979, J VIROL, V31, P596, DOI 10.1128/JVI.31.3.596-607.1979; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; MUMBY MC, 1991, CELL REGUL, V2, P589, DOI 10.1091/mbc.2.8.589; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; RUNDELL K, 1987, J VIROL, V61, P1240, DOI 10.1128/JVI.61.4.1240-1243.1987; Santarelli R, 1996, ONCOGENE, V12, P495; SCHEIDTMANN KH, 1982, J VIROL, V44, P116, DOI 10.1128/JVI.44.1.116-133.1982; Schulze-Garg C, 2000, ONCOGENE, V19, P1028, DOI 10.1038/sj.onc.1203281; SENKITI S, 1979, BIOCHIM BIOPHYS ACTA, V582, P79; Siegel PM, 2000, BIOESSAYS, V22, P554, DOI 10.1002/(SICI)1521-1878(200006)22:6<554::AID-BIES8>3.0.CO;2-A; Sontag E, 1997, EMBO J, V16, P5662, DOI 10.1093/emboj/16.18.5662; Tzeng YJ, 1996, FEBS LETT, V380, P215, DOI 10.1016/0014-5793(96)00021-X; Tzeng YJ, 1998, ONCOGENE, V16, P2103, DOI 10.1038/sj.onc.1201733; TZENG YJ, 1993, ONCOGENE, V8, P1965; Virshup DM, 2000, CURR OPIN CELL BIOL, V12, P180, DOI 10.1016/S0955-0674(99)00074-5; Wakasugi E, 1997, AM J CLIN PATHOL, V107, P684; WANG SQ, 1990, ENDOCRINOLOGY, V127, P2183, DOI 10.1210/endo-127-5-2183; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0	26	19	19	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 26	2001	20	18					2325	2332		10.1038/sj.onc.1204355	http://dx.doi.org/10.1038/sj.onc.1204355			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	427KZ	11402328				2022-12-25	WOS:000168404500015
J	Vu, CCQ; Bortner, CD; Cidlowski, JA				Vu, CCQ; Bortner, CD; Cidlowski, JA			Differential involvement of initiator caspases in apoptotic volume decrease and potassium efflux during Fas- and UV-induced cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAS/FAS LIGAND INTERACTIONS; CYTOCHROME-C; ULTRAVIOLET-LIGHT; LYMPHOCYTE APOPTOSIS; GROWTH-FACTOR; K+ CHANNELS; ACTIVATION; INHIBITORS; SHRINKAGE; CASCADE	Caspase activation and apoptotic volume decrease are fundamental features of programmed cell death; however, the relationship between these components is not well understood. Here we provide biochemical and genetic evidence for the differential involvement of initiator caspases in the apoptotic volume decrease during both intrinsic and extrinsic activation of apoptosis. Apoptosis induction in Jurkat T lymphocytes by Fas receptor engagement (intrinsic) or ultraviolet (UV)-C radiation (extrinsic) triggered the loss of cell volume, which was restricted to cells with diminished intracellular K+ ions. These characteristics kinetically coincided with the proteolytic processing and activation of both initiator and effector caspases. Although the polycaspase inhibitor benzyloxycarbonyl-Val-Ala-Asp fluoromethyl ketone completely inhibited the Fas-mediated apoptotic volume decrease and K+ efflux, it was much less effective in preventing these processes during UV-induced cell death under conditions whereby caspase activities and DNA degradation were blocked. To define the roles of specific initiator caspases, we utilized Jurkat cells genetically deficient in caspase-8 or stably transfected with a dominant-negative mutant of caspase-9. The results show that the activation of caspase-8, but not caspase-9, is necessary for Fas-induced apoptosis. Conversely, caspase-9, but not caspase-8, is important for UV-mediated shrunken morphology and apoptosis progression. Together, these findings indicate that cell shrinkage and K+ efflux during apoptosis are tightly coupled, but are differentially regulated by either caspase-8 or caspase-9 depending on specific pathways of cell death.	NIEHS, Lab Signal Transduct, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Cidlowski, JA (corresponding author), NIEHS, Lab Signal Transduct, NIH, 111 Alexander Dr, Res Triangle Pk, NC 27709 USA.		Cidlowski, John A/G-2548-2019	Cidlowski, John A/0000-0003-1420-0516				Aragane Y, 1998, J CELL BIOL, V140, P171, DOI 10.1083/jcb.140.1.171; Avdonin V, 1998, P NATL ACAD SCI USA, V95, P11703, DOI 10.1073/pnas.95.20.11703; BEAUVAIS F, 1995, J LEUKOCYTE BIOL, V57, P851, DOI 10.1002/jlb.57.6.851; Benson RSP, 1996, AM J PHYSIOL-CELL PH, V270, pC1190, DOI 10.1152/ajpcell.1996.270.4.C1190; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Bortner CD, 2000, METHOD ENZYMOL, V322, P421; Bortner CD, 1998, BIOCHEM PHARMACOL, V56, P1549, DOI 10.1016/S0006-2952(98)00225-1; Bortner CD, 1999, J BIOL CHEM, V274, P21953, DOI 10.1074/jbc.274.31.21953; Bortner CD, 1996, AM J PHYSIOL-CELL PH, V271, pC950, DOI 10.1152/ajpcell.1996.271.3.C950; Bortner CD, 1997, J BIOL CHEM, V272, P32436, DOI 10.1074/jbc.272.51.32436; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Burg MB, 1996, FASEB J, V10, P1598, DOI 10.1096/fasebj.10.14.9002551; Caricchio R, 1998, J IMMUNOL, V161, P241; Chevaile A, 1998, CONTRIB NEPHROL, V123, P110, DOI 10.1159/000059924; COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; Corbet SW, 1999, ONCOGENE, V18, P1537, DOI 10.1038/sj.onc.1202436; Dallaporta B, 1998, J IMMUNOL, V160, P5605; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Ekert PG, 1999, CELL DEATH DIFFER, V6, P1081, DOI 10.1038/sj.cdd.4400594; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Fearnhead HO, 1998, P NATL ACAD SCI USA, V95, P13664, DOI 10.1073/pnas.95.23.13664; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Gomez-Angelats M, 2000, J BIOL CHEM, V275, P19609, DOI 10.1074/jbc.M909563199; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Hu YM, 1999, EMBO J, V18, P3586, DOI 10.1093/emboj/18.13.3586; Hughes FM, 1997, J BIOL CHEM, V272, P30567, DOI 10.1074/jbc.272.48.30567; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; King KL, 2000, CELL DEATH DIFFER, V7, P994, DOI 10.1038/sj.cdd.4400731; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Lang F, 1999, HERZ, V24, P232, DOI 10.1007/BF03044966; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Maeno E, 2000, P NATL ACAD SCI USA, V97, P9487, DOI 10.1073/pnas.140216197; Mesner PW, 1999, J BIOL CHEM, V274, P22635, DOI 10.1074/jbc.274.32.22635; Moustakas A, 1998, CONTRIB NEPHROL, V123, P121, DOI 10.1159/000059925; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Reap EA, 1997, P NATL ACAD SCI USA, V94, P5750, DOI 10.1073/pnas.94.11.5750; Rehemtulla A, 1997, J BIOL CHEM, V272, P25783, DOI 10.1074/jbc.272.41.25783; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; Schotte P, 1999, FEBS LETT, V442, P117, DOI 10.1016/S0014-5793(98)01640-8; Schrantz N, 1999, ONCOGENE, V18, P3511, DOI 10.1038/sj.onc.1202718; Schwarz A, 1998, J IMMUNOL, V160, P4262; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; Szabo I, 1996, J BIOL CHEM, V271, P20465, DOI 10.1074/jbc.271.34.20465; Thornberry NA, 2000, METHOD ENZYMOL, V322, P100; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Villa P, 1997, TRENDS BIOCHEM SCI, V22, P388, DOI 10.1016/S0968-0004(97)01107-9; Wang L, 1999, J BIOL CHEM, V274, P3678, DOI 10.1074/jbc.274.6.3678; Wolf BB, 1999, BLOOD, V94, P1683, DOI 10.1182/blood.V94.5.1683.417k37_1683_1692; Wolf CM, 1997, EXP CELL RES, V230, P22, DOI 10.1006/excr.1996.3401; Wu JC, 1999, METHODS, V17, P320, DOI 10.1006/meth.1999.0746; Yu SP, 1997, SCIENCE, V278, P114, DOI 10.1126/science.278.5335.114; Yu SP, 2000, P NATL ACAD SCI USA, V97, P9360, DOI 10.1073/pnas.97.17.9360; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	59	75	79	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					37602	37611		10.1074/jbc.M104810200	http://dx.doi.org/10.1074/jbc.M104810200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11431480	hybrid			2022-12-25	WOS:000171375700097
J	Ravindranath, RMH; Tam, WY; Bringas, P; Santos, V; Fincham, AG				Ravindranath, RMH; Tam, WY; Bringas, P; Santos, V; Fincham, AG			Amelogenin-cytokeratin 14 interaction in ameloblasts during enamel formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERMEDIATE-FILAMENT PROTEINS; MOUSE TOOTH DEVELOPMENT; MATRIX PROTEINS; IMMUNOPATHOLOGIC FEATURES; MONOCLONAL-ANTIBODIES; EXPRESSION; RAT; EPITHELIA; SEQUENCE; KERATIN	The GMp motif is found in the N-terminal region of CK14, a differentiation marker for ameloblasts. The binding affinity of CK14 and amelogenin was confirmed by dosimetric binding of CK14 to recombinant amelogenin (rM179), and to the tyrosine-rich amelogenin polypeptide. The specific binding site for CK14 was identified in the amelogenin trityrosyl motif peptide (ATMP) of tyrosine-rich amelogenin polypeptide and specific interaction between CK14 and [H-3]ATMP was confirmed by Scatchard analysis. Blocking rM179 with GlcNAc, GMp, or CK14 with ATMP abrogates the CK14-amelogenin interaction. CK14 failed to bind to ATMP when the third proline was substituted with threonine, as in some cases of human X-linked amelogenesis imperfecta or when tyrosyl residues were substituted with phenylalanine. Morphometry of developing teeth distinguished three phases of enamel formation; growth initiation phase (days 0-1), prolific growth phase (days 1-7), and growth cessation phase (post-day 7). Confocal microscopy revealed co-assembly of CK14/amelogenin in the perinuclear region of ameloblasts on day 0, migration of the co-assembled CK14/amelogenin to the apical region of the ameloblasts from day 1, reaching a peak on days 3-5, and a collapse of the co-assembly. Autoradiography with [H-3]ATMP and [H-3]GMp corroborated the dissociation of the co-assembly at the ameloblast Tomes' process. It is proposed that CK14 play a chaperon role for nascent amelogenin polypeptide during amelogenesis.	Univ So Calif, Sch Dent, Ctr Craniofacial Mol Biol, Los Angeles, CA 90033 USA	University of Southern California	Ravindranath, RMH (corresponding author), Univ So Calif, Sch Dent, Ctr Craniofacial Mol Biol, 2250 Alcazar St, Los Angeles, CA 90033 USA.				NIDCR NIH HHS [DE-03660] Funding Source: Medline	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AKITA H, 1992, ARCH ORAL BIOL, V37, P953, DOI 10.1016/0003-9969(92)90067-I; CARTAUD A, 1990, J CELL BIOL, V111, P581, DOI 10.1083/jcb.111.2.581; Collier PM, 1997, ARCH ORAL BIOL, V42, P235, DOI 10.1016/S0003-9969(96)00099-4; COULOMBE PA, 1990, J CELL BIOL, V111, P153, DOI 10.1083/jcb.111.1.153; Domingues MG, 2000, EUR J ORAL SCI, V108, P43, DOI 10.1034/j.1600-0722.2000.00717.x; EASTOE JE, 1979, J DENT RES, V58, P753, DOI 10.1177/00220345790580022701; Fincham AG, 1999, J STRUCT BIOL, V126, P270, DOI 10.1006/jsbi.1999.4130; FINCHAM AG, 1983, BIOCHEM J, V211, P149, DOI 10.1042/bj2110149; FINCHAM AG, 1994, CALCIFIED TISSUE INT, V55, P398, DOI 10.1007/BF00299322; FINCHAM AG, 1998, CONNECT TISSUE RES, V38, P1; FLIEGNER KH, 1990, EMBO J, V9, P749, DOI 10.1002/j.1460-2075.1990.tb08169.x; FOISNER R, 1987, J MOL BIOL, V198, P515, DOI 10.1016/0022-2836(87)90297-X; FOISNER R, 1988, J CELL BIOL, V106, P723, DOI 10.1083/jcb.106.3.723; Foisner R, 1991, CURR OPIN CELL BIOL, V3, P75, DOI 10.1016/0955-0674(91)90168-X; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; GREEN KJ, 1990, J BIOL CHEM, V265, P2603; KASPER M, 1989, DIFFERENTIATION, V40, P207, DOI 10.1111/j.1432-0436.1989.tb00600.x; Lacoste TD, 2000, P NATL ACAD SCI USA, V97, P9461, DOI 10.1073/pnas.170286097; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEENDERS GV, 2000, LAB INVEST, V80, P1251; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; MEHREL T, 1990, CELL, V61, P1103, DOI 10.1016/0092-8674(90)90073-N; MERRIFIELD B, 1996, SCIENCE, V232, P341; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; NAKAMURA M, 1994, ANAT RECORD, V238, P383, DOI 10.1002/ar.1092380313; PERKINS W, 1992, J CUTAN PATHOL, V19, P476, DOI 10.1111/j.1600-0560.1992.tb01600.x; PETERS BP, 1979, BIOCHEMISTRY-US, V18, P5505, DOI 10.1021/bi00591a038; RAVINDRANATH MH, 1994, J IMMUNOL METHODS, V169, P257, DOI 10.1016/0022-1759(94)90270-4; RAVINDRANATH RMH, 1995, INVEST OPHTH VIS SCI, V36, P2482; Ravindranath RMH, 1999, J BIOL CHEM, V274, P2464, DOI 10.1074/jbc.274.4.2464; Ravindranath RMH, 1997, CURR EYE RES, V16, P1036, DOI 10.1076/ceyr.16.10.1036.9015; Ravindranath RMH, 2000, J BIOL CHEM, V275, P39654, DOI 10.1074/jbc.M006471200; RAVINDRANATH RMH, 1992, VIROLOGY, V188, P143, DOI 10.1016/0042-6822(92)90743-9; RAVINDRANATH RMH, 1990, J VIROL, V64, P5430, DOI 10.1128/JVI.64.11.5430-5440.1990; RESING KA, 1989, J BIOL CHEM, V264, P1837; ROBINSON C, 1977, CALC TISS RES, V23, P19, DOI 10.1007/BF02012762; RUGG EL, 1994, GENE DEV, V8, P2563, DOI 10.1101/gad.8.21.2563; SHIBUYA N, 1987, J BIOL CHEM, V262, P1596; SIMMER JP, 1994, CALCIFIED TISSUE INT, V54, P312, DOI 10.1007/BF00295956; Tabata MJ, 1996, ARCH ORAL BIOL, V41, P1019, DOI 10.1016/S0003-9969(96)00087-8; TATEMOTO Y, 1988, VIRCHOWS ARCH A, V413, P341, DOI 10.1007/BF00783027; TERMINE JD, 1980, J BIOL CHEM, V255, P9769; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Trivedi NS, 2000, PHOTOCHEM PHOTOBIOL, V71, P634, DOI 10.1562/0031-8655(2000)071<0634:QAOPLI>2.0.CO;2; VANMUIJEN GNP, 1986, EXP CELL RES, V162, P97, DOI 10.1016/0014-4827(86)90429-5; WICHE G, 1989, CRIT REV BIOCHEM MOL, V24, P41, DOI 10.3109/10409238909082551; YAMASHITA K, 1987, J BIOL CHEM, V262, P1602; Yu WH, 2000, J BIOL CHEM, V275, P31226, DOI 10.1074/jbc.M000907200; ZeichnerDavid M, 1997, INT J DEV BIOL, V41, P27	50	31	32	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36586	36597		10.1074/jbc.M104656200	http://dx.doi.org/10.1074/jbc.M104656200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11425863	hybrid			2022-12-25	WOS:000171194500072
J	Vaz, FM; Ofman, R; Westinga, K; Back, JW; Wanders, RJA				Vaz, FM; Ofman, R; Westinga, K; Back, JW; Wanders, RJA			Molecular and biochemical characterization of rat epsilon-N-Trimethyllysine hydroxylase, the first enzyme of carnitine biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-BUTYROBETAINE HYDROXYLASE; BLUE-NATIVE-ELECTROPHORESIS; ACID BETA-OXIDATION; ZELLWEGER-SYNDROME; HUMAN-LIVER; PURIFICATION; FIBROBLASTS; PROTEINS; COA; DEHYDROGENASE	is an element of -N-Trimethyllysine hydroxylase (EC 1.14.11.8) is the first enzyme in the biosynthetic pathway Of L-carnitine and catalyzes the formation of beta -hydroxy-N-is an element of -trimethyllysine, from is an element of -N-trimethyllysine, a reaction dependent on alpha -ketoglutarate, Fe2+, and oxygen. We purified the enzyme from rat kidney and sequenced two internal peptides by quadrupole-time-of-flight mass spectroscopy. The peptide sequences were used to search the Expressed Sequence Tag data base, which led to the identification of a rat cDNA of 1218 base pairs encoding a polypeptide of 405 amino acids with a calculated molecular mass of 47.5 kDa. Using the rat sequence we also identified the homologous cDNAs from human and mouse. Heterologous expression of both the rat and human cDNAs in COS cells confirmed that they encode is an element of -N-trimethyllysine hydroxylase. Subeellular fractionation studies revealed that the rat enzyme is localized exclusively in mitochondria. Expression studies in yeast indicated that the rat enzyme is synthesized as a 47.5-kDa precursor and subsequently processed to a mature protein of 43 kDa, presumably upon import in mitochondria. The Michaelis-Menten constants of the purified rat enzyme for trimethyllysine, alpha -ketoglutarate, and Fe2+ were 1.1 mM, 109 muM, and 54 muM, respectively. Both gel filtration and blue native polyacrylamide gel electrophoresis analysis showed that the native enzyme has a mass of approximately 87 kDa, indicating that in rat is an element of -N-trimethyllysine hydroxylase is a homodimer.	Univ Amsterdam, Emma Childrens Hosp, Acad Med Ctr, Dept Clin Chem,Lab Genet Metab Dis, NL-1100 DE Amsterdam, Netherlands; Univ Amsterdam, Emma Childrens Hosp, Acad Med Ctr, Dept Pediat,Lab Genet Metab Dis, NL-1100 DE Amsterdam, Netherlands; Univ Amsterdam, Swammerdam Inst Life Sci, Mass Spectrometry Grp, NL-1018 TV Amsterdam, Netherlands	Emma Children's Hospital; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; Emma Children's Hospital; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; University of Amsterdam	Wanders, RJA (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Clin Chem, Lab Genet Metab Dis, F0-224,POB 22700, NL-1100 DE Amsterdam, Netherlands.		B, Jw/N-7879-2019; Back, JW/B-3641-2009	B, Jw/0000-0002-1310-4373; Back, JW/0000-0002-1310-4373; Vaz, Frederic/0000-0002-9048-1041				BECKER D M, 1991, P182; BIEBER LL, 1988, ANNU REV BIOCHEM, V57, P261, DOI 10.1146/annurev.bi.57.070188.001401; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREMER J, 1983, PHYSIOL REV, V63, P1420, DOI 10.1152/physrev.1983.63.4.1420; ENGLARD S, 1979, FEBS LETT, V102, P297, DOI 10.1016/0014-5793(79)80022-8; ENGLARD S, 1978, ARCH BIOCHEM BIOPHYS, V190, P361, DOI 10.1016/0003-9861(78)90287-4; FRANZUSOFF A, 1991, P662; HULSE JD, 1978, J BIOL CHEM, V253, P1654; HULSE JD, 1980, J BIOL CHEM, V255, P1146; JAKOBS BS, 1995, BIOCHEM BIOPH RES CO, V213, P1035, DOI 10.1006/bbrc.1995.2232; Jansen GA, 2000, HUM MOL GENET, V9, P1195, DOI 10.1093/hmg/9.8.1195; KAUFMAN RA, 1977, J BIOL CHEM, V252, P7437; KLEMENT P, 1995, ANAL BIOCHEM, V231, P218, DOI 10.1006/abio.1995.1523; KONDO A, 1981, ARCH BIOCHEM BIOPHYS, V212, P338, DOI 10.1016/0003-9861(81)90374-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDSTEDT G, 1970, J BIOL CHEM, V245, P4178; LINDSTEDT G, 1982, SCAND J CLIN LAB INV, V42, P477; LINDSTEDT G, 1977, BIOCHEMISTRY-US, V16, P2181, DOI 10.1021/bi00629a022; LINDSTEDT S, 1984, BIOCHEM J, V223, P119, DOI 10.1042/bj2230119; McGarry JD, 1997, EUR J BIOCHEM, V244, P1, DOI 10.1111/j.1432-1033.1997.00001.x; RABILLOUD T, 1988, ELECTROPHORESIS, V9, P288, DOI 10.1002/elps.1150090608; REBOUCHE CJ, 1982, FED PROC, V41, P2848; REBOUCHE CJ, 1980, J BIOL CHEM, V255, P8700; REBOUCHE CJ, 1980, BIOCHIM BIOPHYS ACTA, V630, P22, DOI 10.1016/0304-4165(80)90133-6; SACHAN DS, 1980, BIOCHEM BIOPH RES CO, V96, P870, DOI 10.1016/0006-291X(80)91436-9; SACHAN DS, 1980, BIOCHEM J, V188, P529, DOI 10.1042/bj1880529; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; STEIN R, 1981, ANAL BIOCHEM, V116, P230, DOI 10.1016/0003-2697(81)90349-3; STEIN R, 1982, ARCH BIOCHEM BIOPHYS, V217, P324, DOI 10.1016/0003-9861(82)90508-2; Vaz FM, 1998, BIOCHEM BIOPH RES CO, V250, P506, DOI 10.1006/bbrc.1998.9343; Vaz FM, 2000, J BIOL CHEM, V275, P7390, DOI 10.1074/jbc.275.10.7390; Vaz FM, 1999, ADV EXP MED BIOL, V466, P117; Verhoeven NM, 1998, J LIPID RES, V39, P66; WANDERS RJA, 1984, BIOCHEM BIOPH RES CO, V123, P1054, DOI 10.1016/S0006-291X(84)80240-5; Wanders RJA, 1995, J INHERIT METAB DIS, V18, P113, DOI 10.1007/BF00711434; WANDERS RJA, 1986, CLIN CHIM ACTA, V159, P1, DOI 10.1016/0009-8981(86)90160-9; WANDERS RJA, 1994, BBA-MOL BASIS DIS, V1227, P177, DOI 10.1016/0925-4439(94)90092-2	38	46	49	2	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33512	33517		10.1074/jbc.M105929200	http://dx.doi.org/10.1074/jbc.M105929200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11431483	hybrid			2022-12-25	WOS:000170910200031
J	Ziebuhr, J; Thiel, V; Gorbalenya, AE				Ziebuhr, J; Thiel, V; Gorbalenya, AE			The autocatalytic release of a putative RNA virus transcription factor from its polyprotein precursor involves two paralogous papain-like proteases that cleave the same peptide bond	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFECTIOUS-BRONCHITIS VIRUS; MULTIPLE SEQUENCE ALIGNMENT; EQUINE ARTERITIS VIRUS; MURINE CORONAVIRUS; CYSTEINE PROTEINASE; PROTEOLYTIC PRODUCTS; ENCODED PROTEINASES; 3C-LIKE PROTEINASE; STRAIN A59; IDENTIFICATION	The largest replicative protein of coronaviruses is known as p195 in the avian infectious bronchitis virus (IBV) and p210 (p240) in the mouse hepatitis virus. It is autocatalytically released from the precursors pp1a and pp1ab by one zinc finger-containing papain-like protease (PLpro) in IBV and by two paralogous PLpros, PL1pro and PL2pro, in mouse hepatitis virus. The PL-pro-containing proteins have been recently implicated in the control of coronavirus subgenomic mRNA synthesis (transcription). By using comparative sequence analysis, we now show that the respective proteins of all sequenced coronaviruses are flanked by two conserved PLpro cleavage sites and share a complex (multi)domain organization with PL1pro being inactivated in IBV. Based upon these predictions, the processing of the human coronavirus 229E p195/p210 N terminus was studied in detail. First, an 87-kDa protein (p87), which is derived from a pp1a/pp1ab region immediately upstream of p195/p210, was identified in human coronavirus 229E-infected cells. Second, in vitro synthesized proteins representing different parts of pp1a were autocatalytically processed at the predicted site. Surprisingly, both PL1pro and PL2pro cleaved between p87 and p195/p210. The PL1pro-mediated cleavage was slow and significantly suppressed by a non-proteolytic activity of PL2pro. In contrast, PL2pro, whose proteolytic activity and specificity were established in this study, cleaved the same site efficiently in the presence of the upstream domains. Third, a correlation was observed between the overlapping substrate specificities and the parallel evolution of PL1pro and PL2pro. Collectively, our results imply that the p195/p210 autoprocessing mechanisms may be conserved among coronaviruses to an extent not appreciated previously, with PL2pro playing a major role. A large subset of coronaviruses may employ two proteases to cleave the same site(s) and thus regulate the expression of the viral genome in a unique way.	NCI, Frederick Canc Res & Dev Ctr, SAIC, Adv Biomed Comp Ctr, Frederick, MD 21702 USA; Univ Wurzburg, Inst Immunol & Virol, D-97078 Wurzburg, Germany	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; University of Wurzburg	Ziebuhr, J (corresponding author), NCI, Frederick Canc Res & Dev Ctr, SAIC, Adv Biomed Comp Ctr, 430 Miller Dr,Rm 228, Frederick, MD 21702 USA.		Thiel, Volker/AAI-2391-2019; Gorbalenya, Alexander E/J-4818-2012; Ziebuhr, John/G-7669-2015	Gorbalenya, Alexander E/0000-0002-4967-7341; Thiel, Volker/0000-0002-5783-0887; Ziebuhr, John/0000-0002-5741-8825	OFFICE OF THE DIRECTOR, NCI [N01CO056000] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-56000] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Almazan F, 2000, P NATL ACAD SCI USA, V97, P5516, DOI 10.1073/pnas.97.10.5516; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BAKER SC, 1989, J VIROL, V63, P3693, DOI 10.1128/JVI.63.9.3693-3699.1989; BAKER SC, 1993, J VIROL, V67, P6056, DOI 10.1128/JVI.67.10.6056-6063.1993; Bi WZ, 1998, J NEUROVIROL, V4, P594, DOI 10.3109/13550289809114226; BONILLA PJ, 1995, VIROLOGY, V209, P489, DOI 10.1006/viro.1995.1281; BONILLA PJ, 1994, VIROLOGY, V198, P736, DOI 10.1006/viro.1994.1088; Bonilla PJ, 1997, J VIROL, V71, P900, DOI 10.1128/JVI.71.2.900-909.1997; BRIERLEY I, 1987, EMBO J, V6, P3779, DOI 10.1002/j.1460-2075.1987.tb02713.x; Cavanagh D, 1997, ARCH VIROL, V142, P629; DENBOON JA, 1991, J VIROL, V65, P2910, DOI 10.1128/JVI.65.6.2910-2920.1991; DENISON M, 1987, VIROLOGY, V157, P565, DOI 10.1016/0042-6822(87)90303-5; DENISON MR, 1995, VIROLOGY, V207, P316, DOI 10.1006/viro.1995.1085; DONG SH, 1994, VIROLOGY, V204, P541, DOI 10.1006/viro.1994.1567; Eddy SR, 1996, CURR OPIN STRUC BIOL, V6, P361, DOI 10.1016/S0959-440X(96)80056-X; Gorbalenya A.E., 1993, SOV SCI REV D, V11, P1; GORBALENYA AE, 1991, FEBS LETT, V288, P201, DOI 10.1016/0014-5793(91)81034-6; Gorbalenya AE, 1996, PERSPECT DRUG DISCOV, V6, P64, DOI 10.1007/BF02174046; Grotzinger C, 1996, VIROLOGY, V222, P227, DOI 10.1006/viro.1996.0413; HENIKOFF S, 1994, J MOL BIOL, V243, P574, DOI 10.1016/0022-2836(94)90032-9; Herold J, 1996, METHOD ENZYMOL, V275, P68; Herold J, 1998, J VIROL, V72, P910, DOI 10.1128/JVI.72.2.910-918.1998; HEROLD J, 1993, VIROLOGY, V195, P680, DOI 10.1006/viro.1993.1419; Herold J, 1999, J BIOL CHEM, V274, P14918, DOI 10.1074/jbc.274.21.14918; HUGHES SA, 1995, J VIROL, V69, P809, DOI 10.1128/JVI.69.2.809-813.1995; Kanjanahaluethai A, 2000, J VIROL, V74, P7911, DOI 10.1128/JVI.74.17.7911-7921.2000; Kimura M., 1983, NEUTRAL THEORY MOL E, P367, DOI [10.1017/CBO9780511623486, DOI 10.1139/cjz-2013-0127]; KRAUSSLICH HG, 1988, ANNU REV BIOCHEM, V57, P701, DOI 10.1146/annurev.bi.57.070188.003413; Lai MMC, 1997, ADV VIRUS RES, V48, P1, DOI 10.1016/S0065-3527(08)60286-9; LASTARZA MW, 1994, J VIROL, V68, P5781, DOI 10.1128/JVI.68.9.5781-5791.1994; LEE HJ, 1991, VIROLOGY, V180, P567, DOI 10.1016/0042-6822(91)90071-I; Lim KP, 1998, VIROLOGY, V245, P303, DOI 10.1006/viro.1998.9164; Lim KP, 2000, J VIROL, V74, P1674, DOI 10.1128/JVI.74.4.1674-1685.2000; Molenkamp R, 2000, J GEN VIROL, V81, P2491, DOI 10.1099/0022-1317-81-10-2491; Morgenstern B, 1999, BIOINFORMATICS, V15, P211, DOI 10.1093/bioinformatics/15.3.211; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; ROST B, 1995, PROTEIN SCI, V4, P521; Rost B, 1996, METHOD ENZYMOL, V266, P525; Ryan MD, 1997, J GEN VIROL, V78, P699, DOI 10.1099/0022-1317-78-4-699; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Schiller JJ, 1998, VIROLOGY, V242, P288, DOI 10.1006/viro.1997.9010; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; Seybert A, 2000, J VIROL, V74, P9586, DOI 10.1128/JVI.74.20.9586-9593.2000; Seybert A, 2000, RNA, V6, P1056, DOI 10.1017/S1355838200000728; Siddell SG., 1995, CORONAVIRIDAE INTRO, DOI [10.1007/978-1-4899-1531-3, DOI 10.1007/978-1-4899-1531-3]; SWOFFORD DL, 2000, PAUP PHYLOGENETIC AN; Teng H, 1999, J VIROL, V73, P2658, DOI 10.1128/JVI.73.4.2658-2666.1999; Thiel V, 2001, J GEN VIROL, V82, P1273, DOI 10.1099/0022-1317-82-6-1273; Thiel V, 2001, J VIROL, V75, P6676, DOI 10.1128/JVI.75.14.6676-6681.2001; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Tijms MA, 2001, P NATL ACAD SCI USA, V98, P1889, DOI 10.1073/pnas.041390398; Yao Z, 1992, PCR Methods Appl, V1, P205; Yount B, 2000, J VIROL, V74, P10600, DOI 10.1128/JVI.74.22.10600-10611.2000; Ziebuhr J, 2000, J GEN VIROL, V81, P853, DOI 10.1099/0022-1317-81-4-853; ZIEBUHR J, 1995, J VIROL, V69, P4331, DOI 10.1128/JVI.69.7.4331-4338.1995; Ziebuhr J, 1999, J VIROL, V73, P177, DOI 10.1128/JVI.73.1.177-185.1999	56	115	127	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					33220	33232		10.1074/jbc.M104097200	http://dx.doi.org/10.1074/jbc.M104097200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11431476	hybrid, Green Published			2022-12-25	WOS:000170746000108
J	Faour, WH; He, YL; He, QW; de Ladurantaye, M; Quintero, M; Mancini, A; Di Battista, JA				Faour, WH; He, YL; He, QW; de Ladurantaye, M; Quintero, M; Mancini, A; Di Battista, JA			Prostaglandin E-2 regulates the level and stability of cyclooxygenase-2 mRNA through activation of p38 mitogen-activated protein kinase in interleukin-1 beta-treated human synovial fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; FACTOR-KAPPA-B; TRANSCRIPTION FACTOR; GENE-EXPRESSION; ENDOPEROXIDE SYNTHASE; ENDOTHELIAL-CELLS; MAP KINASE; INDUCTION; LIPOPOLYSACCHARIDE; PHOSPHORYLATION	The p38 MAPK mediates transcriptional and posttranscriptional control of cyclooxygenase-2 (COX-2) mRNA following interleukin-1(IL-1)/lipopolysaccharide cellular activation. We explored a positive feedback, prostaglandin E-2 (PGE(2))-dependent stabilization of COX-2 mRNA mediated by the p38 MAPK cascade in IL-1 beta -stimulated human synovial fibroblasts. We observed a rapid (5 min), massive (> 30-fold), and sustained (> 48 h) increase in COX-2 mRNA, protein, and PGE, release following a recombinant human (rh) IL-1 beta signal that was inhibited by NS-398, a COX-2 inhibitor, and SB202190, a selective, cell-permeable p38 MAPK inhibitor. PGE(2) completely reversed NS-398-mediated inhibition but not SB202190-dependent inhibition. The eicosanoid didn't potentiate IL-1 beta -induced COX-2 expression nor did it activate COX-2 gene expression in quiescent cells. Transfection experiments with a human COX-2 promoter construct revealed a minor element of p38 MAPK-dependent transcriptional control after IL-1 beta stimulation. p38 MAPK synergized with the cAMP/cAMP-dependent protein kinase cascade to transactivate the COX-2 promoter. When human synovial fibroblasts were activated with rhIL-1 beta for 3-4 h (steady state) followed by washout, the elevated levels of COX-2 mRNA declined rapidly (<2 h) to control levels. If PGE(2), unlike EP2/3 agonists butaprost and sulprostone, was added to fresh medium, COX-2 mRNA levels remained elevated for up to 16 h. SB202190 or anti-PGE(2) monoclonal antibody compromised the stabilization of COX-2 mRNA by PGE2. Deletion analysis using transfected chimeric luciferase-COX-2 mRNA 3 ' -untranslated region reporter constructs revealed that IL-1 beta increased reporter gene MIRNA stability and translation via AU-containing distal regions of the untranslated region. This response was mediated entirely by a PGE(2)/p38 MAPK-dependent process. We conclude that the magnitude and duration of the induct-ion of COX-2 mRNA, protein, and PGE(2) release by rhIL-1 beta is primarily the result of PGE(2) -dependent stabilization of COX-2 mRNA and stimulation of translation, a process involving a positive feedback loop mediated by the EP4 receptor and the downstream kinases p38 MAPK and, perhaps, cAMP-dependent protein kinase.	Univ Montreal, Ctr Hosp, Unit Rech Arthrose, Hop Notre Dame, Montreal, PQ H2L 4M1, Canada; Univ Los Andes, Dept Med, Rheumatol Unit, Merida, Venezuela	Universite de Montreal; University of Los Andes Venezuela	Di Battista, JA (corresponding author), Univ Montreal, Ctr Hosp, Unit Rech Arthrose, Hop Notre Dame, 1560 Rue Sherbrooke Est, Montreal, PQ H2L 4M1, Canada.		faour, wissam/J-3419-2019	faour, wissam/0000-0002-0746-3687				Akarasereenont P, 1999, MEDIAT INFLAMM, V8, P287, DOI 10.1080/09629359990298; Alaaeddine N, 1997, J RHEUMATOL, V24, P1985; Alaaeddine N, 1999, ARTHRITIS RHEUM-US, V42, P710, DOI 10.1002/1529-0131(199904)42:4<710::AID-ANR14>3.0.CO;2-4; APPLEBY SB, 1994, BIOCHEM J, V302, P723, DOI 10.1042/bj3020723; BEELMAN CA, 1995, CELL, V81, P179, DOI 10.1016/0092-8674(95)90326-7; Callejas NA, 1999, J PHARMACOL EXP THER, V288, P1235; Clerk A, 1998, FEBS LETT, V426, P93, DOI 10.1016/S0014-5793(98)00324-X; CROFFORD LJ, 1994, J CLIN INVEST, V93, P1095, DOI 10.1172/JCI117060; Crofford LJ, 1997, ARTHRITIS RHEUM-US, V40, P226, DOI 10.1002/art.1780400207; Dean JLE, 2001, MOL CELL BIOL, V21, P721, DOI 10.1128/MCB.21.3.721-730.2001; Dean JLE, 1999, J BIOL CHEM, V274, P264, DOI 10.1074/jbc.274.1.264; DEWITT DL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P121, DOI 10.1016/0005-2760(91)90032-D; Di Battista JA, 1999, ARTHRITIS RHEUM, V42, P157, DOI 10.1002/1529-0131(199901)42:1<157::AID-ANR19>3.0.CO;2-P; DiBattista JA, 1996, J CELL BIOCHEM, V63, P320; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Dixon DA, 2000, J BIOL CHEM, V275, P11750, DOI 10.1074/jbc.275.16.11750; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; Eder J, 1997, TRENDS PHARMACOL SCI, V18, P319, DOI 10.1016/S0165-6147(97)01097-3; Fahmi H, 2001, OSTEOARTHR CARTILAGE, V9, P332, DOI 10.1053/joca.2000.0393; FAOUR W, 2000, P 5 WORLD C OST BARC, pS10; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; Geng Y, 1996, J CLIN INVEST, V98, P2425, DOI 10.1172/JCI119056; GOETZL EJ, 1995, FASEB J, V9, P1051, DOI 10.1096/fasebj.9.11.7649404; Gou Q, 1998, BIOCHEM BIOPH RES CO, V242, P508, DOI 10.1006/bbrc.1997.7994; Guan ZH, 1998, J BIOL CHEM, V273, P12901, DOI 10.1074/jbc.273.21.12901; Gutkind JS, 1998, ONCOGENE, V17, P1331, DOI 10.1038/sj.onc.1202186; HAN J, 1990, J EXP MED, V171, P465, DOI 10.1084/jem.171.2.465; HE W, 2001, IN PRESS ARTHRITIS R; Herlaar E, 1999, MOL MED TODAY, V5, P439, DOI 10.1016/S1357-4310(99)01544-0; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; Ichijo H, 1999, ONCOGENE, V18, P6087, DOI 10.1038/sj.onc.1203129; JONES DA, 1993, J BIOL CHEM, V268, P9049; Karin M, 1998, P NATL ACAD SCI USA, V95, P9067, DOI 10.1073/pnas.95.16.9067; KRUYS VI, 1988, GENE, V72, P191, DOI 10.1016/0378-1119(88)90144-8; Kutchera W, 1996, P NATL ACAD SCI USA, V93, P4816, DOI 10.1073/pnas.93.10.4816; Lasa M, 2000, MOL CELL BIOL, V20, P4265, DOI 10.1128/MCB.20.12.4265-4274.2000; Martel-Pelletier J, 1999, OSTEOARTHRITIS CLIN, P156, DOI DOI 10.1007/978-3-642-60026-5_9; Mestre JR, 2001, J BIOL CHEM, V276, P3977, DOI 10.1074/jbc.M005077200; MORIN N, 1999, OSTEOARTHR CARTILAGE, V7, pS21; Muzio M, 1998, J EXP MED, V187, P2097, DOI 10.1084/jem.187.12.2097; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; Newton R, 1998, J BIOL CHEM, V273, P32312, DOI 10.1074/jbc.273.48.32312; Newton R, 1997, BIOCHEM BIOPH RES CO, V237, P28, DOI 10.1006/bbrc.1997.7064; Newton R, 1997, BIOCHEM BIOPH RES CO, V234, P85, DOI 10.1006/bbrc.1997.6586; OBANION MK, 1992, P NATL ACAD SCI USA, V89, P4888, DOI 10.1073/pnas.89.11.4888; OLIW EH, 1986, J BIOL CHEM, V261, P9216; OLIW EH, 1989, BIOCHIM BIOPHYS ACTA, V1001, P107, DOI 10.1016/0005-2760(89)90313-5; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; Proudfoot N, 1996, CELL, V87, P779, DOI 10.1016/S0092-8674(00)81982-0; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Ridley SH, 1998, FEBS LETT, V439, P75, DOI 10.1016/S0014-5793(98)01342-8; RISTIMAKI A, 1994, J BIOL CHEM, V269, P11769; Robertson RP, 1995, TRENDS ENDOCRIN MET, V6, P293, DOI 10.1016/1043-2760(95)00159-X; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; RYSECK RP, 1992, CELL GROWTH DIFFER, V3, P443; SAMUELSSON B, 1978, ANNU REV BIOCHEM, V47, P997, DOI 10.1146/annurev.bi.47.070178.005025; Schmedtje JF, 1997, J BIOL CHEM, V272, P601; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; Tibbles LA, 1999, CELL MOL LIFE SCI, V55, P1230, DOI 10.1007/s000180050369; WANG CY, 1998, SCIENCE, V274, P786; WANG LH, 1993, BIOCHEM BIOPH RES CO, V190, P406, DOI 10.1006/bbrc.1993.1062; Wesselborg S, 1997, J BIOL CHEM, V272, P12422, DOI 10.1074/jbc.272.19.12422; Wu KK, 1996, J LAB CLIN MED, V128, P242, DOI 10.1016/S0022-2143(96)90023-2; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315; Zhang FX, 1999, J BIOL CHEM, V274, P7611, DOI 10.1074/jbc.274.12.7611	66	186	189	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					31720	31731		10.1074/jbc.M104036200	http://dx.doi.org/10.1074/jbc.M104036200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11423555	hybrid			2022-12-25	WOS:000170613500035
J	Lu, WP; Kincaid, E; Sun, YP; Bauer, MD				Lu, WP; Kincaid, E; Sun, YP; Bauer, MD			Kinetics of beta-lactam interactions with penicillin-susceptible and -resistant penicillin-binding protein 2x proteins from Streptococcus pneumoniae - Involvement of acylation and deacylation in beta-lactam resistance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IONIZATION-MASS-SPECTROMETRY; STAPHYLOCOCCUS-AUREUS; ACTIVE-SITE; ANTIBIOTICS; TRANSPEPTIDASE; CONSTANTS; MECHANISM; BACTERIA; GENES; MITIS	Kinetic interactions of beta -lactam antibiotics such as penicillin-G and cefotaxime with normal, penicillin-susceptible PBP2x from Streptococcus pneumoniae and a penicillin-resistant PBP2x (PBP2x(R)) from a resistant clinical isolate (CS109) of the bacterium have been extensively characterized using electrospray mass spectrometry coupled with a fast reaction (quench flow) technique. Kinetic evidence for a two-step acylation of PBP2x by penicillin-G has been demonstrated, and the dissociation constant, K-d of 0.9 mM, and the acylation rate constant, k(2) of 180 s(-1), have been determined for the first time. The millimolar range K-d implies that the beta -lactam fits to the active site pocket of the penicillin-sensitive PEP rather poorly, whereas the extremely fast k(2) value indicates that this step contributes most of the binding affinity of the beta -lactam. The values of K-d (4 mM) and k(2) (0.56 s(-1)) were also determined for PBP2x(R). The combined value of k(2)/K-d, known as overall binding efficiency, for PBP2xR (137 M-1 s(-1)) was over 1000-fold slower than that for PBP2x (200,000 M-1 s(-1)), indicating that a major part is played by the acylation steps in penicillin resistance. Most of the decreased binding efficiency of PBP2xR comes from the decreased (similar to 300-fold) k(2) Kinetic studies of cefotaxime acylation of the two PBP2x proteins confirmed all of the above findings. Deacylation rate constants (k(3)) for the third step of the interact-ions were determined to be 8 x 10(-6) s(-1) for penicilloyl-PBP2x and 5.7 x 10(-4) s(-1) for penicilloyl-PBP2x(R), corresponding to over 70-fold increase of the deacylation rate for the resistant PBP2xR. Similarly, over 80-fold enhancement of the deacylation rate was found for cefotaxime-PBP2x(R) complex (k(3) = 3 x 10(-4) s(-1)) as compared with that of cefotaxime-PBP2x complex (3.5 x 10-6 s(-1)). This is the first time that such a significant increase of k(3) values was found for a beta -lactsm-resistant penicillin-binding protein. These data indicate that the deacylation step also plays a role, which is much more important than previously thought, in PBP2x(R) resistance to beta -lactams.	Procter & Gamble Pharmaceut, Hlth Care Res Ctr, Antiinfect Res, Mason, OH 45040 USA; Procter & Gamble Co, Miami Valley Labs, Corp Res Div, Cincinnati, OH 45253 USA	Procter & Gamble; Procter & Gamble	Lu, WP (corresponding author), Procter & Gamble Pharmaceut, Hlth Care Res Ctr, Antiinfect Res, Mason, OH 45040 USA.							[Anonymous], 1992, CHEM B LACTAMS; Asahi Y, 1999, ANTIMICROB AGENTS CH, V43, P1252, DOI 10.1128/AAC.43.5.1252; Beadle BM, 2001, PROTEIN SCI, V10, P1254, DOI 10.1110/ps.52001; BLUMBERG PM, 1971, P NATL ACAD SCI USA, V68, P2814, DOI 10.1073/pnas.68.11.2814; CHAMBERS HF, 1994, BIOCHEM J, V301, P139, DOI 10.1042/bj3010139; CHRISTENSEN H, 1990, BIOCHEM J, V266, P853; COFFEY TJ, 1995, ANTIMICROB AGENTS CH, V39, P1306, DOI 10.1128/AAC.39.6.1306; COYETTE J, 1994, ADV COMP ENV PHYSL, V20, P233; Di Guilmi AM, 2000, ANAL BIOCHEM, V284, P240, DOI 10.1006/abio.2000.4735; DOWSON CG, 1989, MOL MICROBIOL, V3, P95, DOI 10.1111/j.1365-2958.1989.tb00108.x; DOWSON CG, 1989, P NATL ACAD SCI USA, V86, P8842, DOI 10.1073/pnas.86.22.8842; ELKHARROUBI A, 1991, BIOCHEM J, V280, P463, DOI 10.1042/bj2800463; FRERE JM, 1975, EUR J BIOCHEM, V57, P343, DOI 10.1111/j.1432-1033.1975.tb02307.x; FRESHT A, 1984, ENZYME STRUCTURE MEC, P152; GHUYSEN JM, 1991, ANNU REV MICROBIOL, V45, P37, DOI 10.1146/annurev.mi.45.100191.000345; GHUYSEN JM, 1986, BIOCHEM J, V235, P159, DOI 10.1042/bj2350159; Goffin C, 1998, MICROBIOL MOL BIOL R, V62, P1079, DOI 10.1128/MMBR.62.4.1079-1093.1998; Grebe T, 1996, ANTIMICROB AGENTS CH, V40, P829, DOI 10.1128/AAC.40.4.829; Hakenbeck R, 1998, J BACTERIOL, V180, P1831, DOI 10.1128/JB.180.7.1831-1840.1998; JAMIN M, 1993, BIOCHEM J, V292, P735, DOI 10.1042/bj2920735; KELL CM, 1993, FEMS MICROBIOL LETT, V106, P171; LABILE G, 1991, MOL MICROBIOL, V5, P1993; LAIBLE G, 1992, EUR J BIOCHEM, V207, P943, DOI 10.1111/j.1432-1033.1992.tb17128.x; LU WP, 1990, J BIOL CHEM, V265, P3124; Lu WP, 1999, BIOCHEMISTRY-US, V38, P6537, DOI 10.1021/bi990025e; Massova I, 1998, ANTIMICROB AGENTS CH, V42, P1; Mouz N, 1998, P NATL ACAD SCI USA, V95, P13403, DOI 10.1073/pnas.95.23.13403; Mouz N, 1999, J BIOL CHEM, V274, P19175, DOI 10.1074/jbc.274.27.19175; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; Potgieter E, 1995, MICROB DRUG RESIST, V1, P35, DOI 10.1089/mdr.1995.1.35; Sambrook J., 2002, MOL CLONING LAB MANU; SMITH JM, 1991, NATURE, V349, P29, DOI 10.1038/349029a0; SPRATT BG, 1994, BACTERIAL CELL WALL, P517; STRICKLAND S, 1975, J BIOL CHEM, V250, P4048; WAXMAN DJ, 1983, ANNU REV BIOCHEM, V52, P825, DOI 10.1146/annurev.bi.52.070183.004141; Zechel DL, 1998, BIOCHEMISTRY-US, V37, P7664, DOI 10.1021/bi980445o; Zhao GS, 1997, J BACTERIOL, V179, P4901, DOI 10.1128/jb.179.15.4901-4908.1997	37	52	53	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					31494	31501		10.1074/jbc.M102499200	http://dx.doi.org/10.1074/jbc.M102499200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11408478	hybrid			2022-12-25	WOS:000170613500005
J	Grothe, T; Lenz, R; Kutchan, TM				Grothe, T; Lenz, R; Kutchan, TM			Molecular characterization of the salutaridinol 7-O-acetyltransferase involved in morphine biosynthesis in opium poppy Papaver somniferum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BERBERINE BRIDGE ENZYME; HETEROLOGOUS EXPRESSION; FUNCTIONAL EXPRESSION; CELL-CULTURES; STRICTOSIDINE SYNTHASE; VINDOLINE BIOSYNTHESIS; O-ACETYLTRANSFERASE; CODEINONE REDUCTASE; TRANSFERASE CDNA; CLONING	Salutaridinol 7-O-acetyltransferase (EC 2.3.1.150) catalyzes the conversion of the phenanthrene alkaloid salutaridinol to salutaridinol-7-O-acetate, the immediate precursor of thebaine along the morphine biosynthetic pathway. We have isolated a cDNA clone that corresponds to the internal amino acid sequences of the native enzyme purified from a cell suspension culture of opium poppy Papaver somniferum. The recombinant enzyme acetylated the 7-hydroxyl moiety of salutaridinol in the presence of acetyl-CoA. The apparent K. value for salutaridinol was determined to be 9 mum and 54 mum for acetyl-CoA. The gene transcript was detected in extracts from Papaver orientale and Papaver bracteatum in addition to P. somniferum. Genomic DNA gel blot analysis indicated that there is likely a single copy of this gene in the P. somniferum genome. The amino acid sequence of salutaridinol 7-O-acetyltransferase is most similar (37% identity) to that of deacetylvindoline acetyltransferase of Catharanthus roseus. Salutaridinol 7-O-acetyltransferase is the second enzyme specific to morphine biosynthesis for which we have isolated a cDNA. Taken together with the other cDNAs cloned encoding norcoclaurine 6-O-methyl-transferase, (S)-N-methylcoclaurine 3 ' -hydroxylase, the cytochrome P-450 reductase, and codeinone reductase, significant progress has been made toward accumulating genes of this pathway to enable the end goal of a biotechnological production of morphinan alkaloids.	Leibniz Inst Pflanzenbiochem, D-06120 Halle An Der Saale, Germany; Univ Munich, Lehrstuhl Pharmazeut Biol, D-80333 Munich, Germany	Leibniz Institut fur Pflanzenbiochemie; University of Munich	Kutchan, TM (corresponding author), Leibniz Inst Pflanzenbiochem, Weinberg 3, D-06120 Halle An Der Saale, Germany.	kutch@ipb-halle.de	Kutchan, Toni/L-4625-2013	GROTHE, TORSTEN/0000-0003-3298-4924				BRACHER D, 1992, ARCH BIOCHEM BIOPHYS, V294, P717, DOI 10.1016/0003-9861(92)90746-J; BROWN NF, 1994, J BIOL CHEM, V269, P19157; Decker G, 2000, ELECTROPHORESIS, V21, P3500, DOI 10.1002/1522-2683(20001001)21:16<3500::AID-ELPS3500>3.0.CO;2-O; DEEKNAMKUL W, 1992, PHYTOCHEMISTRY, V31, P813, DOI 10.1016/0031-9422(92)80020-F; DELUCA V, 1985, J PLANT PHYSIOL, V121, P417, DOI 10.1016/S0176-1617(85)80078-X; DITTRICH H, 1991, P NATL ACAD SCI USA, V88, P9969, DOI 10.1073/pnas.88.22.9969; ECKERSKORN C, 1989, CHROMATOGRAPHIA, V28, P92, DOI 10.1007/BF02290390; FAHN W, 1985, PLANT CELL REP, V4, P333, DOI 10.1007/BF00269892; Frick S, 1999, PLANT J, V17, P329, DOI 10.1046/j.1365-313X.1999.00379.x; GERARDY R, 1993, PHYTOCHEMISTRY, V34, P125, DOI 10.1016/S0031-9422(00)90793-3; GERARDY R, 1993, PHYTOCHEMISTRY, V32, P79, DOI 10.1016/0031-9422(92)80111-Q; HENDLE J, 1995, BIOCHEMISTRY-US, V34, P4287, DOI 10.1021/bi00013a018; Huang FC, 2000, PHYTOCHEMISTRY, V53, P555, DOI 10.1016/S0031-9422(99)00600-7; KUTCHAN TM, 1994, PHYTOCHEMISTRY, V35, P353, DOI 10.1016/S0031-9422(00)94763-0; KUTCHAN TM, 1998, ALKALOIDS, V50, P257; KUTCHAN TM, 1985, CHEM BIOL ISOQUINOLI, P281; LENZ R, 1995, EUR J BIOCHEM, V233, P132, DOI 10.1111/j.1432-1033.1995.132_1.x; Lenz R, 1995, J BIOL CHEM, V270, P31091, DOI 10.1074/jbc.270.52.31091; LINSMAIER EM, 1965, PHYSIOL PLANTARUM, V18, P100, DOI 10.1111/j.1399-3054.1965.tb06874.x; Miles E W, 1977, Methods Enzymol, V47, P431; NESSLER CL, 1977, AM J BOT, V64, P541, DOI 10.2307/2442002; NESSLER CL, 1978, AM J BOT, V65, P978, DOI 10.2307/2442685; Novak BH, 2000, CURR ORG CHEM, V4, P343, DOI 10.2174/1385272003376292; Pauli HH, 1998, PLANT J, V13, P793, DOI 10.1046/j.1365-313X.1998.00085.x; PFITZNER A, 1983, TETRAHEDRON LETT, V24, P5197, DOI 10.1016/S0040-4039(00)88395-1; RICE KC, 1980, J ORG CHEM, V45, P3135, DOI 10.1021/jo01303a045; ROBERTS MF, 1983, ARCH BIOCHEM BIOPHYS, V222, P599, DOI 10.1016/0003-9861(83)90558-1; Rosco A, 1997, ARCH BIOCHEM BIOPHYS, V348, P369, DOI 10.1006/abbi.1997.0374; RUSH MD, 1985, PLANT CELL REP, V4, P237, DOI 10.1007/BF00269366; SHAW WV, 1991, ANNU REV BIOPHYS BIO, V20, P363, DOI 10.1146/annurev.biophys.20.1.363; Sinclair JC, 2000, NAT STRUCT BIOL, V7, P560; St-Pierre B, 1998, PLANT J, V14, P703, DOI 10.1046/j.1365-313x.1998.00174.x; St-Pierre B, 1999, PLANT CELL, V11, P887, DOI 10.1105/tpc.11.5.887; Unterlinner B, 1999, PLANT J, V18, P465, DOI 10.1046/j.1365-313X.1999.00470.x; Walker K, 2000, P NATL ACAD SCI USA, V97, P583, DOI 10.1073/pnas.97.2.583; Walker K, 2000, ARCH BIOCHEM BIOPHYS, V374, P371, DOI 10.1006/abbi.1999.1609	38	111	136	1	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					30717	30723		10.1074/jbc.M102688200	http://dx.doi.org/10.1074/jbc.M102688200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11404355	hybrid			2022-12-25	WOS:000170472900019
J	Mahajan, S; Vassilev, A; Sun, N; Ozer, Z; Mao, C; Uckun, FM				Mahajan, S; Vassilev, A; Sun, N; Ozer, Z; Mao, C; Uckun, FM			Transcription factor STAT5A is a substrate of Bruton's tyrosine kinase in B cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-LINKED AGAMMAGLOBULINEMIA; TFII-I; RECEPTOR ENGAGEMENT; BINDING PROTEIN; PH DOMAINS; SRC FAMILY; ACTIVATION; APOPTOSIS; BTK; EXPRESSION	STAT5A is a molecular regulator of proliferation, differentiation, and apoptosis in lymphohematopoietic cells. Here we show that STAT5A can serve as a functional substrate of Bruton's tyrosine kinase (BTK). Purified recombinant BTK was capable of directly binding purified recombinant STAT5A with high affinity (K-d = 44 nm), as determined by surface plasmon resonance using a BIA-core biosensor system. BTK was also capable of tyrosine-phosphorylating ectopically expressed recombinant STAT5A on Tyr(694) both in vitro and in vivo in a Janus kinase 3-independent fashion. BTK phosphorylated the Y665F, Y668F, and Y682F,Y683F mutants but not the Y694F mutant of STAT5A. STAT5A mutations in the Src homology 2 (SH2) and SH3 domains did not alter the BTK-mediated tyrosine phosphorylation. Recombinant BTK proteins with mutant pleckstrin homology, SH2, or SH3 domains were capable of phosphorylating STAT5A, whereas recombinant BTK proteins with SH1/kinase domain mutations were not. In pull-down experiments, only full-length BTK and its SH1/kinase domain (but not the pleckstrin homology, SH2, or SH3 domains) were capable of binding STAT5A. Ectopically expressed BTK kinase domain was capable of tyrosine-phosphorylating STAT5A both in vitro and in vivo. BTK-mediated tyrosine phosphorylation of ectopically expressed wild type (but not Tyr694 mutant) STAT5A enhanced its DNA binding activity. In BTK-competent chicken B cells, anti-IgM-stimulated tyrosine phosphorylation of STAT5 protein was prevented by pretreatment with the BTK inhibitor LFM-A13 but not by pretreatment with the JAK3 inhibitor HI-P131. B cell antigen receptor ligation resulted in enhanced tyrosine phosphorylation of STAT5 in BTK-deficient chicken B cells reconstituted with wild type human BTK but not in BTK-deficient chicken B cells reconstituted with kinase-inactive mutant BTK Similarly, anti-IgM stimulation resulted in enhanced tyrosine phosphorylation of STAT5A in BTK-competent B cells from wild type mice but not in BTK-deficient B cells from XID mice. In contrast to B cells from XID mice, B cells from JAK3 knockout mice showed a normal STAT5A phosphorylation response to anti-IgM stimulation. These findings provide unprecedented experimental evidence that BTK plays a nonredundant and pivotal role in B cell antigen receptor-mediated STAT5A activation in B cells.	Parker Huges Inst, Dept Biochem, St Paul, MN 55113 USA; Parker Huges Inst, Dept Biol Mol, St Paul, MN 55113 USA; Parker Huges Inst, Dept Immunol, St Paul, MN 55113 USA; Parker Huges Inst, Dept Biol Struct, St Paul, MN 55113 USA; Parker Huges Inst, Parker Huges Canc Ctr, Mol Signal Transduct Lab, St Paul, MN 55113 USA		Uckun, FM (corresponding author), Parker Huges Inst, Parker Huges Canc Ctr, Mol Signal Transduct Lab, 2665 Long Lake Rd,Suite 330, St Paul, MN 55113 USA.	fatih-uckun@ih.org		Uckun, Fatih M./0000-0001-9334-183X				Bajpai UD, 2000, J EXP MED, V191, P1735, DOI 10.1084/jem.191.10.1735; CHEN X, 1988, CELL, V93, P827; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Grueneberg DA, 1997, GENE DEV, V11, P2482, DOI 10.1101/gad.11.19.2482; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hata D, 1998, J BIOL CHEM, V273, P10979, DOI 10.1074/jbc.273.18.10979; HEIM MH, 1995, SCIENCE, V267, P1347, DOI 10.1126/science.7871432; Hemmings BA, 1997, SCIENCE, V275, P1899, DOI 10.1126/science.275.5308.1899; Hyvonen M, 1997, EMBO J, V16, P3396, DOI 10.1093/emboj/16.12.3396; Jurlander J, 1997, BLOOD, V89, P4146, DOI 10.1182/blood.V89.11.4146; Kaneko S, 1997, CLIN EXP IMMUNOL, V109, P185, DOI 10.1046/j.1365-2249.1997.4191324.x; Karras JG, 1996, J IMMUNOL, V157, P39; KERNER JD, 1995, IMMUNITY, V3, P301, DOI 10.1016/1074-7613(95)90115-9; Kim DW, 1998, MOL CELL BIOL, V18, P3310, DOI 10.1128/MCB.18.6.3310; Kurosaki T, 1997, CURR OPIN IMMUNOL, V9, P309, DOI 10.1016/S0952-7915(97)80075-1; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; Leonard WJ, 1996, NAT MED, V2, P968, DOI 10.1038/nm0996-968; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; Levy David E., 1997, Cytokine and Growth Factor Reviews, V8, P81, DOI 10.1016/S1359-6101(96)00054-8; LEVY F, 1990, INT IMMUNOL, V2, P995, DOI 10.1093/intimm/2.10.995; LICHTENSTEIN A, 1995, CELL IMMUNOL, V162, P248, DOI 10.1006/cimm.1995.1076; LIU J, 1994, CELL IMMUNOL, V155, P428, DOI 10.1006/cimm.1994.1135; LUO KX, 1991, METHOD ENZYMOL, V201, P149; Mahajan S, 1999, J BIOL CHEM, V274, P9587, DOI 10.1074/jbc.274.14.9587; MAHAJAN S, 1995, MOL CELL BIOL, V15, P5304; Mano H, 1999, INT J HEMATOL, V69, P6; Mohamed AJ, 2000, J BIOL CHEM, V275, P40614, DOI 10.1074/jbc.M006952200; Nakajima H, 1997, IMMUNITY, V7, P691, DOI 10.1016/S1074-7613(00)80389-1; Nosaka T, 1999, EMBO J, V18, P4754, DOI 10.1093/emboj/18.17.4754; Novina CD, 1999, MOL CELL BIOL, V19, P5014; Pericle F, 1997, J IMMUNOL, V159, P2580; Petro JB, 2000, J EXP MED, V191, P1745, DOI 10.1084/jem.191.10.1745; Petro JB, 2001, J BIOL CHEM, V276, P1715, DOI 10.1074/jbc.M009137200; Rajamohan F, 2000, J BIOL CHEM, V275, P3382, DOI 10.1074/jbc.275.5.3382; RAWLINGS DJ, 1994, IMMUNOL REV, V138, P105, DOI 10.1111/j.1600-065X.1994.tb00849.x; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; Reddy EP, 2000, ONCOGENE, V19, P2532, DOI 10.1038/sj.onc.1203594; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; ROY AL, 1993, NATURE, V365, P355, DOI 10.1038/365355a0; Roy AL, 1997, EMBO J, V16, P7091, DOI 10.1093/emboj/16.23.7091; SACK JS, 1988, J MOL GRAPHICS, V6, P224, DOI 10.1016/S0263-7855(98)80040-4; Saharinen P, 1997, BLOOD, V90, P4341; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Sexl V, 2000, BLOOD, V96, P2277, DOI 10.1182/blood.V96.6.2277; Sudbeck EA, 1999, CLIN CANCER RES, V5, P1569; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Tsai YT, 2000, MOL CELL BIOL, V20, P2043, DOI 10.1128/MCB.20.6.2043-2054.2000; TSUKADA S, 1994, P NATL ACAD SCI USA, V91, P11256, DOI 10.1073/pnas.91.23.11256; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; Uckun FM, 1998, BIOCHEM PHARMACOL, V56, P683, DOI 10.1016/S0006-2952(98)00122-1; Uckun FM, 1996, J BIOL CHEM, V271, P6389, DOI 10.1074/jbc.271.11.6389; Uckun FM, 1996, SCIENCE, V273, P1096, DOI 10.1126/science.273.5278.1096; Vassilev A, 1999, J BIOL CHEM, V274, P1646, DOI 10.1074/jbc.274.3.1646; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; Vihinen M, 1999, HUM MUTAT, V13, P280, DOI 10.1002/(SICI)1098-1004(1999)13:4<280::AID-HUMU3>3.0.CO;2-L; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Williams MD, 1998, PROTEIN EXPRES PURIF, V13, P210, DOI 10.1006/prep.1998.0900; Yang WY, 1997, P NATL ACAD SCI USA, V94, P604, DOI 10.1073/pnas.94.2.604; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175	61	58	62	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					31216	31228		10.1074/jbc.M104874200	http://dx.doi.org/10.1074/jbc.M104874200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11413148	hybrid			2022-12-25	WOS:000170472900083
J	Slagsvold, T; Kraus, I; Fronsdal, K; Saatcioglu, F				Slagsvold, T; Kraus, I; Fronsdal, K; Saatcioglu, F			DNA binding-independent transcriptional activation by the androgen receptor through triggering of coactivators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; AMINO-TERMINAL DOMAIN; NUCLEAR RECEPTORS; ESTROGEN-RECEPTOR; LIGAND-BINDING; MOLECULAR MECHANISMS; RETINOIC ACID; AF2 DOMAINS; PROTEIN; FUNCTION-2	Androgens have critical roles in the development and maintenance of the male reproductive system and are important for progression of prostate cancer. The effects of androgens are mediated by the androgen receptor (AR), which is a ligand-modulated transcription factor that belongs to the nuclear receptor superfamily. In the presence of androgens, AR binds to androgen response elements in the vicinity of androgen receptor target genes and activates transcription. In addition, liganded AR can interfere with the activity of other transcription factors, such as activator protein-1 and nuclear factor kappaB, for which DNA binding by AR is not necessary. In this study, we describe a novel ligand-dependent transactivation function for AR that is independent of its DNA binding ability. AR dramatically increased the intrinsic transcriptional activity of the nuclear receptor coactivators glucocorticoid receptor-interacting protein-1 (GRIP1), cAMP response element-binding protein-binding protein, and p300 that are tethered to DNA. This "triggering" phenomenon required both similar and distinctly different regions of AR compared with those needed for ligand-dependent transactivation from androgen-responsive elements. Furthermore, the domains of GRIP1 required for triggering by AR are different from those required when GRIP1 serves as a coactivator for AR at androgen-responsive promoters. These data suggest that triggering may constitute an important part of the mechanism by which AR regulates transcription.	Univ Oslo, Ctr Biotechnol, N-0349 Oslo, Norway; Univ Oslo, Dept Biochem, N-0349 Oslo, Norway; Univ Oslo, Dept Biol, N-0349 Oslo, Norway; Univ Oslo, Inst Clin Med, N-0349 Oslo, Norway	University of Oslo; University of Oslo; University of Oslo; University of Oslo	Saatcioglu, F (corresponding author), Univ Oslo, Ctr Biotechnol, Gaustadalleen 21, N-0349 Oslo, Norway.			Christiansen, Irene Kraus/0000-0001-8850-3304				Aarnisalo P, 1998, P NATL ACAD SCI USA, V95, P2122, DOI 10.1073/pnas.95.5.2122; Alen P, 1999, MOL CELL BIOL, V19, P6085; BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Bevan CL, 1999, MOL CELL BIOL, V19, P8383; Chakravarti D, 1999, CELL, V96, P393, DOI 10.1016/S0092-8674(00)80552-8; Chamberlain NL, 1996, J BIOL CHEM, V271, P26772, DOI 10.1074/jbc.271.43.26772; Chen DG, 2000, J BIOL CHEM, V275, P40810, DOI 10.1074/jbc.M005459200; Collingwood TN, 1999, J MOL ENDOCRINOL, V23, P255, DOI 10.1677/jme.0.0230255; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; de Mora JF, 2000, MOL CELL BIOL, V20, P5041, DOI 10.1128/MCB.20.14.5041-5047.2000; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; Feng WJ, 1998, SCIENCE, V280, P1747, DOI 10.1126/science.280.5370.1747; Fronsdal K, 1998, J BIOL CHEM, V273, P31853, DOI 10.1074/jbc.273.48.31853; Glass CK, 2000, GENE DEV, V14, P121; He B, 1999, J BIOL CHEM, V274, P37219, DOI 10.1074/jbc.274.52.37219; Hong H, 1999, J BIOL CHEM, V274, P3496, DOI 10.1074/jbc.274.6.3496; Ikonen T, 1997, J BIOL CHEM, V272, P29821, DOI 10.1074/jbc.272.47.29821; JENSTER G, 1995, J BIOL CHEM, V270, P7341, DOI 10.1074/jbc.270.13.7341; KITABAYASHI I, 1995, EMBO J, V14, P3496, DOI 10.1002/j.1460-2075.1995.tb07356.x; Koh SS, 2001, J BIOL CHEM, V276, P1089, DOI 10.1074/jbc.M004228200; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LANGLEY E, 1995, J BIOL CHEM, V270, P29983; LINDZEY J, 1994, VITAM HORM, V49, P383; Ma H, 1999, MOL CELL BIOL, V19, P6164; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; McInerney EM, 1996, P NATL ACAD SCI USA, V93, P10069, DOI 10.1073/pnas.93.19.10069; Moras D, 1998, CURR OPIN CELL BIOL, V10, P384, DOI 10.1016/S0955-0674(98)80015-X; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Onate SA, 1998, J BIOL CHEM, V273, P12101, DOI 10.1074/jbc.273.20.12101; Palvimo JJ, 1996, J BIOL CHEM, V271, P24151, DOI 10.1074/jbc.271.39.24151; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; Puigserver P, 1999, SCIENCE, V286, P1368, DOI 10.1126/science.286.5443.1368; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; QUIGLEY CA, 1995, ENDOCR REV, V16, P271, DOI 10.1210/er.16.3.271; Robyr D, 2000, MOL ENDOCRINOL, V14, P329, DOI 10.1210/me.14.3.329; Rowan BG, 2000, MOL CELL BIOL, V20, P8720, DOI 10.1128/MCB.20.23.8720-8730.2000; SAATCIOGLU F, 1993, MOL CELL BIOL, V13, P3675, DOI 10.1128/MCB.13.6.3675; Saatcioglu F, 1997, MOL CELL BIOL, V17, P4687, DOI 10.1128/MCB.17.8.4687; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Slagsvold T, 2000, MOL ENDOCRINOL, V14, P1603, DOI 10.1210/me.14.10.1603; Stallcup MR, 2000, BIOCHEM SOC T, V28, P415, DOI 10.1042/0300-5127:0280415; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; Webb P, 1998, MOL ENDOCRINOL, V12, P1605, DOI 10.1210/me.12.10.1605; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5	49	15	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					31030	31036		10.1074/jbc.M104310200	http://dx.doi.org/10.1074/jbc.M104310200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11429409	hybrid			2022-12-25	WOS:000170472900059
J	Brymora, A; Valova, VA; Larsen, MR; Roufogalis, BD; Robinson, PJ				Brymora, A; Valova, VA; Larsen, MR; Roufogalis, BD; Robinson, PJ			The brain exocyst complex interacts with RaIA in a GTP-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEINS; SACCHAROMYCES-CEREVISIAE; SYNAPTIC VESICLES; RAL-A; IDENTIFICATION; SECRETION; YEAST; ENDOCYTOSIS; EXOCYTOSIS; GTPASES	Ral is a small GTPase involved in critical cellular signaling pathways. The two isoforms, RalA and RalB, are widely distributed in different tissues, with RalA being enriched in brain. The best characterized RalA signaling pathways involve RalBP1 and phospholipase D. To investigate RalA signaling in neuronal cells we searched for RalA-binding proteins in brain. We found at least eight proteins that bound RalA in a GTP-dependent manner. Matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) identified these as the components of the exocyst complex. The yeast exocyst is a regulator of polarized secretion, docking vesicles to regions of the plasma membrane involved in active exocytosis. We identified the human FLJ10893 protein as the mammalian homologue of the yeast exocyst protein Sec3p. The exocyst complex did not contain the previously identified exocyst component rSec15, but a new homologue of both yeast Sec15p, and rSec15, called KIAA0919. Western blots confirmed that two rat exocyst proteins, rSec6 and rSec8, bound active RalA in nerve terminals, as did RalBP1. Phospholipase D bound RalA in a nucleotide-independent manner. This places the RalA signaling system in mammalian nerve terminals, where the exocyst may act as an effector for activated RalA in directing sites of exocytosis.	Childrens Med Res Inst, Cell Signalling Unit, Westmead, NSW 2145, Australia; Univ Sydney, Fac Pharm, Sydney, NSW 2006, Australia	Children's Medical Research Institute - Australia; University of Sydney	Robinson, PJ (corresponding author), Childrens Med Res Inst, Cell Signalling Unit, Locked Bag 23, Westmead, NSW 2145, Australia.		Robinson, Phillip J/G-4008-2011; Larsen, Martin Rossel/F-1411-2015	Robinson, Phillip J/0000-0002-7878-0313; Roufogalis, Basil/0000-0001-9123-5478; Larsen, Martin Rossel/0000-0001-6203-0123				Bhullar RP, 1998, MOL CELL BIOCHEM, V179, P49, DOI 10.1023/A:1006891815211; BIELINSKI DF, 1993, BIOCHIM BIOPHYS ACTA, V1151, P246, DOI 10.1016/0005-2736(93)90109-D; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; CANTOR SB, 1995, MOL CELL BIOL, V15, P4578; CHARDIN P, 1989, NUCLEIC ACIDS RES, V17, P4380, DOI 10.1093/nar/17.11.4380; de Bruyn KMT, 2000, J BIOL CHEM, V275, P29761, DOI 10.1074/jbc.M001160200; Doucet A, 2001, ANAL BIOCHEM, V292, P296, DOI 10.1006/abio.2001.5089; Finger FP, 1998, CELL, V92, P559, DOI 10.1016/S0092-8674(00)80948-4; Finger FP, 1997, MOL BIOL CELL, V8, P647, DOI 10.1091/mbc.8.4.647; Guo W, 1999, J BIOL CHEM, V274, P23558, DOI 10.1074/jbc.274.33.23558; Guo W, 2001, NAT CELL BIOL, V3, P353, DOI 10.1038/35070029; HARSAY E, 1995, J CELL BIOL, V131, P297, DOI 10.1083/jcb.131.2.297; Hazuka CD, 1999, J NEUROSCI, V19, P1324; Hofer F, 1998, CURR BIOL, V8, P839, DOI 10.1016/S0960-9822(98)70327-6; Hsu SC, 1996, NEURON, V17, P1209, DOI 10.1016/S0896-6273(00)80251-2; Jilkina O, 1996, BBA-MOL CELL RES, V1314, P157, DOI 10.1016/S0167-4889(96)00073-0; Jullien-Flores V, 2000, J CELL SCI, V113, P2837; Kee Y, 1997, P NATL ACAD SCI USA, V94, P14438, DOI 10.1073/pnas.94.26.14438; Larsen MR, 2000, FRESEN J ANAL CHEM, V366, P677, DOI 10.1007/s002160051562; Luo JQ, 1997, BIOCHEM BIOPH RES CO, V235, P854, DOI 10.1006/bbrc.1997.6793; Luo JQ, 1998, P NATL ACAD SCI USA, V95, P3632, DOI 10.1073/pnas.95.7.3632; Morinaka K, 1999, ONCOGENE, V18, P5915, DOI 10.1038/sj.onc.1202974; Nakashima S, 1999, EMBO J, V18, P3629, DOI 10.1093/emboj/18.13.3629; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; Ohta Y, 1999, P NATL ACAD SCI USA, V96, P2122, DOI 10.1073/pnas.96.5.2122; Park JB, 1999, BIOCHEM BIOPH RES CO, V263, P765, DOI 10.1006/bbrc.1999.1463; Reuther GW, 2000, CURR OPIN CELL BIOL, V12, P157, DOI 10.1016/S0955-0674(99)00071-X; Robinson NCG, 1999, MOL CELL BIOL, V19, P3580; ROBINSON PJ, 1983, J NEUROCHEM, V41, P909, DOI 10.1111/j.1471-4159.1983.tb09034.x; Shen YJ, 2001, MOL CELL BIOL, V21, P595, DOI 10.1128/MCB.21.2.595-602.2001; TerBush DR, 1996, EMBO J, V15, P6483, DOI 10.1002/j.1460-2075.1996.tb01039.x; TING AE, 1995, P NATL ACAD SCI USA, V92, P9613, DOI 10.1073/pnas.92.21.9613; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VONMOLLARD GF, 1994, J BIOL CHEM, V269, P10971; Wang KL, 1999, J BIOL CHEM, V274, P14525, DOI 10.1074/jbc.274.21.14525; Wang KL, 1997, J BIOL CHEM, V272, P16002, DOI 10.1074/jbc.272.25.16002	36	116	120	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					29792	29797		10.1074/jbc.C100320200	http://dx.doi.org/10.1074/jbc.C100320200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11406615	hybrid			2022-12-25	WOS:000170558000026
J	Kypreos, KE; Teusink, B; van Dijk, KOW; Havekes, LM; Zannis, VI				Kypreos, KE; Teusink, B; van Dijk, KOW; Havekes, LM; Zannis, VI			Analysis of the structure and function relationship of human apolipoprotein E in vivo, using adenovirus-mediated gene transfer	FASEB JOURNAL			English	Article						triglyceride-rich lipoproteins; remnant lipoprotein catabolism hypertriglyceridemia; hypercholesterolemia	LOW-DENSITY-LIPOPROTEIN; RECEPTOR-BINDING DOMAIN; E-DEFICIENT MICE; TRANSGENIC MICE; APO-E; CHOLESTEROL EFFLUX; A-I; ATHEROSCLEROSIS; HYPERLIPOPROTEINEMIA; DIET	We have used adenovirus-mediated gene transfer in apolipoprotein E (apoE)-deficient mice (E-/-) to dissect the domains of apoE required for cholesterol and triglyceride homeostasis in vivo. A dose of 2 x 10(9) pfu of apoE2- apoE3-, or apoE4-expressing adenoviruses failed to decrease the cholesterol levels of E-/- mice and caused severe hypertriglyceridemia, characterized by accumulation of apoE-rich and triglyceride-rich very low density lipoprotein (VLDL). In contrast, the truncated forms apoE4-229 and apoE4-259 at doses of 2 x 10(9) pfu, or 4 x 10(9) pfu, resulted in a 90% reduction in the cholesterol levels of E-/- mice, without affecting plasma triglyceride levels. The triglyceride secretion of mice infected with apoE4 was increased 2.7-fold compared with that of mice infected with apoE4-259. The apoE truncations did not influence apoE secretion by cells and association with VLDL. The levels of apoE4 and apoE4-229 and apoE4-259 mRNA in the livers of infected animals were similar. The findings suggest that the an-lino-terminal 1-229 region of apoE4 contains the domains required for the association of apoE with lipoproteins and their subsequent clearance via apoE-recognizing receptors. Furthermore, the carboxy-terminal 260-299 residues of apoE contribute to the apoE-induced hypertriglyceridemia. Thus, truncated forms of apoE may find useful future application in gene therapy for correction of high cholesterol profiles without triggering hypertriglyceridemia.	Boston Univ, Sch Med, Dept Med, Whitaker Cardiovasc Inst, Boston, MA 02118 USA; Leiden Univ, TNO PG Prevent & Hlth, Leiden, Netherlands; Gaubius Lab, Dept Human & Clin Genet, Leiden, Netherlands; Univ Crete, Dept Biochem, Iraklion, Crete, Greece; Univ Crete, Inst Mol Biol & Biotechnol, Iraklion, Crete, Greece	Boston University; Leiden University; Leiden University - Excl LUMC; Netherlands Organization Applied Science Research; University of Crete; University of Crete	Zannis, VI (corresponding author), Boston Univ, Sch Med, Dept Med, Whitaker Cardiovasc Inst, 700 Albany St,W-509, Boston, MA 02118 USA.	vzannis@bu.edu	KYPREOS, KYRIAKOS/AAN-4485-2020; Kypreos, Kyriakos/AAG-1745-2020; Willems van Dijk, Ko/A-1798-2008	Kypreos, Kyriakos/0000-0001-6784-2710; Teusink, Bas/0000-0003-3929-0423; Willems van Dijk, Ko/0000-0002-2172-7394				AALTOSETALA K, 1992, J CLIN INVEST, V90, P1889, DOI 10.1172/JCI116066; ALESHKOV SA, BIOCHEMISTRY, V36, P10571; CARDIN AD, 1986, BIOCHEM BIOPH RES CO, V134, P783, DOI 10.1016/S0006-291X(86)80489-2; CHAIT A, 1978, METABOLISM, V27, P1055, DOI 10.1016/0026-0495(78)90151-8; CLADARAS C, 1987, J BIOL CHEM, V262, P2310; Cohn JS, 1996, ARTERIOSCL THROM VAS, V16, P149, DOI 10.1161/01.ATV.16.1.149; Cullen P, 1998, J CLIN INVEST, V101, P1670, DOI 10.1172/JCI119887; Dong LM, 1996, NAT STRUCT BIOL, V3, P718, DOI 10.1038/nsb0896-718; DONG LM, 1994, J BIOL CHEM, V269, P22358; EHNHOLM C, 1984, P NATL ACAD SCI-BIOL, V81, P5566, DOI 10.1073/pnas.81.17.5566; ENSEN PCN, 1998, J BIOL CHEM, V271, P14791; Fallaux FJ, 1996, HUM GENE THER, V7, P215, DOI 10.1089/hum.1996.7.2-215; Fan JL, 1998, J CLIN INVEST, V101, P2151, DOI 10.1172/JCI1599; FAZIO S, 1994, ARTERIOSCLER THROMB, V14, P1873, DOI 10.1161/01.ATV.14.11.1873; FAZIO S, 1994, J LIPID RES, V35, P408; Fazio S, 1997, P NATL ACAD SCI USA, V94, P4647, DOI 10.1073/pnas.94.9.4647; FAZIO S, 1993, J CLIN INVEST, V92, P1497, DOI 10.1172/JCI116728; GHISELLI G, 1981, SCIENCE, V214, P1239, DOI 10.1126/science.6795720; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Herz Joachim, 1995, Current Opinion in Lipidology, V6, P97, DOI 10.1097/00041433-199504000-00007; Huang YD, 1999, ARTERIOSCL THROM VAS, V19, P2952, DOI 10.1161/01.ATV.19.12.2952; Huang YD, 1998, J BIOL CHEM, V273, P17483, DOI 10.1074/jbc.273.28.17483; Huang YD, 1997, ARTERIOSCL THROM VAS, V17, P2010, DOI 10.1161/01.ATV.17.10.2010; Huang YD, 1998, J BIOL CHEM, V273, P26388, DOI 10.1074/jbc.273.41.26388; HUANG YD, 1994, P NATL ACAD SCI USA, V91, P1834, DOI 10.1073/pnas.91.5.1834; INNERARITY TL, 1978, BIOCHEMISTRY-US, V17, P1440, DOI 10.1021/bi00601a013; INNERARITY TL, 1983, J BIOL CHEM, V258, P2341; JI ZS, 1994, J BIOL CHEM, V269, P13421; JI ZS, 1994, J BIOL CHEM, V269, P2764; JI ZS, 1993, J BIOL CHEM, V268, P10160; JI ZS, 1995, J LIPID RES, V36, P583; Jong MC, 1997, BIOCHEM J, V328, P745; Kim DH, 1996, J BIOL CHEM, V271, P8373, DOI 10.1074/jbc.271.14.8373; KULPERS F, 1997, J CLIN INVEST, V100, P2915; LALAZAR A, 1988, J BIOL CHEM, V263, P3542; LINTON MF, 1995, SCIENCE, V267, P1034, DOI 10.1126/science.7863332; Mahley RW, 1999, CURR OPIN LIPIDOL, V10, P207, DOI 10.1097/00041433-199906000-00003; MANN WA, 1989, BIOCHIM BIOPHYS ACTA, V1005, P239, DOI 10.1016/0005-2760(89)90043-X; NOLTE RT, 1992, BIOPHYS J, V63, P1221, DOI 10.1016/S0006-3495(92)81698-3; PIEDRAHITA JA, 1992, P NATL ACAD SCI USA, V89, P4471, DOI 10.1073/pnas.89.10.4471; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; RALL SC, 1989, J CLIN INVEST, V83, P1095, DOI 10.1172/JCI113988; RALL SC, 1982, P NATL ACAD SCI-BIOL, V79, P4696, DOI 10.1073/pnas.79.15.4696; REDDICK RL, 1994, ARTERIOSCLER THROMB, V14, P141, DOI 10.1161/01.ATV.14.1.141; Salah D, 1997, J LIPID RES, V38, P904; SCHAEFER EJ, 1986, J CLIN INVEST, V78, P1206, DOI 10.1172/JCI112704; SHIMANO H, 1995, J CLIN INVEST, V95, P469, DOI 10.1172/JCI117687; SMIT M, 1990, GENETIC HETEROGENEIT; TAKAHASHI S, 1992, P NATL ACAD SCI USA, V89, P9252, DOI 10.1073/pnas.89.19.9252; VANDENMAAGDENBERG AMJM, 1989, BIOCHEM BIOPH RES CO, V165, P851, DOI 10.1016/S0006-291X(89)80044-0; VANDENMAAGDENBERG AMJM, 1993, J BIOL CHEM, V268, P10540; vanVlijmen BJM, 1996, J BIOL CHEM, V271, P30595, DOI 10.1074/jbc.271.48.30595; VANVLIJMEN BJM, 1994, J CLIN INVEST, V93, P1403, DOI 10.1172/JCI117117; WARDELL MR, 1987, J CLIN INVEST, V80, P483, DOI 10.1172/JCI113096; WARDELL MR, 1989, J BIOL CHEM, V264, P21205; WEISGRABER KH, 1986, J BIOL CHEM, V261, P2068; WEISGRABER KH, 1983, J BIOL CHEM, V258, P2348; WESTERLUND JA, 1993, J BIOL CHEM, V268, P15745; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194; WOLF BB, 1992, AM J PATHOL, V141, P37; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543; Zhu YH, 1998, P NATL ACAD SCI USA, V95, P7585, DOI 10.1073/pnas.95.13.7585	62	29	31	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY 29	2001	15	7					1598	+		10.1096/fj.00-0882fje	http://dx.doi.org/10.1096/fj.00-0882fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519CQ	11427498				2022-12-25	WOS:000173707700020
J	Nakamura, K; Yano, H; Schaefer, E; Sabe, HA				Nakamura, K; Yano, H; Schaefer, E; Sabe, HA			Different modes and qualities of tyrosine phosphorylation of Fak and Pyk2 during epithelial-mesenchymal transdifferentiation and cell migration: analysis of specific phosphorylation events using site-directed antibodies	ONCOGENE			English	Article						FAK; Pyk2; tyrosine phosphorylation; EMT; cell migration	FOCAL ADHESION KINASE; GROWTH-FACTOR; ANGIOTENSIN-II; PAXILLIN-ALPHA; SRC KINASE; IN-VITRO; V-SRC; PROTEIN; ACTIVATION; CALCIUM	Integrin signaling is activated during epithelial-mesenchymal transdifferentiation (EMT) and cell migration, processes serving as models for carcinogenesis, We have shown that paxillin and p130Cas become highly tyrosine phosphorylated during these processes in NMuMG cells. Here, we examined the regulation of Fak and Pyk2, kinases implicated in this phosphorylation, Pyk2 became phosphorylated at the major autophosphorylation site (Tyr-402) and the potential Grb2-binding site (Tyr-881) during EMT, In contrast, phosphorylation of Fak at the corresponding autophosphorylation site (Tyr-397) occurred even in sedentary epithelial cells, whereas phosphorylation at Tyr-407 and Tyr-861 was induced during EMT. During cell migration, these phosphorylation events, except Fak Tyr-397, were augmented further, and phosphorylation of Fak Tyr-577 and the corresponding Pyk2 Tyr-580, both within the kinase activation loops, was also induced. In all cases, phosphorylation of the putative Grb2-binding site in Fak (Tyr-925) was almost undetectable, Although Fak and Pyk2 have several phosphorylation sites in common, Tyr-407 and Tyr-861 are unique to Fak, Our results revealed that Fak and Pyk2 are non-equivalent in the tyrosine phosphorylation events and thereby likely to evoke different downstream signaling cascades during EMT and cell migration of NMuMG cells, We also show that Fak Tyr-397 phosphorylation occurs exclusively at the cytoplasm, but not at focal contacts, in the sedentary epithelial cells, In contrast, all other tyrosine phosphorylated forms of Fak and Pyk2 are predominantly localized to focal adhesions and the cell periphery in motile cells, all colocalized with paxillin and p130Cas.	Osaka Biosci Inst, Dept Mol Biol, Osaka 5650874, Japan; BioSource Int, Hopkinton, MA 01748 USA; Kyoto Univ, Grad Sch Biostudies, Sakyo Ku, Kyoto 6068502, Japan	Kyoto University	Sabe, HA (corresponding author), Osaka Biosci Inst, Dept Mol Biol, 6-2-4 Furuedai, Osaka 5650874, Japan.							Astier A, 1997, J BIOL CHEM, V272, P19719, DOI 10.1074/jbc.272.32.19719; AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; BELLIS SL, 1995, J BIOL CHEM, V270, P17437, DOI 10.1074/jbc.270.29.17437; Brinson AE, 1998, J BIOL CHEM, V273, P1711, DOI 10.1074/jbc.273.3.1711; Calalb MB, 1996, BIOCHEM BIOPH RES CO, V228, P662, DOI 10.1006/bbrc.1996.1714; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; Cazaubon S, 1997, J NEUROSCI, V17, P6203; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; Dikic I, 1998, J BIOL CHEM, V273, P14301, DOI 10.1074/jbc.273.23.14301; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; EARP HS, 1995, J BIOL CHEM, V270, P28440; Felsch JS, 1998, P NATL ACAD SCI USA, V95, P5051, DOI 10.1073/pnas.95.9.5051; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; Herzog H, 1997, GENOMICS, V41, P315, DOI 10.1006/geno.1997.4684; Hiregowdara D, 1997, J BIOL CHEM, V272, P10804; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Li X, 1997, J BIOL CHEM, V272, P14341, DOI 10.1074/jbc.272.22.14341; Li X, 1999, J BIOL CHEM, V274, P8917, DOI 10.1074/jbc.274.13.8917; Li X, 1998, J BIOL CHEM, V273, P9361, DOI 10.1074/jbc.273.16.9361; Maruyama T, 1999, ENDOCRINOLOGY, V140, P5982, DOI 10.1210/endo.140.12.7184; Mazaki Y, 1998, J BIOL CHEM, V273, P22435, DOI 10.1074/jbc.273.35.22435; MIETTINEN PJ, 1994, J CELL BIOL, V127, P2021, DOI 10.1083/jcb.127.6.2021; Nakamura K, 2000, J BIOL CHEM, V275, P27155; Ostergaard HL, 1998, J BIOL CHEM, V273, P5692, DOI 10.1074/jbc.273.10.5692; Owen JD, 1999, MOL CELL BIOL, V19, P4806; Polte TR, 1997, J BIOL CHEM, V272, P5501, DOI 10.1074/jbc.272.9.5501; SABE H, 1994, P NATL ACAD SCI USA, V91, P3984, DOI 10.1073/pnas.91.9.3984; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; Schaller MD, 1997, J BIOL CHEM, V272, P25319, DOI 10.1074/jbc.272.40.25319; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schlaepfer DD, 1996, MOL CELL BIOL, V16, P5623; SCHLAEPFER DD, 1994, NATURE, V372, P786; Sieg DJ, 1998, EMBO J, V17, P5933, DOI 10.1093/emboj/17.20.5933; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Soltoff SP, 1998, J BIOL CHEM, V273, P2653, DOI 10.1074/jbc.273.5.2653; TACHIBANA K, 1995, J EXP MED, V182, P1089, DOI 10.1084/jem.182.4.1089; Tobe K, 1996, MOL CELL BIOL, V16, P4765; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413; Yano H, 2000, P NATL ACAD SCI USA, V97, P9076, DOI 10.1073/pnas.97.16.9076; Yu H, 1996, J BIOL CHEM, V271, P29993, DOI 10.1074/jbc.271.47.29993; Zhang X, 1999, P NATL ACAD SCI USA, V96, P9021, DOI 10.1073/pnas.96.16.9021; Zheng CH, 1998, J BIOL CHEM, V273, P2384, DOI 10.1074/jbc.273.4.2384	48	68	72	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 10	2001	20	21					2626	2635		10.1038/sj.onc.1204359	http://dx.doi.org/10.1038/sj.onc.1204359			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	431VN	11420674				2022-12-25	WOS:000168652600003
J	Suzuki, T; Shiratori, M; Furuichi, Y; Matsumoto, T				Suzuki, T; Shiratori, M; Furuichi, Y; Matsumoto, T			Diverged nuclear localization of Werner helicase in human and mouse cells	ONCOGENE			English	Article						aging; nucleolar localization signal; rRNA transcription; Werner syndrome; WRN	SYNDROME PROTEIN; SYNDROME GENE; DNA HELICASE; WRN GENE; SEQUENCE; CLONING	Werner syndrome (WS) is a rare autosomal recessive genetic disorder causing premature aging and rare cancers. A gene responsible for WS (WRN) encodes a protein with 1432 amino acids (a.a.) homologous to the E. coli RecQ-type DNA helicase, Transcriptional activation facilitated nucleolar localization of human WRN protein (hWRNp) and serum starvation induced translocation of hWRNp from the nucleoli to the nucleoplasm in human cultured cells, suggesting a nucleolar-nucleoplasm trafficking of hWRNp depending on transcriptional state, Mutant hWRNp lacking the C-terminal 30 a.a. residues (Delta 1403-1432) failed to localize in the nucleolus, whereas Delta 1405-1432 can migrate into the nucleolus. Here we identify a region putative for nucleolar localization signal (NoLS) containing sequence of two positively charged amino acids (Arg(1403)-Lys(1404)) in the C-terminal area of hWRNp, By contrast, the mouse homolog (mWRNp) exists only in the nucleoplasm, We show that the inability of mWRNp to migrate into the nucleolus is due to a difference of a sequence in the region corresponding to the NoLS of hWRNp. In addition, mouse cells cannot recognize the NoLS of hWRNp, Our study suggests that defect in nucleolar function of hWRNp may be linked to the premature aging which is not observed in mWRN(-/-) mice.	AGENE Res Inst, Kanagawa 2470063, Japan		Matsumoto, T (corresponding author), AGENE Res Inst, 200 Kajiwara, Kanagawa 2470063, Japan.							CHIU SM, 1982, BIOCHIM BIOPHYS ACTA, V699, P15, DOI 10.1016/0167-4781(82)90166-X; EPSTEIN CJ, 1966, MEDICINE, V45, P177, DOI 10.1097/00005792-196605000-00001; FARAGHER RGA, 1993, P NATL ACAD SCI USA, V90, P12030, DOI 10.1073/pnas.90.24.12030; GARCIABUSTOS J, 1991, BIOCHIM BIOPHYS ACTA, V1071, P83, DOI 10.1016/0304-4157(91)90013-M; Gray MD, 1998, EXP CELL RES, V242, P487, DOI 10.1006/excr.1998.4124; Gray MD, 1997, NAT GENET, V17, P100, DOI 10.1038/ng0997-100; Huang SR, 1998, NAT GENET, V20, P114, DOI 10.1038/2410; Huang SR, 2000, NUCLEIC ACIDS RES, V28, P2396, DOI 10.1093/nar/28.12.2396; Hubner S, 1997, J BIOL CHEM, V272, P17191, DOI 10.1074/jbc.272.27.17191; Imamura O, 1997, GENOMICS, V41, P298, DOI 10.1006/geno.1997.4661; Kitao S, 1999, GENOMICS, V61, P268, DOI 10.1006/geno.1999.5959; Lebel M, 1998, P NATL ACAD SCI USA, V95, P13097, DOI 10.1073/pnas.95.22.13097; Lombard DB, 2000, MOL CELL BIOL, V20, P3286, DOI 10.1128/MCB.20.9.3286-3291.2000; Marciniak RA, 1998, P NATL ACAD SCI USA, V95, P6887, DOI 10.1073/pnas.95.12.6887; Matsumoto T, 1998, INT J MOL MED, V1, P71; Matsumoto T, 1997, NAT GENET, V16, P335, DOI 10.1038/ng0897-335; SALK D, 1985, ADV EXP MED BIOL, V190, P305; Shiratori M, 1999, J CELL BIOL, V144, P1, DOI 10.1083/jcb.144.1.1; STEWART SE, 1989, MOL CELL BIOL, V9, P3464, DOI 10.1128/MCB.9.8.3464; Suzuki N, 1999, NUCLEIC ACIDS RES, V27, P2361, DOI 10.1093/nar/27.11.2361; Suzuki N, 1997, NUCLEIC ACIDS RES, V25, P2973, DOI 10.1093/nar/25.15.2973; Wang L, 2000, GENETICS, V154, P357; Xiao CY, 1997, J BIOL CHEM, V272, P22191, DOI 10.1074/jbc.272.35.22191; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	24	39	42	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 3	2001	20	20					2551	2558		10.1038/sj.onc.1204344	http://dx.doi.org/10.1038/sj.onc.1204344			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	431VM	11420665				2022-12-25	WOS:000168652500006
J	Mizoue, LS; Sullivan, SK; King, DS; Kledal, TN; Schwartz, TW; Bacon, KB; Handel, TM				Mizoue, LS; Sullivan, SK; King, DS; Kledal, TN; Schwartz, TW; Bacon, KB; Handel, TM			Molecular determinants of receptor binding and signaling by the CX3C chemokine fractalkine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCYTE CHEMOTACTIC PROTEIN-1; CC-CHEMOKINE; MCP-1 RECEPTOR; TYROSINE SULFATION; INVERSE AGONISTS; AMINO-TERMINUS; FACTOR-I; INTERLEUKIN-8; IDENTIFICATION; RESIDUES	Fractalkine/CX3CL1 is a membrane-tethered chemokine that functions as a chemoattractant and adhesion protein by interacting with the receptor CX3CR1. To understand the molecular basis for the interaction, an extensive mutagenesis study of fractalkine's chemokine domain was undertaken. The results reveal a cluster of basic residues (Lys-8, Lys-15, Lys-37, Arg-45, and Arg-48) and one aromatic (Phe-50) that are critical for binding and/or signaling. The mutant R48A could bind but not induce chemotaxis, demonstrating that Arg-48 is a signaling trigger. This result also shows that signaling residues are not confined to chemokine N termini, as generally thought. F50A showed no detectable binding, underscoring its importance to the stability of the complex. K15A displayed unique signaling characteristics, eliciting a wild-type calcium flux but minimal chemotaxis, suggesting that this mutant can activate some, but not all, pathways required for migration. Fractalkine also binds the human cytomegalovirus receptor US28, and analysis of the mutants indicates that US28 recognizes many of the same epitopes of fractalkine as CX3CR1. Comparison of the binding surfaces of fractalkine and the CC chemokine MCP-1 reveals structural details that may account for their dual recognition by US28 and their selective recognition by host receptors.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA; Neurocrine Biosci Inc, San Diego, CA 92121 USA; Univ Copenhagen, Panum Inst, Mol Pharmacol Lab, DK-2200 Copenhagen, Denmark	University of California System; University of California Berkeley; Howard Hughes Medical Institute; University of California System; University of California Berkeley; Neurocrine Biosciences; University of Copenhagen	Handel, TM (corresponding author), Bayer Yakuhin Ltd, 6-5-1-3 Kunimidai, Kyoto 6100216, Japan.	handel@paradise1.berkeley.edu		Schwartz, Thue W./0000-0002-0261-6904				Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0; Blanpain C, 1999, BLOOD, V94, P1899; Boehme SA, 2000, J IMMUNOL, V165, P397, DOI 10.4049/jimmunol.165.1.397; CLARKLEWIS I, 1994, J BIOL CHEM, V269, P16075; CLARKLEWIS I, 1995, J LEUKOCYTE BIOL, V57, P703, DOI 10.1002/jlb.57.5.703; Combadiere C, 1998, J BIOL CHEM, V273, P23799, DOI 10.1074/jbc.273.37.23799; Crump MP, 1997, EMBO J, V16, P6996, DOI 10.1093/emboj/16.23.6996; Damon I, 1998, P NATL ACAD SCI USA, V95, P6403, DOI 10.1073/pnas.95.11.6403; DESJARLAIS JR, 1995, PROTEIN SCI, V4, P2006, DOI 10.1002/pro.5560041006; DOERRING DS, 1992, THESIS CAMBRIDGE MA; Elisseeva EL, 2000, J BIOL CHEM, V275, P26799; Elsner J, 1999, INT ARCH ALLERGY IMM, V118, P462, DOI 10.1159/000024164; Farzan M, 1999, CELL, V96, P667, DOI 10.1016/S0092-8674(00)80577-2; Faure S, 2000, SCIENCE, V287, P2274, DOI 10.1126/science.287.5461.2274; Fong AM, 2000, J BIOL CHEM, V275, P3781, DOI 10.1074/jbc.275.6.3781; Gerard C, 2001, NAT IMMUNOL, V2, P108, DOI 10.1038/84209; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Gong JH, 1996, J BIOL CHEM, V271, P10521, DOI 10.1074/jbc.271.18.10521; GONG JH, 1995, J EXP MED, V181, P631, DOI 10.1084/jem.181.2.631; GRZESIEK S, 1993, J AM CHEM SOC, V115, P12593, DOI 10.1021/ja00079a052; Hammond MEW, 1996, J BIOL CHEM, V271, P8228, DOI 10.1074/jbc.271.14.8228; Harrison JK, 2001, J BIOL CHEM, V276, P21632, DOI 10.1074/jbc.M010261200; Haskell CA, 1999, J BIOL CHEM, V274, P10053, DOI 10.1074/jbc.274.15.10053; HEBERT CA, 1991, J BIOL CHEM, V266, P18989; Hemmerich S, 1999, BIOCHEMISTRY-US, V38, P13013, DOI 10.1021/bi991029m; Ho HH, 1999, J BIOL CHEM, V274, P31327, DOI 10.1074/jbc.274.44.31327; Homey B, 1999, CURR OPIN IMMUNOL, V11, P626, DOI 10.1016/S0952-7915(99)00028-X; Imai T, 1997, CELL, V91, P521, DOI 10.1016/S0092-8674(00)80438-9; Jarnagin K, 1999, BIOCHEMISTRY-US, V38, P16167, DOI 10.1021/bi9912239; Jones SA, 1997, J BIOL CHEM, V272, P16166, DOI 10.1074/jbc.272.26.16166; Kledal TN, 1997, SCIENCE, V277, P1656, DOI 10.1126/science.277.5332.1656; Kledal TN, 1998, FEBS LETT, V441, P209, DOI 10.1016/S0014-5793(98)01551-8; LAROSA GJ, 1992, J BIOL CHEM, V267, P25402; Laurence JS, 2000, BIOCHEMISTRY-US, V39, P3401, DOI 10.1021/bi9923196; Loetscher P, 2001, J BIOL CHEM, V276, P2986, DOI 10.1074/jbc.M005652200; Lowman HB, 1996, J BIOL CHEM, V271, P14344, DOI 10.1074/jbc.271.24.14344; LU ZH, 1995, J BIOL CHEM, V270, P26239; Lusso P, 2000, VIROLOGY, V273, P228, DOI 10.1006/viro.2000.0443; Mackay CR, 2001, NAT IMMUNOL, V2, P95, DOI 10.1038/84298; Mayer MR, 2001, J BIOL CHEM, V276, P13911, DOI 10.1074/jbc.M011202200; McDermott D H, 2000, Science, V290, P2031; McDermott DH, 2000, SPRINGER SEMIN IMMUN, V22, P393, DOI 10.1007/s002810000052; Meucci O, 2000, P NATL ACAD SCI USA, V97, P8075, DOI 10.1073/pnas.090017497; Mizoue LS, 1999, BIOCHEMISTRY-US, V38, P1402, DOI 10.1021/bi9820614; Monteclaro FS, 1996, J BIOL CHEM, V271, P19084, DOI 10.1074/jbc.271.32.19084; Moser B, 2001, NAT IMMUNOL, V2, P123, DOI 10.1038/84219; Murdoch C, 2000, BLOOD, V95, P3032; NEIDHARDT FC, 1974, J BACTERIOL, V119, P736, DOI 10.1128/JB.119.3.736-747.1974; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; Paavola CD, 1998, J BIOL CHEM, V273, P33157, DOI 10.1074/jbc.273.50.33157; Pakianathan DR, 1997, BIOCHEMISTRY-US, V36, P9642, DOI 10.1021/bi970593z; Pan Y, 1997, NATURE, V387, P611, DOI 10.1038/42491; Preobrazhensky AA, 2000, J IMMUNOL, V165, P5295, DOI 10.4049/jimmunol.165.9.5295; Proudfoot AEI, 2000, IMMUNOL REV, V177, P246, DOI 10.1034/j.1600-065X.2000.17721.x; Proudfoot AEI, 1999, J BIOL CHEM, V274, P32478, DOI 10.1074/jbc.274.45.32478; Proudfoot AEI, 1996, J BIOL CHEM, V271, P2599, DOI 10.1074/jbc.271.5.2599; Rodriguez-Frade JM, 1999, J CELL BIOL, V144, P755, DOI 10.1083/jcb.144.4.755; Rosenkilde MM, 2000, J BIOL CHEM, V275, P26309, DOI 10.1074/jbc.M003800200; Rosenkilde MM, 1999, J BIOL CHEM, V274, P956, DOI 10.1074/jbc.274.2.956; Rosenkilde MM, 2000, MOL PHARMACOL, V57, P602, DOI 10.1124/mol.57.3.602; Segerer S, 2000, J AM SOC NEPHROL, V11, P152, DOI 10.1681/ASN.V111152; Thelen M, 2001, NAT IMMUNOL, V2, P129, DOI 10.1038/84224; Weng YM, 1998, J BIOL CHEM, V273, P18288, DOI 10.1074/jbc.273.29.18288; Wilbanks A, 2001, J IMMUNOL, V166, P5145, DOI 10.4049/jimmunol.166.8.5145; Williams G, 1996, J BIOL CHEM, V271, P9579, DOI 10.1074/jbc.271.16.9579; Yen HH, 1997, J LEUKOCYTE BIOL, V61, P529, DOI 10.1002/jlb.61.4.529; Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074-7613(00)80165-X	68	36	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33906	33914		10.1074/jbc.M101348200	http://dx.doi.org/10.1074/jbc.M101348200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11432858	hybrid			2022-12-25	WOS:000170910200084
J	Panse, VG; Beena, K; Philipp, R; Trommer, WE; Vogel, PD; Varadarajan, R				Panse, VG; Beena, K; Philipp, R; Trommer, WE; Vogel, PD; Varadarajan, R			Electron spin resonance and fluorescence studies of the bound-state conformation of a model protein substrate to the chaperone SecB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC TRYPSIN-INHIBITOR; ESCHERICHIA-COLI; MOLTEN GLOBULE; LACTOSE PERMEASE; DISULFIDE BOND; BINDING; PROXIMITY; THERMODYNAMICS; TRANSLOCATION; INTERMEDIATE	SecB is a homotetrameric, cytosolic chaperone that forms part of the protein translocation machinery in Escherichia coli. We have investigated the bound-state conformation of a model protein substrate of SecB, bovine pancreatic trypsin inhibitor (BPTI) as well as the conformation of SecB itself by using proximity relationships based on site-directed spin-labeling and pyrene fluorescence methods. BPTI is a 58-residue protein and contains three disulfide groups between residues 5 and 55, 14 and 38, as well as 30 and 51. Mutants of BPTI that contained only a single disulfide were reduced, and the free cysteines were labeled with either thiol-specific spin labels or pyrene maleimide. The relative proximity of the labeled residues was studied using either electron spin resonance spectroscopy or fluorescence spectroscopy. The data suggest that SecB binds a collapsed coil of reduced unfolded BPTI, which then undergoes a structural rearrangement to a more extended state upon binding to SecB. Binding occurs at multiple sites on the substrate, and the binding site on each SecB monomer accommodates less than 21 substrate residues. In addition, we have labeled four solvent-accessible cysteine residues in the SecB tetramer and have investigated their relative spatial arrangement in the presence and absence of the substrate protein. The electron spin resonance data suggest that these cysteine residues are in close proximity (15 Angstrom) when no substrate protein is bound but move away to a distance of greater than 20 Angstrom when SecB binds substrate. This is the first direct evidence of a conformational change in SecB upon binding of a substrate protein.	Indian Inst Sci, Mol Biophys Unit, Bangalore 560012, Karnataka, India; Jawaharlal Nehru Ctr Adv Sci Res, Chem Biol Unit, Bangalore 560004, Karnataka, India; Univ Kaiserslautern, Biochem Abt, Fachbereich Chem, D-67663 Kaiserslautern, Germany	Indian Institute of Science (IISC) - Bangalore; Department of Science & Technology (India); Jawaharlal Nehru Center for Advanced Scientific Research (JNCASR); University of Kaiserslautern	Varadarajan, R (corresponding author), Indian Inst Sci, Mol Biophys Unit, Bangalore 560012, Karnataka, India.			Vogel, Pia/0000-0002-8135-4649; Panse, Vikram/0000-0001-7950-5746				Altenbach C, 1996, BIOCHEMISTRY-US, V35, P12470, DOI 10.1021/bi960849l; AMIR D, 1988, BIOCHEMISTRY-US, V27, P8889, DOI 10.1021/bi00425a003; AMIR D, 1992, PROTEINS, V13, P162, DOI 10.1002/prot.340130210; BYCHKOVA VE, 1988, FEBS LETT, V238, P231, DOI 10.1016/0014-5793(88)80485-X; Chakravarty S, 1999, STRUCT FOLD DES, V7, P723, DOI 10.1016/S0969-2126(99)80097-5; Creighton T. E., 1990, PROTEIN STRUCTURE PR, P155; Dadlez M, 1996, BIOCHEMISTRY-US, V35, P16153, DOI 10.1021/bi9616054; Darbre A., 1986, PRACTICAL PROTEIN CH; DARBY NJ, 1995, J MOL BIOL, V249, P463, DOI 10.1006/jmbi.1995.0309; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; FASMAN GD, 1995, J PROTEIN CHEM, V14, P595, DOI 10.1007/BF01886885; FEKKES P, 1995, BIOCHEMISTRY-US, V34, P10078, DOI 10.1021/bi00031a032; FERRER M, 1995, NAT STRUCT BIOL, V2, P211, DOI 10.1038/nsb0395-211; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOTTFRIED DS, 1992, BIOCHEMISTRY-US, V31, P12353, DOI 10.1021/bi00164a009; GUSSAKOVSKY EE, 1992, FEBS LETT, V308, P146, DOI 10.1016/0014-5793(92)81263-L; HARDY SJS, 1991, SCIENCE, V251, P439, DOI 10.1126/science.1989077; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Hubbell WL, 1998, CURR OPIN STRUC BIOL, V8, P649, DOI 10.1016/S0959-440X(98)80158-9; Kim J, 1998, J BACTERIOL, V180, P1396, DOI 10.1128/JB.180.6.1396-1401.1998; Knoblauch NTM, 1999, J BIOL CHEM, V274, P34219, DOI 10.1074/jbc.274.48.34219; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LECKER SH, 1990, EMBO J, V9, P2309, DOI 10.1002/j.1460-2075.1990.tb07402.x; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; Lehrer SS, 1997, METHOD ENZYMOL, V278, P286; LUMB KJ, 1994, J MOL BIOL, V236, P412, DOI 10.1006/jmbi.1994.1153; PAN H, 1995, BIOCHEMISTRY-US, V34, P13974, DOI 10.1021/bi00043a002; Panse VG, 2000, BIOCHEMISTRY-US, V39, P2420, DOI 10.1021/bi992065o; Panse VG, 1998, BIOCHEMISTRY-US, V37, P14477, DOI 10.1021/bi980777t; Panse VG, 2000, BIOCHEMISTRY-US, V39, P2362, DOI 10.1021/bi992484l; Panse VG, 2000, J BIOL CHEM, V275, P18698, DOI 10.1074/jbc.275.25.18698; RABENSTEIN MD, 1995, P NATL ACAD SCI USA, V92, P8239, DOI 10.1073/pnas.92.18.8239; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SCHULMAN BA, 1994, PROTEIN SCI, V3, P2226, DOI 10.1002/pro.5560031208; STALEY JP, 1992, P NATL ACAD SCI USA, V89, P1519, DOI 10.1073/pnas.89.5.1519; STALEY JP, 1994, PROTEIN SCI, V3, P1822, DOI 10.1002/pro.5560031021; Steinhoff HJ, 1997, BIOPHYS J, V73, P3287, DOI 10.1016/S0006-3495(97)78353-X; Sun JZ, 1999, BIOCHEMISTRY-US, V38, P3100, DOI 10.1021/bi982360t; Topping TB, 2001, J BIOL CHEM, V276, P7437, DOI 10.1074/jbc.M009584200; VOLODARSKY LB, 1988, IMIDAZOLINE NITROXID, V1; WEISS JB, 1990, J BACTERIOL, V172, P3023, DOI 10.1128/jb.172.6.3023-3029.1990; WENZEL HR, 1976, BIOCHIM BIOPHYS ACTA, V452, P292, DOI 10.1016/0005-2744(76)90179-0; Xu ZH, 2000, NAT STRUCT BIOL, V7, P1172, DOI 10.1038/82040; Zhao M, 1999, BIOCHEMISTRY-US, V38, P7407, DOI 10.1021/bi9906524	44	6	6	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33681	33688		10.1074/jbc.M104466200	http://dx.doi.org/10.1074/jbc.M104466200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11435433	hybrid			2022-12-25	WOS:000170910200054
J	dos Santos, GMA; ten Broeke, T; Strous, GJ				dos Santos, GMA; ten Broeke, T; Strous, GJ			Growth hormone receptor ubiquitination, endocytosis, and degradation are independent of signal transduction via Janus kinase 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-INDUCED INTERNALIZATION; ACTIVATED PROTEIN-KINASE; JAK2 TYROSINE KINASE; EGF RECEPTOR; GH RECEPTOR; PHOSPHORYLATION; IDENTIFICATION; TRANSCRIPTION; CLATHRIN; DOMAINS	The ubiquitin-proteasome system is required in growth hormone receptor (GHR) endocytosis. For cytokine receptors, which lack intrinsic tyrosine kinase activity, signal transduction is initiated by the activation of a member of the Janus kinase (JAK) family. Previously, we have shown that GHR and JAK2 tyrosine (de) phosphorylation are regulated via the ubiquitin system. In this study, we examined the role of JAK2-mediated signal transduction in GHR internalization and downregulation. Mutation of the attachment site for JAK2, box-1, in the GHR cytoplasmic tail resulted in the complete absence of GHR and JAK2 phosphorylation. This modification did not alter the rate and extent of receptor-bound growth hormone internalization as compared with a functional GHR, nor did it change its turnover and transport to the plasma membrane. In addition, the receptor was still normally ubiquitinated and remained dependent on both an intact ubiquitin system and proteasomal action for its internalization. Thus, GHR ubiquitination, endocytosis, and degradation occur independently of GHR signal transduction via JAK2. We conclude that whereas endocytosis and degradation require the ubiquitin system, they are independent of GHR signal transduction.	Univ Utrecht, Med Ctr, Dept Cell Biol, NL-3584 CX Utrecht, Netherlands; Inst Biomembranes, NL-3584 CX Utrecht, Netherlands	Utrecht University	Strous, GJ (corresponding author), Univ Utrecht, Med Ctr, Dept Cell Biol, Heidelberglaan 100,AZU-G02525, NL-3584 CX Utrecht, Netherlands.							ALLEVATO G, 1995, J BIOL CHEM, V270, P17210, DOI 10.1074/jbc.270.29.17210; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; Argetsinger LS, 1996, J BIOL CHEM, V271, P29415, DOI 10.1074/jbc.271.46.29415; Beckman DL, 1999, BLOOD, V94, P2667, DOI 10.1182/blood.V94.8.2667.420k27_2667_2675; BILLESTRUP N, 1995, P NATL ACAD SCI USA, V92, P2725, DOI 10.1073/pnas.92.7.2725; Carter-Su C, 1998, RECENT PROG HORM RES, V53, P61; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; COLOSI P, 1993, J BIOL CHEM, V268, P12617; dos Santos CMA, 2001, J BIOL CHEM, V276, P10839, DOI 10.1074/jbc.M003635200; Ferguson SSG, 1996, CAN J PHYSIOL PHARM, V74, P1095, DOI 10.1139/y96-124; Finidori J, 2000, Vitam Horm, V59, P71, DOI 10.1016/S0083-6729(00)59004-9; FRANK SJ, 1994, ENDOCRINOLOGY, V135, P2228, DOI 10.1210/en.135.5.2228; FREEDMAN NJ, 1996, RECENT PROG HORM RES, V51, P352; GOUJON L, 1994, P NATL ACAD SCI USA, V91, P957, DOI 10.1073/pnas.91.3.957; Govers R, 1999, EMBO J, V18, P28, DOI 10.1093/emboj/18.1.28; Govers R, 1997, EMBO J, V16, P4851, DOI 10.1093/emboj/16.16.4851; Han YL, 1996, J BIOL CHEM, V271, P5947, DOI 10.1074/jbc.271.10.5947; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; KELLY PA, 1993, RECENT PROG HORM RES, V48, P123; LAMAZE C, 1995, J CELL BIOL, V129, P47, DOI 10.1083/jcb.129.1.47; MOLDRUP A, 1991, J BIOL CHEM, V266, P17441; MOLLER C, 1992, J BIOL CHEM, V267, P23403; MURPHY LJ, 1984, ENDOCRINOLOGY, V115, P1625, DOI 10.1210/endo-115-4-1625; ROUPAS P, 1988, MOL CELL ENDOCRINOL, V57, P93, DOI 10.1016/0303-7207(88)90037-8; Smit LS, 1996, MOL ENDOCRINOL, V10, P519, DOI 10.1210/me.10.5.519; Sorkin A, 1996, J BIOL CHEM, V271, P13377, DOI 10.1074/jbc.271.23.13377; SOTIROPOULOS A, 1994, ENDOCRINOLOGY, V135, P1292, DOI 10.1210/en.135.4.1292; Sotiropoulos A, 1996, MOL ENDOCRINOL, V10, P998, DOI 10.1210/me.10.8.998; Strous GJ, 1997, J BIOL CHEM, V272, P40; Thirone ACP, 1999, ENDOCRINOLOGY, V140, P55, DOI 10.1210/en.140.1.55; van Kerkhof P, 2000, J BIOL CHEM, V275, P1575, DOI 10.1074/jbc.275.3.1575; Vanderkuur JA, 1997, ENDOCRINOLOGY, V138, P4301, DOI 10.1210/en.138.10.4301; VANDERKUUR JA, 1994, J BIOL CHEM, V269, P21709; WANG YD, 1995, MOL ENDOCRINOL, V9, P303, DOI 10.1210/me.9.3.303; Wilde A, 1999, CELL, V96, P677, DOI 10.1016/S0092-8674(00)80578-4	35	30	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					32635	32641		10.1074/jbc.M103583200	http://dx.doi.org/10.1074/jbc.M103583200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11418602	hybrid			2022-12-25	WOS:000170746000035
J	Esposito, D; Patel, P; Stephens, RM; Perez, P; Chao, MV; Kaplan, DR; Hempstead, BL				Esposito, D; Patel, P; Stephens, RM; Perez, P; Chao, MV; Kaplan, DR; Hempstead, BL			The cytoplasmic and transmembrane domains of the p75 and Trk a receptors regulate high affinity binding to nerve growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROTROPHIN RECEPTOR; SIGNAL-TRANSDUCTION; NGF BINDING; LIGAND; MODULATION; ACTIVATION; GP75; IDENTIFICATION; ASSOCIATION; DISRUPTION	Ligand-induced receptor oligomerization is an established mechanism for receptor-tyrosine kinase activation. However, numerous receptor-tyrosine kinases are expressed in multicomponent complexes with other receptors that may signal independently or alter the binding characteristics of the receptor-tyrosine kinase. Nerve growth factor (NGF) interacts with two structurally unrelated receptors, the Trk A receptor-tyrosine kinase and p75, a tumor necrosis factor receptor family member. Each receptor binds independently to NGF with predominantly low affinity (K-d = 10(-9) M), but they produce high affinity binding sites (K-d = 10(-11) M) upon receptor co-expression. Here we provide evidence that the number of high affinity sites is regulated by the ratio of the two receptors and by specific domains of Trk A and p75. Co-expression of Trk A containing mutant transmembrane or cytoplasmic domains with p75 yielded reduced numbers of high affinity binding sites. Similarly, co-expression of mutant p75 containing altered transmembrane and cytoplasmic domains with Trk A also resulted in predominantly low affinity binding sites. Surprisingly, extracellular domain mutations of p75 that abolished NGF binding still generated high affinity binding with Trk A. These results indicate that the transmembrane and cytoplasmic domains of Trk A and p75 are responsible for high affinity site formation and suggest that p75 alters the conformation of Trk A to generate high affinity NGF binding.	Cornell Univ, Weill Med Coll, Div Hematol, New York, NY 10021 USA; McGill Univ, Montreal Neurol Inst, Montreal, PQ H3A 2T5, Canada; NYU, Sch Med, Skirball Inst Mol Med, New York, NY 10016 USA; Univ Salamanca, Inst Microbiol Bioquim, E-37008 Salamanca, Spain; NCI, Frederick Canc Res & Dev Ctr, ABL Basic Res Program, Frederick, MD 21701 USA	Cornell University; McGill University; New York University; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Funcional y Genomica (IBFG); University of Salamanca; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Hempstead, BL (corresponding author), Cornell Univ, Weill Med Coll, Div Hematol, Rm C-606,1300 York Ave, New York, NY 10021 USA.	blhempst@mail.med.cornell.edu	Perez, Pilar/B-4948-2010	Perez, Pilar/0000-0003-3557-2247; Chao, Moses/0000-0002-6969-3744	NICHD NIH HHS [HD23315] Funding Source: Medline; NINDS NIH HHS [NS21072, NS3027] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD023315] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R56NS021072, R01NS021072] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BALDWIN AN, 1992, J BIOL CHEM, V267, P8352; Bamji SX, 1998, J CELL BIOL, V140, P911, DOI 10.1083/jcb.140.4.911; BARKER PA, 1994, NEURON, V13, P203, DOI 10.1016/0896-6273(94)90470-7; BENLEVY R, 1992, J BIOL CHEM, V267, P17304; BERG MM, 1991, P NATL ACAD SCI USA, V88, P7106, DOI 10.1073/pnas.88.16.7106; Bibel M, 1999, EMBO J, V18, P616, DOI 10.1093/emboj/18.3.616; CasacciaBonnefil P, 1996, NATURE, V383, P716, DOI 10.1038/383716a0; Casademunt E, 1999, EMBO J, V18, P6050, DOI 10.1093/emboj/18.21.6050; CHAO MV, 1995, TRENDS NEUROSCI, V18, P321, DOI 10.1016/0166-2236(95)93922-K; Dobrowsky RT, 1998, ANN NY ACAD SCI, V845, P32, DOI 10.1111/j.1749-6632.1998.tb09660.x; DONOVAN MJ, 1994, AM J PATHOL, V145, P792; Eketjall S, 1999, EMBO J, V18, P5901, DOI 10.1093/emboj/18.21.5901; Frade JM, 1996, NATURE, V383, P166; Fuh G, 2000, J BIOL CHEM, V275, P26690; Gargano N, 1997, J NEUROSCI RES, V50, P1; Ginsberg Mark H., 1992, Current Opinion in Cell Biology, V4, P766, DOI 10.1016/0955-0674(92)90099-X; HANTZOPOULOS PA, 1994, NEURON, V13, P187, DOI 10.1016/0896-6273(94)90469-3; HEMPSTEAD BL, 1992, NEURON, V9, P883, DOI 10.1016/0896-6273(92)90241-5; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HEMPSTEAD BL, 1990, J BIOL CHEM, V265, P9595; HUBER LJ, 1995, J NEUROSCI RES, V40, P557, DOI 10.1002/jnr.490400415; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; Kaplan DR, 2000, CURR OPIN NEUROBIOL, V10, P381, DOI 10.1016/S0959-4388(00)00092-1; Khursigara G, 1999, J BIOL CHEM, V274, P2597, DOI 10.1074/jbc.274.5.2597; LEE KF, 1994, SCIENCE, V263, P1447, DOI 10.1126/science.8128229; Lewin GR, 1996, ANNU REV NEUROSCI, V19, P289, DOI 10.1146/annurev.ne.19.030196.001445; Liepinsh E, 1997, EMBO J, V16, P4999, DOI 10.1093/emboj/16.16.4999; MAHADEO D, 1994, J BIOL CHEM, V269, P6884; Maliartchouk S, 1997, J NEUROSCI, V17, P6031; Meakin SO, 1999, J BIOL CHEM, V274, P9861, DOI 10.1074/jbc.274.14.9861; Pellegrini L, 2000, NATURE, V407, P1029, DOI 10.1038/35039551; PEREZ P, 1995, MOL CELL NEUROSCI, V6, P97, DOI 10.1006/mcne.1995.1010; Qian XZ, 1998, NEURON, V21, P1017, DOI 10.1016/S0896-6273(00)80620-0; RODRIGUEZTEBAR A, 1992, EMBO J, V11, P917, DOI 10.1002/j.1460-2075.1992.tb05130.x; Ross AH, 1996, J CELL BIOL, V132, P945, DOI 10.1083/jcb.132.5.945; Ross GM, 1998, EUR J NEUROSCI, V10, P890, DOI 10.1046/j.1460-9568.1998.00094.x; RYDEN M, 1995, EMBO J, V14, P1979, DOI 10.1002/j.1460-2075.1995.tb07190.x; Ryden M, 1997, J BIOL CHEM, V272, P16322, DOI 10.1074/jbc.272.26.16322; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; SUTTER A, 1979, J BIOL CHEM, V254, P5972; Trupp M, 1998, MOL CELL NEUROSCI, V11, P47, DOI 10.1006/mcne.1998.0667; URFER R, 1994, EMBO J, V13, P5896, DOI 10.1002/j.1460-2075.1994.tb06935.x; VERDI JM, 1994, NEURON, V12, P733, DOI 10.1016/0896-6273(94)90327-1; Vesa J, 2000, J BIOL CHEM, V275, P24414, DOI 10.1074/jbc.M001641200; WOLF DE, 1995, J BIOL CHEM, V270, P2133, DOI 10.1074/jbc.270.5.2133; Yamashita T, 1999, NEURON, V24, P585, DOI 10.1016/S0896-6273(00)81114-9; YAN H, 1991, J BIOL CHEM, V266, P12099; YAN H, 1991, SCIENCE, V252, P561, DOI 10.1126/science.1850551; Yano H, 2000, Pharm Acta Helv, V74, P253, DOI 10.1016/S0031-6865(99)00036-9	50	179	190	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					32687	32695		10.1074/jbc.M011674200	http://dx.doi.org/10.1074/jbc.M011674200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11435417	hybrid			2022-12-25	WOS:000170746000043
J	Heegaard, NHH; Sen, JW; Kaarsholm, NC; Nissen, MH				Heegaard, NHH; Sen, JW; Kaarsholm, NC; Nissen, MH			Conformational intermediate of the amyloidogenic protein beta(2)-microglobulin at neutral pH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-2-MICROGLOBULIN; FIBRILLOGENESIS; BINDING; PURIFICATION; HEMODIALYSIS; TRANSITIONS; MECHANISMS; CONVERSION; PEPTIDES; LYSOZYME	Aggregation and fibrillation of beta (2)-microglobulin are hallmarks of dialysis-related amyloidosis. We characterize perturbations of the native conformation of beta (2)-microglobulin that may precede fibril formation. For a beta (2)-microglobulin variant cleaved at lysine 58, we show using capillary electrophoresis that two conformers spontaneously exist in aqueous buffers at neutral pH. Upon treatment of wild-type beta (2)-microglobulin with acetonitrile or trifluoroethanol, two conformations were also observed. These conformations were in equilibrium dependent on the sample temperature and the percentage of organic solvent present. Circular dichroism showed a loss of beta -structures and gain of alpha -helices. Reversal to the native conformation occurred when removing the organics. Affinity capillary electrophoresis experiments showed increased specific interactions of the nonnative beta (2)-microglobulin conformation with the dyes 8-anilino-1-naphthalene sulfonic acid and Congo red. The observations may relate to early folding events prior to amyloid fibrillation and facilitate the development of methods to detect and inhibit pro-amyloid protein and peptide conformations.	Univ Copenhagen, Inst Med Anat, DK-2200 Copenhagen N, Denmark; Novo Nordisk AS, Res & Dev, DK-2880 Bagsvaerd, Denmark; Statens Serum Inst, Dept Autoimmunol, DK-2300 Copenhagen S, Denmark	University of Copenhagen; Novo Nordisk; Statens Serum Institut	Heegaard, NHH (corresponding author), Bldg 81,Room 536,Artillerivej 5, DK-2300 Copenhagen S, Denmark.	nhe@ssi.dk	Nissen, Mogens/B-4825-2008	Nissen, Mogens/0000-0001-7729-8667				BECKER JW, 1985, P NATL ACAD SCI USA, V82, P4225, DOI 10.1073/pnas.82.12.4225; Bellotti V, 1998, EUR J BIOCHEM, V258, P61, DOI 10.1046/j.1432-1327.1998.2580061.x; Booth DR, 1997, NATURE, V385, P787, DOI 10.1038/385787a0; Brockwell DJ, 2000, CURR OPIN STRUC BIOL, V10, P16, DOI 10.1016/S0959-440X(99)00043-3; Campistol JM, 1996, KIDNEY INT, V50, P1262, DOI 10.1038/ki.1996.436; Chiti F, 1999, P NATL ACAD SCI USA, V96, P3590, DOI 10.1073/pnas.96.7.3590; Crawford F, 1998, FEBS LETT, V436, P445, DOI 10.1016/S0014-5793(98)01170-3; Damaschun G, 2000, PROTEINS, V39, P204, DOI 10.1002/(SICI)1097-0134(20000515)39:3<204::AID-PROT20>3.0.CO;2-8; Fandrich M, 2001, NATURE, V410, P165, DOI 10.1038/35065514; Gao JM, 1996, SCIENCE, V272, P535, DOI 10.1126/science.272.5261.535; Gast K, 1999, PROTEIN SCI, V8, P625; GEJYO F, 1986, NEW ENGL J MED, V314, P585; Goda S, 2000, PROTEIN SCI, V9, P369; GROSSMAN PD, 1989, ANAL BIOCHEM, V179, P28, DOI 10.1016/0003-2697(89)90195-4; Guijarro JI, 1998, P NATL ACAD SCI USA, V95, P4224, DOI 10.1073/pnas.95.8.4224; Heegaard NHH, 2000, J CHROMATOGR A, V894, P319, DOI 10.1016/S0021-9673(00)00579-3; HEEGAARD NHH, 2001, PROTEIN LIGAND INTER, P171; HILSER VJ, 1995, ANAL BIOCHEM, V224, P465, DOI 10.1006/abio.1995.1075; Jackson GS, 1999, SCIENCE, V283, P1935, DOI 10.1126/science.283.5409.1935; Jadoul M, 1997, KIDNEY INT, V51, P1928, DOI 10.1038/ki.1997.262; Johnson WC, 1999, PROTEINS, V35, P307, DOI 10.1002/(SICI)1097-0134(19990515)35:3<307::AID-PROT4>3.0.CO;2-3; Kayed R, 1999, J MOL BIOL, V287, P781, DOI 10.1006/jmbi.1999.2646; Kelly JW, 1996, CURR OPIN STRUC BIOL, V6, P11, DOI 10.1016/S0959-440X(96)80089-3; KLUNK WE, 1989, J HISTOCHEM CYTOCHEM, V37, P1273, DOI 10.1177/37.8.2666510; Klunk WE, 1999, METHOD ENZYMOL, V309, P285; LADEWIG P, 1945, NATURE, V156, P81, DOI 10.1038/156081a0; Lashuel HA, 1998, BIOCHEMISTRY-US, V37, P17851, DOI 10.1021/bi981876+; Lim A, 2000, J STRUCT BIOL, V130, P363, DOI 10.1006/jsbi.2000.4272; McParland VJ, 2000, BIOCHEMISTRY-US, V39, P8735, DOI 10.1021/bi000276j; MOORE AW, 1995, ANAL CHEM, V67, P3464, DOI 10.1021/ac00115a015; MULQUEEN PM, 1982, ARCH BIOCHEM BIOPHYS, V215, P28, DOI 10.1016/0003-9861(82)90275-2; NISSEN MH, 1987, EUR J BIOCHEM, V163, P21, DOI 10.1111/j.1432-1033.1987.tb10731.x; NISSEN MH, 1990, EUR J BIOCHEM, V189, P423, DOI 10.1111/j.1432-1033.1990.tb15505.x; Nissen MH, 1997, J IMMUNOL METHODS, V205, P29; OKON M, 1992, BIOCHEMISTRY-US, V31, P8906, DOI 10.1021/bi00152a030; OZASA H, 1989, NEPHRON, V53, P87, DOI 10.1159/000185712; Rochet JC, 2000, CURR OPIN STRUC BIOL, V10, P60, DOI 10.1016/S0959-440X(99)00049-4; THOMAS PD, 1993, PROTEIN SCI, V2, P2050, DOI 10.1002/pro.5560021206; Verzola B, 2000, ANAL BIOCHEM, V282, P239, DOI 10.1006/abio.2000.4620; Walsh DM, 1997, J BIOL CHEM, V272, P22364, DOI 10.1074/jbc.272.35.22364; Walsh DM, 1999, J BIOL CHEM, V274, P25945, DOI 10.1074/jbc.274.36.25945; West MW, 1999, P NATL ACAD SCI USA, V96, P11211, DOI 10.1073/pnas.96.20.11211; Westermark P, 1999, AMYLOID, V6, P151, DOI 10.3109/13506129909007319	43	53	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					32657	32662		10.1074/jbc.M104452200	http://dx.doi.org/10.1074/jbc.M104452200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11418618	hybrid			2022-12-25	WOS:000170746000038
J	Wong, PMC; Yuan, Q; Chen, H; Sultzer, BM; Chung, SW				Wong, PMC; Yuan, Q; Chen, H; Sultzer, BM; Chung, SW			A single point mutation at the 3 '-untranslated region of Ran mRNA leads to profound changes in lipopolysaccharide endotoxin-mediated responses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; BICOID MESSENGER-RNA; TOLL-LIKE RECEPTOR-2; FACTOR-ALPHA PRODUCTION; GENETIC-CONTROL; HEMATOPOIETIC-CELLS; BINDING PROTEIN; CUTTING EDGE; BACTERIAL LIPOPOLYSACCHARIDES; INTERLEUKIN-3 GENE	By functional cDNA expression cloning, we have previously established that Ran is important in lipopolysaccharide (LPS) signaling. This was achieved by functional comparison between two cDNAs, differing by a single base substitution within the 3'-untranslated region of the cDNA. This point mutation results in a striking RNA conformational change. No dramatic difference in total RNA at steady state could be found between the two molecules. However, at the protein level, RanC/d (from 870C mRNA) was 5-10-fold higher than RanT/n (from 870T mRNA) and this difference was not observed in non-hematopoietic cells transduced with the same vectors. This tissue-specific difference correlated with a difference in LPS endotoxin responses in corresponding hematopoietic cells. Importantly, the amounts of RanC/d and RanT/n proteins were similar initially but the difference became obvious with time. Both Ran proteins migrated from the cytoplasm to the nucleus, but Ran from RanC/d migrated faster than that of RanT/n. RanT/n protein preferentially remained in the cytoplasm and its overall amount was reduced at steady state, consistent with its degradation by intracellular proteases known to be involved in LPS-mediated signal transduction. As the two proteins are identical, the faster RanC/d nuclear localization and a preferred initial cytoplasmic RanT/n distribution suggest a difference in mRNA intracellular localization between the two molecules, as dictated by their RNA structural difference. By pulse-chase experiments, RanC/d proteins are more resistant to degradation than RanT/n protein; there also appear to have two populations of RanT/n proteins, one may reside in the cytoplasm and the other, in the nucleus. More RanC/d GTPase accumulated in the nuclei would conceivably alter the potency of signal transduction and therefore down-modulate LPS-mediated biological responses.	Temple Univ, Sch Med, Dept Pathol & Lab Med, Fels Inst, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Wong, PMC (corresponding author), Temple Univ, Sch Med, Dept Pathol & Lab Med, Fels Inst, 3307 N Broad St,AHB,Rm 552, Philadelphia, PA 19140 USA.	Petermcw@aol.com	Yuan, Quan/E-7688-2013		NATIONAL CANCER INSTITUTE [R01CA070854] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039159, R01AI045951] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA70854] Funding Source: Medline; NIAID NIH HHS [R01AI39159, R01AI45951] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aliprantis AO, 1999, SCIENCE, V285, P736, DOI 10.1126/science.285.5428.736; Bassell GJ, 1998, J NEUROSCI, V18, P251; BROWDER TM, 1989, MOL CELL BIOL, V9, P204, DOI 10.1128/MCB.9.1.204; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COUTAVAS EE, 1994, MAMM GENOME, V5, P623, DOI 10.1007/BF00411457; Daniel R, 1996, CELL GROWTH DIFFER, V7, P1141; Deshler JO, 1998, CURR BIOL, V8, P489, DOI 10.1016/S0960-9822(98)70200-3; DODON MD, 1985, INFECT IMMUN, V49, P709, DOI 10.1128/IAI.49.3.709-714.1985; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; FAHMI H, 1993, J LEUKOCYTE BIOL, V53, P45, DOI 10.1002/jlb.53.1.45; FERRANDON D, 1994, CELL, V79, P1221, DOI 10.1016/0092-8674(94)90013-2; Garcia-Sanz Jose A., 1997, P425; Gautreau D, 1997, DEVELOPMENT, V124, P5013; GOLDE LM, 1976, J IMMUNOL, V117, P2061; Goldfarb DS, 1997, SCIENCE, V276, P1814, DOI 10.1126/science.276.5320.1814; HAN XD, 1995, P NATL ACAD SCI USA, V92, P11014, DOI 10.1073/pnas.92.24.11014; Havin L, 1998, GENE DEV, V12, P1593, DOI 10.1101/gad.12.11.1593; Hazelrigg T, 1998, CELL, V95, P451, DOI 10.1016/S0092-8674(00)81613-X; Haziot A, 1998, J IMMUNOL, V160, P2570; Haziot A, 1996, IMMUNITY, V4, P407, DOI 10.1016/S1074-7613(00)80254-X; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; Hoshino K, 1999, J IMMUNOL, V162, P3749; JANEWAY CA, 1989, COLD SPRING HARB SYM, V54, P1; Jin FY, 1999, J IMMUNOL, V162, P3596; Jin FY, 1997, CELL, V88, P417, DOI 10.1016/S0092-8674(00)81880-2; Kang AD, 1996, INFECT IMMUN, V64, P4612, DOI 10.1128/IAI.64.11.4612-4617.1996; KAPLAN JG, 1974, EXP CELL RES, V88, P388, DOI 10.1016/0014-4827(74)90257-2; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; Kirschning CJ, 1998, J EXP MED, V188, P2091, DOI 10.1084/jem.188.11.2091; Kislauskis Edward H., 1992, Current Opinion in Cell Biology, V4, P975, DOI 10.1016/0955-0674(92)90128-Y; KISLAUSKIS EH, 1994, J CELL BIOL, V127, P441, DOI 10.1083/jcb.127.2.441; Koepp DM, 1996, CELL, V87, P1, DOI 10.1016/S0092-8674(00)81315-X; KROL A, 1989, METHOD ENZYMOL, V180, P212; KU GSB, 1983, J IMMUNOL, V131, P2494; KUUSREICHEL K, 1986, J IMMUNOL, V137, P472; Macdonald PM, 1998, MOL CELL BIOL, V18, P3788, DOI 10.1128/MCB.18.7.3788; MACDONALD PM, 1995, P NATL ACAD SCI USA, V92, P10787, DOI 10.1073/pnas.92.23.10787; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Modlin RL, 1999, NEW ENGL J MED, V340, P1834, DOI 10.1056/NEJM199906103402312; MOORE MS, 1994, TRENDS BIOCHEM SCI, V19, P211, DOI 10.1016/0968-0004(94)90024-8; Moore MS, 1996, SCIENCE, V272, P47, DOI 10.1126/science.272.5258.47; NORDAN RP, 1987, J IMMUNOL, V139, P813; Ohba T, 1999, SCIENCE, V284, P1356, DOI 10.1126/science.284.5418.1356; PAIGE CJ, 1978, J IMMUNOL, V121, P641; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Qureshi ST, 1999, J EXP MED, V189, P615, DOI 10.1084/jem.189.4.615; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; ROSENSTREICH DL, 1978, J IMMUNOL, V121, P1664; ROSS K, 1997, SITES, V1, P17; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; SULTZER BM, 1972, INFECT IMMUN, V5, P107, DOI 10.1128/IAI.5.1.107-113.1972; SULTZER BM, 1968, NATURE, V219, P1253, DOI 10.1038/2191253a0; SULTZER BM, 1976, INFECT IMMUN, V13, P1579, DOI 10.1128/IAI.13.6.1579-1584.1976; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; VISCHER TL, 1974, J IMMUNOL, V113, P58; Vogel SN, 1999, J IMMUNOL, V162, P5666; WATSON J, 1978, J EXP MED, V147, P39, DOI 10.1084/jem.147.1.39; WATSON J, 1977, J IMMUNOL, V118, P2088; WATSON J, 1974, J EXP MED, V140, P1147, DOI 10.1084/jem.140.5.1147; WATSON J, 1977, J IMMUNOL, V120, P422; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; Wilde A, 1999, SCIENCE, V284, P1359, DOI 10.1126/science.284.5418.1359; WONG BY, 1994, J VIROL, V68, P5523, DOI 10.1128/JVI.68.9.5523-5531.1994; Wong PMC, 2000, SCAND J IMMUNOL, V51, P123; Wong PMC, 1999, P NATL ACAD SCI USA, V96, P11543, DOI 10.1073/pnas.96.20.11543; WONG PMC, 1989, MOL CELL BIOL, V9, P798, DOI 10.1128/MCB.9.2.798; WONG PMC, 1987, GENE DEV, V1, P358, DOI 10.1101/gad.1.4.358; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239; Yuan Q, 2000, P NATL ACAD SCI USA, V97, P2852, DOI 10.1073/pnas.040567797; Zhao FP, 2001, J ENDOTOXIN RES, V7, P53, DOI 10.1179/096805101101532549	73	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					33129	33138		10.1074/jbc.M105400200	http://dx.doi.org/10.1074/jbc.M105400200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11429415	hybrid			2022-12-25	WOS:000170746000099
J	McNamara-Schroeder, KJ; Hennessey, RF; Harding, GA; Jensen, RC; Stumph, WE				McNamara-Schroeder, KJ; Hennessey, RF; Harding, GA; Jensen, RC; Stumph, WE			The Drosophila U1 and U6 gene proximal sequence elements act as important determinants of the RNA polymerase specificity of small nuclear RNA gene promoters in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3' END FORMATION; SEA-URCHIN U1; SNRNA GENE; BINDING-PROTEIN; IN-VITRO; TATA BOX; DISTAL ELEMENTS; U2 SNRNA; TRANSCRIPTION; EXPRESSION	Transcription of genes coding for metazoan spliceosomal snRNAs by RNA polymerase II (U1, U2, U4, U5) or RNA. polymerase III (U6) is dependent upon a unique, positionally conserved regulatory element referred to as the proximal sequence element (PSE). Previous studies in the organism Drosophila melanogaster indicated that as few as three nucleotide differences in the sequences of the U1 and U6 PSEs can play a decisive role in recruiting the different RNA polymerases to transcribe the U1 and U6 snRNA genes in vitro. Those studies utilized constructs that contained only the minimal promoter elements of the U1 and U6 genes in an artificial context. To overcome the limitations of those earlier studies, we have now performed experiments that demonstrate that the Drosophila U1 and U6 PSEs have functionally distinct properties even in the environment of the natural U1 and U6 gene 5 ' -flanking DNAs. Moreover, assays in cells and in transgenic flies indicate that expression of genes from promoters that contain the "incorrect" PSE is suppressed in vivo. The Drosophila U6 PSE is incapable of recruiting RNA polymerase II to initiate transcription from the U1 promoter region, and the U1 PSE is unable to recruit RNA polymerase III to transcribe the U6 gene.	San Diego State Univ, Dept Chem, San Diego, CA 92182 USA; San Diego State Univ, Inst Mol Biol, San Diego, CA 92182 USA	California State University System; San Diego State University; California State University System; San Diego State University	Stumph, WE (corresponding author), San Diego State Univ, Dept Chem, 5500 Campanile Dr, San Diego, CA 92182 USA.							Bartlett JS, 1996, P NATL ACAD SCI USA, V93, P8852, DOI 10.1073/pnas.93.17.8852; Boyd DC, 2000, GENE, V247, P33, DOI 10.1016/S0378-1119(00)00134-7; BURNOL AF, 1993, NATURE, V362, P475, DOI 10.1038/362475a0; CARBON P, 1987, CELL, V51, P71, DOI 10.1016/0092-8674(87)90011-0; DAHLBERG JE, 1991, SCIENCE, V254, P1462, DOI 10.1126/science.1962205; DAHLBERG JE, 1988, NUCLEIC ACIDS RES, V16, P5827, DOI 10.1093/nar/16.13.5827; Dahlberg JE, 1988, STRUCTURE FUNCTION M, P38, DOI [10.1007/978-3-642- 73020-7_2, DOI 10.1007/978-3-642-73020-7_2]; DAS G, 1987, J BIOL CHEM, V262, P1187; *FLYB CONS, 1997, DROS INF SERV, V78, P372; GERLACH VL, 1995, MOL CELL BIOL, V15, P1455; Goodall GJ, 1991, OXFORD SURVEYS PLANT, V7, P255; Hardin SB, 2000, NUCLEIC ACIDS RES, V28, P2771, DOI 10.1093/nar/28.14.2771; Hernandez N, 1992, TRANSCRIPTIONAL REGU, P281; Jensen RC, 1998, NUCLEIC ACIDS RES, V26, P616, DOI 10.1093/nar/26.2.616; KADONAGA JT, 1990, J BIOL CHEM, V265, P2624; KISS T, 1991, CELL, V65, P517, DOI 10.1016/0092-8674(91)90469-F; Kunkel GR, 1998, NUCLEIC ACIDS RES, V26, P1536, DOI 10.1093/nar/26.6.1536; Kunkel GR, 1996, GENE EXPRESSION, V6, P59; Li JM, 1996, MOL CELL BIOL, V16, P1275; LI JM, 1994, MOL CELL BIOL, V14, P2191, DOI 10.1128/MCB.14.3.2191; LOBO SM, 1989, CELL, V58, P55, DOI 10.1016/0092-8674(89)90402-9; LOBO SM, 1994, TRANSCRIPTION MECH R, P127; MATTAJ IW, 1988, CELL, V55, P435, DOI 10.1016/0092-8674(88)90029-3; PARRY HD, 1989, NUCLEIC ACIDS RES, V17, P3633, DOI 10.1093/nar/17.10.3633; PARRY HD, 1989, TRENDS BIOCHEM SCI, V14, P15, DOI 10.1016/0968-0004(89)90083-2; PILCH DR, 1991, GENE EXPRESSION, V1, P41; Ramamurthy L, 1996, NUCLEIC ACIDS RES, V24, P4525, DOI 10.1093/nar/24.22.4525; ROEBUCK KA, 1990, MOL CELL BIOL, V10, P341, DOI 10.1128/MCB.10.1.341; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Schaub M, 1997, EMBO J, V16, P173, DOI 10.1093/emboj/16.1.173; STEFANOVIC B, 1992, MOL CELL BIOL, V12, P650, DOI 10.1128/MCB.12.2.650; STELLER H, 1985, EMBO J, V4, P167, DOI 10.1002/j.1460-2075.1985.tb02332.x; Stunkel W, 1997, MOL CELL BIOL, V17, P4397; Su Y, 1997, EUR J BIOCHEM, V248, P231, DOI 10.1111/j.1432-1033.1997.t01-1-00231.x; Takada S, 2000, CELL, V101, P459, DOI 10.1016/S0092-8674(00)80857-0; VANKAN P, 1989, EMBO J, V8, P3875, DOI 10.1002/j.1460-2075.1989.tb08566.x; WAIBEL F, 1990, NUCLEIC ACIDS RES, V18, P3451, DOI 10.1093/nar/18.12.3451; WAIBEL F, 1990, NATURE, V346, P199, DOI 10.1038/346199a0; Wang Y, 1998, MOL CELL BIOL, V18, P1570, DOI 10.1128/MCB.18.3.1570; Wang Y, 1996, NUCLEIC ACIDS RES, V24, P3100, DOI 10.1093/nar/24.15.3100; WENDELBURG BJ, 1992, NUCLEIC ACIDS RES, V20, P3743, DOI 10.1093/nar/20.14.3743; ZAMROD Z, 1993, MOL CELL BIOL, V13, P5918, DOI 10.1128/MCB.13.9.5918	42	24	26	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					31786	31792		10.1074/jbc.M101273200	http://dx.doi.org/10.1074/jbc.M101273200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11431466	hybrid			2022-12-25	WOS:000170613500043
J	Orzech, E; Livshits, L; Leyt, J; Okhrimenko, H; Reich, V; Cohen, S; Weiss, A; Melamed-Book, N; Lebendiker, M; Altschuler, Y; Aroeti, B				Orzech, E; Livshits, L; Leyt, J; Okhrimenko, H; Reich, V; Cohen, S; Weiss, A; Melamed-Book, N; Lebendiker, M; Altschuler, Y; Aroeti, B			Interactions between adaptor protein-1 of the clathrin coat and microtubules via type 1a microtubule-associated proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; POLARIZED EPITHELIAL-CELLS; BREFELDIN-A CAUSES; GAMMA-ADAPTIN; MDCK CELLS; KINESIN; ENDOSOMES; BINDING; PHOSPHORYLATION; REDISTRIBUTION	The classical view suggests that adaptor proteins of the clathrin coat mediate the sorting of cargo protein passengers into clathrin-coated pits and the recruitment of clathrin into budding areas in the donor membrane. In the present study, we provide biochemical and morphological evidence that the adaptor protein 1 (AP-1) adaptor of the trans-Golgi network clathrin interacts with microtubules. AP-1 in cytosolic extracts interacted with in vitro assembled microtubules, and these interactions were inhibited by ATP depletion of the extracts or in the presence of 5 ' -adenylylimidodiphosphate. An overexpressed gamma -subunit of the AP-1 complex associated with microtubules, suggesting that this subunit may mediate the interaction of AP-1 with the cytoskeleton. Purified AP-1 did not interact with purified microtubules, but interaction occurred when an isolated microtubule-associated protein fraction was added to the reaction mix. The gamma -adaptin subunit of AP-1 specifically co-immunoprecipitated with a microtubule-associated protein of type la from rat brain cytosol. This suggests that type la microtubule-associated protein may mediate the association of AP-1 with microtubules in the cytoplasm. The microtubule binding activity of AP-1 was markedly inhibited in cytosol of mitotic cells. By means of its interaction with microtubule-associated proteins, we propose novel roles for AP-1 adaptors in modulating the dynamics of the cytoskeleton, the stability and shape of coated organelles, and the loading of nascent AP-1-coated vesicles onto appropriate microtubular tracks.	Hebrew Univ Jerusalem, Inst Life Sci, Dept Cell & Anim Biol, IL-91904 Jerusalem, Israel; Hebrew Univ Jerusalem, Inst Life Sci, Prot Purificat Unit, IL-91904 Jerusalem, Israel; Hebrew Univ Jerusalem, Inst Life Sci, Wolfson Ctr Appl Struct Biol, IL-91904 Jerusalem, Israel; Hebrew Univ Jerusalem, Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel; Jerusalem Coll Technol, Dept Elect, IL-91160 Jerusalem, Israel; Hebrew Univ Jerusalem, Fac Med, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hebrew University of Jerusalem	Aroeti, B (corresponding author), Hebrew Univ Jerusalem, Inst Life Sci, Dept Cell & Anim Biol, IL-91904 Jerusalem, Israel.							Apodaca G, 1996, EMBO J, V15, P1471, DOI 10.1002/j.1460-2075.1996.tb00491.x; APODACA G, 1994, J CELL BIOL, V125, P67, DOI 10.1083/jcb.125.1.67; AROETI B, 1993, J CELL BIOL, V123, P1149, DOI 10.1083/jcb.123.5.1149; Bashour AM, 1998, J BIOL CHEM, V273, P19612, DOI 10.1074/jbc.273.31.19612; BERSHADSKY AD, 1994, P NATL ACAD SCI USA, V91, P5686, DOI 10.1073/pnas.91.12.5686; BINDER LI, 1985, J CELL BIOL, V101, P1371, DOI 10.1083/jcb.101.4.1371; BLOOM GS, 1989, J BIOL CHEM, V264, P16083; BLOOM GS, 1984, J CELL BIOL, V98, P331, DOI 10.1083/jcb.98.1.331; BLOOM GS, 1999, GUIDEBOOK CYTOSKELET, P206; Bohm K J, 1991, Acta Histochem Suppl, V41, P65; Boman AL, 1999, CELL MOTIL CYTOSKEL, V44, P119, DOI 10.1002/(SICI)1097-0169(199910)44:2<119::AID-CM4>3.3.CO;2-3; BRAELL WA, 1984, J CELL BIOL, V99, P734, DOI 10.1083/jcb.99.2.734; Brandeis M, 1996, EMBO J, V15, P5280, DOI 10.1002/j.1460-2075.1996.tb00913.x; CLUETT EB, 1993, J CELL BIOL, V120, P15, DOI 10.1083/jcb.120.1.15; Drewes G, 1998, TRENDS BIOCHEM SCI, V23, P307, DOI 10.1016/S0968-0004(98)01245-6; Echard A, 1998, SCIENCE, V279, P580, DOI 10.1126/science.279.5350.580; Folsch H, 1999, CELL, V99, P189, DOI 10.1016/S0092-8674(00)81650-5; Fujii T, 1996, NEUROCHEM INT, V28, P535, DOI 10.1016/0197-0186(95)00128-X; Godi A, 1999, BIOCHEM SOC T, V27, P638, DOI 10.1042/bst0270638; Hannan LA, 1998, MOL BIOL CELL, V9, P2217, DOI 10.1091/mbc.9.8.2217; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; HEUSER JE, 1988, J CELL BIOL, V107, P877, DOI 10.1083/jcb.107.3.877; Hirst J, 2000, J CELL BIOL, V149, P67, DOI 10.1083/jcb.149.1.67; Holleran EA, 1998, TRENDS CELL BIOL, V8, P26, DOI 10.1016/S0962-8924(97)01195-1; Huang KM, 1999, EMBO J, V18, P3897, DOI 10.1093/emboj/18.14.3897; KEON JPR, 1995, GENE, V162, P141, DOI 10.1016/0378-1119(95)00355-A; Kirchhausen T, 2000, ANNU REV BIOCHEM, V69, P699, DOI 10.1146/annurev.biochem.69.1.699; Kirchhausen T, 1999, ANNU REV CELL DEV BI, V15, P705, DOI 10.1146/annurev.cellbio.15.1.705; Lane J, 1998, BBA-REV BIOMEMBRANES, V1376, P27, DOI 10.1016/S0304-4157(97)00010-5; Liao GJ, 1998, J BIOL CHEM, V273, P9797, DOI 10.1074/jbc.273.16.9797; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LIPPINCOTTSCHWARTZ J, 1995, J CELL BIOL, V128, P293, DOI 10.1083/jcb.128.3.293; Lowe M, 2000, J CELL BIOL, V149, P341, DOI 10.1083/jcb.149.2.341; Lowe M, 1998, TRENDS CELL BIOL, V8, P40, DOI 10.1016/S0962-8924(97)01189-6; MACCIONI RB, 1995, PHYSIOL REV, V75, P835, DOI 10.1152/physrev.1995.75.4.835; MANDELKOW E, 1995, CURR OPIN CELL BIOL, V7, P72, DOI 10.1016/0955-0674(95)80047-6; MANDELKOW EM, 1991, J CELL BIOL, V114, P977, DOI 10.1083/jcb.114.5.977; MANFREDI JJ, 1987, J BIOL CHEM, V262, P1218; MELKI R, 1989, BIOCHEMISTRY-US, V28, P9143, DOI 10.1021/bi00449a028; Meyer C, 2000, EMBO J, V19, P2193, DOI 10.1093/emboj/19.10.2193; Ohno H, 1999, FEBS LETT, V449, P215, DOI 10.1016/S0014-5793(99)00432-9; Orzech E, 2000, J BIOL CHEM, V275, P15207, DOI 10.1074/jbc.275.20.15207; Orzech E, 1999, J BIOL CHEM, V274, P2201, DOI 10.1074/jbc.274.4.2201; Page LJ, 1999, J CELL BIOL, V146, P993, DOI 10.1083/jcb.146.5.993; PAGE LJ, 1995, J CELL BIOL, V131, P619, DOI 10.1083/jcb.131.3.619; Parnas D, 1995, INT J DEV NEUROSCI, V13, P767, DOI 10.1016/0736-5748(95)00052-6; Prigozina NL, 1996, CELL BIOL INT, V20, P379, DOI 10.1006/cbir.1996.0045; Rapoport I, 1998, EMBO J, V17, P2148, DOI 10.1093/emboj/17.8.2148; REAVES B, 1992, J CELL BIOL, V116, P85, DOI 10.1083/jcb.116.1.85; Robertson AM, 2000, MOL BIOL CELL, V11, P941, DOI 10.1091/mbc.11.3.941; Takatsu H, 1998, J BIOL CHEM, V273, P24693, DOI 10.1074/jbc.273.38.24693; VONMASSOW A, 1989, CELL MOTIL CYTOSKEL, V14, P562, DOI 10.1002/cm.970140413; WAGNER M, 1994, J CELL SCI, V107, P933; Wilde A, 1996, J CELL BIOL, V135, P635, DOI 10.1083/jcb.135.3.635; WILLIAMS R C JR, 1992, P151; WOOD SA, 1991, CELL, V67, P591, DOI 10.1016/0092-8674(91)90533-5; Zizioli D, 1999, J BIOL CHEM, V274, P5385, DOI 10.1074/jbc.274.9.5385	58	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					31340	31348		10.1074/jbc.M101054200	http://dx.doi.org/10.1074/jbc.M101054200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11418592	hybrid			2022-12-25	WOS:000170472900098
J	Verrecchia, F; Vindevoghel, L; Lechleider, RJ; Uitto, J; Roberts, AB; Mauviel, A				Verrecchia, F; Vindevoghel, L; Lechleider, RJ; Uitto, J; Roberts, AB; Mauviel, A			Smad3/AP-1 interactions control transcriptional responses to TGF-beta in a promoter-specific manner	ONCOGENE			English	Article						TGF-beta; AP-1; Smad; gene regulation; Jun	GROWTH-FACTOR-BETA; COLLAGEN GENE COL7A1; C-JUN; COACTIVATOR P300; SMAD PROTEINS; DNA-BINDING; ACTIVATION; FIBROBLASTS; EXPRESSION; SEQUENCE	Smad proteins transduce signals from TGF-beta receptors and regulate transcription of target genes either directly or in combination with other sequence-specific transcription factors, AP-1 sites and their cognate transcription factors also play important roles in the gene regulatory activities of TGF-beta. In this report, we have investigated the functional interactions of the Smad and AP-1 transcription factors. We demonstrate that Smad and AP-1 complexes specifically bind to their cognate cis-elements and do not interact with each other on-DNA, whereas off-DNA interactions occur between Smad3 and both c-Jun and JunB. Using both artificial constructs specific for either the Smad or AP-1 signaling pathways or natural promoters known to be TGF-beta -responsive, we have determined that Jun family members downregulate Smad3-mediated gene transactivation whereas AP-1-dependent promoters are synergistically activated by Smad3 and Jun proteins, We propose a model where the presence of Smad- and/or AP-1-specific cis-elements within TGF-beta -responsive genes allows dynamic modulation of gene expression, in contrast to the existing model where interactions between Smad and AP-1 proteins are merely an on/off mechanism to regulate TGF-beta /Smad targets.	Hop St Louis, INSERM, U532, Inst Rech Peau, F-75010 Paris, France; Thomas Jefferson Univ, Jefferson Inst Mol Med, Dept Dermatol & Cutaneous Biol, Philadelphia, PA 19107 USA; NCI, Lab Cell Regulat & Carcinogenesis, NIH, Bethesda, MD 20892 USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Jefferson University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Mauviel, A (corresponding author), Hop St Louis, INSERM, U532, Inst Rech Peau, Pavillon Bazin,1 Ave Claude Vellefaux, F-75010 Paris, France.		MAUVIEL, Alain/F-6251-2013; Verrecchia, Franck/G-5535-2018	Verrecchia, Franck/0000-0003-4920-2554	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041439] Funding Source: NIH RePORTER; NIAMS NIH HHS [O1 AR41439] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Atfi A, 1997, J BIOL CHEM, V272, P24731, DOI 10.1074/jbc.272.40.24731; Chen SJ, 1999, J INVEST DERMATOL, V112, P49, DOI 10.1046/j.1523-1747.1999.00477.x; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; Chung KY, 1996, J BIOL CHEM, V271, P3272, DOI 10.1074/jbc.271.6.3272; de Caestecker MP, 1998, GENE DEV, V12, P1587, DOI 10.1101/gad.12.11.1587; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; FRISCH SM, 1990, ONCOGENE, V5, P75; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Hottiger MO, 1998, EMBO J, V17, P3124, DOI 10.1093/emboj/17.11.3124; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KEETON MR, 1991, J BIOL CHEM, V266, P23048; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; Lechleider RJ, 1996, J BIOL CHEM, V271, P17617, DOI 10.1074/jbc.271.30.17617; Lee JS, 1996, MOL CELL BIOL, V16, P4312; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; Maggirwar SB, 2000, J NEUROCHEM, V74, P527, DOI 10.1046/j.1471-4159.2000.740527.x; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 2000, GENE DEV, V14, P627; MAUVIEL A, 1993, CURR BIOL, V3, P822, DOI 10.1016/0960-9822(93)90216-B; Mauviel A, 1996, J BIOL CHEM, V271, P10917, DOI 10.1074/jbc.271.18.10917; PERTOVAARA L, 1989, MOL CELL BIOL, V9, P1255, DOI 10.1128/MCB.9.3.1255; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; PIU F, 1993, CR ACAD SCI III-VIE, V316, P772; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Stroschein SL, 1999, J BIOL CHEM, V274, P9431, DOI 10.1074/jbc.274.14.9431; Verrecchia F, 2000, J BIOL CHEM, V275, P30226, DOI 10.1074/jbc.M005310200; Vindevoghel L, 1998, J BIOL CHEM, V273, P13053, DOI 10.1074/jbc.273.21.13053; Vindevoghel L, 1997, J BIOL CHEM, V272, P10196; Vindevoghel L, 1998, P NATL ACAD SCI USA, V95, P14769, DOI 10.1073/pnas.95.25.14769; Wong C, 1999, MOL CELL BIOL, V19, P1821; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814	38	154	159	0	11	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 7	2001	20	26					3332	3340		10.1038/sj.onc.1204448	http://dx.doi.org/10.1038/sj.onc.1204448			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	441UW	11423983				2022-12-25	WOS:000169248800003
J	Dohn, M; Zhang, SZ; Chen, XB				Dohn, M; Zhang, SZ; Chen, XB			p63 alpha and Delta Np63 alpha can induce cell cycle arrest and apoptosis and differentially regulate p53 target genes	ONCOGENE			English	Article						apoptosis; cell cycle arrest; p63; p53; p73	P53-REGULATED PROTEIN GADD45; TUMOR-SUPPRESSOR P53; KINASE C-ABL; DNA-DAMAGE; TRANSCRIPTIONAL ACTIVITIES; P53-RELATED PROTEIN; HUMAN CANCERS; P73; P63; EXPRESSION	The p53 tumor suppressor protein plays a critical role in the regulation of the cell cycle and apoptosis, The importance of p53's functions is underscored by the high incidence of p53 mutations in human cancers, Recently, two p53-related proteins, p73 and p63, were identified as members of the p53 gene family, Multiple isoforms of p73 have been found, including DeltaN variants in which the N-termini are truncated, p63 is expressed as three major forms, p63 alpha, p63 beta and p63 gamma, each of which differ in their C-termini, All three forms can be alternatively transcribed from a cryptic promoter located within intron 3, producing Delta Np63 alpha, Delta Np63 beta and Delta Np63 gamma, The high degree of similarity of p73 and p63 to evolutionarily conserved regions of p53 suggests that these proteins play an important and potentially redundant role in regulating cell cycle arrest and apoptosis, Here we describe the characterization of cell lines generated to inducibly express p63 alpha and Delta Np63 alpha. We have found that p63 alpha and Delta Np63 alpha can differentially regulate endogenous p53 target genes and induce cell cycle arrest and apoptosis, Deletion of the N-terminal 26 amino acids of Delta Np63 alpha abolished its ability to transactivate p53 target genes and induce cell cycle arrest and apoptosis, This indicates that a putative transactivation domain exists within the N-terminus of the DeltaN variants of p63, Furthermore, the differential regulation of p53 target genes by p63a and Delta Np63 alpha suggests that p63 and p53 utilize both similar and different signaling pathways to execute their cellular functions.	Med Coll Georgia, Inst Mol Med & Genet, Augusta, GA 30912 USA	University System of Georgia; Augusta University	Chen, XB (corresponding author), Med Coll Georgia, Inst Mol Med & Genet, Augusta, GA 30912 USA.				NATIONAL CANCER INSTITUTE [R01CA081237, R29CA076069] Funding Source: NIH RePORTER; NCI NIH HHS [R29 CA76069, R01 CA81237] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agami R, 1999, NATURE, V399, P809; Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Barbosa MS, 1996, CRIT REV ONCOGENESIS, V7, P1; Boyer SN, 1996, CANCER RES, V56, P4620; Candau R, 1997, ONCOGENE, V15, P807, DOI 10.1038/sj.onc.1201244; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Chen XB, 1999, MOL MED TODAY, V5, P387, DOI 10.1016/S1357-4310(99)01545-2; Chinery R, 1997, NAT MED, V3, P1233, DOI 10.1038/nm1197-1233; Crook T, 2000, ONCOGENE, V19, P3439, DOI 10.1038/sj.onc.1203656; Davison TS, 1999, J BIOL CHEM, V274, P18709, DOI 10.1074/jbc.274.26.18709; De Laurenzi V, 2000, BIOCHEM BIOPH RES CO, V273, P342, DOI 10.1006/bbrc.2000.2932; De Laurenzi V, 1999, CELL DEATH DIFFER, V6, P389, DOI 10.1038/sj.cdd.4400521; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Evans SC, 1997, MOL MED TODAY, V3, P390, DOI 10.1016/S1357-4310(97)01105-2; Gong JG, 1999, NATURE, V399, P806; Gu ZM, 2000, MOL CELL BIOL, V20, P233, DOI 10.1128/MCB.20.1.233-241.2000; Hall PA, 2000, CARCINOGENESIS, V21, P153, DOI 10.1093/carcin/21.2.153; HARPER JW, 1993, CELL, V75, P805; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Hibi K, 2000, P NATL ACAD SCI USA, V97, P5462, DOI 10.1073/pnas.97.10.5462; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Jin SQ, 2000, J BIOL CHEM, V275, P16602, DOI 10.1074/jbc.M000284200; JOHANSEN FE, 1994, MOL CELL BIOL, V14, P5920, DOI 10.1128/MCB.14.9.5920; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaelin WG, 1999, J NATL CANCER I, V91, P594, DOI 10.1093/jnci/91.7.594; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Levrero M, 1999, CELL DEATH DIFFER, V6, P1146, DOI 10.1038/sj.cdd.4400624; Levrero M, 2000, J CELL SCI, V113, P1661; Liefer KM, 2000, CANCER RES, V60, P4016; Lohrum MAE, 2000, TRENDS CELL BIOL, V10, P197, DOI 10.1016/S0962-8924(00)01736-0; MAHESWARAN S, 1995, GENE DEV, V9, P2143, DOI 10.1101/gad.9.17.2143; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; MIYASHITA T, 1995, CELL, V80, P293; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Prives C, 1999, J PATHOL, V187, P112; Rouault JP, 1996, NAT GENET, V14, P482, DOI 10.1038/ng1296-482; Scharnhorst V, 2000, J BIOL CHEM, V275, P10202, DOI 10.1074/jbc.275.14.10202; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Schmale H, 1997, ONCOGENE, V15, P1363, DOI 10.1038/sj.onc.1201500; Senoo M, 1998, BIOCHEM BIOPH RES CO, V248, P603, DOI 10.1006/bbrc.1998.9013; Shaul Y, 2000, CELL DEATH DIFFER, V7, P10, DOI 10.1038/sj.cdd.4400626; Shimada A, 1999, CANCER RES, V59, P2781; Smith CL, 1997, J BIOL CHEM, V272, P27493, DOI 10.1074/jbc.272.44.27493; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Trink B, 1998, NAT MED, V4, P747, DOI 10.1038/nm0798-747; Ueda Y, 1999, ONCOGENE, V18, P4993, DOI 10.1038/sj.onc.1202817; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yin YX, 1998, NATURE, V391, P707, DOI 10.1038/35648; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zaika AI, 1999, CANCER RES, V59, P3257; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; Zhu JH, 2000, MOL CELL BIOL, V20, P5602, DOI 10.1128/MCB.20.15.5602-5618.2000; Zhu JH, 1998, J BIOL CHEM, V273, P13030, DOI 10.1074/jbc.273.21.13030; Zhu JH, 1998, CANCER RES, V58, P5061; zur Hausen H, 2000, JNCI-J NATL CANCER I, V92, P690, DOI 10.1093/jnci/92.9.690	73	248	262	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 31	2001	20	25					3193	3205		10.1038/sj.onc.1204427	http://dx.doi.org/10.1038/sj.onc.1204427			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	440ET	11423969				2022-12-25	WOS:000169163500003
J	Lu, WG; Chen, LH; Peng, YH; Chen, JD				Lu, WG; Chen, LH; Peng, YH; Chen, JD			Activation of p53 by roscovitine-mediated suppression of MDM2 expression	ONCOGENE			English	Article						roscovitine; p53; MDM2; cdk; transcription	CYCLIN-DEPENDENT KINASES; SOFT-TISSUE SARCOMAS; DNA-DAMAGE; SYNERGISTIC ACTIVATION; NUCLEAR EXCLUSION; HUMAN SKIN; IN-VIVO; PROTEIN; TRANSCRIPTION; INHIBITION	The p53 tumor suppressor is regulated by the MDM2 oncoprotein. Overexpression of MDM2 maintains p53 at low levels and contributes to the functional inactivation of p53 in a subset of tumors. We found that treatment with roscovitine and olomoucin, which were originally developed as cyclin-dependent kinase (CDK) inhibitors, can efficiently stabilize and activate nuclear p53 in tumor cells with MDM2 amplification or cytoplasmic p53. These inhibitors block the degradation of p53 without affecting p53-MDM2 binding and the nuclear shuttling function of p53 and MDM2. Roscovitine also induces stabilization of the p53 Ala-315 mutant, indicating that it does not act by regulating the CDK phosphorylation of serine 315, Roscovitine induces down-regulation of MDM2 expression at both protein and mRNA levels. Ectopic expression of MDM2 can abrogate the ability of roscovitine to induce p53 stabilization. Low concentrations of roscovitine cooperate with the DNA-damaging agent camptothecin to activate p53 in a synergistic fashion, These results show that the small molecule CDK inhibitors can be used to activate p53 through their potent inhibitory effect on MDM2 expression and may be useful as sensitizing agents for other DNA-damaging drugs.	H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute	Chen, JD (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, 12902 Magnolia Dr, Tampa, FL 33612 USA.							ADDISON C, 1990, ONCOGENE, V5, P423; Andera L, 1997, MOL MED, V3, P852, DOI 10.1007/BF03401721; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; Blattner C, 1999, ONCOGENE, V18, P1723, DOI 10.1038/sj.onc.1202480; Blaydes JP, 2000, ONCOGENE, V19, P3829, DOI 10.1038/sj.onc.1203773; Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; Chang D, 1999, CELL GROWTH DIFFER, V10, P155; Chehab NH, 2000, GENE DEV, V14, P278; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Chen LH, 1998, P NATL ACAD SCI USA, V95, P195, DOI 10.1073/pnas.95.1.195; Chen LH, 1999, MOL MED, V5, P21, DOI 10.1007/BF03402136; CORDONCARDO C, 1994, CANCER RES, V54, P794; DavidPfeuty T, 1996, CELL GROWTH DIFFER, V7, P1211; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Hajduch M, 1999, ADV EXP MED BIOL, V457, P341; HALL PA, 1993, ONCOGENE, V8, P203; Hao MM, 1996, J BIOL CHEM, V271, P29380, DOI 10.1074/jbc.271.46.29380; Hietanen S, 2000, P NATL ACAD SCI USA, V97, P8501, DOI 10.1073/pnas.97.15.8501; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Juven-Gershon T, 1999, MOL MED, V5, P71, DOI 10.1007/BF03402141; Kapoor M, 2000, ONCOGENE, V19, P358, DOI 10.1038/sj.onc.1203300; LEACH FS, 1993, CANCER RES, V53, P2231; Li LW, 2000, J BIOL CHEM, V275, P2410, DOI 10.1074/jbc.275.4.2410; Ljungman M, 1999, ONCOGENE, V18, P583, DOI 10.1038/sj.onc.1202356; Lu H, 1998, P NATL ACAD SCI USA, V95, P6399, DOI 10.1073/pnas.95.11.6399; Lu WG, 2000, ONCOGENE, V19, P232, DOI 10.1038/sj.onc.1203262; McMasters KM, 1996, ONCOGENE, V13, P1731; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Meng RD, 1998, CLIN CANCER RES, V4, P251; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; O'Grady A, 1998, HUM PATHOL, V29, P559, DOI 10.1016/S0046-8177(98)80003-8; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Sankrithi N, 1999, J NEUROCHEM, V72, P605, DOI 10.1046/j.1471-4159.1999.0720605.x; Schang LM, 1999, J VIROL, V73, P2161, DOI 10.1128/JVI.73.3.2161-2172.1999; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Shieh SY, 2000, GENE DEV, V14, P289; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Tao WK, 1999, P NATL ACAD SCI USA, V96, P3077, DOI 10.1073/pnas.96.6.3077; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; VESELY J, 1994, EUR J BIOCHEM, V224, P771, DOI 10.1111/j.1432-1033.1994.00771.x; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; Wu L, 1997, MOL MED, V3, P441, DOI 10.1007/BF03401691; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126	47	98	101	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 31	2001	20	25					3206	3216		10.1038/sj.onc.1204412	http://dx.doi.org/10.1038/sj.onc.1204412			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	440ET	11423970				2022-12-25	WOS:000169163500004
J	Mattila, MMT; Ruohola, JK; Valve, EM; Tasanen, MJ; Seppanen, JA; Harkonen, PL				Mattila, MMT; Ruohola, JK; Valve, EM; Tasanen, MJ; Seppanen, JA; Harkonen, PL			FGF-8b increases angiogenic capacity and tumor growth of androgen-regulated S115 breast cancer cells	ONCOGENE			English	Article						FGF-8 isoforms; angiogenesis; breast cancer; tumorigenesis; androgen; hormone-independence	IN-VIVO; PROGNOSTIC INDICATOR; MOLECULAR-CLONING; STEROID-HORMONES; PROSTATE-CANCER; AUTOCRINE LOOP; STEP METHOD; EXPRESSION; MAMMARY; FGF8	Fibroblast growth factor 8 (FGF-8) is a secreted heparin-binding protein, which has transforming potential. Alternative splicing of the mouse Fgf-8 gene potentially codes for eight protein isoforms (a-h) which differ in their transforming capacity in transfected cells. S115 mouse mammary tumor cells express a transformed phenotype and secrete FGF-8 in an androgen-dependent manner. In order to study the role of FGF-8 isoforms in the induction of transformed phenotype of breast cancer cells, we over-expressed FGF-8 isoforms a, b and e in S115 cells. Over-expression of FGF-8b, but not FGF-8a or FGF-8e, induced androgen and anchorage independent growth of S115 cells. FGF-8b-transfected S115 eels formed rapidly growing tumors with increased vascularization when injected s.c, into nude mice. FGF-8a also slightly increased tumor growth and probably tumor vascularization but FGF-8e was not found to have any effects. The angiogenic activity of FGF-8b and heparin-binding growth factor fraction (HBGF) of S115 cell conditioned media was tested in in vitro and in vivo models for angiogenesis using immortomouse brain capillary endothelial cells (IBEC) and chorion allantoic membrane (CAM) assays. Recombinant FGF-8b protein was able to stimulate proliferation, migration, and vessellike tube formation of IBECs, In addition, stimulatory effect of S115-HBGF on IBE cell proliferation was evident. A positive angiogenic response to FGF-8b was also seen in CAM assay. The results demonstrate that the expression of Fgf-8b is able to promote vessel formation. Angiogenic capacity probably markedly contributes to the ability of FGF-8b to increase tumor growth of androgen-regulated S115 mouse breast cancer cells.	Univ Turku, Inst Biomed, Dept Anat, FIN-20520 Turku, Finland; Univ Turku, MediCity Res Lab, FIN-20520 Turku, Finland	University of Turku; University of Turku	Harkonen, PL (corresponding author), Univ Turku, Inst Biomed, Dept Anat, Kiinamyllnkatu 10, FIN-20520 Turku, Finland.							AUERBACH R, 1974, DEV BIOL, V41, P391, DOI 10.1016/0012-1606(74)90316-9; Blunt AG, 1997, J BIOL CHEM, V272, P3733, DOI 10.1074/jbc.272.6.3733; Bouck N, 1996, ADV CANCER RES, V69, P135, DOI 10.1016/S0065-230X(08)60862-3; Chang YS, 2000, P NATL ACAD SCI USA, V97, P14608, DOI 10.1073/pnas.97.26.14608; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Crossley PH, 1996, NATURE, V380, P66, DOI 10.1038/380066a0; Crossley PH, 1996, CELL, V84, P127, DOI 10.1016/S0092-8674(00)80999-X; CROSSLEY PH, 1995, DEVELOPMENT, V121, P439; Daphna-Iken D, 1998, ONCOGENE, V17, P2711, DOI 10.1038/sj.onc.1202212; DARBRE PD, 1987, CANCER RES, V47, P2937; DARBRE PD, 1988, BREAST CANCER CELLUL, P307; DICKSON RB, 1995, ENDOCR REV, V16, P559, DOI 10.1210/er.16.5.559; Dorkin TJ, 1999, ONCOGENE, V18, P2755, DOI 10.1038/sj.onc.1202624; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; Fukumura D, 1998, CELL, V94, P715, DOI 10.1016/S0092-8674(00)81731-6; Gasparini G, 1997, J NATL CANCER I, V89, P139, DOI 10.1093/jnci/89.2.139; Gemel J, 1996, GENOMICS, V35, P253, DOI 10.1006/geno.1996.0349; Gerwins P, 2000, CRIT REV ONCOL HEMAT, V34, P185, DOI 10.1016/S1040-8428(00)00062-7; Ghosh AK, 1996, CELL GROWTH DIFFER, V7, P1425; GOTO F, 1993, LAB INVEST, V69, P508; Guidi AJ, 1997, CANCER, V80, P1945, DOI 10.1002/(SICI)1097-0142(19971115)80:10<1945::AID-CNCR11>3.0.CO;2-Y; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hansen S, 2000, CLIN CANCER RES, V6, P139; HARKONEN PL, 1990, EXP CELL RES, V186, P288, DOI 10.1016/0014-4827(90)90308-W; HARLEY CB, 1987, GENE ANAL TECH, V4, P17, DOI 10.1016/0735-0651(87)90013-6; HARTMANN KKP, 1990, ENDOCRINOLOGY, V127, P2038, DOI 10.1210/endo-127-4-2038; HEIKINHEIMO M, 1994, MECH DEVELOP, V48, P129, DOI 10.1016/0925-4773(94)90022-1; Jain RK, 1998, P NATL ACAD SCI USA, V95, P10820, DOI 10.1073/pnas.95.18.10820; Johnson MR, 1998, ONCOGENE, V16, P2647, DOI 10.1038/sj.onc.1201789; JOUANNEAU J, 1995, GROWTH FACTORS, V12, P37, DOI 10.3109/08977199509003212; Kanda S, 1996, CELL GROWTH DIFFER, V7, P383; KOUHARA H, 1994, ONCOGENE, V9, P455; LEPPA S, 1992, P NATL ACAD SCI USA, V89, P932, DOI 10.1073/pnas.89.3.932; Lewandoski M, 1997, COLD SPRING HARB SYM, V62, P159; LORENZI MV, 1995, ONCOGENE, V10, P2051; MACARTHUR CA, 1995, DEVELOPMENT, V121, P3603; MACARTHUR CA, 1995, CELL GROWTH DIFFER, V6, P817; MACARTHUR CA, 1995, J VIROL, V69, P2501, DOI 10.1128/JVI.69.4.2501-2507.1995; MAKELA TP, 1992, GENE, V118, P293, DOI 10.1016/0378-1119(92)90203-2; Maniotis AJ, 1999, AM J PATHOL, V155, P739, DOI 10.1016/S0002-9440(10)65173-5; Marsh SK, 1999, ONCOGENE, V18, P1053, DOI 10.1038/sj.onc.1202392; Nicholson RI, 2000, BRIT J CANCER, V82, P501; PEPPER MS, 1992, BIOCHEM BIOPH RES CO, V189, P824, DOI 10.1016/0006-291X(92)92277-5; Relf M, 1997, CANCER RES, V57, P963; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Rudra-Ganguly N, 1998, ONCOGENE, V16, P1487, DOI 10.1038/sj.onc.1201652; Ruohola JK, 1999, MOL CELL ENDOCRINOL, V149, P29, DOI 10.1016/S0303-7207(99)00003-9; RUOHOLA JK, 1995, ENDOCRINOLOGY, V136, P2179, DOI 10.1210/en.136.5.2179; SATO B, 1993, J STEROID BIOCHEM, V47, P91, DOI 10.1016/0960-0760(93)90061-Z; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; Szebenyi G, 1999, INT REV CYTOL, V185, P45; TAKATSUKA D, 1992, ANTICANCER RES, V12, P2001; Tanaka A, 1998, CANCER RES, V58, P2053; TANAKA A, 1995, FEBS LETT, V363, P226, DOI 10.1016/0014-5793(95)00324-3; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; TOI M, 1995, BREAST CANCER RES TR, V36, P193, DOI 10.1007/BF00666040; TOI M, 1994, JAPANESE J CANC RES, V885, P1045; Valve E, 2000, INT J CANCER, V88, P718, DOI 10.1002/1097-0215(20001201)88:5<718::AID-IJC6>3.0.CO;2-F; Valve E, 1997, BIOCHEM BIOPH RES CO, V232, P173, DOI 10.1006/bbrc.1997.6256; Valve EM, 1998, BIOCHEM BIOPH RES CO, V250, P805, DOI 10.1006/bbrc.1998.9397; Wang Q, 1999, J CLIN PATHOL, V52, P29, DOI 10.1136/jcp.52.1.29; WARRI AM, 1993, JNCI-J NATL CANCER I, V85, P1412, DOI 10.1093/jnci/85.17.1412; WEIDNER N, 1992, JNCI-J NATL CANCER I, V84, P1875, DOI 10.1093/jnci/84.24.1875; YAMANISHI H, 1995, J STEROID BIOCHEM, V52, P49, DOI 10.1016/0960-0760(94)00148-F; Yamashita T, 2000, BIOCHEM BIOPH RES CO, V277, P494, DOI 10.1006/bbrc.2000.3696; YAN GC, 1991, IN VITRO CELL DEV B, V27, P437; YATES J, 1981, CANCER RES, V41, P258	67	55	58	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 17	2001	20	22					2791	2804		10.1038/sj.onc.1204430	http://dx.doi.org/10.1038/sj.onc.1204430			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	432TP	11420691				2022-12-25	WOS:000168712000007
J	Ivanov, VN; Fodstad, O; Ronai, Z				Ivanov, VN; Fodstad, O; Ronai, Z			Expression of ring finger-deleted TRAF2 sensitizes metastatic melanoma cells to apoptosis via up-regulation of p38, TNF alpha and suppression of NF-kappa B activities	ONCOGENE			English	Article						p38; TRAF2; melanoma; apoptosis; radiation; anisomycin; actinomycin D	RECEPTOR 1; SIGNAL-TRANSDUCTION; UBIQUITIN LIGASE; DOWN-REGULATION; KINASE JNK; ACTIVATION; FAS; DEATH; COMPLEX; PROTEIN	Mechanisms underlying radiation and chemotherapy resistance, the hallmark of human melanoma, are not well understood. Here we demonstrate that expression levels of signal adaptor protein TRAF2 coincide with melanoma resistance to UV-irradiation. Altered TRAF2 signaling by a form of TRAF2, which lacks the ring finger domain (TRAF2 DeltaN), increases activities of p38 MAPK, ATF2, and the level of TNF alpha expression. Forced expression of TRAF2 DeltaN in HHMSX highly metastatic melanoma cells that lack Fas expression and thus utilize the TNF alpha -TNFR1 as the major apoptotic pathway sensitized cells to UV-induced apoptosis, An over twofold increase in degree of apoptosis was observed in TRAF2 DeltaN expressing cells that were treated with actinomycin D, anisomycin or with the radiomimetic drug neocarzinostatin, Sensitization by TRAF2 DeltaN is selective since it was not observed in response to either Taxol or cis-platinum treatment. TRAF2 DeltaN effects are primarily mediated via p38 since inhibition of p38 reduces, whereas activation of p38 promotes the level of UV-induced apoptosis, Conversely, activation of IKK attenuates the sensitization of melanoma by TRAF2 DeltaN, indicating that p38-mediated suppression of NF-kappaB activity is among TRAF2 DeltaN effects. Our finding identifies p38, TNF alpha and NF-kappaB among key players that efficiently sensitizes melanoma cells to UV-, ribotoxic (anisomycin) and radiomimetic chemicals-induced programmed cell death in response to aberrant TRAF2 signaling.	CUNY Mt Sinai Sch Med, Ruttenberg Canc Ctr, New York, NY 10029 USA; Norwegian Radium Hosp, Dept Tumor Biol, Oslo, Norway	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; University of Oslo	Ronai, Z (corresponding author), CUNY Mt Sinai Sch Med, Ruttenberg Canc Ctr, 1 Gustave L Levy Pl,Box 1130, New York, NY 10029 USA.		Ivanov, Vladimir N/A-3081-2008	Ivanov, Vladimir N/0000-0003-3091-9774; RONAI, ZEEV/0000-0002-3859-0400	NATIONAL CANCER INSTITUTE [R01CA051995, R29CA051995] Funding Source: NIH RePORTER; NCI NIH HHS [CA 51995] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bakker TR, 1999, INT J CANCER, V80, P320; Deak JC, 1998, P NATL ACAD SCI USA, V95, P5595, DOI 10.1073/pnas.95.10.5595; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Faris M, 1998, MOL CELL BIOL, V18, P5414, DOI 10.1128/MCB.18.9.5414; Fuchs SY, 1999, ONCOGENE, V18, P2039, DOI 10.1038/sj.onc.1202760; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; Galibert L, 1998, J BIOL CHEM, V273, P34120, DOI 10.1074/jbc.273.51.34120; Goillot E, 1997, P NATL ACAD SCI USA, V94, P3302, DOI 10.1073/pnas.94.7.3302; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Ivanov VN, 1999, J BIOL CHEM, V274, P14079, DOI 10.1074/jbc.274.20.14079; Ivanov VN, 2000, ONCOGENE, V19, P3003, DOI 10.1038/sj.onc.1203602; Ivanov VN, 2000, ONCOGENE, V19, P933, DOI 10.1038/sj.onc.1203415; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Lin X, 1998, MOL CELL BIOL, V18, P5899, DOI 10.1128/MCB.18.10.5899; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Maniatis T, 1999, GENE DEV, V13, P505, DOI 10.1101/gad.13.5.505; MEIER F, 1998, BIOSCIENCE, V3, pD1005; Minden A, 1997, BBA-REV CANCER, V1333, pF85, DOI 10.1016/S0304-419X(97)00018-8; Moretti S, 1999, INT J CANCER, V84, P160, DOI 10.1002/(SICI)1097-0215(19990420)84:2<160::AID-IJC12>3.3.CO;2-I; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Natoli G, 1997, SCIENCE, V275, P200, DOI 10.1126/science.275.5297.200; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Peixoto JGP, 2000, PHYS MED BIOL, V45, P563, DOI 10.1088/0031-9155/45/3/301; Peli J, 1999, EMBO J, V18, P1824, DOI 10.1093/emboj/18.7.1824; Relaix F, 1998, NAT GENET, V18, P287, DOI 10.1038/ng0398-287; RHOADES KL, 1992, J BIOL CHEM, V267, P22102; Ronai Z, 1998, ONCOGENE, V16, P523, DOI 10.1038/sj.onc.1201566; Ruller S, 1999, CLIN CANCER RES, V5, P2714; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; Tan PL, 1999, MOL CELL, V3, P527, DOI 10.1016/S1097-2765(00)80481-5; Tobin D, 1998, P NATL ACAD SCI USA, V95, P565, DOI 10.1073/pnas.95.2.565; Tyers M, 1999, SCIENCE, V284, P601, DOI 10.1126/science.284.5414.601; TYERS M, 2000, IN PRESS CURR OPIN G; van Dam H, 1998, GENE DEV, V12, P1227, DOI 10.1101/gad.12.8.1227; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Yang YM, 1996, ONCOGENE, V12, P2223; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Yuasa T, 1998, J BIOL CHEM, V273, P22681, DOI 10.1074/jbc.273.35.22681; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	45	36	37	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 26	2001	20	18					2243	2253		10.1038/sj.onc.1204314	http://dx.doi.org/10.1038/sj.onc.1204314			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	427KZ	11402319	Green Published			2022-12-25	WOS:000168404500006
J	Lee, SH; Stehlik, C; Reed, JC				Lee, SH; Stehlik, C; Reed, JC			COP, a caspase recruitment domain-containing protein and inhibitor of caspase-1 activation processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICE DEFICIENT; INTERLEUKIN-1; MECHANISMS; ENZYME; APOPTOSIS; MORTALITY; PATHWAY	The production of bio-active interleukin-1 beta (IL-1 beta), a pro-inflammatory cytokine, is mediated by activated caspase-1. One of the known molecular mechanisms underlying pro-caspase-1 processing and activation involves binding of the caspase-1 prodomain to a caspase recruitment domain (CARD)-containing serine/threonine kinase known as RIP2/CARDIAK/RICK. We have identified a novel protein, COP (CARD only protein), which has a high degree of sequence identity to the caspase-1 prodomain. COP binds to both RIP2 and the caspase-1 prodomain and inhibits RIP2-induced caspase-1 oligomerization. COP inhibits caspase1-induced IL-1 beta secretion as well as lipopolysaccharide-induced IL-1 beta secretion in transfected cells. Our data indicate that COP can regulate IL-1 beta secretion, implying that COP may play a role in down-regulating inflammatory responses analogous to the CARD protein ICEBERG.	Burnham Inst, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Reed, JC (corresponding author), Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	jreed@burnham.org	Stehlik, Christian/AAG-2132-2021	Stehlik, Christian/0000-0002-3782-2484	NIGMS NIH HHS [GM61694] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061694] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AREND WP, 1993, ADV IMMUNOL, V54, P167, DOI 10.1016/S0065-2776(08)60535-0; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; Costanzo A, 1999, J BIOL CHEM, V274, P20127, DOI 10.1074/jbc.274.29.20127; CRIEKINGE WV, 1996, J BIOL CHEM, V271, P27245; DINARELLO CA, 1993, NEW ENGL J MED, V328, P106; FANSLOW WC, 1990, SCIENCE, V248, P739, DOI 10.1126/science.2139736; Gilmore TD, 1999, ONCOGENE, V18, P6842, DOI 10.1038/sj.onc.1203237; Hofmann K, 1999, CELL MOL LIFE SCI, V55, P1113, DOI 10.1007/s000180050361; Humke EW, 2000, CELL, V103, P99, DOI 10.1016/S0092-8674(00)00108-2; Inohara N, 1999, J BIOL CHEM, V274, P14560, DOI 10.1074/jbc.274.21.14560; Inohara N, 1998, J BIOL CHEM, V273, P12296, DOI 10.1074/jbc.273.20.12296; Jackle H, 1993, CURR OPIN CELL BIOL, V5, P505, DOI 10.1016/0955-0674(93)90017-K; Koseki T, 1999, J BIOL CHEM, V274, P9955, DOI 10.1074/jbc.274.15.9955; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; NATANSON C, 1994, ANN INTERN MED, V120, P771, DOI 10.7326/0003-4819-120-9-199405010-00009; NettFiordalisi M, 1995, J LEUKOCYTE BIOL, V58, P717, DOI 10.1002/jlb.58.6.717; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Norman J, 1997, J INTERF CYTOK RES, V17, P113, DOI 10.1089/jir.1997.17.113; OHLSSON K, 1990, NATURE, V348, P550, DOI 10.1038/348550a0; Reed JC, 2000, AM J PATHOL, V157, P1415, DOI 10.1016/S0002-9440(10)64779-7; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; Srinivasula SM, 1999, J BIOL CHEM, V274, P17946, DOI 10.1074/jbc.274.25.17946; Thome M, 1998, CURR BIOL, V8, P885, DOI 10.1016/S0960-9822(07)00352-1; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Wang SY, 1996, J BIOL CHEM, V271, P20580, DOI 10.1074/jbc.271.34.20580; Wright SD, 1999, J EXP MED, V189, P605, DOI 10.1084/jem.189.4.605; Yan MH, 1999, J BIOL CHEM, V274, P10287, DOI 10.1074/jbc.274.15.10287; Zeuner A, 1999, CELL DEATH DIFFER, V6, P1075, DOI 10.1038/sj.cdd.4400596	30	137	149	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					34495	34500		10.1074/jbc.M101415200	http://dx.doi.org/10.1074/jbc.M101415200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11432859	hybrid			2022-12-25	WOS:000171024600021
J	Zhao, Y; Lu, ZG; Wu, M; Han, QQ; Tao, W; Zhai, ZH				Zhao, Y; Lu, ZG; Wu, M; Han, QQ; Tao, W; Zhai, ZH			Effects of phosphocreatine on apoptosis in a cell-free system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS EGG EXTRACTS; DNA FRAGMENTATION; CYTOCHROME-C; DEATH; PHOSPHORYLATION; DEGRADATION; MITOCHONDRIA; CASPASE-9; PATHWAYS; CLEAVAGE	The characteristic morphological and biochemical changes during caspase-mediated apoptosis can be reproduced to a large extent in a Xenopus laevis egg extract cell-free system by addition of mouse liver nuclei and exogenous cytochrome c. We show that in this system phosphocreatine accelerated the apoptotic morphological changes of the nuclei, but selectively inhibited DNA fragmentation. Western blot showed that the degradation of lamins A and C is accelerated, which is possibly responsible for the nuclear changes during cell apoptosis. However, the degradation of ICAD/DFF45-like protein in the egg extracts is inhibited in a time-dependent manner. Exogenous creatine, ATP, and several organic acids have no effect on DNA fragmentation, excluding the possibility that creatine, ATP, or acidic conditions resulting from phosphocreatine are responsible for inhibiting DNA fragmentation. Lithium chloride, a kinase inhibitor, can overcome the phosphocreatine effects and can restore DNA fragmentation. Our results indicate that phosphocreatine protects ICAD/DFF45-like protein from proteolysis, probably through kinase actions, resulting in its resistance to caspase cleavage and leading to an inhibition of DNA fragmentation.	Beijing Univ, Coll Life Sci, Beijing 100871, Peoples R China	Peking University	Zhai, ZH (corresponding author), Beijing Univ, Coll Life Sci, Beijing 100871, Peoples R China.		Wu, Min/AAE-5066-2021	Wu, Min/0000-0003-1372-4764				BLOBEL G, 1966, SCIENCE, V154, P1662, DOI 10.1126/science.154.3757.1662; BLOW JJ, 1986, CELL, V47, P577, DOI 10.1016/0092-8674(86)90622-7; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Eguchi Y, 1997, CANCER RES, V57, P1835; FORBES DJ, 1983, CELL, V34, P13, DOI 10.1016/0092-8674(83)90132-0; Fujita E, 1999, BIOCHEM BIOPH RES CO, V264, P550, DOI 10.1006/bbrc.1999.1387; Golstein P, 1998, SCIENCE, V281, P1283, DOI 10.1126/science.281.5381.1283; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Guerrero-Ontiveros ML, 1998, MOL CELL BIOCHEM, V184, P427, DOI 10.1023/A:1006895414925; Jiang Z, 2000, CELL MOL LIFE SCI, V57, P1117, DOI 10.1007/PL00000748; Jiang ZF, 2000, CELL RES, V10, P221, DOI 10.1038/sj.cr.7290051; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Li HL, 1999, CURR OPIN CELL BIOL, V11, P261, DOI 10.1016/S0955-0674(99)80035-0; LI P, 1997, CELL, V91, P470; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Luderus ME, 1996, J CELL BIOL, V135, P867, DOI 10.1083/jcb.135.4.867; MunozMontano JR, 1997, FEBS LETT, V411, P183, DOI 10.1016/S0014-5793(97)00688-1; Nagata S, 2000, EXP CELL RES, V256, P12, DOI 10.1006/excr.2000.4834; Nakamura N, 2000, CELL DEATH DIFFER, V7, P477, DOI 10.1038/sj.cdd.4400677; NEAMATI N, 1995, J IMMUNOL, V154, P3788; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; Rodriguez J., 2000, SCI, V287, P1363; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Tang DG, 1998, BIOCHEM BIOPH RES CO, V242, P380, DOI 10.1006/bbrc.1997.7969; Walter J, 1999, P NATL ACAD SCI USA, V96, P1391, DOI 10.1073/pnas.96.4.1391; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Yin XM, 2000, CELL RES, V10, P161, DOI 10.1038/sj.cr.7290045; Zhao Y, 2001, CELL MOL LIFE SCI, V58, P298, DOI 10.1007/PL00000857; Zhu S, 1998, CHINESE SCI BULL, V43, P522, DOI 10.1007/BF02883826; Zhu S, 2000, CHINESE SCI BULL, V45, P1977, DOI 10.1007/BF02909691	33	1	3	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					34573	34578		10.1074/jbc.M102319200	http://dx.doi.org/10.1074/jbc.M102319200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11432861	hybrid			2022-12-25	WOS:000171024600032
J	Ahluwalia, JP; Topp, JD; Weirather, K; Zimmerman, M; Stammes, M				Ahluwalia, JP; Topp, JD; Weirather, K; Zimmerman, M; Stammes, M			A role for calcium in stabilizing transport vesicle coats	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; GOLGI MEMBRANES; ENDOPLASMIC-RETICULUM; PROTEIN-TRANSPORT; ENDOSOME FUSION; BINDING PROTEIN; BREFELDIN-A; CA2+; COATOMER; GTP	Calcium has been implicated in regulating vesicle fusion reactions, but its potential role in regulating other aspects of protein transport, such as vesicle assembly, is largely unexplored. We find that treating cells with the membrane-permeable calcium chelator, 1,2-bis(2-amino-phenoxy)ethane-N,N,N ' ,N ' -tetraacetic acid tetrakis(acetoxymethyl ester) (BAPTA-AM), leads to a drams ic redistribution of the vesicle coat protein, coatomer, in the cell. We have used the cell-free reconstitution of coat-protomer I (COPI) vesicle assembly to characterize the mechanisms of this redistribution. We find that the recovery of COPI-coated Golgi vesicles is inhibited by the addition of BAPTA to the cell-free vesicle budding assay. When coatomer-coated membranes are incubated in the presence of calcium chelators, the membranes "uncoat," indicating that calcium is necessary for maintaining the integrity of the coat. This uncoating is reversed by the addition of calcium. Interestingly, BAPTA, a calcium chelator with fast binding kinetics, is more potent at uncoating the coatomer-coated membrane than EGTA, suggesting that a calcium transient or a calcium gradient is important for stabilizing COPI vesicle coat. The primary target for the effects of calcium on coatomer recruitment is a step that occurs after ADP-ribosylation factor binding to the membrane. We suggest that a calcium gradient may serve to regulate the timing of vesicle uncoating.	Univ Iowa, Coll Med, SW Med Ctr, Dept Internal Med, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Physiol & Biophys, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Biosci Program, Iowa City, IA 52242 USA	University of Iowa; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Iowa; University of Iowa	Stammes, M (corresponding author), Univ Iowa, Coll Med, SW Med Ctr, Dept Internal Med, 5-550 BSB, Iowa City, IA 52242 USA.			Stamnes, Mark/0000-0002-5869-7985; Zimmerman, Matthew/0000-0001-5658-9051				Aballay A, 1995, BIOCHEM J, V312, P919, DOI 10.1042/bj3120919; BAKER D, 1990, P NATL ACAD SCI USA, V87, P355, DOI 10.1073/pnas.87.1.355; BECKERS CJM, 1989, J CELL BIOL, V108, P1245, DOI 10.1083/jcb.108.4.1245; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Colombo MI, 1997, J BIOL CHEM, V272, P7707, DOI 10.1074/jbc.272.12.7707; DONALDSON JG, 1991, J CELL BIOL, V112, P579, DOI 10.1083/jcb.112.4.579; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; Fucini RV, 2000, J BIOL CHEM, V275, P18824, DOI 10.1074/jbc.M000024200; HARAKUGE S, 1994, J CELL BIOL, V124, P883, DOI 10.1083/jcb.124.6.883; HELMS JB, 1993, J CELL BIOL, V121, P751, DOI 10.1083/jcb.121.4.751; IVESSA NE, 1995, J BIOL CHEM, V270, P25960, DOI 10.1074/jbc.270.43.25960; Kits KS, 1999, BIOPHYS J, V76, P1693, DOI 10.1016/S0006-3495(99)77328-5; Lin P, 1999, J CELL BIOL, V145, P279, DOI 10.1083/jcb.145.2.279; Lin P, 1998, J CELL BIOL, V141, P1515, DOI 10.1083/jcb.141.7.1515; Lin RC, 2000, ANNU REV CELL DEV BI, V16, P19, DOI 10.1146/annurev.cellbio.16.1.19; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; MAYORGA LS, 1994, J BIOL CHEM, V269, P30927; Mellman I, 2000, CELL, V100, P99, DOI 10.1016/S0092-8674(00)81687-6; ORCI L, 1993, NATURE, V364, P732, DOI 10.1038/364732a0; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; Peters C, 1998, NATURE, V396, P575, DOI 10.1038/25133; PIND SN, 1994, J CELL BIOL, V125, P239, DOI 10.1083/jcb.125.2.239; Pinton P, 1998, EMBO J, V17, P5298, DOI 10.1093/emboj/17.18.5298; Porat A, 2000, J BIOL CHEM, V275, P29233, DOI 10.1074/jbc.M005316200; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; Pryor PR, 2000, J CELL BIOL, V149, P1053, DOI 10.1083/jcb.149.5.1053; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; SAMBROOK JF, 1990, CELL, V61, P197, DOI 10.1016/0092-8674(90)90798-J; Scherer PE, 1996, J CELL BIOL, V133, P257, DOI 10.1083/jcb.133.2.257; SCHWANINGER R, 1991, J BIOL CHEM, V266, P13055; Sonnichsen B, 1998, J CELL BIOL, V140, P1013, DOI 10.1083/jcb.140.5.1013; Springer S, 1999, CELL, V97, P145, DOI 10.1016/S0092-8674(00)80722-9; SULLIVAN KMC, 1993, CELL, V73, P1411, DOI 10.1016/0092-8674(93)90366-X; TANG BL, 1995, EUR J CELL BIOL, V68, P199; TANIGAWA G, 1993, J CELL BIOL, V123, P1365, DOI 10.1083/jcb.123.6.1365; Taylor RS, 1997, MOL BIOL CELL, V8, P1911, DOI 10.1091/mbc.8.10.1911; TSIEN RY, 1980, BIOCHEMISTRY-US, V19, P2396, DOI 10.1021/bi00552a018; Vasudevan C, 1998, J CELL SCI, V111, P1277; WAHL M, 1992, J CELL PHYSIOL, V150, P593, DOI 10.1002/jcp.1041500321; ZHA XH, 1995, AM J PHYSIOL-CELL PH, V268, pC1133, DOI 10.1152/ajpcell.1995.268.5.C1133; ZHA XH, 1995, AM J PHYSIOL-CELL PH, V269, pC923, DOI 10.1152/ajpcell.1995.269.4.C923	41	42	44	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					34148	34155		10.1074/jbc.M105398200	http://dx.doi.org/10.1074/jbc.M105398200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11435443	hybrid			2022-12-25	WOS:000170910200114
J	Wolf, BB; Schuler, M; Li, W; Eggers-Sedlet, B; Lee, W; Tailor, P; Fitzgerald, P; Mills, GB; Green, DR				Wolf, BB; Schuler, M; Li, W; Eggers-Sedlet, B; Lee, W; Tailor, P; Fitzgerald, P; Mills, GB; Green, DR			Defective cytochrome c-dependent caspase activation in ovarian cancer cell lines due to diminished or absent apoptotic protease activating factor-1 activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEGATIVE REGULATION; APAF-1 APOPTOSOME; DEATH; PROCASPASE-9; FAS; OLIGOMERIZATION; EXPRESSION; CARCINOMA; SURVIVAL; AP-1	Apoptosis via the mitochondrial pathway requires release of cytochrome c into the cytosol to initiate formation of an oligomeric apoptotic protease-activating factor-1 (APAF-1) apoptosome. The apoptosome recruits and activates caspase-9, which in turn activates caspase-3 and -7, which then kill the cell by proteolysis. Because inactivation of this pathway may promote oncogenesis, we examined 10 ovarian cancer cell lines for resistance to cytochrome c-dependent caspase activation using a cell-free system. Strikingly, we found that cytosolic extracts from all cell lines had diminished cytochrome c-dependent caspase activation compared with normal ovarian epithelium extracts. The resistant cell lines expressed APAF-1 and caspase-9, -3, and -7; however, each demonstrated diminished APAF-1 activity relative to the normal ovarian epithelium cell lines. A competitive APAF-1 inhibitor may account for the diminished APAF-1 activity because we did not detect dominant APAF-1 inhibitors, altered APAF-1 isoform expression, or APAF-1 deletion, degradation, or mutation. Lack of APAF-1 activity correlated in some but not all cell lines with resistance to apoptosis. These data suggest that regulation of APAF-1 activity may be important for apoptosis regulation in some ovarian cancers.	McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA	McGill University; University of Texas System; UTMD Anderson Cancer Center	Wolf, BB (corresponding author), La Jolla Inst Allergy & Immunol, 10355 Sci Ctr Dr, San Diego, CA 92121 USA.		Green, Douglas R/N-8083-2018	Green, Douglas R/0000-0002-7332-1417	NCI NIH HHS [CA69831] Funding Source: Medline; NIAID NIH HHS [AI40646] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040646] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Auersperg N, 1998, SEMIN ONCOL, V25, P281; Bala S, 2000, GENE CHROMOSOME CANC, V28, P258, DOI 10.1002/1098-2264(200007)28:3<258::AID-GCC3>3.0.CO;2-R; Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; Benedict MA, 2000, J BIOL CHEM, V275, P8461, DOI 10.1074/jbc.275.12.8461; Bruey JM, 2000, NAT CELL BIOL, V2, P645, DOI 10.1038/35023595; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chauhan D, 2001, J BIOL CHEM, V276, P24453, DOI 10.1074/jbc.C100074200; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Hahn C, 1999, BIOCHEM BIOPH RES CO, V261, P746, DOI 10.1006/bbrc.1999.1124; Harwood FG, 2000, J BIOL CHEM, V275, P10023, DOI 10.1074/jbc.275.14.10023; Jaattela M, 1999, EXP CELL RES, V248, P30, DOI 10.1006/excr.1999.4455; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Li BY, 2000, P NATL ACAD SCI USA, V97, P3850, DOI 10.1073/pnas.070047997; LI P, 1997, CELL, V91, P470; Lynch HT, 1998, SEMIN ONCOL, V25, P265; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; Pandey P, 2000, EMBO J, V19, P4310, DOI 10.1093/emboj/19.16.4310; Perkins C, 1998, CANCER RES, V58, P4561; Saleh A, 2000, NAT CELL BIOL, V2, P476, DOI 10.1038/35019510; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; THIGPEN JT, 2000, CLIN ONCOLOGY, P2016; Wolf BB, 1999, J BIOL CHEM, V274, P30651, DOI 10.1074/jbc.274.43.30651; Wolf BB, 1999, BLOOD, V94, P1683, DOI 10.1182/blood.V94.5.1683.417k37_1683_1692; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; Yamamoto H, 2000, CELL DEATH DIFFER, V7, P238, DOI 10.1038/sj.cdd.4400651; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	32	110	111	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					34244	34251		10.1074/jbc.M011778200	http://dx.doi.org/10.1074/jbc.M011778200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11429402	hybrid			2022-12-25	WOS:000170910200127
J	Johansson, AS; Mannervik, B				Johansson, AS; Mannervik, B			Human glutathione transferase A3-3, a highly efficient catalyst of double-bond isomerization in the biosynthetic pathway of steroid hormones	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLACENTAL 3-BETA-HYDROXY-5-ENE-STEROID DEHYDROGENASE; S-TRANSFERASES; HETEROLOGOUS EXPRESSION; TISSUE DISTRIBUTION; LIPID-PEROXIDATION; HUMAN-LIVER; MU-CLASS; IDENTIFICATION; PURIFICATION; ISOMERASE	The cDNA of a novel human glutathione transferase (GST) of the Alpha class was cloned, and the corresponding protein, denoted GST A3-3, was heterologously expressed and characterized. GST A3-3 was found to efficiently catalyze obligatory double-bond isomerizations of Delta (5)-androstene-3,17-dione and Delta5-pregnene-3,20-dione, precursors to testosterone and progesterone, respectively, in steroid hormone biosynthesis. The catalytic efficiency (k(cat)/K-m) with Delta (5)-androstene-3,17-dione was determined as 5 X 10(6) M-1 s(-1), which is considerably higher than with any other GST substrate tested. The rate of acceleration afforded by GST A3-3 is 6 x 10(8) based on the ratio between k(cat) and the rate constant for the nonenzymatic isomerization of Delta (5)-androstene-3,17-dione. Besides being high in absolute numbers, the k(cat)/K-m value of GST A3-3 exceeds by a factor of similar to 230 that of 3 beta -hydroxysteroid dehydrogenase/isomerase, the enzyme generally considered to catalyze the Delta (5)-Delta (4) double-bond isomerization. Furthermore, GSTA3-specific polymerase chain reaction analysis of cDNA libraries from various tissues showed a message only in those characterized by active steroid hormone biosynthesis, indicating a selective expression of GST A3-3 in these tissues. Based on this finding and the high activity with steroid substrates, we propose that GST A3-3 has evolved to catalyze isomerization reactions that contribute to the biosynthesis of steroid hormones.	Uppsala Univ, Dept Biochem, Biomed Ctr, SE-75123 Uppsala, Sweden	Uppsala University	Mannervik, B (corresponding author), Uppsala Univ, Dept Biochem, Biomed Ctr, Box 576, SE-75123 Uppsala, Sweden.			Jemth, Ann-Sofie/0000-0002-7550-1833				BENSON AM, 1977, P NATL ACAD SCI USA, V74, P158, DOI 10.1073/pnas.74.1.158; Beuckmann CT, 2000, NEUROCHEM RES, V25, P733, DOI 10.1023/A:1007579507804; BJORNESTEDT R, 1992, BIOCHEM J, V282, P505; Board PG, 1998, BIOCHEM J, V330, P827; BURGESS JR, 1989, BIOCHEM BIOPH RES CO, V158, P497, DOI 10.1016/S0006-291X(89)80076-2; CAMPBELL JAH, 1980, CANCER, V45, P503, DOI 10.1002/1097-0142(19800201)45:3<503::AID-CNCR2820450315>3.0.CO;2-8; Fersht A., 1999, STRUCTURE MECH PROTE, DOI 10.1142/10574; FUKAI F, 1992, J CLIN BIOCHEM NUTR, V12, P93; HAO XY, 1994, BBA-MOL BASIS DIS, V1225, P223, DOI 10.1016/0925-4439(94)90082-5; HAWKINSON DC, 1991, BIOCHEMISTRY-US, V30, P10849, DOI 10.1021/bi00109a007; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; Hubatsch I, 1998, BIOCHEM J, V330, P175, DOI 10.1042/bj3300175; Jakobsson PJ, 1999, P NATL ACAD SCI USA, V96, P7220, DOI 10.1073/pnas.96.13.7220; KOLM RH, 1995, BIOCHEM J, V311, P453, DOI 10.1042/bj3110453; KULIOPULOS A, 1989, BIOCHEMISTRY-US, V28, P149, DOI 10.1021/bi00427a022; M PG, 1995, ADV DRUG METABOLISM, P407; MANNERVIK B, 1985, P NATL ACAD SCI USA, V82, P7202, DOI 10.1073/pnas.82.21.7202; MANNERVIK B, 1992, BIOCHEM J, V282, P305, DOI 10.1042/bj2820305; MEYER DJ, 1995, BIOCHEM J, V306, P565, DOI 10.1042/bj3060565; Montgomery R., 1996, BIOCH CASE ORIENTED, P587; Muller K, 1996, FEBS LETT, V388, P165, DOI 10.1016/0014-5793(96)00559-5; Nilsson LO, 2000, P NATL ACAD SCI USA, V97, P9408, DOI 10.1073/pnas.150084897; Pettersson PL, 2001, J BIOL CHEM, V276, P11698, DOI 10.1074/jbc.M009146200; Rowe JD, 1997, BIOCHEM J, V325, P481, DOI 10.1042/bj3250481; SAMUELS LT, 1951, SCIENCE, V113, P490, DOI 10.1126/science.113.2939.490; Sherratt PJ, 1997, BIOCHEM J, V326, P837, DOI 10.1042/bj3260837; SIMONS PC, 1977, ANAL BIOCHEM, V82, P334, DOI 10.1016/0003-2697(77)90169-5; SINNING I, 1993, J MOL BIOL, V232, P192, DOI 10.1006/jmbi.1993.1376; STENBERG G, 1992, PROTEIN EXPRES PURIF, V3, P80, DOI 10.1016/1046-5928(92)90060-A; STENBERG G, 1991, BIOCHEM J, V274, P549, DOI 10.1042/bj2740549; STOCKMAN PK, 1987, BIOCHEM J, V244, P55, DOI 10.1042/bj2440055; Suc I, 1998, FASEB J, V12, P665, DOI 10.1096/fasebj.12.9.665; SUZUKI T, 1993, GENOMICS, V18, P680, DOI 10.1016/S0888-7543(05)80373-8; TALALAY P, 1955, BIOCHIM BIOPHYS ACTA, V18, P300, DOI 10.1016/0006-3002(55)90079-2; THOMAS JL, 1988, J STEROID BIOCHEM, V31, P785, DOI 10.1016/0022-4731(88)90287-7; THOMAS JL, 1989, J STEROID BIOCHEM, V33, P209, DOI 10.1016/0022-4731(89)90296-3; VANOMMEN B, 1990, BIOCHEM J, V269, P609, DOI 10.1042/bj2690609; ZHAO TGJ, 1999, ARCH BIOCHEM BIOPHYS, V267, P216	38	146	154	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					33061	33065		10.1074/jbc.M104539200	http://dx.doi.org/10.1074/jbc.M104539200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11418619	hybrid			2022-12-25	WOS:000170746000091
J	La Celle, PT; Polakowska, RR				La Celle, PT; Polakowska, RR			Human homeobox HOXA7 regulates keratinocyte transglutaminase type 1 and inhibits differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; INVOLUCRIN PROMOTER ACTIVITY; HUMAN-PAPILLOMAVIRUS TYPE-16; GENE-EXPRESSION; GROWTH-FACTOR; EPIDERMAL DIFFERENTIATION; HOMEODOMAIN PROTEIN; TRANSCRIPTIONAL REGULATION; RETINOIC ACID; BINDING	Keratinocyte proliferation and differentiation result from expression of specific groups of genes regulated by unique combinations of transcription factors. To better understand these regulatory processes, we studied HOXA7 expression and its regulation of differentiation-specific keratinocyte genes. We isolated the homeobox transcription factor HOXA7 from keratinocytes through binding to a differentiation-dependent viral enhancer and analyzed its effect on endogenous differentiation-dependent genes, primarily transglutaminase 1. HOXA7 overexpression repressed transglutaminase 1-reporter activity. HOXA7 message markedly decreased, and transglutaminase RNA increased, upon phorbol ester-induced differentiation, in a protein kinase C-dependent manner. Overexpression of HOXA7 attenuated the transglutaminase 1 induction by phorbol ester, demonstrating that HOXAB7 expression is inversely related to keratinocyte differentiation, and to transglutaminase 1 expression. Antisense HOXA7 expression activated transglutaminase 1, involucrin, and keratin 10 message and protein levels, demonstrating that endogenous HOXA7 down-regulates multiple differentiation-specific keratinocyte genes. In keeping with these observations, epidermal growth factor receptor activation stimulated HOXA7 expression. HOX genes function in groups, and we found that HOXA5 and HOXB7 were also down-regulated by phorbol ester. These results provide the first example of protein kinase C-mediated homeobox gene regulation in keratinocytes, and new evidence that HOXA7, potentially in conjunction with HOXA5 and HOXAD7, silences differentiation-specific genes during keratinocyte proliferation, that are then released from inhibition in response to differentiation signals.	Univ Rochester, Sch Med & Dent, Dept Dermatol, Rochester, NY 14642 USA; Univ Lille 2, Fac Med, INSERM U459, F-59045 Lille, France	University of Rochester; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille	La Celle, PT (corresponding author), Univ Rochester, Sch Med & Dent, Dept Dermatol, Box 697,601 Elmwood Ave, Rochester, NY 14642 USA.	peter_lacelle@urmc.rochester.edu						ANDERSEN B, 1993, SCIENCE, V260, P78, DOI 10.1126/science.7682011; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BEACHY PA, 1993, MOL CELL BIOL, V13, P6941, DOI 10.1128/MCB.13.11.6941; BIEBERICH CJ, 1991, ANN NY ACAD SCI, V642, P346; BLESSING M, 1987, EMBO J, V6, P567, DOI 10.1002/j.1460-2075.1987.tb04792.x; Blumenberg M, 1997, EXS, V78, P1; BONCINELLI E, 1994, GENETICA, V94, P127, DOI 10.1007/BF01443427; BUTZ K, 1993, J VIROL, V67, P6476, DOI 10.1128/JVI.67.11.6476-6486.1993; Capecchi MR, 1997, COLD SPRING HARB SYM, V62, P273, DOI 10.1101/SQB.1997.062.01.034; Care A, 1998, ONCOGENE, V16, P3285, DOI 10.1038/sj.onc.1201875; Care A, 1996, MOL CELL BIOL, V16, P4842; Care A, 1999, ONCOGENE, V18, P1993, DOI 10.1038/sj.onc.1202498; CHAN WK, 1990, NUCLEIC ACIDS RES, V18, P763, DOI 10.1093/nar/18.4.763; Chang PY, 1998, BIOCHEM BIOPH RES CO, V248, P749, DOI 10.1006/bbrc.1998.9076; Chariot A, 1999, ONCOGENE, V18, P4007, DOI 10.1038/sj.onc.1202776; Chariot A, 1999, J BIOL CHEM, V274, P5318, DOI 10.1074/jbc.274.9.5318; Chen CY, 1996, DEV GENET, V19, P119, DOI 10.1002/(SICI)1520-6408(1996)19:2<119::AID-DVG3>3.0.CO;2-C; COLBERGPOLEY AM, 1985, NATURE, V314, P713, DOI 10.1038/314713a0; CRIPE TP, 1987, EMBO J, V6, P3745, DOI 10.1002/j.1460-2075.1987.tb02709.x; Crooks GM, 1999, BLOOD, V94, P519, DOI 10.1182/blood.V94.2.519.414k20_519_528; Delhase M, 1996, J BIOL CHEM, V271, P32349, DOI 10.1074/jbc.271.50.32349; DETMER K, 1993, J INVEST DERMATOL, V101, P517, DOI 10.1111/1523-1747.ep12365890; DLUGOSZ AA, 1994, CELL GROWTH DIFFER, V5, P1283; DLUGOSZ AA, 1994, J INVEST DERMATOL, V102, P409, DOI 10.1111/1523-1747.ep12372171; DLUGOSZ AA, 1993, J CELL BIOL, V120, P217, DOI 10.1083/jcb.120.1.217; Dong XP, 1999, J GEN VIROL, V80, P2097, DOI 10.1099/0022-1317-80-8-2097; DUVIC M, 1994, J INVEST DERMATOL, V102, P462, DOI 10.1111/1523-1747.ep12373021; Eckert RL, 1996, MOL BIOL REP, V23, P59, DOI 10.1007/BF00357073; Eckert RL, 1997, J INVEST DERMATOL, V109, P501, DOI 10.1111/1523-1747.ep12336477; ECKERT RL, 1989, PHYSIOL REV, V69, P1316, DOI 10.1152/physrev.1989.69.4.1316; Efimova T, 1998, J BIOL CHEM, V273, P24387, DOI 10.1074/jbc.273.38.24387; FAUS I, 1994, MOL CELL BIOL, V14, P3263, DOI 10.1128/MCB.14.5.3263; Fischer DF, 1996, MOL CELL BIOL, V16, P5365, DOI 10.1128/mcb.16.10.5365; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; FUCHS E, 1980, CELL, V19, P1033, DOI 10.1016/0092-8674(80)90094-X; FUCHS E, 1990, J CELL BIOL, V111, P2807, DOI 10.1083/jcb.111.6.2807; GIAMPAOLO A, 1994, BLOOD, V84, P3637, DOI 10.1182/blood.V84.11.3637.bloodjournal84113637; GROSS MK, 1994, MOL CELL BIOL, V14, P238, DOI 10.1128/MCB.14.1.238; GRUENEBERG DA, 1995, MOL CELL BIOL, V15, P3318; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; Jang SI, 1996, J BIOL CHEM, V271, P24105, DOI 10.1074/jbc.271.39.24105; KALIONIS B, 1993, MECH DEVELOP, V43, P57, DOI 10.1016/0925-4773(93)90023-Q; KANZLER B, 1994, INT J DEV BIOL, V38, P633; KING LE, 1990, J INVEST DERMATOL, V94, pS164, DOI 10.1111/1523-1747.ep12876141; Knoepfler PS, 1997, P NATL ACAD SCI USA, V94, P14553, DOI 10.1073/pnas.94.26.14553; Komuves LG, 2000, DEV DYNAM, V218, P636; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LEVINE M, 1988, CELL, V55, P537, DOI 10.1016/0092-8674(88)90209-7; Lorentz O, 1999, J BIOL CHEM, V274, P7196, DOI 10.1074/jbc.274.11.7196; LU QA, 1995, MOL CELL BIOL, V15, P3786; MARCHUK D, 1985, P NATL ACAD SCI USA, V82, P1609, DOI 10.1073/pnas.82.6.1609; MATHEWS CHE, 1993, DIFFERENTIATION, V52, P177, DOI 10.1111/j.1432-0436.1993.tb00628.x; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MCGINNIS W, 1984, CELL, V37, P403, DOI 10.1016/0092-8674(84)90370-2; Morasso MI, 1996, J CELL BIOL, V135, P1879, DOI 10.1083/jcb.135.6.1879; Nakamura T, 1996, NAT GENET, V12, P149, DOI 10.1038/ng0296-149; Newman CS, 2000, MECH DEVELOP, V91, P369, DOI 10.1016/S0925-4773(99)00291-9; OCONNOR M, 1995, VIROLOGY, V207, P77, DOI 10.1006/viro.1995.1053; OConnor MJ, 1996, J VIROL, V70, P6529, DOI 10.1128/JVI.70.10.6529-6539.1996; Oka M, 2000, J INVEST DERMATOL, V115, P699, DOI 10.1046/j.1523-1747.2000.00095.x; Packer AI, 2000, DEV DYNAM, V217, P62, DOI 10.1002/(SICI)1097-0177(200001)217:1<62::AID-DVDY6>3.0.CO;2-U; Park GT, 1999, J BIOL CHEM, V274, P26599, DOI 10.1074/jbc.274.37.26599; PHELAN ML, 1995, MOL CELL BIOL, V15, P3989; PILLAI S, 1990, J CELL PHYSIOL, V143, P294, DOI 10.1002/jcp.1041430213; POLAKOWSKA RR, 1992, P NATL ACAD SCI USA, V89, P4476, DOI 10.1073/pnas.89.10.4476; Polakowska RR, 1999, J CELL BIOCHEM, V73, P355; RIEGER E, 1994, J INVEST DERMATOL, V103, P341, DOI 10.1111/1523-1747.ep12394888; Rodeck U, 1997, J CELL SCI, V110, P113; Rossi A, 1998, J INVEST DERMATOL, V110, P34, DOI 10.1046/j.1523-1747.1998.00071.x; SAUNDERS NA, 1993, MOL ENDOCRINOL, V7, P387, DOI 10.1210/me.7.3.387; Schnabel CA, 1996, MOL CELL BIOL, V16, P2678; SCOTT GA, 1993, J INVEST DERMATOL, V101, P3, DOI 10.1111/1523-1747.ep12358258; Shanmugam K, 1999, MOL CELL BIOL, V19, P7577; Shen WF, 1996, NUCLEIC ACIDS RES, V24, P898, DOI 10.1093/nar/24.5.898; Srebrow A, 1998, J CELL BIOCHEM, V69, P377, DOI 10.1002/(SICI)1097-4644(19980615)69:4<377::AID-JCB1>3.0.CO;2-K; Stelnicki EJ, 1998, J INVEST DERMATOL, V110, P110, DOI 10.1046/j.1523-1747.1998.00092.x; Subramaniam N, 1998, J BIOL CHEM, V273, P23567, DOI 10.1074/jbc.273.36.23567; THACHER SM, 1985, CELL, V40, P685, DOI 10.1016/0092-8674(85)90217-X; Wang JM, 1999, MOL CELL BIOL, V19, P7106; Welter JF, 1996, J BIOL CHEM, V271, P14727, DOI 10.1074/jbc.271.25.14727; YAMADA K, 1994, BIOCHEM MOL BIOL INT, V34, P827; YUKAWA K, 1993, GENE, V133, P163; Yukawa K, 1996, J VIROL, V70, P10, DOI 10.1128/JVI.70.1.10-16.1996; YUSPA SH, 1989, J CELL BIOL, V109, P1207, DOI 10.1083/jcb.109.3.1207	86	43	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					32844	32853		10.1074/jbc.M104598200	http://dx.doi.org/10.1074/jbc.M104598200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11435435	hybrid			2022-12-25	WOS:000170746000064
J	Rajpal, A; Turi, TG				Rajpal, A; Turi, TG			Intracellular stability of anti-caspase-3 intrabodies determines efficacy in retargeting the antigen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHAGE DISPLAY LIBRARY; IN-VIVO; HUMAN-ANTIBODIES; CELL-DEATH; PROTEIN; CASPASE-3; APOPTOSIS; KNOCKOUT; AFFINITY; SYSTEM	Although intracellular antibodies (intrabodies) are being explored as putative therapeutic and research reagents, little is known about the principles that dictate the efficacy of these molecules. In our efforts to address this issue, we generated a panel of five intrabodies, directed against catalytically inactive murine caspase-3, by screening single-chain antibody (Fv) phage display libraries. Here we determined criteria that single-chain Fv fragments must fulfill to act as efficient intrabodies. The affinities of these intrabodies, as measured by surface plasmon resonance, varied similar to5-fold (50-250 rim). Despite their substantial sequence similarity, only two of the five intrabodies were able to significantly accumulate intracellularly. These disparities in intracellular expression levels were reflected by differences in the stability of the purified protein species when analyzed by urea denaturation studies. We observed varied efficiencies in retargeting the antigen murine caspase-3, from the cytosol to the nucleus, mediated by intrabodies tagged with an SV40 nuclear localization signal. Our results demonstrate that the intrinsic stability of the intrabody, rather than its affinity for the antigen, dictates its intracellular efficacy.	Pfizer Inc, Cent Res, Dept Genet Technol, Groton, CT 06340 USA	Pfizer	Turi, TG (corresponding author), Pfizer Inc, Cent Res, Dept Genet Technol, Eastern Point Rd, Groton, CT 06340 USA.	tom_g_turi@groton.pfizer.com						BIOCCA S, 1995, BIO-TECHNOL, V13, P1110, DOI 10.1038/nbt1095-1110; Deshane J, 1995, J CLIN INVEST, V96, P2980, DOI 10.1172/JCI118370; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69; Hassanzadeh G, 1998, FEBS LETT, V437, P81, DOI 10.1016/S0014-5793(98)01205-8; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; LERNER M, 2000, EUR J BIOCHEM, V267, P1196; Los M, 1999, IMMUNITY, V10, P629, DOI 10.1016/S1074-7613(00)80062-X; Mancini M, 1998, J CELL BIOL, V140, P1485, DOI 10.1083/jcb.140.6.1485; Marasco WA, 1997, GENE THER, V4, P11, DOI 10.1038/sj.gt.3300346; Marasco WA, 1998, HUM GENE THER, V9, P1627, DOI 10.1089/hum.1998.9.11-1627; Morton TA, 1998, METHOD ENZYMOL, V295, P268; Pace C. N., 1997, PROTEIN STRUCTURE PR; PACE CN, 1990, TRENDS BIOTECHNOL, V8, P93, DOI 10.1016/0167-7799(90)90146-O; Pini A, 1998, J BIOL CHEM, V273, P21769, DOI 10.1074/jbc.273.34.21769; Porter AG, 1999, CELL DEATH DIFFER, V6, P99, DOI 10.1038/sj.cdd.4400476; Rajpal A, 2000, PROTEINS, V40, P49, DOI 10.1002/(SICI)1097-0134(20000701)40:1<49::AID-PROT70>3.3.CO;2-C; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Ruberti F, 2000, J NEUROSCI, V20, P2589; Sheets MD, 1998, P NATL ACAD SCI USA, V95, P6157, DOI 10.1073/pnas.95.11.6157; Stennicke HR, 1998, BBA-PROTEIN STRUCT M, V1387, P17, DOI 10.1016/S0167-4838(98)00133-2; Vaughan TJ, 1996, NAT BIOTECHNOL, V14, P309, DOI 10.1038/nbt0396-309; Visintin M, 1999, P NATL ACAD SCI USA, V96, P11723, DOI 10.1073/pnas.96.21.11723; Worn A, 2000, J BIOL CHEM, V275, P2795, DOI 10.1074/jbc.275.4.2795; Xue D, 1996, GENE DEV, V10, P1073, DOI 10.1101/gad.10.9.1073; Zheng TS, 1998, P NATL ACAD SCI USA, V95, P13618, DOI 10.1073/pnas.95.23.13618; Zhu QA, 1999, J IMMUNOL METHODS, V231, P207, DOI 10.1016/S0022-1759(99)00158-1	27	29	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					33139	33146		10.1074/jbc.M101332200	http://dx.doi.org/10.1074/jbc.M101332200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11425853	hybrid			2022-12-25	WOS:000170746000100
J	Stotz, SC; Zamponi, GW				Stotz, SC; Zamponi, GW			Identification of inactivation determinants in the domain IIS6 region of high voltage-activated calcium channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-RESIDUES; CA2+ CHANNEL; BETA-SUBUNIT; DEPENDENT INACTIVATION; MOLECULAR DETERMINANTS; ALPHA(1A) SUBUNIT; K+ CHANNEL; P-TYPE; MUSCLE; PALMITOYLATION	We have recently reported that transfer of the domain IIS6 region from rapidly inactivating R-type (alpha (1E)) calcium channels to slowly inactivating L-type (alpha (1C)) calcium channel confers rapid inactivation (Stotz, S. C., Hamid, J., Spaetgens, R. L., Jarvis, S. E., and Zamponi, G. W. (2000) J. Biol. Chem. 275, 24575-24582). Here we have identified individual amino acid residues in the IIS6 regions that are responsible for these effects. In this region, alpha (1C) and alpha (1E) channels differ in seven residues, and exchanging five of those residues individually or in combination did not significantly affect inactivation kinetics. By contrast, replacement of residues Phe-823 or Ile-829 of alpha (1C) with the corresponding alpha (1E): residues significantly accelerated inactivation rates and, when substituted concomitantly, approached the rapid inactivation kinetics of R-type channels. A systematic substitution of these residues with a series of other amino acids revealed that decreasing side chain size at position 823 accelerates inactivation, whereas a dependence of the inactivation kinetics on the degree of hydrophobicity could be observed at position 829. Although these point mutations facilitated rapid entry into the inactivated state of the channel, they had little to no effect on the rate of recovery from inactivation. This suggests that the development of and recovery from inactivation are governed by separate structural determinants. Finally, the effects of mutations that accelerated alpha (1C) inactivation could still be antagonized following coexpression of the rat beta (2a). subunit or by domain I-II linker substitutions that produce ultra slow inactivation of wild type channels, indicating that the inactivation kinetics seen with the mutants remain subject to regulation by the domain I-II linker. Overall, our results provide novel insights into a complex process underlying calcium channel inactivation.	Univ Calgary, Dept Physiol & Biophys, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Pharmacol & Therapeut, Neurosci Res Grp, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Pharmacol & Therapeut, Smooth Muscle Res Grp, Calgary, AB T2N 4N1, Canada	University of Calgary; University of Calgary; University of Calgary	Zamponi, GW (corresponding author), Univ Calgary, Dept Physiol & Biophys, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.			Zamponi, Gerald W./0000-0002-0644-9066				AKAIKE N, 1989, J PHYSIOL-LONDON, V416, P141, DOI 10.1113/jphysiol.1989.sp017754; Berjukow S, 2001, J BIOL CHEM, V276, P17076, DOI 10.1074/jbc.M010491200; Berrou L, 2001, BIOPHYS J, V80, P215, DOI 10.1016/S0006-3495(01)76008-0; Bourinet E, 1999, NAT NEUROSCI, V2, P407, DOI 10.1038/8070; Branchaw JL, 1997, J NEUROSCI, V17, P5772; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; Cens T, 1999, J BIOL CHEM, V274, P5483, DOI 10.1074/jbc.274.9.5483; Chien AJ, 1996, J BIOL CHEM, V271, P26465, DOI 10.1074/jbc.271.43.26465; CHOI DW, 1988, TRENDS NEUROSCI, V11, P465, DOI 10.1016/0166-2236(88)90200-7; CHOTHIA C, 1975, J MOL BIOL, V105, P1; DEMO SD, 1991, NEURON, V7, P743, DOI 10.1016/0896-6273(91)90277-7; DeWaard M, 1997, NATURE, V385, P446, DOI 10.1038/385446a0; DEWAARD M, 1994, NEURON, V13, P495, DOI 10.1016/0896-6273(94)90363-8; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; DUNLAP K, 1995, TRENDS NEUROSCI, V18, P89, DOI 10.1016/0166-2236(95)93882-X; EAHOLTZ G, 1994, NEURON, V12, P1041, DOI 10.1016/0896-6273(94)90312-3; Ertel EA, 2000, NEURON, V25, P533, DOI 10.1016/S0896-6273(00)81057-0; Forsythe ID, 1998, NEURON, V20, P797, DOI 10.1016/S0896-6273(00)81017-X; Hering S, 1997, P NATL ACAD SCI USA, V94, P13323, DOI 10.1073/pnas.94.24.13323; Herlitze S, 1997, P NATL ACAD SCI USA, V94, P1512, DOI 10.1073/pnas.94.4.1512; HILLE B, 1994, IONIC CHANNELS EXCIT; HOSHI T, 1991, NEURON, V7, P547, DOI 10.1016/0896-6273(91)90367-9; Hurley JF, 2000, P NATL ACAD SCI USA, V97, P9293, DOI 10.1073/pnas.160589697; Jimenez C, 2000, NEUROPHARMACOLOGY, V39, P1, DOI 10.1016/S0028-3908(99)00153-7; Kraus RL, 2000, J BIOL CHEM, V275, P9239, DOI 10.1074/jbc.275.13.9239; LACERDA AE, 1991, NATURE, V352, P527, DOI 10.1038/352527a0; MCCONKEY DJ, 1989, ARCH BIOCHEM BIOPHYS, V269, P365, DOI 10.1016/0003-9861(89)90119-7; Monteil A, 2000, J BIOL CHEM, V275, P16530, DOI 10.1074/jbc.C000090200; OLCESE R, 1994, NEURON, V13, P1433, DOI 10.1016/0896-6273(94)90428-6; Perez-Reyes E, 1998, NATURE, V391, P896, DOI 10.1038/36110; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; Qin N, 1998, P NATL ACAD SCI USA, V95, P4690, DOI 10.1073/pnas.95.8.4690; Restituito S, 2000, J NEUROSCI, V20, P9046; ROSE GD, 1985, SCIENCE, V229, P834, DOI 10.1126/science.4023714; Roux B, 1999, SCIENCE, V285, P100, DOI 10.1126/science.285.5424.100; Smith MR, 1997, BIOPHYS J, V73, P1885, DOI 10.1016/S0006-3495(97)78219-5; Soldatov NM, 1998, J BIOL CHEM, V273, P957, DOI 10.1074/jbc.273.2.957; Spaetgens RL, 1999, J BIOL CHEM, V274, P22428, DOI 10.1074/jbc.274.32.22428; STEA A, 1994, P NATL ACAD SCI USA, V91, P10576, DOI 10.1073/pnas.91.22.10576; STEA A, 1995, HDB RECEPTORS CHANNE, P113; Stotz SC, 2001, TRENDS NEUROSCI, V24, P176, DOI 10.1016/S0166-2236(00)01738-0; Stotz SC, 2000, J BIOL CHEM, V275, P24575, DOI 10.1074/jbc.M000399200; SUN JP, 1995, J PHARMACOL EXP THER, V274, P419; Sutton KG, 1999, NATURE, V401, P800, DOI 10.1038/44586; VARADI G, 1991, NATURE, V352, P159, DOI 10.1038/352159a0; WEST JW, 1992, P NATL ACAD SCI USA, V89, P10910, DOI 10.1073/pnas.89.22.10910; ZAGOTTA WN, 1990, J GEN PHYSIOL, V95, P29, DOI 10.1085/jgp.95.1.29; Zamponi GW, 1997, NATURE, V385, P442, DOI 10.1038/385442a0; ZHANG JF, 1994, NATURE, V372, P97, DOI 10.1038/372097a0	49	44	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					33001	33010		10.1074/jbc.M104387200	http://dx.doi.org/10.1074/jbc.M104387200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11402052	hybrid			2022-12-25	WOS:000170746000084
J	Bachman, KE; Rountree, MR; Baylin, SB				Bachman, KE; Rountree, MR; Baylin, SB			Dnmt3a and Dnmt3b are transcriptional repressors that exhibit unique localization properties to heterochromatin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA METHYLTRANSFERASE GENE; CHROMOSOME INSTABILITY; HISTONE DEACETYLASE; REGULATOR ATRX; HUMAN CANCER; ICF SYNDROME; METHYLATION; COMPLEX; MUTATIONS; PROTEINS	We demonstrate that the recently identified DNA methyltransferases, Dnmt3a and Dnmt3b, like DNMT1, repress transcription in a methylation-independent manner. Dnmt3a and Dnmt3b repress transcription primarily through a plant homeodomain-like motif that is shared with the ATRX protein but is not present in DNMT1. Unlike DNMT1, which localizes to replication foci during S-phase in murine embryonic fibroblasts, Dnmt3a co-localizes with heterochromatin protein I a (HP1 alpha) and methyl-CpG binding proteins throughout the cell cycle to late-replicating pericentromeric heterochromatin. In contrast to Dnmt3a, Dnmt3b remained diffuse in the nucleus of embryonic fibroblasts at all cell cycle stages. However, Dnmt3a and Dnmt3b co-localize to these pericentromeric heterochromatin regions in murine embryonic stem cells. This finding is important to the fact that mutations in DNMT3B are found in the developmental syndrome, ICF (immunodeficiency, centromeric heterochromatin instability, and facial anomalies), which involves extensive loss of methylation from pericentromeric regions. The localization of Dnmt3a and Dnmt3b was unaffected in Dnmt1 null embryonic stem cells, which lose the majority of methylation at pericentromeric major satellite repeats, suggesting that these enzymes are not dependent upon preexisting methylation for their targeting. DNMT1 is then positioned to reestablish transcriptionally repressive chromatin as cells replicate, while Dnmt3a and Dnmt3b may help to establish such chromatin in late S-phase and maintain this repressive heterochromatin throughout the cell cycle in a developmentally and/or cell type manner.	Johns Hopkins Univ, Sch Med, Tumor Biol Lab, Johns Hopkins Oncol Ctr, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Grad Program Cellular & Mol Med, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University	Baylin, SB (corresponding author), Johns Hopkins Univ, Sch Med, Tumor Biol Lab, Johns Hopkins Oncol Ctr, Baltimore, MD 21231 USA.		Rountree, Michael R/C-6332-2018	Rountree, Michael R/0000-0003-2371-6389	NCI NIH HHS [CA-43318] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043318] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; Fuks F, 2001, EMBO J, V20, P2536, DOI 10.1093/emboj/20.10.2536; Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750; Gibbons RJ, 1997, NAT GENET, V17, P146, DOI 10.1038/ng1097-146; Gibbons RJ, 2000, NAT GENET, V24, P368, DOI 10.1038/74191; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; Hendrich B, 2000, CURR TOP MICROBIOL, V249, P55; Herman JG, 2000, CURR TOP MICROBIOL, V249, P35; JEANPIERRE M, 1993, HUM MOL GENET, V2, P731, DOI 10.1093/hmg/2.6.731; Lei H, 1996, DEVELOPMENT, V122, P3195; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Liu YL, 1998, NUCLEIC ACIDS RES, V26, P1038, DOI 10.1093/nar/26.4.1038; Masselink H, 2000, ONCOGENE, V19, P1538, DOI 10.1038/sj.onc.1203421; McDowell TL, 1999, P NATL ACAD SCI USA, V96, P13983, DOI 10.1073/pnas.96.24.13983; Murzina N, 1999, MOL CELL, V4, P529, DOI 10.1016/S1097-2765(00)80204-X; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Rhee I, 2000, NATURE, V404, P1003, DOI 10.1038/35010000; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; Sadoni N, 1999, J CELL BIOL, V146, P1211, DOI 10.1083/jcb.146.6.1211; Tuck-Muller CM, 2000, CYTOGENET CELL GENET, V89, P121, DOI 10.1159/000015590; Xie SP, 1999, GENE, V236, P87, DOI 10.1016/S0378-1119(99)00252-8; Xu GL, 1999, NATURE, V402, P187, DOI 10.1038/46052; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4	28	343	354	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					32282	32287		10.1074/jbc.M104661200	http://dx.doi.org/10.1074/jbc.M104661200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11427539	hybrid			2022-12-25	WOS:000170613500109
J	van Es, S; Weening, KE; Devreotes, PN				van Es, S; Weening, KE; Devreotes, PN			The protein kinase YakA regulates G-protein-linked signaling responses during growth and development of Dictyostelium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DUAL-SPECIFICITY; MEDIATED ACTIVATION; TYROSINE RESIDUES; ADENYLYL-CYCLASE; BETA-SUBUNIT; DYRK; DISCOIDEUM; CHEMOTAXIS; MUTANTS; CHEMOATTRACTANT	A genetic screen for Dictyostelium mutants that phenotypically resemble cells lacking the G-protein beta -subunit yielded the protein kinase YakA. Like g beta -null cells, yakA-null cells fail to enter development and display slow growth on bacterial lawns. We created a temperature-sensitive yakA mutant and showed that YakA activity is required not only at the onset but also during development. The yakA-null cells have strong defects in folic acid-induced responses, such as actin polymerization and cGMP accumulation, indicating that they play a role in G-protein-mediated signaling responses. We propose that YakA acts downstream of G-proteins, because cAMP receptors still couple to G-proteins in the yakA mutant. In addition, the previously observed growth arrest induced by overexpression of YakA also occurs in g beta mutants. We localized YakA-GFP to the cytosol suggesting that YakA may be a functional homolog of its mammalian counterparts Dyrk2 and Dyrk3, a subclass of dual-specificity Yak-related kinases (Dyrk) with unknown function.	Johns Hopkins Univ, Sch Med, Dept Cell Biol, Baltimore, MD 21205 USA; Univ Dundee, Dept Biochem, Dundee DD1 5EH, Scotland	Johns Hopkins University; University of Dundee	Devreotes, PN (corresponding author), Johns Hopkins Univ, Sch Med, Dept Cell Biol, 725 N Wolfe St, Baltimore, MD 21205 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM028007, R01GM028007] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM28007] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI H, 1994, BIOCHEM BIOPH RES CO, V205, P1808, DOI 10.1006/bbrc.1994.2880; ASHWORTH JM, 1970, BIOCHEM J, V119, P175, DOI 10.1042/bj1190175; Becker W, 1999, PROG NUCLEIC ACID RE, V62, P1; Becker W, 1998, J BIOL CHEM, V273, P25893, DOI 10.1074/jbc.273.40.25893; GARRETT S, 1991, MOL CELL BIOL, V11, P4045, DOI 10.1128/MCB.11.8.4045; HADWIGER JA, 1994, P NATL ACAD SCI USA, V91, P10566, DOI 10.1073/pnas.91.22.10566; HARTLEY AD, 1994, GENETICS, V136, P465; Himpel S, 2000, J BIOL CHEM, V275, P2431, DOI 10.1074/jbc.275.4.2431; HSU JC, 1994, GENE DEV, V8, P2176, DOI 10.1101/gad.8.18.2176; INSALL R, 1994, J CELL BIOL, V126, P1537, DOI 10.1083/jcb.126.6.1537; Jin T, 1998, EMBO J, V17, P5076, DOI 10.1093/emboj/17.17.5076; Kassis S, 2000, BIOCHEM J, V348, P263, DOI 10.1042/0264-6021:3480263; Kentrup H, 1996, J BIOL CHEM, V271, P3488; KUMAGAI A, 1991, J BIOL CHEM, V266, P1220; LILLY PJ, 1995, J CELL BIOL, V129, P1659, DOI 10.1083/jcb.129.6.1659; Ma H, 1997, EMBO J, V16, P4317, DOI 10.1093/emboj/16.14.4317; Ma YC, 2000, CELL, V102, P635, DOI 10.1016/S0092-8674(00)00086-6; Parente CA, 1998, CELL, V95, P81, DOI 10.1016/S0092-8674(00)81784-5; Peracino B, 1998, J CELL BIOL, V141, P1529, DOI 10.1083/jcb.141.7.1529; Shindoh N, 1996, BIOCHEM BIOPH RES CO, V225, P92, DOI 10.1006/bbrc.1996.1135; Smith DJ, 1997, HUM MOL GENET, V6, P1729, DOI 10.1093/hmg/6.10.1729; Smith DJ, 1997, NAT GENET, V16, P28, DOI 10.1038/ng0597-28; Souza GM, 1998, DEVELOPMENT, V125, P2291; SUSSMAN M, 1987, MOL BIOL DICTYOSTELI, V28, P67; TEJEDOR F, 1995, NEURON, V14, P287, DOI 10.1016/0896-6273(95)90286-4; van Es S, 1999, CELL MOL LIFE SCI, V55, P1341, DOI 10.1007/s000180050374; VANHAASTERT PJM, 1984, BIOCHEM BIOPH RES CO, V124, P597, DOI 10.1016/0006-291X(84)91596-1; WILLIAMS JG, 1993, PHILOS T ROY SOC B, V340, P305, DOI 10.1098/rstb.1993.0072; WU LJ, 1995, J CELL BIOL, V129, P1667, DOI 10.1083/jcb.129.6.1667	29	14	16	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					30761	30765		10.1074/jbc.M103365200	http://dx.doi.org/10.1074/jbc.M103365200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11410593	hybrid			2022-12-25	WOS:000170472900025
J	Campomenosi, P; Monti, P; Aprile, A; Abbondandolo, A; Frebourg, T; Gold, B; Crook, T; Inga, A; Resnick, MA; Iggo, R; Fronza, G				Campomenosi, P; Monti, P; Aprile, A; Abbondandolo, A; Frebourg, T; Gold, B; Crook, T; Inga, A; Resnick, MA; Iggo, R; Fronza, G			p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements	ONCOGENE			English	Article						p53; yeast functional assay; p53 responsive elements	YEAST FUNCTIONAL ASSAY; CELL-CYCLE ARREST; DNA-BINDING; BREAST-CANCER; MUTATIONS; PROTEIN; APOPTOSIS; TUMORS; TRANSFORMATION; IDENTIFICATION	The human p53 protein acts mainly as a stress inducible transcription factor transactivating several genes involved in cell cycle arrest (e,g, p21) or apoptosis (e,g, Bax, PIG3), Roughly half of all human tumours contains p53 missense mutations. Virtually all tumour-derived p53 mutants are unable to activate Bax transcription but some retain the ability to activate p21 transcription, Identification of these mutants may have valuable clinical implications. We have determined the transactivation ability of 77 p53 mutants using reporter yeast strains containing a p53-regulated ADE2 gene whose promoter is regulated by p53 responsive elements derived from the regulatory region of the p21, BRS and PIG3 genes, We also assessed the influence of temperature on transactivation, Our results indicate that a significant proportion of mutants [16/77 (21%); 10/64 (16%) considering only tumour-derived mutants] are transcriptionally active, especially with the p21 promoter. Discriminant mutants preferentially affect less conserved (P < 0.04, Fisher's exact test), more rarely mutated (P < 0.006, Fisher's exact test) amino acids. Temperature sensitivity is frequently observed, but is more common among discriminant than non-discriminant mutants (P < 0.003, Fisher's exact test), Finally, we extended the analysis to a group of mutants isolated in BRCA-associated tumours that surprisingly were indistinguishable from wild type in standard transcription, growth suppression and apoptosis assays in human cells, but showed gain of function in transformation assays. The incidence of transcriptionally active mutations among this group was significantly higher than in the panel of mutants studied previously (P < 0.001, Fisher's exact test), Since it is not possible to predict the behaviour of a mutant from first principles, we propose that the yeast assay be used to compile a functional p53 database and fill the gap between the biophysical, pharmacological and clinical fields.	Natl Inst Canc Res, Mutagenesis Lab, I-16132 Genoa, Italy; Univ Genoa, Dept Oncol Biol & Genet, Genoa, Italy; IFRMP, INSERM EP19906, Fac Med & Pharm, F-76183 Rouen, France; Univ Nebraska, Med Ctr, Dept Pharmaceut Sci, Omaha, NE 68198 USA; St Marys Hosp, Sch Med, Ludwig Inst Canc Res, Sect Cell Biol & Expt Pathol, London W2 1PG, England; NIEHS, Chromosome Stabil Grp, NIH, Res Triangle Pk, NC 27709 USA; Swiss Inst Expt Canc Res, ISREC, CH-1066 Epalinges, Switzerland	University of Genoa; IRCCS AOU San Martino IST; University of Genoa; Institut National de la Sante et de la Recherche Medicale (Inserm); University of Nebraska System; University of Nebraska Medical Center; Imperial College London; Ludwig Institute for Cancer Research; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Swiss Institute Experimental Cancer Research	Fronza, G (corresponding author), Natl Inst Canc Res, Mutagenesis Lab, Largo R Benzi 10, I-16132 Genoa, Italy.		Iggo, Richard/G-3546-2014; Inga, Alberto/AAC-3815-2022; Fronza, Gilberto/AAG-8735-2019; resnick, Michael/F-1668-2019; Monti, Paola/Y-1118-2019; Frebourg, Thierry/AAK-8390-2020; Campomenosi, Paola/C-9729-2011	Inga, Alberto/0000-0002-8767-1637; Fronza, Gilberto/0000-0003-3722-553X; resnick, Michael/0000-0002-8473-7506; Monti, Paola/0000-0002-1978-4998; Campomenosi, Paola/0000-0002-8853-1134	NATIONAL CANCER INSTITUTE [R01CA029088] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES065079, Z01ES065079] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA29088] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aas T, 1996, NAT MED, V2, P811, DOI 10.1038/nm0796-811; BORRESEN AL, 1995, GENE CHROMOSOME CANC, V14, P71, DOI 10.1002/gcc.2870140113; Bullock AN, 2000, ONCOGENE, V19, P1245, DOI 10.1038/sj.onc.1203434; Campomenosi P, 1997, INT J CANCER, V73, P816, DOI 10.1002/(SICI)1097-0215(19971210)73:6&lt;816::AID-IJC8&gt;3.0.CO;2-5; Chappuis PO, 1999, INT J CANCER, V84, P587, DOI 10.1002/(SICI)1097-0215(19991222)84:6<587::AID-IJC8>3.0.CO;2-8; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; Duddy PM, 2000, J MOL DIAGN, V2, P139, DOI 10.1016/S1525-1578(10)60629-0; Flaman JM, 1998, ONCOGENE, V16, P1369, DOI 10.1038/sj.onc.1201889; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; FREEMAN J, 1994, EMBO J, V13, P5393, DOI 10.1002/j.1460-2075.1994.tb06874.x; Friedlander P, 1996, J BIOL CHEM, V271, P25468, DOI 10.1074/jbc.271.41.25468; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Hernandez-Boussard T, 1999, HUM MUTAT, V14, P1; Inga A, 1997, ONCOGENE, V14, P1307, DOI 10.1038/sj.onc.1200952; Inga A, 1999, CANCER RES, V59, P689; Inga A, 1998, CARCINOGENESIS, V19, P741, DOI 10.1093/carcin/19.5.741; ISHIOKA C, 1995, ONCOGENE, V10, P1485; Kelly JD, 1999, J BIOL CHEM, V274, P18327, DOI 10.1074/jbc.274.26.18327; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; Monti P, 2000, MUTAGENESIS, V15, P127, DOI 10.1093/mutage/15.2.127; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Prives C, 1999, J PATHOL, V187, P112; Robert V, 2000, CARCINOGENESIS, V21, P563, DOI 10.1093/carcin/21.4.563; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; Saller E, 1999, EMBO J, V18, P4424, DOI 10.1093/emboj/18.16.4424; Smith PD, 1999, ONCOGENE, V18, P2451, DOI 10.1038/sj.onc.1202565; Soussi T, 1996, J MOL BIOL, V260, P623, DOI 10.1006/jmbi.1996.0425; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Waldman T, 1997, NAT MED, V3, P1034, DOI 10.1038/nm0997-1034; Walker DR, 1999, ONCOGENE, V18, P211, DOI 10.1038/sj.onc.1202298; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; Waridel F, 1997, ONCOGENE, V14, P163, DOI 10.1038/sj.onc.1200812	38	116	122	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 14	2001	20	27					3573	3579		10.1038/sj.onc.1204468	http://dx.doi.org/10.1038/sj.onc.1204468			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	445VB	11429705				2022-12-25	WOS:000169478300014
J	Ikeda, W; Nakanishi, H; Tanaka, Y; Tachibana, K; Takai, Y				Ikeda, W; Nakanishi, H; Tanaka, Y; Tachibana, K; Takai, Y			Cooperation of Cdc42 small G protein-activating and actin filament-binding activities of frabin in microspike formation	ONCOGENE			English	Article						frabin; Cdc42; microspikes; actin cytoskeleton; F-actin-binding activity	NUCLEOTIDE EXCHANGE FACTOR; CELL-CELL ADHESION; AARSKOG-SYNDROME; SYNDROME GENE; MDCK CELLS; N-WASP; RAC; DOMAIN; EXPRESSION; INVASION	Frabin is a GDP/GTP exchange protein for Cdc42 with actin filament (F-actin)-binding activity. Cdc42 is a small GTP-binding protein that forms filopodia-like microspikes in a variety of cells. Expression of frabin indeed forms microspikes through at Least activation of Cdc42 in MDCK cells and fibroblasts such as COS7, L, and NIH3T3 cells. However, the role of the F-actin-binding activity of frabin in the microspike formation remains unknown. We have examined here this role of frabin by expressing various frabin mutants, which have lost Cdc42-activating or F-actin-binding activity, with or without a dominant active mutant of Cdc42 in MDCK and COS7 cells. We show here that for the microspike formation, either of the Cdc42-activating and F- actin-binding activities of frabin alone is not sufficient and both the activities are necessary and that both the activities play a cooperative role in the microspike formation, The present results, together with the earlier finding that Cdc42 reorganizes the actin cytoskeleton at least through the N-WASP-Arp2/3 complex, suggest that frabin directly and indirectly reorganizes the actin cytoskeleton through its F-actin-binding and Cdc42-activating activities, respectively, in a cooperative manner, eventually leading to microspike formation.	Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, Suita, Osaka 5650871, Japan	Osaka University	Takai, Y (corresponding author), Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, Suita, Osaka 5650871, Japan.		Ikeda, Wataru/V-8531-2019	Ikeda, Wataru/0000-0002-6907-9058; Nakanishi, Hiroyuki/0000-0002-9765-0266				Bellanger JM, 2000, NAT CELL BIOL, V2, P888, DOI 10.1038/35046533; Bourguignon LYW, 2000, J CELL BIOL, V150, P177, DOI 10.1083/jcb.150.1.177; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Debant A, 1996, P NATL ACAD SCI USA, V93, P5466, DOI 10.1073/pnas.93.11.5466; Gorski JL, 2000, DEV DYNAM, V218, P573, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1015>3.3.CO;2-6; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; Jou TS, 1998, J CELL BIOL, V142, P85, DOI 10.1083/jcb.142.1.85; Kodama A, 1999, ONCOGENE, V18, P3996, DOI 10.1038/sj.onc.1202773; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mandai K, 1997, J CELL BIOL, V139, P517, DOI 10.1083/jcb.139.2.517; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Obaishi H, 1998, J BIOL CHEM, V273, P18697, DOI 10.1074/jbc.273.30.18697; Ono Y, 2000, ONCOGENE, V19, P3050, DOI 10.1038/sj.onc.1203631; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; Pasteris NG, 1999, GENOMICS, V60, P57, DOI 10.1006/geno.1999.5903; Pasteris NG, 2000, GENE, V242, P237, DOI 10.1016/S0378-1119(99)00518-1; PASTERIS NG, 1994, CELL, V79, P669; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Takahashi K, 1999, J CELL BIOL, V145, P539, DOI 10.1083/jcb.145.3.539; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; Umikawa M, 1999, J BIOL CHEM, V274, P25197, DOI 10.1074/jbc.274.36.25197; Yasuda T, 2000, GENES CELLS, V5, P583, DOI 10.1046/j.1365-2443.2000.00349.x	26	23	23	1	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 14	2001	20	27					3457	3463		10.1038/sj.onc.1204463	http://dx.doi.org/10.1038/sj.onc.1204463			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	445VB	11429692				2022-12-25	WOS:000169478300001
J	Bachmeyer, C; Benz, R; Barth, H; Aktories, K; Gibert, M; Popoff, MR				Bachmeyer, C; Benz, R; Barth, H; Aktories, K; Gibert, M; Popoff, MR			Interaction of Clostridium botulinum C2-toxin with lipid bilayer membranes and vero cells: inhibition of channel function by chloroquine and related compounds in vitro and intoxification in vivo	FASEB JOURNAL			English	Article						channel-formation; chloroquine-analogues; malaria	ANTHRAX PROTECTIVE ANTIGEN; DIPHTHERIA-TOXIN; C2 TOXIN; BINARY TOXIN; ION CHANNELS; TRANSLOCATION; IDENTIFICATION; ACTIN; SPIROFORME; COMPONENTS	Several intracellularly acting bacterial protein toxins, which are known to enter cells by endocytosis, are shown to produce channels. This finding also holds true for the C2-II binding component of C2-toxin of Clostridium botulinum. There is evidence that toxin translocation across the target cell membrane and channel formation by the binding component are related phenomena. Here, we demonstrate that C2-II is fully reconstituted when it is added to only one side of the lipid bilayer membrane. Chloroquine and some related compounds, known as potent drugs against malaria infection of humans, efficiently block the C2-II-mediated channel in a dose-dependent way. The half-saturation constant for binding of chloroquine and some of the related compounds to C2-II is in the micromolar to millimolar range. Their binding to the C2-II channel is asymmetric with respect to its addition to one side of the membrane, and the half-saturation constant is smaller when both inhibitor and protein are added to the same side of the membrane, the cis-side, which corresponds to the external surface of target cells. In vivo experiments with Vero cells demonstrate that chloroquine and related compounds also efficiently block intoxication of the cells by C2-toxin in the same concentration range as they block in vitro the channels.	Univ Wurzburg, Biozentrum, Theodor Boveri Inst, Lehrstuhl Biotechnol, D-97074 Wurzburg, Germany; Univ Freiburg, Inst Expt & Klin Pharmakol & Toxikol, D-79104 Freiburg, Germany; Inst Pasteur, F-75724 Paris 15, France	University of Wurzburg; University of Freiburg; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Benz, R (corresponding author), Univ Wurzburg, Biozentrum, Theodor Boveri Inst, Lehrstuhl Biotechnol, D-97074 Wurzburg, Germany.	roland.benz@mail.uni-wuerzburg.de	Barth, Holger/E-7920-2013; Aktories, Klaus/CAJ-5682-2022	Aktories, Klaus/0000-0002-5397-0436; Benz, Roland/0000-0002-9510-9265				AKTORIES K, 1986, NATURE, V322, P390, DOI 10.1038/322390a0; AKTORIES K, 1992, CURR TOP MICROBIOL, V175, P97; Barth H, 2000, J BIOL CHEM, V275, P18704, DOI 10.1074/jbc.M000596200; Benson EL, 1998, BIOCHEMISTRY-US, V37, P3941, DOI 10.1021/bi972657b; BENZ R, 1978, BIOCHIM BIOPHYS ACTA, V511, P305, DOI 10.1016/0005-2736(78)90269-9; BENZ R, 1986, J BACTERIOL, V165, P978, DOI 10.1128/jb.165.3.978-986.1986; BENZ R, 1987, J MEMBRANE BIOL, V100, P21, DOI 10.1007/BF02209137; BLAUSTEIN RO, 1989, P NATL ACAD SCI USA, V86, P2209, DOI 10.1073/pnas.86.7.2209; BOQUET P, 1982, P NATL ACAD SCI-BIOL, V79, P7614, DOI 10.1073/pnas.79.24.7614; Bray Patrick G., 1999, Novartis Foundation Symposium, V226, P252; CONSIDINE RV, 1991, TOXICON, V29, P913, DOI 10.1016/0041-0101(91)90076-4; DONOVAN JJ, 1981, P NATL ACAD SCI-BIOL, V78, P172, DOI 10.1073/pnas.78.1.172; DONOVAN JJ, 1986, BIOCHEMISTRY-US, V25, P2872, DOI 10.1021/bi00358a020; HOCH DH, 1985, P NATL ACAD SCI USA, V82, P1692, DOI 10.1073/pnas.82.6.1692; KAGAN BL, 1981, P NATL ACAD SCI-BIOL, V78, P4950, DOI 10.1073/pnas.78.8.4950; Kimura K, 1998, VET MICROBIOL, V62, P27, DOI 10.1016/S0378-1135(98)00195-3; LEPPLA SH, 1980, J BIOL CHEM, V255, P2247; LEPPLA SH, 1999, COMPREHENSIVE SOURCE, P243; Miller CJ, 1999, BIOCHEMISTRY-US, V38, P10432, DOI 10.1021/bi990792d; Oh KJ, 1999, P NATL ACAD SCI USA, V96, P8467, DOI 10.1073/pnas.96.15.8467; OHISHI I, 1987, INFECT IMMUN, V55, P1461, DOI 10.1128/IAI.55.6.1461-1465.1987; OHISHI I, 1980, INFECT IMMUN, V30, P668; OHISHI I, 1992, INFECT IMMUN, V60, P4648, DOI 10.1128/IAI.60.11.4648-4655.1992; OLSNES S, 1999, COMPREHENSIVE SOURCE, P73; PAPINI E, 1988, EMBO J, V7, P3353, DOI 10.1002/j.1460-2075.1988.tb03207.x; Perelle S, 1997, FEMS MICROBIOL LETT, V146, P117, DOI [10.1016/S0378-1097(96)00463-6, 10.1111/j.1574-6968.1997.tb10180.x]; Petosa C, 1997, NATURE, V385, P833, DOI 10.1038/385833a0; POPOFF MR, 1988, BIOCHEM BIOPH RES CO, V152, P1361, DOI 10.1016/S0006-291X(88)80435-2; REUNER KH, 1987, EUR J CELL BIOL, V43, P134; Sanchez CP, 1997, J BIOL CHEM, V272, P2652, DOI 10.1074/jbc.272.5.2652; SANDVIG K, 1988, J BIOL CHEM, V263, P12352; SCHERING B, 1988, EUR J BIOCHEM, V171, P225, DOI 10.1111/j.1432-1033.1988.tb13780.x; SCHMID A, 1994, J BIOL CHEM, V269, P16706; SCHMID MF, 1993, NATURE, V364, P827, DOI 10.1038/364827a0; SCHULEIN K, 1991, MOL MICROBIOL, V5, P2233, DOI 10.1111/j.1365-2958.1991.tb02153.x; SIMPSON LI, 1989, J PHARMACOL EXP THER, V251, P1223; SIMPSON LL, 1989, INFECT IMMUN, V57, P255, DOI 10.1128/IAI.57.1.255-261.1989; SIMPSON LL, 1987, INFECT IMMUN, V55, P118, DOI 10.1128/IAI.55.1.118-122.1987; SIMPSON LL, 1982, J PHARMACOL EXP THER, V222, P43; VANDEKERCKHOVE J, 1988, J BIOL CHEM, V263, P696; WEISS MS, 1991, FEBS LETT, V280, P379, DOI 10.1016/0014-5793(91)80336-2; WELKOS SL, 1988, GENE, V69, P287, DOI 10.1016/0378-1119(88)90439-8; Wesche J, 1998, BIOCHEMISTRY-US, V37, P15737, DOI 10.1021/bi981436i; Wunsch S, 1998, J CELL BIOL, V140, P335, DOI 10.1083/jcb.140.2.335; ZHAO JM, 1995, J BIOL CHEM, V270, P18626, DOI 10.1074/jbc.270.31.18626	45	66	67	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY 29	2001	15	7					1658	+		10.1096/fj.00-0671fje	http://dx.doi.org/10.1096/fj.00-0671fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519CQ	11427518				2022-12-25	WOS:000173707700004
J	Gredilla, R; Sanz, A; Lopez-Torres, M; Barja, G				Gredilla, R; Sanz, A; Lopez-Torres, M; Barja, G			Caloric restriction decreases mitochondrial free radical generation at complex I and lowers oxidative damage to mitochondrial DNA in the rat heart	FASEB JOURNAL			English	Article						8-hydroxydeoxyguanosine; aging; oxygen radical production; hydrogen peroxide	FOOD RESTRICTION; AGE; STRESS; MUTATIONS; SITES; BRAIN	The effect of caloric restriction (CR) (40%) on the rates of mitochondrial H2O2 production and oxygen consumption and oxidative damage to nuclear DNA (nDNA) and mitochondrial DNA (mtDNA) was studied for short-term (6-wk) and long-term (1-year) periods in the heart of young and old rats. Short-term CR did not change any of the parameters measured. However, long-term CR significantly decreased the rate of mitochondrial H2O2 generation (by 45%) and significantly lowered oxidative damage to mtDNA (by 30%) without modifying damage to nDNA. The decrease in H2O2 production occurred exclusively at the complex I free radical generator of the respiratory chain. The mechanism allowing that decrease was not a simple decrease in mitochondrial oxygen consumption. Instead, the mitochondria of caloric-restricted animals released fewer oxygen radicals per unit electron flow in the respiratory chain. This was due to a decrease in the degree of reduction of the complex I generator in caloric-restricted mitochondria. The results are consistent with die concept that CR decreases the aging rate at least in part by decreasing the rate of mitochondrial oxygen radical generation and then the rate of attack on mtDNA.	Univ Complutense, Fac Biol, Dept Anim Biol Anim Physiol 2, E-28040 Madrid, Spain	Complutense University of Madrid	Barja, G (corresponding author), Univ Complutense, Fac Biol, Dept Biol Anim 2, E-28040 Madrid, Spain.		Sanz, Alberto/O-2329-2015; Barja, Gustavo/AAA-5903-2019; Gustavo, Barja/B-5591-2012; SANZ, ALBERTO/F-8432-2011	Sanz, Alberto/0000-0003-2149-1753; Barja, Gustavo/0000-0001-5736-4735; GREDILLA, RICARDO/0000-0003-4501-1355				Barja G, 2000, FASEB J, V14, P312, DOI 10.1096/fasebj.14.2.312; Barja G, 2000, AGING CLIN EXP RES, V12, P342, DOI 10.1007/BF03339859; Barja G, 1999, J BIOENERG BIOMEMBR, V31, P347, DOI 10.1023/A:1005427919188; Barja G, 1999, METHODS AGING RES, P533; Beckman K B, 1996, Methods Enzymol, V264, P442, DOI 10.1016/S0076-6879(96)64040-3; Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; BOVERIS A, 1976, BIOCHEM J, V156, P435, DOI 10.1042/bj1560435; CHUNG MH, 1992, FREE RADICAL BIO MED, V12, P523, DOI 10.1016/0891-5849(92)90105-P; de Grey ADNJ, 2000, ARCH BIOCHEM BIOPHYS, V373, P295, DOI 10.1006/abbi.1999.1509; DeLaAsuncion JG, 1996, FASEB J, V10, P333, DOI 10.1096/fasebj.10.2.8641567; DJURIC Z, 1992, TOXICOL APPL PHARM, V115, P156, DOI 10.1016/0041-008X(92)90318-M; Gabbita SP, 1997, FREE RADICAL BIO MED, V23, P191, DOI 10.1016/S0891-5849(97)00043-9; Greenberg JA, 2000, MECH AGEING DEV, V113, P37, DOI 10.1016/S0047-6374(99)00094-9; GUARNIERI C, 1992, FREE RADICALS AGING, P73; Hansford RG, 1997, J BIOENERG BIOMEMBR, V29, P89, DOI 10.1023/A:1022420007908; HARMAN D, 1972, J AM GERIATR SOC, V20, P145, DOI 10.1111/j.1532-5415.1972.tb00787.x; HAYAKAWA M, 1992, BIOCHEM BIOPH RES CO, V189, P979, DOI 10.1016/0006-291X(92)92300-M; Herrero A, 1997, J BIOENERG BIOMEMBR, V29, P241, DOI 10.1023/A:1022458010266; Herrero A, 1997, MECH AGEING DEV, V98, P95, DOI 10.1016/S0047-6374(97)00076-6; Kaneko T, 1996, MUTAT RES-DNAGING G, V316, P277, DOI 10.1016/S0921-8734(96)90010-7; Kovalenko SA, 1998, ANN NY ACAD SCI, V854, P171, DOI 10.1111/j.1749-6632.1998.tb09900.x; Lass A, 1998, FREE RADICAL BIO MED, V25, P1089, DOI 10.1016/S0891-5849(98)00144-0; LATORRE A, 1986, P NATL ACAD SCI USA, V83, P8649, DOI 10.1073/pnas.83.22.8649; Lee J, 1999, FREE RADICAL BIO MED, V26, P260, DOI 10.1016/S0891-5849(98)00195-6; Loft S, 1999, METHOD ENZYMOL, V300, P166; MCCARTER R, 1985, AM J PHYSIOL, V248, pE488; Mela L, 1979, Methods Enzymol, V55, P39; Melov S, 1999, MUTAT RES-DNA REPAIR, V434, P233, DOI 10.1016/S0921-8777(99)00031-2; Muscari C, 1996, AGING-CLIN EXP RES, V8, P429, DOI 10.1007/BF03339606; NAGLEY P, 1998, MITOCHONDRIAL DNA MU, P205; NAPIWOTZKI J, 1999, OXIDAT STRESS DIS, V2, P251; NOHL H, 1986, BIOCHEM BIOPH RES CO, V138, P533, DOI 10.1016/S0006-291X(86)80529-0; NOHL H, 1978, EUR J BIOCHEM, V82, P563, DOI 10.1111/j.1432-1033.1978.tb12051.x; Orr W. C., 2000, ANTIOXIDANTS REDOX R, P517; OZAWA T, 1995, EXP GERONTOL, V30, P269, DOI 10.1016/0531-5565(94)00057-A; Ozawa T, 1999, J BIOENERG BIOMEMBR, V31, P377, DOI 10.1023/A:1005479920097; RUCH W, 1983, J IMMUNOL METHODS, V63, P347, DOI 10.1016/S0022-1759(83)80008-8; SOHAL RS, 1994, MECH AGEING DEV, V74, P121, DOI 10.1016/0047-6374(94)90104-X; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; SOHAL RS, 1994, MECH AGEING DEV, V76, P215, DOI 10.1016/0047-6374(94)91595-4; SOHAL RS, 1995, MECH AGEING DEV, V81, P15, DOI 10.1016/0047-6374(94)01578-A; TURRENS JF, 1980, BIOCHEM J, V191, P421, DOI 10.1042/bj1910421; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; Wang ED, 1997, MUTAT RES-FUND MOL M, V377, P157, DOI 10.1016/S0027-5107(97)00091-2; Weindruch R, 1997, NEW ENGL J MED, V337, P986, DOI 10.1056/NEJM199710023371407	45	293	304	0	28	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY 29	2001	15	7					1589	+		10.1096/fj.00-0764fje	http://dx.doi.org/10.1096/fj.00-0764fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519CQ	11427495				2022-12-25	WOS:000173707700027
J	Murphy, JF; Fitzgerald, DJ				Murphy, JF; Fitzgerald, DJ			Vascular endothelial cell growth factor (VEGF) induces cyclooxygenase (COX)-dependent proliferation of endothelial cells (EC) via the VEGF-2 receptor	FASEB JOURNAL			English	Article						vascular endothelial growth factor; cyclooxygenase; endothelial cell; prostacyclin		Vascular endothelial cell growth factor (VEGF) stimulates endothelial cell (EC) proliferation and migration and mediates vascular growth and angiogenesis through two receptors, VEGFR-1 (Flt-1) and VEGFR-2 (KDR). Similar biological activity has been attributed to cyclooxygenase (COX)-1 and -2, particularly in the angiogenic response to colon cancer. VEGF(165) (50 ng/ml for 3 h) increased the generation of 6-keto-PGF(1alpha) in EC (2.8+/-0.36 ng/ml vs. 0.69+/-0.08 ng/ml, P<0.05; n=9), which was prevented by the specific COX-2 inhibitor NS398 (0.7+/-0.5 ng/ml). VEGF also induced COX-2 protein expression. Extended exposure to VEGF (8-10 h) leads to COX-1 protein expression. A peptide derived from the third globular domain of the VEGFR-2 consisting of residues 247-261 (1 mu M-1 mM) inhibited VEGF-induced 6-keto-PGF(1 alpha) generation and COX induction. Prolonged exposure (7-9 h) of EC to VEGF induced cell proliferation that was inhibited by a combination of COX-1 and -2 inhibitors (SC560 and NS398), suggesting that proliferation is dependent on both isoforms. The inhibitory effect of the combined inhibitors was also seen with aspirin and was reversed by the addition of the stable PGI(2) analog iloprost but not by the PGE(2) or PGH(2) analogs dinoprostone or U46619. In an angiogenic assay, new blood vessel formation induced by VEGF over 14 days was blocked by COX-1 inhibition. COX induction and prostaglandin formation are downstream effectors of VEGF-dependent EC activation and angiogenesis.	Royal Coll Surgeons Ireland, Dept Clin Pharmacol, Dublin 2, Ireland	Royal College of Surgeons - Ireland	Murphy, JF (corresponding author), Royal Coll Surgeons Ireland, Dept Clin Pharmacol, 123 St Stephens Green, Dublin 2, Ireland.	jmurphy@rcsi.ie						Adderley SR, 1999, J BIOL CHEM, V274, P5038, DOI 10.1074/jbc.274.8.5038; ANGELOV L, 1999, CANCER RES, P5536; Bamba H, 2000, BIOCHEM BIOPH RES CO, V273, P485, DOI 10.1006/bbrc.2000.2969; Bishop-Bailey D, 1999, J BIOL CHEM, V274, P17042, DOI 10.1074/jbc.274.24.17042; Brockman JA, 1998, GASTROENTEROLOGY, V115, P1049, DOI 10.1016/S0016-5085(98)70072-1; Bryant CE, 1998, LIFE SCI, V62, P2195, DOI 10.1016/S0024-3205(98)00197-0; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; Fuh G, 1998, J BIOL CHEM, V273, P11197, DOI 10.1074/jbc.273.18.11197; GOSPODAROWICZ D, 1989, P NATL ACAD SCI USA, V86, P7311, DOI 10.1073/pnas.86.19.7311; Gupta RA, 2000, P NATL ACAD SCI USA, V97, P13275, DOI 10.1073/pnas.97.24.13275; He H, 1999, J BIOL CHEM, V274, P25130, DOI 10.1074/jbc.274.35.25130; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; HOUCK KA, 1992, J BIOL CHEM, V267, P26031; Hsu AL, 2000, J BIOL CHEM, V275, P11397, DOI 10.1074/jbc.275.15.11397; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; JAKEMAN LB, 1992, J CLIN INVEST, V89, P244, DOI 10.1172/JCI115568; JONES DA, 1993, J BIOL CHEM, V268, P9049; Jones MK, 1999, NAT MED, V5, P1418; Kanno S, 2000, ONCOGENE, V19, P2138, DOI 10.1038/sj.onc.1203533; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; LIU XH, 2000, J UROLOGY, P820; Makinen T, 2001, NAT MED, V7, P199, DOI 10.1038/84651; MARTINYBARON G, 1995, CURR OPIN BIOTECH, V6, P675, DOI 10.1016/0958-1669(95)80111-1; MASFERRER JL, 2000, CANCER RES, P1306; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; OIDA H, 1995, BRIT J PHARMACOL, P2828; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Piossek C, 1999, J BIOL CHEM, V274, P5612, DOI 10.1074/jbc.274.9.5612; Poltorak Z, 1997, J BIOL CHEM, V272, P7151, DOI 10.1074/jbc.272.11.7151; Prescott SM, 2000, J CLIN INVEST, V105, P1511, DOI 10.1172/JCI10241; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; SALEH M, 1996, CANCER RES, P393; Sawaoka H, 1999, LAB INVEST, V79, P1469; SHEEHAN KM, 1999, JAMA-J AM MED ASSOC, P1254; Sheng HM, 1997, J CLIN INVEST, V99, P2254, DOI 10.1172/JCI119400; Smith CJ, 1998, P NATL ACAD SCI USA, V95, P13313, DOI 10.1073/pnas.95.22.13313; Smith T., 1893, US DEP AGR BUREAU AN, V1; Smith WL, 1996, ADV IMMUNOL, V62, P167, DOI 10.1016/S0065-2776(08)60430-7; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; Wallace JL, 2000, GASTROENTEROLOGY, V119, P706, DOI 10.1053/gast.2000.16510; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Wheeler-Jones C, 1997, FEBS LETT, V420, P28, DOI 10.1016/S0014-5793(97)01481-6; Williams CS, 2000, J CLIN INVEST, V105, P1589, DOI 10.1172/JCI9621; Wu LW, 2000, J BIOL CHEM, V275, P5096, DOI 10.1074/jbc.275.7.5096; Zachary I, 1998, INT J BIOCHEM CELL B, V30, P1169, DOI 10.1016/S1357-2725(98)00082-X	49	55	58	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY 29	2001	15	7					1667	+		10.1096/fj.00-0757fje	http://dx.doi.org/10.1096/fj.00-0757fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519CQ	11427521				2022-12-25	WOS:000173707700001
J	Peters, DG; Klucher, KM; Perlingeiro, RCR; Dessain, SK; Koh, EY; Daley, GQ				Peters, DG; Klucher, KM; Perlingeiro, RCR; Dessain, SK; Koh, EY; Daley, GQ			Autocrine and paracrine effects of an ES-cell derived, BCR/ABL-transformed hematopoietic cell line that induces leukemia in mice	ONCOGENE			English	Article						BCR/ABL; embryonic stem cell; chronic myeloid leukemia; interleukin-3	CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; COLONY-STIMULATING FACTOR; EMBRYONIC STEM-CELLS; BCR-ABL; IN-VITRO; DIFFERENTIATION; GROWTH; EXPRESSION; ONCOGENE	During differentiation in vitro, Embryonic Stem (ES) cells generate both primitive erythroid and definitive myeloid lineages in a process that mimics hematopoiesis in the mammalian yolk sac, To investigate leukemic transformation of these embryonic hematopoietic progenitors, we infected differentiating cultures of ES cells with the Chronic Myeloid Leukemia-specific BCR/ABL oncoprotein. Following a period of liquid culture, we isolated two transformed subclones, EB57 and EB67, that retained characteristics of embryonic hematopoietic progenitors and induced a fatal leukemia in mice characterized by massive splenomegaly and granulocytosis, Histopathology of the spleen revealed an abundance of undifferentiated blast-like cells. Investigation of the clonal origins of the granulocytes in the peripheral blood demonstrated that the injected donor cells contributed modestly to the granulocyte population while the majority were host-derived, EB57 secretes IL-3 and unidentified cytokines that can stimulate autocrine and paracrine cell proliferation, presumably accounting for the reactive granulocytosis in diseased mice. These BCR/ABL transformed hematopoietic derivatives of ES cells recapitulate the relationship of BCR/ABL expression to IL-3 production that has been described for primitive hematopoietic progenitors from human CML patients, and illustrates the potential for autocrine and paracrine effects of BCR/ABL-infected cells in murine models.	Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Hematol Oncol, Boston, MA 02115 USA; Whitehead Inst, Cambridge, MA 02142 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Massachusetts Institute of Technology (MIT); Whitehead Institute	Daley, GQ (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Hematol Oncol, Boston, MA 02115 USA.				NATIONAL CANCER INSTITUTE [R29CA076418, R01CA086991] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL004463] Funding Source: NIH RePORTER; NCI NIH HHS [CA86991-01, CA76418-01] Funding Source: Medline; NHLBI NIH HHS [K08 HL 04463] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson SM, 1996, BLOOD, V87, P238; Choi K, 1998, DEVELOPMENT, V125, P725; CROSS NCP, 1994, LEUKEMIA, V8, P186; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Dexter T M, 1984, Prog Clin Biol Res, V148, P13; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; EAVES AC, 1979, EXP HEMATOL, V7, P65; ELEFANTY AG, 1992, BLOOD, V79, P1271; FORSTEN KE, 1992, BIOPHYS J, V63, P857, DOI 10.1016/S0006-3495(92)81661-2; Ghaffari S, 1999, P NATL ACAD SCI USA, V96, P13186, DOI 10.1073/pnas.96.23.13186; GISHIZKY ML, 1993, P NATL ACAD SCI USA, V90, P3755, DOI 10.1073/pnas.90.8.3755; GUTIERREZRAMOS JC, 1992, P NATL ACAD SCI USA, V89, P9171, DOI 10.1073/pnas.89.19.9171; Hariharan I K, 1988, Oncogene Res, V3, P387; ILARIA RL, 1995, BLOOD, V86, P3897, DOI 10.1182/blood.V86.10.3897.bloodjournal86103897; ISSAAD C, 1994, BLOOD, V84, P3447; Jiang X, 2000, LEUKEMIA, V14, P1112, DOI 10.1038/sj.leu.2401752; Jiang XY, 1999, P NATL ACAD SCI USA, V96, P12804, DOI 10.1073/pnas.96.22.12804; Keller G, 1998, BLOOD, V92, P877, DOI 10.1182/blood.V92.3.877.415k11_877_887; KELLER G, 1993, MOL CELL BIOL, V13, P473, DOI 10.1128/MCB.13.1.473; KELLER GM, 1995, CURR OPIN CELL BIOL, V7, P862, DOI 10.1016/0955-0674(95)80071-9; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; Klucher KM, 1998, BLOOD, V91, P3927, DOI 10.1182/blood.V91.10.3927.3927_3927_3934; KOH EY, 2001, IN PRESS CHRONIC MYE; LANEUVILLE P, 1991, ONCOGENE, V6, P275; LEMOINE FM, 1988, EXP HEMATOL, V16, P718; Li S, 1999, BLOOD, V94, p600A; Li SG, 1999, J EXP MED, V189, P1399, DOI 10.1084/jem.189.9.1399; MANDANAS RA, 1992, LEUKEMIA, V6, P796; SCOTT ML, 1991, P NATL ACAD SCI USA, V88, P6506, DOI 10.1073/pnas.88.15.6506; SIRARD C, 1994, BLOOD, V83, P1575; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; VANDERIJN M, 1989, P NATL ACAD SCI USA, V86, P4634; WILES MV, 1991, DEVELOPMENT, V111, P259; Zhang XW, 1998, BLOOD, V92, P3829, DOI 10.1182/blood.V92.10.3829	35	34	37	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 10	2001	20	21					2636	2646		10.1038/sj.onc.1204374	http://dx.doi.org/10.1038/sj.onc.1204374			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	431VN	11420675				2022-12-25	WOS:000168652600004
J	Szutorisz, H; Palmqvist, R; Roos, G; Stenling, R; Schorderet, DF; Reddell, R; Lingner, J; Nabholz, M				Szutorisz, H; Palmqvist, R; Roos, G; Stenling, R; Schorderet, DF; Reddell, R; Lingner, J; Nabholz, M			Rearrangements of minisatellites in the human telomerase reverse transcriptase gene are not correlated with its expression in colon carcinomas	ONCOGENE			English	Article						hTERT; minisatellites; rearrangements; colon carcinoma	CATALYTIC SUBUNIT HTERT; SOMATIC MUTATIONS; SUSCEPTIBILITY LOCUS; VARIABLE NUMBER; INSULIN GENE; HUMAN THYMUS; ALLELIC LOSS; LIFE-SPAN; C-MYC; ACTIVATION	Telomerase activation is crucial in human carcinogenesis. The limiting component of telomerase, the catalytic subunit (hTERT), is undetectable in normal somatic cells but present in most tumor cells, including the earliest stages of colon carcinoma, The mechanisms involved in the differential expression in normal and tumor cells are not understood. In normal cells hTERT expression is shut down by a repressor, and upregulation could be a consequence of cis-acting changes in the hTERT gene, making it resistant to repression, We have identified a polymorphic and a monomorphic minisatellite in the second intron of the hTERT gene, and polymorphic one in intron 6, The polymorphic minisatellite in intron 2 contains binding sites for c-Myc, which has been shown to upregulate hTERT transcription, Screening colon carcinoma DNAs for rearrangements of hTERT minisatellites we detected no changes in 33 samples from tumors, most of which express hTERT, This indicates that size rearrangements of the hTERT minisatellites are not required for telomerase expression in colon carcinomas, Minor changes and one LOH were seen in five tumors.	Inst Expt Canc Res, CH-1066 Epalinges, Switzerland; Umea Univ, Dept Med Biosci, SE-90187 Umea, Sweden; CHU Vaudois, Div Med Genet, CH-1011 Lausanne, Switzerland; Childrens Med Res Inst, Westmead, NSW 2145, Australia	Umea University; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Children's Medical Research Institute - Australia	Nabholz, M (corresponding author), Inst Expt Canc Res, CH-1066 Epalinges, Switzerland.		Reddel, Roger R/A-6635-2014	Reddel, Roger R/0000-0002-6302-6107; Lingner, Joachim/0000-0002-2853-5803				Alakurtti K, 2000, GENE, V242, P65, DOI 10.1016/S0378-1119(99)00550-8; ARMOUR JAL, 1989, GENOMICS, V4, P328, DOI 10.1016/0888-7543(89)90338-8; BENNETT ST, 1995, NAT GENET, V9, P284, DOI 10.1038/ng0395-284; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Bryce LA, 2000, NEOPLASIA, V2, P197, DOI 10.1038/sj.neo.7900092; Cong YS, 1999, HUM MOL GENET, V8, P137, DOI 10.1093/hmg/8.1.137; Cuthbert AP, 1999, JNCI-J NATL CANCER I, V91, P37, DOI 10.1093/jnci/91.1.37; Dickson MA, 2000, MOL CELL BIOL, V20, P1436, DOI 10.1128/MCB.20.4.1436-1447.2000; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Fennelly J, 1997, LEUKEMIA, V11, P807, DOI 10.1038/sj.leu.2400674; Fiskerstrand CE, 1999, FEBS LETT, V458, P171, DOI 10.1016/S0014-5793(99)01150-3; Greenberg RA, 1999, ONCOGENE, V18, P1219, DOI 10.1038/sj.onc.1202669; Gutierrez B, 1998, HUM GENET, V103, P319, DOI 10.1007/s004390050823; Harrington L, 1997, GENE DEV, V11, P3109, DOI 10.1101/gad.11.23.3109; HOFFOLSEN P, 1995, HUM MUTAT, V5, P329, DOI 10.1002/humu.1380050410; Horikawa I, 1999, CANCER RES, V59, P826; HORN GT, 1989, NUCLEIC ACIDS RES, V17, P2140, DOI 10.1093/nar/17.5.2140; JEFFREYS AJ, 1994, NAT GENET, V6, P136, DOI 10.1038/ng0294-136; Jeffreys AJ, 1997, HUM MOL GENET, V6, P129, DOI 10.1093/hmg/6.1.129; JEFFREYS AJ, 1985, NATURE, V314, P67, DOI 10.1038/314067a0; Jiang XR, 1999, NAT GENET, V21, P111, DOI 10.1038/5056; Kaplanski C, 1997, INT J CANCER, V72, P248, DOI 10.1002/(SICI)1097-0215(19970717)72:2<248::AID-IJC8>3.0.CO;2-R; KENNEDY GC, 1995, NAT GENET, V9, P293, DOI 10.1038/ng0395-293; Kilian A, 1997, HUM MOL GENET, V6, P2011, DOI 10.1093/hmg/6.12.2011; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kominato Y, 1997, J BIOL CHEM, V272, P25890, DOI 10.1074/jbc.272.41.25890; Kyo S, 2000, NUCLEIC ACIDS RES, V28, P669, DOI 10.1093/nar/28.3.669; Kyo S, 1999, CANCER RES, V59, P5917; Larson GP, 1999, HUM MOL GENET, V8, P1985, DOI 10.1093/hmg/8.11.1985; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Migliaccio M, 2000, J IMMUNOL, V165, P4978, DOI 10.4049/jimmunol.165.9.4978; Murray J, 1999, GENOME RES, V9, P130; NAGEL S, 1995, CANCER RES, V55, P2866; Nakabayashi K, 1999, EXP CELL RES, V252, P376, DOI 10.1006/excr.1999.4619; NAKAMURA Y, 1988, NUCLEIC ACIDS RES, V16, P5707, DOI 10.1093/nar/16.12.5707; Nikiforov YE, 1998, ONCOGENE, V17, P1983, DOI 10.1038/sj.onc.1202120; Oh S, 2000, ONCOGENE, V19, P1485, DOI 10.1038/sj.onc.1203439; Oh S, 1999, J BIOL CHEM, V274, P37473, DOI 10.1074/jbc.274.52.37473; Palmqvist R, 1998, BRIT J CANCER, V77, P917, DOI 10.1038/bjc.1998.152; Paquette J, 1998, J BIOL CHEM, V273, P14158, DOI 10.1074/jbc.273.23.14158; Phelan CM, 1996, NAT GENET, V12, P309, DOI 10.1038/ng0396-309; PHILLIPS N, 1993, INT J CANCER, V54, P85, DOI 10.1002/ijc.2910540115; Phillips NJ, 1996, CANCER RES, V56, P606; Prokhortchouk EB, 1998, J MOL BIOL, V280, P227, DOI 10.1006/jmbi.1998.1857; Pugliese A, 1997, NAT GENET, V15, P293, DOI 10.1038/ng0397-293; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Shipman R, 1996, EUR J CANCER, V32A, P335, DOI 10.1016/0959-8049(95)00535-8; Takakura M, 1999, CANCER RES, V59, P551; Tanaka H, 1998, GENE CHROMOSOME CANC, V23, P123, DOI 10.1002/(SICI)1098-2264(199810)23:2<123::AID-GCC5>3.0.CO;2-4; TREPICCHIO WL, 1992, NUCLEIC ACIDS RES, V20, P2427, DOI 10.1093/nar/20.10.2427; TREPICCHIO WL, 1993, NUCLEIC ACIDS RES, V21, P977, DOI 10.1093/nar/21.4.977; Ulaner GA, 2000, INT J CANCER, V85, P330, DOI 10.1002/(SICI)1097-0215(20000201)85:3<330::AID-IJC6>3.0.CO;2-U; Vafiadis P, 1997, NAT GENET, V15, P289, DOI 10.1038/ng0397-289; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; Weitzel JN, 2000, CANCER RES, V60, P259; Wick M, 1999, GENE, V232, P97, DOI 10.1016/S0378-1119(99)00108-0; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; Yan P, 1999, J PATHOL, V189, P207, DOI 10.1002/(SICI)1096-9896(199910)189:2<207::AID-PATH424>3.0.CO;2-H; Yang JW, 1999, J BIOL CHEM, V274, P26141, DOI 10.1074/jbc.274.37.26141; Yoshida R, 1999, ANTICANCER RES, V19, P2167	61	16	17	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 3	2001	20	20					2600	2605		10.1038/sj.onc.1204346	http://dx.doi.org/10.1038/sj.onc.1204346			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	431VM	11420670				2022-12-25	WOS:000168652500011
J	Yin, ZN; Babaian, RJ; Troncoso, P; Strom, SS; Spitz, MR; Caudell, JJ; Stein, JD; Kagan, J				Yin, ZN; Babaian, RJ; Troncoso, P; Strom, SS; Spitz, MR; Caudell, JJ; Stein, JD; Kagan, J			Limiting the location of putative human prostate cancer tumor suppressor genes on chromosome 18q	ONCOGENE			English	Article						chromosome 18q; prostate cancer; loss of heterozygosity; tumor suppressor gene; Smad2; Smad4; DCC	IN-VIVO ALTERATIONS; GROWTH-FACTOR-BETA; HUMAN LUNG CANCERS; ALLELIC LOSS; DCC GENE; MUTATIONAL ANALYSIS; FREQUENT LOSS; COLORECTAL CARCINOMAS; CELL CARCINOMA; P53 PROTEIN	We studied loss of heterozygosity (LOH) on the long arm of human chromosome 18 in prostate cancer to determine the location of a putative tumor suppressor gene (TSG) and to correlate these losses with the pathological grade and stage of the cancer, Of 48 specimens analysed 17 (35.4%) lost at least one allele on chromosome 18q, All the specimens with allelic losses lost at least one allele within chromosomal region 18q21, Allelic losses picked at D18S51 (19%) and D18S858 (17%), A 0.58 cM DNA segment that includes the D18S858 locus and is flanked by the microsatellite loci D18S41 and D18S381, was lost in eight (47%) of 17 specimens with allelic losses, This segment was designated as a LOH cluster region 1 (LCR 1), Although Smad2 resides within LCR 1, it was not mutated in any of the six prostate cell lines (five prostate cancer cell lines and one immortalized prostate epithelial cell line) analysed, suggesting that it is not a candidate TSG in prostate cancer. A second LCR at 18q21, LCR 2, includes the D18S51 locus and is flanked by the D18S1109 and D18S68 loci, which are separated by 7.64 cM, LCR 2 was lost in six (35%) of the 17 specimens with chromosome 18q losses. These results suggest that chromosome 18q21 may harbor two candidate prostate cancer TSGs, The candidate TSGs DCC and Smad4 are located centromeric to the LCRs, No alleles were lost within or in close proximity to these genes, suggesting that they are not targets for inactivation by allelic losses in prostate cancer. Although there was no obvious correlation between chromosome 18q LOH and the pathological grade or stage, three (37.5%) of eight low-grade cancers and nine (32.1%) of 28 organ-confined cancers lost alleles at 18q21, suggesting that allelic losses are relatively early events in the development of invasive prostate cancer.	Univ Texas, MD Anderson Canc Ctr, Div Pathol & Lab Med, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Urol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Epidemiol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Kagan, J (corresponding author), Univ Texas, MD Anderson Canc Ctr, Div Pathol & Lab Med, 1515 Holcombe Blvd,Box 054, Houston, TX 77030 USA.				NCI NIH HHS [CA68578-05] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA068578] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDROW MG, 1995, CANCER RES, V55, P1452; [Anonymous], 1997, AJCC CANC STAGING MA; BERGERHEIM USR, 1991, GENE CHROMOSOME CANC, V3, P215, DOI 10.1002/gcc.2870030308; BOVA GS, 1993, CANCER RES, V53, P3869; BREWSTER SF, 1994, BRIT J CANCER, V70, P697, DOI 10.1038/bjc.1994.376; Brooks JD, 1996, CANCER RES, V56, P3814; Cairns P, 1997, CANCER RES, V57, P5356; CARTER BS, 1990, P NATL ACAD SCI USA, V87, P8751, DOI 10.1073/pnas.87.22.8751; CHENEVIXTRENCH G, 1992, ONCOGENE, V7, P1059; CHO KR, 1994, GENOMICS, V19, P525, DOI 10.1006/geno.1994.1102; CLIBY W, 1993, CANCER RES, V53, P2393; Collins A, 1996, P NATL ACAD SCI USA, V93, P14771, DOI 10.1073/pnas.93.25.14771; Cooney KA, 1996, CANCER RES, V56, P1142; CROPP CS, 1990, P NATL ACAD SCI USA, V87, P7737, DOI 10.1073/pnas.87.19.7737; Crundwell MC, 1996, INT J CANCER, V69, P295, DOI 10.1002/(SICI)1097-0215(19960822)69:4<295::AID-IJC10>3.3.CO;2-#; Cunningham JM, 1996, CANCER RES, V56, P4475; DEGEORGES A, 1995, INT J CANCER, V62, P724, DOI 10.1002/ijc.2910620613; DEVILEE P, 1991, ONCOGENE, V6, P311; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; GAO X, 1995, CANCER RES, V55, P1002; GAO X, 1993, CANCER RES, V53, P2723; Gleason DF, 1977, UROLOGIC PATHOLOGY P, P171; Goggins M, 1998, CANCER RES, V58, P5329; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hahn SA, 1998, CANCER RES, V58, P1124; HAHN SA, 1995, CANCER RES, V55, P4670; HEDRICK L, 1994, GENE DEV, V8, P1174, DOI 10.1101/gad.8.10.1174; HUANG Y, 1992, CANCER RES, V52, P6525; Ittmann M, 1996, CANCER RES, V56, P2143; Jenkins R, 1998, GENE CHROMOSOME CANC, V21, P131, DOI 10.1002/(SICI)1098-2264(199802)21:2<131::AID-GCC9>3.0.CO;2-1; KAGAN J, 1995, ONCOGENE, V11, P2121; Kim SK, 1996, CANCER RES, V56, P2519; Kong XT, 1997, CANCER RES, V57, P3772; KUNIMI K, 1991, GENOMICS, V11, P530, DOI 10.1016/0888-7543(91)90059-N; Latil A, 1999, PROSTATE, V40, P225, DOI 10.1002/(SICI)1097-0045(19990901)40:4<225::AID-PROS3>3.0.CO;2-3; LATIL A, 1994, GENE CHROMOSOME CANC, V11, P119, DOI 10.1002/gcc.2870110208; Li CD, 1998, ONCOGENE, V16, P481, DOI 10.1038/sj.onc.1201554; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; MACGROGAN D, 1994, GENE CHROMOSOME CANC, V10, P151, DOI 10.1002/gcc.2870100302; MacGrogan D, 1997, ONCOGENE, V15, P1111, DOI 10.1038/sj.onc.1201232; MACOSKA JA, 1995, CANCER RES, V55, P5390; Melamed J, 1997, CLIN CANCER RES, V3, P1867; Mottaz AE, 1997, PROSTATE, V31, P209; Nagatake M, 1996, CANCER RES, V56, P2718; NAVONE NM, 1993, J NATL CANCER I, V85, P1657, DOI 10.1093/jnci/85.20.1657; Raff T, 1997, BIOTECHNIQUES, V23, P456, DOI 10.2144/97233st02; REALE MA, 1994, CANCER RES, V54, P4493; Riggins GJ, 1996, NAT GENET, V13, P347, DOI 10.1038/ng0796-347; Salem CE, 1997, J UROLOGY, V158, P510, DOI 10.1016/S0022-5347(01)64520-8; Schutte M, 1996, CANCER RES, V56, P2527; SHIBAGAKI L, 1994, CANCER RES, V54, P2995; SHISEKI M, 1994, CANCER RES, V54, P5643; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; SUZUKI H, 1995, GENE CHROMOSOME CANC, V13, P168, DOI 10.1002/gcc.2870130306; TAKITA J, 1995, ONCOGENE, V11, P1829; Teng DHF, 1997, CANCER RES, V57, P5221; Thiagalingam S, 1996, NAT GENET, V13, P343, DOI 10.1038/ng0796-343; TRAPMAN J, 1994, CANCER RES, V54, P6061; Uchida K, 1996, CANCER RES, V56, P5583; UCHINO S, 1992, CANCER RES, V52, P3099; Ueda T, 1997, GENE CHROMOSOME CANC, V20, P140, DOI 10.1002/(SICI)1098-2264(199710)20:2<140::AID-GCC4>3.0.CO;2-3; VISAKORPI T, 1995, CANCER RES, V55, P342; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; Yin ZN, 1999, ONCOGENE, V18, P7576, DOI 10.1038/sj.onc.1203203; ZAR JH, 1991, BIOSTATISTICAL ANAL; ZENKLUSEN JC, 1994, CANCER RES, V54, P6370; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	70	21	23	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 26	2001	20	18					2273	2280		10.1038/sj.onc.1204310	http://dx.doi.org/10.1038/sj.onc.1204310			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	427KZ	11402322				2022-12-25	WOS:000168404500009
J	Clark, KD; Volkman, BF; Thoetkiattikul, H; Hayakawa, Y; Strand, MR				Clark, KD; Volkman, BF; Thoetkiattikul, H; Hayakawa, Y; Strand, MR			N-terminal residues of plasmatocyte-spreading peptide possess specific determinants required for biological activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOTH PSEUDOPLUSIA-INCLUDENS; HEMOCYTES; HEMOLYMPH; IMMUNITY	Plasmatocyte-spreading peptide (PSP) is a 23-amino acid cytokine that activates a class of insect immune cells called plasmatocytes. The tertiary structure of PSP consists of an unstructured N terminus (residues 1-6) and a well structured core (residues 7-23). A prior study indicated that deletion of the N terminus from PSP eliminated all biological activity. Alanine substitution of the first three residues (Glu(1)-Asn(2)-Phe(3)) further indicated that only replacement of Phe(3) resulted in a loss of activity equal to the N-terminal deletion mutant. Here, we characterized structural determinants of the N terminus. Adding a hydroxyl group to the aromatic ring of Phe(3) (making a Tyr) greatly reduced activity, whereas the addition of a fluorine (p-fluoro) did not. Substitutions that changed the chirality or replaced the aromatic ring of Phe(3) with a branched aliphatic chain (making a Val) also greatly decreased activity. The addition of a methylene group to Val (making a Leu) partially restored activity, whereas the removal of a methylene group from Phe (phenyl-Gly) eliminated all activity. These results indicated that a branched carbon chain with a methylene spacer at the third residue is the minimal structural motif required for activity. The deletion of Glu(1) also eliminated activity. Additional experiments identified the charged N-terminal amine and backbone of Glu(1) as key determinants for activity.	Univ Wisconsin, Dept Entomol, Russell Labs 237, Madison, WI 53706 USA; Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA; Hokkaido Univ, Inst Low Temp Sci, Biochem Lab, Sapporo, Hokkaido 0600819, Japan	University of Wisconsin System; University of Wisconsin Madison; Medical College of Wisconsin; Hokkaido University	Strand, MR (corresponding author), Univ Wisconsin, Dept Entomol, Russell Labs 237, Madison, WI 53706 USA.		Volkman, Brian F./ABE-7312-2020; Clark, Kevin/GQA-9811-2022; Volkman, Brian F./ABE-7306-2020	Volkman, Brian F./0000-0002-6681-5179; Volkman, Brian F./0000-0002-6681-5179	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032917] Funding Source: NIH RePORTER; NIAID NIH HHS [AI32917] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Clark KD, 1997, J BIOL CHEM, V272, P23440, DOI 10.1074/jbc.272.37.23440; Clark KD, 1998, BIOCHEM BIOPH RES CO, V250, P479, DOI 10.1006/bbrc.1998.9145; Clark KD, 2001, J BIOL CHEM, V276, P18491, DOI 10.1074/jbc.M100579200; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Gardiner EMM, 1999, J INSECT PHYSIOL, V45, P113, DOI 10.1016/S0022-1910(98)00092-4; Gillespie JP, 1997, ANNU REV ENTOMOL, V42, P611, DOI 10.1146/annurev.ento.42.1.611; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; KING DS, 1990, INT J PEPT PROT RES, V36, P255; Pech LL, 1996, J CELL SCI, V109, P2053; PECH LL, 1994, CELL TISSUE RES, V277, P159, DOI 10.1007/BF00303092; SCARBOROUGH RM, 1992, J BIOL CHEM, V267, P13146; STRAND MR, 1995, ANNU REV ENTOMOL, V40, P31, DOI 10.1146/annurev.en.40.010195.000335; Strand MR, 2000, J INSECT PHYSIOL, V46, P817, DOI 10.1016/S0022-1910(99)00171-7; STRAND MR, 1990, ANN ENTOMOL SOC AM, V83, P538, DOI 10.1093/aesa/83.3.538; Volkman BF, 1999, J BIOL CHEM, V274, P4493, DOI 10.1074/jbc.274.8.4493; Wang Y, 1999, INSECT BIOCHEM MOLEC, V29, P1075, DOI 10.1016/S0965-1748(99)00086-7	16	25	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	2001	276	40					37431	37435		10.1074/jbc.M105235200	http://dx.doi.org/10.1074/jbc.M105235200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478YD	11432871	hybrid			2022-12-25	WOS:000171375700076
J	Wang, LJ; Gout, I; Proud, CG				Wang, LJ; Gout, I; Proud, CG			Cross-talk between the ERK and p70 S6 kinase (S6K) signaling pathways - MEK-dependent activation of S6K2 in cardiomyocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA TRANSLATION; PROTEIN-KINASE; CARDIAC MYOCYTES; INSULIN; RAPAMYCIN; STIMULATION; INHIBITION; PHOSPHORYLATION; MECHANISM; AKT	The alpha (1)-adrenergic agonist phenylephrine (PE) and insulin each stimulate protein synthesis in cardiomyocytes. Activation of protein synthesis by PE is involved in the development of cardiac hypertrophy. One component involved here is p70 S6 kinase 1 (S6K1), which lies downstream of mammalian target of rapamycin, whose regulation is thought to involve phosphatidylinositol 3-kinase and protein kinase B (PKB). S6K2 is a recently identified homolog of S6K1 whose regulation is poorly understood. Here we demonstrate that in adult rat ventricular cardiomyocytes, PE and insulin each activate S6K2, activation being 3.5- and 5-fold above basal, respectively. Rapamycin completely blocked S6K2 activation by either PE or insulin. Three different inhibitors of MEK1/2 abolished PE-induced activation of S6K2 whereas expression of constitutively active MEK1 activated S6K2, without affecting the p38 mitogen-activated protein kinase and JNK pathways, indicating that MEK/ERK signaling plays a key role in regulation of S6K2 by PE. PE did not activate PKB, and expression of dominant negative PKB failed to block activation of S6K2 by PE, indicating PE-induced S6K2 activation is independent of PKB. However, this PKB mutant did partially block S6K2 activation by insulin, indicating PKB is required here. Another hypertrophic agent, endothelin 1, also activated S6K2 in a MEK-dependent manner. Our findings provide strong evidence for novel signaling connections between MEK/ERK and S6K2.	Univ Dundee, Sch Life Sci, Div Mol Physiol, Dundee DD1 5EH, Scotland; UCL Royal Free & Univ Coll, Sch Med, Ludwig Inst Canc Res, Cell Regulat Lab, London W1W 7BS, England	University of Dundee; Ludwig Institute for Cancer Research; University of London; University College London; UCL Medical School	Proud, CG (corresponding author), Univ Dundee, Sch Life Sci, Div Mol Physiol, Dow St, Dundee DD1 5EH, Scotland.	c.g.proud@dundee.ac.uk	Wang, Lijun/A-5573-2013	Proud, Christopher/0000-0003-0704-6442				Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; BALLOU LM, 1991, NATURE, V349, P348, DOI 10.1038/349348a0; Bogoyevitch MA, 1996, BIOCHEM J, V314, P115, DOI 10.1042/bj3140115; BOGOYEVITCH MA, 1995, J BIOL CHEM, V270, P29710; BOGOYEVITCH MA, 1994, J BIOL CHEM, V269, P1110; Boluyt MO, 1997, CIRC RES, V81, P176, DOI 10.1161/01.RES.81.2.176; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; Conus NM, 1998, J BIOL CHEM, V273, P4776, DOI 10.1074/jbc.273.8.4776; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; FULLER SJ, 1990, BIOCHEM J, V266, P727, DOI 10.1042/bj2660727; Fumagalli S, 2000, COLD SPRING HARBOR M, V39, P695; Glennon PE, 1996, CIRC RES, V78, P954, DOI 10.1161/01.RES.78.6.954; Gout I, 1998, J BIOL CHEM, V273, P30061, DOI 10.1074/jbc.273.46.30061; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; Kamakura S, 1999, J BIOL CHEM, V274, P26563, DOI 10.1074/jbc.274.37.26563; Kitamura T, 1998, MOL CELL BIOL, V18, P3708, DOI 10.1128/MCB.18.7.3708; Koh H, 1999, ONCOGENE, V18, P5115, DOI 10.1038/sj.onc.1202895; Kotani K, 1999, J BIOL CHEM, V274, P21305, DOI 10.1074/jbc.274.30.21305; Lali FV, 2000, J BIOL CHEM, V275, P7395, DOI 10.1074/jbc.275.10.7395; Lee-Fruman KK, 1999, ONCOGENE, V18, P5108, DOI 10.1038/sj.onc.1202894; Martin KA, 2001, J BIOL CHEM, V276, P7884, DOI 10.1074/jbc.M006969200; Martin KA, 2001, J BIOL CHEM, V276, P7892, DOI 10.1074/jbc.M009972200; Miyazaki T, 2000, J CELL BIOL, V148, P333, DOI 10.1083/jcb.148.2.333; MOULE SK, 1995, BIOCHEM J, V311, P595, DOI 10.1042/bj3110595; MUKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649; SHUBEITA HE, 1990, J BIOL CHEM, V265, P20555; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; TERADA N, 1994, P NATL ACAD SCI USA, V91, P11477, DOI 10.1073/pnas.91.24.11477; Wang LJ, 2000, AM J PHYSIOL-HEART C, V278, pH1056, DOI 10.1152/ajpheart.2000.278.4.H1056; WENG QP, 1995, MOL CELL BIOL, V15, P2333; Yue TL, 2000, J BIOL CHEM, V275, P37895, DOI 10.1074/jbc.M007037200	42	110	113	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					32670	32677		10.1074/jbc.M102776200	http://dx.doi.org/10.1074/jbc.M102776200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11431469	hybrid			2022-12-25	WOS:000170746000040
J	Bengtson, P; Larson, C; Lundblad, A; Larson, G; Pahlsson, P				Bengtson, P; Larson, C; Lundblad, A; Larson, G; Pahlsson, P			Identification of a missense mutation (G329A; Arg(110) -> Gln) in the human FUT7 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA(1,3)FUCOSYLTRANSFERASE FUC-TVII; LEUKOCYTE ADHESION DEFICIENCY; FUCOSYL-TRANSFERASE GENE; HIGH ENDOTHELIAL VENULES; E-SELECTIN LIGAND-1; BLOOD-GROUP SYSTEM; MOLECULAR-CLONING; LEWIS-X; ALPHA(1,3)-FUCOSYL-TRANSFERASE GENE; P-SELECTIN	The human FUT7 gene codes for the alpha1,3-fucosyltransferase VII (Fue-TVII), which is involved in the biosynthesis of the sialyl Lewis x (SLe(X)) epitope on human leukocytes. The FUT7 gene has so far been considered to be monomorphic. Neutrophils isolated from patients with ulcerative colitis were examined for apparent alterations in protein glycosylation patterns by Western blot analysis using monoclonal antibodies directed against SLe(X) and SLe(X)-related epitopes. One individual showed lower levels of SLe(X) expression and an elevated expression of CD65s compared to controls. The coding regions of the FUT7 gene from this individual were cloned, and a G329A point mutation (Arg(110) --> Gln) was found in one allele, whereas the other FUT7 allele was wild type. No Fuc-TVII enzyme activity was detected in COS-7 cells transiently transfected with the mutated FUT7 construct. The FUT7 Arg(110) is conserved in all previously cloned vertebrate alpha1,3-fucosyltransferases. Polymerase chain reaction followed by restriction enzyme cleavage was used to screen 364 unselected Caucasians for the G329A mutation, and a frequency of less than or equal to1% for this mutation was found (3 heterozygotes). Genetic characterization of the family members of one of the additional heterozygotes identified one individual carrying the G329A mutation in both FUT7 alleles. Peripheral blood neutrophils of this homozygously mutated individual showed a lowered expression of SLe(X) and an elevated expression of CD65s when analyzed by Western blot and flow cytometry. The homozygous individual was diagnosed with ulcer disease, non-insulin-dependent diabetes, osteoporosis, spondyloarthrosis, and Sjogren's syndrome but had no history of recurrent bacterial infections or leukocytosis.	Sahlgrens Univ Hosp, Dept Clin Chem & Transfus Med, Inst Lab Med, SE-41345 Gothenburg, Sweden; Linkoping Univ, Dept Biomed & Surg, Div Clin Chem, SE-58185 Linkoping, Sweden	Sahlgrenska University Hospital; Linkoping University	Larson, G (corresponding author), Sahlgrens Univ Hosp, Dept Clin Chem & Transfus Med, Inst Lab Med, SE-41345 Gothenburg, Sweden.		Larson, Göran/AAF-3404-2019					Britten CJ, 1998, GLYCOBIOLOGY, V8, P321, DOI 10.1093/glycob/8.4.321; Clarke JL, 1997, GLYCOBIOLOGY, V7, P835, DOI 10.1093/glycob/7.6.835; Costache M, 1997, J BIOL CHEM, V272, P29721, DOI 10.1074/jbc.272.47.29721; DAVIS LG, 1986, BASIC METHODS MOL BI, P290; DOHI T, 1993, ANTICANCER RES, V13, P1277; Dupuy F, 1999, J BIOL CHEM, V274, P12257, DOI 10.1074/jbc.274.18.12257; Elmgren A, 2000, HUM MUTAT, V16, P473, DOI 10.1002/1098-1004(200012)16:6<473::AID-HUMU4>3.0.CO;2-T; Elmgren A, 1997, J BIOL CHEM, V272, P21994, DOI 10.1074/jbc.272.35.21994; ETZIONI A, 1992, NEW ENGL J MED, V327, P1789, DOI 10.1056/NEJM199212173272505; FOXALL C, 1992, J CELL BIOL, V117, P895, DOI 10.1083/jcb.117.4.895; Frenette PS, 1996, CELL, V84, P563, DOI 10.1016/S0092-8674(00)81032-6; GOELZ S, 1994, J BIOL CHEM, V269, P1033; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; Grabenhorst E, 1998, J BIOL CHEM, V273, P30985, DOI 10.1074/jbc.273.47.30985; Handa K, 1997, BIOCHEMISTRY-US, V36, P12412, DOI 10.1021/bi971181t; Handa K, 1998, BIOCHEM BIOPH RES CO, V243, P199, DOI 10.1006/bbrc.1998.8080; Hiraiwa N, 1996, J BIOL CHEM, V271, P31556, DOI 10.1074/jbc.271.49.31556; HOLMES EH, 1986, J BIOL CHEM, V261, P3737; Huang MC, 2000, J BIOL CHEM, V275, P31353, DOI 10.1074/jbc.M005449200; Kageyama N, 1999, J BIOCHEM-TOKYO, V125, P838, DOI 10.1093/oxfordjournals.jbchem.a022357; Kaneko M, 1999, FEBS LETT, V452, P237, DOI 10.1016/S0014-5793(99)00640-7; Kansas GS, 1996, BLOOD, V88, P3259, DOI 10.1182/blood.V88.9.3259.bloodjournal8893259; Knibbs RN, 1996, J CELL BIOL, V133, P911, DOI 10.1083/jcb.133.4.911; KUMAR R, 1991, J BIOL CHEM, V266, P21777; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Larson G, 1996, VOX SANG, V71, P233, DOI 10.1046/j.1423-0410.1996.7140233.x; Larson G, 1999, VOX SANG, V77, P227, DOI 10.1046/j.1423-0410.1999.7740227.x; LASKY LA, 1995, ANNU REV BIOCHEM, V64, P113, DOI 10.1146/annurev.bi.64.070195.000553; LOWE JB, 1991, J BIOL CHEM, V266, P17467; Luhn K, 2001, NAT GENET, V28, P69, DOI 10.1038/ng0501-69; Maly P, 1996, CELL, V86, P643, DOI 10.1016/S0092-8674(00)80137-3; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MOLLICONE R, 1994, J BIOL CHEM, V269, P20987; MOLLICONE R, 1994, J BIOL CHEM, V269, P12662; MOLLICONE R, 1990, EUR J BIOCHEM, V191, P169, DOI 10.1111/j.1432-1033.1990.tb19107.x; NATSUKA S, 1994, J BIOL CHEM, V269, P16789; Niemela R, 1998, J BIOL CHEM, V273, P4021, DOI 10.1074/jbc.273.7.4021; NISHIHARA S, 1994, J BIOL CHEM, V269, P29271; Nishihara S, 1999, GLYCOBIOLOGY, V9, P373, DOI 10.1093/glycob/9.4.373; Pang H, 1998, HUM GENET, V102, P675, DOI 10.1007/s004390050760; Pang H, 1999, ANN HUM GENET, V63, P277, DOI 10.1046/j.1469-1809.1999.6340277.x; Phillips ML, 1995, J CLIN INVEST, V96, P2898, DOI 10.1172/JCI118361; SASAKI K, 1994, J BIOL CHEM, V269, P14730; Shinoda K, 1997, J BIOL CHEM, V272, P31992, DOI 10.1074/jbc.272.51.31992; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Smith PL, 1996, J BIOL CHEM, V271, P8250, DOI 10.1074/jbc.271.14.8250; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Swarte VVR, 1998, EUR J IMMUNOL, V28, P3040, DOI 10.1002/(SICI)1521-4141(199810)28:10<3040::AID-IMMU3040>3.0.CO;2-5; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VARKI A, 1994, P NATL ACAD SCI USA, V91, P7390, DOI 10.1073/pnas.91.16.7390; Wagers AJ, 1997, J IMMUNOL, V159, P1917; Wagers AJ, 1996, BLOOD, V88, P2125, DOI 10.1182/blood.V88.6.2125.bloodjournal8862125; Weninger W, 2000, IMMUNITY, V12, P665, DOI 10.1016/S1074-7613(00)80217-4; Weston BW, 1999, EUR J HAEMATOL, V63, P42; WINDER A, 1995, BIOCHEM SOC T, V23, pS165, DOI 10.1042/bst023165s; Zollner O, 1996, J BIOL CHEM, V271, P33002, DOI 10.1074/jbc.271.51.33002	57	20	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					31575	31582		10.1074/jbc.M104165200	http://dx.doi.org/10.1074/jbc.M104165200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11404359	hybrid			2022-12-25	WOS:000170613500016
J	Canete-Soler, R; Wu, JH; Zhai, JB; Shamim, M; Schlaepfer, WW				Canete-Soler, R; Wu, JH; Zhai, JB; Shamim, M; Schlaepfer, WW			P190RhoGEF binds to a destabilizing element in the 3 ' untranslated region of light neurofilament subunit mRNA and alters the stability of the transcript	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; POSTNATAL-DEVELOPMENT; UP-REGULATION; PROTEINS; EXPRESSION; CALIBER; SYSTEM; HEAVY; GENE	Stabilization of neurofilament (NF) mRNAs plays a major role in regulating levels of NF expression and in establishing axonal size and rate of axonal conduction. Previous studies have identified a 68-nucleotide destabilizing element at the junction of the coding region and 3 ' untranslated region of the light NF subunit (NF-L) mRNA. The present study has used the destabilizing element (probe A) to screen a rat brain cDNA library for interactive proteins. A cDNA clone encoding 1068 nucleotides in the C-terminal domain of p190RhoGEF (clone 39) was found to bind strongly and specifically to the RNA probe. The interaction was confirmed using a glutathione S-transferase/clone 39 fusion protein in Northwestern, gel-shift, and cross-linkage studies. The glutathione S-transferase/clone 39 fusion protein also enhanced the cross-linkage of a major 43-kDa protein in brain extract to the destabilizing element. Functional studies on stably transfected neuronal cells showed that p190RhoGEF expression increased the half-life of a wild-type NF-L mRNA but did not alter the half-life of a mutant NF-L mRNA lacking the destabilizing element. The findings reveal a novel interactive feature of p190PhoGEF that Un the exchange factor with NF mRNA stability and regulation of the axonal cytoskeleton.	Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Canete-Soler, R (corresponding author), Univ Penn, Sch Med, Dept Pathol & Lab Med, 608 Stellar Chance Labs, Philadelphia, PA 19104 USA.	racansol@mail.med.upenn.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS015722] Funding Source: NIH RePORTER; NINDS NIH HHS [NS15722] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Antic D, 1999, GENE DEV, V13, P449, DOI 10.1101/gad.13.4.449; BEAUDET L, 1993, MOL BRAIN RES, V18, P23, DOI 10.1016/0169-328X(93)90170-T; Canete-Soler R, 1998, J BIOL CHEM, V273, P12655, DOI 10.1074/jbc.273.20.12655; Canete-Soler R, 1999, J NEUROSCI, V19, P1273; Canete-Soler R, 2000, BRAIN RES, V867, P265, DOI 10.1016/S0006-8993(00)02389-1; CANETESOLER R, 1998, J BIOL CHEM, V273, P12550; Cusack Stephen, 1999, Current Opinion in Structural Biology, V9, P66; Ford LP, 1999, GENE DEV, V13, P188, DOI 10.1101/gad.13.2.188; Gao M, 2001, EMBO J, V20, P1134, DOI 10.1093/emboj/20.5.1134; Gebbink MFBG, 1997, J CELL BIOL, V137, P1603, DOI 10.1083/jcb.137.7.1603; GOLDSTEIN ME, 1988, MOL BRAIN RES, V3, P287, DOI 10.1016/0169-328X(88)90051-4; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HOFFMAN PN, 1987, P NATL ACAD SCI USA, V84, P3472, DOI 10.1073/pnas.84.10.3472; Meyer D, 1999, J BIOL CHEM, V274, P35113, DOI 10.1074/jbc.274.49.35113; SCHLAEPFER WW, 1990, J NEUROSCI RES, V25, P39, DOI 10.1002/jnr.490250106; SCHWARTZ ML, 1992, J BIOL CHEM, V267, P24596; SCHWARTZ ML, 1990, J NEUROSCI RES, V27, P193, DOI 10.1002/jnr.490270209; SCHWARTZ ML, 1995, J BIOL CHEM, V270, P26364, DOI 10.1074/jbc.270.44.26364; SCHWARTZ ML, 1994, MOL BRAIN RES, V27, P215, DOI 10.1016/0169-328X(94)90003-5; Smith CA, 2000, MOL CELL, V6, P1067, DOI 10.1016/S1097-2765(00)00105-2; SMITH CWJ, 1998, RNA PROTEIN INTERACT, P183; Turnage MA, 2000, MOL CELL BIOL, V20, P8198, DOI 10.1128/MCB.20.21.8198-8208.2000; van Horck FPG, 2001, J BIOL CHEM, V276, P4948, DOI 10.1074/jbc.M003839200; VOYVODIC JT, 1989, NATURE, V342, P430, DOI 10.1038/342430a0; Weiss MA, 1998, BIOPOLYMERS, V48, P167, DOI 10.1002/(SICI)1097-0282(1998)48:2<167::AID-BIP6>3.0.CO;2-8; Westhof E, 1999, CURR OPIN STRUC BIOL, V9, P293, DOI 10.1016/S0959-440X(99)80039-6; Wilusz CJ, 2001, NAT REV MOL CELL BIO, V2, P237, DOI 10.1038/35067025	27	47	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					32046	32050		10.1074/jbc.M104104200	http://dx.doi.org/10.1074/jbc.M104104200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11435431	hybrid			2022-12-25	WOS:000170613500079
J	Fonseca, MV; Escalante-Semerena, JC				Fonseca, MV; Escalante-Semerena, JC			An in vitro reducing system for the enzymic conversion of cobalamin to adenosylcobalamin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT METHIONINE SYNTHASE; ATP-CORRINOID ADENOSYLTRANSFERASE; SALMONELLA-TYPHIMURIUM; ESCHERICHIA-COLI; PSEUDOMONAS-DENITRIFICANS; ANGSTROM RESOLUTION; FLAVODOXIN; ACTIVATION; COENZYME; VITAMIN-B-12	Homogeneous ferredoxin (flavodoxin):NADP(+) reductase and flavodoxin A proteins served as electron donors for the reduction of co(III)rrinoids to co(I)rrinoids in vitro. The resulting co(I)rrinoids served as substrates for the ATP: co(I)rrinoid adenosyltransferase (CobA) enzyme of Salmonella enterica serovar Typhimurium LT2 and were converted to their respective adenosylated derivatives. The reaction products were isolated by reverse phase high performance liquid chromatography, and their identities were confirmed by UV-visible spectroscopy, mass spectrometry, and in vivo biological activity assays. Adenosylcobalamin generated by this system supported the activity of 1,2-propanediol dehydratase as effectively as authentic adenosylcobalamin. This is the first report of a protein system that can be coupled to the adenosyltransferase CobA enzyme for the conversion of co(III)rrinoids to their adenosylated derivatives.	Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Escalante-Semerena, JC (corresponding author), Univ Wisconsin, Dept Bacteriol, 1550 Linden Dr, Madison, WI 53706 USA.		Fernández, Ester/K-9734-2014		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040313, R37GM040313] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM040313, GM17528, GM40313] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BANERJEE RV, 1990, BIOCHEMISTRY-US, V29, P1129, DOI 10.1021/bi00457a005; BATTERSBY AR, 1994, SCIENCE, V264, P1551, DOI 10.1126/science.8202709; Bauer CB, 2001, BIOCHEMISTRY-US, V40, P361, DOI 10.1021/bi002145o; BLANCHE F, 1995, ANGEW CHEM INT EDIT, V34, P383, DOI 10.1002/anie.199503831; BLANCHE F, 1992, J BACTERIOL, V174, P7452, DOI 10.1128/jb.174.22.7452-7454.1992; BRADY RO, 1962, J BIOL CHEM, V223, P2325; Braford MM, 1976, ANAL BIOCHEM, V72, P248; DEBUSSCHE L, 1991, J BACTERIOL, V173, P6300, DOI 10.1128/jb.173.19.6300-6302.1991; DRENNAN CL, 1994, SCIENCE, V266, P1660; ESCALANTESEMERENA JC, 1990, J BACTERIOL, V172, P273, DOI 10.1128/JB.172.1.273-280.1990; Fonseca MV, 2000, J BACTERIOL, V182, P4304, DOI 10.1128/JB.182.15.4304-4309.2000; FUJII K, 1977, ARCH BIOCHEM BIOPHYS, V178, P662, DOI 10.1016/0003-9861(77)90238-7; FUJII K, 1974, J BIOL CHEM, V249, P6745; Gaudu P, 2000, J BACTERIOL, V182, P1788, DOI 10.1128/JB.182.7.1788-1793.2000; Hall DA, 2000, BIOCHEMISTRY-US, V39, P10711, DOI 10.1021/bi001096c; Hogenkamp H. P. C., 1975, COBALAMIN BIOCH PATH, P21; Hoover DM, 1997, PROTEIN SCI, V6, P2525; Hoover DM, 1997, BIOCHEMISTRY-US, V36, P127, DOI 10.1021/bi961693s; Jarrett JT, 1998, BIOCHEMISTRY-US, V37, P5372, DOI 10.1021/bi9730893; Jarrett JT, 1998, BIOCHEMISTRY-US, V37, P12649, DOI 10.1021/bi9808565; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE JG, 1995, J BACTERIOL, V177, P6371, DOI 10.1128/jb.177.22.6371-6380.1995; LEXA D, 1983, ACCOUNTS CHEM RES, V16, P235, DOI 10.1021/ar00091a001; Mancia F, 1996, STRUCTURE, V4, P339, DOI 10.1016/S0969-2126(96)00037-8; Mulliez E, 2001, BIOCHEMISTRY-US, V40, P3730, DOI 10.1021/bi001746c; OTOOLE GA, 1993, J BACTERIOL, V175, P3317, DOI 10.1128/jb.175.11.3317-3326.1993; Raux E, 1997, J BACTERIOL, V179, P3202, DOI 10.1128/jb.179.10.3202-3212.1997; Reitzer R, 1999, STRUCTURE, V7, P891, DOI 10.1016/S0969-2126(99)80116-6; Rondon MR, 1997, PROG NUCLEIC ACID RE, V56, P347, DOI 10.1016/S0079-6603(08)61010-7; Santander PJ, 1997, CHEM BIOL, V4, P659, DOI 10.1016/S1074-5521(97)90221-0; SASSE J, 1991, CURRENT PROTOCOLS MO, V1, DOI DOI 10.6.1-10.6.8; SCHRAUZER GN, 1968, J AM CHEM SOC, V90, P2441, DOI 10.1021/ja01011a054; Shibata N, 1999, STRUCTURE, V7, P997, DOI 10.1016/S0969-2126(99)80126-9; SUH SJ, 1995, J BACTERIOL, V177, P921, DOI 10.1128/jb.177.4.921-925.1995; SUH SJ, 1993, GENE, V129, P93, DOI 10.1016/0378-1119(93)90701-4; Thomas MG, 2000, J BACTERIOL, V182, P4227, DOI 10.1128/JB.182.15.4227-4233.2000; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TORAYA T, 1977, J BIOL CHEM, V252, P963; VERVOORT J, 1985, EUR J BIOCHEM, V151, P49, DOI 10.1111/j.1432-1033.1985.tb09067.x; VETTER H, 1971, H-S Z PHYSIOL CHEM, V352, P433, DOI 10.1515/bchm2.1971.352.1.433; VITOLS E, 1966, J BIOL CHEM, V241, P1455; VOGEL HJ, 1956, J BIOL CHEM, V218, P97; WALKER GA, 1969, ARCH BIOCHEM BIOPHYS, V134, P95, DOI 10.1016/0003-9861(69)90255-0	44	70	73	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					32101	32108		10.1074/jbc.M102510200	http://dx.doi.org/10.1074/jbc.M102510200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11408479	hybrid			2022-12-25	WOS:000170613500086
J	Kanke, T; Macfarlane, SR; Seatter, MJ; Davenport, E; Paul, A; McKenzie, RC; Plevin, R				Kanke, T; Macfarlane, SR; Seatter, MJ; Davenport, E; Paul, A; McKenzie, RC; Plevin, R			Proteinase-activated receptor-2-mediated activation of stress-activated protein kinases and inhibitory kappa B kinases in NCTC 2544 keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INVOLUCRIN PROMOTER ACTIVITY; THROMBIN RECEPTOR; MOLECULAR-CLONING; GENE-EXPRESSION; IKK-ALPHA; INDEPENDENT ACTIVATION; SIGNAL-TRANSDUCTION; TERMINAL KINASE; ERK KINASE; BETA	In this study we examined the regulation of the stress-activated protein (SAP) kinases and inhibitory KB kinases (IKKs) through stimulation of the novel G-protein-coupled receptor proteinase-activated receptor-2 in the human keratinocyte cell line NCTC2544. Trypsin and the peptide SLIGKV stimulated a time-dependent increase in both c-Jun N-terminal kinase and p38 mitogen-activated protein kinase activity. Trypsin also stimulated NF kappaB-DNA binding and the activation of the upstream kinases IKK alpha and -beta. Phorbol 12-myristate 13-acetate also strongly activated both SAP kinases and = isoforms, suggesting the potential for a protein kinase C-mediated regulatory mechanism underlying the effects of trypsin. Pre-incubation with selective protein kinase C (PKC) inhibitors GF109203X and Go6983, or transfection of dominant negative (DN)-PKC alpha, abolished phorbol 12-myristate 13-acetate-mediated c-Jun N-terminal kinase activity, although it only partially inhibited the response to trypsin. In contrast, Go6983 reduced trypsin-stimulated p38 mitogen-activated protein kinase activity to a greater extent than GF109203X, although DN-PKC alpha or PKC zeta had no substantial effect. Additionally, inhibitors of PKC zeta partially reduced trypsin-stimulated IKK alpha activity but abolished that of IKK beta, whereas DN-PKC zeta but not DN-PKC zeta substantially reduced trypsin-stimulated Flag-IKK beta activity. This study shows for the first time proteinase-activated receptor-2-mediated stimulation of both SAP kinase and = signaling and differing roles for PKC isoforms in the regulation of each pathway.	Univ Strathclyde, Dept Physiol & Pharmacol, Inst Biomed Sci, Glasgow G4 0NR, Lanark, Scotland; Univ Edinburgh, Royal Infirm, Dept Dermatol, Edinburgh EH3 9YW, Midlothian, Scotland	University of Strathclyde; Royal Infirmary of Edinburgh; University of Edinburgh	Plevin, R (corresponding author), Univ Strathclyde, Dept Physiol & Pharmacol, Inst Biomed Sci, 27 Taylor St, Glasgow G4 0NR, Lanark, Scotland.	r.plevin@strath.ac.uk		Paul, Andrew/0000-0001-5775-2332; Plevin, Robin/0000-0002-7849-1220				Alexandrov A, 1999, BIOCHEM BIOPH RES CO, V261, P372, DOI 10.1006/bbrc.1999.1015; Banks EB, 1999, BIOCHEM J, V337, P507, DOI 10.1042/0264-6021:3370507; Belham CL, 1996, BIOCHEM J, V320, P939, DOI 10.1042/bj3200939; Blank JL, 1996, J BIOL CHEM, V271, P5361, DOI 10.1074/jbc.271.10.5361; Bohm SK, 1996, BIOCHEM J, V314, P1009; Bretschneider E, 1999, BRIT J PHARMACOL, V126, P1735, DOI 10.1038/sj.bjp.0702509; Cocks TM, 1999, NATURE, V398, P156, DOI 10.1038/18223; D'Andrea MR, 1998, J HISTOCHEM CYTOCHEM, V46, P157; DENNING MF, 1995, CELL GROWTH DIFFER, V6, P149; Dery O, 1998, AM J PHYSIOL-CELL PH, V274, pC1429, DOI 10.1152/ajpcell.1998.274.6.C1429; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Efimova T, 1998, J BIOL CHEM, V273, P24387, DOI 10.1074/jbc.273.38.24387; Fox MT, 1997, FEBS LETT, V417, P267, DOI 10.1016/S0014-5793(97)01298-2; Garcia-Paramio P, 1998, BIOCHEM J, V333, P631, DOI 10.1042/bj3330631; Gerwins P, 1997, J BIOL CHEM, V272, P8288, DOI 10.1074/jbc.272.13.8288; Glusa E, 1996, SEMIN THROMB HEMOST, V22, P261, DOI 10.1055/s-2007-999017; Gschwendt M, 1996, FEBS LETT, V392, P77, DOI 10.1016/0014-5793(96)00785-5; Han YQ, 1999, CIRC RES, V84, P695, DOI 10.1161/01.RES.84.6.695; Hofmann J, 1997, FASEB J, V11, P649, DOI 10.1096/fasebj.11.8.9240967; Hoshi S, 2000, J BIOL CHEM, V275, P883, DOI 10.1074/jbc.275.2.883; Hou L, 1998, IMMUNOLOGY, V94, P356, DOI 10.1046/j.1365-2567.1998.00528.x; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Ishihara H, 1997, NATURE, V386, P502, DOI 10.1038/386502a0; KONDO S, 1993, J INVEST DERMATOL, V101, P690, DOI 10.1111/1523-1747.ep12371677; KRAVCHENKO VV, 1995, J BIOL CHEM, V270, P14928, DOI 10.1074/jbc.270.25.14928; Lallena MJ, 1999, MOL CELL BIOL, V19, P2180; Li JD, 1998, P NATL ACAD SCI USA, V95, P5718, DOI 10.1073/pnas.95.10.5718; Li JJ, 1997, CANCER RES, V57, P3569; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Mani I, 1999, J INVEST DERMATOL, V112, P42, DOI 10.1046/j.1523-1747.1999.00480.x; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; Mercurio F, 1999, MOL CELL BIOL, V19, P1526; MURAMATSU I, 1992, CAN J PHYSIOL PHARM, V70, P996, DOI 10.1139/y92-137; Nagao M, 1998, J BIOL CHEM, V273, P22892, DOI 10.1074/jbc.273.36.22892; Nemoto S, 1998, MOL CELL BIOL, V18, P7336, DOI 10.1128/MCB.18.12.7336; NYSTEDT S, 1995, EUR J BIOCHEM, V232, P84, DOI 10.1111/j.1432-1033.1995.tb20784.x; NYSTEDT S, 1994, P NATL ACAD SCI USA, V91, P9208, DOI 10.1073/pnas.91.20.9208; O'Mahony A, 2000, MOL CELL BIOL, V20, P1170, DOI 10.1128/MCB.20.4.1170-1178.2000; Ohba M, 1998, MOL CELL BIOL, V18, P5199, DOI 10.1128/MCB.18.9.5199; Ozes ON, 1999, NATURE, V401, P82; Pan ZXK, 1998, J IMMUNOL, V160, P3038; Paul A, 2000, J BIOL CHEM, V275, P13243, DOI 10.1074/jbc.275.18.13243; PLEVIN R, 1994, BRIT J PHARMACOL, V112, P311, DOI 10.1111/j.1476-5381.1994.tb13070.x; REE K, 1981, ACTA PATH MICRO IM A, V89, P73; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; SANTULLI RJ, 1995, P NATL ACAD SCI USA, V92, P9151, DOI 10.1073/pnas.92.20.9151; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Shimizu H, 1999, J INVEST DERMATOL, V112, P769, DOI 10.1046/j.1523-1747.1999.00582.x; Steinhoff M, 1999, EXP DERMATOL, V8, P282; Takahashi H, 1998, J INVEST DERMATOL, V110, P218, DOI 10.1046/j.1523-1747.1998.00110.x; Tibbles LA, 1999, CELL MOL LIFE SCI, V55, P1230, DOI 10.1007/s000180050369; Tobin D, 1996, ONCOGENE, V12, P785; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; Wakita H, 1997, P ASSOC AM PHYSICIAN, V109, P190; Way KJ, 2000, TRENDS PHARMACOL SCI, V21, P181, DOI 10.1016/S0165-6147(00)01468-1; Wood KM, 1998, ONCOGENE, V16, P2131, DOI 10.1038/sj.onc.1201735; Xie P, 2000, J BIOL CHEM, V275, P24907, DOI 10.1074/jbc.M001051200; Xu WF, 1998, P NATL ACAD SCI USA, V95, P6642, DOI 10.1073/pnas.95.12.6642; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zhao Q, 1999, J BIOL CHEM, V274, P8355, DOI 10.1074/jbc.274.13.8355	65	92	95	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					31657	31666		10.1074/jbc.M100377200	http://dx.doi.org/10.1074/jbc.M100377200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11413129	hybrid			2022-12-25	WOS:000170613500027
J	Rogers, PA; Ding, HG				Rogers, PA; Ding, HG			L-cysteine-mediated destabilization of dinitrosyl iron complexes in proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FE-S CLUSTERS; NITRIC-OXIDE; ESCHERICHIA-COLI; SULFUR PROTEINS; ACTIVATED MACROPHAGES; RESONANCE DETECTION; BIOLOGICAL-SYSTEMS; 2FE-2S FERREDOXIN; ENDONUCLEASE-III; CENTERS	Nitric oxide is a signaling molecule in intercellular communication as well as a powerful weapon used by macrophages to kill tumor cells and pathogenic bacteria. Here, we show that when Escherichia coli cells are exposed to nitric oxide, its ferredoxin [2Fe-2S] cluster is nitrosylated, forming the dinitrosyl iron complex with a characteristic EPR signal at g(av) = 2.04. Such formed ferredoxin dinitrosyl iron complex is efficiently repaired in E. coli cells even in the absence of new protein synthesis. However, the repair activity is completely inactivated once E. coli cells are disrupted, indicating that repairing the ferredoxin dinitrosyl iron complex requires cellular reducing equivalents. In search of such cellular factors, we find that L-cysteine can effectively eliminate the EPR signal of the ferredoxin dinitrosyl iron complex and release the ferrous iron from the complex. In contrast, N-acetyl-L-eysteine and reduced glutathione are much less effective. L-Cysteine seems to have a general function, since it can also remove the otherwise stable dinitrosyl iron complexes from proteins in the cell extracts prepared from the E. coli cells treated with nitric oxide. We propose that L-cysteine is responsible for removing the dinitrosyl iron complexes from the nitric oxide-modified proteins into which a new iron-sulfur cluster will be reassembled.	Louisiana State Univ, Dept Biol Sci, Baton Rouge, LA 70803 USA	Louisiana State University System; Louisiana State University	Ding, HG (corresponding author), Louisiana State Univ, Dept Biol Sci, 508 Life Sci Bldg, Baton Rouge, LA 70803 USA.		Ding, Huangen/AAJ-8550-2020	Ding, Huangen/0000-0002-4815-7336				Agar JN, 2000, BIOCHEMISTRY-US, V39, P7856, DOI 10.1021/bi000931n; Aspinwall R, 1997, P NATL ACAD SCI USA, V94, P109, DOI 10.1073/pnas.94.1.109; Beinert H, 2000, J BIOL INORG CHEM, V5, P2, DOI 10.1007/s007750050002; Beinert H, 1999, CURR OPIN CHEM BIOL, V3, P152, DOI 10.1016/S1367-5931(99)80027-1; Cooper CE, 1999, BBA-BIOENERGETICS, V1411, P290, DOI 10.1016/S0005-2728(99)00021-3; CUNNINGHAM RP, 1989, BIOCHEMISTRY-US, V28, P4450, DOI 10.1021/bi00436a049; Demple B, 1999, BIOCHEM SOC SYMP, P119; Ding HE, 1996, P NATL ACAD SCI USA, V93, P9449, DOI 10.1073/pnas.93.18.9449; Ding HG, 2000, P NATL ACAD SCI USA, V97, P5146, DOI 10.1073/pnas.97.10.5146; Ding HG, 1998, BIOCHEMISTRY-US, V37, P17280, DOI 10.1021/bi980532g; Drapier JC, 1997, METHODS, V11, P319, DOI 10.1006/meth.1996.0426; DRAPIER JC, 1991, J BIOL CHEM, V266, P10162; Foster HW, 1999, J AM CHEM SOC, V121, P4093; GREENBERG JT, 1986, J BACTERIOL, V168, P1026, DOI 10.1128/jb.168.2.1026-1029.1986; HENRY Y, 1991, EUR BIOPHYS J, V20, P1; Hoff KG, 2000, P NATL ACAD SCI USA, V97, P7790, DOI 10.1073/pnas.130201997; Ignarro LJ, 1999, J CARDIOVASC PHARM, V34, P879, DOI 10.1097/00005344-199912000-00016; Jensen LT, 2000, MOL CELL BIOL, V20, P3918, DOI 10.1128/MCB.20.11.3918-3927.2000; Johnson MK, 1998, CURR OPIN CHEM BIOL, V2, P173, DOI 10.1016/S1367-5931(98)80058-6; Jung YS, 1999, J BIOL CHEM, V274, P32402, DOI 10.1074/jbc.274.45.32402; Kennedy MC, 1997, J BIOL CHEM, V272, P20340, DOI 10.1074/jbc.272.33.20340; Keyer K, 1996, P NATL ACAD SCI USA, V93, P13635, DOI 10.1073/pnas.93.24.13635; LANCASTER JR, 1990, P NATL ACAD SCI USA, V87, P1223, DOI 10.1073/pnas.87.3.1223; Lange H, 2000, P NATL ACAD SCI USA, V97, P1050, DOI 10.1073/pnas.97.3.1050; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; Ollagnier S, 1997, J BIOL CHEM, V272, P24216, DOI 10.1074/jbc.272.39.24216; Porello SL, 1998, BIOCHEMISTRY-US, V37, P6465, DOI 10.1021/bi972433t; REDDY D, 1983, SCIENCE, V221, P769, DOI 10.1126/science.6308761; Rouault TA, 1996, TRENDS BIOCHEM SCI, V21, P174, DOI 10.1016/0968-0004(96)10024-4; Schwartz CJ, 2000, P NATL ACAD SCI USA, V97, P9009, DOI 10.1073/pnas.160261497; Sellers VM, 1996, BIOCHEMISTRY-US, V35, P2699, DOI 10.1021/bi952631p; TA DT, 1992, J BIOL CHEM, V267, P11120; Takahashi Y, 1999, J BIOCHEM, V126, P917, DOI 10.1093/oxfordjournals.jbchem.a022535; Vanin A F, 1993, Biokhimiia, V58, P1094; VANIN A F, 1965, Biofizika, V10, P167; Vanin AF, 1998, BIOCHEMISTRY-MOSCOW+, V63, P782; VITHAYTHIL IA, 1965, NATURE, V207, P1246; Welter R, 1996, ARCH BIOCHEM BIOPHYS, V331, P9, DOI 10.1006/abbi.1996.0276; Yuvaniyama P, 2000, P NATL ACAD SCI USA, V97, P599, DOI 10.1073/pnas.97.2.599; ZHENG LM, 1994, J BIOL CHEM, V269, P18723; Zheng LM, 1998, J BIOL CHEM, V273, P13264, DOI 10.1074/jbc.273.21.13264	41	56	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					30980	30986		10.1074/jbc.M101037200	http://dx.doi.org/10.1074/jbc.M101037200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11423535	Green Published, hybrid			2022-12-25	WOS:000170472900053
J	Nahum, A; Hirsch, K; Danilenko, M; Watts, CKW; Prall, OWJ; Levy, J; Sharoni, Y				Nahum, A; Hirsch, K; Danilenko, M; Watts, CKW; Prall, OWJ; Levy, J; Sharoni, Y			Lycopene inhibition of cell cycle progression in breast and endometrial cancer cells is associated with reduction in cyclin D levels and retention of p27(Kip1) in the cyclin E-cdk2 complexes	ONCOGENE			English	Article						lycopene; breast cancer; endometrial cancer; cell cycle; cyclin D1; retinoblastoma; p27(kip1)	1,25-DIHYDROXYVITAMIN D-3; ALPHA-CAROTENE; EXPRESSION; GROWTH; DIFFERENTIATION; RETINOIDS; RISK; P21; KINASES; GENE	Numerous studies have demonstrated the anticancer activity of the tomato carotenoid, lycopene. However, the molecular mechanism of this action remains unknown. Lycopene inhibition of human breast and endometrial cancer cell growth is associated with inhibition of cell cycle progression at the G(1) phase. In this study we determined the lycopene-mediated changes in the cell cycle machinery. Cells synchronized in the G1 phase by serum deprivation were treated with lycopene or vehicle and restimulated with 5% serum. Lycopene treatment decreased serum-induced phosphorylation of the retinoblastoma protein and related pocket proteins. This effect was associated with reduced cyclin-dependent kinase (cdk4 and cdk2) activities with no alterations in CDK protein levels. Lycopene caused a decrease in cyclin D1 and D3 levels whereas cyclin E levels did not change. The CDK inhibitor p21(Cip1/Waf1) abundance was reduced while p27(Kip1) levels were unaltered in comparison to control cells. Serum stimulation of control cells resulted in reduction in the p27 content in the cyclin E-cdk2 complex and its accumulation in the cyclin D1-cdk4 complex. This change in distribution was largely prevented by lycopene treatment. These results suggest that lycopene inhibits cell cycle progression via reduction of the cyclin D level and retention of p27 in cyclin E-cdk2, thus leading to inhibition of G(1) CDK activities.	Ben Gurion Univ Negev, Fac Hlth Sci, Dept Clin Biochem, IL-84105 Beer Sheva, Israel; Soroka Med Ctr Kupat Holim, Beer Sheva, Israel; St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, Sydney, NSW 2010, Australia	Ben Gurion University; Ben Gurion University; Soroka Medical Center; Garvan Institute of Medical Research; St Vincents Hospital Sydney	Sharoni, Y (corresponding author), Ben Gurion Univ Negev, Fac Hlth Sci, Dept Clin Biochem, POB 653, IL-84105 Beer Sheva, Israel.		Danilenko, Michael/F-2283-2012; SHARONI, YOAV/F-1223-2012	Danilenko, Michael/0000-0001-9466-6169				Amir H, 1999, NUTR CANCER, V33, P105, DOI 10.1080/01635589909514756; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; COUNTRYMAN C, 1991, Clinical Chemistry, V37, P1056; Giovannucci E, 1999, JNCI-J NATL CANCER I, V91, P317, DOI 10.1093/jnci/91.4.317; GIOVANNUCCI E, 1995, J NATL CANCER I, V87, P1767, DOI 10.1093/jnci/87.23.1767; Hankinson SE, 1998, LANCET, V351, P1393, DOI 10.1016/S0140-6736(97)10384-1; Hiyama H, 1998, ONCOGENE, V16, P1513, DOI 10.1038/sj.onc.1201667; JEOUNG DI, 1995, J BIOL CHEM, V270, P18367, DOI 10.1074/jbc.270.31.18367; Karas M, 2000, NUTR CANCER, V36, P101, DOI 10.1207/S15327914NC3601_14; Kim DJ, 1997, CANCER LETT, V120, P15, DOI 10.1016/S0304-3835(97)00281-4; Kobayashi T, 1996, ANTI-CANCER DRUG, V7, P195, DOI 10.1097/00001813-199602000-00008; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LEVY J, 1995, NUTR CANCER, V24, P257, DOI 10.1080/01635589509514415; Liu Y, 1996, CANCER RES, V56, P31; Ma J, 1999, J NATL CANCER I, V91, P620, DOI 10.1093/jnci/91.7.620; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Mantzoros CS, 1997, BRIT J CANCER, V76, P1115, DOI 10.1038/bjc.1997.520; MAZARS P, 1995, FEBS LETT, V362, P295, DOI 10.1016/0014-5793(95)00247-7; Michaud DS, 2000, AM J CLIN NUTR, V72, P990; Musgrove EA, 1998, MOL CELL BIOL, V18, P1812, DOI 10.1128/MCB.18.4.1812; NAGASAWA H, 1995, ANTICANCER RES, V15, P1173; Narisawa T, 1996, CANCER LETT, V107, P137, DOI 10.1016/0304-3835(96)04354-6; Sharoni Y, 1997, CANCER DETECT PREV, V21, P118; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SILVA MDP, 1997, MOL CELL BIOL, V17, P4059; Sweeney K J, 1996, Cancer Treat Res, V83, P141; TABIBZADEH S, 1990, IN VITRO CELL DEV B, V26, P1173; Teixeira C, 1997, MOL ENDOCRINOL, V11, P1191, DOI 10.1210/me.11.9.1191; WANG C-J, 1989, Proceedings of the National Science Council Republic of China Part B Life Sciences, V13, P176; WANG CJ, 1989, CANCER LETT, V48, P135, DOI 10.1016/0304-3835(89)90050-5; Wang QM, 1996, CANCER RES, V56, P264; WATTS CKW, 1994, BREAST CANCER RES TR, V31, P95, DOI 10.1007/BF00689680; WATTS CKW, 1995, MOL ENDOCRINOL, V9, P1804, DOI 10.1210/me.9.12.1804; WEINSTATSASLOW D, 1995, NAT MED, V1, P1257, DOI 10.1038/nm1295-1257; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; Zhang SM, 1997, AM J CLIN NUTR, V66, P626, DOI 10.1093/ajcn/66.3.626; Zhou Q, 1997, ONCOGENE, V15, P107, DOI 10.1038/sj.onc.1201142	40	166	171	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 7	2001	20	26					3428	3436		10.1038/sj.onc.1204452	http://dx.doi.org/10.1038/sj.onc.1204452			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	441UW	11423993				2022-12-25	WOS:000169248800013
J	Kim, H; You, S; Farris, J; Foster, LK; Foster, DN				Kim, H; You, S; Farris, J; Foster, LK; Foster, DN			Post-transcriptional inactivation of p53 in immortalized murine embryo fibroblast cells	ONCOGENE			English	Article						p53 mRNA; immortal MEF; half-life; cycloheximide; emetine; actinomycin D	MYC MESSENGER-RNA; DEGRADATION; PROMOTES; DECAY; MDM2	The steady-state levels of p53 mRNA and protein were barely detectable by Northern and Western blot analysis in spontaneously immortalized (10)3 and (10)7 murine embryo fibroblast (MEF) cells, But when cells were treated with cycloheximide (CHX) or emetine, expression levels were restored to those observed in primary and immortal (10)10 MEF cells. However, levels of p53 mRNA were not changed in primary or (10)10 MEF cells by CHX treatment. De novo p53 mRNA synthetic rates were similar in primary, (10)10, (10)3, and (10)7 MEF cells treated with or without CHX. Treatment with actinomycin D (ActD) showed that p53 mRNA in primary and (10)10 MEF cells had a relatively long half-life of 22 h, compared to less than 2 h for (10)3 and (10)7 MEF cells. Pulse-chase analysis of p53 mRNA turnover using CHX and ActD showed that the rapid destabilization of p53 mRNA in (10)3 and (10)7 MEF cells could be regulated at the transcriptional and translational levels. In addition, the destabilization of p53 mRNA appeared to occur in the nucleus for (10)3 and (10)7 cells, but not for primary and (10)10 MEF cells. Taken together, the present study demonstrates: that inactivation of the p53 gene occurs at the posttranscriptional level by rapid destabilization of its mRNA in the nucleus of spontaneously immortalized (10)3 and (10)7 MEF cells.	Univ Minnesota, Dept Anim Sci, St Paul, MN 55108 USA; Seoul Natl Univ, Sch Agr Biotechnol, Suwon 441744, South Korea	University of Minnesota System; University of Minnesota Twin Cities; Seoul National University (SNU)	Foster, DN (corresponding author), Univ Minnesota, Dept Anim Sci, St Paul, MN 55108 USA.		Kang, Phil Jun/F-4716-2013; Kim, Hyunggee/F-2673-2013; You, Seungkwon/H-3067-2015	Kim, Hyunggee/0000-0002-4738-0990; 				Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HERRICK DJ, 1994, MOL CELL BIOL, V14, P2119, DOI 10.1128/MCB.14.3.2119; Jackson DA, 2000, FASEB J, V14, P242, DOI 10.1096/fasebj.14.2.242; Jarzembowski J A, 1997, Prog Mol Subcell Biol, V18, P141; JIANG D, 1993, ONCOGENE, V8, P2805; Kim H, 2001, ONCOGENE, V20, P2671, DOI 10.1038/sj.onc.1204378; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LEVINE AJ, 1994, BRIT J CANCER, V69, P409, DOI 10.1038/bjc.1994.76; Madisen L, 1998, MOL CELL BIOL, V18, P6281, DOI 10.1128/MCB.18.11.6281; Maquat LE, 2001, CELL, V104, P173, DOI 10.1016/S0092-8674(01)00202-1; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; Yeilding NM, 1998, J BIOL CHEM, V273, P15749, DOI 10.1074/jbc.273.25.15749	16	17	21	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 31	2001	20	25					3306	3310		10.1038/sj.onc.1204423	http://dx.doi.org/10.1038/sj.onc.1204423			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	440ET	11423980				2022-12-25	WOS:000169163500014
J	Simon, MP; Navarro, M; Roux, D; Pouyssegur, J				Simon, MP; Navarro, M; Roux, D; Pouyssegur, J			Structural and functional analysis of a chimeric protein COL1A1-PDGFB generated by the translocation t(17;22)(q22;q13.1) in Dermatofibrosarcoma Protuberans (DP)	ONCOGENE			English	Article						dermatofibrosarcoma protuberans; translocations; COL1A1-PDGFB	RECEPTOR TYROSINE KINASES; GROWTH-FACTOR RECEPTORS; SIMIAN SARCOMA-VIRUS; COLLAGEN GENE COL1A1; B-CHAIN GENE; PDGF-BB; V-SIS; FUSION; EXPRESSION; ACTIVATION	Dermatofibrosarcoma protuberans (DP), an infiltrative skin tumour of intermediate malignancy, presents specific cytogenetic features such as reciprocal translocations t(17;22)(q22;q13.1) or supernumerary ring chromosomes derived from t(17;22), We have previously shown that both rings and translocated chromosomes derived from t(17;22) presented the same molecular rearrangement with fusion of the COL1A1 gene on chromosome 17 to the PDGFB gene on chromosome 22, To study the structure and function of the COL1A1-PDGFB chimeric protein, we used a tumour-derived chimeric COL1A1-PDGFB cDNA to perform stable and transient transfections in the Chinese hamster lung fibroblastic cell line PS200 and the human epithelial cell line HEK293. We demonstrated that the stably transfected clones that expressed the COL1A1-PDGFB chimeric protein became growth factors independent and tumorigenic in nude mice. In addition, COL1A1-PDGFB transfected cell supernatants significantly stimulated fibroblastic cell growth, through the activation of the PDGFB receptor pathway. By using anti-PDGFB and specific anti-COL1A1-PDGFB antibodies, we showed that, similar to PDGFB, the COL1A1-PDGFB chimeric proteins are processed in transfected cells into mature PDGFB dimers, These results strongly suggest that the COL1A1-PDGFB chimeric gene expression associated with DP, induces tumours formation through production of mature PDGFB, in an autocrine or paracrine way, Strikingly, mutagenesis experiments indicated that uncleaved COL1A1-PDGFB forms are mitogenic and therefore could contribute, as well as mature PDGFB, to the establishment of a transformed phenotype. Oncogene (2001) 20, 2965-2975.	Ctr Antoine Lacassagne, Inst Signalling Dev Biol & Canc Res, CNRS, UMR 6543, F-06189 Nice 2, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; UNICANCER; Centre Antoine Lacassagne	Simon, MP (corresponding author), Ctr Antoine Lacassagne, Inst Signalling Dev Biol & Canc Res, CNRS, UMR 6543, F-06189 Nice 2, France.		SIMON, Marie-Pierre/B-8017-2012					ALVES F, 1995, ONCOGENE, V10, P609; Dalgleish R, 1997, NUCLEIC ACIDS RES, V25, P181, DOI 10.1093/nar/25.1.181; DIRKS RPH, 1993, EUR J BIOCHEM, V216, P487, DOI 10.1111/j.1432-1033.1993.tb18167.x; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; Enzinger FM, 1995, SOFT TISSUE TUMORS, V3rd; Fish FS, 1996, DERMATOL SURG, V22, P268, DOI 10.1111/j.1524-4725.1996.tb00318.x; FLEMING TP, 1989, P NATL ACAD SCI USA, V86, P8063, DOI 10.1073/pnas.86.20.8063; Greco A, 1998, ONCOGENE, V17, P1313, DOI 10.1038/sj.onc.1202051; Heldin CH, 1998, BBA-REV CANCER, V1378, pF79, DOI 10.1016/S0304-419X(98)00015-8; KIKUCHI K, 1993, BIOCHEM BIOPH RES CO, V196, P409, DOI 10.1006/bbrc.1993.2264; Li XR, 2000, NAT CELL BIOL, V2, P302, DOI 10.1038/35010579; MELOCHE S, 1992, MOL ENDOCRINOL, V6, P845, DOI 10.1210/me.6.5.845; MELOCHE S, 1992, MOL BIOL CELL, V3, P63, DOI 10.1091/mbc.3.1.63; Mentzel T, 1998, AM J SURG PATHOL, V22, P576, DOI 10.1097/00000478-199805000-00009; Navarro M, 1998, GENE CHROMOSOME CANC, V23, P263, DOI 10.1002/(SICI)1098-2264(199811)23:3<263::AID-GCC9>3.0.CO;2-#; O'Brien KP, 1998, GENE CHROMOSOME CANC, V23, P187, DOI 10.1002/(SICI)1098-2264(199810)23:2<187::AID-GCC13>3.3.CO;2-R; OSTMAN A, 1992, J CELL BIOL, V118, P509, DOI 10.1083/jcb.118.3.509; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PEDEUTOUR F, 1995, CANCER RES, V55, P2400; Pedeutour F, 1996, CYTOGENET CELL GENET, V72, P171, DOI 10.1159/000134178; PEREZRODRIGUEZ R, 1981, J CELL PHYSIOL, V109, P387, DOI 10.1002/jcp.1041090303; RAO CD, 1988, MOL CELL BIOL, V8, P284, DOI 10.1128/MCB.8.1.284; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; Shimizu A, 1999, CANCER RES, V59, P3719; Shrivastava A, 1997, MOL CELL, V1, P25, DOI 10.1016/S1097-2765(00)80004-0; Simon MP, 1997, NAT GENET, V15, P95, DOI 10.1038/ng0197-95; SMITS A, 1992, AM J PATHOL, V140, P639; Vogel W, 1997, MOL CELL, V1, P13, DOI 10.1016/S1097-2765(00)80003-9; Wang J, 1999, DIAGN MOL PATHOL, V8, P113, DOI 10.1097/00019606-199909000-00002; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; Westermark B, 1993, CYTOKINES, V5, P1	31	66	69	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 24	2001	20	23					2965	2975		10.1038/sj.onc.1204426	http://dx.doi.org/10.1038/sj.onc.1204426			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	435VA	11420709				2022-12-25	WOS:000168901800012
J	Schoch, G; Goepfert, S; Morant, M; Hehn, A; Meyer, D; Ullmann, P; Werck-Reichhart, D				Schoch, G; Goepfert, S; Morant, M; Hehn, A; Meyer, D; Ullmann, P; Werck-Reichhart, D			CYP98A3 from Arabidopsis thaliana is a 3 '-hydroxylase of phenolic esters, a missing link in the phenylpropanoid pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							QUINATE HYDROXYCINNAMOYL TRANSFERASE; CAFFEOYL-COA 3-O-METHYLTRANSFERASE; COENZYME-A 3-O-METHYLTRANSFERASE; CHLOROGENIC ACID BIOSYNTHESIS; ADENOSYL-L-METHIONINE; PARTIAL-PURIFICATION; LIGNIN BIOSYNTHESIS; CINNAMATE 4-HYDROXYLASE; O-METHYLTRANSFERASES; ELICITOR	The 4- and 5-hydroxylations of phenolic compounds in plants are catalyzed by cytochrome P450 enzymes. The 3-hydroxylation step leading to the formation of caffeic acid from p-coumaric acid remained elusive, however, alternatively described as a phenol oxidase, a dioxygenase, or a P450 enzyme, with no decisive evidence for the involvement of any in the reaction in planta. In this study, we show that the gene encoding CYP98A3, which was the best possible P450 candidate for a 3-hydroxylase in the Arabidopsis genome, is highly expressed in inflorescence stems and wounded tissues. Recombinant CYP98A3 expressed in yeast did not metabolize free p-coumaric acid or its glucose or CoA esters, p-coumaraldehyde, or p-coumaryl alcohol, but very actively converted the 5-O-shikimate and 5-O-D-quinate esters of trans-p-coumaric acid into the corresponding caffeic acid conjugates. The shikimate ester was converted four times faster than the quinate derivative. Antibodies directed against recombinant CYP98A3 specifically revealed differentiating vascular tissues in stem and root. Taken together, these data show that CYP98A3 catalyzes the synthesis of chlorogenic acid and very likely also the 3-hydroxylation of lignin monomers. This hydroxylation occurs on depsides, the function of which was so far not understood, revealing an additional and unexpected level of networking in lignin biosynthesis.	Inst Plant Mol Biol, CNRS UPR 2357, Dept Plant Stress Response, F-67083 Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB)	Werck-Reichhart, D (corresponding author), Inst Plant Mol Biol, CNRS UPR 2357, Dept Plant Stress Response, 28 Rue Goethe, F-67083 Strasbourg, France.	daniele.werck@ibmp-ulp.u-strasbg.fr	WERCK-REICHHART, Danièle/U-3713-2019	WERCK-REICHHART, Danièle/0000-0003-2869-4262; Hehn, Alain/0000-0003-4507-8031				Allona I, 1998, P NATL ACAD SCI USA, V95, P9693, DOI 10.1073/pnas.95.16.9693; DOLAN L, 1993, DEVELOPMENT, V119, P71; DUGGLEBY RG, 1984, COMPUT BIOL MED, V14, P447, DOI 10.1016/0010-4825(84)90045-3; Fraissinet-Tachet L, 1998, FEBS LETT, V437, P319, DOI 10.1016/S0014-5793(98)01257-5; GIRAUDAT J, 1992, PLANT CELL, V4, P1251, DOI 10.1105/tpc.4.10.1251; Guo DJ, 2001, PLANT CELL, V13, P73, DOI 10.1105/tpc.13.1.73; HANSON KR, 1965, BIOCHEMISTRY-US, V4, P2719, DOI 10.1021/bi00888a023; HELLER W, 1985, ARCH BIOCHEM BIOPHYS, V241, P453, DOI 10.1016/0003-9861(85)90570-3; Hotta H, 2001, BBA-GEN SUBJECTS, V1526, P159, DOI 10.1016/S0304-4165(01)00123-4; Humphreys JM, 1999, P NATL ACAD SCI USA, V96, P10045, DOI 10.1073/pnas.96.18.10045; Jefcoate C R, 1978, Methods Enzymol, V52, P258; KAMSTEEG J, 1981, Z PFLANZENPHYSIOL, V102, P435, DOI 10.1016/S0044-328X(81)80178-X; KNEUSEL RE, 1989, ARCH BIOCHEM BIOPHYS, V269, P455, DOI 10.1016/0003-9861(89)90129-X; KOCH BM, 1995, ARCH BIOCHEM BIOPHYS, V323, P177; KOJIMA M, 1984, AGR BIOL CHEM TOKYO, V48, P2397, DOI 10.1080/00021369.1984.10866515; KUHNL T, 1987, ARCH BIOCHEM BIOPHYS, V258, P226, DOI 10.1016/0003-9861(87)90339-0; KUHNL T, 1989, PLANT SCI, V60, P21, DOI 10.1016/0168-9452(89)90039-3; Latunde-Dada AO, 2001, J BIOL CHEM, V276, P1688, DOI 10.1074/jbc.M006277200; Lee D, 1997, PLANT CELL, V9, P1985, DOI 10.1105/tpc.9.11.1985; Lehfeldt C, 2000, PLANT CELL, V12, P1295, DOI 10.1105/tpc.12.8.1295; Lim EK, 2001, J BIOL CHEM, V276, P4344, DOI 10.1074/jbc.M007263200; LOTFY S, 1994, PLANT PHYSIOL BIOCH, V32, P355; LOTFY S, 1992, PHYTOCHEMISTRY, V31, P767, DOI 10.1016/0031-9422(92)80010-C; MACHEIX J, 1998, FLAVONOIDS HLTH DIS; MAHER EA, 1994, P NATL ACAD SCI USA, V91, P7802, DOI 10.1073/pnas.91.16.7802; Maury S, 1999, PLANT PHYSIOL, V121, P215, DOI 10.1104/pp.121.1.215; MOCK HP, 1993, PHYTOCHEMISTRY, V32, P575, DOI 10.1016/S0031-9422(00)95139-2; NEGREL J, 1984, PHYTOCHEMISTRY, V23, P31, DOI 10.1016/0031-9422(84)83072-1; OMURA T, 1964, J BIOL CHEM, V239, P2370; Osakabe K, 1999, P NATL ACAD SCI USA, V96, P8955, DOI 10.1073/pnas.96.16.8955; PAKUSCH AE, 1989, ARCH BIOCHEM BIOPHYS, V271, P488, DOI 10.1016/0003-9861(89)90299-3; Parvathi K, 2001, PLANT J, V25, P193, DOI 10.1046/j.1365-313x.2001.00956.x; Petersen M, 1997, PHYTOCHEMISTRY, V45, P1165, DOI 10.1016/S0031-9422(97)00135-0; Petersen M., 1999, BIOCH PLANT SECONDAR, V2, P151; PIERREL MA, 1994, EUR J BIOCHEM, V224, P835, DOI 10.1111/j.1432-1033.1994.00835.x; Pincon G, 2001, PHYTOCHEMISTRY, V57, P1167, DOI 10.1016/S0031-9422(01)00098-X; Pompon D, 1996, METHOD ENZYMOL, V272, P51, DOI 10.1016/S0076-6879(96)72008-6; RHODES MJC, 1976, PHYTOCHEMISTRY, V15, P947, DOI 10.1016/S0031-9422(00)84376-9; RHODES MJC, 1979, PHYTOCHEMISTRY, V18, P1125, DOI 10.1016/0031-9422(79)80119-3; Schalk M, 1997, BIOCHEMISTRY-US, V36, P15253, DOI 10.1021/bi971575k; Sterky F, 1998, P NATL ACAD SCI USA, V95, P13330, DOI 10.1073/pnas.95.22.13330; STOCKIGT J, 1975, Z NATURFORSCH C, V30, P352; TANAKA M, 1991, ARCH BIOCHEM BIOPHYS, V284, P151, DOI 10.1016/0003-9861(91)90277-P; Turner SR, 1997, PLANT CELL, V9, P689, DOI 10.1105/tpc.9.5.689; ULBRICH B, 1980, PHYTOCHEMISTRY, V19, P1625, DOI 10.1016/S0031-9422(00)83782-6; ULBRICH B, 1979, PHYTOCHEMISTRY, V18, P929, DOI 10.1016/S0031-9422(00)91451-1; URBAN P, 1994, EUR J BIOCHEM, V222, P843, DOI 10.1111/j.1432-1033.1994.tb18931.x; Wang ZX, 1997, ARCH BIOCHEM BIOPHYS, V347, P249, DOI 10.1006/abbi.1997.0337; Werck-Reichhart Daniele, 1995, Drug Metabolism and Drug Interactions, V12, P221; WERCKREICHHART D, 1993, PLANT PHYSIOL, V102, P1291, DOI 10.1104/pp.102.4.1291; Whetten RW, 1998, ANNU REV PLANT PHYS, V49, P585, DOI 10.1146/annurev.arplant.49.1.585; Wittstock U, 2000, J BIOL CHEM, V275, P14659, DOI 10.1074/jbc.275.19.14659; Ye ZH, 1997, PLANT PHYSIOL, V115, P1341, DOI 10.1104/pp.115.4.1341; YE ZH, 1994, PLANT CELL, V6, P1427, DOI 10.1105/tpc.6.10.1427; Zhong RQ, 1998, PLANT CELL, V10, P2033, DOI 10.1105/tpc.10.12.2033	55	320	361	7	65	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36566	36574		10.1074/jbc.M104047200	http://dx.doi.org/10.1074/jbc.M104047200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11429408	Green Published, hybrid			2022-12-25	WOS:000171194500070
J	Pfeiffer, S; Lass, A; Schmidt, K; Mayer, B				Pfeiffer, S; Lass, A; Schmidt, K; Mayer, B			Protein tyrosine nitration in cytokine-activated murine macrophages - Involvement of a peroxidase/nitrite pathway rather than peroxynitrite	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE; REACTIVE NITROGEN; SUPEROXIDE-DISMUTASE; IN-VIVO; ELECTROCHEMICAL DETECTION; PERITONEAL-MACROPHAGES; SURFACE ADHERENCE; LEISHMANIA-MAJOR; GUANYLYL CYCLASE; BLOOD MONOCYTES	Peroxynitrite, formed in a rapid reaction of nitric oxide (NO) and superoxide anion radical (O . (-)(2)), is thought to mediate protein tyrosine nitration in various inflammatory and infectious diseases. However, a recent in vitro study indicated that peroxynitrite exhibits poor nitrating efficiency at biologically relevant steady-state concentrations (Pfeiffer, S., Schmidt, K., and Mayer, B. (2000) J. Biol Chem. 275, 6346-6352). To investigate the molecular mechanism of protein tyrosine nitration in intact cells, murine RAW 264.7 macrophages were activated with immunological stimuli, causing inducible NO synthase expression (interferon-gamma in combination with either lipopolysaccharide or zymosan A), followed by the determination of protein-bound 3-nitrotyrosine levels and release of potential triggers of nitration (NO, O . (-)(2), H2O2, peroxynitrite, and nitrite). Levels of 3-nitrotyrosine started to increase at 16-18 h and exhibited a maximum at 20-24 h post-stimulation. Formation of O . (-)(2) was maximal at 1-5 h and decreased to base line 5 h after stimulation. Release of NO peaked at similar to6 and similar to9 h after stimulation with interferon-gamma /lipopolysaccharide and interferon-gamma /zymosan A, respectively, followed by a rapid decline to base line within the next 4 h. NO formation resulted in accumulation of nitrite, which leveled off at about 50 mum 15 h post-stimulation. Significant release of peroxynitrite was detectable only upon treatment of cytokine-activated cells with phorbol 12-myristate-13-acetate, which led to a 2.2-fold increase in dihydrorhodamine oxidation without significantly increasing the levels of 3-nitrotyrosine. Tyrosine nitration was inhibited by azide and catalase and mimicked by incubation of unstimulated cells with nitrite. Together with the striking discrepancy in the time course of NO/O . (-)(2) release versus 3-nitrotyrosine formation, these results suggest that protein tyrosine nitration in activated macrophages is caused by a nitrite-dependent peroxidase reaction rather than peroxynitrite.	Karl Franzens Univ Graz, Inst Pharmakol & Toxikol, A-8010 Graz, Austria	University of Graz	Mayer, B (corresponding author), Karl Franzens Univ Graz, Inst Pharmakol & Toxikol, Univ Pl 2, A-8010 Graz, Austria.	mayer@kfunigraz.ac.at	Lass, Achim/C-3332-2008; Mayer, Bernd/B-9391-2008	Lass, Achim/0000-0002-8190-7151; Mayer, Bernd/0000-0002-2921-3494				ASSREUY J, 1994, EUR J IMMUNOL, V24, P672, DOI 10.1002/eji.1830240328; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; BECKMAN JS, 1988, J BIOL CHEM, V263, P6884; BIGGAR WD, 1976, LAB INVEST, V34, P31; BODEL PT, 1977, J EXP MED, V145, P264, DOI 10.1084/jem.145.2.264; BODEL PT, 1978, AM J PATHOL, V91, P107; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bruno JG, 1999, IN VITRO CELL DEV-AN, V35, P376; Crow JP, 1997, NITRIC OXIDE-BIOL CH, V1, P145, DOI 10.1006/niox.1996.0113; DAUGHERTY A, 1994, J CLIN INVEST, V94, P437, DOI 10.1172/JCI117342; DELAHARPE J, 1985, J IMMUNOL METHODS, V78, P323, DOI 10.1016/0022-1759(85)90089-4; DEMENDEZ I, 1991, ARCH BIOCHEM BIOPHYS, V289, P319, DOI 10.1016/0003-9861(91)90417-H; Eiserich JP, 1998, NATURE, V391, P393, DOI 10.1038/34923; ERNSTER L, 1995, BBA-MOL BASIS DIS, V1271, P195, DOI 10.1016/0925-4439(95)00028-3; FAULKNER KM, 1994, J BIOL CHEM, V269, P23471; Ferrer-Sueta G, 1999, CHEM RES TOXICOL, V12, P442, DOI 10.1021/tx980245d; Fricker SP, 1999, ANTICANCER RES, V19, P553; GARTHWAITE J, 1995, MOL PHARMACOL, V48, P184; Goldstein S, 2000, J BIOL CHEM, V275, P3031, DOI 10.1074/jbc.275.5.3031; Halliwell B, 1999, FREE RADICAL RES, V31, P651, DOI 10.1080/10715769900301221; HEINECKE JW, 1993, J BIOL CHEM, V268, P4069; HIBBS JB, 1987, J IMMUNOL, V138, P550; Hodges GR, 2000, CHEM RES TOXICOL, V13, P1287, DOI 10.1021/tx0001272; Ischiropoulos H, 1998, ARCH BIOCHEM BIOPHYS, V356, P1, DOI 10.1006/abbi.1998.0755; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P446, DOI 10.1016/0003-9861(92)90433-W; Kalns J, 1998, NITRIC OXIDE-BIOL CH, V2, P366, DOI 10.1006/niox.1998.0191; Kettle AJ, 1997, REDOX REP, V3, P3, DOI 10.1080/13510002.1997.11747085; KIYOTAKI C, 1984, J IMMUNOL, V133, P923; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lass A, 1997, J BIOL CHEM, V272, P19199, DOI 10.1074/jbc.272.31.19199; LI Y, 1992, EUR J IMMUNOL, V22, P441, DOI 10.1002/eji.1830220223; MALLE E, 2000, EUR J BIOCHEM, V267, P1; Mayer B, 1997, TRENDS BIOCHEM SCI, V22, P477, DOI 10.1016/S0968-0004(97)01147-X; Murray HW, 1999, J EXP MED, V189, P741, DOI 10.1084/jem.189.4.741; NAKAGAWARA A, 1981, J CLIN INVEST, V68, P1243, DOI 10.1172/JCI110370; PAUL BB, 1973, SCIENCE, V181, P849, DOI 10.1126/science.181.4102.849; Pfeiffer S, 2000, J BIOL CHEM, V275, P6346, DOI 10.1074/jbc.275.9.6346; Pfeiffer S, 1997, J BIOL CHEM, V272, P3465, DOI 10.1074/jbc.272.6.3465; Pfeiffer S, 1998, MOL PHARMACOL, V53, P795, DOI 10.1124/mol.53.4.795; Pfeiffer S, 1998, J BIOL CHEM, V273, P27280, DOI 10.1074/jbc.273.42.27280; Reynolds WF, 1999, EXP NEUROL, V155, P31, DOI 10.1006/exnr.1998.6977; Sawa T, 2000, J BIOL CHEM, V275, P32467, DOI 10.1074/jbc.M910169199; SCHMIDT K, 1997, NITRIC OXIDE PROTOCO, P101; Shigenaga MK, 1999, METHOD ENZYMOL, V301, P27; Shigenaga MK, 1997, P NATL ACAD SCI USA, V94, P3211, DOI 10.1073/pnas.94.7.3211; STRAUSS RR, 1975, NATURE, V255, P343, DOI 10.1038/255343a0; STUEHR DJ, 1989, J EXP MED, V169, P1011, DOI 10.1084/jem.169.3.1011; Sugiyama S, 2001, AM J PATHOL, V158, P879, DOI 10.1016/S0002-9440(10)64036-9; UEDA T, 1995, HISTOCHEM CELL BIOL, V103, P11, DOI 10.1007/BF01464470; van der Vliet A, 1999, AM J RESP CRIT CARE, V160, P1; vanderVliet A, 1997, J BIOL CHEM, V272, P7617, DOI 10.1074/jbc.272.12.7617; VANDERVLIET A, 1995, ARCH BIOCHEM BIOPHYS, V319, P341, DOI 10.1006/abbi.1995.1303; WARNOCK ML, 1987, AM J PATHOL, V128, P171; Wu WJ, 1999, J BIOL CHEM, V274, P25933, DOI 10.1074/jbc.274.36.25933	54	104	106	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					34051	34058		10.1074/jbc.M100585200	http://dx.doi.org/10.1074/jbc.M100585200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11425852	hybrid			2022-12-25	WOS:000170910200102
J	Suzuki, T; Terasaki, M; Takemoto-Hori, C; Hanada, T; Ueda, T; Wada, A; Watanabe, K				Suzuki, T; Terasaki, M; Takemoto-Hori, C; Hanada, T; Ueda, T; Wada, A; Watanabe, K			Proteomic analysis of the mammalian mitochondrial ribosome - Identification of protein components in the 28 S small subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORRESPONDING GENE-SEQUENCES; TANDEM-MASS-SPECTROMETRY; DIMENSIONAL GEL-ELECTROPHORESIS; INDUCED CELL-DEATH; ESCHERICHIA-COLI; NUCLEAR GENES; MYCOBACTERIUM-TUBERCULOSIS; STREPTOMYCIN RESISTANCE; ANGSTROM RESOLUTION; LIVER-MITOCHONDRIA	The mammalian mitochondrial ribosome (mitoribosome) has a highly protein-rich composition with a small sedimentation coefficient of 55 S, consisting of 39 S large and 28 S small subunits. In the previous study, we analyzed 39 S large subunit proteins from bovine mitoribosome (Suzuki, T., Terasaki, M, Takemoto-Hori, C., Hanada, T., Ueda, T., Wada, A., and Watanabe, VL (2001) J. BioL Chem. 276,21724-21736). The results suggested structural compensation for the rRNA deficit through proteins of increased molecular mass in the mitoribosome. We report here the identification of 28 S small subunit proteins. Each protein was separated by radical-free high-reducing two-dimensional polyacrylamide gel electrophoresis and analyzed by liquid chromatography/mass spectrometry/mass spectrometry using electrospray ionization/ion trap mass spectrometer to identify DNA sequence by expressed sequence tag data base searches in silico. Twenty one proteins from the small subunit were identified, including 11 new proteins along with their complete cDNA sequences from human and mouse. In addition to these proteins, three new proteins were also identified in the 55 S mitoribosome. We have clearly identified a mitochondrial homologue of S12, which is a key regulatory protein of translation fidelity and a candidate for the autosomal dominant deafness gene, DFNA4. The apoptosis-related protein DAP3 was found to be a component of the small subunit, indicating a new function for the mitoribosome in programmed cell death. In summary, we have mapped a total of 55 proteins from the 55 S mitoribosome on the two-dimensional polyacrylamide gels.	Univ Tokyo, Grad Sch Frontier Sci, Dept Integrated Biosci, Kashiwa, Chiba 2778562, Japan; Univ Tokyo, Grad Sch Engn, Dept Chem & Biotechnol, Bunkyo Ku, Tokyo 1138656, Japan; RIKEN, Yokohama Inst, Genom Sci Ctr, Prot Res Grp,Tsurumi Ku, Yokohama, Kanagawa 2300045, Japan; Osaka Med Coll, Dept Phys, Takatsuki, Osaka 5690084, Japan	University of Tokyo; University of Tokyo; RIKEN; Osaka Medical College	Suzuki, T (corresponding author), Univ Tokyo, Grad Sch Frontier Sci, Dept Integrated Biosci, 5-1-5 Kashiwanoha, Kashiwa, Chiba 2778562, Japan.	t-suzuki@k.u-tokyo.ac.jp; kw@kwl.t.u-tokyo.ac.jp	Ueda, Takuya/K-5217-2014; Suzuki, Tsutomu/J-1776-2015	Ueda, Takuya/0000-0002-7760-8271; Suzuki, Tsutomu/0000-0002-9731-1731; Hanada, Takao/0000-0003-2732-4008				Alnemri ES, 1999, NAT CELL BIOL, V1, pE40, DOI 10.1038/10034; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ATTARDI G, 1985, INT REV CYTOL, V93, P93, DOI 10.1016/S0074-7696(08)61373-X; Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; Berger T, 2000, J CELL SCI, V113, P3603; BIEMANN K, 1990, METHOD ENZYMOL, V193, P455, DOI 10.1016/0076-6879(90)93433-L; BRAKIERGINGRAS L, 1984, CAN J BIOCHEM CELL B, V62, P231, DOI 10.1139/o84-033; BRECKENRIDGE L, 1970, GENETICS, V65, P9; Cate JH, 1999, SCIENCE, V285, P2095, DOI 10.1126/science.285.5436.2095; CHAMPNEY WS, 1980, BIOCHIM BIOPHYS ACTA, V609, P464, DOI 10.1016/0005-2787(80)90120-3; CHEN AH, 1995, HUM MOL GENET, V4, P1073, DOI 10.1093/hmg/4.6.1073; CHUNG HKJ, 1990, J BIOL CHEM, V265, P21000; Culver GM, 1999, SCIENCE, V285, P2133, DOI 10.1126/science.285.5436.2133; DENSLOW ND, 1991, J BIOL CHEM, V266, P9586; Dongre AR, 1997, TRENDS BIOTECHNOL, V15, P418, DOI 10.1016/S0167-7799(97)01110-4; Earnshaw WC, 1999, NATURE, V397, P387, DOI 10.1038/17015; FINKEN M, 1993, MOL MICROBIOL, V9, P1239, DOI 10.1111/j.1365-2958.1993.tb01253.x; Gatlin CL, 2000, ANAL CHEM, V72, P757, DOI 10.1021/ac991025n; Goldschmidt-Reisin S, 1998, J BIOL CHEM, V273, P34828, DOI 10.1074/jbc.273.52.34828; Graack HR, 1999, BIOCHEMISTRY-US, V38, P16569, DOI 10.1021/bi991543s; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; GUTELL RR, 1990, NUCLEIC ACIDS RES, V18, P2319, DOI 10.1093/nar/18.suppl.2319; Hamasaki K, 1997, BIOCHEMISTRY-US, V36, P12323, DOI 10.1021/bi970962r; HAMILTON MG, 1974, BIOCHEMISTRY-US, V13, P5400, DOI 10.1021/bi00723a024; Inoue K, 1996, BIOCHEM BIOPH RES CO, V223, P496, DOI 10.1006/bbrc.1996.0923; Johnson DF, 1998, GENOMICS, V52, P363, DOI 10.1006/geno.1998.5448; KISSIL JL, 1995, J BIOL CHEM, V270, P27932, DOI 10.1074/jbc.270.46.27932; Kissil JL, 1999, EMBO J, V18, P353, DOI 10.1093/emboj/18.2.353; Koc EC, 2000, J BIOL CHEM, V275, P32585, DOI 10.1074/jbc.M003596200; Koc EC, 1999, BIOCHEM BIOPH RES CO, V266, P141, DOI 10.1006/bbrc.1999.1785; Koc EC, 2001, FEBS LETT, V492, P166, DOI 10.1016/S0014-5793(01)02250-5; Koc EC, 2001, J BIOL CHEM, V276, P19363, DOI 10.1074/jbc.M100727200; Koc EC, 2001, PROTEIN SCI, V10, P471, DOI 10.1110/ps.35301; Kowalak JA, 1996, PROTEIN SCI, V5, P1625, DOI 10.1002/pro.5560050816; Levy-Strumpf N, 1998, ONCOGENE, V17, P3331, DOI 10.1038/sj.onc.1202588; Liu MQ, 2000, J BIOL CHEM, V275, P29400, DOI 10.1074/jbc.M002173200; Ma JH, 1996, J BIOL CHEM, V271, P5805, DOI 10.1074/jbc.271.10.5805; MATTHEWS DE, 1982, J BIOL CHEM, V257, P8788; MEIER A, 1994, ANTIMICROB AGENTS CH, V38, P228, DOI 10.1128/AAC.38.2.228; NEEFS JM, 1991, NUCLEIC ACIDS RES, V19, P1987, DOI 10.1093/nar/19.suppl.1987; Nicholas K.B., 1997, EMBNEW NEWS, V4, P14, DOI DOI 10.11118/ACTAUN201361041061; Nikulin A, 2000, NAT STRUCT BIOL, V7, P273; Nissen P, 2000, SCIENCE, V289, P920, DOI 10.1126/science.289.5481.920; O'Brien TW, 1999, J BIOL CHEM, V274, P36043, DOI 10.1074/jbc.274.51.36043; O'Brien TW, 2000, J BIOL CHEM, V275, P18153, DOI 10.1074/jbc.M909762199; OBRIEN TW, 1971, J BIOL CHEM, V246, P3409; OBRIEN TW, 1993, STRUCTURE FUNCTION M, P575; OJALA DK, 1980, NATURE, V287, P79, DOI 10.1038/287079a0; Patel VB, 2001, J BIOL CHEM, V276, P6739, DOI 10.1074/jbc.M005781200; Pioletti M, 2001, EMBO J, V20, P1829, DOI 10.1093/emboj/20.8.1829; ROYDEN CS, 1987, CELL, V51, P165, DOI 10.1016/0092-8674(87)90144-9; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; Schluenzen F, 2000, CELL, V102, P615, DOI 10.1016/S0092-8674(00)00084-2; Schwartzbach C J, 1996, Methods Enzymol, V264, P248, DOI 10.1016/S0076-6879(96)64025-7; SCHWARTZBACH CJ, 1989, J BIOL CHEM, V264, P19125; Shah ZH, 1998, GENOMICS, V48, P384, DOI 10.1006/geno.1997.5166; Shah ZH, 1997, GENE, V204, P55, DOI 10.1016/S0378-1119(97)00521-0; Smeitink J, 1999, AM J HUM GENET, V64, P1505, DOI 10.1086/302432; Smeitink JAM, 1998, HUM MOL GENET, V7, P1573, DOI 10.1093/hmg/7.10.1573; Suzuki T, 2001, J BIOL CHEM, V276, P21724, DOI 10.1074/jbc.M100432200; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TIMMS AR, 1992, MOL GEN GENET, V232, P89, DOI 10.1007/BF00299141; Tizon B, 1999, YEAST, V15, P145, DOI 10.1002/(SICI)1097-0061(19990130)15:2<145::AID-YEA346>3.0.CO;2-J; WADA A, 1986, J BIOCHEM, V100, P1583, DOI 10.1093/oxfordjournals.jbchem.a121866; WADA A, 1986, J BIOCHEM-TOKYO, V100, P1595, DOI 10.1093/oxfordjournals.jbchem.a121867; WALKER JE, 1992, J MOL BIOL, V226, P1051, DOI 10.1016/0022-2836(92)91052-Q; Wimberly BT, 2000, NATURE, V407, P327, DOI 10.1038/35030006; Yokogawa T, 2000, J BIOL CHEM, V275, P19913, DOI 10.1074/jbc.M908473199	68	118	157	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					33181	33195		10.1074/jbc.M103236200	http://dx.doi.org/10.1074/jbc.M103236200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11402041	hybrid			2022-12-25	WOS:000170746000105
J	Waldron, RT; Rey, O; Iglesias, T; Tugal, T; Cantrell, D; Rozengurt, E				Waldron, RT; Rey, O; Iglesias, T; Tugal, T; Cantrell, D; Rozengurt, E			Activation loop Ser(744) and Ser(748) in protein kinase D are transphosphorylated in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; PHORBOL ESTERS; D PKD; INTACT-CELLS; C-MU; PHOSPHORYLATION SITES; PROTEOLYTIC CLEAVAGE; MEDIATED REGULATION; RAPID ACTIVATION; STRUCTURAL BASIS	The importance of activation loop phosphorylation in the regulation of protein kinase D (PKD/protein kinase C (PKC) mu) activity has become controversial. In order to clarify the mechanism(s) of PKD activation, we developed a novel phosphospecific antibody recognizing phosphorylated Ser(748) in PKD (pS748). Western blot analysis with the pS748 antibody, carried out with a variety of PKD forms and in a variety of cell types including full-length PKD transfected in COS-7 and EIEK 293 cells, a green fluorescent protein-PKD fusion protein transfected in either Swiss 3T3 fibroblasts or Madin-Darby canine kidney epithelial cells, and endogenous PKD expressed in A20 lymphocytes and Rat-1 fibroblasts, indicated that Ser(748) phosphorylation was absent from unstimulated cells. In contrast, dramatic increases in Ser(748) phosphorylation were induced by phorbol esters, bombesin, or cross-linking of B lymphocyte antigen receptors or by cotransfection with active PKC epsilon or PKC eta. Western analysis using a second phosphospecific antibody, which primarily recognizes PKD phosphorylated at Ser(744), revealed that Ser(744) phosphorylation accompanies Ser(748) phosphorylation during PKD activation in vivo. Ser(744)/Ser(748) phosphorylation requires PKC but not PKD activity, indicative of transphosphorylation. Our results provide new experimental evidence indicating that activation loop phosphorylation at Ser(744) and Ser(748) occurs during PKD activation in vivo and support the notion of a PKC-PKD phosphorylation cascade.	Inst Invest Biomed Albeto Sols, Madrid 28029, Spain; Imperial Canc Res Fund, Lymphocyte Activat Lab, London WC2A 3PX, England; Univ Calif Los Angeles, CURE Digest Dis Res Ctr, Los Angeles, CA 90095 USA	Cancer Research UK; University of California System; University of California Los Angeles	Rozengurt, E (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Med,Div Digest Dis, Unit Signal Transduct & Gastrointestinal Canc, 900 Vet Ave,Warren Hall,Rm 11-124, Los Angeles, CA 90095 USA.		Vacas, Teresa Iglesias/ABF-8663-2020; Waldron, Richard Taliesin/ABF-2773-2020	Vacas, Teresa Iglesias/0000-0002-4326-9005; Waldron, Richard Taliesin/0000-0003-3151-6002; Rey, Osvaldo/0000-0003-1575-9864	NCI NIH HHS [P50 CA90388-01] Funding Source: Medline; NIDDK NIH HHS [DK56930, DK55003-01S1, DK55003, DK17294, K01 DK 02834-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA090388] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK002834, R37DK017294, R01DK017294, R01DK056930] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abedi H, 1998, FEBS LETT, V427, P209, DOI 10.1016/S0014-5793(98)00427-X; Bagowski CP, 1999, EMBO J, V18, P5567, DOI 10.1093/emboj/18.20.5567; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Black JD, 2000, FRONT BIOSCI-LANDMRK, V5, pD406, DOI 10.2741/Black; Bowden ET, 1999, ONCOGENE, V18, P4440, DOI 10.1038/sj.onc.1202827; Brooks G, 1997, J MOL CELL CARDIOL, V29, P2273, DOI 10.1006/jmcc.1997.0466; CARTER RH, 1991, P NATL ACAD SCI USA, V88, P2745, DOI 10.1073/pnas.88.7.2745; Chiu T, 2001, AM J PHYSIOL-CELL PH, V280, pC929, DOI 10.1152/ajpcell.2001.280.4.C929; Chiu T, 2001, FEBS LETT, V489, P101, DOI 10.1016/S0014-5793(01)02076-2; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429, DOI 10.1152/ajplung.2000.279.3.L429; Endo K, 2000, J BIOL CHEM, V275, P18476, DOI 10.1074/jbc.M002266200; Haussermann S, 1999, FEBS LETT, V462, P442, DOI 10.1016/S0014-5793(99)01577-X; Haworth RS, 1999, AM J PHYSIOL-CELL PH, V277, pC1202, DOI 10.1152/ajpcell.1999.277.6.C1202; Hayashi A, 1999, BBA-MOL CELL RES, V1450, P99, DOI 10.1016/S0167-4889(99)00040-3; Hurd C, 2001, BIOCHEM BIOPH RES CO, V282, P404, DOI 10.1006/bbrc.2001.4591; Iglesias T, 1998, J BIOL CHEM, V273, P27662, DOI 10.1074/jbc.273.42.27662; Jaken S, 2000, BIOESSAYS, V22, P245, DOI 10.1002/(SICI)1521-1878(200003)22:3<245::AID-BIES6>3.0.CO;2-X; Jamora C, 1999, CELL, V98, P59, DOI 10.1016/S0092-8674(00)80606-6; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Johnson LN, 1998, FEBS LETT, V430, P1, DOI 10.1016/S0014-5793(98)00606-1; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Liljedahl M, 2001, CELL, V104, P409, DOI 10.1016/S0092-8674(01)00228-8; Matthews S, 1999, FEBS LETT, V457, P515, DOI 10.1016/S0014-5793(99)01090-X; Matthews SA, 2000, EMBO J, V19, P2935, DOI 10.1093/emboj/19.12.2935; Matthews SA, 2000, J EXP MED, V191, P2075, DOI 10.1084/jem.191.12.2075; Matthews SA, 1997, J BIOL CHEM, V272, P20245, DOI 10.1074/jbc.272.32.20245; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Paolucci L, 2000, AM J PHYSIOL-CELL PH, V278, pC33, DOI 10.1152/ajpcell.2000.278.1.C33; Paolucci L, 1999, CANCER RES, V59, P572; Prestle J, 1996, J CELL BIOL, V134, P1401, DOI 10.1083/jcb.134.6.1401; Rey O, 2001, J BIOL CHEM, V276, P32616, DOI 10.1074/jbc.M101649200; Rozengurt E, 1997, BIOCHEM SOC T, V25, P565, DOI 10.1042/bst0250565; Rozengurt E, 1995, MUTAT RES-FUND MOL M, V333, P153, DOI 10.1016/0027-5107(95)00141-7; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; Sturany S, 2001, J BIOL CHEM, V276, P3310, DOI 10.1074/jbc.M008719200; VALVERDE AM, 1994, P NATL ACAD SCI USA, V91, P8572, DOI 10.1073/pnas.91.18.8572; VANLINT J, 1995, J BIOL CHEM, V270, P1455, DOI 10.1074/jbc.270.3.1455; Vertommen D, 2000, J BIOL CHEM, V275, P19567, DOI 10.1074/jbc.M001357200; Waldron RT, 2000, J BIOL CHEM, V275, P17114, DOI 10.1074/jbc.M908959199; Waldron RT, 1999, J BIOL CHEM, V274, P9224, DOI 10.1074/jbc.274.14.9224; Waldron RT, 1999, ELECTROPHORESIS, V20, P382, DOI 10.1002/(SICI)1522-2683(19990201)20:2<382::AID-ELPS382>3.0.CO;2-N; Yuan JZ, 2000, J BIOL CHEM, V275, P2157, DOI 10.1074/jbc.275.3.2157; Zugaza JL, 1996, EMBO J, V15, P6220, DOI 10.1002/j.1460-2075.1996.tb01012.x; Zugaza JL, 1997, J BIOL CHEM, V272, P23952, DOI 10.1074/jbc.272.38.23952	50	139	142	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					32606	32615		10.1074/jbc.M101648200	http://dx.doi.org/10.1074/jbc.M101648200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11410586	hybrid			2022-12-25	WOS:000170746000032
J	Wallace, TJ; Kodsi, EM; Langston, TB; Gergis, MR; Grogan, WM				Wallace, TJ; Kodsi, EM; Langston, TB; Gergis, MR; Grogan, WM			Mutation of residues 423 (Met/Ile), 444 (Thr/Met), and 506 (Asn/Ser) confer cholesteryl esterase activity on rat lung carboxylesterase - Ser-506 is required for activation by cAMP-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; LIVER CARBOXYLESTERASE; NUCLEOTIDE-SEQUENCE; CDNA CLONING; LIPOPROTEIN-LIPASE; MULTIGENE FAMILY; IMMUNOLOGICAL CHARACTERIZATION; MICROSOMAL CARBOXYLESTERASES; ORGANOPHOSPHORUS COMPOUNDS; PUTATIVE CARBOXYLESTERASE	Site-directed mutagenesis is used to identify amino acid residues that dictate reported differences in substrate specificity between rat hepatic neutral cytosolic cholesteryl ester hydrolase (hneCEH) and rat lung carboxylesterase (LCE), proteins differing by only 4 residues in their primary sequences. Beginning with LCE, the substitution Met(423) --> Ile(423) alone or in combination with other mutations increased activity with p-nitrophenylcaprylate (PNPC) relative to more hydrophilic p-nitrophenylacetate (PNPA), typical of hneCEH. The substitution Thr(444) --> Met(444) was necessary but not sufficient for expression of cholesteryl esterase activity in COS-7 cells. The substitution Asn(506) --> Se-506, creating a potential phosphorylation site, uniformly increased activity with both PNPA and PNPC, was necessary but not sufficient for expression of cholesteryl esterase activity and conferred susceptibility to activation by cAMP-dependent protein kinase, a property of hncCEH. The 3 mutations in combination were necessary and sufficient for expression of cholesteryl esterase activity by the mutated LCE. The substitution Gln(186) --> Arg(186) selectively reduced esterase activity with PNPA and PNPC but was not required for cholesteryl esterase activity. Homology modeling from x-ray structures of acetylcholinesterases is used to propose three-dimensional models for hncCEH and LCE that provide insight into the effects of these mutations on substrate specificity.	Virginia Commonwealth Univ, Sch Med, Dept Biochem & Mol Biophys, Richmond, VA 23298 USA	Virginia Commonwealth University	Grogan, WM (corresponding author), Virginia Commonwealth Univ, Sch Med, Dept Biochem & Mol Biophys, Richmond, VA 23298 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044613] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK44613] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AIDA K, 1993, BIOCHIM BIOPHYS ACTA, V1174, P72, DOI 10.1016/0167-4781(93)90093-S; ALEXSON SEH, 1993, EUR J BIOCHEM, V214, P719, DOI 10.1111/j.1432-1033.1993.tb17973.x; ARPAGAUS M, 1991, J BIOL CHEM, V266, P6966; ARPAGAUS M, 1990, BIOCHEMISTRY-US, V29, P124, DOI 10.1021/bi00453a015; Barr F, 1998, AM J PHYSIOL-LUNG C, V274, pL404, DOI 10.1152/ajplung.1998.274.3.L404; BECKER A, 1994, ARTERIOSCLER THROMB, V14, P1346, DOI 10.1161/01.ATV.14.8.1346; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; BOURNE Y, 1995, CELL, V83, P503, DOI 10.1016/0092-8674(95)90128-0; BRAULT D, 1992, GENE, V121, P237, DOI 10.1016/0378-1119(92)90127-B; Carriere F, 1998, BBA-REV BIOMEMBRANES, V1376, P417, DOI 10.1016/S0304-4157(98)00016-1; COLWELL NS, 1993, BIOCHIM BIOPHYS ACTA, V1172, P175, DOI 10.1016/0167-4781(93)90288-O; Cordle RA, 1998, J LIPID RES, V39, P1759; David L, 1998, EUR J BIOCHEM, V257, P142, DOI 10.1046/j.1432-1327.1998.2570142.x; DEAN RA, 1995, J PHARMACOL EXP THER, V275, P965; DUGI KA, 1992, J BIOL CHEM, V267, P25086; FREY PA, 1994, SCIENCE, V264, P1927, DOI 10.1126/science.7661899; GAUSTAD R, 1991, BIOCHEM J, V274, P693, DOI 10.1042/bj2740693; Ghosh S, 1995, BBA-LIPID LIPID MET, V1259, P305, DOI 10.1016/0005-2760(95)00184-0; GHOSH S, 1992, BIOCHEM CELL BIOL, V70, P800, DOI 10.1139/o92-121; Ghosh S, 1998, AM J PHYSIOL-GASTR L, V274, pG662, DOI 10.1152/ajpgi.1998.274.4.G662; GHOSH S, 1991, LIPIDS, V26, P793, DOI 10.1007/BF02536160; GHOSH S, 1989, LIPIDS, V24, P733, DOI 10.1007/BF02535213; GHOSH S, 1990, LIPIDS, V25, P221, DOI 10.1007/BF02535751; GROGAN WM, 1991, LIPIDS, V26, P907, DOI 10.1007/BF02535976; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hansen JE, 1998, GLYCOCONJUGATE J, V15, P115, DOI 10.1023/A:1006960004440; HOLM C, 1988, NUCLEIC ACIDS RES, V16, P9879, DOI 10.1093/nar/16.20.9879; HOSOKAWA M, 1987, MOL PHARMACOL, V31, P579; Islam MR, 1999, ARCH BIOCHEM BIOPHYS, V372, P53, DOI 10.1006/abbi.1999.1449; KISSEL JA, 1989, BIOCHIM BIOPHYS ACTA, V1006, P227, DOI 10.1016/0005-2760(89)90201-4; Kojima A, 1998, CANCER RES, V58, P4368; KOMAROMY MC, 1987, P NATL ACAD SCI USA, V84, P1526, DOI 10.1073/pnas.84.6.1526; KORZA G, 1988, J BIOL CHEM, V263, P3486; Krishnasamy S, 1997, BIOCHEM BIOPH RES CO, V235, P180, DOI 10.1006/bbrc.1997.6719; KROETZ DL, 1993, BIOCHEMISTRY-US, V32, P11606, DOI 10.1021/bi00094a018; KYGER EM, 1989, BIOCHEM BIOPH RES CO, V164, P1302, DOI 10.1016/0006-291X(89)91811-1; LEGAY C, 1993, FEBS LETT, V315, P163, DOI 10.1016/0014-5793(93)81155-S; Li B, 2000, J NEUROCHEM, V75, P1320, DOI 10.1046/j.1471-4159.2000.751320.x; LONG RM, 1988, BIOCHEM BIOPH RES CO, V156, P866, DOI 10.1016/S0006-291X(88)80924-0; MACKAY K, 1995, GENE, V165, P255, DOI 10.1016/0378-1119(95)00564-M; MATSUSHIMA M, 1991, FEBS LETT, V293, P37, DOI 10.1016/0014-5793(91)81147-Z; MAXWELL DM, 1992, TOXICOL APPL PHARM, V114, P306, DOI 10.1016/0041-008X(92)90082-4; MCCRACKEN NW, 1993, BIOCHEM PHARMACOL, V45, P31, DOI 10.1016/0006-2952(93)90373-5; MENTLEIN R, 1987, BIOCHIM BIOPHYS ACTA, V913, P27, DOI 10.1016/0167-4838(87)90228-7; MENTLEIN R, 1984, ARCH BIOCHEM BIOPHYS, V234, P612, DOI 10.1016/0003-9861(84)90311-4; MORGAN EW, 1994, ARCH BIOCHEM BIOPHYS, V315, P495, DOI 10.1006/abbi.1994.1531; Mori M, 1999, FEBS LETT, V458, P17, DOI 10.1016/S0014-5793(99)01111-4; NAKAGAWA H, 1995, J LIPID RES, V36, P2212; NAMBU K, 1987, BIOCHEM PHARMACOL, V36, P1715, DOI 10.1016/0006-2952(87)90058-X; Natarajan R, 1999, J LIPID RES, V40, P2091; Natarajan R, 1998, BIOCHEM BIOPH RES CO, V243, P349, DOI 10.1006/bbrc.1997.8030; Natarajan R, 1996, BIOCHEM BIOPH RES CO, V225, P413, DOI 10.1006/bbrc.1996.1188; NILSSON J, 1990, EUR J BIOCHEM, V192, P543, DOI 10.1111/j.1432-1033.1990.tb19259.x; OVNIC M, 1991, GENOMICS, V11, P956, DOI 10.1016/0888-7543(91)90020-F; OVNIC M, 1991, GENOMICS, V9, P344, DOI 10.1016/0888-7543(91)90263-E; OZOLS J, 1989, J BIOL CHEM, V264, P12533; PARK YH, 1994, BIOCHEM MOL BIOL INT, V34, P351; PAYNE RM, 1994, AM J PHYSIOL, V266, pG914, DOI 10.1152/ajpgi.1994.266.5.G914; Peitsch M C, 2000, Pharmacogenomics, V1, P257, DOI 10.1517/14622416.1.3.257; Potter PM, 1998, CANCER RES, V58, P2646; RACHINSKY TL, 1990, NEURON, V5, P317, DOI 10.1016/0896-6273(90)90168-F; ROBBI M, 1990, BIOCHEM J, V269, P451, DOI 10.1042/bj2690451; ROBBI M, 1994, BIOCHEM BIOPH RES CO, V203, P1404, DOI 10.1006/bbrc.1994.2341; ROBBI M, 1983, EUR J BIOCHEM, V137, P293, DOI 10.1111/j.1432-1033.1983.tb07828.x; Robbi M, 1996, BIOCHEM J, V313, P821, DOI 10.1042/bj3130821; Satoh T, 1998, ANNU REV PHARMACOL, V38, P257, DOI 10.1146/annurev.pharmtox.38.1.257; Schwer H, 1997, BIOCHEM BIOPH RES CO, V233, P117, DOI 10.1006/bbrc.1997.6413; SONE T, 1994, BBA-PROTEIN STRUCT M, V1207, P138, DOI 10.1016/0167-4838(94)90063-9; Sone T, 1997, COMPREHENSIVE TOXICO, P265; SOREQ H, 1990, P NATL ACAD SCI USA, V87, P9688, DOI 10.1073/pnas.87.24.9688; Sun GS, 1997, J BIOL CHEM, V272, P24488, DOI 10.1074/jbc.272.39.24488; TAKAGI Y, 1988, J BIOCHEM-TOKYO, V104, P801, DOI 10.1093/oxfordjournals.jbchem.a122553; TANG BK, 1995, EUR J CLIN PHARMACOL, V47, P449; VANTILBEURGH H, 1994, J BIOL CHEM, V269, P4626; Wallace TJ, 1999, AM J RESP CELL MOL, V20, P1201, DOI 10.1165/ajrcmb.20.6.3402; Wang XQ, 1997, STRUCTURE, V5, P1209, DOI 10.1016/S0969-2126(97)00271-2; WIEGREBE W, 1984, ARZNEIMITTEL-FORSCH, V34-1, P48; YAN BF, 1994, J BIOL CHEM, V269, P29688	79	11	12	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					33165	33174		10.1074/jbc.M105644200	http://dx.doi.org/10.1074/jbc.M105644200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11429416				2022-12-25	WOS:000170746000103
J	Leppa, S; Kajanne, R; Arminen, L; Sistonen, L				Leppa, S; Kajanne, R; Arminen, L; Sistonen, L			Differential induction of Hsp70-encoding genes in human hematopoietic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; LINKED HSP70 GENES; MOLECULAR CHAPERONES; TRANSCRIPTION FACTOR; INDUCED EXPRESSION; BINDING ACTIVITY; THERMAL-STRESS; ACTIVATION; FAMILY; THERMOTOLERANCE	The rapid transcriptional activation of heat shock genes in response to stress is crucial for the cellular survival and the development of thermotolerance. Although heat shock response is a widespread phenomenon, certain cells exhibit a diminished induction of heat shock gene expression upon stress stimuli. Here we have analyzed the development of thermotolerance and induction of distinct Hsp70 encoding genes in three cell lines representing different hematopoietic cell types. We show that in response to heat shock, cell survival and induction of thermotolerance are impaired in Raji and HL60 cells, as compared with K562 cells. Accordingly, transcriptional induction of the hsp70 gene is diminished in Raji and HL60 cells. This appears to be due to inability of transcription factors, including HSF1 to bind to the hsp70.1 promoter in vivo. Consistent with the genomic footprint, analysis of hsp70.1 mRNA expression using a specific 3 ' -untranslated region probe reveals that induction of the hsp70.1 gene upon heat shock is completely abolished in Raji and HL60 cells. The suppression of the hsp70.1 promoter is not caused by impaired function of HSF1, since HSF1 is equally activated in all cell types and occupies another heat-inducible promoter, hsp90a. Furthermore, among distinct inducible hsp70 genes, suppression seems to be specific for the hsp70.1 gene, since heat shock results in induction of hsp70.2 and hsp70B ' mRNA expression in all cell lines. Taken together, our results demonstrate that distinct Hsp70-encoding genes contribute to the heat shock response in a cell type-dependent manner.	Univ Turku, Abo Akad Univ, Turku Ctr Biotechnol, FIN-20521 Turku, Finland; Univ Helsinki, Cent Hosp, Dept Oncol, FIN-00029 Helsinki, Finland; Univ Helsinki, Mol Canc Biol Res Program, Biomed Helsinki & Haartman Inst, FIN-00014 Helsinki, Finland; Univ Turku, Turku Ctr Biotechnol, Abo Akad Univ, FIN-20521 Turku, Finland; Abo Akad Univ, Dept Biol, FIN-20521 Turku, Finland	Abo Akademi University; University of Turku; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; Abo Akademi University; University of Turku; Abo Akademi University	Leppa, S (corresponding author), Univ Turku, Abo Akad Univ, Turku Ctr Biotechnol, POB 123, FIN-20521 Turku, Finland.			Sistonen, Lea/0000-0003-1341-2867; Leppa, Sirpa/0000-0002-8265-511X				ABRAVAYA K, 1991, MOL CELL BIOL, V11, P586, DOI 10.1128/MCB.11.1.586; AMICI C, 1992, P NATL ACAD SCI USA, V89, P6227, DOI 10.1073/pnas.89.14.6227; BALER R, 1993, MOL CELL BIOL, V13, P2486, DOI 10.1128/MCB.13.4.2486; BANERJI SS, 1984, MOL CELL BIOL, V4, P2437, DOI 10.1128/MCB.4.11.2437; BHATTACHARYYA T, 1995, J BIOL CHEM, V270, P1705, DOI 10.1074/jbc.270.4.1705; Buchner J, 1996, FASEB J, V10, P10, DOI 10.1096/fasebj.10.1.8566529; BURSTON SG, 1995, ESSAYS BIOCHEM, V29, P125; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Dressel R, 1999, J CELL BIOCHEM, V72, P558, DOI 10.1002/(SICI)1097-4644(19990315)72:4<558::AID-JCB11>3.3.CO;2-O; Dressel R, 1998, MELANOMA RES, V8, P482, DOI 10.1097/00008390-199812000-00002; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GORZOWSKI JJ, 1995, J BIOL CHEM, V270, P26940, DOI 10.1074/jbc.270.45.26940; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HARTL FU, 1995, CURR OPIN STRUC BIOL, V5, P92; HEADS RJ, 1994, J MOL CELL CARDIOL, V26, P695, DOI 10.1006/jmcc.1994.1084; HENDREY J, 1991, MOL REPROD DEV, V28, P1, DOI 10.1002/mrd.1080280102; Hendrick JP, 1995, FASEB J, V9, P1559, DOI 10.1096/fasebj.9.15.8529835; HICKEY E, 1989, MOL CELL BIOL, V9, P2615, DOI 10.1128/MCB.9.6.2615; Holmberg CI, 1997, J BIOL CHEM, V272, P6792, DOI 10.1074/jbc.272.10.6792; Kaarniranta K, 1998, P NATL ACAD SCI USA, V95, P2319, DOI 10.1073/pnas.95.5.2319; LEUNG TKC, 1990, BIOCHEM J, V267, P125, DOI 10.1042/bj2670125; LI GC, 1992, P NATL ACAD SCI USA, V89, P2036, DOI 10.1073/pnas.89.6.2036; MARTINEZBALBAS MA, 1995, CELL, V83, P29, DOI 10.1016/0092-8674(95)90231-7; MATHUR SK, 1994, P NATL ACAD SCI USA, V91, P8695, DOI 10.1073/pnas.91.18.8695; McMillan DR, 1998, J BIOL CHEM, V273, P7523, DOI 10.1074/jbc.273.13.7523; MILNER CM, 1990, IMMUNOGENETICS, V32, P242; Mirkes PE, 1999, DEV DYNAM, V214, P159, DOI 10.1002/(SICI)1097-0177(199902)214:2<159::AID-AJA6>3.0.CO;2-Y; MIVECHI NF, 1991, CANCER RES, V51, P6608; MIVECHI NF, 1989, CANCER RES, V49, P1954; MIVECHI NF, 1990, CANCER RES, V50, P2877; Morimoto RI, 1998, GENE DEV, V12, P3788, DOI 10.1101/gad.12.24.3788; Mosser DD, 1997, MOL CELL BIOL, V17, P5317, DOI 10.1128/MCB.17.9.5317; MOSSER DD, 1988, MOL CELL BIOL, V8, P4736, DOI 10.1128/MCB.8.11.4736; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; Nakai A, 1997, MOL CELL BIOL, V17, P469, DOI 10.1128/MCB.17.1.469; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; PARSELL DA, 1993, ANNU REV GENET, V27, P437, DOI 10.1146/annurev.ge.27.120193.002253; Pirkkala L, 2001, FASEB J, V15, P1118, DOI 10.1096/fj00-0294rev; RABINDRAN SK, 1991, P NATL ACAD SCI USA, V88, P6906, DOI 10.1073/pnas.88.16.6906; RABINDRAN SK, 1993, SCIENCE, V259, P230, DOI 10.1126/science.8421783; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; SARGE KD, 1991, GENE DEV, V5, P1902, DOI 10.1101/gad.5.10.1902; SCHUETZ TJ, 1991, P NATL ACAD SCI USA, V88, P6911, DOI 10.1073/pnas.88.16.6911; SISTONEN L, 1992, MOL CELL BIOL, V12, P4104, DOI 10.1128/MCB.12.9.4104; Tavaria M, 1996, CELL STRESS CHAPERON, V1, P23, DOI 10.1379/1466-1268(1996)001<0023:AHSGTT>2.3.CO;2; THEODORAKIS NG, 1987, MOL CELL BIOL, V7, P4357, DOI 10.1128/MCB.7.12.4357; Wissing D, 1996, INT J HYPERTHER, V12, P125, DOI 10.3109/02656739609023695; WU B, 1985, MOL CELL BIOL, V5, P330, DOI 10.1128/MCB.5.2.330; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441	51	20	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					31713	31719		10.1074/jbc.M104375200	http://dx.doi.org/10.1074/jbc.M104375200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11423545	hybrid			2022-12-25	WOS:000170613500034
J	Li, J; Verkman, AS				Li, J; Verkman, AS			Impaired hearing in mice lacking aquaporin-4 water channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-BRAIN; F1-HYBRID STRAINS; PLASMA-MEMBRANES; KNOCKOUT MICE; MULLER CELLS; INNER-EAR; EXPRESSION; GENETICS; PROTEIN; TRANSPORT	A role for aquaporins (AQPs) in hearing has been suggested from the specific expression of aquaporins in inner ear and the need for precise volume regulation in epithelial cells involved in acoustic signal transduction. Using mice deficient in selected aquaporins as controls, we localized AQP1 in fibrocytes in the spiral ligament and AQP4 in supporting epithelial cells (Hensen's, Claudius, and inner sulcus cells) in the organ of Corti. To determine whether aquaporins play a role in hearing, auditory brain stem response (ABR) thresholds were compared in wild-type mice and transgenic null mice lacking (individually) AQP1, AQP3, AQP4, and AQP5. In 4-5-week-old mice in a CD1 genetic background, ABR thresholds in response to a click stimulus were remarkably increased by > 12 db in AQP4 null mice compared with wild-type mice (p < 0.001), whereas ABR thresholds were not affected by AQP1, AQP3, or AQP5 deletion. In a C57/b16 background, nearly all AQP4 null mice were deaf, whereas ABRs could be elicited in wildtype controls. ABRs in AQP4 null CD1 mice measured in response to tone bursts (4-20 kHz) indicated a frequency-independent hearing deficit. Light microscopy showed no differences in cochlear morphology of wildtype versus AQP4 null mice. These results provide the first direct evidence that an aquaporin water channel plays a role in hearing. AQP4 may facilitate rapid osmotic equilibration in epithelial cells in the organ of Corti, which are subject to large K+ fluxes during mechano-electric signal transduction.	Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, Dept Physiol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Verkman, AS (corresponding author), Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, Box 0521,1246 Hlth Sci E Tower, San Francisco, CA 94143 USA.				NHLBI NIH HHS [HL60288, HL59198] Funding Source: Medline; NIDDK NIH HHS [DK35124, DK43840] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059198, P50HL060288] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043840, R37DK035124, R01DK035124] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Beitz E, 1999, HEARING RES, V132, P76, DOI 10.1016/S0378-5955(99)00036-2; Belyantseva IA, 2000, J NEUROSCI, V20, P8996; Chou CL, 1998, AM J PHYSIOL-CELL PH, V274, pC549, DOI 10.1152/ajpcell.1998.274.2.C549; DEEN PMT, 1994, SCIENCE, V264, P92, DOI 10.1126/science.8140421; Erway LC, 1996, HEARING RES, V93, P181, DOI 10.1016/0378-5955(95)00226-X; ERWAY LC, 1993, HEARING RES, V65, P125, DOI 10.1016/0378-5955(93)90207-H; FRIGERI A, 1995, P NATL ACAD SCI USA, V92, P4328, DOI 10.1073/pnas.92.10.4328; HASEGAWA H, 1994, J BIOL CHEM, V269, P5497; HENRY KR, 1992, AUDIOLOGY, V31, P190; Johnson KR, 1997, HEARING RES, V114, P83, DOI 10.1016/S0378-5955(97)00155-X; JUNG JS, 1994, P NATL ACAD SCI USA, V91, P13052, DOI 10.1073/pnas.91.26.13052; Kubisch C, 1999, CELL, V96, P437, DOI 10.1016/S0092-8674(00)80556-5; Ma TH, 1998, J BIOL CHEM, V273, P4296, DOI 10.1074/jbc.273.8.4296; Ma TH, 1999, J BIOL CHEM, V274, P20071, DOI 10.1074/jbc.274.29.20071; Ma TH, 1997, J CLIN INVEST, V100, P957, DOI 10.1172/JCI231; Ma TH, 2000, P NATL ACAD SCI USA, V97, P4386, DOI 10.1073/pnas.080499597; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; MARKAND ON, 1994, J CLIN NEUROPHYSIOL, V11, P319, DOI 10.1097/00004691-199405000-00004; Mhatre AN, 1999, BIOCHEM BIOPH RES CO, V264, P157, DOI 10.1006/bbrc.1999.1323; MINAMI Y, ACTA OTOLARYNGOL S, V533, P19; Misaka T, 1996, FEBS LETT, V381, P208, DOI 10.1016/0014-5793(96)00092-0; MULLER AR, 1994, J CLIN NEUROPHYSIOL, V11, P284; Nagelhus EA, 1999, GLIA, V26, P47, DOI 10.1002/(SICI)1098-1136(199903)26:1<47::AID-GLIA5>3.0.CO;2-5; Nagelhus EA, 1998, J NEUROSCI, V18, P2506; Nielsen S, 1997, J NEUROSCI, V17, P171; Patuzzi R., 1996, COCHLEA, P186; PRESTON GM, 1994, SCIENCE, V265, P1585, DOI 10.1126/science.7521540; RANDOM BR, 1996, TRENDS NEUROSCI, V19, P352; Rash JE, 1998, P NATL ACAD SCI USA, V95, P11981, DOI 10.1073/pnas.95.20.11981; Sakaguchi N, 1998, HEARING RES, V118, P114, DOI 10.1016/S0378-5955(98)00022-7; Stankovic KM, 1995, AM J PHYSIOL-CELL PH, V269, pC1450, DOI 10.1152/ajpcell.1995.269.6.C1450; Steel KP, 1999, SCIENCE, V285, P1363, DOI 10.1126/science.285.5432.1363; Takumi Y, 1998, EUR J NEUROSCI, V10, P3584, DOI 10.1046/j.1460-9568.1998.00360.x; TRAYNELIS SF, 1989, J NEUROPHYSIOL, V61, P927, DOI 10.1152/jn.1989.61.5.927; Verbavatz JM, 1997, J CELL SCI, V110, P2855; Verkman AS, 2000, EXP PHYSIOL, V85, p233S, DOI 10.1111/j.1469-445X.2000.tb00028.x; Wang KS, 2000, AM J PHYSIOL-GASTR L, V279, pG448, DOI 10.1152/ajpgi.2000.279.2.G448; WILLOTT JF, 1995, HEARING RES, V88, P143, DOI 10.1016/0378-5955(95)00107-F; YANG B, 2000, AM J PHYSIOL, V278, pC1008; Yang BX, 1996, J BIOL CHEM, V271, P4577; Yang BX, 1997, J BIOL CHEM, V272, P16140, DOI 10.1074/jbc.272.26.16140; Yang BX, 2001, J BIOL CHEM, V276, P2775, DOI 10.1074/jbc.M008216200; Zheng QY, 1999, HEARING RES, V130, P94, DOI 10.1016/S0378-5955(99)00003-9	43	202	222	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					31233	31237		10.1074/jbc.M104368200	http://dx.doi.org/10.1074/jbc.M104368200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11406631	hybrid			2022-12-25	WOS:000170472900085
J	Perrais, M; Pigny, P; Ducourouble, MP; Petitprez, D; Porchet, N; Aubert, JP; Van Seuningen, I				Perrais, M; Pigny, P; Ducourouble, MP; Petitprez, D; Porchet, N; Aubert, JP; Van Seuningen, I			Characterization of human mucin gene MUC4 promoter - Importance of growth factors and proinflammatory cytokines for its regulation in pancreatic cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; SURFACE SIALOMUCIN COMPLEX; RNA-POLYMERASE-II; INTERFERON-GAMMA; TRANSCRIPTION FACTORS; SIGNAL-TRANSDUCTION; TYROSINE KINASE; FACTOR RECEPTOR; IN-VITRO; C-SRC	The human mucin gene MUC4 encodes a large transmembrane mucin that is thought to play important roles in tumor cell biology and that is overexpressed in human pancreatic carcinomas. In this report, we describe the structure and functional activity of the 5 ' -flanking region, including 1.0 kilobase of the promoter. The long 5 ' -untranslated region (2.7 kilobases) is characterized by a high content of GC in its 3 ' -end. The first TATA box was located at -2672/-2668. Multiple transcription start sites and a high density of putative binding sites for Sp1 (GC and CACCC boxes), AP-1/-2/-4, cAMP-responsive element-binding protein, GATA, GR, and STAT transcription factors were found within the 5 ' -flanking region. Transcriptional activity of the promoter was assessed using pGL3-luciferase deletion mutants in two MUC4-expressing (CAPAN-1 and CAPAN-2) and one nonexpressing (PANC-1) pancreatic cancer cell line. Two highly active fragments (-219/-1 and -2781/-2572) that drive MUC4 transcription in CAPAN-1 and CAPAN-2 cells were identified. Gel retardation assays indicated that Sp1 and Sp3 bind to cognate cis-elements found in the 5 ' -flanking region and that Sp1 transactivates, whereas Sp3 inhibits the GC-rich region (-464/-1) in CAPAN-2 cells. Activation of protein kinase C with phorbol ester and treatment of cells with epidermal growth factor and transforming growth factor-alpha resulted in upregulation of the promoter. Tumor necrosis factor-alpha and interferon (IFN)-gamma inflammatory cytokines had no or mild effect on MUC4 transcriptional activity when used alone. However, a very strong synergistic effect (10-12-fold activation) between IFN-gamma and tumor necrosis factor-a or IFN-gamma and transforming growth factor-a was obtained in CAPAN-2 cells. Altogether these results demonstrate that the 5 ' -flanking region of MUC4 contains epithelial cell-specific, positive, and negative regulatory cis-elements, that Sp1/Sp3 are important regulators of MUC4 basal expression, and that its regulation in pancreatic cancer cells involves complex interplay between several signaling pathways.	INSERM, U377, F-59045 Lille, France; Ctr Hosp Reg & Univ Lille, Hop Huriez, Lab Endocrinol, F-59037 Lille, France; Ctr Hosp Reg & Univ Lille, Hop Huriez, Lab Biochim & Biol Mol, F-59037 Lille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; CHU Lille; Universite de Lille - ISITE; CHU Lille	Van Seuningen, I (corresponding author), INSERM, U377, Pl Verdun, F-59045 Lille, France.	vanseuni@lille.oinserm.fr	VAN SEUNINGEN, Isabelle/N-6176-2016	VAN SEUNINGEN, Isabelle/0000-0002-3131-2694				Asano K, 1997, J CLIN INVEST, V99, P1057, DOI 10.1172/JCI119233; Aslam F, 2001, CANCER RES, V61, P570; AUDIE JP, 1995, HUM REPROD, V10, P98, DOI 10.1093/humrep/10.1.98; AUDIE JP, 1993, J HISTOCHEM CYTOCHEM, V41, P1479, DOI 10.1177/41.10.8245407; Bahr MJ, 1999, HEPATOLOGY, V29, P839, DOI 10.1002/hep.510290333; BALAGUE C, 1994, GASTROENTEROLOGY, V106, P1054, DOI 10.1016/0016-5085(94)90767-6; BALAGUE C, 1995, GASTROENTEROLOGY, V109, P953, DOI 10.1016/0016-5085(95)90406-9; Bernacki SH, 1999, AM J RESP CELL MOL, V20, P595, DOI 10.1165/ajrcmb.20.4.3442; Buckley CD, 1997, MOL MED TODAY, V3, P449, DOI 10.1016/S1357-4310(97)01128-3; Buisine MP, 1999, INFLAMM BOWEL DIS, V5, P24, DOI 10.1097/00054725-199902000-00004; Buisine MP, 1998, GUT, V43, P519, DOI 10.1136/gut.43.4.519; Buisine MP, 1999, AM J RESP CELL MOL, V20, P209, DOI 10.1165/ajrcmb.20.2.3259; Carraway KL, 1999, J BIOL CHEM, V274, P5263, DOI 10.1074/jbc.274.9.5263; Carraway KL, 2000, FRONT BIOSCI, V5, pD95, DOI 10.2741/Carraway; Cheshire JL, 1997, MOL CELL BIOL, V17, P6746, DOI 10.1128/MCB.17.11.6746; Choudhury A, 2000, J BIOL CHEM, V275, P33929, DOI 10.1074/jbc.M005115200; Choudhury A, 2000, J BIOCHEM-TOKYO, V128, P233, DOI 10.1093/oxfordjournals.jbchem.a022746; Copin MC, 2000, INT J CANCER, V86, P162, DOI 10.1002/(SICI)1097-0215(20000415)86:2<162::AID-IJC3>3.3.CO;2-I; Dabbagh K, 1999, J IMMUNOL, V162, P6233; Davies DE, 1999, ALLERGY, V54, P771; Fischer BM, 1999, AM J RESP CELL MOL, V20, P413, DOI 10.1165/ajrcmb.20.3.3393; FOGH J, 1977, J NATL CANCER I, V58, P209, DOI 10.1093/jnci/58.2.209; FORSTNER G, 1995, ANNU REV PHYSIOL, V57, P585, DOI 10.1146/annurev.ph.57.030195.003101; GENDLER SJ, 1995, ANNU REV PHYSIOL, V57, P607, DOI 10.1146/annurev.ph.57.030195.003135; Gollub EG, 1995, BIOCHEM BIOPH RES CO, V217, P1006, DOI 10.1006/bbrc.1995.2870; GROSS MS, 1992, ANN GENET-PARIS, V35, P21; Gum JR, 1997, BIOCHEM J, V325, P259, DOI 10.1042/bj3250259; Gumina RJ, 1997, BLOOD, V89, P1260, DOI 10.1182/blood.V89.4.1260; HOLLINGSWORTH MA, 1994, INT J CANCER, V57, P198, DOI 10.1002/ijc.2910570212; HULL SR, 1990, BIOCHEM J, V265, P121, DOI 10.1042/bj2650121; Ince TA, 1995, J BIOL CHEM, V270, P30249, DOI 10.1074/jbc.270.51.30249; KARIN M, 1984, NATURE, V308, P513, DOI 10.1038/308513a0; Komatsu M, 2000, INT J CANCER, V87, P480, DOI 10.1002/1097-0215(20000815)87:4<480::AID-IJC4>3.0.CO;2-6; Kost ER, 1999, GYNECOL ONCOL, V72, P392, DOI 10.1006/gyno.1998.5257; Kovarik A, 1996, J BIOL CHEM, V271, P18140, DOI 10.1074/jbc.271.30.18140; Kumar CC, 1998, ONCOGENE, V17, P1365, DOI 10.1038/sj.onc.1202172; LESUFFLEUR T, 1994, CRIT REV ONCOL HEMAT, V17, P153, DOI 10.1016/1040-8428(94)90053-1; LEVINE SJ, 1995, AM J RESP CELL MOL, V12, P196, DOI 10.1165/ajrcmb.12.2.7865217; Lewis M, 1999, J CELL BIOCHEM, V72, P373, DOI 10.1002/(SICI)1097-4644(19990301)72:3<373::AID-JCB7>3.0.CO;2-N; Li JD, 1997, P NATL ACAD SCI USA, V94, P967, DOI 10.1073/pnas.94.3.967; Li YQ, 2001, J BIOL CHEM, V276, P6061, DOI 10.1074/jbc.C000754200; Longphre M, 1999, J CLIN INVEST, V104, P1375, DOI 10.1172/JCI6097; MARIN MG, 1994, PHARMACOL REV, V46, P35; Matsuura H, 1999, J BIOL CHEM, V274, P29138, DOI 10.1074/jbc.274.41.29138; Moniaux N, 2000, EUR J BIOCHEM, V267, P4536, DOI 10.1046/j.1432-1327.2000.01504.x; Moniaux N, 1999, BIOCHEM J, V338, P325, DOI 10.1042/0264-6021:3380325; Nguyen PL, 1996, TUMOR BIOL, V17, P176, DOI 10.1159/000217980; Nogami H, 1997, GENE, V198, P191, DOI 10.1016/S0378-1119(97)00314-4; Nollet S, 1998, BIOCHEM J, V332, P739, DOI 10.1042/bj3320739; Ohmori Y, 1997, J BIOL CHEM, V272, P14899, DOI 10.1074/jbc.272.23.14899; Paludan SR, 2000, J LEUKOCYTE BIOL, V67, P18, DOI 10.1002/jlb.67.1.18; PANDEY P, 1995, CANCER RES, V55, P4000; Park C, 1998, METHODS, V15, P175, DOI 10.1006/meth.1998.0622; Perrais M, 2001, J BIOL CHEM, V276, P15386, DOI 10.1074/jbc.M010534200; PORCHET N, 1991, BIOCHEM BIOPH RES CO, V175, P414, DOI 10.1016/0006-291X(91)91580-6; Porchet Nicole, 1999, Journal de la Societe de Biologie, V193, P85; Price-Schiavi SA, 2000, BIOCHEM J, V349, P641, DOI 10.1042/0264-6021:3490641; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; SassoneCorsi P, 1995, ANNU REV CELL DEV BI, V11, P355, DOI 10.1146/annurev.cellbio.11.1.355; Satoh S, 2000, INT J CANCER, V88, P507, DOI 10.1002/1097-0215(20001115)88:4<507::AID-IJC1>3.0.CO;2-0; SHENG Z, 1990, J BIOL CHEM, V265, P8505; Shimura S, 2000, CELL SIGNAL, V12, P271, DOI 10.1016/S0898-6568(00)00066-8; Takeyama K, 1999, P NATL ACAD SCI USA, V96, P3081, DOI 10.1073/pnas.96.6.3081; Van Seuningen I, 2000, BIOCHEM J, V348, P675; Vandenhaute B, 1997, J HEPATOL, V27, P1057, DOI 10.1016/S0168-8278(97)80150-X; vandeStolpe A, 1996, J MOL MED, V74, P13, DOI 10.1007/BF00202069; VANSEUNINGEN I, 1995, J BIOL CHEM, V270, P26976, DOI 10.1074/jbc.270.45.26976; VANSUNINGEN I, 2001, IN PRESS FRONT BIOSC; von Mensdorff-Pouilly S, 2000, INT J BIOL MARKER, V15, P343, DOI 10.1177/172460080001500413; Weis L, 1997, MOL CELL BIOL, V17, P2973, DOI 10.1128/MCB.17.6.2973; Williams SJ, 1999, CANCER RES, V59, P4083; WRIGHT WC, 1981, J NATL CANCER I, V66, P239; YONEZAWA S, 1991, BIOCHEM J, V276, P599, DOI 10.1042/bj2760599; Yu M, 1997, J BIOL CHEM, V272, P29060, DOI 10.1074/jbc.272.46.29060	74	67	68	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					30923	30933		10.1074/jbc.M104204200	http://dx.doi.org/10.1074/jbc.M104204200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11418607	hybrid, Green Published, Green Submitted			2022-12-25	WOS:000170472900046
J	Xiao, GQ; Qu, YX; Hu, K; Boutjdir, M				Xiao, GQ; Qu, YX; Hu, K; Boutjdir, M			Down-regulation of L-type calcium channel in pups born to 52 kDa SSA/Ro immunized rabbits	FASEB JOURNAL			English	Article						autoantibody; AV block; immunization; cardiac myocyte	CONGENITAL HEART-BLOCK; SS-A/RO; HUMAN KERATINOCYTES; MURINE MODEL; ANTIBODIES; AUTOANTIBODIES; EXPRESSION; ANTIGENS; CHILDREN; MOTHERS	Congenital heart block is considered a model of passively acquired autoimmune disease in which the mother generates anti-SSA/Ro and/or anti-SSB/La antibodies that cross the placenta and presumably injure the heart of developing fetus. CHB is accompanied by ECG abnormalities including AV block, sinus bradycardia, and ventricular dysfunction. Our previous data indicate that these abnormalities are caused by maternal autoantibody-mediated disturbance of L-type Ca channels. To investigate the consequence of chronic exposure of L-type Ca channels in newborn pups to maternal autoantibodies during pregnancy, we immunized female rabbits with human 52 kDa-SSA/Ro (Ro52) recombinant protein. ECG revealed that pups from the immunized group had varying degrees of conduction defects. In addition, I-CaL density and protein were reduced in hearts of pups from the immunized group. Sera and purified IgG from immunized rabbits inhibited I-Ba recorded from oocytes with expressed alpha (1C) and beta (2a) subunits of L-type Ca channel. Pups born to Ro52 immunized mothers exhibited down-regulation of L-type calcium channels in heart. The data provide new insight into the pathogenesis of congenital heart block.	New York Harbor Hlth Care Syst, Mol & Cellular Cardiol Program, Res & Dev Off 151, Brooklyn, NY 11209 USA; SUNY Hlth Sci Ctr, Brooklyn, NY 11209 USA	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center	Boutjdir, M (corresponding author), New York Harbor Hlth Care Syst, Mol & Cellular Cardiol Program, Res & Dev Off 151, 800 Poly Pl, Brooklyn, NY 11209 USA.	mohamed.boutjdir@med.va.gov		Boutjdir, Mohamed/0000-0002-6068-223X	NHLBI NIH HHS [HL55401] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055401] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARNAIZVILLENA A, 1989, ARTHRITIS RHEUM-US, V32, P1421, DOI 10.1002/anr.1780321111; BOUCEK RJ, 1984, PEDIATR RES, V18, P948, DOI 10.1203/00006450-198418100-00008; Boutjdir M, 1998, PEDIATR RES, V44, P11, DOI 10.1203/00006450-199807000-00002; Boutjdir M, 1997, CIRC RES, V80, P354, DOI 10.1161/01.RES.80.3.354; Brucato A, 2000, CIRCULATION, V102, pE88, DOI 10.1161/01.CIR.102.11.e88; Buyon JP, 1998, J AM COLL CARDIOL, V31, P1658, DOI 10.1016/S0735-1097(98)00161-2; BUYON JP, 1995, LUPUS, V4, P116, DOI 10.1177/096120339500400207; CHAN EKL, 1991, J CLIN INVEST, V87, P68, DOI 10.1172/JCI115003; DEUTSCHER SL, 1988, P NATL ACAD SCI USA, V85, P9479, DOI 10.1073/pnas.85.24.9479; DORNER T, 1995, ANN RHEUM DIS, V54, P904, DOI 10.1136/ard.54.11.904; FURUKAWA F, 1988, J IMMUNOL, V141, P1480; GOTTLIEB E, 1989, EMBO J, V8, P851, DOI 10.1002/j.1460-2075.1989.tb03446.x; HO SY, 1986, AM J CARDIOL, V58, P291, DOI 10.1016/0002-9149(86)90064-0; Hoerter J A, 1982, Adv Myocardiol, V3, P373; HUYNH TV, 1992, CIRC RES, V70, P508, DOI 10.1161/01.RES.70.3.508; LEE LA, 1983, ANN INTERN MED, V99, P592, DOI 10.7326/0003-4819-99-5-592; Li JM, 1996, CLIN EXP IMMUNOL, V104, P388; MAYLIE JG, 1982, AM J PHYSIOL, V242, pH834, DOI 10.1152/ajpheart.1982.242.5.H834; Mazel JA, 1999, CIRCULATION, V99, P1914, DOI 10.1161/01.CIR.99.14.1914; Miranda ME, 1998, J IMMUNOL, V161, P5061; Miranda-Carus ME, 1998, J IMMUNOL, V161, P5886; Qu YX, 2000, CARDIOVASC RES, V45, P866, DOI 10.1016/S0008-6363(99)00402-2; RENGASAMY A, 1985, BIOCHEM BIOPH RES CO, V126, P1, DOI 10.1016/0006-291X(85)90563-7; WALTUCK J, 1994, ANN INTERN MED, V120, P544, DOI 10.7326/0003-4819-120-7-199404010-00003; Wang DR, 1999, J CLIN INVEST, V104, P1265, DOI 10.1172/JCI8003; Xiao GQ, 2001, CIRCULATION, V103, P1599	26	28	28	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2001	15	9					1539	1545		10.1096/fj.01-0052com	http://dx.doi.org/10.1096/fj.01-0052com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	460PV	11427485				2022-12-25	WOS:000170318500005
J	Tellam, J; Sherritt, M; Thomson, S; Tellam, R; Moss, DJ; Burrows, SR; Wiertz, E; Khanna, R				Tellam, J; Sherritt, M; Thomson, S; Tellam, R; Moss, DJ; Burrows, SR; Wiertz, E; Khanna, R			Targeting of EBNA1 for rapid intracellular degradation overrides the inhibitory effects of the Gly-Ala repeat domain and restores CD8+T cell recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPSTEIN-BARR-VIRUS; N-END RULE; PROTEIN-DEGRADATION; NUCLEAR ANTIGEN-1; PROTEASOME; UBIQUITIN; IMMUNIZATION; PROTEOLYSIS; RESPONSES; MECHANISM	Epstein-Barr virus (EBV)-encoded nuclear antigen 1 (EBNA1) includes a unique glycine-alanine repeat domain that inhibits the endogenous presentation of cytotoxic T lymphocyte (CTL) epitopes through the class I pathway by blocking proteasome-dependent degradation of this antigen. This immune evasion mechanism has been implicated in the pathogenesis of EBV-associated diseases. Here, we show that cotranslational ubiquitination combined with N-end rule targeting enhances the intracellular degradation of EBNA1, thus resulting in a dramatic reduction in the half-life of the antigen. Using DNA expression vectors encoding different forms of ubiquitinated EBNA1 for in vivo studies revealed that this rapid degradation, remarkably, leads to induction of a very strong CTL response to an EBNA1-specific CTL epitope. Furthermore, this targeting also restored the endogenous processing of HLA class I-restricted CTL epitopes within EBNA1 for immune recognition by human EBV-specific CTLs. These observations provide, for the first time, evidence that the glycine-alanine repeat-mediated proteasomal block on EBNA1 can be reversed by specifically targeting this antigen for rapid degradation resulting in enhanced CD8+ T cell-mediated recognition in vitro and in vivo.	Univ Queensland, Queensland Inst Med Res, Bancroft Ctr, Div Infect Dis & Immunol,Tumor Immunol Lab, Brisbane, Qld 4006, Australia; Univ Queensland, Joint Oncol Program, Brisbane, Qld 4006, Australia; Australian Natl Univ, John Curtin Sch Med Res, Viral Engn & Cytokine Res Grp, Synthet Vaccines Lab, Canberra, ACT 2006, Australia; CSIRO, Indooroopilly, Qld 4068, Australia; Leiden Univ, Med Ctr, Dept Med Microbiol, NL-2300 RC Leiden, Netherlands	QIMR Berghofer Medical Research Institute; University of Queensland; University of Queensland; Australian National University; John Curtin School of Medical Research; Commonwealth Scientific & Industrial Research Organisation (CSIRO); Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Khanna, R (corresponding author), Univ Queensland, Queensland Inst Med Res, Bancroft Ctr, Div Infect Dis & Immunol,Tumor Immunol Lab, Brisbane, Qld 4006, Australia.		Tellam, Ross/T-2423-2019; Khanna, Rajiv/A-7691-2008; Burrows, Scott/G-2050-2011; Tellam, Ross/H-2798-2013	Khanna, Rajiv/0000-0003-2241-0353; Burrows, Scott/0000-0002-1430-0472; Tellam, Ross/0000-0003-2353-1640				Blake N, 1997, IMMUNITY, V7, P791, DOI 10.1016/S1074-7613(00)80397-0; BURROWS SR, 1992, EUR J IMMUNOL, V22, P191, DOI 10.1002/eji.1830220128; Carbone FR, 1998, IMMUNOL TODAY, V19, P368, DOI 10.1016/S0167-5699(98)01301-2; Cerundolo V, 1997, EUR J IMMUNOL, V27, P336, DOI 10.1002/eji.1830270148; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Dantuma NP, 2000, P NATL ACAD SCI USA, V97, P8381, DOI 10.1073/pnas.140217397; ECKER DJ, 1989, J BIOL CHEM, V264, P7715; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; Khanna R, 1997, J IMMUNOL, V158, P3619; KHANNA R, 1995, MICROBIOL REV, V59, P387, DOI 10.1128/MMBR.59.3.387-405.1995; KHANNA R, 1992, J EXP MED, V176, P169, DOI 10.1084/jem.176.1.169; Levitskaya J, 1997, P NATL ACAD SCI USA, V94, P12616, DOI 10.1073/pnas.94.23.12616; LEVITSKAYA J, 1995, NATURE, V375, P685, DOI 10.1038/375685a0; Manickan E, 1997, J LEUKOCYTE BIOL, V61, P125, DOI 10.1002/jlb.61.2.125; Mukherjee S, 1998, J EXP MED, V187, P445, DOI 10.1084/jem.187.3.445; RICKINSON AB, 1996, EPSTEIN BARR VIRUS F, P2397; RICKINSON AB, 1997, ANN REV IMMUNOL, V15; Rock KL, 1999, ANNU REV IMMUNOL, V17, P739, DOI 10.1146/annurev.immunol.17.1.739; Rodriguez F, 1997, J VIROL, V71, P8497, DOI 10.1128/JVI.71.11.8497-8503.1997; Sharipo A, 1998, NAT MED, V4, P939, DOI 10.1038/nm0898-939; Tobery TW, 1997, J EXP MED, V185, P909, DOI 10.1084/jem.185.5.909; TOWNSEND A, 1988, J EXP MED, V168, P1211, DOI 10.1084/jem.168.4.1211; TRIVEDI P, 1991, INT J CANCER, V48, P794, DOI 10.1002/ijc.2910480527; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; Varshavsky A, 1996, P NATL ACAD SCI USA, V93, P12142, DOI 10.1073/pnas.93.22.12142; Zhou PB, 2000, MOL CELL, V6, P751, DOI 10.1016/S1097-2765(00)00074-5	28	46	48	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33353	33360		10.1074/jbc.M104535200	http://dx.doi.org/10.1074/jbc.M104535200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11435434	hybrid			2022-12-25	WOS:000170910200011
J	Branscombe, TL; Frankel, A; Lee, JH; Cook, JR; Yang, ZH; Pestka, S; Clarke, S				Branscombe, TL; Frankel, A; Lee, JH; Cook, JR; Yang, ZH; Pestka, S; Clarke, S			PRMT5 (Janus kinase-binding protein 1) catalyzes the formation of symmetric dimethylarginine residues in proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST ARGININE METHYLTRANSFERASE; SACCHAROMYCES-CEREVISIAE; N-METHYLTRANSFERASE; FISSION YEAST; HUMAN HOMOLOG; METHYLATION; INTERACTS; MYELIN; SKB1; OLIGOMERIZATION	We have identified a new mammalian protein arginine N-methyltransferase, PRMT5, formerly designated Janus kinase-binding protein 1, that can catalyze the formation of omega -N-G-monomethylarginine and symmetric omega -N-G,N-G '-dimethylarginine in a variety of proteins. A hemagglutinin peptide-tagged PRMT5 complex purified from human HeLa cells catalyzes the S-adenosyl-L-[methyl-H-3]methionine-dependent in vitro methylation of myelin basic protein. When the radiolabeled myelin basic protein was acid-hydrolyzed to free amino acids, and the products were separated by high-resolution cation exchange chromatography, we were able to detect two tritiated species. One species co-migrated with a omega -N-G-monomethylarginine standard, and the other cochromatographed with a symmetric omega -N-G,N-G '-dimethylarginine standard. Upon base treatment, this second species formed methylamine, a breakdown product characteristic of symmetric omega -N-G,N-G '-dimethylarginine. Further analysis of these two species by thin layer chromatography confirmed their identification as omega -N-G-monomethylarginine and symmetric omega -N-G,N-G '-dimethylarginine. The hemagglutinin-PRMT5 complex was also able to monomethylate and symmetrically dimethylate bovine histone H2A and a glutathione S-transferase-fibrillarin (amino acids 1-148) fusion protein (glutathione S-transferase-GAR). A mutation introduced into the S-adenosyl-L-methionine-binding motif I of a myc-tagged PRMT5 construct in COS-1 cells led to a near complete loss of observed enzymatic activity. PRMT5 is the first example of a catalytic chain for a type II protein arginine N-methyltransferase that can result in the formation of symmetric dimethylarginine residues as observed previously in myelin basic protein, Sm small nuclear ribonucleoproteins, and other polypeptides.	Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Mol Genet & Microbiol, Piscataway, NJ 08854 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Rutgers State University New Brunswick; Rutgers State University Medical Center	Clarke, S (corresponding author), Univ Calif Los Angeles, Dept Chem & Biochem, 607 Charles E Young Dr E, Los Angeles, CA 90095 USA.				NCI NIH HHS [CA46465, CA72720] Funding Source: Medline; NIAID NIH HHS [AI43369, AI36450] Funding Source: Medline; NIGMS NIH HHS [GM26020, GM07185] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA072720, R01CA046465] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043369, R01AI036450] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026020, T32GM007185, R37GM026020] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschuler L, 1999, J INTERF CYTOK RES, V19, P189, DOI 10.1089/107999099314333; ASPILLAGA MO, 1977, J NEUROCHEM, V28, P1147, DOI 10.1111/j.1471-4159.1977.tb10683.x; BALDWIN GS, 1971, SCIENCE, V171, P579, DOI 10.1126/science.171.3971.579; Bedford MT, 2000, J BIOL CHEM, V275, P16030, DOI 10.1074/jbc.M909368199; Brahms H, 2000, J BIOL CHEM, V275, P17122, DOI 10.1074/jbc.M000300200; BROSTOFF S, 1971, P NATL ACAD SCI USA, V68, P765, DOI 10.1073/pnas.68.4.765; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; DINN JJ, 1980, IRISH J MED SCI, V149, P53, DOI 10.1007/BF02939111; EYLAR EH, 1972, ANN NY ACAD SCI, V195, P481, DOI 10.1111/j.1749-6632.1972.tb54829.x; Fujita T, 1999, P NATL ACAD SCI USA, V96, P8522, DOI 10.1073/pnas.96.15.8522; Gary JD, 1998, PROG NUCLEIC ACID RE, V61, P65, DOI 10.1016/S0079-6603(08)60825-9; Gary JD, 1996, J BIOL CHEM, V271, P12585, DOI 10.1074/jbc.271.21.12585; Gilbreth M, 1998, P NATL ACAD SCI USA, V95, P14781, DOI 10.1073/pnas.95.25.14781; Gilbreth M, 1996, P NATL ACAD SCI USA, V93, P13802, DOI 10.1073/pnas.93.24.13802; GOTTSCHLING H, 1962, NATURE, V196, P829, DOI 10.1038/196829a0; KIM S, 1990, PROTEIN METHYLATION, P77; Lee JH, 2000, BIOCHEM BIOPH RES CO, V274, P105, DOI 10.1006/bbrc.2000.3049; Lin WJ, 1996, J BIOL CHEM, V271, P15034, DOI 10.1074/jbc.271.25.15034; Ma XJ, 1996, GENE DEV, V10, P1327, DOI 10.1101/gad.10.11.1327; McBride AE, 2000, J BIOL CHEM, V275, P3128, DOI 10.1074/jbc.275.5.3128; Niewmierzycka A, 1999, J BIOL CHEM, V274, P814, DOI 10.1074/jbc.274.2.814; NORRANDER J, 1983, GENE, V26, P101, DOI 10.1016/0378-1119(83)90040-9; PAIK WK, 1970, J BIOL CHEM, V245, P88; Pollack BP, 1999, J BIOL CHEM, V274, P31531, DOI 10.1074/jbc.274.44.31531; Rho J, 2001, J BIOL CHEM, V276, P16592; SCOTT JM, 1981, LANCET, V2, P334; STONER GL, 1984, J NEUROCHEM, V43, P433, DOI 10.1111/j.1471-4159.1984.tb00919.x; Tang J, 2000, J BIOL CHEM, V275, P19866, DOI 10.1074/jbc.M000023200; Tang J, 1998, J BIOL CHEM, V273, P16935, DOI 10.1074/jbc.273.27.16935; Weiss VH, 2000, NAT STRUCT BIOL, V7, P1165; XIE HY, 1993, J BIOL CHEM, V268, P13364; Zhang X, 2000, EMBO J, V19, P3509, DOI 10.1093/emboj/19.14.3509; Zobel-Thropp P, 1998, J BIOL CHEM, V273, P29283, DOI 10.1074/jbc.273.45.29283	33	292	299	0	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					32971	32976		10.1074/jbc.M105412200	http://dx.doi.org/10.1074/jbc.M105412200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11413150	hybrid			2022-12-25	WOS:000170746000080
J	Lee, J; Hur, J; Lee, P; Kim, JY; Cho, N; Kim, SY; Kim, H; Lee, MS; Suk, K				Lee, J; Hur, J; Lee, P; Kim, JY; Cho, N; Kim, SY; Kim, H; Lee, MS; Suk, K			Dual role of inflammatory stimuli in activation-induced cell death of mouse microglial cells - Initiation of two separate apoptotic pathways via induction of interferon regulatory factor-1 and caspase-11	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; NITRIC-OXIDE SYNTHASE; TUMOR-NECROSIS-FACTOR; TRANSCRIPTIONAL ACTIVATOR; GENE-EXPRESSION; T-LYMPHOCYTES; GLIAL-CELLS; MACROPHAGES; IRF-1; BRAIN	We have previously shown that mouse microglial cells undergo apoptosis upon inflammatory activation and that nitric oxide (NO) is the major autocrine mediator in this process (Lee, P., Lee, J., Kim, S., Yagita, H., Lee, M. S., Kim, S. Y., Kim, H., and Suk, K. (2001) Brain Res. 892, 380-385). Here, we present evidence that interferon regulatory factor-1 (IRF-1) and caspase-11 are the essential molecules in activation-induced cell death of microglial cells. The apoptogenic action of inflammatory stimuli such as lipopolysaccharide (LPS) and interferon-gamma (IFN gamma) was mediated through the induction of IRF-1 and caspase-11 expression in two separate events. Although IRF-1 was required for NO synthesis, caspase-11 induction was necessary for NO-independent apoptotic pathway. Microglial cells from IRF-1-deficient mice showed markedly decreased NO production, and they were partially resistant to apoptosis in response to LPS/IFN gamma but were sensitive to NO donor exposure. LPS/IFN gamma treatment resulted in the induction of caspase-11 followed by activation of caspase-11, -1, and -3. Inactivation of caspase-11 by the transfection of dominant-negative mutant or treatment with the caspase inhibitors rendered microglial cells partially resistant to LPS/IFN gamma -induced apoptosis. Inhibition of both NO synthesis and caspase-11 completely blocked LPS/IFN gamma -induced cytotoxicity. These results indicated that LPS/IFN gamma not only induced the production of cytotoxic NO through IRF-1 but also initiated the NO-independent apoptotic pathway through the induction of caspase-11 expression.	Kyung Hee Univ, Dept Herbal Pharmacol, Grad Sch East West Med Sci, Tongdaemun Ku, Seoul 130701, South Korea; Sungkyunkwan Univ, Sch Med, Dept Med, Samsung Med Ctr, Seoul 135710, South Korea	Kyung Hee University; Sungkyunkwan University (SKKU); Samsung Medical Center	Suk, K (corresponding author), Kyung Hee Univ, Dept Herbal Pharmacol, Grad Sch East West Med Sci, Tongdaemun Ku, Seoul 130701, South Korea.	mslee@smc.samsung.co.kr	Lee, Myung Shik/C-9606-2011					ADLER B, 1995, BIOCHEM BIOPH RES CO, V215, P921, DOI 10.1006/bbrc.1995.2552; ALBINA JE, 1993, J IMMUNOL, V150, P5080; Aloisi F, 1999, J NEUROSCI RES, V56, P571; BALLARD DW, 1992, P NATL ACAD SCI USA, V89, P1875, DOI 10.1073/pnas.89.5.1875; BARBER SA, 1995, INFECT IMMUN, V63, P601, DOI 10.1128/IAI.63.2.601-608.1995; BLASI E, 1990, J NEUROIMMUNOL, V27, P229, DOI 10.1016/0165-5728(90)90073-V; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; Chung HT, 2001, BIOCHEM BIOPH RES CO, V282, P1075, DOI 10.1006/bbrc.2001.4670; Conti B, 1999, MOL BRAIN RES, V67, P46, DOI 10.1016/S0169-328X(99)00034-0; Crispe IN, 1999, IMMUNOL RES, V19, P143, DOI 10.1007/BF02786483; Donjerkovic D, 2000, CELL RES, V10, P179, DOI 10.1038/sj.cr.7290047; Drache B, 1997, J NEUROSCI RES, V47, P98; Drew PD, 1995, J INTERF CYTOK RES, V15, P1037, DOI 10.1089/jir.1995.15.1037; Fujimura M, 1997, BRAIN RES, V759, P247, DOI 10.1016/S0006-8993(97)00264-3; GEHRMANN J, 1995, BRAIN RES REV, V20, P269, DOI 10.1016/0165-0173(94)00015-H; Gonzalez-Scarano F, 1999, ANNU REV NEUROSCI, V22, P219, DOI 10.1146/annurev.neuro.22.1.219; Hisahara S, 2001, J EXP MED, V193, P111, DOI 10.1084/jem.193.1.111; KAMIJO R, 1994, SCIENCE, V263, P1612, DOI 10.1126/science.7510419; Kang SJ, 2000, J CELL BIOL, V149, P613, DOI 10.1083/jcb.149.3.613; Kano A, 1999, BIOCHEM BIOPH RES CO, V257, P672, DOI 10.1006/bbrc.1999.0276; Lakics V, 2000, J IMMUNOL, V165, P2729, DOI 10.4049/jimmunol.165.5.2729; LEE B, 2001, J NEUROCHEM, V892, P182; Lee KY, 1999, J BIOL CHEM, V274, P13451, DOI 10.1074/jbc.274.19.13451; Lee P, 2001, BRAIN RES, V892, P380, DOI 10.1016/S0006-8993(00)03257-1; Liu B, 2001, J NEUROCHEM, V77, P182, DOI 10.1046/j.1471-4159.2001.t01-1-00216.x; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; MIGHELI A, 1994, NEUROREPORT, V5, P1906, DOI 10.1097/00001756-199410000-00016; Minghetti L, 1998, PROG NEUROBIOL, V54, P99, DOI 10.1016/S0301-0082(97)00052-X; NEISH AS, 1995, MOL CELL BIOL, V15, P2558; Okada S, 1998, J IMMUNOL, V160, P2590; Pahan K, 1999, J BIOL CHEM, V274, P7528, DOI 10.1074/jbc.274.11.7528; Sanz JM, 2000, J IMMUNOL, V164, P4893, DOI 10.4049/jimmunol.164.9.4893; Saura M, 1999, J MOL BIOL, V289, P459, DOI 10.1006/jmbi.1999.2752; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Shibata M, 2000, J CLIN INVEST, V106, P643, DOI 10.1172/JCI10203; Stoll G, 1999, PROG NEUROBIOL, V58, P233, DOI 10.1016/S0301-0082(98)00083-5; Suk K, 2001, FEBS LETT, V495, P66, DOI 10.1016/S0014-5793(01)02335-3; Suk K, 2001, J BIOL CHEM, V276, P13153, DOI 10.1074/jbc.M007646200; Suk K, 2001, J IMMUNOL, V166, P4481, DOI 10.4049/jimmunol.166.7.4481; Suk K, 2001, BRAIN RES, V900, P342, DOI 10.1016/S0006-8993(01)02326-5; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; von Knethen A, 1998, ONCOGENE, V17, P387, DOI 10.1038/sj.onc.1201926; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang SY, 1996, J BIOL CHEM, V271, P20580, DOI 10.1074/jbc.271.34.20580; Wang SY, 1998, CELL, V92, P501, DOI 10.1016/S0092-8674(00)80943-5; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739	48	97	102	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					32956	32965		10.1074/jbc.M104700200	http://dx.doi.org/10.1074/jbc.M104700200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11402054	hybrid			2022-12-25	WOS:000170746000078
J	Pai, KS; Mahajan, VB; Lau, A; Cunningham, DD				Pai, KS; Mahajan, VB; Lau, A; Cunningham, DD			Thrombin receptor signaling to cytoskeleton requires Hsp90	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEASE-ACTIVATED RECEPTOR-1; EXCHANGER REGULATORY FACTOR; NEURITE RETRACTION; BETA(2)-ADRENERGIC RECEPTOR; MOLECULAR CHAPERONE; TYROSINE KINASE; ATP BINDING; CELL-DEATH; G-PROTEINS; IN-VIVO	Thrombin is a serine protease that evokes various cellular responses involved in injury and repair of the nervous system through the activation of protease-activated receptor-1 (PAR-1). Signals that modulate cell morphology precede most PAR-1 effects, but the initial signal transduction molecules are not known. Using the yeast two-hybrid system, we identified Hsp90, a chaperone with known signaling properties, as a binding partner of PAR-1. The interaction was confirmed by glutathione S-transferase pull-down, overlay, and co-immunoprecipitation assays. Morphological assays in mouse astrocytes were carried out to evaluate the importance of Hsp90 during cytoskeletal signaling. Reducing Hsp90 levels by antisense treatment or disruption of the Hsp90-PAR-1 complex by the Hsp90-specific drug geldanamycin attenuated thrombin-mediated astrocyte shape changes. Furthermore, overexpression of the PAR-1 cytoplasmic tail abrogated thrombin-induced cytoskeletal changes in neuronal cells. Treatment with geldanamycin specifically inhibited activation of RhoA without affecting thrombin-mediated intracellular calcium release, revealing the regulation of a distinct signaling pathway by Hsp90. Taken together, these studies demonstrate that Hsp90 may be essential for PAR-1-mediated signaling to the cytoskeleton.	Univ Calif Irvine, Coll Med, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA	University of California System; University of California Irvine	Cunningham, DD (corresponding author), Univ Calif Irvine, Coll Med, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA.				NIA NIH HHS [AG00538] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BERNDT MC, 1981, PLATELETS BIOL PATHO, P43; BOHEN SP, 1995, SCIENCE, V268, P1303, DOI 10.1126/science.7761850; Conconi M, 1998, BIOCHEM J, V333, P407, DOI 10.1042/bj3330407; COUGHLIN SR, 1994, SEMIN HEMATOL, V31, P270; CUTFORTH T, 1994, CELL, V77, P1027, DOI 10.1016/0092-8674(94)90442-1; Donovan FM, 1998, J BIOL CHEM, V273, P12746, DOI 10.1074/jbc.273.21.12746; Donovan FM, 1997, J NEUROSCI, V17, P5316; Essler M, 1998, J BIOL CHEM, V273, P21867, DOI 10.1074/jbc.273.34.21867; Even-Ram S, 1998, NAT MED, V4, P909, DOI 10.1038/nm0898-909; Garcia-Cardena G, 1998, NATURE, V392, P821, DOI 10.1038/33934; Gingrich MB, 2000, TRENDS NEUROSCI, V23, P399, DOI 10.1016/S0166-2236(00)01617-9; GRABHAM P, 1995, J NEUROCHEM, V64, P583; Grand RJA, 1996, BIOCHEM J, V313, P353, DOI 10.1042/bj3130353; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Hall RA, 1998, P NATL ACAD SCI USA, V95, P8496, DOI 10.1073/pnas.95.15.8496; JALINK K, 1992, J CELL BIOL, V118, P411, DOI 10.1083/jcb.118.2.411; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; Klages B, 1999, J CELL BIOL, V144, P745, DOI 10.1083/jcb.144.4.745; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; LUTTRELL LM, 1993, SCIENCE, V259, P1453, DOI 10.1126/science.8383880; Mahajan VB, 2000, P NATL ACAD SCI USA, V97, P12062, DOI 10.1073/pnas.97.22.12062; NATHAN DF, 1995, MOL CELL BIOL, V15, P3917; Obermann WMJ, 1998, J CELL BIOL, V143, P901, DOI 10.1083/jcb.143.4.901; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; Panaretou B, 1998, EMBO J, V17, P4829, DOI 10.1093/emboj/17.16.4829; Pratt WB, 1997, ANNU REV PHARMACOL, V37, P297, DOI 10.1146/annurev.pharmtox.37.1.297; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Reid T, 1996, J BIOL CHEM, V271, P13556, DOI 10.1074/jbc.271.23.13556; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; RUTHERFORD SL, 1994, CELL, V79, P1129, DOI 10.1016/0092-8674(94)90003-5; Seasholtz TM, 1999, MOL PHARMACOL, V55, P949, DOI 10.1124/mol.55.6.949; Shapiro MJ, 1998, J BIOL CHEM, V273, P29009, DOI 10.1074/jbc.273.44.29009; Shapiro MJ, 1996, J BIOL CHEM, V271, P32874, DOI 10.1074/jbc.271.51.32874; SMITHSWINTOSKY VL, 1995, J NEUROSCI, V15, P5840; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Striggow F, 2000, P NATL ACAD SCI USA, V97, P2264, DOI 10.1073/pnas.040552897; SUIDAN HS, 1992, NEURON, V8, P363, DOI 10.1016/0896-6273(92)90302-T; Suidan HS, 1997, GLIA, V21, P244, DOI 10.1002/(SICI)1098-1136(199710)21:2<244::AID-GLIA7>3.0.CO;2-6; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Trejo J, 1998, P NATL ACAD SCI USA, V95, P13698, DOI 10.1073/pnas.95.23.13698; Turgeon VL, 1998, J NEUROSCI, V18, P6882; Ubl JJ, 1997, GLIA, V21, P361, DOI 10.1002/(SICI)1098-1136(199712)21:4<361::AID-GLIA3>3.0.CO;2-6; VAUGHAN PJ, 1995, J NEUROSCI, V15, P5389; Verrall S, 1997, J BIOL CHEM, V272, P6898, DOI 10.1074/jbc.272.11.6898; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WEINSTEIN JR, 1995, J NEUROSCI, V15, P2906; XU Y, 1993, P NATL ACAD SCI USA, V90, P7074, DOI 10.1073/pnas.90.15.7074	47	42	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					32642	32647		10.1074/jbc.M104212200	http://dx.doi.org/10.1074/jbc.M104212200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11413145	hybrid			2022-12-25	WOS:000170746000036
J	Sugihara, TM; Kudryavtseva, EI; Kumar, V; Horridge, JJ; Andersen, B				Sugihara, TM; Kudryavtseva, EI; Kumar, V; Horridge, JJ; Andersen, B			The POU domain factor skin-1a represses the keratin 14 promoter independent of DNA binding - A possible role for interactions between Skn-1a and creb-binding protein/p300	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIATION-SPECIFIC EXPRESSION; ETS TRANSCRIPTION FACTOR; FACTOR-KAPPA-B; GENE-EXPRESSION; GLUCOCORTICOID RECEPTOR; NUCLEAR INTEGRATION; TRANSGENIC MICE; P300; COACTIVATOR; EPIDERMIS	The genes encoding keratin 5 and 14 are highly expressed in the basal cell layer keratinocytes of the epidermis, but both genes are silenced when keratinocytes move into the suprabasal compartment. The POU homeodomain factors Skn-1a and Tst-1, which are expressed in epidermis, may play a role in the suprabasal repression of the keratin 5 and 14 genes because keratin 14 mRNA expression persists in suprabasal cells in Skn-1/Tst-1 double knockout mice. In transfection experiments, both Skn-1a and Tst-1 repress the keratin 14 promoter, with the POU domain being sufficient for repression. The region of the keratin 14 gene sufficient and required for repression by Skn-1a is a 100-base pair sequence lacking POU-binding sites adjacent to the transcription start site. DNA-binding defective mutants of Skn-1a and Tst-1 are as effective at mediating repression as the wild type proteins, suggesting that protein-protein interactions rather than direct DNA binding are important for repression. We also show that CREB-binding protein (CBP)/p300 co-activators are strong activators of keratin 14 gene expression, acting through sequences close to the keratin 14 promoter. Further, CBP interacts directly with the POU domain of Skn-1a, and increasing concentrations of CBP can overcome Skn-1a-mediated repression, suggesting that POU domain factors may repress keratin 14 gene expression by interfering with the activity of co-activators such as CBP/p300.	Univ Calif Irvine, Dept Med, Div Endocrinol & Metab, Irvine, CA 92697 USA; Univ Calif San Diego, Dept Med, Div Endocrinol & Metab, Dept Biol, La Jolla, CA 92093 USA	University of California System; University of California Irvine; University of California System; University of California San Diego	Andersen, B (corresponding author), Univ Calif Irvine, Dept Med, Div Endocrinol & Metab, Med Sci 1,Rm C350,ZOT4086, Irvine, CA 92697 USA.		Kumar, Vivek/P-8749-2014	Kumar, Vivek/0000-0001-6643-7465	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044882, K02AR002080] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR44882, AR02080] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ahringer J, 2000, TRENDS GENET, V16, P351, DOI 10.1016/S0168-9525(00)02066-7; ANDERSEN B, 1993, SCIENCE, V260, P78, DOI 10.1126/science.7682011; Andersen B, 1997, J BIOL CHEM, V272, P15905, DOI 10.1074/jbc.272.25.15905; Andersen B, 1997, GENE DEV, V11, P1873, DOI 10.1101/gad.11.14.1873; ANDERSEN B, 1993, J BIOL CHEM, V268, P23390; Andersen B, 2001, ENDOCR REV, V22, P2, DOI 10.1210/er.22.1.2; Andreoli JM, 1997, NUCLEIC ACIDS RES, V25, P4287, DOI 10.1093/nar/25.21.4287; Bermingham JR, 1996, GENE DEV, V10, P1751, DOI 10.1101/gad.10.14.1751; Cho H, 1998, MOL CELL BIOL, V18, P5355, DOI 10.1128/MCB.18.9.5355; Coulombe PA, 1997, BIOCHEM BIOPH RES CO, V236, P231, DOI 10.1006/bbrc.1997.6945; Dallas PB, 1997, J VIROL, V71, P1726, DOI 10.1128/JVI.71.2.1726-1731.1997; Dasen JS, 1999, CELL, V97, P587, DOI 10.1016/S0092-8674(00)80770-9; DiSepio D, 1999, DIFFERENTIATION, V64, P225, DOI 10.1046/j.1432-0436.1999.6440225.x; DISEPIO D, 1995, J BIOL CHEM, V270, P10792, DOI 10.1074/jbc.270.18.10792; Eckert RL, 1997, J INVEST DERMATOL, V109, P501, DOI 10.1111/1523-1747.ep12336477; FAUS I, 1994, MOL CELL BIOL, V14, P3263, DOI 10.1128/MCB.14.5.3263; Felzien LK, 1999, MOL CELL BIOL, V19, P4241; Fronsdal K, 1998, J BIOL CHEM, V273, P31853, DOI 10.1074/jbc.273.48.31853; Fuchs E, 1995, ANNU REV CELL DEV BI, V11, P123, DOI 10.1146/annurev.cb.11.110195.001011; FUCHS E, 1994, CURR OPIN GENET DEV, V4, P725, DOI 10.1016/0959-437X(94)90140-X; Goodman RH, 2000, GENE DEV, V14, P1553; Gordon DF, 1997, J BIOL CHEM, V272, P24339, DOI 10.1074/jbc.272.39.24339; Hampsey M, 1999, CURR OPIN GENET DEV, V9, P132, DOI 10.1016/S0959-437X(99)80020-3; HE X, 1991, MOL CELL BIOL, V11, P1739, DOI 10.1128/MCB.11.3.1739; HERR W, 1988, GENE DEV, V2, P1513, DOI 10.1101/gad.2.12a.1513; Hildesheim J, 1999, J BIOL CHEM, V274, P26399, DOI 10.1074/jbc.274.37.26399; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; Ip YT, 1997, CURR BIOL, V7, pR216, DOI 10.1016/S0960-9822(06)00104-7; Jaegle M, 1996, SCIENCE, V273, P507, DOI 10.1126/science.273.5274.507; Jang SI, 2000, J BIOL CHEM, V275, P15295, DOI 10.1074/jbc.275.20.15295; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KLEMM JD, 1994, CELL, V77, P21, DOI 10.1016/0092-8674(94)90231-3; Kurokawa R, 1998, SCIENCE, V279, P700, DOI 10.1126/science.279.5351.700; LEASK A, 1990, GENE DEV, V4, P1985, DOI 10.1101/gad.4.11.1985; Mannervik M, 1999, SCIENCE, V284, P606, DOI 10.1126/science.284.5414.606; MISSERO C, 1993, J CELL BIOL, V121, P1109, DOI 10.1083/jcb.121.5.1109; Nibu Y, 1998, EMBO J, V17, P7009, DOI 10.1093/emboj/17.23.7009; Oettgen P, 1997, MOL CELL BIOL, V17, P4419, DOI 10.1128/MCB.17.8.4419; Oettgen P, 1999, J BIOL CHEM, V274, P29439, DOI 10.1074/jbc.274.41.29439; Radoja N, 2000, MOL CELL BIOL, V20, P4328, DOI 10.1128/MCB.20.12.4328-4339.2000; Ryan AK, 1997, GENE DEV, V11, P1207, DOI 10.1101/gad.11.10.1207; SAATCIOGLU F, 1994, SEMIN CANCER BIOL, V5, P347; Sheppard KA, 1998, J BIOL CHEM, V273, P29291, DOI 10.1074/jbc.273.45.29291; Sinha S, 2000, MOL CELL BIOL, V20, P2543, DOI 10.1128/MCB.20.7.2543-2555.2000; Sock E, 1996, J BIOL CHEM, V271, P17512, DOI 10.1074/jbc.271.29.17512; Speir E, 2000, CIRC RES, V87, P1006, DOI 10.1161/01.RES.87.11.1006; Sugihara TM, 1998, P NATL ACAD SCI USA, V95, P15418, DOI 10.1073/pnas.95.26.15418; VASSAR R, 1989, P NATL ACAD SCI USA, V86, P1563, DOI 10.1073/pnas.86.5.1563; Wang XM, 1997, P NATL ACAD SCI USA, V94, P219, DOI 10.1073/pnas.94.1.219; Welter JF, 1996, J BIOL CHEM, V271, P14727, DOI 10.1074/jbc.271.25.14727; Welter JF, 1995, ONCOGENE, V11, P2681; Xu L, 1998, NATURE, V395, P301, DOI 10.1038/26270; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Yukawa K, 1996, J VIROL, V70, P10, DOI 10.1128/JVI.70.1.10-16.1996; Zanger K, 1999, MOL ENDOCRINOL, V13, P268, DOI 10.1210/me.13.2.268; Zhang WJ, 2001, MOL CELL BIOL, V21, P2413, DOI 10.1128/MCB.21.7.2413-2422.2001	56	36	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					33036	33044		10.1074/jbc.M103000200	http://dx.doi.org/10.1074/jbc.M103000200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11429405	hybrid			2022-12-25	WOS:000170746000088
J	D'Addario, M; Arora, PD; Fan, J; Ganss, B; Ellen, RP; McCulloch, CAG				D'Addario, M; Arora, PD; Fan, J; Ganss, B; Ellen, RP; McCulloch, CAG			Cytoprotection against mechanical forces delivered through beta(1) integrins requires induction of filamin A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN-BINDING PROTEIN; SMOOTH-MUSCLE ACTIN; CELL-ADHESION; EXPRESSION; FIBROBLASTS; TRANSCRIPTION; PURIFICATION; FILAMENTS; MIGRATION; APOPTOSIS	Cells in mechanically active environments can activate cytoprotective mechanisms to maintain membrane integrity in the face of potentially lethal applied forces. Cytoprotection may be mediated by expression of membrane-associated cytoskeletal proteins including filamin A, an actin-binding protein that increases the rigidity of the subcortical actin cytoskeleton. In this study, we tested the hypotheses that applied forces induce the expression of filamin A specifically and that this putative protective response inhibits cell death. Magnetically generated forces were applied to protein-coated magnetite beads bound to human gingival fibroblasts, cells with constitutively low basal levels of filamin A mRNA and protein. Forces applied through collagen or fibronectin, but not bovine serum albumin or poly-L-lysine-coated beads, increased mRNA and protein content of filamin A by 3-7-fold. Forces had no effect on the expression of other filamin isotypes or other cytoskeletal proteins. This effect was dependent on the duration of force and was blocked by anti-beta (1) integrin antibodies. Force also stimulated a 60% increase in expression of luciferase under the control of a filamin A promoter in transiently transfected Rat2 fibroblasts and was dependent on Sp1 transcription factor binding sites located immediately upstream of the transcription start site. Experiments with actinomycin D-treated cells showed that the increased filamin A expression after force application was due in part to prolongation of mRNA half-life. Antisense filamin oligonucleotides blocked force-induced filamin A expression and increased cell death by >2-fold above controls. The force-induced regulation of filamin A was dependent on intact actin filaments. We conclude that cells from mechanically active environments can couple diverse signals from forces applied through beta -integrins to up-regulate the production of cytoprotective cytoskeletal proteins, typified by filamin A.	Univ Toronto, Canadian Inst Hlth Res Grp Periodont Physiol, Toronto, ON M5S 3E2, Canada; Univ Toronto, Fac Dent, Inst Dent Res, Toronto, ON M5S 3E2, Canada	University of Toronto; University of Toronto	McCulloch, CAG (corresponding author), Rm 244,Fitzgerald Bldg,150 Coll St, Toronto, ON M5S 3E2, Canada.							ANDREWS RK, 1991, J BIOL CHEM, V266, P7144; Arora PD, 1999, AM J PATHOL, V154, P871, DOI 10.1016/S0002-9440(10)65334-5; Birukov KG, 1998, ARTERIOSCL THROM VAS, V18, P922, DOI 10.1161/01.ATV.18.6.922; BROWN KD, 1993, EXP CELL RES, V209, P325, DOI 10.1006/excr.1993.1317; Calderwood DA, 2000, J BIOL CHEM, V275, P22607, DOI 10.1074/jbc.R900037199; Chen EY, 1996, HUM MOL GENET, V5, P659, DOI 10.1093/hmg/5.5.659; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cooper JA, 2000, CURR OPIN CELL BIOL, V12, P97, DOI 10.1016/S0955-0674(99)00062-9; Critchley DR, 2000, CURR OPIN CELL BIOL, V12, P133, DOI 10.1016/S0955-0674(99)00067-8; CUNNINGHAM CC, 1992, SCIENCE, V255, P325, DOI 10.1126/science.1549777; D'Addario M, 1999, FASEB J, V13, P2203, DOI 10.1096/fasebj.13.15.2203; D'Addario M, 2000, J MOL BIOL, V298, P765, DOI 10.1006/jmbi.2000.3717; Fox JW, 1998, NEURON, V21, P1315, DOI 10.1016/S0896-6273(00)80651-0; Glogauer M, 1997, J CELL SCI, V110, P11; Glogauer M, 1998, J BIOL CHEM, V273, P1689, DOI 10.1074/jbc.273.3.1689; GOELZ SE, 1985, BIOCHEM BIOPH RES CO, V130, P118, DOI 10.1016/0006-291X(85)90390-0; GORLIN JB, 1990, J CELL BIOL, V111, P1089, DOI 10.1083/jcb.111.3.1089; Hui MZ, 1997, J CELL PHYSIOL, V172, P323, DOI 10.1002/(SICI)1097-4652(199709)172:3<323::AID-JCP6>3.0.CO;2-Q; Jacquelin B, 2001, BLOOD, V97, P1721, DOI 10.1182/blood.V97.6.1721; KULKARNI GV, 1995, J CELL PHYSIOL, V165, P119, DOI 10.1002/jcp.1041650115; Lemon B, 2000, GENE DEV, V14, P2551, DOI 10.1101/gad.831000; Leonardi A, 2000, J BIOL CHEM, V275, P271, DOI 10.1074/jbc.275.1.271; Lew AM, 1999, BIOCHEM J, V341, P647, DOI 10.1042/0264-6021:3410647; Liu GP, 1997, J CELL BIOL, V139, P1719, DOI 10.1083/jcb.139.7.1719; Loo DT, 1998, J BIOL CHEM, V273, P23304, DOI 10.1074/jbc.273.36.23304; Mack CP, 1999, CIRC RES, V84, P852; Maniotis AJ, 1997, P NATL ACAD SCI USA, V94, P849, DOI 10.1073/pnas.94.3.849; OHTA Y, 1991, CELL, V67, P275, DOI 10.1016/0092-8674(91)90179-3; Ohta Y, 1999, P NATL ACAD SCI USA, V96, P2122, DOI 10.1073/pnas.96.5.2122; Ott I, 1998, J CELL BIOL, V140, P1241, DOI 10.1083/jcb.140.5.1241; PENDER N, 1991, J CELL SCI, V100, P187; Pfaff M, 1998, J BIOL CHEM, V273, P6104, DOI 10.1074/jbc.273.11.6104; PRESTRIDGE DS, 1995, J MOL BIOL, V249, P923, DOI 10.1006/jmbi.1995.0349; Schwarzman AL, 1999, P NATL ACAD SCI USA, V96, P7932, DOI 10.1073/pnas.96.14.7932; Segal G, 2001, J CELL SCI, V114, P119; Sinha S, 2001, P NATL ACAD SCI USA, V98, P2455, DOI 10.1073/pnas.051633598; Swartz EA, 1998, AM J PHYSIOL-CELL PH, V275, pC608, DOI 10.1152/ajpcell.1998.275.2.C608; Tidball JG, 1999, J BIOL CHEM, V274, P33155, DOI 10.1074/jbc.274.46.33155; Wang J, 2000, AM J PHYSIOL-HEART C, V279, pH2776, DOI 10.1152/ajpheart.2000.279.6.H2776; WANG K, 1977, BIOCHEMISTRY-US, V16, P1857, DOI 10.1021/bi00628a015; WATSON PA, 1991, FASEB J, V5, P2013, DOI 10.1096/fasebj.5.7.1707019; WILSON E, 1995, J CLIN INVEST, V96, P2364, DOI 10.1172/JCI118293	42	50	52	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					31969	31977		10.1074/jbc.M102715200	http://dx.doi.org/10.1074/jbc.M102715200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11423540	hybrid			2022-12-25	WOS:000170613500069
J	Froehlich, JE; Benning, C; Dormann, P				Froehlich, JE; Benning, C; Dormann, P			The digalactosyldiacylglycerol (DGDG) synthase DGD1 is inserted into the outer envelope membrane of chloroplasts in a manner independent of the general import pathway and does not depend on direct interaction with monogalactosyldiacylglycerol synthase for DGDG biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN IMPORT; GALACTOLIPID BIOSYNTHESIS; MUTANT DEFICIENT; LIPID-SYNTHESIS; METABOLISM; SIGNAL; GALACTOSYLTRANSFERASE; MITOCHONDRIAL; COMPONENT; PEPTIDES	Galactolipids make up the bulk of chloroplast lipids. Therefore, the genes involved in the synthesis of the galactolipids monogalactosyldiacylglycerol (MGDG) and digalactosyldiacylglycerol (DGDG) play a critical role in chloroplast development. In this study, we analyzed the subcellular localization of the Arabidopsis DGDG synthase DGD1, which was recently identified by complementation of the Arabidopsis dgd1 mutant. In vitro import experiments demonstrated that DGD1 was targeted to the chloroplast outer envelope in an ATP-independent manner. DGD1 could not be extracted from the membranes by high salt or alkali, suggesting that it is an integral membrane protein. Uptake experiments with truncated versions of DGD1 indicated that the information for targeting and insertion into the outer envelope resides in the N-terminal half of DGD1, but not in the first 33 amino acids. DGD1 apparently does not contain a cleavable signal peptide. Antibodies to Arabidopsis DGD1 detected a 90-kDa protein localized to the chloroplast envelopes of both pea and Arabidopsis. Transformation of DGD1 constructs into cyanobacteria resulted in the expression of active DGDG synthase and demonstrated that DGDG synthesis depends on MGDG lipid, but does not require direct interaction with the plant MGDG synthase.	Michigan State Univ, Dept Energy, Plant Res Lab, E Lansing, MI 48823 USA; Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48823 USA; Max Planck Inst Mol Plant Physiol, D-14476 Golm, Germany	Michigan State University; Michigan State University; Max Planck Society	Dormann, P (corresponding author), Michigan State Univ, Dept Energy, Plant Res Lab, E Lansing, MI 48823 USA.	doermann@mpimp-golm.mpg.de	Benning, Christoph/Y-2528-2019	Benning, Christoph/0000-0001-8585-3667				BLACK TA, 1994, J BACTERIOL, V176, P2282, DOI 10.1128/JB.176.8.2282-2292.1994; BROWSE J, 1986, BIOCHEM J, V235, P25, DOI 10.1042/bj2350025; BROWSE J, 1986, ANAL BIOCHEM, V152, P141, DOI 10.1016/0003-2697(86)90132-6; BRUCE BD, 1994, PLANT MOL BIOL MANUA, V2; Chen DD, 1997, J BIOL CHEM, V272, P6614, DOI 10.1074/jbc.272.10.6614; Chen LJ, 1998, PLANT J, V16, P33, DOI 10.1046/j.1365-313x.1998.00270.x; CLINE K, 1983, PLANT PHYSIOL, V71, P366, DOI 10.1104/pp.71.2.366; CLINE K, 1984, PLANT PHYSIOL, V75, P675, DOI 10.1104/pp.75.3.675; Dormann P, 1999, SCIENCE, V284, P2181, DOI 10.1126/science.284.5423.2181; DORMANN P, 1995, PLANT CELL, V7, P1801, DOI 10.1105/tpc.7.11.1801; DORNE AJ, 1982, FEBS LETT, V145, P30, DOI 10.1016/0014-5793(82)81200-3; DOUCE R, 1974, SCIENCE, V183, P852, DOI 10.1126/science.183.4127.852; DOUCE R, 1996, ADV PHOTOSYNTHESIS, V4; ELBAI J, 1988, METHOD ENZYMOL, V167, P747; FISCHER K, 1994, PLANT MOL BIOL, V25, P167, DOI 10.1007/BF00023235; FITZPATRICK L, 2001, IN PRESS PLANT J; Froehlich JE, 2001, PLANT PHYSIOL, V125, P306, DOI 10.1104/pp.125.1.306; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; FUJIKI Y, 1982, J CELL BIOL, V93, P103, DOI 10.1083/jcb.93.1.103; FURSTE JP, 1986, GENE, V48, P119, DOI 10.1016/0378-1119(86)90358-6; Guler S, 1996, J BIOL CHEM, V271, P7501; Hartel H, 1998, PLANT PHYSIOL BIOCH, V36, P407, DOI 10.1016/S0981-9428(98)80204-0; HEEMSKERK JWM, 1986, BIOCHIM BIOPHYS ACTA, V877, P281, DOI 10.1016/0005-2760(86)90305-X; HEINZ E, 1983, PLANT PHYSIOL, V72, P273, DOI 10.1104/pp.72.2.273; Jarvis P, 2000, P NATL ACAD SCI USA, V97, P8175, DOI 10.1073/pnas.100132197; Jorasch P, 2000, EUR J BIOCHEM, V267, P3770, DOI 10.1046/j.1432-1327.2000.01414.x; Jorasch P, 1999, TRENDS PLANT SCI, V4, P469, DOI 10.1016/S1360-1385(99)01505-8; Joyard J, 1998, PLANT PHYSIOL, V118, P715, DOI 10.1104/pp.118.3.715; Keegstra K, 1999, PLANT CELL, V11, P557, DOI 10.1105/tpc.11.4.557; KO K, 1992, J BIOL CHEM, V267, P2986; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee AG, 2000, CURR BIOL, V10, pR377, DOI 10.1016/S0960-9822(00)00477-2; LI HM, 1991, PLANT CELL, V3, P709, DOI 10.1105/tpc.3.7.709; Li HM, 1996, PLANT CELL, V8, P2117, DOI 10.1105/tpc.8.11.2117; Lubeck J, 1997, J CELL BIOL, V137, P1279, DOI 10.1083/jcb.137.6.1279; Marechal E, 1997, PHYSIOL PLANTARUM, V100, P65, DOI 10.1034/j.1399-3054.1997.1000106.x; Miege C, 1999, EUR J BIOCHEM, V265, P990, DOI 10.1046/j.1432-1327.1999.00801.x; Nielsen E, 1997, EMBO J, V16, P935, DOI 10.1093/emboj/16.5.935; Nielsen H, 1999, PROTEIN ENG, V12, P3, DOI 10.1093/protein/12.1.3; OLSEN LJ, 1992, J BIOL CHEM, V267, P433; PERRY SE, 1994, PLANT CELL, V6, P93, DOI 10.1105/tpc.6.1.93; PRENTKI P, 1981, GENE, V14, P289, DOI 10.1016/0378-1119(81)90161-X; Roughan PG, 1996, PLANT PHYSIOL, V110, P1239, DOI 10.1104/pp.110.4.1239; SALOMON M, 1990, P NATL ACAD SCI USA, V87, P5778, DOI 10.1073/pnas.87.15.5778; SATO N, 1993, BIOCH MOL BIOL MEMBR; Schnell DJ, 1998, ANNU REV PLANT PHYS, V49, P97, DOI 10.1146/annurev.arplant.49.1.97; Shimojima M, 1997, P NATL ACAD SCI USA, V94, P333, DOI 10.1073/pnas.94.1.333; Tietje C, 1998, PLANTA, V206, P72, DOI 10.1007/s004250050375; Tranel PJ, 1996, PLANT CELL, V8, P2093, DOI 10.1105/tpc.8.11.2093; TRANEL PJ, 1995, EMBO J, V14, P2436, DOI 10.1002/j.1460-2075.1995.tb07241.x; VONHEIJNE G, 1991, FEBS LETT, V278, P1, DOI 10.1016/0014-5793(91)80069-F; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; WU CB, 1993, J BIOL CHEM, V268, P19384	54	87	94	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					31806	31812		10.1074/jbc.M104652200	http://dx.doi.org/10.1074/jbc.M104652200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11429410	hybrid			2022-12-25	WOS:000170613500046
J	Kuwae, A; Yoshida, S; Tamano, K; Mimuro, H; Suzuki, T; Sasakawa, C				Kuwae, A; Yoshida, S; Tamano, K; Mimuro, H; Suzuki, T; Sasakawa, C			Shigella invasion of macrophage requires the insertion of IpaC into the host plasma membrane - Functional analysis of IpaC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED PHAGOCYTOSIS; PROTEIN-TYROSINE KINASE; LARGE VIRULENCE PLASMID; SRC-FAMILY KINASES; SALMONELLA-TYPHIMURIUM; HUMAN NEUTROPHILS; EPITHELIAL-CELLS; FLEXNERI 2A; MAMMALIAN-CELLS; HELA-CELLS	Shigella infects residential macrophages via the M cell entry, after which the pathogen induces macrophage cell death. The bacterial strategy of macrophage infection, however, remains largely speculative. Wild type Shigella flexneri (YSH6000) invaded macrophages more efficiently than the noninvasive mutants, where YSH6000 induced large scale lamellipodial extension including ruffle formation around the bacteria. When macrophages were infected with the noninvasive ipaC mutant, the invasiveness and induction of membrane extension were dramatically reduced as compared with that of YSH6000. J774 macrophages infected with YSH6000 showed tyrosine phosphorylation of several proteins including paxillin and c-Cbl, and this pattern was distinctive from those stimulated by Salmonella typhimurium or phorbol ester. Upon addition of IpaC into the external medium of macrophages, membrane extensions were rapidly induced, and this promoted uptake of Escherichia coli. The exogenously added IpaC was found to be integrated into the host cell membrane as detected by immunostaining. The IpaC domain required for the induction of membrane extension from J774 was narrowed down within the region of residues 117-169, which contains a putative membrane-spanning sequence. Our data indicate that Shigella directs its own entry into macrophages, and the IpaC domain which is required for the association with its host membrane is crucial.	Univ Tokyo, Inst Med Sci, Dept Microbiol & Immunol, Tokyo 1088639, Japan	University of Tokyo	Sasakawa, C (corresponding author), Univ Tokyo, Inst Med Sci, Dept Microbiol & Immunol, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.		Tamano, Koichi/K-8918-2018; Tamano, Koichi/AAQ-4392-2020	Tamano, Koichi/0000-0002-2985-7548; Yoshida, Sei/0000-0002-4771-3900				ALPUCHEARANDA CM, 1994, J EXP MED, V179, P601, DOI 10.1084/jem.179.2.601; Arondel J, 1999, INFECT IMMUN, V67, P6056, DOI 10.1128/IAI.67.11.6056-6066.1999; BERNARDINI ML, 1989, P NATL ACAD SCI USA, V86, P3867, DOI 10.1073/pnas.86.10.3867; BERTON G, 1994, J CELL BIOL, V126, P1111, DOI 10.1083/jcb.126.4.1111; BLAKE TJ, 1992, ONCOGENE, V7, P757; Blocker A, 1999, J CELL BIOL, V147, P683, DOI 10.1083/jcb.147.3.683; Bourdet-Sicard R, 1999, EMBO J, V18, P5853, DOI 10.1093/emboj/18.21.5853; Brumell JH, 2001, CELL MICROBIOL, V3, P75, DOI 10.1046/j.1462-5822.2001.00087.x; Buchrieser C, 2000, MOL MICROBIOL, V38, P760, DOI 10.1046/j.1365-2958.2000.02179.x; Caron E, 1998, SCIENCE, V282, P1717, DOI 10.1126/science.282.5394.1717; Chen LM, 1996, MOL MICROBIOL, V21, P1101, DOI 10.1046/j.1365-2958.1996.471410.x; Chimini G, 2000, NAT CELL BIOL, V2, pE191, DOI 10.1038/35036454; CLERC PL, 1987, INFECT IMMUN, V55, P521, DOI 10.1128/IAI.55.3.521-527.1987; Collazo CM, 1997, MOL MICROBIOL, V24, P747, DOI 10.1046/j.1365-2958.1997.3781740.x; DURAND JM, 1994, J BACTERIOL, V176, P4627, DOI 10.1128/JB.176.15.4627-4634.1994; FernandezPrada CM, 1997, INFECT IMMUN, V65, P1486, DOI 10.1128/IAI.65.4.1486-1496.1997; GINOCCHIO CC, 1994, CELL, V76, P717, DOI 10.1016/0092-8674(94)90510-X; GRAHAM IL, 1994, J CELL BIOL, V127, P1139, DOI 10.1083/jcb.127.4.1139; GREENBERG S, 1994, J BIOL CHEM, V269, P3897; Hakansson S, 1996, EMBO J, V15, P5812, DOI 10.1002/j.1460-2075.1996.tb00968.x; Hersh D, 1999, P NATL ACAD SCI USA, V96, P2396, DOI 10.1073/pnas.96.5.2396; Kiefer F, 1998, MOL CELL BIOL, V18, P4209, DOI 10.1128/MCB.18.7.4209; Lee VT, 1998, MOL MICROBIOL, V28, P593, DOI 10.1046/j.1365-2958.1998.00822.x; Lee VT, 1999, IMMUNOL REV, V168, P241, DOI 10.1111/j.1600-065X.1999.tb01296.x; Li JX, 1996, J BIOL CHEM, V271, P12985, DOI 10.1074/jbc.271.22.12985; MAKINO S, 1986, CELL, V46, P551, DOI 10.1016/0092-8674(86)90880-9; May RC, 2000, NAT CELL BIOL, V2, P246, DOI 10.1038/35008673; Menard R, 1996, P NATL ACAD SCI USA, V93, P1254, DOI 10.1073/pnas.93.3.1254; MENARD R, 1993, J BACTERIOL, V175, P5899; MENARD R, 1994, CELL, V79, P515, DOI 10.1016/0092-8674(94)90260-7; Meng FY, 1998, EMBO J, V17, P4391, DOI 10.1093/emboj/17.15.4391; Monack DM, 1996, P NATL ACAD SCI USA, V93, P9833, DOI 10.1073/pnas.93.18.9833; NINOMIYA N, 1994, J BIOL CHEM, V269, P22732; Nonaka T, 1999, FEMS MICROBIOL LETT, V174, P89, DOI 10.1111/j.1574-6968.1999.tb13553.x; Parsot C, 1994, Curr Top Microbiol Immunol, V192, P217; Picking WL, 2001, MOL MICROBIOL, V39, P100, DOI 10.1046/j.1365-2958.2001.02210.x; Renesto P, 1996, INFECT IMMUN, V64, P719, DOI 10.1128/IAI.64.3.719-723.1996; ROSQVIST R, 1994, EMBO J, V13, P964, DOI 10.1002/j.1460-2075.1994.tb06341.x; SANSONETTI PJ, 1991, VACCINE, V9, P416, DOI 10.1016/0264-410X(91)90128-S; SANSONETTI PJ, 1986, INFECT IMMUN, V51, P461, DOI 10.1128/IAI.51.2.461-469.1986; Sansonetti PJ, 1998, FOLIA MICROBIOL, V43, P239, DOI 10.1007/BF02818608; SANSONETTI PJ, 1995, J CLIN INVEST, V96, P884, DOI 10.1172/JCI118135; Sansonetti PJ, 1996, INFECT IMMUN, V64, P2752, DOI 10.1128/IAI.64.7.2752-2764.1996; Sansonetti PJ, 2001, FEMS MICROBIOL REV, V25, P3, DOI 10.1111/j.1574-6976.2001.tb00569.x; SASAKAWA C, 1992, CURR TOP MICROBIOL, V180, P21; SASAKAWA C, 1989, MOL MICROBIOL, V3, P1191, DOI 10.1111/j.1365-2958.1989.tb00269.x; SASAKAWA C, 1986, INFECT IMMUN, V54, P32, DOI 10.1128/IAI.54.1.32-36.1986; SASAKAWA C, 1988, J BACTERIOL, V170, P2480, DOI 10.1128/jb.170.6.2480-2484.1988; Sato N, 1999, J IMMUNOL, V163, P6123; Skoudy A, 2000, CELL MICROBIOL, V2, P19, DOI 10.1046/j.1462-5822.2000.00028.x; SMALL PLC, 1987, INFECT IMMUN, V55, P1674, DOI 10.1128/IAI.55.7.1674-1679.1987; SORY MP, 1994, MOL MICROBIOL, V14, P583, DOI 10.1111/j.1365-2958.1994.tb02191.x; Suzuki T, 1998, EMBO J, V17, P2767, DOI 10.1093/emboj/17.10.2767; Tamano K, 2000, EMBO J, V19, P3876, DOI 10.1093/emboj/19.15.3876; Tapper H, 1997, J IMMUNOL, V159, P409; TOBE T, 1994, MOL MICROBIOL, V12, P267, DOI 10.1111/j.1365-2958.1994.tb01015.x; Tran N, 2000, INFECT IMMUN, V68, P3710, DOI 10.1128/IAI.68.6.3710-3715.2000; Tran Van Nhieu G., 1997, EMBO J, V16, P2717; Uchiya K, 1999, EMBO J, V18, P3924, DOI 10.1093/emboj/18.14.3924; Van Nhieu GT, 1999, CURR OPIN MICROBIOL, V2, P51; Van Nhieu GT, 1999, EMBO J, V18, P3249, DOI 10.1093/emboj/18.12.3249; VANNHIEU GT, 2000, CELL MICROBIOL, V2, P187, DOI DOI 10.1046/J.1462-5822.2000.00046.X; VANSTRIJP JAG, 1993, J IMMUNOL, V151, P3324; WASSEF JS, 1989, INFECT IMMUN, V57, P858, DOI 10.1128/IAI.57.3.858-863.1989; Watarai M, 1996, J EXP MED, V183, P991, DOI 10.1084/jem.183.3.991; Yan SR, 1997, J IMMUNOL, V158, P1902; Zheng LM, 1996, P NATL ACAD SCI USA, V93, P8431, DOI 10.1073/pnas.93.16.8431; ZYCHLINSKY A, 1994, J CLIN INVEST, V94, P1328, DOI 10.1172/JCI117452; ZYCHLINSKY A, 1992, NATURE, V358, P167, DOI 10.1038/358167a0; [No title captured]	70	38	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					32230	32239		10.1074/jbc.M103831200	http://dx.doi.org/10.1074/jbc.M103831200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11413141	hybrid			2022-12-25	WOS:000170613500103
J	Hellstern, S; Pegoraro, S; Karim, CB; Lustig, A; Thomas, DD; Moroder, L; Engel, J				Hellstern, S; Pegoraro, S; Karim, CB; Lustig, A; Thomas, DD; Moroder, L; Engel, J			Sarcolipin, the shorter homologue of phospholamban, forms oligomeric structures in detergent micelles and in liposomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC SARCOPLASMIC-RETICULUM; TRANSMEMBRANE DOMAIN; CIRCULAR-DICHROISM; MEMBRANE-PROTEINS; HIGH-RESOLUTION; LIPID BILAYERS; CA-ATPASE; CA2+-ATPASE; PHOSPHORYLATION; MECHANISM	The human 31-amino acid integral membrane protein sarcolipin (SLN), which regulates the sarcoplasmic reticulum Ca-ATPase in fast-twitch skeletal muscle, was chemically synthesized. Appropriate synthesis and purification strategies were used to achieve high purity and satisfactory yields of this hydrophobic and poorly soluble protein. Structural and functional properties of SIN were analyzed and compared with the homologous region of human phospholamban (PLB) comprising residues Ala(24)-Leu(52) (PLB(24-52)), the regulatory protein of the cardiac sarcoplasmic reticulum Ca-ATPase. Circular dichroism spectroscopy showed that SLN is a predominantly alpha -helical protein and that the secondary structure is highly resistant to SDS and thermal denaturation. In this respect SLN is remarkably similar to PLB-(24-52). However, SLN is monomeric in SDS gels, whereas PLB-(24-52) shows a monomer-pentamer equilibrium typical for native PLB. Analytical ultracentrifugation experiments revealed that SLN oligomerizes in the presence of the nonionic detergents octylpolyoxyethylene and octyl glucoside in a concentration-dependent manner. No plateau was observed, and a pentameric state was only reached at much higher protein concentrations compared with PLB-(24-52). Chemical cross-linking showed that also in liposomes SLN has the ability to self-associate to oligomers. PLB-(24-52) specifically oligomerized to pentamers in the presence of octylpolyoxyethylene as well as in liposomes at low protein concentrations. In the presence of octylpolyoxyethylene pentamers were the main oligomeric species, whereas in liposomes monomers and dimers were predominant. Increasing the protein concentration led to self-association of PLB-(24-52) pentamers in the presence of octylpolyoxyethylene. Functional reconstitution of Ca-ATPase with PLB-(24-52) and SLN in liposomes showed that both proteins regulate the Ca-ATPase in a similar manner.	Univ Basel, Biozentrum, Dept Biophys Chem, CH-4056 Basel, Switzerland; Max Planck Inst Biochem, D-82152 Martinsried, Germany; Univ Minnesota, Dept Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA	University of Basel; Max Planck Society; University of Minnesota System; University of Minnesota Twin Cities	Engel, J (corresponding author), Univ Basel, Biozentrum, Dept Biophys Chem, Klingelbergstr 70, CH-4056 Basel, Switzerland.		Thomas, David D/B-4257-2012	Moroder, Luis/0000-0001-9570-5713; Karim, Christine/0000-0002-7321-7695; Thomas, David D./0000-0002-8822-2040	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027906] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM27906] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS PD, 1995, NAT STRUCT BIOL, V2, P154, DOI 10.1038/nsb0295-154; Arkin IT, 1997, ANNU REV BIOPH BIOM, V26, P157, DOI 10.1146/annurev.biophys.26.1.157; ARKIN IT, 1995, J MOL BIOL, V248, P824, DOI 10.1006/jmbi.1995.0263; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; Cornea RL, 1997, BIOCHEMISTRY-US, V36, P2960, DOI 10.1021/bi961955q; FERNANDEZ JL, 1980, BIOCHIM BIOPHYS ACTA, V599, P552, DOI 10.1016/0005-2736(80)90199-6; Frank S, 2000, BIOCHEMISTRY-US, V39, P6825, DOI 10.1021/bi0000972; HEUKESHOVEN J, 1988, ELECTROPHORESIS, V9, P28, DOI 10.1002/elps.1150090106; Hughes G, 1996, BIOCHEM J, V318, P973, DOI 10.1042/bj3180973; JONES LR, 1985, J BIOL CHEM, V260, P7721; Karim CB, 1998, BIOCHEMISTRY-US, V37, P12074, DOI 10.1021/bi980642n; Karim CB, 2000, BIOCHEMISTRY-US, V39, P10892, DOI 10.1021/bi0003543; Kimura Y, 1996, J BIOL CHEM, V271, P21726, DOI 10.1074/jbc.271.36.21726; KOVACS RJ, 1988, J BIOL CHEM, V263, P18364; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lakowicz JR, 1999, PRINCIPLES FLUORESCE; Luo WS, 1998, J BIOL CHEM, V273, P4734, DOI 10.1074/jbc.273.8.4734; Lustig A, 2000, BBA-BIOMEMBRANES, V1464, P199, DOI 10.1016/S0005-2736(99)00254-0; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; Mayer EJ, 1996, J BIOL CHEM, V271, P1669, DOI 10.1074/jbc.271.3.1669; Minamisawa S, 1999, CELL, V99, P313, DOI 10.1016/S0092-8674(00)81662-1; MUTTER M, 1995, PEPTIDE RES, V8, P145; Odermatt A, 1997, GENOMICS, V45, P541, DOI 10.1006/geno.1997.4967; Odermatt A, 1998, J BIOL CHEM, V273, P12360, DOI 10.1074/jbc.273.20.12360; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PARK K, 1992, PROTEIN SCI, V1, P1032, DOI 10.1002/pro.5560010809; PEGORARO S, 2000, P 16 AM AM PEPT S; REDDY LG, 1995, J BIOL CHEM, V270, P9390, DOI 10.1074/jbc.270.16.9390; Reddy LG, 1999, J BIOL CHEM, V274, P7649, DOI 10.1074/jbc.274.12.7649; Rosenbusch JP, 2001, MICRON, V32, P75, DOI 10.1016/S0968-4328(00)00021-4; SASAKI T, 1992, J BIOL CHEM, V267, P1674; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHIRE SJ, 1994, MODERN ANAL ULTRACEN, V14, P276; SIMMERMAN HKB, 1989, BIOCHIM BIOPHYS ACTA, V997, P322, DOI 10.1016/0167-4838(89)90203-3; Simmerman HKB, 1996, J BIOL CHEM, V271, P5941, DOI 10.1074/jbc.271.10.5941; Simmerman HKB, 1998, PHYSIOL REV, V78, P921, DOI 10.1152/physrev.1998.78.4.921; SIMMERMAN HKB, 1986, J BIOL CHEM, V261, P3333; Stokes DL, 1997, CURR OPIN STRUC BIOL, V7, P550, DOI 10.1016/S0959-440X(97)80121-2; STOKES DL, 1990, BIOPHYS J, V57, P1, DOI 10.1016/S0006-3495(90)82501-7; Torres J, 2000, J MOL BIOL, V300, P677, DOI 10.1006/jmbi.2000.3885; VORHERR T, 1993, PROTEIN SCI, V2, P339; WAWRZYNOW A, 1992, ARCH BIOCHEM BIOPHYS, V298, P620, DOI 10.1016/0003-9861(92)90457-8; WEGENER AD, 1989, J BIOL CHEM, V264, P11468	43	57	59	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					30845	30852		10.1074/jbc.M102495200	http://dx.doi.org/10.1074/jbc.M102495200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11413134	hybrid			2022-12-25	WOS:000170472900036
J	Majumder, A; Basak, S; Chowdhury, SP; Chattopadhyay, D; Roy, S				Majumder, A; Basak, S; Chowdhury, SP; Chattopadhyay, D; Roy, S			Effect of osmolytes and chaperone-like action of P-protein on folding of nucleocapsid protein of Chandipura virus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICULAR STOMATITIS-VIRUS; LAMBDA-REPRESSOR; IN-VITRO; TRANSCRIPTION; REPLICATION; EXPRESSION; DOMAIN; RNA; PHOSPHORYLATION; PHOSPHOPROTEIN	Amino acid sequences of nucleocapsid proteins are mostly conserved among different rhabdoviruses. The protein plays a common functional role in different RNA viruses by enwrapping the viral genomic RNA in an RNase-resistant form. Upon expression of the nucleocapsid protein alone in COS cells and in bacteria, it forms large insoluble aggregates. In this work, we have reported for the first time the full-length cloning of the N gene of Chandipura virus and its expression in Escherichia coli in a soluble monomeric form and purification using nonionic detergents. The biological activity of the soluble recombinant protein has been tested, and it was found to possess efficient RNA-binding ability. The state of aggregation of the recombinant protein was monitored using light scattering. In the absence of nonionic detergents, it formed large aggregates. Aggregation was significantly reduced in the presence of osmolytes such as D-sorbitol. Aggregate formation was suppressed in the presence of another viral product, phosphoprotein P, in a chaperone-like manner. Both the osmolyte and phosphoprotein P also suppressed aggregation to a great extent during refolding from a guanidine hydrochloride-denatured form. The function of the phosphoprotein and osmolyte appears to be synergistic to keep the N-protein in a soluble biologically competent form in virus-infected cells.	Univ Coll Sci Calcutta, Dept Biochem, Kolkata 700019, W Bengal, India; Univ Coll Sci Calcutta, Dr BC Guha Ctr Genet Engn & Biotechnol, Kolkata 700019, W Bengal, India; Bose Inst, Dept Biophys, Kolkata 700054, W Bengal, India	University of Calcutta; University of Calcutta; Department of Science & Technology (India); Bose Institute	Roy, S (corresponding author), Univ Coll Sci Calcutta, Dept Biochem, 35 Ballygunge Circular Rd, Kolkata 700019, W Bengal, India.	djc@netkracker.com; sidroy@vsnl.com		Basak, Soumen/0000-0002-3586-1279; Palchaudhuri, Santanu/0000-0003-1220-8135				Bandyopadhyay S, 1996, BIOCHEMISTRY-US, V35, P5033, DOI 10.1021/bi952123f; BANERJEE AK, 1987, MICROBIOL REV, V51, P66, DOI 10.1128/MMBR.51.1.66-87.1987; BANIK U, 1993, J BIOL CHEM, V268, P3938; Baskakov I, 1998, J BIOL CHEM, V273, P4831, DOI 10.1074/jbc.273.9.4831; BHATT PN, 1967, INDIAN J MED RES, V55, P1295; Biswas SK, 1998, J VIROL, V72, P5493, DOI 10.1128/JVI.72.7.5493-5501.1998; DAS T, 1983, VIROLOGY, V193, P340; DRAGUNOVA J, 1979, ACTA VIROL, V23, P319; Green TJ, 2000, J VIROL, V74, P9515, DOI 10.1128/JVI.74.20.9515-9524.2000; Gupta AK, 1997, J VIROL, V71, P4264, DOI 10.1128/JVI.71.6.4264-4271.1997; HSU CH, 1979, J VIROL, V32, P304, DOI 10.1128/JVI.32.1.304-313.1979; Hyre DE, 1998, J MOL BIOL, V279, P929, DOI 10.1006/jmbi.1998.1811; MASTERS PS, 1988, J VIROL, V62, P2658, DOI 10.1128/JVI.62.8.2658-2664.1988; MASTERS PS, 1987, VIROLOGY, V157, P298, DOI 10.1016/0042-6822(87)90272-8; Pattnaik AK, 1997, J VIROL, V71, P8167, DOI 10.1128/JVI.71.11.8167-8175.1997; Raha T, 1999, BIOCHEMISTRY-US, V38, P2110, DOI 10.1021/bi980734c; SPRAGUE J, 1983, J VIROL, V45, P773, DOI 10.1128/JVI.45.2.773-781.1983; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAKEMOTO L, 1993, BIOCHEM J, V294, P435, DOI 10.1042/bj2940435; Voziyan PA, 2000, J PHARM SCI-US, V89, P1036, DOI 10.1002/1520-6017(200008)89:8<1036::AID-JPS8>3.0.CO;2-5	20	33	38	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					30948	30955		10.1074/jbc.M011705200	http://dx.doi.org/10.1074/jbc.M011705200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11413127	hybrid			2022-12-25	WOS:000170472900049
J	Hu, VW; Heikka, DS; Dieffenbach, PB; Ha, L				Hu, VW; Heikka, DS; Dieffenbach, PB; Ha, L			Metabolic radiolabeling: experimental tool or Trojan horse? S-35-Methionine induces DNA fragmentation and p53-dependent ROS production	FASEB JOURNAL			English	Article						metabolic labeling; radioisotopes; DNA fragmentation; reactive oxygen species; p53	MAMMALIAN-CELLS; SIGNAL-TRANSDUCTION; GROWTH ARREST; RADIATION; APOPTOSIS	Despite the general assumption that widely used radiolabeled metabolites such as [S-35] methionine and H-3-thymidine do not adversely affect or perturb cell function, we and others have shown that such low-energy beta -emitters can cause cell cycle arrest and apoptosis of proliferating cells. The goal of the present study was to elucidate the targets and mechanisms of [S-35] methionine-induced cellular toxicity. Comet analyses (single-cell electrophoresis) demonstrated dose-dependent DNA fragmentation in rabbit smooth muscle cells within a time frame (1-4 h) well within that of most radiolabeling protocols, whereas fluorescence analyses using a peroxide/hydroperoxide-sensitive dye revealed production of reactive oxygen species (ROS). Although ROS generation was inhibitable by antioxidants, DNA fragmentation was not inhibited and was in fact observed even under hypoxic conditions, suggesting that beta -radiation-induced DNA damage can occur independently of ROS formation. Studies with p53(+/+) and p53(-/-) human colorectal carcinoma cells further demonstrated the dissociation of early DNA damage from ROS formation in that both cell types exhibited DNA fragmentation in response to radiolabeling whereas only the p53(+/+) cells exhibited significant increases in ROS formation, which occurred well after significant DNA damage was observed. These findings demonstrate that metabolically incorporated low-energy beta -emitters such as [S-35] methionine and H-3-thymidine can induce DNA damage, thereby initiating cellular responses leading to cell cycle arrest or apoptosis. The results of this study require a reevaluation using low-energy beta -emitters to follow not only experimental protocols in vivo processes, but also acceptable exposure levels of these genotoxic compounds in the workplace and environment.	George Washington Univ, Sch Med & Hlth Sci, Dept Biochem & Mol Biol, Washington, DC 20037 USA	George Washington University	Hu, VW (corresponding author), George Washington Univ, Sch Med & Hlth Sci, Dept Biochem & Mol Biol, 2300 Eye St NW,Ross Hall 526, Washington, DC 20037 USA.	bcmvwh@gwumc.edu		Hu, Valerie/0000-0002-3357-0777				Bond JA, 1999, ONCOGENE, V18, P3788, DOI 10.1038/sj.onc.1202733; CARTER WO, 1994, J LEUKOCYTE BIOL, V55, P253; DOVER R, 1994, J CELL SCI, V107, P1181; Hu VW, 2000, FASEB J, V14, P448, DOI 10.1096/fasebj.14.3.448; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Lander HM, 1997, FASEB J, V11, P118, DOI 10.1096/fasebj.11.2.9039953; Nakamura H, 1997, ANNU REV IMMUNOL, V15, P351, DOI 10.1146/annurev.immunol.15.1.351; OSTLING O, 1984, BIOCHEM BIOPH RES CO, V123, P291, DOI 10.1016/0006-291X(84)90411-X; POLLARD JW, 1996, PROTEIN PROTOCOLS HD; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; RADFORD IR, 1986, INT J RADIAT BIOL, V49, P611; ROTHE G, 1990, J LEUKOCYTE BIOL, V47, P440, DOI 10.1002/jlb.47.5.440; SOLARY E, 1992, EXP CELL RES, V203, P495, DOI 10.1016/0014-4827(92)90027-6; Suzuki YJ, 1997, FREE RADICAL BIO MED, V22, P269, DOI 10.1016/S0891-5849(96)00275-4; WARD JF, 1988, PROG NUCLEIC ACID RE, V35, P95, DOI 10.1016/S0079-6603(08)60611-X; Yanokura M, 2000, INT J RADIAT BIOL, V76, P295, DOI 10.1080/095530000138637; YEARGIN J, 1995, CURR BIOL, V5, P423, DOI 10.1016/S0960-9822(95)00083-2	17	31	31	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2001	15	9					1562	1568		10.1096/fj.01-0102com	http://dx.doi.org/10.1096/fj.01-0102com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	460PV	11427488				2022-12-25	WOS:000170318500008
J	Powell, DJ; Russell, JP; Li, GQ; Kuo, BA; Fidanza, V; Huebner, K; Rothstein, JL				Powell, DJ; Russell, JP; Li, GQ; Kuo, BA; Fidanza, V; Huebner, K; Rothstein, JL			Altered gene expression in immunogenic poorly differentiated thyroid carcinomas from RET/PTC3p53 mice	ONCOGENE			English	Article						anaplastic carcinoma; Fhit; neoplasia; RET/PTC; SCID; thyroid carcinoma	THYROTROPIN RECEPTOR GENE; RET TYROSINE KINASE; PAPILLARY CARCINOMA; FHIT GENE; ONCOGENE ACTIVATION; P53 GENE; NEOPLASTIC TRANSFORMATION; CLINICAL IMPLICATIONS; PREMALIGNANT LESIONS; EPITHELIAL-CELLS	Cancers develop and progress via activation of oncogenes and loss of tumor suppressor genes, a progression that can be recapitulated through cross breeding mouse strains harboring genetic mutations. To define the role of RET/PTC3, p53 and Fhit in thyroid carcinogenesis, we intercrossed RET/PTC3 transgenics with p53-/-mice. This new strain, RET/PTC3(p53-/-), succumb to rapidly growing and strikingly large multilobed thyroid tumors containing mixtures of both well and poorly differentiated, highly proliferative follicular epithelial cells. Interestingly, transplanted tumors from RET/PTC3(p53-/-) mice grew in SCID but not syngeneic immunocompetent mice indicating that these advanced tumors were immunogenic, RET/PTC3 protein expression was reduced to undetectable levels in tumors of older mice suggesting that the continued elevated expression of RET/PTC3 may not be necessary for tumor progression. Similarly, expression of Fhit protein was reduced in early tumors and undetected in older tumors irrespective of tumor histopathology, In contrast to RET/PTC3(p53-/-) mice, RET/PTC3(Fhit-/-) mice did not develop advanced thyroid carcinomas, These studies support a model of human thyroid cancer whereby thyroid epithelium expresses RET/PTC3 protein at early stages of tumor development, followed by the reduction of RET/PTC3 and loss of p53 function with progressive reduction of Fhit protein expression coincident with malignant progression.	Thomas Jefferson Univ, Kimmel Canc Inst, Dept Microbiol Immunol & Otolaryngol Head & Neck, Philadelphia, PA 19107 USA	Jefferson University	Rothstein, JL (corresponding author), Thomas Jefferson Univ, Kimmel Canc Inst, Dept Microbiol Immunol & Otolaryngol Head & Neck, 233 S 10th St,BLSB 909, Philadelphia, PA 19107 USA.				NCI NIH HHS [CA21124, T32-CA09678, T32-CA72318, CA76259] Funding Source: Medline; NIAID NIH HHS [T32-AI07492] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA021124, P01CA076259, T32CA072318, T32CA009678] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007492] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arezzo A, 1998, AM SURGEON, V64, P307; Arighi E, 1997, ONCOGENE, V14, P773, DOI 10.1038/sj.onc.1200896; Ausubel FM, 1995, SHORT PROTOCOLS MOL, V3rd; BATTISTA S, 1995, ONCOGENE, V11, P2029; BECKER KL, 1995, PRINCIPLES PRACTICES; Birrer MJ, 1999, CANCER RES, V59, P5270; BOUNACER A, 1997, ONCOGENE, V15, P1236; BRAVERMAN LE, 1995, THYROID FUNDAMENTAL; CALIFANO D, 1995, ONCOGENE, V11, P107; Canaris GJ, 2000, ARCH INTERN MED, V160, P526, DOI 10.1001/archinte.160.4.526; CARCANGIU ML, 1985, AM J CLIN PATHOL, V83, P135, DOI 10.1093/ajcp/83.2.135; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; Chang RS, 1998, ACAD EMERG MED, V5, P247, DOI 10.1111/j.1553-2712.1998.tb02621.x; Chen ST, 2000, J ENDOCRINOL, V165, P379, DOI 10.1677/joe.0.1650379; Corvi R, 2000, ONCOGENE, V19, P4236, DOI 10.1038/sj.onc.1203772; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DUH QY, 1995, SURG CLIN N AM, V75, P421; Dumon KR, 2001, P NATL ACAD SCI USA, V98, P3346, DOI 10.1073/pnas.061020098; Durick K, 1996, J BIOL CHEM, V271, P12691, DOI 10.1074/jbc.271.22.12691; FABBRO D, 1994, CANCER RES, V54, P4744; FAGIN JA, 1993, J CLIN INVEST, V91, P179, DOI 10.1172/JCI116168; Fong LYY, 2000, P NATL ACAD SCI USA, V97, P4742, DOI 10.1073/pnas.080063497; FUSCO A, 1995, J ENDOCRINOL INVEST, V18, P127, DOI 10.1007/BF03349720; Gatalica Z, 2000, CANCER-AM CANCER SOC, V88, P1378, DOI 10.1002/(SICI)1097-0142(20000315)88:6<1378::AID-CNCR15>3.3.CO;2-9; Giannini R, 2000, INT J ONCOL, V16, P485; Gire V, 2000, ONCOGENE, V19, P737, DOI 10.1038/sj.onc.1203399; Glover TW, 1998, CANCER RES, V58, P3409; Hao XP, 2000, CANCER RES, V60, P18; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Ivan M, 1997, ONCOGENE, V14, P2417, DOI 10.1038/sj.onc.1201083; Jhiang SM, 1996, ENDOCRINOLOGY, V137, P375, DOI 10.1210/en.137.1.375; JHIANG SM, 1994, J LAB CLIN MED, V123, P331; Jossart GH, 1996, J CLIN ENDOCR METAB, V81, P3498, DOI 10.1210/jc.81.10.3498; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Kholodnyuk ID, 2000, CANCER RES, V60, P7119; Klugbauer S, 2000, CANCER RES, V60, P7028; Komminoth P, 1997, VIRCHOWS ARCH, V431, P1, DOI 10.1007/s004280050062; La Perle KMD, 2000, AM J PATHOL, V157, P671, DOI 10.1016/S0002-9440(10)64577-4; Manning AP, 1999, MOL CARCINOGEN, V24, P218, DOI 10.1002/(SICI)1098-2744(199903)24:3<218::AID-MC8>3.0.CO;2-A; Marchetti A, 1998, J PATHOL, V184, P240, DOI 10.1002/(SICI)1096-9896(199803)184:3<240::AID-PATH20>3.0.CO;2-B; Mayr B, 1999, LANGENBECK ARCH SURG, V384, P54, DOI 10.1007/s004230050174; McIver B, 2000, CLIN ENDOCRINOL, V52, P749, DOI 10.1046/j.1365-2265.2000.01009.x; Mizuno T, 1997, ONCOGENE, V15, P1455, DOI 10.1038/sj.onc.1201313; Moretti F, 1997, ONCOGENE, V14, P729, DOI 10.1038/sj.onc.1200887; Mori M, 2000, CANCER RES, V60, P1177; Mueller J, 2000, Recent Results Cancer Res, V155, P29; Nikiforov YE, 1997, CANCER RES, V57, P1690; Nikiforova MN, 2000, SCIENCE, V290, P138, DOI 10.1126/science.290.5489.138; OKAYASU I, 1995, CANCER-AM CANCER SOC, V76, P2312, DOI 10.1002/1097-0142(19951201)76:11<2312::AID-CNCR2820761120>3.0.CO;2-H; PANDEY A, 1995, J BIOL CHEM, V270, P21461, DOI 10.1074/jbc.270.37.21461; Papadimitrakopoulou VA, 1996, CANCER METAST REV, V15, P53, DOI 10.1007/BF00049487; Pellegrini S, 1999, INT J MOL MED, V4, P419; Pisarchik AV, 2000, THYROID, V10, P25, DOI 10.1089/thy.2000.10.25; Powell DJ, 1998, CANCER RES, V58, P5523; Qin GZ, 1999, INT J CANCER, V80, P345, DOI 10.1002/(SICI)1097-0215(19990129)80:3<345::AID-IJC2>3.3.CO;2-E; Rabes HM, 2000, CLIN CANCER RES, V6, P1093; ROSAI J, 1990, TUMORS THYROID GLAND; Russell JP, 2000, ONCOGENE, V19, P5729, DOI 10.1038/sj.onc.1203922; Salassidis K, 2000, CANCER RES, V60, P2786; SANTORO M, 1993, CELL GROWTH DIFFER, V4, P77; Santoro M, 1996, ONCOGENE, V12, P1821; Sheils OM, 2000, INT J SURG PATHOL, V8, P185, DOI 10.1177/106689690000800305; SHI YF, 1993, CLIN ENDOCRINOL, V39, P269, DOI 10.1111/j.1365-2265.1993.tb02365.x; Siprashvili Z, 1997, P NATL ACAD SCI USA, V94, P13771, DOI 10.1073/pnas.94.25.13771; Soravia C, 1999, AM J PATHOL, V154, P127, DOI 10.1016/S0002-9440(10)65259-5; Sozzi G, 1998, CANCER RES, V58, P5032; Sugg SL, 1998, J CLIN ENDOCR METAB, V83, P4116, DOI 10.1210/jc.83.11.4116; Sweetser DA, 1997, ONCOGENE, V15, P2783, DOI 10.1038/sj.onc.1201452; Tallini G, 1998, CLIN CANCER RES, V4, P287; THOMPSON TC, 1995, ONCOGENE, V10, P869; VIGLIETTO G, 1995, ONCOGENE, V11, P1207; VINETTE DSJ, 1991, DIAGN CYTOPATHOL, V7, P75, DOI 10.1002/dc.2840070120; Virgilio L, 1996, P NATL ACAD SCI USA, V93, P9770, DOI 10.1073/pnas.93.18.9770; Visconti R, 1997, ONCOGENE, V15, P1987, DOI 10.1038/sj.onc.1201373; Wirtschafter A, 1997, LARYNGOSCOPE, V107, P95, DOI 10.1097/00005537-199701000-00019; Xiao GH, 1997, AM J PATHOL, V151, P1541; Yokota T, 2000, J HUM GENET, V45, P6, DOI 10.1007/s100380050002; Yoshino K, 2000, INT J CANCER, V85, P6, DOI 10.1002/(SICI)1097-0215(20000101)85:1<6::AID-IJC2>3.0.CO;2-6; Zou M, 1999, EUR J CANCER, V35, P467, DOI 10.1016/S0959-8049(98)00370-0; ZOU MJ, 1993, J CLIN ENDOCR METAB, V77, P1054, DOI 10.1210/jc.77.4.1054	80	37	37	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 31	2001	20	25					3235	3246		10.1038/sj.onc.1204425	http://dx.doi.org/10.1038/sj.onc.1204425			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	440ET	11423973				2022-12-25	WOS:000169163500007
J	Lew, RA; Boulos, E; Stewart, KM; Perlmutter, P; Harte, MF; Bond, S; Reeve, SB; Norman, MU; Lew, MJ; Aguilar, MI; Smith, AI				Lew, RA; Boulos, E; Stewart, KM; Perlmutter, P; Harte, MF; Bond, S; Reeve, SB; Norman, MU; Lew, MJ; Aguilar, MI; Smith, AI			Substrate analogues incorporating beta-amino acids: potential application for peptidase inhibition	FASEB JOURNAL			English	Article						bradykinin; peptidomimetic; peptidase inhibitor; endopeptidase 24.15	ENDOPEPTIDASE EC-3.4.24.15; RAT TESTES; SPECIFICITY; BRADYKININ; STABILITY; ENZYME; TETRAPEPTIDE; ANTAGONISTS; NO	We hypothesize that substitution of alpha-amino acids at or around the scissile bond of a peptide substrate with beta-amino acids (containing an extra carbon in the peptide backbone) will confer resistance to proteolytic cleavage without necessarily abolishing enzyme binding; indeed, such a stabilized analogue may act as a specific inhibitor of the peptidase. To test this possibility, we synthesised a series of beta-amino acid-containing bradykinin analogues and examined their degradation by the soluble metalloendopeptidase EC 3.4.24.15. Inclusion of a beta-amino acid at or near the cleavage site of bradykinin completely prevented degradation by this enzyme. Furthermore, such analogues could still act as competitive inhibitors, with die most potent peptides exhibiting affinities for recombinant EC 3.4.24.15 only 1.5- to 2.5-fold lower than bradykinin itself. Interestingly, these analogues also acted as agonists at the B-2 bradykinin receptor in coronary artery segments, although their potencies were 2-3 orders of magnitude less than the native peptide. In conclusion, substitution of beta-amino acids at the scissile bond can stabilize peptides against hydrolysis with only a moderate decrease in enzyme affinity. Thus, peptidomimetics incorporating beta-amino acids may have utility in the design and development of novel, specific, substrate-based peptidase inhibitors.	Baker Med Res Inst, Melbourne, Vic 8008, Australia; Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3800, Australia; Monash Univ, Dept Chem, Clayton, Vic 3800, Australia; Univ Melbourne, Dept Pharmacol, Melbourne, Vic 3010, Australia	Baker Heart and Diabetes Institute; Monash University; Monash University; University of Melbourne	Smith, AI (corresponding author), Baker Med Res Inst, POB 6492,St Kilda Rd Cent, Melbourne, Vic 8008, Australia.	ian.smith@baker.edu.au	Lew, Rebecca A/C-5454-2008; Lew, Michael/E-1247-2012	Smith, Ian/0000-0002-4143-2892; Lew, Michael/0000-0002-2523-7990; Perlmutter, Patrick/0000-0003-4105-4526; Norman, Maarit/0000-0002-3032-3957				AHMAD S, 1992, P SOC EXP BIOL MED, V200, P115; DANDO PM, 1993, BIOCHEM J, V294, P451, DOI 10.1042/bj2940451; Dendorfer A, 1999, IMMUNOPHARMACOLOGY, V45, P199, DOI 10.1016/S0162-3109(99)00078-8; Gademann K, 1999, ANGEW CHEM INT EDIT, V38, P1223, DOI 10.1002/(SICI)1521-3773(19990503)38:9<1223::AID-ANIE1223>3.0.CO;2-A; Guichard G, 1998, HELV CHIM ACTA, V81, P187, DOI 10.1002/hlca.19980810202; Hintermann T, 1997, CHIMIA, V51, P244; KILPATRICK EV, 1994, BRIT J PHARMACOL, V112, P557, DOI 10.1111/j.1476-5381.1994.tb13110.x; Lew RA, 1996, BRIT J PHARMACOL, V118, P1269, DOI 10.1111/j.1476-5381.1996.tb15533.x; LEW RA, 1995, BIOCHEM BIOPH RES CO, V209, P788, DOI 10.1006/bbrc.1995.1569; Lew RA, 2000, J PEPT SCI, V6, P440, DOI 10.1002/1099-1387(200009)6:9<440::AID-PSC280>3.0.CO;2-K; ONDETTI MA, 1975, J MED CHEM, V18, P761, DOI 10.1021/jm00241a024; ORLOWSKI M, 1989, BIOCHEM J, V261, P951, DOI 10.1042/bj2610951; Poenaru S, 1999, J MED CHEM, V42, P2318, DOI 10.1021/jm981123l; REGOLI D, 1980, PHARMACOL REV, V32, P1; Rioli V, 1998, BIOCHEM BIOPH RES CO, V250, P5, DOI 10.1006/bbrc.1998.8941; RODRIGUEZ M, 1989, J MED CHEM, V32, P522, DOI 10.1021/jm00123a003; Roques BP, 1998, PATHOL BIOL, V46, P191; Scarborough RM, 1999, CURR MED CHEM, V6, P971; Seebach D, 1998, CHIMIA, V52, P734; SHRIMPTON CN, 2000, BIOCHEM J, V345, P341; Vincent B, 1996, BRAIN RES, V709, P51, DOI 10.1016/0006-8993(95)01260-5	21	11	11	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY 29	2001	15	7					1664	+		10.1096/fj.00-0805fje	http://dx.doi.org/10.1096/fj.00-0805fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519CQ	11427520				2022-12-25	WOS:000173707700002
J	Dell'Era, P; Belleri, M; Stabile, H; Massardi, ML; Ribatti, D; Presta, M				Dell'Era, P; Belleri, M; Stabile, H; Massardi, ML; Ribatti, D; Presta, M			Paracrine and autocrine effects of fibroblast growth factor-4 in endothelial cells	ONCOGENE			English	Article						angiogenesis; cell transfection; endothelium; FGF; FGF receptor; hemangioma	NIH 3T3 CELLS; FACTOR RECEPTOR; FGF RECEPTOR; KAPOSIS-SARCOMA; BIOLOGICAL PROPERTIES; ANGIOGENIC ACTIVITY; FACTOR FAMILY; HEPARIN; EXPRESSION; PROTEIN	Recombinant Fibroblast Growth Factor-4 (FGF4) and FGF2 induce extracellular signal-regulated kinase-1/2 activation and DNA synthesis in murine aortic endothelial (MAE) cells. These cells co-express the IIIc/Ig-3 loops and the novel glyccpsaminoglycan-modified Illc/Ig-2 loops isoforms of FGF receptor-2 (FGFR2). The affinity of FGP4/FGFR2 interaction is 20-30 times lower than that of FGF2 and is enhanced by heparin, Overexpression of FGF2 or FGF4 cDNA in MAE cells results in a transformed phenotype and increased proliferative capacity, more evident for FGF2 than FGF4 transfectants, Both transfectants induce angiogenesis when applied on the top of the chick embryo chorioallantoic membrane. However, in contrast with FG2-transfected cells, FGF4 transfectants show a limited capacity to growth under anchorage-independent conditions and lack the ability to invade 3D fibrin gel and to undergo morphogenesis in vitro. Also, they fail to induce hemangiomas when injected into the allantoic sac of the chick embryo. In conclusion, although exogenous FGF2 and FGF4 exert a similar response in MAE cells, significant differences are observed in the biological behavior of FGF4 ver sus FGF2 transfectants, indicating that the expression of the various members of the FGF family can differently affect the behavior of endothelial cells and, possibly, of other cell types, including tumor cells.	Univ Brescia, Dept Biomed Sci & Biotechnol, Unit Gen Pathol & Immunol, I-25123 Brescia, Italy; Univ Bari, Dept Human Anat & Histol, I-70124 Bari, Italy	University of Brescia; Universita degli Studi di Bari Aldo Moro	Presta, M (corresponding author), Univ Brescia, Dept Biomed Sci & Biotechnol, Unit Gen Pathol & Immunol, I-25123 Brescia, Italy.		Presta, Marco/B-4345-2010; Dell'Era, Patrizia/ABD-5848-2020; Dell'Era, Patrizia/N-6964-2019; Dell'Era, Patrizia/G-5294-2010	Dell'Era, Patrizia/0000-0001-6682-6321; PRESTA, Marco/0000-0002-4398-8376				BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Bastaki M, 1997, ARTERIOSCL THROM VAS, V17, P454, DOI 10.1161/01.ATV.17.3.454; BESSER D, 1995, CELL GROWTH DIFFER, V6, P1009; BIKFALVI A, 1995, J CELL BIOL, V129, P233, DOI 10.1083/jcb.129.1.233; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; CHELLAIAH AT, 1994, J BIOL CHEM, V269, P11620; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLTRINI D, 1994, BIOCHEM J, V303, P583, DOI 10.1042/bj3030583; COUDERC B, 1991, CELL REGUL, V2, P709, DOI 10.1091/mbc.2.9.709; DELLIBOVI P, 1988, MOL CELL BIOL, V8, P2933, DOI 10.1128/MCB.8.7.2933; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; Dong QG, 1997, ARTERIOSCL THROM VAS, V17, P1599, DOI 10.1161/01.ATV.17.8.1599; ENSOLI B, 1994, NATURE, V371, P674, DOI 10.1038/371674a0; ENSOLI B, 1994, J CLIN INVEST, V94, P1736, DOI 10.1172/JCI117521; Escaffit F, 2000, INT J CANCER, V85, P555, DOI 10.1002/(SICI)1097-0215(20000215)85:4<555::AID-IJC18>3.0.CO;2-H; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; Gaubert F, 2001, J BIOL CHEM, V276, P1545, DOI 10.1074/jbc.M001184200; GRANT DS, 1989, CELL, V58, P933, DOI 10.1016/0092-8674(89)90945-8; GRINSPAN JB, 1983, J CELL PHYSIOL, V114, P328, DOI 10.1002/jcp.1041140312; GUALANDRIS A, 1994, J CELL PHYSIOL, V161, P149, DOI 10.1002/jcp.1041610118; Gualandris A, 1996, CELL GROWTH DIFFER, V7, P147; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; ISACCHI A, 1991, P NATL ACAD SCI USA, V88, P2628, DOI 10.1073/pnas.88.7.2628; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; Kiuru-Kuhlefelt S, 2000, MODERN PATHOL, V13, P433, DOI 10.1038/modpathol.3880074; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; MANSUKHANI A, 1992, P NATL ACAD SCI USA, V89, P3305, DOI 10.1073/pnas.89.8.3305; MIGNATTI P, 1992, J CELL PHYSIOL, V151, P81, DOI 10.1002/jcp.1041510113; MOSCATELLI D, 1989, J CELL BIOL, V109, P2519, DOI 10.1083/jcb.109.5.2519; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; Oliver R T, 1999, Curr Opin Oncol, V11, P236; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; Plotnikov AN, 2000, CELL, V101, P413, DOI 10.1016/S0092-8674(00)80851-X; QUARTO N, 1991, CELL REGUL, V2, P699, DOI 10.1091/mbc.2.9.699; RENKO M, 1990, J CELL PHYSIOL, V144, P108, DOI 10.1002/jcp.1041440114; Ribatti D, 1999, J PATHOL, V189, P590; Ribatti D, 1997, J VASC RES, V34, P455, DOI 10.1159/000159256; Ribatti D, 1999, J CELL SCI, V112, P4213; Sakaguchi K, 1999, MOL CELL BIOL, V19, P6754; SATO Y, 1988, J CELL BIOL, V107, P1199, DOI 10.1083/jcb.107.3.1199; Shimon I, 1998, CLIN ENDOCRINOL, V48, P23, DOI 10.1046/j.1365-2265.1998.00332.x; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; TAKAHASHI K, 1994, J CLIN INVEST, V93, P2357, DOI 10.1172/JCI117241; TALARICO D, 1991, MOL CELL BIOL, V11, P1138, DOI 10.1128/MCB.11.2.1138; THEILLET C, 1989, ONCOGENE, V4, P915; Twigg SRF, 1998, HUM MOL GENET, V7, P685, DOI 10.1093/hmg/7.4.685; Uematsu F, 2000, BIOCHEM BIOPH RES CO, V272, P830, DOI 10.1006/bbrc.2000.2872; YOSHIDA T, 1994, CANCER LETT, V83, P261, DOI 10.1016/0304-3835(94)90328-X	51	46	46	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 10	2001	20	21					2655	2663		10.1038/sj.onc.1204368	http://dx.doi.org/10.1038/sj.onc.1204368			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	431VN	11420677				2022-12-25	WOS:000168652600006
J	McCormick, F				McCormick, F			ONYX-015 selectivity and the p14ARF pathway	ONCOGENE			English	Article						p53; ONYX-015; adenovirus; p14ARF	TUMOR-CELLS; P53 STATUS; ADENOVIRUS MUTANT; MESSENGER-RNA; REPLICATION; PROTEIN; INFECTION; INDUCTION; P19(ARF); EFFICACY	ONYX-015, dl1520, is an adenovirus that lacks the E1B 55K gene and therefore lacks the capacity to neutralize p53 during infection. This virus induces high levels of p53 and fails to grow efficiently in primary epithelial cells. However, it does replicate in many tumor cells, including those expressing wild-type p53. In these cells, ONYX-015 fails to induce active p53. This is because the pathway from Ela to p53 is disrupted through loss of p14ARF. We propose that high levels of Mdm2 activity resulting from loss of p14ARF, and high levels of Mdm2 protein resulting from activated Ras prevent accumulation of functional p53 during infection of tumor cells that retain wild-type p53.	Univ Calif San Francisco, Ctr Comprehens Canc, Inst Canc Res, San Francisco, CA 94115 USA	University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center	McCormick, F (corresponding author), Univ Calif San Francisco, Ctr Comprehens Canc, Inst Canc Res, 2340 Sutter St, San Francisco, CA 94115 USA.							BABISS LE, 1985, MOL CELL BIOL, V5, P2552, DOI 10.1128/MCB.5.10.2552; BELTZ GA, 1979, J MOL BIOL, V131, P353, DOI 10.1016/0022-2836(79)90081-0; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; Chiou SK, 1997, J VIROL, V71, P3515, DOI 10.1128/JVI.71.5.3515-3525.1997; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; Goodrum FD, 1998, J VIROL, V72, P9479, DOI 10.1128/JVI.72.12.9479-9490.1998; Harada JN, 1999, J VIROL, V73, P5333, DOI 10.1128/JVI.73.7.5333-5344.1999; Heise C, 1997, NAT MED, V3, P639, DOI 10.1038/nm0697-639; Howley P M, 1989, Princess Takamatsu Symp, V20, P199; Khuri FR, 2000, NAT MED, V6, P879, DOI 10.1038/78638; Ries S, 2000, CELL, V103, P321, DOI 10.1016/S0092-8674(00)00123-9; Ries SJ, 2000, NAT MED, V6, P1128, DOI 10.1038/80466; Rothmann T, 1998, J VIROL, V72, P9470, DOI 10.1128/JVI.72.12.9470-9478.1998; Rubenwolf S, 1997, J VIROL, V71, P1115, DOI 10.1128/JVI.71.2.1115-1123.1997; SARNOW P, 1984, J VIROL, V49, P692, DOI 10.1128/JVI.49.3.692-700.1984; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Turnell AS, 1999, J VIROL, V73, P2074, DOI 10.1128/JVI.73.3.2074-2083.1999; Wildner O, 1999, GENE THER, V6, P57, DOI 10.1038/sj.gt.3300810	19	31	34	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 27	2000	19	56					6670	6672		10.1038/sj.onc.1204096	http://dx.doi.org/10.1038/sj.onc.1204096			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415CY	11426653				2022-12-25	WOS:000167704000014
J	Ansmant, I; Motorin, Y; Massenet, S; Grosjean, H; Branlant, C				Ansmant, I; Motorin, Y; Massenet, S; Grosjean, H; Branlant, C			Identification and characterization of the tRNA :Psi(31)-synthase (Pus6p) of Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-PSEUDOURIDINE SYNTHASE; 23S RIBOSOMAL-RNA; ESCHERICHIA-COLI; PEPTIDYLTRANSFERASE CENTER; 2'-O-RIBOSE METHYLATION; SUBSTRATE-SPECIFICITY; SECONDARY STRUCTURE; YEAST PROTEIN; IN-VIVO; GENE	To characterize the substrate specificity of the putative RNA:pseudouridine (Psi)-synthase encoded by the Saccharomyces cerevisiae open reading frame (ORF) YGR169c, the corresponding gene was deleted in yeast, and the consequences of the deletion on tRNA and small nuclear RNA modification were tested. The resulting Delta YGR169c strain showed no detectable growth phenotype, and the only difference in Psi formation in stable cellular RNAs was the absence of Psi at position 31 in cytoplasmic and mitochondrial tRNAs. Complementation of the Delta YGR169c strain by a plasmid bearing the wild-type YGR169c ORF restored Psi (31) formation in tRNA, whereas a point mutation of the enzyme active site (Asp 168 --->Ala) abolished tRNA:Psi (31)-synthase activity. Moreover, recombinant His(6)-tagged Ygr169 protein produced in Escherichia coli was capable of forming Psi (31) in vitro using tRNAs extracted from the Delta YGR169c yeast cells as substrates. These results demonstrate that the protein encoded by the S. cerevisiae ORF YGR169c is the Psi -synthase responsible for modification of cytoplasmic and mitochondrial tRNAs at position 31. Because this is the sixth RNA:Psi -synthase characterized thus far in yeast, we propose to rename the corresponding gene PUS6 and the expressed protein Pus6p. Finally, the cellular localization of the green fluorescent protein-tagged Pus6p was studied by functional tests and direct fluorescence microscopy.	Univ Nancy 1, Fac Sci, Lab Maturat ARN & Enzymol Mol, CNRS,UMR 7567, F-54506 Vandoeuvre Les Nancy, France; CNRS, UPR 9093, Lab Enzymol & Biochim Struct, F-91198 Gif Sur Yvette, France	Centre National de la Recherche Scientifique (CNRS); Universite de Lorraine; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Branlant, C (corresponding author), Univ Nancy 1, Fac Sci, Lab Maturat ARN & Enzymol Mol, CNRS,UMR 7567, BP 239, F-54506 Vandoeuvre Les Nancy, France.	Christiane.Branlant@maem.uhp-nancy.fr	MOTORIN, Yuri/AAQ-9527-2020; MOTORIN, Yuri/E-2499-2011; BEHM-ANSMANT, Isabelle/B-1406-2012	MOTORIN, Yuri/0000-0002-8018-334X; Behm-Ansmant, Isabelle/0000-0001-8909-0660; Branlant, Christiane/0000-0003-4728-5499; Motorin, Alexandr/0000-0001-9622-4591; Severine, Massenet/0000-0001-5187-8356				Adams A, 1997, METHODS YEAST GENETI; Ansmant I, 2000, NUCLEIC ACIDS RES, V28, P1941, DOI 10.1093/nar/28.9.1941; ARNEZ JG, 1994, BIOCHEMISTRY-US, V33, P7560, DOI 10.1021/bi00190a008; Auffinger P, 1997, J MOL BIOL, V269, P326, DOI 10.1006/jmbi.1997.1022; Auffinger P, 1998, Modification and Editing of RNA, P103, DOI [10.1128/9781555818296.ch6, DOI 10.1128/9781555818296.CH6]; BAKIN A, 1994, BIOCHEMISTRY-US, V33, P13475, DOI 10.1021/bi00249a036; BAKIN A, 1993, BIOCHEMISTRY-US, V32, P9754, DOI 10.1021/bi00088a030; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; Becker HF, 1997, NUCLEIC ACIDS RES, V25, P4493, DOI 10.1093/nar/25.22.4493; BRANLANT C, 1981, NUCLEIC ACIDS RES, V9, P4303, DOI 10.1093/nar/9.17.4303; BRIMACOMBE R, 1993, FASEB J, V7, P161, DOI 10.1096/fasebj.7.1.8422963; CARBONE MLA, 1991, CURR GENET, V19, P1; Charette M, 2000, IUBMB LIFE, V49, P341; Conrad J, 1999, RNA, V5, P751, DOI 10.1017/S1355838299990167; Conrad J, 1998, J BIOL CHEM, V273, P18562, DOI 10.1074/jbc.273.29.18562; Davis DR, 1995, NUCLEIC ACIDS RES, V23, P5020, DOI 10.1093/nar/23.24.5020; DAVIS DR, 1991, BIOCHEMISTRY-US, V30, P4223, DOI 10.1021/bi00231a017; Durant PC, 1999, J MOL BIOL, V285, P115, DOI 10.1006/jmbi.1998.2297; Ferrigno P, 1998, EMBO J, V17, P5606, DOI 10.1093/emboj/17.19.5606; Ganot P, 1999, MOL CELL BIOL, V19, P6906; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GRIFFEY RH, 1985, J BIOL CHEM, V260, P9734; GROSJEAN H, 1995, BIOCHIMIE, V77, P139, DOI 10.1016/0300-9084(96)88117-X; Gustafsson C, 1996, NUCLEIC ACIDS RES, V24, P3756, DOI 10.1093/nar/24.19.3756; Gutgsell N, 2000, RNA, V6, P1870, DOI 10.1017/S1355838200001588; HAGERVALL TG, 1990, BIOCHIM BIOPHYS ACTA, V1050, P263, DOI 10.1016/0167-4781(90)90178-5; HALL KB, 1992, NUCLEIC ACIDS RES, V20, P1883, DOI 10.1093/nar/20.8.1883; HALL KB, 1991, BIOCHEMISTRY-US, V30, P1795, DOI 10.1021/bi00221a010; Huang LX, 1998, BIOCHEMISTRY-US, V37, P15951, DOI 10.1021/bi981002n; Huang LX, 1998, BIOCHEMISTRY-US, V37, P344, DOI 10.1021/bi971874+; Jady BE, 2001, EMBO J, V20, P541, DOI 10.1093/emboj/20.3.541; Jiang HQ, 1997, NUCLEIC ACIDS RES, V25, P2694, DOI 10.1093/nar/25.14.2694; JIANG WD, 1993, MOL CELL BIOL, V13, P4884, DOI 10.1128/MCB.13.8.4884; KAMMEN HO, 1988, J BIOL CHEM, V263, P2255; Koonin EV, 1996, NUCLEIC ACIDS RES, V24, P2411, DOI 10.1093/nar/24.12.2411; Lafontaine DLJ, 1998, GENE DEV, V12, P527, DOI 10.1101/gad.12.4.527; Lane BG, 1998, MODIFICATION EDITING, P1; Lecointe F, 1998, J BIOL CHEM, V273, P1316, DOI 10.1074/jbc.273.3.1316; MARTIN NC, 1994, BIOCHIMIE, V76, P1161, DOI 10.1016/0300-9084(94)90045-0; Massenet S, 1999, MOL CELL BIOL, V19, P2142; Massenet S., 1998, MODIFICATION EDITING, P201; Meroueh M, 2000, NUCLEIC ACIDS RES, V28, P2075, DOI 10.1093/nar/28.10.2075; Mihara K, 2000, BIOESSAYS, V22, P364, DOI 10.1002/(SICI)1521-1878(200004)22:4<364::AID-BIES6>3.0.CO;2-N; Motorin Y, 1998, RNA, V4, P856, DOI 10.1017/S1355838298980396; Motorin Y, 1999, RNA, V5, P1105, DOI 10.1017/S1355838299982201; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; Niu LH, 1999, BIOCHEMISTRY-US, V38, P629, DOI 10.1021/bi9821869; NURSE K, 1995, RNA, V1, P102; Ofengand J, 1997, J MOL BIOL, V266, P246, DOI 10.1006/jmbi.1996.0737; Ofengand J., 1998, MODIFICATION EDITING, P229, DOI DOI 10.1128/9781555818296.CH12; Pfanner N, 2000, CURR BIOL, V10, pR412, DOI 10.1016/S0960-9822(00)00507-8; Ramamurthy V, 1999, J BIOL CHEM, V274, P22225, DOI 10.1074/jbc.274.32.22225; Raychaudhuri S, 1999, J BIOL CHEM, V274, P18880, DOI 10.1074/jbc.274.27.18880; Raychaudhuri S, 1998, RNA, V4, P1407, DOI 10.1017/S1355838298981146; Reinhardt A, 1998, NUCLEIC ACIDS RES, V26, P2230, DOI 10.1093/nar/26.9.2230; REMME J, 2000, RIBOSOME BIOGENESIS, P111; ROSE AM, 1995, BIOCHIMIE, V77, P45, DOI 10.1016/0300-9084(96)88103-X; SAMUELSSON T, 1990, J BIOL CHEM, V265, P8782; Simos G, 1996, EMBO J, V15, P2270, DOI 10.1002/j.1460-2075.1996.tb00580.x; Sprinzl M, 1998, NUCLEIC ACIDS RES, V26, P148, DOI 10.1093/nar/26.1.148; SZWEYKOWSKAKULINSKA Z, 1994, EMBO J, V13, P4636, DOI 10.1002/j.1460-2075.1994.tb06786.x; TSUI HCT, 1991, J BACTERIOL, V173, P7395, DOI 10.1128/jb.173.22.7395-7400.1991; Tycowski KT, 1998, MOL CELL, V2, P629, DOI 10.1016/S1097-2765(00)80161-6; VELDMAN GM, 1981, NUCLEIC ACIDS RES, V9, P6935, DOI 10.1093/nar/9.24.6935; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Watkins NJ, 1998, RNA, V4, P1549, DOI 10.1017/S1355838298980761; WRZESINSKI J, 1995, BIOCHEMISTRY-US, V34, P8904, DOI 10.1021/bi00027a043; WRZESINSKI J, 1995, RNA, V1, P437; Yarian CS, 1999, NUCLEIC ACIDS RES, V27, P3543, DOI 10.1093/nar/27.17.3543; Zebarjadian Y, 1999, MOL CELL BIOL, V19, P7461	71	41	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					34934	34940		10.1074/jbc.M103131200	http://dx.doi.org/10.1074/jbc.M103131200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11406626	hybrid			2022-12-25	WOS:000171024600079
J	Nofer, JR; Levkau, B; Wolinska, I; Junker, R; Fobker, M; von Eckardstein, A; Seedorf, U; Assmann, G				Nofer, JR; Levkau, B; Wolinska, I; Junker, R; Fobker, M; von Eckardstein, A; Seedorf, U; Assmann, G			Suppression of endothelial cell apoptosis by high density lipoproteins (HDL) and HDL-associated lysophingolipids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; HUMAN ATHEROSCLEROTIC PLAQUES; SHED MEMBRANE MICROPARTICLES; HUMAN SKIN FIBROBLASTS; NITRIC-OXIDE SYNTHASE; SIGNALING PATHWAYS; OXIDIZED LDL; AKT; ACTIVATION; SURVIVAL	Apoptotic cell death following injury of vascular endothelium. is assumed to play an important role in the pathogenesis of atherosclerosis. In this report, we demonstrate that high density lipoproteins (HDL), a major anti-atherogenic lipoprotein fraction, protect endothelial cells against growth factor deprivation-induced apoptosis. HDL blocked the mitochondrial pathway of apoptosis by inhibiting dissipation of mitochondrial potential (Atom), generation of reactive oxygen species, and release of cytochrome c into the cytoplasm. As a consequence, HDL prevented activation of caspases 9 and 3 and apoptotic alterations of the plasma membrane such as increase of permeability and translocation of phosphatidylserine. Treatment of endothelial cells with HDL induced activation of the protein kinase Akt, an ubiquitous transducer of anti-apoptotic signals, and led to phosphorylation of BAD, a major Akt substrate. Suppression of Akt activity both by wortmannin and LY294002 or by a dominant negative Akt mutant abolished the anti-apoptotic effect of HDL. Two bioactive lysosphingolipids present in HDL particles, sphingosylphosphorycholine and lysosulfatide, fully mimicked the survival effect of HDL by blocking the mitochondrial pathway of apoptosis and potently activating Akt. In conclusion, the present study identifies HDL as a carrier of endogenous endothelial survival factors and suggests that inhibition of endothelial apoptosis by HDL-associated lysosphingolipids may represent an important and novel aspect of the anti-atherogenic activity of HDL.	Univ Munster, Inst Klin Chem & Lab Med, D-48129 Munster, Germany; Univ Munster, Inst Arterioskleroseforsch, D-48129 Munster, Germany	University of Munster; University of Munster	Nofer, JR (corresponding author), Univ Munster, Inst Klin Chem & Lab Med, Albert Schweitzer Str 33, D-48129 Munster, Germany.	nofer@uni-muenster.de	Levkau, Bodo/N-9144-2017; Junker, Ralf/M-2358-2013					ASSMANN G, 1992, AM J CARDIOL, V70, P733, DOI 10.1016/0002-9149(92)90550-I; BAUMGARTNERPARZER SM, 1995, DIABETES, V44, P1323, DOI 10.2337/diabetes.44.11.1323; Chin TY, 1998, AM J PHYSIOL-CELL PH, V275, pC1255, DOI 10.1152/ajpcell.1998.275.5.C1255; Cockerill GW, 1999, ARTERIOSCL THROM VAS, V19, P910, DOI 10.1161/01.ATV.19.4.910; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; DAVIES PF, 1986, P NATL ACAD SCI USA, V83, P2114, DOI 10.1073/pnas.83.7.2114; Deeg MA, 1997, ARTERIOSCL THROM VAS, V17, P1667, DOI 10.1161/01.ATV.17.9.1667; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Dimmeler S, 1997, J EXP MED, V185, P601, DOI 10.1084/jem.185.4.601; Dimmeler S, 1997, CIRC RES, V81, P970; Dimmeler S, 1998, CIRC RES, V83, P334, DOI 10.1161/01.RES.83.3.334; Fujio Y, 1999, J BIOL CHEM, V274, P16349, DOI 10.1074/jbc.274.23.16349; GORDON DJ, 1989, NEW ENGL J MED, V321, P1311; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; Hermann C, 2000, ARTERIOSCL THROM VAS, V20, P402, DOI 10.1161/01.ATV.20.2.402; Hisano N, 1999, BLOOD, V93, P4293, DOI 10.1182/blood.V93.12.4293.412k26_4293_4299; Honda HM, 1999, ATHEROSCLEROSIS, V143, P299, DOI 10.1016/S0021-9150(98)00302-5; Irani K, 2000, CIRC RES, V87, P179, DOI 10.1161/01.RES.87.3.179; Jankowski J, 1998, CLIN SCI, V95, P489, DOI 10.1042/CS19980068; Kinscherf R, 1998, FASEB J, V12, P461, DOI 10.1096/fasebj.12.6.461; Levkau B, 1999, NAT CELL BIOL, V1, P227, DOI 10.1038/12050; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; Loeffler M, 2000, EXP CELL RES, V256, P19, DOI 10.1006/excr.2000.4833; Mallat Z, 1999, CIRCULATION, V99, P348, DOI 10.1161/01.CIR.99.3.348; Mallat Z, 2000, CIRCULATION, V101, P841, DOI 10.1161/01.CIR.101.8.841; Napoli C, 2000, FASEB J, V14, P1996, DOI 10.1096/fj.99-0986com; Nofer JR, 2000, BIOCHEMISTRY-US, V39, P15199, DOI 10.1021/bi001162a; OKAJIMA F, 1995, J BIOL CHEM, V270, P26332, DOI 10.1074/jbc.270.44.26332; Okamoto H, 1999, BIOCHEM BIOPH RES CO, V260, P203, DOI 10.1006/bbrc.1999.0886; Ozes ON, 1999, NATURE, V401, P82; Papapetropoulos A, 2000, J BIOL CHEM, V275, P9102, DOI 10.1074/jbc.275.13.9102; Poppe M, 2001, J NEUROSCI, V21, P4551, DOI 10.1523/JNEUROSCI.21-13-04551.2001; QuilletMary A, 1997, J BIOL CHEM, V272, P21388, DOI 10.1074/jbc.272.34.21388; SEUFFERLEIN T, 1995, J BIOL CHEM, V270, P24343, DOI 10.1074/jbc.270.41.24343; Spyridopoulos I, 1997, CIRCULATION, V95, P1505; Stein O, 1999, ATHEROSCLEROSIS, V144, P285, DOI 10.1016/S0021-9150(99)00065-9; Suc I, 1997, ARTERIOSCL THROM VAS, V17, P2158, DOI 10.1161/01.ATV.17.10.2158; Sugano M, 2000, BIOCHEM BIOPH RES CO, V272, P872, DOI 10.1006/bbrc.2000.2877; Tricot O, 2000, CIRCULATION, V101, P2450, DOI 10.1161/01.CIR.101.21.2450; Uittenbogaard A, 2000, J BIOL CHEM, V275, P11278, DOI 10.1074/jbc.275.15.11278; von Eckardstein A, 2001, ARTERIOSCL THROM VAS, V21, P13, DOI 10.1161/01.ATV.21.1.13; VONECKARDSTEIN A, 1990, J BIOL CHEM, V265, P8610; WALTER M, 1995, ARTERIOSCL THROM VAS, V15, P1975, DOI 10.1161/01.ATV.15.11.1975	44	299	316	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					34480	34485		10.1074/jbc.M103782200	http://dx.doi.org/10.1074/jbc.M103782200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11432865	hybrid			2022-12-25	WOS:000171024600019
J	Mizenina, O; Musatkina, E; Yanushevich, Y; Rodina, A; Krasilnikov, M; de Gunzburg, J; Camonis, JH; Tavitian, A; Tatosyan, A				Mizenina, O; Musatkina, E; Yanushevich, Y; Rodina, A; Krasilnikov, M; de Gunzburg, J; Camonis, JH; Tavitian, A; Tatosyan, A			A novel group IIA phospholipase A(2) interacts with v-Src oncoprotein from RSV-transformed hamster cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; ROUS-SARCOMA VIRUS; PHOSPHORYLATION SITES; 2-HYBRID SYSTEM; N-RAS; EXPRESSION; TUMORIGENICITY; PP60(V-SRC); METASTASIS; ONCOGENE	We have isolated a novel isoform of phospholipase A(2). This enzyme was designated srPLA(2) because it was discovered while analyzing the proteins interacting with different forms of the v-Src oncoproteins isolated from Rous sarcoma virus-transformed hamster cells. It contains all the functional regions of the PLA(2) group IIA proteins but differs at its C-terminal end where there is an additional stretch of 8 amino acids. The SrPLA(2) isoform was detected as a 17-kDa precursor in cells and as a mature 14-kDa form secreted in culture medium. A direct interaction of the 17-kDa precursor with the Src protein was observed in lysates of transformed cells. Both the 17- and 14-kDa forms were found to be phosphorylated on tyrosine. To our knowledge, this is the first report of a PLA(2) group II protein that is tyrosine phosphorylated. We surmise that srPLA(2) interacts with the Src protein at the cell membrane during the process of its maturation.	Russian Acad Med Sci, Canc Res Ctr, Inst Carcinogenesis, Oncogene Regulat Lab, Moscow 115478, Russia; INSERM, U548, Inst Curie, F-75248 Paris 05, France	Russian Academy of Medical Sciences; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Tatosyan, A (corresponding author), Russian Acad Med Sci, Canc Res Ctr, Inst Carcinogenesis, Oncogene Regulat Lab, Kashirskoye Shosse 24, Moscow 115478, Russia.		Yanushevich, Yurii/AAF-9750-2020	Yanushevich, Yurii/0000-0001-9061-752X				ALONSO T, 1990, BIOCHEM BIOPH RES CO, V171, P14, DOI 10.1016/0006-291X(90)91349-W; BARBOUR SE, 1993, J BIOL CHEM, V268, P21875; BARTEL JV, 1993, PRACTICAL APPROACH, P153; Battey, 1986, BASIC METHODS MOL BI; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; BRAQUET P, 1987, PHARMACOL REV, V39, P97; BRASHISHKITE D A, 1989, Molekulyarnaya Biologiya (Moscow), V23, P758; CHEN J, 1994, J BIOL CHEM, V269, P23018; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIDPFEUTY T, 1990, J CELL BIOL, V111, P3097, DOI 10.1083/jcb.111.6.3097; DEICHMAN GI, 1989, INT J CANCER, V44, P908, DOI 10.1002/ijc.2910440527; DEICHMAN GI, 1992, INT J CANCER, V51, P903, DOI 10.1002/ijc.2910510612; Deichman GI, 1996, INT J CANCER, V66, P747, DOI 10.1002/(SICI)1097-0215(19960611)66:6<747::AID-IJC7>3.0.CO;2-#; FELLER SM, 1995, METHOD ENZYMOL, V255, P369; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FORSTER S, 1985, BRIT J DERMATOL, V112, P135, DOI 10.1111/j.1365-2133.1985.tb00077.x; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; Kaiser C., 1994, METHODS YEAST GENETI; KOMADA M, 1989, J BIOCHEM-TOKYO, V106, P545, DOI 10.1093/oxfordjournals.jbchem.a122890; KRAMER RM, 1989, J BIOL CHEM, V264, P5768; Kreegipuu A, 1999, NUCLEIC ACIDS RES, V27, P237, DOI 10.1093/nar/27.1.237; Kundu GC, 1997, J BIOL CHEM, V272, P2346; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mizenina O, 1998, FEBS LETT, V422, P79, DOI 10.1016/S0014-5793(97)01568-8; MUKHERJEE AB, 1994, BIOCHEM PHARMACOL, V48, P1, DOI 10.1016/0006-2952(94)90216-X; Ostermeyer AG, 1996, EXP HEMATOL, V24, P176; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHRODER T, 1980, SCAND J GASTROENTERO, V15, P633, DOI 10.3109/00365528009182227; Shakhov AN, 2000, GENES IMMUN, V1, P191, DOI 10.1038/sj.gene.6363659; SIDDIQI AR, 1991, EUR J BIOCHEM, V201, P675, DOI 10.1111/j.1432-1033.1991.tb16328.x; Songyang Zhou, 1995, Trends in Biochemical Sciences, V20, P470, DOI 10.1016/S0968-0004(00)89103-3; Tatosyan A, 1996, VIROLOGY, V216, P347, DOI 10.1006/viro.1996.0070; Tischfield JA, 1997, J BIOL CHEM, V272, P17247, DOI 10.1074/jbc.272.28.17247; TOPOL LZ, 1993, MOL CARCINOGEN, V8, P167, DOI 10.1002/mc.2940080307; TRANSY C, 1995, MOL BIOL REP, V21, P119, DOI 10.1007/BF00986502; VADAS P, 1985, LIFE SCI, V36, P579, DOI 10.1016/0024-3205(85)90640-X; VADAS P, 1984, J LAB CLIN MED; Valentin E, 1999, J BIOL CHEM, V274, P31195, DOI 10.1074/jbc.274.44.31195; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C	41	8	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					34006	34012		10.1074/jbc.M011320200	http://dx.doi.org/10.1074/jbc.M011320200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11427522	hybrid			2022-12-25	WOS:000170910200096
J	Rotem-Yehudar, R; Galperin, E; Horowitz, M				Rotem-Yehudar, R; Galperin, E; Horowitz, M			Association of insulin-like growth factor 1 receptor with EHD1 and SNAP29	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; VESICLE FORMATION; PROTEIN; EPS15; DOMAIN; ENDOCYTOSIS; MEMBRANE; INSULIN; INTERSECTIN; INHIBITION	Ligand-induced receptor-mediated endocytosis plays a central role in regulating signaling conveyed by tyrosine kinase receptors. This process depends on the recruitment of the adaptor protein 2 (AP-2) complex, clathrin, dynamin, and other accessory proteins to the ligand-bound receptor. We show here that besides AP-2 and clathrin, two other proteins participate in the endocytic process of the insulin-like growth factor receptor (IGF-1R); they are EHD1, an Eps15 homology (EH) domain-containing protein 1, and SNAP29, a synaptosomal-associated protein. EHD1 and SNAP29 form complexes with alpha -adaptin of AP-2 and co-localize in endocytic vesicles, indicating a role for them in endocytosis. EHD1 and SNAP29 interact directly with each other and are present in complexes with IGF-1R. After IGF-1 induction, EHD1 and IGF-1R co-localize intracellularly. Overexpression of EHD1 in Chinese hamster ovary cells represses IGF-1-mediated signaling, as measured by mitogen-activated protein kinase phosphorylation and Akt phosphorylation, indicating that EHD1 plays a role as a down-regulator in IGF-1 signaling pathway.	Stil Biotechnol, IL-52656 Ramat Gan, Israel; Tel Aviv Univ, Dept Cell Res & Immunol, IL-69978 Ramat Aviv, Israel	Tel Aviv University	Horowitz, M (corresponding author), Stil Biotechnol, IL-52656 Ramat Gan, Israel.	horwitzm@post.tau.ac.il		Galperin, Emilia/0000-0002-8743-026X				Adams A, 2000, J BIOL CHEM, V275, P27414; Benmerah A, 1999, J CELL SCI, V112, P1303; Benmerah A, 1996, J BIOL CHEM, V271, P12111, DOI 10.1074/jbc.271.20.12111; Benmerah A, 1998, J CELL BIOL, V140, P1055, DOI 10.1083/jcb.140.5.1055; Carbone R, 1997, CANCER RES, V57, P5498; Ceresa BP, 2000, CURR OPIN CELL BIOL, V12, P204, DOI 10.1016/S0955-0674(99)00077-0; Clague MJ, 1998, BIOCHEM J, V336, P271, DOI 10.1042/bj3360271; Coda L, 1998, J BIOL CHEM, V273, P3003, DOI 10.1074/jbc.273.5.3003; de Beer T, 1998, SCIENCE, V281, P1357, DOI 10.1126/science.281.5381.1357; DiFiore PP, 1997, TRENDS BIOCHEM SCI, V22, P411, DOI 10.1016/S0968-0004(97)01127-4; Kirchhausen T, 1997, CURR OPIN CELL BIOL, V9, P488, DOI 10.1016/S0955-0674(97)80024-5; LEROITH D, 1993, ANN NY ACAD SCI, V692, P1; Lewin DA, 1998, BBA-MOL CELL RES, V1401, P129, DOI 10.1016/S0167-4889(97)00130-4; Marsh M, 1999, SCIENCE, V285, P215, DOI 10.1126/science.285.5425.215; Mayer BJ, 1999, CURR BIOL, V9, pR70, DOI 10.1016/S0960-9822(99)80014-1; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Miele C, 2000, J BIOL CHEM, V275, P21695, DOI 10.1074/jbc.M000805200; Mintz L, 1999, GENOMICS, V59, P66, DOI 10.1006/geno.1999.5800; Okamoto M, 1999, J BIOL CHEM, V274, P18446, DOI 10.1074/jbc.274.26.18446; Owen DJ, 1998, SCIENCE, V282, P1327, DOI 10.1126/science.282.5392.1327; Pohl U, 2000, GENOMICS, V63, P255, DOI 10.1006/geno.1999.6087; ROBINSON MS, 1987, J CELL BIOL, V104, P887, DOI 10.1083/jcb.104.4.887; ROTHMAN JE, 1994, ADV SEC MESS PHOSPH, V29, P81; Salcini AE, 1999, INT J BIOCHEM CELL B, V31, P805, DOI 10.1016/S1357-2725(99)00042-4; Salcini AE, 1997, GENE DEV, V11, P2239, DOI 10.1101/gad.11.17.2239; Schmid SL, 1998, CURR OPIN CELL BIOL, V10, P504, DOI 10.1016/S0955-0674(98)80066-5; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; Simpson F, 1999, NAT CELL BIOL, V1, P119, DOI 10.1038/10091; SORKIN A, 1993, BIOESSAYS, V15, P375, DOI 10.1002/bies.950150603; Steegmaier M, 1998, J BIOL CHEM, V273, P34171, DOI 10.1074/jbc.273.51.34171; Stewart CEH, 1996, PHYSIOL REV, V76, P1005, DOI 10.1152/physrev.1996.76.4.1005; Tebar F, 1997, J BIOL CHEM, V272, P15413, DOI 10.1074/jbc.272.24.15413; Tong XK, 2000, EMBO J, V19, P1263, DOI 10.1093/emboj/19.6.1263; Torrisi MR, 1999, MOL BIOL CELL, V10, P417, DOI 10.1091/mbc.10.2.417; Vogel K, 2000, J BIOL CHEM, V275, P2959, DOI 10.1074/jbc.275.4.2959; Weis WI, 1998, NATURE, V395, P328, DOI 10.1038/26354; Werner H, 1997, CRIT REV ONCOGENESIS, V8, P71, DOI 10.1615/CritRevOncog.v8.i1.40; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707	38	98	101	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					33054	33060		10.1074/jbc.M009913200	http://dx.doi.org/10.1074/jbc.M009913200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11423532	hybrid			2022-12-25	WOS:000170746000090
J	Camoni, L; Visconti, S; Marra, M; Aducci, P				Camoni, L; Visconti, S; Marra, M; Aducci, P			Adenosine 5 '-monophosphate inhibits the association of 14-3-3 proteins with the plant plasma membrane H+-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							14-3-3 PROTEINS; NITRATE REDUCTASE; BINDING; PHOSPHORYLATION; MODULATION; SPINACH; GROWTH	Although a well ascertained evidence proves that the activity of the plant plasma membrane H+-ATPase is regulated by 14-3-3 proteins, information about physiological factors modulating the phosphorylation-dependent association between 14-3-3 proteins and the proton pump is largely incomplete. In this paper we show that the 5 ' -AMP-mimetic, 5-aminoimidazole-4-carboxamide ribonucleoside (AICAR), inhibits the fusicoccin-promoted proton extrusion in maize roots. We also demonstrate that 5 ' -AMP inhibits the association of 14-3-3 proteins with the C-terminal domain of the H+-ATPase in an overlay assay as well as the 14-3-3-dependent stimulation of the Arabidopsis thaliana H+-ATPase AHA1 isoform expressed in yeast membranes. Finally, by means of affinity chromatography with immobilized 5 ' -AMP and trinitrophenyl-AMP fluorescence analysis, we demonstrate that the 14-3-3 isoform GF14-6 from maize is able to bind 5 ' -AMP. The possible role of 5 ' -AMP as a general regulator of 14-3-3 functions in the plant cell is discussed.	Univ Roma Tor Vergata, Dept Biol, I-00133 Rome, Italy; Univ Sannio, Dept Earth Sci, I-82100 Benevento, Italy	University of Rome Tor Vergata; University of Sannio	Aducci, P (corresponding author), Univ Roma Tor Vergata, Dept Biol, Via Ricerca Sci, I-00133 Rome, Italy.	aducci@uniroma2.it	Camoni, Lorenzo/C-2584-2012					ADUCCI P, 1980, PLANTA, V148, P208, DOI 10.1007/BF00380028; Aitken A, 1996, TRENDS CELL BIOL, V6, P341, DOI 10.1016/0962-8924(96)10029-5; Athwal GS, 1998, PLANT PHYSIOL, V118, P1041, DOI 10.1104/pp.118.3.1041; Athwal GS, 2000, PLANT CELL PHYSIOL, V41, P523, DOI 10.1093/pcp/41.4.523; BALLIO A, 1968, Annali dell'Istituto Superiore di Sanita, V4, P317; Baunsgaard L, 1998, PLANT J, V13, P661, DOI 10.1046/j.1365-313X.1998.00083.x; BISHOP JE, 1986, BIOCHEMISTRY-US, V25, P696, DOI 10.1021/bi00351a029; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Camoni L, 2000, J BIOL CHEM, V275, P9919, DOI 10.1074/jbc.275.14.9919; Ferl RJ, 1996, ANNU REV PLANT PHYS, V47, P49, DOI 10.1146/annurev.arplant.47.1.49; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Fuglsang AT, 1999, J BIOL CHEM, V274, P36774, DOI 10.1074/jbc.274.51.36774; Fullone MR, 1998, J BIOL CHEM, V273, P7698, DOI 10.1074/jbc.273.13.7698; Huber SC, 1996, PHYSIOL PLANTARUM, V98, P833, DOI 10.1111/j.1399-3054.1996.tb06692.x; Jahn T, 1997, PLANT CELL, V9, P1805, DOI 10.1105/tpc.9.10.1805; KAISER WM, 1991, PLANT PHYSIOL, V96, P368, DOI 10.1104/pp.96.2.368; Kinoshita T, 1999, EMBO J, V18, P5548, DOI 10.1093/emboj/18.20.5548; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Marra M, 1996, FEBS LETT, V382, P293, DOI 10.1016/0014-5793(96)00187-1; Marra M, 2000, PLANT BIOLOGY, V2, P11, DOI 10.1055/s-2000-9458; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Oecking C, 1997, PLANT J, V12, P441, DOI 10.1046/j.1365-313X.1997.12020441.x; Olsson A, 1998, PLANT PHYSIOL, V118, P551, DOI 10.1104/pp.118.2.551; Palmgren MG, 1998, ADV BOT RES, V28, P1; REGENBERG B, 1995, PLANT CELL, V7, P1655, DOI 10.1105/tpc.7.10.1655; SABINA RL, 1985, J BIOL CHEM, V260, P6107; SERRANO R, 1988, METHOD ENZYMOL, V157, P533; Sturm A, 1999, TRENDS PLANT SCI, V4, P401, DOI 10.1016/S1360-1385(99)01470-3; SULLIVAN JE, 1994, BIOCHEM BIOPH RES CO, V200, P1551, DOI 10.1006/bbrc.1994.1627; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0	30	32	34	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					31709	31712		10.1074/jbc.M104194200	http://dx.doi.org/10.1074/jbc.M104194200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11423544	hybrid			2022-12-25	WOS:000170613500033
J	Du, GG; Guo, XH; Khanna, VK; MacLennan, DH				Du, GG; Guo, XH; Khanna, VK; MacLennan, DH			Functional characterization of mutants in the predicted pore region of the rabbit cardiac muscle Ca2+ release channel (Ryanodine receptor isoform 2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL CORE DISEASE; SKELETAL-MUSCLE; SARCOPLASMIC-RETICULUM; MALIGNANT HYPERTHERMIA; MOLECULAR-IDENTIFICATION; CALMODULIN-BINDING; FORMING SEGMENT; C-TERMINUS; SITES; SELECTIVITY	A highly conserved amino acid sequence, GVRAGG-GIGD(4831), which may form part of the Ca2+ release channel pore in RyR2, was subjected to Ala scanning or Ala to Val mutagenesis; function was then measured by expression in HEK-293 cells, followed by Ca2+ photometry, high affinity [H-3]ryanodine binding, and single-channel recording. All mutants except I4829A and 14829T (corresponding to the I4S97T central core disease mutant in RyR1) displayed caffeine-induced Ca2+ release in HEK-293 cells; only mutants G4826A, I4829V, and G4830A retained high affinity [3H]ryanodine binding; and single-channel function was found for all mutants tested, except for G4822A and A4825V. EC50 values for caffeine-induced Ca2+ release were increased for G4822A, R4824A, G4826A, G4828A, and D4831A; decreased for V4823A, and unchanged for A4825V, G4827A, I4829V, and G4830A. Ryanodine (10 muM), which did not stimulate Ca2+ release in wild type (wt), did so in Ala mutants in amino acids 4823-4827. It inhibited the caffeine response in wt and most mutants, but enhanced the amplitude of caffeine-induced Ca2+ release in mutant G4828A It also restored caffeine-induced Ca2+ release in mutants I4829A and I4929T. In single-channel recordings, mutants 14829V and G4830A retained normal conductance, whereas all others had decreased unitary channel conductances ranging from 27 to 540 picosiemens. Single-channel modu-lation was retained in G4826A, I4S29V, and G4830A, but was lost in other mutants. In contrast to wt and G4826A, I4S29V, and G4830A, in which divalent metals were preferentially conducted, mutants with loss of modulation had no selectivity of divalent cations over a monovalent cation. Analysis of Gly(4822) to Asp(4831) mutants in RyR2 supports the view that this highly conserved sequence constitutes part of the ion-conducting pore of the Ca2+ release channel and plays a key role in ryanodine and caffeine binding and activation.	Univ Toronto, Charles H Best Inst, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada	University of Toronto	MacLennan, DH (corresponding author), Univ Toronto, Charles H Best Inst, Banting & Best Dept Med Res, 112 Coll St, Toronto, ON M5G 1L6, Canada.	david.maclennan@utoronto.ca						Avila G, 2001, P NATL ACAD SCI USA, V98, P4215, DOI 10.1073/pnas.071048198; Balshaw D, 1999, P NATL ACAD SCI USA, V96, P3345, DOI 10.1073/pnas.96.7.3345; Bhat MB, 1997, BIOPHYS J, V73, P1329, DOI 10.1016/S0006-3495(97)78166-9; Boehning D, 2001, J BIOL CHEM, V276, P13509, DOI 10.1074/jbc.C100094200; CALLAWAY C, 1994, J BIOL CHEM, V269, P15876; Chen SRW, 1997, BIOPHYS J, V73, P1904, DOI 10.1016/S0006-3495(97)78221-3; Chen SRW, 1998, J BIOL CHEM, V273, P14675, DOI 10.1074/jbc.273.24.14675; CHEN SRW, 1994, J BIOL CHEM, V269, P22698; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Du GC, 2000, J BIOL CHEM, V275, P11778, DOI 10.1074/jbc.275.16.11778; Du GG, 1998, J BIOL CHEM, V273, P31867, DOI 10.1074/jbc.273.48.31867; Du GG, 1999, J BIOL CHEM, V274, P26120, DOI 10.1074/jbc.274.37.26120; Du GG, 1998, J BIOL CHEM, V273, P33259, DOI 10.1074/jbc.273.50.33259; Fessenden JD, 2001, P NATL ACAD SCI USA, V98, P2865, DOI 10.1073/pnas.041608898; FranziniArmstrong C, 1997, PHYSIOL REV, V77, P699, DOI 10.1152/physrev.1997.77.3.699; Gao L, 2000, BIOPHYS J, V79, P828, DOI 10.1016/S0006-3495(00)76339-9; GRUNWALD R, 1995, J BIOL CHEM, V270, P11338, DOI 10.1074/jbc.270.19.11338; Herrmann-Frank A, 1999, J MUSCLE RES CELL M, V20, P223, DOI 10.1023/A:1005496708505; LAI FA, 1989, J BIOL CHEM, V264, P16776; LEE KS, 1984, J PHYSIOL-LONDON, V354, P253, DOI 10.1113/jphysiol.1984.sp015374; Loke J, 1998, AM J MED, V104, P470, DOI 10.1016/S0002-9343(98)00108-9; Lynch PJ, 1999, P NATL ACAD SCI USA, V96, P4164, DOI 10.1073/pnas.96.7.4164; MACLENNAN DH, 1995, SOC GEN PHY, V50, P89; Manjunatha B, 1997, J GEN PHYSIOL, V110, P749, DOI 10.1085/jgp.110.6.749; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; MENEGAZZI P, 1994, BIOCHEMISTRY-US, V33, P9078, DOI 10.1021/bi00197a008; Moore CP, 1999, J BIOL CHEM, V274, P36831, DOI 10.1074/jbc.274.52.36831; Nakai J, 1999, FEBS LETT, V459, P154, DOI 10.1016/S0014-5793(99)01232-6; OTSU K, 1990, J BIOL CHEM, V265, P13472; Priori SG, 2001, CIRCULATION, V103, P196; PROCITA L, 1956, J PHARMACOL EXP THER, V117, P363; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; Tiso N, 2001, HUM MOL GENET, V10, P189, DOI 10.1093/hmg/10.3.189; Tong JF, 1999, J BIOL CHEM, V274, P693, DOI 10.1074/jbc.274.2.693; Tong JF, 1997, J BIOL CHEM, V272, P26332, DOI 10.1074/jbc.272.42.26332; Welch W, 1996, BIOCHEMISTRY-US, V35, P7165, DOI 10.1021/bi9527294; WITCHER DR, 1994, J BIOL CHEM, V269, P13076; YANG J, 1993, NATURE, V366, P158, DOI 10.1038/366158a0; Zhao MC, 1999, J BIOL CHEM, V274, P25971, DOI 10.1074/jbc.274.37.25971; ZORZATO F, 1990, J BIOL CHEM, V265, P2244; Zucchi R, 1997, PHARMACOL REV, V49, P1	41	46	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					31760	31771		10.1074/jbc.M102751200	http://dx.doi.org/10.1074/jbc.M102751200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11427530	hybrid			2022-12-25	WOS:000170613500040
J	Yamaguchi, Y; Fukuhara, S; Nagase, T; Tomita, T; Hitomi, S; Kimura, S; Kurihara, H; Ouchi, Y				Yamaguchi, Y; Fukuhara, S; Nagase, T; Tomita, T; Hitomi, S; Kimura, S; Kurihara, H; Ouchi, Y			A novel mouse beta-defensin, mBD-6, predominantly expressed in skeletal muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NATURAL PEPTIDE ANTIBIOTICS; ANTIMICROBIAL PEPTIDE; HUMAN BETA-DEFENSIN-1; PANETH CELLS; HUMAN SKIN; LIPOPOLYSACCHARIDE; HBD-1; LUNG; PURIFICATION; EPITHELIUM	Defensins comprise a family of cationic, antimicrobial peptides that is characterized by the conserved 6 cysteine residues. They are expressed in the epithelial cells of various organs and are identified as key elements in the host defense system at the mucosal surface. We isolated a novel mouse beta -defensin gene from the bacterial artificial chromosome DNA containing the mouse beta -defensin-3 gene. The full-length cDNA was cloned from skeletal muscle cDNA and called mouse beta -defensin-6 (mBD-6). The predicted peptide conserved the 6-cysteine motif and had 59% amino acid sequence identity with mouse beta -defensin-3 and 59% identity with mouse beta -defensin-4. We demonstrated the-expression of mBD-6 in skeletal muscle in addition to the esophagus, tongue, and trachea. In animal models of endotoxemia, mBD-6 expression was also induced in the lung. mBD-6 showed potent antimicrobial activity against Escherichia coli and would play an important role in host defense in the esophagus, airways, and skeletal muscle. mBD-6 is the first reported beta -defensin predominantly expressed in skeletal muscle. This unique tissue specificity suggests some, novel physiological roles of this peptide family.	Kumamoto Univ, Inst Mol Embryol & Genet, Div Integrat Cell Biol, Dept Embryogenesis, Kumamoto 8600811, Japan; Univ Tokyo, Grad Sch Med, Dept Geriatr Med, Tokyo 1138655, Japan; Univ Tokyo, Grad Sch Med, Dept Infect Control & Prevent, Tokyo 1138655, Japan; Univ Tsukuba, Inst Clin Med, Dept Infect Dis, Tsukuba, Ibaraki 3058575, Japan	Kumamoto University; University of Tokyo; University of Tokyo; University of Tsukuba	Kurihara, H (corresponding author), Kumamoto Univ, Inst Mol Embryol & Genet, Div Integrat Cell Biol, Dept Embryogenesis, 2-2-1 Honjo,Kumamoto Shi, Kumamoto 8600811, Japan.			Kurihara, Hiroki/0000-0002-6476-5593				Bals R, 1999, INFECT IMMUN, V67, P3542, DOI 10.1128/IAI.67.7.3542-3547.1999; Bals R, 1998, INFECT IMMUN, V66, P1225, DOI 10.1128/IAI.66.3.1225-1232.1998; Bals R, 1998, J CLIN INVEST, V102, P874, DOI 10.1172/JCI2410; Becker MN, 2000, J BIOL CHEM, V275, P29731, DOI 10.1074/jbc.M000184200; BENSCH KW, 1995, FEBS LETT, V368, P331, DOI 10.1016/0014-5793(95)00687-5; DIAMOND G, 1991, P NATL ACAD SCI USA, V88, P3952, DOI 10.1073/pnas.88.9.3952; Fulton C, 1997, LANCET, V350, P1750, DOI 10.1016/S0140-6736(05)63574-X; GANZ T, 1985, J CLIN INVEST, V76, P1427, DOI 10.1172/JCI112120; GILL D, 2000, INFECT IMMUN, V68, P113; Goldman MJ, 1997, CELL, V88, P553, DOI 10.1016/S0092-8674(00)81895-4; Hamil KG, 2000, ENDOCRINOLOGY, V141, P1245, DOI 10.1210/en.141.3.1245; Harder J, 2001, J BIOL CHEM, V276, P5707, DOI 10.1074/jbc.M008557200; Harder J, 1997, NATURE, V387, P861, DOI 10.1038/43088; HARWIG SSL, 1994, METHOD ENZYMOL, V236, P160; Hughes AL, 1999, CELL MOL LIFE SCI, V56, P94, DOI 10.1007/s000180050010; Huttner KM, 1997, FEBS LETT, V413, P45, DOI 10.1016/S0014-5793(97)00875-2; Jia HP, 1999, INFECT IMMUN, V67, P4827, DOI 10.1128/IAI.67.9.4827-4833.1999; Jia HP, 2000, J BIOL CHEM, V275, P33314, DOI 10.1074/jbc.M006603200; Jia HP, 2001, GENE, V263, P211; JONES DE, 1993, FEBS LETT, V315, P187, DOI 10.1016/0014-5793(93)81160-2; JONES DE, 1992, J BIOL CHEM, V267, P23216; Li P, 2001, SCIENCE, V291, P1783, DOI 10.1126/science.1056545; McCray PB, 1997, AM J RESP CELL MOL, V16, P343, DOI 10.1165/ajrcmb.16.3.9070620; Morrison GM, 1999, FEBS LETT, V442, P112, DOI 10.1016/S0014-5793(98)01630-5; O'Neil DA, 1999, J IMMUNOL, V163, P6718; Pagenstecher A, 2000, AM J PATHOL, V157, P197, DOI 10.1016/S0002-9440(10)64531-2; SCHONWETTER BS, 1995, SCIENCE, V267, P1645, DOI 10.1126/science.7886453; Valore EV, 1998, J CLIN INVEST, V101, P1633, DOI 10.1172/JCI1861; WILDE CG, 1989, J BIOL CHEM, V264, P11200; Yang D, 1999, SCIENCE, V286, P525, DOI 10.1126/science.286.5439.525; Zhao CQ, 1996, FEBS LETT, V396, P319, DOI 10.1016/0014-5793(96)01123-4	31	33	34	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					31510	31514		10.1074/jbc.M104149200	http://dx.doi.org/10.1074/jbc.M104149200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11408484	hybrid			2022-12-25	WOS:000170613500007
J	Bajenova, OV; Zimmer, R; Stolper, E; Salisbury-Rowswell, J; Nanji, A; Thomas, P				Bajenova, OV; Zimmer, R; Stolper, E; Salisbury-Rowswell, J; Nanji, A; Thomas, P			Heterogeneous RNA-binding protein M4 is a receptor for carcinoembryonic antigen in Kupffer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HNRNP-M PROTEINS; MEDIATED ENDOCYTOSIS; ARGININE METHYLATION; MESSENGER-RNA; IN-VIVO; EXPRESSION; GENE; PHOSPHORYLATION; IDENTIFICATION; RECOGNITION	Here we report the isolation of the recombinant cDNA clone from rat macrophages, Kupffer cells (KC) that encodes a protein interacting with carcinoembryonic antigen (CEA). To isolate and identify the CEA receptor gene we used two approaches: screening of a KC cDNA library with a specific antibody and the yeast two-hybrid system for protein interaction using as a bait the N-terminal part of the CEA encoding the binding site. Both techniques resulted in the identification of the rat heterogeneous RNA-binding protein (hnRNP) M4 gene. The rat ortholog cDNA sequence has not been previously described. The open reading frame for this gene contains a 2351-base pair sequence with the polyadenylation signal AATAAA and a termination poly(A) tail. The mRNA shows ubiquitous tissue expression as a 2.4-kilobase transcript. The deduced amino acid sequence comprised a 78-kDa membrane protein with 3 putative RNA-binding domains, arginine/methionine/glutamine-rich C terminus and 3 potential membrane spanning regions. When hnRNP M4 protein is expressed in pGEX4T-3 vector system in Escherichia coli it binds I-125-labeled CEA in a Ca2+-dependent fashion. Transfection of rat hnRNP M4 cDNA into a non-CEA binding mouse macrophage cell line p388D1 resulted in CEA binding. These data provide evidence for a new function of hnRNP M4 protein as a CEA-binding protein in Kupffer cells.	Boston Univ, Sch Med, Lab Surg Biol, Dept Surg, Boston, MA 02118 USA	Boston University	Thomas, P (corresponding author), Boston Univ, Sch Med, Lab Surg Biol, Dept Surg, 801 Albany St,Rm 310, Boston, MA 02118 USA.	pthomas@bu.edu		Bajenova, Olga/0000-0001-7506-4736	NCI NIH HHS [CA74941] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA074941] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BLANCK I, 1995, GENOMICS, V27, P561; BLANCK O, 1994, GENOMICS, V21, P18, DOI 10.1006/geno.1994.1219; BOER U, 2000, BIOCHEM J, V15, P839; Bomsztyk K, 1997, FEBS LETT, V403, P113, DOI 10.1016/S0014-5793(97)00041-0; BOSSER R, 1995, MOL CELL BIOL, V15, P661; DATAR KV, 1993, NUCLEIC ACIDS RES, V21, P439, DOI 10.1093/nar/21.3.439; Eggert M, 1997, J BIOL CHEM, V272, P28471, DOI 10.1074/jbc.272.45.28471; Fierro-Monti I, 2000, TRENDS BIOCHEM SCI, V25, P241, DOI 10.1016/S0968-0004(00)01580-2; Gallouzi IE, 2000, P NATL ACAD SCI USA, V97, P3073, DOI 10.1073/pnas.97.7.3073; Gangopadhyay A, 1996, CANCER RES, V56, P4805; Gangopadhyay A, 1997, CANCER LETT, V118, P1, DOI 10.1016/S0304-3835(97)00216-4; Gangopadhyay A, 1996, ARCH BIOCHEM BIOPHYS, V334, P151, DOI 10.1006/abbi.1996.0440; Gangopadhyay A, 1996, ARCH BIOCHEM BIOPHYS, V328, P151, DOI 10.1006/abbi.1996.0155; Gattoni R, 1996, NUCLEIC ACIDS RES, V24, P2535, DOI 10.1093/nar/24.13.2535; GORLACH M, 1993, MOL BIOL REP, V18, P73, DOI 10.1007/BF00986759; HAAS S, 1995, J BIOL CHEM, V270, P12503, DOI 10.1074/jbc.270.21.12503; HASHINO J, 1994, CLIN EXP METASTAS, V12, P324, DOI 10.1007/BF01753839; HOSTETTER RB, 1990, J NATL CANCER I, V82, P380, DOI 10.1093/jnci/82.5.380; Huang S, 2000, J STRUCT BIOL, V129, P233, DOI 10.1006/jsbi.2000.4247; Jessup JM, 1998, CELL ADHES COMMUN S, V5, P195; Kafasla P, 2000, BIOCHEM J, V350, P495, DOI 10.1042/0264-6021:3500495; Keesee SK, 1996, CRIT REV EUKAR GENE, V6, P189, DOI 10.1615/CritRevEukarGeneExpr.v6.i2-3.50; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; Kim JC, 1999, MOL CELLS, V9, P133; Kim MK, 1999, MOL CELL BIOL, V19, P6833; Krecic AM, 1999, CURR OPIN CELL BIOL, V11, P363, DOI 10.1016/S0955-0674(99)80051-9; Leconte A, 1999, BRIT J CANCER, V80, P1373, DOI 10.1038/sj.bjc.6690531; Lee MH, 1996, J BIOL CHEM, V271, P3420; Leverrier S, 2000, BIOL CHEM, V381, P1031, DOI 10.1515/BC.2000.127; LIU Q, 1995, MOL CELL BIOL, V15, P2800; Loflin P, 1999, GENE DEV, V13, P1884, DOI 10.1101/gad.13.14.1884; Mahe D, 2000, BBA-GENE STRUCT EXPR, V1492, P414, DOI 10.1016/S0167-4781(00)00144-5; Rudd PM, 1999, J MOL BIOL, V293, P351, DOI 10.1006/jmbi.1999.3104; Schullery DS, 1999, J BIOL CHEM, V274, P15101, DOI 10.1074/jbc.274.21.15101; Shen EC, 1998, GENE DEV, V12, P679, DOI 10.1101/gad.12.5.679; THOMAS P, 1995, CANCER LETT, V92, P59, DOI 10.1016/0304-3835(95)03764-N; Tolnay M, 1999, BIOCHEM J, V338, P417, DOI 10.1042/0264-6021:3380417; TOTH CA, 1985, CANCER RES, V45, P392; TOTH CA, 1982, BIOCHEM J, V204, P377, DOI 10.1042/bj2040377; TOTH CA, 1989, J LEUKOCYTE BIOL, V45, P370, DOI 10.1002/jlb.45.4.370; WAGNER HE, 1992, CLIN EXP METASTAS, V10, P25, DOI 10.1007/BF00163573; Witte MM, 1997, P NATL ACAD SCI USA, V94, P1212, DOI 10.1073/pnas.94.4.1212; Zimmer R, 2001, CANCER RES, V61, P2822; 2000, CELL, V102, P135	44	32	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					31067	31073		10.1074/jbc.M104093200	http://dx.doi.org/10.1074/jbc.M104093200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11406629	hybrid			2022-12-25	WOS:000170472900064
J	Wang, ZG; White, PS; Ackerman, SH				Wang, ZG; White, PS; Ackerman, SH			Atp11p and Atp12p are assembly factors for the F-1-ATPase in human mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SUBUNIT; YEAST; GENE; SYNTHASE; PROTEIN; IDENTIFICATION; DISEASE; DELETION; REGION; DISRUPTION	Atp11p and Atp12p were first described as proteins required for assembly of the F-1 component of the mitochondrial ATP synthase in Saccharomyces cerevisiae (Ackerman, S. H., and Tzagoloff, A. (1990) Proc. Natl Acad. Sci. U. S. A. 87, 4986-4990). Here we report the isolation of the cDNAs and the characterization of the human genes for Atp11p and Atp12p and show that the human proteins function like their yeast counterparts. Human ATP11 spans 24 kilobase pairs in 9 exons and maps to 1p32.3-p33, while ATP12 contains greater than or equal to8 exons and localizes to 17p11.2. Both genes are broadly conserved in eukaryotes and are expressed in a wide range of tissues, which suggests that Atp11p and Atp12p are essential housekeeping proteins of human cells. The information reported herein will be useful in the evaluation of patients with ascertained deficiencies in the ATP synthase, in which the underlying biochemical defect is unknown and may reside in a protein that influences the assembly of the enzyme.	Wayne State Univ, Sch Med, Dept Surg, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA; Univ Penn, Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA 19104 USA; Univ Penn, Dept Pediat, Philadelphia, PA 19104 USA	Wayne State University; Wayne State University; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania	Ackerman, SH (corresponding author), Wayne State Univ, Sch Med, Dept Surg, 421 E Canfield Ave, Detroit, MI 48201 USA.	sackerm@med.wayne.edu			NIGMS NIH HHS [GM48157] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048157] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACKERMAN SH, 1992, J BIOL CHEM, V267, P7386; ACKERMAN SH, 1990, P NATL ACAD SCI USA, V87, P4986, DOI 10.1073/pnas.87.13.4986; ACKERMAN SH, 1990, J BIOL CHEM, V265, P9952; Arnold I, 1999, J BIOL CHEM, V274, P36, DOI 10.1074/jbc.274.1.36; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; BOWMAN S, 1991, J BIOL CHEM, V266, P7517; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; CHANCE PF, 1993, CELL, V72, P143, DOI 10.1016/0092-8674(93)90058-X; Corman B, 1999, AM J HUM GENET, V64, P126, DOI 10.1086/302206; Deloukas P, 1998, SCIENCE, V282, P744, DOI 10.1126/science.282.5389.744; Engle EC, 1997, AM J HUM GENET, V60, P1150; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Garcia JJ, 2000, J BIOL CHEM, V275, P11075, DOI 10.1074/jbc.275.15.11075; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HOLME E, 1992, PEDIATR RES, V32, P731, DOI 10.1203/00006450-199212000-00022; Houstek J, 1999, HUM MOL GENET, V8, P1967; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; KATAOKA H, 1991, BIOCHIM BIOPHYS ACTA, V1089, P393, DOI 10.1016/0167-4781(91)90183-M; LEMIRE BD, 1989, J BIOL CHEM, V264, P20206; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Miller PR, 1999, CYTOGENET CELL GENET, V85, P157; OHTA S, 1986, J BIOCHEM-TOKYO, V99, P135, DOI 10.1093/oxfordjournals.jbchem.a135452; PATEL PI, 1992, NAT GENET, V1, P159, DOI 10.1038/ng0692-159; Ragnarsson G, 1999, BRIT J CANCER, V79, P1468, DOI 10.1038/sj.bjc.6690234; SAMBROOK J, 1982, MOL CLONING LAN MANU; SCHAGGER H, 1995, EUR J BIOCHEM, V227, P916, DOI 10.1111/j.1432-1033.1995.tb20219.x; Scheurlen WG, 1997, GENE CHROMOSOME CANC, V18, P50, DOI 10.1002/(SICI)1098-2264(199701)18:1<50::AID-GCC6>3.0.CO;2-0; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SMITH ACM, 1986, AM J MED GENET, V24, P393, DOI 10.1002/ajmg.1320240303; Sulman EP, 1998, CANCER RES, V58, P3226; TATUCH Y, 1992, AM J HUM GENET, V50, P852; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Velours J, 2001, J BIOL CHEM, V276, P8602, DOI 10.1074/jbc.M008123200; Wang ZG, 1998, J BIOL CHEM, V273, P2993, DOI 10.1074/jbc.273.5.2993; Wang ZG, 2000, EMBO J, V19, P1486, DOI 10.1093/emboj/19.7.1486; Wang ZG, 1999, FEBS LETT, V452, P305, DOI 10.1016/S0014-5793(99)00676-6; Wang ZG, 1996, J BIOL CHEM, V271, P4887; Wang ZG, 2000, J BIOL CHEM, V275, P5767, DOI 10.1074/jbc.275.8.5767; WHITE M, 1995, ARCH BIOCHEM BIOPHYS, V319, P299, DOI 10.1006/abbi.1995.1296; White PS, 1999, GENOME RES, V9, P978, DOI 10.1101/gr.9.10.978	40	72	78	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					30773	30778		10.1074/jbc.M104133200	http://dx.doi.org/10.1074/jbc.M104133200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11410595	hybrid			2022-12-25	WOS:000170472900027
J	Abu-Amer, Y; Dowdy, SF; Ross, FP; Clohisy, JC; Teitelbaum, SL				Abu-Amer, Y; Dowdy, SF; Ross, FP; Clohisy, JC; Teitelbaum, SL			TAT fusion proteins containing tyrosine 42-deleted I kappa B alpha arrest osteoclastogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; BONE-RESORPTION; TRANSDUCTION; CELLS; PHOSPHORYLATION; DEGRADATION; ACTIVATION; DELIVERY; MACROPHAGES	In most circumstances, NF-kappaB, which is essential for osteoclastogenesis, is activated following serine 32/36 phosphorylation of its cytosolic inhibitory protein, I kappaB alpha. In contrast to other cell types, I kappaB alpha, in bone marrow macrophages (BMMs), which are osteoclast precursors, is tyrosine-phosphorylated by c-Src kinase. To address the role of I kappaB alpha phosphorylation in osteoclastogenesis, we generated TAT fusion proteins containing wild-type I kappaB alpha (TAT-WT-I kappaB), I kappaB alpha lacking its NH2-terminal 45 amino acids (TAT-I kappaB(46-317)), and I kappaB alpha in which tyrosine residue 42, the c-Src target, is mutated into phenylalanine (TAT-I kappaB(Y42F)). TAT-I kappaB efficiently enters BMMs, and the NF-kappaB-inhibitory protein, once intracellular, is functional. While TAT-WT-I kappaB only Slightly inhibits osteoclastogenesis, osteoclast recruitment is diminished > 80% by TAT-I kappaB(46-317), an event mirrored by dentin resorption. The fact that TAT alone does not impact osteoclastogenesis, which also resumes following withdrawal of TAT-I kappaB(46-317), establishes that the mutant's anti-osteoclastogenic properties do not reflect toxicity. Affirming a functional role for I kappaB(Tyr(42)) in osteoclastogenesis, TAT-I kappaB(Y42F) is as efficient as TAT-I kappaB(46-317) in blocking osteoclast differentiation. Thus, dominant-negative I kappaB alpha constructs block osteoclastogenesis, and Tyr 42 is essential to the process, increasing the possibility that nonphosphorylatable forms Of I kappaB alpha may be a means of preventing pathological bone loss.	Washington Univ, Sch Med, Dept Orthoped Res, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Howard Hughes Med Inst, St Louis, MO 63110 USA; Washington Univ, Sch Med, Div Mol Oncol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL)	Abu-Amer, Y (corresponding author), Washington Univ, Sch Med, Dept Orthoped Surg, 1 Barnes Hosp Plaza,Suite 11300,Campus Box 8233, St Louis, MO 63110 USA.			Teitelbaum, Steven/0000-0002-4054-6679	NIAMS NIH HHS [AR45623, AR47096, AR32788] Funding Source: Medline; NIDCR NIH HHS [DE05413, DE13754] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R03AR047096, R01AR032788] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE013754] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Abu-Amer Y, 1998, J BIOL CHEM, V273, P29417, DOI 10.1074/jbc.273.45.29417; Abu-Amer Y, 2001, J CLIN INVEST, V107, P1375, DOI 10.1172/JCI10530; AbuAmer Y, 1997, J CLIN INVEST, V100, P1557, DOI 10.1172/JCI119679; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664; Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197-1285; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lissy NA, 1998, IMMUNITY, V8, P57, DOI 10.1016/S1074-7613(00)80458-6; Mukhopadhyay A, 2000, J BIOL CHEM, V275, P8549, DOI 10.1074/jbc.275.12.8549; MUNDY GR, 1996, OSTEOPOROSIS, V11, P302; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; Schwarze SR, 2000, TRENDS CELL BIOL, V10, P290, DOI 10.1016/S0962-8924(00)01771-2; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Singh S, 1996, J BIOL CHEM, V271, P31049, DOI 10.1074/jbc.271.49.31049; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; Teitelbaum SL, 1997, J LEUKOCYTE BIOL, V61, P381, DOI 10.1002/jlb.61.4.381; Teitelbaum Steven L., 1996, P61; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010; Vocero-Akbani AM, 1999, NAT MED, V5, P29, DOI 10.1038/4710	22	76	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30499	30503		10.1074/jbc.M104725200	http://dx.doi.org/10.1074/jbc.M104725200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11408488	hybrid			2022-12-25	WOS:000170558000117
J	Dammann, R; Takahashi, T; Pfeifer, GP				Dammann, R; Takahashi, T; Pfeifer, GP			The CpG island of the novel tumor suppressor gene RASSF1A is intensely methylated in primary small cell lung carcinomas	ONCOGENE			English	Article						RASSF1; methylation; CpG island; tumor suppressor gene; small cell lung cancer; 3p21	HUMAN-CHROMOSOME 3P21.3; ONCOGENIC RAS; DNA HYPERMETHYLATION; HOMOZYGOUS DELETIONS; DENOVO METHYLATION; ALLELIC LOSS; CANCER; LINES; 3P; APOPTOSIS	Loss of heterozygosity at 3p21.3 occurs in more than 90% of small cell lung carcinomas (SCLCs). The Ras association domain family 1 (RASSF1) gene cloned from the lung tumor suppressor locus 3p21.3 consists of two major alternative transcripts, RASSF1A and RASSF1C. Epigenetic inactivation of isoform A (RASSF1A) was observed in 40% of primary non-small cell lung carcinomas and in several tumor cell lines. Transfection of RASSF1A suppressed the growth of lung cancer cells in vitro and in nude mice. Here we have analysed the methylation status of the CPG island promoters of RASSF1A and RASSF1C in primary SCLCs. In 22 of 28 SCLCs (=79%) the promoter of RASSF1A was highly methylated at all CpG sites analysed, None of the SCLCs showed evidence for methylation of the CpG island of RASSF1C. The results suggest that hypermethylation of the CpG island promoter of the RASSF1A gene is associated with SCLC pathogenesis.	City Hope Canc Ctr, Beckman Res Inst, Dept Biol, Duarte, CA 91010 USA; Aichi Canc Ctr, Inst Res, Div Mol Oncol, Chikusa Ku, Nagoya, Aichi 4648681, Japan	City of Hope; Beckman Research Institute of City of Hope; Aichi Cancer Center	Pfeifer, GP (corresponding author), City Hope Canc Ctr, Beckman Res Inst, Dept Biol, Duarte, CA 91010 USA.		Takahashi, Takashi/I-7262-2014	Takahashi, Takashi/0000-0003-0615-7001				ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Baylin SB, 1998, ADV CANCER RES, V72, P141; Belinsky SA, 1998, P NATL ACAD SCI USA, V95, P11891, DOI 10.1073/pnas.95.20.11891; Chen CY, 1998, J BIOL CHEM, V273, P16700, DOI 10.1074/jbc.273.27.16700; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; Girard L, 2000, CANCER RES, V60, P4894; HIBI K, 1992, ONCOGENE, V7, P445; HUNG J, 1995, JAMA-J AM MED ASSOC, V273, P558, DOI 10.1001/jama.273.7.558; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; JONES PA, 1990, P NATL ACAD SCI USA, V87, P6117, DOI 10.1073/pnas.87.16.6117; KILLARY AM, 1992, P NATL ACAD SCI USA, V89, P10877, DOI 10.1073/pnas.89.22.10877; Kohno T, 1999, CARCINOGENESIS, V20, P1403, DOI 10.1093/carcin/20.8.1403; Kok K, 1997, ADV CANCER RES, V71, P27, DOI 10.1016/S0065-230X(08)60096-2; Lerman MI, 2000, CANCER RES, V60, P6116; Lindblad-Toh K, 2000, NAT BIOTECHNOL, V18, P1001, DOI 10.1038/79269; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MITSUDOMI T, 1991, ONCOGENE, V6, P1353; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; OTTERSON GA, 1995, ONCOGENE, V11, P1211; Palmisano WA, 2000, CANCER RES, V60, P5954; Sekido Y, 1998, ONCOGENE, V16, P3151, DOI 10.1038/sj.onc.1201858; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shao JY, 2000, J BIOL CHEM, V275, P22916, DOI 10.1074/jbc.M002235200; SHAPIRO GI, 1995, CANCER RES, V55, P6200; SUNDARESAN V, 1992, ONCOGENE, V7, P1989; Tang XM, 2000, JNCI-J NATL CANCER I, V92, P1511, DOI 10.1093/jnci/92.18.1511; THIBERVILLE L, 1995, CANCER RES, V55, P5133; Todd S, 1997, CANCER RES, V57, P1344; Vavvas D, 1998, J BIOL CHEM, V273, P5439, DOI 10.1074/jbc.273.10.5439; Vos MD, 2000, J BIOL CHEM, V275, P35669, DOI 10.1074/jbc.C000463200; WAGNER SN, 1993, VIRCHOWS ARCH B, V63, P325, DOI 10.1007/BF02899279; Wei MH, 1996, CANCER RES, V56, P1487; WHANGPENG J, 1982, SCIENCE, V215, P181, DOI 10.1126/science.6274023; Wingo PA, 1999, J NATL CANCER I, V91, P675, DOI 10.1093/jnci/91.8.675; Wistuba II, 2000, CANCER RES, V60, P1949; Wistuba II, 1999, ONCOGENE, V18, P643, DOI 10.1038/sj.onc.1202349; Wu WG, 1999, CANCER RES, V59, P1846; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532; YAMAKAWA K, 1993, ONCOGENE, V8, P327; Yatabe Y, 2000, AM J PATHOL, V157, P985, DOI 10.1016/S0002-9440(10)64611-1; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252	46	141	157	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 14	2001	20	27					3563	3567		10.1038/sj.onc.1204469	http://dx.doi.org/10.1038/sj.onc.1204469			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	445VB	11429703				2022-12-25	WOS:000169478300012
J	Kannan, K; Kaminski, N; Rechavi, G; Jakob-Hirsch, J; Amariglio, N; Givol, D				Kannan, K; Kaminski, N; Rechavi, G; Jakob-Hirsch, J; Amariglio, N; Givol, D			DNA microarray analysis of genes involved in p53 mediated apoptosis: activation of Apaf-1	ONCOGENE			English	Article						apoptosis; ts-p53; DNA microarray; clustering; Apaf-1	TEMPERATURE-SENSITIVE MUTANT; WILD-TYPE P53; P53-DEPENDENT APOPTOSIS; EXPRESSION PATTERNS; SUMO-1 MODIFICATION; CELL-DEATH; C-JUN; INTERLEUKIN-6; INHIBITION; GELSOLIN	The transcription regulation activity of p53 controls cellular response to a variety of stress conditions, leading to growth arrest and apoptosis. Despite major progress in the understanding of the global effects of p53 on cellular function the pathways by which p53 activates apoptosis are not well defined. To study genes activated in the p53 induced apoptotic process, we used a mouse myeloid leukemic cell line (LTR6) expressing the temperature-sensitive p53 (val135) that undergoes apoptosis upon shifting the temperature to 32 degreesC. We analysed the gene expression profile at different time points after p53 activation using oligonucleotide microarray capable of detecting similar to 11 000 mRNA species. Cluster analysis of the p53-regulated genes indicate a pattern of early and late induced sets of genes. We show that 91 and 44 genes were substantially up and down regulated, respectively, by p53. Functional classification of these genes reveals that they are involved in many aspects of cell function, in addition to growth arrest and apoptosis, Comparison of p53 regulated gene expression profile in LTR6 cells to that of a human lung cancer cell line (H1299) that undergoes growth arrest but not apoptosis demonstrates that only 15% of the genes are common to both systems. This observation supports the presence of two distinct transcriptional programs in response to p53 signaling, one leading to growth arrest and the other to apoptosis. The proapoptotic genes induced only in LTR6 cells like Apaf-1, Sumo-1 and gelsolin among others may suggest a possible explanation for apoptosis in LTR6 cells.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Chaim Sheba Med Ctr, Funct Genom Unit, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Chaim Sheba Med Ctr, Dept Pediat Hematol Oncol, IL-69978 Tel Aviv, Israel	Weizmann Institute of Science; Tel Aviv University; Sackler Faculty of Medicine; Chaim Sheba Medical Center; Tel Aviv University; Chaim Sheba Medical Center; Tel Aviv University	Givol, D (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.			Kaminski, Naftali/0000-0001-5917-4601				Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Jimenez GS, 2000, NAT GENET, V26, P37, DOI 10.1038/79152; Kaminski N, 2000, P NATL ACAD SCI USA, V97, P1778, DOI 10.1073/pnas.97.4.1778; Kaminski N, 2000, Ann N Y Acad Sci, V919, P1; Kannan K, 2000, FEBS LETT, V470, P77, DOI 10.1016/S0014-5793(00)01291-6; Kannan K, 2001, ONCOGENE, V20, P2225, DOI 10.1038/sj.onc.1204319; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Kusano H, 2000, ONCOGENE, V19, P4807, DOI 10.1038/sj.onc.1203868; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LEVY N, 1993, MOL CELL BIOL, V13, P7942, DOI 10.1128/MCB.13.12.7942; Maxwell SA, 2000, P NATL ACAD SCI USA, V97, P13009, DOI 10.1073/pnas.230445997; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Scherer SJ, 2000, J BIOL CHEM, V275, P37469, DOI 10.1074/jbc.M006990200; Shikama N, 1999, MOL CELL, V4, P365, DOI 10.1016/S1097-2765(00)80338-X; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Wang YC, 1998, ONCOGENE, V17, P1923, DOI 10.1038/sj.onc.1202113; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Zhao RB, 2000, GENE DEV, V14, P981	30	126	132	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 7	2001	20	26					3449	3455		10.1038/sj.onc.1204446	http://dx.doi.org/10.1038/sj.onc.1204446			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	441UW	11423996				2022-12-25	WOS:000169248800016
J	Tsukasaki, K; Miller, CW; Greenspun, E; Eshaghian, S; Kawabata, H; Fujimoto, T; Tomonaga, M; Sawyers, C; Said, JW; Koeffler, HP				Tsukasaki, K; Miller, CW; Greenspun, E; Eshaghian, S; Kawabata, H; Fujimoto, T; Tomonaga, M; Sawyers, C; Said, JW; Koeffler, HP			Mutations in the mitotic check point gene, MAD1L1, in human cancers	ONCOGENE			English	Article						MAD1L1; mitotic checkpoint; chromosomal instability; prostate cancer; breast cancer; adult T-cell leukemia/lymphoma	HUMAN LUNG CANCERS; VIRUS TYPE-I; SPINDLE CHECKPOINT; INSTABILITY; LYMPHOMA; CELLS; FRESH	Aneuploidy is a characteristic of the majority of human cancers, and recent studies suggest that defects of mitotic checkpoints play a role in carcinogenesis. MAD1L1 is a checkpoint gene, and its dysfunction is associated with chromosomal instability. Rare mutations of this gene have been reported in colon and lung cancers. We examined a total of 44 cell lines (hematopoietic, prostate, osteosarcoma, breast, glioblastoma and lung) and 133 fresh cancer cells (hematopoietic, prostate, breast and glioblastoma) for alterations of MAD1L1 by RT-PCR-SSCP and nucleotide sequencing. Eight mutations consisting of missense, nonsense and frameshift mutations were found, together with a number of nucleotide polymorphisms. All the alterations in cell lines were heterozygous, Frequency of mutations was relatively high in prostate cancer (2/7 cell lines and 2/33 tumor specimens). We placed a mutant truncated MAD1L1, found in a lymphoma sample, into HOS, Ht161 and SJSA cell lines and found that it was less inhibitory than wild type MAD1L1 at decreasing cell proliferation. Go-expression experiments showed that the mutant form had a dominant-negative effect. Furthermore, this mutant impaired the mitotic checkpoint as shown by decreased mitotic indices in HOS cells expressing mutant MAD1L1 after culture with the microtubule-disrupting agent, nocodazole, Our results suggest a pathogenic role of MAD1L1 mutations in various types of human cancer.	Univ Calif Los Angeles, Cedars Sinai Med Ctr, Sch Med, Div Hematol Oncol, Los Angeles, CA 90048 USA; Nagasaki Univ, Sch Med, Atom Bomb Dis Inst, Dept Hematol, Nagasaki 852, Japan; Univ Calif Los Angeles, Sch Med, Hlth Sci Ctr, Dept Med, Los Angeles, CA 90048 USA; Univ Calif Los Angeles, Sch Med, Hlth Sci Ctr, Dept Pathol, Los Angeles, CA 90048 USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Nagasaki University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Tsukasaki, K (corresponding author), Univ Calif Los Angeles, Cedars Sinai Med Ctr, Sch Med, Div Hematol Oncol, Los Angeles, CA 90048 USA.		Sawyers, Charles/G-5327-2016					Amon A, 1999, CURR OPIN GENET DEV, V9, P69, DOI 10.1016/S0959-437X(99)80010-0; Arvanitakis L, 1996, BLOOD, V88, P2648, DOI 10.1182/blood.V88.7.2648.bloodjournal8872648; Cahill DP, 1999, GENOMICS, V58, P181, DOI 10.1006/geno.1999.5831; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Chen RH, 1999, MOL BIOL CELL, V10, P2607, DOI 10.1091/mbc.10.8.2607; Cunningham JM, 1996, CANCER RES, V56, P4475; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; GOMBART AF, 1995, BLOOD, V86, P1534, DOI 10.1182/blood.V86.4.1534.bloodjournal8641534; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; KAMIHIRA S, 1994, LEUKEMIA RES, V18, P79, DOI 10.1016/0145-2126(94)90122-8; Kawabata H, 1999, J BIOL CHEM, V274, P20826, DOI 10.1074/jbc.274.30.20826; KINOSHITA T, 1989, P NATL ACAD SCI USA, V86, P5620, DOI 10.1073/pnas.86.14.5620; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Nomoto S, 1999, ONCOGENE, V18, P7180, DOI 10.1038/sj.onc.1203141; Ohshima K, 2000, CANCER LETT, V158, P141, DOI 10.1016/S0304-3835(00)00512-7; Pihan GA, 1999, SEMIN CANCER BIOL, V9, P289, DOI 10.1006/scbi.1999.0131; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; Said JW, 1996, BLOOD, V87, P4937, DOI 10.1182/blood.V87.12.4937.bloodjournal87124937; Sciavolino PJ, 1998, ANN MED, V30, P357, DOI 10.3109/07853899809029935; Takahashi T, 1999, ONCOGENE, V18, P4295, DOI 10.1038/sj.onc.1202807; Tsukasaki K, 1999, BRIT J HAEMATOL, V105, P369, DOI 10.1111/j.1365-2141.1999.01323.x; Tsukasaki K, 2000, BEST PRACT RES CL HA, V13, P231, DOI 10.1053/beha.1999.0070	22	76	84	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 31	2001	20	25					3301	3305		10.1038/sj.onc.1204421	http://dx.doi.org/10.1038/sj.onc.1204421			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	440ET	11423979				2022-12-25	WOS:000169163500013
J	Bezombes, C; Plo, I; Mas, WMD; Quillet-Mary, A; Negre-Salvayre, A; Laurent, G; Jaffrezou, JP				Bezombes, C; Plo, I; Mas, WMD; Quillet-Mary, A; Negre-Salvayre, A; Laurent, G; Jaffrezou, JP			Oxidative stress-induced activation of Lyn recruits sphingomyelinase and is requisite for its stimulation by Ara-C	FASEB JOURNAL			English	Article						apoptosis; Lyn kinase; reactive oxygen species	INTERNUCLEOSOMAL DNA FRAGMENTATION; P56/P53(LYN) TYROSINE KINASE; MYELOID-LEUKEMIA CELLS; INDUCED APOPTOSIS; CERAMIDE GENERATION; PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; IONIZING-RADIATION; HYDROGEN-PEROXIDE; CELLULAR-RESPONSE	Induction of apoptosis is considered to be the underlying mechanism that accounts for the efficiency of chemotherapeutic drugs. The identification of ceramide as a key mediator of apoptosis has made it possible to identify cellular entities that regulate drug-induced sphingomyelinase activation. Using human leukemia cell lines, we demonstrate that 1-beta-D-arabinofuranosylcytosine (Ara-C) stimulated ceramide generation, which was dependent on reactive oxygen species (ROS). Co-immunoprecipitation studies revealed that Ara-C-generated ROS activated the scr kinase p53/p56 Lyn, which then recruited neutral sphingomyelinase and was responsible for its activation. These effects were blocked by herbimycin A and Lyn antisense oligonucleotides. In conclusion, this study establishes a series of events in which early ROS generated by Ara-C leads to Lyn-dependent neutral sphingomyelinase activation, JNK phosphorylation, and apoptosis.	Inst Claudius Regaud, INSERM, E9910, F-31052 Toulouse, France; CHU Purpan, Hematol Serv, F-31059 Toulouse, France; CHU Rangueil, INSERM, U466, Lab Biochim Med, F-31403 Toulouse, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Claudius Regaud; CHU de Toulouse; CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm)	Jaffrezou, JP (corresponding author), Inst Claudius Regaud, INSERM, E9910, 20 Rue Pont St Pierre, F-31052 Toulouse, France.	jaffrezou@icr.fnclcc.fr	Bezombes, Christine/G-2743-2017; QUILLET-MARY, Anne/H-4690-2013; Plo, Isabelle/C-9056-2017; Bezombes, christine/X-8479-2019; Plo, Isabelle/AAT-6742-2021; Bezombes, Christine/AAC-1724-2020	Plo, Isabelle/0000-0002-5915-6910; Bezombes, christine/0000-0003-4079-4872; QUILLET-MARY, Anne/0000-0002-1849-6388; Negre-Salvayre, Anne/0000-0003-2136-5706				Backway KL, 1997, CANCER RES, V57, P2446; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Bradshaw CD, 1996, BIOCHEM MOL BIOL INT, V40, P709; Bruno AP, 1998, CELL DEATH DIFFER, V5, P172, DOI 10.1038/sj.cdd.4400330; CHABNER BA, 1989, CANC PRINCIPALS PRAC, P154; Corey SJ, 1999, BLOOD, V93, P1, DOI 10.1182/blood.V93.1.1; FRAM RJ, 1982, CANCER RES, V42, P4050; FREI E, 1969, CANCER RES, V29, P1325; GarciaRuiz C, 1997, J BIOL CHEM, V272, P11369; Goldkorn T, 1998, J CELL SCI, V111, P3209; Goldman R, 1997, ADV EXP MED BIOL, V400, P25; GUNJI H, 1991, CANCER RES, V51, P741; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HU ZB, 1995, LEUKEMIA, V9, P789; Huang YY, 1997, ONCOGENE, V15, P1947, DOI 10.1038/sj.onc.1201376; Jaffrezou JP, 1996, EMBO J, V15, P2417, DOI 10.1002/j.1460-2075.1996.tb00599.x; JI L, 1995, BIOCHEM BIOPH RES CO, V212, P640, DOI 10.1006/bbrc.1995.2017; Kharbanda S, 1995, J BIOL CHEM, V270, P30278, DOI 10.1074/jbc.270.51.30278; KHARBANDA S, 1994, ONCOGENE, V9, P3005; KHARBANDA S, 1994, J BIOL CHEM, V269, P20739; Manna SK, 1998, J BIOL CHEM, V273, P13245, DOI 10.1074/jbc.273.21.13245; Mansat-De Mas V, 1999, MOL PHARMACOL, V56, P867, DOI 10.1124/mol.56.5.867; Maziere C, 2001, BIOCHEM BIOPH RES CO, V281, P289, DOI 10.1006/bbrc.2001.4348; Min DS, 1998, J BIOL CHEM, V273, P29986, DOI 10.1074/jbc.273.45.29986; NAKANISHI O, 1993, J BIOL CHEM, V268, P10754; PLEIMAN CM, 1993, MOL CELL BIOL, V13, P5877, DOI 10.1128/MCB.13.9.5877; QuilletMary A, 1997, J BIOL CHEM, V272, P21388, DOI 10.1074/jbc.272.34.21388; STRUM JC, 1994, J BIOL CHEM, V269, P15493; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; YAMANASHI Y, 1992, P NATL ACAD SCI USA, V89, P1118, DOI 10.1073/pnas.89.3.1118; YUAN ZM, 1995, BIOCHEMISTRY-US, V34, P1058, DOI 10.1021/bi00003a041	31	30	31	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY 29	2001	15	7					1583	+		10.1096/fj.00-0787fje	http://dx.doi.org/10.1096/fj.00-0787fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519CQ	11427493				2022-12-25	WOS:000173707700029
J	Park, JS; Park, WY; Cho, KA; Kim, DI; Jhun, BH; Kim, SR; Park, SC				Park, JS; Park, WY; Cho, KA; Kim, DI; Jhun, BH; Kim, SR; Park, SC			Down-regulation of amphiphysin-1 is responsible for reduced receptor-mediated endocytosis in the senescent cells	FASEB JOURNAL			English	Article						amphiphysin-1; endocytosis; senescence; human diploid fibroblast	EPIDERMAL GROWTH-FACTOR; HUMAN-FIBROBLASTS; DOMAIN; BINDING; DYNAMIN; PHOSPHORYLATION; EXPRESSION; CULTURE; PROTEIN; SITE	Senescent cells have been generally characterized to have improper responsiveness to external stimuli and inefficient uptake of materials compared with presenescent cells, probably by down-regulation of receptor-mediated endocytosis. Using transferrin-uptake assay and Western blot of endocytosis-related proteins, we found that a significant decrease of amphiphysin-1 is strongly related to the reduction of receptor-mediated endocytosis in both human diploid fibroblasts of multipassages and hydrogen peroxide-induced premature senescence. We reconfirmed the pivotal role of amphiphysin-1 in senescence by showing that transfection of dominant negative amphiphysin-1 reduces transferrin uptake in presenescent cells and that microinjection of wild-type amphiphysin-1 into senescent cells restores the ability of the transferrin uptake nearly up to that of the presenescent cell. We conclude that the loss of endocytotic activity of senescent cells is directly related to the down-regulation of amphiphysin-1, and its functional restorability can be induced by simple microinjection of amphiphysin-1 gene in the senescent cells.	Seoul Natl Univ, Coll Med, Dept Biochem & Mol Biol, Seoul 110799, South Korea; Pusan Natl Univ, Coll Pharm, Dept Pharmacol, Pusan 609735, South Korea; Chungbuk Natl Univ, Coll Med, Dept Biochem, Cheongju, South Korea	Seoul National University (SNU); Pusan National University; Chungbuk National University	Park, SC (corresponding author), Seoul Natl Univ, Coll Med, Dept Biochem & Mol Biol, 28 Yongondong, Seoul 110799, South Korea.	separk@snu.ac.kr	park, woongyang/D-5727-2012					Chen QM, 1998, BIOCHEM J, V332, P43, DOI 10.1042/bj3320043; David C, 1996, P NATL ACAD SCI USA, V93, P331, DOI 10.1073/pnas.93.1.331; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; JHUN BH, 1994, MOL CELL BIOL, V14, P7466, DOI 10.1128/MCB.14.11.7466; JIN Y, 2001, IN PRESS EXP MOL MED; MATRISIAN LM, 1987, EXP GERONTOL, V22, P81, DOI 10.1016/0531-5565(87)90043-X; MATSUDA T, 1992, J CELL PHYSIOL, V150, P510, DOI 10.1002/jcp.1041500311; McMahon HT, 1997, FEBS LETT, V413, P319, DOI 10.1016/S0014-5793(97)00928-9; Na SY, 1999, J BIOL CHEM, V274, P28491, DOI 10.1074/jbc.274.40.28491; Park SC, 1999, J GERONTOL A-BIOL, V54, pB78, DOI 10.1093/gerona/54.2.B78; Park WY, 2000, J BIOL CHEM, V275, P20847, DOI 10.1074/jbc.M908162199; PHILLIPS PD, 1983, J CELL PHYSIOL, V114, P311, DOI 10.1002/jcp.1041140309; Ramjaun AR, 1998, J NEUROCHEM, V70, P2369; ROTHENBERGER S, 1987, CELL, V49, P423, DOI 10.1016/0092-8674(87)90295-9; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; Shupliakov O, 1997, SCIENCE, V276, P259, DOI 10.1126/science.276.5310.259; Slepnev VI, 1998, SCIENCE, V281, P821, DOI 10.1126/science.281.5378.821; Takei K, 1999, NAT CELL BIOL, V1, P33, DOI 10.1038/9004; TANG ZQ, 1994, MECH AGEING DEV, V73, P57, DOI 10.1016/0047-6374(94)90038-8; Urrutia R, 1997, P NATL ACAD SCI USA, V94, P377, DOI 10.1073/pnas.94.2.377; WANG LH, 1995, J BIOL CHEM, V270, P10079, DOI 10.1074/jbc.270.17.10079; Wigge P, 1997, CURR BIOL, V7, P554, DOI 10.1016/S0960-9822(06)00254-5	24	33	33	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY 29	2001	15	7					1625	+		10.1096/fj.00-0723fje	http://dx.doi.org/10.1096/fj.00-0723fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519CQ	11427507				2022-12-25	WOS:000173707700023
J	Joseph, B; Ekedahl, J; Lewensohn, R; Marchetti, P; Formstecher, P; Zhivotovsky, B				Joseph, B; Ekedahl, J; Lewensohn, R; Marchetti, P; Formstecher, P; Zhivotovsky, B			Defective caspase-3 relocalization in non-small cell lung carcinoma	ONCOGENE			English	Article						lung cancer; sensitivity; caspase; apoptosis	T-LYMPHOCYTE STIMULATION; CYTOCHROME-C; POLY(ADP-RIBOSE) POLYMERASE; IONIZING-RADIATION; DNA FRAGMENTATION; INDUCED APOPTOSIS; ANTICANCER DRUGS; FAMILY MEMBERS; DEATH; ACTIVATION	Many anticancer drugs exert their cytotoxicity through DNA damage and induction of apoptosis, Small cell lung carcinoma (SCLC) and non-small cell lung carcinoma (NSCLC) have different sensitivity to treatment,vith radiation and chemotherapeutic agents with SCLC being more sensitive than NSCLC both in vitro and in vivo, This difference might be related to the different susceptibility of small and non-small cell lung carcinoma to undergo apoptosis, The aim of this study was to investigate if deficiencies in the apoptotic pathways can explain the intrinsic resistance of NSCLC to anti-cancer treatment, Three different triggers were used to induce apoptosis, Etoposide and gamma -radiation, which are important parts of clinical lung cancer treatment, induce DNA-damage, whereas Fas ligation induces receptor-mediated apoptotic pathways. NSCLC cells were cross-resistant to all treatments, whereas SCLC cells, which do not express pro-caspase-8, were resistant to alpha Fas-, but not to DNA-damage-induced apoptosis. Cytochrome c release, activation of caspase-9 and the executioner caspase-3 were observed in both types of lung cancer cells, However, cleavage of known nuclear substrates for caspase-3, such as PARP and DFF45/ICAD, was documented only in the sensitive SCLC cells but not in the resistant NSCLC cells. Moreover, relocalization of active caspase-3 from the cytosol into the nucleus upon treatment was observed only in the SCLC cell line. These results indicate that the inhibition of apoptosis in NSCLC occurs downstream of mitochondrial changes and caspase activation, and upstream of nuclear events. Oncogene (2001) 20, 2877-2888.	Karolinska Inst, Inst Environm Med, Dept Toxicol, S-17177 Stockholm, Sweden; Karolinska Inst, Canc Ctr Karolinska R800, Unit Med Radiobiol, S-17176 Stockholm, Sweden; Fac Med Lille, Biol Cellulaire Lab, INSERM, U459, F-59045 Lille, France	Karolinska Institutet; Karolinska Institutet; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille	Zhivotovsky, B (corresponding author), Karolinska Inst, Inst Environm Med, Dept Toxicol, Box 210, S-17177 Stockholm, Sweden.		Zhivotovsky, Boris/A-4346-2014	Zhivotovsky, Boris/0000-0002-2238-3482; MARCHETTI, Philippe/0000-0002-4663-6800; Joseph, Bertrand/0000-0001-5655-9979				Alam A, 1999, J EXP MED, V190, P1879, DOI 10.1084/jem.190.12.1879; Belka C, 1999, ONCOGENE, V18, P4983, DOI 10.1038/sj.onc.1202878; BERGH J, 1985, ACTA PATH MICRO IM A, V93, P133; BERGH J, 1982, ACTA PATH MICRO IM A, V90, P149; Blagosklonny MV, 2000, LEUKEMIA, V14, P1502, DOI 10.1038/sj.leu.2401864; Boesen-de Cock JGR, 1999, J BIOL CHEM, V274, P14255, DOI 10.1074/jbc.274.20.14255; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; CASTRO J, 1993, CYTOMETRY, V14, P793, DOI 10.1002/cyto.990140712; Chen Q, 1998, BLOOD, V92, P4545, DOI 10.1182/blood.V92.12.4545.424k41_4545_4553; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; De Maria R, 1999, NATURE, V401, P489, DOI 10.1038/46809; Fadeel B, 1999, LEUKEMIA, V13, P719, DOI 10.1038/sj.leu.2401411; Garcia-Calvo M, 1999, CELL DEATH DIFFER, V6, P362, DOI 10.1038/sj.cdd.4400497; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Germain M, 1999, J BIOL CHEM, V274, P28379, DOI 10.1074/jbc.274.40.28379; Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Hartmann A, 2000, P NATL ACAD SCI USA, V97, P2875, DOI 10.1073/pnas.040556597; Jaattela M, 1999, EXP CELL RES, V248, P30, DOI 10.1006/excr.1999.4455; Jaattela M, 1998, EMBO J, V17, P6124, DOI 10.1093/emboj/17.21.6124; Joseph B, 1999, BIOCHEM BIOPH RES CO, V262, P381, DOI 10.1006/bbrc.1999.1191; Kennedy NJ, 1999, J EXP MED, V190, P1891, DOI 10.1084/jem.190.12.1891; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Miossec C, 1997, J BIOL CHEM, V272, P13459, DOI 10.1074/jbc.272.21.13459; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nakagawara A, 1997, CANCER RES, V57, P4578; Newton K, 2000, J EXP MED, V191, P195, DOI 10.1084/jem.191.1.195; OWENS AH, 1985, MED ONCOL, P715; Rich T, 1999, NAT CELL BIOL, V1, pE69, DOI 10.1038/11038; Robertson JD, 2000, J STRUCT BIOL, V129, P346, DOI 10.1006/jsbi.2000.4254; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Sekido Y, 1998, BBA-REV CANCER, V1378, pF21, DOI 10.1016/S0304-419X(98)00010-9; Sirzen F, 1998, LUNG CANCER-J IASLC, V22, P1, DOI 10.1016/S0169-5002(98)00066-X; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; Tamm I, 1998, CANCER RES, V58, P5315; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Vaux DL, 1999, CELL DEATH DIFFER, V6, P493, DOI 10.1038/sj.cdd.4400523; Watanabe Y, 1999, J CELL PHYSIOL, V179, P45, DOI 10.1002/(SICI)1097-4652(199904)179:1<45::AID-JCP6>3.0.CO;2-H; Wesselborg S, 1999, BLOOD, V93, P3053, DOI 10.1182/blood.V93.9.3053; Wilhelm S, 1998, EUR J IMMUNOL, V28, P891, DOI 10.1002/(SICI)1521-4141(199803)28:03<891::AID-IMMU891>3.3.CO;2-O; Xanthoudakis S, 2000, NAT CELL BIOL, V2, pE163, DOI 10.1038/35023643; Zhivotovsky B, 1999, EXP CELL RES, V248, P10, DOI 10.1006/excr.1999.4452; Zhivotovsky B, 1998, NATURE, V391, P449, DOI 10.1038/35060; Zhivotovsky B, 1999, CELL DEATH DIFFER, V6, P644, DOI 10.1038/sj.cdd.4400536	47	60	63	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 24	2001	20	23					2877	2888		10.1038/sj.onc.1204402	http://dx.doi.org/10.1038/sj.onc.1204402			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	435VA	11420700				2022-12-25	WOS:000168901800003
J	Daniel, R; Chung, SW; Eisenstein, TK; Sultzer, BM; Wong, PMC				Daniel, R; Chung, SW; Eisenstein, TK; Sultzer, BM; Wong, PMC			Specific association of type I c-abl with ran GTPase in lipopolysaccharide-mediated differentiation	ONCOGENE			English	Article						Ran; LPS; endotoxin; sepsis; c-Abl isoform	TYROSINE KINASE INHIBITORS; TUMOR-NECROSIS-FACTOR; 3' UNTRANSLATED REGION; ALPHA MESSENGER-RNA; CELL-CYCLE; ANTISENSE SEQUENCES; RETROVIRAL TRANSFER; MURINE MACROPHAGES; PROTEIN; BINDING	Each of several isoforms of c-Abl may be involved in different biological functions. Type I c-Abl has been shown to be involved in LPS-induced differentiation and Type IV c-Abl, apoptosis, Ran has recently been shown to be involved in LPS endotoxin signal transduction, Here we show that Type I c-Abl associates with Ran. Formation of this complex is specific, as Ran did not associate with the highly homologous Type IV c-Abl isoform, In non-stimulated lymphoid B cells, Type I c-Abl tyrosine kinase is inactive, whereas Type IV kinase is active. Formation of Type I c-Abl/Ran complex and activation of Type I c-Abl kinase activity are LPS dose-dependent. This complex is detectable in B cells of endotoxin-sensitive inbred mice but absent in B cells of endotoxin-resistant mice. These findings therefore suggest that Type I c-Abl and Ran are important targets in lipopolysaccharide-induced biological responses of hematopoietic cells.	Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Dept Pathol & Lab Med, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Dept Microbiol & Immunol, Philadelphia, PA 19140 USA; Stem Cell Therapeut, King Of Prussia, PA 19406 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Wong, PMC (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Dept Pathol & Lab Med, Philadelphia, PA 19140 USA.			Daniel, Rene/0000-0002-3876-6242	NCI NIH HHS [R01CA70854] Funding Source: Medline; NIAID NIH HHS [R01AI39159] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA070854] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039159] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Barila D, 2000, EMBO J, V19, P273, DOI 10.1093/emboj/19.2.273; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; BASKARAN R, 1993, P NATL ACAD SCI USA, V90, P11167, DOI 10.1073/pnas.90.23.11167; Belasco J.G., 2012, CONTROL MESSENGER RN; BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; BISCHOFF FR, 1995, P NATL ACAD SCI USA, V92, P1749, DOI 10.1073/pnas.92.5.1749; Chan SK, 1997, NATURE, V388, P634, DOI 10.1038/41692; Daniel R, 1996, CELL GROWTH DIFFER, V7, P1141; Daniel R, 1998, J BIOMED SCI, V5, P383; DANIEL R, 1995, ONCOGENE, V10, P1607; DONG ZY, 1993, J LEUKOCYTE BIOL, V53, P53, DOI 10.1002/jlb.53.1.53; DONG ZY, 1993, J IMMUNOL, V151, P2717; Dorsch M, 1996, P NATL ACAD SCI USA, V93, P13131, DOI 10.1073/pnas.93.23.13131; Dubnau J, 1996, NATURE, V379, P694, DOI 10.1038/379694a0; EVANS TC, 1994, CELL, V77, P183, DOI 10.1016/0092-8674(94)90311-5; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; Goldfield EM, 1997, CHEM PHYS LETT, V276, P1, DOI 10.1016/S0009-2614(97)00818-X; Hardin JD, 1996, CELL IMMUNOL, V172, P100, DOI 10.1006/cimm.1996.0220; Hel Z, 1996, MOL CELL BIOL, V16, P5579; Hel Z, 1998, NUCLEIC ACIDS RES, V26, P2803, DOI 10.1093/nar/26.11.2803; Kang AD, 1996, INFECT IMMUN, V64, P4612, DOI 10.1128/IAI.64.11.4612-4617.1996; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; KISLAUSKIS EH, 1993, J CELL BIOL, V123, P165, DOI 10.1083/jcb.123.1.165; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; Koepp DM, 1996, CELL, V87, P1, DOI 10.1016/S0092-8674(00)81315-X; Le Q, 1998, J IMMUNOL, V160, P3330; Moore MS, 1996, SCIENCE, V272, P47, DOI 10.1126/science.272.5258.47; NOVOGRODSKY A, 1994, SCIENCE, V264, P1319, DOI 10.1126/science.8191285; Ohba T, 1999, SCIENCE, V284, P1356, DOI 10.1126/science.284.5418.1356; Orlicek SL, 1996, J INFECT DIS, V174, P638, DOI 10.1093/infdis/174.3.638; OSTARECKLEDERER A, 1994, EMBO J, V13, P1476, DOI 10.1002/j.1460-2075.1994.tb06402.x; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; RiveraPomar R, 1996, NATURE, V379, P746, DOI 10.1038/379746a0; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SULTZER BM, 1972, INFECT IMMUN, V5, P107, DOI 10.1128/IAI.5.1.107-113.1972; Taagepera S, 1998, P NATL ACAD SCI USA, V95, P7457, DOI 10.1073/pnas.95.13.7457; Van Etten RA, 1999, TRENDS CELL BIOL, V9, P179, DOI 10.1016/S0962-8924(99)01549-4; WANG JYJ, 1993, CURR OPIN GENET DEV, V3, P35, DOI 10.1016/S0959-437X(05)80338-7; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; Wen ST, 1996, EMBO J, V15, P1583, DOI 10.1002/j.1460-2075.1996.tb00503.x; Wilde A, 1999, SCIENCE, V284, P1359, DOI 10.1126/science.284.5418.1359; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; Wong HW, 1999, DUKE MATH J, V96, P1, DOI 10.1215/S0012-7094-99-09601-1; WONG KK, 1995, ONCOGENE, V10, P705; Wong PMC, 2000, SCAND J IMMUNOL, V51, P123; Wong PMC, 2000, J HEMATOTH STEM CELL, V9, P629, DOI 10.1089/15258160050196669; Yuan Q, 2000, P NATL ACAD SCI USA, V97, P2852, DOI 10.1073/pnas.040567797; ZHAO F, 2001, IN PRESS J ENDO RES	50	6	7	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 10	2001	20	21					2618	2625		10.1038/sj.onc.1204361	http://dx.doi.org/10.1038/sj.onc.1204361			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	431VN	11420673				2022-12-25	WOS:000168652600002
J	Garcia, R; Bowman, TL; Niu, GL; Yu, H; Minton, S; Muro-Cacho, CA; Cox, CE; Falcone, R; Fairclough, R; Parsons, S; Laudano, A; Gazit, A; Levitzki, A; Kraker, A; Jove, R				Garcia, R; Bowman, TL; Niu, GL; Yu, H; Minton, S; Muro-Cacho, CA; Cox, CE; Falcone, R; Fairclough, R; Parsons, S; Laudano, A; Gazit, A; Levitzki, A; Kraker, A; Jove, R			Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells	ONCOGENE			English	Article						STAT proteins; breast cancer; Src; JAK; EGF receptor; tyrosine kinase inhibitors	FACTOR RECEPTOR FAMILY; DNA-BINDING ACTIVITY; OVEREXPRESSING C-SRC; V-SRC; TRANSCRIPTION FACTORS; EPITHELIAL-CELLS; MITOGENIC RESPONSIVENESS; CELLULAR-TRANSFORMATION; MYELOID DIFFERENTIATION; MAMMARY TUMORIGENESIS	Constitutive activation of signal transducer and activator of transcription (STAT) proteins has been detected in a wide variety of human primary tumor specimens and tumor cell lines including blood malignancies, head and neck cancer, and breast cancer. We have previously demonstrated a high frequency of Stat3 DNA-binding activity that is constitutively-induced by an unknown mechanism in human breast cancer cell lines possessing elevated EGF receptor (EGF-R) and c-Src kinase activities. Using tyrosine kinase selective inhibitors, we show here that Src and JAK family tyrosine kinases cooperate to mediate constitutive Stat3 activation in the absence of EGF stimulation in model human breast cancer cell lines. Inhibition of Scr or JAKs results in dose-dependent suppression of Stat3 DNA-binding activity, which is accompanied by growth inhibition and induction of programmed cell death. In addition, transfection of a dominant-negative form Stat3 leads to growth inhibition involving apoptosis of breast cancer cells. These results indicate that the biological effects of the Src and JAK tyrosine kinase inhibitors are at least partially mediated by blocking Stat3 signaling. While EGF-R kinase activity is not required for constitutive Stat3 activation in breast cancer cells, EGF stimulation further increases STAT DNA-binding activity, consistent with an important role for EGF-R in STAT signaling and malignant progression. Analysis of primary breast tumor specimens from patients with advanced disease revealed that the majority exhibit elevated STAT DNA-binding activity compared to adjacent non-tumor tissues. Our findings, taken together, suggest that tyrosine kinases transduce signals through Stat3 protein that contribute to the growth and survival of human breast cancer cells in culture and potentially in vivo.	Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA; Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Program Immunol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Clin Invest Program, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Oncol, Tampa, FL 33612 USA; Univ Virginia, Hlth Sci Ctr, Dept Microbiol, Charlottesville, VA 22908 USA; Univ New Hampshire, Dept Biochem & Mol Biol, Durham, NH 03824 USA; Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel; Pfizer Global Res & Dev, Ann Arbor, MI 48106 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; University of Virginia; University System Of New Hampshire; University of New Hampshire; Hebrew University of Jerusalem; Pfizer	Jove, R (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, 12902 Magnolia Dr, Tampa, FL 33612 USA.			YU, Hua/0000-0003-0931-1000	NATIONAL CANCER INSTITUTE [R01CA055652, P01CA082533] Funding Source: NIH RePORTER; NCI NIH HHS [CA82533, CA55652] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akira S, 2000, ONCOGENE, V19, P2607, DOI 10.1038/sj.onc.1203478; Akira S, 1999, STEM CELLS, V17, P138, DOI 10.1002/stem.170138; Ariyoshi K, 2000, J BIOL CHEM, V275, P24407, DOI 10.1074/jbc.M909771199; Besser D, 1999, MOL CELL BIOL, V19, P1401; Biscardi JS, 1999, ADV CANCER RES, V76, P61; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Caldenhoven E, 1996, J BIOL CHEM, V271, P13221, DOI 10.1074/jbc.271.22.13221; CANCE WG, 1995, BREAST CANCER RES TR, V35, P105, DOI 10.1007/BF00694751; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Catlett-Falcone Robyn, 1999, Current Opinion in Oncology, V11, P490, DOI 10.1097/00001622-199911000-00010; Chaturvedi P, 1998, ONCOGENE, V16, P1749, DOI 10.1038/sj.onc.1201972; Chaturvedi P, 1997, MOL CELL BIOL, V17, P3295, DOI 10.1128/MCB.17.6.3295; Coffer PJ, 2000, ONCOGENE, V19, P2511, DOI 10.1038/sj.onc.1203479; Cohen BD, 1998, BIOCHEM SOC SYMP, P199; Danial NN, 2000, ONCOGENE, V19, P2523, DOI 10.1038/sj.onc.1203484; Darnell JE, 1998, J INTERF CYTOK RES, V18, P549, DOI 10.1089/jir.1998.18.549; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; David M, 1996, J BIOL CHEM, V271, P9185, DOI 10.1074/jbc.271.16.9185; de Groot RP, 1999, BLOOD, V94, P1108, DOI 10.1182/blood.V94.3.1108.415k07_1108_1112; Dearolf CR, 1999, CELL MOL LIFE SCI, V55, P1578, DOI 10.1007/s000180050397; Decker T, 1999, CELL MOL LIFE SCI, V55, P1535, DOI 10.1007/s000180050393; Demoulin JB, 2000, CANCER RES, V60, P3971; Egan C, 1999, ONCOGENE, V18, P1227, DOI 10.1038/sj.onc.1202233; Fernandes A, 1999, INT J CANCER, V83, P564, DOI 10.1002/(SICI)1097-0215(19991112)83:4<564::AID-IJC20>3.0.CO;2-Q; Frank DA, 1996, LEUKEMIA, V10, P1724; Fry DW, 1999, PHARMACOL THERAPEUT, V82, P207, DOI 10.1016/S0163-7258(98)00050-3; Garcia R, 1997, CELL GROWTH DIFFER, V8, P1267; Garcia R, 1998, J BIOMED SCI, V5, P79, DOI 10.1159/000025316; Gullick WJ, 1998, BREAST CANCER RES TR, V52, P43, DOI 10.1023/A:1006107016969; Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551; Ihle JN, 1998, CANCER J SCI AM, V4, pS84; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; Kim H, 1999, EXP CELL RES, V253, P78, DOI 10.1006/excr.1999.4706; KLOTH MT, 2001, UNPU; Kraker AJ, 2000, BIOCHEM PHARMACOL, V60, P885, DOI 10.1016/S0006-2952(00)00405-6; LAUDANO AP, 1986, P NATL ACAD SCI USA, V83, P892, DOI 10.1073/pnas.83.4.892; Leaman DW, 1996, MOL CELL BIOL, V16, P369; Levitzki A, 1999, PHARMACOL THERAPEUT, V82, P231, DOI 10.1016/S0163-7258(98)00066-7; Levy DE, 1999, CELL MOL LIFE SCI, V55, P1559, DOI 10.1007/s000180050395; Lin TS, 2000, ONCOGENE, V19, P2496, DOI 10.1038/sj.onc.1203486; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; LUTTRELL DK, 1988, MOL CELL BIOL, V8, P497, DOI 10.1128/MCB.8.1.497; Ma L, 1998, INT J CANCER, V78, P112, DOI 10.1002/(SICI)1097-0215(19980925)78:1<112::AID-IJC18>3.0.CO;2-D; MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981; Moasser MM, 1999, CANCER RES, V59, P6145; Morrissey JJ, 1998, CELL BIOL INT, V22, P413, DOI 10.1006/cbir.1998.0269; Mui ALF, 1999, CELL MOL LIFE SCI, V55, P1547, DOI 10.1007/s000180050394; MUTHUSWAMY SK, 1994, ADV CANCER RES, V64, P111, DOI 10.1016/S0065-230X(08)60836-2; Nelson KL, 1998, J BIOL CHEM, V273, P7072, DOI 10.1074/jbc.273.12.7072; Niu GL, 1999, CANCER RES, V59, P5059; Olayioye MA, 1999, J BIOL CHEM, V274, P17209, DOI 10.1074/jbc.274.24.17209; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; Parsons JT, 1997, CURR OPIN CELL BIOL, V9, P187, DOI 10.1016/S0955-0674(97)80062-2; RAJKUMAR T, 1994, BREAST CANCER RES TR, V29, P3, DOI 10.1007/BF00666177; Reddy EP, 2000, ONCOGENE, V19, P2532, DOI 10.1038/sj.onc.1203594; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; Sartor CI, 1997, CANCER RES, V57, P978; Schindler C, 1999, CELL MOL LIFE SCI, V55, P1509, DOI 10.1007/s000180050391; Sheffield LG, 1998, BIOCHEM BIOPH RES CO, V250, P27, DOI 10.1006/bbrc.1998.9214; Shuai K, 1996, ONCOGENE, V13, P247; Smithgall TE, 2000, ONCOGENE, V19, P2612, DOI 10.1038/sj.onc.1203477; Song JI, 2000, ONCOGENE, V19, P2489, DOI 10.1038/sj.onc.1203483; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Vignais ML, 1996, MOL CELL BIOL, V16, P1759; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; Wang YZ, 2000, ONCOGENE, V19, P2075, DOI 10.1038/sj.onc.1203548; WATSON CJ, 1995, BRIT J CANCER, V71, P840, DOI 10.1038/bjc.1995.162; WILSON LK, 1990, ONCOGENE, V5, P1471; WILSON LK, 1989, MOL CELL BIOL, V9, P1536, DOI 10.1128/MCB.9.4.1536; Yeh TC, 1999, CELL MOL LIFE SCI, V55, P1523, DOI 10.1007/s000180050392; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Zhang Y, 2000, J BIOL CHEM, V275, P24935, DOI 10.1074/jbc.M002383200; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; Zong CS, 1998, J BIOL CHEM, V273, P28065, DOI 10.1074/jbc.273.43.28065; ZUYAO N, 2000, CANCER RES, V60, P1225	81	637	697	1	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 3	2001	20	20					2499	2513		10.1038/sj.onc.1204349	http://dx.doi.org/10.1038/sj.onc.1204349			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	431VM	11420660				2022-12-25	WOS:000168652500001
J	Kennedy, MW; Heikema, AP; Cooper, A; Bjorkman, PJ; Sanchez, LM				Kennedy, MW; Heikema, AP; Cooper, A; Bjorkman, PJ; Sanchez, LM			Hydrophobic ligand binding by Zn-alpha(2)-glycoprotein, a soluble fat-depleting factor related to major histocompatibility complex proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID-MOBILIZING FACTOR; RAT-LIVER; CRYSTAL-STRUCTURE; TRANSFERRIN RECEPTOR; ARACHIDONIC-ACID; MHC MOLECULES; FC RECEPTOR; HEMOCHROMATOSIS; CRYSTALLIZATION; GENE	Zn-alpha (2)-glycoprotein (ZAG) is a member of the major histocompatibility complex (MHC) class I family of proteins and is identical in amino acid sequence to a tumor-derived lipid-mobilizing factor associated with cachexia in cancer patients. ZAG is present in plasma and other body fluids, and its natural function, like leptin's, probably lies in lipid store homeostasis. X-ray crystallography has revealed an open groove between the helices of ZAG's alpha (1). and alpha (2) domains, containing an unidentified small ligand in a position similar to that of peptides in MHC proteins (Sanchez, L. M., Chirino, A. J., and Bjorkman, P. J. (1999) Science 283,1914-1919). Here we show, using serum-derived and bacterial recombinant protein, that ZAG binds the fluorophore-tagged fatty acid 11-(dansylamino)undecanoic acid (DAUDA) and, by competition, natural fatty acids such as arachidonic, linolenic, eicosapentaenoic, and docosahexaenoic acids. Other MHC class I-related proteins (FcRn, HFE, HLA-Cw*0702) showed no such evidence of binding. Fluorescence and isothermal calorimetry analysis showed that ZAG binds DAUDA with K-d in the micromolar range, and differential scanning calorimetry showed that ligand binding increases the thermal stability of the protein. Addition of fatty acids to ZAG alters its intrinsic (tryptophan) fluorescence emission spectrum, providing a strong indication that ligand binds in the expected position close to a cluster of exposed tryptophan side chains in the groove. This study therefore shows that ZAG binds small hydrophobic ligands, that the natural ligand may be a polyunsaturated fatty acid, and provides a fluorescence-based method for investigating ZAG-ligand interactions.	Univ Glasgow, Inst Biomed & Life Sci, Div Environm & Evolutionary Biol, Glasgow G12 8QQ, Lanark, Scotland; Univ Glasgow, Dept Chem, Glasgow G12 8QQ, Lanark, Scotland; CALTECH, Div Biol, Pasadena, CA 91125 USA; CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA	University of Glasgow; University of Glasgow; California Institute of Technology; California Institute of Technology; Howard Hughes Medical Institute	Kennedy, MW (corresponding author), Univ Glasgow, Inst Biomed & Life Sci, Div Environm & Evolutionary Biol, Graham Kerr Bldg, Glasgow G12 8QQ, Lanark, Scotland.	malcolm.kennedy@bio.gla.ac.uk	Cooper, Alan/F-7813-2011	Cooper, Alan/0000-0001-6709-7343				Beckman EM, 1996, J IMMUNOL, V157, P2795; BEEKMAN EM, 1994, NATURE, V372, P691, DOI 10.1038/372691a0; BUERGI W, 1961, J BIOL CHEM, V236, P1066; BURMEISTER WP, 1994, NATURE, V372, P336, DOI 10.1038/372336a0; Chapman TL, 1999, IMMUNITY, V11, P603, DOI 10.1016/S1074-7613(00)80135-1; Cooper A, 1994, Methods Mol Biol, V22, P137; Cooper A, 2000, PROTEIN LIGAND INTER; de Urquiza AM, 2000, SCIENCE, V290, P2140, DOI 10.1126/science.290.5499.2140; DIEZITZA I, 1993, EUR J CANCER, V29A, P1256, DOI 10.1016/0959-8049(93)90068-Q; EFTINK MR, 1984, BIOCHEMISTRY-US, V23, P3891, DOI 10.1021/bi00312a016; EFTINK MR, 1976, BIOCHEMISTRY-US, V15, P672, DOI 10.1021/bi00648a035; Feder JN, 1998, P NATL ACAD SCI USA, V95, P1472, DOI 10.1073/pnas.95.4.1472; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Garboczi DN, 1996, J IMMUNOL, V157, P5403; GASTINEL LN, 1992, P NATL ACAD SCI USA, V89, P638, DOI 10.1073/pnas.89.2.638; Gasymov OK, 1999, BBA-PROTEIN STRUCT M, V1433, P307, DOI 10.1016/S0167-4838(99)00133-8; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Groh V, 1996, P NATL ACAD SCI USA, V93, P12445, DOI 10.1073/pnas.93.22.12445; HAUGHLAND RP, 1992, HDB FLUORESCENT PROB; Hirai K, 1998, CANCER RES, V58, P2359; Hsu KT, 1996, J BIOL CHEM, V271, P13317, DOI 10.1074/jbc.271.23.13317; KENNEDY MW, 1995, J BIOL CHEM, V270, P19277, DOI 10.1074/jbc.270.33.19277; Kennedy MW, 1997, J BIOL CHEM, V272, P29442, DOI 10.1074/jbc.272.47.29442; KENNEDY MW, 1995, BIOCHEMISTRY-US, V34, P6700, DOI 10.1021/bi00020a015; LALONDE JM, 1994, J BIOL CHEM, V269, P25339; Lebron JA, 1998, CELL, V93, P111, DOI 10.1016/S0092-8674(00)81151-4; Li PW, 1999, IMMUNITY, V10, P577, DOI 10.1016/S1074-7613(00)80057-6; MADDEN DR, 1995, ANNU REV IMMUNOL, V13, P587, DOI 10.1146/annurev.iy.13.040195.003103; Malkowski MG, 2000, SCIENCE, V289, P1933, DOI 10.1126/science.289.5486.1933; Puerta L, 1999, INT ARCH ALLERGY IMM, V119, P181, DOI 10.1159/000024193; Sanchez LM, 1999, SCIENCE, V283, P1914, DOI 10.1126/science.283.5409.1914; Sanchez LM, 1997, P NATL ACAD SCI USA, V94, P4626, DOI 10.1073/pnas.94.9.4626; STORCH J, 1989, J BIOL CHEM, V264, P8708; TADA T, 1991, J HISTOCHEM CYTOCHEM, V39, P1221, DOI 10.1177/39.9.1918940; THUMSER AEA, 1994, BIOCHEM J, V300, P827, DOI 10.1042/bj3000827; THUMSER AEA, 1994, BIOCHEM J, V297, P103, DOI 10.1042/bj2970103; Thumser AEA, 1996, BIOCHEM J, V320, P729, DOI 10.1042/bj3200729; Thunnissen MMGM, 2001, NAT STRUCT BIOL, V8, P131, DOI 10.1038/84117; Tisdale MJ, 1999, J NUTR, V129, p243S, DOI 10.1093/jn/129.1.243S; TISDALE MJ, 1991, BIOCHEM PHARMACOL, V41, P103, DOI 10.1016/0006-2952(91)90016-X; Todorov PT, 1998, CANCER RES, V58, P2353; Veerkamp JH, 1999, MOL CELL BIOCHEM, V192, P137, DOI 10.1023/A:1006866119264; WILKINSON TCI, 1986, BIOCHEM J, V238, P419, DOI 10.1042/bj2380419; WILTON DC, 1990, BIOCHEM J, V270, P163, DOI 10.1042/bj2700163; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3	46	43	47	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					35008	35013		10.1074/jbc.C100301200	http://dx.doi.org/10.1074/jbc.C100301200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11425849	hybrid, Green Accepted, Green Submitted			2022-12-25	WOS:000171024600088
J	Araki, T; Nagarajan, R; Milbrandt, J				Araki, T; Nagarajan, R; Milbrandt, J			Identification of genes induced in peripheral nerve after injury - Expression profiling and novel gene discovery	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIP-LIKE KINASE; NEUROTROPHIC FACTOR; ADHESION MOLECULE; CELL-ADHESION; SCHWANN-CELLS; N-CAM; APOPTOSIS; RECEPTOR; GLYCOPROTEIN; REGENERATION	Peripheral nerve injury results in axonal degeneration and in phenotypic changes of the surrounding Schwann cells, whose presence is critical for nerve regeneration. To identify genes induced after nerve injury in Schwann cells, we developed a strategy that included differential screening of a subtractive library enriched for cDNAs expressed in injured nerve, sequence analysis, and expression profiling. By using real time quantitative reverse transcriptase-polymerase chain reaction, we found that injury-induced genes could be categorized into four temporal expression patterns. Among the clones we identified were a number that were homologous only to expressed sequence tags in the data base. These were stratified based on their expression profile, presence of identifiable sequence motifs, homologies to other proteins, and evolutionary conservation. We chose one representative gene, nin283, to analyze in detail. The nin283 gene encodes a 227-residue protein containing both a zinc finger and a RING finger motif. nin283 is highly expressed in the central nervous system, particularly in the developing cortical plate in embryos. It is also expressed in peripheral ganglia and is induced by nerve growth factor in PC12 cells. Subcellular localization analysis demonstrated that Nin283 is located in the endosome/lysosome compartment, suggesting that it may participate in ubiquitin-mediated protein modification.	Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA	Washington University (WUSTL)	Milbrandt, J (corresponding author), Washington Univ, Sch Med, Dept Pathol & Immunol, 660 S Euclid Ave,Campus Box 8118, St Louis, MO 63110 USA.	jeff@pathbox.wustl.edu	Araki, Toshiyuki/H-4289-2019	Araki, Toshiyuki/0000-0003-3625-2042; Milbrandt, Jeffrey/0000-0002-5477-7689	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS040745] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS40745] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Agnello D, 2000, J NEUROIMMUNOL, V109, P105, DOI 10.1016/S0165-5728(00)00279-4; ALTMEYER A, 1995, J BIOL CHEM, V270, P25584, DOI 10.1074/jbc.270.43.25584; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Araki T, 1997, J BIOL CHEM, V272, P21373, DOI 10.1074/jbc.272.34.21373; Araki T, 1996, NEURON, V17, P353, DOI 10.1016/S0896-6273(00)80166-X; Araki T, 2000, J NEUROSCI, V20, P187, DOI 10.1523/JNEUROSCI.20-01-00187.2000; Attwood TK, 1999, NUCLEIC ACIDS RES, V27, P220, DOI 10.1093/nar/27.1.220; Baloh RH, 1997, NEURON, V18, P793, DOI 10.1016/S0896-6273(00)80318-9; BARBACID M, 1995, CURR OPIN CELL BIOL, V7, P148, DOI 10.1016/0955-0674(95)80022-0; Bateman A, 1999, NUCLEIC ACIDS RES, V27, P260, DOI 10.1093/nar/27.1.260; BENFEY M, 1982, NATURE, V296, P150, DOI 10.1038/296150a0; BIXBY JL, 1988, J CELL BIOL, V107, P353, DOI 10.1083/jcb.107.1.353; Braissant O, 1998, BIOCHEMICA, V1, P10; Carninci P, 2000, GENOME RES, V10, P1617, DOI 10.1101/gr.145100; Carroll SL, 1997, J NEUROSCI, V17, P1642; Cheng YC, 2000, DEV BRAIN RES, V121, P233, DOI 10.1016/S0165-3806(00)00049-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORBI AL, 1988, J BIOL CHEM, V263, P12403; Corpet F, 1999, NUCLEIC ACIDS RES, V27, P263, DOI 10.1093/nar/27.1.263; DODD J, 1988, NEURON, V1, P105, DOI 10.1016/0896-6273(88)90194-8; Edelman GM, 1998, BRAIN RES REV, V26, P337, DOI 10.1016/S0165-0173(97)00034-9; FAWCETT JW, 1990, ANNU REV NEUROSCI, V13, P43, DOI 10.1146/annurev.neuro.13.1.43; Freemont PS, 2000, CURR BIOL, V10, pR84, DOI 10.1016/S0960-9822(00)00287-6; Fu SY, 1997, MOL NEUROBIOL, V14, P67, DOI 10.1007/BF02740621; GERDES J, 1984, J IMMUNOL, V133, P1710; Goodman Adam R., 1996, Cytokine and Growth Factor Reviews, V7, P191, DOI 10.1016/1359-6101(96)00019-6; Grimaldi M, 1999, J BIOL CHEM, V274, P33557, DOI 10.1074/jbc.274.47.33557; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HALL SM, 1986, NEUROPATH APPL NEURO, V12, P401, DOI 10.1111/j.1365-2990.1986.tb00151.x; Henikoff S, 1999, BIOINFORMATICS, V15, P471, DOI 10.1093/bioinformatics/15.6.471; HEUMANN R, 1987, P NATL ACAD SCI USA, V84, P8735, DOI 10.1073/pnas.84.23.8735; Hofmann K, 1999, NUCLEIC ACIDS RES, V27, P215, DOI 10.1093/nar/27.1.215; Hughes TR, 2000, CELL, V102, P109, DOI 10.1016/S0092-8674(00)00015-5; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Kasof GM, 2000, FEBS LETT, V473, P285, DOI 10.1016/S0014-5793(00)01473-3; Lee SL, 1996, MOL CELL BIOL, V16, P4566; Madore N, 1999, J NEUROCHEM, V72, P708, DOI 10.1046/j.1471-4159.1999.0720708.x; Martin KJ, 2000, P NATL ACAD SCI USA, V97, P3789, DOI 10.1073/pnas.97.8.3789; MARTINI R, 1994, J NEUROCYTOL, V23, P1, DOI 10.1007/BF01189813; MARTINI R, 1988, J CELL BIOL, V106, P1735, DOI 10.1083/jcb.106.5.1735; MEYER M, 1992, J CELL BIOL, V119, P45, DOI 10.1083/jcb.119.1.45; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; Morrison TB, 1998, BIOTECHNIQUES, V24, P954; Pazdernik NJ, 1999, MOL CELL BIOL, V19, P6500; Polentarutti N, 2000, J NEUROIMMUNOL, V106, P87, DOI 10.1016/S0165-5728(00)00214-9; RIEGER F, 1988, J CELL BIOL, V107, P707, DOI 10.1083/jcb.107.2.707; RUBENSTEIN JLR, 1990, NUCLEIC ACIDS RES, V18, P4833, DOI 10.1093/nar/18.16.4833; Ryan AK, 1997, GENE DEV, V11, P1207, DOI 10.1101/gad.11.10.1207; Sawasdikosol S, 2000, BBA-REV CANCER, V1471, pM1, DOI 10.1016/S0304-419X(00)00013-5; Sheu JY, 2000, EXP NEUROL, V166, P392, DOI 10.1006/exnr.2000.7508; Simpson JC, 2000, EMBO REP, V1, P287, DOI 10.1093/embo-reports/kvd058; Stoll G, 1999, BRAIN PATHOL, V9, P313; Sun XQ, 1999, J BIOL CHEM, V274, P16871, DOI 10.1074/jbc.274.24.16871; Svaren J, 2000, J BIOL CHEM, V275, P38524, DOI 10.1074/jbc.M005220200; Svaren J, 1996, MOL CELL BIOL, V16, P3545; Tamayo P, 1999, P NATL ACAD SCI USA, V96, P2907, DOI 10.1073/pnas.96.6.2907; TANIUCHI M, 1988, J NEUROSCI, V8, P664; Tarasova NI, 1997, CELL TISSUE RES, V287, P325, DOI 10.1007/s004410050757; Trupp M, 1997, J NEUROSCI, V17, P3554; Wang SM, 2000, P NATL ACAD SCI USA, V97, P4162, DOI 10.1073/pnas.97.8.4162; WHITE FV, 1989, J NEUROCHEM, V52, P1085, DOI 10.1111/j.1471-4159.1989.tb01851.x; Wittwer CT, 1997, BIOTECHNIQUES, V22, P130, DOI 10.2144/97221bi01; Xian CJ, 1999, MOL NEUROBIOL, V20, P157, DOI 10.1007/BF02742440; Yu PW, 1999, CURR BIOL, V9, P539, DOI 10.1016/S0960-9822(99)80239-5; Zoidl G, 1997, J NEUROSCI RES, V49, P32, DOI 10.1002/(SICI)1097-4547(19970701)49:1<32::AID-JNR4>3.0.CO;2-E	65	57	59	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					34131	34141		10.1074/jbc.M104271200	http://dx.doi.org/10.1074/jbc.M104271200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11427537	hybrid			2022-12-25	WOS:000170910200112
J	Brouet, A; Sonveaux, P; Dessy, C; Balligand, JL; Feron, O				Brouet, A; Sonveaux, P; Dessy, C; Balligand, JL; Feron, O			Hsp90 ensures the transition from the early Ca2+-dependent to the late phosphorylation-dependent activation of the endothelial nitric-oxide synthase in vascular endothelial growth factor-exposed endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUID SHEAR-STRESS; PROTEIN-KINASE-B; CARDIAC MYOCYTES; ENOS ACTIVATION; CAVEOLIN; AKT; TRANSLOCATION; ANGIOGENESIS; PROSTACYCLIN; DISSOCIATION	Vascular endothelial growth factor (VEGF) exerts its angiogenic effects partly through the activation of endothelial nitric-oxide synthase (eNOS). Association with heat shock protein 90 (hsp90) and phosphorylation by Akt were recently shown to separately activate eNOS upon VEGF stimulation in endothelial cells. Here, we examined the interplay between these different mechanisms in VEGF-exposed endothelial cells. We documented that hsp90 binding to eNOS is, in fact, the crucial event triggering the transition from the Ca2+-dependent activation of eNOS to the phosphorylation-mediated potentiation of its activity by VEGF. Accordingly, we showed that early VEGF stimulation first leads to the Ca2+/calmodulin disruption of the caveolin-eNOS complex and promotes the association between eNOS and hsp90. eNOS-bound hsp90 can then recruit VEGF-activated (phosphorylated) Akt to the complex, which in turn can phosphorylate eNOS. Further experiments in transfected COS cells expressing either wild-type or S1177A mutant eNOS led us to identify the serine 1177 as the critical residue for the hsp90-dependent Akt-mediated activation of eNOS. Finally, we documented that although the V-EGF-induced phosphorylation of eNOS leads to a sustained production of NO independently of a maintained increase in [Ca2+](i), this late stage of eNOS activation is strictly conditional on the initial VEGF-induced Ca2+-dependent stimulation of the enzyme. These data establish the critical temporal sequence of events leading to the sustained activation of eNOS by VEGF and suggest new ways of regulating the production of NO in response to this cytokine through the ubiquitous chaperone protein, hsp90.	Univ Catholique Louvain, Sch Med, Pharmacol & Therapeut Unit, B-1200 Brussels, Belgium	Universite Catholique Louvain; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Feron, O (corresponding author), Univ Catholique Louvain, Sch Med, Pharmacol & Therapeut Unit, FATH 5349,53 Ave E Mounier, B-1200 Brussels, Belgium.		Balligand, Jean-Luc J/D-7543-2012; FERON, Olivier/AAM-6395-2020	FERON, Olivier/0000-0001-5360-0286; Sonveaux, Pierre/0000-0001-6484-8834; BALLIGAND, Jean-Luc/0000-0002-0522-4156				BALLIGAND JL, 2000, NITRIC OXIDE BIOL PA; Bernier SG, 2000, J BIOL CHEM, V275, P30707, DOI 10.1074/jbc.M005116200; Bucci M, 2000, NAT MED, V6, P1362, DOI 10.1038/82176; Butt E, 2000, J BIOL CHEM, V275, P5179, DOI 10.1074/jbc.275.7.5179; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Chen ZP, 1999, FEBS LETT, V443, P285, DOI 10.1016/S0014-5793(98)01705-0; Dimmeler S, 2000, FEBS LETT, V477, P258, DOI 10.1016/S0014-5793(00)01657-4; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Feng YY, 1999, BIOCHEM BIOPH RES CO, V256, P192, DOI 10.1006/bbrc.1998.9790; Feron O, 1998, J BIOL CHEM, V273, P3125, DOI 10.1074/jbc.273.6.3125; Feron O, 1999, Curr Opin Clin Nutr Metab Care, V2, P291, DOI 10.1097/00075197-199907000-00007; Feron O, 1998, J BIOL CHEM, V273, P30249, DOI 10.1074/jbc.273.46.30249; Feron O, 1999, J CLIN INVEST, V103, P897, DOI 10.1172/JCI4829; Fisslthaler B, 2000, ACTA PHYSIOL SCAND, V168, P81; Fleming I, 1998, CIRC RES, V82, P686, DOI 10.1161/01.RES.82.6.686; Fleming I, 1999, CARDIOVASC RES, V43, P532, DOI 10.1016/S0008-6363(99)00094-2; Fleming I, 2001, CIRC RES, V88, pE68, DOI 10.1161/hh1101.092677; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Gallis B, 1999, J BIOL CHEM, V274, P30101, DOI 10.1074/jbc.274.42.30101; Garcia-Cardena G, 1998, NATURE, V392, P821, DOI 10.1038/33934; Gratton JP, 2000, J BIOL CHEM, V275, P22268, DOI 10.1074/jbc.M001644200; Harris MB, 2001, J BIOL CHEM, V276, P16587, DOI 10.1074/jbc.M100229200; He H, 1999, J BIOL CHEM, V274, P25130, DOI 10.1074/jbc.274.35.25130; Igarashi J, 2001, J BIOL CHEM, V276, P12420, DOI 10.1074/jbc.M008375200; Ignarro LJ, 1999, J CARDIOVASC PHARM, V34, P879, DOI 10.1097/00005344-199912000-00016; McCabe TJ, 2000, J BIOL CHEM, V275, P6123, DOI 10.1074/jbc.275.9.6123; Michel JB, 1997, J BIOL CHEM, V272, P15583, DOI 10.1074/jbc.272.25.15583; Michell BJ, 2001, J BIOL CHEM, V276, P17625, DOI 10.1074/jbc.C100122200; Michell BJ, 1999, CURR BIOL, V9, P845, DOI 10.1016/S0960-9822(99)80371-6; Morales-Ruiz M, 2001, J BIOL CHEM, V276, P19672, DOI 10.1074/jbc.M009993200; Murga C, 2000, J BIOL CHEM, V275, P12069, DOI 10.1074/jbc.275.16.12069; Murohara T, 1998, CIRCULATION, V97, P99, DOI 10.1161/01.CIR.97.1.99; Murohara T, 1998, J CLIN INVEST, V101, P2567, DOI 10.1172/JCI1560; Nuszkowski A, 2001, J BIOL CHEM, V276, P14212, DOI 10.1074/jbc.M007659200; Pham FH, 2000, CIRC RES, V86, P1252, DOI 10.1161/01.RES.86.12.1252; Prabhakar P, 1998, J BIOL CHEM, V273, P27383, DOI 10.1074/jbc.273.42.27383; Pritchard KA, 2001, J BIOL CHEM, V276, P17621, DOI 10.1074/jbc.C100084200; Rizzo V, 1998, J BIOL CHEM, V273, P34724, DOI 10.1074/jbc.273.52.34724; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; Sowa G, 1999, J BIOL CHEM, V274, P22524, DOI 10.1074/jbc.274.32.22524; Su YC, 2000, AM J PHYSIOL-LUNG C, V278, pL1204, DOI 10.1152/ajplung.2000.278.6.L1204; Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147	42	183	191	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					32663	32669		10.1074/jbc.M101371200	http://dx.doi.org/10.1074/jbc.M101371200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11425855	hybrid			2022-12-25	WOS:000170746000039
J	Penn, RB; Pascual, RM; Kim, YM; Mundell, SJ; Krymskaya, VP; Panettieri, RA; Benovic, JL				Penn, RB; Pascual, RM; Kim, YM; Mundell, SJ; Krymskaya, VP; Panettieri, RA; Benovic, JL			Arrestin specificity for G protein-coupled receptors in human airway smooth muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EP4 PROSTAGLANDIN RECEPTORS; GREEN FLUORESCENT PROTEIN; BETA-ARRESTIN; BETA(2)-ADRENERGIC RECEPTOR; DEPENDENT ENDOCYTOSIS; ACTIVATED RECEPTOR-2; SELECTIVE REGULATION; KINASE ACTIVATION; OPIOID RECEPTORS; TERMINAL DOMAIN	Despite a widely accepted role of arrestins as "uncouplers" of G protein-coupled receptor (GPCR) signaling, few studies have demonstrated the ability of arrestins to affect second messenger generation by endogenously expressed receptors in intact cells. In this study we demonstrate arrestin specificity for endogenous GPCRs in primary cultures of human airway smooth muscle (HA,SM). Expression of arrestin-green fluorescent protein (ARR2-GFP or ARR3-GFP) chimeras in HASM significantly attenuated isoproterenol (beta (2)-adrenergic receptor (beta (2)AR)-mediated)- and 5'-(N-ethylcarboxamido)adenosine (A2b adenosine receptor-mediated)stimulated cAMP production, with fluorescent microscopy demonstrating agonist-promoted redistribution of cellular ARR2-GFP into a punctate formation. Conversely, prostaglandin E-2 (PGE(2))-mediated cAMP production was unaffected by arrestin-GFP, and PGE(2) had little effect on arrestin-GFP distribution. The pharmacological profile of various selective EP receptor ligands suggested a predominantly EP2 receptor population in HASM. Further analysis in COS-1 cells revealed that ARR2-GFP expression increased agonist-promoted internalization of wild type beta (2)AR and EP4 receptors, whereas EP2 receptors remained resistant to internalization. However, expression of an arrestin whose binding to GPCRs is largely independent of receptor phosphorylation (ARR2(R169E)-GFP) enabled substantial agonist-promoted EP2 receptor internalization, increased beta (2)AR internalization to a greater extent than did ARR2-GFP, yet promoted EP4 receptor internalization to the same degree as did ARR2-GFP. Signaling via endogenous EP4 receptors in CHO-KI cells was attenuated by ARR2-GFP expression, whereas ARR2(R169E)-GFP expression in HASM inhibited EP2 receptor-mediated cAMP production. These findings demonstrate differential effects of arrestins in altering endogenous GPCR signaling in a physiologically relevant cell type and reveal a variable dependence on receptor phosphorylation in dictating arrestin-receptor interaction.	Thomas Jefferson Univ, Kimmel Canc Inst, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA; Jefferson Med Coll, Dept Med, Div Crit Care Pulm Allerg & Immunol Dis, Philadelphia, PA 19107 USA; Univ Penn, Sch Med, Dept Med, Div Pulm & Crit Care, Philadelphia, PA 19104 USA	Jefferson University; Jefferson University; University of Pennsylvania	Penn, RB (corresponding author), Thomas Jefferson Univ, Kimmel Canc Inst, Dept Microbiol & Immunol, Rm 930 BLSB,233 S 10th St, Philadelphia, PA 19107 USA.		panettieri, reynold/AAG-9485-2019; Kim, You-Me/I-5553-2013	Kim, You-Me/0000-0001-8780-704X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058506, R29HL058506] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM047417, R01GM047417] Funding Source: NIH RePORTER; NHLBI NIH HHS [R29 HL058506, HL58506] Funding Source: Medline; NIGMS NIH HHS [R37 GM047417, R01 GM047417, GM47417] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ammit AJ, 2001, FASEB J, V15, P1212, DOI 10.1096/fj.00-0742fje; AN SZ, 1993, BIOCHEM BIOPH RES CO, V197, P263, DOI 10.1006/bbrc.1993.2470; Aramori I, 1997, EMBO J, V16, P4606, DOI 10.1093/emboj/16.15.4606; Barlic J, 2000, NAT IMMUNOL, V1, P227, DOI 10.1038/79767; Barlic J, 1999, J BIOL CHEM, V274, P16287, DOI 10.1074/jbc.274.23.16287; Bastepe M, 1999, BRIT J PHARMACOL, V126, P365, DOI 10.1038/sj.bjp.0702291; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Crider JY, 2000, PROSTAG LEUKOTR ESS, V62, P21, DOI 10.1054/plef.1999.0120; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; DeFea KA, 2000, P NATL ACAD SCI USA, V97, P11086, DOI 10.1073/pnas.190276697; DeGraff JL, 1999, J BIOL CHEM, V274, P11253, DOI 10.1074/jbc.274.16.11253; Dery O, 1999, J BIOL CHEM, V274, P18524, DOI 10.1074/jbc.274.26.18524; Desai S, 2000, MOL PHARMACOL, V58, P1279, DOI 10.1124/mol.58.6.1279; Diviani D, 1996, J BIOL CHEM, V271, P5049; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; FREEDMAN NJ, 1995, J BIOL CHEM, V270, P17953, DOI 10.1074/jbc.270.30.17953; Gaborik Z, 2001, MOL PHARMACOL, V59, P239, DOI 10.1124/mol.59.2.239; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; GUREVICH VV, 1993, J BIOL CHEM, V268, P11628; Gurevich VV, 1997, J BIOL CHEM, V272, P28849, DOI 10.1074/jbc.272.46.28849; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; GUREVICH VV, 1995, J BIOL CHEM, V270, P6010, DOI 10.1074/jbc.270.11.6010; Hosey MM, 1999, LIFE SCI, V64, P363, DOI 10.1016/S0024-3205(98)00575-X; Iacovelli L, 1996, MOL ENDOCRINOL, V10, P1138, DOI 10.1210/me.10.9.1138; Kallal L, 1998, J BIOL CHEM, V273, P322, DOI 10.1074/jbc.273.1.322; Kohout TA, 2001, P NATL ACAD SCI USA, V98, P1601, DOI 10.1073/pnas.041608198; Kovoor A, 1999, J BIOL CHEM, V274, P6831, DOI 10.1074/jbc.274.11.6831; Kovoor A, 1997, J BIOL CHEM, V272, P27605, DOI 10.1074/jbc.272.44.27605; Li JG, 1999, J BIOL CHEM, V274, P12087, DOI 10.1074/jbc.274.17.12087; McConalogue K, 1999, J BIOL CHEM, V274, P16257, DOI 10.1074/jbc.274.23.16257; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; McGraw DW, 1997, J BIOL CHEM, V272, P7338, DOI 10.1074/jbc.272.11.7338; Mundell SJ, 2000, BIOCHEMISTRY-US, V39, P12828, DOI 10.1021/bi0010928; Mundell SJ, 2000, J BIOL CHEM, V275, P12900, DOI 10.1074/jbc.275.17.12900; Mundell SJ, 1999, BIOCHEMISTRY-US, V38, P8723, DOI 10.1021/bi990361v; Mundell SJ, 2001, AM J RESP CELL MOL, V24, P155, DOI 10.1165/ajrcmb.24.2.4243; MURRAY RK, 1993, AM J PHYSIOL, V264, pC485, DOI 10.1152/ajpcell.1993.264.2.C485; Nakamura K, 1999, MOL ENDOCRINOL, V13, P1295, DOI 10.1210/me.13.8.1295; Nakamura K, 1998, J BIOL CHEM, V273, P24346, DOI 10.1074/jbc.273.38.24346; Narumiya S, 1999, PHYSIOL REV, V79, P1193, DOI 10.1152/physrev.1999.79.4.1193; Neuschafer-Rube F, 1999, MOL PHARMACOL, V56, P419, DOI 10.1124/mol.56.2.419; Nishigaki N, 1996, MOL PHARMACOL, V50, P1031; Orsini MJ, 1999, J BIOL CHEM, V274, P31076, DOI 10.1074/jbc.274.43.31076; PalsRylaarsdam R, 1997, J BIOL CHEM, V272, P23682, DOI 10.1074/jbc.272.38.23682; PANETTIERI RA, 1989, AM J PHYSIOL, V256, pC329, DOI 10.1152/ajpcell.1989.256.2.C329; Penn RB, 1998, AM J RESP CELL MOL, V19, P338, DOI 10.1165/ajrcmb.19.2.3025; Penn RB, 1998, HANDBK PHYS, V1, P125; REGAN JW, 1994, MOL PHARMACOL, V46, P213; Santini F, 2000, J CELL SCI, V113, P2463; Shui Z, 2001, J BIOL CHEM, V276, P11691, DOI 10.1074/jbc.M011007200; Smyth EM, 2000, J BIOL CHEM, V275, P32037, DOI 10.1074/jbc.M003873200; SterneMarr R, 1995, VITAM HORM, V51, P193, DOI 10.1016/S0083-6729(08)61039-0; Troispoux C, 1999, MOL ENDOCRINOL, V13, P1599, DOI 10.1210/me.13.9.1599; Whistler JL, 1998, P NATL ACAD SCI USA, V95, P9914, DOI 10.1073/pnas.95.17.9914; Zeng L, 1996, BIOCHEMISTRY-US, V35, P7159, DOI 10.1021/bi960036x; Zhang J, 1997, J BIOL CHEM, V272, P27005, DOI 10.1074/jbc.272.43.27005; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	57	79	80	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					32648	32656		10.1074/jbc.M104143200	http://dx.doi.org/10.1074/jbc.M104143200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11418617	hybrid			2022-12-25	WOS:000170746000037
J	Yu, LN; Sabet, N; Chambers, A; Morse, RH				Yu, LN; Sabet, N; Chambers, A; Morse, RH			The N-terminal and C-terminal domains of RAP1 are dispensable for chromatin opening and GCN4-mediated HIS4 activation in budding yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN RAP1; TRANSCRIPTIONAL ACTIVATION; SACCHAROMYCES-CEREVISIAE; MEIOTIC RECOMBINATION; NUCLEOSOME DISRUPTION; HISTONE TAILS; IN-VIVO; DNA; GENE; COMPLEX	Repressor activator protein 1 (RAP1) assists GCN4-mediated HIS4 activation by overcoming some repressive aspect of chromatin structure to facilitate GCN4 binding. RAP1 also participates in other nuclear processes, and discrete domains of RAP1 have been shown to have specific properties including DNA binding, DNA bending, transcriptional activation, and silencing and telomere functions. To investigate whether specific domains of RAP1 are required to "open" chromatin and help GCN4 to activate the HIS4 gene, we examined the abilities of different truncated RAP1 proteins to perturb positioned nucleosomes via a nucleosomal RAP1 site in a yeast episome in vivo, and we tested HIS4 activation in yeast strains harboring truncated RAP1 mutants. We found that neither the DNA bending domain nor the putative activation domain of RAP1 is required for its ability to perturb the chromatin structure of a plasmid containing a RAP1 site. Similarly, neither the putative activation domain nor the N-terminal DNA-bending domain was required for GCN4-mediated activation of HIS4. We also used a rap1(ts) mutant to show that continuous occupancy of the HIS4 promoter by RAP1. is required for GCN4-mediated gene activation.	SUNY Albany, Sch Publ Hlth, Dept Biomed Sci, Albany, NY 12201 USA; New York State Dept Hlth, Wadsworth Ctr Labs & Res, Lab Dev Genet, Albany, NY 12201 USA; Univ Nottingham, Queens Med Ctr, Div Genet, Nottingham NG7 2UH, England	State University of New York (SUNY) System; State University of New York (SUNY) Albany; State University of New York (SUNY) System; Wadsworth Center; University of Nottingham	Morse, RH (corresponding author), SUNY Albany, Sch Publ Hlth, Dept Biomed Sci, Albany, NY 12201 USA.			Morse, Randall/0000-0003-0000-8718	NIGMS NIH HHS [GM51993] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051993] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AXELROD JD, 1993, GENE DEV, V7, P857, DOI 10.1101/gad.7.5.857; Balasubramanian B, 1999, MOL CELL BIOL, V19, P2977; Bi X, 1999, GENE DEV, V13, P1089, DOI 10.1101/gad.13.9.1089; Biggar SR, 1999, EMBO J, V18, P2254, DOI 10.1093/emboj/18.8.2254; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; CAVALLI G, 1993, EMBO J, V12, P4603, DOI 10.1002/j.1460-2075.1993.tb06149.x; COCKELL M, 1995, J CELL BIOL, V129, P909, DOI 10.1083/jcb.129.4.909; DEVLIN C, 1991, MOL CELL BIOL, V11, P3642, DOI 10.1128/MCB.11.7.3642; Drazinic CM, 1996, MOL CELL BIOL, V16, P3187; FLETCHER TM, 1995, J BIOL CHEM, V270, P25359, DOI 10.1074/jbc.270.43.25359; GARCIARAMIREZ M, 1992, J BIOL CHEM, V267, P19587; GILSON E, 1995, NUCLEIC ACIDS MOL BI, V9, P308; Graham IR, 1999, MOL CELL BIOL, V19, P7481; HARDY CFJ, 1992, MOL CELL BIOL, V12, P1209, DOI 10.1128/MCB.12.3.1209; HARDY CFJ, 1992, GENE DEV, V6, P801, DOI 10.1101/gad.6.5.801; HILL J, 1991, NUCLEIC ACIDS RES, V19, P5791, DOI 10.1093/nar/19.20.5791; JIANG YW, 1995, GENETICS, V140, P103; KENT NA, 1993, NUCLEIC ACIDS RES, V21, P4653, DOI 10.1093/nar/21.19.4653; Kirkpatrick DT, 1999, GENETICS, V152, P101; KURTZ S, 1991, GENE DEV, V5, P616, DOI 10.1101/gad.5.4.616; LEE KP, 1982, CAN J BIOCHEM CELL B, V60, P379, DOI 10.1139/o82-045; LEEDS P, 1991, GENE DEV, V5, P2303, DOI 10.1101/gad.5.12a.2303; Leuba SH, 1998, BIOPHYS J, V74, P2830, DOI 10.1016/S0006-3495(98)77990-1; Lopez MC, 1998, P NATL ACAD SCI USA, V95, P14112, DOI 10.1073/pnas.95.24.14112; Marton MJ, 1998, NAT MED, V4, P1293, DOI 10.1038/3282; MCNEIL JB, 1990, CURR GENET, V18, P405, DOI 10.1007/BF00309909; MORETTI P, 1994, GENE DEV, V8, P2257, DOI 10.1101/gad.8.19.2257; MORSE RH, 1993, SCIENCE, V262, P1563, DOI 10.1126/science.8248805; MORSE RH, 1987, NUCLEIC ACIDS RES, V15, P10311, DOI 10.1093/nar/15.24.10311; MORSE RH, 1992, MOL CELL BIOL, V12, P4015, DOI 10.1128/MCB.12.9.4015; Morse RH, 2000, TRENDS GENET, V16, P51, DOI 10.1016/S0168-9525(99)01936-8; MULLER T, 1994, J STRUCT BIOL, V113, P1, DOI 10.1006/jsbi.1994.1027; NEDOSPASOV SA, 1980, BIOCHEM BIOPH RES CO, V92, P532, DOI 10.1016/0006-291X(80)90366-6; PINEIRO M, 1991, BIOCHEMISTRY-US, V30, P5805, DOI 10.1021/bi00237a025; REECE RJ, 1993, SCIENCE, V261, P909, DOI 10.1126/science.8346441; Reid JL, 2000, MOL CELL, V6, P1297, DOI 10.1016/S1097-2765(00)00128-3; Rossetti L, 2001, J MOL BIOL, V306, P903, DOI 10.1006/jmbi.2001.4458; Ryan MP, 2000, MOL CELL BIOL, V20, P5847, DOI 10.1128/MCB.20.16.5847-5857.2000; SAAVEDRA RA, 1986, CELL, V45, P65, DOI 10.1016/0092-8674(86)90538-6; Schroeder SC, 1998, J BIOL CHEM, V273, P19884, DOI 10.1074/jbc.273.31.19884; SHIMIZU M, 1991, EMBO J, V10, P3033, DOI 10.1002/j.1460-2075.1991.tb07854.x; SHORE D, 1994, TRENDS GENET, V10, P408, DOI 10.1016/0168-9525(94)90058-2; Stafford GA, 1997, J BIOL CHEM, V272, P11526; Stafford GA, 2001, MOL CELL BIOL, V21, P4568, DOI 10.1128/MCB.21.14.4568-4578.2001; Stafford GA, 1998, J BIOL CHEM, V273, P34240, DOI 10.1074/jbc.273.51.34240; Sudarsanam P, 1999, EMBO J, V18, P3101, DOI 10.1093/emboj/18.11.3101; SVAREN J, 1994, EMBO J, V13, P4856, DOI 10.1002/j.1460-2075.1994.tb06812.x; VIGNAIS ML, 1990, J BIOL CHEM, V265, P14669; WHITE MA, 1991, P NATL ACAD SCI USA, V88, P9755, DOI 10.1073/pnas.88.21.9755; WU C, 1980, NATURE, V286, P854, DOI 10.1038/286854a0; Wyrick JJ, 1999, NATURE, V402, P418, DOI 10.1038/46567; Yu LN, 1999, MOL CELL BIOL, V19, P5279	52	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					33257	33264		10.1074/jbc.M104354200	http://dx.doi.org/10.1074/jbc.M104354200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11413146	hybrid			2022-12-25	WOS:000170746000112
J	Chernov, MV; Bean, LJH; Lerner, N; Stark, GR				Chernov, MV; Bean, LJH; Lerner, N; Stark, GR			Regulation of ubiquitination and degradation of p53 in unstressed cells through C-terminal phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR P53; DNA-BINDING FUNCTION; CYCLE ARREST; MURINE P53; IN-VITRO; DAMAGE; MDM2; ACTIVATION; PROTEIN; KINASE	Previously, we found that the protein kinase C (PKC) inhibitor H7 stimulates p53 to accumulate in a form incapable of inducing transcription from p53-dependent promoters. We concluded that H7 inhibits constitutive C-terminal phosphorylation of p53, which regulates its turnover in unstressed cells. We now show that p53 and its inhibitor MDM2 (HDM2 in human cells) are together in the nuclei of H7-treated cells and can be co-immunoprecipitated. Despite this association of p53 with the ubiquitin ligase MDM2, ubiquitinated p53 was not detected in H7-treated cells. Furthermore, co-treatment with H7 and the proteosome inhibitor LLnL prevented the accumulation of ubiquitinated p53 that was observed in cells treated solely with LLnL. In addition, treatment of cells with the PKC activator phorbol ester stimulated the ubiquitination of p53 and reduced its ability to accumulate after stress. H7 did not induce the phosphorylation of human p53 on Ser-15 (Ser-18 in mouse protein), a modification that occurs in response to DNA damage and leads to the release of MDM2 and to transactivation by p53. We conclude that phosphorylation of the C-terminal domain of p53 by PKC increases its ubiquitination and degradation in unstressed cells.	Cleveland Clin Fdn, Dept Mol Biol, Lerner Res Inst, Cleveland, OH 44195 USA; Case Western Reserve Univ, Sch Med, Dept Genet, Cleveland, OH 44106 USA	Cleveland Clinic Foundation; Case Western Reserve University	Stark, GR (corresponding author), Cleveland Clin Fdn, Dept Mol Biol, Lerner Res Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049345, T32GM008613] Funding Source: NIH RePORTER; NIGMS NIH HHS [5-T32-GM08613, GM49345] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agarwal ML, 2001, ONCOGENE, V20, P2527, DOI 10.1038/sj.onc.1204353; Alarcon R, 1999, CANCER RES, V59, P6046; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Bottger A, 1997, J MOL BIOL, V269, P744, DOI 10.1006/jmbi.1997.1078; Burma S, 1999, J BIOL CHEM, V274, P17139, DOI 10.1074/jbc.274.24.17139; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chang YC, 1998, CELL GROWTH DIFFER, V9, P79; Chehab NH, 2000, GENE DEV, V14, P278; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; Chernov MV, 1997, ONCOGENE, V14, P2503, DOI 10.1038/sj.onc.1201104; Chernov MV, 1998, P NATL ACAD SCI USA, V95, P2284, DOI 10.1073/pnas.95.5.2284; Chernova OB, 1998, MOL CELL BIOL, V18, P536, DOI 10.1128/MCB.18.1.536; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DEOCALUNA R, 1995, NATURE, V0378; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; Dumaz N, 1999, FEBS LETT, V463, P312, DOI 10.1016/S0014-5793(99)01647-6; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; FISCELLA M, 1993, ONCOGENE, V8, P1519; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1994, COLD SPRING HARB SYM, V59, P195, DOI 10.1101/SQB.1994.059.01.024; Jayaraman L, 1999, CELL MOL LIFE SCI, V55, P76, DOI 10.1007/s000180050271; Kapoor M, 2000, ONCOGENE, V19, P358, DOI 10.1038/sj.onc.1203300; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kobet E, 2000, P NATL ACAD SCI USA, V97, P12547, DOI 10.1073/pnas.97.23.12547; Kubbutat MHG, 1998, MOL CELL BIOL, V18, P5690, DOI 10.1128/MCB.18.10.5690; Lakin ND, 1999, ONCOGENE, V18, P3989, DOI 10.1038/sj.onc.1202973; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Li XQ, 1996, J VIROL, V70, P4509, DOI 10.1128/JVI.70.7.4509-4516.1996; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; Liu L, 1999, MOL CELL BIOL, V19, P1202; Lu H, 1998, P NATL ACAD SCI USA, V95, P6399, DOI 10.1073/pnas.95.11.6399; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; Milne DM, 1996, ONCOGENE, V13, P205; Nakamura S, 2000, MOL CELL BIOL, V20, P9391, DOI 10.1128/MCB.20.24.9391-9398.2000; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; Nitta M, 1997, ONCOGENE, V15, P561, DOI 10.1038/sj.onc.1201210; Ohnishi T, 1998, ONCOGENE, V16, P1507, DOI 10.1038/sj.onc.1201663; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; PICKSLEY SM, 1994, ONCOGENE, V9, P2523; PRICE BD, 1993, ONCOGENE, V8, P3055; Rodriguez MS, 2000, MOL CELL BIOL, V20, P8458, DOI 10.1128/MCB.20.22.8458-8467.2000; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Shaulian E, 2000, CELL, V103, P897, DOI 10.1016/S0092-8674(00)00193-8; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 1999, EMBO J, V18, P1815, DOI 10.1093/emboj/18.7.1815; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Thut CJ, 1997, GENE DEV, V11, P1974, DOI 10.1101/gad.11.15.1974; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126	59	46	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					31819	31824		10.1074/jbc.M103170200	http://dx.doi.org/10.1074/jbc.M103170200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11431470	hybrid			2022-12-25	WOS:000170613500048
J	Wang, LH; Yang, XY; Mihalic, K; Xiao, WH; Li, DP; Farrar, WL				Wang, LH; Yang, XY; Mihalic, K; Xiao, WH; Li, DP; Farrar, WL			Activation of estrogen receptor blocks interleukin-6-inducible cell growth of human multiple myeloma involving molecular cross-talk between estrogen receptor and STAT3 mediated by co-regulator PLAS3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN INHIBITOR; SIGNAL-TRANSDUCTION; ER-ALPHA; APOPTOSIS; MODULATION; EXPRESSION; PROMOTER; MODEL; GP130; ACTS	Estrogen receptors (ERs)(1) highly expressed by multiple myeloma (NM) cells and stimulation of estrogenic ligands leads to cell apoptosis. Interleukin (IL)-6 is a major growth factor in the pathogenesis of MM. However, little is known concerning the molecular consequences of ER activation on IL-6-regulated AM cell growth. Here we show that the ER agonist 17 beta -estradiol completely abolished IL-6-inducible AM cell proliferation. By contrast, the ER antagonist ICI 182,780 overcame the inhibitory effect of estrogen. Estrogen blocked STAT3 DNA binding and transactivation but failed to affect the mRNA expression of IL-6 receptor chains or activation of JAK2 and STAT3. Estrogen-activated ER did not associate directly with STAT3. Estrogen induced the mRNA expression of PIAS3 ((p) under bar rotein (i) under bar nhibitor of (a) under bar ctivated (S) under bar TAT (3) under bar) and increased PIAS3 physical association with STAT3, suggesting a possible mechanism of STAT3 inhibition requiring PIAS3 as a co-regulator modulating the cross-talk between ER and STAT3. These data directly demonstrate STAT3 to be a molecular participant in ER inhibition of the IL-6 signaling pathway in human AM cells and provides the molecular basis for the potential use of estrogenic ligands in the treatment of AM or other tumors where IL-6 has an autocrine or paracrine role.	Sci Applicat Int Corp, Intramural Res Support Program, NCI, Frederick, MD 21702 USA; NCI, Div Basic Sci, Mol Immunoregulat Lab, Cytokine Mol Mech Sect, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Wang, LH (corresponding author), Sci Applicat Int Corp, Intramural Res Support Program, NCI, Frederick, MD 21702 USA.		Xiao, Weihua/N-2775-2013	Xiao, Weihua/0000-0001-9102-6326	NCI NIH HHS [N01-CO-56000] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO056000] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson K, 1999, SEMIN ONCOL, V26, P10; Barille S, 1999, BRIT J HAEMATOL, V106, P532, DOI 10.1046/j.1365-2141.1999.01563.x; BATAILLE R, 1989, J CLIN INVEST, V84, P2008, DOI 10.1172/JCI114392; BERTHOIS Y, 1986, P NATL ACAD SCI USA, V83, P2496, DOI 10.1073/pnas.83.8.2496; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chen YH, 1997, LEUKEMIA LYMPHOMA, V27, P11, DOI 10.3109/10428199709068267; Chiu JJ, 1996, CLIN CANCER RES, V2, P215; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; Cooke PS, 1998, BIOL REPROD, V59, P470, DOI 10.1095/biolreprod59.3.470; Cowley SM, 1999, J STEROID BIOCHEM, V69, P165, DOI 10.1016/S0960-0760(99)00055-2; Dankbar B, 2000, BLOOD, V95, P2630, DOI 10.1182/blood.V95.8.2630; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Duhe RJ, 2001, CELL BIOCHEM BIOPHYS, V34, P17, DOI 10.1385/CBB:34:1:17; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Gado K, 2000, CELL BIOL INT, V24, P195, DOI 10.1006/cbir.2000.0497; Glass CK, 2000, GENE DEV, V14, P121; Govind AP, 2001, J CELL BIOCHEM, V80, P571, DOI 10.1002/1097-4644(20010315)80:4<571::AID-JCB1011>3.0.CO;2-H; Hallek M, 1998, BLOOD, V91, P3, DOI 10.1182/blood.V91.1.3.3_3_21; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; Kastrinakis NG, 2000, ANN ONCOL, V11, P1217, DOI 10.1023/A:1008331714186; KLEIN B, 1995, BLOOD, V85, P863, DOI 10.1182/blood.V85.4.863.bloodjournal854863; Kotaja N, 2000, MOL ENDOCRINOL, V14, P1986, DOI 10.1210/me.14.12.1986; Kurebayashi J, 1998, ONCOLOGY-BASEL, V55, P23, DOI 10.1159/000055256; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; Liu KD, 1998, CURR OPIN IMMUNOL, V10, P271, DOI 10.1016/S0952-7915(98)80165-9; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; NILSSON K, 1990, CURR TOP MICROBIOL, V166, P3; Otsuki T, 2000, CANCER RES, V60, P1434; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; POTTRATZ ST, 1994, J CLIN INVEST, V93, P944, DOI 10.1172/JCI117100; Rebouissou C, 1998, BLOOD, V91, P4727, DOI 10.1182/blood.V91.12.4727.412k35_4727_4737; Reece D E, 1998, Curr Opin Hematol, V5, P460, DOI 10.1097/00062752-199811000-00018; Rodel B, 2000, EMBO J, V19, P5845, DOI 10.1093/emboj/19.21.5845; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; Seiden Michael V., 1994, Current Opinion in Oncology, V6, P41, DOI 10.1097/00001622-199401000-00006; Shuai K, 2000, ONCOGENE, V19, P2638, DOI 10.1038/sj.onc.1203522; Sjak-Shie NN, 2000, CURR OPIN HEMATOL, V7, P241, DOI 10.1097/00062752-200007000-00007; STEIN B, 1995, MOL CELL BIOL, V15, P4971; Tan JA, 2000, MOL ENDOCRINOL, V14, P14, DOI 10.1210/me.14.1.14; Treon S P, 1998, Curr Opin Hematol, V5, P42; Treon SP, 2000, SEMIN ONCOL, V27, P598; Treon SP, 1998, BLOOD, V92, P1749, DOI 10.1182/blood.V92.5.1749.417k38_1749_1757; Ueki N, 1999, J HUM GENET, V44, P193, DOI 10.1007/s100380050141; Varterasian Mary L., 1999, Current Opinion in Oncology, V11, P3, DOI 10.1097/00001622-199901000-00002; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; Wang LH, 1999, J IMMUNOL, V162, P3897; Wang LH, 2000, BLOOD, V95, P1249, DOI 10.1182/blood.V95.4.1249.004k39_1249_1257; Westendorf JJ, 1996, LEUKEMIA, V10, P866; Xu FH, 1998, BLOOD, V92, P241, DOI 10.1182/blood.V92.1.241.413k28_241_251; Yamamoto T, 2000, FEBS LETT, V486, P143, DOI 10.1016/S0014-5793(00)02296-1; Yang XY, 2000, J BIOL CHEM, V275, P4541, DOI 10.1074/jbc.275.7.4541; Zhang ZX, 1997, J BIOL CHEM, V272, P30607, DOI 10.1074/jbc.272.49.30607; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	54	67	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					31839	31844		10.1074/jbc.M105185200	http://dx.doi.org/10.1074/jbc.M105185200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11429412	hybrid			2022-12-25	WOS:000170613500051
J	Gallego, RG; Blanco, JLJ; Thijssen-van Zuylen, CWEM; Gotfredsen, CH; Voshol, H; Duus, JO; Schachner, M; Vliegenthart, JFG				Gallego, RG; Blanco, JLJ; Thijssen-van Zuylen, CWEM; Gotfredsen, CH; Voshol, H; Duus, JO; Schachner, M; Vliegenthart, JFG			Epitope diversity of N-glycans from bovine peripheral myelin glycoprotein P0 revealed by mass spectrometry and nano probe magic angle spinning H-1 NMR spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED CARBOHYDRATE CHAINS; NEURAL CELL-ADHESION; L-SELECTIN; L2/HNK-1 CARBOHYDRATE; EXPRESSION CLONING; NERVOUS-SYSTEM; PROTEIN ZERO; PO PROTEIN; SULFOGLUCURONYL GLYCOLIPIDS; BRAIN GLYCOPROTEINS	The carbohydrate structures present on the glycoproteins in the central and peripheral nerve systems are essential in many cell adhesion processes. The PO glycoprotein, expressed by myelinating Schwann cells, plays an important role during the formation and maintenance of myelin, and it is the most abundant constituent of myelin. Using monoclonal antibodies, the homophilic binding of the PO glycoprotein was shown to be mediated via the human natural keller cell (HNK)-1 epitope (3-O-SO3H-GlcUA(beta1-3)Gal(beta1-4)GlcNAc) present on the N-glycans. We recently described the structure of the N-glycan carrying the HNK-1 epitope, present on bovine peripheral myelin PO (Voshol, H., van Zuylen, C. W. E. M., Orberger, G., Vliegenthart, J. F. G., and Schachner, M. (1996) J. Biol Chem. 271, 22957-22960). In this study, we report on the structural characterization of the detectable glycoforms, present on the single N-glycosylation site, using state-of-the-art NMR and mass spectrometry techniques. Even though all structures belong to the hybrid- or biantennary complex-type structures, the variety of epitopes is remarkable. In addition to the 3-O-sulfate present on the HNK-1-carrying structures, most of the glycans contain a 6-O-sulfated N-acetylglucosamine residue. This indicates the activity of a 6-O-sulfo-GlcNAc-transferase, which has not been described before in peripheral nervous tissue. The presence of the disialo-, galactosyl-, and 6-O-sulfosialyl-Lewis X epitopes provides evidence for glycosyltransferase activities not detected until now. The finding of such an epitope diversity triggers questions related to their function and whether events, previously attributed merely to the HNK-1 epitope, could be mediated by the structures described here.	Univ Utrecht, Bijvoet Ctr, Dept Bioorgan Chem, NL-3508 TB Utrecht, Netherlands; Swiss Fed Inst Technol, Dept Neurobiol, CH-8093 Zurich, Switzerland; Carlsberg Lab, Dept Chem, DK-2500 Copenhagen, Denmark	Utrecht University; Swiss Federal Institutes of Technology Domain; ETH Zurich	Vliegenthart, JFG (corresponding author), Univ Utrecht, Bijvoet Ctr, Dept Bioorgan Chem, POB 80075, NL-3508 TB Utrecht, Netherlands.	vlieg@pobox.uu.nl	Jiménez-Blanco, José L/M-3946-2013; Duus, Jens Øllgaard/N-4279-2013; Gotfredsen, Charlotte Held/ABC-8211-2021	Jiménez-Blanco, José L/0000-0002-5249-9013; Duus, Jens Øllgaard/0000-0003-3625-1250; Gotfredsen, Charlotte Held/0000-0002-7386-119X; Gutierrez Gallego, Ricardo/0000-0001-9639-2181				Angata K, 2000, J BIOL CHEM, V275, P18594, DOI 10.1074/jbc.M910204199; BADACHE A, 1992, DEV NEUROSCI-BASEL, V14, P342, DOI 10.1159/000111681; Bakker H, 1997, J BIOL CHEM, V272, P29942, DOI 10.1074/jbc.272.47.29942; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BAX A, 1985, J MAGN RESON, V63, P207, DOI 10.1016/0022-2364(85)90171-4; BERGWERFF AA, 1995, GLYCOCONJUGATE J, V12, P318, DOI 10.1007/BF00731335; Bistrup A, 1999, J CELL BIOL, V145, P899, DOI 10.1083/jcb.145.4.899; BOUCHON B, 1992, GLYCOCONJUGATE J, V9, P27, DOI 10.1007/BF00731175; Bowman KG, 1998, CHEM BIOL, V5, P447, DOI 10.1016/S1074-5521(98)90161-2; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; Broberg A, 2000, CARBOHYD RES, V328, P375, DOI 10.1016/S0008-6215(00)00108-7; BRUNDEN KR, 1992, J NEUROCHEM, V58, P1659, DOI 10.1111/j.1471-4159.1992.tb10038.x; BURGER D, 1990, J NEUROCHEM, V54, P1569, DOI 10.1111/j.1471-4159.1990.tb01206.x; BURGER D, 1992, J NEUROCHEM, V58, P845, DOI 10.1111/j.1471-4159.1992.tb09334.x; BURGER D, 1992, J NEUROCHEM, V58, P854, DOI 10.1111/j.1471-4159.1992.tb09335.x; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; DASGUPTA S, 1994, ARCH BIOCHEM BIOPHYS, V310, P373, DOI 10.1006/abbi.1994.1181; Degroote S, 1997, J BIOL CHEM, V272, P29493, DOI 10.1074/jbc.272.47.29493; DEWAARD P, 1991, J BIOL CHEM, V266, P4237; DORLAND L, 1986, CARBOHYD RES, V151, P233, DOI 10.1016/S0008-6215(00)90344-6; Fan OW, 1999, GLYCOBIOLOGY, V9, P947, DOI 10.1093/glycob/9.9.947; FIELD MC, 1992, J NEUROCHEM, V58, P993, DOI 10.1111/j.1471-4159.1992.tb09353.x; FILBIN MT, 1991, NEURON, V7, P845, DOI 10.1016/0896-6273(91)90286-9; FILBIN MT, 1993, J CELL BIOL, V122, P451, DOI 10.1083/jcb.122.2.451; FINNE J, 1989, CIBA F SYMP, V145, P173; FINNE J, 1977, BIOCHEM BIOPH RES CO, V74, P405, DOI 10.1016/0006-291X(77)90318-7; FINNE J, 1977, EUR J BIOCHEM, V77, P319, DOI 10.1111/j.1432-1033.1977.tb11670.x; FINNE J, 1975, BIOCHIM BIOPHYS ACTA, V412, P317, DOI 10.1016/0005-2795(75)90046-X; FUKUDA M, 1984, J BIOL CHEM, V259, P4782; FUKUDA M, 1987, J BIOL CHEM, V262, P11952; Funakoshi Y, 1997, GLYCOBIOLOGY, V7, P195, DOI 10.1093/glycob/7.2.195; GALILI U, 1993, SPRINGER SEMIN IMMUN, V15, P155; Galustian C, 1997, BIOCHEM BIOPH RES CO, V240, P748, DOI 10.1006/bbrc.1997.7737; Georgiou J, 1999, GLIA, V27, P101, DOI 10.1002/(SICI)1098-1136(199908)27:2<101::AID-GLIA1>3.0.CO;2-H; GIESE KP, 1992, CELL, V71, P565, DOI 10.1016/0092-8674(92)90591-Y; Gilbert M, 2000, J BIOL CHEM, V275, P3896, DOI 10.1074/jbc.275.6.3896; GRIESINGER C, 1988, J AM CHEM SOC, V110, P7870, DOI 10.1021/ja00231a044; GRIFFITH LS, 1992, J NEUROSCI RES, V33, P639, DOI 10.1002/jnr.490330417; HALL H, 1995, GLYCOBIOLOGY, V5, P435, DOI 10.1093/glycob/5.4.435; HALL H, 1993, EUR J NEUROSCI, V5, P34, DOI 10.1111/j.1460-9568.1993.tb00202.x; Hall H, 1997, EUR J BIOCHEM, V246, P233, DOI 10.1111/j.1432-1033.1997.t01-1-00233.x; Hall H, 1997, J NEUROCHEM, V68, P544; HARDY MR, 1994, METHOD ENZYMOL, V230, P208; Hiraoka N, 1999, IMMUNITY, V11, P79, DOI 10.1016/S1074-7613(00)80083-7; ILYAS AA, 1990, J NEUROCHEM, V55, P594, DOI 10.1111/j.1471-4159.1990.tb04175.x; Jaques AJ, 1996, BIOCHEM J, V316, P427, DOI 10.1042/bj3160427; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; KANDA T, 1995, P NATL ACAD SCI USA, V92, P7897, DOI 10.1073/pnas.92.17.7897; KIANG WL, 1982, J BIOL CHEM, V257, P1651; Kimura N, 1999, P NATL ACAD SCI USA, V96, P4530, DOI 10.1073/pnas.96.8.4530; KITAJIMA K, 1984, BIOCHEMISTRY-US, V23, P310, DOI 10.1021/bi00297a021; Kupce E, 1998, J MAGN RESON, V135, P361, DOI 10.1006/jmre.1998.1607; Lee JK, 1999, BIOCHEM BIOPH RES CO, V263, P543, DOI 10.1006/bbrc.1999.1324; MANZI A, 1995, J BIOL CHEM, V270, P9154, DOI 10.1074/jbc.270.16.9154; MARTINI R, 1994, GLIA, V10, P70, DOI 10.1002/glia.440100109; MARTINI R, 1992, EUR J NEUROSCI, V4, P628, DOI 10.1111/j.1460-9568.1992.tb00171.x; MARTINI R, 1988, DEV BIOL, V129, P330, DOI 10.1016/0012-1606(88)90380-6; MARTINI R, 1995, NAT GENET, V11, P281, DOI 10.1038/ng1195-281; MCGARRY RC, 1983, NATURE, V306, P376, DOI 10.1038/306376a0; MICHALSKI JC, 1991, EUR J BIOCHEM, V201, P439, DOI 10.1111/j.1432-1033.1991.tb16302.x; MICHON F, 1987, BIOCHEMISTRY-US, V26, P8399, DOI 10.1021/bi00399a055; MOHAN PS, 1990, J NEUROCHEM, V54, P2024, DOI 10.1111/j.1471-4159.1990.tb04907.x; Nastuk MA, 1998, J NEUROSCI, V18, P7167; NEEDHAM LK, 1993, P NATL ACAD SCI USA, V90, P1359, DOI 10.1073/pnas.90.4.1359; NOGUCHI S, 1992, EUR J BIOCHEM, V209, P883, DOI 10.1111/j.1432-1033.1992.tb17361.x; Ong E, 1998, J BIOL CHEM, V273, P5190, DOI 10.1074/jbc.273.9.5190; PODUSLO JF, 1990, J BIOL CHEM, V265, P3719; Sato C, 1998, ANAL BIOCHEM, V261, P191, DOI 10.1006/abio.1998.2718; Sato C, 1998, J BIOL CHEM, V273, P2575, DOI 10.1074/jbc.273.5.2575; Sato C, 2000, J BIOL CHEM, V275, P15422, DOI 10.1074/jbc.275.20.15422; Sato Y, 1999, GLYCOBIOLOGY, V9, P655, DOI 10.1093/glycob/9.7.655; SCHACHNER M, 1995, TRENDS NEUROSCI, V18, P183, DOI 10.1016/0166-2236(95)93899-9; Schachner M, 1995, PROG BRAIN RES, V105, P183; SCHNEIDERSCHAULIES J, 1990, J NEUROSCI RES, V27, P286, DOI 10.1002/jnr.490270307; SEPPO A, 1994, GLYCOCONJUGATE J, V11, P217, DOI 10.1007/BF00731221; Spiro RG, 1996, BIOCHEM J, V319, P209, DOI 10.1042/bj3190209; Stroop CJM, 2000, ARCH BIOCHEM BIOPHYS, V374, P42, DOI 10.1006/abbi.1999.1660; THALL AD, 1995, J BIOL CHEM, V270, P21437, DOI 10.1074/jbc.270.37.21437; Uchimura K, 1998, J BIOL CHEM, V273, P22577, DOI 10.1074/jbc.273.35.22577; UYEMURA K, 1991, COMP BIOCHEM PHYS C, V98, P63; VLIEGENTHART JFG, 1983, ADV CARBOHYD CHEM BI, V41, P209, DOI 10.1016/S0065-2318(08)60059-1; VORM O, 1994, J AM SOC MASS SPECTR, V5, P955, DOI 10.1016/1044-0305(94)80013-8; Voshol H, 1996, J BIOL CHEM, V271, P22957, DOI 10.1074/jbc.271.38.22957; Warner LE, 1996, NEURON, V17, P451, DOI 10.1016/S0896-6273(00)80177-4; Weiss Eveline, 1991, Agraroekologie, V1, P1; YAZAKI T, 1992, FEBS LETT, V307, P361, DOI 10.1016/0014-5793(92)80713-Q; Yoshida M, 1996, NEURON, V16, P1115, DOI 10.1016/S0896-6273(00)80138-5; Zhang K, 1996, J NEUROSCI RES, V45, P525, DOI 10.1002/(SICI)1097-4547(19960901)45:5<525::AID-JNR2>3.0.CO;2-E	88	43	44	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					30834	30844		10.1074/jbc.M101013200	http://dx.doi.org/10.1074/jbc.M101013200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11410585	hybrid			2022-12-25	WOS:000170472900035
J	Kreuger, J; Salmivirta, M; Sturiale, L; Gimenez-Gallego, G; Lindahl, U				Kreuger, J; Salmivirta, M; Sturiale, L; Gimenez-Gallego, G; Lindahl, U			Sequence analysis of heparan sulfate epitopes with graded affinities for fibroblast growth factors 1 and 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOGENIC ACTIVITY; CRYSTAL-STRUCTURE; BINDING SEQUENCE; CELL-SURFACE; BASIC FGF; PROTEOGLYCANS; RECEPTOR; DOMAINS; OLIGOSACCHARIDES; 6-O-SULFATION	Proteins that belong to the fibroblast growth factor (FGF) family regulate proliferation, migration, and differentiation of many cell types. Several FGFs, including the prototype factors FGF-1 and FGF-2, depend on interactions with heparan sulfate (HS) proteoglycans for activity. We have assessed tissue-derived HS fragments for binding to FGF-1 and FGF-2 to identify the authentic saccharide motifs required for interactions. Sequence information on a range of N-sulfated HS octasaccharides spanning from low to high affinity for FGF-1 was obtained. All octasaccharides with high affinity for FGF-1 (greater than or equal to0.5 m NaCl required for elution) contained an internal IdoUA(2-OSO3)-GlcNSO(3)(6-OSO3)-IdoUA(2-OSO3)-trisaccharide motif. Octasaccharides with a higher overall degree of sulfation but lacking the specific trisaccharide motif showed lower affinity for FGF-1. FGF-2 was shown to bind to a mono-O-sulfated HS 6-mer carrying a single internal IdoUA(2-OSO3)-unit. However, a di-O-sulfated -IdoUA(2-OSO3)-GlcNSO(3)-IdoUA(2-OSO3)-trisaccharide sequence within a HS 8-mer gave stronger binding. These findings show that not only the number but also the positions of individual sulfate groups determine affinity of HS for FGFs. Our findings support the notion that FGF-dependent processes can be modulated in vivo by regulated expression of distinct HS sequences.	Uppsala Univ, Dept Med Biochem & Micorbiol, S-75123 Uppsala, Sweden; Abo Akad Univ, FIN-20521 Turku, Finland; Univ Turku, Turku Ctr Biotechnol, FIN-20521 Turku, Finland; BioTic Therapies Corp, FIN-20520 Turku, Finland; G Ronzoni Inst Chem & Biochem Res, I-20133 Milan, Italy; CSIC, Ctr Invest Biol, E-28006 Madrid, Spain	Uppsala University; Abo Akademi University; University of Turku; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)	Lindahl, U (corresponding author), Uppsala Univ, Dept Med Biochem & Micorbiol, POB 582, S-75123 Uppsala, Sweden.		Kreuger, Johan/HDM-1503-2022	STURIALE, LUISELLA/0000-0002-3996-1138				Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; BLUMENKR.N, 1973, ANAL BIOCHEM, V54, P484, DOI 10.1016/0003-2697(73)90377-1; BOURIN MC, 1993, BIOCHEM J, V289, P313, DOI 10.1042/bj2890313; CASU B, 2001, IN PRESS ADV CARBOHY; Chang Z, 2000, FASEB J, V14, P137, DOI 10.1096/fasebj.14.1.137; DiGabriele AD, 1998, NATURE, V393, P812, DOI 10.1038/31741; ESKO JD, 2001, IN PRESS J CLIN INVE; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; Feyzi E, 1998, J BIOL CHEM, V273, P13395, DOI 10.1074/jbc.273.22.13395; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; HABUCHI H, 1992, BIOCHEM J, V285, P805, DOI 10.1042/bj2850805; ISHIHARA M, 1994, GLYCOBIOLOGY, V4, P451, DOI 10.1093/glycob/4.4.451; ISHIHARA M, 1994, GLYCOBIOLOGY, V4, P817, DOI 10.1093/glycob/4.6.817; JACOBSSON I, 1984, J BIOL CHEM, V259, P1056; Kreuger J, 1999, GLYCOBIOLOGY, V9, P723, DOI 10.1093/glycob/9.7.723; Lander AD, 1998, MATRIX BIOL, V17, P465, DOI 10.1016/S0945-053X(98)90093-2; Lindahl B, 1997, J BIOL CHEM, V272, P26091, DOI 10.1074/jbc.272.42.26091; LINDAHL B, 1995, BIOCHEM J, V306, P177, DOI 10.1042/bj3060177; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; Loo BM, 2001, J BIOL CHEM, V276, P16868, DOI 10.1074/jbc.M011226200; Lyon M, 1998, MATRIX BIOL, V17, P485, DOI 10.1016/S0945-053X(98)90096-8; LYON M, 1994, J BIOL CHEM, V269, P11208; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; Maccarana M, 1996, J BIOL CHEM, V271, P17804, DOI 10.1074/jbc.271.30.17804; Merry CLR, 1999, J BIOL CHEM, V274, P18455, DOI 10.1074/jbc.274.26.18455; NURCOMBE V, 1993, SCIENCE, V260, P103, DOI 10.1126/science.7682010; Nurcombe V, 2000, J BIOL CHEM, V275, P30009, DOI 10.1074/jbc.M003038200; Pellegrini L, 2000, NATURE, V407, P1029, DOI 10.1038/35039551; Pye DA, 1998, J BIOL CHEM, V273, P22936, DOI 10.1074/jbc.273.36.22936; Rahmoune H, 1998, J BIOL CHEM, V273, P7303, DOI 10.1074/jbc.273.13.7303; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; Safaiyan F, 2000, BIOCHEMISTRY-US, V39, P10823, DOI 10.1021/bi000411s; Salmivirta M, 1996, FASEB J, V10, P1270, DOI 10.1096/fasebj.10.11.8836040; Schlessinger J, 2000, MOL CELL, V6, P743, DOI 10.1016/S1097-2765(00)00073-3; THUNBERG L, 1982, CARBOHYD RES, V100, P393, DOI 10.1016/S0008-6215(00)81050-2; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; Turnbull JE, 1999, P NATL ACAD SCI USA, V96, P2698, DOI 10.1073/pnas.96.6.2698; van Kuppevelt TH, 1998, J BIOL CHEM, V273, P12960, DOI 10.1074/jbc.273.21.12960; vandenBorn J, 1995, J BIOL CHEM, V270, P31303, DOI 10.1074/jbc.270.52.31303; Venkataraman G, 1999, SCIENCE, V286, P537, DOI 10.1126/science.286.5439.537; Vives RR, 1999, BIOCHEM J, V339, P767, DOI 10.1042/0264-6021:3390767; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; Yoneda A, 2000, NAT BIOTECHNOL, V18, P641, DOI 10.1038/76487; ZAZO M, 1992, GENE, V113, P231, DOI 10.1016/0378-1119(92)90400-J	44	186	189	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					30744	30752		10.1074/jbc.M102628200	http://dx.doi.org/10.1074/jbc.M102628200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11406624	hybrid, Green Published			2022-12-25	WOS:000170472900023
J	Rogers, GW; Richter, NJ; Lima, WF; Merrick, WC				Rogers, GW; Richter, NJ; Lima, WF; Merrick, WC			Modulation of the helicase activity of eIF4A by eIF4B, eIF4H, and eIF4F	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EUKARYOTIC INITIATION-FACTORS; SINGLE-STRANDED-DNA; BOX PROTEIN EIF4A; CRYSTAL-STRUCTURE; FACTOR 4A; ANTISENSE OLIGONUCLEOTIDES; SACCHAROMYCES-CEREVISIAE; KINETIC CHARACTERIZATION; MESSENGER-RNA; STEP-SIZE	Eukaryotic initiation factor (eIF) 4A is a DEAD box RNA helicase that works in conjunction with eIF4B, eIF4H, or as a subunit of eIF4F to unwind secondary structure in the 5 ' -untranslated region of mRNA, which facilitates binding of the mRNA to the 40 S ribosomal subunit. This study demonstrates how the helicase activity of eIF4A is modulated by eIF4B, eIF4H, or as a subunit of eIF4F. Results indicate that a linear relationship exists between the initial rate or amplitude of unwinding and duplex stability for all factor combinations tested. eIF4F, like eIF4A, behaves as a non-processive helicase. Either eIF4B or eIF4H stimulated the initial rate and amplitude of eIF4A-dependent duplex unwinding, and the magnitude of stimulation is dependent on duplex stability. Furthermore, eIF4A (or eIF4F) becomes a slightly processive helicase in the presence of eIF4B or eIF4H. All combinations of factors tested indicate that the rate of duplex unwinding is equivalent in the 5 ' --> 3 ' and 3 ' --> 5 ' directions. However, the optimal rate of unwinding was dependent on the length of the single-stranded region of the substrate when different combinations of factors were used. The combinations of eIF4A, eIF4A + eIF4B, eIF4A + eIF4H, and cIF4F showed differences in their ability to unwind chemically modified duplexes. A simple model of how eIF4B or eIF4H affects the duplex unwinding mechanism of eIF4A is proposed.	Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA; ISIS Pharmaceut Inc, Carlsbad, CA 92008 USA	Case Western Reserve University; Isis Pharmaceuticals Inc	Merrick, WC (corresponding author), Case Western Reserve Univ, Sch Med, Dept Biochem, 10900 Euclid Ave, Cleveland, OH 44106 USA.	wcm2@po.cwru.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026796] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK07319] Funding Source: Medline; NIGMS NIH HHS [GM26796] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMSON RD, 1988, J BIOL CHEM, V263, P6016; ABRAMSON RD, 1987, J BIOL CHEM, V262, P3826; ABRAMSON RD, 1988, J BIOL CHEM, V263, P5462; Ali JA, 1997, SCIENCE, V275, P377, DOI 10.1126/science.275.5298.377; Altmann KH, 1996, BIOCHEM SOC T, V24, P630, DOI 10.1042/bst0240630; Altmann KH, 1996, CHIMIA, V50, P168; Benz J, 1999, STRUCTURE, V7, P671, DOI 10.1016/S0969-2126(99)80088-4; Bi XP, 2000, BIOCHEMISTRY-US, V39, P5758, DOI 10.1021/bi992322p; Bjornson KP, 1998, BIOCHEMISTRY-US, V37, P891, DOI 10.1021/bi9719307; Caruthers JM, 2000, P NATL ACAD SCI USA, V97, P13080, DOI 10.1073/pnas.97.24.13080; CROOKE ST, 1995, THERAPEUTIC APPL OLI, P53; de la Cruz J, 1999, TRENDS BIOCHEM SCI, V24, P192, DOI 10.1016/S0968-0004(99)01376-6; Dillingham MS, 2000, BIOCHEMISTRY-US, V39, P205, DOI 10.1021/bi992105o; Freier SM, 1997, NUCLEIC ACIDS RES, V25, P4429, DOI 10.1093/nar/25.22.4429; GOYER C, 1993, MOL CELL BIOL, V13, P4860, DOI 10.1128/MCB.13.8.4860; GRIFO JA, 1983, J BIOL CHEM, V258, P5804; GRIFO JA, 1984, J BIOL CHEM, V259, P8648; Hershey JWB, 2000, COLD SPRING HARBOR M, V39, P33; Jankowsky E, 2000, NATURE, V403, P447, DOI 10.1038/35000239; Johnson ER, 1999, RNA, V5, P1526, DOI 10.1017/S1355838299991410; Kim JL, 1998, STRUCTURE, V6, P89, DOI 10.1016/S0969-2126(98)00010-0; Korolev S, 1997, CELL, V90, P635, DOI 10.1016/S0092-8674(00)80525-5; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; KOZAK M, 1989, MOL CELL BIOL, V9, P5134, DOI 10.1128/MCB.9.11.5134; LAWSON TG, 1989, BIOCHEMISTRY-US, V28, P4729, DOI 10.1021/bi00437a033; LINDER P, 1989, NATURE, V337, P121, DOI 10.1038/337121a0; Lorsch JR, 1998, BIOCHEMISTRY-US, V37, P2180, DOI 10.1021/bi972430g; Lorsch JR, 1998, BIOCHEMISTRY-US, V37, P2194, DOI 10.1021/bi9724319; Luking A, 1998, CRIT REV BIOCHEM MOL, V33, P259, DOI 10.1080/10409239891204233; Merrick W C, 1979, Methods Enzymol, V60, P101, DOI 10.1016/S0076-6879(79)60010-1; Merrick WC, 1997, METHODS, V11, P333, DOI 10.1006/meth.1996.0431; Merrick WC., 1996, TRANSLATION CONTROL, P31; METHOT N, 1994, MOL CELL BIOL, V14, P2307, DOI 10.1128/MCB.14.4.2307; Methot N, 1996, MOL CELL BIOL, V16, P5328; Methot N, 1996, RNA, V2, P38; NARANDA T, 1994, J BIOL CHEM, V269, P14465; Pestova TV, 1996, MOL CELL BIOL, V16, P6859, DOI 10.1128/mcb.16.12.6859; Richter NJ, 1999, J BIOL CHEM, V274, P35415, DOI 10.1074/jbc.274.50.35415; Richter-Cook NJ, 1998, J BIOL CHEM, V273, P7579, DOI 10.1074/jbc.273.13.7579; Rogers GW, 1999, J BIOL CHEM, V274, P12236, DOI 10.1074/jbc.274.18.12236; Rogers GW, 2001, J BIOL CHEM, V276, P12598, DOI 10.1074/jbc.M007560200; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; RUNYON GT, 1993, BIOCHEMISTRY-US, V32, P4128, DOI 10.1021/bi00066a039; SantaLucia J, 1996, BIOCHEMISTRY-US, V35, P3555, DOI 10.1021/bi951907q; SONENBERG N, 1981, CELL, V27, P563, DOI 10.1016/0092-8674(81)90398-6; Soultanas P, 2000, EMBO J, V19, P3799, DOI 10.1093/emboj/19.14.3799; SUGIMOTO N, 1995, BIOCHEMISTRY-US, V34, P11211, DOI 10.1021/bi00035a029; TURNER DH, 1988, ANNU REV BIOPHYS BIO, V17, P167; Velankar SS, 1999, CELL, V97, P75, DOI 10.1016/S0092-8674(00)80716-3; Yao NH, 1997, NAT STRUCT BIOL, V4, P463, DOI 10.1038/nsb0697-463	50	252	257	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					30914	30922		10.1074/jbc.M100157200	http://dx.doi.org/10.1074/jbc.M100157200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11418588	hybrid			2022-12-25	WOS:000170472900045
J	Viswanathan, M; Burdett, V; Baitinger, C; Modrich, P; Lovett, ST				Viswanathan, M; Burdett, V; Baitinger, C; Modrich, P; Lovett, ST			Redundant exonuclease involvement in Escherichia coli methyl-directed mismatch repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL HETEROLOGOUS SEQUENCES; MUTANTS DEFICIENT; RECJ-GENE; DNA; RECOMBINATION; MUTS; HELICASE; PURIFICATION; REPLICATION; SPECIFICITY	Previous biochemical analysis of Escherichia coli methyl-directed mismatch repair implicates three redundant single-strand DNA-specific exonucleases (RecJ, ExoI, and ExoVII) and at least one additional unknown exonuclease in the excision reaction (Cooper, D. L., Lahue, IL S., and Modrich, P. (1993) J. BioL Chem. 268, 11823-11829). We show here that ExoX also participates in methyl-directed mismatch repair. Analysis of the reaction with crude extracts and purified components demonstrated that ExoX can mediate repair directed from a strand signal 3 ' of a mismatch. Whereas extracts of all possible single, double, and triple exonuclease mutants displayed significant residual mismatch repair, extracts deficient in RecJ, ExoI, ExoVII, and ExoX exonucleases were devoid of normal repair activity. The RecJ(-) ExoVII(-) ExoI(-) ExoX(-) strain displayed a 7-fold increase in mutation rate, a significant increase, but less than that observed for other blocks of the mismatch repair pathway. This elevation is epistatic to deficiency for MutS, suggesting an effect via the mismatch repair pathway. Our other work (Burdett, V., Baitinger, C., Viswanathan, M., Lovett, S. T., and Modrich, P. (2001) Proc. Natl. Acad. Sci. U. S. A 98, 6765-6770) suggests that mutants are under-recovered in the exonuclease-deficient strain due to loss of viability that is triggered by mismatched base pairs in this genetic background. The availability of any one exonuclease is enough to support full mismatch correction, as evident from the normal mutation rates of all triple mutants. Because three of these exonucleases possess a strict polarity of digestion, this suggests that mismatch repair can occur exclusively from a 3 ' or a 5 ' direction to the mismatch, if necessary.	Brandeis Univ, Rosenstiel Basic Med Sci Res Ctr, Waltham, MA 02254 USA; Brandeis Univ, Dept Biol, Waltham, MA 02254 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA	Brandeis University; Brandeis University; Duke University; Duke University; Howard Hughes Medical Institute	Lovett, ST (corresponding author), Rosenstiel Basic Med Sci Res Ctr, MS029, Waltham, MA 02454 USA.	lovett@brandeis.edu	Lovett, Susan/AAC-1810-2021	Lovett, Susan/0000-0003-2792-1857; Modrich, Paul/0000-0001-8708-9885	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM023719, R01GM043889, R01GM023719] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM43889, GM07122, GM23719] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen DJ, 1997, EMBO J, V16, P4467, DOI 10.1093/emboj/16.14.4467; AU KG, 1992, J BIOL CHEM, V267, P12142; Burdett V, 2001, P NATL ACAD SCI USA, V98, P6765, DOI 10.1073/pnas.121183298; CHASE JW, 1974, J BIOL CHEM, V249, P4553; CHASE JW, 1977, J BACTERIOL, V129, P934, DOI 10.1128/JB.129.2.934-947.1977; CHASE JW, 1974, J BIOL CHEM, V249, P4545; COOPER DL, 1993, J BIOL CHEM, V268, P11823; Courcelle J, 1999, MOL GEN GENET, V262, P543, DOI 10.1007/s004380051116; Dao V, 1998, J BIOL CHEM, V273, P9202, DOI 10.1074/jbc.273.15.9202; Fang WH, 1997, J BIOL CHEM, V272, P22714, DOI 10.1074/jbc.272.36.22714; FENG WY, 1995, GENETICS, V140, P1175; Friedman-Ohana R, 1998, P NATL ACAD SCI USA, V95, P6909, DOI 10.1073/pnas.95.12.6909; Galio L, 1999, NUCLEIC ACIDS RES, V27, P2325, DOI 10.1093/nar/27.11.2325; GLICKMAN BW, 1980, P NATL ACAD SCI-BIOL, V77, P1063, DOI 10.1073/pnas.77.2.1063; GRILLEY M, 1989, J BIOL CHEM, V264, P1000; GRILLEY M, 1993, J BIOL CHEM, V268, P11830; Harris RS, 1998, J BACTERIOL, V180, P989, DOI 10.1128/JB.180.4.989-993.1998; KRISTENSEN CS, 1995, J BACTERIOL, V177, P52, DOI 10.1128/jb.177.1.52-58.1995; KUSHNER SR, 1971, P NATL ACAD SCI USA, V68, P824, DOI 10.1073/pnas.68.4.824; LAHUE RS, 1989, SCIENCE, V245, P160, DOI 10.1126/science.2665076; LEA DE, 1949, J GENET, V49, P264, DOI 10.1007/BF02986080; LEHMAN IR, 1964, J BIOL CHEM, V239, P2628; LOVETT ST, 1995, GENETICS, V140, P27; LOVETT ST, 1989, P NATL ACAD SCI USA, V86, P2627, DOI 10.1073/pnas.86.8.2627; LOVETT ST, 1984, J BACTERIOL, V157, P190, DOI 10.1128/JB.157.1.190-196.1984; MESELSON M, 1988, RECOMBINATION GENETI, P91; Miesel L, 1996, J BACTERIOL, V178, P3146, DOI 10.1128/jb.178.11.3146-3155.1996; Miller J.H., 1992, SHORT COURSE BACTERI, P150; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; PARKER BO, 1992, P NATL ACAD SCI USA, V89, P1730, DOI 10.1073/pnas.89.5.1730; Razavy H, 1996, GENETICS, V142, P333; Saveson CJ, 1997, GENETICS, V146, P457; SU SS, 1986, P NATL ACAD SCI USA, V83, P5057, DOI 10.1073/pnas.83.14.5057; SU SS, 1988, J BIOL CHEM, V263, P6829; Viswanathan M, 1999, J BIOL CHEM, V274, P30094, DOI 10.1074/jbc.274.42.30094; Viswanathan M, 2000, J MOL BIOL, V302, P553, DOI 10.1006/jmbi.2000.4088; Viswanathan M, 1998, GENETICS, V149, P7; WAGNER R, 1976, P NATL ACAD SCI USA, V73, P4135, DOI 10.1073/pnas.73.11.4135	38	101	102	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					31053	31058		10.1074/jbc.M105481200	http://dx.doi.org/10.1074/jbc.M105481200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11418610	hybrid			2022-12-25	WOS:000170472900062
J	Kao, GD; McKenna, WG; Yen, TJ				Kao, GD; McKenna, WG; Yen, TJ			Detection of repair activity during the DNA damage-induced G2 delay in human cancer cells	ONCOGENE			English	Article						DNA damage; G2; DNA repair; BrdU	HUMAN-DIPLOID FIBROBLASTS; STRAND BREAK REPAIR; HAMSTER OVARY CELLS; HELA-CELLS; NUCLEAR-LOCALIZATION; KINASE ACTIVATION; NITROGEN-MUSTARD; MAMMALIAN-CELLS; EXCISION-REPAIR; UV IRRADIATION	All eukaryotic cells manifest cell cycle delay after exposure to DNA damaging agents. It has been proposed that such cell cycle checkpoints may allow DNA repair but direct evidence of such activity during the radiation-induced G2 delay has been lacking. We report here that cells arrested in G2 by radiation (2-3 Gy) and etoposide incorporate bromodeoxyuridine (BrdU) at discrete foci in the nucleus. We detected G2 cells with CENP-F, a nuclear protein maximally expressed in G2, Caffeine and okadaic acid, both established radiosensitizers, inhibit the incorporation of BrdU in G2 cells. Radioresistant HT29 and OVCAR cells demonstrate BrdU foci formation more frequently during the G2 delay when compared to the more radiosensitive A2780 cell line. The repair foci formed during G2 may be followed through mitosis and observed in daughter cells in G1, Taken together, these observations are consistent with the detection of DNA repair activity during the radiation-induced G2 delay after relatively low doses of radiation.	Hosp Univ Penn, Dept Radiat Oncol, Philadelphia, PA 19104 USA; Fox Chase Canc Ctr, Philadelphia, PA 19111 USA	University of Pennsylvania; Pennsylvania Medicine; Fox Chase Cancer Center	Yen, TJ (corresponding author), Hosp Univ Penn, Dept Radiat Oncol, 3400 Spruce St, Philadelphia, PA 19104 USA.			Yen, Tim/0000-0003-2159-0997	NCI NIH HHS [P01 CA06927] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHMED FE, 1977, CANCER RES, V37, P3414; Balajee AS, 1998, MUTAT RES-FUND MOL M, V404, P3, DOI 10.1016/S0027-5107(98)00088-8; Barratt RA, 1998, CANCER RES, V58, P2639; BEETHAM KL, 1982, J CELL PHYSIOL, V113, P385, DOI 10.1002/jcp.1041130306; BEISKER W, 1988, EXP CELL RES, V174, P156, DOI 10.1016/0014-4827(88)90151-6; Biade S, 1997, RADIAT RES, V147, P416, DOI 10.2307/3579497; COHN SM, 1984, J BIOL CHEM, V259, P2463; DOLBEARE F, 1983, P NATL ACAD SCI-BIOL, V80, P5573, DOI 10.1073/pnas.80.18.5573; Featherstone C, 1999, CURR BIOL, V9, pR759, DOI 10.1016/S0960-9822(00)80005-6; FOX MH, 1991, J CELL SCI, V99, P247; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Haaf T, 1999, J CELL BIOL, V144, P11, DOI 10.1083/jcb.144.1.11; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HOY CA, 1993, MUTAT RES, V290, P217, DOI 10.1016/0027-5107(93)90162-9; JACQUET P, 1995, INT J RADIAT BIOL, V67, P347, DOI 10.1080/09553009514550401; Jin P, 1998, J CELL BIOL, V141, P875, DOI 10.1083/jcb.141.4.875; Juan G, 1997, CANCER RES, V57, P803; JUNG T, 1992, INT J RADIAT BIOL, V62, P161, DOI 10.1080/09553009214551971; KALLE WHJ, 1993, ANAL BIOCHEM, V208, P228, DOI 10.1006/abio.1993.1037; Kao GD, 1999, J BIOL CHEM, V274, P34779, DOI 10.1074/jbc.274.49.34779; Kao GD, 1997, CANCER RES, V57, P753; Kaufmann WK, 1998, MUTAT RES-FUND MOL M, V400, P153, DOI 10.1016/S0027-5107(98)00041-4; KILL IR, 1991, J CELL SCI, V100, P869; LAU CC, 1982, P NATL ACAD SCI-BIOL, V79, P2942, DOI 10.1073/pnas.79.9.2942; Li J, 1997, P NATL ACAD SCI USA, V94, P502, DOI 10.1073/pnas.94.2.502; LIAO H, 1995, J CELL BIOL, V130, P507, DOI 10.1083/jcb.130.3.507; LOCK RB, 1992, CANCER RES, V52, P1817; MAITY A, 1995, EMBO J, V14, P603, DOI 10.1002/j.1460-2075.1995.tb07036.x; MURNANE JP, 1995, CANCER METAST REV, V14, P17, DOI 10.1007/BF00690208; NAGASAWA H, 1994, INT J RADIAT BIOL, V66, P373, DOI 10.1080/09553009414551311; NAKAYASU H, 1989, J CELL BIOL, V108, P1, DOI 10.1083/jcb.108.1.1; Nishii K, 1996, ONCOGENE, V13, P2225; OCONNOR PM, 1993, J BIOL CHEM, V268, P8298; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; OKEEFE RT, 1992, J CELL BIOL, V116, P1095, DOI 10.1083/jcb.116.5.1095; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; PINES J, 1994, EMBO J, V13, P3772, DOI 10.1002/j.1460-2075.1994.tb06688.x; RICHOLD M, 1972, INT J RADIAT BIOL RE, V21, P127, DOI 10.1080/09553007214550151; Rieber MS, 1997, DNA CELL BIOL, V16, P121, DOI 10.1089/dna.1997.16.121; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; SELDEN JR, 1993, CYTOMETRY, V14, P154, DOI 10.1002/cyto.990140207; SHERWOOD SW, 1994, EXP CELL RES, V211, P275, DOI 10.1006/excr.1994.1087; STEFANINI M, 1982, SOMAT CELL GENET, V8, P635, DOI 10.1007/BF01542856; Takata M, 1998, EMBO J, V17, P5497, DOI 10.1093/emboj/17.18.5497; TSAO YP, 1992, CANCER RES, V52, P1823; VANDIERENDONCK JH, 1989, CYTOMETRY, V10, P143, DOI 10.1002/cyto.990100205; VIJG J, 1984, MUTAT RES, V132, P129, DOI 10.1016/0167-8817(84)90007-5; WANG XQ, 1994, EXP CELL RES, V212, P176, DOI 10.1006/excr.1994.1133; Wang Y, 2000, GENE DEV, V14, P927; ZELLE B, 1980, MUTAT RES, V73, P157, DOI 10.1016/0027-5107(80)90144-X; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	51	67	70	0	9	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 14	2001	20	27					3486	3496		10.1038/sj.onc.1204445	http://dx.doi.org/10.1038/sj.onc.1204445			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	445VB	11429695				2022-12-25	WOS:000169478300004
J	Chen, SY; Wilkemeyer, MF; Sulik, KK; Charness, ME				Chen, SY; Wilkemeyer, MF; Sulik, KK; Charness, ME			Octanol antagonism of ethanol teratogenesis	FASEB JOURNAL			English	Article						fetal alcohol syndrome; L1 cell adhesion molecule; alcohol, ethyl; fetal development; apoptosis	FETAL ALCOHOL SYNDROME; CEREBELLAR GRANULE NEURONS; ADHESION MOLECULES L1; CELL-CELL ADHESION; NEURAL CREST CELLS; POTASSIUM CHANNELS; FREE-RADICALS; DEATH; INHIBITION; APOPTOSIS	Alcohol may cause birth defects in part by disrupting the developmentally critical L1 cell adhesion molecule. Because 1-octanol antagonizes ethanol inhibition of L1-mediated cell adhesion, we asked whether 1-octanol also prevents ethanol teratogenicity. L1 was detected in control mouse embryos as early as gestational day 8 (GD8), an early stage of vulnerability to ethanol teratogenesis. Culture of GD8 embryos with ethanol increased apoptotic cell death and decreased numbers of somite pairs. 1-Octanol markedly reduced both ethanol effects. The paradoxical inhibition of ethanol teratogenicity by a longer chain 1-alcohol suggests a strategy for developing compounds that prevent alcohol-related birth defects.	Univ N Carolina, Bowles Ctr Alcohol Studies, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Dept Cell Biol & Anat, Chapel Hill, NC 27599 USA; VA Boston Healthcare Syst, Neurol Serv, W Roxbury, MA 02132 USA; Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Neurol, Boston, MA 02115 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Charness, ME (corresponding author), Harvard Med Sch, VA Boston Healthcare Syst, Dept Neurol 127, 1400 VFW Pkwy, W Roxbury, MA 02132 USA.	mcharness@hms.harvard.edu		Charness, Michael/0000-0002-3301-8966				BATTIFORA H, 1995, ADV PATHOL LAB MED, V8, P101; Bearer CF, 1999, J BIOL CHEM, V274, P13264, DOI 10.1074/jbc.274.19.13264; Bhave SV, 1997, J NEUROCHEM, V68, P578, DOI 10.1046/j.1471-4159.1997.68020578.x; Bhave SV, 1999, J NEUROSCI, V19, P3277, DOI 10.1523/jneurosci.19-09-03277.1999; Cartwright MM, 1998, ALCOHOL CLIN EXP RES, V22, P142, DOI 10.1097/00000374-199802000-00019; Cartwright MM, 1995, ALCOHOL CLIN EXP RES, V19, P1454, DOI 10.1111/j.1530-0277.1995.tb01007.x; CHARNESS ME, 1994, J BIOL CHEM, V269, P9304; Chen S, 1999, J NEUROBIOL, V38, P428, DOI 10.1002/(SICI)1097-4695(19990215)38:3<428::AID-NEU10>3.0.CO;2-6; Chen SY, 1996, ALCOHOL CLIN EXP RES, V20, P1071, DOI 10.1111/j.1530-0277.1996.tb01948.x; Chu BS, 1997, ALCOHOL CLIN EXP RES, V21, P1103, DOI 10.1097/00000374-199709000-00025; Cui SJ, 1997, ALCOHOL CLIN EXP RES, V21, P1121, DOI 10.1111/j.1530-0277.1997.tb04262.x; DAVIS WL, 1990, J CRAN GENET DEV BIO, V10, P277; Diamond I, 1997, PHYSIOL REV, V77, P1, DOI 10.1152/physrev.1997.77.1.1; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; Frisch SM, 1999, CURR BIOL, V9, P1047, DOI 10.1016/S0960-9822(99)80455-2; Ikonomidou C, 2000, SCIENCE, V287, P1056, DOI 10.1126/science.287.5455.1056; Kamiguchi H, 1998, J NEUROSCI, V18, P3749, DOI 10.1523/jneurosci.18-10-03749.1998; KOTCH LE, 1992, TERATOLOGY, V46, P323, DOI 10.1002/tera.1420460403; KOTCH LE, 1992, AM J MED GENET, V44, P168, DOI 10.1002/ajmg.1320440210; KOTCH LE, 1992, INT J DEV NEUROSCI, V10, P273, DOI 10.1016/0736-5748(92)90016-S; KOTCH LE, 1995, TERATOLOGY, V52, P128, DOI 10.1002/tera.1420520304; Lewohl JM, 1999, NAT NEUROSCI, V2, P1084, DOI 10.1038/16012; Li AE, 1999, CIRC RES, V85, P304, DOI 10.1161/01.RES.85.4.304; Liesi P, 1997, J NEUROSCI RES, V48, P439, DOI 10.1002/(SICI)1097-4547(19970601)48:5<439::AID-JNR5>3.0.CO;2-F; Minami K, 1997, J PHARMACOL EXP THER, V281, P1136; Mitchell JJ, 1999, ALCOHOL, V17, P163, DOI 10.1016/S0741-8329(98)00051-2; MOSCOSO LM, 1995, J COMP NEUROL, V352, P321, DOI 10.1002/cne.903520302; NAKAHIRO M, 1991, J PHARMACOL EXP THER, V259, P235; Ramanathan R, 1996, J CELL BIOL, V133, P381, DOI 10.1083/jcb.133.2.381; REID RA, 1992, J MOL NEUROSCI, V3, P127, DOI 10.1007/BF02919404; SADLER TW, 1979, J EMBRYOL EXP MORPH, V49, P17; SADLER TW, 1984, PHARMACOL REV, V36, P1455; SULIK KK, 1981, SCIENCE, V214, P936, DOI 10.1126/science.6795717; Takeda Y, 1996, J NEUROCHEM, V66, P2338; Vallejo Y, 1997, J BIOL CHEM, V272, P12244, DOI 10.1074/jbc.272.18.12244; WEST JR, 1990, ALCOHOL CLIN EXP RES, V14, P813, DOI 10.1111/j.1530-0277.1990.tb01820.x; Wilkemeyer MF, 1999, ALCOHOL CLIN EXP RES, V23, P1711, DOI 10.1097/00000374-199911000-00002; Wilkemeyer MF, 1998, J NEUROCHEM, V71, P2382; Wilkemeyer WF, 2000, P NATL ACAD SCI USA, V97, P3690, DOI 10.1073/pnas.97.7.3690; Yamamoto Y, 1999, DEV BIOL, V214, P60, DOI 10.1006/dbio.1999.9413; Zhang FX, 1998, J NEUROCHEM, V71, P196, DOI 10.1046/j.1471-4159.1998.71010196.x	41	48	49	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY 29	2001	15	7					1649	+		10.1096/fj.00-0862fje	http://dx.doi.org/10.1096/fj.00-0862fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519CQ	11427515				2022-12-25	WOS:000173707700011
J	Lutzker, SG; Mathew, R; Taller, DR				Lutzker, SG; Mathew, R; Taller, DR			A p53 dose-response relationship for sensitivity to DNA damage in isogenic teratocarcinoma cells	ONCOGENE			English	Article						p53; apoptosis; DNA damage; teratocarcinoma cells	APOPTOSIS; GENE; EXPRESSION; CISPLATIN; PROTEIN; TUMORS	Teratocarcinomas are tumors that arise from primordial germ cells and are readily curable with DNA-damaging chemotherapeutic drugs. Teratocarcinoma cells ex vivo in tissue culture are also relatively chemosensitive and undergo apoptotic death in response to DNA damage, We have previously hypothesized that the observed sensitivity of this tumor type to DNA damage is related to high basal expression of wild-type p53 protein, We have now addressed this issue by characterizing the DNA damage response of isogenic teratocarcinoma cells that differ only in their level of expression of wild-type p53 protein, We find a clear p53 dose-response relationship in these cells for rapid apoptosis following DNA damage that correlates with diminished colony formation in clonogenic survival assays. These results suggest that strategies to increase basal wild-type p53 protein expression prior to treatment with DNA-damaging drugs may improve curability in other tumor types. Oncogene (2001) 20, 2982-2986.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Med, New Brunswick, NJ 08901 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, New Brunswick, NJ 08901 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Genet & Microbiol, New Brunswick, NJ 08901 USA; Univ Med & Dent New Jersey, Inst Canc, New Brunswick, NJ 08901 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center	Lutzker, SG (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Med, New Brunswick, NJ 08901 USA.							ALMON E, 1993, DEV BIOL, V156, P107, DOI 10.1006/dbio.1993.1062; Brown JM, 1999, CANCER RES, V59, P1391; Burger H, 1999, INT J CANCER, V81, P620, DOI 10.1002/(SICI)1097-0215(19990517)81:4<620::AID-IJC19>3.3.CO;2-J; Chresta CM, 1996, CANCER RES, V56, P1834; Corbet SW, 1999, ONCOGENE, V18, P1537, DOI 10.1038/sj.onc.1202436; Eid H, 1997, ANTICANCER RES, V17, P2663; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; HALE TK, 1995, NUCLEIC ACIDS RES, V23, P663, DOI 10.1093/nar/23.4.663; Houldsworth J, 1998, ONCOGENE, V16, P2345, DOI 10.1038/sj.onc.1201770; Lutzker SG, 1998, MOL MED TODAY, V4, P404, DOI 10.1016/S1357-4310(98)01329-X; Lutzker SG, 1998, APMIS, V106, P85, DOI 10.1111/j.1699-0463.1998.tb01323.x; Lutzker SG, 1996, NAT MED, V2, P804, DOI 10.1038/nm0796-804; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; NICOL CJ, 1995, NAT GENET, V10, P181, DOI 10.1038/ng0695-181; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Roy B, 1996, ONCOGENE, V13, P2359; Sabapathy K, 1997, EMBO J, V16, P6217, DOI 10.1093/emboj/16.20.6217; SCHMID P, 1991, DEVELOPMENT, V113, P857; Schmidt-Kastner PK, 1998, ONCOGENE, V16, P3003, DOI 10.1038/sj.onc.1201835; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 1999, EMBO J, V18, P1815, DOI 10.1093/emboj/18.7.1815; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Zamble DB, 1998, P NATL ACAD SCI USA, V95, P6163, DOI 10.1073/pnas.95.11.6163	25	34	36	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 24	2001	20	23					2982	2986		10.1038/sj.onc.1204394	http://dx.doi.org/10.1038/sj.onc.1204394			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	435VA	11420711				2022-12-25	WOS:000168901800014
J	Delmas, C; Manenti, S; Boudjelal, A; Peyssonnaux, C; Eychene, A; Darbon, JM				Delmas, C; Manenti, S; Boudjelal, A; Peyssonnaux, C; Eychene, A; Darbon, JM			The p42/p44 mitogen-activated protein kinase activation triggers p27(Kip1) degradation independently of CDK2/cyclin E in NIH 3T3 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-MEDIATED DEGRADATION; DEPENDENT-KINASE; GROWTH-FACTOR; S PHASE; DOWN-REGULATION; CDK INHIBITOR; SIGNAL-TRANSDUCTION; RESTRICTION POINT; CYCLIN E-CDK2; UP-REGULATION	The p42/p44 mitogen-activated protein (MAP) kinase is stimulated by various mitogenic stimuli, and its sustained activation is necessary for cell cycle G(1) progression and G(1)/S transition. G(1) progression and G(1)/S transition also depend on sequential cyclin-dependent kinase (CDK) activation. Here, we demonstrate that MAP kinase inhibition leads to accumulation of the CDK inhibitor P27(Kip1) in NIH 3T3 cells. Blocking the proteasome-dependent degradation of p27(Kip1) impaired this accumulation, suggesting that MAP kinase does not act on p271(Kip1) protein synthesis. In the absence of extracellular signals (growth factors or cell adhesion), genetic activation of MAP kinase decreased the expression of P27(Kip1) as assessed by cotransfection experiments and by immunofluorescence detection. Importantly, MAP kinase activation also decreased the expression of a p27(Kip1) mutant, which cannot be phosphorylated by CDK2, suggesting that MAP kinase-dependent p27(Kip1) regulation is CDK2-independent. Accordingly, expression of dominant-negative CDK2 did not impair the down-regulation of p27(Kip1) induced by MAP kinase activation. These data demonstrate that the MAP kinase pathway regulates p27(Kip1) expression in fibroblasts essentially through a degradation mechanism, independently of p27(Kip1) phosphorylation by CDK2. This strengthens the role of this CDK inhibitor as a key effector of G(1) growth arrest, whose expression can be controlled by extracellular stimuli-dependent signaling pathways.	Univ Toulouse 3, Lab Biol Cellulaire & Mol Controle Proliferat, CNRS, UMR 5088, F-31062 Toulouse, France; Inst Curie, CNRS, UMR 146, Lab 110, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Manenti, S (corresponding author), Univ Toulouse 3, Lab Biol Cellulaire & Mol Controle Proliferat, CNRS, UMR 5088, 118 Route Narbonne, F-31062 Toulouse, France.	manenti@cict.fr	Peyssonnaux, Carole/L-4057-2017; Eychene, Alain/M-8838-2017; Peyssonnaux, Carole/GLU-5786-2022; manenti, stephane/P-1518-2014	Peyssonnaux, Carole/0000-0002-1392-8225; manenti, stephane/0000-0002-4793-3196; EYCHENE, Alain/0000-0002-6818-7225				Agrawal D, 1996, MOL CELL BIOL, V16, P4327; Bottazzi ME, 1997, TRENDS CELL BIOL, V7, P348, DOI 10.1016/S0962-8924(97)01114-8; Busse D, 2000, J BIOL CHEM, V275, P6987, DOI 10.1074/jbc.275.10.6987; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Casagrande F, 1998, FEBS LETT, V422, P385, DOI 10.1016/S0014-5793(98)00043-X; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; Collado M, 2000, J BIOL CHEM, V275, P21960, DOI 10.1074/jbc.M000759200; Eymin B, 1999, ONCOGENE, V18, P4839, DOI 10.1038/sj.onc.1202860; GANG W, 1999, ONCOGENE, V18, P5204; Greulich H, 1998, J BIOL CHEM, V273, P13280, DOI 10.1074/jbc.273.21.13280; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Hirai A, 1997, J BIOL CHEM, V272, P13; Hu WM, 1999, J BIOL CHEM, V274, P3396, DOI 10.1074/jbc.274.6.3396; Ishida N, 2000, J BIOL CHEM, V275, P25146, DOI 10.1074/jbc.M001144200; Kamiyama J, 1999, FEBS LETT, V455, P281, DOI 10.1016/S0014-5793(99)00899-6; Kerkhoff E, 1997, MOL CELL BIOL, V17, P2576, DOI 10.1128/MCB.17.5.2576; Ladha MH, 1998, MOL CELL BIOL, V18, P6605, DOI 10.1128/MCB.18.11.6605; Le Gall M, 1998, ONCOGENE, V17, P1271, DOI 10.1038/sj.onc.1202057; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; Lin TH, 1997, J BIOL CHEM, V272, P8849; Lisztwan J, 1998, EMBO J, V17, P368, DOI 10.1093/emboj/17.2.368; Loubat A, 1999, ONCOGENE, V18, P3324, DOI 10.1038/sj.onc.1202668; Marshall C, 1999, CURR OPIN CELL BIOL, V11, P732, DOI 10.1016/S0955-0674(99)00044-7; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Millard SS, 1997, J BIOL CHEM, V272, P7093, DOI 10.1074/jbc.272.11.7093; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; Moro A, 2000, BIOCHEM BIOPH RES CO, V269, P31, DOI 10.1006/bbrc.2000.2256; Muller D, 2000, EMBO J, V19, P2168, DOI 10.1093/emboj/19.10.2168; Muller D, 1997, ONCOGENE, V15, P2561, DOI 10.1038/sj.onc.1201440; Orend G, 1998, ONCOGENE, V16, P2575, DOI 10.1038/sj.onc.1201791; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; Papin C, 1998, J BIOL CHEM, V273, P24939, DOI 10.1074/jbc.273.38.24939; Patel YM, 2000, J BIOL CHEM, V275, P17653, DOI 10.1074/jbc.M910445199; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Ravi RK, 1998, J CLIN INVEST, V101, P153, DOI 10.1172/JCI831; Renshaw MW, 1997, EMBO J, V16, P5592, DOI 10.1093/emboj/16.18.5592; Rivard N, 1999, AM J PHYSIOL-CELL PH, V277, pC652, DOI 10.1152/ajpcell.1999.277.4.C652; Rivard N, 1996, J BIOL CHEM, V271, P18337, DOI 10.1074/jbc.271.31.18337; Servant MJ, 2000, J CELL BIOL, V148, P543, DOI 10.1083/jcb.148.3.543; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; Sgambato A, 2000, J CELL PHYSIOL, V183, P18, DOI 10.1002/(SICI)1097-4652(200004)183:1<18::AID-JCP3>3.0.CO;2-S; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shirane M, 1999, J BIOL CHEM, V274, P13886, DOI 10.1074/jbc.274.20.13886; Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Takuwa N, 1997, MOL CELL BIOL, V17, P5348, DOI 10.1128/MCB.17.9.5348; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Treinies I, 1999, MOL CELL BIOL, V19, P321; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Weber JD, 1997, J BIOL CHEM, V272, P32966, DOI 10.1074/jbc.272.52.32966; Yang HY, 2000, J BIOL CHEM, V275, P24735, DOI 10.1074/jbc.C000147200	58	56	57	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					34958	34965		10.1074/jbc.M101714200	http://dx.doi.org/10.1074/jbc.M101714200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11418594	hybrid			2022-12-25	WOS:000171024600082
J	Gervois, P; Vu-Dac, N; Kleemann, R; Kockx, M; Dubois, G; Laine, B; Kosykh, V; Fruchart, JC; Kooistra, T; Staels, B				Gervois, P; Vu-Dac, N; Kleemann, R; Kockx, M; Dubois, G; Laine, B; Kosykh, V; Fruchart, JC; Kooistra, T; Staels, B			Negative regulation of human fibrinogen gene expression by peroxisome proliferator-activated receptor alpha agonists via inhibition of CCAAT box/enhancer-binding protein beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TRANSCRIPTION FACTOR; PPAR-ALPHA; ALPHA-1-ACID GLYCOPROTEIN; 5-FLANKING REGION; RAT-LIVER; GAMMA; CYTOKINE; ATHEROSCLEROSIS; PROMOTER	Fibrinogen is a coagulation factor and an acute phase reactant up-regulated by inflammatory cytokines, such as interleukin 6 (IL-6). Elevated plasma fibrinogen levels are associated with coronary heart diseases. Fibrates are clinically used hypolipidemic drugs that act via the nuclear receptor peroxisome proliferator-activated receptor a (PPA-R alpha). In addition, most fibrates also reduce plasma fibrinogen levels, but the molecular mechanism is unknown. In this study, we demonstrate that fibrates decrease basal and IL-6-stimulated expression of the human fibrinogen-beta gene in human primary hepatocytes and hepatoma HepG2 cells. Fibrates diminish basal and IL-6-induced fibrinogen-beta promoter activity, and this effect is enhanced in the presence of co-transfected PPAR alpha. Site-directed mutagenesis experiments demonstrate that PPAR alpha activators decrease human fibrinogen-beta promoter activity via the CCAAT box/enhancer-binding protein (C/EBP) response element. Co-transfection of the transcriptional intermediary factor glucocorticoid receptor-interacting protein 1/transc riptional intermediary factor 2 (GRIP1/TIF2) enhances fibrinogen-beta gene transcription and alleviates the repressive effect of PPAR alpha. Co-immunoprecipitation experiments demonstrate that PPAR alpha and GRIP1/TIF2 physically interact in vivo in human liver. These data demonstrate that PPARa agonists repress human fibrinogen gene expression by interference with the C/EBP beta pathway through titration of the coactivator GRIP1/TIF2. We observed that the anti-inflammatory action of PPAR alpha is not restricted to fibrinogen but also applies to other acute phase genes containing a C/EBP response element; it also occurs under conditions in which the stimulating action of IL-6 is potentiated by dexamethasone. These findings identify a novel molecular mechanism of negative gene regulation by PPAR alpha and reveal the direct implication of PPAR alpha in the modulation of the inflammatory gene response in the liver.	Inst Pasteur, INSERM, U545, Dept Atherosclerose, F-59019 Lille, France; Univ Lille 2, Fac Pharm, F-59019 Lille, France; TNO, Gaubius Lab, NL-2301 CE Leiden, Netherlands; Fac Med H Warembourg, INSERM, U459, Biol Cellulaire Lab, F-59045 Lille, France; Cardiol Res Complex, Moscow 721552, Russia	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille; Universite de Lille - ISITE; Universite de Lille; Netherlands Organization Applied Science Research; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille; National Medical Research Center of Cardiology	Gervois, P (corresponding author), Inst Pasteur, INSERM, U545, Dept Atherosclerose, F-59019 Lille, France.	philippe.gervois@pasteur-lille.fr; Bart.Staels@pasteur-lille.fr	Staels, Bart/N-9497-2016	Staels, Bart/0000-0002-3784-1503				ANDERSON GM, 1993, J BIOL CHEM, V268, P22650; [Anonymous], 1994, CIRCULATION, V89, P1329; BAUMANN H, 1992, J BIOL CHEM, V267, P19744; BAUMANN H, 1989, ANN NY ACAD SCI, V557, P280; BAUMANN H, 1983, J BIOL CHEM, V258, P563; BAUMANN H, 1991, J BIOL CHEM, V266, P20390; Chang CJ, 1998, MOL CELL BIOL, V18, P5880, DOI 10.1128/MCB.18.10.5880; Colville-Nash PR, 1998, J IMMUNOL, V161, P978; Corton JC, 1998, MOL PHARMACOL, V54, P463, DOI 10.1124/mol.54.3.463; COURTOIS G, 1988, P NATL ACAD SCI USA, V85, P7937, DOI 10.1073/pnas.85.21.7937; DALMON J, 1993, MOL CELL BIOL, V13, P1183, DOI 10.1128/MCB.13.2.1183; Delerive P, 1999, J BIOL CHEM, V274, P32048, DOI 10.1074/jbc.274.45.32048; Devchand PR, 1996, NATURE, V384, P39, DOI 10.1038/384039a0; FOWLKES DM, 1984, P NATL ACAD SCI-BIOL, V81, P2313, DOI 10.1073/pnas.81.8.2313; Frick MH, 1997, CIRCULATION, V96, P2137; Gervois P, 1999, MOL ENDOCRINOL, V13, P1535, DOI 10.1210/me.13.9.1535; Gervois P, 2000, CLIN CHEM LAB MED, V38, P3, DOI 10.1515/CCLM.2000.002; HATTORI M, 1990, P NATL ACAD SCI USA, V87, P2364, DOI 10.1073/pnas.87.6.2364; HEINRICH J, 1994, ARTERIOSCLER THROMB, V14, P54, DOI 10.1161/01.ATV.14.1.54; Hokanson J E, 1996, J Cardiovasc Risk, V3, P213, DOI 10.1097/00043798-199604000-00014; Hollenberg AN, 1997, J BIOL CHEM, V272, P5283, DOI 10.1074/jbc.272.8.5283; HU CH, 1995, J BIOL CHEM, V270, P28342; HUBER P, 1990, J BIOL CHEM, V265, P5695; KANT JA, 1985, P NATL ACAD SCI USA, V82, P2344, DOI 10.1073/pnas.82.8.2344; Kockx M, 1999, BLOOD, V93, P2991; LIU ZY, 1995, J BIOL CHEM, V270, P7580, DOI 10.1074/jbc.270.13.7580; Madej A, 1998, INT J CLIN PHARM TH, V36, P345; Marx N, 1999, CIRCULATION, V99, P3125, DOI 10.1161/01.CIR.99.24.3125; MASIAKOWSKI P, 1982, NUCLEIC ACIDS RES, V10, P7895, DOI 10.1093/nar/10.24.7895; MEADE TW, 1986, LANCET, V2, P533, DOI 10.1016/S0140-6736(86)90111-X; MIZUGUCHI J, 1995, J BIOL CHEM, V270, P28350; MORGAN JG, 1988, MOL CELL BIOL, V8, P2628, DOI 10.1128/MCB.8.6.2628; NONAKA M, 1990, MOL CELL BIOL, V10, P6283, DOI 10.1128/MCB.10.12.6283; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; RON D, 1992, J CLIN INVEST, V89, P223, DOI 10.1172/JCI115566; ROY SN, 1990, J BIOL CHEM, V265, P6389; Ruotolo G, 1998, J AM COLL CARDIOL, V32, P1648, DOI 10.1016/S0735-1097(98)00442-2; SIRTORI CR, 1993, CARDIOVASC DRUG THER, V7, P817, DOI 10.1007/BF00878936; Staels B, 1998, CIRCULATION, V98, P2088, DOI 10.1161/01.CIR.98.19.2088; STAELS B, 1995, J CLIN INVEST, V95, P705, DOI 10.1172/JCI117717; Staels B, 1998, NATURE, V393, P790, DOI 10.1038/31701; STAELS B, 1992, DEVELOPMENT, V115, P1035; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; WILHELMSEN L, 1984, NEW ENGL J MED, V311, P501, DOI 10.1056/NEJM198408233110804; YU S, 1987, THROMB RES, V46, P281, DOI 10.1016/0049-3848(87)90290-8; YU S, 1983, J BIOL CHEM, V258, P3407; ZHANG ZX, 1995, J BIOL CHEM, V270, P24287, DOI 10.1074/jbc.270.41.24287	47	134	138	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33471	33477		10.1074/jbc.M102839200	http://dx.doi.org/10.1074/jbc.M102839200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11418615	Green Published, hybrid			2022-12-25	WOS:000170910200026
J	Kyriakopoulou, CB; Nordvarg, H; Virtanen, A				Kyriakopoulou, CB; Nordvarg, H; Virtanen, A			A novel nuclear human poly(A) polymerase (PAP), PAP gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOGNITION PARTICLE RNA; MESSENGER-RNA; SIGNAL RECOGNITION; MULTIPLE FORMS; HUMAN GENOME; POLYADENYLATION; PURIFICATION; COMPLEX; CELLS; PHOSPHORYLATION	Poly(A) polymerase (PAP) is present in multiple forms in mammalian cells and tissues. Here we show that the 90-kDa isoform is the product of the gene PAPOLG, which is distinct from the previously identified genes for poly(A) polymerases. The 90-kDa isoform. is referred to as human PAP gamma (hsPAP gamma). hsPAP gamma shares 60% identity to human PAPII (hsPAPII) at the amino acid level. hsPAP gamma exhibits fundamental properties of a bona flde poly(A) polymerase, specificity for ATP, and cleavage and polyadenylation specificity factor/hexanucleotide-dependent polyadenylation activity. The catalytic parameters indicate similar catalytic efficiency to that of hsPAPII Mutational analysis and sequence comparison revealed that hsPAP gamma and hsPAPII have similar organization of structural and functional domains. hsPAP gamma contains a U1A protein-interacting region in its C terminus, and PAP gamma activity can be inhibited, as hsPAPII, by the U1A protein. hsPAP gamma is restricted to the nucleus as revealed by in situ staining and by transfection experiments. Based on this and previous studies, it is obvious that multiple isoforms of PAP are generated by three distinct mechanisms: gene duplication, alternative RNA processing, and post-translational modification. The exclusive nuclear localization of hsPAP gamma establishes that multiple forms of PAP are unevenly distributed in the cell, implying specialized roles for the various isoforms.	Uppsala Univ, Dept Cell & Mol Biol, SE-75124 Uppsala, Sweden; Uppsala Univ, Rudbeck Lab, Dept Genet & Pathol, SE-75185 Uppsala, Sweden	Uppsala University; Uppsala University	Virtanen, A (corresponding author), Uppsala Univ, Dept Cell & Mol Biol, Box 596, SE-75124 Uppsala, Sweden.	anders.virtanen@icm.uu.se						Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ASTROM A, 1991, EUR J BIOCHEM, V202, P765, DOI 10.1111/j.1432-1033.1991.tb16431.x; BALLANTYNE S, 1995, RNA, V1, P64; Barabino SML, 1999, CELL, V99, P9, DOI 10.1016/S0092-8674(00)80057-4; Bard J, 2000, SCIENCE, V289, P1346, DOI 10.1126/science.289.5483.1346; BIENROTH S, 1993, EMBO J, V12, P585, DOI 10.1002/j.1460-2075.1993.tb05690.x; BIENROTH S, 1991, J BIOL CHEM, V266, P19768; Bond GL, 2000, MOL CELL BIOL, V20, P5310, DOI 10.1128/MCB.20.14.5310-5320.2000; BREATHNACH R, 1978, P NATL ACAD SCI USA, V75, P4853, DOI 10.1073/pnas.75.10.4853; Colgan DF, 1996, NATURE, V384, P282, DOI 10.1038/384282a0; Colgan DF, 1998, EMBO J, V17, P1053, DOI 10.1093/emboj/17.4.1053; GEBAUER F, 1995, MOL CELL BIOL, V15, P1422; Gunderson SI, 1997, GENE DEV, V11, P761, DOI 10.1101/gad.11.6.761; Gunnewiek JMTK, 2000, MOL CELL BIOL, V20, P2209, DOI 10.1128/MCB.20.6.2209-2217.2000; Jans DA, 2000, BIOESSAYS, V22, P532, DOI 10.1002/(SICI)1521-1878(200006)22:6<532::AID-BIES6>3.0.CO;2-O; JAREBORG N, 1991, J GEN VIROL, V72, P2269, DOI 10.1099/0022-1317-72-9-2269; Kashiwabara S, 2000, DEV BIOL, V228, P106, DOI 10.1006/dbio.2000.9894; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lee YJ, 2000, FEBS LETT, V487, P287, DOI 10.1016/S0014-5793(00)02367-X; LINGNER J, 1991, NATURE, V354, P496, DOI 10.1038/354496a0; Martin G, 1996, EMBO J, V15, P2593, DOI 10.1002/j.1460-2075.1996.tb00617.x; Martin G, 2000, EMBO J, V19, P4193, DOI 10.1093/emboj/19.16.4193; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Mitchell P, 2000, CURR OPIN GENET DEV, V10, P193, DOI 10.1016/S0959-437X(00)00063-0; Perumal K, 2001, J BIOL CHEM, V276, P21791, DOI 10.1074/jbc.M101905200; PETTERSSON I, 1984, J BIOL CHEM, V259, P5907; RAABE T, 1994, MOL CELL BIOL, V14, P2946, DOI 10.1128/MCB.14.5.2946; RAABE T, 1991, NATURE, V353, P229, DOI 10.1038/353229a0; RYNER LC, 1989, MOL CELL BIOL, V9, P4229, DOI 10.1128/MCB.9.10.4229; Sachs AB, 2000, NAT STRUCT BIOL, V7, P356, DOI 10.1038/75120; Schul W, 1996, EMBO J, V15, P2883, DOI 10.1002/j.1460-2075.1996.tb00649.x; Schul W, 1998, EXP CELL RES, V238, P1, DOI 10.1006/excr.1997.3808; SHEETS MD, 1989, GENE DEV, V3, P1401, DOI 10.1101/gad.3.9.1401; Sidow A, 1996, CURR OPIN GENET DEV, V6, P715, DOI 10.1016/S0959-437X(96)80026-8; Sinha R, 1999, J BIOL CHEM, V274, P30826, DOI 10.1074/jbc.274.43.30826; SKOLNIKDAVID H, 1987, GENE DEV, V1, P672, DOI 10.1101/gad.1.7.672; Skrabanek L, 1998, CURR OPIN GENET DEV, V8, P694, DOI 10.1016/S0959-437X(98)80039-7; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; THURESSON AC, 1994, P NATL ACAD SCI USA, V91, P979, DOI 10.1073/pnas.91.3.979; TSIAPALIS CM, 1975, J BIOL CHEM, V250, P4486; Tupler R, 2001, NATURE, V409, P832, DOI 10.1038/35057011; VASSALLI JD, 1995, CURR BIOL, V5, P476, DOI 10.1016/S0960-9822(95)00095-9; WAHLE E, 1991, J BIOL CHEM, V266, P3131; WAHLE E, 1991, EMBO J, V10, P4251, DOI 10.1002/j.1460-2075.1991.tb05003.x; Wahle E, 1999, FEMS MICROBIOL REV, V23, P277, DOI 10.1016/S0168-6445(99)00008-X; Wittmann T, 1997, BBA-GENE STRUCT EXPR, V1350, P293, DOI 10.1016/S0167-4781(96)00164-9; Zhao J, 1999, MICROBIOL MOL BIOL R, V63, P405, DOI 10.1128/MMBR.63.2.405-445.1999; Zhao WQ, 1998, MOL CELL BIOL, V18, P5010, DOI 10.1128/MCB.18.9.5010; Zhao WQ, 1996, MOL CELL BIOL, V16, P2378	50	48	52	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33504	33511		10.1074/jbc.M104599200	http://dx.doi.org/10.1074/jbc.M104599200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11431479	hybrid			2022-12-25	WOS:000170910200030
J	Bellin, RM; Huiatt, TW; Critchley, DR; Robson, RM				Bellin, RM; Huiatt, TW; Critchley, DR; Robson, RM			Synemin may function to directly link muscle cell intermediate filaments to both myofibrillar Z-lines and costameres	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DESMIN KNOCK-OUT; PROTEIN SYNEMIN; ALPHA-ACTININ; SKELETAL-MUSCLE; INTRAMOLECULAR ASSOCIATION; MOLECULAR CHARACTERISTICS; VIMENTIN FILAMENTS; FORCE TRANSMISSION; CARDIAC-MUSCLE; CROSS-LINKING	Synemin is a large intermediate filament (IF) protein that has been identified in all types of muscle cells in association with desmin- and/or vimentin-containing IFs. Our previous studies (Bellin, R. M., Sernett, S. W., Becker, B., Ip, W., Huiatt, T. W., and Robson, R. M. (1999) J. Biol. Chem. 274, 29493-29499) demonstrated that synemin forms heteropolymeric IFs with major IF proteins and contains a binding site for the myofibrillar Z-line protein alpha -actinin. By utilizing blot overlay assays, we show herein that synemin also interacts with the costameric protein vinculin. Furthermore, extensive assays utilizing the Gal4 yeast two-hybrid system demonstrate interactions of synemin with desmin and vimentin and additionally define more precisely the protein subdomains involved in the synemin/alpha -actinin and synemin/vinculin interact-ions. The C-terminal similar to 300-amino acid region of synemin binds to the N-terminal head and central rod domains of alpha -actinin and the similar to 150-amino acid C-terminal tail of vinculin. Overall, these interactions indicate that synemin may anchor IFs to myofibrillar Z-lines via interactions with alpha -actinin and to costameres at the sarcolemma via interactions with vinculin and/or alpha -actinin. These linkages would enable the IFs to directly link all cellular myofibrils and to anchor the peripheral layer of myofibrils to the costameres.	Iowa State Univ, Muscle Biol Grp, Dept Biochem Biophys, Ames, IA 50011 USA; Iowa State Univ, Muscle Biol Grp, Dept Biol Mol, Ames, IA 50011 USA; Iowa State Univ, Muscle Biol Grp, Dept Anim Sci, Ames, IA 50011 USA; Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England	Iowa State University; Iowa State University; Iowa State University; University of Leicester	Robson, RM (corresponding author), Iowa State Univ, Muscle Biol Grp, Dept Biochem Biophys, 3110 Mol Biol Bldg, Ames, IA 50011 USA.	rmrobson@iastate.edu						Agbulut O, 1996, BIOL CELL, V88, P131, DOI 10.1016/S0248-4900(97)83528-9; ARIMURA C, 1988, EUR J BIOCHEM, V177, P649, DOI 10.1111/j.1432-1033.1988.tb14419.x; Bakolitsa C, 1999, CELL, V99, P603, DOI 10.1016/S0092-8674(00)81549-4; BARON MD, 1987, J BIOL CHEM, V262, P17623; BECKER B, 1995, BIOCHEM BIOPH RES CO, V213, P796, DOI 10.1006/bbrc.1995.2200; BELKIN AM, 1988, J CELL BIOL, V107, P545, DOI 10.1083/jcb.107.2.545; Bellin RM, 1999, J BIOL CHEM, V274, P29493, DOI 10.1074/jbc.274.41.29493; BELLIN RM, 1999, GUIDEBOOK CYTOSKELET, P322; Bilak SR, 1998, ARCH BIOCHEM BIOPHYS, V355, P63, DOI 10.1006/abbi.1998.0702; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Capetanaki Y, 1997, CELL STRUCT FUNCT, V22, P103, DOI 10.1247/csf.22.103; Carlsson L, 2000, HISTOCHEM CELL BIOL, V114, P39; Carpenter DA, 1996, J CELL SCI, V109, P2493; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; Coulombe PA, 2000, TRENDS CELL BIOL, V10, P420, DOI 10.1016/S0962-8924(00)01828-6; CRAIG SW, 1983, CELL MOTIL CYTOSKEL, V3, P449, DOI 10.1002/cm.970030513; Critchley DR, 1999, BIOCHEM SOC SYMP, V65, P79; DANOWSKI BA, 1992, J CELL BIOL, V118, P1411, DOI 10.1083/jcb.118.6.1411; Djinovic-Carugo K, 1999, CELL, V98, P537, DOI 10.1016/S0092-8674(00)81981-9; EVANS RR, 1984, J BIOL CHEM, V259, P3916; Foisner R, 1997, BIOESSAYS, V19, P297, DOI 10.1002/bies.950190407; Fuchs E, 1998, SCIENCE, V279, P514, DOI 10.1126/science.279.5350.514; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; Fuchs E, 1999, CELL, V98, P547, DOI 10.1016/S0092-8674(00)80041-0; Gilmore AP, 1996, NATURE, V381, P531, DOI 10.1038/381531a0; GINIGER E, 1987, NATURE, V330, P670, DOI 10.1038/330670a0; GRANGER BL, 1979, CELL, V18, P1053, DOI 10.1016/0092-8674(79)90218-6; GRANGER BL, 1980, CELL, V22, P727, DOI 10.1016/0092-8674(80)90549-8; GRANGER BL, 1982, J CELL BIOL, V92, P299, DOI 10.1083/jcb.92.2.299; GRANGER BL, 1984, MOL CELL BIOL, V4, P1943, DOI 10.1128/MCB.4.10.1943; GRANGER BL, 1982, CELL, V30, P263, DOI 10.1016/0092-8674(82)90032-0; Hemken PM, 1997, J BIOL CHEM, V272, P32489, DOI 10.1074/jbc.272.51.32489; Herrmann H, 1996, J MOL BIOL, V264, P933, DOI 10.1006/jmbi.1996.0688; Herrmann H, 1999, J MOL BIOL, V286, P1403, DOI 10.1006/jmbi.1999.2528; Herrmann H, 2000, CURR OPIN CELL BIOL, V12, P79, DOI 10.1016/S0955-0674(99)00060-5; Herrmann H, 1998, CURR OPIN STRUC BIOL, V8, P177, DOI 10.1016/S0959-440X(98)80035-3; Herrmann H, 1998, Subcell Biochem, V31, P319; Hijikata T, 1999, J CELL SCI, V112, P867; Imanaka-Yoshida K, 1999, CELL MOTIL CYTOSKEL, V42, P1; ImanakaYoshida K, 1996, CELL MOTIL CYTOSKEL, V33, P263, DOI 10.1002/(SICI)1097-0169(1996)33:4<263::AID-CM3>3.0.CO;2-A; Johnson RP, 2000, J BIOL CHEM, V275, P95, DOI 10.1074/jbc.275.1.95; JOHNSON RP, 1995, BIOCHEM BIOPH RES CO, V210, P159, DOI 10.1006/bbrc.1995.1641; JOHNSON RP, 1994, J BIOL CHEM, V269, P12611; Kowalczyk AP, 1999, INT REV CYTOL, V185, P237; LAZARIDES E, 1980, NATURE, V283, P249, DOI 10.1038/283249a0; LETAI A, 1995, P NATL ACAD SCI USA, V92, P92, DOI 10.1073/pnas.92.1.92; Li ZL, 1996, DEV BIOL, V175, P362, DOI 10.1006/dbio.1996.0122; Li ZL, 1997, J CELL BIOL, V139, P129, DOI 10.1083/jcb.139.1.129; Meng JJ, 1996, J BIOL CHEM, V271, P1599, DOI 10.1074/jbc.271.3.1599; Meng JJ, 1997, J BIOL CHEM, V272, P21495, DOI 10.1074/jbc.272.34.21495; MENG JJ, 1994, J BIOL CHEM, V269, P18679; Meng JJ, 2001, METH MOL B, V161, P255; Milner DJ, 1996, J CELL BIOL, V134, P1255, DOI 10.1083/jcb.134.5.1255; North AJ, 1999, J CELL SCI, V112, P4325; OTEY CA, 1993, J BIOL CHEM, V268, P21193; PARDO JV, 1983, P NATL ACAD SCI-BIOL, V80, P1008, DOI 10.1073/pnas.80.4.1008; PRICE MG, 1983, J CELL BIOL, V97, P1860, DOI 10.1083/jcb.97.6.1860; Reipert S, 1999, EXP CELL RES, V252, P479, DOI 10.1006/excr.1999.4626; RICHARDSON FL, 1981, EUR J CELL BIOL, V26, P91; Robson RM, 1989, CURR OPIN CELL BIOL, V1, P36, DOI 10.1016/S0955-0674(89)80034-1; SANDOVAL IV, 1983, J BIOL CHEM, V258, P2568; Schmidt JM, 1999, ARCH BIOCHEM BIOPHYS, V366, P139, DOI 10.1006/abbi.1999.1204; Schroder R, 1999, EUR J CELL BIOL, V78, P288, DOI 10.1016/S0171-9335(99)80062-4; Schroder R, 2000, LAB INVEST, V80, P455, DOI 10.1038/labinvest.3780051; Schweitzer SC, 2001, J CELL SCI, V114, P1079; Severs NJ, 2000, BIOESSAYS, V22, P188, DOI 10.1002/(SICI)1521-1878(200002)22:2<188::AID-BIES10>3.0.CO;2-T; SHOEMAN RL, 1993, BIOESSAYS, V15, P605, DOI 10.1002/bies.950150906; SMALL JV, 1992, EUR J BIOCHEM, V208, P559, DOI 10.1111/j.1432-1033.1992.tb17220.x; STAPPENBECK TS, 1993, J CELL BIOL, V123, P691, DOI 10.1083/jcb.123.3.691; Steimle PA, 1999, J BIOL CHEM, V274, P18414, DOI 10.1074/jbc.274.26.18414; Steinbock FA, 1999, BIOL CHEM, V380, P151, DOI 10.1515/BC.1999.023; Steinert PM, 1999, J BIOL CHEM, V274, P9881, DOI 10.1074/jbc.274.14.9881; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; Strelkov SV, 2001, J MOL BIOL, V306, P773, DOI 10.1006/jmbi.2001.4442; Sultana S, 2000, GLIA, V30, P143, DOI 10.1002/(SICI)1098-1136(200004)30:2<143::AID-GLIA4>3.0.CO;2-Z; Svitkina TM, 1996, J CELL BIOL, V135, P991, DOI 10.1083/jcb.135.4.991; Thornell LE, 1997, J MOL CELL CARDIOL, V29, P2107, DOI 10.1006/jmcc.1997.0446; TOKUYASU KT, 1983, J CELL BIOL, V96, P1736, DOI 10.1083/jcb.96.6.1736; Weekes J, 1996, BIOCHEM J, V314, P827, DOI 10.1042/bj3140827; Wiche G, 1998, J CELL SCI, V111, P2477; Yuan J, 1999, ARCH BIOCHEM BIOPHYS, V363, P314, DOI 10.1006/abbi.1998.1096	82	94	96	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					32330	32337		10.1074/jbc.M104005200	http://dx.doi.org/10.1074/jbc.M104005200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11418616	hybrid			2022-12-25	WOS:000170613500115
J	Jaiswal, BS; Conti, M				Jaiswal, BS; Conti, M			Identification and functional analysis of splice variants of the germ cell soluble adenylyl cyclase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBONIC-ANHYDRASE; MAMMALIAN SPERMATOZOA; RESPONSE ELEMENT; RAT TESTIS; BICARBONATE; CREM; SPERMIOGENESIS; LOCALIZATION; SPERM; CAMP	In mammalian germ cells, cAMP signaling is dependent on two forms of adenylyl cyclase, the conventional membrane-bound ACIII and a soluble form of adenylyl cyclase (SAC). Recent elucidation of the SAC sequence indicates that this enzyme is phylogenetically distinct from the membrane-bound AC, does not interact with G proteins, and its activity is regulated by bicarbonate ions. Here we have investigated the properties and regulation of this enzyme during spermatogenesis. Two different transcripts encoding a full-length and truncated sAC were identified by reverse transcriptase-polymerase chain reaction and RNase protection analysis. The truncated sAC transcript lacks exon 11 with a premature termination of the open reading frame after the catalytic domain. Reverse transcriptase-polymerase chain reaction with testis RNA from adult mouse and rat of different ages, as well as RNase protection, showed that both transcripts are absent at I I days of age, appear between 20 and 30 days of age, and are retained in the adult test-is. The presence of corresponding proteins in testis, germ cells, and spermatozoa was demonstrated by fast protein liquid chromatography and differential immunoprecipitation with full-length sAC-specific antibodies. Bicarbonate ions activated both sAC forms and increased cAMP levels in germ cells isolated from 25-and 50-day-old rats and adult rats in a concentration-dependent manner. These findings provide evidence that full-length and truncated sAC are generated by alternate splicing. Both forms are active in spermatids, and the bicarbonate present in the seminiferous tubule may be a signal that regulates cAMP levels in these cells.	Stanford Univ, Div Reprod Biol, Dept Gynecol & Obstet, Sch Med, Stanford, CA 94305 USA	Stanford University	Conti, M (corresponding author), Stanford Univ, Div Reprod Biol, Dept Gynecol & Obstet, Sch Med, 300 Pasteur Dr,Rm A344, Stanford, CA 94305 USA.	marco.conti@stanford.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD031544] Funding Source: NIH RePORTER; NICHD NIH HHS [HD31544, R01 HD031544] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ADAMO S, 1980, BIOCHEM BIOPH RES CO, V97, P607, DOI 10.1016/0006-291X(80)90307-1; ALVAREZ R, 1992, ANAL BIOCHEM, V203, P76, DOI 10.1016/0003-2697(92)90045-9; Blendy JA, 1996, NATURE, V380, P162, DOI 10.1038/380162a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUN T, 1975, P NATL ACAD SCI USA, V72, P1097, DOI 10.1073/pnas.72.3.1097; BRAUN T, 1991, METHOD ENZYMOL, V195, P130; Buck J, 1999, P NATL ACAD SCI USA, V96, P79, DOI 10.1073/pnas.96.1.79; Chen YQ, 2000, SCIENCE, V289, P625, DOI 10.1126/science.289.5479.625; Defer N, 1998, FEBS LETT, V424, P216, DOI 10.1016/S0014-5793(98)00178-1; DEGROOT RP, 1993, EMBO J, V12, P3903, DOI 10.1002/j.1460-2075.1993.tb06068.x; DELMAS V, 1993, MOL ENDOCRINOL, V7, P1502, DOI 10.1210/me.7.11.1502; EKSTEDT E, 1991, ACTA ANAT, V141, P257, DOI 10.1159/000147131; FANDE JK, 1966, P SOC EXP BIOL MED, V121, P899; GARBERS DL, 1980, BIOL REPROD, V22, P526, DOI 10.1093/biolreprod/22.3.526; Gautier-Courteille C, 1998, ENDOCRINOLOGY, V139, P2588, DOI 10.1210/en.139.5.2588; GORDELADZE JO, 1981, MOL CELL ENDOCRINOL, V23, P125, DOI 10.1016/0303-7207(81)90064-2; GORDELADZE JO, 1981, INT J ANDROL, V4, P172, DOI 10.1111/j.1365-2605.1981.tb00701.x; GORDELADZE JO, 1982, ARCH ANDROLOGY, V8, P199, DOI 10.3109/01485018208987040; GORDELADZE JO, 1981, J CLIN ENDOCR METAB, V53, P465, DOI 10.1210/jcem-53-3-465; JAISWAL BS, 2001, FERTILIZATION; Kaunisto K, 1999, BIOL REPROD, V61, P1521, DOI 10.1095/biolreprod61.6.1521; Kaupp UB, 2000, SCIENCE, V289, P559, DOI 10.1126/science.289.5479.559; KISTLER MK, 1994, BIOL REPROD, V51, P1322, DOI 10.1095/biolreprod51.6.1322; Mezquita P, 1999, MOL HUM REPROD, V5, P199, DOI 10.1093/molehr/5.3.199; Nantel F, 1996, NATURE, V380, P159, DOI 10.1038/380159a0; Naro F, 1996, ENDOCRINOLOGY, V137, P2464, DOI 10.1210/en.137.6.2464; Newcombe N, 2000, INT J ANDROL, V23, P46, DOI 10.1046/j.1365-2605.2000.00204.x; OKAMURA N, 1985, J BIOL CHEM, V260, P9699; OKAMURA N, 1990, BIOCHIM BIOPHYS ACTA, V1035, P83, DOI 10.1016/0304-4165(90)90177-X; Oki N, 2000, J BIOL CHEM, V275, P10831, DOI 10.1074/jbc.275.15.10831; PANDE JK, 1967, J CLIN ENDOCR METAB, V27, P892, DOI 10.1210/jcem-27-6-892; PARKKILA S, 1991, HISTOCHEMISTRY, V95, P477, DOI 10.1007/BF00315743; RODRIGUEZMARTINEZ H, 1990, ACTA ANAT, V139, P173, DOI 10.1159/000146995; ROJAS FJ, 1993, ENDOCRINOLOGY, V133, P3030, DOI 10.1210/en.133.6.3030; Salanova M, 1999, ENDOCRINOLOGY, V140, P2297, DOI 10.1210/en.140.5.2297; Sassone-Corsi P, 1998, SEMIN CELL DEV BIOL, V9, P475, DOI 10.1006/scdb.1998.0200; Sinclair ML, 2000, MOL REPROD DEV, V56, P6, DOI 10.1002/(SICI)1098-2795(200005)56:1&lt;6::AID-MRD2&gt;3.0.CO;2-M; STEINER AL, 1972, J BIOL CHEM, V247, P1114; STENGEL D, 1982, J BIOL CHEM, V257, P818; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; TAUSSIG R, 1995, J BIOL CHEM, V270, P1, DOI 10.1074/jbc.270.1.1; TUCK RR, 1970, PFLUG ARCH EUR J PHY, V318, P225, DOI 10.1007/BF00593663; Visconti PE, 1999, BIOL REPROD, V61, P76, DOI 10.1095/biolreprod61.1.76; WALES RG, 1966, J REPROD FERTIL, V12, P139, DOI 10.1530/jrf.0.0120139; Yanagimachi R., 1994, P189; Zhou YD, 1996, P NATL ACAD SCI USA, V93, P12262, DOI 10.1073/pnas.93.22.12262	46	110	121	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					31698	31708		10.1074/jbc.M011698200	http://dx.doi.org/10.1074/jbc.M011698200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11423534	hybrid			2022-12-25	WOS:000170613500032
J	Peri, R; Triggle, DJ; Singh, S				Peri, R; Triggle, DJ; Singh, S			Regulation of L-type calcium channels in pituitary GH(4)C(1) cells by depolarization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT SODIUM-CHANNELS; THYROTROPIN-RELEASING-HORMONE; PROTEIN-COUPLED RECEPTORS; SENSITIVE CA2+ CHANNELS; PHARMACOLOGICAL CHARACTERIZATION; CA2+-SENSITIVE INACTIVATION; MOLECULAR DETERMINANTS; VERTEBRATE CELLS; CA-2+ CHANNELS; CURRENTS	The neurosecretory anterior pituitary GH(4)C(1) cells exhibit the high voltage-activated dihydropyridine-sensitive L-type and the low voltage-activated T-type calcium currents. The activity of L-type calcium channels is tightly coupled to secretion of prolactin and other hormones in these cells. Depolarization induced by elevated extracellular K+ reduces the dihydropyridine (+)[(3) H]PN200-110 binding site density and Ca-45(2+) uptake in these cells (22). This study presents a functional analysis by electrophysiological techniques of short term regulation of L-type Ca2+ channels in GH(4)C(1) cells by membrane depolarization. Depolarization of GH(4)C(1) cells by 50 mm K+ rapidly reduced the barium currents through L-type calcium channels by similar to 70% and shifted the voltage dependence of activation by 10 mV to more depolarized potentials. Down-regulation depended on the strength of the depolarizing stimuli and was reversible. The currents recovered to near control levels on repolarization. Down-regulation of the calcium channel currents was calcium-dependent but may not have been due to excessive accumulation of intracellular calcium. Membrane depolarization by voltage clamping and by veratridine also produced a down-regulation of calcium channel currents. The down-regulation of the currents had an autocrine component. This study reveals a calcium-dependent down-regulation of the L-type calcium channel currents by depolarization.	SUNY Buffalo, Dept Pharmacol & Toxicol, Buffalo, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Singh, S (corresponding author), SUNY Buffalo, Dept Pharmacol & Toxicol, 102 Farber Hall, Buffalo, NY 14214 USA.				NIGMS NIH HHS [GM-50779] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM050779] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARMSTRONG CM, 1985, SCIENCE, V227, P65, DOI 10.1126/science.2578071; BEAN BP, 1989, ANNU REV PHYSIOL, V51, P367, DOI 10.1146/annurev.physiol.51.1.367; BERDAN RC, 1993, J NEUROPHYSIOL, V69, P151, DOI 10.1152/jn.1993.69.1.151; COHEN CJ, 1987, J PHYSIOL-LONDON, V387, P195, DOI 10.1113/jphysiol.1987.sp016570; Dargent B, 1996, NEUROSCIENCE, V73, P209, DOI 10.1016/0306-4522(95)00608-7; DARGENT B, 1995, J NEUROCHEM, V65, P407; DARGENT B, 1990, P NATL ACAD SCI USA, V87, P5907, DOI 10.1073/pnas.87.15.5907; DELEON M, 1995, SCIENCE, V270, P1502, DOI 10.1126/science.270.5241.1502; DELORME EM, 1986, BRAIN RES, V397, P189, DOI 10.1016/0006-8993(86)91385-5; DELORME EM, 1988, J PHARMACOL EXP THER, V244, P838; DUBINSKY JM, 1984, J GEN PHYSIOL, V83, P309, DOI 10.1085/jgp.83.3.309; ENYEART JJ, 1985, AM J PHYSIOL, V248, pC510, DOI 10.1152/ajpcell.1985.248.5.C510; ERTEL EA, 1994, NEURON, V13, P505; FERRANTE J, 1990, BIOCHEM PHARMACOL, V39, P1267, DOI 10.1016/0006-2952(90)90001-2; FERRANTE J, 1991, CAN J PHYSIOL PHARM, V69, P914, DOI 10.1139/y91-139; FERRANTE J, 1990, PHARMACOL REV, V42, P29; FITZPATRICK DB, 1984, J PHARMACOL EXP THER, V228, P761; FRANKLIN JL, 1992, J NEUROSCI, V12, P1726; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; Greenberg DA, 1999, MUSCLE NERVE, V22, P1341, DOI 10.1002/(SICI)1097-4598(199910)22:10<1341::AID-MUS2>3.0.CO;2-9; HAGIWARA S, 1983, J PHYSIOL-LONDON, V336, P649, DOI 10.1113/jphysiol.1983.sp014603; Hering S, 2000, J PHYSIOL-LONDON, V528, P237, DOI 10.1111/j.1469-7793.2000.t01-1-00237.x; Hockerman GH, 1997, ANNU REV PHARMACOL, V37, P361, DOI 10.1146/annurev.pharmtox.37.1.361; IMREDY JP, 1994, NEURON, V12, P1301, DOI 10.1016/0896-6273(94)90446-4; LIU J, 1994, MOL PHARMACOL, V45, P1198; MATTESON DR, 1986, J GEN PHYSIOL, V87, P161, DOI 10.1085/jgp.87.1.161; MILLER RJ, 1987, SCIENCE, V235, P46, DOI 10.1126/science.2432656; MILLER RJ, 1992, J BIOL CHEM, V267, P1403; Mukherjee R, 1998, J MOL CELL CARDIOL, V30, P1899, DOI 10.1006/jmcc.1998.0755; NEELY A, 1994, BIOPHYS J, V66, P1895, DOI 10.1016/S0006-3495(94)80983-X; Ophoff RA, 1998, HISTOL HISTOPATHOL, V13, P827, DOI 10.14670/HH-13.827; PASSAFARO M, 1992, J NEUROSCI, V12, P3372; Peri R, 2000, J MED CHEM, V43, P2906, DOI 10.1021/jm000028l; ROSENTHAL W, 1988, FASEB J, V2, P2784, DOI 10.1096/fasebj.2.12.2457531; ROSENTHAL W, 1988, EMBO J, V7, P1627, DOI 10.1002/j.1460-2075.1988.tb02989.x; SCHERUBL H, 1991, P ROY SOC B-BIOL SCI, V245, P127, DOI 10.1098/rspb.1991.0098; SCHULTZ G, 1993, ARZNEIMITTEL-FORSCH, V43-1, P229; SHER E, 1991, NEUROSCIENCE, V42, P301, DOI 10.1016/0306-4522(91)90376-Y; SIMASKO SM, 1991, ENDOCRINOLOGY, V128, P2015, DOI 10.1210/endo-128-4-2015; SIMASKO SM, 1988, AM J PHYSIOL, V254, pE328, DOI 10.1152/ajpendo.1988.254.3.E328; Sokolov S, 2000, J PHYSIOL-LONDON, V527, P445, DOI 10.1111/j.1469-7793.2000.t01-1-00445.x; Striessnig J, 1998, TRENDS PHARMACOL SCI, V19, P108, DOI 10.1016/S0165-6147(98)01171-7; TAN KN, 1984, J BIOL CHEM, V259, P427; Triggle DJ., 1998, CALCIUM ANTAGONISTS, P1; TSIEN RW, 1995, TRENDS NEUROSCI, V18, P52; WANG GK, 1994, J GEN PHYSIOL, V103, P501, DOI 10.1085/jgp.103.3.501; WICKMAN KD, 1995, CURR OPIN NEUROBIOL, V5, P278, DOI 10.1016/0959-4388(95)80039-5; ZHANG JF, 1994, NATURE, V372, P97, DOI 10.1038/372097a0; Zuhlke RD, 1999, NATURE, V399, P159, DOI 10.1038/20200	49	5	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					31667	31673		10.1074/jbc.M102613200	http://dx.doi.org/10.1074/jbc.M102613200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11413135	hybrid			2022-12-25	WOS:000170613500028
J	Zocchi, E; Podesta, M; Pitto, A; Usai, C; Bruzzone, S; Franco, L; Guida, L; Bacigalupo, A; De Flora, A				Zocchi, E; Podesta, M; Pitto, A; Usai, C; Bruzzone, S; Franco, L; Guida, L; Bacigalupo, A; De Flora, A			Stroma-generated cyclic ADP-ribose stimulates the expansion of early human hemopoietic progenitors by a paracrine interaction	FASEB JOURNAL			English	Article						paracrine communication; NAD(+); CD38	HUMAN MARROW CULTURES; CALCIUM-CONCENTRATION; LIMITING DILUTION; STEM-CELLS; HUMAN CD38; MECHANISMS; EXPRESSION; MICROENVIRONMENT; GLYCOPROTEIN; SECRETION	Both mammalian ectoenzymes CD38 and BST-1, which convert NAD+ into the potent intracellular calcium regulator cyclic ADP-ribose (cADPR), are expressed in the bone marrow microenvironment. Therefore, we investigated the effect of extracellular cADPR on human long-term culture-initiating cells (LTC-IC), the most immature hemopoietic progenitors (HP). A threefold expansion of LTC-IC was elicited by exposure of cord blood mononuclear cells for 24 h either to micromolar concentrations of exogenously added cADPR or to the nanomolar concentrations of cADPR that are produced by CD38-transfected murine stromal cell lines cocultured with the HP. The latter effect was due to connexin 43-mediated release of NAD(+) from feeder cells and to subsequent CD38-catalyzed generation of cADPR at their outer surface. The increased [Ca2+](i) induced in the feeder cells by autocrinally generated cADPR, however, increased production of interferon gamma, a potent hemopoiesis-inhibiting cytokine. Thus, long-term culture (5 wk) of HP over undiluted CD38(+) feeders decreased LTC-IC output by 90%, whereas a fivefold increase was observed when HP were cultured over a mixed CD38(+/-) feeder (1:10), whose ecto-ADP-ribosyl cyclase activity was as low as that expressed by native human stroma. These results demonstrate a new paracrine role for cADPR in the regulation of human hemopoiesis.	Univ Genoa, Dept Expt Med, Biochem Sect, I-16132 Genoa, Italy; San Martino Hosp, Dept Hematol, Genoa, Italy; CNR, Inst Cybernet & Biophys, Genoa, Italy; G Gaslini Inst Children, Genoa, Italy	University of Genoa; University of Genoa; IRCCS AOU San Martino IST; Consiglio Nazionale delle Ricerche (CNR); Istituto di Cibernetica "Eduardo Caianiello" (ICIB-CNR); University of Genoa; IRCCS Istituto Giannina Gaslini	Zocchi, E (corresponding author), Univ Genoa, Dept Expt Med, Biochem Sect, Viale Benedetto XV-1, I-16132 Genoa, Italy.	toninodf@unige.it	Bruzzone, Santina/A-4264-2015; Podestà, Marina/K-3875-2016	Bruzzone, Santina/0000-0003-2034-3716; Podestà, Marina/0000-0002-6755-613X; Usai, Cesare/0000-0001-8863-7759				Ausiello CM, 1996, CELL IMMUNOL, V173, P192, DOI 10.1006/cimm.1996.0267; BACIGALUPO A, 1991, EXP HEMATOL, V19, P829; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bruzzone S, 2001, FASEB J, V15, P10; Cancelas JA, 2000, BLOOD, V96, P498; EAVES CJ, 1991, BLOOD, V78, P110; Eaves CJ, 1991, J TISSUE CULTURE MET, V13, P55; Emerson SG, 1996, BLOOD, V87, P3082, DOI 10.1182/blood.V87.8.3082.bloodjournal8783082; Erices A, 2000, BRIT J HAEMATOL, V109, P235, DOI 10.1046/j.1365-2141.2000.01986.x; Franco L, 2001, AM J PHYSIOL-LUNG C, V280, pL98; Franco L, 1998, FASEB J, V12, P1507; Graeff RM, 1997, METHOD ENZYMOL, V280, P230; GRAEFF RM, 1994, J BIOL CHEM, V269, P30260; HOWARD M, 1993, SCIENCE, V262, P1056, DOI 10.1126/science.8235624; JACKSON DG, 1990, J IMMUNOL, V144, P2811; KAISHO T, 1994, P NATL ACAD SCI USA, V91, P5325, DOI 10.1073/pnas.91.12.5325; Kojima S, 1998, INT J HEMATOL, V68, P19; Lee HC, 1997, PHYSIOL REV, V77, P1133, DOI 10.1152/physrev.1997.77.4.1133; LEE HC, 1994, VITAM HORM, V48, P199, DOI 10.1016/S0083-6729(08)60499-9; Masuda W, 1997, FEBS LETT, V405, P104, DOI 10.1016/S0014-5793(97)00168-3; Mehta K, 1996, FASEB J, V10, P1408, DOI 10.1096/fasebj.10.12.8903511; Montecino-Rodriguez E, 2000, BLOOD, V96, P917, DOI 10.1182/blood.V96.3.917.015k45_917_924; Podesta M, 2000, FASEB J, V14, P680, DOI 10.1096/fasebj.14.5.680; PORTER EH, 1963, BRIT J CANCER, V17, P583, DOI 10.1038/bjc.1963.78; ROSENDAAL M, 1994, J CELL SCI, V107, P29; Selleri C, 1996, BLOOD, V87, P4149, DOI 10.1182/blood.V87.10.4149.bloodjournal87104149; SUTHERLAND HJ, 1990, P NATL ACAD SCI USA, V87, P3584, DOI 10.1073/pnas.87.9.3584; SUTHERLAND HJ, 1989, BLOOD, V74, P1563; SUTHERLAND HJ, 1991, BLOOD, V78, P666, DOI 10.1182/blood.V78.3.666.bloodjournal783666; TAKASAWA S, 1993, SCIENCE, V259, P370, DOI 10.1126/science.8420005; TASWELL C, 1981, J IMMUNOL, V126, P1614; VANDERSLUIJS JP, 1990, EXP HEMATOL, V18, P893; WALSETH TF, 1993, BIOCHIM BIOPHYS ACTA, V1178, P235, DOI 10.1016/0167-4889(93)90199-Y; Wineman J, 1996, BLOOD, V87, P4082, DOI 10.1182/blood.V87.10.4082.bloodjournal87104082; Wu Y, 1997, SCIENCE, V278, P2126, DOI 10.1126/science.278.5346.2126; Young NS, 2000, SEMIN HEMATOL, V37, P3, DOI 10.1016/S0037-1963(00)90026-X; ZEREZ CR, 1987, ANAL BIOCHEM, V164, P367, DOI 10.1016/0003-2697(87)90506-9; Zocchi E, 1999, FASEB J, V13, P273, DOI 10.1096/fasebj.13.2.273; Zocchi E, 1998, J BIOL CHEM, V273, P8017, DOI 10.1074/jbc.273.14.8017	39	24	25	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY 29	2001	15	7					1610	+		10.1096/fj.00-0803fje	http://dx.doi.org/10.1096/fj.00-0803fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519CQ	11427502				2022-12-25	WOS:000173707700017
J	Prasher, JM; Elenitoba-Johnson, KSJ; Kelley, LL				Prasher, JM; Elenitoba-Johnson, KSJ; Kelley, LL			Loss of p53 tumor suppressor function is required for in vivo progression of Friend erythroleukemia	ONCOGENE			English	Article						p53; erythroleukemia; Friend virus	VIRUS-INDUCED ERYTHROLEUKEMIA; MURINE LEUKEMIA-VIRUS; MULV-INDUCED-ERYTHROLEUKEMIAS; TRANSGENIC MICE DEVELOP; ERYTHROPOIETIN RECEPTOR; F-MULV; CELL-DEATH; GENE; GROWTH; ONCOGENE	A role for p53 in the in vivo progression of Friend virus-induced erythroleukemia has been suggested but not clearly defined, We developed a Friend virus-sensitive, p53-deficient mouse model to directly address the role of p53 in Friend erythroleukemia. When infected with the polycythemia-inducing strain of Friend virus (FVP), p53 null mice exhibited accelerated progression to erythroleukemia and accelerated death following diagnosis when compared to wild type mice. Confirmation that p53 mutations were required for disease progression was provided by sequence analysis of p53 transcripts in leukemic wild type and heterozygous mice. All transcripts evaluated had point mutations, deletions or insertions in the p53 gene. The ability to grow tumor colonies in vitro and derive cell lines was enhanced in FVP-infected p53 null animals, Although PU.1 oncogene overexpression is a common mutation observed in cell lines derived from Friend virus-infected p53 wild type mice, it was not a universal finding in cell lines derived from p53 null animals. Our data conclusively demonstrate that loss of p53 function is a requirement for progression of Friend erythroleukemia in vivo. Further, the data demonstrate that erythroleukemias arising in Friend virus-infected p53 null mice are biologically and genetically distinct from those that occur in wild type animals, suggesting that the temporal order of PU.1 and p53 mutations is an important parameter in the pathogenesis of leukemic development. Oncogene (2001) 20, 3946-2955.	Univ Utah, Sch Med, Dept Pathol, Salt Lake City, UT 84132 USA; Huntsman Canc Inst, Salt Lake City, UT 84132 USA; Univ Utah, Sch Med, Dept Med, Salt Lake City, UT 84132 USA	Utah System of Higher Education; University of Utah; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah	Kelley, LL (corresponding author), Univ Utah, Dept Med, Div Hematol, SOM 4C416, Salt Lake City, UT 84102 USA.	linda.kelley@hsc.utah.edu		Elenitoba-Johnson, Kojo/0000-0002-1082-1545	NCI NIH HHS [CA83984-01] Funding Source: Medline; NIDDK NIH HHS [P50DK49219] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R21CA083984] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK049219] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barnache S, 1998, ONCOGENE, V16, P2989, DOI 10.1038/sj.onc.1202095; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; CHOW V, 1987, J VIROL, V61, P2777, DOI 10.1128/JVI.61.9.2777-2781.1987; DAVID YB, 1988, ONCOGENE, V3, P179; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Donehower LA, 1996, SEMIN CANCER BIOL, V7, P269, DOI 10.1006/scbi.1996.0035; Hainaut P, 2000, ADV CANCER RES, V77, P81; HARVEY M, 1993, FASEB J, V7, P938, DOI 10.1096/fasebj.7.10.8344491; HICKS GG, 1988, J VIROL, V62, P4752, DOI 10.1128/JVI.62.12.4752-4755.1988; HOFER E, 1981, CELL, V23, P585, DOI 10.1016/0092-8674(81)90154-9; Howard J, 1996, CELL GROWTH DIFFER, V7, P1651; HOWARD JC, 1993, ONCOGENE, V8, P2721; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; Kelley LL, 1998, ONCOGENE, V17, P1119, DOI 10.1038/sj.onc.1202037; Khanna KK, 2000, JNCI-J NATL CANCER I, V92, P795, DOI 10.1093/jnci/92.10.795; Koury MJ, 1997, BLOOD, V90, P4054, DOI 10.1182/blood.V90.10.4054; LAVIGUEUR A, 1991, ONCOGENE, V6, P2197; LAVIGUEUR A, 1989, MOL CELL BIOL, V9, P3982, DOI 10.1128/MCB.9.9.3982; LI JP, 1995, J VIROL, V69, P1714, DOI 10.1128/JVI.69.3.1714-1719.1995; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MAGER DL, 1981, P NATL ACAD SCI-BIOL, V78, P1703, DOI 10.1073/pnas.78.3.1703; MoreauGachelin F, 1996, MOL CELL BIOL, V16, P2453; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MOREAUGACHELIN F, 1990, LEUKEMIA, V4, P20; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; MUNROE DG, 1990, MOL CELL BIOL, V10, P3307, DOI 10.1128/MCB.10.7.3307; MUNROE DG, 1988, ONCOGENE, V2, P621; Ney PA, 2000, BLOOD, V96, P3675, DOI 10.1182/blood.V96.12.3675.h8003675_3675_3680; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; PAUL R, 1989, J VIROL, V63, P4958, DOI 10.1128/JVI.63.11.4958-4961.1989; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Quang CT, 1997, EMBO J, V16, P5639, DOI 10.1093/emboj/16.18.5639; RAY D, 1992, MOL CELL BIOL, V12, P4297, DOI 10.1128/MCB.12.10.4297; ROVINSKI B, 1987, MOL CELL BIOL, V7, P847, DOI 10.1128/MCB.7.2.847; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; SCHUETZE S, 1993, MOL CELL BIOL, V13, P5670, DOI 10.1128/MCB.13.9.5670; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; SHIBUYA T, 1982, CELL, V31, P483, DOI 10.1016/0092-8674(82)90141-6; SILVER J, 1986, J VIROL, V57, P526, DOI 10.1128/JVI.57.2.526-533.1986; SOUSSI T, 2001, ANN NY ACAD SCI, P121; TAMBOURIN PE, 1973, BRIT J HAEMATOL, V24, P511, DOI 10.1111/j.1365-2141.1973.tb01677.x; Wong KS, 1999, ONCOGENE, V18, P5525, DOI 10.1038/sj.onc.1202938; Yamada T, 1997, BLOOD, V89, P1383, DOI 10.1182/blood.V89.4.1383; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	48	13	13	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 24	2001	20	23					2946	2955		10.1038/sj.onc.1204395	http://dx.doi.org/10.1038/sj.onc.1204395			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	435VA	11420707				2022-12-25	WOS:000168901800010
J	D'Agnano, I; Valentini, A; Fornari, C; Bucci, B; Starace, G; Felsani, A; Citro, G				D'Agnano, I; Valentini, A; Fornari, C; Bucci, B; Starace, G; Felsani, A; Citro, G			Myc down-regulation induces apoptosis in M14 melanoma cells by increasing p27(kip1) levels	ONCOGENE			English	Article						c-myc; melanoma; p27; apoptosis	ANTISENSE OLIGODEOXYNUCLEOTIDES ENHANCE; KINASE INHIBITOR P27(KIP1); C-MYC; CYCLE PROGRESSION; GROWTH ARREST; PHOSPHOROTHIOATE OLIGODEOXYNUCLEOTIDES; GENE-EXPRESSION; IN-VITRO; PROTEIN; DEATH	In recent years, increasing evidence indicated the importance of a deregulated c-myc gene in the melanoma pathogenesis, We have previously demonstrated that treatment of melanoma cells with c-myc antisense oligodeoxynucleotides can inhibit cell proliferation and activate apoptosis, To gain insight into the mechanisms activated by Myc down-regulation, we have now developed an experimental model that allows modulating Myc protein expression in melanoma cells. This was achieved by originating stable melanoma cell clones expressing ecdysone-inducible c-myc antisense RNA. We show that the induction of c-myc antisense RNA in M14 melanoma cells leads to an inhibition of cell proliferation characterized by accumulation of cells in the G(1) phase of the cell cycle (up to 80%) and activation of apoptosis (50%), These data are associated with an increase of p27(kipl) levels and a significant reduction of the cdk2-associated kinase activity, In addition, we show that an ectopic overexpression of p27(kiPl) in this experimental model can enhance the apoptotic rate. Our results indicate that down-regulation of Myc protein induces a G(1) arrest and activates apoptosis by increasing p27(kipl) content in melanoma cells, that are known to be defective for the p16-cyclinD/cdk4-pRb G(1) checkpoint. This is particularly relevant for identifying new therapeutic strategies based on the re-establishment of the apoptotic pathways in cancer cells.	CNR, Ist Tecnol Biomed, I-00137 Rome, Italy; CNR, Ist Med Sperimentale, I-00137 Rome, Italy; Ist Regina Elena, I-00158 Rome, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); Consiglio Nazionale delle Ricerche (CNR); IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena	D'Agnano, I (corresponding author), CNR, Ist Tecnol Biomed, V Marx 43, I-00137 Rome, Italy.		Felsani, Armando/D-1784-2010; bucci, barbara/K-6694-2012; D'Agnano, Igea/AAR-7282-2020	Felsani, Armando/0000-0001-8851-6295; D'Agnano, Igea/0000-0002-2646-9224				Bartkova J, 1996, CANCER RES, V56, P5475; BURGESS TL, 1995, P NATL ACAD SCI USA, V92, P4051, DOI 10.1073/pnas.92.9.4051; Castellano M, 1999, MELANOMA RES, V9, P421, DOI 10.1097/00008390-199910000-00001; Citro G, 1998, CANCER RES, V58, P283; Crooke ST, 1996, ANTISENSE NUCLEIC A, V6, P145, DOI 10.1089/oli.1.1996.6.145; D'Agnano I, 1998, ENVIRON MOL MUTAGEN, V32, P56, DOI 10.1002/(SICI)1098-2280(1998)32:1<56::AID-EM7>3.0.CO;2-9; DAKSIS JI, 1994, ONCOGENE, V9, P3635; Dang CV, 1999, MOL CELL BIOL, V19, P1; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Ezhevsky SA, 1996, MOL BIOL CELL, V7, P553, DOI 10.1091/mbc.7.4.553; FISCHER G, 1994, J EXP MED, V179, P221, DOI 10.1084/jem.179.1.221; HANSON KD, 1994, MOL CELL BIOL, V14, P5748, DOI 10.1128/MCB.14.9.5748; HOANG AT, 1994, P NATL ACAD SCI USA, V91, P6875, DOI 10.1073/pnas.91.15.6875; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; Kalejta RF, 1997, CYTOMETRY, V29, P286, DOI 10.1002/(SICI)1097-0320(19971201)29:4<286::AID-CYTO4>3.0.CO;2-8; Katayose Y, 1997, CANCER RES, V57, P5441; KIMURA S, 1995, CANCER RES, V55, P1379; KRIEG AM, 1995, ANTISENSE RES DEV, V5, P241, DOI 10.1089/ard.1995.5.241; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; Leonetti C, 1996, JNCI-J NATL CANCER I, V88, P419, DOI 10.1093/jnci/88.7.419; LESNIKOWSKI ZJ, 1990, NUCLEIC ACIDS RES, V18, P2109, DOI 10.1093/nar/18.8.2109; Maelandsmo GM, 1996, BRIT J CANCER, V73, P909, DOI 10.1038/bjc.1996.181; Mateyak MK, 1999, MOL CELL BIOL, V19, P4672; O'Hagan RC, 2000, GENE DEV, V14, P2185, DOI 10.1101/gad.827200; Obaya AJ, 1999, ONCOGENE, V18, P2934, DOI 10.1038/sj.onc.1202749; PerezRoger I, 1997, ONCOGENE, V14, P2373, DOI 10.1038/sj.onc.1201197; Ross DA, 1998, BRIT J SURG, V85, P46; Ryan KM, 1996, BIOCHEM J, V314, P713, DOI 10.1042/bj3140713; Schlagbauer-Wadl H, 1999, J INVEST DERMATOL, V112, P332, DOI 10.1046/j.1523-1747.1999.00506.x; Schmidt EV, 1999, ONCOGENE, V18, P2988, DOI 10.1038/sj.onc.1202751; Schraml P, 1999, CLIN CANCER RES, V5, P1966; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SKORSKI T, 1995, J EXP MED, V182, P1645, DOI 10.1084/jem.182.6.1645; Stein CA, 1998, ANTISENSE NUCLEIC A, V8, P129, DOI 10.1089/oli.1.1998.8.129; Stein CA, 1996, J NATL CANCER I, V88, P391, DOI 10.1093/jnci/88.7.391; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; VanWardenburg RCAM, 1997, INT J CANCER, V73, P544, DOI 10.1002/(SICI)1097-0215(19971114)73:4<544::AID-IJC15>3.3.CO;2-C; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; Wang XT, 1997, ONCOGENE, V15, P2991, DOI 10.1038/sj.onc.1201450; Wu M, 1999, J IMMUNOL, V163, P6530	43	47	49	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 17	2001	20	22					2814	2825		10.1038/sj.onc.1204392	http://dx.doi.org/10.1038/sj.onc.1204392			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	432TP	11420693				2022-12-25	WOS:000168712000009
J	Ludes-Meyers, JH; Liu, YM; Munoz-Medellin, D; Hilsenbeck, SG; Brown, PH				Ludes-Meyers, JH; Liu, YM; Munoz-Medellin, D; Hilsenbeck, SG; Brown, PH			AP-1 blockade inhibits the growth of normal and malignant breast cells	ONCOGENE			English	Article						AP-1; breast cancer; signal transduction; human mammary epithelial cells; carcinogenesis	MAMMARY EPITHELIAL-CELLS; C-JUN; INDUCED TRANSFORMATION; DELETION MUTANT; P53 MUTATIONS; CANCER CELLS; EXPRESSION; LINES; ACTIVATION; INDUCTION	We have previously demonstrated that basal AP-1 transcriptional activity is high in normal human mammary epithelial cells, intermediate in immortal breast cells, and relatively low in breast cancer cells. In this study we investigated whether differences in AP-1 transcriptional activity reflect differences in breast cells' dependence on AP-I for proliferation. The cJun dominant negative, TAM-67, was used to determine the effect of AP-1 blockade on the growth of normal, immortal and malignant breast cells. We first showed that TAM-67 inhibits AP-1 activity in normal and malignant breast cells. We then determined whether this AP-1 inhibitor affected colony forming efficiency of the immortalized and malignant breast cells. The AP-I inhibitor reduced colony formation of immortal breast cells by over 50% (by 58% in 184B5 cells and 62% in MCF10A cells), and reduced colony formation in the breast cancer cell line MCF7 by 43%, but did not reduce colony formation in the other breast cancer cell lines (T47D, MDA MB231 and MDA MB 435), We also determined the effect of AP-1 blockade on the growth of normal breast cells using a single cell proliferation assay. Using this assay, the growth of normal breast cells was extremely sensitive to AP-1 blockade, while immortal breast cells were moderately sensitive. We next directly tested the effect of TAM-67 expression on the growth of MCF7 breast cancer cells, using cells stably transfected with TAM-67 under the control of a doxycycline-inducible promoter. Upon induction, TAM-67 was expressed and AP-1 activity was inhibited in these cells. We then measured the growth of these cells in the presence or absence of TAM-67, The results of these studies show that the growth of MCF7 cells was suppressed by the AP-1 inhibitor, TAM-67. These results demonstrate that normal and immortalized breast cells, and some breast cancer cells (such as MCF7), require AP-1 to transduce proliferative signals, while other breast cancer cells (such as T47D, MDA MB231 and MDA MB 435) do not. These studies suggest that the AP-1 transcription factor is a potential target for future agents for the prevention or treatment of breast cancer.	Baylor Coll Med, Breast Ctr, Dept Mol & Cell Biol, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Dept Med, Div Med Oncol, San Antonio, TX 78284 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA	Baylor College of Medicine; University of Texas System; University of Texas Health San Antonio; Baylor College of Medicine	Brown, PH (corresponding author), Baylor Coll Med, Breast Ctr, Dept Mol & Cell Biol, Alkek 570-N,MS 600,1 Baylor Plaza, Houston, TX 77030 USA.			Brown, Powel/0000-0002-3398-163X	NCI NIH HHS [CA70091] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA070091] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bamberger AM, 1999, INT J CANCER, V84, P533, DOI 10.1002/(SICI)1097-0215(19991022)84:5<533::AID-IJC16>3.0.CO;2-J; BASELGA J, 1994, BREAST CANCER RES TR, V29, P127, DOI 10.1007/BF00666188; BERENBLUM I, 1947, BRIT J CANCER, V1, P379, DOI 10.1038/bjc.1947.35; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; Bonsing BA, 1997, CYTOMETRY, V28, P11, DOI 10.1002/(SICI)1097-0320(19970501)28:1<11::AID-CYTO2>3.3.CO;2-H; BOX GEP, 1964, J ROY STAT SOC B, V26, P211, DOI 10.1111/j.2517-6161.1964.tb00553.x; BROWN PH, 1993, ONCOGENE, V8, P877; Chen TK, 1996, MOL CARCINOGEN, V15, P215, DOI 10.1002/(SICI)1098-2744(199603)15:3<215::AID-MC7>3.0.CO;2-G; CIARDIELLO F, 1990, CELL GROWTH DIFFER, V1, P407; DOMANN FE, 1994, CELL GROWTH DIFFER, V5, P9; DONG ZG, 1994, P NATL ACAD SCI USA, V91, P609, DOI 10.1073/pnas.91.2.609; Gee JMW, 2000, INT J CANCER, V89, P177, DOI 10.1002/(SICI)1097-0215(20000320)89:2<177::AID-IJC13>3.0.CO;2-0; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; HARRIS JR, 1993, CANC PRINCIPLES PRAC, P1264; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Katayose D, 1995, CLIN CANCER RES, V1, P889; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; LESOONWOOD LA, 1995, HUM GENE THER, V6, P395, DOI 10.1089/hum.1995.6.4-395; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; PETRAK D, 1994, J IMMUNOL, V153, P2046; Smith LM, 1997, CANCER RES, V57, P3046; SOULE HD, 1990, CANCER RES, V50, P6075; STAMPFER M, 1980, IN VITRO CELL DEV B, V16, P415; STAMPFER MR, 1993, EXP CELL RES, V208, P175, DOI 10.1006/excr.1993.1236; STAMPFER MR, 1985, P NATL ACAD SCI USA, V82, P2394, DOI 10.1073/pnas.82.8.2394; STAMPFER MR, 1992, TRANSFORMATION HUMAN, P117; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; TRIPATHY D, 1993, ACTIVATED ONCOGENES, P15; YOSHIOKA K, 1995, P NATL ACAD SCI USA, V92, P4972, DOI 10.1073/pnas.92.11.4972; ZAJCHOWSKI D, 1988, CANCER RES, V48, P7041	32	51	53	1	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 17	2001	20	22					2771	2780		10.1038/sj.onc.1204377	http://dx.doi.org/10.1038/sj.onc.1204377			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	432TP	11420689				2022-12-25	WOS:000168712000005
J	Agarwal, ML; Ramana, CV; Hamilton, M; Taylor, WR; DePrimo, SE; Bean, LJH; Agarwal, A; Agarwal, MK; Wolfman, A; Stark, GR				Agarwal, ML; Ramana, CV; Hamilton, M; Taylor, WR; DePrimo, SE; Bean, LJH; Agarwal, A; Agarwal, MK; Wolfman, A; Stark, GR			Regulation of p53 expression by the RAS-MAP kinase pathway	ONCOGENE			English	Article						mutant cells; p53; mRNA levels; p21 expression	TUMOR-SUPPRESSOR P53; ALPHA-INTERFERON; SIGNALING PATHWAY; MAMMALIAN-CELLS; IN-VIVO; PROTEIN; GENE; TRANSFORMATION; SENESCENCE; CASCADE	Activation of MAP kinase leads to the activation of p53-dependent pathways, and vice-versa. Although the amount of p53 protein increases in response to MAP kinase-dependent signaling, the basis of this increase is not yet fully understood. We have isolated the mutant cell line AP14, defective in p53 expression, from human HT1080 fibrosarcoma cells, which have an activated ras allele, The expression of p53 mRNA and protein is similar to 10-fold lower in AP14 cells than in the parental cells. The high constitutive phosphorylation and activities of the MAP kinases ERK1 and ERK2 in HT1080 cells are greatly reduced in AP14 cells, although the levels of these proteins are unchanged, suggesting that the defect in the mutant cells affects the steady-state phosphorylation of ERK1 and ERK2, Overexpression of ERK2 in AP14 cells restored both MAP kinase activity and p53 expression, and incubation of the mutant cells with the phosphatase inhibitor orthovanadate resulted in strong coordinate elevation of MAP kinase activity and p53 expression. The levels of expression of the p53-regulated gene p21 parallel those of p53 throughout, showing that basal p21 expression depends on p53, The levels of p53 mRNA increased by 5-8-fold when activated ras was introduced into wild-type cells, and the levels of the p53 and p21 proteins decreased substantially in wild-type cells treated with the MEK inhibitor U0216, We conclude that MAP kinase-dependent pathways help to regulate p53 levels by regulating the expression of p53 mRNA.	Cleveland Clin Fdn, Lerner Res Inst, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Stark, GR (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.			chilakamarti, ramana/0000-0002-5153-8252	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051277] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM51277] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; ANDERSON MJ, 1994, GENE CHROMOSOME CANC, V9, P266, DOI 10.1002/gcc.2870090407; CASEY G, 1993, CANCER LETT, V69, P151, DOI 10.1016/0304-3835(93)90168-9; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; DEFFIE A, 1993, MOL CELL BIOL, V13, P3415, DOI 10.1128/MCB.13.6.3415; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; Fukasawa K, 1997, MOL CELL BIOL, V17, P506, DOI 10.1128/MCB.17.1.506; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Hamilton M, 1998, ONCOGENE, V16, P1417, DOI 10.1038/sj.onc.1201653; Harlow E., 1988, ANTIBODIES LAB MANUA; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAND H, 1983, SCIENCE, V222, P771, DOI 10.1126/science.6356358; Lee SW, 2000, P NATL ACAD SCI USA, V97, P8302, DOI 10.1073/pnas.150024397; LEUNG S, 1995, MOL CELL BIOL, V15, P1312; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li XX, 1999, MOL CELL BIOL, V19, P4643; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; MCKENDRY R, 1991, P NATL ACAD SCI USA, V88, P11455, DOI 10.1073/pnas.88.24.11455; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; PELLEGRINI S, 1989, MOL CELL BIOL, V9, P4605, DOI 10.1128/MCB.9.11.4605; Plattner R, 1996, P NATL ACAD SCI USA, V93, P6665, DOI 10.1073/pnas.93.13.6665; Raman V, 2000, NATURE, V405, P974, DOI 10.1038/35016125; SAMBROOK J, 1989, MOL CLONING, V9, P14; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sherr CJ, 2000, CANCER RES, V60, P3689; Stark GR, 1999, HUM MOL GENET, V8, P1925, DOI 10.1093/hmg/8.10.1925; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Tang H, 1998, J BIOL CHEM, V273, P29156, DOI 10.1074/jbc.273.44.29156; Venanzoni MC, 1996, ONCOGENE, V12, P1199; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Weinberg RA, 1997, CELL, V88, P573, DOI 10.1016/S0092-8674(00)81897-8; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	42	42	43	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 3	2001	20	20					2527	2536		10.1038/sj.onc.1204353	http://dx.doi.org/10.1038/sj.onc.1204353			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	431VM	11420662				2022-12-25	WOS:000168652500003
J	Jiang, YX; Cui, L; Yie, TA; Rom, WN; Cheng, H; Tchou-Wong, KM				Jiang, YX; Cui, L; Yie, TA; Rom, WN; Cheng, H; Tchou-Wong, KM			Inhibition of anchorage-independent growth and lung metastasis of A549 lung carcinoma cells by I kappa B beta	ONCOGENE			English	Article						I kappa B beta; anchorage-independent; growth in low serum; apoptosis; metastasis	TRANSCRIPTION FACTOR; CANCER CELLS; TUMOR-GROWTH; ACTIVATION; ALPHA; TUMORIGENICITY; EXPRESSION; APOPTOSIS; RAS; TRANSFORMATION	To evaluate the role of the NF-kappaB signaling pathway in oncogenic transformation, we expressed I kappaB beta, a specific inhibitor of NF-kappaB, in two human lung adenocarcinoma cell lines, A549 and H441, Expression of I kappaB beta significantly reduced NF-kappaB activation induced by cotransfection with p65/RelA or TNF-alpha and abrogated the basal NF-kappaB activity in A549 cells. Transfection of I kappaB beta into A549, H441 and K-uas-transformed NIH3T3 cells suppressed anchorage-independent growth as measured by colony formation in soft agar, Anchorage-independent growth of vector-transfected A549 cells in reduced serum could be enhanced by both EGF and IGF-I. In contrast, only EGF but not IGF-I could induce anchorage-independent growth of I kappaB beta -expressing A549 cells, suggesting that the IGF-I signaling pathway regulating growth and survival may be blocked by I kappaB beta. Interestingly, expression of I kappaB beta suppressed growth of A549 cells in low serum in vitro without affecting in vivo growth subcutaneously in nude mice, However, metastatic growth of I kappaB beta -expressing A549 cells in the lungs of nude mice was significantly inhibited, These results provide evidence that NF kappaB plays an important role in anchorage-independent growth and metastatic growth of lung carcinoma cells.	NYU, Sch Med, Dept Med, Div Pulm & Crit Care Med, New York, NY 10016 USA; NYU, Sch Med, Dept Pediat, New York, NY 10016 USA; NYU, Sch Med, Dept Environm Med, New York, NY 10016 USA; NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA	New York University; New York University; New York University; New York University	Tchou-Wong, KM (corresponding author), NYU, Sch Med, Dept Med, Div Pulm & Crit Care Med, 550 1st Ave,MSB 147, New York, NY 10016 USA.			Rom, William/0000-0002-8793-7028	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059832, R01HL062055] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009161] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL62055, R01 HL59832] Funding Source: Medline; NIEHS NIH HHS [R01 ES09161] Funding Source: Medline; PHS HHS [M0100096 GCRC] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Arsura M, 2000, MOL CELL BIOL, V20, P5381, DOI 10.1128/MCB.20.15.5381-5391.2000; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Batra RK, 1999, AM J RESP CELL MOL, V21, P238, DOI 10.1165/ajrcmb.21.2.3470; BEAUPARLANT P, 1994, ONCOGENE, V9, P3189; Biswas DK, 2000, P NATL ACAD SCI USA, V97, P8542, DOI 10.1073/pnas.97.15.8542; Bost F, 1999, MOL CELL BIOL, V19, P1938; DODSON MG, 1981, CANCER RES, V41, P1441; Duffey DC, 1999, CANCER RES, V59, P3468; Feig BW, 1999, SURGERY, V126, P399, DOI 10.1067/msy.1999.98787; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; Foo SY, 1999, TRENDS GENET, V15, P229; HASTINGS RJ, 1981, INT J CANCER, V27, P15, DOI 10.1002/ijc.2910270104; Heck S, 1999, J BIOL CHEM, V274, P9828, DOI 10.1074/jbc.274.14.9828; HIGGINS KA, 1993, P NATL ACAD SCI USA, V90, P9901, DOI 10.1073/pnas.90.21.9901; Huang S, 2000, CLIN CANCER RES, V6, P2573; Jiang YX, 1999, ONCOGENE, V18, P6071, DOI 10.1038/sj.onc.1202984; Johnson DR, 1996, J BIOL CHEM, V271, P16317, DOI 10.1074/jbc.271.27.16317; Jones DR, 2000, ANN THORAC SURG, V70, P930, DOI 10.1016/S0003-4975(00)01635-0; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Maniatis T, 1997, SCIENCE, V278, P818, DOI 10.1126/science.278.5339.818; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; Mayo MW, 2000, BBA-REV CANCER, V1470, pM55, DOI 10.1016/S0304-419X(00)00002-0; MITSUDOMI T, 1991, ONCOGENE, V6, P1353; OVADIA H, 1975, EUR J CANCER, V11, P413, DOI 10.1016/0014-2964(75)90072-9; Piette J, 1997, BIOL CHEM, V378, P1237; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; Sharma HW, 1996, ANTICANCER RES, V16, P589; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SIEGFRIED JM, 1987, CANCER RES, V47, P2903; Simeonidis S, 1997, P NATL ACAD SCI USA, V94, P14372, DOI 10.1073/pnas.94.26.14372; Sun L, 1998, ONCOGENE, V16, P2095, DOI 10.1038/sj.onc.1201731; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; Tran K, 1997, MOL CELL BIOL, V17, P5386, DOI 10.1128/MCB.17.9.5386; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984	35	41	47	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 26	2001	20	18					2254	2263		10.1038/sj.onc.1204293	http://dx.doi.org/10.1038/sj.onc.1204293			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	427KZ	11402320				2022-12-25	WOS:000168404500007
